# (19) World Intellectual Property Organization International Bureau



# (43) International Publication Date 15 May 2003 (15.05.2003)

### **PCT**

# (10) International Publication Number WO 03/040096 A2

(51) International Patent Classification7:

C07D

(21) International Application Number: PCT/US02/36072

(22) International Filing Date:

8 November 2002 (08.11.2002)

(25) Filing Language:

ţ.

English

(26) Publication Language:

English

(30) Priority Data:

60/337,122 8 November 2001 (08.11.2001) US 60/344,086 28 December 2001 (28.12.2001) US 60/345,635 3 January 2002 (03.01.2002)

(71) Applicants (for all designated States except US): ELAN PHARMACEUTICALS, INC. [US/US]; 800 Gateway Boulevard, South San Francisco, CA 94080 (US). PHARMACIA & UPJOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49007 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): JOHN, Varghese [US/US]; 1722 18th Avenue, San Francisco, CA 94122 (US). MAILLARD, Michel [US/US]; 219 Shorebird Circle, Redwood Shores, CA 94065 (US). JAGODZINSKA, Barbara [US/US]; 1485 Kentfield Avenue, Redwood City, CA 94061 (US). BECK, James, P. [US/US]; 8351 Canary Lane, Kalamazoo, MI 49009 (US). GAILUNAS, Andrea [US/US]; 1105 Baywater Avenue #1, Burlingame, CA 94010 (US). FANG, Larry [US/US]; 1193 Beach Park Blvd., Foster City, CA 94404 (US). SEALY, Jennifer [US/US]; 37 Lorton Avenue #3, Burlingame, CA 94010 (US). TENBRINK, Ruth [IN/US]; 5725 DE Avenue East,

Kalamazoo, MI 49004 (US). FRESKOS, John [US/US]; 7572 York Drive, Clayton, MO 63105 (US). MICKEL-SON, John [US/US]; 60887 Valley View Blvd., Mattawan, MI 49071 (US). SAMALA, Lakshman [IN/US]; 6238 Independence Drive, Portage, MI 49024 (US). HOM, Rov [US/US]; 82 Ina Drive, San Francisco, CA 94112 (US).

(74) Agent: SARUSSI, Steven, J.; McDonnell Boehnen Hulbert & Berghoff, 300 South Wacker Drive, Suite 3200, Chicago, IL 60606 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

# (54) Title: N, N'-SUBSTTTUTED-1,3-DIAMINO-2-HYDROX YPROPANE DERIVATIVES



(57) Abstract: Disclosed are compounds of the formula (I), wherein the variables R<sub>N</sub>, R<sub>C</sub>, R<sub>1</sub>, R<sub>25</sub>, R<sub>2</sub>, and R<sub>3</sub> are as defined herein. These compounds have activity as inhibitors of betasecretase and are therefore useful in treating a variety of discorders such as Alzheimer's Disease.

N, N'-SUBSTITUTED-1, 3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES

#### BACKGROUND OF THE INVENTION

#### 1. Field of the Invention

10

15

20

25

5 The invention is directed to compounds useful in treatment of Alzheimer's disease and similar diseases.

# 2. Description of the Related Art

Alzheimer's disease (AD) is a progressive degenerative disease of the brain primarily associated with aging. Clinical ation of AD is characterized by loss of memory, cognition, reasoning, judgment, and orientation. As the disease progresses, motor, sensory, and linguistic abilities are also affected until there is global impairment of multiple cognitive functions. These cognitive losses occur gradually, but typically lead to severe impairment and eventual death in the range of four to twelve years.

Alzheimer's disease is characterized by two major pathologic observations in the brain: neurofibrillary tangles and beta amyloid (or neuritic) plaques, comprised predominantly of an aggregate of a peptide fragment know as A beta. Individuals with AD exhibit characteristic beta-amyloid deposits in the brain (beta amyloid plaques) and in cerebral blood vessels (beta amyloid angiopathy) as well as neurofibrillary tangles. Neurofibrillary tangles occur not only in Alzheimer's disease but also in other dementia-inducing disorders. On autopsy, large numbers of these lesions are generally found in areas of the human brain important for memory and cognition.

30 Smaller numbers of these lesions in a more restricted anatomical distribution are found in the brains of most aged humans who do not have clinical AD. Amyloidogenic plaques and vascular amyloid angiopathy also characterize the brains of individuals with Trisomy 21 (Down's Syndrome), Hereditary

Cerebral Hemorrhage with Amyloidosis of the Dutch-Type (HCHWA-D), and other neurogenerative disorders. Beta-amyloid is a defining feature of AD, now believed to be a causative precursor or factor in the development of the disease. Deposition of A beta in areas of the brain responsible for cognitive activities is a major factor in the development of AD. Beta-amyloid plaques are predominantly composed of amyloid beta peptide (A beta, also sometimes designated betaA4). beta peptide is derived by proteolysis of the amyloid precursor 10 protein (APP) and is comprised of 39-42 amino acids. proteases called secretases are involved in the processing of APP.

Cleavage of APP at the N-terminus of the A beta peptide by beta-secretase and at the C-terminus by one or more gamma-secretases constitutes the beta-amyloidogenic pathway, i.e. the pathway by which A beta is formed. Cleavage of APP by alphasecretase produces alpha-sAPP, a secreted form of APP that does not result in beta-amyloid plaque formation. This alternate pathway precludes the formation of A beta peptide.

15

25

30

An aspartyl protease has been identified as the enzyme responsible for processing of APP at the beta-secretase cleavage site. The beta-secretase enzyme has been disclosed using varied nomenclature, including BACE, Asp, and Memapsin.

Several lines of evidence indicate that progressive cerebral deposition of beta-amyloid peptide (A beta) plays a seminal role in the pathogenesis of AD and can precede cognitive symptoms by years or decades. Release of A beta from neuronal cells grown in culture and the presence of A beta in cerebrospinal fluid (CSF) of both normal individuals and AD patients has been demonstrated.

It has been proposed that A beta peptide accumulates as a result of APP processing by beta secretase, thus inhibition of this enzyme's activity is desirable for the treatement of AD. In vivo processing of APP at the beta-secretase cleavage site

is thought to be a rate-limiting step in A beta production, and is thus a therapeutic target for the treatment of AD.

BACE1 knockout mice fail to produce A beta, and a normal phenotype. When crossed with transgenic mice that overexpress APP, the progeny show reduced amounts of A beta in brain extracts as compared with control animals (Luo et. al., 2001 Nature Neuroscience 4:231-232). This evidence further supports the proposal that inhibition of beta-secretase activity and reduction of A beta in the brain provides a therapeutic method for the treatment of AD and other beta amyloid disorders.

At present there are no effective treatments for halting, preventing, or reversing the progression of Alzheimer's disease. Therefore, there is an urgent need for pharmaceutical agents capable of slowing the progression of Alzheimer's disease and/or preventing it in the first place.

10

20

Compounds that are effective inhibitors of beta-secretase, that inhibit beta-secretase-mediated cleavage of APP, that are effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques, are needed for the treatment and prevention of disease characterized by amyloid beta deposits or plaques, such as AD.

# SUMMARY OF INVENTION

In a broad aspect, the invention provides compounds of formula X:

and the pharmaceutically acceptable salts thereof wherein  $R_1 \text{ is } -(CH_2)_{1-2} - S(0)_{0-2} - (C_1 - C_6 \text{ alkyl}) \text{, or}$ 

10

15

20

25

30

 $C_1-C_{10}$  alkyl optionally substituted with 1, 2, or 3 groups independently selected from halogen, -OH, =0, -SH, -C $\equiv$ N, -CF<sub>3</sub>, -C<sub>1</sub>-C<sub>3</sub> alkoxy, amino, mono- or dialkylamino, -N(R)C(O)R'-, -OC(=O)-amino and -OC(=O)-mono- or dialkylamino, or

C<sub>2</sub>-C<sub>6</sub> alkenyl or C<sub>2</sub>-C<sub>6</sub> alkynyl, each of which is optionally
substituted with 1, 2, or 3 groups independently
selected from halogen, -OH, -SH, -C≡N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub>
alkoxy, amino, and mono- or dialkylamino, or

aryl, heteroaryl, heterocyclyl,  $-C_1-C_6$  alkyl-aryl,  $-C_1-C_6$  alkyl-heteroaryl, or  $-C_1-C_6$  alkyl-heterocyclyl, where the ring portions of each are optionally substituted with 1, 2, 3, or 4 groups independently selected from halogen, -OH, -SH,  $-C\equiv N$ ,  $-NR_{105}R'_{105}$ ,  $-CO_2R$ , -N(R)COR', or  $-N(R)SO_2R'$ ,  $-C(=O)-(C_1-C_4)$  alkyl,  $-SO_2$ -amino,  $-SO_2$ -mono or dialkylamino, -C(=O)-amino, -C(=O)-mono or dialkylamino,  $-SO_2-(C_1-C_4)$  alkyl, or

 $C_1\text{--}C_6$  alkoxy optionally substituted with 1, 2, or 3 groups which are independently selected from halogen, or

 $C_3-C_7$  cycloalkyl optionally substituted with 1, 2, or 3 groups independently selected from halogen, - OH, -SH, -C=N, -CF<sub>3</sub>,  $C_1-C_3$  alkoxy, amino, - $C_1-C_6$  alkyl and mono- or dialkylamino, or

 $C_1$ - $C_{10}$  alkyl optionally substituted with 1, 2, or 3 groups independently selected from halogen, -OH,

-SH, -C $\equiv$ N, -CF<sub>3</sub>, -C<sub>1</sub>-C<sub>3</sub> alkoxy, amino, mono- or dialkylamino and -C<sub>1</sub>-C<sub>3</sub> alkyl, or

 $C_2$ - $C_{10}$  alkenyl or  $C_2$ - $C_{10}$  alkynyl each of which is optionally substituted with 1, 2, or 3 groups independently selected from halogen, -OH, -SH, -C=N, -CF<sub>3</sub>,  $C_1$ - $C_3$  alkoxy, amino,  $C_1$ - $C_6$  alkyl and mono- or dialkylamino; and the heterocyclyl group is optionally further substituted with oxo;

where R and R' independently are hydrogen,  $C_1-C_{10}$  alkyl,  $C_1-C_{10}$  alkylaryl or  $C_1-C_{10}$  alkylheteroaryl;

5

15

20

C<sub>6</sub>)alkylamino;

 $R_2$  is hydrogen,  $C_1$ - $C_6$  alkyl optionally substituted with one, two or three substituents independently selected from the group consisting of  $C_1$ - $C_3$  alkyl, halogen hydroxy, -SH, cyano, -CF<sub>3</sub>,  $C_1$ - $C_3$  alkoxy, amino, mono( $C_1$ - $C_6$ ) alkylamino, or di( $C_1$ -

 $R_3$  is selected from the group consisting of hydrogen,  $C_1$ - $C_6$  alkyl optionally substituted with one, two or three substituents independently selected from the group consisting of  $C_1$ - $C_3$  alkyl, halogen hydroxy, -SH, cyano, -CF<sub>3</sub>,  $C_1$ - $C_3$  alkoxy, amino, mono( $C_1$ - $C_6$ ) alkylamino; or di( $C_1$ - $C_6$ ) alkylamino:

or  $R_2$  and  $R_3$  are taken together with the carbon to which they are attached to form a 3 or 4-membered carbocyclic ring;

each  $R_{25}$  is independently selected from the group consisting of hydrogen or  $C_1$ - $C_6$  alkyl;

R<sub>C</sub> is hydrogen,  $-(CR_{245}R_{250})_{0-4}$ -aryl,  $-(CR_{245}R_{250})_{0-4}$ -heteroaryl,  $-(CR_{245}R_{250})_{0-4}$ -heteroaryl,  $-(CR_{245}R_{250})_{0-4}$ -aryl-heteroaryl,  $-(CR_{245}R_{250})_{0-4}$ -aryl-heteroaryl,  $-(CR_{245}R_{250})_{0-4}$ -aryl-heteroaryl,  $-(CR_{245}R_{250})_{0-4}$ -heteroaryl-aryl,  $-(CR_{245}R_{250})_{0-4}$ -heteroaryl-heteroaryl-heteroaryl-heteroaryl-heteroaryl-heteroaryl,  $-(CR_{245}R_{250})_{0-4}$ -heteroaryl-heteroaryl,  $-(CR_{245}R_{250})_{0-4}$ -heterocyclyl-heteroaryl,  $-(CR_{245}R_{250})_{0-4}$ -heterocyclyl-heterocyclyl,  $-(CR_{245}R_{250})_{0-4}$ -heterocyclyl-aryl,  $-(CR_{245}R_{250})_{0-4}$ -heterocyclyl-aryl,  $-(CR_{245}R_{250})_{0-4}$ -heterocyclyl-aryl,  $-(CR_{245}R_{250})_{0-4}$ -heterocyclyl-aryl,  $-(CR_{255})_{2}$ ,  $-(CR_{245})_{2}$ ,  $-(CR_{245})_{$ 

-CH(heteroaryl)<sub>2</sub>, -CH(heterocyclyl)<sub>2</sub>, -CH(aryl) (heteroaryl), -(CH<sub>2</sub>)<sub>0-1</sub>-CH((CH<sub>2</sub>)<sub>0-6</sub>-OH)-(CH<sub>2</sub>)<sub>0-1</sub>aryl, -(CH<sub>2</sub>)<sub>0-1</sub>-CH((CH<sub>2</sub>)<sub>0-6</sub>-OH-(CH<sub>2</sub>)<sub>0-1</sub>-heteroaryl, -CH(-aryl-heteroary1)-CO-O( $C_1$ - $C_4$  alky1), -CH(-CH<sub>2</sub>-OH)-CH(OH)-5  $CH(-O-CH_2-CH_3)_2$ ,  $-(CH_2)_{0-6}-C(=NR_{235})(NR_{235}R_{240})$ , or  $C_1-C_{10}$  alkyl optionally substituted with 1, 2, or 3 groups independently selected from the group consisting of  $-OC = ONR_{235}R_{240}$ ,  $-S(=O)_{0-2}(C_1-C_6)$ alkyl), 10  $-NR_{235}C=ONR_{235}R_{240}$ ,  $-C=ONR_{235}R_{240}$ , and  $-S(=0)_2NR_{235}R_{240}$ , or  $-(CH_2)_{0-3}-(C_3-C_8)$  cycloalkyl wherein the cycloalkyl is optionally substituted with 1, 2, or 3 groups independently selected, from the group consisting of  $R_{205}$ ,  $-CO_2H$ , and  $-CO_2-(C_1-C_4 \text{ alkyl})$ , or cyclopentyl, cyclohexyl, or cycloheptyl ring fused to 15 aryl, heteroaryl, or heterocyclyl wherein one, or three carbons of the cyclopentyl, cyclohexyl, or cycloheptyl is optionally replaced with a heteroatom independently selected from NH,  $NR_{215}$ , O, or  $S(=0)_{0-2}$ , 20 and wherein the cyclopentyl, cyclohexyl, cycloheptyl group can be optionally substituted with one or two groups that are independently  $R_{205}$ , =0,  $-CO-NR_{235}R_{240}$ , or  $-SO_2-(C_1-C_4 \text{ alkyl})$ , or  $C_2-C_{10}$  alkenyl or  $C_2-C_{10}$  alkynyl, each of which 25 optionally substituted with 1, 2, or 3  $R_{205}$  groups, wherein each aryl and heteroaryl is optionally substituted with 1, 2, or 3  $R_{200}$ , and wherein each heterocyclyl is optionally substituted with 1, 2, 3, or 4 R210; R<sub>200</sub> at each occurrence is independently selected from -OH, 30  $-NO_2$ , halogen,  $-CO_2H$ ,  $C\equiv N$ ,  $-(CH_2)_{0-4}-CO-NR_{220}R_{225}$ ,  $-(CH_2)_{0-4}-CO-NR_{220}R_{225}$  $CO-(C_1-C_{12} \text{ alkyl}), -(CH_2)_{0-4}-CO-(C_2-C_{12} \text{ alkenyl}), -(CH_2)_{0-4} CO-(C_2-C_{12} \text{ alkynyl}), -(CH_2)_{0-4}-CO-(C_3-C_7 \text{ cycloalkyl}), -(CH_2)_{0-4}$  $_{4}$ -CO-aryl, -(CH<sub>2</sub>)<sub>0-4</sub>-CO-heteroaryl,- (CH<sub>2</sub>)<sub>0-4</sub>-CO-

heterocyclyl,  $-(CH_2)_{0-4}-CO-O-R_{215}$ ,  $-(CH_2)_{0-4}-SO_2-NR_{220}R_{225}$ , - $(CH_2)_{0-4}-SO-(C_1-C_8 \quad alkyl), \quad -(CH_2)_{0-4}-SO_{2-}(C_1-C_{12} \quad alkyl), \quad R_{215}$ ,  $-(CH_2)_{0-4}-N(H Or R_{215})-CO-N(R_{215})_2$ ,  $-(CH_2)_{0-4}-N-CS-$ 5  $N(R_{215})_2$ ,  $-(CH_2)_{0-4}-N(-H \text{ or } R_{215})-CO-R_{220}$ ,  $-(CH_2)_{0-4}-NR_{220}R_{225}$ ,  $-(CH_2)_{0-4}-O-CO-(C_1-C_6)$ alkyl), -(CH<sub>2</sub>)<sub>0-4</sub>-O-P(O)-(OR<sub>240</sub>)<sub>2</sub>, $-(CH_2)_{0-4}-O-CO-N(R_{215})_2$ ,  $-(CH_2)_{0-4}-O-CS-N(R_{215})_2$ ,  $-(CH_2)_{0-4}-O-CS-N(R_{215})_2$  $(R_{215})$ ,  $-(CH_2)_{0-4}$ -O- $(R_{215})$ -COOH,  $-(CH_2)_{0-4}$ -S- $(R_{215})$ ,  $-(CH_2)_{0-4}$ -O- $(C_1-C_6 \text{ alkyl optionally substituted with 1, 2, 3, or 5 -}$ 10 F),  $C_3-C_7$  cycloalkyl,  $-(CH_2)_{0-4}-N(H \text{ or } R_{215})-SO_2-R_{220}$ ,  $-(CH_2)_{0-4}-N(H \text{ or } R_{215})-SO_2-R_{220}$ 4- C3-C7 cycloalkyl, or  $C_1-C_{10}$  alkyl optionally substituted with 1, 2, or 3  $R_{205}$ groups, or

 $C_2-C_{10}$  alkenyl or  $C_2-C_{10}$  alkynyl, each of which is optionally substituted with 1 or 2  $R_{205}$  groups, wherein

- the aryl and heteroaryl groups at each occurrence are optionally substituted with 1, 2, or 3 groups that are independently  $R_{205},\ R_{210},$  or
- 20  $C_1$ - $C_6$  alkyl substituted with 1, 2, or 3 groups that are independently  $R_{205}$  or  $R_{210}$ , and wherein
  - the heterocyclyl group at each occurrence is optionally substituted with 1, 2, or 3 groups that are independently  $R_{210}$ ;
- 25  $R_{205}$  at each occurrence is independently selected from  $C_1$ - $C_6$  alkyl, halogen, -OH, -O-phenyl, -SH, -C $\equiv$ N, -CF<sub>3</sub>,  $C_1$ - $C_6$  alkoxy, NH<sub>2</sub>, NH( $C_1$ - $C_6$  alkyl) or N-( $C_1$ - $C_6$  alkyl);
- $R_{210}$  at each occurrence is independently selected from halogen,  $C_1\text{--}C_6 \text{ alkoxy, } C_1\text{--}C_6 \text{ haloalkoxy, } -NR_{220}R_{225}, \text{ OH, } C\equiv N, \text{--}CO\text{--}(C_1\text{--}C_4 \text{ alkyl}), } -SO_2\text{--}NR_{235}R_{240}, \text{--}CO\text{--}NR_{235}R_{240}, } -SO_2\text{--}(C_1\text{--}C_4 \text{ alkyl}), } = O, \text{ or }$

 $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl or  $C_3$ - $C_7$  cycloalkyl, each of which is optionally substituted with 1, 2, or 3  $R_{205}$  groups;

 $R_{215}$  at each occurrence is independently selected from  $C_1$ - $C_6$  alkyl,  $-(CH_2)_{0-2}$ -(aryl),  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_3$ - $C_7$  cycloalkyl, and  $-(CH_2)_{0-2}$ -(heteroaryl),  $-(CH_2)_{0-2}$ -(heterocyclyl), wherein

10

- the aryl group at each occurrence is optionally substituted with 1, 2, or 3 groups that are independently  $R_{205}$  or  $R_{210}$ , and wherein
- the heterocyclyl and heteroaryl groups at each occurrence are optionally substituted with 1, 2, or 3  $R_{210}$ ;
- $R_{220}$  and  $R_{225}$  at each occurrence are independently selected from -H,  $-C_3-C_7$  cycloalkyl,  $-(C_1-C_2 \text{ alkyl})-(C_3-C_7 \text{ cycloalkyl})$ ,  $-(C_1-C_6 \text{ alkyl})-O-(C_1-C_3 \text{ alkyl})$ ,  $-C_2-C_6 \text{ alkenyl}$ ,  $-C_2-C_6 \text{ alkynyl}$ ,  $-C_1-C_6 \text{ alkyl}$  chain with one double bond and one triple bond, -aryl, -heteroaryl, and -heterocyclyl, or  $-C_1-C_{10}$  alkyl optionally substituted with -OH,  $-\text{NH}_2$  or halogen, wherein
- 20 the aryl, heterocyclyl and heteroaryl groups at each occurrence are optionally substituted with 1, 2, or 3  $$R_{\rm 270}$$  groups
  - $R_{235}$  and  $R_{240}$  at each occurrence are independently H, or  $C_1\text{--}C_6$  alkyl;
- 25  $R_{245}$  and  $R_{250}$  at each occurrence are independently selected from -H,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkylaryl,  $C_1$ - $C_4$  alkylheteroaryl,  $C_1$ - $C_4$  hydroxyalkyl,  $C_1$ - $C_4$  alkoxy,  $C_1$ - $C_4$  haloalkoxy, -(CH<sub>2</sub>)<sub>0-4</sub>- $C_3$ - $C_7$  cycloalkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl, and phenyl; or
- 30  $R_{245}$  and  $R_{250}$  are taken together with the carbon to which they are attached to form a carbocycle of 3, 4, 5, 6, or 7 carbon atoms, where one carbon atom is optionally replaced by a heteroatom selected from -O-, -S-, -SO<sub>2</sub>-, and -NR<sub>220</sub>-;

R<sub>255</sub> and R<sub>260</sub> at each occurrence are independently selected from -H,  $-(CH_2)_{1-2}-S(O)_{0-2}-(C_1-C_6 \text{ alkyl})$ ,  $-(C_1-C_4 \text{ alkyl})-\text{aryl}$ ,  $-(C_1-C_4 \text{ alkyl})-\text{heteroaryl}$ ,  $-(C_1-C_4 \text{ alkyl})-\text{heterocyclyl}$ , - aryl, -heteroaryl, -heterocyclyl,  $-(CH_2)_{1-4}-R_{265}-(CH_2)_{0-4}-$  aryl,  $-(CH_2)_{1-4}-R_{265}-(CH_2)_{0-4}-\text{heterocyclyl}$ , or

5

15

- $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl or - $(CH_2)_{0-4}$ - $C_3$ - $C_7$  cycloalkyl, each of which is optionally substituted with 1, 2, or 3  $R_{205}$  groups, wherein
- each aryl or phenyl is optionally substituted with 1, 2, or 3 groups that are independently  $R_{205}$ ,  $R_{210}$ , or  $C_1$ - $C_6$  alkyl substituted with 1, 2, or 3 groups that are independently  $R_{205}$  or  $R_{210}$ , and wherein
  - each heterocyclyl is optionally substituted with 1, 2, 3, or 4  $R_{210}$ ;
  - $R_{265}$  at each occurrence is independently -O-, -S- or -N(C1-C6 alky1)-;
  - $R_{270}$  at each occurrence is independently  $R_{205},$  halogen  $C_1-C_6$  alkoxy,  $C_1-C_6$  haloalkoxy,  $NR_{235}R_{240},$  -OH, -C=N, -CO-( $C_1-C_4$  alkyl),  $_{-}SO_2-NR_{235}R_{240},$  -CO-NR\_{235}R\_{240}, -SO\_2-( $C_1-C_4$  alkyl), =0, or
    - $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl or -(CH<sub>2</sub>)<sub>0-4</sub>- $C_3$ - $C_7$  cycloalkyl, each of which is optionally substituted with 1, 2, or 3  $R_{205}$  groups;
- 25  $R_N$  is  $R'_{100}$ ,  $-SO_2R'_{100}$ ,  $-(CRR')_{1-6}R'_{100}$ ,  $-C(=O) (CRR')_{0-6}R_{100}$ ,  $-C(=O) (CRR')_{1-6} C(=O) (CRR')_{1-6} C(=O) (CRR')_{1-6} C(=O) (CRR')_{1-6} C(=O) (CRR')_{1-6} SO_2 R_{100}$  or  $-C(=O) (CRR')_{1-6} NR_{100} R'_{100}$ ;
- R<sub>100</sub> and R'<sub>100</sub> independently re aryl, heteroaryl, -aryl-W-aryl, aryl-W-heteroaryl, -aryl-W-heterocyclyl, -heteroaryl-Waryl, -heteroaryl-W-heteroaryl, -heteroaryl-Wheterocyclyl, -heterocyclyl-W-aryl, -heterocyclyl-Wheteroaryl, -heterocyclyl-W-heterocyclyl, -CH[(CH<sub>2</sub>)<sub>0-2</sub>-0R<sub>150</sub>]-(CH<sub>2</sub>)<sub>0-2</sub>-aryl, -CH[(CH<sub>2</sub>)<sub>0-2</sub>-0-R<sub>150</sub>]-(CH<sub>2</sub>)<sub>0-2</sub>-heterocyclyl

or  $-CH[(CH_2)_{0-2}-O-R_{150}]-(CH_2)_{0-2}$ -heteroaryl, where the ring portions of each are optionally substituted with 1, 2, or 3 groups independently selected from

```
-OR, -NO<sub>2</sub>, halogen, -C\equivN, -OCF<sub>3</sub>, -CF<sub>3</sub>, -(CH<sub>2</sub>)<sub>0-4</sub>-O-
 5
                           P(=O) (OR) (OR'), -(CH<sub>2</sub>)<sub>0-4</sub>-CO-NR<sub>105</sub>R'<sub>105</sub>, <math>-(CH<sub>2</sub>)<sub>0-4</sub>-O-
                           (CH_2)_{0-4}-CONR_{102}R_{102}', -(CH_2)_{0-4}-CO-(C_1-C_{12} alkyl), -(CH_2)_{0-4}
                           _{4}-CO-(C<sub>2</sub>-C<sub>12</sub> alkenyl), -(CH<sub>2</sub>)_{0-4}-CO-(C<sub>2</sub>-C<sub>12</sub> alkynyl),
                           -(CH_2)_{0-4}-CO-(CH_2)_{0-4}(C_3-C_7 \text{ cycloalkyl}), -(CH_2)_{0-4}-R_{110},
                           -(CH_2)_{0-4}-R_{120}, -(CH_2)_{0-4}-R_{130}, -(CH_2)_{0-4}-CO-R_{110}, -(CH_2)_{0-4}-CO-R_{110}
10
                           CO-R_{120}, -(CH_2)_{0-4}-CO-R_{130}, -(CH_2)_{0-4}-CO-R_{140}, -(CH_2)_{0-4}-CO-R_{140}
                           O-R_{150}, -(CH_2)_{0-4}-SO_2-NR_{105}R'_{105}, -(CH_2)_{0-4}-SO_-(C_1-C_8)
                           alkyl), -(CH_2)_{0-4}-SO_{2-}(C_1-C_{12} \text{ alkyl}), -(CH_2)_{0-4}-SO_{2-}
                           (CH_2)_{0-4}-(C_3-C_7 \text{ cycloalkyl}), -(CH_2)_{0-4}-N(R_{150})-CO-O-R_{150},
                           -\left(\text{CH}_{2}\right){_{0-4}}-\text{N}\left(\text{R}_{150}\right)-\text{CO-N}\left(\text{R}_{150}\right){_{2}},\quad-\left(\text{CH}_{2}\right){_{0-4}}-\text{N}\left(\text{R}_{150}\right)-\text{CS-}
15
                           N(R_{150})_2, -(CH_2)_{0-4}-N(R_{150})-CO-R_{105}, -(CH_2)_{0-4}-NR_{105}R'_{105},
                           -(CH_2)_{0-4}-R_{140}, -(CH_2)_{0-4}-O-CO-(C_1-C_6 \text{ alkyl}), -(CH_2)_{0-4}-O-CO-(C_1-C_6 \text{ alkyl})
                           P(O) - (O-R_{110})_2, -(CH_2)_{0-4} - O-CO-N(R_{150})_2, -(CH_2)_{0-4} - O-CS-
                           N(R_{150})_2, -(CH_2)_{0-4}-O-(R_{150}), -(CH_2)_{0-4}-O-R_{150}'-COOH, -
                           (CH_2)_{0-4}-S-(R_{150}), -(CH_2)_{0-4}-N(R_{150})-SO_2-R_{105}, -(CH_2)_{0-4}-
20
                           C_3-C_7 cycloalkyl, (C_2-C_{10}) alkenyl, or (C_2-C_{10}) alkynyl,
                           or
```

 $R_{100}$  is  $C_1$ - $C_{10}$  alkyl optionally substituted with 1, 2, or 3  $R_{115}$  groups, or

 $R_{100}$  is  $-(C_1-C_6 \text{ alkyl})-O-C_1-C_6 \text{ alkyl})$  or  $-(C_1-C_6 \text{ alkyl})-S-(C_1-C_6 \text{ alkyl})$ , each of which is optionally substituted with 1, 2, or 3  $R_{115}$  groups, or

 $R_{100}$  is  $C_3$ - $C_8$  cycloalkyl optionally substituted with 1, 2, or 3  $R_{115}$  groups;

 $\mbox{W is } -(\mbox{CH}_2)_{\,0-4}-, \ -\mbox{O-}, \ -\mbox{S(O)}_{\,0-2}-, \ -\mbox{N(R}_{135})-, \ -\mbox{CR(OH)}- \ \mbox{or } -\mbox{C(O)}-; \label{eq:chi2}$ 

30  $R_{102}$  and  $R_{102}$ ' independently are hydrogen, or

25

 $C_1-C_{10}$  alkyl optionally substituted with 1, 2, or 3 groups that are independently halogen, aryl or  $-R_{110}$ ;

 $R_{105}$  and  $R'_{105}$  independently re -H,  $-R_{110}$ ,  $-R_{120}$ ,  $C_3$ - $C_7$  cycloalkyl,  $-(C_1-C_2 \text{ alkyl})-(C_3-C_7 \text{ cycloalkyl}), -(C_1-C_6 \text{ alkyl})-O-(C_1-C_3$ 

alkyl),  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl, or  $C_1$ - $C_6$  alkyl chain with one double bond and one triple bond, or  $C_1$ - $C_6$  alkyl optionally substituted with -OH or -NH<sub>2</sub>; or,  $C_1$ - $C_6$  alkyl optionally substituted with 1, 2, or 3 groups independently selected from halogen, or

 $R_{105}$  and  $R'_{105}$  together with the atom to which they are attached form a 3 to 7 membered carbocylic ring, where one member is optionally a heteratom selected from -O-, -S(0) $_{0-2}$ -, - N( $R_{135}$ )-, the ring being optionally substituted with 1, 2 or three  $R_{140}$  groups;

5

10

25

- R<sub>115</sub> at each occurrence is independently halogen, -OH, -CO<sub>2</sub>R<sub>102</sub>, -C<sub>1</sub>-C<sub>6</sub> thioalkoxy, -CO<sub>2</sub>-phenyl, -NR<sub>105</sub>R'<sub>135</sub>, -SO<sub>2</sub>-(C<sub>1</sub>-C<sub>8</sub> alkyl), -C(=O)R<sub>180</sub>, R<sub>180</sub>, -CONR<sub>105</sub>R'<sub>105</sub>, -SO<sub>2</sub>NR<sub>105</sub>R'<sub>105</sub>, -NH-CO-(C<sub>1</sub>-C<sub>6</sub> alkyl), -NH-C(=O)-OH, -NH-C(=O)-OR, -NH-C(=O)-O-phenyl, -O-C(=O)-(C<sub>1</sub>-C<sub>6</sub> alkyl), -O-C(=O)-amino -O-C(=O)
- phenyl,  $-O-C(=O)-(C_1-C_6 \text{ alkyl})$ , -O-C(=O)-amino, -O-C(=O)-mono- or dialkylamino, -O-C(=O)-phenyl,  $-O-(C_1-C_6 \text{ alkyl})-CO_2H$ ,  $-NH-SO_2-(C_1-C_6 \text{ alkyl})$ ,  $C_1-C_6 \text{ alkoxy}$  or  $C_1-C_6$  haloalkoxy;
- R<sub>135</sub> is C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl,  $-(CH_2)_{0-2}-(aryl)$ ,  $-(CH_2)_{0-2}-(heteroaryl)$ , or  $-(CH_2)_{0-2}-(heterocyclyl)$ ;
  - R<sub>140</sub> is heterocyclyl optionally substituted with 1, 2, 3, or 4 groups independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, halogen, hydroxy, cyano, nitro, amino, mono(C<sub>1</sub>-C<sub>6</sub>)alkylamino, di(C<sub>1</sub>-C<sub>6</sub>)alkylamino, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, C<sub>1</sub>-C<sub>6</sub> haloalkoxy, amino(C<sub>1</sub>-
    - $C_6$ ) alkyl, mono  $(C_1-C_6)$  alkylamino  $(C_1-C_6)$  alkyl, di  $(C_1-C_6)$  alkylamino  $(C_1-C_6)$  alkyl, and =0;
- $R_{150}$  is hydrogen,  $C_3$ - $C_7$  cycloalkyl,  $-(C_1$ - $C_2$  alkyl)- $(C_3$ - $C_7$  cycloalkyl),  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_1$ - $C_6$  alkyl with one double bond and one triple bond,  $-R_{110}$ ,  $-R_{120}$ , or  $C_1$ - $C_6$  alkyl optionally substituted with 1, 2, 3, or 4 groups independently selected from -OH, -NH<sub>2</sub>,  $C_1$ - $C_3$

alkoxy, R<sub>110</sub>, and halogen;

 $R_{150}$ ' is  $C_3$ - $C_7$  cycloalkyl,  $-(C_1$ - $C_3$  alkyl)- $(C_3$ - $C_7$  cycloalkyl),  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_1$ - $C_6$  alkyl with one double bond and one triple bond,  $-R_{110}$ ,  $-R_{120}$ , or

 $C_1$ - $C_6$  alkyl optionally substituted with 1, 2, 3, or 4 groups independently selected from -OH, -NH<sub>2</sub>,  $C_1$ - $C_3$  alkoxy,  $R_{110}$ , and halogen;

5

25

- $R_{180}$  is selected from morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl, homomorpholinyl, homothiomorpholinyl, homothiomorpholinyl S-oxide, homothiomorpholinyl 10 dioxide, pyrrolinyl and pyrrolidinyl, each of which is optionally substituted with 1, 2, 3, or 4 independently selected from  $C_1-C_6$  alkyl,  $C_1-C_6$  alkoxy, halogen, hydroxy, cyano, nitro, amino, mono ( $C_1$ - $C_6$ ) alkylamino, di  $(C_1-C_6)$  alkylamino,  $C_2-C_6$  alkenyl,  $C_2-C_6$ 15 alkynyl,  $C_1-C_6$  haloalkyl,  $C_1-C_6$  haloalkoxy,  $amino(C_1$ mono  $(C_1-C_6)$  alkylamino  $(C_1-C_6)$  alkyl,  $C_6$ ) alkyl,  $di(C_1 C_6$ ) alkylamino ( $C_1$ - $C_6$ ) alkyl, and =0;
  - $R_{110}$  is aryl optionally substituted with 1 or 2  $R_{125}$  groups;
- $R_{125}$  at each occurrence is independently halogen, amino, mono-or dialkylamino, -OH, -C $\equiv$ N, -SO<sub>2</sub>-NH<sub>2</sub>, -SO<sub>2</sub>-NH-C<sub>1</sub>-C<sub>6</sub> alkyl, -SO<sub>2</sub>-N(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>2</sub>, -SO<sub>2</sub>-(C<sub>1</sub>-C<sub>4</sub> alkyl), -CO-NH<sub>2</sub>, -CO-NH-C<sub>1</sub>-

 $C_6$  alkyl, or  $-CO-N(C_1-C_6$  alkyl)<sub>2</sub>, or

- $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl or  $C_2$ - $C_6$  alkynyl, each of which is optionally substituted with 1, 2, or 3 groups that are independently selected from  $C_1$ - $C_3$  alkyl, halogen, -OH, -SH, -C $\equiv$ N, -CF $_3$ ,  $C_1$ - $C_3$  alkoxy, amino, and monoand dialkylamino, or
- $C_1\text{--}C_6$  alkoxy optionally substituted with one, two or three of halogen;
- $R_{120}$  is heteroaryl, which is optionally substituted with 1 or 2  $R_{125}$  groups; and
  - $R_{130}$  is heterocyclyl optionally substituted with 1 or 2  $R_{125}$  groups.

In another broad aspect, the invention provides compounds of Formula X where  $\ensuremath{\mathtt{R}}_1$  is:

- (I)  $C_1$ - $C_6$  alkyl, optionally substituted with one, two or three substituents selected from the group consisting of  $C_1$ - $C_3$  alkyl,  $C_1$ - $C_7$  alkyl (optionally substituted with  $C_1$ - $C_3$  alkyl and  $C_1$ - $C_3$  alkoxy), -F, -Cl, -Br, -I, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>,  $C_1$ - $C_3$  alkoxy, -NR<sub>1-a</sub>R<sub>1-b</sub>, and -OC=O-NR<sub>1-a</sub>R<sub>1-b</sub>, where R<sub>1-a</sub> and R<sub>1-b</sub> are independently at each occurence-H or  $C_1$ - $C_6$  alkyl,
- 10 (II)  $-CH_2-S(O)_{0-2}-(C_1-C_6 \text{ alkyl})$ ,

20

- (III)  $-CH_2-CH_2-S(O)_{0-2}-(C_1-C_6 \text{ alkyl})$ ,
- (IV)  $C_2$ - $C_6$  alkenyl with one or two double bonds, optionally substituted with one, two or three substituents selected from the group consisting of -F, -Cl, -OH, -SH, -C=N,
- 15 -CF3,  $C_1$ - $C_3$  alkoxy, -NR $_{1-a}$ R $_{1-b}$  where R $_{1-a}$  and R $_{1-b}$  are -H or  $C_1$ - $C_6$  alkyl,
  - (V)  $C_2$ - $C_6$  alkynyl with one or two triple bonds, optionally substituted with one, two or three substituents selected from the group consisting of -F, -Cl, -OH, -SH, -C $\equiv$ N, -CF $_3$ ,  $C_1$ - $C_3$  alkoxy, -NR $_{1-a}$ R $_{1-b}$  where R $_{1-a}$  and R $_{1-b}$  are -H or  $C_1$ - $C_6$  alkyl,
  - $({\rm VI})$  - $({\rm CH_2})_{\rm n1}$ - $({\rm R_{1-aryl}})$  where  ${\rm n_1}$  is zero or one and where  ${\rm R_{1-aryl}}$  is phenyl, naphthyl, indanyl, indenyl, dihydronaphthayl, or tetralinyl each of which is optionally substituted with one, two, three, four, or five of the following substituents on the aryl ring:
  - (A)  $C_1$ - $C_6$  alkyl optionally substituted with one, two or three substituents selected from the group consisting of  $C_1$ - $C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -NR<sub>1-a</sub>R<sub>1-b</sub>, -C $\equiv$ N, -CF<sub>3</sub>, and  $C_1$ - $C_3$  alkoxy,
- 30 (B)  $C_2$ - $C_6$  alkenyl optionally substituted with one, two or three substituents selected from the group consisting of -F, -Cl, -OH, -SH, -C $\equiv$ N, -CF $_3$ ,  $C_1$ - $C_3$  alkoxy, and -NR $_{1-a}$ R $_{1-b}$ ,

(C)  $C_2$ - $C_6$  optionally substituted with one, two or three substituents selected from the group consisting of -F, -C1, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>,  $C_1$ - $C_3$  alkoxy, and -NR<sub>1-a</sub>R<sub>1-b</sub>,

(D) -F, Cl, -Br and -I,

(E)  $-C_1-C_6$  haloalkoxy

(F)  $-C_1-C_6$  alkoxy

(G)  $-NR_{N-2}R_{N-3}$ ,

(H) -OH,

5

15

(I) -C≡N,

10 (J)  $C_3-C_7$  cycloalkyl, optionally substituted with one, two or three substituents independently selected from the group consisting of -F, -Cl, -OH, -SH, -C $\equiv$ N, -CF $_3$ , C $_1$ -C $_3$  alkoxy, and -NR $_{1-a}$ R $_{1-b}$ ,

(K)  $-CO-(C_1-C_4 \text{ alkyl})$ ,

(L)  $-SO_2-NR_{1-a}R_{1-b}$ ,

(M)  $-CO-NR_{1-a}R_{1-b}$ ,

(N)  $-SO_2 - (C_1 - C_4 \text{ alkyl})$ ,

 $(VII) - (CH_2)_{n1} - (R_{1-heteroary1})$  where  $R_{1-heteroary1}$  is selected from the group consisting of pyridinyl, pyrimidinyl, quinolinyl, 20 benzothienyl, indolyl, indolinyl, pryidazinyl, pyrazinyl, isoindoly1, quinazolinyl, quinoxalinyl, isoquinolyl, phthalazinyl, imidazolyl, isoxazolyl, pyrazolyl, oxazolyl, benzothiazolyl, thiazolyl, indolizinyl, indazolyl, benzimidazolyl, benzofuranyl, furanyl, thienyl, pyrrolyl, 25 oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, imidazopyridinyl, oxazolopyridinyl, isothiazolyl, naphthyridinyl, cinnolinyl, carbazolyl, beta-carbolinyl, isochromanyl, chromanyl, tetrahydroisoquinolinyl, isoindolinyl, isobenzotetrahydrofuranyl, isobenzotetrahydrothienyl, 30 isobenzothienyl, benzoxazolyl, pyridopyridinyl, benzotetrahydrofuranyl, benzotetrahydrothienyl, purinyl, benzodioxolyl, triazinyl, phenoxazinyl, phenothiazinyl, pteridinyl, benzothiazolyl, imidazopyridinyl, imidazothiazolyl, dihydrobenzisoxazinyl, benzisoxazinyl, benzoxazinyl,

dihydrobenzisothiazinyl, benzopyranyl, benzothiopyranyl, coumarinyl, isocoumarinyl, chromonyl, chromonyl, tetrahydroquinolinyl, dihydroquinolinyl, dihydroquinolinonyl, dihydrocoumarinyl,

- dihydroisocoumarinyl, 5 isoindolinonyl, benzodioxanyl, benzoxazolinonyl, pyridinyl-N-oxide, pyrrolyl N-oxide, pyrimidinyl N-oxide, pyridazinyl N-oxide, pyrazinyl N-oxide, quinolinyl N-oxide, indolyl N-oxide, indolinyl N-oxide, isoquinolyl N-oxide, quinazolinyl N-oxide, quinoxalinyl Noxide, phthalazinyl N-oxide, imidazolyl N-oxide, isoxazolyl N-10 oxide, oxazolyl N-oxide, thiazolyl N-oxide, indolizinyl Noxide, indazolyl N-oxide, benzothiazolyl N-oxide, benzimidazolyl N-oxide, pyrrolyl N-oxide, oxadiazolyl N-oxide, thiadiazolyl N-oxide, triazolyl N-oxide, tetrazolyl N-oxide,
- 15 benzothiopyranyl S-oxide, and benzothiopyranyl S,S-dioxide,

where the  $R_{1\text{-heteroary1}}$  group is bonded to  $-(CH_2)_{n1}$  by any ring atom of the parent  $R_{N\text{-heteroary1}}$  group substituted by hydrogen such that the new bond to the  $R_{1\text{-heteroary1}}$  group replaces the hydrogen atom and its bond, where heteroary1 is optionally substituted with one, two, three, four, or five of:

- (1)  $C_1$ - $C_6$  alkyl optionally substituted with one, two or three substituents selected from the group consisting of  $C_1$ - $C_3$  alkyl, -F, -Cl, -Br, -I, -OH,
- -SH, -NR<sub>1-a</sub>R<sub>1-b</sub>, -C $\equiv$ N, -CF<sub>3</sub>, and C<sub>1</sub>-C<sub>3</sub> alkoxy,

- (2)  $C_2$ - $C_6$  alkenyl with one or two double bonds, optionally substituted with one, two or three substituents selected from the group consisting of -F, -Cl, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>,  $C_1$ - $C_3$  alkoxy, and -NR<sub>1-a</sub>R<sub>1-b</sub>,
- (3)  $C_2-C_6$  alkynyl with one or two triple bonds, optionally substituted with one, two or three substituents selected from the group consisting of -F, -Cl, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>,  $C_1-C_3$  alkoxy, and -NR<sub>1-a</sub>R<sub>1-b</sub>,
  - (4) -F, -C1, -Br and -I,
  - (5)  $-C_1-C_6$  haloalkoxy,

- (6)  $-C_1-C_6$  alkoxy
- $(7) -NR_{N-2}R_{N-3}$ ,
- (8) OH,
- (9) -C≡N,
- 5 (10)  $C_3-C_7$  cycloalkyl, optionally substituted with one, two or three substituents independently selected from the group consisting of -F, -Cl, -OH, -SH, -C $\equiv$ N, -CF $_3$ , C $_1$ -C $_3$  alkoxy, and -NR $_{1-a}$ R $_{1-b}$ ,
  - (11)  $-CO-(C_1-C_4 \text{ alkyl})$ ,
- 10 (12)  $-SO_2-NR_{1-a}R_{1-b}$ ,
  - (13)  $-CO-NR_{1-a}R_{1-b}$ ,
  - (14)  $-SO_2-(C_1-C_4 \text{ alkyl})$ , with the proviso that when  $n_1$  is zero  $R_{1\text{-heteroaryl}}$  is not bonded to the carbon chain by nitrogen,
- (VIII) -(CH2) $_{n1}$ -(R1-heterocycle) where  $n_1$  is as defined above 15 and  $R_{1-\text{heterocycle}}$  is selected from the group consisting of thiomorpholinyl morpholinyl, thiomorpholinyl, thiomorpholinyl S,S-dioxide, piperazinyl, homopiperazinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl, piperidinyl, 20 tetrahydrofuranyl, tetrahydrothienyl, homopiperidinyl, homomorpholinyl, homothiomorpholinyl, homothiomorpholinyl S,Sdioxide, oxazolidinonyl, dihydropyrazolyl, dihydropyrrolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrazinyl, dihydropyranyl, tetrahydrothienyl dihydrofuryl, S-oxide, S,S-dioxide, homothiomorpholinyl 25 tetrahydrothienyl S-oxide, dithianyl, dihydrofuranyl, pyrrolidinonyl, pyranyl, imidazolidinonyl, imidazolidinondionyl, wherein each of the above is optionally fused to a benzene, pyridine, or pyrimidine ring, and
- where the  $R_{1-heterocycle}$  group is bonded by any atom of the parent  $R_{1-heterocycle}$  group substituted by hydrogen such that the new bond to the  $R_{1-heterocycle}$  group replaces the hydrogen atom and its bond, where heterocycle is optionally substituted with one, two, three or four:

(1)  $C_1$ - $C_6$  alkyl optionally substituted with one, two or three substituents independently selected from the group consisting of  $C_1$ - $C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -NR<sub>1-a</sub>R<sub>1-b</sub>, -C=N, -CF<sub>3</sub>, and  $C_1$ - $C_3$  alkoxy,

- 5 (2)  $C_2$ - $C_6$  alkenyl optionally substituted with one, two or three substituents selected from the group consisting of -F, -Cl, -OH, -SH, -C $\equiv$ N, -CF $_3$ ,  $C_1$ - $C_3$  alkoxy, -NR $_{1-a}$ R $_{1-b}$ ,
- (3)  $C_2$ - $C_6$  alkynyl optionally substituted with one, two or three substituents independently selected from the group consisting of -F, -Cl, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, and -NR<sub>1-a</sub>R<sub>1-b</sub>,
  - (4) -F, -Cl, -Br and -I,
  - (5)  $C_1-C_6$  alkoxy,
  - (6) -C<sub>1</sub>-C<sub>6</sub> haloalkoxy,
- 15 (7)  $-NR_{N-2}R_{N-3}$ ,
  - (8) -OH,
  - (9) -C≡N,
- (10)  $C_3$ - $C_7$  cycloalkyl, optionally substituted with one, two or three substituents independently selected from the group consisting of -F, -Cl, -OH, -SH
  - -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, and -NR<sub>1-a</sub>R<sub>1-b</sub>,
    - (11)  $-CO-(C_1-C_4 \text{ alkyl})$ ,
    - (12)  $-SO_2-NR_{1-a}R_{1-b}$ ,
    - (13)  $-CO-NR_{1-a}R_{1-b}$ ,
- 25  $(14) -SO_2 (C_1 C_4 \text{ alkyl}),$ 
  - (15) =0, with the proviso that when  $n_1$  is zero  $R_{1-}$  heterocycle is not bonded to the carbon chain by nitrogen; where  $R_2$  is selected from the group consisting of:
    - (I)-H,
- 30 (II)  $C_1-C_6$  alkyl, optionally substituted with one, two or three substituents independently selected from the group consisting of  $C_1-C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>,  $C_1-C_3$  alkoxy, and -NR<sub>1-a</sub>R<sub>1-b</sub>,

(III) -(CH<sub>2</sub>)<sub>0-4</sub>-R<sub>30</sub> where R<sub>30</sub> is R<sub>1-aryl</sub>, R<sub>1-heteroaryl</sub>, or R<sub>1-heterocycle</sub>

- (IV)  $C_2$ - $C_6$  alkenyl with one or two double bonds, optionally substituted with one, two or three substituents independently selected from the group consisting of
- -F, -C1, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, and -NR<sub>1-a</sub>R<sub>1-b</sub>,
- (V)  $C_2$ - $C_6$  alkynyl optionally substituted with one, two or three substituents independently selected from the group consisting of -F, -Cl, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, and -NR<sub>1-a</sub>R<sub>1-b</sub>,
- (VI)  $-(CH_2)_{0-4}-C_3-C_7$  cycloalkyl, optionally substituted with one, two or three substituents independently selected from the group consisting of -F, -Cl, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, and -NR<sub>1-a</sub>R<sub>1-b</sub>,
- 15 where R3 is selected from the group consisting of:

(I)-H,

5

10

- (II)  $C_1$ - $C_6$  alkyl, optionally substituted with one, two or three substituents selected from the group consisting of  $C_1$ - $C_3$  alkyl, -F, -Cl, -Br, -I, -OH,
- 20 -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, and -NR<sub>1-a</sub>R<sub>1-b</sub>,
  - (III)  $-(CH_2)_{0-4}-R_{30}$ ,
  - (IV)  $C_2-C_6$  alkenyl,
  - (V)  $C_2-C_6$  alkynyl,

or  $R_2$  and  $R_3$  are taken together with the carbon to which they are attached to form a carbocycle of three, four, five, six,

30 and seven carbon atoms, optionally where one carbon atom is replaced by a heteroatom selected from the group consisting of -O-, -S-,  $-SO_2-$ ,  $-NR_{N-2}-$ ;

 $R_N$  is:

(I)  $R_{N-1}\!-\!X_N\!-\!$  where  $X_N$  is selected from the group consisting of:

- (A) -CO-,
- (B)  $-SO_{2}-$ ,
- 5 (C)  $-(CR'R'')_{1-6}$  wherein

 $\mbox{\sc R'}$  and  $\mbox{\sc R''}$  at each occurrence are the same or different and are -H or  $\mbox{\sc C}_1-\mbox{\sc C}_4$  alkyl,

- (D) -CO-(CR'R")  $_{1\text{-}6}\text{--}X_{N\text{-}1}$  wherein  $X_{N\text{-}1}$  is selected from the group consisting of -O-, -S- and -NR'-,
- 10 (E) a single bond, and
  - (F) -CO-(CR'R")<sub>1-6</sub>-

where  $\ensuremath{R_{N\text{--}1}}$  is selected from the group consisting of:

- (A)  $R_{N-aryl}$  wherein  $R_{N-aryl}$  at each occurrence is independently phenyl; naphthyl; tetralinyl; indanyl; indenyl;
- dihydronaphthyl; or 6,7,8,9-tetrahydro-5H-benzo[a]cycloheptenyl; each of which is optionally substituted with 1, 2, or 3 groups that at each occurrence are independently:
- (1)  $C_1$ - $C_6$  alkyl, optionally substituted with one, two or three substituents selected from the group consisting of  $C_1$ - $C_3$  alkyl, -F, -Cl, -Br, -I,

-OH, -SH, -C $\equiv$ N, -CF $_3$ , C $_1$ -C $_3$  alkoxy, and -NR $_{1-a}$ R $_{1-b}$ , wherein R $_{1-a}$  and R $_{1-b}$  at each occurrence are independently H or C $_1$ -C $_6$  alkyl,

- (2) -OH,
- 25  $(3) -NO_2$ ,
  - (4) -F, -Cl, -Br, -I,
  - (5) -CO<sub>2</sub>H,
  - (6) -C≡N,
- (7)  $-(CH_2)_{0-4}-CO-NR_{N-2}R_{N-3}$  wherein at each occurence  $R_{N-2}$  and  $R_{N-3}$  are the same or different and are selected from the group consisting of:
  - (a) -H,
  - (b)  $-C_1-C_8$  alkyl optionally substituted with one substituent selected from the group consisting of:

- (i) -OH,
- (ii)  $-NH_2$ ,
- (iii) phenyl,

-C<sub>1</sub>-C<sub>8</sub> alkyl optionally substituted with 1, 2, or 3 groups that are independently -F, -C1, -Br, or -I,

- (d)  $-C_3-C_8$  cycloalkyl,
- (e)  $-(C_1-C_2 \text{ alkyl})-(C_3-C_8 \text{ cycloalkyl})$ ,
- (f)  $-(C_1-C_6 \text{ alkyl})-O-(C_1-C_3 \text{ alkyl})$ ,
- (g)  $-C_2-C_6$  alkenyl,
- (h)  $-C_2-C_6$  alkynyl,
- (i) -C₁-C6 alkyl chain with one double bond and one triple bond,
  - $(j) -R_{1-aryl}$
  - (k) -R<sub>1-heteroaryl</sub>,

10

15

25

(1)  $-R_{1-heterocyle}$ , or

(m)  $R_{N-2}$ ,  $R_{N-3}$  and the nitrogen to which they are attached form a 5, 6, or 7 membered heterocycloalkyl or heteroaryl group, wherein said heterocycloalkyl or heteroaryl 20 group is optionally fused to a benzene, pyridine, or pyrimidine ring, and said groups are unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that at each occurrence are independently  $C_1-C_6$  alkyl,  $C_1-C_6$  alkoxy, halogen, halo  $C_1-C_6$  alkyl, halo  $C_1-C_6$ alkoxy, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, NH( $C_1$ - $C_6$  alkyl), N( $C_1$ - $C_6$  alkyl)( $C_1$ - $C_6$ alkyl), -OH,  $-C(O)NH_2$ ,  $-C(O)NH(C_1-C_6 alkyl)$ ,  $-C(O)N(C_1-C_6)$ alkyl)( $C_1$ - $C_6$  alkyl),  $C_1$ - $C_6$  alkoxy  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  thioalkoxy, and  $C_1$ - $C_6$  thioalkoxy  $C_1$ - $C_6$  alkyl;

(B)  $-R_{N-heteroaryl}$  where  $R_{N-heteroaryl}$  is selected from the group consisting of pyridinyl, pyrimidinyl, quinolinyl, 30 benzothienyl, indolyl, indolinyl, pryidazinyl, pyrazinyl, isoindolyl, quinazolinyl, quinoxalinyl, isoquinolyl, phthalazinyl, imidazolyl, isoxazolyl, pyrazolyl, oxazolyl, thiazolyl, indolizinyl, indazolyl, benzisothiazolyl, benzimidazolyl, benzofuranyl, furanyl, thienyl, pyrrolyl,

oxadiazolyl, thiadiazoly1, triazolyl, tetrazolyl, oxazolopyridinyl, imidazopyridinyl, isothiazolyl, naphthyridinyl, cinnolinyl, carbazolyl, beta-carbolinyl, isochromanyl, chromanyl, tetrahydroisoquinolinyl, isoindolinyl, isobenzotetrahydrofuranyl, 5 isobenzotetrahydrothienyl, isobenzothienyl, benzoxazolyl, pyridopyridinyl, benzotetrahydrofuranyl, benzotetrahydrothienyl, purinyl, benzodioxolyl, triazinyl, henoxazinyl, phenothiazinyl, pteridinyl, benzothiazolyl, imidazothiazolyl, 10 dihydrobenzisoxazinyl, benzisoxazinyl, benzoxazinyl, dihydrobenzisothiazinyl, benzopyranyl, benzothiopyranyl, coumarinyl, isocoumarinyl, chromonyl, chromanonyl, tetrahydroquinolinyl, dihydroquinolinyl, dihydroquinolinonyl, dihydroisoquinolinonyl, dihydrocoumarinyl, dihydroisocoumarinyl, 15 isoindolinonyl, benzodioxanyl, benzoxazolinonyl, pyridinyl-N-oxide, pyrrolyl N-oxide, pyrimidinyl N-oxide, pyridazinyl N-oxide, pyrazinyl N-oxide, quinolinyl N-oxide, indolyl N-oxide, indolinyl N-oxide, isoquinolyl N-oxide, quinazolinyl N-oxide, quinoxalinyl Noxide, phthalazinyl N-oxide, imidazolyl N-oxide, isoxazolyl N-20 oxide, oxazolyl N-oxide, thiazolyl N-oxide, indolizinyl Noxide, indazolyl N-oxide, benzothiazolyl N-oxide, benzimidazolyl N-oxide, pyrrolyl N-oxide, oxadiazolyl N-oxide, thiadiazolyl N-oxide, triazolyl N-oxide, tetrazolyl N-oxide, benzothiopyranyl S-oxide, benzothiopyranyl 25 S,S-dioxide, imidazopyrazolyl, quinazolinonyl, pyrazopyridyl, benzooxadiazolyl, dihydropyrimidinonyl, dihydrobenzfuranonyl, where each of the above is optionally fused to a benzene, pyridine, or pyrimidine ring,

where the  $R_{N-heteroaryl}$  group is bonded by any atom of the parent  $R_{N-heteroaryl}$  group substituted by hydrogen such that the new bond to the  $R_{N-heteroaryl}$  group replaces the hydrogen atom and its bond, where heteroaryl is optionally substituted with one, two, three, or four of:

```
(1) C_1-C_6 alkyl, optionally substituted with one, two or three substituents independently selected from the group consisting of C_1-C_3 alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C\equivN, -CF_3, C_1-C_3 alkoxy, and -NR_{1-a}R_{1-b},
```

```
5
                                     (2) -OH,
                                     (3) -NO<sub>2</sub>,
                                     (4) -F, -Cl, -Br, -I,
                                     (5) -CO<sub>2</sub>H,
                                     (6) -C≡N,
10
                                     (7) -(CH_2)_{0-4}-CO-NR_{N-2}R_{N-3},
                                     (8) -(CH_2)_{0-4}-CO-(C_1-C_{12} \text{ alkyl}),
                                     (9) - (CH<sub>2</sub>)<sub>0-4</sub>-CO-(C<sub>2</sub>-C<sub>12</sub> alkeny1),
                                     (10) -(CH_2)_{0-4}-CO-(C_2-C_{12} \text{ alkynyl}),
                                     (11) - (CH<sub>2</sub>)<sub>0-4</sub>-CO-(C<sub>3</sub>-C<sub>8</sub> cycloalky1),
15
                                     (12) -(CH_2)_{0-4}-CO-R_{1-aryl},
                                     (13) -(CH_2)_{0-4}-CO-R_{1-heteroaryl},
                                     (14) -(CH_2)_{0-4}-CO-R_{1-heterocycle},
                                     (15) -(CH_2)_{0-4}-CO-R_{N-4}
                                     (16) -(CH_2)_{0-4}-CO_2-R_{N-5}
20
                                     (17) -(CH_2)_{0-4}-SO_2-NR_{N-2}R_{N-3},
                                     (18) -(CH_2)_{0-4}-SO-(aryl C_1-C_8 alkyl),
                                     (19) -(CH_2)_{0-4}-SO_{2-}(C_1-C_{12} \text{ alkyl}),
                                     (20) - (CH<sub>2</sub>)<sub>0-4</sub>-SO<sub>2</sub>-(C<sub>3</sub>-C<sub>8</sub> cycloalkyl),
                                     (21) -(CH_2)_{0-4}-N(H \text{ or } R_{N-5})-CO-O-R_{N-5},
25
                                     (22) -(CH_2)_{0-4}-N(H \text{ or } R_{N-5})-CO-N(R_{N-5})_2,
                                     (23) -(CH_2)_{0-4}-N-CS-N(R_{N-5})_2,
                                     (24) - (CH<sub>2</sub>)<sub>0-4</sub>-N(-H or R<sub>N-5</sub>)-CO-R<sub>N-2</sub>,
                                     (25) - (CH<sub>2</sub>)<sub>0-4</sub> - NR<sub>N-2</sub>R<sub>N-3</sub>,
                                     (26) - (CH<sub>2</sub>)<sub>0-4</sub> - R<sub>N-4</sub>,
30
                                     (27) - (CH<sub>2</sub>)<sub>0-4</sub>-O-CO-(C<sub>1</sub>-C<sub>6</sub> alkyl),
                                     (28) - (CH<sub>2</sub>)<sub>0-4</sub> - O - P(O) - (OR<sub>100</sub>)<sub>2</sub>,
                                     (29) -(CH_2)_{0-4}-O-CO-N(R_{N-5})_2,
                                     (30) -(CH_2)_{0-4}-O-CS-N(R_{N-5})_{2}
```

(31) - (CH<sub>2</sub>)<sub>0-4</sub> - O - (R<sub>N-5</sub>),

```
(32) -(CH_2)_{0-4}-O-(R_{N-5})-COOH,
```

(33) 
$$-(CH_2)_{0-4}-S-(R_{N-5})$$
,

(34)  $-(CH_2)_{0-4}-O-(C_1-C_6)$  alkyl optionally substituted with one, two, three, four, or five of -F),

5 (35) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,

(36)  $C_2$ - $C_6$  alkenyl optionally substituted with  $C_1$ - $C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C $\equiv$ N, -CF $_3$ ,  $C_1$ - $C_3$  alkoxy, or -NR $_1$ -aR $_1$ -b,

(37)  $C_2$ - $C_6$  alkynyl optionally substituted with 10  $C_1$ - $C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C $\equiv$ N, -CF $_3$ ,  $C_1$ - $C_3$  alkoxy, or -NR $_{1-a}$ R $_{1-b}$ ,

(38) 
$$-(CH_2)_{0-4}-N(-H \text{ or } R_{N-5})-SO_2-R_{N-2}$$
,

(39) 
$$-(CH_2)_{1-4}-C_3-C_8$$
 cycloalkyl,

(C)  $R_{N-aryl}-W-R_{N-aryl}$ ,

15 (D)  $R_{N-aryl}-W-R_{N-heteroaryl}$ ,

(E)  $R_{N-aryl}-W-R_{1-heterocycle}$ ,

(F)  $R_{N-heteroaryl}-W-R_{N-aryl}$ ,

(G)  $R_{N-heteroaryl}-W-R_{N-heteroaryl}$ ,

(H) R<sub>N-heteroaryl</sub>-W-R<sub>1-heterocycle</sub>,

20 (I)  $R_{N-heterocycle}-W-R_{N-aryl}$ ,

25

(J) R<sub>N-heterocycle</sub>-W-R<sub>N-heteroaryl</sub>,

(K)  $R_{N-heterocycle}-W-R_{1-heterocycle}$ ,

where W is

(1)  $-(CH_2)_{1-4}-$ ,

(2) -0-,

 $(3) -S(0)_{0-2}$ 

(4)  $-N(R_{N-5})-$ ,

(5) -CO-; or

(6) a bond;

30 (II)  $-CO-(C_1-C_{10} \text{ alkyl})$  wherein the alkyl is optionally substituted with one two or three substituents independently selected from the group consisting of:

(A) -OH,

(B)  $-C_1-C_6$  alkoxy,

- (C)  $-C_1-C_6$  thioalkoxy,
- (D)  $-CO_2-R_{N-8}$  where  $R_{N-8}$  at each occurrence is independently -H,  $C_1-C_6$  alkyl or -phenyl which is optionally substituted with 1 or 2 groups that are independently halogen,  $C_1-C_4$  alkoxy,  $C_1-C_4$  alkyl or  $-C(0)NH_2$ ,
  - (E)  $-CO-NR_{N-2}R_{N-3}$ ,
  - (F) -CO-R<sub>N-4</sub>,
  - (G)  $-SO_2-(C_1-C_8 \text{ alkyl})$ ,
- 10 (H)  $-SO_2-NR_{N-2}R_{N-3}$ ,
  - (I)  $-NH-CO-(C_1-C_6 \text{ alkyl})$ ,
  - (J)  $-NH-CO-O-R_{N-8}$ ,
  - (K)  $-NR_{N-2}R_{N-3}$ ,
  - (L)  $-R_{N-4}$ ,
- 15 (M)  $-O-CO-(C_1-C_6 \text{ alkyl})$ ,
  - (N)  $-O-CO-NR_{N-8}R_{N-8}$ ,
  - (0)  $-0-(C_1-C_5 \text{ alkyl})-COOH$ ,
- (P)  $-O-(C_1-C_6$  alkyl optionally substituted with one, two, or three groups that are independently -F, -CI, -Br, or -20 I),
  - (Q)  $-NH-SO_2-(C_1-C_6 \text{ alkyl})$ ,
  - (R) halogen,
  - (S)  $-N(H \text{ or } R_{N-5})-SO_2-R_{N-2}$ ,
  - (T)  $-N(H \text{ or } R_{N-5})-CO-(R_{N-2})$ , and
- 25 (U)  $-SO_2-R_{N-2}$ ,
  - (V) R<sub>N-arvl</sub>;
  - (III) -CO-( $C_1$ - $C_6$  alkyl)-O-( $C_1$ - $C_6$  alkyl) wherein each alkyl is unsubstituted or independently substituted with one, two, or three substituents selected from the group consisting of :
- 30 (A) -OH,
  - (B)  $-C_1-C_6$  alkoxy,
  - (C)  $-C_1-C_6$  thioalkoxy,
  - (D)  $-CO-O-R_{N-8}$ ,
  - (E)  $-CO-NR_{N-2}R_{N-3}$ ,

```
(F) -CO-R_{N-4},
                            (G) -SO_2-(C_1-C_8 \text{ alkyl}),
                            (H) -SO_2-NR_{N-2}R_{N-3},
                           (I) -NH-CO-(C_1-C_6 \text{ alkyl}),
   5
                            (J) -NH-CO-O-R_{N-8},
                           (K) -NR_{N-2}R_{N-3},
                           (L) -R_{N-4},
                           (M) -O-CO-(C_1-C_6 \text{ alkyl}),
                           (N) -O-CO-NR_{N-8}R_{N-8},
 10
                           (O) -O-(C_1-C_5 \text{ alkyl})-CO_2H,
                           (P) -O-(C_1-C_6 alkyl optionally substituted with
       one, two, or three groups that are independently -F, -CI, -Br,
       or -I),
                           (Q) -NH-SO_2-(C_1-C_6 \text{ alkyl}),
 15
                           (R) halogen,
                          (S) -N(H \text{ or } R_{N-5})-SO_2-R_{N-2},
                          (T) -N(H or R_{N-5})-CO-(R_{N-2}),
                           (U) -SO_2-R_{N-2}, and
                          (V) R<sub>N-aryl</sub>;
             (IV) -CO-(C_1-C_6 \text{ alkyl})-S-(C_1-C_6 \text{ alkyl}) wherein each alkyl
20
      is unsubstituted or substituted with one, two, or three of
      substituents independently selected from the group consisting
      of:
                   (A) -OH,
25
                   (B) -C_1-C_6 alkoxy,
                   (C) -C_1-C_6 thioalkoxy,
                   (D) -CO-O-R_{N-8},
                   (E) -CO-NR_{N-2}R_{N-3},
                   (F) -CO-R_{N-4},
30
                   (G) -SO_2-(C_1-C_8 \text{ alkyl}),
                   (H) -SO_2-NR_{N-2}R_{N-3},
                   (I) -NH-CO-(C_1-C_6 \text{ alkyl}),
                   (J) -NH-CO-O-R_{N-8},
```

(K)  $-NR_{N-2}R_{N-3}$ ,

```
(L) -R_{N-4},
(M) -O-CO-(C_1-C_6 alky1),
```

(N)  $-O-CO-NR_{N-8}R_{N-8}$ ,

(0)  $-0-(C_1-C_5 \text{ alkyl})-COOH$ ,

(P)  $-0-(C_1-C_6)$  alkyl optionally substituted with one, 5 two, or three groups that are independently -F, -Cl, -Br, or -I),

- (Q)  $-NH-SO_2-(C_1-C_6 \text{ alkyl})$ ,
- (R) halogen,

(S)  $-N(H \text{ or } R_{N-5})-SO_2-R_{N-2}$ , 10

(T)  $-N(H \text{ or } R_{N-5})-CO-(R_{N-2})$ ,

- (U)  $-SO_2-R_{N-2}$ , and
- (V) R<sub>N-aryl</sub>;

 $-CO-CH(-(CH_2)_{0-2}-O-R_{N-10})-(CH_2)_{0-2}-(R_{N-aryl} \text{ or } R_{N-heteroaryl}))$ (V)

15 wherein

20

 $R_{N-10}$  is selected from the group consisting of:

- (1) -H,
- (2)  $C_1$ - $C_6$  alkyl,
- (3)  $C_3-C_8$  cycloalkyl,
- (4)  $C_2$ - $C_6$  alkenyl,
- (5)  $C_2$ - $C_6$  alkynyl,
- (6) R<sub>1-aryl</sub>,
- (7) R<sub>N-heteroaryl</sub>,
- (8) R<sub>N-heterocycle</sub>,

(VI)  $-CO-(C_3-C_8$  cycloalkyl) where the cycloalkyl group is 25 optionally substituted with two substituents one orindependently selected from the group consisting of:

- (A)  $-(CH_2)_{0-4}-OH$ ,
- (B)  $-(CH_2)_{0-4}-C_1-C_6$  alkoxy,
- (C) -(CH<sub>2</sub>)<sub>0-4</sub>-C<sub>1</sub>-C<sub>6</sub> thioalkoxy,30
  - (D)  $-(CH_2)_{0-4}-CO-O-R_{N-8}$ ,
  - (E)  $-(CH_2)_{0-4}-CO-NR_{N-2}R_{N-3}$ ,
  - (F)  $-(CH_2)_{0-4}-CO-R_{N-4}$ ,

```
(G) -(CH_2)_{0-4}-SO_2-(C_1-C_8 \text{ alkyl}),
```

- (H)  $-(CH_2)_{0-4}-SO_2-NR_{N-2}R_{N-3}$ ,
- (I)  $-(CH_2)_{0-4}-NH-CO-(C_1-C_6 \text{ alkyl})$ ,
- (J)  $-NH-CO-O-R_{N-8}$ ,

5 (K)  $-(CH_2)_{0-4}-NR_{N-2}R_{N-3}$ ,

- (L)  $-(CH_2)_{0-4}-R_{N-4}$ ,
- $(M) -O-CO-(C_1-C_6 \text{ alkyl}),$
- (N)  $-O-CO-NR_{N-8}R_{N-8}$ ,
- (0)  $-O-(C_1-C_6 \text{ alkyl})-CO_2H$ ,
- 10 (P)  $-O-(C_1-C_6$  alkyl optionally substituted with one, two, or three groups that are independently selected from -F, -Cl, -Br, and -I),
  - (Q)  $-NH-SO_2-(C_1-C_6 \text{ alkyl})$ ,
  - (R) halogen,
- 15 (S)  $-N(H \text{ or } R_{N-5}) SO_2 R_{N-2}$ ,
  - (T)  $-N(H \text{ or } R_{N-5})-CO-(R_{N-2})$ ,
  - (U)  $-SO_2-R_{N-2}$ , and
  - (V) R<sub>N-aryl</sub>;

where Rc is:

25

- 20 (I)  $-C_1-C_{10}$  alkyl optionally substituted with one, two or three substituents selected from the group consisting of  $C_1-C_3$  alkyl, -F, -Cl, -Br, -I, -OH,
  - -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkoxy, -O-phenyl, -NR<sub>1-a</sub>R<sub>1-b</sub>, -OC=O NR<sub>1-a</sub>R<sub>1-b</sub>, -S(=O)<sub>0-2</sub> R<sub>1-a</sub>, NR<sub>1-a</sub>C=O NR<sub>1-a</sub>R<sub>1-b</sub>, -C=O NR<sub>1-a</sub>R<sub>1-b</sub>, and -S(=O)<sub>2</sub> NR<sub>1-a</sub>R<sub>1-b</sub>,
  - (II)  $-(CH_2)_{0-3}-(C_3-C_8)$  cycloalkyl where cycloalkyl can be optionally substituted with one, two or three substituents independently selected from the group consisting of  $C_1-C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>,  $C_1$ -C<sub>6</sub> alkoxy, -O-phenyl, -CO<sub>2</sub>H, -CO<sub>2</sub>-( $C_1$ -C<sub>4</sub> alkyl), and -NR<sub>1-a</sub>R<sub>1-b</sub>,
  - (III)  $-(CR_{C-x}R_{C-y})_{0-4}-R_{C-aryl}$  at each occurrence is independently phenyl; naphthyl; tetralinyl; indanyl; indenyl; dihydronaphthyl; or 6,7,8,9-tetrahydro-5H-

benzo[a]cycloheptenyl; each of which is optionally substituted with 1, 2, or 3 groups that at each occurrence are independently:

(1)  $C_1$ - $C_6$  alkyl, optionally substituted with one, two or three substituents selected from the group consisting of  $C_1$ - $C_3$  alkyl, -F, -Cl, -Br, -I,

-OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, and -NR<sub>1-a</sub>R<sub>1-b</sub>,

- (2) OH,
- $(3) -NO_2,$
- 10 (4) -F, -Cl, -Br, -I,
  - (5) -CO<sub>2</sub>H,
  - (6)  $-C \equiv N$ , and
  - (7)  $-(CH_2)_{0-4}-CO-NR_{N-2}R_{N-3}$ ;

where  $R_{C-x}$  and  $R_{C-y}$  are independently

15 -H,

F,

 $C_1\text{-}C_4$  alkyl optionally substituted with one or two - OH,

 $C_1$ - $C_4$  alkoxy optionally substituted with 1, 2, or 3 -

-(CH<sub>2</sub>)<sub>0-4</sub>-C<sub>3</sub>-C<sub>8</sub> cycloalkyl,

 $C_2-C_6$  alkenyl,

 $C_2-C_6$  alkynyl, and

phenyl,

or  $R_{C-x}$  and  $R_{C-y}$  are taken together with the carbon to which they are attached to form a carbocycle of three, four, five, six and seven carbon atoms, optionally where one carbon atom is replaced by a heteroatom selected from the group consisting of -O-, -S-,  $-SO_2-$ ,  $-NR_{N-2}-$  and  $R_{C-aryl}$  is defined as is defined above;

30 (IV)  $-(CR_{C-x}R_{C-y})_{0-4}-R_{C-heteroaryl}$  where  $R_{C-heteroaryl}$  at each occurrence is independently selected from the group consisting of pyridinyl, pyrimidinyl, quinolinyl, benzothienyl, indolyl, indolinyl, pryidazinyl, pyrazinyl, isoindolyl, isoquinolyl, quinazolinyl, quinoxalinyl, phthalazinyl, imidazolyl,

isoxazolyl, pyrazolyl, oxazolyl, thiazolyl, indolizinyl, indazolyl, benzoisothiazolyl, benzimidazolyl, benzofuranyl, furanyl, thienyl, pyrrolyl, oxadiazoly1, thiadiazolyl, triazolyl, tetrazolyl, oxazolopyridinyl, isothiazolyl, 5 naphthyridinyl, cinnolinyl, carbazolyl, beta-carbolinyl, isochromanyl, chromanyl, tetrahydroisoquinolinyl, isoindolinyl, isobenzotetrahydrofuranyl, isobenzotetrahydrothienyl, isobenzothienyl, benzoxazolyl, pyridopyridinyl, benzotetrahydrofuranyl, benzotetrahydrothienyl, purinyl, 10 benzodioxolyl, triazinyl, henoxazinyl, phenothiazinyl, pteridinyl, benzothiazolyl, imidazopyridinyl, imidazothiazolyl, dihydrobenzisoxazinyl, benzisoxazinyl, benzoxazinyl, dihydrobenzisothiazinyl, benzopyranyl, benzothiopyranyl, coumarinyl, isocoumarinyl, chromonyl, chromanonyl, tetrahydroquinolinyl, dihydroquinolinyl, dihydroquinolinonyl, 15 dihydroisoquinolinonyl, dihydrocoumarinyl, dihydroisocoumarinyl, isoindolinonyl, benzodioxanyl, benzoxazolinonyl, imidazopyrazolyl, quinazolinonyl, pyrazopyridyl, benzooxadiazolyl, dihydropyrimidinonyl, 20 dihydrobenzofuranonyl, pyridinyl-N-oxide, pyrrolyl N-oxide, pyrimidinyl N-oxide, pyridazinyl N-oxide, pyrazinyl N-oxide, quinolinyl N-oxide, indolyl N-oxide, indolinyl N-oxide, isoquinolyl N-oxide, quinazolinyl N-oxide, quinoxalinyl Noxide, phthalazinyl N-oxide, imidazolyl N-oxide, isoxazolyl N-25 oxide, oxazolyl N-oxide, thiazolyl N-oxide, indolizinyl Noxide, indazolyl N-oxide, benzothiazolyl benzimidazolyl N-oxide, pyrrolyl N-oxide, oxadiazolyl N-oxide, thiadiazolyl N-oxide, triazolyl N-oxide, tetrazolyl N-oxide, benzothiopyranyl S-oxide, and benzothiopyranyl S,S-dioxide,

where the  $R_{C-heteroaryl}$  group is bonded by any atom of the parent  $R_{C-heteroaryl}$  group substituted by hydrogen such that the new bond to the  $R_{C-heteroaryl}$  group replaces the hydrogen atom and its bond, where heteroaryl is optionally substituted 1, 2, 3, or 4 groups that are independently:

```
(1) C_1-C_6 alkyl, optionally substituted with 1, 2, or 3 groups independently selected from the group consisting of C_1-C_3 alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C\equivN, -CF<sub>3</sub>, C_1-C_3 alkoxy, and -NR<sub>1-a</sub>R<sub>1-b</sub>,
```

- 5 (2) -OH,
  - (3) -NO<sub>2</sub>,
  - (4) -F, -Cl, -Br, -I,
  - (5) -CO-OH,
  - (6) -C≡N,
- 10  $(7) (CH_2)_{0-4} CO NR_{N-2}R_{N-3}$ ,
  - (8)  $-(CH_2)_{0-4}-CO-(C_1-C_{12} \text{ alkyl})$ ,
  - (9) (CH<sub>2</sub>)<sub>0-4</sub> CO (C<sub>2</sub> C<sub>12</sub> alkenyl),
  - (10)  $-(CH_2)_{0-4}-CO-(C_2-C_{12} \text{ alkynyl})$ ,
  - (11)  $-(CH_2)_{0-4}-CO-(C_3-C_7 \text{ cycloalkyl})$ ,
- 15  $(12) (CH_2)_{0-4} CO R_{1-aryl}$ ,
  - (13)  $-(CH_2)_{0-4}-CO-R_{1-heteroaryl}$ ,
  - (14) (CH<sub>2</sub>)<sub>0-4</sub>-CO-R<sub>1-heterocycle</sub>,
  - (15) (CH<sub>2</sub>)<sub>0-4</sub> CO R<sub>N-4</sub>,
  - (16)  $-(CH_2)_{0-4}-CO-O-R_{N-5}$ ,
- 20  $(17) (CH_2)_{0-4} SO_2 NR_{N-2}R_{N-3}$ ,
  - (18)  $-(CH_2)_{0-4}-SO-(C_1-C_8 \text{ alkyl})$ ,
  - (19) (CH<sub>2</sub>)<sub>0-4</sub> SO<sub>2</sub> (C<sub>1</sub> C<sub>12</sub> alky1),
  - (20) (CH<sub>2</sub>)<sub>0-4</sub> SO<sub>2</sub> (C<sub>3</sub> C<sub>7</sub> cycloalkyl),
  - (21)  $-(CH_2)_{0-4}-N(H \text{ or } R_{N-5})-CO-O-R_{N-5}$ ,
- 25  $(22) (CH_2)_{0-4} N(H \text{ or } R_{N-5}) CO N(R_{N-5})_2$ ,
  - (23)  $-(CH_2)_{0-4}-N-CS-N(R_{N-5})_2$ ,
  - (24) (CH<sub>2</sub>)<sub>0-4</sub>-N(-H or R<sub>N-5</sub>)-CO-R<sub>N-2</sub>,
  - (25) (CH<sub>2</sub>)<sub>0-4</sub> NR<sub>N-2</sub>R<sub>N-3</sub>,
  - (26) (CH<sub>2</sub>)<sub>0-4</sub> R<sub>N-4</sub>,
- 30  $(27) (CH_2)_{0-4} O CO (C_1 C_6 \text{ alkyl}),$ 
  - (28)  $-(CH_2)_{0-4}-O-P(O)-(OR_{100})_2$ ,
  - (29)  $-(CH_2)_{0-4}-O-CO-N(R_{N-5})_2$ ,
  - (30)  $-(CH_2)_{0-4}-O-CS-N(R_{N-5})_2$ ,
  - (31)  $-(CH_2)_{0-4}-O-(R_{N-5})$ ,

- (32)  $-(CH_2)_{0-4}-O-(R_{N-5})-COOH$ ,
- (33)  $-(CH_2)_{0-4}-S-(R_{N-5})$ ,

(34)  $-(CH_2)_{0-4}-O-(C_1-C_6)$  alkyl optionally substituted with one, two, three, four, or five of -F),

(35)  $C_3-C_8$  cycloalkyl,

5

ring, and

(36)  $C_2-C_6$  alkenyl optionally substituted with  $C_1-C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C $\equiv$ N, -CF $_3$ ,  $C_1-C_3$  alkoxy, or -NR $_{1-a}$ R $_{1-b}$ ,

(37)  $C_2-C_6$  alkynyl optionally substituted with  $C_1-C_3$  10 alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C $\equiv$ N, -CF $_3$ ,  $C_1-C_3$  alkoxy, or -NR $_{1-a}$ R $_{1-b}$ ,

- (38)  $-(CH_2)_{0-4}-N(-H \text{ or } R_{N-5})-SO_2-R_{N-2}$ , and
- (39)  $-(CH_2)_{1-4}-(C_3-C_8 \text{ cycloalkyl})$ ,
- (V)  $-(CR_{C-x}R_{C-y})_{0-4}-R_{C-aryl}-R_{C-aryl}$ ,
- 15  $(VI) (CR_{C-x}R_{C-y})_{0-4} R_{C-aryl} R_{C-heteroaryl},$ 
  - (VII)  $-(CR_{C-x}R_{C-y})_{0-4}-R_{C-heteroaryl}-R_{C-aryl}$ ,
  - (VIII) (CR<sub>C-x</sub>R<sub>C-y</sub>)<sub>0-4</sub>-R<sub>C-heteroaryl</sub>-R<sub>C-heteroaryl</sub>,
- (IX) -  $(CR_{C-x}R_{C-y})_{0-4}$ - $R_{C-aryl}$ - $R_{C-heterocycle}$ , wherein R<sub>C-heterocycle</sub> is selected from the group consisting of 20 morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S,S-dioxide, piperazinyl, homopiperazinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl, piperidinyl, tetrahydrofuranyl, tetrahydrothienyl, homopiperidinyl, homomorpholinyl, homothiomorpholinyl, homothiomorpholinyl S,S-25 dioxide, oxazolidinonyl, dihydropyrazolyl, dihydropyrrolyl, dihydropyrazinyl, dihydropyridinyl, dihydropyrimidinyl, dihydrofuryl, dihydropyranyl, tetrahydrothienyl S-oxide, tetrahydrothienyl S,S-dioxide, homothiomorpholinyl S-oxide, dithianyl, pyranyl, dihydrofuranyl, pyrrolidinonyl, 30 imidazolidinonyl, imidazolidinondionyl, wherein each of the above is optionally fused to a benzene, pyridine, or pyrimidine

where the  $R_{1\text{-heterocycle}}$  group is bonded by any atom of the parent  $R_{1\text{-heterocycle}}$  group substituted by hydrogen such that the

new bond to the  $R_{1-heterocycle}$  group replaces the hydrogen atom and its bond, where heterocycle is optionally substituted with one, two, three or four:

- (1)  $C_1$ - $C_6$  alkyl optionally substituted with one, two or three substituents independently selected from the group consisting of  $C_1$ - $C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -NR<sub>1-a</sub>R<sub>1-b</sub>, -C=N, -CF<sub>3</sub>, and  $C_1$ - $C_3$  alkoxy,
- (2)  $C_2$ - $C_6$  alkenyl optionally substituted with one, two or three substituents selected from the group consisting of -F, -Cl, -OH, -SH, -C $\equiv$ N, -CF $_3$ ,  $C_1$ - $C_3$  alkoxy, -NR $_{1-a}$ R $_{1-b}$ ,
- (3)  $C_2$ - $C_6$  alkynyl optionally substituted with one, two or three substituents independently selected from the group consisting of -F, -Cl, -OH, -SH, -C=N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, and -NR<sub>1-a</sub>R<sub>1-b</sub>,
- 15 (4) -F, -Cl, -Br and -I,
  - (5)  $C_1$ - $C_6$  alkoxy,
  - (6)  $-C_1-C_6$  haloalkoxy,
  - (7)  $-NR_{N-2}R_{N-3}$ ,
  - (8) OH,
- 20 (9) -C≡N,

5

10

(10)  $C_3-C_7$  cycloalkyl, optionally substituted with one, two or three substituents independently selected from the group consisting of -F, -Cl, -OH, -SH

 $-C \equiv N$ ,  $-CF_3$ ,  $C_1-C_3$  alkoxy, and  $-NR_{1-a}R_{1-b}$ ,

- 25 (11)  $-CO-(C_1-C_4 \text{ alkyl})$ ,
  - (12)  $-SO_2-NR_{1-a}R_{1-b}$ ,
  - (13)  $-CO-NR_{1-a}R_{1-b}$ ,
  - $(14) -SO_2 (C_1 C_4 \text{ alkyl}),$
  - (15) =0, with the proviso that when  $n_1$  is zero  $R_{1-}$
- 30 heterocycle is not bonded to the carbon chain by nitrogen;
  - (X) (CR<sub>C-x</sub>R<sub>C-y</sub>)<sub>0-4</sub>-R<sub>C-heteroaryl</sub>-R<sub>C-heterocycle</sub>,
  - (XI)  $-(CR_{C-x}R_{C-y})_{0-4}-R_{C-heterocycle}-R_{C-aryl}$ ,
  - (XII) (CR<sub>C-x</sub>R<sub>C-y</sub>)<sub>0-4</sub>-R<sub>C-heterocycle</sub>-R<sub>C-heteroaryl</sub>,

(XIII) - (CR<sub>C-x</sub>R<sub>C-y</sub>)<sub>0-4</sub>-R<sub>C-heterocycle</sub>-R<sub>C-heterocycle</sub>,

(XIV)  $-(CR_{C-x}R_{C-y})_{0-4}-R_{C-heterocycle}$ ,

(XV)  $-[C(R_{C-1})(R_{C-2})]_{1-3}-CO-N-(R_{C-3})_2$  where  $R_{C-1}$  and  $R_{C-2}$  are the same or different and are selected from the group consisting of:

- (A) -H
- (B)  $-C_1-C_6$  alkyl, optionally substituted with one, two or three substituents selected from the group consisting of  $C_1-C_3$  alkyl, -F, -Cl, -Br, -I, -OH,
- 10 -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkoxy, -O-phenyl, and -NR<sub>1-a</sub>R<sub>1</sub>,
  - (C)  $C_2$ - $C_6$  alkenyl optionally substituted with one, two or three substituents selected from the group consisting of  $C_1$ - $C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C $\equiv$ N, -CF $_3$ ,  $C_1$ - $C_6$  alkoxy, -O-phenyl, and -NR $_{1-a}$ R $_{1-b}$ ,
- (D)  $C_2-C_6$  alkynyl optionally substituted with one, two or three substituents selected from the group consisting of  $C_1-C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C $\equiv$ N, -CF $_3$ ,  $C_1-C_6$  alkoxy, -O-phenyl, and -NR $_{1-a}$ R $_{1-b}$ ,
  - (E)  $-(CH_2)_{1-2}-S(O)_{0-2}-(C_1-C_6 \text{ alkyl})$ ,
- (F)  $-(CH_2)_{0-4}-C_3-C_8$  cycloalkyl, optionally substituted with one, two or three substituents selected from the group consisting of  $C_1-C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>,  $C_1-C_6$  alkoxy, -O-phenyl, and -NR<sub>1-a</sub>R<sub>1-b</sub>
  - (G)  $-(C_1-C_4 \text{ alkyl})-R_{C-aryl}$ ,
- 25 (H)  $-(C_1-C_4 \text{ alkyl})-R_{C-heteroaryl}$ ,
  - (I)  $-(C_1-C_4 \text{ alkyl})-R_{C-heterocycle}$
  - (J) -R<sub>C-heteroaryl</sub>,
  - (K) -R<sub>C-heterocycle</sub>,
  - (M)  $-(CH_2)_{1-4}-R_{C-4}-(CH_2)_{0-4}-R_{C-aryl}$  where  $R_{C-4}$  is -O-, -S-
- 30 or
  - -NR<sub>C-5</sub>- where  $R_{C-5}$  is  $C_1$ - $C_6$  alkyl,
    - (N)  $-(CH_2)_{1-4}-R_{C-4}-(CH_2)_{0-4}-R_{C-heteroaryl}$ ,
    - $(0) -R_{C-aryl}$

and where  $R_{C-3}$  at each occurrence is the same or different and is:

(A) -H,

10

15

25

- (B)  $-C_1-C_6$  alkyl optionally substituted with one, two or three substituents independently selected from the group consisting of  $C_1-C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>,  $C_1-C_6$  alkoxy, -O-phenyl, and -NR<sub>1-a</sub>R<sub>1-b</sub>,
  - (C)  $C_2-C_6$  alkenyl with one or two double bonds, optionally substituted with one, two or three substituents independently selected from the group consisting of  $C_1-C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>,  $C_1-C_6$  alkoxy, -O-phenyl, and -NR<sub>1-a</sub>R<sub>1-b</sub>,
  - (D)  $C_2$ - $C_6$  alkynyl optionally substituted with one, two or three substituents independently selected from the group consisting of  $C_1$ - $C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>,  $C_1$ - $C_6$  alkoxy, -O-phenyl, and -NR<sub>1-a</sub>R<sub>1-b</sub>,
    - (E)  $-(CH_2)_{0-4}-C_3-C_8$  cycloalkyl, optionally substituted with one, two or three substituents independently selected from the group consisting of  $C_1-C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -
- 20 SH,  $-C \equiv N$ ,  $-CF_3$ ,  $C_1-C_6$  alkoxy, -O-phenyl,  $-NR_{1-a}R_{1-b}$ ,
  - (F) -R<sub>C-aryl</sub>,
  - (G) -R<sub>C-heteroaryl</sub>,
  - (H) -R<sub>C-heterocycle</sub>,
  - (I)  $-(C_1-C_4 \text{ alkyl})-R_{C-aryl}$ ,
  - J)  $-(C_1-C_4 \text{ alkyl})-R_{C-heteroaryl}$ ,
  - (K)  $-(C_1-C_4 \text{ alkyl})-R_{C-heterocycle}$ ,

(XVI) -CH  $(R_{C-arvl})_2$ ,

(XVII) -CH(R<sub>C-heteroaryl</sub>)<sub>2</sub>,

(XVIII)  $-CH(R_{C-aryl})(R_{C-heteroaryl})$ ,

30 (XIX) -cyclopentyl, -cyclohexyl, or -cycloheptyl ring fused to  $R_{C-aryl}$  or  $R_{C-heteroaryl}$  or  $R_{C-heterocycle}$ , where one carbon of cyclopentyl, cyclohexyl, or -cycloheptyl is optionally replaced with NH,  $NR_{N-5}$ , O,  $S(=0)_{0-2}$ , and where cyclopentyl, cyclohexyl,

or -cycloheptyl can be optionally substituted with one or two -  $C_1$ - $C_3$  alkyl, -F, -OH, -SH, -C $\equiv$ N, -CF $_3$ ,  $C_1$ - $C_6$  alkoxy, =0, and -NR $_{1-a}$ R $_{1-b}$ ,

(XX)  $C_2$ - $C_{10}$  alkenyl optionally substituted with one, two or three substituents selected from the group consisting of  $C_1$ - $C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C $\equiv$ N, -CF $_3$ ,  $C_1$ - $C_6$  alkoxy, -Ophenyl, and -NR $_{1-a}$ R $_{1-b}$ ,

(XXI)  $C_2$ - $C_{10}$  alkynyl optionally substituted with one, two or three substituents selected from the group consisting of  $C_1$ - $C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C $\equiv$ N, -CF $_3$ ,  $C_1$ - $C_6$  alkoxy, -O-phenyl, and -NR $_{1-a}$ R $_{1-b}$ ,

(XXI)  $-(CH_2)_{0-1}-CHR_{C-6}-(CH_2)_{0-1}-R_{C-ary1}$  where  $R_{C-6}$  is  $-(CH_2)_{0-6}-CH_1$ 

(XXVII)  $-CH_2-NH-CH_2-CH(-O-CH_2-CH_3)_2$ .

(XXVIII) -H,

10

15

20  $(XXIX) - (CH_2)_{0-6} - C (=NR_{1-a}) (NR_{1-a}R_{1-b});$ 

 $R_{25}$  at each occurrence is independently selected from the group consisting of hydrogen,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  alkyl, hydroxy  $C_1$ - $C_6$  alkyl, halo  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkanoyl, each of which is unsubstituted or substituted with 1,

25 2, 3, or 4 groups independently selected from halogen, alkyl, hydroxy, alkoxy, and NH<sub>2</sub>, and  $-R_{26}-R_{27}$ , wherein

 $R_{26}$  is selected from the group consisting of -C(0)-, -O-, -S-, -SO-, -SO<sub>2</sub>-, -CO<sub>2</sub>-, -C(0)NH-, and -C(0)N(C<sub>1</sub>-C<sub>6</sub> alkyl)-;

 $R_{27}$  is selected from the group consisting of alkyl, alkoxy, phenyl, pyridyl, and cyclopropyl, and pharmaceutically acceptable salts thereof.

Disclosed is a method of treating a patient who has, or in preventing a patient from getting, a disease or condition selected from the group consisting of Alzheimer's disease, for helping prevent or delay the onset of Alzheimer's disease, for treating patients with mild cognitive impairment (MCI) preventing or delaying the onset of Alzheimer's disease in those who would progress from MCI to AD, for treating Down's syndrome, for treating humans who have Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type, for treating cerebral amyloid angiopathy and preventing its potential consequences, i.e. single and recurrent lobar hemorrhages, for treating other degenerative dementias, including dementias of mixed vascular and degenerative origin, dementia associated with Parkinson's disease, dementia associated with progressive supranuclear palsy, dementia associated with cortical basal degeneration, or diffuse Lewy body type of Alzheimer's disease and who is in need of such treatment which comprises administration of a therapeutically effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof.

10

15

20

25

30

Also disclosed are methods for inhibiting beta-secretase activity, for inhibiting cleavage of amyloid precursor protein (APP), in a reaction mixture, at a site between Met596 and Asp597, numbered for the APP-695 amino acid isotype; or at a corresponding site of an isotype or mutant thereof, for inhibiting production of amyloid beta peptide (A beta) in a cell, for inhibiting the production of beta-amyloid plaque in animal, and for treating or preventing а disease an characterized by beta-amyloid deposits in the brain which comprise administration of a therapeutically effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof.

The invention also discloses pharmaceutial compositions comprising compounds of the invention.

The invention provides compounds, compositions, kits, and methods for inhibiting beta-secretase-mediated cleavage of amyloid precursor protein (APP). More particularly, the compounds, compositions, and methods of the invention are effective to inhibit the production of A beta peptide and to treat or prevent any human or veterinary disease or condition associated with a pathological form of A beta peptide.

5

30

10 The compounds, compositions, and methods of the invention are useful for treating humans who have Alzheimer's Disease (AD), for helping prevent or delay the onset of AD, for treating patients with mild cognitive impairment (MCI), and preventing or delaying the onset of AD in those patients who 15 would otherwise be expected to progress from MCI to AD, for treating Down's syndrome, for treating Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch Type, for treating cerebral beta-amyloid angiopathy and preventing its potential consequences such as single and recurrent lobar hemorrhages, 20 for treating other degenerative dementias, including dementias of mixed vascular and degenerative origin, for dementia associated with Parkinson's disease, dementia associated with progressive supranuclear palsy, associated with cortical basal degeneration, and diffuse Lewy 25 body type AD.

The compounds of the invention possess beta-secretase inhibitory activity. The inhibitory activities of the compounds of the invention are readily demonstrated, for example, using one or more of the assays described herein or known in the art.

## DETAILED DESCRIPTION OF THE INVENTION

In a specific aspect within Formula X, the invention provides compounds of formula Z1:

or a pharmaceutically acceptable salt thereof, wherein 5 selected from the group consisting  $R_{30}$ of phenyl, pyrazolopyrimidinyl, oxa-aza-benzoazulenyl, isoxazolyl, triazolopyridinyl, pyrrolidinonyl, tetrahydrothia-azafluorenyl, pyridyl, piperidinyl, 10 dihydrocyclopentaquinolinyl, furyl, naphthothienyl, phthalazinonyl, thiadiazolyl, thienopyrimidinonyl, oxadiaza-cyclopentanaphthalenyl, dihydrobenzodioxepinyl, chromanonyl, chromenonyl, oxazolidinyl, benzophenone, pyrazinyl mono N-oxide, benzofuranyl, pyrazolyl, 15 -isoxazolyl-phenyl, phenyl-triazolyl, benzimidazolyl, indolyl, phenyl-pyrrolyl, chromanyl, isoquinolinyl, -thienyl-thienyl, benzothienyl, -phenyl-thiadiazolyl, chromanonyl, quinolinyl, -pyrrolyl-C(O)-phenyl, -phenyl-Ophenyl, -phenyl-oxazolyl, -pyrrolidinonyl-phenyl, -phenylpyrimidinyl, -phenyl-oxadiazolyl, bicyclo[2.2.1]heptenyl, 20 cyclopentyl, thieno[2,3-b]thiophene, cyclohexyl, -phenylimidazolyl, benzoxazole; dihydro-1H-indolyl; 2,3-dihydrobenzo[b]thiophene 1,1-dioxide; benzo[b]thiophene 1,1dioxide; 2,3-dihydro-benzo[d]isothiazole 1,1-dioxide; -25 phenyl-thiazolyl; -phenyl-pyrazolyl, -phenyl-C(0)piperidyl, -phenyl-C(0)-pyrrolidinyl, -phenyl-isoxazolyl, isoindolyl, purinyl, oxaxolyl, thiazolyl, pyridazinonyl, thiazolyl, pyranyl, dihydropyranopyridinyl, diazepanyl, cyclopropyl, dihydronaphthoisoxazolyl, benzoindazole, 30 dihydrocyclopentachromenonyl, imidazopyrazolyl, tetrahydrocyclopentachromenonyl, dihydroquinolinonyl, pyridyl N-oxide. isochromanyl, quinazolinonyl,

dihydrobenzothiophene pyrazolopyridinyl, dioxide, dihydrofurobenzoisoxazolyl, dihydropyrimidine dionyl, thienopyrazolyl, oxazolyl, tetrahydrocyclopentapyrazolyl, dihydronaphthalenonyl, dihydrobenzofuranonyl, 5 dihydrocyclopentathienyl, tetrahydrocyclopentapyrazolyl, tetrahydropyrazoloazepinyl, indazolyl, tetrahydrocycloheptaisoxazolyl, tetrahydroindolonyl, pyrrolidinyl, thienopyridinyl, dioxodihydrobenzoisothiazolonyl, triazolopyrimidinyl, 10 thienyl, dihydrothienopyrimidinonyl, and benzooxadiazolyl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently selected from the group consisting of  $C_1-C_{10}$  alkyl optionally substituted with 1 phenyl or 1 CN; 15 OH, hydroxy C<sub>1</sub>-C<sub>10</sub> alkyl optionally substituted with phenyl or  $(C_1-C_4 \text{ alkyl})$  phenyl,  $C_1-C_6 \text{ alkoxy optionally}$ substituted with 1 or 2 groups that are independently hydroxy or phenyl; haloalkyl, haloalkoxy, (CH2)0- $_4\text{C}\text{(O)}\,\text{NR}_{31}\text{R}_{32}\text{, -NR}_{31}\text{-SO}_2\text{-}\text{(C}_1\text{-C}_6\text{ alkyl)}$  wherein the alkyl 20 group is optionally substituted with 1, 2, or 3 groups that are independently halogen or R33, -SO2- $NH(C_1-C_6 \text{ alkyl})$  wherein the alkyl group is optionally substituted with 1 or 2 groups that are independently halogen, OH, alkoxy, or  $R_{33}$ ;  $-(C_1-C_6 \text{ alkyl})-SO_2-(C_1-C_6)$ 25 alkyl) wherein the alkyl group is optionally substituted with 1 or 2 groups that are independently halogen, OH,  $C_1-C_4$  alkoxy, or  $R_{33}$ ;  $-SO_2-(C_1-C_6$  alkyl) wherein the alkyl group is optionally substituted with 1 or 2 groups that are independently OH or  $C_1$ - $C_4$ 30 alkoxy,  $-SO_2-N(C_1-C_6$  alkyl)  $(C_1-C_6$  alkyl) wherein each alkyl group is optionally substituted with 1 or 2 groups that are independently halogen, OH or R33;  $-SO_2-NH(C_1-C_6$  alkyl)-phenyl wherein the phenyl is optionally substituted with 1 or 2 groups that are

5

10

15

20

25

30

independently  $C_1-C_4$  alkoxy or halogen,  $-0-(C_1-C_6)$ alkyl)-phenyl, - (C<sub>1</sub>-C<sub>6</sub> alkyl)-O-phenyl,  $-(C_1-C_6)$  $alkyl)-O-(C_1-C_6$ alkyl)-phenyl, triazolidine-3,5dione, halogen,  $-NHC(0)NH_2$ ,  $-NHC(0)NH(C_1-C_6 alkyl)$ ,  $-NHC(O)N(C_1-C_6)$ alkyl) ( $C_1$ - $C_6$ alkyl),  $-N(C_1-C_6)$  $alkyl)C(O)NH_2$ ,  $-N(C_1-C_6$   $alkyl)C(O)NH(C_1-C_6$  alkyl),  $- \text{N} \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \text{C} \left( \text{O} \right) \text{N} \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right), \quad - \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl$ alkyl) thienyl,  $-(C_1-C_6 \text{ alkyl})$  furanyl, alkyl) phenyl,  $-SO_2NR_{31}R_{32}$ ,  $-C(O)-NR_{31}R_{32}$ ,  $-NR_{31}R_{32}$ , dithiane,  $-NHC(S)NH_2$ ,  $-NHC(S)NH(C_1-C_6)$ alkyl), -NHC(S)N( $C_1$ - $C_6$  alkyl) ( $C_1$ - $C_6$  alkyl), - $CO_2$ ( $C_1$ - $C_6$  alkyl), tetrahydropyran, phenyl optionally substituted with 1 or 2 groups that are independently F, Cl or Br; pyridine,  $-C_2-C_4$  alkynyl-phenyl,  $-O-C_3-C_8$  cycloalkyl, -O-( $C_1$ - $C_6$  alkyl)- $R_{33}$ ; pyrrole optionally substituted with one or two methyl groups; 2,3-dihydrobenzofuran; benzo[1,2,5]oxadiazole,  $-C(0)-(C_1-C_{10})$ alkyl) wherein the alkyl group is optionally substituted with NH2, N(C1-C6 alkyl), or N(C1-C6 alkyl)( $C_1-C_6$  alkyl); -C(0)NH-phenyl,  $-C(0)N(C_1-C_6)$ alkyl)-phenyl, 4,4-dimethyl-4,5-dihydro-oxazole, - $(C_1-C_6 \text{ alkyl})-S$ -pyridine,  $-(C_1-C_6 \text{ alkyl})-SO_2$ -pyridine,  $-(C_1-C_6$  thioalkoxy)-pyridine, thiazole optionally substituted with 1 or 2 methyl groups, pyrazole, S- $(C_1-C_6 \quad alkyl)$ , indole,  $(C_1-C_6 \quad thioalkoxy)-(C_1-C_6)$ alkyl),  $C_2-C_8$  alkynyl,  $-CO_2-\left(C_1-C_6 \text{ alkyl}\right)$ ,  $C_1-C_{10}$ alkanoyl;  $-(CH_2)_{0-4}-SO_2-(C_1-C_{10}$  alkyl) wherein the alkyl group is optionally substituted with OH; wherein  $R_{31}$  and  $R_{32}$  at each occurrence are independently selected from the group consisting of hydrogen,  $C_1\text{-}C_8$ alkyl,  $C_2$ - $C_8$  alkenyl, hydroxy  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$ haloalkyl,  $C_1-C_6$  alkoxy  $C_1-C_6$  alkyl,  $-\left(CH_2\right)_{0-4}-SO_2-\left(C_1-C_1-C_6\right)$  $C_6$  alkyl) wherein the alkyl is optionally substituted

with 1, 2, 3 or 4 independently selected halogen

5

10

15

20

atoms; -(CH<sub>2</sub>)<sub>0-4</sub>-SO<sub>2</sub>-imidazolyl, -(C<sub>1</sub>-C<sub>6</sub>)alkyl)- $C(0)NH_2$ ,  $-(C_1-C_6 \text{ alkyl})-C(0)NH(C_1-C_6 \text{ alkyl})$ ,  $-(C_1-C_6)$ alkyl)- $C(0)N(C_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl}), -(C_1-C_6 \text{ alkyl}) NH_2$ ,  $-(C_1-C_6 \text{ alkyl})-NH(C_1-C_6 \text{ alkyl})$ ,  $-(C_1-C_6 \text{ alkyl}) N(C_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl}), -(C_1-C_6 \text{ alkyl})$ phenyl,  $-(C_1-C_6 \text{ alkyl})$  pyridyl, -C(0) furanyl,  $(C_1-C_6 \text{ alkyl})$  tetrahydrofuran, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,  $-CO_2-(C_1-C_6 \text{ alkyl})$ ,  $-(C_1-C_6)$ alkyl)-furanyl,  $-(CH_2)_{0-4}-SO_2$ -thienyl , wherein the phenyl and pyridyl groups are unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently  $C_1-C_4$  alkyl, hydroxy,  $C_1-C_4$ alkoxy, halogen, or

R<sub>31</sub>, R<sub>32</sub> and the nitrogen to which they are attached form a 5, 6, or 7 membered heterocycloalkyl or a 6 membered heteroaryl ring, each of which is optionally fused to a benzene, pyridine or pyrimidine ring and each of which is optionally substituted with C<sub>1</sub>-C<sub>6</sub> alkoxy, hydroxy, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl, -C(0)NH<sub>2</sub>, -C(0)NH-(C<sub>1</sub>-C<sub>6</sub> alkyl)-phenyl;

 $R_{33}$  at each occurrence is independently, H, NH2, NH(C1-C6 alkyl), N(C1-C6 alkyl)(C1-C6 alkyl), N(C1-C6 alkyl), N(C1-C6 alkyl);

R<sub>35</sub> is phenyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, -S-phenyl, benzodioxole,
thienyl, C<sub>1</sub>-C<sub>6</sub> alkyl, furanyl, imidazolyl, each of which
is unsubstituted or substituted with 1, 2, 3, 4, or 5
groups that are independently C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy,
OH, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, halogen, halo C<sub>1</sub>-C<sub>6</sub> alkyl, halo
C<sub>1</sub>-C<sub>6</sub> alkoxy, -O-(C<sub>1</sub>-C<sub>6</sub> alkyl)-phenyl, -CO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub> alkyl), (C<sub>1</sub>-C<sub>4</sub> alkyl)-(C<sub>5</sub>-C<sub>6</sub> cycloalkyl), or (CH<sub>2</sub>)<sub>0-4</sub>CN;

 $R_{40}$  is phenyl, -phenyl-pyridyl, biphenyl, -phenyl-benzothienyl, -phenyl-thienyl, -phenyl-furanyl, -phenyl-pyrimidinyl, -phenyl-isoxazolyl, -C(0)-pyridyl, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-O-C(0)NH-phenyl wherein the phenyl is optionally substituted with

1, 2, or 3 halogen atoms;  $-(C_1-C_4 \text{ alkyl})-0-C(0)N(C_1-C_6)$ alkyl)-phenyl,  $-(C_1-C_6 \text{ alkyl})$ -phenyl,  $-(C_1-C_4 \text{ alkyl})-SO_2NH_2$ ,  $-(C_1-C_4 \text{ alkyl})-SO_2NH(C_1-C_6 \text{ alkyl}), -(C_1-C_4 \text{ alkyl})-SO_2N(C_1-C_6)$  $alkyl)(C_1-C_6 \ alkyl), -SO_2NH_2, -SO_2NH(C_1-C_6 \ alkyl), -SO_2N(C_1-C_6)$ 5  $C_6$  alkyl) ( $C_1$ - $C_6$  alkyl), CN, -( $CH_2$ )<sub>0-4</sub>-( $C_3$ - $C_8$  cycloalkyl), - $(C_1-C_4 \text{ alkyl})-C(0)0-(C_1-C_4 \text{ alkyl}), -(C_1-C_4 \text{ alkyl})-R_{33}, C_1-C_{10}$ alkyl,  $C_2-C_8$  alkenyl,  $-(C_1-C_4$  alkyl)-NHC(0)-( $C_1-C_4$  alkyl), - $(CH_2)_{0-4}-C(O)NH_2$ ,  $-(CH_2)_{0-4}-C(O)NH(C_1-C_6$  alky1),  $-(CH_2)_{0-4}-C(CH_2)_{0-4}$  $C(0)N(C_1-C_6)$ alkyl)  $(C_1-C_6)$ alkyl), naphthyl, 10 tetrahydronapthyl, dihydronaphthyl, -(CH<sub>2</sub>)<sub>0-4</sub>-imidazolyl, -(CH<sub>2</sub>)<sub>0-4</sub>-pyrrolidinyl, oxazolidinone 3,4-dihydrobenzo[e][1,2]oxathiine 2,2-dioxide, pyrimidinyl, dihydro-2H-benzo[e][1,2]thiazine 1,1-dioxide, pyridyl, or alkoxyalkyl, -phenyl-benzothienyl, -phenylpyrimidyl, 15 cyclohexyl, -phenyl-cyclopentyl, -phenyl- $(C_1-C_6 \text{ alkyl})$ cyclopentyl, -phenyl- $(C_1-C_6 \text{ alkyl})$ -cyclohexyl, -phenyloxazolyl, furanyl, tetrahydrofuranyl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently halogen,  $C_1-C_8$  alkyl 20 optionally substituted with 1 or two groups that are independently CN or OH;  $C_1-C_6$  alkoxy, halo  $(C_1-C_8$  alkyl), halo  $(C_1-C_4 \text{ alkoxy})$ ,  $-O-(C_1-C_4 \text{ alkyl})$ -phenyl wherein the phenyl is optionally substituted with 1 or 2 halogens, CN,  $C_1-C_4$  thioalkoxy,  $-NHSO_2-(C_1-C_6$  alkyl),  $-N(C_1-C_4)$  $alkyl)SO_2-(C_1-C_4$  alkyl) wherein the alkyl groups are optionally substituted with 1, 2, or 3 halogens; OH; -SO<sub>2</sub>R<sub>33</sub>; R<sub>33</sub>; C<sub>2</sub>-C<sub>8</sub> alkynyl; C<sub>2</sub>-C<sub>8</sub> alkenyl; thioalkoxyalkyl; - $SO_2-(C_1-C_{10} \text{ alkyl}); -NR_{31}R_{32}; -C(O)-NR_{31}R_{32}; -OC(O)R_{33}; C_1-C_8$ alkanoyl;  $-(C_1-C_6 \text{ alkyl})-C(0)-(C_1-C_6 \text{ alkoxy});$ 

30  $R_{41a}$  and  $R_{41}$  are independently H, cyclohexyl, phenyl, or  $C_1$ - $C_6$ alkyl optionally substituted with 1 or 2 groups that are phenyl, hydroxy,  $C_1-C_4$  thioalkoxy,  $C_1-C_4$  thioalkoxy  $C_1-C_6$ alkyl; or  $-C_1-C_6$  alkyl $-SO_2-C_1-C_6$  alkyl;

25

 $R_{40}$ ,  $R_{41}$ , and the atom to which they are attached form a  $C_3$ - $C_8$  cycloalkyl ring which is optionally substituted with  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, halogen,  $-CO_2NH_2$ ,  $-CO_2NH(C_1$ - $C_6$  alkyl),  $-CO_2N(C_1$ - $C_6$  alkyl)( $C_1$ - $C_6$  alkyl), thiazolyl optionally substituted with  $C_1$ - $C_6$  alkyl, isoxazolyl optionally substituted with  $C_1$ - $C_6$  alkyl, or phenyl which is optionally substituted with 1, 2, or 3 groups that are independently halogen or  $C_1$ - $C_6$  alkyl;

and

5

10  $R_{42}$  is H,  $C_1$ - $C_6$  alkyl optionally substituted with OH; benzyl; - NHC(O)-( $C_1$ - $C_6$  alkyl); -NHC(O)-phenyl wherein the phenyl is optionally substituted with 1 or 2 alkyl groups.

Preferred compounds of formula Z1 include the compounds of formula Z2:

 $Z_2$ 

or a pharmaceutically acceptable salt thereof, wherein

 $R_{51}$  at each occurrence is independently  $C_1\text{--}C_6$  alkyl,  $C_1\text{--}C_6$ 20 alkoxy,  $-NHSO_2-(C_1-C_4)$  alkyl) wherein the alkyl group is optionally substituted with 1, 2, or 3 halogens,  $-SO_2-NH (C_1-C_6 \text{ alkyl})-NH_2$ ,  $-SO_2-NH-(C_1-C_6 \text{ alkyl})-NH(C_1-C_4 \text{ alkyl})$ ,  $-SO_2-NH-(C_1-C_6)$  $alkyl) - N(C_1 - C_4$ alkyl) ( $C_1-C_4$ alkyl), 25 -NHC(0)N( $C_1$ - $C_6$  alkyl)( $C_1$ - $C_6$  alkyl), alkyl),  $-N(C_1-C_6)$  $\texttt{alkyl)C(O)NH}_2, \quad -\texttt{N(C}_1-\texttt{C}_6 \quad \texttt{alkyl)C(O)NH(C}_1-\texttt{C}_6 \quad \texttt{alkyl)} \;, \quad -\texttt{N(C}_1-\texttt{C}_6 \quad \texttt{a$  $alkyl)C(O)N(C_1-C_6 \ alkyl)(C_1-C_6 \ alkyl)$ , halogen,  $-CF_3$ , OH,  $-\text{SO}_2\text{NR}_{31}\text{R}_{32}, \quad -\text{C(O)NR}_{31}\text{R}_{32}, \quad -\text{NR}_{31}\text{R}_{32}, \quad \text{hydroxy} \quad \text{C}_1-\text{C}_{10} \quad \text{alkyl}$ optionally substituted with phenyl or  $(C_1-C_4 \text{ alkyl})$  phenyl, 30 -O- (C<sub>1</sub>-C<sub>4</sub> alkyl)-phenyl,  $-NHC(S)NH_2$ ,  $-NHC(S)NH(C_1-C_6)$ alkyl), -NHC(S)N( $C_1$ - $C_6$  alkyl)( $C_1$ - $C_6$  alkyl), ( $C_1$ - $C_4$  alkyl)-Ophenyl,  $-C(0)-(C_1-C_6 \text{ alkyl})$  wherein the alkyl group is

5

10

15

optionally substituted with  $NH_2$ ,  $N(C_1-C_6 \ alkyl)$ , or  $N(C_1-C_6 \ alkyl)$  ( $C_1-C_6 \ alkyl)$ ;  $-O-C_3-C_6 \ cycloalkyl$ , oxazole optionally substituted with 1, or 2 groups that are independently  $C_1-C_4 \ alkyl$  or phenyl, hydroxy  $C_1-C_4 \ alkoxy$ , aminoalkoxy,  $NH(C_1-C_6 alkyl)-alkoxy$ ,  $N(C_1-C_6 alkyl)(C_1-C_6 alkyl)-alkoxy$ ,

wherein  $R_{31}$  and  $R_{32}$  at each occurrence are independently selected from the group consisting of hydrogen,  $C_1$ - $C_6$  alkyl, hydroxy  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  haloalkyl,  $-(C_1$ - $C_6$  alkyl)- $C(0)NH_2$ ,  $-(C_1$ - $C_6$  alkyl)- $C(0)NH(C_1$ - $C_6$  alkyl),  $-(C_1$ - $C_6$  alkyl)- $C(0)N(C_1$ - $C_6$  alkyl)( $C_1$ - $C_6$  alkyl),  $-(C_1$ - $C_6$  alkyl)- $NH_2$ ,  $-(C_1$ - $C_6$  alkyl)- $NH(C_1$ - $C_6$  alkyl),  $-(C_1$ - $C_6$  alkyl)- $NH(C_1$ - $C_6$  alkyl),  $-(C_1$ - $C_6$  alkyl)- $NH(C_1$ - $C_6$  alkyl),  $-(C_1$ - $C_6$  alkyl)- $NH(C_1$ - $C_6$ 

the phenyl and pyridyl groups are unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently  $C_1-C_4$  alkyl, hydroxy,  $C_1-C_4$  alkoxy, halogen, or

wherein at each occurrence R<sub>31</sub>, R<sub>32</sub> and the nitrogen to which they are attached independently form a pyrrolidinyl, piperazinyl, piperidinyl, azepanyl, pyridinyl, or pyrimidinyl ring, each of which is optionally fused to a benzene, pyridine or pyrimidine ring and each of which is optionally substituted with C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> alkyl, hydroxy, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl, -C(0)NH<sub>2</sub>, or -C(0)NH-(C<sub>1</sub>-C<sub>6</sub> alkyl)-phenyl.

Preferred compounds of Z2 are those wherein  $R_{41}$  and  $R_{42}$  are both hydrogen.

Other preferred compounds of Z2 are those wherein  $R_{35}$  is phenyl, cyclohexyl,, -S-phenyl, benzodioxole, thienyl,  $C_3$ - $C_6$  alkyl, furanyl, each of which is unsubstituted or substituted

with 1, 2, 3, 4, or 5 groups that are independently  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, OH, hydroxy  $C_1$ - $C_6$  alkyl, halogen, halo  $C_1$ - $C_6$  alkyl, halo  $C_1$ - $C_6$  alkoxy, -O-( $C_1$ - $C_6$  alkyl)-phenyl, -CO<sub>2</sub>-( $C_1$ - $C_6$  alkyl), -( $C_1$ - $C_4$  alkyl)-( $C_5$ - $C_6$  cycloalkyl).

5

10

Other preferred compounds of Z1 are those wherein

R<sub>35</sub> is phenyl, cyclohexyl, -S-phenyl, benzodioxole, thienyl, C<sub>3</sub>-C<sub>6</sub> alkyl, furanyl, each of which is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, OH, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, halogen, halo C<sub>1</sub>-C<sub>6</sub> alkyl, halo C<sub>1</sub>-C<sub>6</sub> alkoxy, -O-(C<sub>1</sub>-C<sub>6</sub> alkyl)-phenyl, -CO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub> alkyl), -(C<sub>1</sub>-C<sub>4</sub> alkyl)-(C<sub>5</sub>-C<sub>6</sub> cycloalkyl);

 $R_{40}$ phenyl, -phenyl-pyridine, biphenyl, -phenylbenzothienyl, -phenyl-thienyl, -phenyl-furanyl, -phenyl-15  $\label{eq:pyrimidinyl} {\tt pyrimidinyl}, \quad {\tt -phenyl-isooxazolyl}, \quad {\tt -C(O)-pyridyl}, \quad {\tt -(C_1-C_4)}$ alkyl)-0-C(0)NH-phenyl,  $-(C_1-C_4)$  $alkyl)-O-C(O)N(C_1-C_6)$ alkyl)-phenyl, -( $C_1$ - $C_4$  alkyl)-phenyl, -( $C_1$ - $C_4$  alkyl)- $SO_2NH_2$ ,  $-\left(\text{C}_1-\text{C}_4 \text{ alkyl}\right)-\text{SO}_2\text{NH}\left(\text{C}_1-\text{C}_6 \text{ alkyl}\right), \quad -\left(\text{C}_1-\text{C}_4 \text{ alkyl}\right)-\text{SO}_2\text{N}\left(\text{C}_1-\text{C}_6 \text{ alkyl}\right)$ 20 alkyl)( $C_1$ - $C_6$  alkyl), CN, -( $CH_2$ ) $_{0-4}$ -( $C_3$ - $C_8$  cycloalkyl), -( $C_1$ - $\text{C}_4 \quad \text{alkyl}) - \text{C} \text{(O)} \text{O} - \text{(C}_1 - \text{C}_4 \quad \text{alkyl)} \;, \quad - \text{(C}_1 - \text{C}_4 \quad \text{alkyl)} - \text{R}_{33} \;, \quad \text{C}_1 - \text{C}_8$ -( $C_1$ - $C_4$  alkyl)-NHC(O)-( $C_1$ - $C_4$  alkyl), -( $C_1$ )0-4alkyl,  $\texttt{C(O)NH}_2\,,\quad -\,(\texttt{CH}_2)_{\,0-4}-\texttt{C(O)NH}\,(\texttt{C}_1-\texttt{C}_6\quad \texttt{alkyl})\,\,,\quad -\,(\texttt{CH}_2)_{\,0-4}-\texttt{C(O)N}\,(\texttt{C}_1-\texttt{C}_6)\,\,.$ alkyl)( $C_1$ - $C_6$  alkyl), tetrahydronapthyl, dihydronaphthyl, 25 wherein each of the above is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently halogen,  $C_1-C_4$  alkyl,  $C_1-C_4$  alkoxy, halo  $(C_1-C_4$  alkyl), -0- $(C_1-C_4$  alkyl)-phenyl wherein the phenyl is optionally substituted with 1 or 2 halogens, -CHO,  $C_1$ - $C_4$  thioalkoxy, 30  $-NHSO_2-(C_1-C_4 \quad alkyl)$ ,  $-N(C_1-C_4 \quad alkyl)SO_2-(C_1-C_4)$ wherein the alkyl groups are optionally substituted with 1, 2, or 3 halogens; OH,  $SO_2R_{33}$ ,  $R_{33}$ ;

 $R_{41}$  is H, cyclohexyl, phenyl, or  $C_1$ - $C_6$  alkyl optionally substituted with 1 or 2 groups that are phenyl, hydroxy, or  $C_1$ - $C_4$  thioalkoxy; and

 $R_{42}$  is hydrogen or -CH<sub>2</sub>CN.

5

10

More preferred compounds of Z2 include those wherein

R<sub>35</sub> is phenyl,  $C_3$ - $C_8$  cycloalkyl, -S-phenyl, benzodioxole, thienyl,  $C_3$ - $C_6$  alkyl, furanyl, each of which is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, OH, hydroxy  $C_1$ - $C_6$  alkyl, halogen, CF<sub>3</sub>, OCF<sub>3</sub>, -Obenzyl, -CO<sub>2</sub>-( $C_1$ - $C_6$  alkyl), -( $C_1$ - $C_4$  alkyl)-( $C_5$ - $C_6$  cycloalkyl);

-phenyl-pyridine, biphenyl,  $R_{40}$ is phenyl, -phenylbenzothienyl, -phenyl-thienyl, -phenyl-furanyl, -phenylpyrimidinyl, -phenyl-isoxazolyl, -C(0)-pyridyl, -( $C_1$ - $C_4$ 15 alkyl)-O-C(O)NH-phenyl,- (C<sub>1</sub>-C<sub>4</sub> alkyl)-O-C(O)N( $C_1$ - $C_6$ alky1)-pheny1,  $-(C_1-C_4 \ alky1)$ -pheny1,  $-(C_1-C_4 \ alky1)-SO_2NH_2$ ,  $-(C_1-C_4 \text{ alkyl})-SO_2NH(C_1-C_6 \text{ alkyl}), -(C_1-C_4 \text{ alkyl})-SO_2N(C_1-C_6)$ alkyl)  $(C_1-C_6 \text{ alkyl})$ , CN,  $-(C_1-C_4 \text{ alkyl})-(C_3-C_6 \text{ cycloalkyl})$ , 20  $-(C_1-C_4 \text{ alkyl})-C(0)O-(C_1-C_4 \text{ alkyl}), -(C_1-C_4 \text{ alkyl})-R_{33}, C_1-C_8$ alkyl,  $-(C_1-C_4 alkyl)-NHC(O)-(C_1-C_4 alkyl)$ ,  $-C(O)NH_2$ , wherein each of the above rings is unsubstituted or substituted with 1, 2, or 3 groups that are independently halogen,  $C_1-C_4$  alkyl,  $C_1-C_4$  alkoxy,  $CF_3$ ,  $-O-(C_1-C_4$  alkyl)-25 phenyl wherein the phenyl is optionally substituted with 1 2 halogens, -CHO, -NHSO<sub>2</sub>-( $C_1$ - $C_4$  alkyl), -N( $C_1$ - $C_4$  $alkyl)SO_2-(C_1-C_4 \ alkyl)$  wherein the alkyl is optionally substituted with 1, 2, or 3 halogens,

 $R_{41}$  is H, cyclohexyl, phenyl, or  $C_1$ - $C_6$  alkyl optionally substituted with 1 or 2 groups that are phenyl, hydroxy, or  $C_1$ - $C_4$  thioalkoxy; and

R<sub>42</sub> is hydrogen or -CH<sub>2</sub>CN;

 $R_{51}$  at each occurrence is independently  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy, -NHSO<sub>2</sub>-( $C_1$ - $C_4$  alkyl) wherein the alkyl group is

5

10

15

20

25

optionally substituted with 1, 2, or 3 halogens, -SO2-NH- $(C_1-C_6 \text{ alkyl})-NH_2$ ,  $-SO_2-NH-(C_1-C_6 \text{ alkyl})-NH(C_1-C_4 \text{ alkyl})$ , - $SO_2$ -NH-( $C_1$ - $C_6$  $alkyl)-N(C_1-C_4$ alkyl) ( $C_1-C_4$ alkyl), [1,2,4] triazolidine-3,5-dione, -NHC(0)NH<sub>2</sub>, -NHC(0)NH( $C_1-C_6$ alkyl),  $-NHC(0)N(C_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl})$ ,  $\texttt{alkyl)C(O)NH}_2, \quad -\texttt{N(C}_1-\texttt{C}_6 \quad \texttt{alkyl)C(O)NH(C}_1-\texttt{C}_6 \quad \texttt{alkyl)}, \quad -\texttt{N(C}_1-\texttt{C}_6 \quad \texttt{alkyl)}, \quad -\texttt{N(C}_1$  $alkyl)C(0)N(C_1-C_6 \ alkyl)(C_1-C_6 \ alkyl)$ , halogen,  $-CF_3$ , OH,  $-SO_2NR_{31}R_{32}$ ,  $-C(0)NR_{31}R_{32}$ ,  $-NR_{31}R_{32}$ , hydroxy  $C_1-C_{10}$  alkyl optionally substituted with phenyl or 2-methylphenyl, -0- $(C_1-C_4 \text{ alkyl})-\text{phenyl}, -\text{NHC}(S)NH_2, -\text{NHC}(S)NH(C_1-C_6 \text{ alkyl}),$ -NHC(S)N( $C_1$ - $C_6$  alkyl)( $C_1$ - $C_6$  alkyl), ( $C_1$ - $C_4$  alkyl)-O-phenyl,  $-C(0)-(C_1-C_6 \text{ alkyl})$  wherein the alkyl group is optionally substituted with NH2, N(C1-C6 alkyl), or N(C1-C6 alkyl)(C1alkyl); -O-C<sub>3</sub>-C<sub>6</sub> cycloalkyl, oxazole optionally substituted with 1, or 2 groups that are independently  $C_1$ - $C_4$  alkyl or phenyl, hydroxy  $C_1$ - $C_4$  alkoxy, aminoalkoxy,  $NH(C_1-C_6alkyl)-alkoxy$ ,  $N(C_1-C_6alkyl)(C_1-C_6alkyl)-alkoxy$ , wherein  $R_{31}$  and  $R_{32}$  at each occurrence are independently selected from the group consisting of hydrogen,  $C_1\text{--}C_6$ alkyl, hydroxy  $C_1-C_6$  alkyl,  $-(C_1-C_6$  alkyl) $-C(O)N(C_1-C_6)$ alkyl)( $C_1$ - $C_6$  alkyl), -( $C_1$ - $C_6$  alkyl)-NH( $C_1$ - $C_6$  alkyl), - $(C_1-C_6 \text{ alkyl})-N(C_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl}), -(C_1-C_6)$ alkyl)phenyl,  $-(C_1-C_6 \text{ alkyl})$ pyridyl, -C(0)furanyl, (C<sub>1</sub>-C<sub>6</sub> alkyl)-tetrahydrofuran, wherein the phenyl group is unsubstituted or substituted with 1, 2, or 3 groups that are independently  $C_1-C_4$ alkoxy, or halogen,

wherein at each occurrence R<sub>31</sub>, R<sub>32</sub> and the nitrogen to which they are attached independently form a pyrrolidinyl, piperazinyl, piperidinyl, or azepanyl, each of which is optionally fused to a benzene, pyridine or pyrimidine ring and each of which is optionally substituted with hydroxy, C<sub>1</sub>-C<sub>6</sub> alkyl,

hydroxy  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_4$  alkoxy  $C_1$ - $C_6$  alkyl, - C(0) NH<sub>2</sub>, or -C(0) NH-benzyl.

Even more preferred compounds of Z2 are those wherein is phenyl; halophenyl, dihalophenyl; trihalophenyl

- 5 R<sub>35</sub> is phenyl; halophenyl, dihalophenyl; trihalophenyl; tetrahalophenyl; pentahalophenyl; halo, benzyloxyphenyl; halo, alkylphenyl; benzyloxyphenyl; cyclohexyl; (C<sub>1</sub>-C<sub>4</sub> alkoxy)carbonylphenyl; (C<sub>1</sub>-C<sub>4</sub> alkoxy)phenyl; -S-phenyl, or benzodioxole;
- 10  $R_{41}$  is H, cyclohexyl, phenyl, or  $C_1\text{--}C_6$  alkyl optionally substituted with 1 or 2 groups that are phenyl, hydroxy, or  $C_1\text{--}C_4$  thioalkoxy; and

 $R_{42}$  is hydrogen or  $-CH_2CN$ .

- Other preferred compounds of Z2 are those wherein R<sub>35</sub> is 3,5-dihalophenyl;
- -phenyl-pyridine, biphenyl, -phenylphenyl, R40 benzothienyl, -phenyl-thienyl, -phenyl-furanyl, -phenylpyrimidinyl, -phenyl-isoxazolyl, - $(C_1-C_4 \text{ alkyl})-O-C(O)NH$ phenyl,  $-(C_1-C_4 \text{ alkyl})-0-C(0)N(C_1-C_6 \text{ alkyl})-phenyl, -(C_1-C_4)$ 20  $alkyl) - SO_2NH_2$  CN,  $-(C_1-C_4 \ alkyl) - (C_3-C_6 \ cycloalkyl)$ ,  $-(C_1-C_4 \ alkyl)$  $alkyl) - C(0)0 - (C_1 - C_4 \ alkyl), - (C_1 - C_4 \ alkyl) - R_{33}, or C_1 - C_8$ alkyl, wherein each of the above is unsubstituted or substituted with 1, 2, or 3 groups that are independently halogen,  $C_1-C_4$  alkyl,  $C_1-C_4$  alkoxy,  $CF_3$ ,  $-0-(C_1-C_4$  alkyl)-25 phenyl wherein the phenyl is optionally substituted with 1 or 2 halogens, -CHO, or -NHSO<sub>2</sub>-( $C_1$ - $C_4$  alkyl).

Even more preferred compounds of Z2 are those wherein

- 30 R<sub>35</sub> is 3,5-difluorophenyl; 3,5-dichlorophenyl; or 3-chloro,5-fluorophenyl; and
  - $R_{40}$  is phenyl which is unsubstituted or substituted with 1, 2, or 3 groups that are independently fluoro, chloro, bromo, iodo, methyl, ethyl, methoxy, ethoxy,  $CF_3$ , or -Obenzyl

wherein the phenyl is optionally substituted with 1 or 2 groups that are independently halogen, or  $-NHSO_2CH_3$ .

Even more preferred compounds of Z2 are those wherein

- 5 R<sub>51</sub> at each occurrence is independently  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $-NHSO_2CH_3$ ,  $-SO_2$ -NH-(ethyl)-NH( $CH_3$ ),[1,2,4]triazolidine-3,5-dione, -NHC(0) $NH_2$ ,  $-CF_3$ , OH,  $-SO_2NR_{31}R_{32}$ , -C(0) $NR_{31}R_{32}$ , hydroxyoctyl, -CH(OH)-2-methylphenyl, -Obenzyl, or -NHC(S)NH( $CH_3$ );
- wherein  $R_{31}$  and  $R_{32}$  at each occurrence are independently selected from the group consisting of hydrogen,  $C_1$ - $C_6$  alkyl, hydroxy  $C_1$ - $C_6$  alkyl, -(CH<sub>2</sub>)C(O)N(CH<sub>3</sub>)<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>, benzyl, phenethyl, -CH<sub>2</sub>CH<sub>2</sub>pyridyl, -C(O)furanyl, or
- at each occurrence R<sub>31</sub>, R<sub>32</sub> and the nitrogen to which they are attached independently form a pyrrolidinyl, piperazinyl, piperidinyl, or azepanyl, each of which is optionally substituted with hydroxymethyl, hydroxyethyl, methoxymethyl, or -C(O)NH<sub>2</sub>.

20

30

Even more preferred compounds of Z2 are those wherein  $R_{40}$  is 3-ethylphenyl or 3-methoxyphenyl; and  $R_{42}$  is hydrogen.

- 25 Preferred compounds of Z2 include those wherein
  - $R_{51}$  at each occurrence is independently  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $-C(0)NR_{31}R_{32}$ ,  $-C(0)CH_2NH_2$ , cyclopentyloxy, -NHC(0)NH(ethyl), oxazole optionally substituted with 1 or 2 groups that are independently  $C_1$ - $C_4$  alkyl or phenyl, hydroxyethoxy, diethylaminoethoxy,
    - wherein  $R_{31}$  and  $R_{32}$  at each occurrence are independently selected from the group consisting of hydrogen,  $C_1$ - $C_6$  alkyl, hydroxy  $C_1$ - $C_6$  alkyl, -CH<sub>2</sub>-tetrahydrofuran.

Other preferred compounds of Z2 include those wherein  $\ensuremath{R_{35}}$  is cyclohexyl.

More preferred compounds include those wherein

 $R_{40}$  is phenyl, or  $C_1-C_8$  alkyl, wherein each is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently halogen,  $C_1-C_4$  alkyl,  $C_1-C_4$  alkoxy, halo ( $C_1-C_4$  alkyl); and

 $R_{42}$  and  $R_{41}$  are both hydrogen.

10

15

20

25

30

More preferred compounds include those wherein

R<sub>40</sub> is phenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3-ethoxyphenyl, 4-ethoxyphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-methylphenyl, 3-methylphenyl, 2-ethylphenyl, 3-ethylphenyl, or C<sub>3</sub>-C<sub>6</sub> alkyl; and

 $R_{51}$  at each occurrence is independently  $C_1-C_6$  alkyl,  $C_1-C_6$  alkoxy, or halogen,

wherein  $R_{31}$  and  $R_{32}$  at each occurrence are independently selected from the group consisting of hydrogen,  $C_1$ - $C_6$  alkyl, hydroxy  $C_1$ - $C_6$  alkyl, and -( $C_1$ - $C_6$  alkyl)phenyl wherein the phenyl group is unsubstituted or substituted with 1, 2, or 3 groups that are independently  $C_1$ - $C_4$  alkoxy, or halogen,

wherein at each occurrence R<sub>31</sub>, R<sub>32</sub> and the nitrogen to which they are attached independently form a pyrrolidinyl, piperazinyl, piperidinyl, or azepanyl, each of which is optionally fused to a benzene, pyridine or pyrimidine ring and each of which is optionally substituted with hydroxy, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl, -C(0)NH<sub>2</sub>, or -C(0)NH-benzyl.

More preferred compounds include those wherein

 $R_{35}$  is 3-halo, 5-benzyloxyphenyl; 3-benzyloxyphenyl; or 4-benzyloxyphenyl;

 $R_{41}$  is H, cyclohexyl, phenyl, or  $C_1\text{--}C_6$  alkyl optionally substituted with 1 or 2 groups that are phenyl, hydroxy, or  $C_1\text{--}C_4$  thioalkoxy; and

 $R_{42}$  is hydrogen or -CH<sub>2</sub>CN.

5

More preferred compounds include those wherein

10 is phenyl, -phenyl-pyridine, biphenyl,  $-(C_1-C_4 \text{ alkyl})-O-C(0) \text{NH-phenyl}$ ,  $-(C_1-C_4 \text{ alkyl})-O-C(0) \text{N}(C_1-C_6 \text{ alkyl})-phenyl$ ,  $-(C_1-C_4 \text{ alkyl})-SO_2\text{NH}_2$ ,  $-(C_1-C_4 \text{ alkyl})-(C_3-C_6 \text{ cycloalkyl})$ ,  $-(C_1-C_4 \text{ alkyl})-C(0)O-(C_1-C_4 \text{ alkyl})$ ,  $-(C_1-C_4 \text{ alkyl})-R_{33}$ , or  $C_1-C_8 \text{ alkyl}$ , wherein each of the above is unsubstituted or substituted with 1, 2, or 3 groups that are independently halogen,  $C_1-C_4 \text{ alkyl}$ ,  $C_1-C_4 \text{ alkoxy}$ ,  $CF_3$ , -Obenzyl wherein the phenyl is optionally substituted with 1 or 2 halogens, -CHO, or  $-NHSO_2-(C_1-C_4 \text{ alkyl})$ .

More preferred compounds include those wherein

- 20  $R_{40}$  is phenyl or  $C_1$ - $C_8$  alkyl, wherein each of the above is unsubstituted or substituted with 1, 2, or 3 groups that are independently halogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy,  $CF_3$ , -Obenzyl wherein the phenyl is optionally substituted with 1 or 2 halogens, -CHO, or -NHSO<sub>2</sub>-( $C_1$ - $C_4$  alkyl); and
- 25  $R_{41}$  is hydrogen or  $C_1$ - $C_6$  alkyl optionally substituted with 1 or 2 groups that are phenyl, hydroxy, or  $C_1$ - $C_4$  thioalkoxy;

 $R_{42}$  is hydrogen; and

5

10

15

20

wherein  $R_{31}$  and  $R_{32}$  at each occurrence are independently selected from the group consisting of hydrogen,  $C_1$ - $C_6$  alkyl, hydroxy  $C_1$ - $C_6$  alkyl,  $-(C_1$ - $C_6$  alkyl)-NH( $C_1$ - $C_6$  alkyl),  $-(C_1$ - $C_6$  alkyl)-N( $C_1$ - $C_6$  alkyl)( $C_1$ - $C_6$  alkyl), and benzyl wherein the phenyl group is unsubstituted or substituted with 1, or 2 groups that are independently  $C_1$ - $C_4$  alkoxy, or halogen,

wherein at each occurrence  $R_{31}$ ,  $R_{32}$  and the nitrogen to which they are attached independently form a pyrrolidinyl, piperazinyl, or piperidinyl, each of which is optionally substituted with hydroxy, hydroxy  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_4$  alkoxy  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_0$  NH<sub>2</sub>, or - C(0) NH-benzyl.

More preferred compounds include those wherein

 $R_{40}$  is phenyl or  $C_1$ - $C_8$  alkyl, wherein each of the above is unsubstituted or substituted with 1, 2, or 3 groups that are independently halogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, or  $CF_3$ ; and

 $R_{51} \ \ \, \text{at each occurrence is independently $C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, $-NHSO_2CH_3$, $-NHSO_2CF_3$, halogen, $-CF_3$, $OH$, <math display="block">-SO_2NR_{31}R_{32}$, $-C(0)NR_{31}R_{32}$, $-NR_{31}R_{32}$, hydroxy $C_1$-$C_{10}$ alkyl, hydroxy $C_1$-$C_4$ alkoxy, aminoalkoxy, $NH(C_1$-$C_6alkyl)$-alkoxy, $N(C_1$-$C_6alkyl)$($C_1$-$C_6alkyl)$-alkoxy, $C_1$-$C_6alkyl)$-alkoxy, $C_1$-$C_6alkyl)$-alkoxy,$ 

wherein  $R_{31}$  and  $R_{32}$  at each occurrence are independently selected from the group consisting of hydrogen,  $C_1\text{--}C_6$ 

alkyl, hydroxy  $C_1$ - $C_6$  alkyl, and benzyl wherein the phenyl group is unsubstituted or substituted with 1 or 2 groups that are independently methoxy, ethoxy, or halogen, or

wherein at each occurrence R<sub>31</sub>, R<sub>32</sub> and the nitrogen to which they are attached independently form a pyrrolidinyl, piperazinyl, or piperidinyl ring each of which is optionally substituted with hydroxy, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl, or-C(0)NH<sub>2</sub>.

More preferred compounds include those wherein  $$R_{35}$$  is 3-fluoro, 5-benzyloxyphenyl or 3-chloro, 5-benzyloxyphenyl.

15

20

More preferred compounds include those wherein  $R_{35}$  is -S-phenyl, benzo[1,3]dioxole, furanyl, or thienyl;  $R_{41}$  is H, cyclohexyl, phenyl, or  $C_1$ - $C_6$  alkyl optionally substituted with 1 or 2 groups that are phenyl, hydroxy, or  $C_1$ - $C_4$  thioalkoxy; and  $R_{42}$  is hydrogen or -CH<sub>2</sub>CN.

More preferred compounds include those wherein

R<sub>40</sub> is phenyl, -phenyl-pyridine, biphenyl, -phenyl-pyrimidinyl,
-(C<sub>1</sub>-C<sub>4</sub> alkyl)-O-C(O)NH-phenyl, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-O-C(O)N(C<sub>1</sub>-C<sub>6</sub>
alkyl)-phenyl, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-SO<sub>2</sub>NH<sub>2</sub>, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-(C<sub>3</sub>-C<sub>6</sub>
cycloalkyl), -(C<sub>1</sub>-C<sub>4</sub> alkyl)-C(O)O-(C<sub>1</sub>-C<sub>4</sub> alkyl), -(C<sub>1</sub>-C<sub>4</sub>
alkyl)-R<sub>33</sub>, or C<sub>1</sub>-C<sub>8</sub> alkyl, wherein each of the above is
unsubstituted or substituted with 1, 2, or 3 groups that
are independently halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, CF<sub>3</sub>,
-Obenzyl wherein the phenyl is optionally substituted with
1 or 2 halogens, -CHO, or -NHSO<sub>2</sub>-(C<sub>1</sub>-C<sub>4</sub> alkyl), -NHSO<sub>2</sub>CF<sub>3</sub>.

Still more preferred compounds include those wherein

 $R_{40}$  is phenyl or  $C_1$ - $C_8$  alkyl, wherein each of the above is unsubstituted or substituted with 1, 2, or 3 groups that are independently halogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy,  $CF_3$ , -Obenzyl wherein the phenyl is optionally substituted with 1 or 2 halogens, -CHO, or -NHSO<sub>2</sub>-( $C_1$ - $C_4$  alkyl); and

 $R_{41}$  is hydrogen or  $C_1$ - $C_6$  alkyl optionally substituted with 1 or 2 groups that are phenyl, hydroxy, or  $C_1$ - $C_4$  thioalkoxy; and;

R<sub>42</sub> is hydrogen; and

5

- $R_{51}$  at each occurrence is independently  $C_1\text{--}C_6$  alkyl,  $C_1\text{--}C_6$ 10 alkoxy,  $-NHSO_2-(C_1-C_4$  alkyl) wherein the alkyl group is optionally substituted with 1, 2, or 3 halogens,  $-SO_2-NH (C_1-C_6 \text{ alkyl})-NH_2$ ,  $-SO_2-NH-(C_1-C_6 \text{ alkyl})-NH(C_1-C_4 \text{ alkyl})$ ,  $alkyl)-N(C_1-C_4$  $SO_2-NH-(C_1-C_6)$ alkyl)  $(C_1-C_4)$ alkyl), 15 -NHC(0)NH<sub>2</sub> $-NHC(O)NH(C_1-C_6)$ alkyl),  $-NHC(O)N(C_1-C_6)$ alkyl)  $(C_1-C_6)$ alkyl),  $-N(C_1-C_6 \quad alkyl)C(0)NH_2$  $-N(C_1-C_6)$  $alkyl)C(0)NH(C_1-C_6 alkyl)$ ,  $-N(C_1-C_6 \quad alkyl)C(0)N(C_1-C_6$ alkyl)( $C_1-C_6$  alkyl), halogen,  $-CF_3$ , OH,  $-SO_2NR_{31}R_{32}$  $-C(0)NR_{31}R_{32}$ ,  $-NR_{31}R_{32}$ , hydroxy  $C_1-C_{10}$  alkyl, -Obenzyl, -20  $\label{eq:nhc} \mbox{NHC(S)NH}_2, \ -\mbox{NHC(S)NH}_{(C_1-C_6 \ alkyl)}, \ -\mbox{NHC(S)N}_{(C_1-C_6 \ alkyl)}_{(C_1-C_6 \$  $C_6$  alkyl),  $(C_1-C_4$  alkyl)-O-phenyl,  $-C(0)-(C_1-C_6$  alkyl), -Ocyclopentyl, -0-cyclohexyl, hydroxy C₁-C₄ alkoxy, aminoalkoxy,  $NH(C_1-C_6 \text{ alkyl})-alkoxy$ ,  $N(C_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl})$ alkyl)-alkoxy,
- wherein  $R_{31}$  and  $R_{32}$  at each occurrence are independently selected from the group consisting of hydrogen,  $C_1$ - $C_6$  alkyl, hydroxy  $C_1$ - $C_6$  alkyl,  $-(C_1$ - $C_6$  alkyl)-NH( $C_1$ - $C_6$  alkyl),  $-(C_1$ - $C_6$  alkyl)-N( $C_1$ - $C_6$  alkyl)( $C_1$ - $C_6$  alkyl), and benzyl wherein the phenyl group is unsubstituted or substituted with 1, or 2 groups that are independently  $C_1$ - $C_4$  alkoxy, or halogen,
  - wherein at each occurrence  $R_{31}$ ,  $R_{32}$  and the nitrogen to which they are attached independently form a pyrrolidinyl, piperazinyl, or piperidinyl, each of

which is optionally substituted with hydroxy, hydroxy  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_4$  alkoxy  $C_1$ - $C_6$  alkyl, -C(0)NH<sub>2</sub>, or -C(0)NH-benzyl.

- 5 Still more preferred compounds include those wherein
  - $R_{40}$  is phenyl or  $C_1$ - $C_8$  alkyl, wherein each of the above is unsubstituted or substituted with 1, 2, or 3 groups that are independently halogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, or  $CF_3$ ; and
- 10  $R_{51}$  at each occurrence is independently  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy, -NHSO<sub>2</sub>CH<sub>3</sub>, -NHSO<sub>2</sub>CF<sub>3</sub>, halogen, -CF<sub>3</sub>, OH, -SO<sub>2</sub>NR<sub>31</sub>R<sub>32</sub>, -C(O)NR<sub>31</sub>R<sub>32</sub>, -NR<sub>31</sub>R<sub>32</sub>, hydroxy  $C_1$ - $C_{10}$  alkyl, hydroxy  $C_1$ - $C_4$  alkoxy, aminoalkoxy, NH( $C_1$ - $C_6$ alkyl)-alkoxy, N( $C_1$ - $C_6$ alkyl)( $C_1$ - $C_6$ alkyl)-alkoxy,
- wherein R<sub>31</sub> and R<sub>32</sub> at each occurrence are independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, and benzyl wherein the phenyl group is unsubstituted or substituted with 1 or 2 groups that are independently methoxy, ethoxy, or halogen, or
  - wherein at each occurrence R<sub>31</sub>, R<sub>32</sub> and the nitrogen to which they are attached independently form a pyrrolidinyl, piperazinyl, or piperidinyl ring each of which is optionally substituted with hydroxy, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl, or-C(O)NH<sub>2</sub>.

Particularly preferred compounds of Formula X are those where  $R_1$  is 3,5-difluorophenyl.

In another specific aspect within Formula X, the invention provides compounds of formula Z3

25

or a pharmaceutically acceptable salt thereof, wherein is selected from the group consisting  $R_{30}$ of phenyl, pyrazolopyrimidinyl, oxa-aza-benzoazulenyl, isoxazolyl, 5 triazolopyridinyl, pyrrolidinonyl, tetrahydrothia-azafluorenyl, pyridyl, piperidinyl, dihydrocyclopentaguinolinyl, furyl, naphthothienyl, phthalazinonyl, thiadiazolyl, thienopyrimidinonyl, oxadiaza-cyclopentanaphthalenyl, dihydrobenzodioxepinyl, 10 chromanonyl, chromenonyl, oxazolidinyl, purinyl, oxaxolyl, thiazolyl, pyridazinonyl, thiazolyl, pyranyl, dihydropyranopyridinyl, diazepanyl, cyclopropyl, dihydronaphthoisoxazolyl, benzoindazole, dihydrocyclopentachromenonyl, imidazopyrazolyl, tetrahydrocyclopentachromenonyl, 15 dihydroquinolinonyl, pyridyl, isochromanyl, quinazolinonyl, pyrazolopyridinyl, dihydrobenzothiophene dioxide, dihydrofurobenzoisoxazolyl, dihydropyrimidine dionyl, thienopyrazolyl, oxazolyl, tetrahydrocyclopentapyrazolyl, dihydronaphthalenonyl, 20 dihydrobenzofuranonyl, dihydrocyclopentathienyl, tetrahydrocyclopentapyrazolyl, tetrahydropyrazoloazepinyl, indazolyl, tetrahydrocycloheptaisoxazolyl, tetrahydroindolonyl, pyrrolidinyl, thienopyridinyl, dioxodihydrobenzoisothiazolonyl, triazolopyrimidinyl, 25 thienyl, dihydrothienopyrimidinonyl, and benzooxadiazolyl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently selected from the group consisting of  $C_1-C_{10}$  alkyl optionally substituted with phenyl, hydroxy, 30 hydroxy  $C_1$ - $C_{10}$  alkyl optionally substituted with phenyl or  $(C_1-C_4 \text{ alkyl})$  phenyl,  $C_1-C_6 \text{ alkoxy optionally}$ substituted with 1 or 2 hydroxy groups, -C(0)NR31R32,  $-NR_{31}-SO_2-(C_1-C_6$  alkyl) wherein the alkyl group is optionally substituted with 1, 2, or 3 R<sub>33</sub> groups, -

5

10

15

20

25

30

 $SO_2-NH(C_1-C_6$  alkyl) wherein the alkyl group is optionally substituted with 1 or 2 R<sub>33</sub> groups, -SO<sub>2</sub>- $N(C_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl})$  wherein each alkyl group is optionally substituted with 1 or 2  $R_{33}$  groups, - $SO_2-NH(C_1-C_6$  alkyl)-phenyl wherein the phenyl is optionally substituted with 1 or 2 groups that are independently  $C_1-C_4$  alkoxy or halogen,  $-0-(C_1-C_6)$ alkyl)-phenyl,  $-(C_1-C_6 \quad alkyl)-O-phenyl,$  $alkyl)-O-(C_1-C_6$  alkyl)-phenyl,triazolidine-3,5dione, halogen,  $-NHC(0)NH_2$ ,  $-N(C_1-C_6 alkyl)C(0)NH_2$ ,  $-N(C_1-C_6)$  $alkyl)C(O)NH(C_1-C_6$ alkyl),  $-N(C_1-C_6)$  $alkyl)C(0)N(C_1-C_6 \ alkyl)(C_1-C_6 \ alkyl), -(C_1-C_6 \ alkyl)$ thienyl,  $-(C_1-C_6 \text{ alkyl})$  furanyl,  $-S-(C_1-C_6 \text{ alkyl})$ phenyl,  $-SO_2NR_{31}R_{32}$ , -C(O)  $-NR_{31}R_{32}$ ,  $-NR_{31}R_{32}$ , dithiane,  $-NHC(S)NH_2$ , -NHC(S)NH( $C_1$ - $C_6$  alkyl), -NHC(S)N( $C_1$ - $C_6$ alkyl)  $(C_1-C_6$ alkyl),  $-CO_2(C_1-C_6)$ alkyl), tetrahydropyran, phenyl optionally substituted with 1 or 2 groups that are independently F, Cl or Br, pyridine,  $-C_2-C_4$  alkynyl-phenyl,  $-0-C_3-C_6$  cycloalkyl,  $-0-(C_1-C_6 \text{ alkyl})-R_{33}$ , benzo[1,2,5]oxadiazole,  $-C(0)-C_1$  $(C_1-C_6 \text{ alkyl})$  wherein the alkyl group is optionally substituted with NH2, N(C1-C6 alkyl), or N(C1-C6 alkyl)( $C_1-C_6$  alkyl); -C(0)NH-phenyl,  $-C(0)N(C_1-C_6)$ alkyl)-phenyl, 4,4-Dimethyl-4,5-dihydro-oxazole, - $(C_1-C_6 \text{ alkyl})-S-pyridine, -(C_1-C_6 \text{ alkyl})-SO_2-pyridine,$  $-(C_1-C_6 \text{ thioalkoxy})-pyridine,$ 

wherein  $R_{31}$  and  $R_{32}$  at each occurrence are independently selected from the group consisting of hydrogen,  $C_1$ - $C_6$  alkyl, hydroxy  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  haloalkyl,  $-(C_1$ - $C_6$  alkyl)- $C(0)NH_2$ ,  $-(C_1$ - $C_6$  alkyl)- $C(0)NH(C_1$ - $C_6$  alkyl),  $-(C_1$ - $C_6$  alkyl)- $C(0)N(C_1$ - $C_6$  alkyl)( $C_1$ - $C_6$  alkyl),  $-(C_1$ - $C_6$  alkyl)- $NH_2$ ,  $-(C_1$ - $C_6$  alkyl)- $NH(C_1$ - $C_6$  alkyl),  $-(C_1$ - $C_6$  alkyl)- $N(C_1$ - $C_6$  alkyl),  $-(C_1$ - $C_6$  alkyl),  $-(C_1$ - $C_6$ 

5

10

15

20

25

alkyl)phenyl,  $-(C_1-C_6 \text{ alkyl})$ pyridyl, -C(0) furanyl,  $(C_1-C_6 \text{ alkyl})$ -tetrahydrofuran, wherein

the phenyl and pyridyl groups are unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently  $C_1-C_4$  alkyl, hydroxy,  $C_1-C_4$  alkoxy, halogen, or

R<sub>31</sub>, R<sub>32</sub> and the nitrogen to which they are attached form a 5, 6, or 7 membered heterocycloalkyl or a 6 membered heteroaryl ring, each of which is optionally fused to a benzene, pyridine or pyrimidine ring and each of which is optionally substituted with C<sub>1</sub>-C<sub>6</sub> alkoxy, hydroxy, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl, -C(0)NH<sub>2</sub>, -C(0)NH-(C<sub>1</sub>-C<sub>6</sub> alkyl)-phenyl, ;

 $R_{33}$  at each occurrence is independently, H,  $NH_2$ ,  $NH(C_1-C_6$  alkyl),  $N(C_1-C_6$  alkyl)( $C_1-C_6$  alkyl),  $N(C_1-C_6$  alkyl);

R<sub>35</sub> is phenyl,  $C_3$ - $C_8$  cycloalkyl, -S-phenyl, benzodioxole, thienyl,  $C_1$ - $C_6$  alkyl, furanyl, each of which is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, OH, hydroxy  $C_1$ - $C_6$  alkyl, halogen, halo  $C_1$ - $C_6$  alkyl, halo  $C_1$ - $C_6$  alkoxy, -O-( $C_1$ - $C_6$  alkyl)-phenyl, -CO<sub>2</sub>-( $C_1$ - $C_6$  alkyl), -( $C_1$ - $C_4$  alkyl)-( $C_5$ - $C_6$  cycloalkyl);

 $R_{42}$  is H,  $C_1$ - $C_6$  alkyl, benzyl, -NHC(0)-( $C_1$ - $C_6$  alkyl), or -NHC(0)-phenyl wherein the phenyl is optionally substituted with 1 or 2 alkyl groups,

R<sub>55</sub> is cyclohexyl; cyclopentyl; azepanone; phenyl; piperidinyl;
-SO<sub>2</sub>-phenyl; pyrrolidinyl; or 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine; wherein each is optionally

substituted with -C(O)NH<sub>2</sub>; -C(O)NH(C<sub>1</sub>-C<sub>6</sub> alkyl); -C(O)N(C<sub>1</sub>-C<sub>6</sub> alkyl) (C<sub>1</sub>-C<sub>6</sub> alkyl); C<sub>1</sub>-C<sub>6</sub> alkoxycarbonyl; -O-(C<sub>1</sub>-C<sub>6</sub>
alkyl)-C(O)NR<sub>31</sub>R<sub>32</sub>; -(C<sub>1</sub>-C<sub>6</sub> alkyl)-phenyl; 4,5-dihydro-2Hpyridazin-3-one; C<sub>5</sub>-C<sub>6</sub> cycloalkyl which is optionally
substituted with one CN group, phenyloxy wherein the

phenyl group is optionally substituted with -NHC(0)C1-C6 alkyl, -N(C1-C6 alkyl)-C(0)C1-C6 alkyl, wherein

 $R_{31}$ ,  $R_{32}$  and the nitrogen to which they are attached form a pyrrolidine, piperidine, piperazine, morpholine, or thiamorpholine ring, wherein each ring is unsubstituted or substituted with 1, 2, or 3 groups that are independently OH,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $-(C_1$ - $C_6$  alkyl)-imidazole wherein the imidazole is optionally substituted with 1 or 2  $C_1$ - $C_4$  alkyl groups, or hydroxy ( $C_1$ - $C_6$  alkyl) wherein the alkyl group is optionally substituted with 1 phenyl ring,

or

5

10

R<sub>42</sub>, R<sub>55</sub> and the nitrogen to which they are attached form a tetrahydroisoquinolinyl, dihydroisoquinolinyl, or isoquinolinyl group which is optionally substituted by 1, 2, 3, or 4 groups that are independently halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, CN, OH, and phenyl, wherein the phenyl is optionally substituted with halogen, hydroxyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, and C<sub>1</sub>-C<sub>4</sub> alkyl.

20

25

30

More preferred compounds of Z3 include those wherein selected from the group consisting of phenyl,  $R_{30}$ pyrrolidinonyl, pyridyl, piperidinyl, furyl, cyclopropyl, and thienyl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently selected from the group consisting of  $C_1-C_{10}$  alkyl, hydroxy, hydroxy  $C_1-C_{10}$  alkyl  $C_1-C_6$  alkoxy,  $-NR_{31}-SO_2-\left(C_1-C_6 \quad \text{alkyl}\right), \quad -SO_2-NH\left(C_1-C_6 \quad \text{alkyl}\right),$  $N(C_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl}), \text{ halogen},$ -NHC(O)NH<sub>2</sub> $-N(C_1-C_6 \quad alkyl)C(O)NH_2, \quad -N(C_1-C_6 \quad alkyl)C(O)NH(C_1-C_6)$ alkyl),  $-N(C_1-C_6 \text{ alkyl})C(O)N(C_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl})$ ,  $-SO_{2}NR_{31}R_{32},\quad -C\left( O\right) \quad -NR_{31}R_{32},\quad -NR_{31}R_{32},\quad -C_{2}-C_{4}\quad \text{alkynyl-}$ phenyl,  $-O-C_3-C_6$  cycloalkyl,  $-O-(C_1-C_6$  alkyl)- $R_{33}$ , benzo[1,2,5]oxadiazole,  $-C(0)-(C_1-C_6 \text{ alkyl};$ 

5

10

15

20

25

30

wherein  $R_{31}$  and  $R_{32}$  at each occurrence are independently selected from the group consisting of hydrogen,  $C_1$ - $C_6$  alkyl, hydroxy  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  haloalkyl,  $-(C_1$ - $C_6$  alkyl)- $C(0)NH_2$ ,  $-(C_1$ - $C_6$  alkyl)- $C(0)NH(C_1$ - $C_6$  alkyl),  $-(C_1$ - $C_6$  alkyl)- $C(0)N(C_1$ - $C_6$  alkyl)( $C_1$ - $C_6$  alkyl),  $-(C_1$ - $C_6$  alkyl)- $NH_2$ ,  $-(C_1$ - $C_6$  alkyl)- $NH(C_1$ - $C_6$  alkyl), benzyl, and -C(0) furanyl, wherein

the phenyl and pyridyl groups are unsubstituted or substituted with 1, 2, or 3, groups that are independently  $C_1-C_4$  alkyl, hydroxy,  $C_1-C_4$  alkoxy, or halogen, or

R<sub>31</sub>, R<sub>32</sub> and the nitrogen to which they are attached form a 5, 6, or 7 membered heterocycloalkyl or a 6 membered heteroaryl ring, each of which is optionally substituted with C<sub>1</sub>-C<sub>6</sub> alkoxy, hydroxy, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl, or -C(0)NH<sub>2</sub>;

 $R_{35}$  is phenyl,  $C_3-C_6$  cycloalkyl, or -S-phenyl, each of which is unsubstituted or substituted with 1, 2, or 3 groups that are independently  $C_1-C_4$  alkyl,  $C_1-C_4$  alkoxy,  $CF_3$ ,  $OCF_3$ , halogen, -Obenzyl,  $-CO_2-(C_1-C_6$  alkyl),  $-(C_1-C_4$  alkyl)- $(C_5-C_6$  cycloalkyl);

 $R_{42}$  is H,  $C_1$ - $C_6$  alkyl, benzyl, -NHC(0)-( $C_1$ - $C_6$  alkyl), or -NHC(0)-phenyl wherein the phenyl is optionally substituted with 1 or 2 alkyl groups,

R<sub>55</sub> is cyclohexyl; azepanone; phenyl; piperidinyl; -SO<sub>2</sub>-phenyl; pyrrolidinyl; or 4,5,6,7-tetrahydro-thiazolo[5,4-c]pyridine; wherein each is optionally substituted with -C(0)NH<sub>2</sub>; C<sub>1</sub>-C<sub>6</sub> alkoxycarbonyl; -O-(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(0)NR<sub>31</sub>R<sub>32</sub>; -(C<sub>1</sub>-C<sub>6</sub> alkyl)-phenyl; 4,5-dihydro-2H-pyridazin-3-one; cyclopentyl which is optionally substituted with one CN group, phenyloxy wherein the phenyl group is optionally substituted with -NHC(0)C<sub>1</sub>-C<sub>6</sub> alkyl, wherein

 $R_{31}$ ,  $R_{32}$  and the nitrogen to which they are attached form a pyrrolidine, piperidine, piperazine, or morpholine ring, wherein each ring is unsubstituted or substituted with 1, 2, or 3 groups that are independently OH,  $-(C_1-C_6 \text{ alkyl})$ -imidazole wherein the imidazole is optionally substituted with 1 or 2  $C_1-C_4$  alkyl groups, or hydroxy ( $C_1-C_6$  alkyl) wherein the alkyl group is optionally substituted with 1 phenyl ring,

10 or .

15

30

5

 $R_{42}$ ,  $R_{55}$  and the nitrogen to which they are attached form a tetrahydroisoquinolinyl, group which is optionally substituted by 1, 2, 3, or 4 groups that are independently halogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, CN, OH, and phenyl, wherein the phenyl is optionally substituted with halogen, hydroxyl,  $C_1$ - $C_4$  alkoxy, and  $C_1$ - $C_4$  alkyl.

Even more preferred compounds of Z3 include those wherein R<sub>30</sub> is selected from the group consisting of phenyl, pyridyl, or piperidinylwherein each of the above is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently selected from the group consisting of C<sub>1</sub>-C<sub>10</sub> alkyl, hydroxy, hydroxy C<sub>1</sub>-C<sub>10</sub> alkyl C<sub>1</sub>-C<sub>6</sub> alkoxy, halogen, -SO<sub>2</sub>NR<sub>31</sub>R<sub>32</sub>, -C(O) -NR<sub>31</sub>R<sub>32</sub>, -NR<sub>31</sub>R<sub>32</sub>, -O-C<sub>3</sub>-C<sub>6</sub> cycloalkyl, -C(O)-(C<sub>1</sub>-C<sub>6</sub> alkyl);

wherein  $R_{31}$  and  $R_{32}$  at each occurrence are independently selected from the group consisting of hydrogen,  $C_1$ - $C_6$  alkyl, hydroxy  $C_1$ - $C_6$  alkyl, -( $C_1$ - $C_6$  alkyl)-NH( $C_1$ - $C_6$  alkyl), -( $C_1$ - $C_6$  alkyl)), -( $C_1$ - $C_6$  alkyl)-N( $C_1$ - $C_6$  alkyl), benzyl, and -C(0) furanyl, wherein

the phenyl group is unsubstituted or substituted with 1, 2, or 3, groups that are independently  $C_1$ - $C_4$  alkyl, hydroxy,  $C_1$ - $C_4$  alkoxy, or halogen, or

 $R_{31}$ ,  $R_{32}$  and the nitrogen to which they are attached form a pyrrolidinyl, piperidinyl, morpholinyl, pyridinyl, or pyrimidinyl ring, each of which is optionally substituted with  $C_1$ - $C_6$  alkoxy, hydroxy, hydroxy  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_4$  alkoxy  $C_1$ - $C_6$  alkyl, or -C(0)NH<sub>2</sub>;

R<sub>35</sub> is phenyl, cyclohexyl, cyclopentyl, or -S-phenyl, each of which is unsubstituted or substituted with 1, 2, or 3 groups that are independently C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, CF<sub>3</sub>, OCF<sub>3</sub>, halogen, -Obenzyl, -CO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub> alkyl), -(C<sub>1</sub>-C<sub>4</sub> alkyl)-(C<sub>5</sub>-C<sub>6</sub> cycloalkyl).

In a specific aspect, the invention provides compounds of formula X100:

15 **x100** 

5

10

and the pharmaceutically acceptable salts thereof, wherein n, p, and q are independently 0, 1 or 2; a dashed line res a single or double bond;

 $\ensuremath{R_1}\xspace,\ \ensuremath{R_2}\xspace,\ \ensuremath{R_3}\xspace,\ \ensuremath{and}\ \ensuremath{R_4}\xspace$  are independently selected from

20 hydrogen, halogen,  $C_1$ - $C_6$  alkyl, hydroxy,  $C_1$ - $C_6$  alkoxy, halo $(C_1$ - $C_6)$  alkyl, hydroxy $(C_1$ - $C_6)$  alkyl, halo $(C_1$ - $C_6)$  alkoxy, thio $(C_1$ - $C_6)$  alkyl,  $(C_1$ - $C_6)$  alkoxy $(C_1$ - $C_6)$  alkyl, amino $(C_1$ - $C_6)$  alkyl, mono $(C_1$ - $C_6)$  alkylamino $(C_1$ - $C_6)$  alkylamino $(C_1$ - $C_6)$  alkyl,

25 -(CH<sub>2</sub>)<sub>0-4</sub>-aryl or <math>-(CH<sub>2</sub>)<sub>0-4</sub>-heteroaryl,

 $C_2$ - $C_6$  alkenyl or  $C_2$ - $C_6$  alkynyl, each of which is optionally substituted with one, two or three substituents independently selected from the group consisting of halogen, hydroxy, -SH, cyano, -CF<sub>3</sub>,  $C_1$ - $C_3$  alkoxy,

amino, mono  $(C_1-C_6)$  alkylamino, and di  $(C_1-C_6)$  alkylamino,

-(CH<sub>2</sub>)<sub>0-4</sub>- C<sub>3</sub>-C<sub>7</sub> cycloalkyl, where the cycloalkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halogen, hydroxy, -SH, cyano, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, amino, mono(C<sub>1</sub>-C<sub>6</sub>)alkylamino, and di(C<sub>1</sub>-C<sub>6</sub>)alkylamino;

 $R_z,\;R_z{'}\,',\;R_z{'}\,',\;$  and  $R_z{'}\,''$  independently re

5

10  $C_1$ - $C_6$  alkyl, optionally substituted with one, two or three substituents independently selected from  $C_1$ - $C_3$  alkyl, halogen, -OH, -SH, -C $\equiv$ N, -CF $_3$ ,  $C_1$ - $C_6$  alkoxy, amino, mono  $(C_1$ - $C_6)$  alkylamino, and di  $(C_1$ - $C_6)$  alkylamino,

hydroxy, nitro, halogen, -CO2H, cyano,

- $-(CH_2)_{0-4}-CO-(C_1-C_{12} \text{ alkyl}), \quad -(CH_2)_{0-4}-CO-(C_2-C_{12} \text{ alkenyl}),$   $CH_2)_{0-4}-CO-(C_2-C_{12}) \text{ alkynyl}, \qquad -(CH_2)_{0-4}-CO-(C_3-C_7)$   $Cycloalkyl), \quad -(CH_2)_{0-4}-CO-R_{1-axyl} \text{ where } R_{1-axyl} \text{ is as defined above, } -(CH_2)_{0-4}-CO-R_{1-heteroaryl} \text{ where } R_{1-heteroaryl}$  is as defined above,  $-(CH_2)_{0-4}-CO-R_{1-heterocycle}, \quad -(CH_2)_{0-4}-CO-R_{1-heterocycle}, \quad -(CH_2)_{0-4}-CO-R_{1-heterocycle}, \quad -(CH_2)_{0-4}-CO-R_{146} \text{ where } R_{146} \text{ is heterocycloalkyl, where the heterocycloalkyl is optionally substituted with 1-4 of C_1-C_6 alkyl,}$ 
  - -(CH $_2$ ) $_{0-4}$ -CO-O-R $_{148}$  where R $_{148}$  is selected from the group consisting of: C $_1$ -C $_6$  alkyl, -(CH $_2$ ) $_{0-2}$ -(R $_{1-aryl}$ ), C $_2$ -C $_6$

5

alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_3$ - $C_7$  cycloalkyl, and -(CH<sub>2</sub>)<sub>0-2</sub>-(R<sub>1-heteroaryl</sub>),

- $-(CH_2)_{0-4} SO_2 N \ R_{142}R_{144}, -(CH_2)_{0-4} SO_- (C_1 C_8 \ alkyl), -(CH_2)_{0-4} SO_2 (C_1 C_{12} \ alkyl), -(CH_2)_{0-4} SO_2 (C_3 C_7 \ cycloalkyl), -(CH_2)_{0-4} N (H \ or \ R_{148}) CO_- C_{148}, -(CH_2)_{0-4} N (H \ or \ R_{148}) CO_- N (R_{148})_2, -(CH_2)_{0-4} N (-C_1 C_2)_{0-4} N (-C_2 C_3 C_7 \ cycloalkyl), -(CH_2)_{0-4} N (H \ or \ R_{148}) CO_- R_{148}, -(CH_2)_{0-4} N (R_{148})_2, -(CH_2)_{0-4} N (-C_1 C_2)_{0-4} N (-C_2 C_3 C_7 \ cycloalkyl), -(CH_2)_{0-4} N (H \ or \ R_{148}) CO_- R_{148}, -(CH_2)_{0-4} N (R_{148})_2, -(CH_2)_{0-4} N (-C_1 C_2)_{0-4} N (-C_1 C_2)_{0-4} N (-C_1 C_2)_{0-4} R_{146} \ where \ R_{N-4} \ is as defined above,$
- $-(CH_2)_{0-4}-O-CO-(C_1-C_6 \text{ alkyl}), -(CH_2)_{0-4}-O-P(O)-(OR_{150})_2 \text{ where} \\ = \text{ach } R_{150} \text{ is independently hydrogen or } C_1-C_4 \text{ alkyl}, -(CH_2)_{0-4}-O-CO-N(R_{148})_2, -(CH_2)_{0-4}-O-CS-N(R_{148})_2 -(CH_2)_{0-4}-O-(R_{148})_2, -(CH_2)_{0-4}-O-(R_{148})_2-CO_2H, -(CH_2)_{0-4}-S-(R_{148})_2, -(CH_2)_{0-4}-O-halo(C_1-C_6) \text{ alkyl}, -(CH_2)_{0-4}-O-(C_1-C_6) \text{ alkyl}, \\ = C_3-C_7 \text{ cycloalkyl},$
- C<sub>2</sub>-C<sub>6</sub> alkenyl or C<sub>2</sub>-C<sub>6</sub> alkynyl, each of which is optionally substituted with  $C_1$ -C<sub>3</sub> alkyl, halogen, hydroxy, -SH, cyano, -CF<sub>3</sub>,  $C_1$ -C<sub>3</sub> alkoxy, amino, mono(C<sub>1</sub>-C<sub>6</sub>)alkylamino, and di(C<sub>1</sub>-C<sub>6</sub>)alkylamino,
- $-(CH_2)_{0-4}-N(-H \text{ or } R_{148})-SO_2-R_{142}, \text{ or } -(CH_2)_{0-4}-C_3-C_7$ 20 cycloalkyl;
- R<sub>35</sub> is phenyl, cyclohexyl, -S-phenyl, benzodioxole, thienyl, C<sub>3</sub>-C<sub>6</sub> alkyl, furanyl, each of which is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, OH, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, halogen, halo C<sub>1</sub>-C<sub>6</sub> alkyl, halo C<sub>1</sub>-C<sub>6</sub> alkoxy, -O-(C<sub>1</sub>-C<sub>6</sub> alkyl)-phenyl, -CO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub> alkyl), or -(C<sub>1</sub>-C<sub>4</sub> alkyl)-(C<sub>5</sub>-C<sub>6</sub> cycloalkyl);
  - X and Y are independently selected from O, NR5, C(O), CR1R2, SO2, and S,
- where  $R_5$  is hydrogen,  $C_1$ - $C_6$  alkyl,  $SO_2R_5$ ',  $C(O)R_5$ ' where  $R_5$ ' is hydrogen, halogen,  $C_1$ - $C_6$  alkyl, hydroxy,  $C_1$ - $C_6$  alkoxy, halo $(C_1$ - $C_6)$  alkyl, halo $(C_1$ - $C_6)$  alkyl,  $(C_1$ - $C_6)$  alkyl, amino $(C_1$ - $C_6)$  alkyl,

mono  $(C_1-C_6)$  alkylamino  $(C_1-C_6)$  alkyl,  $(C_6)$  alkylamino  $(C_1-C_6)$  alkyl,

di (C1-

-(CH<sub>2</sub>)<sub>0-4</sub>-aryl or -(CH<sub>2</sub>)<sub>0-4</sub>-heteroaryl,

5

20

 $C_2$ - $C_6$  alkenyl or  $C_2$ - $C_6$  alkynyl, each of which is optionally substituted with one, two or three substituents independently selected from the group consisting of halogen, hydroxy, -SH, cyano, -CF<sub>3</sub>,  $C_1$ - $C_3$  alkoxy, amino, mono  $(C_1$ - $C_6)$  alkylamino, and di( $C_1$ - $C_6)$  alkylamino,

-(CH<sub>2</sub>)<sub>0-4</sub>- C<sub>3</sub>-C<sub>7</sub> cycloalkyl, where the cycloalkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halogen, hydroxy, -SH, cyano, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, amino, mono(C<sub>1</sub>-C<sub>6</sub>)alkylamino, and di(C<sub>1</sub>-C<sub>6</sub>)alkylamino;

R<sub>140</sub> res phenyl or naphthyl, each of which is optionally substituted with 1-5 groups independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, optionally substituted with one, two or three substituents selected from the group consisting of C<sub>1</sub>-C<sub>3</sub> alkyl, -halogen, hydroxy, -SH, cyano, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, amino, mono(C<sub>1</sub>-C<sub>6</sub>)alkylamino, and di(C<sub>1</sub>-C<sub>6</sub>)alkylamino,

hydroxy, nitro, halogen, -CO2H, cyano,

- $-(CH_2)_{0-4}-CO-NR_{142}R_{144} \text{ where } R_{142} \text{ and } R_{144} \text{ independently re}$   $-(CH_2)_{0-4}-CO-NR_{142}R_{144} \text{ where } R_{142} \text{ and } R_{144} \text{ independently re}$   $-(CH_2)_{0-4}-CO-NR_{142}R_{144} \text{ where } R_{142} \text{ and } R_{144} \text{ independently re}$   $-(CH_2)_{0-4}-CO-NR_{142}R_{144} \text{ where } R_{1-aryl} \text{ is as defined above, or } -R_{1-heteroaryl} \text{ where } R_{1-heteroaryl},$ 
  - $-(CH_2)_{0-4}-CO-(C_1-C_{12} \quad alkyl), \quad -(CH_2)_{0-4}-CO-(C_2-C_{12} \quad alkenyl), \\ CH_2)_{0-4}-CO-(C_2-C_{12}) alkynyl, \quad -(CH_2)_{0-4}-CO-(C_3-C_7)$

5

10

15

20

25

cycloalkyl),  $-(CH_2)_{0-4}-CO-R_{1-aryl}$  where  $R_{1-aryl}$  is as defined above,  $-(CH_2)_{0-4}-CO-R_{1-heteroaryl}$  where  $R_{1-heteroaryl}$  is as defined above,  $-(CH_2)_{0-4}-CO-R_{1-heterocycle}$ ,  $-(CH_2)_{0-4}-CO-R_{1-heterocycle}$ , where  $R_{146}$  is heterocycloalkyl, where the heterocycloalkyl is optionally substituted with 1-4 of  $C_1-C_6$  alkyl,

- -(CH<sub>2</sub>)<sub>0-4</sub>-CO-O-R<sub>148</sub> where R<sub>148</sub> is selected from the group consisting of:  $C_1$ -C<sub>6</sub> alkyl, -(CH<sub>2</sub>)<sub>0-2</sub>-(R<sub>1-aryl</sub>),  $C_2$ -C<sub>6</sub> alkenyl,  $C_2$ -C<sub>6</sub> alkynyl,  $C_3$ -C<sub>7</sub> cycloalkyl, and -(CH<sub>2</sub>)<sub>0-2</sub>-(R<sub>1-heteroaryl</sub>),

- $C_2$ - $C_6$  alkenyl or  $C_2$ - $C_6$  alkynyl, each of which is optionally substituted with  $C_1$ - $C_3$  alkyl, halogen, hydroxy, -SH, cyano, -CF<sub>3</sub>,  $C_1$ - $C_3$  alkoxy, amino, mono( $C_1$ - $C_6$ ) alkylamino, and di( $C_1$ - $C_6$ ) alkylamino, and
- $-(CH_2)_{0-4}-N(-H ext{ or } R_{148})-SO_2-R_{142}, ext{ or } -(CH_2)_{0-4}-C_3-C_7$  cycloalkyl.
- In a more preferred embodiment q is 1.

In a more preferred embodiment, two or three of  $R_z,\,R_z{}'\,,\,R_z{}'\,,$  and  $R_z{}'\,'\,'$  is hydrogen, and

the other one or two of  $R_z$ ,  $R_z$ ',  $R_z$ '', and  $R_z$ ''' is hydroxy, nitro, halogen,  $-CO_2H$ , cyano, or  $C_1-C_6$  alkyl, where the alkyl is optionally substituted with one, two or three substituents independently selected from  $C_1-C_3$  alkyl, halogen, -OH, -SH,  $-C\equiv N$ ,  $-CF_3$ ,  $C_1-C_6$  alkoxy, amino, mono  $(C_1-C_6)$  alkylamino, and di  $(C_1-C_6)$  alkylamino.

Preferred compounds of formula X100 include those where three of  $R_z$ ,  $R_z{'}$ ,  $R_z{'}{'}$ , and  $R_z{'}{'}{'}$  are hydrogen and the other is ( $C_1-C_6$ )alkyl, halogen, or ( $C_1-C_6$ )alkoxy.

Other preferred compounds of formula X100 include those where wherein  $R_{140}$  is phenyl substituted with 1, 2, or 3 groups independently selected from

- 15  $C_1$ - $C_6$  alkyl, optionally substituted with one, two or three groups independently selected from  $C_1$ - $C_3$  alkyl, halogen, hydroxy, -SH, cyano, -CF<sub>3</sub>,  $C_1$ - $C_3$  alkoxy, amino, mono( $C_1$ - $C_6$ ) alkylamino, and di( $C_1$ - $C_6$ ) alkylamino, hydroxy, nitro, halogen, - $CO_2$ H, cyano,
- $-(CH_2)_{0-4}-CO-NR_{142}R_{144} \ \ where \ R_{142} \ \ and \ \ R_{144} \ \ independently \ re$   $hydrogen, \ C_1-C_6 \ \ alkyl, \ \ hydroxy(C_1-C_6)alkyl, \ \ amino(C_1-C_6)alkyl, \ \ and \ \ C_3-C_7 \ \ cycloalkyl.$

Still other preferred compounds of formula X100 include those where  $R_{140}$  is phenyl substituted with

- one of hydroxy, nitro, halogen,  $-CO_2H$ , cyano, or  $C_1-C_6$  alkyl where the alkyl is optionally substituted with one, two or three groups independently selected from  $C_1-C_3$  alkyl, -halogen, hydroxy, -SH, cyano, -CF<sub>3</sub>,  $C_1-C_3$  alkoxy, amino, mono  $(C_1-C_6)$  alkylamino, and di  $(C_1-C_6)$  alkylamino; and
- one of  $-(CH_2)_{0-4}-CO-NR_{142}R_{144}$ .

5

30

Other preferred compounds of formula X100 are those where  $R_{140}$  is phenyl substituted with one of  $-C(0)NR_{142}R_{144}$  and  $R_{142}$  and  $R_{144}$  are independently hydrogen or  $C_1-C_6$  alkyl.

More preferred compounds of formula X100 include those where  $R_{142}$  and  $R_{144}$  are the same and are propyl.

Other specific compounds of formula X100 include those where R<sub>35</sub> is phenyl substituted with 1-5 halogen, or substituted with 1, 2, or 3 groups independently selected from (C<sub>1</sub>-C<sub>6</sub>) alkyl, hydroxy, halogen, (C<sub>1</sub>-C<sub>6</sub>) alkoxy, amino, mono(C<sub>1</sub>-C<sub>6</sub>) alkylamino, and di(C<sub>1</sub>-C<sub>6</sub>) alkylamino.

Preferred compounds of formula X100 include those where 15  $R_{35}$  is phenyl substituted with 2 halogens.

Still other preferred compounds of formula X100 are those where  $R_{35}$  is 3,5-difluorophenyl.

Other specific compounds of formula X100 include those where  $R_{140}$  is phenyl substituted with

one of hydroxy, nitro, halogen,  $-CO_2H$ , cyano, or  $C_1-C_6$  alkyl where the alkyl is optionally substituted with one, two or three groups independently selected from  $C_1-C_3$  alkyl, - halogen, hydroxy, -SH, cyano,  $-CF_3$ ,  $C_1-C_3$  alkoxy, amino, mono( $C_1-C_6$ ) alkylamino, and di( $C_1-C_6$ ) alkylamino; and one of  $-(CH_2)_{0-4}-CO-NR_{142}R_{144}$ .

25

Preferred specific compounds of formula X100 are those 30 where  $R_{140}$  is phenyl substituted with one of  $-C(O)NR_{142}R_{144}$  and  $R_{142}$  and  $R_{144}$  are independently hydrogen or  $C_1-C_6$  alkyl.

Other preferred specific compounds of formula X100 are those where  $R_{142}$  and  $R_{144}$  are the same and are propyl.

Preferred compounds of formula X100 are those where n is 1 and p is 0.

Still other preferred compounds of formula X100 are those where the dashed lines all re single bonds.

In other preferred compounds of formula X100,  $\ensuremath{\text{R}}_1$  is hydrogen and X is  $SO_2\,.$ 

In other preferred compounds of Z100, Y is methylene.

 $\,$  More preferred compounds of X100 are those where Z' is 2-10  $\,$  propyl.

Other more preferred compounds of X100 are those where Y is methylene and  $R_2$  is hydrogen, hydroxy( $C_1-C_3$ )alkyl, or ( $C_1-C_3$ )alkyl.

A preferred R2 group is methyl.

In another specific aspect of formula X100,  $R_1$  is hydrogen;

X is  $SO_2$  and Y is  $NR_5$ , or X is  $NR_5$  and Y is  $SO_2$ , where each  $R_5$  is hydrogen,  $(C_1-C_6)$  alkyl, or hydroxy( $C_1-C_6$ ) alkyl.

In a preferred aspect of X100,

20 R<sub>1</sub> is hydrogen;

25

X is C(0) and Y is NR5, or X is NR5 and Y is C(0), where each R5 is hydrogen,  $(C_1-C_6)$  alkyl, or hydroxy( $C_1-C_6$ ) alkyl.

Preferred compounds of formula  $\rm X100$  include those of formula  $\rm X101$ 

X101.

Other preferred compounds of formula X100 include those of formula  $\rm X102$ 

-69-

Preferred compounds of formula X100 include those of formula X103

Other preferred compounds of formula X100 include those of 10  $\,$  formula X104  $\,$ 

Preferred compounds of formula X103 include those wherein 15  $\ R_2$  is (C1-C3)alkyl.

Other preferred compounds of formula X103 include those wherein  $\ensuremath{R_2}$  is methyl.

Still other preferred compounds of formula X103 include those wherein  $R_2$  is hydroxy( $C_1-C_3$ )alkyl.

20 Preferred compounds of formula X104 include those wherein  $R_2$  is  $(C_1-C_3)$  alkyl.

Other preferred compounds of formula X104 include those wherein  $\ensuremath{R_2}$  is methyl.

Still other preferred compounds of formula X104 include those wherein  $R_2$  is hydroxy( $C_1-C_3$ )alkyl.

In a specific aspect, the invention provides compounds of the formula  ${\bf Z4:}$ 

wherein

5

 $R_{100}$  is H,  $C_1\text{--}C_8$  alkoxycarbonyl, phenyl  $C_1\text{--}C_6$  alkyl, or phenyl  $C_1\text{--}C_6$  alkoxycarbonyl;

10  $R_{110}$  is phenyl  $C_1$ - $C_6$  alkyl, thienyl, -S-phenyl, furanyl, or benzodioxolyl, wherein each is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, or phenyl  $C_1$ - $C_6$  alkoxy; and

15 is H, phenyl  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_8$  cycloalkyl optionally substituted with  $C_1$ - $C_6$  alky or phenyl,  $C_3$ - $C_8$  cycloalkyl  $C_1$ - $C_4$  alkyl, or  $C_1$ - $C_6$  alkyl optionally substituted with  $-C(0)NR_{121}R_{122}$ , wherein each of the above is optionally substituted with 1, 2, or 3 groups that are independently  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl, halogen, or  $C_1$ - $C_6$  alkoxy; wherein

 $R_{121}$  and  $R_{122}$  are independently H, or  $C_1\text{--}C_6$  alkyl.

More preferred compound of Z4 inlcude those wherein  $R_{\rm 100}$  is tertiary butoxy carbonyl.

More preferred compound of Z4 inlcude those wherein  $R_{110}$  is phenyl  $C_1$ - $C_6$  alkyl optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, or phenyl  $C_1$ - $C_6$  alkoxy.

More preferred compound of Z4 inlcude those wherein  $R_{110}$  is monohalophenyl, dihalophenyl, or trihalophenyl.

More preferred compound of Z4 inlcude those wherein  $R_{110}$  is thienyl, or -S-phenyl each of which is optionally substituted

with 1, 2, 3, 4, or 5 groups that are independently halogen,  $C_1-C_4$  alkyl,  $C_1-C_4$  alkoxy, benzyloxy.

More preferred compound of Z4 inlcude those wherein  $R_{110}$  is furanyl, or benzodioxolyl each of which is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, benzyloxy.

More preferred compound of Z4 inlcude those wherein  $R_{120}$  is benzyl optionally substituted with 1, 2, or 3 groups that are independently  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl, halogen, or  $C_1$ - $C_6$  alkoxy.

10

15

20

More preferred compound of Z4 inlcude those wherein  $R_{120}$  is cyclopropyl optionally substituted with  $C_1$ - $C_6$  alky or phenyl; or cyclopropyl  $C_1$ - $C_4$  alkyl, wherein each of the above is optionally substituted with 1, 2, or 3 groups that are independently  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl, halogen, or  $C_1$ - $C_6$  alkoxy.

Even more preferred compound of Z4 inlcude those wherein  $R_{110}$  is phenyl  $C_1$ - $C_6$  alkyl optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, or phenyl  $C_1$ - $C_6$  alkoxy; and

 $R_{120}$  is H or benzyl optionally substituted with 1, 2, or 3 groups that are independently  $C_1-C_6$  alkyl,  $C_2-C_6$  alkenyl,  $C_2-C_6$  alkynyl, halogen, or  $C_1-C_6$  alkoxy.

- Other even more preferred compound of Z4 inlcude those wherein
  - $R_{110}$  is phenyl  $C_1$ - $C_6$  alkyl optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, or phenyl  $C_1$ - $C_6$  alkoxy; and
- 30  $R_{120}$  is cyclopropyl optionally substituted with  $C_1$ - $C_6$  alky or phenyl; or cyclopropyl  $C_1$ - $C_4$  alkyl, wherein each of the above is optionally substituted with 1, 2, or 3 groups that are independently  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl, halogen, or  $C_1$ - $C_6$  alkoxy.

Other even more preferred compound of  ${\tt Z4}$  inlcude those wherein

 $R_{110}$  is thienyl, or -S-phenyl each of which is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen,  $C_1-C_4$  alkyl,  $C_1-C_4$  alkoxy, benzyloxy; and

 $R_{120}$  is H or benzyl optionally substituted with 1, 2, or 3 groups that are independently  $C_1-C_6$  alkyl,  $C_2-C_6$  alkenyl,  $C_2-C_6$  alkynyl, halogen, or  $C_1-C_6$  alkoxy.

10

Other even more preferred compound of  ${\bf Z4}$  inlcude those wherein

 $R_{110}$  is thienyl, or -S-phenyl each of which is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen,  $C_1-C_4$  alkyl,  $C_1-C_4$  alkoxy, benzyloxy; and

R<sub>120</sub> is cyclopropyl optionally substituted with C<sub>1</sub>-C<sub>6</sub> alky or phenyl; or cyclopropyl C<sub>1</sub>-C<sub>4</sub> alkyl, wherein each of the above is optionally substituted with 1, 2, or 3 groups that are independently C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, halogen, or C<sub>1</sub>-C<sub>6</sub> alkoxy.

Other even more preferred compound of  ${\tt Z4}$  inlcude those  ${\tt 25}$  wherein

 $R_{110}$  is furanyl, or benzodioxolyl each of which is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen,  $C_1\text{-}C_4$  alkyl,  $C_1\text{-}C_4$  alkoxy, or benzyloxy.

30  $R_{120}$  is H or benzyl optionally substituted with 1, 2, or 3 groups that are independently  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl, halogen, or  $C_1$ - $C_6$  alkoxy. Even more preferred compound of Z4 inlcude those wherein

 $R_{110}$  is furanyl, or benzodioxolyl each of which is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen,  $C_1\text{--}C_4$  alkyl,  $C_1\text{--}C_4$  alkoxy, or benzyloxy;

5  $R_{120}$  is cyclopropyl optionally substituted with  $C_1$ - $C_6$  alky or phenyl; or cyclopropyl  $C_1$ - $C_4$  alkyl, wherein each of the above is optionally substituted with 1, 2, or 3 groups that are independently  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl, halogen, or  $C_1$ - $C_6$  alkoxy.

10

Other even more preferred compounds of the instant invention are those wherein

R<sub>51</sub> at each occurrence is independently H, -SO<sub>2</sub>NH-propyl-OH,  $-SO_2NH-ethyl-OH$ ,  $-SO_2NH-ethyl-OCH_3$ ,  $-SO_2NH-CH(CH_3)_2-CH_2OH$ ,  $-SO_2NH-(CH_2CH(OH)CH_3)$ ,  $-SO_2NH-ethyl-NH(CH_3)$ ,  $-SO_2NH(CH_2CH_2OH)_2$ , 15  $-SO_2NHCH(CH_3)CH_2OH, \qquad -SO_2N(CH_3)_2, \qquad -SO_2NH(CH_2CH(OH)CH_3), \qquad -SO_2-CH_2CH(OH)CH_3)_2, \qquad -SO_2NHCH(CH_3CH(OH)CH_3)_2, \qquad -SO_2NHCH(CH_3CH(OH)CH_3)_2, \qquad -SO_3NHCH(CH_3CH(OH)CH_3)_2, \qquad -SO_3NHCH(CH_3CH(OH)CH_3CH(OH)CH_3CH(OH)CH_3CH(OH)CH_3CH(CH_3CH(OH)$ pyrrolidine, -SO<sub>2</sub>-(2,6-dimethylpiperidine), -SO<sub>2</sub>-(2propylpiperidine),  $-SO_2$ -(hydroxypropyl), -C(0)-(2methoxymethylpyrrolidine), -C(0)-(2-methylpyrrolidine), -C(0)-20 (2,6-dimethylpyrrolidine),-C(0)-(2-hydroxymethylpyrrolidine), -C(O)N(methyl)(ethyl), -C(O)N(methyl)(propyl), -C(O)N(methyl)(butyl), -C(O)N(propyl)(butyl), -C(0)N(allyl)(cyclopentyl), -C(O)N(allyl)(cyclohexyl), -C(O)N(methyl)(methyl), -C(0)N(ethyl)(ethyl), 25 -C(0)N(butyl)(butyl), -C(0)N(isopropyl)(isopropyl), -C(O)N(propyl)(propyl), -C(0)N(methyl)(cyclohexyl), -C(0)N(ethyl)(cyclohexyl), -C(0)NH(cyclobutyl), -C(0)NH(cyclopentyl), -C(0)N(CH<sub>3</sub>)(cyclopentyl), -C(0)NH(2methylcyclohexyl), -C(O)NH(pentyl), -C(O)N(pentyl)(pentyl), 30 -C(0)NH(isopentyl), -C(0)NH(ethoxyethyl), -C(O)N(CH<sub>3</sub>) (methoxyethyl), -C(O)N(propyl) (methoxyethyl), -C(0)N(methoxyethyl)(methoxyethyl), -C(O)N(ethoxyethyl) (ethoxyethyl), -C(O)N(ethyl) (methoxyethyl), -C(0)N(propyl)(hydroxyethyl), -C(0)N(hydroxyethyl)(ethyl),

ethynyl, methyl, bromo,  $-N(CH_3)SO_2(CH_3)$ ,  $-N(CH_3)SO_2$ -thienyl,  $-N(hydroxypropyl)SO_2CH_3$ ,  $-CH_2)-SO_2-(CH_3)$ , or  $-C(O)-CH(CH_3)CH_2CH_2CH_3$ .

Still more preferred are compounds wherein there are two  $R_{51}\ \mbox{groups.}$ 

5

Yet even more preferred are compounds wherein the  $R_{51}$  groups are at the 3 and 5 positions of the phenyl group.

More preferred compounds of the instant invention are those wherein

 $\ensuremath{R_{51}}$  at each occurrence is independently selected from the 10 group consisting of  $C_1-C_4$  alkyl,  $-C(0)N(C_1-C_6$  alkyl)( $C_1-C_6$ alkyl),  $-C(0)NH_2$ ,  $-C(0)N(C_2-C_6$  alkenyl)( $C_3-C_8$  cycloalkyl),  $-C(O)NH(C_3-C_8$  cycloalkyl),  $-C(O)NH(C_1-C_6$  alkyl), (pyrrolidine) optionally substituted with 1 or two groups that are independently alkoxyalkyl or hydroxy, halogen,  $-C(0)N(C_1-C_6)$ 15 hydroxyalkyl) (C<sub>1</sub>-C<sub>6</sub> alkyl), -C(O)NH(alkoxyalkyl), -C(O)N(alkoxyalkyl)(alkoxyalkyl),  $-C(0)N(C_1-C_6)$ (alkoxyalkyl),  $-C(0)N(C_1-C_6 \text{ hydroxyalkyl})(alkyl)$ ,  $-NHSO_2CF_3$ , - $\label{eq:ncondition} \texttt{N(C_1-C_6} \qquad \texttt{alkyl)-SO_2-thienyl}, \qquad -\texttt{N(C_1-C_6} \qquad \texttt{hydroxyalkyl)SO_2-(C_1-C_6)}$ alkyl),  $-NHC(0)C_1-C_4$  alkyl, oxazolyl optionally substituted 20 with 1 or 2 methyl groups, thiazolyl optionally substituted with 1 or 2 methyl groups, pyrazolyl optionally substituted with 1 or 2 methyl groups, imidazolyl optionally substituted with 1 or 2 methyl groups, isoxazolyl optionally substituted with 1 or 2 methyl groups, pyrimidinyl optionally substituted with 1 or 2 methyl or halogen groups,  $-NHSO_2CH_3$ ,  $-NHSO_2$ imidazolyl wherein the imidazole ring is optionally substituted with 1 or 2 methyl groups,  $-N(C_1-C_6 \text{ alkyl})SO_2(C_1-C_6 \text{ alkyl})$ ,  $-SO_2NH-C_1-C_6 \quad \text{hydroxyalkyl} \,, \quad -SO_2NH-C_1-C_6 \quad \text{alkyl-NH} \, (C_1-C_4 \quad \text{alkyl}) \,,$  $-SO_2$ -piperazinyl optionally substituted with 1 or 2 methyl 30 groups,  $-SO_2$ -pyrrolidine optionally substituted with 1 or 2 methyl groups,  $-SO_2$ -piperidine optionally substituted with 1 or  $C_1-C_4$ alkyl groups,  $-SO_2N(C_1-C_4)$  hydroxyalkyl)  $(C_1-C_4)$  $\label{eq:hydroxyalkyl} \text{hydroxyalkyl),} \quad -\text{SO}_2\text{NH}_2, \quad -\text{SO}_2\text{N}\left(\text{C}_1-\text{C}_6 \quad \text{alkyl}\right) \left(\text{C}_1-\text{C}_6 \quad \text{alkyl}\right), \quad \text{C}_2-\text{C}_6$ 

alkynyl,  $-SO_2-(C_1-C_6 \text{ hydroxyalkyl})$ ,  $-SO_2NH(C_1-C_6 \text{ hydroxyalkyl})$ ,  $-SO_2N(C_1-C_6 \text{ alkyl})(C_1-C_6 \text{ hydroxyalkyl})$ ,  $-(C_1-C_4 \text{ alkyl})-SO_2-(C_1-C_4 \text{ alkyl})$ , or  $-C(0)-(C_1-C_{10} \text{ alkyl})$ .

Even more preferred compounds of the instant invention are those wherein R<sub>51</sub> at each occurrence is independently selected from the group consisting of -SO<sub>2</sub>NH-propyl-OH, -SO<sub>2</sub>NH-ethyl-OH,  $-SO_2NH-ethy1-OCH_3$ ,  $-SO_2NH-CH(CH_3)_2-CH_2OH$ ,  $-SO_2NH-(CH_2CH(OH)CH_3)$ ,  $-SO_2NH-ethyl-NH(CH_3)$ ,  $-SO_2NH(-CH_2CH_2OH)_2$ ,  $-SO_2NHCH(CH_3)CH_2OH$ ,  $-SO_2N(CH_3)_2$ ,  $-SO_2NH(CH_2CH(OH)CH_3)$ ,  $-SO_2$ -pyrrolidine,  $-SO_2$ -(2,6dimethylpiperidine), -SO<sub>2</sub>-(2-propylpiperidine), 10 -SO<sub>2</sub>-(hydroxypropyl), -C(0)-(2-methoxymethylpyrrolidine), -C(0)-(2-methoxymethylpyrrolidine)methylpyrrolidine), -C(0)-(2,6-dimethylpyrrolidine),-C(0)-(2hydroxymethylpyrrolidine), -C(O)N(methyl)(ethyl), -C(O)N(methyl)(propyl), -C(O)N(methyl)(butyl), -C(0)N(allyl)(cyclopentyl), 15 -C(O)N(propyl)(butyl), -C(O)N(allyl)(cyclohexyl), -C(O)N(methyl)(methyl), -C(0)N(ethyl)(ethyl), -C(0)N(butyl)(butyl), -C(0)N(isopropyl)(isopropyl), -C(0)N(propyl)(propyl), -C(O)N(methyl)(cyclohexyl), -C(0)N(ethyl)(cyclohexyl), 20 -C(0)NH(cyclobutyl), -C(0)NH(cyclopentyl), -C(O)N(CH<sub>3</sub>)(cyclopentyl), -C(0)NH(2-methylcyclohexyl), -C(0)NH(pentyl), -C(0)N(pentyl)(pentyl), -C(0)NH(isopentyl), -C(0)NH(ethoxyethyl), -C(0)N(methoxyethyl) (methoxyethyl),  $-C(0)N(CH_3)$  (methoxyethyl), -C(0)N(propyl) (methoxyethyl), 25 -C(O)N(ethoxyethyl), -C(O)N(ethyl)(methoxyethyl), -C(O)N(propyl)(hydroxyethyl), -C(0)N(hydroxyethyl)(ethyl), ethynyl, methyl, bromo,  $-N(CH_3)SO_2(CH_3)$ ,  $-N(CH_3)SO_2$ -thienyl, -N(hydroxypropyl) $SO_2CH_3$ , -(CH<sub>2</sub>)- $SO_2$ -(CH<sub>3</sub>), or -C(0)- $CH(CH_3)CH_2CH_2CH_3$ .

More preferred compounds of the instant invention are those wherein

 $R_{30}$  is pyridyl which is unsubstituted or substituted with 1 or 2 groups that are independently selected from the group consisting of  $C_1-C_4$  alkyl,  $-C(0)N(C_1-C_6$  alkyl)( $C_1-C_6$  alkyl),


 $-\texttt{C(O)NH}_2, \quad -\texttt{C(O)N(C}_2-\texttt{C}_6 \quad \texttt{alkenyl)(C}_3-\texttt{C}_8 \quad \texttt{cycloalkyl)}, \quad -\texttt{C(O)NH(C}_3-\texttt{C}_8$ cycloalkyl),  $-C(0)NH(C_1-C_6$  alkyl), C(0)-(pyrrolidine) optionally substituted with 1 or two groups that are independently alkoxyalkyl or hydroxy, halogen,  $-C(0)N(C_1-C_6)$ hydroxyalkyl) ( $C_1-C_6$ alkyl), -C(0)NH(alkoxyalkyl), -C(0)N(alkoxyalkyl)(alkoxyalkyl),  $-C(0)N(C_1-C_6)$ alkyl) (alkoxyalkyl),  $-C(0)N(C_1-C_6 \text{ hydroxyalkyl})(alkyl)$ ,  $-NHSO_2CF_3$ , - $\label{eq:NC1-C6} \text{N(C$_1$-$C$_6$} \quad \text{alkyl)-$SO$_2$-thienyl,} \quad \text{-N(C$_1$-$C$_6$} \quad \text{hydroxyalkyl)} \\ \text{SO$_2$-(C$_1$-$C$_6$} \quad \text{hydroxyalkyl)} \\ \text{$ alkyl), -NHC(0) $C_1$ - $C_4$  alkyl, oxazolyl optionally substituted with 1 or 2 methyl groups, thiazolyl optionally substituted 10 with 1 or 2 methyl groups, pyrazolyl optionally substituted with 1 or 2 methyl groups, imidazolyl optionally substituted with 1 or 2 methyl groups, isoxazolyl optionally substituted with 1 or 2 methyl groups, pyrimidinyl optionally substituted with 1 or 2 methyl or halogen groups,  $-NHSO_2CH_3$ ,  $-NHSO_2-$ 15 imidazolyl wherein the imidazole ring is optionally substituted with 1 or 2 methyl groups,  $-N(C_1-C_6 \text{ alkyl})SO_2(C_1-C_6 \text{ alkyl})$ ,  $-SO_2NH-C_1-C_6 \quad \text{hydroxyalkyl} \,, \quad -SO_2NH-C_1-C_6 \quad \text{alkyl-NH} \, (C_1-C_4 \quad \text{alkyl}) \,,$  $-SO_2$ -piperazinyl optionally substituted with 1 or 2 methyl 20 groups,  $-SO_2$ -pyrrolidine optionally substituted with 1 or 2 methyl groups,  $-SO_2$ -piperidine optionally substituted with 1 or 2 C1-C4 alkyl groups,  $-SO_2N(C_1-C_4)$  hydroxyalkyl)( $C_1-C_4$  $\label{eq:hydroxyalkyl} \text{hydroxyalkyl),} \quad -\text{SO}_2\text{NH}_2, \quad -\text{SO}_2\text{N}\left(\text{C}_1-\text{C}_6 \quad \text{alkyl}\right) \left(\text{C}_1-\text{C}_6 \quad \text{alkyl}\right), \quad \text{C}_2-\text{C}_6$ alkynyl,  $-SO_2-(C_1-C_6 \text{ hydroxyalkyl})$ ,  $-SO_2NH(C_1-C_6 \text{ hydroxyalkyl})$ ,  $-SO_2N\left(C_1-C_6 \text{ alkyl}\right)\left(C_1-C_6 \text{ hydroxyalkyl}\right), \quad -\left(C_1-C_4 \text{ alkyl}\right)-SO_2-\left(C_1-C_4 \text{ alkyl}\right)$ 25 alkyl), or  $-C(0)-(C_1-C_{10} \text{ alkyl})$ .

Even more preferred compounds of the instant invention are those wherein

 $R_{30}$  is pyridyl which is unsubstituted or substituted with 30 at least one group that is  $-SO_2NH-propyl-OH$ ,  $-SO_2NH-ethyl-OH$ ,  $-SO_2NH-ethyl-OCH_3$ ,  $-SO_2NH-CH(CH_3)_2-CH_2OH$ ,  $-SO_2NH-(CH_2CH(OH)CH_3)$ ,  $-SO_2NH-ethyl-NH(CH_3)$ ,  $-SO_2NH(-CH_2CH_2OH)_2$ ,  $-SO_2NHCH(CH_3)CH_2OH$ ,  $-SO_2N(CH_3)_2$ ,  $-SO_2NH(CH_2CH(OH)CH_3)$ ,  $-SO_2-pyrrolidine$ ,  $-SO_2-(2,6-dimethylpiperidine)$ ,  $-SO_2-(2-propylpiperidine)$ 

(hydroxypropyl), -C(0)-(2-methoxymethylpyrrolidine), -C(0)-(2-methoxymethylpyrrolidine)methylpyrrolidine), -C(0)-(2,6-dimethylpyrrolidine),-C(0)-(2-dimethylpyrrolidine)hydroxymethylpyrrolidine), -C(O)N(methyl)(ethyl), -C(O)N(methyl)(propyl), -C(O)N(methyl)(butyl), 5 -C(O)N(propyl)(butyl), -C(O)N(allyl)(cyclopentyl), -C(0)N(allyl)(cyclohexyl), -C(O)N(methyl)(methyl), -C(O)N(ethyl)(ethyl), -C(O)N(butyl)(butyl), -C(O)N(isopropyl)(isopropyl), -C(O)N(propyl)(propyl), -C(0)N(methyl)(cyclohexyl), -C(O)N(ethyl)(cyclohexyl), 10 -C(0)NH(cyclobutyl), -C(O)NH(cyclopentyl), -C(O)N(CH<sub>3</sub>)(cyclopentyl), -C(0)NH(2-methylcyclohexyl), -C(0)NH(pentyl), -C(0)N(pentyl)(pentyl), -C(0)NH(isopentyl), -C(0)NH(ethoxyethyl),  $-C(0)N(CH_3)$  (methoxyethyl), -C(0)N(propyl) (methoxyethyl), 15 -C(O)N(methoxyethyl) (methoxyethyl), -C(0)N(ethoxyethyl) (ethoxyethyl), -C(0)N(ethyl) (methoxyethyl), -C(0)N(propyl)(hydroxyethyl), -C(0)N(hydroxyethyl)(ethyl), ethynyl, methyl, bromo, -N(CH<sub>3</sub>)SO<sub>2</sub>(CH<sub>3</sub>), -N(CH<sub>3</sub>)SO<sub>2</sub>-thienyl, -N(hydroxypropyl)SO<sub>2</sub>CH<sub>3</sub>,  $-(CH_2)-SO_2-(CH_3)$ , or -C(0)-20 CH (CH<sub>3</sub>) CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>.

Other preferred compounds of the formula  ${\tt X}$  are those of formula  ${\tt Z5}$ 



 $z_5$ 

or a pharmaceutically acceptable salt thereof, wherein  $R_1$  is  $C_1$ - $C_4$  alkyl,  $C_2$ - $C_4$  alkynyl, or  $CF_3$ ;  $R_2$  and  $R_3$  are both hydrogen; or  $R_2$  and  $R_3$  and the carbon to which they are attached form a cyclopropyl ring;

 $R_4$  is oxazolyl optionally substituted with methyl, thiazolyl,  $C_2\hbox{-} C_4 \text{ alkynyl, or } C_1\hbox{-} C_4 \text{ alkyl;}$ 

 $R_5$  is  $C_1-C_4$  alkyl;

 $R_6$  is  $C_1-C_4$  alkyl;

25

5 X and Y are independently halogen;
Z is CH or N.

Preferred compounds within Formula Z5 are those where Z is CH. Within this group, more preferred are those wherein  $R_2$  and  $R_3$  are both H.

Other preferred compounds of the invention are those of formula Z6

**Z6** 

Preferred compounds of Formula Z6 include those where  $R_1$  is ethyl, ethynyl or  $CF_3$ ; and  $R_4$  is 2-oxazolyl optionally substituted with methyl, 2-thiazolyl, ethynyl, or methyl, hereinafter compounds of Z6-1. Preferred compounds of Z6-1 are those where  $R_5$  is propyl; and  $R_6$  is propyl. More preferably,  $R_1$  is ethyl;  $R_4$  is 2-oxazolyl optionally substituted with methyl; and X and Y are both F.

Other preferred compounds of Z6-1 are those where  $R_1$  is ethyl, or  $CF_3$ ; and  $R_4$  is 2-thiazolyl. More preferably,  $R_5$  is propyl; and  $R_6$  is propyl; or  $R_5$  is methyl; and  $R_6$  is propyl or butyl; and X and Y are both F. Still more preferable are compounds where  $R_1$  is ethyl. Particularly preferred compounds are those where  $R_1$  is  $CF_3$ ;  $R_5$  is propyl; and  $R_6$  is propyl.

Other preferred compounds of Z6-1 are those where  $R_1$  is ethynyl; and  $R_4$  is ethynyl, methyl, or 2-oxazolyl. More preferably,  $R_5$  is propyl; and  $R_6$  is propyl; and X and Y are

both F. Even more preferred are compounds where  $R_4$  is ethynyl or methyl.


Other preferred compounds of the invention are those of formula Z7

**Z7** 

Preferred compounds of Z7 are those where  $R_1$  is ethyl or ethynyl;  $R_4$  is methyl or 2-oxazolyl, hereinafter compounds of formula Z7-1.

10 Preferred compounds of Z7-1 include those where  $R_5$  and  $R_6$  are both propyl; and X and Y are both F. More preferably, Z is N; and  $R_4$  is methyl. Even more preferred are compounds of Z7-1 where Z is CH; and  $R_4$  is methyl or 2-oxazolyl.

Other preferred compounds of the invention are those 15 of formula Z8



Z8

or a pharmaceutically acceptable salt thereof, wherein

20  $R_1$  is  $C_2$ - $C_3$  alkyl;

5

R<sub>2</sub> and R<sub>3</sub> are both hydrogen; or

 $R_f$  and  $R_g$  are independently halogen;

R<sub>5</sub> is C<sub>1</sub>-C<sub>2</sub> alkyl sulfonyl;

 $R_6$  is hydroxy( $C_1-C_4$ )alkyl, preferably hydroxyethyl or ( $C_1-$ 

25  $C_4$ ) alkoxy  $(C_1-C_4)$  alkyl, preferably methoxyethyl. .

Yet other preferred compounds of the invention are those of formula Z9

5

7.9

or a pharmaceutically acceptable salt thereof, wherein

 $R_1$  is  $C_2-C_3$  alkyl;

 $R_2$  and  $R_3$  are both hydrogen; or

 $R_f$  and  $R_g$  are independently halogen;

10  $R_5$  and  $R_6$  are independently  $C_3$ - $C_4$  alkyl; or

 $R_5$  is H and  $R_6$  is  $C_3$  alkyl; or

 $R_5$ ,  $R_6$ , and the nitrogen to which they are attached form a pyrrolidinyl ring optionally substituted with methoxymethyl; and

15  $R_s$  is  $C_1-C_2$  alkyl, hydroxy( $C_2-C_4$ ) alkyl, N-[hydroxy( $C_2-C_4$ ) alkyl]-N-( $C_1-C_2$ ) alkylamino, N-methyl-N-( $C_4$  (t-butyl)alkyl)amino, -NH( $C_1-C_4$  hydroxyalkyl), -N( $C_1-C_3$  hydroxyalkyl)( $C_1-C_3$  hydroxyalkyl), -N( $C_1-C_2$  alkyl)( $C_1-C_2$  alkyl), pyrrolidin-1-yl optionally substituted with hydroxymethyl or methoxymethyl,  $C_1-C_2$  alkoxy  $C_2-C_3$  alkyl, 1-piperazinyl, -NH<sub>2</sub>, -NH( $C_2-C_3$  alkyl-NH( $C_1-C_2$  alkyl)), or  $C_1-C_4$  alkylamino.

Preferred compounds of formula Z9 include those where  $R_s$  is N-[hydroxy(C4-alkyl]-N-methylamino, -N(C1-C3

25 hydroxyalkyl)( $C_1-C_3$  hydroxyalkyl), or  $-NH(C_1-C_4$  hydroxyalkyl), hereinafter compounds of Z9-1.

Preferred compounds of formula Z9-1 include those where the hydroxyalkyl is 2-hydroxy-1,1-dimethylethyl; 2-hydroxyethyl; 3-hydroxypropyl; 1(R)-2-hydroxy-1-methylethyl;

1(S)-2-hydroxy-1-methylethyl; 1(S)-2-hydroxy-1-methylethyl; 2(R)-2-hydroxypropyl; or 2(S)-2-hydroxypropyl.

Preferred compound of formula Z9 include those wherein  $R_s$  is 3-hydroxypropyl, 4-hydroxybutyl.

5

10

15

20

25

Other preferred compound of formula Z9 include those wherein  $R_s$  is 2(R)-2-methoxymethylpyrrolidin-1-yl, 2(R)-2-hydroxymethylpyrrolidin-1-yl, 2(S)-2-hydroxymethylpyrrolidin-1-yl, pyrrolidin-1-yl or 1-piperazinyl, hereinafter Z9-1A. More preferably,  $R_s$  is 2(R)-2-methoxymethylpyrrolidin-1-yl, 2(R)-2-hydroxymethylpyrrolidin-1-yl, or 2(S)-2-hydroxymethylpyrrolidin-1-yl.

Still other preferred compound of formula Z9 include those wherein  $R_5$ ,  $R_6$ , and the nitrogen to which they are attached form a 2(S)-2-methoxymethyl)pyrrolidin-1-yl, hereinafter compounds of Z9-2.

Preferred compound of formula Z9-2 include those wherein  $R_s$  is -NH(tert-butyl), -N(CH<sub>3</sub>)(CH<sub>2</sub>CH<sub>3</sub>), -N(CH<sub>3</sub>)<sub>2</sub>, or 2(S)-2-methoxymethylpyrrolidin-1-yl, hereinafter Z9-3.

Preferred compounds of formula Z9 include those where  $R_s$  is N-[hydroxy( $C_4$  alkyl)]-N-methylamino. Particularly preferred are those where  $R_s$  is N-(hydroxy-t-butyl)-N-methylamino. By "hydroxy-t-butyl" is meant a 1-Hydroxy-1-methyl-ethyl group.

Other preferred compounds include those of Z9, Z9-1, Z9-1A, Z9-2, and Z9-3, wherein  $R_1$  is ethyl or isopropyl. More preferably,  $R_1$  is ethyl.

Other preferred compounds of the invention are those of formula  ${\tt Z10}$ 

Z10

or a pharmaceutically acceptable salt thereof, wherein  $R_1$  is  $C_2\text{-}C_3$  alkyl;

 $R_2$  and  $R_3$  are both hydrogen; or

5  $R_f$  and  $R_g$  are independently halogen;

 $\ensuremath{\text{R}}_5$  and  $\ensuremath{\text{R}}_6$  are independently  $\ensuremath{\text{C}}_1\text{--}\ensuremath{\text{C}}_4$  alkyl; and

 $R_d$  is  $C_1-C_2$  alkyl (preferably methyl),  $N-hydroxy(C_2-C_3)$  alkyl- $N-(C_1-C_2)$  alkylamino, or  $C_1-C_2$  alkylamino.

Other preferred compounds of the invention are those of 10 formula Z11

Z11

or a pharmaceutically acceptable salt thereof, wherein X is nitrogen or CH;

15  $R_1$  is  $C_2-C_3$  alkyl, amino, mono( $C_1-C_3$ ) alkylamino, di( $C_1-C_3$ ) alkylamino, amino( $C_1-C_3$ ) alkyl, mono( $C_1-C_3$ ) alkylamino( $C_1-C_2$ ) alkyl, or di( $C_1-C_3$ ) alkylamino( $C_1-C_2$ ) alkyl;

 $\ensuremath{\text{R}}_2$  and  $\ensuremath{\text{R}}_3$  are both hydrogen; or

25

 $R_{\mathrm{f}}$  and  $R_{\mathrm{g}}$  are both hydrogen or independently halogen;

20  $R_5$  and  $R_6$  are independently methyl or  $C_2-C_3-C_4$  alkyl, where at least one of  $R_5$  and  $R_6$  is not methyl.

Preferred compounds of Z11 include those where at least one of  $R_5$  and  $R_6$  is  $C_3$  alkyl, hereinafter compounds of Z1-1. Even more preferred compounds of Z11 are those where each of  $R_5$  and  $R_6$  is propyl.

Preferred compounds of Z11 and Z11-1 are those where X is CH. More preferably,  $R_1$  is di( $C_1-C_2$ )alkylamino. Even more preferred are those where at least one of  $R_5$  and  $R_6$  is propyl.

Other preferred compounds of Z11-1 are those where X is nitrogen. More preferably, both of  $R_5$  and  $R_6$  are not methyl. Other more preferred compounds of Z11-1 are those where  $R_1$  is  $\text{di}(C_1-C_2)\,\text{alkylamino}\,(C_1-C_2)\,\text{alkyl}$ . More preferably, the  $\text{di}(C_1-C_2)\,\text{alkylamino}\,(C_1-C_2)\,\text{alkyl}$  group is N,N-dimethyl- $(C_1-C_2)\,\text{alkyl}$ .

Other preferred compounds of the invention are those of formula Z12

Z12

or a pharmaceutically acceptable salt thereof, wherein  $R_1$  is  $C_2-C_3$  alkyl,;

 $R_2$  and  $R_3$  are both hydrogen; or

 $R_2$ ,  $R_3$ , and the carbon to which they are attached form a cyclopropyl ring;

15  $R_f$  and  $R_g$  are independently halogen;

 $R_5$  and  $R_6$  are independently  $C_3-C_4$  alkyl (more preferably, at least one of  $R_5$  and  $R_6$  is propyl); and

 $R_j$  is hydrogen or  $C_1-C_2$  alkoxymethyl.

Other preferred compounds of the invention are those of 20 formula Z13

**Z13** 

or a pharmaceutically acceptable salt thereof, wherein

 $R_1$  is  $C_2$ - $C_4$  alkynyl,  $C_2$ - $C_4$  alkyl preferably ethyl, isopropyl, or trifluoromethyl;

 $R_2$  and  $R_3$  are both hydrogen; or

 $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached;

 $R_f$  and  $R_g$  are independently halogen; and

R<sub>5</sub> and R<sub>6</sub> are independently C<sub>3</sub>-C<sub>4</sub> alkyl; or

one of  $R_5$  and  $R_6$  is methyl or ethyl and the other is  $C_3$  or  $C_{4,5}$  (butyl)alkyl.

10

15

20

5

Preferred compounds of formula Z13 include those where  $R_1$  is ethyl, n-propyl, isopropyl, or trifluoromethyl, more preferably ethyl or isopropyl. Even more preferred are compounds where  $R_5$  and  $R_6$  are independently propyl or butyl. Still more preferred are compounds where both of  $R_2$  and  $R_3$  are hydrogen. Particularly preferred are those wherein  $R_f$  and  $R_g$ 

Other preferred compounds of Z13 are those where  $R_1$  is ethyl or trifluoromethyl, hereinafter compounds of Z13-1. Among these, compounds where  $R_5$  is methyl, ethyl or propyl and  $R_6$  is  $C_3-C_4$  alkyl are more preferred. Even more preferred are

those where  $R_6$  is propyl or butyl. Particularly preferred are those where  $R_6$  is butyl and  $R_5$  is methyl.

are both chloro or fluoro.

Other preferred compounds of Formula Z13 are those where  $R_5$  is methyl, hereinafter compounds of Z13-2. Preferred compounds of Z13-2 include those where  $R_f$  and  $R_g$  are both chloro or fluoro. More preferably, both of  $R_2$  and  $R_3$  are hydrogen.

Other preferred compounds of Formula Z13 are those wherein 30 both of  $R_2$  and  $R_3$  are hydrogen; and  $R_1$  is  $C_2$ - $C_3$  alkynyl.

Still other preferred compounds of Formula Z13 are those wherein  $R_5$  and  $R_6$  are independently propyl or butyl, hereinafter Z13-3. More preferably, in compounds of Formula

Z13-3, both of  $R_2$  and  $R_3$  are hydrogen. Still more preferably,  $R_f$  and  $R_g$  are both chloro or fluoro. Even more preferably,  $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached.

Other preferred compounds of the invention are those of formula Z14

714

or a pharmaceutically acceptable salt thereof, wherein

10 one of X or  $X_1$  is nitrogen or  $N^+-0^-$  while the other is CH;

 $R_1$  is  $C_2-C_4$  alkynyl, cyano, or  $C_1-C_3$  alkyl;

R<sub>2</sub> and R<sub>3</sub> are both hydrogen; or

5

20

25

 $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached;

15  $R_f$  and  $R_g$  are independently halogen;

 $R_p$  is hydrogen,  $C_1\text{-}C_2$  alkyl, or oxazolyl; and

 $R_5$  and  $R_6$  are independently  $C_3-C_4$  alkyl.

Preferred compounds of formula Z14 include those where X is nitrogen;  $R_1$  is  $C_1-C_2$  alkyl;  $R_2$  and  $R_3$  are hydrogen; and  $R_p$  is hydrogen,  $C_1-C_2$  alkyl, or oxazol-2-yl.

Other preferred compounds of Z14 are those where X is nitrogen;  $R_1$  is  $C_2$ - $C_3$  alkynyl;  $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached; and  $R_p$  is  $C_1$ - $C_2$  alkyl. Even more preferred are compounds where X is nitrogen; and  $R_1$  is  $C_2$  alkynyl.

Other preferred compounds of Z14 are those where X is nitrogen;  $R_1$  is  $C_1-C_2$  alkyl, preferably ethyl;  $R_2$  and  $R_3$  are hydrogen; and  $R_p$  is hydrogen,  $C_1-C_2$  alkyl, or oxazol-2-yl.

Still other preferred compounds of Z14 are those where X is nitrogen;  $R_1$  is  $C_1$ - $C_2$  alkyl;  $R_2$  and  $R_3$  are hydrogen; and  $R_p$  is hydrogen,  $C_1$ - $C_2$  alkyl, oxazol-2-yl, or cyano. More preferably,  $R_p$  is cyano, methyl or oxazol-2-yl. Even more preferably,  $R_p$  is methyl. Equally preferably,  $R_p$  is oxazol-2-yl. Equally preferably,  $R_p$  is cyano.

Yet other preferred compounds of Z14 are those wherein X is nitrogen;  $R_1$  is  $C_2$ - $C_3$  alkyl;  $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached; and  $R_p$  is  $C_1$ - $C_2$  alkyl.

10

20

Preferred compounds of Z14 include those where  $R_f$  and  $R_g$  are both chloro or fluoro. Still other preferred compounds of Z14 are those where  $R_5$  and  $R_6$  are independently propyl or butyl.

Yet still other compounds of Z14 include those wherein  $R_{\rm f}$  and  $R_{\rm g}$  are both chloro or fluoro, and  $R_{\rm 5}$  and  $R_{\rm 6}$  are independently propyl or butyl.

Still other compounds of formula Z14 include those wherein X is CH and X' is N. More preferably, Rp is is cyano, methyl or oxazol-2-yl. More preferably,  $R_f$  and  $R_g$  are both chloro or fluoro, and  $R_5$  and  $R_6$  are independently propyl or butyl. Equally preferably, compounds of Z14 include those wherein  $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached.

25 Still other preferred compounds of the invention are those of formula Z15

Z15

or a pharmaceutically acceptable salt thereof, wherein

 $R_c$  is a group of the formula

$$J^{\mathcal{E}'}$$
 $X \subseteq X'$ 

where one of X and X' is nitrogen and the other is CH and  $R_1$  is  $C_2-C_4$  alkyl or  $-(C_1-C_2$  alkyl)- $N(C_1-C_2$  alkyl);

5 R<sub>f</sub> and R<sub>g</sub> are independently halogen;

 $R_p$  is  $C_1-C_2$  alkyl; and

 $R_{5}$  and  $R_{6}$  are independently hydrogen or  $C_{3}\text{--}C_{4}$  (sec butyl) alkyl.

Preferred compounds of Z15 include those where X is nitrogen; X' is CH; and  $R_{\rm 5}$  and  $R_{\rm 6}$  are independently propyl or butyl.

Other preferred compounds of Z15 are those where X is CH; X' is nitrogen; and  $R_5$  and  $R_6$  are independently propyl or butyl. More preferably,  $R_1$  is  $-CH_2N(CH_3)CH_3$ , or ethyl. Still more preferably  $R_1$  is  $-CH_2N(CH_3)CH_3$ .

Particularly preferred compounds of Z15 include those where one of  $R_5$  and  $R_6$  is hydrogen and the other is  $C_4$  butyl, more preferably sec-butyl.

Other preferred compounds of the invention are those of formula  ${\tt Z16}$ 

20

10

**Z16** 

or a pharmaceutically acceptable salt thereof, wherein  $R_{\text{s}}$  is methylamino, ethylamino,  $C_{3}$  alkylamino, di( $C_{3}$ -alkyl)amino, or a group of the formula

$$\mathbb{R}^{d}$$

25

where  $R_q$  is  $C_1$ - $C_2$  alkoxy( $C_1$ - $C_2$ )alkyl;

 $R_1$  is  $C_2-C_3$  alkyl;

 $R_2$  and  $R_3$  are both hydrogen; and  $R_{\rm f}$  and  $R_{\rm g}$  are independently halogen.

Other preferred compounds of the invention are those of formula Z17

5

10

25

Z17

or a pharmaceutically acceptable salt thereof, wherein

Z is CH<sub>2</sub> when the dashed line represents a single bond or CH or a nitrogen atom when the dashed line represents a double bond;

 $R_1$  is  $C_2$ - $C_3$  alkyl,;

 $R_2$  and  $R_3$  are both hydrogen; or

 $R_2$ ,  $R_3$  and the carbon to which they are attached form a cyclopropyl ring;

15  $R_f$  and  $R_g$  are independently halogen;

 $R_p$  is hydrogen, cyano,  $C_1-C_3$  alkyl, amino,  $N-(C_1-C_3$  alkylsulfonyl)- $N-((C_1-C_3)$  alkyl) amino (good when Z=CH), 2-oxazolyl, or 1-pyrrolyl optionally substituted in the 2 and 5 positions with  $C_1-C_2$  alkyl; and

20  $R_j$  is  $C_1-C_5$  alkyl.

Preferred compounds of formula Z17 include those where Rp is  $-N(CH_3)SO_2(C_1-C_2 \text{ alkyl})$ ; and  $R_1$  is ethyl.

Other preferred compounds of formula Z17 include those where Z is  $CH_2$ , hereinafter compounds of Z17-1. Preferred compounds of Z17-1 include those where  $R_p$  is  $N-(C_1-C_3)$  alkylsulfonyl)- $N-((C_1-C_3)$  alkyl)amino.

Other preferred compounds of Z17 are those where  $\ensuremath{\text{R}}_{\text{j}}$  is methyl.

Still other preferred compounds of Z17-1 are those where  $R_p$  is N-(methylsulfonyl)-N-(( $C_1-C_2$ )alkyl)amino; and  $R_j$  is  $C_3-C_4$  alkyl, preferably butyl, hereinafter Z17-2.

Preferred compounds of Z17-2 include those wherein  $R_p$  is -N(CH<sub>3</sub>)SO<sub>2</sub>(C<sub>1</sub>-C<sub>2</sub> alkyl); and  $R_1$  is ethyl.

Other preferred compounds of Z17 are those where  $R_p$  is 2-oxazolyl. In these compounds, Z is preferably  $CH_2$  or CH. More preferably, Z is CH.

Other preferred compounds of Z17 are those where  $R_p$  is 10 cyano; Z is  $CH_2$  or CH; and  $R_j$  is  $C_3-C_4$  alkyl. Preferably, Z is CH and  $R_j$  is butyl.

Still other preferred compounds of Z17, Z17-1, and Z17-2 are those wherein at least one of Rf and Rg is fluorine. More preferably, both are fluorine.

Still other preferred compounds of Z17, Z17-1, and Z17-2 are those wherein R2, R3, and the carbon to which they are attached form a cyclopropyl ring.

Other preferred compounds of the invention are those of formula Z18

20

5

**Z18** 

or a pharmaceutically acceptable salt thereof, wherein both of X and X' are CH, or one of X and X' is nitrogen and the other is CH;

25 R<sub>1</sub> is C<sub>2</sub>-C<sub>3</sub> alkynyl, C<sub>1,2</sub>-C<sub>3</sub> alkyl, amino, mono(C<sub>1</sub>-C<sub>3</sub>)alkylamino, or di(C<sub>1</sub>-C<sub>3</sub>) alkylamino, aminoalkyl, mono(C<sub>1</sub>-C<sub>3</sub>)alkylamino(C<sub>1</sub>-C<sub>2</sub>)alkyl, di(C<sub>1</sub>-C<sub>3</sub>)alkylamino(C<sub>1</sub>-C<sub>2</sub>)alkyl, CF<sub>3</sub>, C<sub>1</sub>-C<sub>2</sub> alkoxy, halogen, -NHSO<sub>2</sub>(C<sub>1</sub>-C<sub>2</sub> alkyl);

R<sub>2</sub> and R<sub>3</sub> are both hydrogen; or

15

 $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached;

 $R_f$  and  $R_g$  are both hydrogen or independently halogen;

 $R_5$  and  $R_6$  are independently  $C_{1,2,3}$ - $C_4$  alkyl; or

one of  $R_5$  and  $R_6$  is methyl or ethyl and the other is  $C_3$  or  $C_4$  alkyl, preferably butyl.

 $\label{eq:preferred} \mbox{ Preferred compounds of Formula Z18 include those where $R_1$ } \\ 10 \mbox{ is bromo or chloro.}$ 

Other preferred compounds of Z18 include those of Z18-1, i.e., compounds of formula Z18 where  $R_1$  is  $C_2-C_3$  alkyl.

Other preferred compounds of Z18 include those of Z18-2, i.e., compounds of formula Z18 where  $R_1$  is di( $C_1$ - $C_3$ )alkylamino and both of  $R_f$  and  $R_g$  are chloro or fluoro.

Still other pPreferred compounds of Z18 include those of Z18-3, i.e., compounds of formula Z18 where  $R_1$  is di( $C_1$ - $C_3$ )alkylamino( $C_1$ - $C_2$ )alkyl, and both of  $R_f$  and  $R_g$  are chloro or fluoro.

More preferred compounds of formula Z18 include those where X is nitrogen;  $R_f$  and  $R_g$  are both fluoro;  $R_1$  is  $C_1$ - $C_3$  alkyl; and  $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached.

Preferred compounds of Z18-1 include those where both X and X' are CH; and  $R_{\rm f}$  and  $R_{\rm g}$  are both chloro or fluoro, hereinafter compounds of formula Z18-1-A. More preferred compounds of Z18-1 and Z18-1-A are those where one of  $R_{\rm 5}$  and  $R_{\rm 6}$  is methyl or ethyl and the other is  $C_{\rm 3}$  or  $C_{\rm 4}$  alkyl, preferably butyl.

Still other more preferred compounds of Z18-1 include compounds of formula Z18-1-B, i.e., compounds of Z18-1 where  $R_5$  and  $R_6$  are independently  $C_2$ - $C_4$  alkyl. Preferred compounds of Z18-1-B include those where  $R_5$  is  $C_2$ - $C_4$  alkyl and  $R_6$  is ethyl.

Other preferred compounds of Z18-1-A are those where one of  $R_5$  and  $R_6$  is methyl or ethyl and the other is  $C_3$  or  $C_4$  alkyl, preferably butyl. More preferably, one of of  $R_5$  and  $R_6$  is methyl. Yet other preferred compounds of Z18-1-A are those where  $R_5$  and  $R_6$  are independently propyl or butyl.

Other preferred compounds of formula Z18 are compounds of formula Z18-4, i.e., compounds of formula Z18 where  $R_1$  is  $C_2$  alkynyl. Preferred compounds of Z18-4 include those where both X and X' are CH; and  $R_{\rm f}$  and  $R_{\rm g}$  are both chloro or fluoro.

Other preferred compounds of Z18-4 include those wherein  $\mbox{X}$  is nitrogen and  $\mbox{X'}$  is  $CH_3$ .

Other preferred compounds of Z18-1-A are those where  $R_{5}$  and  $R_{6}$  are independently propyl or butyl.

Still other preferred compounds of Z18 include those compounds wherein  $R_1$  is  $CF_3$ , or  $-NHSO_2CH_3$ ;  $R_2$  and  $R_3$  are both H; and  $R_5$  and  $R_6$  are independently  $C_3$  or  $C_4$  alkyl, hereinafter Z18-5.

Yet still other preferred compounds of Z18 include those 20 wherein X is CH and X' is nitrogen, hereinafter Z18-6.

Preferred compounds of any of the embodiments of Z18, Z18-1-A, -1-B, Z18-2, Z18-3, Z18-4, Z18-5, Z18-6 are those where  $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached, hereinafter Z18-7.

More preferred compounds of Z18-7 include those wherein at least one of  $R_f$  and  $R_g$  is fluoro. More preferably, both Rf and Rg are fluoro.

Other preferred compounds of the invention are those of formula Z19

30

10

Z19

or a pharmaceutically acceptable salt thereof, wherein  $R_1$  is  $C_2-C_3$  alkyl, or  $C_1-C_2$  alkoxy;

R<sub>2</sub> and R<sub>3</sub> are both hydrogen;

 $R_f$  and  $R_g$  are independently halogen;

 $R_{\text{s}}$  is  $\text{C}_3\text{--}\text{C}_9$  alkyl (preferably C3-C4 alkyl), thiazolinyl or thiazolidinyl.

Preferred compounds of formula Z19 include those where  $R_S$  is 2-thiazolidinyl or 2- thiazolinyl and  $R_1$  is  $C_2-C_3$  alkyl.

Other preferred compounds of Z19 are those where  $R_{\rm S}$  is methyl, propyl or, more preferably, t-butyl. Still more preferably at least one of Rf and Rg is fluoro. Even more preferably,  $R_{\rm 1}$  is also  $C_2-C_3$  alkyl.

Other preferred compounds of formula Z19 include those wherein Rs is  $C_8$  alkyl. More preferably, the  $C_8$  alkyl is  $-CH_2CH(n-propyl)$  (n-propyl). Even more preferably  $R_1$  is also  $C_1-C_2$  alkoxy. Even more preferably,  $R_1$  is methoxy.

Other preferred compounds of the invention are those of formula Z20

20

15

Z20

or a pharmaceutically acceptable salt thereof, wherein  $R_1$  is  $C_2-C_3$  alkyl,  $CF_3$ , or  $-NH(C_3-C_6$  cycloalkyl);

R<sub>2</sub> and R<sub>3</sub> are both hydrogen; or

 $R_2$  and  $R_3$  together with the carbon atom to which they are attached form a 3-membered ring;

 $R_p$  is pyridyl, piperazinyl, amino, amino( $C_1$ - $C_{5(3)}$ )alkyl, mono( $C_1$ - $C_2$ )alkylamino( $C_1$ - $C_5$ )alkyl, di( $C_1$ - $C_2$ )alkylamino( $C_1$ - $C_{(4)5}$ )alkyl, mono( $C_1$ - $C_3$ )alkylamino, di( $C_1$ - $C_3$ )alkylamino,

amino  $(C_3-C_4)$  alkynyl, mono  $(C_1-C_2)$  alkylamino  $(C_3-C_4)$  alkynyl, di  $(C_1-C_2)$  alkylamino  $(C_3-C_5)$  alkynyl, -N( $C_1-C_2$  alkyl) -SO<sub>2</sub>( $C_1-C_2$  alkyl), -N( $C_1-C_2$  alkyl), -N( $C_1-C_2$  alkyl) -SO<sub>2</sub>-thienyl, -N( $C_1-C_2$  alkyl) -SO<sub>2</sub>( $C_1-C_2$  haloalkyl), di  $(C_1-C_2)$  alkylamino  $(C_2-C_4)$  alkynyl, pyrimidinyl, pyrazolyl

 $C_2$ ) alkylamino ( $C_3$ - $C_4$ ) alkynyl, pyrimidinyl, pyrazolyl, imidazolyl, or  $C_2$ - $C_4$  alkynyl;

 $R_{\rm f}$  and  $R_{\rm g}$  are independently halogen;  $R_{\rm 5}$  and  $R_{\rm 6}$  are independently  $C_3$ - $C_4$  alkyl.

5

20

25

30

Preferred compounds of Formula Z20 include those of 10 formula Z20-1, i.e., compounds of Z20 where  $R_5$  and  $R_6$  are both  $C_3$  alkyl.

Other preferred compounds of Formula Z20 include those of formula Z20-2, i.e., compounds of Z20 where  $R_2$  and  $R_3$  are hydrogen.

Still other preferred compounds of Z20 are compounds of formula Z20-3, i.e., compounds of Z20 where  $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached.

Preferred compounds of Z20-1, -2, and -3 are those where  $R_p$  is 4-pyridyl, 2-pyrimidinyl, 4-pyrazolyl, or 4-imidazolyl, more preferably  $R_p$  is 4-pyridyl, hereinafter Z20-3A. Other preferred compounds of formulas Z20-1, -2, and -3 are those where  $R_p$  is diethylamino or dimethylamino, hereinafter Z20-3B. Still other preferred compounds of formulas Z20-1, -2, and -3 are those  $R_p$  is amino or  $C_1$ - $C_6$  alkylamino, hereinafter Z20-3C. Yet other preferred compounds of Z20-1, -2, and -3 are those where  $R_p$  is 1-piperazinyl, hereinafter Z20-3D. Still other preferred compounds of Z20-1, -2, and -3 include compounds where  $R_p$  is amino  $(C_2$ - $C_4$ ) alkyl where the amino is optionally mono substituted with  $C_1$ - $C_2$  alkyl, hereinafter Z20-3E; or where  $R_p$  is -N(CH<sub>3</sub>)-SO<sub>2</sub>CH<sub>3</sub>, -NH-SO<sub>2</sub>CH<sub>3</sub>, -N(CH<sub>3</sub>)-SO<sub>2</sub>-thien-2-yl, or -N(CH<sub>3</sub>)-SO<sub>2</sub>CF<sub>3</sub>, hereinafter Z20-3F.

Other preferred compounds of Z20 are those where  $R_p$  is  $di(C_1-C_2)$  alkylamino( $C_3-C_5$ ) alkyl, more preferably, N,N-dimethylamino( $C_3-C_5$ ) alkyl, hereinafter Z20-3G.

Particularly preferred compounds of Z20-1, -2, and -3 are those where  $R_p$  is 3-(mono( $C_1$ - $C_2$ )alkylamino)propyn-1-yl, hereinafter Z20-3H. Other particularly preferred compounds of Z20 are those where  $R_p$  is 3-(mono( $C_1$ - $C_2$ )alkylamino)propyn-1-yl, or 4-(di( $C_1$ - $C_2$ )alkylamino)propyn-1-yl, hereinafter Z20-3I.

Other preferred compounds of Z20, Z20-1, -2, and -3 are those where  $R_p$  is di(C<sub>1</sub>-C<sub>2</sub>)alkylamino(C<sub>3</sub>-C<sub>5</sub>)alkyl; and  $R_5$  and  $R_6$  are both C<sub>3</sub> alkyl, hereinafter Z20-3J.

Still other preferred compounds of Z20, Z20-1, -2, -3, are those where  $R_p$  is  $C_2$ - $C_3$  alkynyl, hereinafter Z20-4. More preferably,  $R_p$  is  $C_2$  alkynyl.

15

Also preferred are compounds of formulas Z20, Z20-1, -2, -3, -3A to -3J and Z20-4 when  $R_1$  is -NH( $C_3$ - $C_6$  cycloalkyl) preferably -NHcyclopropyl. More preferably, at least one of  $R_f$  and  $R_g$  is fluoro. Even more preferably, both are fluoro.

Also preferred are compounds of formulas Z20, Z20-1, -2, -3, -3A to -3J and Z20-4 when  $R_1$  is  $CF_3$ . More preferably, at least one of  $R_f$  and  $R_g$  is fluoro. Even more preferably, both are fluoro.

Other preferred compounds of Z20, Z20-1, -2, -3, -3A to

-3J and -4 include those wherein R<sub>1</sub> is ethyl or isopropyl.

Preferably R<sub>1</sub> is isopropyl. More preferably R<sub>1</sub> is ethyl. More preferably, at least one of R<sub>f</sub> and R<sub>g</sub> is fluoro. Even more preferably, both are fluoro. Still more preferably, Rf and Rg are attached to the 3 and 5 positions of the phenyl ring (with position 1 being the point of attachment to the CH<sub>2</sub> group.)

Other preferred compounds of the invention are those of formula Z21

Z21

or a pharmaceutically acceptable salt thereof, wherein  $R_1$  is  $C_2\text{-}C_3$  alkynyl;

 $R_2$  and  $R_3$  are both hydrogen;

R<sub>p</sub> is C<sub>1</sub>-C<sub>3</sub> alkyl;

 $R_{\text{f}}$  and  $R_{\text{g}}$  are independently halogen;

 $\ensuremath{\text{R}}_5$  and  $\ensuremath{\text{R}}_6$  are independently  $\ensuremath{\text{C}}_3\text{-}\ensuremath{\text{C}}_4$  alkyl; or

one of  $R_5$  and  $R_6$  is methyl and the other is  $C_3$  or  $C_4$  alkyl.

10 Preferred compounds of formula Z21 include those where one of  $R_5$  and  $R_6$  is methyl and the other is butyl, herein after Z21-1.

Other preferred compounds of formula Z21 and Z21-1 include those where  $R_{\text{p}}$  is methyl.

Other preferred compounds of the invention are those of formula Z22

Z22

20 or a pharmaceutically acceptable salt thereof, wherein

 $R_1$  is  $C_1-C_2$  alkyl,  $C_2-C_4$  alkynyl or  $C_3$  (isopropyl)- $C_4$  alkyl;

 $\ensuremath{\text{R}}_2$  and  $\ensuremath{\text{R}}_3$  are both hydrogen; or

 $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached;

25  $R_f$  and  $R_g$  are independently halogen;

 $\mbox{R}_{\mbox{\footnotesize p}}$  is  $\mbox{C}_1\mbox{-}\mbox{C}_3$  alkyl or a group of the formula:  $\mbox{R}_{\mbox{\footnotesize s}}\mbox{SO}_2\mbox{-}$  where  $\mbox{R}_{\mbox{\footnotesize s}}$  is

 $R_{51}R_{61}N$ - and  $R_{51}$  and  $R_{61}$  independently represent hydrogen or  $C_1$ - $C_4$  alkyl groups; or a group of the formula:

 $R_t$ 

where  $R_t$  is  $C_1-C_2$  alkoxy( $C_1-C_2$ ) alkyl; and

 $\textbf{R}_{\textbf{q}}$  is  $\textbf{C}_1-\textbf{C}_3$  alkoxy(C\_1-C\_2)alkyl, C\_1-C\_4 alkyl, -C(0)NH\_2, or H.

Preferred compounds of formula Z22 include those where  $R_1$  is  $C_2$  alkynyl;  $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached; and  $R_p$  is  $R_sSO_2$ -

where 
$$R_s$$
 is  $^{\sim}N$ 

5

10

15

25

Other preferred compounds of formula Z22 include those where  $R_1$  is  $C_1$ - $C_2$  alkyl;  $R_2$  and  $R_3$  are hydrogen; and  $R_p$  is  $R_sSO_2$ -where  $R_s$  is  $C_3$ - $C_4$  amino, preferably propyl, more preferably tbutylamino.

Still other preferred compounds of formula Z22 include those where  $R_1$  is  $C_1-C_2$  alkyl;  $R_2$  and  $R_3$  are hydrogen;  $R_p$  is  $C_1-C_2$  alkyl; and  $R_q$  is  $C_3-C_4$  alkyl, preferably propyl or butyl.

Yet other preferred compounds of formula Z22 include those 20 where  $R_1$  is  $C_1-C_2$  alkyl;  $R_2$  and  $R_3$  are hydrogen;  $R_p$  is  $C_1-C_2$  alkyl; and  $R_q$  is propoxy( $C_1-C_2$ ) alkyl.

Other preferred compounds of formula Z22 include those where  $R_1$  is  $C_1-C_2$  alkyl;  $R_2$  and  $R_3$  are hydrogen;  $R_p$  is  $C_1-C_2$  alkyl; and  $R_q$  is methoxy( $C_1-C_2$ )alkyl.

Other preferred compounds of formula Z22 include those where  $R_1$  is  $C_1$ - $C_2$  alkyl;  $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached;  $R_p$  is  $C_1$ - $C_2$  alkyl; and  $R_q$  is  $C_1$ - $C_2$  alkyl.

Other preferred compounds of formula Z22 include those where  $R_1$  is  $C_1-C_2$  alkyl;  $R_2$  and  $R_3$  are hydrogen;  $R_p$  is  $C_1-C_2$  alkyl; and  $R_q$  is  $C_1-C_2$  alkyl.

Particularly preferred are compounds of Z22 where  $\ensuremath{R_1}$  is isopropyl.

Other preferred compounds of Z22 include those wherein  $R_q$  is (R)-methoxymethyl, methyl, propyl, (S)-propyl, (R)-propyl, butyl, (R)-butyl, (S)-butyl, (R)-2-methoxymethyl, or (R)-2-methoxyethyl.

Other preferred compounds of the invention are those of formula Z23

10

5

**Z23** 

or a pharmaceutically acceptable salt thereof, wherein Z is oxygen, nitrogen, or sulfur;

 $R_1$  is chloro, bromo, hydrogen or  $C_1$ - $C_2$  alkyl;

 $R_f$  and  $R_g$  are independently halogen; and  $R_5$  and  $R_6$  are independently  $C_3-C_4$  alkyl; or one of  $R_5$  and  $R_6$  is methyl and the other is  $C_3$  or  $C_4$  alkyl.

Preferred compounds of Formula Z23 include those where Z is nitrogen; and  $R_1$  is  $C_1\text{-}C_3$  alkyl.

20 Preferred compounds of formula Z23 are those where R<sub>1</sub> is bromo, and Z is oxygen, hereinafter Z23-1. Other preferred compounds of formula Z23 are those wherein Z is nitrogen, hereinafter Z23-2. Still other preferred compounds of formula Z23 are those wherein Z is sulfur, hereinafter compounds of formula Z23 are those wherein Z is sulfur, hereinafter compounds of formula Z23-3.

Particularly preferred compounds of Z23, Z23-1, Z23-2, and Z23-3 are those where one of  $R_5$  and  $R_6$  is methyl and the other is butyl. Equally preferred are those where at least one of  $R_5$ 

and  $R_6$  is propyl. Still more preferably,  $R_1$  is  $C_1-C_3$  alkyl. Even more preferably,  $R_1$  is  $C_2-C_3$  alkyl.  $R_1$  can also be ethyl.

Other preferred compounds of the invention are those of formula Z24

5

Z24

or a pharmaceutically acceptable salt thereof, wherein  $R_1$  is  $C_1 - C_2 - C_3$  alkyl,;

10 R<sub>2</sub> and R<sub>3</sub> are both hydrogen; or

 $R_p$  is  $C_1-C_2$  alkyl;

 $R_{\rm f}$  and  $R_{\rm g}$  are both hydrogen or independently halogen; and  $R_{\rm 5}$  and  $R_{\rm 6}$  are independently  $C_3-C_4$  alkyl.

Preferred compounds of formula Z24 include those where  $R_1$  is ethyl. More preferably,  $R_p$  is also methyl. Still more preferably,  $R_f$  and  $R_g$  are both halogen.

Other preferred compounds of the invention are those of formula  ${\tt Z25}$ 

20

Z25

or a pharmaceutically acceptable salt thereof, wherein one of X and X' is nitrogen and the other is CH or  $CR_1$ ;  $R_1$  is  $C_1$ - $C_2$ - $C_3$  alkyl

25  $R_2$  and  $R_3$  are both hydrogen; or

 $R_2$ ,  $R_3$ , and the carbon to which they are attached form a cyclopropyl ring;

 $R_p$  is  $C_1-C_2$  alkyl;

 $R_f$  and  $R_g$  are independently halogen; and

5  $R_5$  and  $R_6$  are independently  $C_3-C_4$  alkyl.

Preferred compounds of Z25 include compounds where X is CH and X' is nitrogen. Particularly preferred compounds of formula Z25 include those where  $R_1$  is ethyl. Even more preferred is when  $R_2$  and  $R_3$  are both hydrogen.

Other preferred compounds of the invention are those of formula Z26

Z26

or a pharmaceutically acceptable salt thereof, wherein  $R_1$  is a group of the formula:

one of  $R_{\rm s11}$  and  $R'_{\rm s11}$  is hydrogen and the other is  $C_1$ -  $C_3$  acyl,  $C_1$ - $C_2$  alkyl or CHO; or

one of  $R_{\rm s11}$  and  $R^{\prime}_{\,\rm s11}$  is methyl and the other is CHO or methyl,

each  $R_{\rm s21}$  is  $C_1-C_3$  alkoxy, halogen, H,  $C_1-C_2$  alkyl or cyano; or

 $R_1$  is cyclopentyl, cyclohexyl, oxazolyl, isoxazolyl optionally substituted with one or two  $C_1\text{-}C_2$  alkyl groups, phenyl,

thien-2-yl optionally substituted with CHO, unsubstituted thien-3-yl;

R<sub>2</sub> and R<sub>3</sub> are both hydrogen;

20

 $R_p$  is  $C_1-C_2$  alkyl;

5

20

 $R_{\text{f}}$  and  $R_{\text{g}}$  are independently halogen; and

 $R_5$  and  $R_6$  are independently  $C_3-C_4$  alkyl.

Preferred compounds of formula Z26 include compounds of Z26 where  $R_1$  is  $6-(C_1-C_2)$  alkoxypyridin-2-yl.

Other preferred compounds of formula Z26 include compounds of Z26 where  $R_1$  is 2-formylthien-3-yl.

Still other preferred compounds of formula Z26 include compounds of Z26 where  $R_1$  is 5-formylthien-3-yl.

Other preferred compounds of formula Z26 include compounds where  $R_{\rm s21}$  is cyano.

Yet other preferred compounds of formula Z26 include compounds of Z26 where  $R_1$  is 5-cyanopyrid-3-yl.

Other preferred compounds of formula Z26 are those of formula Z26-1, i.e., compounds of Z26 where  $R_1$  is 6-halopyrid-3-yl. Particularly preferred compounds of Z26-1 are those where halogen in  $R_1$  is fluoro or chloro.

Still other preferred compounds of formula Z26 are those wherein  $R_1$  is a thienyl group optionally substituted with  $R_s11$ , or  $R'_s11$ , cyclopentyl, cyclohexyl, oxazolyl, isoxazolyl optionally substituted with one or two  $C_1-C_2$  alkyl groups, phenyl, or thien-2-yl optionally substituted with CHO. More preferably, the unsubstituted thienyl group is a thien-3-yl or a thien-2-yl.

Other preferred compounds of the invention are those of formula Z27

Z27

or a pharmaceutically acceptable salt thereof, wherein

Z is , , , pyridyl or the pyridyl N-oxide

wherein the pyridyl or the pyridyl N-oxide is substituted with  $C(0)\,NR_5R_6$ , wherein

 $R_5$  and  $R_6$  are independently  $C_3-C_4$  alkyl; or

 $R_5$  is methyl or ethyl and  $R_6$  is  $C_3$  alkyl;

R<sub>1</sub> is C<sub>1</sub>-C<sub>3</sub> alkyl or halogen;

5

15

R<sub>2</sub> and R<sub>3</sub> are both hydrogen;

 $R_s$  is  $C_1-C_3$  alkylsulfonyl,  $C_1-C_3$  alkylsulfonyl( $C_1-C_3$ )alkyl,

 $-NHSO_2(C_1-C_2 \mbox{ alkyl}), \mbox{ or } -N(C_1-C_2 \mbox{ alkyl})SO_2(C_1-C_2 \mbox{ alkyl}); \mbox{ and} \\ 10 \mbox{ R}_f \mbox{ and } R_g \mbox{ are independently halogen.}$ 

Preferably R<sub>1</sub> in compounds of formula Z27 is ethyl. More

preferably, Z is 
$$R_S \longrightarrow S \longrightarrow S$$

Equally preferably,  $R_S$  is  $C_1-C_3$  alkylsulfonyl,  $C_1-C_3$  alkylsulfonyl( $C_1-C_3$ ) alkyl, -NHSO<sub>2</sub>CH<sub>3</sub>, or -NCH<sub>3</sub>SO<sub>2</sub>CH<sub>3</sub>.

Other preferred compounds include those wherein Z is pyridyl substituted with  $C(0)NR_5R_6$ , wherein  $R_5$  and  $R_6$  are independently  $C_3-C_4$  alkyl; or  $R_5$  is methyl or ethyl and  $R_6$  is  $C_3$  alkyl. More preferably,  $R_5$  and  $R_6$  are propyl. Still more

preferably, Z is

or the N-oxide thereof.

Other preferred compounds of the invention are those of formula Z28

Z28

or a pharmaceutically acceptable salt thereof, wherein

 $R_1$  is  $C_2-C_3$  alkyl;

 $R_2$  and  $R_3$  are both hydrogen;

 $R_5$  and  $R_6$  independently represent (a)  $C_1\text{--}C_3$  alkyl optionally substituted with phenyl and (b) phenyl optionally substituted with halogen; and

 $R_{\text{f}}$  and  $R_{\text{g}}$  are independently halogen.

Preferred compounds of formula Z28 include those where  $R_{\rm 5}$  is methyl optionally substituted with phenyl and  $R_{\rm 6}$  is phenyl.

Other preferred compounds of formula Z28 include those where  $R_5$  is  $C_1-C_2$  alkyl and  $R_6$  is 4-halophenyl, preferably 4-chlorophenyl.

Other preferred compounds of the invention are those of formula Z29

15

5

Z29

or a pharmaceutically acceptable salt thereof, wherein X is nitrogen or  $N^+-O^-;$ 

 $R_1$  is  $C_2-C_4$  alkynyl or  $C_1-C_3$  alkyl;

20  $R_2$  and  $R_3$  are both hydrogen; or

 $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached;

 $R_f$  and  $R_g$  are independently halogen;

 $R_p$  is hydrogen or  $C_1$ - $C_2$  alkyl; and

25  $R_5$  and  $R_6$  are independently  $C_3$ - $C_4$  alkyl.

Preferred compounds of formula Z29 include those where  $R_1$  is ethyl. More preferred compounds of formula Z29 include those where X is nitrogen;  $R_p$  is  $C_1$ - $C_2$  alkyl (preferably methyl); and  $R_1$  is ethyl.

Other preferred compounds of the invention are those of formula Z30

Z30

5 or a pharmaceutically acceptable salt thereof, wherein

 $R_1$  is hydrogen or  $C_1$ - $C_3$  alkyl;

 $R_2$  and  $R_3$  are both hydrogen;

 $R_p$  is  $C_1-C_2$  alkyl;

 $R_{\text{f}}$  and  $R_{\text{g}}$  are independently halogen; and

10  $R_5$  and  $R_6$  are independently  $C_3$ - $C_4$  alkyl.

Another preferred group of compounds of the invention is represented by formula Z31

Z31

or a pharmaceutically acceptable salt thereof, wherein  $R_{\text{s}}$  is  $NR_{\text{s}31}R_{\text{s}41}$  where

 $R_{S31}$  is  $C_1-C_2$  alkyl; and

 $R_{S41}$  is  $C_1-C_6$  alkyl, allyl, cyano( $C_1-C_3$ )alkyl, ( $C_4-$ 

 $C_7$ ) cycloalkyl, pyridyl( $C_1-C_3$ ) alkyl, phenyl, phenyl( $C_1-C_3$ )

 $C_3$ ) alkyl, amino  $(C_1-C_3)$  alkyl, mono  $(C_1-C_3)$  alkylamino  $(C_1-C_3)$ 

 $C_2$ ) alkyl, or di( $C_1$ - $C_3$ ) alkylamino( $C_1$ - $C_2$ ) alkyl; or

 $R_s$  is  $CH_3$ ,  $-N(C_1-C_2$  alkyl)phenyl, or  $-N(C_2-C_3$  alkyl)( $C_3-C_4$  alkyl);

 $R_1$  is  $C_2-C_3$  alkyl;

20

25 R<sub>2</sub> and R<sub>3</sub> are both hydrogen; and

 $R_{\text{f}}$  and  $R_{\text{g}}$  are independently halogen.

Preferred compounds of formula Z31 include those where  $R_{\rm S41}$  is pyridylethyl or phenylethyl.

Other preferred compounds of Z31 are those where  $R_{S41}$  is diethylamino( $C_1-C_2$ )alkyl, more preferably diethylaminomethyl.

Still other preferred compounds of Z31 are those where  $R_{\text{S41}}$  is  $C_{\text{3-5}}$  alkyl.

Particularly preferred compounds of formula Z31 include those where  $R_S$  is (2-cyanoethyl)(methyl)amino.


10 Other particularly preferred compounds of formula Z31 include those where  $R_S$  is (cyclohexyl)(methyl)amino.

In a preferred aspect of formula Z31,  $R_{S41}$  is  $C_1-C_6$  alkyl, allyl, cyano( $C_1-C_3$ ) alkyl, ( $C_4-C_7$ ) cycloalkyl, pyridyl( $C_1-C_3$ ) alkyl, phenyl, or phenyl( $C_1-C_3$ ) alkyl.

In another preferred aspect of Z31,  $R_{\rm S41}$  is phenyl or cyclohexyl.

In yet another preferred aspect of Z31,  $R_s$  is  $-N(CH_3)$  phenyl, or  $-N(ethyl)(C_3-C_4 \text{ alkyl})$ .

Other preferred compounds of the invention are those of 20 formula Z32



Z32

or a pharmaceutically acceptable salt thereof, wherein

 $R_1$  is  $C_2-C_3$  alkynyl or  $C_1-C_3$  alkyl;

 $R_f$  and  $R_g$  are independently halogen;

 $R_5$  and  $R_6$  are independently  $C_1$ - $C_4$  alkyl.

Preferred compounds of formula Z33 include those where  $\ensuremath{R_5}$  and  $\ensuremath{R_6}$  are  $\ensuremath{C_3}$  alkyl.

Other preferred compounds of formula Z33 include those where  $R_5$  is methyl and  $R_6$  is  $C_3$  alkyl.

Particularly compounds of formula Z33 include those where  $R_1$  is ethyl.

Other particularly preferred compounds of formula Z33 include those where  $R_5$  and  $R_6$  are both propyl or  $R_5$  is methyl and  $R_6$  is propyl, hereinafter Z33-1.

Still other preferred compounds of formula Z33 and Z33-1 include those wherein  $R_1$  is  $C_2\text{--}C_3$  alkynyl (preferably  $C_2$  alkynyl).

Other preferred compounds of the invention are those of formula Z33

**Z33** 

or a pharmaceutically acceptable salt thereof, wherein

 $R_s$  is  $C_1-C_4$  alkyl;

5

10

 $R_m$  is  $C_1-C_4$  alkyl;

 $R_1$  is  $C_2-C_3$  alkyl;

 $R_2$  and  $R_3$  are both hydrogen; and

20  $R_f$  and  $R_g$  are independently halogen.

Other preferred compounds of the invention are those of formula  ${\tt Z34}$ 

Z34

25 or a pharmaceutically acceptable salt thereof, wherein

 $R_m$  is  $C_1-C_4$  alkyl;

 $R_1$  is  $C_2-C_3$  alkyl;

 $R_2$  and  $R_3$  are both hydrogen; and

 $R_{\text{f}}$  and  $R_{\text{g}}$  are independently halogen;

5 Z is S, S(0), S(0)<sub>2</sub>, or 0.

Preferred compounds of formula Z34 include those where Z is S or S(0). More preferably,  $R_1$  is  $C_2$  alkyl.

Other preferred compounds of the invention are those of 10 formula 235

**Z35** 

or a pharmaceutically acceptable salt thereof, wherein one of X and X' is CH and the other is N;

15  $R_1$  is  $C_2-C_4$  alkynyl; amino( $C_1-C_3$ )alkyl, mono( $C_1-C_3$ )alkylamino( $C_1-C_2$ )alkyl, or di( $C_1-C_3$ )alkylamino( $C_1-C_2$ )alkyl;

 $\ensuremath{\text{R}}_2$  and  $\ensuremath{\text{R}}_3$  are both hydrogen; or

 $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached;

20  $R_f$  and  $R_g$  are independently halogen;

 $\mbox{R}_{5}$  and  $\mbox{R}_{6}$  are independently  $\mbox{C}_{1}\mbox{-}\mbox{C}_{3}\mbox{-}\mbox{C}_{4}$  alkyl.

Preferred compounds of formula Z35 include those where  $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached; X is N; and X' is CH, hereinafter Z35-

25 1.

Other preferred compounds of formula Z35 include those of formula Z35-1, i.e., compounds of Z35 where  $R_2$  and  $R_3$  are hydrogen; X' is N; and X is CH, hereinafter Z35-2.

More preferred compounds of Z35, Z35-1, and Z35-2 include those where  $R_1$  is  $C_2$  alkynyl. More preferably,  $R_1$  is also di( $C_1$ - $C_3$ )alkylamino( $C_1$ - $C_3$ )alkyl. Even more preferably,  $R_1$  is dimethylamino( $C_1$ - $C_2$ )alkyl.

5 Other preferred compounds of the invention are those of formula Z36

**Z36** 

or a pharmaceutically acceptable salt thereof, wherein

10  $R_1$  is  $C_2-C_3$  alkyl,;

 $R_2$  and  $R_3$  are both hydrogen;

 $R_{\text{f}}$  and  $R_{\text{g}}$  are independently halogen;

 $R_p$  is hydrogen, cyano,  $C_1-C_3$  alkyl, amino,  $N\text{-}(C_1-C_3$  alkylsulfonyl)-N-((C\_1-C\_3)alkyl)amino, 2-oxazolyl, or 1-

pyrrolyl optionally substituted in the 2 and 5 positions with  $C_1$ - $C_2$  alkyl;

 $R_a$  is  $C_1-C_3$  alkyl, H or trifluoromethyl; and  $R_j$  is  $C_1-C_5$  alkyl.

20 Preferred compounds of Z36 include those where  $R_j$  is methyl or ethyl and  $R_p$  is hydrogen, methyl, or ethyl.

Other preferred compounds of Z36 include those where  $R_{\rm j}$  is methyl and  $R_{\rm p}$  is hydrogen.

Other preferred compounds of the invention are those of 25 formula Z37

**Z37** 

or a pharmaceutically acceptable salt thereof, wherein X is nitrogen or  $N^+-0^-$ ;

5 R<sub>1</sub> is  $C_2$ - $C_4$  alkynyl, cyano,  $C_1$ - $C_3$  alkyl, or  $CF_3$ ;

 $R_2$  and  $R_3$  are both hydrogen; or

15

20

 $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached;

 $R_{\rm f}$  and  $R_{\rm g}$  are independently halogen;

10  $R_p$  is hydrogen, cyano or  $C_1$ - $C_2$  alkyl; and

 $\ensuremath{\text{R}}_5$  and  $\ensuremath{\text{R}}_6$  are independently  $\ensuremath{\text{C}}_1\text{--}\ensuremath{\text{C}}_4$  alkyl.

Preferred compounds of formula Z37 include those of formula Z37-1, i.e., compounds of Z37 where X is N. Preferred compounds of Z37-1 include those where  $R_p$  is cyano. More preferred compounds of Z37-1 are those where  $R_5$  is methyl and  $R_6$  is  $C_2-C_4$  alkyl. Particularly preferred compounds of Z37-1 are those where  $R_6$  is propyl.

Other preferred compounds of formula Z37 include those wherein  $R_1$  is  $C_2$ - $C_3$  alkyl;  $R_p$  is methyl or ethyl; and  $R_5$  and  $R_6$  are independently  $C_3$ - $C_4$  alkyl. More preferably,  $R_2$  and  $R_3$  are also hydrogen.

Other preferred compounds of Z37 include those wherein  $R_1$  is  $C_2\hbox{--} C_3$  alkynyl, or  $C_2$  alkyl; and  $R_p$  is methyl.

Still other preferred compounds of Z37 include those wherein  $R_1$  is  $CF_3$ . More preferably,  $R_2$  is also methyl. Even more preferably X is CH.

Other preferred compounds of the invention are those of formula Z38

**Z38** 

or a pharmaceutically acceptable salt thereof, wherein  $R_1$  is hydrogen, methyl, or  $-CH_2OH$ ;

5 R<sub>2</sub> and R<sub>3</sub> are both hydrogen; or

 $R_2$  and  $R_3$  together with the carbon atom to which they are attached form a 3-membered ring;

 $R_p$  is  $C_2-C_3$  alkynyl or  $C_1-C_3$  alkyl;

R<sub>f</sub> and R<sub>g</sub> are independently halogen;

10  $R_5$  and  $R_6$  are independently  $C_3$ - $C_4$  alkyl, or

 $R_5$  is methyl and  $R_6$  is  $C_3-C_4$  alkyl.

15

20

In preferred compounds of Formula Z38 include those wherein  $R_{\text{p}}$  is methyl, hereinafter Z38-1.

Other preferred compounds of Formula Z38 include those wherein  $R_p$  is  $C_2$  alkynyl, hereinafter Z38-2.

Other preferred compounds of Z38, Z38-1, and Z38-2 include those wherein  $R_1$  is hydrogen and  $R_2$  and  $R_3$  are both hydrogen, hereinafter Z38-3. Preferred compounds of Z38-3 include those wherein  $R_5$  and  $R_6$  are both  $C_3-C_4$  alkyl. Even more preferably, both are  $C_3$  alkyl.

Still other preferred compounds of Z38, Z38-1, and Z38-2 include those wherein  $R_1$  is hydrogen and  $R_2$  and  $R_3$  form a 3-membered ring, hereinafter Z38-4.

Other preferred compounds of Z38, Z38-1, and Z38-2 include 25 those wherein  $R_1$  is -CH<sub>2</sub>OH. Preferably,  $R_2$  and  $R_3$  are also hydrogen, hereinafter Z38-4A.

Even more preferred compounds of Z38 are those where  $R_1$  is hydrogen and  $R_2$  and  $R_3$  together with the carbon atom to which they are attached form a 3-membered ring, hereinafter Z38-5.

Preferred compounds of formula Z38-5 include those wherein  $R_p$  is  $C_2$ - $C_3$  alkynyl (preferably  $C_2$  alkynyl) or methyl. More preferably, at least one of  $R_5$  and  $R_6$  is  $C_3$  alkyl. Still more preferably,  $R_5$  is methyl or propyl and  $R_6$  is propyl,

Still other preferred Z38, Z38-1,Z38-2, Z38-3, Z38-4, Z38-4A, Z38-5 and Z38-5A include compounds are those where  $R_{\rm f}$  and  $R_{\rm g}$  are both chloro or fluoro. Particularly preferred among Z38 compounds are those where  $R_{\rm f}$  and  $R_{\rm g}$  are both fluoro and are in the 3 and 5 positions with respect to the point of attachment of the phenyl group.

Other preferred compounds of the invention are those of formula Z39

15

20

5

10

Z39

wherein

 $R_1$  is  $C_2-C_3$  alkyl;

hereinafter Z38-5A.

 $R_2$  and  $R_3$  are both methyl or

 $R_2$ ,  $R_3$ , and the carbon to which they are attached form a cyclopropyl ring;

 $R_{\text{f}}$  and  $R_{\text{g}}$  are independently halogen;

 $R_5$  and  $R_6$  are independently  $C_3-C_4$  alkyl; and

 $R_s$  is  $-NH(C_1-C_4$  hydroxyalkyl).

Preferred compounds of Z39 include those wherein the hydroxyalkyl group is 2-hydroxy-1,1,dimethylethyl. More preferably, R<sub>1</sub> is also ethyl.

Preferably  $R_2$  and  $R_3$  are both methyl. Equally preferably,  $R_2$ ,  $R_3$ , and the carbon to which they are attached form a cyclopropyl ring.

Other preferred compounds of the invention are those of formula  ${\tt Z40}$ 

Z40

5 wherein

 $R_1$  is  $C_2$ - $C_3$  alkynyl;

 $R_2$  and  $R_3$  are both hydrogen; or

 $R_f$  and  $R_q$  are independently halogen;

 $\ensuremath{R_5}$  and  $\ensuremath{R_6}$  are independently  $\ensuremath{C_3\text{-}C_4}$  alkyl; and

10  $R_s$  is -NH( $C_2$ - $C_4$  hydroxyalkyl).

Preferred compounds of Z40 include those wherein the hydroxyalkyl group is 2-hydroxy-1,1,dimethylethyl; or 2-hydroxyethyl.

Other preferred compounds of the invention are those of formula Z41

**Z41** 

wherein,

R<sub>c</sub> is C<sub>4</sub>-C<sub>5</sub> alkyl; cyclopropyl; tetrahydronaphthylenyl; -CH(C<sub>2</sub>

alkyl-S-(C<sub>1</sub>-C<sub>2</sub>) alkyl)C(O)NH(C<sub>4</sub> alkyl); -CH(C<sub>2</sub> alkyl-SO<sub>2</sub>(C<sub>1</sub>-C<sub>2</sub>) alkyl)C(O)NH(C<sub>4</sub> alkyl); pyrimidyl optionally
substituted with C<sub>3</sub>-C<sub>4</sub> alkyl; thiochroman 1,1-dioxide;
-CH<sub>2</sub>-thiazolyl optionally substituted with C<sub>3</sub>-C<sub>4</sub> alkyl, or
-CH<sub>2</sub>-isoxazolyl optionally substituted with C<sub>1</sub>-C<sub>5</sub> alkyl;

 $R_{\text{f}}$  and  $R_{\text{g}}$  are independently halogen;

 $R_p$  is  $-NHSO_2CF_3$ ,  $-SO_2NH\,(C_3-C_4$  hydroxyalkyl),  $-NHSO_2CH_3$ , oxazol-2-yl, or  $C_2-C_4$  alkynyl; and

 $R_5$  and  $R_6$  are independently  $C_3-C_4$  alkyl.

Preferred compounds of Z41 include those wherein

R<sub>c</sub> is C<sub>4</sub>-C<sub>5</sub> alkyl (preferably isobutyl or isopentyl);

cyclopropyl; tetrahydronaphthylenyl; -CH(C<sub>2</sub> alkyl-S-(C<sub>1</sub>-C<sub>2</sub>)

alkyl)C(O)NH(C<sub>4</sub> alkyl); -CH(C<sub>2</sub> alkyl-SO<sub>2</sub>-(C<sub>1</sub>-C<sub>2</sub>) alkyl)C(O)NH(C<sub>4</sub>

alkyl); pyrimidyl optionally substituted with C<sub>3</sub>-C<sub>4</sub> alkyl;

thiochroman 1,1-dioxide; -CH<sub>2</sub>-thiazolyl optionally substituted with C<sub>3</sub>-C<sub>4</sub> alkyl, hereinafter Z41-1.

More Preferred compounds of Z41-1 include those wherein  $R_c$  is isobutyl; 1,2,3,4-tetrahydronaphthylen-1-yl, -CH(CH<sub>2</sub>CH<sub>2</sub> - S-CH<sub>3</sub>)C(O)NH(C<sub>1</sub>-C<sub>5</sub> alkyl) where the alkyl group is preferably

15 isobutyl, or 2-tert butylpyrimidin-4-yl, hereinafter Z41-2.

Other preferred compounds of Z41 include those wherein  $R_p$  is  $-SO_2NH(2-hydroxy-1,1-dimethylethyl)$ , hereinafter z41-3.

Other preferred compounds of Z41, Z41-1, Z41-2, and Z41-3 include those wherein  $R_5$  and  $R_6$  are both  $C_3$  alkyl.

Other preferred compounds of Z41 include those wherein  $R_p$  is oxazol-2-yl; and  $R_c$  is -CH<sub>2</sub>-(2-isobutylthiazol-5-yl).

Still other preferred compounds of Z41 include those wherein  $R_p$  is  $C_2\!-\!C_3$  alkynyl (preferably  $C_2$  alkynyl) and  $R_c$  is  $-\text{CH}_2\text{-}(2\text{-isobutylthiazol-5-yl})$  .

Yet other preferred compounds of formula Z41 include those wherein R<sub>p</sub> is -CH<sub>2</sub>-isoxazolyl optionally substituted with C<sub>1</sub>-C<sub>5</sub> alkyl. More preferably, Rp is -CH<sub>2</sub>-isoxazol-5-yl. Even more preferably, it is -CH<sub>2</sub>-(3-isobutylisoxazol-5-yl). Even more preferably R<sub>p</sub> is also C<sub>2</sub>-C<sub>3</sub> alkynyl. Still more preferably R<sub>5</sub> and R<sub>6</sub> are both C<sub>3</sub> alkyl.

Other preferred compounds of the invention are those of formula  ${\tt Z42}$ 

**Z42** 

wherein

10

 $R_1$  is  $C_2$ - $C_3$  alkyl, or halogen;

5 R<sub>2</sub> and R<sub>3</sub> are both hydrogen; or

 $R_2$ ,  $R_3$ , and the carbon to which they are attached form a cyclopropyl ring;

 $R_{\text{f}}$  and  $R_{\text{g}}$  are independently halogen; and

 $R_m$  is  $-NH-SO_2CF_3\,,$   $oxazol-2-yl\,,$   $-N\,(CH_3)\,SO_2CH_3\,,$   $-N\,(C_3-C4$ 

hydroxyalkyl) $SO_2(C_1-C_2 \text{ alkyl})$ , and  $R_p$  is H; or

 $R_m$  is H and  $R_p$  is  $-NH-SO_2CF_3$ ,  $-CH_2SO_2(C_1-C_2$  alkyl) where the alkyl group is preferably methyl; or

 $R_m$  is -C(0) pyrrolidinyl and  $R_p$  is OH.

Preferred compounds of formula Z42 include those wherein R<sub>m</sub> is H and R<sub>p</sub> is -NH-SO<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>SO<sub>2</sub>(C<sub>1</sub>-C<sub>2</sub> alkyl), hereinafter Z42-1. Also preferred are compounds of Z42 wherein R<sub>m</sub> is -NH-SO<sub>2</sub>CF<sub>3</sub>, oxazol-2-yl, -N(CH<sub>3</sub>)SO<sub>2</sub>CH<sub>3</sub>, -N(C<sub>3</sub>-C4 hydroxyalkyl)SO<sub>2</sub>(C<sub>1</sub>-C<sub>2</sub> alkyl), and R<sub>p</sub> is H, hereinafter Z42-2.

Preferred compounds of Z42, Z42-1, and Z42-2 include those 20 wherein R1 is ethyl, bromo, or iodo. More preferred is when  $R_2$  and  $R_3$  are also both hydrogen;

Other preferred compounds of the invention are those of formula Z43

wherein

5

 $\begin{array}{l} R_1 \text{ is } C_2\text{--}C_5 \text{ alkyl}, \ C_3\text{--}C_6 \text{ cyanoalkyl}, \ C_3\text{--}C_6 \text{ alkenyl}, \ -\text{NHSO}_2(C_1\text{--}C_2 \\ \text{alkyl}), \ C_4\text{--}C_5 \text{ haloalkyl}, \ -C_3 \text{ alkyl}\text{--}CO_2\text{--}(C_1\text{--}C_2 \text{ alkyl}), \ CN, \\ -\text{N}(C_1\text{--}C_2 \text{ alkyl}) \text{SO}_2(C_1\text{--}C_2 \text{ alkyl}), \ -\text{SO}_2(C_1\text{--}C_2 \text{ alkyl}), \ -\text{S}(0) (C_1\text{--}C_6 \text{ alkyl}), \ -\text{NH}\text{--}(C_3\text{--}C_6 \text{ cycloalkyl}), \ \text{or } -\text{OC}(0) \text{N}(C_1\text{--}C_2 \text{ alkyl}), \\ \text{alkyl}) (C_1\text{--}C_2 \text{ alkyl}), \end{array}$ 

R<sub>2</sub> and R<sub>3</sub> are both hydrogen;

 $R_f$  and  $R_g$  are independently halogen;

 $R_p$  is  $C_1-C_2$  alkyl;

10 R<sub>5</sub> and R<sub>6</sub> are independently C<sub>3</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>2</sub> alkoxy C<sub>1</sub>-C<sub>3</sub> alkyl, or C<sub>3</sub>-C<sub>5</sub> alkenyl (preferably C<sub>3</sub> alkenyl) or R<sub>5</sub> is H and R<sub>6</sub> is C<sub>4</sub>-C<sub>6</sub> alkyl or (C<sub>1</sub>-C<sub>2</sub> alkoxy)-(C<sub>2</sub>-C<sub>3</sub> alkyl),; R<sub>5</sub> is ethyl and R<sub>6</sub> is C<sub>2</sub>-C<sub>3</sub> hydroxyalkyl or -(C<sub>1</sub>-C<sub>2</sub> alkyl)-N(C<sub>1</sub>-C<sub>2</sub> alkyl); or

15  $R_5$  is  $CH_3$  and  $R_6$  is  $C_4-C_5$  alkyl, cyclohexyl,  $-(C_1-C_2$  alkyl)-phenyl,  $-(C_1-C_2$  alkyl)-pyridyl, or  $-CH_2$ -furyl; or

 $R_5$  is methyl or ethyl and  $R_6$  is  $(C_1-C_2\mbox{ alkoxy})-(C_2-C_3\mbox{ alkyl})$  or  $-CH_2-(C_3-C_6\mbox{ cycloalkyl})\,,$  or

R<sub>5</sub>, R<sub>6</sub>, and the nitrogen to which they are attached form a piperidinyl ring optionally substituted with C<sub>3</sub>-C<sub>4</sub> alkyl or OH, azepanyl, pyrrolidine-2-carboxylic acid amide, 3-hydroxypiperidin-1-yl.

Preferred compounds of formula Z43 include those wherein  $R_1$  is  $C_2$ - $C_4$  alkyl, hereinafter Z43-1. Preferably,  $R_1$  is ethyl, isopropyl, isobutyl, sec-butyl, or isopentyl. More preferably ethyl or isopropyl. Still more preferably ethyl.

Other preferred compounds of formula Z43 and Z43-1 include those wherein  $R_{5}$  and  $R_{6}$  are simultaneously ethoxyethyl

(hereinafter Z43-1A),  $R_5$  is propyl and  $R_6$  is butyl (hereinafter Z43-1B),  $R_5$  is ethyl and  $R_6$  is butyl (hereinafter Z43-1C),  $R_5$  is methyl or ethyl and  $R_6$  is -CH<sub>2</sub>-(cyclopropyl), isobutyl, or  $C_2$ - $C_4$  alkynyl(hereinafter Z43-1D), or  $R_5$  is ethyl and  $R_6$  is propyl

(hereinafter Z43-1E), or  $R_5$  is hydrogen and  $R_6$  is sec-butyl (hereinafter Z43-1F).

Even more preferred compounds of Z43, Z43-1, Z43-1A, Z43-1B, Z43-1C, Z43-1D, Z43-1E and Z431F are those wherein  $R_p$  is methyl or  $C_2$  alkynyl.

Other preferred compounds of formula Z43 include those wherein  $R_5$ ,  $R_6$ , and the nitrogen to which they are attached form a 2-propyl piperidin-1-yl ring.

5

Still other preferred compounds of formula Z43 include

those wherein R<sub>1</sub> is cyclopentyl, cyclohexyl, propenyl, allyl,
or -(C<sub>3</sub>-C<sub>6</sub> alkyl)-CN, 4-chlorobutyl, 3-pyridyl, methyl 2methylpropanoate, hex-5-enyl, CN, -N(CH<sub>3</sub>)SO<sub>2</sub>CH<sub>3</sub>, -SO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, 3methylpyrid-2-yl, oxazol-2-yl, 3,5-dimethylisoxazol-4-yl, 3methylthien-2-yl, 2-pyridyl, 4-carbaldehydefuran-5-yl, and 2carbaldehydethien-5-yl, 2-carbaldehyde-3-methylthien-5-yl, 2methoxypyridin-4-yl, -NH-cyclopropyl, -NHSO<sub>2</sub>CH<sub>3</sub>; and R<sub>p</sub> is
methyl, hereinafter Z43-2. Preferred compounds of formula Z432 include those wherein R<sub>5</sub> and R<sub>6</sub> are also both C<sub>3</sub> alkyl. Also
preferred is when R<sub>5</sub> is ethyl and R<sub>6</sub> is butyl.

Preferred compounds of Z43, Z43-1, and Z43-2 include those wherein  $R_1$  is  $C_2$ - $C_3$  alkynyl (preferably  $C_2$  alkynyl), hereinafter Z43-3.

Preferred compounds of Z43, Z43-1, Z43-2, and Z43-3 include those wherein  $R_5$  and  $R_6$  are independently  $C_3$ - $C_5$  alkyl,  $C_1$ - $C_2$  alkoxy  $C_1$ - $C_3$  alkyl. Other preferred compounds of Z43, Z43-1, Z43-2, and Z43-3 include those wherein  $R_5$  is H and  $R_6$  is  $C_4$ ,5- $C_6$  alkyl or  $(C_1$ - $C_2$  alkoxy)- $(C_2$ - $C_3$  alkyl). Still other preferred compounds of Z43, Z43-1, Z43-2, and Z43-3 include those wherein  $R_5$  is ethyl and  $R_6$  is  $C_2$ - $C_3$  hydroxyalkyl or - $(C_1$ - $C_2$  alkyl)- $N(C_1$ - $C_2$  alkyl)  $(C_1$ - $C_2$  alkyl). More preferably, the - $(C_1$ - $C_2$  alkyl)- $N(C_1$ - $C_2$  alkyl)  $(C_1$ - $C_2$  alkyl) is - $(C_1$ - $C_2$  alkyl)- $N(C_1$ - $C_2$  alkyl)  $(C_1$ - $C_2$  alkyl) is - $(C_1$ - $C_2$  alkyl)- $N(C_1$ - $C_2$  alkyl)  $(C_1$ - $C_2$  alkyl) is - $(C_1$ - $C_2$  alkyl)- $N(C_1$ - $C_2$  alkyl)  $(C_1$ - $C_2$  alkyl) is - $(C_1$ - $C_2$  alkyl)- $N(C_1$ - $C_2$  alkyl).

Yet still other preferred compounds of Z43, Z43-1, Z43-2, and Z43-3 include those wherein  $R_5$  is  $CH_3$  and  $R_6$  is  $C_4-C_5$  alkyl, cyclohexyl,  $-(C_1-C_2$  alkyl)-phenyl,  $-(C_1-C_2$  alkyl)-pyridyl, or -

CH<sub>2</sub>-furyl. Preferably,  $R_5$  is CH<sub>3</sub> and  $R_6$  is  $C_4$ - $C_5$  alkyl, hereinafter Z43-4. Still yet other preferred compounds of Z43, Z43-1, Z43-2, and Z43-3 include those wherein  $R_5$  is methyl or ethyl and  $R_6$  is  $(C_1$ - $C_2$  alkoxy)- $(C_2$ - $C_3$  alkyl).

Other preferred compounds of Z43, Z43-1, Z43-2, and Z43-3 include those wherein  $R_5$ ,  $R_6$ , and the nitrogen to which they are attached form a piperidinyl ring optionally substituted with  $C_3$ - $C_4$  alkyl or OH, azepanyl, pyrrolidine-2-carboxylic acid amide, or 3-hydroxypiperidin-1-yl.

Further preferred compounds Z43, Z43-1, Z43-2, Z43-3, and Z43-4 include those wherein  $R_{\rm p}$  is methyl.

Other preferred compounds of the invention are those of formula  ${\tt Z44}$ 

**Z44** 

wherein

15

 $R_1$  is  $C_2-C_3$  alkyl, halogen, -NH( $C_3-C_6$  cycloalkyl) preferably the cycloalkyl group is a cyclopropyl group,

 $R_{\text{f}}$  and  $R_{\text{g}}$  are independently halogen;

20  $R_p$  is  $C_1-C_2$  alkyl, oxazolyl, thiazolyl, or  $C_2-C_3$  alkynyl;  $R_2$ ,  $R_3$ , and the carbon to which they are attached form a cyclopropyl ring; or

 $R_2$  and  $R_3$  are both methyl;

 $\ensuremath{R_{5}}$  and  $\ensuremath{R_{6}}$  are independently  $C_{3}\text{-}C_{4}$  alkyl; or

25  $R_5$  is methyl and  $R_6$  is  $C_3$ - $C_5$  alkyl.

Preferred compounds of formula Z44 inlude those wherein  $R_2$  and  $R_3$  are both methyl; and  $R_5$  and  $R_6$  are independently  $C_3\text{--}C_4$  alkyl, hereinafter Z44-1.

Preferred compounds of formula Z44 and Z44-1 include those wherein  $R_p$  is oxazol-2-yl or thiazol-2-yl.

Preferred compounds of formula Z44 inlude those wherein  $R_p$  is  $C_2$ - $C_3$  alkynyl; and  $R_5$  and  $R_6$  are independently  $C_3$ - $C_4$  alkyl.

Also preferred are compounds wherein R1 is bromo, chloro, or iodo or -NH(cyclopropyl).

Other preferred compounds of the invention are those of formula Z45

10 Z45

wherein

20

25

5

 $R_c$  is isoxazolyl optionally substituted with  $C_3-C_5$  alkyl, thiazolyl optionally substituted with  $C_3-C_4$  alkyl, or  $-C_1-C_3$  alkyl- $C(0)NH(C_1-C_3$  alkyl);

R<sub>f</sub> and R<sub>g</sub> are independently halogen;  $R_p \text{ is } C_1-C_2 \text{ alkyl, oxazolyl, thiazolyl, or } C_2-C_4 \text{ alkynyl;}$   $R_5 \text{ and } R_6 \text{ are independently } C_3-C_4 \text{ alkyl.}$ 

Preferred compounds of formula Z45 include those wherein  $R_p$  is oxazol-2-yl or thiazol-2-yl, hereinafter Z45-1. More preferred compounds of Z45-1 include those wherein  $R_c$  is 3-isobutylisoxazol-5-yl or N-isobutyl-2-methylpropion-2-yl amide; and  $R_f$  and  $R_g$  are independently Cl or F.

Other preferred compounds of formula Z45 include those wherein  $R_{\text{c}}$  is 2-isobutylthiazol-2-yl; and  $R_{\text{f}}$  and  $R_{\text{g}}$  are independently Cl or F.

Still other preferred compounds of formula Z45 include those wherein  $R_c$  is 3-isobutylisoxazol-5-yl or N-isobutyl-2-methylpropion-2-yl amide;  $R_f$  and  $R_g$  are independently Cl or F; and  $R_p$  is  $C_2-C_3$  alkynyl.

Other preferred compounds of the invention are those of formula  ${\tt Z46}$ 

Z46

5 wherein

Hal is a halogen;

 $R_1$  is  $C_1$ - $C_2$  alkyl, or halogen;

 $R_2$  and  $R_3$  are both hydrogen;

 $R_{\text{f}}$  and  $R_{\text{g}}$  are independently halogen;

10  $R_z$  is  $C_1-C_2$  alkyl;

 $\ensuremath{R_5}$  and  $\ensuremath{R_6}$  are independently  $\ensuremath{C_3\text{-}C_4}$  alkyl.

Preferred compounds of formula Z45 include those wherein Hal is bromo or chloro. More preferably,  $R_1$  is also methyl, ethyl, bromo or iodo. More preferably  $R_1$  is methyl or ethyl.

15 Even more preferably, it is ethyl.

Other preferred compounds of the invention are those of formula  ${\tt Z47}$ 

Z47

20 n is 0, 1 or 2;

 $R_1$  is  $C_1-C_2$  alkyl;

 $R_2$  and  $R_3$  are both hydrogen;

 $R_{\rm f}$  and  $R_{\rm g}$  are independently halogen;

 $R_s$  is  $(C_1-C_2 \text{ alkoxy})-(C_1-C_2 \text{ alkyl})$ .

Preferred compounds of Z47 include those wherein  $R_{\rm s}$  is methoxymethyl. Preferably n is 1.

Other preferred compounds of the invention are those of formula Z48

Z48

wherein

5

20

25

R<sub>1</sub> is C<sub>1</sub>-C<sub>2</sub> alkyl;

R<sub>2</sub> and R<sub>3</sub> are both hydrogen;

10  $R_f$  and  $R_g$  are independently halogen;

 $R_{\tt p}$  is isoxazole optionally substituted with  ${\tt C_1-C_2}$  alkyl;

 $R_5$  and  $R_6$  are independently  $C_3$ - $C_4$  alkyl.

Preferred compounds of formula Z48 include those wherein  $R_{\text{p}}$  is 3-methylisoxazol-4-yl, 5-oxazolyl, 3-oxazolyl, 3-  $\,$ 

15 methyloxazol-2-yl, 3-ethyloxazol-2-yl.

Preferred compounds of  $Z_1$ - $Z_{48}$  include those wherein at least one of  $R_f$  and  $R_g$  is fluoro. More preferably, both are fluoro. Even more preferably,  $R_f$  and  $R_g$  are in the 3 and 5 positions with respect to the point of attachment of the phenyl group.

In another aspect, the invention includes compounds of the formula Z49:

**Z49** 

$$R_{I}$$
 $N^{2}\zeta$ 
or  $-N(CH_{2}CH_{2}CH_{3})_{2}$ ;

 $R_{\text{f}}$  and  $R_{\text{g}}$  are both hydrogen or taken together with the carbon to which they are attached form a carbonyl;

 $X_a$  is a covalent bond or a carbonyl;

 $R_n$  is hydrogen or hydroxy;

 $R_{\rm i}$  and  $R_{\rm j}$  are independently hydrogen or a halogen selected from Br, F, Cl or I;

 $R_k$  is  $-C_{1-6}$  alkyl;

15

30

wherein Ya is

 $R_1$  is  $-C_{1-6}$  alkyl or phenyl optionally substituted with  $C_1-C_6$  10 alkyl,  $C_1-C_6$  alkoxy, halogen, hydroxy, amino, mono( $C_1-C_6$ ) alkylamino, di( $C_1-C_6$ ) alkylamino, trifluoromethyl; and m is 0 or 1.

In this embodiment,  $R_f$  and  $R_g$  preferably are taken together with the carbon to which they are attached to form a carbonyl,  $X_a$  is preferably a covalent bond,  $R_h$  is preferably hydrogen, m is preferably 1, and  $R_i$  and  $R_j$  are preferably hydrogen. More preferably,  $R_k$  is ethyl and  $R_e$  is a metasubstituted ethyl phenyl group,  $-CH_2CH_2CH(CH_3)_2$ , methyl or phenyl.  $R_1$  is preferably phenyl.

In another preferred aspect of Z49,  $R_f$  and  $R_g$  are hydrogen,  $X_a$  is a carbonyl,  $R_h$  is hydroxyl,  $R_i$  and  $R_j$  are hydrogen and  $R_k$  is ethyl. In another aspect, and in accordance with these preferred groups,  $R_e$  is preferably a metasubstituted ethyl phenyl group,  $-CH_2CH_2CH(CH_3)_2$ , or a methyl group.

In accordance with this embodiment,  $R_a$  is preferably methyl and  $R_d$  is preferably ethyl, X is preferably 0, and  $R_b$  and  $R_c$  are preferably hydrogen. In another aspect, and in accordance with these preferred groups,  $R_e$  is preferably a meta-substituted ethyl phenyl group,  $-CH_2CH_2CH(CH_3)_2$ , methyl or phenyl. Alternatively, and in accordance with this embodiment, X is preferably S,  $R_b$  and  $R_c$  are hydrogen, and  $R_e$  is a meta-

substituted ethyl phenyl group or a methyl group.  $R_{\rm e}$  is preferably phenyl.

In another aspect, the invention provides compounds of the formula Z50:

Z50

wherein

5

 $R_a$  and  $R_d$  are  $C_{1-6}$  alkyl;

X is 0 or S;

10  $R_b$  and  $R_c$  are independently hydrogen or a halogen selected from Br, F, Cl or I; and

 $R_e$  is  $-C_{1-6}$  alkyl or phenyl optionally substituted with  $C_1-C_6$  alkyl,  $C_1-C_6$  alkoxy, halogen, hydroxy, amino, mono( $C_1-C_6$ ) alkylamino, di( $C_1-C_6$ ) alkylamino, trifluoromethyl.

In another aspect, the invention provides compounds of formula Z51:

Z51

and pharmaceutically acceptable salts thereof wherein

20 m is 0-5;

B is aryl or heteroaryl optionally substituted with one or two groups independently selected from  $R_6$ ,  $R'_6$ ,  $R''_6$  and  $R'''_6$ , or

B is cycloalkyl or heterocycloalkyl optionally substituted with one, two, three, four, five, six, seven or eight groups independently selected from R<sub>6a</sub>, R<sub>6b</sub>, R'<sub>6a</sub>, R'<sub>6b</sub>, R''<sub>6a</sub>, R''<sub>6a</sub> and R'''<sub>6b</sub>;

 $\text{C}_1\text{--}\text{C}_8$  alkyl,  $\text{C}_2\text{--}\text{C}_7$  alkenyl or  $\text{C}_2\text{--}\text{C}_7$  alkynyl, each of which is optionally substituted with one, two or three groups selected from -NRR', -SR, -CN, -OCF3, -CF3, -CONRR',  $-CO_2R$ ,  $-SO_2NRR'$ , -O-P(=O) (OR) (OR'), -N(R)5 C(=O)(R'),  $-N(R)(SO_2R')$ ,  $-SO_2R$ , -C(=O)R,  $-NO_2$ , halogen,  $-(CH_2)_{0-4}$ -aryl, and  $-(CH_2)_{0-4}$ -heteroaryl, or R and R' independently are -H, -( $C_1$ - $C_{10}$ ) alkyl, -( $CH_2$ )<sub>0-4</sub>- $R_{aryl}$ , -(CH<sub>2</sub>) $_{0-4}$ -R<sub>heteroaryl</sub>, -(CH<sub>2</sub>) $_{0-4}$ -R<sub>heterocyclyl</sub>, or  $C_2-C_7$  alkenyl or  $C_2-C_7$  alkynyl, each of which is optionally 10 substituted with one, two or three substituents selected from the group consisting of halogen, -OH,  $-C\equiv N$ ,  $-CF_3$ ,  $C_1-C_3$  alkoxy, amino, dialkylamino, and  $C_1$ - $C_6$  alkyl, or  $-(CH_2)_{0-4}-C_3-C_7$  cycloalkyl optionally substituted with one, 15 two or three substituents selected from the group consisting of halogen, -OH, -SH, -C $\equiv$ N, -CF $_3$ , C $_1$ -C $_3$ alkoxy, amino, mono- or dialkylamino, and  $C_1\text{--}C_6$ alkyl; benzyl where the phenyl ring is optionally substituted 20 with 1-3 groups independently selected from halogen, -OH, -SH, -C $\equiv$ N, mono or dialkylamino, C<sub>1</sub>-C<sub>6</sub> alkoxy, or trifluoromethyl;  $R_6,\ R''_6,\ R'''_6,\ R'''_6,\ R_{6a},\ R_{6b},\ R''_{6a},\ R''_{6b},\ R'''_{6a},\ R'''_{6b},\ R'''_{6a}\ and$  $R'''_{6b}$  independently are -OR, -NO<sub>2</sub>, halogen, -CO<sub>2</sub>R, -C $\equiv$ N, -NRR', -SR,  $-SO_2R$ , -C(=O)R,  $-OCF_3$ ,  $-CF_3$ , -CONRR',  $-SO_2NRR'$ , 25 -O-P(=O)(OR)(OR'), -N(R)(COR'),  $-N(R)(SO_2R')$ ,  $-(CH_2)_{0-4}-CO-P(=O)(OR)(OR')$  $NR_7R'_7$ , - (CH<sub>2</sub>)<sub>0-4</sub>-O-(CH<sub>2</sub>)<sub>0-4</sub>-CONRR', - (CH<sub>2</sub>)<sub>0-4</sub>-CO-(C<sub>1</sub>-C<sub>12</sub> alkyl),  $-(CH_2)_{0-4}-CO-(C_2-C_{12} \text{ alkenyl})$ ,  $-(CH_2)_{0-4}-CO-(C_2-C_{12})$ alkynyl),  $-(CH_2)_{0-4}-CO-(C_3-C_7 \text{ cycloalkyl})$ ,  $-(CH_2)_{0-4}-R_{aryl}$ , -30  $(CH_2)_{0-4}-R_{heteroaryl}$ ,  $-(CH_2)_{0-4}-R_{heterocyclyl}$ ,  $-(CH_2)_{0-4}-CO-R_{aryl}$ , -  $(CH_2)_{0-4}$ -CO- $R_{heteroary1}$ , -  $(CH_2)_{0-4}$ -CO- $R_{heterocycly1}$ , -  $(CH_2)_{0-4}$ -CO- $R_{10}, -(CH_2)_{0-4}-CO-O-R_{11}, -(CH_2)_{0-4}-SO_2-NR_7R'_7, -(CH_2)_{0-4}-SO-(C_{1-1}-CH_2)_{0-4$  $C_8$  alkyl),  $-(CH_2)_{0-4}-SO_{2-}(C_1-C_{12} \text{ alkyl})$ ,  $-(CH_2)_{0-4}-SO_{2-}(C_3-C_7)$ 

cycloalkyl),  $-(CH_2)_{0-4}-N(H \text{ or } R_{11})-CO-O-R_{11}, -(CH_2)_{0-4}-N(H \text{ or } R_{11})-CO-O-R_{11}$  $R_{11}$ )-CO-N( $R_{11}$ )<sub>2</sub>, -(CH<sub>2</sub>)<sub>0-4</sub>-N(H or  $R_{11}$ )-CS-N( $R_{11}$ )<sub>2</sub>, -(CH<sub>2</sub>)<sub>0-4</sub>-N(-H or  $R_{11}$ )-CO- $R_7$ , -(CH<sub>2</sub>)<sub>0-4</sub>-NR<sub>7</sub>R'<sub>7</sub>, -(CH<sub>2</sub>)<sub>0-4</sub>-R<sub>10</sub>, -(CH<sub>2</sub>)<sub>0-4</sub>-O-5  $N(R_{11})_2$ ,  $-(CH_2)_{0-4}$  -O -CS  $-N(R_{11})_2$ ,  $-(CH_2)_{0-4}$  -O  $-(R_{11})$ ,  $-(CH_2)_{0-4}$  -O  $-(CH_2)_{0-4}$  -O $(R_{11})$  -COOH, -  $(CH_2)_{0-4}$ -S- $(R_{11})$ ,  $C_3$ -C7 cycloalkyl, -  $(CH_2)_{0-4}$ -N(-H or  $R_{11}$ )- $SO_2$ - $R_7$ , or -( $CH_2$ )<sub>0-4</sub>-  $C_3$ - $C_7$  cycloalkyl, or C1-C8 alkyl optionally substituted with one, two or three groups independently selected from C1-C6 alkyl, -F, -C1, -Br, -I, -OR,  $-NO_2$ , -F, -C1, -Br, -I,  $-CO_2R$ , -10  $C \equiv N$ , -NRR', -SR,  $-SO_2R$ , -C(=O)R,  $-OCF_3$ ,  $-CF_3$ , -CONRR',  $-SO_2NRR'$ , -O-P(=O)(OR)(OR'), -N(R)(COR'), - $N(R) (SO_2R')$ ,  $-(CH_2)_{0-4}-CO-NR_7R'_7$ ,  $-(CH_2)_{0-4}-CO-(C_1-C_{12})_{0-4}$ alkyl),  $-(CH_2)_{0-4}-CO-(C_2-C_{12} \text{ alkenyl})$ ,  $-(CH_2)_{0-4}-CO-(C_2-C_{12} \text{ alkenyl})$ 15  $C_{12}$  alkynyl),  $-(CH_2)_{0-4}-CO-(C_3-C_7 \text{ cycloalkyl})$ ,  $-(CH_2)_{0-4}$  $_{4}-R_{aryl}$ ,  $-(CH_{2})_{0-4}-R_{heteroaryl}$ ,  $-(CH_{2})_{0-4}-R_{heterocyclyl}$ ,  $-(CH_{2})_{0-4}$  $_{4}$ -CO- $_{Rary1}$ , -(CH<sub>2</sub>) $_{0-4}$ -CO- $_{Rheteroary1}$ , -(CH<sub>2</sub>) $_{0-4}$ -CO- $R_{\text{heterocyclyl}}$ , - (CH<sub>2</sub>)<sub>0-4</sub>-CO-R<sub>10</sub>, - (CH<sub>2</sub>)<sub>0-4</sub>-CO-O-R<sub>11</sub>, - (CH<sub>2</sub>)<sub>0-4</sub>  $_4-SO_2-NR_7R'_7$ ,  $_-(CH_2)_{0-4}-SO_-(C_1-C_8 \text{ alkyl})$ ,  $_-(CH_2)_{0-4}-SO_2-$ 20  $(C_1-C_{12} \text{ alkyl}), -(CH_2)_{0-4}-SO_2-(C_3-C_7 \text{ cycloalkyl}),$ -  $(CH_2)_{0-4}$ -N(H or  $R_{11}$ )-CO-O- $R_{11}$ , -  $(CH_2)_{0-4}$ -N(H or  $R_{11}$ )-CO- $N(R_{11})_2$ ,  $-(CH_2)_{0-4}-N(H \text{ or } R_{11})-CS-N(R_{11})_2$ ,  $-(CH_2)_{0-4}-N(-H)$ or  $R_{11}$ )-CO- $R_7$ , -(CH<sub>2</sub>)<sub>0-4</sub>-NR<sub>7</sub>R'<sub>7</sub>, -(CH<sub>2</sub>)<sub>0-4</sub>-R<sub>10</sub>, -(CH<sub>2</sub>)<sub>0-4</sub>-O-CO- $(C_1-C_6 \text{ alkyl})$ ,  $-(CH_2)_{0-4}$ -O-P(O)- $(O-R_{aryl})_2$ ,  $-(CH_2)_{0-4}$ 25  $_{4}$ -O-CO-N(R<sub>11</sub>)<sub>2</sub>, -(CH<sub>2</sub>)<sub>0-4</sub>-O-CS-N(R<sub>11</sub>)<sub>2</sub>, -(CH<sub>2</sub>)<sub>0-4</sub>-O-(R<sub>11</sub>),  $-(CH_2)_{0-4}-O-(R_{11})-COOH$ ,  $-(CH_2)_{0-4}-S-(R_{11})$ ,  $C_3-C_7$ cycloalkyl,  $-(CH_2)_{0-4}-N(-H \text{ or } R_{11})-SO_2-R_7$ , or  $-(CH_2)_{0-4}-$ C<sub>3</sub>-C<sub>7</sub> cycloalkyl, or C2-C7 alkenyl or C2-C7 alkynyl, each of which is 30 optionally substituted with one, two or three groups independently selected from halogen or -OH, or

 $C_2$ - $C_7$  alkenyl or  $C_2$ - $C_7$  alkynyl, each of which is optionally substituted with one, two or three groups

independently selected from halogen,  $C_1$ - $C_3$  alkyl, -OH, -SH, -C $\equiv$ N, -CF $_3$ , C $_1$ -C $_3$  alkoxy, amino, and monoor dialkylamino, or  $-(CH_2)_{0-4}-O-(C_1-C_6 \text{ alkyl})$ , where the alkyl portion is optionally substituted with one, two, three, four, or 5 five of halogen, or any two of  $R_{6a}$ ,  $R_{6b}$ ,  $R'_{6a}$ ,  $R'_{6b}$ ,  $R''_{6a}$ ,  $R''_{6b}$ ,  $R'''_{6a}$  and  $R'''_{6b}$ together are oxo;  $R_7$  and  $R'_7$  are the same or different and represent -H,  $-C_3-C_7$ 10 cycloalkyl,  $-(C_1-C_2 \text{ alkyl})-(C_3-C_7 \text{ cycloalkyl})$ ,  $-(C_1-C_6 \text{ cycloalkyl})$ alkyl)-0-( $C_1$ - $C_3$  alkyl), - $C_2$ - $C_6$  alkenyl, - $C_2$ - $C_6$  alkynyl, - $C_1$ - $C_6$  alkyl chain with one double bond and one triple bond, or $-C_1-C_6$  alkyl optionally substituted with -OH or  $-NH_2$ ; or;  $-C_1-C_6$  alkyl optionally substituted with one, two or three 15 groups independently selected from halogen; or heterocyclyl optionally substituted with halogen, amino, mono- or dialkylamino, -OH, -C $\equiv$ N, -SO<sub>2</sub>-NH<sub>2</sub>, -SO<sub>2</sub>-NH- $\text{C}_1\text{--}\text{C}_6$  alkyl,  $-\text{SO}_2\text{--}\text{N}(\text{C}_1\text{--}\text{C}_6 \text{ alkyl})_2, -\text{SO}_2\text{--}(\text{C}_1\text{--}\text{C}_4 \text{ alkyl}), -\text{--}$ 20  $\text{CO-NH}_2$ ,  $-\text{CO-NH-C}_1-\text{C}_6$  alkyl, oxo and  $-\text{CO-N}\left(\text{C}_1-\text{C}_6\right)$ alkyl)2; or  $C_1$ - $C_6$  alkyl optionally substituted with one, two or three groups independently selected from C1-C3 alkyl, halogen, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> 25 alkoxy, amino, and mono- or dialkylamino; or  $C_2\text{-}C_6$  alkenyl or  $C_2\text{-}C_6$  alkynyl, each of which is optionally substituted with one, two or three groups independently selected from  $C_1$ - $C_3$  alkyl,

 $C_1\text{--}C_6$  alkoxy optionally substituted with one, two or three of halogen;

amino, and mono- or dialkylamino; or

halogen, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy,

aryl or heteroaryl, each of which is optionally substituted with halogen, amino, mono- or dialkylamino, -OH, -C $\equiv$ N, -SO<sub>2</sub>-NH<sub>2</sub>, -SO<sub>2</sub>-NH-C<sub>1</sub>-C<sub>6</sub> alkyl,  $-SO_2-N(C_1-C_6 \text{ alkyl})_2$ ,  $-SO_2-(C_1-C_4 \text{ alkyl})$ , -CO-5  $NH_2$ ,  $-CO-NH-C_1-C_6$  alkyl, and  $-CO-N(C_1-C_6$  alkyl)<sub>2</sub>; or  $C_1$ - $C_6$  alkyl optionally substituted with one, two or three groups independently selected from C1-C3 alkyl, halogen, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, amino, and mono- or dialkylamino; or 10  $C_2$ - $C_6$  alkenyl or  $C_2$ - $C_6$  alkynyl, each of which is optionally substituted with one, two or three groups independently selected from C1-C3 alkyl, halogen, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, amino, and mono- or dialkylamino; or 15  $C_1\text{--}C_6$  alkoxy optionally substituted with one, two or three of halogen;  $R_{10}$  is heterocyclyl optionally substituted with one, two, three or four groups independently selected from  $C_1-C_6$  alkyl;  $R_{11}$  is  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_3$ - $C_7$ 20 cycloalkyl,  $-(CH_2)_{0-2}-R_{aryl}$ , or  $-(CH_2)_{0-2}-R_{heteroaryl}$ ; R<sub>aryl</sub> is aryl optionally substituted with halogen, amino, monoor dialkylamino, -OH, -C $\equiv$ N, -SO<sub>2</sub>-NH<sub>2</sub>, -SO<sub>2</sub>-NH-C<sub>1</sub>-C<sub>6</sub> alkyl,  $C_6$  alkyl, or  $-CO-N(C_1-C_6$  alkyl)<sub>2</sub>; or 25  $C_1$ - $C_6$  alkyl optionally substituted with one, two or three groups independently selected from  $C_1-C_3$  alkyl, halogen, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, amino, and mono- or dialkylamino; or  $C_2\text{--}C_6$  alkenyl or  $C_2\text{--}C_6$  alkynyl, each of which is optionally 30 substituted with one, two or three groups independently selected from C1-C3 alkyl, halogen, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, amino, and monoor dialkylamino; or

 $C_1$ - $C_6$  alkoxy optionally substituted with one, two or three of halogen;

- $SO_2-NH_2$ ,  $-SO_2-NH-C_1-C_6$  alkyl,  $-SO_2-N(C_1-C_6$  alkyl),  $-SO_2-(C_1-C_4$  alkyl),  $-CO-NH_2$ ,  $-CO-NH-C_1-C_6$  alkyl, or  $-CO-N(C_1-C_6$  alkyl); or

5

15

25

- $C_1-C_6$  alkyl optionally substituted with one, two or three groups independently selected from  $C_1-C_3$  alkyl,
- halogen, -OH, -SH, -C $\equiv$ N, -CF $_3$ , C $_1$ -C $_3$  alkoxy, amino, and mono- or dialkylamino; or
  - $C_2$ - $C_6$  alkenyl or  $C_2$ - $C_6$  alkynyl, each of which is optionally substituted with one, two or three groups independently selected from  $C_1$ - $C_3$  alkyl, halogen, OH, -SH, -C $\equiv$ N, -CF $_3$ ,  $C_1$ - $C_3$  alkoxy, amino, and monoor dialkylamino; or
  - $C_1\text{--}C_6$  alkoxy optionally substituted with one, two or three of halogen;
- $R_{\rm heterocycly1}$  is heterocyclyl optionally substituted with halogen, amino, mono- or dialkylamino, -OH, -C $\equiv$ N, -SO<sub>2</sub>-NH<sub>2</sub>, -SO<sub>2</sub>-NH-C<sub>1</sub>-C<sub>6</sub> alkyl, -SO<sub>2</sub>-N(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>2</sub>, -SO<sub>2</sub>-(C<sub>1</sub>-C<sub>4</sub> alkyl), -CO-NH<sub>2</sub>, -CO-NH-C<sub>1</sub>-C<sub>6</sub> alkyl, =O or -CO-N(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>2</sub>; or C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with one, two or three
  - groups independently selected from  $C_1-C_3$  alkyl, halogen, -OH, -SH, -C $\equiv$ N, -CF $_3$ ,  $C_1-C_3$  alkoxy, amino, and mono- or dialkylamino; or
    - $C_2$ - $C_6$  alkenyl or  $C_2$ - $C_6$  alkynyl, each of which is optionally substituted with one, two or three groups independently selected from  $C_1$ - $C_3$  alkyl, halogen, OH, -SH, -C $\equiv$ N, -CF $_3$ ,  $C_1$ - $C_3$  alkoxy, amino, and monoor dialkylamino; or
    - $C_1\text{--}C_6$  alkoxy optionally substituted with one, two or three of halogen;

 $R_2$  and  $R_3$  are independently hydrogen or  $C_1$ - $C_6$  alkyl; or  $R_2$  and  $R_3$  taken together with the carbon atom to which they are attached form a 3 or 4-membered ring;

 $R_C$  is hydrogen or phenyl optionally substituted with  $C_1-C_3$  alkyl,  $C_2-C_4$  alkynyl, trifluoromethyl, or  $C_1-C_2$  alkoxy.

In another aspect, the invention provides compounds of formula Z52:

10 252

5

15

25

30

or pharmaceutically acceptable salts thereof, wherein n is 0, 1, 2, or 3 (preferably 1);

 $R_1$  is  $C_1$ - $C_3$  alkoxy (preferably methoxy), halogen (preferably iodo),  $C_1$ - $C_3$  alkyl (preferably ethyl or isopropyl), or  $C_2$ - $C_3$  alkynyl (preferably  $C_2$  alkynyl);

 $R_f$  and  $R_g$  are independently halogen, or both are hydrogen; and Alk is  $C_1\text{--}C_6$  alkyl (preferably methyl, ethyl, isobutyl or isopentyl).

Preferred examples of Z52 include those wherein n is 1 and 20  $R_1$  is methoxy,  $C_2$  alkynyl or ethyl. More preferably, R1 is methoxy.

The compounds of the invention inhibit beta-secretase and are therefor useful in treating and preventing Alzheimer's disease. The compounds of the invention are made by methods well known to those skilled in the art from starting compounds known to those skilled in the art. The process chemistry is well known to those skilled in the art. The most general process to prepare compounds of the invention is set forth in CHART A. Typically, amino acid (I) is protected at the amino

group, yielding protected amino acid (II). Compound (II) is converted to an ester intermediate, and the intermediate is reacted with a carbon nucleofile yielding compound (III). The ketone moiety in compound (III) is reduced to yield alcohol (IV), which forms epoxide(V). The addition of amine  $R_{\rm C}$ -NH $_{\rm 2}$  (VI) opens the epoxide, forming the protected alcohol (VII). The amine protecting group is removed, and the deprotected amine (VIII) is reacted with an amide forming agent of the formula  $(R_{\rm N-1}-X_{\rm N})_{\rm 2}{\rm O}$  or  $R_{\rm N-1}-X_{\rm N}-X_{\rm 2}$  or  $R_{\rm N-1}-X_{\rm N}-{\rm OH}$  (IX) to produce a target compound of formula (X).

The backbone of the compounds of the invention is a hydroxyethylamine moiety, -NH-CH(R)-CH(OH)-.It can be readily prepared by methods disclosed in the literature and known to those skilled in the art. For example, J. Med. Chem., 36, 288-291 (1992), Tetrahedron Letters, 28, 5569-5572 (1987), J. Med. Chem., 38, 581-584 (1994) and Tetrahedron Letters, 38, 619-620 (1997)all disclose processes to prepare hydroxyethylamine type compounds.

10

15

CHART A sets forth a general method used in the invention 20 to prepare the appropriately substituted amines (X). compounds of the invention are prepared by starting with the corresponding amino acid (I). The amino acids (I) are well known to those skilled in the art or can be readily prepared from known compounds by methods well known to those skilled in 25 The substituted amines (X) of the invention have at least two enantiomeric centers which give four enantiomers. The first of these enantiomeric centers derives from the amino acid starting material (I). It is preferred to commercially obtain or produce the desired enantiomer (S) rather than 30 produce an enantiomerically impure mixture and then have to separate out the desired enantiomer (S). It is preferred to start the process with enantiomerically pure (S)-amino acid (I)

of the same configuration as that of the substituted amine (X) product.

The first step of the process is to protect the free amino group of the (S)-amino acid (I) with an amino protecting group 5 to produce the (S)-protected amino acid (II) by methods well known to those skilled in the art. Amino protecting groups are well known to those skilled in the art. See for example, "Protecting Groups in Organic Synthesis", John Wiley and sons, New York, N.Y., 1981, Chapter 7; "Protecting Groups in Organic Chemistry", Plenum Press, New York, N.Y., 1973, Chapter 2. The function of the amino protecting group is to protect the free amino functionality (-NH<sub>2</sub>) during subsequent reactions on the (S)-amino acid (I) which would not proceed well, either because the amino group would react and be functionalized in a way that 15 is inconsistent with its need to be free for subsequent reactions, or the free amino group would interfere in the reaction. When the amino protecting group is no longer needed, it is removed by methods well known to those skilled in the By definition the amino protecting group must be readily 20 removable as is known to those skilled in the art by methods well known to those skilled in the art. Suitable amino PROTECTING GROUP is selected from the group consisting of tbutoxycarbonyl, benzyloxycarbonyl, formyl, trityl, trichloroacetyl, dichloroacetyl, chloroacetyl, trifluoroacetyl, difluoroacetyl, fluoroacetyl, 4-phenylbenzyloxycarbonyl, methylbenzyloxycarbonyl, 4-ethoxybenzyloxycarbonyl, 4 – fluorobenzyloxycarbonyl, 4-chlorobenzyloxycarbonyl, 3chlorobenzyloxycarbonyl, 2-chlorobenzyloxycarbonyl, 2,4dichlorobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 3 bromobenzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4cyanobenzyloxycarbonyl, 2-(4-xenyl)isopropoxycarbonyl, diphenyleth-1-yloxycarbonyl, 1,1-diphenylprop-1-yloxycarbonyl, 2-phenylprop-2-yloxycarbonyl, 2-(p-toluyl)prop-2-yloxycarbonyl, cyclopentanyloxycarbonyl, 1-methylcyclopentanyloxycarbonyl,

10

25

cyclohexanyloxycarbonyl, 1-methylcyclohexanyloxycabonyl, 2methylcyclohexanyloxycarbonyl, 2-(4toluylsulfonyl)ethoxycarbonyl, 2-(methylsulfonyl)ethoxycarbonyl, 2-(triphenylphosphino)ethoxycarbonyl, fluorenylmethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, 1-(trimethylsilylmethyl)prop-1-enyloxycarbonyl, 5benzisoxalylmethoxycarbonyl, 4-acetoxybenzyloxycarbonyl, 2,2,2trichloroethoxycarbonyl, 2-ethynyl-2-propoxycarbonyl, cyclopropylmethoxycarbonyl, 10 4-(decyloxyl)benzyloxycarbonyl, isobornyloxycarbonyl and 1-piperidyloxycarbonyl, 9fluorenylmethyl carbonate, -CH-CH=CH<sub>2</sub> and phenyl-C(=N-)-H. It is preferred that the protecting group be t-butoxycarbonyl (BOC) and 15 benzyloxycarbonyl (CBZ), it is more preferred that the protecting group be t-butoxycarbonyl. One skilled in the art will understand the preferred methods of introducing a tbutoxycarbonyl or benzyloxycarbonyl protecting group and may additionally consult T.W. Green and P.G.M. Wuts in "Protective 20 Groups in Organic Chemistry," John Wiley and Sons, 1991 for guidance.

The (S)-protected compound (II) is transformed to a (S)protected compound of formula (III) by first converting the (S)-protected amino acid (II) to a corresponding alkyl ester according to methods well established in the art, for example by reaction with a diazocompound. The ester inermediate is then reacted with a carbanionic nucleofile of those known to those skilled in the art, for example an organometallic compound obtained by reacting a compound of formula  $X_1-C(R_2)(R_3)-X_1$ with a strong metal base, wherein wherein the reaction yields a halogen-metal exchange, and wherein  $-X_1$  is a halogen selected from the group consisting of chlorine, bromine or iodine. The addition of this carbanionic nucleophile to the ester intermediate yields the (S)-protected compound (III).

25

Suitable bases include, but are not limited to the alkyllithiums including, for example, sec-butyllithium, nand t-butyllithium. butyllithium, Said reactions are preferably conducted at low temperature, for example -78 degrees C. Suitable reaction conditions include running the reaction in the presence of inert solvents or mixtures thereof, for example but not only ether, tetrahydrofuran or a mixture thereof. Wherein R2 and R3 are both hydrogen, then examples of  $X_1-C(R_2)(R_3)-X_1$ include dibromomethane, diiodomethane, chloroiodomethane, bromoiodomethane and bromochloromethane. One skilled in the art knows the preferred conditions required to conduct this reaction. Furthermore, if  $R_2$  and/or  $R_3$  are not -H, then by the addition of  $-C(R_2)(R_3)-X_1$  to esters of the (S)protected amino acid (II) to produce the (S)-protected compound (III), an additional chiral center will be incorporated into the product, provided that  $R_2$  and  $R_3$  are not the same.

5

10

15

20

25

30

The (S)-protected compound (III) is then reduced by methods known to those skilled in the art for the reduction of ketones to the corresponding alcohol (IV). The reactants and reaction conditions for reducing the (S)-protected compound (III) to the corresponding alcohol (IV) include, for example, sodium borohydride, lithium borohydride, borane, diisobutylaluminum hydride, and lithium aluminium hydride. Sodium borohydride is the preferred reducing agent. reduction is carried out for a period of time between 1 hour and 3 days at temperatures ranging from about -78 degrees C the reflux temperature of the reaction mixture. preferred to conduct the reduction between about -78 degrees C and about 0 degrees C. A borane complex may be used, for example, borane-methyl sulfide complex, borane-piperidine complex, or borane-tetrahydrofuran complex. The preferred combination of reducing agents and reaction conditions needed are known to those skilled in the art, see for example, Larock, R.C. in Comprehensive Organic Transformations, VCH Publishers,

1989. The reduction of the (S)-protected compound (III) to the corresponding alcohol (IV) produces the second chiral center (third chiral center if  $R_2$  and  $R_3$  are not the same). reduction of the (S)-protected compound (III) produces a mixture of enantiomers at the second center, (S, R/S)-alcohol This enantiomeric mixture is then separated by means (IV). known to those skilled in the art such as selective lowtemperature recrystallization or chromatographic separation, for example by HPLC, employing commercially available chiral stationary phases. The enantiomer that is used in the remainder of the process of CHART A is the (S,S)-alcohol (IV) this enantiomer is a precursor to the biologically active anti-Alzheimer (S,R)-substituted amine (X).

10

30

(S, S)-alcohol (IV) reacts intramolecularly to yield the corresponding epoxide (V) by means known to those skilled in 15 the art. The stereochemistry of the ( carbon bound to the  $-\mathrm{OH}$ moiety in compound (IV) is maintained in the epoxide (V). Preferred reaction conditions include contacting compound (IV) with a base, for example, but not limited to, sodium hydroxide, potassium hydroxide, or lithium hydroxide. 20 Reaction conditions include the presence of a C<sub>1</sub>-C<sub>6</sub> alcohol solvent; ethanol is preferred. A common co-solvent, for example ethyl acetate, may also be employed. The reactions is preferably conducted at temperatures ranging from about  $\,$  -45 degrees C to the reflux temperature of the reaction mixture; preferred 25 temperature ranges are between about -20 degrees C and about 20-25 degrees C.

The epoxide (V) is then reacted with the appropriately substituted C-terminal amine,  $R_{\text{C}}\text{-NH}_2$  (VI) in reaction conditions known to those skilled in the art, leading to the opening the epoxide to yield the enantiomerically pure (S,R)-protected alcohol (VII). The substituted C-terminal amines,  $R_{\text{C}}\text{-NH}_2$  (VI) of this invention are commercially available or are known to those skilled in the art and can be readily prepared

10

15

20

25

30

from known compounds. Further, it is preferred that when  $R_{\text{C}}$  is phenyl, it is substituted in the 3-position or 3,5-positions.

Suitable reaction conditions for opening the epoxide (V) include running the reaction in an organic, preferably inert w. C<sub>1</sub>-C<sub>6</sub> alcohol solvents are preferred and isopropyl alcohol most The reaction can be run at temperatures ranging preferred. from about 20-25 degrees C up to the reflux temperature of the reaction mixture and preferably at a temperature between about 50 degrees C and the reflux temperature of the reaction mixture. When the substituted C-terminal amine (VI) is a 1amino-3,5-cis-dimethyl cyclohexyldicarboxylate it is preferrably prepared follows. To as dimethyl-5aminoisophthalate in acetic acid and methanol, is added rhodium in alumina in a high-pressure bottle. The bottle is saturated with hydrogen at 55 psi and shaken for one week of time. mixture is then filtered through a layer of diatomaceous earth and rinsed with methanol three times, the solvents are removed under reduced pressure (with heat) to give a concentrate. concentrate is triturated with ether and filtered again to give the desired C-terminal amine (VI). When the substituted Cterminal amine (VI) is 1-amino-3,5-cis-dimethoxy cyclohexane it is prepared by following the general procedure above and making non-critical variations but starting wth 3,5-dimethoxyaniline. When the substituted C-terminal amine (VI) is an aminomethyl group where the substituent on the methyl group is an aryl group, for example  $NH_2-CH_2-R_{C-aryl}$ , and  $NH_2-CH_2-R_{C-aryl}$  is not commercially available it is preferrably prepared as follows. A suitable starting material is the (appropriately substituted) aralkyl compound. The first step is bromination of the alkyl substitutent via methods known to those skilled in the art, see for example R.C. Larock in Comprehensive Organic Transformations, VCH Publishers, 1989, p. 313. Next the alkyl halide is reacted with azide to produce the aryl-(alkyl)-azide. Last the azide is reduced to the corresponding amine by

hydrogen/catalyst to give the C-terminal amine (VI) of formula  $NH_2-CH_2-R_{C-arvl}$ . The suitably functionalized C-terminal amines (VI) may readily be prepared by one skilled in the art via known methods in the literature, making non-significant modifications. Select literature references include 1) Calderwood, et al., Tet. Lett., 1997, 38, 1241, 2) Ciganek, J. Org. Chem., 1992, 57, 4521, 3) Thurkauf, et al., J. Med. Chem., 1990, 33, 1452, 4) Werner, et al., Org. Syn., Coll. Vol. 5, 273, 5) J. Med. Chem., 1999, 42, 4193, 6) Chem. Rev. 1995, 95, 2457, 7) J. Am. Chem. Soc., 1986, 3150, 8) Felman et al., J. Med. Chem., 1992, 35, 1183, 9) J. Am. Chem. Soc. 1970, 92, 3700, 10) J. Med. Chem., 1997, 40, 2323.

10

15

20

25

30

CHART B discloses an alternative process for the synthesis of the enantiomerically pure (S,R)-protected alcohol (VII) from the (S)-protected compound (III). In this process, (S)-protected compound (III) is reacted with the appropriately substituted C-terminal amine  $R_{C}$ -NH $_{2}$  (VI) in the preferred reaction conditions described above to yield (S)-protected ketone (XI) which is reduced in the preferred conditions described above to yield above to yield (S,R)-protected alcohol (VII).

CHART C discloses another alternative process for the synthesis of enantiomerically pure (S,R)-protected alcohol (VII) from the epoxide (V). Epoxide (V) is reacted with azide, yielding the enantiomerically pure (S,R)-protected azide (XII) in reaction conditions known to those skilled in the art, for example, J. March, Advanced Organic Chemistry, 3<sup>rd</sup> Edition, John Wiley & Sons Publishers, 1985, p. 380. (S,R)-protected azide (XII) is reduced to protected amine (XIII) by methods known to those skilled in the art for the reduction of an azide group in the presence of a t-butoxycarbonyl N-protecting group, for example catalytic hydrogenation. Alternative reducing conditions which may be used to avoid N-deprotection with protecting groups other than t-butoxycarbonyl are known to those skilled in the art, see for example, R.C. Larock in

Comprehensive Organic Transformations, VCH Publishers, 1989, p. 409.

The (S,R)-protected compound (XIII)) is deprotected yield (S,R)-amine (VII) by methods known to those skilled in the art for removal of amine protecting group. reaction conditions for the removal of an amine protecting group depend on the type of protecting group. For example, it is preferable to remove the preferred protecting group, BOC, by contacting (S,R)-protected alcohol (VII) with a mixture of and acid and an organic solvent, e.g. a trifluoroacetic 10 acid/dichloromethane mixture, yielding the protonated salt of (S,R)-amine (VII). Optionally, (S,R)-amine (VII) can be purified by methods known to those skilled in the art, for example recrystallization. The free-base (S,R)-amine (VII) can be obtained by means known to those skilled in the art, 15 such as for example, preparing the free base amine by contacting the salt with mild basic conditions. Additional BOC deprotection conditions and deprotection conditions for other protecting groups can be found in T.W. Green and P.G.M. Wuts in "Protective Groups in Organic Chemistry," 20 John Wiley and Sons, 1991, p. 309. Typical chemically suitable salts include trifluoroacetate, chloride, sulfate, phosphate; preferred is trifluoroacetate and chloride.

(S,R)-amine (VIII) is reacted with an appropriately substituted acylating reagent (IX) such as an anhydride, acyl halide, or acid of the formula  $(R_{N-1}-X_N)_2O$  or  $R_{N-1}-X_N-X_2$  or  $R_{N-1}-X_N-OH$  (IX) in reaction conditions known to those skilled in the art to produce (S,R)-substituted amine (X). Reaction conditions known to those skilled in the art can be found, for example, in R.C. Larock in Comprehensive Organic Transformations, VCH Publishers, 1989, p. 981, 979, and 972.  $R_N$  is preferably selected from the group consisting of:

25

30

 $R_{N-1}-X_{N^-}$  wherein  $X_N$  is -CO-,  $R_{N-1}$  is  $R_{N-aryl}$  or  $R_{N-heteroaryl}$  wherein  $R_{N-aryl}$  is phenyl where the substitution on phenyl is

1,3-, and wherein  $R_{N-\text{aryl}}$  or  $R_{N-\text{heteroaryl}}$  are substituted with one -  $\text{CO-NR}_{N-2}R_{N-3}$  ,

 $R_{N-1}-X_N-$  wherein  $X_N$  is-CO-,  $R_{N-1}$  is  $R_{N-aryl}$  or  $R_{N-heteroaryl}$  wherein  $R_{N-aryl}$  is phenyl substituted with one  $C_1$  alkyl wherein the substitution on the phenyl is 1,3,5-, and wherein  $R_{N-aryl}$  or  $R_{N-heteroaryl}$  are substituted with one  $-CO-NR_{N-2}R_{N-3}$ ,

 $R_{N-1}-X_{N^-}$  wherein  $X_N$  is -CO-, and  $R_{N-1}$  is  $R_{N-heteroaryl}$  wherein  $R_{N-heteroaryl}$  is substituted with one -CO-NR\_{N-2}R\_{N-3}.  $R_{N-2}$  and  $R_{N-3}$  are preferably the same and are  $C_3$  alkyl,

10  $R_{N-1}-X_N-$  wherein  $X_N$  is -CO-, and  $R_{N-1}$  is  $R_{N-aryl}$  wherein  $R_{N-aryl}$  is phenyl substituted with one -CO-NR<sub>N-2</sub>R<sub>N-3</sub> wherein the substitution on phenyl is 1,3-,

 $R_{N-1}-X_N$ — wherein  $X_N$  is-CO-, and  $R_{N-1}$  is  $R_{N-aryl}$  wherein  $R_{N-aryl}$  is phenyl substituted with one  $C_1$  alkyl and with one  $-CO-NR_{N-2}R_{N-1}$  3 wherein the substitution on the phenyl is 1,3,5-.  $X_N$  is preferably (A) -CO- and (B) -SO<sub>2</sub>-; more preferably  $X_N$  is -CO-.  $X_2$  is selected from the group consisting of -Cl, -Br; more preferably,  $X_2$  is -Cl.

Acylating reagents,  $(R_{N-1}-X_N)_{20}$  or  $R_{N-1}-X_N-X_2$  or  $R_{N-$ 

 $R_{N-2}R_{N-3}N$ -CO-(CH<sub>3</sub>-)phenyl-CO- where the substitution is 5-methyl-1,3-isophthalic acid are the preferred acylating reagents. The most preferred 5-methyl-1,3-isophthalic acid derivative is 3-[(N,N-dipropylamino)carbonyl]-5-methylbenzoic acid (IX). These compounds are preferably synthesized according to the following method. An ester, preferably the monomethyl ester of isophthalic acid or methyl 5-methyl-1,3-isophthalate is dissolved in an organanic solvent or a mixture of solvents, preferably a THF/DMF mixture. 1,1'-Carbonyldiimidazole is

added at a temperature of about 20-25 degrees C. A preferred amine  $(H-NR_{N-2}R_{N-3})$  is added. Following from about 1 hr to about 24 hrs of stirring at a temperature from about 20 degrees C to the reflux temperature of the reaction mixture, the reaction mixture is partitioned between saturated aqueous ammonium chloride and a water immiscible organic solvent, for example ethyl acetate. The aqueous layer is separated and extracted twice more with the organic solvent. The organic extracts are combined and washed with a saturated aqueous solutions of bicarbonate and saline and dried over anhydrous sodium sulfate or magnesium sulfate. Filtration of the drying agent and removal of solvents by reduced pressure yields the methyl ester οf the desired  $R_{N-2}R_{N-3}N-CO-phenyl-CO-O-CH_3$ а methylisophthalic acid acylating agent (IX)  $R_{N-2}R_{N-3}N$ -CO-(CH<sub>3</sub>-)phenyl-CO-O-CH<sub>3</sub>. Purification of the (methyl) ester can be carried out for example via chromatography on silica gel eluting with a mixture of ethyl acetate and hexanes as mobile The isophthalate ester or methylisophthalate ester of the mono-alkyl or di-alkyl amide iscontacted with an aqueous alkaline solution, for example lithium hydroxide in a minimum amount of THF/methanol/water and stirred 3-24 hours at 20 degrees C to the reflux temperature of the reaction mixture. The solvents are then removed under reduced pressure and the products partitioned between water and a water immiscible solvent, for example ethyl acetate. If the formation of an emulsion hinders the separation of the two phases, a small amount of saline is added to aid the separation. The aqueous phase is extracted once more with a water immiscible solvent, for example ethyl acetate. The aqueous phase is then acidified via the addition of an acid, preferably hydrochloric acid, to 3.The resulting mixture is extracted three times with a water immiscible solvent, for example ethyl acetate. The combined organic extracts are dried over anhydrous sodium or magnesium sulfate. The drying agent is removed by filtration

10

15

20

25

and the organic solvent is removed under reduced pressure to yield the product. The mono- or di-alkyl amide isophthalate/methylisophthalate is reacted with (S,R)-amine (VIII) to produce the (S,R)-substituted amine (X).

If  $R_{N-2}$  and  $R_{N-3}$  are both -H, the  $\,$  following method is 5 An ester, preferably the methyl of isophthalate or methyl 5-methyl-1,3-isophthalate is dissolved in an organic solvent or a mixture of organic solvents, preferably a THF/DMF mixture. CDI is added at about 20-25 degrees C. After five to thirty minutes, ammonia gas is bubbled 10 into the mixture for 1 hr. The mixture is cooled to about  $\boldsymbol{0}$ degrees C for the duration of the ammonia bubbling. reaction mixture is left stirring under a balloon of ammonia overnight at about 20-25 degrees C, and partitioned between saturated aqueous ammonium chloride and a water immiscible 15 solvent, for example ethyl acetate . The phases are separated and the aqueous phase is twice extracted with ethyl acetate. organic extracts are washed with saturated aqueous solutions of bicarbonate and saline and dried over anhydrous sodium or magnesium sulfate. Filtration of the drying agent 20 and removal of solvents under reduced pressure yields the ester of the desired isophthalic acid or the isophthalic acid derivative acylating reagent (IX). Purification of the (methyl) ester can be carried by example via chromatography on 25 silica gel with an isopropanol/chloroform eluting mixture. The isophthalate ester or methylisophthalate ester of the primary amide is contacted with an aqueous alkaline solution such as lithium hydroxide in THF/methanol/water and stirred overnight at about 20-25 degrees C after which time the solvents are removed under reduced pressure and the solids are 30 partitioned between water and a water immiscible solvent, for example ethyl acetate. If the formation of an emulsions hinders separation of the two phases, a small amount of saline solution is added to improve separation. The aqueous phase is

separated and extracted with a water immiscible solvent, for example ethyl acetate. The aqueous phase is then acidified with acid, preferably hydrochloric acid, to  $pH \leq 3$ . The resulting mixture is extracted with ethyl acetate. The combined organic extracts are dried over anhydrous sodium or magnesium sulfate. The drying agent is removed by filtration and the organic solvent removed under reduced pressure to yield the product. The amide isophthalic acid derivative is reacted with (VIII) to produce (X).

5

10 When it is preferred that the amine moiety be part of cyclic group, for example morpholinyl, piperazinyl, piperidinyl and pyrrolidinyl, etc the following method is preferably used. An ester, preferably the methyl ester of isophthalic acid ormethyl 5-methyl-1,3-isophthalate 15 dissolved in an anhydrous solvent, for example methylene chloride, and a small quantity of a dipolar aprotic solvent, for example DMF is added. The mixture is cooled to about 0 degrees C and oxalyl chloride is added. The mixture is stirred at about 0 degrees C for about 30 minutes to about two hours 20 after which the solvents are removed under reduced pressure. The crude acid chloride solid is left under vacuum overnight, and dissolved in dry methylene and cooled to about 0 degrees C prior to the addition of a cyclic amine and a tertiary amine for example N-methyl piperidine. The reaction mixture is stirred at about 0 degrees C for about 1 to about 6 hrs 25 before the solvents are removed under reduced pressure. residue is diluted with water and a water immiscible solvent, for example ethyl acetate, for example, and the phases are separated. The aqueous phase is extracted with a water 30 immiscible solvent, for example ethyl acetate, , and the combined organic extracts are washed with saturated aqueous bicarbonate and dried over anhydrous sodium or magnesium sulfate. Filtration of the drying agent and removal of solvents under reduced pressure yields the product cyclic

amide. The cyclic amide is contacted with an aqueous alkaline solution, for example lithium hydroxide in THF/methanol/water and stirred overnight at about 20-25 degrees C, after which time the solvents are removed under reduced pressure and the residue is partitioned between water and a water immiscible solvent, for example ethyl acetate. The aqueous phase is extracted with ethyl acetate. Removal of water from the aqueous phase under reduced pressure yields the target cyclic amide product (IX).

10 When the  $R_{\mbox{\tiny ML-1}}$  moiety in the target product is carbocycle, for example but not limited to, cyclohexane, with the starting reagent may be a suitably functionalized dimethyl isophthalate and the method one of those taught in the literature (Meyers, A.I., Org. Syn., 1971, 51, 103) one may reduce the six-membered ring with reducing agents such as 15 rhodium (5%) on alumina in the presence of acetic acid and methanol under a hydrogen atmosphere to afford the corresponding dimethyl cyclohexane dicarboxylate.

CHART D sets forth an alternative process for production of the (S,R)-substituted amine (X) from the (S,R)-protected 20 azide (XII), which is produced from the corresponding epoxide (V) in CHART C. The amino protecting group is removed to produce the corresponding unprotected azide (XIV) by methods previously described in CHART A for the conversion of (S,R)protected alcohol (VII) to the corresponding (S,R)-amine (VIII). The (S,R)-unprotected azide (XIV) is then acylated on nitrogen to produce the corresponding (S,R)-azide (XV). Next, the azide functionality is reduced as previously discussed for the conversion of the (S,R)-protected azide (XII) to the corresponding (S,R)-protected amine (XIII) to give the (S,R)free amine (XVI). Last, the (S,R)-free amine (XVI) transformed to the corresponding (S,R)-substituted amine (X) by nitrogen alkylation with a compound of the formula  $\ensuremath{R_{\text{C}}\mbox{-}}\ensuremath{X_3}$  to give the corresponding (S,R)-substituted amine (X).  $X_3$  is an

25

appropriate leaving group, such as but not limited to, -Cl, -Br, -I, -O-mesylate, -O-tosylate, O-triflate, etc.  $X_3$  may also be an aldehyde; the corresponding coupling with (XVI) via the well known reductive amination procedure gives the (S,R)-substituted amine (X).

Carbocylic amide forming agents (IX) are also provided for by the invention. For example, the carbocyclic amide forming agents of the formula

|----|

5

R'-CH-C(R'')(R''')-CH-X<sub>N</sub>-OH (IX) are readily prepared from known starting materials by methods disclosed in the literature and known to those skilled in the art, for example, J. Med. Chem. 1998, 41, 1581, J. Org. Chem. 2000, 65, 1305. It is also understood that instead of the carboxylic acid, one may readily employ an acyl halide, where the halide is preferably choride, or a suitable group to produce a mixed anhydride; these methods are taught by CHART A. For additional guidance on the formation of carbocyles and preferably cyclopropanes, one may consult M.P. Doyle; M.A. McKervery; T. Ye in Modern Catalytic Methods for Organic Synthesis with Diazo Compounds From Cyclopropanes to Ylides, Wiley-Interscience, 1998, pp. 163-279.

CHARTS E, F, G, and H disclose various methods to produce the  $R_N$  portion of the substituted amine (X) where the phenyl ring of the  $R_N$  1,3-disubstituted moiety,

25 -CO-phenyl-CO-, is further substituted in the 5-position with various groups such as amides, nitriles, halides, and amines. These compounds are prepared by methods known to those skilled in the art. The process chemistry of each reaction is known to those skilled in the art. The novelty here is represented by the order of each process step and/or the specific reactants used. One skilled in the art knowing the desired product would know at least one method to prepare the desired product by using known starting materials. Hence, the following

discussion is not necessary but is set forth to further aid those interested in preparing the compounds of the invention.

CHART E discloses alternate processes for the transformation of the aniline (XVII) or acid ester (XVIII) to the corresponding acid (IX-XXIII). One process begins with the commercially available aniline (XVII). The aniline (XVII) is treated with a diazotizing reagent such as sodium or potassium nitrite in mineral acid, followed by a halogen source such as copper (II) halide or alkali metal halide, or by an organic diazotizing reagent such as an alkyl nitrite in a strong acid such as acetic acid or trifluoroacetic acid, followed by a halide source such as copper (II) halide or alkali metal halide to give the halo acid ester (XIX).

Alternatively, the acid ester (XVIII) is treated with N-halosuccinimide and trifluoromethanesulfonic acid to give the halo acid ester (XIX). The halo acid ester (XIX) is then converted to the ester amide (XXI) using a primary or secondary amine of the formula  $H-NG_1G_2$  where  $G_1$  and  $G_2$  are the same or different or can be cyclized.  $G_1$  and  $G_2$  become part of the substituted amine (X) and are included in the definition of  $R_N$ .  $R_N$  includes  $R_{N-1}-X_N-$  where the linker,  $-X_N-$ , includes -CO- and -CO- and -CO- includes -CO- inclu

 $-\text{CO-NR}_{N-2}R_{N-3}$  and

25  $-CO-R_{N-4}$ .

10

15

20

30

Alternatively, the halo acid ester (XIX) is converted to the acid chloride halo ester (XX) by methods known to those skilled in the art. One of skill in the art will appreciate that other acid halides may also be used. The dihalo ester (XX) is treated with a primary or secondary amine of the formula  $H-NG_1G_2$  to give the ester amide (XXI). The ester amide (XXI) is then reacted with an AMINE in a carbon monoxide atmosphere in the presence of a palladium catalyst using methods such as those reviewed by Heck, (Palladium Reagents in

Organic Synthesis, 1985 pp. 342-365). to give the diamide (XXII). Hydrolysis of the ester portion of the diamide (XXII) using methods well known to those skilled in the art gives the diamide acid (XXIII).

5 In CHART F, an alternate route to intermediate diamide (XXII) is shown starting from commercially available phenol The phenol (XXIV) is treated with trifluoromethanesulfonating reagent such as trifluoromethanesulfonic anhydride to give triflate (XXV). The 10 triflate (XXV) is reacted under the conditions of palladium catalysis in the presence of carbon monoxide and an amine of the formula H-NR<sub>Nalpha</sub>R<sub>Nbeta</sub> (AMINE) as for the conversion of the ester amide (XXI) to the corresponding diamide (XXII) in CHART E to give the diester (XXVI). The diester (XXVI) is hydrolyzed using methods known to those skilled in the art to give the 15 monoacid (XXVII). The monoacid (XXVII) is then converted to the diamide (XXII) using conditions such as for the conversion of the halo acid ester (XIX) to the ester amide (XXI) in CHART E.

20 CHART G discloses another route to prepare the ester amide The reaction starts with commercially available nitro compound (XXVIII) which is condensed with an (AMINE) using coupling methods known to those skilled in the art to give the nitro amide (XXX). The nitro amide (XXX) can also be prepared by first treating the nitro compound (XXVIII) with reagents 25 such as thionyl chloride, or DMF and oxalyl chloride, or other methods known to those skilled in the art to give the acyl chloride (XXIX), which upon treatment with the (AMINE) gives the nitro amide (XXX). Reduction of the nitro amide (XXX) using methods known to those skilled in the art (see, for 30 example, Smith and March, Advanced Organic Chemistry, 5th ed.) gives amide aniline (XXXI). The amide aniline (XXXI) is then treated with diazotizing reagents such as sodium or potassium nitrite in mineral acid, followed by a halogen source such as

copper (II) halide or alkali metal halide, or by an organic diazotizing reagent such as an alkyl nitrite in a strong acid such as acetic acid or trifluoroacetic acid, followed by a halide source such as copper (II) halide or alkali metal halide to give the ester amide (XXI).

CHART H discloses a process to prepare the diamide acid (IX-XXIII) from the ester amide (XXI), where one of the amides is unsubstituted and is -CO-NH2. This process starts from either the ester or the acid, for example the ester amide (XXI) 10 treated with copper (I) cyanide (CuCN) methylpyrrolidinone or DMF, preferably N-methylpyrrolidinone, to give the nitrile (XXXII). The nitrile (XXXII) is converted to the primary amide (XXXIII) using urea-hydrogen peroxide complex (see Synth. Commun. (1993) 3149) or the methods of Synth. Commun. (1990) 1445, Synth. Commun. (1997) 3119, J. Org. 15 Chem. (1992) 2521, Tet. Lett. (1996) 6555, Ind. J. Chem., Sect. B, (1999) 974, Tet. Lett. (1995) 3469, Tet. Lett. (1998) 3005, When the ester amide (XXI) is in the form of an or others. ester, an additional hydrolysis step using lithium hydroxide, sodium hydroxide, potassium hydroxide, barium hydroxide, or 20 other hydrolysis methods known to those skilled in the art is used to convert the diamide ester (XXXIII) to the diamide acid (IX-XXIII).

CHART I discloses an alternate synthetic route from the protected alcohol (VII) to the substituted amine (X) which uses a diprotected intermediate (XXXIV) wherein the nitrogen atom attached to the R<sub>c</sub> substitutent is protected. Using the process of CHART I, the mono protected alcohol (VII) is reacted with a new protecting group to form the orthogonally protected (XXXIV). This is a common strategy employed in traditional peptide chemistry by those skilled in the art, see M. Bodansky, Principles of Peptide Chemistry. When the mono protected alcohol (VII) is protected with CBZ one skilled in the art could react it with either (BOC) 20 in methylene chloride or

25

similar organic solvent or FMOC-Cl in methylene chloride or similar organic solvent to prepare orthogonally protected (XXXIV). Then the CBZ group is removed by hydrogenation in the presence of a catalytic amount of palladium on carbon in an alcoholic solvent, such as methanol, or ethyl acetate, or with catalytic palladium on carbon in alcoholic solvents in the presence of ammonium formate as is known to those skilled in This gives the  $R_{c}-N$  protected (XXXV). the art. Similarly, when the mono protected alcohol (VII) is protected as a BOC it can be reacted with CBZ-Cl under Schotten-Bauman conditions or CBZ-OSu in THF to prepare the reversed (XXXIV). Then the BOC group can be cleaved with hydrochloric acid (4 N) in methanol, ethanol or dioxane or with trifluoroacetic acid in methylene chloride or by other methods such as those described in The Peptides, Analysis, Synthesis, Biology, Vol. 3, Ed. E. Gross and J. Meienhofer (1981) to liberate the CBZ  $R_c$ -N protected This functional group manipulation gives various permutations in the sequence (VII) to (XXXIV) to (XXXV) as is apparent to one skilled in the art. When the appropriately  $R_{C^-}$ N protected compound (XXXV) is reacted with the amide forming agent (IX), in acid form, under standard peptide coupling conditions, for example, EDC/HOBt in methylene chloride or DMF or a previously activated acid,  $(R_{N-})_{2}O$  gives the corresponding  $R_N$ -substituted  $R_C$ -N protected (XXXVI). Simple de-protection of the  $R_N$ -substituted  $R_C$ -N protected (XXXVI) then gives the desired substituted amine (X). Thus when the  $R_N$ -substituted  $R_{\text{C}}\text{-N}$  protected (XXXVI) is protected with BOC, treatment with hydrochloric acid (4N) in dioxane or the other reagents discussed above gives the substituted amine (X). When the  $R_{N^-}$ substituted Rc-N protected (XXXVI) is protected with CBZ, treatment with hydrogen from 10 - 50 psi in alcoholic solvents, such as methanol with a catalytic amount of palladium on carbon will give, after work-up, the desired substituted amine (X). Similarly when the  $R_N$ -substituted  $R_C$ -N protected (XXXVI) is

10

15

20

25

protected with FMOC, treatment with a secondary amine, preferably either piperidine (10 %) or diethylamine (10 %) in an inert solvent such as, for example, methylene chloride will give after work up the desired substituted amine (X).

CHART J discloses a process to prepare compounds where the 5 phenyl ring of the  $R_N$  substituent of -CO-phenyl-COsubstituted with a sulfonamide group in the 5-position. The process starts with the halo amide ester (XXI, CHART E) which is reacted with sodium nitrite, sulfur dioxide, copper chloride (II) and acetic acid by the method disclosed in  $J.\ Med.\ Chem.$ , 10 42, 3797 (1999) to prepare the sulfonyl chloride (XXXVII). sulfonyl chloride (XXXVII) is then reacted with AMINE, as defined above, by methods known to those skilled in the art to produce the corresponding sulfonamide (XXXVIII). Last the sulfonamide (XXXVIII) is transformed to the corresponding 15 sulfonamide acid (XXXIX) by methods known to those skilled in the art such as using lithium hydroxide, sodium hydroxide, potassium hydroxide, barium hydroxide, or other hydrolysis methods known to those skilled in the art.

CHART K discloses how to prepare the  $R_{\text{N}}$  substituents where 20  $R_N$  is  $R_{N-1}-X_{N^-},$  where  $X_N$  is -CO- and  $R_{N-1}$  is  $R_{N-{\tt aryl}}$  where  $R_{N-{\tt aryl}}$  is phenyl substituted with one alkyl group and one  $\text{-CO-NR}_{N-2}R_{N-3}$  or See the discussion above for CHART E regarding the amine,  $\text{H-NR}_{\text{Nalpha}} R_{\text{Nbeta}}$  (AMINE), used to form the amide  $R_{\text{N}}$ substituents. The process starts with the halo amide ester (XXI) which is then reacted with an alkyl boronic acid having the desired alkyl group in the presence of a palladium catalyst such as  $Pd(PPh_3)Cl_2$  using the general method described in J. Med.Chem., 4288 (2000). The alkyl boronic acids are commercially available or can be prepared by the process described in J. Am. Chem. Soc., 60, 105 (1938). It is preferred that  $R_{N-b}$  is bromo. This step produces the alkyl ester (XL) which is then hydrolyzed by means known to those skilled in the art to produce the desired alkyl acid (XLI).

25

5

10

15

20

25

30

CHART L discloses a process to prepare the amide forming agent (IX - XLVII) where the  $R_N$  substituent is  $R_{N-1}-X_{N^-}$ , where the linker,  $-X_N-$  is -CO-, where  $R_{N-1}$  is  $R_{N-aryl}$  and where  $R_{N-aryl}$  is phenyl (-phenyl) substituted with groups:

C<sub>1</sub>-C<sub>6</sub> alkyl, optionally substituted with one, two or three substituents selected from the group consisting of  $C_1-C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C $\equiv$ N, -CF $_3$ , C $_1$ -C $_3$  alkoxy, -NR $_{1-a}$ R $_{1-b}$ where  $R_{1-a}$  and  $R_{1-b}$  are as defined above, and -N(-H and  $C_1-C_3$  $alkyl)-CO-R_{N-5}$ This specific amide forming agent, (IX - XLVII) is prepared by starting with the phenyl nitro compoud (XLII) which is reduced to the corresponding phenyl nitro hydroxy compound (XLIII) using borane-methyl sulfide or borane in THF. The phenyl nitro hydroxy compound (XLIII) is reduced to the corresponding phenyl amino hydroxy compound (XLIV) using hydrogen and palladium catalyst as is known to those skilled in The phenyl amino hydroxy compound (XLIV) is reacted with an aldehyde in the presence of a reducing agent such as sodium cyanoborohydride or sodium triacetoxyborohydride to give the phenyl substituted amino hydroxy compound (XLV). phenyl substituted amino hydroxy compound (XLV) is acylated with an acid chloride or acid anhydride by methods known to those skilled in the art to give the phenyl disubstituted amino hydroxy compound (XLVI). The phenyl disubstituted amino hydroxy compound is hydrolyzed using (XLVI) an hydroxide, followed by acidification, to give the amide forming agent (IX - XLVII). The amide forming agent (XLVII) is then coupled with amine (VIII) using methods known to those skilled in the art and methods previously discussed, such as with diethyl cyanophosphonate, to give the substituted amine (X). Further treatment of the substituted amine (X) with diethyl cyanophosphonate gives the substituted amine the hydroxyalkyl substitutent on the phenyl ring has a phosphate substitutent.

CHART M discloses a process to prepare amide forming agents (IX- L) where the  $R_N$  substituent is  $R_{N-1}-X_N-$ , where the linker,  $-X_N-$  is -CO-, where  $R_{N-1}$  is  $R_{N-aryl}$  and where  $R_{N-aryl}$  is phenyl (-phenyl) substituted with two groups. The first substituent at what is usually identified as position "5-" can be either:

-R<sub>N-aryl</sub> or

 $^{-R_{\mbox{\scriptsize N-heteroaryl}}}.$  The second substituent at what is usually identified as postion "3-" can be either:

 $-\text{CO-NR}_{N-2}\text{R}_{N-3} \text{ or }$ 

15

20

25

30

 $-CO-R_{N-4}$ .  $R_{\text{Nalpha}}$  and  $R_{\text{Nbeta}}$  include both the non-cyclic amides,-CO-NR $_{\!N-2}R_{\!N-3}$  and the cyclic amides-CO-R $_{\!N-4}$  where  $R_{\!N-2}$  ,  $R_{N\!-3}$  and  $R_{N\!-4}$  are as defined in the claims. The process starts with the trisubstituted phenyl compound (XLVIII) where  $R_{N-d}$  is -Cl, -Br, -I or -O-triflate. Treatment with an aryl or heteroaryl boronic acid or heteroaryl or aryl boronic acid ester such as (aryl or heteroaryl)-B(OH)2 or (aryl or heteroaryl)-B(OR $^{a}$ )(OR $^{b}$ ) (where R $^{a}$  and R $^{b}$  are lower alkyl, ie.  $C_1$ - $C_6$ , or taken together,  $R^a$  and  $R^b$  are lower alkylene, ie.  $C_2$ - $C_{12}$ ) in the presence of a metal catalyst with or without a base in an inert solvent yields (XLIX). Metal catalysts in these transformations include, but are not limited to, salts or phosphine complexes of Cu, Pd, or Ni (eg.  $Cu(OAc)_2$ ,  $PdCl_2(PPh_3)_2$ ,  $NiCl_2(PPh_3)_2$ ). Bases may include, but are not limited to, alkaline earth carbonates, alkaline earth metal bicarbonates, metal alkaline earth metal hydroxides, alkali metal carbonates, alkali metal bicarbonates, alkali metal hydroxides, alkali metal hydrides (preferably sodium hydride), alkali metal (preferably sodium methoxide alkoxides or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium diisopropylamide), alkali metal bis(trialkylsilyl)amides (preferably sodium

5

10

15

20

25

30

bis(trimethylsilyl)amide), trialkyl amines (preferably diisopropylethylamine or triethylamine) or aromatic amines (preferably pyridine). Inert solvents may include, but not limited to, acetonitrile, dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylacetamides dimethylacetamide), (preferably N, N-dialkylformamides (preferably dimethylformamide), dialkylsulfoxides (preferably dimethylsulfoxide), aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes (preferably methylene chloride). Preferred reaction temperatures range from room temperature up to the boiling point of the solvent employed. The reactions may be run in conventional glassware or in one of many commercially available parallel synthesizer units. Non-commercially available boronic acids or boronic acid esters may be obtained from the corresponding optionally substituted aryl halide as described in Tetrahedron, 50, 979-988 (1994). Intermediate (XLIX) is then hydrolyzed using alkali metal hydroxide, for example lithium, sodium or potassium hydroxide, followed by acidification, to give aryl or heteroaryl coupled acids (IX-L). Alternatively, as described in Tetrahedron, 50, 979-988 (1994), one may convert the  $R_{\mathrm{N-d}}$  to the corresponding boronic acid or boronic acid ester  $(OH)_2B-$  or  $(OR^a)_1(OR^b)_B-$  and obtain the same products set forth above by treating with a suitable aryl or heteroaryl halide or triflate.

CHART N discloses a process to prepare amide forming agents (IX - LII) where the  $R_N$  substituent is  $R_{N-1}-X_N-$  where the linker,  $-X_N-$  is -CO-, where  $R_{N-1}$  is  $R_{N-aryl}$  and where  $R_{N-aryl}$  is phenyl (-phenyl) substituted with two groups. The first substitutent at what is usually identified as postion "5-" is -C=C-R. The second substituent at what is usually identified as

postion "3-" can be either  $-\text{CO-NR}_{N-2}R_{N-3}$  or  $-\text{CO-R}_{N-4}$ . The halo ester (XXI) is treated with a mixture of  $\text{PdCl}_2(\text{Pphenyl}_3)_2$  and trimethylsilyl acetylene, using methods known to those skilled in the art, to give acetylene ester (LI). Acetylene ester (LI) is then hydrolyzed using alkali metal hydroxide, followed by acidification, to give acetylene acid (IX - LII).

CHARTs O and O' disclose processes to prepare amide forming agents (IX - LX) and (IX - LXIII) with an extended methylene group where the  $R_N$  substituent is  $R_{N-1}\!-\!X_{N^-}$  where the linker, -X\_N- is -CO-, where  $R_{N-1}$  is  $R_{N\text{-aryl}}$  and where  $R_{N\text{-aryl}}$  is 10 phenyl (-phenyl) substituted with two groups. The substituent at what is usually identified as postion "3-" can be either - $CO-NR_{N-2}R_{N-3}$  or In the process of CHART O, the  $-CO-R_{N-4}$ . substituent at the 5-position is  $-CH_2CO-NH_2$  and in the process of CHART O', the substituent at the 5-position is -  $\text{CH}_2\text{C}\equiv N$ . 15 The starting diester acid (LIII) is reduced with borane in solvents such as THF to give the corresponding diester alcohol The diester alcohol (LIV) (LIV). is converted to the corresponding diester bromo compound (LV) using a brominating agent such as PBr3, CBr4, or other halogenating agent such as 20 are known to those skilled in the art. The bromine of the diester bromo compound (LV) is then displaced with cyanide to give the corresponding nitrile (LVI). In CHART O', the nitrile (LVI) is then hydrolyzed to the corresponding cyano ester 25 The cyano ester (LXI) is then coupled with  $\text{H-NR}_{N\alpha} R_{N\beta}$ (LXI). (AMINE), as previously described using methods known to those skilled in the art to give the corresponding cyano amide The cyano amide (LXII) is then hydrolyzed to the (LXII). corresponding cyano acid (IX-LXIII) which is in turn coupled 30 with amine (VIII) to give the substituted amine (X). substitutent on the extended methyl group is  $-\text{CO-NH}_2$ , the process of CHART O is used. There the nitrile (LVI) converted to the corresponding diester amine (LVII) by methods known to those skilled in the art. The next steps are the same

as for CHART O' where the diester amide (LVII) is hydrolyzed to the corresponding ester amine (LVIII) which is then converted to the corresponding diamide ester (LIX) which is hydrolyzed to the corresponding diamide acid (IX - LX). The diamide acid (IX - XL) is then coupled with the appropriate amine (VIII) to produce the desired substituted amide (X).

CHART P discloses a process to prepare amide forming agents (IX - LXVII) with an extended hydroxymethylene group where the  $R_N$  substituent is  $R_{N-1} - X_N -$  where the linker,  $-X_N -$  is -CO-, where the  $R_{N-1}$  is  $R_{N-\mathrm{aryl}},$  where  $R_{N-\mathrm{aryl}}$  is phenyl (-phenyl) 10 substituted with two groups. The substituent at what is usually identified as position "3-" can be either-CO-NR  $_{N-2}\mbox{R}_{N-3}$  or -CO-R  $_{N-1}\mbox{R}_{N-1}$ The process begins with a halo amide (LXIV), preferably iodo, which is converted to the corresponding aldehyde (LXV) and then to the corresponding alcohol (LXVI) by the method 15 described in Synth. Commun. 28, 4270 (1998), optionally with variations known to those skilled in the art. Hydrolysis of the alcohol (LXVI) using alkali hydroxides, followed by acidification, gives the desired hydroxy acid (IX - LXVII). The hydroxy acid (IX - LXVII) is then coupled with the 20 appropriate amine (VIII) to give the desired substituted amine (X).

CHART Q discloses a process to prepare amide forming agents (IX - LXXII) with an alkyl group or a halogen atom or an 25 amino group at the 5-position where the  $R_{N}$  substituent is  $R_{N-1}\text{--}$  $X_{N^-}$  where the linker,  $-X_{N^-}$  is -CO-, where the  $R_{N-1}$  is  $R_{N-aryl}$ , where  $R_{N-aryl}$  is phenyl (-phenyl) substituted with two groups. The substituent at what is usually identified as position "3-" can be either  $\text{-CO-NR}_{N-2}R_{N-3}$  or  $\text{-CO-R}_{N-4}.$  The process begins with 30 appropriately 5-substituted diacid (LXVIII) which esterified by methods known to those skilled in the art to give the corresponding diester (LXIX). The diester (LXIX) is then hydrolyzed using alkali hydroxides, followed by acidification, to give the corresponding monoacid (LXX). Alternatively, the

monoacid (LXX) can be produced directly from the diacid (LXVIII) by known methods. The monoacid (LXX) is then coupled with  $H-NR_{Nalpha}R_{Nbeta}$  (AMINE)

to give the corresponding amide ester (LXXI). The amide ester (LXXI) is then hydrolyzed using alkali hydroxides, followed by acidification, to give the corresponding acid amide (IX - LXXII).

CHART R discloses a general process to prepare the amide forming agents (IX - LXXVII) which, for example, have an alkyl group at what is known as the 5-position and a ketone at the 3-10 position. These acids (IX- LXXVII) are formed by starting with the acid (LXXIII) which is converted to the corresponding acid halide (LXXIV) using methods known to those skilled in the The acid halide (LXXIV) is preferrably the acid chloride. The acid halide (LXXIV) in the presence of copper (I) bromide 15 and tetrahydrofuran and at temperatures ranging from -78 degrees C to 0 degreesC is treated with a Grignard reagent (aryl-Mg-X, or alkyl-Mg-X, where X is -Cl or -Br) to give the ketone esters (LXXVI and LXXVI'). Many Grignard reagents are available for purchase; others are prepared by methods known to 20 those skilled in the art. An alternative method for preparing the ketone esters (LXXVI, LXXVI') is to prepare the Weinreb amide (LXXV), either from the acid (LXXIII) directly or by way of acid halide (LXXIV) followed by treatment with N, Odimethylhydroxylamine to give Weinreb amide (LXXV) and then 25 treating the Weinreb amide (LXXV) with a Grignard reagent, by methods known to those skilled in the art. The ketone esters (LXXVI, LXXVI') are then hydrolyzed using alkali hydroxides, followed by acidification, to give the ketone acids (LXXVII, LXXVII'). 30

CHART S discloses various methods to modify the  $R_N$  portion of the substituted amine (X) where the phenyl ring of the  $R_N$  moiety is further substituted in the 3-position with various groups such as aryl and heteroaryl. These compounds are

prepared by methods known to those skilled in the art. The process chemistry of each reaction is known to those skilled in the art. What is novel here is the order of each process step and/or the specific reactants used. One skilled in the art knowing the desired product would know at least one method to prepare the desired product by using known starting materials. Hence, the following discussion is not necessary but is set forth to further aid those interested in preparing the compounds of the invention.

10

15

20

25

30

CHART S sets forth a general method used in the invention to prepare the substitued amines (X) where  $R_{\rm N}$  =  $R_{\rm N-aryl}-R_{\rm N-}$ aryl-X<sub>N</sub> or R<sub>N</sub>-heteroaryl-R<sub>N</sub>-aryl-X<sub>N</sub>. Treatment of the (S,R)amine (VIII) with amide forming agents (IX) according to the methods set forth above where for CHART S,  $R_{N-1}$ is  $Br-R_{N-arvl}$ generates the corresponding (S,R)-substituted amine (X) where  $R_N$  is  $Br-N_{R-arvl}-X_N$ . Further treatment with an aryl boronic acid or aryl boronic acid ester such as (aryl or heteroaryl)- $B(OH)_2$  or (aryl or heteroaryl)- $B(OR^a)(OR^b)$  (where  $R^a$  and  $R^b$  are lower alkyl, ie.  $C_1$ - $C_6$ , or taken together,  $R^a$  and  $R^b$  are lower alkylene, ie.  $C_2$ - $C_{12}$ ) in the presence of a metal catalyst with or without a base in an inert solvent yields the (S,R)substituted amine (X) where  $\textbf{R}_{N}$  is  $\textbf{N}_{R-\text{aryl}}-\textbf{N}_{R-\text{aryl}}-\textbf{X}_{N}$  or  $\textbf{R}_{N-}$ heteroaryl-RN-aryl-XN. Metal catalysts in these transformations include, but are not limited to, salts or phosphine complexes of Cu, Pd, or Ni (eg. PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, NiCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>). Bases may include, but are not limited to, alkaline earth metal carbonates, alkaline earth metal bicarbonates, alkaline earth metal hydroxides, alkali metal carbonates, alkali metal bicarbonates, alkali metal hydroxides, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali

dialkylamides (preferably lithium diisopropylamide), alkali bis(trialkylsilyl)amides (preferably bis(trimethylsilyl)amide), trialkyl amines (preferably diisopropylethylamine or triethylamine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, acetonitrile, dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4dioxane), N,N-dialkylacetamides (preferably dimethylacetamide), N, N-dialkylformamides (preferably dimethylformamide), dialkylsulfoxides (preferably dimethylsulfoxide), 10 hydrocarbons (preferably benzene or toluene) or haloaalkanes (preferably methylene chloride). Preferred temperatures range from room temperature up to the boiling point of the solvent employed. The reactions may be run in conventional glassware or in one of many commercially available 15 parallel synthesizer units. Non-commercially available boronic acids or boronic acid esters may be obtained from the corresponding optionally substituted aryl halide as described in Tetrahedron, 50, 979-988 (1994).

Where the above chemistry is incompatible with other 20 functionality in the (S,R)-substituted amine (X) where  $\textbf{R}_{N}$  is  ${\rm Br-N_{R-aryl-X_N}}$ , then one skilled in the art will readily understand that an alternative sequence of coupling steps is required. For example, treatment of an appropriately substituted amide forming agent (IX)  $\mathbf{R}_{N-1}\text{-}\mathbf{X}_{N}\text{-}\mathbf{OH}$  where  $\mathbf{R}_{N-1}$  is 25  $Br-R_{\hbox{\it N}-aryl}$  with a boronic acid or boronic acid ester under the conditions described above will afford the appropriately substituted amide forming agent (IX) where  ${\tt R}_{N-1}$  is  ${\tt N}_{R-aryl}{\tt -}{\tt N}_{R-}$ aryl or  $R_{N-heteroaryl}-R_{N-aryl}$ . When the amide forming agent (IX) where  ${\tt R}_{N-1}$  is  ${\tt N}_{R-aryl}{\tt -N}_{R-aryl}$  or  ${\tt R}_{N-heteroaryl}{\tt -R}_{N-aryl}$  is 30 treated with the (S,R)-amine (VIII), one then obtains the same substituted amines (X) set forth in CHART S.

The above examples for CHART S are not meant to limit the scope of the chemistry. In addition to bromine, a suitable group may include iodine or triflate. Alternatively, described in Tetrahedron, 50, 979-988 (1994), one may convert the Br-R<sub>N-aryl</sub> to the corresponding boronic acid or boronic acid ester (OH)  $_2B-R_{N-arvl}$  or (OR $^a$ ) (OR $^b$ )  $B-R_{N-arvl}$  and obtain the same products set forth above by treating with a suitable aryl or heteroaryl halide or triflate. Additionally, each  $-R_{N-arvl}$ and -R<sub>N-heteroaryl</sub> are interchangeable at each occurrence in the chemistry described above.

discloses a process to prepare amide forming CHART T agents (IX - LXXIX) where the  $R_N$  substituent is  $R_{N-1}-X_{N}-$ , where the linker,  $-X_N-$  is -CO-, where  $R_{N-1}$  is  $R_{N-aryl}$  and where  $R_{N-aryl}$  is phenyl substituted with  $-\text{CO-NR}_{\text{Nalpha}}R_{\text{Nbeta}}$  (AMINE) and with an amide of the formulas:

 $-(CH_2)_{0-4}-N(-H \text{ and } R_{N-5})-CO-R_{N-2}$ 

10

15

20

30

 $-(CH_2)_{0-4}-N(-H \text{ or } R_{N-5})-SO_2-R_{N-2}$ .

The process begins with the amide aniline (XXXI) which is reacted with the corresponding acid halide or sulfonyl halide, or acid anhydride or sulfonyl anhydride to produce the corresponding amide ester (LXXVIII). Suitable solvents include THF or dichloromethane at temperatures ranging from -78 degrees to 100 degrees C. The amide ester (LXXVIII) is then hydrolyzed to the corresponding amide acid (IX - LXXIX) by methods known to those skilled in the art. When the amide forming agent (IX 25 - LXXIX) is reacted with the appropriate amine (VIII), the desired compound (X) is obtained.

CHART U discloses a general method for preparing various C-terminal amines (VI) as reed by the preparation of C-terminal amine (LXXXIV). Methods to prepare amines of this type are well understood using methods known to those skilled in the art, or one may consult the references: 1) JACS, 1970, 92, 3700, and 2) US patent 4,351,842.

CHART V further discloses general methods for preparing various C-terminal amines (VI) as reed by the preparation of C-terminal amines (LXXXIX). Multiple examples of heterocyclic carboxylic acids or acid chlorides are commercially available. Optionally, the carboxylic acid (LXXXV) may be converted to the acid chloride (LXXXVI) with reagents such as, but not limited to, thionyl chloride. Displacement with ammonia generates the common intermediate amides (LXXXVII) which are readily reduced to amines (VI -LXXXIX) using a variety of methods detailed previously. Alternatively, other heteroaryls are commecially available as the methyl halide (LXXXVIII) which are treated with ammonia to yield the title C-terminal amines (VI -LXXXVIII).

10

15 CHART discloses general methods for preparing thiazolyl containing C-terminal amines as reed by the preparation of C-terminal amines (LXXXXI). The synthesis of the thiazoles is outlined in CHART W; these procedures are amply taught in the literature and are modified from the procedures outlined in: Mashraqui, SH; Keehn, PM. J. Am. 20 Chem. 1982, Soc. 104, 4461-4465. The synthesis substituted 5-aminomethylthiazoles (XCI) was achieved from 5-hydroxymethylthiazole (XC) by the procedure described in: Alterman et al. J. Med. Chem. 1998, 41, 3782-3792. other thiazole analogs were transformed to the hydroxymethyl 25 derivative using CHART W, and converted to the aminomethyl derivative by the Alterman procedure without notable changes.

CHART X discloses general methods for preparing isoxazolyl containing C-terminal amines as reed by the preparation of C-terminal amines (XCII). The synthesis of isoxazole derivatives was modified from the procedure in: Felman, SW et al. J. Med. Chem. 1992, 35, 1183-1190 and is readily understood by those skilled in the art making non-notable changes to achieve the

title compounds. The substituted hydroxylamine precursors were synthesized using the procedure taught by Bousquet, EW. Org. Synth. Coll. Vol II, 313-315. Commercially available propargylamine may be protected using any number of methods known in the art (see: Greene, TW; Wuts, PGM. Protective Groups in Organic Synthesis, 3<sup>rd</sup> Ed. New York: John Wiley, 1999. Chapter 7.), prefered is a BOC protecting group. Substituted propargyl amines may be obtained by a number of methods commonly known in the art.

10 CHART Y discloses а general route to prepare hydroxyethylamines where one carbon atom of the peptide backbone, along with R2 and R3 form a ring. It is understood that the invention also allows for a heteroatom to be incorporated into the ring. In summary, the synthesis of compounds where  $R_2$  and  $R_3$  may form a ring proceeds from a 15 suitably protected amino acid aldehyde and cycloalkyllithium species, both of which are commercially available or where known procedures for making such compounds are known in the The general procedure involved is also precedent in the literature, for example, see Klumpp, et al., J. Am. Chem. Soc., 20 1979, 101, 7065, and it is intended that making non-critical variations, one may obtain the title compounds provided for by CHART Y. Treatment of a suitably protected amino acid aldehyde and cycloalkyllithium species affords alcohol (XCIII). 25 reactions are carried out in an inert solvent such as, for example, tetrahydrofuran or diethyl ether. Optimally the reactions are conducted at low temperatures, for example below 0 degrees C. Carbonylation via the Klumpp procedure yields the (XCIV) acid which when exposed to Curtius, or related procedures well known to those skilled in the art, generates 30 the primary amine (XCV). The primary amines (XCV) may be capped C-terminally via the conditions set forth in CHART C  $\&\ D$ followed by nitrogen deprotection and capping N-terminally via the conditions set forth in CHART A.

The compounds of the invention may contain geometric or optical isomers as well as tautomers. Thus, the invention includes all tautomers and pure geometric isomers, such as the E and Z geometric isomers, as well as mixtures thereof. Futhermore, the invention includes pure enantiomers and diasteriomers as well as mixtures thereof, including racemic mixtures. The individual geometric isomers, enantiomers, or diasteriomers may be prepared or isolated by methods known in the art.

10 Compounds of the invention with the stereochemistry designated in formula X may be included in mixtures, including racemic mixtures, with other enantiomers, diasteriomers, geometric isomers or tautomers. Compounds of the invention with the stereochemistry designated in formula X are typically 15 in these mixtures in excess of 50 percent. Preferably, compounds of the invention with the stereochemistry designated in formula X are in these mixtures in excess of 80 percent. preferably, compounds of the invention with Most stereochemistry designated in formula X are in these mixtures 20 in excess of 90 percent.

The compounds of the invention are typically amines and as such form salts when reacted with acids. Pharmaceutically acceptable salts are preferred over the corresponding (S,R)substituted amines (X) and and the substituted amines with  $R_{N}$ cyclized (X') since they produce compounds which are more water soluble, stable and/or more crystalline. Pharmaceutically acceptable salts are any salt which retains the activity of the parent compound and does not impart any deleterious or undesirable effect on the subject to whom it is administered and in the context in which it is administered. aceutically acceptable salts include salts of both inorganic and organic acids. The preferred pharmaceutically acceptable salts include salts of the following acids acetic, aspartic, benzenesulfonic, benzoic, bicarbonic, bisulfuric, bitartaric,

25

butyric, calcium edetate, camsylic, carbonic, chlorobenzoic, citric, edetic, edisylic, estolic, esyl, esylic, formic, fumaric, gluceptic, gluconic, glutamic, glycollylarsanilic, hexamic, hexylresorcinoic, hydrabamic, hydrobromic, hydrochloric, hydroiodic, hydroxynaphthoic, isethionic, lactic, lactobionic, maleic, malic, malonic, mandelic, methanesulfonic, methylnitric, methylsulfuric, mucic, muconic, napsylic, nitric, p-nitromethanesulfonic, oxalic, pamoic, pantothenic, phosphoric, monohydrogen phosphoric, dihydrogen phosphoric, phthalic, polygalactouronic, propionic, salicylic, stearic, 10 succinic, succinic, sulfamic, sulfanilic, sulfonic, sulfuric, tannic, tartaric, teoclic and toluenesulfonic. For other acceptable salts, see Int. J. Pharm., 33, 201-217 (1986) and J. Pharm. Sci., 66(1), 1, (1977).

The invention provides compounds, compositions, kits, and methods for inhibiting beta-secretase enzyme activity and A beta peptide production. Inhibition of beta-secretase enzyme activity halts or reduces the production of A beta from APP and reduces or eliminates the formation of beta-amyloid deposits in the brain.

# Methods of the Invention

25

30

The compounds of the invention, and pharmaceutically acceptable salts thereof, are useful for treating humans or animals suffering from a condition characterized by a pathological form of beta-amyloid peptide, such as beta-amyloid plaques, and for helping to prevent or delay the onset of such a condition. The compounds and compositions of the invention are particularly useful for treating or preventing Alzheimer's disease. The compounds of the invention can either be used individually or in combination, as is best for the patient.

As used herein, the term "treating" means that the compounds of the invention can be used in humans with at least a tentative diagnosis of disease. The compounds of the

5

10

15

20

25

30

invention will delay or slow the progression of the disease thereby giving the individual a more useful life span.

The term "preventing" means that the compounds of the invention are useful when administered to a patient who has not been diagnosed as possibly having the disease at the time of administration, but who would normally be expected to develop the disease or be at increased risk for the disease. The compounds of the invention will slow the development of disease symptoms, delay the onset of the disease, or prevent the individual from developing the disease at all. Preventing also includes administration of the compounds of the invention to those individuals thought to be predisposed to the disease due to age, familial history, genetic or chromosomal abnormalities, and/or due to the presence of one or more biological markers for the disease, such as a known genetic mutation of APP or APP cleavage products in brain tissues or fluids.

In treating or preventing the above diseases, the compounds οf the invention administered are therapeutically effective amount. The therapeutically effective amount will vary depending on the particular compound used and the route of administration, as is known to those skilled in the art.

In addition, the compounds of the invention can also be used with inhibitors of P-glycoproten (P-gp). The use of P-gp inhibitors is known to those skilled in the art. See for example, Cancer Research, 53, 4595-4602 (1993), Clin. Cancer Res., 2, 7-12 (1996), Cancer Research, 56, 4171-4179 (1996), International Publications W099/64001 and W001/10387. The important thing is that the blood level of the P-gp inhibitor be such that it exerts its effect in inhibiting P-gp from decreasing brain blood levels of the compounds of the invention. To that end the P-gp inhibitor and the compounds of the invention can be administered at the same time, by the same or different route of administration, or at different times.

The important thing is not the time of administration but having an effective blood level of the P-gp inhibitor.

Suitable P-gp inhibitors include cyclosporin A, verapamil, tamoxifen, quinidine, Vitamin E-TGPS, ritonavir, megestrol acetate, progesterone, rapamycin, 10,11-methanodibenzosuberane, phenothiazines, acridine derivatives such as GF120918, FK506, VX-710, LY335979, PSC-833, GF-102,918 and other steroids. is to be understood that additional agents will be found that do the same function and are also considered to be useful.

5

15

25

30

10 The P-gp inhibitors can be administered orally, parenterally, (IV, IM, IM-depo, SQ, SQ-depo), topically, sublingually, rectally, intranasally, intrathecally and by implant.

The therapeutically effective amount of the inhibitors is from about 0.1 to about 300 mg/kg/day, preferably about 0.1 to about 150 mg/kg daily. It is understood that while a patient may be started on one dose, that dose may have to be varied over time as the patient's condition changes.

When administered orally, the P-gp inhibitors can be 20 administered in usual dosage forms for oral administration as is known to those skilled in the art. These dosage forms include the usual solid unit dosage forms of tablets and capsules as well as liquid dosage forms such as solutions, suspensions and elixirs. When the solid dosage forms are used, it is preferred that they be of the sustained release type so that the P-gp inhibitors need to be administered only once or The oral dosage forms are administered to the twice daily. patient one thru four times daily. It is preferred that the Pgp inhibitors be administered either three or fewer times a day, more preferably once or twice daily. Hence, it is preferred that the P-gp inhibitors be administered in solid dosage form and further it is preferred that the solid dosage form be a sustained release form which permits once or twice daily dosing. It is preferred that what ever dosage form is

used, that it be designed so as to protect the P-gp inhibitors from the acidic environment of the stomach. Enteric coated tablets are well known to those skilled in the art. In addition, capsules filled with small spheres each coated to protect from the acidic stomach, are also well known to those skilled in the art.

In addition, the P-gp inhibitors can be administered parenterally. When administered parenterally they can be administered IV, IM, depo-IM, SQ or depo-SQ.

The P-gp inhibitors can be given sublingually. When given sublingually, the P-gp inhibitors should be given one thru four times daily in the same amount as for IM administration.

10

15

20

25

30

The P-gp inhibitors can be given intranasally. When given by this route of administration, the appropriate dosage forms are a nasal spray or dry powder as is known to those skilled in the art. The dosage of the P-gp inhibitors for intranasal administration is the same as for IM administration.

The P-gp inhibitors can be given intrathecally. When given by this route of administration the appropriate dosage form can be a parenteral dosage form as is known to those skilled in the art.

The P-gp inhibitors can be given topically. When given by this route of administration, the appropriate dosage form is a cream, ointment or patch. Because of the amount of the P-gp inhibitors needed to be administered the patch is preferred. However, the amount that can be delivered by a patch is limited. Therefore, two or more patches may be required. The number and size of the patch is not important, what is important is that a therapeutically effective amount of the P-gp inhibitors be delivered as is known to those skilled in the art.

The P-gp inhibitors can be administered rectally by suppository as is known to those skilled in the art.

The P-gp inhibitors can be administered by implants as is known to those skilled in the art.

There is nothing novel about the route of administration nor the dosage forms for administering the P-gp inhibitors. Given a particular P-gp inhibitor, and a desired dosage form, one skilled in the art would know how to prepare the appropriate dosage form for the P-gp inhibitor.

It should be apparent to one skilled in the art that the exact dosage and frequency of administration will depend on the particular compounds of the invention administered, the particular condition being treated, the severity of the condition being treated, the age, weight, general physical condition of the particular patient, other medication the individual may be taking as is well known to those skilled in the art.

# Dosage forms and amounts

5

10

15

20

The compounds of the invention can be administered orally, parenternally, (IV, IM, depo-IM, SQ, and depo SQ), sublingually, intranasally (inhalation), intrathecally, topically, or rectally. Dosage forms known to those of skill in the art are suitable for delivery of the compounds of the invention.

Compositions are provided that contain therapeutically 25 effective amounts of the compounds of the invention. The compounds are preferably formulated into suitable pharmaceutical preparations such as tablets, capsules, elixirs for oral administration or in sterile solutions or suspensions for parenternal administration. Typically the compounds described above are formulated into pharmaceutical 30 compositions using techniques and procedures well known in the art.

About 1 to 500 mg of a compound or mixture of compounds of the invention or a physiologically acceptable salt or ester is

compounded with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, flavor, etc., in a unit dosage form as called for by accepted pharmaceutical The amount of active substance in those compositions practice. or preparations is such that a suitable dosage in the range indicated is obtained. The compositions are preferably formulated in a unit dosage form, each dosage containing from about 2 to about 100 mg, more preferably about 10 to about 30 mg of the active ingredient. The term "unit dosage from" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.

10

30

To prepare compositions, one or more compounds of the 15 invention are mixed with a suitable pharmaceutically acceptable Upon mixing or addition of the compound(s), the resulting mixture may be a solution, suspension, emulsion, or like. Liposomal suspensions may also be suitable as pharmaceutically acceptable carriers. These may be prepared 20 according to methods known to those skilled in the art. form of the resulting mixture depends upon a number of factors, including the intended mode οf administration and solubility of the compound in the selected carrier or vehicle. The effective concentration is sufficient for lessening or 25 ameliorating at least one symptom of the disease, disorder, or condition treated and may be empirically determined.

Pharmaceutical carriers or vehicles suitable for administration of the compounds provided herein include any such carriers known to those skilled in the art to be suitable for the particular mode of administration. In addition, the active materials can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, or have another action. The

compounds may be formulated as the sole pharmaceutically active ingredient in the composition or may be combined with other active ingredients.

Where the compounds exhibit insufficient solubility, methods for solubilizing may be used. Such methods are known and include, but are not limited to, using cosolvents such as dimethylsulfoxide (DMSO), using surfactants such as Tween®, and dissolution in aqueous sodium bicarbonate. Derivatives of the compounds, such as salts or prodrugs may also be used in formulating effective pharmaceutical compositions.

10

15

20

25

30

The concentration of the compound is effective for delivery of an amount upon administration that lessens or ameliorates at least one symptom of the disorder for which the compound is administered. Typically, the compositions are formulated for single dosage administration.

The compounds of the invention may be prepared with carriers that protect them against rapid elimination from the body, such as time-release formulations or coatings. Such carriers include controlled release formulations, such as, but not limited to, microencapsulated delivery systems. The active compound is included in the pharmaceutically acceptable carrier in an amount sufficient to exert a therapeutically useful effect in the absence of undesirable side effects on the patient treated. The therapeutically effective concentration may be determined empirically by testing the compounds in known in vitro and in vivo model systems for the treated disorder.

The compounds and compositions of the invention can be enclosed in multiple or single dose containers. The enclosed compounds and compositions can be provided in kits, for example, including component parts that can be assembled for use. For example, a compound inhibitor in lyophilized form and a suitable diluent may be provided as separated components for combination prior to use. A kit may include a compound inhibitor and a second therapeutic agent for co-administration.

The inhibitor and second therapeutic agent may be provided as separate component parts. A kit may include a plurality of containers, each container holding one or more unit dose of the compound of the invention. The containers are preferably adapted for the desired mode of administration, including, but not limited to tablets, gel capsules, sustained-release capsules, and the like for oral administration; depot products, pre-filled syringes, ampules, vials, and the like for parenternal administration; and patches, medipads, creams, and the like for topical administration.

The concentration of active compound in the drug composition will depend on absorption, inactivation, and excretion rates of the active compound, the dosage schedule, and amount administered as well as other factors known to those of skill in the art.

10

15

20

25

30

The active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at It is understood that the precise dosage intervals of time. and duration of treatment is a function of the disease being treated and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test It is to be noted that concentrations and dosage values may also vary with the severity of the condition to be It is to be further understood that for any alleviated. particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions.

If oral administration is desired, the compound should be provided in a composition that protects it from the acidic environment of the stomach. For example, the composition can be formulated in an enteric coating that maintains its

integrity in the stomach and releases the active compound in the intestine. The composition may also be formulated in combination with an antacid or other such ingredient.

Oral compositions will generally include an inert diluent or an edible carrier and may be compressed into tablets or enclosed in gelatin capsules. For the purpose of oral therapeutic administration, the active compound or compounds can be incorporated with excipients and used in the form of tablets, capsules, or troches. Pharmaceutically compatible binding agents and adjuvant materials can be included as part of the composition.

5

10

15

20

25

30

The tablets, pills, capsules, troches, and the like can contain any of the following ingredients or compounds of a similar nature: a binder such as, but not limited to, gum tragacanth, acacia, corn starch, or gelatin; an excipient such as microcrystalline cellulose, starch, or lactose; a disintegrating agent such as, but not limited to, alginic acid and corn starch; a lubricant such as, but not limited to, magnesium stearate; a gildant, such as, but not limited to, colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; and a flavoring agent such as peppermint, methyl salicylate, or fruit flavoring.

When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, dosage unit forms can contain various other materials, which modify the physical form of the dosage unit, for example, coatings of sugar and other enteric The compounds can also be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the A syrup may contain, in addition to the active like. compounds, sucrose as a sweetening agent and preservatives, dyes and colorings, and flavors.

The active materials can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action.

Solutions orsuspensions used for parenternal, intradermal, subcutaneous, or topical application can include 5 any of the following components: a sterile diluent such as water for injection, saline solution, fixed oil, a naturally occurring vegetable oil such as sesame oil, coconut oil, peanut oil, cottonseed oil, and the like, or a synthetic fatty vehicle such as ethyl oleate, and the like, polyethylene glycol, 10 glycerine, propylene glycol, or other synthetic solvent; antimicrobial agents such as benzyl alcohol and methyl parabens; antioxidants such as ascorbic acid and sodium bisulfite; chelating agents such as ethylenediaminetetraacetic 15 acid (EDTA); buffers such as acetates, citrates, phosphates; and agents for the adjustment of tonicity such as sodium chloride and dextrose. Parenternal preparations can be enclosed in ampoules, disposable syringes, or multiple dose vials made of glass, plastic, or other suitable material. Buffers, preservatives, antioxidants, and the like can be 20 incorporated as required.

Where administered intravenously, suitable carriers include physiological saline, phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents such as glucose, polyethylene glycol, polypropyleneglycol, and mixtures thereof. Liposomal suspensions including tissuetargeted liposomes may also be suitable as pharmaceutically acceptable carriers. These may be prepared according to methods known for example, as described in U.S. Patent No. 4,522,811.

25

30

The active compounds may be prepared with carriers that protect the compound against rapid elimination from the body, such as time-release formulations or coatings. Such carriers include controlled release formulations, such as, but not

limited to, implants and microencapsulated delivery systems, and biodegradable, biocompatible polymers such as collagen, ethylene vinyl acetate, polyanhydrides, polyglycolic acid, polyorthoesters, polylactic acid, and the like. Methods for preparation of such formulations are known to those skilled in the art.

The compounds of the invention can be administered orally, parenternally (IV, IM, depo-IM, SQ, and depo-SQ), sublingually, intranasally (inhalation), intrathecally, topically, or rectally. Dosage forms known to those skilled in the art are suitable for delivery of the compounds of the invention.

10

15

20

25

30

Compounds of the invention may be administered enterally or parenterally. When administered orally, compounds of the invention can be administered in usual dosage forms for oral administration as is well known to those skilled in the art. These dosage forms include the usual solid unit dosage forms of tablets and capsules as well as liquid dosage forms such as solutions, suspensions, and elixirs. When the solid dosage forms are used, it is preferred that they be of the sustained release type so that the compounds of the invention need to be administered only once or twice daily.

The oral dosage forms are administered to the patient 1, 2, 3, or 4 times daily. It is preferred that the compounds of the invention be administered either three or fewer times, more preferably once or twice daily. Hence, it is preferred that the compounds of the invention be administered in oral dosage form. It is preferred that whatever oral dosage form is used, that it be designed so as to protect the compounds of the invention from the acidic environment of the stomach. Enteric coated tablets are well known to those skilled in the art. In addition, capsules filled with small spheres each coated to protect from the acidic stomach, are also well known to those skilled in the art.

When administered orally, an administered amount therapeutically effective to inhibit beta-secretase activity, to inhibit A beta production, to inhibit A beta deposition, or to treat or prevent AD is from about 0.1 mg/day to about 1,000 mg/day. It is preferred that the oral dosage is from about 1 mg/day to about 100 mg/day. It is more preferred that the oral dosage is from about 5 mg/day to about 50 mg/day. It is understood that while a patient may be started at one dose, that dose may be varied over time as the patient's condition changes.

Compounds of the invention may also be advantageously delivered in a nano crystal dispersion formulation. Preparation of such formulations is described, for example, in U.S. Patent 5,145,684. Nano crystalline dispersions of HIV protease inhibitors and their method of use are described in US 6,045,829. The nano crystalline formulations typically afford greater bioavailability of drug compounds.

10

15

20

25

The compounds of the invention can be administered parenterally, for example, by IV, IM, depo-IM, SC, or depo-SC. When administered parenterally, a therapeutically effective amount of about 0.5 to about 100 mg/day, preferably from about 5 to about 50 mg daily should be delivered. When a depot formulation is used for injection once a month or once every two weeks, the dose should be about 0.5 mg/day to about 50 mg/day, or a monthly dose of from about 15 mg to about 1,500 mg. In part because of the forgetfulness of the patients with Alzheimer's disease, it is preferred that the parenteral dosage form be a depo formulation.

The compounds of the invention can be administered 30 sublingually. When given sublingually, the compounds of the invention should be given one to four times daily in the amounts described above for IM administration.

The compounds of the invention can be administered intranasally. When given by this route, the appropriate dosage

forms are a nasal spray or dry powder, as is known to those skilled in the art. The dosage of the compounds of the invention for intranasal administration is the amount described above for IM administration.

The compounds of the invention can be administered intrathecally. When given by this route the appropriate dosage form can be a parenternal dosage form as is known to those skilled in the art. The dosage of the compounds of the invention for intrathecal administration is the amount described above for IM administration.

5

10

15

20

25

30

The compounds of the invention can be administered When given by this route, the appropriate dosage topically. form is a cream, ointment, or patch. Because of the amount of the compounds of the invention to be administered, the patch is When administered topically, the dosage is from preferred. about 0.5 mg/day to about 200 mg/day. Because the amount that can be delivered by a patch is limited, two or more patches may be used. The number and size of the patch is not important, what is important is that a therapeutically effective amount of the compounds of the invention be delivered as is known to those skilled in the art. The compounds of the invention can be administered rectally by suppository as is known to those skilled in the art. When administered by suppository, the therapeutically effective amount is from about 0.5 mg to about 500 mg.

The compounds of the invention can be administered by implants as is known to those skilled in the art. When administering a compound of the invention by implant, the therapeutically effective amount is the amount described above for depot administration.

The invention here is the new compounds of the invention and new methods of using the compounds of the invention. Given a particular compound of the invention and a desired dosage

form, one skilled in the art would know how to prepare and administer the appropriate dosage form.

The compounds of the invention are used in the same manner, by the same routes of administration, using the same pharmaceutical dosage forms, and at the same dosing schedule as described above, for preventing disease or treating patients with MCI (mild cognitive impairment) and preventing or delaying the onset of Alzheimer's disease in those who would progress from MCI to AD, for treating or preventing Down's syndrome, for treating humans who have Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type, for treating cerebral amyloid angiopathy and preventing its potential consequences, i.e. single and recurrent lobar hemorrhages, for treating other degenerative dementias, including dementias of mixed vascular and degenerative origin, dementia associated with Parkinson's dementia associated with progressive supranuclear palsy, dementia associated with cortical basal degeneration, Frontotemporal dementias with parkinsonism (FTDP) and diffuse Lewy body type of Alzheimer's disease.

10

15

20 The compounds of the invention can be used in combination, with each other or with other therapeutic agents or approaches used to treat or prevent the conditions listed above. Such agents orapproaches include: acetylcholine esterase inhibitors such as tacrine (tetrahydroaminoacridine, marketed as COGNEX®), donepezil hydrochloride, (marketed as Aricept® and 25 rivastigmine (marketed as Exelon®); gamma-secretase inhibitors; anti-inflammatory agents such as cyclooxygenase II inhibitors; anti-oxidants such as Vitamin E and ginkolides; immunological approaches, such as, for example, immunization with A beta peptide or administration of anti-A beta peptide 30 antibodies; statins; and direct or indirect neurotropic agents such as Cerebrolysin®, AIT-082 (Emilieu, 2000, Arch. Neurol. 57:454), and other neurotropic agents of the future.

It should be apparent to one skilled in the art that the exact dosage and frequency of administration will depend on the particular compounds of the invention administered, the particular condition being treated, the severity of the condition being treated, the age, weight, general physical condition of the particular patient, and other medication the individual may be taking as is well known to administering physicians who are skilled in this art.

### 10 Inhibition of APP Cleavage

15

20

25

30

The compounds of the invention inhibit cleavage of APP between Met595 and Asp596 numbered for the APP695 isoform, or a mutant thereof, or at a corresponding site of a different isoform, such as APP751 or APP770, or a mutant thereof "beta secretase (sometimes referred to as the site"). Inhibitory activity is demonstrated in one of a variety of inhibition assays, whereby cleavage of an APP substrate in the presence of a beta-secretase enzyme is analyzed in the presence compound, of the inhibitory under conditions sufficient to result in cleavage at the beta-secretase cleavage site. Reduction of APP cleavage at the beta-secretase cleavage site compared with an untreated or inactive control correlated with inhibitory activity. Assay systems that can be used to demonstrate efficacy of the compound inhibitors of the invention are known. Reative assay systems are described, for example, in U.S. Patents No. 5,942,400, 5,744,346, as well as in the Examples below.

The enzymatic activity of beta-secretase and the production of A beta can be analyzed in vitro or in vivo, using natural, mutated, and/or synthetic APP substrates, natural, mutated, and/or synthetic enzyme, and the test compound. The analysis may involve primary or secondary cells expressing native, mutant, and/or synthetic APP and enzyme, animal models expressing native APP and enzyme, or may utilize transgenic

animal models expressing the substrate and enzyme. Detection of enzymatic activity can be by analysis of one or more of the cleavage products, for example, by immunoassay, flurometric or chromogenic assay, HPLC, or other means of detection. Inhibitory compounds are determined as those having the ability to decrease the amount of beta-secretase cleavage product produced in comparison to a control, where beta-secretase mediated cleavage in the reaction system is observed and measured in the absence of inhibitory compounds.

10

# Beta-secretase

Various forms of beta-secretase enzyme are known, and are available and useful for assay of enzyme activity and inhibition of enzyme activity. These include native, recombinant, and synthetic forms of the enzyme. Human beta-15 secretase is known as Beta Site APP Cleaving Enzyme (BACE), Asp2, and memapsin 2, and has been characterized, for example, Patent No. 5,744,346 and published PCT patent in U.S. applications WO98/22597, WO00/03819, WO01/23533, WO00/17369, as well as in literature publications 20 et.al., 1999, Mol.Cell.Neurosci. 14:419-427; Vassar et.al., 1999, Science 286:735-741; Yan et.al., 1999, Nature 402:533-537; Sinha et.al., 1999, Nature 40:537-540; and Lin et.al., 2000, PNAS USA 97:1456-1460). Synthetic forms of the enzyme 25 have also been described (WO98/22597 and WO00/17369). Betasecretase can be extracted and purified from human brain tissue and can be produced in cells, for example mammalian cells expressing recombinant enzyme.

Useful inhibitory compounds are effective to inhibit 50% of beta-secretase enzymatic activity at a concentration of less than 50 micromolar, preferably at a concentration of 10 micromolar or less, more preferably 1 micromolar or less, and most preferably 10 nanomolar or less.

#### APP substrate

5

10

15

20

25

30

Assays that demonstrate inhibition of beta-secretase-mediated cleavage of APP can utilize any of the known forms of APP, including the 695 amino acid "normal" isotype described by Kang et.al., 1987, Nature 325:733-6, the 770 amino acid isotype described by Kitaguchi et. al., 1981, Nature 331:530-532, and variants such as the Swedish Mutation (KM670-1NL) (APP-SW), the London Mutation (V7176F), and others. See, for example, U.S. Patent No. 5,766,846 and also Hardy, 1992, Nature Genet. 1:233-234, for a review of known variant mutations. Additional useful substrates include the dibasic amino acid modification, APP-KK disclosed, for example, in WO 00/17369, fragments of APP, and synthetic peptides containing the beta-secretase cleavage site, wild type (WT) or mutated form, e.g., SW, as described, for example, in U.S. Patent No 5,942,400 and WO00/03819.

The APP substrate contains the beta-secretase cleavage site of APP (KM-DA or NL-DA) for example, a complete APP peptide or variant, an APP fragment, a recombinant or synthetic APP, or a fusion peptide. Preferably, the fusion peptide includes the beta-secretase cleavage site fused to a peptide having a moiety useful for enzymatic assay, for example, having isolation and/or detection properties. A useful moiety may be an antigenic epitope for antibody binding, a label or other detection moiety, a binding substrate, and the like.

# Antibodies

Products characteristic of APP cleavage can be measured by immunoassay using various antibodies, as described, for example, in Pirttila et.al., 1999, Neuro.Lett. 249:21-4, and in U.S. Patent No. 5,612,486. Useful antibodies to detect A beta include, for example, the monoclonal antibody 6E10 (Senetek, St. Louis, MO) that specifically recognizes an epitope on amino acids 1-16 of the A beta peptide; antibodies 162 and 164 (New

York State Institute for Basic Research, Staten Island, NY) that are specific for human A beta 1-40 and 1-42, respectively; and antibodies that recognize the junction region of beta-amyloid peptide, the site between residues 16 and 17, as described in U.S. Patent No. 5,593,846. Antibodies raised against a synthetic peptide of residues 591 to 596 of APP and SW192 antibody raised against 590-596 of the Swedish mutation are also useful in immunoassay of APP and its cleavage products, as described in U.S. Patent Nos. 5,604,102 and 5,721,130.

### Assay Systems

5

10

15

30

Assays for determining APP cleavage at the beta-secretase cleavage site are well known in the art. Exemplary assays, are described, for example, in U.S. Patent Nos. 5,744,346 and 5,942,400, and described in the Examples below.

### Cell free assays

Exemplary assays that can be used to demonstrate the inhibitory activity of the compounds of the invention are described, for example, in WOOO/17369, WO OO/03819, and U.S. Patents No. 5,942,400 and 5,744,346. Such assays can be performed in cell-free incubations or in cellular incubations using cells expressing a beta-secretase and an APP substrate having a beta-secretase cleavage site.

An APP substrate containing the beat-secretase cleavage site of APP, for example, a complete APP or variant, an APP fragment, a recombinant or synthetic APP substrate orcontaining the amino acid sequence: KM-DA or NL-DA, incubated in the presence of beta-secretase enzyme, a fragment thereof, or a synthetic or recombinant polypeptide variant having beta-secretase activity and effective to cleave the beta-secretase cleavage site of APP, under incubation conditions suitable for the cleavage activity of the enzyme.

Suitable substrates optionally include derivatives that may be fusion proteins or peptides that contain the substrate peptide and a modification useful to facilitate the purification or detection of the peptide or its beta-secretase cleavage products. Useful modifications include the insertion of a known antigenic epitope for antibody binding; the linking of a label or detectable moiety, the linking of a binding substrate, and the like.

10

15

20

25

30

Suitable incubation conditions for a cell-free in vitro assay include, for example: approximately 200 nanomolar to 10 micromolar substrate, approximately 10 to 200 picomolar enzyme, and approximately 0.1 nanomolar to 10 micromolar inhibitor compound, in aqueous solution, at an approximate pH of 4 -7, approximately 37 degrees C, for a time period approximately 10 minutes to 3 hours. These incubation conditions are exemplary only, and can be varied as required for the particular assay components and/or desired measurement Optimization of the incubation conditions for the particular assay components should account for the specific beta-secretase enzyme used and its pH optimum, any additional enzymes and/or markers that might be used in the assay, and the like. Such optimization is routine and will not require undue experimentation.

One useful assay utilizes a fusion peptide having maltose binding protein (MBP) fused to the C-terminal 125 amino acids of APP-SW. The MBP portion is captured on an assay substrate by anti-MBP capture antibody. Incubation of the captured fusion protein in the presence of beta-secretase results in cleavage of the substrate at the beta-secretase cleavage site. Analysis of the cleavage activity can be, for example, by immunoassay of cleavage products. One such immunoassay detects a unique epitope exposed at the carboxy terminus of the cleaved fusion protein, for example, using the antibody SW192. This assay is described, for example, in U.S. Patent No 5,942,400.

### Cellular assay

10

15

20

25

Numerous cell-based assays can be used to analyze beta-secretase activity and/or processing of APP to release A beta. Contact of an APP substrate with a beta-secretase enzyme within the cell and in the presence or absence of a compound inhibitor of the invention can be used to demonstrate beta-secretase inhibitory activity of the compound. Preferably, assay in the presence of a useful inhibitory compound provides at least about 30%, most preferably at least about 50% inhibition of the enzymatic activity, as compared with a non-inhibited control.

In one embodiment, cells that naturally express betasecretase are used. Alternatively, cells are modified to
express a recombinant beta-secretase or synthetic variant
enzyme as discussed above. The APP substrate may be added to
the culture medium and is preferably expressed in the cells.
Cells that naturally express APP, variant or mutant forms of
APP, or cells transformed to express an isoform of APP, mutant
or variant APP, recombinant or synthetic APP, APP fragment, or
synthetic APP peptide or fusion protein containing the betasecretase APP cleavage site can be used, provided that the
expressed APP is permitted to contact the enzyme and enzymatic
cleavage activity can be analyzed.

Human cell lines that normally process A beta from APP provide a useful means to assay inhibitory activities of the compounds of the invention. Production and release of A beta and/or other cleavage products into the culture medium can be measured, for example by immunoassay, such as Western blot or enzyme-linked immunoassay (EIA) such as by ELISA.

30 Cells expressing an APP substrate and an active betasecretase can be incubated in the presence of a compound inhibitor to demonstrate inhibition of enzymatic activity as compared with a control. Activity of beta-secretase can be measured by analysis of one or more cleavage products of the

APP substrate. For example, inhibition of beta-secretase activity against the substrate APP would be expected to decrease release of specific beta-secretase induced APP cleavage products such as A beta.

Although both neural and non-neural cells process and release A beta, levels of endogenous beta-secretase activity are low and often difficult to detect by EIA. The use of cell types known to have enhanced beta-secretase activity, enhanced processing of APP to A beta, and/or enhanced production of A beta are therefore preferred. For example, transfection of cells with the Swedish Mutant form of APP (APP-SW); with APP-KK; or with APP-SW-KK provides cells having enhanced beta-secretase activity and producing amounts of A beta that can be readily measured.

In such assays, for example, the cells expressing APP and beta-secretase are incubated in a culture medium under conditions suitable for beta-secretase enzymatic activity at its cleavage site on the APP substrate. On exposure of the cells to the compound inhibitor, the amount of A beta released into the medium and/or the amount of CTF99 fragments of APP in the cell lysates is reduced as compared with the control. The cleavage products of APP can be analyzed, for example, by immune reactions with specific antibodies, as discussed above.

Preferred cells for analysis of beta-secretase activity include primary human neuronal cells, primary transgenic animal neuronal cells where the transgene is APP, and other cells such as those of a stable 293 cell line expressing APP, for example, APP-SW.

## 30 In vivo assays: animal models

5

10

25

Various animal models can be used to analyze betasecretase activity and /or processing of APP to release A beta, as described above. For example, transgenic animals expressing APP substrate and beta-secretase enzyme can be used

to demonstrate inhibitory activity of the compounds of the invention. Certain transgenic animal models have been described, for example, in U.S. Patent Nos: 5,877,399; 5,612,486; 5,387,742; 5,720,936; 5,850,003; 5,877,015,, and and in Ganes et.al., 1995, Nature 373:523. 5,811,633, Preferred are animals that exhibit characteristics associated with the pathophysiology of AD. Administration of the compound inhibitors of the invention to the transgenic mice described herein provides an alternative method for demonstrating the inhibitory activity of the compounds. Administration of the compounds in a pharmaceutically effective carrier and via an administrative route that reaches the target tissue in an appropriate therapeutic amount is also preferred.

5

10

15

20

25

30

Inhibition of beta-secretase mediated cleavage of APP at the beta-secretase cleavage site and of A beta release can be analyzed in these animals by measure of cleavage fragments in the animal's body fluids such as cerebral fluid or tissues. Analysis of brain tissues for A beta deposits or plaques is preferred.

On contacting an APP substrate with a beta-secretase enzyme in the presence of an inhibitory compound of the invention and under conditions sufficient to permit enzymatic mediated cleavage of APP and/or release of A beta from the substrate, the compounds of the invention are effective to reduce beta-secretase-mediated cleavage of APP at the beta-secretase cleavage site and/or effective to reduce released amounts of A beta. Where such contacting is the administration of the inhibitory compounds of the invention to an animal model, for example, as described above, the compounds are effective to reduce A beta deposition in brain tissues of the animal, and to reduce the number and/or size of beta amyloid plaques. Where such administration is to a human subject, the compounds are effective to inhibit or slow the progression of disease characterized by enhanced amounts of A beta, to slow

the progression of AD in the, and/or to prevent onset or development of AD in a patient at risk for the disease.

Unless defined otherwise, all scientific and technical terms used herein have the same meaning as commonly understood by one of skill in the art to which this invention belongs. All patents and publications referred to herein are hereby incorporated by reference for all purposes.

### **DEFINITIONS**

30

By "alkyl" and "C<sub>1</sub>-C<sub>6</sub> alkyl" in the invention is meant straight or branched chain alkyl groups having 1-6 carbon atoms, such as, methyl, ethyl, propyl, isopropyl, n-butyl, secbutyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. It is understood that in cases where an alkyl chain of a substituent (e.g. of an alkyl, alkoxy or alkenyl group) is shorter or longer than 6 carbons, it will be so indicated in the second "C" as, for example, "C<sub>1</sub>-C<sub>10</sub>" indicates a maximum of 10 carbons.

By "alkoxy" and "C<sub>1</sub>-C<sub>6</sub> alkoxy" in the invention is meant 20 straight or branched chain alkyl groups having 1-6 carbon atoms, attached through at least one divalent oxygen atom, such as, for example, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, pentoxy, isopentoxy, neopentoxy, hexoxy, and 3-methylpentoxy.

By the term "halogen" in the invention is meant fluorine, bromine, chlorine, and iodine.

"Alkenyl" and " $C_2$ - $C_6$  alkenyl" means straight and branched hydrocarbon radicals having from 2 to 6 carbon atoms and from one to three double bonds and includes, for example, ethenyl, propenyl, 1-but-3-enyl, 1-pent-3-enyl, 1-hex-5-enyl and the like.

"Alkynyl" and " $C_2$ - $C_6$  alkynyl" means straight and branched hydrocarbon radicals having from 2 to 6 carbon atoms and one or

two triple bonds and includes ethynyl, propynyl, butynyl, pentyn-2-yl and the like.

As used herein, the term "cycloalkyl" refers to saturated carbocyclic radicals having three to twelve carbon atoms. cycloalkyl can be monocyclic, or a polycyclic fused system. Examples of such radicals include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. The cycloalkyl groups herein are unsubstituted or, as specified, substituted in one or more substitutable positions with various groups. example, such cycloalkyl groups may be optionally substituted with  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy, halogen, hydroxy, cyano, nitro, amino, mono  $(C_1-C_6)$  alkylamino, di  $(C_1-C_6)$  alkylamino,  $C_2-C_6$  alkenyl,  $C_2-C_6$ alkynyl,  $C_1-C_6$  haloalkyl,  $C_1-C_6$  haloalkoxy, amino(C<sub>1</sub>- $C_6$ ) alkyl,  $mono(C_1-C_6)$  alkylamino  $(C_1-C_6)$  alkyl  $di(C_1 C_6$ ) alkylamino ( $C_1$ - $C_6$ ) alkyl.

10

15

20

25

30

By "aryl" is meant an aromatic carbocyclic group having a single ring (e.g., phenyl), multiple rings (e.g., biphenyl), or multiple condensed rings in which at least one is aromatic, 1,2,3,4-tetrahydronaphthyl, (e.g., naphthyl), which optionally mono-, di-, or trisubstituted. Preferred aryl groups of the invention are phenyl, 1-naphthyl, 2-naphthyl, indanyl, indenyl, dihydronaphthyl, tetralinyl or 6,7,8,9tetrahydro-5H-benzo[a]cycloheptenyl. The aryl groups herein are unsubstituted or, as specified, substituted in one or more substitutable positions with various groups. For example, such aryl groups may be optionally substituted with, for example,  $C_1-C_6$  alkyl,  $C_1-C_6$  alkoxy, halogen, hydroxy, cyano, nitro, amino, mono( $C_1-C_6$ ) alkylamino, di( $C_1-C_6$ ) alkylamino,  $C_2-C_6$  alkenyl,  $C_2-C_6$ alkynyl,  $C_1-C_6$  haloalkyl,  $C_1-C_6$  haloalkoxy, amino ( $C_1$ - $C_6$ ) alkyl, mono  $(C_1-C_6)$  alkylamino  $(C_1-C_6)$  alkyl, di (C1- $C_6$ ) alkylamino ( $C_1$ - $C_6$ ) alkyl, -COOH,  $-C (=0) O (C_1 - C_6)$ alkyl),  $-C(=0)NH_2$ ,  $-C(=0)N(mono-or di-C_1-C_6 alkyl)$ ,  $-S(C_1-C_6 alkyl)$ ,  $-SO_2(C_1-C_6 \quad alkyl)$ ,  $-O-C(=0)(C_1-C_6 \text{ alkyl}), -NH-C(=0)-(C_1-C_6)$ alkyl),  $-N(C_1-C_6 \text{ alkyl})-C(=0)-(C_1-C_6 \text{ alkyl})$ ,  $-NH-SO_2-(C_1-C_6)$ 

alkyl),  $-N(C_1-C_6 \text{ alkyl})-SO_2-(C_1-C_6 \text{ alkyl})$ ,  $-NH-C(=O)NH_2$ ,  $-NH-C(=O)N(mono- \text{ or } di-C_1-C_6 \text{ alkyl})$ ,  $-NH(C_1-C_6 \text{ alkyl})-C(=O)-NH_2 \text{ or } -NH(C_1-C_6 \text{ alkyl})-C(=O)-N-(mono- \text{ or } di-C_1-C_6 \text{ alkyl})$ .

By "heteroaryl" is meant one or more aromatic ring systems of 5-, 6-, or 7-membered rings which includes fused ring 5 systems of 9-11 atoms containing at least one and up to four selected from nitrogen, oxygen, or sulfur. heteroatoms Preferred heteroaryl groups of the invention include pyridinyl, pyrimidinyl, quinolinyl, benzothienyl, indolyl, indolinyl, pryidazinyl, pyrazinyl, isoindolyl, isoquinolyl, quinazolinyl, 10 quinoxalinyl, phthalazinyl, imidazolyl, isoxazolyl, pyrazolyl, oxazolyl, thiazolyl, indolizinyl, indazolyl, benzothiazolyl, benzimidazolyl, benzofuranyl, furanyl, thienyl, pyrrolyl, tetrazolyl, triazoly1, thiadiazolyl, oxadiazolyl, imidazopyridinyl, isothiazolyl, oxazolopyridinyl, 15 naphthyridinyl, cinnolinyl, carbazolyl, beta-carbolinyl, isochromanyl, chromanyl, tetrahydroisoquinolinyl, isoindolinyl, isobenzotetrahydrothienyl, isobenzotetrahydrofuranyl, pyridopyridinyl, benzoxazolyl, isobenzothienyl, benzotetrahydrofuranyl, benzotetrahydrothienyl, purinyl, 20 benzodioxolyl, triazinyl, phenoxazinyl, phenothiazinyl, pteridinyl, benzothiazolyl, imidazopyridinyl, imidazothiazolyl, benzisoxazinyl, benzoxazinyl, dihydrobenzisoxazinyl, dihydrobenzisothiazinyl, benzopyranyl, benzothiopyranyl, coumarinyl, isocoumarinyl, chromonyl, chromanonyl, pyridinyl-N-25 dihydroquinolinyl, tetrahydroquinolinyl, dihydroquinolinonyl, dihydroisoquinolinonyl, dihydrocoumarinyl, isoindolinonyl, dihydroisocoumarinyl, benzodioxanyl, benzoxazolinonyl, pyrrolyl N-oxide,, pyrimidinyl N-oxide, pyridazinyl N-oxide, pyrazinyl N-oxide, quinolinyl N-oxide, indolyl N-oxide, indolinyl N-oxide, isoquinolyl quinazolinyl N-oxide, quinoxalinyl N-oxide, phthalazinyl Noxide, imidazolyl N-oxide, isoxazolyl N-oxide, oxazolyl Noxide, thiazolyl N-oxide, indolizinyl N-oxide, indazolyl N-

oxide, benzothiazolyl N-oxide, benzimidazolyl N-oxide, pyrrolyl N-oxide, oxadiazolyl N-oxide, thiadiazolyl N-oxide, triazolyl N-oxide, tetrazolyl N-oxide, benzothiopyranyl S-oxide, benzothiopyranyl S,S-dioxide. The heteroaryl groups herein are unsubstituted or, as specified, substituted in one or more substitutable positions with various groups. For example, such heteroaryl groups may be optionally substituted with  $C_1\text{-}C_6$ alkyl, C1-C6 alkoxy, halogen, hydroxy, cyano, nitro, amino,  $mono(C_1-C_6)$  alkylamino, di  $(C_1-C_6)$  alkylamino,  $C_2-C_6$  alkenyl,  $C_2-C_6$  $C_6$ alkynyl,  $C_1$ - $C_6$  haloalkyl,  $C_1$ - $C_6$  haloalkoxy, amino  $(C_1$ - $C_6)$ alkyl,  $mono(C_1-C_6)$  alkylamino  $(C_1-C_6)$  alkylamino  $(C_1-C_6)$  alkylamino  $(C_1-C_6)$  alkylamino  $(C_1-C_6)$ or  $di-C_1-C_6$  alkyl),  $-S(C_1-C_6$  alkyl),  $-SO_2(C_1-C_6$  alkyl), -O- $\texttt{C(=O)(C_1-C_6\ alkyl),\ -NH-C(=O)-(C_1-C_6\ alkyl),\ -N(C_1-C_6\ alkyl)- }$  $C(=0)-(C_1-C_6 \text{ alkyl}), -NH-SO_2-(C_1-C_6 \text{ alkyl}), -N(C_1-C_6 \text{ alkyl})-SO_2 (C_1-C_6 \quad alkyl)$ ,  $-NH-C(=0)NH_2$ ,  $-NH-C(=0)N(mono-or di-C_1-C_6)$ alkyl),  $-NH(C_1-C_6 \text{ alkyl})-C(=0)-NH_2 \text{ or } -NH(C_1-C_6 \text{ alkyl})-C(=0)-N-$ (mono- or  $di-C_1-C_6$  alkyl).

5

10

15

By "heterocycle", "heterocycloalkyl" or "heterocyclyl" is 20 meant one or more carbocyclic ring systems of 4-, 5-, 6-, or 7membered rings which includes fused ring systems of 9-11 atoms containing at least one and up to four heteroatoms selected from nitrogen, oxygen, or sulfur. Preferred heterocycles of the invention include morpholinyl, thiomorpholinyl, 25 thiomorpholinyl S-oxide, thiomorpholinyl S,S-dioxide, piperazinyl, homopiperazinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl, piperidinyl, tetrahydrofuranyl, tetrahydrothienyl, homopiperidinyl, homomorpholinyl, homothiomorpholinyl, homothiomorpholinyl S, S-dioxide, 30 oxazolidinonyl, dihydropyrazolyl, dihydropyrrolyl, dihydropyrazinyl, dihydropyridinyl, dihydropyrimidinyl, dihydrofuryl, dihydropyranyl, tetrahydrothienyl S-oxide, tetrahydrothienyl S,S-dioxide and homothiomorpholinyl S-oxide. Heterocycles may be fused to aryl rings. Examples include

tetrahydroisoquinoline and indoline. The heterocycle groups herein are unsubstituted or, as specified, substituted in one or more substitutable positions with various groups. For example, such heterocycle groups may be optionally substituted with  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy, halogen, hydroxy, cyano, nitro, amino, mono( $C_1$ - $C_6$ ) alkylamino, di( $C_1$ - $C_6$ ) alkylamino,  $C_2$ - $C_6$ alkenyl,  $C_2$ - $C_6$ alkynyl,  $C_1$ - $C_6$  haloalkyl,  $C_1$ - $C_6$  haloalkoxy, amino( $C_1$ - $C_6$ ) alkyl, mono( $C_1$ - $C_6$ ) alkylamino( $C_1$ - $C_6$ )

10

All temperatures are in degrees Celsius.

TLC refers to thin-layer chromatography.

psi refers to pounds/in2.

HPLC refers to high pressure liquid chromatography.

15 THF refers to tetrahydrofuran.

DMF refers to dimethylformamide.

EDC refers to ethyl-1-(3-dimethylaminopropyl)carbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride.

HOBt refers to 1-hydroxy benzotriazole hydrate.

20 NMM refers to N-methylmorpholine.

NBS refers to N-bromosuccinimide.

TEA refers to triethylamine.

BOC refers to 1,1-dimethylethoxy carbonyl or t-butoxycarbonyl, -CO-O-C(CH<sub>3</sub>)<sub>3</sub>.

25 CBZ refers to benzyloxycarbonyl, -CO-O-CH2-phenyl.

FMOC refers to 9-fluorenylmethyl carbonate.

TFA refers to trifluoracetic acid.

CDI refers to 1,1'-carbonyldiimidazole.

Saline refers to an aqueous saturated sodium chloride 30 solution.

Chromatography (column and flash chromatography) refers to purification/separation of compounds expressed as (support, eluent). It is understood that the appropriate fractions are pooled and concentrated to give the desired compound(s).

CMR refers to C-13 magnetic resonance spectroscopy, chemical shifts are reported in ppm ( $\delta$ ) downfield from TMS.

NMR refers to nuclear (proton) magnetic resonance spectroscopy, chemical shifts are reported in ppm  $(\delta)$  downfield from TMS.

IR refers to infrared spectroscopy.

5

10

15

MS refers to mass spectrometry expressed as m/e, m/z or mass/charge unit. MH<sup>+</sup> refers to the positive ion of a parent plus a hydrogen atom. EI refers to electron impact. CI refers to chemical ionization. FAB refers to fast atom bombardment.

HRMS refers to high resolution mass spectrometry.

Ether refers to diethyl ether.

Pharmaceutically acceptable refers to those properties and/or substances which are acceptable to the patient from a pharmacological/toxicological point of view and to the manufacturing pharmaceutical chemist from a physical/chemical point of view regarding composition, formulation, stability, patient acceptance and bioavailability.

When solvent pairs are used, the ratios of solvents used 20 are volume/volume (v/v).

When the solubility of a solid in a solvent is used the ratio of the solid to the solvent is weight/volume (wt/v).

BOP refers to benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate.

TBDMSCl refers to t-butyldimethylsilyl chloride.

TBDMSOTf refers to t-butyldimethylsilyl trifluosulfonic acid ester.

Trisomy 21 refers to Down's Syndrome.

The following terms are used (in EXAMPLEs 321 and above) 30 for the amide forming agent (IX):

"PHTH" refers to  $(CH_3-CH_2-CH_2-)_2N-CO$ -phenyl-CO-OH where the attachment to the - phenyl- ring is 1,3-;

"5-Me-PHTH" refers to  $(CH_3-CH_2-CH_2-)_2N-CO-(CH_3-)$  phenyl - CO-OH where the attachment to the - phenyl - ring is 1,3- for the carbonyl groups and 5- for the methyl group;

"3,5-pyridinyl" refers to (CH<sub>3</sub>-CH<sub>2</sub>-CH<sub>2</sub>-)<sub>2</sub>N-CO-(pyridinyl)5 CO-OH where the attachment to the -pyridinyl- ring is 3,5- for the carbonyl groups;

"- $SO_2$ -" refers to  $(CH_3-CH_2-CH_2-)_2CH-SO_2$ - phenyl -CO-OH where the attachment to the - phenyl - ring is 1,3-;

"5-OMe-PHTH" refers to (CH<sub>3</sub>-CH<sub>2</sub>-CH<sub>2</sub>-)<sub>2</sub>N-CO-(CH<sub>3</sub>-O-) phenyl 10 -CO-OH where the attachment to the - phenyl - ring is 1,3- for the carbonyl groups and 5- for the methoxy group;

"5-Cl-PHTH" refers to  $(CH_3-CH_2-CH_2-)_2N-CO-(Cl-)$  phenyl-CO-OH where the attachment to the -phenyl- ring is 1,3- for the carbonyl groups and 5- for the chlorine atom;

"5-F-PHTH" refers to  $(CH_3-CH_2-CH_2-)_2N-CO-(F-)$ phenyl-CO-OH where the attachment to the -phenyl- ring is 1,3- for the carbonyl groups and 5- for the fluorine atom;

"thienyl" refers to  $(CH_3-CH_2-CH_2-)_2N-CO-thienyl-CO-OH$  where the attachment to the thiophene ring is -2,5;

"2,4-pyridinyl" refers to (CH<sub>3</sub>-CH<sub>2</sub>-CH<sub>2</sub>-)<sub>2</sub>N-CO-(pyridinyl)-CO-OH where the attachment to the -pyridinyl- ring is 2,4- for the carbonyl groups;

"4,6-pyrimidinyl" refers to  $(CH_3-CH_2-CH_2-)_2N-CO-$  (pyrimidinyl-)phenyl-CO-OH where the attachment to the -pyrimidiny-l ring is 4,6- for the carbonyl groups;

25

"morpholinyl" refers to morpholinyl-CO-phenyl-CO-OH where the attachment to the -phenyl- ring is 1,3 for the carbonyl groups.

APP, amyloid precursor protein, is defined as any APP 30 polypeptide, including APP variants, mutations, and isoforms, for example, as disclosed in U.S. Patent No. 5,766,846.

A beta, amyloid beta peptide, is defined as any peptide resulting from beta-secretase mediated cleavage of APP, including peptides of 39, 40, 41, 42, and 43 amino acids, and

extending from the beta-secretase cleavage site to amino acids 39, 40, 41, 42, or 43.

Beta-secretase (BACE1, Asp2, Memapsin 2) is an aspartyl protease that mediates cleavage of APP at the amino-terminal edge of A beta. Human beta-secretase is described, for example, in WO00/17369.

"Pharmaceutically acceptable" refers to those properties and/or substances that are acceptable to the patient from a pharmacological/toxicological point of view and to the manufacturing pharmaceutical chemist from a physical/chemical point of view regarding composition, formulation, stability, patient acceptance and bioavailability.

A therapeutically effective amount is defined as an amount effective to reduce or lessen at least one symptom of the disease being treated or to reduce or delay onset of one or more clinical markers or symptoms of the disease.

The invention provides compounds, compositions, and methods for inhibiting beta-secretase enzyme activity and A beta peptide production. Inhibition of beta-secretase enzyme activity halts or reduces the production of A beta from APP and reduces or eliminates the formation of beta-amyloid deposits in the brain.

#### EXAMPLES

5

10

15

20

The following examples describe how to prepare the various compounds and/or perform the various processes of the invention and are to be construed as merely illustrative, and not limitations of the preceding disclosure. Those skilled in the art will promptly recognize appropriate variations from the procedures both as to reactants and as to reaction conditions and techniques.

PREPARATION 1 3-Amino-5-(methoxycarbonyl)benzoic acid (XVII)

A suspension of *mono*-methyl 5-nitro-isophthalate (22.5 g, 100 mmol) and palladium on carbon (5%, 2.00 g) in methanol (100 mL) is shaken in a hydrogenation apparatus under hydrogen (50 psi) for 3 hours. The mixture is then filtered through diatomaceous earth and concentrated to give the title compound, NMR (300 MHz, CDCl<sub>3</sub>) delta 7.67, 7.41, 7.40 and 3.83; MS (ESI-) for  $C_9H_9NO_4$  m/z (M-H)<sup>-</sup> = 194.

## PREPARATION 2 3-Bromo-5-(methoxycarbonyl)benzoic acid (XIX)

A mixture of copper (II) bromide (1.85 g, 8.30 mmol), nbutyl nitrite (1.07 g, 10.4 mmol), and acetonitrile (30 mL) is stirred in a round bottomed flask in a water bath to which a few chunks of ice has been added. 3-Amino-5-(methoxycarbonyl)benzoic acid (XVII, PREPARATION 1, 1.35 g, 6.92 mmol) is added as a slurry in warm acetonitrile (70 mL) over 15 min and the mixture is stirred at 20-25 degrees C for an additional 2 hour, at which time the mixture is partitioned between dichloromethane and hydrochloric acid (3N). organic phase is separated and dried over sodium sulfate and concentrated to dryness. Chromatography (silica gel, 125 mL; methanol/dichloromethane, 15/85) and concentration of the appropriate fractions gives a solid which is crytallized from methanol to give the title compound in two crops, NMR (DMSO- $d_6$ ) delta 3.90, 8.26 and 8.65.

25

30

10

15

20

## PREPARATION 3 Methyl

3-bromo-5-

[(dipropylamino)carbonyl]benzoate (XXI)

Carbonyl diimidazole (3.0 g, 18 mmol) is added to a solution of 3-bromo-5-(methoxycarbonyl)benzoic acid (XIX, PREPARATION 2, 3.9 g, 15 mmol) in THF (30 mL). The mixture is stirred for 0.5 hours. Dipropylamine (AMINE, 4.2 mL, 30 mmol) is added to the mixture, which is then stirred for 24 hours. The solvent is then removed under reduced pressure and the mixture is partitioned between ethyl acetate and water. The

organic phase is then washed with saline, dried over anhydrous magnesium sulfate, filtered, and concentrated. Column chromatography (silica gel; ethyl acetate/hexanes, 15/85) gives the title compound, IR (diffuse reflectance) 2968, 2958, 1714, 1637, 1479, 1440, 1422, 1321, 1310, 1288, 1273, 1252, 889, 772 and 718 cm<sup>-1</sup>; NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.21, 7.96, 7.70, 3.95, 3.46, 3.15, 1.69, 1.57, 1.00 and 0.78; MS (ESI+) for  $C_{15}H_{20}BrNO_3$  m/z (M+H)<sup>+</sup> = 344.1.

PREPARATION 4 3-Bromo-5-[(dipropylamino)carbonyl]benzoic acid 10 Toa solution of methyl 3-bromo-5-[(dipropylamino)carbonyl]benzoate (XXI, PREPARATION 3, 1.4 g, 4.1 mmol) in THF/water/methanol (4/2/2, 8 mL) is added to lithium hydroxide monohydrate (0.17 g, 4.05 mmol). The mixture is stirred at 20 degrees -25 degrees C for 1 hour and then 15 solvent is removed under reduced pressure. The residue is dissolved in water (50 mL) and hydrochloric acid (1 N) is added to adjust the pH to about 3. The aqueous mixture is extracted with ethyl acetate and the organic phase is separated and dried over magnesium sulfate to give the title compound. Analytical 20 calculated for  $C_{14}H_{18}BrNO_3$ : C, 51.23; H, 5.53; N, 4.27; Br, 24.35. Found: C, 51.37; H, 5.56; N, 4.28.

PREPARATION 5 Methyl 3-(aminocarbonyl)-5[(dipropylamino)carbonyl]- benzoate (XXII)

25

30

To а mixture of methyl 3-bromo-5-[(dipropylamino)carbonyl]benzoate (XXI, PREPARATION 3, 0.5 g, 1.47 mmol) in dry N-methyl pyrrolidinone under a carbon monoxide atmosphere is added palladium (II) acetate (0.017 g, 0.074 mmol), 1,3-bis(diphenylphosphino)propane (0.045 g, 0.11 mmol), hexamethyldisilazane (1.0 mL, 4.7 mmol), diisopropylethylamine (0.38 g, 2.94 mmol). The mixture is heated at 100 degrees C for 24 hours. The mixture is cooled to 20-25 degrees C and partitioned between water and ethyl

acetate. The layers are separated and the aqueous phase is back-washed with ethyl acetate. The organic phases are combined and washed three times with saline, dried over anhydrous magnesium sulfate, filtered and concentrated. Column chromatography (silica gel, 75 mL; methanol/methylene chloride, 2.5/97.5) gives the title compound, NMR (CDCl<sub>3</sub>) delta 0.77, 1.02, 1.57, 1.71, 3.17, 3.49, 3.98, 5.78, 6.34, 8.07, 8.20 and 8.48.

5

10 PREPARATION 6 3-(Aminocarbonyl)-5[(dipropylamino)carbonyl]benzoic acid (XXIII)

Toа mixture of methyl 3-(aminocarbonyl)-5-[(dipropylamino)carbonyl]benzoate (XXII, PREPARATION 5, 0.197 g, 0.64 mmol) in methanol (5.0 mL) is added sodium hydroxide 15 (1N, 3.0 mL). The mixture is stirred at 20-25 degrees C for 24  $\,$ The mixture is acidified to about pH 5 with hydrochloric acid (10%). Water (50 mL) is added and the mixture is washed twice with ethyl acetate (2  $\times$  50 mL). 20 organic extracts are combined and dried over anhydrous magnesium sulfate and concentrated to give the title compound, NMR (DMSO- $d_6$ ) delta 0.66, 0.930, 1.48, 1.62, 3.12, 3.35, 7.54, 7.98, 8.22 and 8.51.

PREPARATION 7 3-Cyano-5-[(dipropylamino)carbonyl]benzoic acid (IX/XXXII)

A mixture of 3-bromo-5-[(dipropylamino)carbonyl]benzoic acid (PREPARATION 4, 0.596 g, 1.82 mmol) and copper nitrile (0.325 g, 3.63 mmol) in N-methylpyrrolidinone (1.5 mL) is stirred at 175 degrees C for 2.5 hour, at which time the mixture is cooled and partitioned between ethyl acetate and hydrochloric acid (3N). The organic layer is washed twice more with hydrochloric acid (3N) and then twice more with saline which had been acidified with a small amount of hydrochloric

acid (3N). The organic layer is dried over magnesium sulfate and concentrated under high vacuum to give the title compound, NMR  $(CDCl_3)$  delta 0.80, 1.02, 1.60, 1.73, 3.17, 3.51, 7.90, 8.31 and 8.41; an aliquot is crystallized from ethyl ether/dichloromethane/hexane - IR (diffuse reflectance) 3017, 2970, 2937, 2898, 2877, 2473, 2432, 2350, 2318, 2236, 1721, 1608, 1588, 1206 and 1196 cm<sup>-1</sup>.

PREPARATION 8 3-(Aminocarbonyl)-5-

10

15

20

25

[(dipropylamino)carbonyl]benzoic acid (XXXIII)

A mixture of 3-cyano-5-[(dipropylamino)carbonyl]benzoic acid (IX/XXXII, PREPARATION 7, 0.602 g, 2.19 mmol), potassium carbonate (0.212 g, 1.53 mmol), and acetone (2.5 mL) is stirred at 20-25 degrees C. Water (2.5 mL) and urea-hydrogen peroxide adduct (0.825 g, 8.78 mmol) are added and the mixture is stirred for 15 hours at 20-25 degrees C, at which time additional urea-hydrogen peroxide adduct (0.204 g) is added; after stirring for another 3 hours, an additional 0.205 g of urea-hydrogen peroxide is added. After a total of 39 hours has elapsed, the acetone is removed under reduced pressure and the residue is acidified with hydrochloric acid (3N) to pH = 2-4. The mixture is extracted with dichloromethane, the organic layer is separated and washed with hydrochloric acid (0.5 N), and the organic phase is dried with anhydrous magnesium sulfate to solid. The solid is crystallized dichloromethane/hexane/methanol to give the title compound, MS (ESI+) for  $C_{15}H_{20}N_2O_4 \ m/z \ (M+H)^+ = 293.2$ .

30 PREPARATION 9 Methyl 3-[(dipropylamino)carbonyl]-5nitrobenzoate (XXX)

Carbonyl diimidazole (3.90 g, 24.0 mmol) is added to a mixture of mono-methyl 5-nitro-isophthalate (XXVIII, 4.50 g, 20.0 mmol) in dry THF (50 mL). The mixture is stirred for 0.5

hours. Dipropylamine (3.28 mL, 24.0 mmol) is added slowly to the mixture. The reaction mixture is then stirred for 4 hours. The solvent is removed under reduced pressure and the mixture is partitioned between ethyl acetate and water. The organic phase is separated and washed with saline, dried over anhydrous sodium sulfate, filtered, and concentrated. Column chromatography (silica gel; ethyl acetate/hexanes, 15/85) gives the title compound, NMR (300 MHz, CDCl<sub>3</sub>) delta 8.88, 8.41, 8.35, 4.00, 3.48, 3.15, 1.72, 1.57, 1.00 and 0.77; MS (ESI+) for  $C_{15}H_{20}N_2O_5$  m/z  $(M+H)^+ = 309.2$ .

## PREPARATION 10 Methyl

10

25

30

3-amino-5-

[(dipropylamino)carbonyl]benzoate (XXXI)

A suspension of methyl 3-[(dipropylamino)carbonyl]-515 nitrobenzoate (XXX, PREPARATION 9, 6.00g, 20.0 mmol) and
palladium on carbon (5%, 0.600 g) in methanol (40 mL) is shaken
in a hydrogenation apparatus under hydrogen (45 psi) for 3
hours. The mixture is then filtered through diatomaceous earth
and concentrated to give the title compound, NMR (300 MHz,
20 CDCl<sub>3</sub>) delta 7.27, 6.77, 4.10, 3.82, 3.38, 3.10, 1.62, 1.46,
0.91 and 0.68.

# PREPARATION 11 Methyl 3-(chlorosulfonyl)-5[(dipropylamino)carbonyl]- benzoate (XXXVII)

Methyl 3-amino-5-[(dipropylamino)carbonyl]benzoate (XXXI, PREPARATION 10, 1.11 g, 4 mmol) is added to a mixture of water (5 mL) and concentrated hydrochloric acid (1 mL). Sodium nitrite (0.276 g, 4 mmol) is added to the mixture slowly at 0 degrees C. The mixture is then added to an acetic acid solution (5 mL) of CuCl<sub>2</sub>\*2H<sub>2</sub>O saturated with sulfur dioxide. The mixture is stirred for 0.5 hours and poured into ice water. The mixture is extracted with ethyl acetate. The organic phase is separated and washed with saturated sodium bicarbonate, water, and saline and dried over anhydrous sodium sulfate,

filtered, and concentrated to give the title compound, NMR (300 MHz, CDCl<sub>3</sub>) delta 8.69, 8.38, 8.20, 4.01, 3.49, 3.14, 1.72, 1.59, 1.01 and 0.79; MS (ESI+) for  $C_{15}H_{20}ClNO_5S$  m/z (M+H)<sup>+</sup> = 362.2

5

PREPARATION 12 Methyl 3-(aminosulfonyl)-5[(dipropylamino)carbonyl]- benzoate (XXXVIII)

To solution of methyl 3-(chlorosulfonyl)-5-[(dipropylamino)carbonyl]benzoate (XXXVII, 10 PREPARATION 0.100 g, 0.300 mmol) in dry THF (3 mL) is added ammonia (7 N  $\,$ solution in methanol, 0.214 mL, 1.50 mmol). The mixture is stirred for 18 hours and solvent is then removed. The residue is partitioned between ethyl acetate and water. The organic phase is separate and washed with saline, dried over anhydrous 15 sodium sulfate, filtered, and concentrated to give the title compound, NMR (300 MHz, CDCl<sub>3</sub>) delta 8.45, 8.07, 8.01, 6.05, 3.93, 3.44, 3.09, 1.67, 1.52, 0.96 and 0.73; MS (ESI+) for  $C_{12}H_{22}N_2O_5S \ m/z \ (M+H)^+ = 343.3.$ 

20

25

30

## PREPARATION 13 3-(Aminosulfonyl)-5-

[(dipropylamino)carbonyl]benzoic acid (XXXVIII)

Lithium hydroxide monohydrate (0.011 g, 0.263 mmol) is added to a solution of methyl 3-(aminosulfonyl)-5-[(dipropylamino)carbonyl]benzoate (XXXVIII, PREPARATION 12, 0.090 g, 0.263 mmol) in a mixture of THF/methanol/water (2/1/1, 2 mL). The mixture is stirred at 20-25 degrees C for 3 hours. The mixture is then diluted with water and hydrochloric acid (1 N) is added to bring the pH to less than 3. The aqueous solution is extracted with ethyl acetate. The organic phase is separated and washed with saline, dried over anhydrous sodium sulfate, filtered and concentrated to give the title compound.  $^{1}$ H NMR (300 MHz, CDCl<sub>3</sub>) delta 10.36 (s, 1 H), 8.39 (s, 1 H), 8.09 (s, 2 H), 6.06 (s, 2 H), 3.48 (t, J = 7 Hz, 2 H), 3.15 (t,

J = 7 Hz, 2 H), 1.71 (m, 2 H), 1.55 (m, 2 H), 0.97 (t, J = 7 Hz, 3 H), 0.74 (t, J = 7 Hz, 3 H). MS (ESI+) for  $C_{11}H_{20}N_2O_5S$  m/z 329.2 (M+H)<sup>+</sup>.

5 PREPARATION 14 Methyl 3-[(dipropylamino)carbonyl]-5-(1-pyrrolidinylsulfonyl)-benzoate (XXXVIII)

Following the general procedure of PREPARATION 12 and making non-critical variations but using pyrrolidine (0.347 mL, 4.16 mmol), the title compound is obtained, MS (ESI+) for  $C_{19}H_{28}N_2O_5S$  m/z (M+H)<sup>+</sup> = 397.1.

PREPARATION 15 3-[(Dipropylamino)carbonyl]-5-(1-pyrrolidinylsulfonyl)benzoic acid (XXXIX)

10

30

Following the general procedure of PREPARATION 13 and 15 making non-critical variations, the title compound is obtained, MS (ESI+) for  $C_{18}H_{26}N_2O_5S$  m/z  $(M+H)^+ = 383.3$ .

- PREPARATION 16 Methyl 3-[(dipropylamino)carbonyl]-5[(methylamino)-sulfonyl]benzoate (XXXVIII)
- Following the general procedure of PREPARATION 12 and making non-critical variations but using methyl amine (2 N solution in THF, 0.692 mL, 1.38 mmol), the title compound is obtained, MS (ESI+) for  $C_{16}H_{24}N_2O_5S$  m/z  $(M+H)^+ = 357.1$ .
- 25 PREPARATION 17 3-[(Dipropylamino)carbonyl]-5[(methylamino)- sulfonyl]benzoic acid (XXXIX)

Following the general procedure of PREPARATION 13 and making non-critical variations, the title compound is obtained, MS (ESI+) for  $C_{15}H_{22}N_2O_5S$  m/z (M+H)<sup>+</sup> = 343.1.

PREPARATION 18 Methyl 3-[(dimethylamino)sulfonyl]-5[(dipropylamino)- carbonyl]benzoate (XXXVIII)

Following the general procedure of PREPARATION 12 and making non-critical variations but using dimethylamine (2 N  $\,$ 

solution in THF, 0.692 mL, 1.38 mmol), the title compound is obtained, MS (ESI+) for  $C_{17}H_{26}N_2O_5S$  m/z  $(M+H)^+=371.1$ .

## PREPARATION 19 3-[(Dimethylamino)sulfonyl]-5-

5

15

20

[(dipropylamino)carbonyl]- benzoic acid (XXXIX)

Following the general procedure of PREPARATION 13 and making non-critical variations, the title compound is obtained, MS (ESI+) for  $C_{16}H_{24}N_2O_5S$  m/z  $(M+H)^+ = 357.1$ .

10 PREPARATION 20 Methyl 3-[(dipropylamino)carbonyl]-5-ethylbenzoate (IX)

Ethylboronic acid (0.800 g, 10.8 mmol), dichlorobis(triphenylphosphine) - palladium(II) (0.252 g, 0.360 mmol), potassium carbonate (2.50 g, 18.0 mmol) and lithium chloride (0.151 g, 3.60 mmol) are added to a mixture of methyl 3-bromo-5-[(dipropylamino)carbonyl]benzoate (1.23 g, 3.60 mmol) in dry DMF (20 mL). The mixture is heated at 100 degrees C for The mixture is then partitioned between ethyl 18 hours. acetate and water. The phases are separated and the ethyl acetate phase is washed with saline, dried over sodium sulfate and concentrated. The concentrate is column chromatographed (silica gel; ethyl acetate/hexanes, 15/85) to give the title compound, MS (ESI+) for  $C_{17}H_{25}NO_3 \ m/z \ (M+H)^+ = 292.2$ .

25 PREPARATION 21 3-[(Dipropylamino)carbonyl]-5-ethylbenzoic acid (IX)

Lithium hydroxide monohydrate (0.0680 g, 1.6 mmol) is added to a mixture of methyl 3-[(dipropylamino)carbonyl]-5-ethylbenzoate (PREPARATION 20, 0.450 g, 1.6 mmol) in a mixture of THF/methanol/water (2/1/1, 8 mL). The mixture is stirred at 20-25 degrees C for 3 hours. The mixture is then diluted with water (20 mL) and hydrochloric acid (1 N) is added to bring the pH to less than 3. The aqueous mixture is extracted with ethyl acetate. The organic phase is separated and washed with

saline, dried over anhydrous magnesium sulfate, filtered and concentrated to give the title compound, MS (ESI+) for  $C_{16}H_{23}NO_3$  m/z  $(M+H)^+ = 278.2$ .

5 EXAMPLE 1 tert-Butyl (1S)-3-bromo-1-(3,5-difluorobenzyl)2-oxopropylcarbamate (III)

N-methyl-morpholine (5.83 Ml, 53 mmole, 1.05 eq.) is added to (2S)-2-[(tert-butoxycarbonyl)amino]-3-(3,5-difluorophenyl)propanoic acid (II, 15 g, 50 mmole) in THF (100 mL) and the reaction is cooled to -78 degrees C. Isobutyl chloroformate (6.87 mL, 53 mmole, 1.05 eq.) is added rapidly. The cold bath is then removed and the mixture stirred for 1 hour. The reaction is monitored by TLC to insure completion of the reaction and the mixture is then filtered and washed with dry THF (50 ml) and kept cold in the filtered flask at -20 degrees C.

10

15

20

25

30

In an ice-salt bath is placed a 500 ml graduate cylinder containing ether (200 mL) and aqueous potassium hydroxide (40%, 60 ml). 1-Methyl-3-nitro-1-nitrosoguanidine (5.6 g, 106 mmole, 2.1 eq.) is added slowly with stirring and temperature kept below 0 degrees C. The mixture turned yellow and the bubbling lasted for 10 minutes. The stirring is stopped and without mixing the layers, the top diazomethane ethereal layer is transferred with non-ground tip pipette into the stirred mixed anhydride mixture at -20 degrees C. The reaction is monitored by TLC (ethyl acetate/hexane, 50/50;  $R_f = 0.69$ ). After 1 hour nitrogen is then bubbled into the mixture. The solvent is removed under reduced pressure (with heat) and the mixture is partitioned between ether and water. The phases are separated, the organic phase is washed with bicarbonate, saline, dried over anhydrous sodium sulfate and solvent removed under reduced pressure (with heat). The residue is dissolved in ether (100 mL) and hydrobromic acid (48%, 15 mL, 135 mmole, 2.7 eq,) is added at -20 degrees C, the cold bath is removed and the

mixture is stirred for another 0.5 hours. The reaction is monitored by TLC (ethyl acetate/hexane, 50/50;  $R_{\rm f}=0.88$ ). The mixture is partitioned between ether and water, washed with bicarbonate, saline, dried over anhydrous sodium sulfate and the solvent removed. The residue is recrystallized from ethanol to give the title compound, TLC (ethyl acetate/hexane, 50/50)  $R_{\rm f}=0.88$ ; MS (MH $^{+}$ ) = 379.3.

5

10

15

20

30

EXAMPLE 2 tert-Butyl (1S, 2S)-3-bromo-1-(3,5-difluorobenzyl)-2-hydroxypropylcarbamate (IV)

Sodium borohydride (1.32 g, 34.9 mmole, 1.1 eq.) is added to tert-Butyl (1s) -3-bromo-1-(3,5-difluorobenzyl)-2oxopropylcarbamate (III, EXAMPLE 1, 12 g, 31.75 mmole) dissolved in absolute alcohol (500 mL) at -78 degrees C. reaction mixture is stirred for 0.5 hour and monitored by TLC (ethyl acetate/hexane, 20/80;  $R_f = 0.2$ ). The mixture is quenched with water (10 mL) and the solvent removed under reduced pressure with heat (not exceeding 30 degrees C) to The solid is partitioned between dichloromethane and water, washed with saline, dried over anhydrous sodium sulfate. The solvent is removed under reduced pressure to give the title compound, TLC (ethyl acetate/hexane, 20/80)  $R_f = 0.2$ ; MS (MH<sup>+</sup>) = 381.2.

25 EXAMPLE 3 tert-Butyl (1S)-2-(3,5-difluorophenyl)-1-[(2S)-oxiranyl]ethylcarbamate (V)

hydroxypropylcarbamate (IV, EXAMPLE 2) is dissolved in absolute alcohol (150 mL) and ethyl acetate (100 mL) and potassium hydroxide (2.3 g, 34.9 mmole, 1.1eq.) in ethyl alcohol (85%, 5mL) is added at -20 degrees C. The cold bath is then removed and the mixture stirred for 0.5 hour. The reaction is monitored by TLC (ethyl acetate/hexane, 20/80). When the reaction is complete, it is diluted with dichloromethane and

extracted, washed with water, saline, dried over anhydrous sodium sulfate and the solvent removed under reduced pressure. The crude material is purified by flash chromatography on silica gel to give the title compound, TLC (ethyl acetate/hexane, 20/80)  $R_f = 0.3$ ; MS (MH $^+$ ) = 300.4.

EXAMPLE 4 tert-Butyl (1S, 2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-

methoxybenzyl)amino]propylcarbamate (VII)

10 tert-Butyl (1S)-2-(3,5-difluorophenyl)-1-[(2S)-oxiranyl]ethylcarbamate (V, EXAMPLE 3, 245 mg, 0.82 mmol) is suspended in isopropyl alcohol (6 mL) and 3-methoxybenzylamine (160 microL, 1.22 mmol) is added with stirring at 20-25 degrees C. This mixture is heated to gentle reflux (bath temp 85 degrees C) under nitrogen for 2 hours, whereupon the resulting mixture is concentrated under reduced pressure to give the title compound. The title compound is purified by flash chromatography (2-5% methanol/methylene chloride; gradient elution) to give purified title compound.

20

EXAMPLE 5 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol trifluoroacetate (VIII)

tert-Butyl (1S, 2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3[(3-methoxybenzyl)amino]propylcarbamate (VII, EXAMPLE 4, 258 mg, 0.59 mmol) is dissolved in methylene chloride (1 mL) at 2025 degrees C, and trifluoroacetic acid (1 mL) is added with stirring under nitrogen. The reaction mixture is stirred at 20-25 degrees C for 1 hour, whereupon the reaction mixture is concentrated under reduced pressure to give the title compound. The title compound is used in the next reaction without further purification.

EXAMPLE 6  $N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-5-methyl- $N^3$ ,  $N^3$ dipropylisophthalamide (X)

(2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-

methoxybenzyl)amino]-2-butanol trifluoroacetate salt 5 (VIII, EXAMPLE 5) is dissolved in anhydrous DMF (3 mL) and cooled to 0degrees C. Triethylamine (500 microliter, 3.6 mmol) and 5methyl-N, N-dipropylisophthalamic acid (156 mg, 0.59 mmol) are added with stirring. The mixture is warmed to 20-25 degrees C briefly to allow for complete dissolution of the carboxylic 10 acid, before recooling to 0 degrees C. 1-Hydroxybenzotriazole (157 mg, 1.2 mmol) is added with stirring, followed by 1-(3dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (229 mg, 1.2 mmol). The resulting mixture is stirred at 0 degrees C for 5 minutes, then warmed to 20-25 degrees C for 15 hours. The 15 reaction mixture is then quenched with aqueous citric acid (10%), and the mixture extracted three times with ethyl acetate. The combined organic extracts are washed with saturated sodium bicarbonate, saline, dried over sodium sulfate, filtered and concentrated under reduced pressure to 20 give the the title compound in crude form. This material is purified by flash chromatography (2-10% methanol/methylene chloride gradient elution) to give purified title compound, MS (ES)  $MH^+ = 582.3$ .

25

30

## EXAMPLEs 7-9

Following the general procedure of EXAMPLE 1 and making non critical variations but starting with the protecting group of Column A and using the acid of Column B, the protected compound (III) of Column C is obtained:

EXAMPLE	Column A	Column B	Column C
7		Hydrochloric	tert-butyl (1S)-3-chloro- 1-(3,5-difluorobenzyl)-2-
			oxopropylcarbamate

8	CBZ	Hydrobromic	benzyl (1S)-3-bromo-1- (3,5-difluorobenzyl)-2- oxopropylcarbamate
9	CBZ	Hydrochloric	benzyl (1S)-3-chloro-1- (3,5-difluorobenzyl)-2- oxopropylcarbamate

## EXAMPLEs 10-12

Following the general procedure of EXAMPLE 2 and making non critical variations but starting with the protected compound (III) of Column A, the alcohol (IV) of Column B is obtained:

EXAMPLE	Column A	Column B
10	7	Tert-butyl (1S, 2S)-3-chloro-1-(3,5-
		difluorobenzyl)-2-hydroxypropylcarbamate
11	8	Benzyl (1S, 2S)-3-bromo-1-(3,5-
		difluorobenzyl)-2-hydroxypropylcarbamate
12	9	Benzyl (1S, 2S)-3-chloro-1-(3,5-
		difluorobenzyl)-2-hydroxypropylcarbamate

# EXAMPLE 13 Benzyl (1S)-2-(3,5-difluorophenyl)-1-[(2S)-oxiranyl]ethylcarbamate (V)

10 Following the general procedure of EXAMPLE 3 and making non critical variations but starting with the alcohol (IV) of EXAMPLE 12, the title compound is obtained.

## EXAMPLEs 14-107

Following the general procedure of EXAMPLE 4 and making non-critical variations but reacting tert-butyl (1S,2S)-1-(2-oxiranyl)-2-phenylethylcarbamate (V, commercially available) with the C-terminal amine (VI) of Column A, the protected alcohol (VII) of Column B is obtained.

20

Exampl	Column A	Column B
е	C-terminal amine	Protected alcohol (VII)
No.	(VI)	
14	H <sub>2</sub> N-CH <sub>2</sub> CH <sub>3</sub>	tert-butyl (1S,2R)-1-benzyl-3-
		(ethylamino)-2-
		hydroxypropylcarbamate

15	H <sub>2</sub> N-CH <sub>2</sub> -phenyl	tert-butyl (1S,2R)-1-benzyl-3-
ŀ	_	(benzylamino)-2-
L		hydroxypropylcarbamate
16	H <sub>2</sub> N-CH(CH <sub>3</sub> ) <sub>2</sub>	tert-butyl (1S, 2R) -1-benzyl-3-
	- 3,2	(isopropylamino)-2-
		hydroxypropylcarbamate
17	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-4	tert-butyl (1S,2R)-1-benzyl-2-
	CH <sub>3</sub>	hydroxy-3-[(4-
	_	
18	H <sub>2</sub> N-(CH <sub>2</sub> ) <sub>2</sub> -	methylbenzyl)amino]propylcarbamate tert-butyl (1S,2R)-1-benzyl-2-
ļ	phenyl-4-OCH <sub>3</sub>	hydroxy-3-{[2-(4-
	1 2 2 2 3 3 3 3	
		methoxyphenyl)ethyl]amino}propylcarbamate
19	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-3-	
	OCH <sub>3</sub>	1
	00223	hydroxy-3-[(3-
}		methoxybenzyl)amino]propylcarbamat
20	H <sub>2</sub> N-CH(-phenyl)-	e chinal (6/05 oct
= 0	CO-OC <sub>2</sub> H <sub>5</sub>	ethyl ({(2R,3S)-3-[(tert-
	00 002115	butoxycarbonyl)amino]-2-hydroxy-4-
21	U.N. (CH.) -b7	<pre>phenylbutyl}amino)(phenyl)acetate</pre>
21	$H_2N-(CH_2)_2$ -phenyl	( / / / - DCI1Z y 1 - Z -
		hydroxy-3-[(2-
22	TIN CITY CITY	phenylethyl)amino]propylcarbamate
44	$H_2N-CH(-CH_2OH)-$	tert-butyl (1S,2R)-1-benzyl-2-
	CH(OH)-phenyl-4-	
	$NO_2$	(hydroxymethyl)-2-(4-
		nitrophenyl)ethyl]amino}propylcarb
23	II N CH 1	amate
23	$H_2N-CH_2-phenyl-2-$	1 2 (22/22) 4 2011294-3-11/2-
	Cl	chlorobenzyl)amino]-2-
24	TI N. CIV.	hydroxypropylcarbamate
24	$H_2N-CH_2-phenyl-4-$	1
	Cl	chlorobenzyl)amino]-2-
25		hydroxypropylcarbamate
25	$H_2N-(CH_2)_2-O-$	tert-butyl (1S,2R)-1-benzyl-2-
	(CH <sub>2</sub> ) <sub>2</sub> -OH	hydroxy-3-{[2-(2-
		hydroxyethoxy)ethyl]amino}propylca
26	77.77.1	rbamate
∠0	H <sub>2</sub> N-1-indanyl	tert-butyl (1S,2R)-1-benzyl-3-
		(2,3-dihydro-1H-inden-1-ylamino)-
0.7		2-hydroxypropylcarbamate
27	$H_2N-CH_2-CH(OH)-$	tert-butyl (1S,2R)-1-benzyl-2-
	CH <sub>3</sub>	hydroxy-3-[(2-
		hydroxypropyl)amino]propylcarbamat
		<u>e</u>
28	H <sub>2</sub> N-CH <sub>2</sub> -	tert-butyl (1S,2R)-1-benzyl-2-
	tetrahydrofurany	hydroxy-3-[(tetrahydro-2-
	] 1	furanylmethyl)amino]propylcarbamat
		e

29	77 37 677 677 /	
129	H <sub>2</sub> N-CH <sub>2</sub> -CH (-	tert-butyl (1S,2R)-1-benzyl-3-
	OCH <sub>2</sub> CH <sub>3</sub> )	[(2,2-diethoxyethyl)amino]-2-
		hydroxypropylcarbamate
30	$H_2N-(CH_2)_4-CH_3$	tert-butyl (1S,2R)-1-benzyl-2-
ļ		hydroxy-3-(pentylamino)
		propylcarbamate
31	H <sub>2</sub> N-cyclohexyl	tert-butyl (1S,2R)-1-benzyl-3-
-		(cyclohexylamino) -2-
		hydroxypropylcarbamate
32	H <sub>2</sub> N-CH <sub>2</sub> -pyridin-	tert-butyl (1S,2R)-1-benzyl-2-
	2-y1	hydroxy-3-[(2-
	1	pyridinylmethyl)amino]propylcarbam
		ate
33	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-2-	
	NH <sub>2</sub>	1
	14112	aminobenzyl)amino]-1-benzyl-2-
34	II N. CII.	hydroxypropylcarbamate
34	H <sub>2</sub> N-CH <sub>2</sub> -pyridin-	tert-butyl (1S,2R)-1-benzyl-2-
	3-y1	hydroxy-3-[(3-
		pyridinylmethyl)amino]propylcarbam
		ate
35	$H_2N-(CH_2)_2-$	tert-butyl (1S,2R)-1-benzyl-2-
	pyrrolidin-1-yl	hydroxy-3-{[2-(1-
		pyrrolidinyl)ethyl]amino}propylcar
		bamate
36	$H_2N-CH_2-CH(OH)-$	tert-butyl (1S,2R)-1-benzyl-2-
	phenyl	hydroxy-3-[(2-hydroxy-2-
		phenylethyl)amino]propylcarbamate
37	H <sub>2</sub> N-(CH <sub>2</sub> ) <sub>3</sub> -O-	tert-butyl (1S, 2R) -1-benzyl-3-[(3-
	(CH <sub>2</sub> ) <sub>3</sub> -CH <sub>3</sub>	butoxypropyl)amino]-2-
		hydroxypropylcarbamate
38	H <sub>2</sub> N-(CH <sub>2</sub> ) <sub>3</sub> -O-	tert-butyl (1S,2R)-1-benzyl-2-
	CH (CH <sub>3</sub> ) <sub>2</sub>	hydroxy-3-[(3-
	, , , , , , , , , , , , , , , , , , , ,	isopropoxypropyl)amino]propylcarba
		mate
39	H <sub>2</sub> N-(CH <sub>2</sub> ) <sub>2</sub> -	tert-butyl (1S,2R)-1-benzyl-2-
	CH (CH <sub>3</sub> ) <sub>2</sub>	
	C11 (C113 / 2	hydroxy-3-(isopentylamino)
40	H <sub>2</sub> N-(CH <sub>2</sub> ) <sub>3</sub> -phenyl	propylcarbamate
40	$H_2N = (CH_2)_3$ -pneny1	tert-butyl (1S, 2R) -1-benzyl-2-
		hydroxy-3-[(3-
41		phenylpropyl)amino]propylcarbamate
41	$H_2N-(CH_2)_2-OCH_3$	tert-butyl (1S,2R)-1-benzyl-2-
		hydroxy-3-[(2-
		methoxyethyl)amino]propylcarbamate
42	$H_2N-(CH_2)_2-O-$	tert-butyl (1S,2R)-1-benzyl-2-
	phenyl	hydroxy-3-[(2-
		phenoxyethyl)amino]propylcarbamate
43	H <sub>2</sub> N-(CH <sub>2</sub> ) <sub>2</sub> -O-	tert-butyl (1S,2R)-1-benzyl-2-
	(CH <sub>2</sub> ) <sub>2</sub> -CH <sub>3</sub>	hydroxy-3-[(2-
		propoxyethyl)amino]propylcarbamate
		1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -

44	$H_2N-(CH_2)_2-C(CH_3)$	) <sub>3</sub> tert-butyl (1s,2R)-1-benzyl-3-
		[(3,3-dimethylbutyl)amino]-2-
<u> </u>		I IIVOIOXVOropyl carbamata
45	$H_2N-(CH_2)_4$ -pheny	l tert-butyl (1S,2R)-1-benzyl-2-
		hydroxy-3-[(4-
		phenylbutyl)aminolpropylas-b
46	$H_2N-CH_2-phenyl-3$	- tert-butyl (1S,2R)-1-benzyl-2-
	I	hydroxy-3-[(3-
		iodobenzyl)amino]propylcarbamate
47	$H_2N-CH_2-phenyl-4$	- tert-butyl (1S,2R)-1-benzyl-2-
	NO <sub>2</sub>	hydroxy-3-[(4-
		nitrobenzyl) aminologogod
48	$H_2N-CH_2-phenyl-3$	tert-butyl (1c 2p) 1 b
	Cl	tert-butyl (1S,2R)-1-benzyl-3-[(3-chlorobenzyl)amino]-2-
		hydroxypropylcarbamate
49	$H_2N - (CH_2)_2 -$	tert-butyl (10 2D) 1 1
	phenyl-4-Cl	tert-butyl (1S,2R)-1-benzyl-3-{[2-(4-chlorophenyl)chb.]
		(4-chlorophenyl)ethyl]amino}-2- hydroxypropylcarbamate
50	H <sub>2</sub> N-(CH <sub>2</sub> ) <sub>2</sub> -	tert-butyl /10 22 4
	pyridin-2-yl	tert-butyl (1S,2R)-1-benzyl-2- hydroxy-3-{[2-(2-
		Dyridinyl) otherland
		pyridinyl)ethyl]amino}propylcarbam
51	H <sub>2</sub> N-CH <sub>2</sub> -pyridin-	
	4-y1	tert-butyl (1S,2R)-1-benzyl-2- hydroxy-3-[(4-
		Dyridinylmothyd
		pyridinylmethyl)amino]propylcarbam ate
52	$H_2N-(CH_2)_2-(N-$	
	methylpyrrolidin	tert-butyl (1S,2R)-1-benzyl-2- hydroxy-3-{[2-(1-methyl-2-
	-2-y1)	1 " 4 - (14 /4 MC(11V)-/-
		pyrrolidinyl)ethyl]amino}propylcar bamate
53	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-	tert-butyl (1S, 2R)-1-benzyl-3-
	2,3-dimethyl	[(2,3-dimethylbenzyl)amino]-2-
		hydroxypropylcarbamate
54	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-2-	tert-butyl (1S,2R)-1-benzyl-2-
	OCF <sub>3</sub>	hydroxy-3-{[2-
	j	(trifluoromethovalboness)
		(trifluoromethoxy)benzyl]amino}propylcarbamate
55	$H_2N-CH_2-pheny1-2-$	tert-butyl (1S, 2R) -1-benzyl-3-[(2-
	Cl-6-0-phenyl	chloro-6-phenoxybenzyl)amino]-2-
		hydroxypropylcarbamate
6	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-4-	tert-butyl (1S, 2R)-1-benzyl-2-
	CF <sub>3</sub>	hydroxy-3-{[4-
	1	(trifluoromethyl)benzyl]amino}prop
		ylcarbamate
7	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-	tert-butyl (1S, 2R)-1-benzyl-3-
	2,3-dichloro	[(2,3-dichlorobenzyl)amino]-2-
		hydroxypropylcarbamate
8	n2m-cn2-pneny1-	tert-butyl (1S, 2R) -1-benzyl-3-
	10	[(3,5-dichlorobenzyl)amino]-2-
	1	hydroxypropylcarbamate

59	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-	tert-butyl (1S,2R)-1-benzyl-3-
	3,5-difluoro	[(3,5-difluorobenzyl)amino]-2-
		hydroxypropylcarbamate
60	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-4-	tert-butyl (1S,2R)-1-benzyl-2-
	OCF <sub>3</sub>	hydroxy-3-{[4-
		(trifluoromethoxy)benzyl]amino)pro
		pylcarbamate
61	H <sub>2</sub> N-(CH <sub>2</sub> ) <sub>2</sub> -	tert-butyl (1S,2R)-3-{[4-
"-	phenyl-4-SO <sub>2</sub> -NH <sub>2</sub>	(aminosulfonyl)benzyl]amino}-1-
		benzyl-2-hydroxypropylcarbamate
62	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-4-	tert-butyl (1S,2R)-1-benzyl-2-
"-	OCH <sub>3</sub>	hydroxy-3-[(4-
	50113	methoxybenzyl)amino]propylcarbamat
		e
63	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-4-	tert-butyl (1S,2R)-1-benzyl-2-
""	CH <sub>3</sub>	hydroxy-3-[(4-
	0.13	methylbenzyl)amino]propylcarbamate
64	H <sub>2</sub> N-CH <sub>2</sub> -Ph-	tert-butyl (1S,2R)-1-benzyl-2-
	(3,4,5-	hydroxy-3-[(3,4,5-
	trimethoxy)	trimethoxybenzyl)amino]propylcarba
		mate
65	H <sub>2</sub> N-CH <sub>2</sub> -pheny1-3-	tert-butyl (1S,2R)-1-benzyl-2-
	OCF <sub>3</sub>	hydroxy-3-{[3-
	3323	(trifluoromethoxy)benzyl]amino)pro
		pylcarbamate
66	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-	tert-butyl (1S,2R)-1-benzyl-3-
	3,5-dimethoxy	[(3,5-dimethoxybenzyl)amino]-2-
	,	hydroxypropylcarbamate
67	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-	tert-butyl (1S,2R)-1-benzyl-3-
	2,4-dimethoxy	[(2,4-dimethoxybenzyl)amino]-2-
	· -	hydroxypropylcarbamate
68	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-	tert-butyl (1S,2R)-1-benzyl-3-
	phenyl	[([1,1'-biphenyl]-3-
	_	ylmethyl)amino]-2-
		hydroxypropylcarbamate
69	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-	tert-butyl (1S,2R)-1-benzyl-3-
	3,4-dichloro	[(3,4-dichlorobenzyl)amino]-2-
		hydroxypropylcarbamate
70	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-4-	tert-butyl (1S, 2R) -1-benzyl-3-[(4-
	F	fluorobenzyl)amino]-2-
		hydroxypropylcarbamate
71	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-3-	tert-butyl (1S,2R)-1-benzyl-2-
	CF <sub>3</sub>	hydroxy-3-{[3-
		(trifluoromethyl)benzyl]amino}prop
		ylcarbamate
72	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-2-	tert-butyl (1S,2R)-1-benzyl-2-
	CH <sub>3</sub>	hydroxy-3-[(2-
		methylbenzyl)amino]propylcarbamate

73	$H_2N-CH((R)-CH_3)-$	tert-butyl (1S,2R)-1-benzyl-2-
	phenyl	hydroxy-3-{[(1R)-1-
7.4		phenylethyl]amino}propylcarbamate
74	$H_2N-CH((S)-CH_3)-$	tert-butyl (1S,2R)-1-benzyl-2-
	phenyl	hydroxy-3-{[(1S)-1-
<u></u>		phenylethyl]amino}propylcarbamate
75	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-	tert-butyl (1S,2R)-1-benzyl-3-
	3,5-	{[3,5-bis(trifluoromethyl)
1	(bis)trifluorome	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
	thyl	hydroxypropylcarbamate
76	$H_2N-CH_2-phenyl-2-$	tert-butyl (1S,2R)-1-benzyl-2-
	CF <sub>3</sub>	hydroxy-3-{[2-
		(trifluoromethyl)benzyl]
		amino}propylcarbamate
77	$H_2N-CH(S)-CH_3)-$	tert-butyl (1S,2R)-1-benzyl-2-
	(naphth-1-yl)	hydroxy-3-{[(1S)-1-(1-
		naphthyl)ethyl]amino}propyl
<u></u>		carbamate
78	$-NH_2-CH((R)-CH_3)-$	
	(naphth-1-yl)	hydroxy-3-{[(1R)-1-(1-
		naphthyl)ethyl]amino}propylcarbama
		te
79	$H_2N-CH_2-pheny1-3-$	tert-butyl (1S,2R)-1-benzyl-2-
	OCH <sub>3</sub> -4-OH	hydroxy-3-[(4-hydroxy-3-
1.		methoxybenzyl)amino]propylcarbamat
		е
80	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-	tert-butyl (1S,2R)-1-benzyl-3-
	3,4-dihydroxy	[(3,4-dihydroxybenzyl)amino]-2-
		hydroxypropylcarbamate
81	$H_2N-(CH_2)_3-OCH_3$	tert-butyl (1S,2R)-1-benzyl-2-
		hydroxy-3-[(3-
		methoxypropyl)amino]propylcarbamat
82	77 77 677 ( 5	е
04	H <sub>2</sub> N-CH((S)-CH <sub>3</sub> )-	tert-butyl (1S,2R)-1-benzyl-2-
	СН2-ОН	hydroxy-3-{[(1S)-2-hydroxy-1-
02	T 37 GT ( /= )	methylethyl]amino}propyl carbamate
83	$H_2N-CH((R)-CH_3)-$	tert-butyl (1S,2R)-1-benzyl-2-
	CH <sub>2</sub> -OH	hydroxy-3-{[(1R)-2-hydroxy-1-
84		methylethyl]amino}propyl carbamate
04	H <sub>2</sub> N-CH <sub>2</sub> -C≡CH	tert-butyl (1S, 2R) -1-benzyl-2-
		hydroxy-3-(2-propynylamino)
85	II NI /OII \	propylcarbamate
رن	$H_2N-(CH_2)_2-$	tert-butyl (1S,2R)-1-benzyl-3-{[2-
	phenyl-2-F	(2-fluorophenyl)ethyl] amino}-2-
86	H.N. (CIT.)	hydroxypropylcarbamate
00	$H_2N-(CH_2)_2-$	tert-butyl (1S, 2R) -1-benzyl-3-{[2-
	phenyl-3-F	(3-fluorophenyl)ethyl] amino}-2-
		hydroxypropyl carbamate

0.77	1 (0 )	1 1 1 1 7 (4 2 2 2
87	$H_2N-(CH_2)_2-$	tert-butyl (1S, 2R) -1-benzyl-3-{[2-
	phenyl-4-F	(4-fluorophenyl)ethyl] amino}-2-
		hydroxypropyl carbamate
88	$H_2N-(CH_2)_2-$	tert-butyl (1S, 2R) -1-benzyl-3-{[2-
	phenyl-4-Br	(4-bromophenyl)ethyl] amino}-2-
		hydroxypropyl carbamate
89	$H_2N-(CH_2)_2-$	tert-butyl (1S, 2R) -1-benzyl-2-
	phenyl-3-OCH <sub>3</sub>	hydroxy-3-{[2-(3-
	,	methoxyphenyl)ethyl]amino)propylca
		rbamate
90	$H_2N-(CH_2)_2-$	tert-butyl (1S, 2R) -1-benzyl-3-{[2-
	phenyl-2,4-	(2,4-dichlorophenyl)ethyl]amino}-
	dichloro	2-hydroxypropylcarbamate
91	$H_2N-(CH_2)_2-$	tert-butyl (1S, 2R) -1-benzyl-3-{[2-
	phenyl-3-Cl	(3-chlorophenyl)ethyl]amino}-2-
		hydroxypropylcarbamate
92	$H_2N-(CH_2)_2-$	tert-butyl (1S,2R)-1-benzyl-3-{[2-
	phenyl-2,5-	(2,5-dimethoxyphenyl)
	dimethoxy	ethyl]amino}-2-
		hydroxypropylcarbamate
93	$H_2N-(CH_2)_2-$	tert-butyl (1S,2R)-1-benzyl-2-
	phenyl-4-CH <sub>3</sub>	hydroxy-3-{[2-(4-
		methylphenyl)ethyl]amino}propylcar
		bamate
94	$H_2N-CH(-(R)CH_2-$	tert-butyl (1S,2R)-1-benzyl-3-
	OH)-CH2-phenyl	{[(1R)-1-benzy1-2-
		hydroxyethyl]amino}-2-
		hydroxypropylcarbamate
95	$H_2N-(CH_2)_3-(1-$	tert-butyl (1S,2R)-1-benzyl-2-
	morpholinyl)	hydroxy-3-{[3-(4-
		morpholinyl)propyl]amino)propylcar
0.0		bamate
96	$H_2N-CH_2-C(CH_3)_2$	tert-butyl (1S, 2R) -1-benzyl-3-
		[(3,3-dimethylbutyl)amino]-2-
07	<del>                                     </del>	hydroxypropylcarbamate
97	H <sub>2</sub> N-(CH <sub>2</sub> ) <sub>2</sub> -(1-	tert-butyl (1S, 2R) -1-benzyl-2-
	morpholinyl)	hydroxy-3-{[2-(4-
		morpholinyl)ethyl]amino}propylcarb
		amate
98	$H_2N-CH(OH)-CH_2-$	tert-butyl (1S,2R)-1-benzyl-2-
	CH <sub>3</sub>	hydroxy-3-[(1-
		hydroxypropyl)amino]propylcarbamat
		е
99	$H_2N-(CH_2)_2-$	tert-butyl (1S,2R)-1-benzyl-2-
	(thien-2-y1)	hydroxy-3-[(2-
		thienylmethyl)amino]propylcarbamat
400		е
100	$H_2N-(CH_2)_4-OH$	tert-butyl (1S,2R)-1-benzyl-2-
		hydroxy-3-[(4-
		hydroxybutyl)amino]propylcarbamate

101	$H_2N-CH(-(S)CH_2-$	tert-butyl (1S,2R)-1-benzyl-2-
	OH)-phenyl	hydroxy-3-{[(1S)-2-hydroxy-1-
1	1	phenylethyl]amino} propylcarbamate
102	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-	tert-butyl (1S,2R)-1-benzyl-3-
Ì	2,4-dichloro	[(2,4-dichlorobenzyl)amino]-2-
Ì	1	hydroxypropylcarbamate
103	II N CII ( /D) CII	
103	$H_2N-CH(-(R)CH_2-$	tert-butyl (1S,2R)-1-benzyl-2-
	OH)-phenyl	hydroxy-3-{[(1R)-2-hydroxy-1-
1		<pre>phenylethyl]amino} propylcarbamate</pre>
104	$H_2N-CH_2-phenyl-4-$	tert-butyl $(1S,2R)-1$ -benzyl-3- $[(4-$
ĺ	C (CH <sub>3</sub> ) <sub>3</sub>	tert-butylbenzyl)amino]-2-
		hydroxypropylcarbamate
105	$H_2N-CH(CH_3)-$	tert-butyl (1S,2R)-1-benzyl-2-
	phenyl	hydroxy-3-[(1-
		phenylethyl)amino]propylcarbamate
106	H <sub>2</sub> N-(1R,2S)-2-	tert-butyl (1S,2R)-1-benzyl-2-
	hydroxyinden-1-	hydroxy-3-{[(1R,2S)-2-hydroxy-2,3-
	yl	dihydro-1H-inden-1-
		yl]amino}propylcarbamate
107	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-	tert-butyl (1S,2R)-1-benzyl-3-
	3,4-dimethyl	[(3,4-dimethylbenzyl)amino]-2-
		hydroxypropylcarbamate

## EXAMPLES 108-164

Following the general procedure of EXAMPLE 4 and making non-critical variations but reacting tert-butyl (1S)-2-(3,5-difluorophenyl)-1-[(2S)-oxiranyl]ethylcarbamate (V, EXAMPLE 3) with the C-terminal amine (VI) of Column A, the protected alcohol (VII) of Column B is obtained.

EXA	Column A	Column B
	C-terminal amine (VI)	Protected alcohol (VII)
108	H <sub>2</sub> N-(CH <sub>2</sub> ) <sub>6</sub> -CO-O-CH <sub>3</sub>	methyl 7-{[(2R,3S)-3-[(tert-butoxycarbonyl)amino]-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}heptanoate
109	H <sub>2</sub> N-CH(-CH <sub>3</sub> )-CO-NH- CH <sub>2</sub> -CH(CH <sub>3</sub> ) <sub>2</sub> r/s	tert-butyl (1S,2R)-1-(3,5- difluorobenzyl)-2-hydroxy-3-{[2- (isobutylamino)-1-methyl-2- oxoethyl]amino}propylcarbamate
110	H <sub>2</sub> N-CH((S)-CH <sub>3</sub> )-CO- NH-CH <sub>2</sub> -CH(CH <sub>3</sub> ) <sub>2</sub>	tert-butyl (1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(1S)-2-(isobutylamino)-1-methyl-2-oxoethyl]amino}propylcarbamate

111	H <sub>2</sub> N-C (-CH <sub>3</sub> ) <sub>2</sub> -CO-NH-	tert-butyl (1S, 2R)-1-(3,5-
111	l -	difluorobenzyl)-2-hydroxy-3-{[2-
	CH <sub>2</sub> -CH (CH <sub>3</sub> ) <sub>2</sub>	(isobutylamino)-1,1-dimethyl-2-
		oxoethyl]amino}propylcarbamate
110	H <sub>2</sub> N-CH <sub>2</sub> -CO-NH-CH <sub>2</sub> -	tert-butyl (1S, 2R) -1-(3, 5-
112	· ·	difluorobenzyl)-2-hydroxy-3-{[2-
	CH(CH <sub>3</sub> ) <sub>2</sub>	(isobutylamino)-2-
		oxoethyl]amino}propylcarbamate
113	H <sub>2</sub> N-CH((S)-CH <sub>2</sub> CH <sub>3</sub> )-	tert-butyl (1S, 2R) -1-(3, 5-
113	CO-NH-CH2-CH(CH3)2	difluorobenzyl)-2-hydroxy-3-
	CO-IVII-CII2 CII (CII372	({(1S)-1-
		[(isobutylamino)carbonyl]propyl}a
l		mino)propylcarbamate
114	H <sub>2</sub> N-CH((R)-CH <sub>2</sub> CH <sub>3</sub> )-	tert-butyl (1S, 2R) -1-(3,5-
1774	CO-NH-CH <sub>2</sub> -CH (CH <sub>3</sub> ) <sub>2</sub>	difluorobenzyl)-2-hydroxy-3-
	CO WII CII2 CII (CII3) 2	({(1R)-1-
		[(isobutylamino)carbonyl]propyl}a
		mino)propylcarbamate
115	H <sub>2</sub> N-CH <sub>2</sub> -phenyl	tert-butyl (1S, 2R) -3-
113	11214 6112 [211616]	(benzylamino)-1-(3,5-
		difluorobenzyl)-2-
		hydroxypropylcarbamate
116	H <sub>2</sub> N-CH <sub>2</sub> -CH <sub>3</sub>	tert-butyl (1S, 2R) -1-(3,5-
		difluorobenzyl)-3-(ethylamino)-2-
		ydroxypropylcarbamate
117	H <sub>2</sub> N-CH <sub>2</sub> -CH (CH <sub>3</sub> ) <sub>2</sub>	tert-butyl (1S,2R)-1-(3,5-
	_	difluorobenzyl)-2-hydroxy-3-
		(isobutylamino)propylcarbamate
118	H <sub>2</sub> N-CH <sub>2</sub> -CH (CH <sub>3</sub> )-	tert-butyl (1S,2R)-1-(3,5-
	CONH-CH <sub>2</sub> -CH(CH <sub>3</sub> ) <sub>2</sub>	difluorobenzyl)-2-hydroxy-3-{[3-
İ		(isobutylamino)-2-methyl-3-
L		oxopropyl]amino}propylcarbamate
119	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-4-	tert-butyl (1S,2R)-1-(3,5-
	N(CH <sub>3</sub> ) <sub>2</sub>	difluorobenzyl)-3-{[4-
		(dimethylamino)benzyl]amino}-2-
<u> </u>		hydroxypropylcarbamate
120	$H_2N-CH((S)-CH_2-$	tert-butyl (1s, 2R) -3-{[(1s)-1-
	phenyl)-CO-NH-CH <sub>2</sub> -	(3,5-difluorobenzyl)-2-
	CH(CH <sub>3</sub> ) <sub>2</sub>	(isobutylamino) -2-
		oxoethyl]amino}-1-(3,5-
[		difluorobenzy1)-2-
100	1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	hydroxypropylcarbamate
121	H <sub>2</sub> N-CH ((S) -	tert-butyl (1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
	CH (CH <sub>3</sub> ) <sub>2</sub> ) -CO-NH-CH <sub>2</sub> -	({(1s)-1-
	CH(CH <sub>3</sub> ) <sub>2</sub>	[(isobutylamino)carbonyl]-3-
		methylbutyl}amino)propylcarbamate
100	TIN OIL OIL NI/OIL	tert-butyl (1s,2R)-1-(3,5-
122	$H_2N-CH_2-CH_2-N(CH_3)_2$	difluorobenzyl)-3-{[2-
		(dimethylamino)ethyl]amino}-2-
L		(dimedity ramitio) edity i amitio) 2

L		hydroxypropylcarbamate
123	H <sub>2</sub> N-CH <sub>2</sub> -(pyridin-3-	tert-butyl (1S,2R)-1-(3,5-
	y1)	difluorobenzyl) -2-hydroxy-3-[(3-
		pyridinylmethyl)amino]propylcarba
		mate
124	H <sub>2</sub> N-CH((S)-CH <sub>2</sub> -O-	tert-butyl (1S,2R)-3-{[(1S)-1-
	CH <sub>2</sub> -phenyl)-CO-NH-	[(benzyloxy)methy1]-2-
	CH <sub>2</sub> -CH (CH <sub>3</sub> ) <sub>2</sub>	(isobutylamino)-2-
		oxoethyl]amino}-1-(3,5-
		difluorobenzyl)-2-
		hydroxypropylcarbamate
125	$H_2N-C(-CH_3)_2$ -phenyl	tert-butyl (1s, 2R) -1-(3, 5-
	3,2 passing 2	difluorobon == 1 2 1 2 1 3 5 -
		difluorobenzyl)-2-hydroxy-3-[(1-methyl-1-
126	H <sub>2</sub> N-CH((R)-	phenylethyl)amino]propylcarbamate
	CH (CH <sub>3</sub> ) <sub>2</sub> ) -CO-NH-CH <sub>2</sub> -	tert-butyl (1s, 2r) -1-(3,5-
	$CH(CH_3)_2$ $CH(CH_3)_2$	
		({(1R)-1-
		[(isobutylamino)carbonyl]-3-
127	H <sub>2</sub> N-CH((S)-CH <sub>2</sub> -CH <sub>2</sub> -	methylbutyl}amino)propylcarbamate
	$CH_3$ ) $-CO-NH-CH_2-$	tert-butyl (1S,2R)-1-(3,5-
	CH (CH <sub>3</sub> ) <sub>2</sub>	difluorobenzyl)-2-hydroxy-3-
	(0113)2	({(1s)-1-
		[(isobutylamino)carbonyl]butyl}am
128	HoN-CH/(C) CH OH)	ino)propylcarbamate
120	$H_2N-CH((S)-CH_2-OH)-$	tert-butyl (1S, 2R)-1-(3,5-
	CO-NH-CH <sub>2</sub> -CH(CH <sub>3</sub> ) <sub>2</sub>	difluorobenzy1)-2-hydroxy-3-
ĺ		{[(1S)-1-(hydroxymethy1)-2-
i		(isobutylamino)-2-
129	H-N-CH CH	oxoethyl]amino}propylcarbamate
	H <sub>2</sub> N-CH <sub>2</sub> -CH <sub>2</sub> -phenyl	tert-butyl (1S,2R)-1-(3,5-
		difluorobenzyl)-2-hydroxy-3-[(2-
130	U.N. CII ( (C) CII )	phenylethyl)amino]propylcarbamate
.50	$H_2N-CH((S)-CH_3)-CO-$	tert-butyl $(1S, 2R) - 3 - \{ [2 -$
	NH-CH <sub>2</sub> -phenyl	(benzylamino)-1-methyl-2-
		oxoethyl]amino}-1-(3,5-
]	ļ	difluorobenzyl)-2-
31	H M CH ( C)	hydroxypropylcarbamate
i	$H_2N-CH((S)-CH_2-CH_3)-$	tert-butyl (1S, 2R) -1-(3, 5-
	phenyl	difluorobenzyl)-3-{[(1S)-2-
	ł	(benzylamino)-1-methyl-2-
		oxoethyl]amino}-2-
32	II N CV	hydroxypropylcarbamate
	H <sub>2</sub> N-CH <sub>2</sub> -pheny1-3-	tert-butyl (1S, 2R) -1-(3.5-
-	OCH <sub>3</sub>	difluorobenzyl)-2-hydroxy-3-1(3-
		methoxybenzyl)amino]propylcarbama
		te
	H <sub>2</sub> N-CH((S)-	tert-butyl (1S, 2R) -1-(3,5-
	buenAt)CO-	difluorobenzyl)-2-hydroxy-3-
	NHCH <sub>2</sub> CH (CH <sub>3</sub> ) <sub>2</sub>	$\{[(1S)-2-(isobutylamino)-2-oxo-1-$

		phenylethyl]amino}propylcarbamate
134	H <sub>2</sub> N-CH <sub>2</sub> -CH <sub>2</sub> -CH (CH <sub>3</sub> ) <sub>2</sub>	tert-butyl (1S,2R)-1-(3,5-
		difluorobenzyl)-2-hydroxy-3-
		(isopentylamino)propylcarbamate
135	H <sub>2</sub> N-cyclohexyl	tert-butyl (1S, 2R) -1-(3,5-
		difluorobenzyl)-3-
		(cyclohexylamino)-2-
	:	hydroxypropylcarbamate
136	H <sub>2</sub> N-(CH <sub>2</sub> ) <sub>3</sub> -CH <sub>3</sub>	tert-butyl (1S,2R)-1-(3,5-
		difluorobenzyl)-3-(butylamino)-2-
		hydroxypropylcarbamate
137	H <sub>2</sub> N-(CH <sub>2</sub> ) <sub>3</sub> -O-CH <sub>3</sub>	tert-butyl (1S,2R)-1-(3,5-
		difluorobenzyl)-2-hydroxy-3-[(3-
		methoxypropyl)amino]propylcarbama
		te
138	H <sub>2</sub> N-CH <sub>2</sub> -CH (OH) -	tert-butyl (1S,2R)-1-(3,5-
	phenyl	difluorobenzyl)-2-hydroxy-3-[(2-
		hydroxy-2-
		phenylethyl)amino]propylcarbamate
139	H <sub>2</sub> N-cyclohexyl-3,5-	tert-butyl (1S,2R)-1-(3,5-
	dimethoxy	difluorobenzy1)-3-{[(3R,5S)-3,5-
		dimethoxycyclohexyl]amino}-2-
		hydroxypropylcarbamate
140	$H_2N$ -cyclohexyl-3,5-	dimethyl $(1R,3S)-5-({(2R,3S)-3-}$
	di-(-CO-OCH <sub>3</sub> )	[(tert-butoxycarbonyl)amino]-2-
	·	hydroxy-4-phenylbutyl}amino)-1,3-
		cyclohexanedicarboxylate
141	$H_2N$ -cyclohexyl-3,5-	(1R,3S)-5-({(2R,3S)-3-[(tert-
	di-(-COOH)	butoxycarbonyl)amino]-2-hydroxy-
		4-phenylbutyl}amino)-1,3-
140		cyclohexanedicarboxylic acid
142	$H_2N-CH((R)-CH_2-CH_3)-$	tert-butyl (1S,2R)-1-(3,5-
	phenyl	difluorobenzyl)-2-hydroxy-3-
		{[(1R)-1-
		phenylpropyl]amino}propylcarbamat
143	H.N. CH. phonel 2 Cl	e tort butyl (10 2D) 1 (2 5
143	$H_2N-CH_2-pheny1-3-C1$	tert-butyl (1S,2R)-1-(3,5-
		difluorobenzyl)-3-[(3- chlorobenzyl)amino]-2-
		hydroxypropylcarbamate
144	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-3-	tert-butyl (1S,2R)-1-(3,5-
	OCH <sub>3</sub>	difluorobenzyl)-2-hydroxy-3-[(3-
	00113	methoxybenzyl)amino]propylcarbama
]		te
145	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-	tert-butyl (1S,2R)-1-(3,5-
	phenyl	difluorobenzyl)-3-[([1,1'-
}		biphenyl]-3-ylmethyl)amino]-2-
		hydroxypropylcarbamate
146	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-3-I	tert-butyl (1S,2R)-1-(3,5-
		difluorobenzyl)-2-hydroxy-3-[(3-
	<u> </u>	WILLWOLDDCHAYI/ A-HYULONY J [ (J-

Γ		
147	II N CII	iodobenzyl)amino]propylcarbamate
14/	$H_2N-CH_2-pheny1-3-CH_3$	-1- (, -10, 1 (0,0
		difluorobenzyl)-2-hydroxy-3-[(3-
-		methylbenzyl)amino]propylcarbamat
140	17 17 622 622 6	e
148	$H_2N-CH_2-CH(-CH_3)-$	tert-butyl (1s,2R)-1-(3,5-
	phenyl	difluorobenzyl)-2-hydroxy-3-[(2-
		phenylpropyl)amino]propylcarbamat
140		<u>e</u>
149	$H_2N-CH_2-(thiazol-5-$	tert-butyl (1S,2R)-1-(3,5-
	yl)	difluorobenzyl)-2-hydroxy-3-
		[(1,3-thiazol-5-
150		ylmethyl)amino]propylcarbamate
150	H <sub>2</sub> N-CH <sub>2</sub> -(thien-2-	tert-butyl (1S,2R)-1-(3,5-
	y1)	difluorobenzyl)-2-hydroxy-3-[(2-
		thienylmethyl)amino]propylcarbama
1.54		te
151	H <sub>2</sub> N-4-	tert-butyl (1S,2R)-1-(3,5-
	methoxytetralin-1-	difluorobenzyl)-2-hydroxy-3-[(5-
	yl yl	methoxy-1,2,3,4-tetrahydro-1-
L		naphthalenyl)amino]propylcarbamat
150		e
152	H <sub>2</sub> N-CH <sub>2</sub> -pyrazin-2-	tert-butyl (1S, 2R)-1-(3,5-
	Υl	difluorobenzyl)-2-hydroxy-3-[(2-
ĺ		pyrazinylmethyl)amino]propylcarba
152	W. W. G. W	mate
153	$H_2N-CH_2-pheny1-3,5-$	tert-butyl (1S,2R)-1-(3,5-
1	difluoro	difluorobenzyl)-3-[(3,5-
		difluorobenzyl)amino]-2-
154	II N CII 1 2 4	hydroxypropylcarbamate
104	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-3,4-	tert-butyl (1S,2R)-3-[(1,3-
	methylenedioxy	benzodioxol-5-ylmethyl)amino]-1-
		(3,5-difluorobenzyl)-2-
155	H.M. CH. ph. 7. 2. 7	hydroxypropylcarbamate
T22	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-3,5-	tert-butyl (1S,2R)-1-(3,5-
	dimethoxy	difluorobenzyl)-3-[(3,5-
		dimethoxybenzyl)amino]-2-
156	HoN-CU phon-1 2 Cm	hydroxypropylcarbamate
100	$H_2N-CH_2-phenyl-3-CF_3$	tert-butyl (1S,2R)-1-(3,5-
		difluorobenzyl)-2-hydroxy-3-{[3-
ĺ		(trifluoromethyl)benzyl]amino)pro
157	H <sub>2</sub> N-CH <sub>2</sub> -(furan-2-	pylcarbamate
13,	y1)	tert-butyl (1S, 2R) -1-(3, 5-
	3 - 1	difluorobenzyl)-3-[(2-
		furylmethyl)amino]-2-
158	H <sub>2</sub> N-(7-	hydroxypropylcarbamate
130	methoxytetralin-1-	tert-butyl (1S, 2R) -1-(3, 5-
	yl)	difluorobenzyl)-2-hydroxy-3-[(7-
	1-1	methoxy-1,2,3,4-tetrahydro-1-
!		naphthalenyl)amino]propylcarbamat

		е
159	H <sub>2</sub> N-CH <sub>2</sub> -pheny1-3-0- CF <sub>3</sub>	<pre>tert-butyl (1S,2R)-1-(3,5- difluorobenzyl)-2-hydroxy-3-{[3- (trifluoromethoxy)benzyl]amino}pr opylcarbamate</pre>
160	H <sub>2</sub> N-CH <sub>2</sub> -phenyl-3-F	tert-butyl (1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- fluorobenzyl)amino]-2- hydroxypropylcarbamate
161	H <sub>2</sub> N-CH <sub>2</sub> -pheny1-3-0- CH(CH <sub>3</sub> ) <sub>2</sub>	tert-butyl (1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-isopropoxybenzyl)amino]propylcarb amate
162	H <sub>2</sub> N-CH <sub>2</sub> -pheny1-3-Br	tert-butyl (1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- bromobenzyl)amino]-2- hydroxypropylcarbamate
163	H <sub>2</sub> N-CH <sub>2</sub> -(5- methylfuran-2-yl)	tert-butyl (1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(5-methyl-2-furyl)methyl]amino}propylcarbamate
164	H <sub>2</sub> N-(5-methoxytetralin-1-yl)	tert-butyl (1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(5-methoxy-1,2,3,4-tetrahydro-1-naphthalenyl)amino]propylcarbamate

EXAMPLE 165 tert-Butyl-(1S, 2R)-3-azido-1-(3,5-difluorobenzyl)-2-hydroxypropylcarbamate (XII)

Sodium azide (0.22 g, 4 mmole) and ammonium chloride (2 eq) are added to tert-butyl (1S)-2-(3,5-difluorophenyl)-1- [(2S)-oxiranyl]ethylcarbamate (V, EXAMPLE 3, 0.6 g, 2 mmole). The reaction is heated to 75-80 degrees C and stirred for 16 hours. The reaction is monitored by TLC to insure completion. The solvent is removed under reduced pressure. The concentrate is partitioned between ethyl acetate and water, the phases are separated and the organic phase is washed with bicarbonate and saline, dried over anhydrous sodium sulfate and concentrated to give the title compound, TLC (ethyl acetate/hexane)  $R_{\rm f} = 0.45$ ; MS (MH<sup>+</sup>) = 343.

10

5

EXAMPLE 166 (2R, 3S)-3-amino-1-azido-4-(3,5-difluorophenyl)-2-butanol (XIV)

tert-Butyl-(1S, 2R)-3-azido-1-(3,5-difluorobenzyl)-2hydroxypropylcarbamate (XII, EXAMPLE 165, 0.48 g, 1.41 mmole) 5 is dissolved dichloromethane in (20 m1) trifluoroacetic acid (5 ml) is added. The reaction is stirred at 20-25 degrees C for 16 hours and the solvent is removed under reduced pressure with heat. Ethyl acetate is added twice and evaporated twice to give the title compound as the trifluoroacetic acid salt which is used in the next reaction 10 without further purification; MS  $(MH^+) = 242$ .

EXAMPLE 167  $N^{1}-[(1S,2R)-3-azido-1-(3,5-difluorobenzyl)-2-hydroxypropyl]5-methyl-<math>N^{3}$ ,  $N^{3}$ -

15 dipropylisophthalamide (XV)

To (2R, 3S)-3-amino-1-azido-4-(3,5-difluorophenyl)-2-buta (XIV, EXAMPLE 166, 0.34 g, 1.4 mmole) in dichloromethane (20 ml) is added N,N-dipropylamidoisophthalic acid (IX, 0.53 g, 2mmole), t-butyl alcohol (0.27 g, 2 mmole) and triethylamine 20 (0.84 ml, 6 mmole) and ethyl-1-(3dimethylaminopropyl)carbodiimide (0.58 g, 3 mmole). mixture is stirred at 20-25 degrees C for 16 hours. The reaction is monitored by TLC (methanol/dichloromethane, 20/80 + ethyl acetate/hexane, 50/50;  $R_{\rm f}$  = 0.76). When the reaction is complete as measured by TLC, the reaction mixture 25 partitioned between dichloromethane and water, washed with hydrochloric acid (0.5 N), bicarbonate, saline, dried over anhydrous sodium sulfate and the solvent is removed under reduced pressure with heat to produce a concentrate. concentrate is column chouromatographed on silica gel to give 30 the title compound; MS  $(MH^+)$  = 488.

EXAMPLE 168  $N^{1}$ -[(1S,2R)-3-amino-1-(3,5-difluorobenzyl)-2-hydroxypropyl]-5-methyl- $N^{3}$ ,  $N^{3}$ -dipropylisophthalamide acetic acid salt (XVI)

 $N^{1}-[(1S,2R)-3-azido-1-(3,5-difluorobenzyl)-2-$ 5 hydroxypropyl | 5-methyl- $N^{3}$ ,  $N^{3}$ -dipropyl | sophthal amide

hydroxypropyl]5-methyl-N³,N³-dipropylisophthalamide (XV, EXAMPLE 167, 0.3 g, 0.62 mmole) in ethyl acetate (20 ml) and acetic acid (5ml) is placed in a Parr pressure bottle. Palladium on carbon (10%, 5 g) is added and the mixture shaken under hydrogen at 50 psi for 2 hours. The mixture is filtered through a diatomaceous earth and the filtrate is concentrated to give the title compound; MS (MH⁺) = 462.

EXAMPLE 169  $N^1 - \{(1S, 2R) - 1 - (3, 5 - diffluorobenzy1) - 3 - [(2 - furylmethyl) amino] - 2 - hydroxypropyl\} - 5 - methyl - N^3, N^3 -$ 

15 dipropylisophthalamide (X)

20

25

N<sup>1</sup>-[(1S,2R)-3-amino-1-(3,5-difluorobenzyl)-2-hydroxypropyl]-5-methyl-N<sup>3</sup>,N<sup>3</sup>-dipropylisophthalamide acetic acid salt (XVI, EXAMPLE 168, 76 mg, 0.146 mmol) is dissolved in absolute ethanol (2 mL). 3-Furaldehyde (20 microL, 0.231 mmol) and triethylamine (30 microL, 0.215 mmol) are added via syringe, with stirring at 20-25 degrees C. After 10 minutes, palladium on carbon 122 mg, 5 weight %) is added and the mixture placed under a hydrogen atmosphere (50 psi) and shaken for 20 minutes. The resulting mixture is then filtered through diatomaceous earth, with ethanol washings. The filtrate is purified by flash chromatography (2-10% methanol/methylene chloride) to give purified title compound, MS (MH<sup>+</sup>) = 542.2.

EXAMPLE 169a tert-butyl (1S,2R)-1-(3,5-difluorobenzyl)
3-{[(1S)-2-(ethylamino)-1-methyl-2oxoethyl]amino}-2-hydroxypropylcarbamate (VII)

Following the general procedure of EXAMPLES 4 and 14-164 and making non-critical variations and reacting tert-butyl

(1s)-2-(3,5-difluorophenyl)-1-[(2s)-oxiranyl] ethylcarbamate (V, EXAMPLE 3) with (2s)-2-amino-N-ethylpropanamide (VI), the title compound is obtained.

## 5 EXAMPLES 170-320

Following the general procedure of EXAMPLE 5 and making non-critical variations but starting with the protected alcohol (VII) of Column A, the amine (VIII) of Column B is obtained.

Column A lists the Protected Alcohols (VII) by reference to a specific Example number above.

EXA	A	Column B
		Amine (VIII)
170		(2R, 3S) -3-amino-1-(ethylamino) -4-phenyl-2-butanol
171	. 15	(2R,3S)-3-amino-1-(benzylamino)-4-phenyl-2-butanol
172	16	(2R,3S)-3-amino-1-(isopropylamino)-4-phenyl-2-
		_   Ducanor
173	17	(2R,3S)-3-amino-1-[(4-methylbenzyl)amino]-4-phenyl
		2-butanol
174	18	(2R,3S)-3-amino-1-{[2-(4-
		methoxyphenyl)ethyllamino}-4-phenyl 2 but1
175	19	(2R,3S)-3-amino-1-[(3-methoxybenzyl)amino]-4-
	<del> </del>	pheny1-2-bucano1
176	20	ethyl {[(2R,3S)-3-amino-2-hydroxy-4-
		[phenylbutyl]amino}(phenyl)acetate
177	21	(2R,3S) -3-amino-4-phenyl-1- $[(2-pheny]$ ethyl) aminol
4==	ļ	[2-bucanor
178	22	(2S)-2-{[(2R,3S)-3-amino-2-hydroxy-4-
		pnenylbutyl]amino}-1-(4-nitorphenyl)-1 3-
100	-	propanediol
179	23	(2R, 3S) -3-amino-1-[(2-chlorobenzyl)amino]-4-phenyl-
100	-	2 Ducanor
180	24	(2R, 3S) -3-amino-1-[(4-chlorobenzyl)amino]-4-phenyl-
101	0.5	2 Ducanor
181	25	(2R,3S)-3-amino-1-{[2-(2-
182	0.6	hydroxyethoxy) ethyl]amino}-4-phenyl-2-butanol
18∠	26	(2k, 35) -3-amino-1- $(2, 3$ -dihydro-1H-inden-1-ylamino)
183	25	Tarbitetty 1-2-butanot
102	27	(2R,3S)-3-amino-1-[(2-hydroxypropyl)amino]-4-
184	28	pilelly1-2-butano1
104	28	(2R,3S)-3-amino-4-phenyl-1-[(tetrahydro-2-
185	29	[Iuranyimethyi)amino]-2-butano]
-05	29	(2R,3S)-3-amino-1-[(2,2-diethoxyethyl)amino]-4-
		phenyl-2-butanol

186	30	(2R,3S)-3-amino-1-(butylamino)-4-phenyl-2-butanol
187	31	(2R,3S)-3-amino-1-(cyclohexylamino)-4-phenyl-2-
		butanol
188	32	(2R,3S)-3-amino-4-phenyl-1-[(2-
	-	pyridinylmethyl)amino]-2-butanol
189	33	(2R,3S)-3-amino-1-[(2-aminobenzyl)amino]-4-phenyl-
100		2-butanol
190	34	(2R,3S)-3-amino-4-phenyl-1-[(3-
100		pyridinylmethyl)amino]-2-butanol
191	35	(2R,3S)-3-amino-4-phenyl-1-{[2-(1-
		pyrrolidinyl)ethyl]amino}-2-butanol
192	36	(2R,3S)-3-amino-1-[(2-hydroxy-2-phenylethyl)amino]-
192	30	4-phenyl-2-butanol
193	37	(2R,3S)-3-amino-1-[(3-butoxypropyl)amino]-4-phenyl-
133	37	2-butanol
194	38	(2R,3S)-3-amino-1-[(3-isopropoxypropyl)amino]-4-
134	30	
195	39	phenyl-2-butanol (2R,3S)-3-amino-1-(isopentylamino)-4-phenyl-2-
132	39	butanol
100	40	
196	40	(2R,3S)-3-amino-4-phenyl-1-[(3-phenylpropyl)amino]-
107	41	2-butanol (2R,3S)-3-amino-1-[(2-methoxyethyl)amino]-4-phenyl-
197	41	
100	42	2-butanol
198	42	(2R,3S)-3-amino-1-[(2-phenoxyethyl)amino]-4-phenyl-
199	43	2-butanol
199	43	(2R,3S)-3-amino-4-phenyl-1-[(2-propoxyethyl)amino]-
200	44	2-butanol (2R,3S)-3-amino-1-[(3,3-dimethylbutyl)amino]-4-
200	44	
201	45	phenyl-2-butanol (2R,3S)-3-amino-4-phenyl-1-[(4-phenylbutyl)amino]-
201	45	2-butanol
202	46	(2R,3S)-3-amino-1-[(3-iodobenzyl)amino]-4-phenyl-2-
202	40	butanol
203	47	
203	4/	(2R,3S)-3-amino-1-[(4-nitrobenzyl)amino]-4-phenyl- 2-butanol
204	48	(2R,3S)-3-amino-1-[(3-chlorobenzyl)amino]-4-phenyl-
204	40	2-butanol
205	49	(2R,3S)-3-amino-1-{[2-(4-chlorophenyl)ethyl]amino}-
205	49	=-
206	50	4-phenyl-2-butanol (2R,3S)-3-amino-4-phenyl-1-{[2-(2-
200	1 50	
207	51	pyridinyl)ethyl]amino}-2-butanol
207	1 21	(2R,3S)-3-amino-4-phenyl-1-[(4-
208	52	pyidinylmethyl)amino]-2-butanol
208	54	(2R, 3S) - 3 - amino - 1 - { [2 - (1 - methy1 - 2 - methy
200	E 2	pyrrolidinyl)ethyl]amino}-4-phenyl-2-butanol
209	53	(2R,3S)-3-amino-1-[(2,3-dimethylbenzyl)amino]-4-
210	F 4	phenyl-2-butanol
210	54	(2R,3S)-3-amino-4-phenyl-1-{[2-
L	L	(trifluoromethoxy)benzyl]amino}-2-butanol

1	011	TEE	1/07/2010
1	211	55	(2R,3S)-3-amino-1-[(2-chloro-6-
(trifluoromethyl)benzyl]amino}-2-butanol  (2R,3S)-3-amino-1-[(2,3-dichlorobenzyl)amino]-4- phenyl-2-butanol  (2R,3S)-3-amino-1-[(3,5-dichlorobenzyl)amino]-4- phenyl-2-butanol  (2R,3S)-3-amino-1-[(3,5-difluorobenzyl)amino]-4- phenyl-2-butanol  (2R,3S)-3-amino-4-phenyl-1-[(4- (trifluoromethoxy)benzyl)amino}-2-butanol  4-(([(2R,3S)-3-amino-2-hydroxy-4-phenyl) butyl]amino]methyl)benzenesulfonamide  (2R,3S)-3-amino-1-[(4-methoxybenzyl)amino]-4- phenyl-2-butanol  (2R,3S)-3-amino-1-[(4-methylbenzyl)amino]-4- phenyl-2-butanol  (2R,3S)-3-amino-4-phenyl-1-([3,4,5- trimethoxybenzyl)amino]-2-butanol  (2R,3S)-3-amino-4-phenyl-1-([3- (trifluoromethoxy)benzyl)amino]-2-butanol  (2R,3S)-3-amino-1-[(3,5-dimethoxybenzyl)amino]-4- phenyl-2-butanol  (2R,3S)-3-amino-1-[(2,4-dimethoxybenzyl)amino]-4- phenyl-2-butanol  (2R,3S)-3-amino-1-[(1,1'-biphenyl)-3- ylmethyl)amino]-4-phenyl-2-butanol  (2R,3S)-3-amino-1-[(3,4-dichlorobenzyl)amino]-4- phenyl-2-butanol  (2R,3S)-3-amino-1-[(2-fluorobenzyl)amino]-4-phenyl-2-butanol  (2R,3S)-3-amino-1-[(2-fluorobenzyl)amino]-4-phenyl-2-butanol  (2R,3S)-3-amino-1-[(2-fluorobenzyl)amino]-4-phenyl-2-butanol  (2R,3S)-3-amino-1-[(2-fluorobenzyl)amino]-4-phenyl-2-butanol  (2R,3S)-3-amino-1-[(2-fluorobenzyl)amino]-4-phenyl-2-butanol  (2R,3S)-3-amino-1-[(2-fluorobenzyl)amino]-4-phenyl-2-butanol  (2R,3S)-3-amino-1-[(2-fluorobenzyl)amino]-4-phenyl-2-butanol  (2R,3S)-3-amino-4-phenyl-1-[([1S)-1- phenylethyl]amino)-2-butanol  (2R,3S)-3-amino-4-phenyl-1-[([1S)-1- phenylethyl]amino)-2-butanol  (2R,3S)-3-amino-1-([(1R)-1-(1- nphenylethyl]amino)-2-butanol  (2R,3S)-3-amino-1-([(1S)-1-(1- naphthyl)ethyl]amino)-2-butanol		<del> </del>	phenoxybenzyl)amino]-4-phenyl-2-butanol
13   57	212	56	
phenyl-2-butanol   214 58		<u> </u>	(trifluoromethyl)benzyl]amino}-2-butanol
214 58 (2R,3S)-3-amino-1-[(3,5-dichlorobenzyl) amino]-4-phenyl-2-butanol 215 59 (2R,3S)-3-amino-1-[(3,5-difluorobenzyl) amino]-4-phenyl-2-butanol 216 60 (2R,3S)-3-amino-4-phenyl-1-[(4-(trifluoromethoxy) benzyl] amino]-2-butanol 217 61 4-(([(2R,3S))-3-amino-2-hydroxy-4-phenyl butyl] amino]methyl) benzenesulfonamide 218 62 (2R,3S)-3-amino-1-[(4-methoxybenzyl) amino]-4-phenyl-2-butanol 219 63 (2R,3S)-3-amino-1-[(4-methylbenzyl) amino]-4-phenyl-2-butanol 220 64 (2R,3S)-3-amino-4-phenyl-1-[(3,4,5-trimethoxybenzyl) amino]-2-butanol 221 65 (2R,3S)-3-amino-4-phenyl-1-[(3,6-trifluoromethoxy) benzyl] amino}-2-butanol 222 66 (2R,3S)-3-amino-1-[(3,5-dimethoxybenzyl) amino]-4-phenyl-2-butanol 223 67 (2R,3S)-3-amino-1-[(1,1'-biphenyl]-3-yhmethyl) amino]-4-phenyl-2-butanol 224 68 (2R,3S)-3-amino-1-[(1,1'-biphenyl]-3-yhmethyl) amino]-4-phenyl-2-butanol 225 69 (2R,3S)-3-amino-1-[(3,4-dichlorobenzyl) amino]-4-phenyl-2-butanol 226 70 (2R,3S)-3-amino-1-[(2-fluorobenzyl) amino]-4-phenyl-2-butanol 227 71 (2R,3S)-3-amino-1-[(2-fluorobenzyl) amino]-4-phenyl-2-butanol 228 72 (2R,3S)-3-amino-1-[(2-methylbenzyl) amino]-4-phenyl-2-butanol 229 73 (2R,3S)-3-amino-4-phenyl-1-([(1R)-1-phenylethyl] amino)-2-butanol 230 74 (2R,3S)-3-amino-4-phenyl-1-([(1S)-1-phenylethyl] amino)-2-butanol 231 75 (2R,3S)-3-amino-1-[(3,5-bis(trifluoromethyl) benzyl] amino)-4-phenyl-2-butanol 232 76 (2R,3S)-3-amino-1-([(1S)-1-(1-naphtyl) ethyl) amino)-4-phenyl-2-butanol 233 77 (2R,3S)-3-amino-1-([(1S)-1-(1-naphtyl) ethyl] amino)-4-phenyl-2-butanol 234 78 (2R,3S)-3-amino-1-([(1S)-1-(1-naphtyl) ethyl] amino)-4-phenyl-2-butanol	213	57	(2R,3S)-3-amino-1-[(2,3-dichlorobenzyl)amino]-4-
phenyl-2-butanol (2R,3S)-3-amino-1-[(3,5-difluorobenzyl)amino]-4-phenyl-2-butanol (2R,3S)-3-amino-4-phenyl-1-([4-(trifluoromethoxy)benzyl]amino}-2-butanol (2R,3S)-3-amino-4-phenyl-1-([4-(trifluoromethoxy)benzyl]amino}-2-butanol (2R,3S)-3-amino-1-[(4-methoxybenzyl)amino]-4-phenyl-2-butanol (2R,3S)-3-amino-1-[(4-methylbenzyl)amino]-4-phenyl-2-butanol (2R,3S)-3-amino-4-phenyl-1-[(3,4,5-trimethoxybenzyl)amino]-2-butanol (2R,3S)-3-amino-4-phenyl-1-[(3,4,5-trimethoxybenzyl)amino]-2-butanol (2R,3S)-3-amino-4-phenyl-1-[(3,4-5-trimethoxybenzyl)amino]-2-butanol (2R,3S)-3-amino-1-[(3,5-dimethoxybenzyl)amino]-4-phenyl-2-butanol (2R,3S)-3-amino-1-[(2,4-dimethoxybenzyl)amino]-4-phenyl-2-butanol (2R,3S)-3-amino-1-[(1,1'-biphenyl)-3-ylmethyl)amino]-4-phenyl-2-butanol (2R,3S)-3-amino-1-[(3,4-dichlorobenzyl)amino]-4-phenyl-2-butanol (2R,3S)-3-amino-1-[(2-fluorobenzyl)amino]-4-phenyl-2-butanol (2R,3S)-3-amino-1-[(2-fluorobenzyl)amino]-4-phenyl-2-butanol (2R,3S)-3-amino-4-phenyl-1-([3-(trifluoromethyl)benzyl]amino)-2-butanol (2R,3S)-3-amino-4-phenyl-1-([(1R)-1-phenylethyl)amino]-2-butanol (2R,3S)-3-amino-4-phenyl-1-([(1S)-1-phenylethyl)amino)-2-butanol (2R,3S)-3-amino-4-phenyl-1-([(1S)-1-phenylethyl)amino)-2-butanol (2R,3S)-3-amino-1-([(3,5-bis(trifluoromethyl)benzyl)amino)-4-phenyl-2-butanol (2R,3S)-3-amino-1-([(1S)-1-(1-naphtyl)chyl)amino)-2-butanol			
215   59   (2R,3S)-3-amino-1-[(3,5-difluorobenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-4-phenyl-1-{[4-(trifluoromethoxy)benzyl]amino}-2-butanol   (2R,3S)-3-amino-2-hydroxy-4-phenyl   butyl]amino]methyl)benzenesulfonamide   (2R,3S)-3-amino-1-[(4-methoxybenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(4-methylbenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(3,4,5-trimethoxybenzyl)amino]-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(3,4,5-trifluoromethoxy)benzyl]amino]-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(3,5-dimethoxybenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(2,4-dimethoxybenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(1,1'-biphenyl)-3-ylmethyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(1,4-dimethoxybenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(1,4-dimethoxybenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(2,4-dimethoxybenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(1,4-dimethoxybenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(2,4-dimethoxybenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(1,4-dimethoxybenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(2,4-dimethoxybenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(1,4-dimethoxybenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(2,4-dimethoxybenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(2,4-dimethoxybenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(2,4-dimethoxybenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(2,4-dimethoxybenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(2,4-dimethoxybenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(2,4-dimethoxybenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(3,5-bis(trifluoromethyl)amino)-2-butanol   (2R,3S)-3-amino-1-[(3,5-bis(trifluoromethyl)amino]-2-butanol   (2R,3S)-3-amino-1-[(3,5-bis(trifluoromethyl)amino]-2-butanol   (2R,3S)-3-amino-1-[(3,5-bis(trifluoromethyl)amino]-2-butanol   (2R,3S)-3-amino-1-[(3,5-bis(trifluoromethyl)amino]-2-butanol   (2R,3S)-3-amino-1-[(3,5-bis(trifluoromethyl)amino]-2	214	58	(2R,3S)-3-amino-1-[(3,5-dichlorobenzyl)amino]-4-
pheny1-2-butanol   (2R,3S)-3-amino-4-pheny1-1-{[4-(trifluoromethoxy)benzy1]amino}-2-butanol   (2r,3S)-3-amino-2-hydroxy-4-pheny1   buty1]amino}methy1)benzenesulfonamide   (2R,3S)-3-amino-1-[(4-methoxybenzy1)amino]-4-pheny1-2-butanol   (2R,3S)-3-amino-1-[(4-methylbenzy1)amino]-4-pheny1-2-butanol   (2R,3S)-3-amino-4-pheny1-1-[(3,4,5-trimethoxybenzy1)amino]-2-butanol   (2R,3S)-3-amino-4-pheny1-1-{[3-(trifluoromethoxy)benzy1]amino}-2-butanol   (2R,3S)-3-amino-4-pheny1-1-{[3-(trifluoromethoxy)benzy1]amino}-2-butanol   (2R,3S)-3-amino-1-[(3,5-dimethoxybenzy1)amino]-4-pheny1-2-butanol   (2R,3S)-3-amino-1-[(2,4-dimethoxybenzy1)amino]-4-pheny1-2-butanol   (2R,3S)-3-amino-1-[(1,1'-bipheny1)-3-ylmethy1)amino]-4-pheny1-2-butanol   (2R,3S)-3-amino-1-[(3,4-dichlorobenzy1)amino]-4-pheny1-2-butanol   (2R,3S)-3-amino-1-[(2-fluorobenzy1)amino]-4-pheny1-2-butanol   (2R,3S)-3-amino-1-[(2-fluorobenzy1)amino]-4-pheny1-2-butanol   (2R,3S)-3-amino-4-pheny1-1-([3-(trifluoromethy1)benzy1]amino}-2-butanol   (2R,3S)-3-amino-4-pheny1-1-[((1R)-1-phenylethy1]amino}-2-butanol   (2R,3S)-3-amino-4-pheny1-1-[((1S)-1-phenylethy1]amino}-2-butanol   (2R,3S)-3-amino-1-[(3,5-bis(trifluoromethy1)benzy1]amino}-4-pheny1-2-butanol   (2R,3S)-3-amino-1-[(3,5-bis(trifluoromethy1)benzy1]amino}-2-butanol   (2R,3S)-3-amino-1-[(3,5-bis(trifluoromethy1)benzy1]amino}-2-butanol   (2R,3S)-3-amino-1-[(1,5)-1-(1-naphthy1)ethy1]amino}-2-butanol   (2R,3S)-3-amino-1-[(1,5)-1-(1-naphthy1)ethy1]amino}-2-butanol   (2R,3S)-3-amino-1-[(1,5)-1-(1-naphthy1)ethy1]amino}-2-butanol   (2R,3S)-3-amino-1-[(1,5)-1-(1-naphthy1)ethy1]amino}-2-butanol   (2R,3S)-3-amino-1-[(1,5)-1-(1-naphthy1)ethy1]amino}-2-butanol   (2R,3S)-3-amino-1-[(1,5)-1-(1-naphthy1)ethy1]amino}-2-butanol   (2R,3S)-3-amino-1-[(1,5)-1-(1-naphthy1)ethy1]amino]-2-butanol   (2R,3S)-3-amino-1-[(1,5)-1-(1-naphthy1)ethy1]amino]-2-butanol   (2R,3S)-3-amino-1-[(1,5)-1-(1-naphthy1)ethy1]amino]-2-butanol   (2R,3S)-3-amino-1-[(1,5)-1-(1-naphthy1)ethy1]amino]-2-butanol   (2R,3S)-3-amino-1-[(1,5)-1-(1-naphthy1)ethy1]amino]-2-b		ļ	
216   60   (2R,3S)-3-amino-4-phenyl-1-{[4-(trifluoromethoxy) benzyl]amino}-2-butanol   217   61   4-([(2R,3S)-3-amino-2-hydroxy-4-phenyl butyl]amino)methyl) benzenesulfonamide   218   62   (2R,3S)-3-amino-1-[(4-methoxybenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(4-methylbenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(3,4,5-trimethoxybenzyl)amino]-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(3,-trifluoromethoxy)benzyl]amino]-2-butanol   (2R,3S)-3-amino-1-[(3,5-dimethoxybenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(2,4-dimethoxybenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(1,1*-biphenyl)-3-ylmethyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(3,4-dichlorobenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(3,4-dichlorobenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(2-fluorobenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-4-phenyl-1-([3-(trifluoromethyl)benzyl]amino)-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(1R)-1-phenylethyl]amino)-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(1S)-1-phenylethyl]amino)-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(1S)-1-phenylethyl]amino)-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(1S)-1-phenylethyl]amino)-2-butanol   (2R,3S)-3-amino-1-[(3,5-bis(trifluoromethyl)benzyl]amino)-2-butanol   (2R,3S)-3-amino-1-[(3,5-bis(trifluoromethyl)benzyl]amino)-2-butanol   (2R,3S)-3-amino-1-[(1S)-1-(1-naphthyl)ethyl]amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(1S)-1-(1-naphthyl)ethyl]amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(1S)-1-(1-naphthyl)ethyl]amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(1S)-1-(1-naphthyl)ethyl]amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(1S)-1-(1-naphthyl)ethyl]amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(1S)-1-(1-naphthyl)ethyl]amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(1S)-1-(1-naphthyl)ethyl]amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(1S)-1-(1-naphthyl)ethyl]amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(1R)-1-(1-naphthyl)ethyl]amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(1R)-1-(1-naphthyl)ethyl]amino	215	59	
(trifluoromethoxy) benzyl] amino} -2-butanol  4-([[(2R,3S)-3-amino-2-hydroxy-4-phenyl] butyl] amino} methyl) benzenesulfonamide  (2R,3S)-3-amino-1-[(4-methoxybenzyl) amino]-4-phenyl-2-butanol  (2R,3S)-3-amino-1-[(4-methylbenzyl) amino]-4-phenyl-2-butanol  (2R,3S)-3-amino-4-phenyl-1-[(3,4,5-trimethoxybenzyl) amino]-2-butanol  (2R,3S)-3-amino-4-phenyl-1-[(3-(trifluoromethoxy) benzyl] amino]-2-butanol  (2R,3S)-3-amino-1-[(3,5-dimethoxybenzyl) amino]-4-phenyl-2-butanol  (2R,3S)-3-amino-1-[(2,4-dimethoxybenzyl) amino]-4-phenyl-2-butanol  (2R,3S)-3-amino-1-[(1,1'-biphenyl)-3-yhmethyl) amino]-4-phenyl-2-butanol  (2R,3S)-3-amino-1-[(3,4-dichlorobenzyl) amino]-4-phenyl-2-butanol  (2R,3S)-3-amino-1-[(2-fluorobenzyl) amino]-4-phenyl-2-butanol  (2R,3S)-3-amino-1-[(2-fluorobenzyl) amino]-4-phenyl-2-butanol  (2R,3S)-3-amino-1-[(2-methylbenzyl) amino]-4-phenyl-2-butanol  (2R,3S)-3-amino-1-[(2-methylbenzyl) amino]-4-phenyl-2-butanol  (2R,3S)-3-amino-1-[(3,5-bis(trifluoromethyl) benzyl] amino)-2-butanol  (2R,3S)-3-amino-1-[(3,5-bis(trifluoromethyl) benzyl] amino)-4-phenyl-2-butanol			
217 61	216	60	
butyl amino methyl benzenesulfonamide   (2R,3S)-3-amino-1-[(4-methoxybenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(4-methylbenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(3,4,5-trimethoxybenzyl)amino]-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(3,4,5-trimethoxybenzyl)amino]-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(3,5-dimethoxybenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(3,5-dimethoxybenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[([1,1'-biphenyl])amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[([1,1'-biphenyl])amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(3,4-dichlorobenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(2-fluorobenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(3-(trifluoromethyl)benzyl]amino]-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(1R)-1-phenylethyl]amino]-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(1S)-1-phenylethyl]amino]-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(1S)-1-phenylethyl]amino]-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(1S)-1-phenylethyl]amino]-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(1S)-1-phenylethyl]amino]-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(1S)-1-phenylethyl]amino]-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(1R)-1-phenylethyl]amino]-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(1R)-1-phenylethyl]amino]-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(1R)-1-phenylethyl]amino]-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(1R)-1-phenylethyl]amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(1R)-1-(1-naphthyl)ethyl]amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(1R)-1-(1-naphthyl)ethyl]amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(1R)-1-(1-naphthyl)ethyl]amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(1R)-1-(1-naphthyl)ethyl]amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(1R)-1-(1-naphthyl)ethyl]amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(1R)-1-(1-naphthyl)ethyl]amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(1R)-1-(1-naphthyl)ethyl]amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(1R)-1-(1-naphthyl)ethyl]amino]-4-phenyl-2-butan			(trifluoromethoxy)benzyl]amino}-2-butanol
218 62 (2R,3S)-3-amino-1-[(4-methoxybenzyl)amino]-4-phenyl-2-butanol 219 63 (2R,3S)-3-amino-1-[(4-methylbenzyl)amino]-4-phenyl-2-butanol 220 64 (2R,3S)-3-amino-4-phenyl-1-[(3,4,5-trimethoxybenzyl)amino]-2-butanol 221 65 (2R,3S)-3-amino-4-phenyl-1-{[3-(trifluoromethoxy)benzyl]amino}-2-butanol 222 66 (2R,3S)-3-amino-1-[(3,5-dimethoxybenzyl)amino]-4-phenyl-2-butanol 223 67 (2R,3S)-3-amino-1-[(2,4-dimethoxybenzyl)amino]-4-phenyl-2-butanol 224 68 (2R,3S)-3-amino-1-[([1,1'-biphenyl]-3-ylmethyl)amino]-4-phenyl-2-butanol 225 69 (2R,3S)-3-amino-1-[(3,4-dichlorobenzyl)amino]-4-phenyl-2-butanol 226 70 (2R,3S)-3-amino-1-[(2-fluorobenzyl)amino]-4-phenyl-2-butanol 227 71 (2R,3S)-3-amino-4-phenyl-1-{[3-(trifluoromethyl)benzyl]amino}-2-butanol 228 72 (2R,3S)-3-amino-1-[(2-methylbenzyl)amino]-4-phenyl-2-butanol 229 73 (2R,3S)-3-amino-4-phenyl-1-{[(1R)-1-phenylethyl]amino}-2-butanol 230 74 (2R,3S)-3-amino-4-phenyl-1-{[(1S)-1-phenylethyl]amino}-2-butanol 231 75 (2R,3S)-3-amino-1-[(3,5-bis(trifluoromethyl)benzyl]amino}-4-phenyl-2-butanol 232 76 (2R,3S)-3-amino-1-[([1S)-1-(1-naphthyl)ethyl]amino}-2-butanol 233 77 (2R,3S)-3-amino-1-{[(1S)-1-(1-naphthyl)ethyl]amino}-4-phenyl-2-butanol 234 78 (2R,3S)-3-amino-1-{[(1R)-1-(1-naphthyl)ethyl]amino}-4-phenyl-2-butanol	217	61	4-({[(2R,3S)-3-amino-2-hydroxy-4-phenyl
phenyl-2-butanol   (2R,3S)-3-amino-1-[(4-methylbenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(3,4,5-trimethoxybenzyl)amino]-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(3-(trifluoromethoxy)benzyl]amino}-2-butanol   (2R,3S)-3-amino-1-[(3,5-dimethoxybenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(3,4-dimethoxybenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(1,1'-biphenyl)-3-ylmethyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(3,4-dichlorobenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(2-fluorobenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(2-fluorobenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(2-fluorobenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(2-methylbenzyl)amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(1R)-1-phenylethyl]amino)-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(1S)-1-phenylethyl]amino)-2-butanol   (2R,3S)-3-amino-1-[(3,5-bis(trifluoromethyl)benzyl]amino)-4-phenyl-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(2-(trifluoromethyl)benzyl]amino)-2-butanol   (2R,3S)-3-amino-1-[(3,5-bis(trifluoromethyl)benzyl]amino)-2-butanol   (2R,3S)-3-amino-1-[(1S)-1-(1-naphthyl)ethyl]amino)-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(1R)-1-(1-naphthyl)ethyl]amino-1-[(1R)-1-(1-naphthyl)ethyl]amino-1-[(1R)-1-(1-naphthyl)ethyl]amino-1-[(1R)-1-(1R)-1-(1R)-			butyl]amino}methyl)benzenesulfonamide
219 63 (2R,3S)-3-amino-1-[(4-methylbenzyl)amino]-4-phenyl- 2-butanol 220 64 (2R,3S)-3-amino-4-phenyl-1-[(3,4,5- trimethoxybenzyl)amino]-2-butanol 221 65 (2R,3S)-3-amino-4-phenyl-1-{{3-	218	62	(2R,3S)-3-amino-1-[(4-methoxybenzyl)amino]-4-
2-butanol  220 64 (2R,3S)-3-amino-4-phenyl-1-[(3,4,5-trimethoxybenzyl)amino]-2-butanol  221 65 (2R,3S)-3-amino-4-phenyl-1-[(3-(trifluoromethoxy)benzyl]amino}-2-butanol  222 66 (2R,3S)-3-amino-1-[(3,5-dimethoxybenzyl)amino]-4-phenyl-2-butanol  223 67 (2R,3S)-3-amino-1-[(2,4-dimethoxybenzyl)amino]-4-phenyl-2-butanol  224 68 (2R,3S)-3-amino-1-[([1,1'-biphenyl]-3-ylmethyl)amino]-4-phenyl-2-butanol  225 69 (2R,3S)-3-amino-1-[(3,4-dichlorobenzyl)amino]-4-phenyl-2-butanol  226 70 (2R,3S)-3-amino-1-[(2-fluorobenzyl)amino]-4-phenyl-2-butanol  227 71 (2R,3S)-3-amino-4-phenyl-1-{[3-(trifluoromethyl)benzyl]amino}-2-butanol  228 72 (2R,3S)-3-amino-1-[(2-methylbenzyl)amino]-4-phenyl-2-butanol  229 73 (2R,3S)-3-amino-4-phenyl-1-{[(1R)-1-phenylethyl]amino}-2-butanol  230 74 (2R,3S)-3-amino-4-phenyl-1-{[(1S)-1-phenylethyl]amino}-2-butanol  231 75 (2R,3S)-3-amino-1-[(3,5-bis(trifluoromethyl)benzyl]amino}-4-phenyl-2-butanol  232 76 (2R,3S)-3-amino-4-phenyl-1-{[2-(trifluoromethyl)benzyl]amino}-2-butanol  233 77 (2R,3S)-3-amino-1-[[(1S)-1-(1-naphthyl)ethyl]amino}-4-phenyl-2-butanol  234 78 (2R,3S)-3-amino-1-{[(1S)-1-(1-naphthyl)ethyl]amino}-4-phenyl-2-butanol			
220 64 (2R,3S)-3-amino-4-phenyl-1-[(3,4,5-trimethoxybenzyl)amino]-2-butanol  221 65 (2R,3S)-3-amino-4-phenyl-1-{[3-(trifluoromethoxy)benzyl]amino}-2-butanol  222 66 (2R,3S)-3-amino-1-[(3,5-dimethoxybenzyl)amino]-4-phenyl-2-butanol  223 67 (2R,3S)-3-amino-1-[(2,4-dimethoxybenzyl)amino]-4-phenyl-2-butanol  224 68 (2R,3S)-3-amino-1-[([1,1'-biphenyl]-3-ylmethyl)amino]-4-phenyl-2-butanol  225 69 (2R,3S)-3-amino-1-[(3,4-dichlorobenzyl)amino]-4-phenyl-2-butanol  226 70 (2R,3S)-3-amino-1-[(2-fluorobenzyl)amino]-4-phenyl-2-butanol  227 71 (2R,3S)-3-amino-4-phenyl-1-{[3-(trifluoromethyl)benzyl]amino}-2-butanol  228 72 (2R,3S)-3-amino-1-[(2-methylbenzyl)amino]-4-phenyl-2-butanol  229 73 (2R,3S)-3-amino-4-phenyl-1-{[(1R)-1-phenylethyl]amino}-2-butanol  230 74 (2R,3S)-3-amino-4-phenyl-1-{[(1S)-1-phenylethyl]amino}-2-butanol  231 75 (2R,3S)-3-amino-4-phenyl-1-{[(2-(trifluoromethyl)benzyl]amino}-4-phenyl-2-butanol  232 76 (2R,3S)-3-amino-4-phenyl-1-{[2-(trifluoromethyl)benzyl]amino}-2-butanol  233 77 (2R,3S)-3-amino-1-{[(1S)-1-(1-naphthyl)ethyl]amino}-4-phenyl-2-butanol  234 78 (2R,3S)-3-amino-1-{[(1S)-1-(1-naphthyl)ethyl]amino}-4-phenyl-2-butanol	219	63	(2R,3S)-3-amino-1-[(4-methylbenzyl)amino]-4-phenyl-
trimethoxybenzyl)amino]-2-butanol  (2R,3S)-3-amino-4-phenyl-1-{[3-(trifluoromethoxy)benzyl]amino}-2-butanol  (2R,3S)-3-amino-1-[(3,5-dimethoxybenzyl)amino]-4-phenyl-2-butanol  (2R,3S)-3-amino-1-[(2,4-dimethoxybenzyl)amino]-4-phenyl-2-butanol  (2R,3S)-3-amino-1-[([1,1'-biphenyl]-3-ylmethyl)amino]-4-phenyl-2-butanol  (2R,3S)-3-amino-1-[(3,4-dichlorobenzyl)amino]-4-phenyl-2-butanol  (2R,3S)-3-amino-1-[(2-fluorobenzyl)amino]-4-phenyl-2-butanol  (2R,3S)-3-amino-4-phenyl-1-{[3-(trifluoromethyl)benzyl]amino}-2-butanol  (2R,3S)-3-amino-4-phenyl-1-{[(1R)-1-phenylethyl]amino}-2-butanol  (2R,3S)-3-amino-4-phenyl-1-{[(1S)-1-phenylethyl]amino}-2-butanol  (2R,3S)-3-amino-4-phenyl-1-{[(1S)-1-phenylethyl]amino}-2-butanol  (2R,3S)-3-amino-4-phenyl-1-{[(1S)-1-phenylethyl]amino}-2-butanol  (2R,3S)-3-amino-1-{[(3,5-bis(trifluoromethyl)benzyl]amino}-4-phenyl-2-butanol  (2R,3S)-3-amino-1-{[(1S)-1-(1-naphtyl)]amino}-2-butanol  (2R,3S)-3-amino-4-phenyl-1-{[2-(trifluoromethyl)benzyl]amino}-2-butanol			
221 65 (2R,3S)-3-amino-4-phenyl-1-{[3-(trifluoromethoxy)benzyl]amino}-2-butanol 222 66 (2R,3S)-3-amino-1-[(3,5-dimethoxybenzyl)amino]-4-phenyl-2-butanol 223 67 (2R,3S)-3-amino-1-[(2,4-dimethoxybenzyl)amino]-4-phenyl-2-butanol 224 68 (2R,3S)-3-amino-1-[([1,1'-biphenyl]-3-ylmethyl)amino]-4-phenyl-2-butanol 225 69 (2R,3S)-3-amino-1-[(3,4-dichlorobenzyl)amino]-4-phenyl-2-butanol 226 70 (2R,3S)-3-amino-1-[(2-fluorobenzyl)amino]-4-phenyl-2-butanol 227 71 (2R,3S)-3-amino-4-phenyl-1-{[3-(trifluoromethyl)benzyl]amino}-2-butanol 228 72 (2R,3S)-3-amino-4-phenyl-1-{[(1R)-1-phenylethyl]amino}-2-butanol 229 73 (2R,3S)-3-amino-4-phenyl-1-{[(1S)-1-phenylethyl]amino}-2-butanol 230 74 (2R,3S)-3-amino-4-phenyl-1-{[(1S)-1-phenylethyl]amino}-2-butanol 231 75 (2R,3S)-3-amino-1-{[3,5-bis(trifluoromethyl)benzyl]amino}-4-phenyl-2-butanol 232 76 (2R,3S)-3-amino-4-phenyl-1-{[2-(trifluoromethyl)benzyl]amino}-2-butanol 233 77 (2R,3S)-3-amino-1-{[(1S)-1-(1-naphthyl)ethyl]amino}-4-phenyl-2-butanol 234 78 (2R,3S)-3-amino-1-{[(1S)-1-(1-naphthyl)ethyl]amino}-4-phenyl-2-butanol	220	64	
(trifluoromethoxy)benzyl]amino}-2-butanol  (2R, 3S)-3-amino-1-[(3,5-dimethoxybenzyl)amino]-4-phenyl-2-butanol  (2R, 3S)-3-amino-1-[(2,4-dimethoxybenzyl)amino]-4-phenyl-2-butanol  (2R, 3S)-3-amino-1-[([1,1'-biphenyl]-3-ylmethyl)amino]-4-phenyl-2-butanol  (2R, 3S)-3-amino-1-[(3,4-dichlorobenzyl)amino]-4-phenyl-2-butanol  (2R, 3S)-3-amino-1-[(2-fluorobenzyl)amino]-4-phenyl-2-butanol  (2R, 3S)-3-amino-4-phenyl-1-[(3-(trifluoromethyl)benzyl]amino}-2-butanol  (2R, 3S)-3-amino-1-[(2-methylbenzyl)amino]-4-phenyl-2-butanol  (2R, 3S)-3-amino-4-phenyl-1-[((1R)-1-phenylethyl]amino}-2-butanol  (2R, 3S)-3-amino-4-phenyl-1-[((1S)-1-phenylethyl]amino}-2-butanol  (2R, 3S)-3-amino-1-[(3,5-bis(trifluoromethyl)benzyl]amino}-4-phenyl-2-butanol  (2R, 3S)-3-amino-1-[(1S)-1-(1-naphtyl)]amino}-2-butanol			trimethoxybenzyl)amino]-2-butanol
222 66 (2R,3S)-3-amino-1-[(3,5-dimethoxybenzyl)amino]-4-phenyl-2-butanol 223 67 (2R,3S)-3-amino-1-[(2,4-dimethoxybenzyl)amino]-4-phenyl-2-butanol 224 68 (2R,3S)-3-amino-1-[([1,1'-biphenyl]-3-ylmethyl)amino]-4-phenyl-2-butanol 225 69 (2R,3S)-3-amino-1-[(3,4-dichlorobenzyl)amino]-4-phenyl-2-butanol 226 70 (2R,3S)-3-amino-1-[(2-fluorobenzyl)amino]-4-phenyl-2-butanol 227 71 (2R,3S)-3-amino-4-phenyl-1-{[3-(trifluoromethyl)benzyl]amino}-2-butanol 228 72 (2R,3S)-3-amino-1-[(2-methylbenzyl)amino]-4-phenyl-2-butanol 229 73 (2R,3S)-3-amino-4-phenyl-1-{[(1R)-1-phenylethyl]amino}-2-butanol 230 74 (2R,3S)-3-amino-4-phenyl-1-{[(1S)-1-phenylethyl]amino}-2-butanol 231 75 (2R,3S)-3-amino-1-{[3,5-bis(trifluoromethyl)benzyl]amino}-4-phenyl-2-butanol 232 76 (2R,3S)-3-amino-4-phenyl-1-{[2-(trifluoromethyl)benzyl]amino}-2-butanol 233 77 (2R,3S)-3-amino-1-{[(1S)-1-(1-naphthyl)ethyl]amino}-4-phenyl-2-butanol 234 78 (2R,3S)-3-amino-1-{[(1R)-1-(1-	221	65	
phenyl-2-butanol  223 67 (2R,3S)-3-amino-1-[(2,4-dimethoxybenzyl)amino]-4-phenyl-2-butanol  224 68 (2R,3S)-3-amino-1-[([1,1'-biphenyl]]-3-ylmethyl)amino]-4-phenyl-2-butanol  225 69 (2R,3S)-3-amino-1-[(3,4-dichlorobenzyl)amino]-4-phenyl-2-butanol  226 70 (2R,3S)-3-amino-1-[(2-fluorobenzyl)amino]-4-phenyl-2-butanol  227 71 (2R,3S)-3-amino-4-phenyl-1-{[3-(trifluoromethyl)benzyl]amino}-2-butanol  228 72 (2R,3S)-3-amino-1-[(2-methylbenzyl)amino]-4-phenyl-2-butanol  229 73 (2R,3S)-3-amino-4-phenyl-1-{[(1R)-1-phenylethyl]amino}-2-butanol  230 74 (2R,3S)-3-amino-4-phenyl-1-{[(1S)-1-phenylethyl]amino}-2-butanol  231 75 (2R,3S)-3-amino-1-{[3,5-bis(trifluoromethyl)benzyl]amino}-4-phenyl-2-butanol  232 76 (2R,3S)-3-amino-4-phenyl-1-{[2-(trifluoromethyl)benzyl]amino}-2-butanol  233 77 (2R,3S)-3-amino-1-{[(1S)-1-(1-naphthyl)ethyl]amino}-4-phenyl-2-butanol  234 78 (2R,3S)-3-amino-1-{[(1R)-1-(1-			(trifluoromethoxy)benzyl]amino}-2-butanol
223 67 (2R,3S)-3-amino-1-[(2,4-dimethoxybenzyl)amino]-4-phenyl-2-butanol  224 68 (2R,3S)-3-amino-1-[([1,1'-biphenyl]-3-ylmethyl)amino]-4-phenyl-2-butanol  225 69 (2R,3S)-3-amino-1-[(3,4-dichlorobenzyl)amino]-4-phenyl-2-butanol  226 70 (2R,3S)-3-amino-1-[(2-fluorobenzyl)amino]-4-phenyl-2-butanol  227 71 (2R,3S)-3-amino-4-phenyl-1-{[3-(trifluoromethyl)benzyl]amino}-2-butanol  228 72 (2R,3S)-3-amino-1-[(2-methylbenzyl)amino]-4-phenyl-2-butanol  229 73 (2R,3S)-3-amino-4-phenyl-1-{[(1R)-1-phenylethyl]amino}-2-butanol  230 74 (2R,3S)-3-amino-4-phenyl-1-{[(1S)-1-phenylethyl]amino}-2-butanol  231 75 (2R,3S)-3-amino-1-{[3,5-bis(trifluoromethyl)benzyl]amino}-4-phenyl-2-butanol  232 76 (2R,3S)-3-amino-4-phenyl-1-{[2-(trifluoromethyl)benzyl]amino}-2-butanol  233 77 (2R,3S)-3-amino-1-{[(1S)-1-(1-naphthyl)ethyl]amino}-4-phenyl-2-butanol  234 78 (2R,3S)-3-amino-1-{[(1R)-1-(1-	222	66	(2R,3S)-3-amino-1-[(3,5-dimethoxybenzyl)amino]-4-
phenyl-2-butanol   (2R,3S)-3-amino-1-[([1,1'-biphenyl]-3-ylmethyl) amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(3,4-dichlorobenzyl) amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-1-[(2-fluorobenzyl) amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-4-phenyl-1-{[3-(trifluoromethyl) benzyl] amino}-2-butanol   (2R,3S)-3-amino-1-[(2-methylbenzyl) amino]-4-phenyl-2-butanol   (2R,3S)-3-amino-4-phenyl-1-{[(1R)-1-phenylethyl] amino}-2-butanol   (2R,3S)-3-amino-4-phenyl-1-{[(1S)-1-phenylethyl] amino}-2-butanol   (2R,3S)-3-amino-4-phenyl-1-{[(1S)-1-phenylethyl] amino}-2-butanol   (2R,3S)-3-amino-1-{[3,5-bis(trifluoromethyl) benzyl] amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-4-phenyl-1-{[2-(trifluoromethyl) benzyl] amino}-2-butanol   (2R,3S)-3-amino-1-{[(1S)-1-(1-naphthyl) ethyl] amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[(1S)-1-(1-naphthyl) ethyl] amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[(1R)-1-(1-maphthyl) ethyl] amino}   (2R,3S)-3-amino-1-{[(1R)-1-(1-maphthyl) ethyl] amino}   (2R,3S)-3-amino-1-{[(1R)-1-(1-maphthyl) ethyl] amino}   (2R,3S)-3-amino-1-{[(1R)-1-(1-maphthyl) ethyl]   (2R,3S			
224   68   (2R,3S)-3-amino-1-[([1,1'-bipheny1]-3-ylmethy1) amino]-4-pheny1-2-butano1  225   69   (2R,3S)-3-amino-1-[(3,4-dichlorobenzy1) amino]-4-pheny1-2-butano1  226   70   (2R,3S)-3-amino-1-[(2-fluorobenzy1) amino]-4-pheny1-2-butano1  227   71   (2R,3S)-3-amino-4-pheny1-1-{[3-(trifluoromethy1) benzy1] amino}-2-butano1  228   72   (2R,3S)-3-amino-1-[(2-methylbenzy1) amino]-4-pheny1-2-butano1  229   73   (2R,3S)-3-amino-4-pheny1-1-{[(1R)-1-phenylethy1] amino}-2-butano1  230   74   (2R,3S)-3-amino-4-pheny1-1-{[(1S)-1-phenylethy1] amino}-2-butano1  231   75   (2R,3S)-3-amino-1-{[3,5-bis(trifluoromethy1) benzy1] amino}-4-pheny1-2-butano1  232   76   (2R,3S)-3-amino-4-pheny1-1-{[2-(trifluoromethy1) benzy1] amino}-2-butano1  233   77   (2R,3S)-3-amino-1-{[(1S)-1-(1-naphthy1) ethy1] amino}-4-pheny1-2-butano1  234   78   (2R,3S)-3-amino-1-{[(1R)-1-(1-	223	67	(2R,3S)-3-amino-1-[(2,4-dimethoxybenzyl)amino]-4-
ylmethyl)amino]-4-phenyl-2-butanol   225   69   (2R,3S)-3-amino-1-[(3,4-dichlorobenzyl)amino]-4-phenyl-2-butanol   226   70   (2R,3S)-3-amino-1-[(2-fluorobenzyl)amino]-4-phenyl-2-butanol   227   71   (2R,3S)-3-amino-4-phenyl-1-{[3-(trifluoromethyl)benzyl]amino}-2-butanol   228   72   (2R,3S)-3-amino-1-[(2-methylbenzyl)amino]-4-phenyl-2-butanol   229   73   (2R,3S)-3-amino-4-phenyl-1-{[(1R)-1-phenylethyl]amino}-2-butanol   230   74   (2R,3S)-3-amino-4-phenyl-1-{[(1S)-1-phenylethyl]amino}-2-butanol   231   75   (2R,3S)-3-amino-1-{[3,5-bis(trifluoromethyl)benzyl]amino}-4-phenyl-2-butanol   232   76   (2R,3S)-3-amino-4-phenyl-1-{[2-(trifluoromethyl)benzyl]amino}-2-butanol   233   77   (2R,3S)-3-amino-1-{[(1S)-1-(1-naphthyl)ethyl]amino}-4-phenyl-2-butanol   234   78   (2R,3S)-3-amino-1-{[(1R)-1-(1-			
225 69 (2R,3S)-3-amino-1-[(3,4-dichlorobenzyl)amino]-4- phenyl-2-butanol  226 70 (2R,3S)-3-amino-1-[(2-fluorobenzyl)amino]-4-phenyl- 2-butanol  227 71 (2R,3S)-3-amino-4-phenyl-1-{[3- (trifluoromethyl)benzyl]amino}-2-butanol  228 72 (2R,3S)-3-amino-1-[(2-methylbenzyl)amino]-4-phenyl- 2-butanol  229 73 (2R,3S)-3-amino-4-phenyl-1-{[(1R)-1- phenylethyl]amino}-2-butanol  230 74 (2R,3S)-3-amino-4-phenyl-1-{[(1S)-1- phenylethyl]amino}-2-butanol  231 75 (2R,3S)-3-amino-1-{[3,5- bis(trifluoromethyl)benzyl]amino}-4-phenyl-2- butanol  232 76 (2R,3S)-3-amino-4-phenyl-1-{[2- (trifluoromethyl)benzyl]amino}-2-butanol  233 77 (2R,3S)-3-amino-1-{[(1S)-1-(1- naphthyl)ethyl]amino}-4-phenyl-2-butanol  234 78 (2R,3S)-3-amino-1-{[(1R)-1-(1-	224	68	
phenyl-2-butanol  226 70			
226 70	225	69	
2-butanol  227 71 (2R,3S)-3-amino-4-phenyl-1-{[3-(trifluoromethyl)benzyl]amino}-2-butanol  228 72 (2R,3S)-3-amino-1-[(2-methylbenzyl)amino]-4-phenyl-2-butanol  229 73 (2R,3S)-3-amino-4-phenyl-1-{[(1R)-1-phenylethyl]amino}-2-butanol  230 74 (2R,3S)-3-amino-4-phenyl-1-{[(1S)-1-phenylethyl]amino}-2-butanol  231 75 (2R,3S)-3-amino-1-{[3,5-bis(trifluoromethyl)benzyl]amino}-4-phenyl-2-butanol  232 76 (2R,3S)-3-amino-4-phenyl-1-{[2-(trifluoromethyl)benzyl]amino}-2-butanol  233 77 (2R,3S)-3-amino-1-{[(1S)-1-(1-naphthyl)ethyl]amino}-4-phenyl-2-butanol  234 78 (2R,3S)-3-amino-1-{[(1R)-1-(1-			
227 71 (2R,3S)-3-amino-4-phenyl-1-{[3- (trifluoromethyl)benzyl]amino}-2-butanol 228 72 (2R,3S)-3-amino-1-[(2-methylbenzyl)amino]-4-phenyl- 2-butanol 229 73 (2R,3S)-3-amino-4-phenyl-1-{[(1R)-1- phenylethyl]amino}-2-butanol 230 74 (2R,3S)-3-amino-4-phenyl-1-{[(1S)-1- phenylethyl]amino}-2-butanol 231 75 (2R,3S)-3-amino-1-{[3,5- bis(trifluoromethyl)benzyl]amino}-4-phenyl-2- butanol 232 76 (2R,3S)-3-amino-4-phenyl-1-{[2- (trifluoromethyl)benzyl]amino}-2-butanol 233 77 (2R,3S)-3-amino-1-{[(1S)-1-(1- naphthyl)ethyl]amino}-4-phenyl-2-butanol 234 78 (2R,3S)-3-amino-1-{[(1R)-1-(1-	226	70	(2R,3S)-3-amino-1-[(2-fluorobenzyl)amino]-4-phenyl-
(trifluoromethyl) benzyl] amino} -2-butanol  (2R, 3S) -3-amino-1-[(2-methylbenzyl) amino] -4-phenyl- 2-butanol  (2R, 3S) -3-amino-4-phenyl-1-{[(1R)-1-phenylethyl] amino} -2-butanol  (2R, 3S) -3-amino-4-phenyl-1-{[(1S)-1-phenylethyl] amino} -2-butanol  (2R, 3S) -3-amino-1-{[3,5-bis(trifluoromethyl) benzyl] amino} -4-phenyl-2-butanol  (2R, 3S) -3-amino-4-phenyl-1-{[2-(trifluoromethyl) benzyl] amino} -2-butanol  (2R, 3S) -3-amino-1-{[(1S)-1-(1-naphthyl) ethyl] amino} -4-phenyl-2-butanol  (2R, 3S) -3-amino-1-{[(1R)-1-(1-2-butanol) 234 78 (2R, 3S) -3-amino-1-{[(1R)-1-(1-4-2-butanol) 24-butanol 24-2-butanol 24-2-bu			
228 72 (2R,3S)-3-amino-1-[(2-methylbenzyl)amino]-4-phenyl- 2-butanol  229 73 (2R,3S)-3-amino-4-phenyl-1-{[(1R)-1- phenylethyl]amino}-2-butanol  230 74 (2R,3S)-3-amino-4-phenyl-1-{[(1S)-1- phenylethyl]amino}-2-butanol  231 75 (2R,3S)-3-amino-1-{[3,5- bis(trifluoromethyl)benzyl]amino}-4-phenyl-2- butanol  232 76 (2R,3S)-3-amino-4-phenyl-1-{[2- (trifluoromethyl)benzyl]amino}-2-butanol  233 77 (2R,3S)-3-amino-1-{[(1S)-1-(1- naphthyl)ethyl]amino}-4-phenyl-2-butanol  234 78 (2R,3S)-3-amino-1-{[(1R)-1-(1-	227	71	
2-butanol  229 73 (2R,3S)-3-amino-4-phenyl-1-{[(1R)-1-phenylethyl]amino}-2-butanol  230 74 (2R,3S)-3-amino-4-phenyl-1-{[(1S)-1-phenylethyl]amino}-2-butanol  231 75 (2R,3S)-3-amino-1-{[3,5-bis(trifluoromethyl)benzyl]amino}-4-phenyl-2-butanol  232 76 (2R,3S)-3-amino-4-phenyl-1-{[2-(trifluoromethyl)benzyl]amino}-2-butanol  233 77 (2R,3S)-3-amino-1-{[(1S)-1-(1-naphthyl)ethyl]amino}-4-phenyl-2-butanol  234 78 (2R,3S)-3-amino-1-{[(1R)-1-(1-			
229 73 (2R,3S)-3-amino-4-phenyl-1-{[(1R)-1-phenylethyl]amino}-2-butanol 230 74 (2R,3S)-3-amino-4-phenyl-1-{[(1S)-1-phenylethyl]amino}-2-butanol 231 75 (2R,3S)-3-amino-1-{[3,5-bis(trifluoromethyl)benzyl]amino}-4-phenyl-2-butanol 232 76 (2R,3S)-3-amino-4-phenyl-1-{[2-(trifluoromethyl)benzyl]amino}-2-butanol 233 77 (2R,3S)-3-amino-1-{[(1S)-1-(1-naphthyl)ethyl]amino}-4-phenyl-2-butanol 234 78 (2R,3S)-3-amino-1-{[(1R)-1-(1-	228	72	(2R, 3S)-3-amino-1-[(2-methylbenzyl)amino]-4-phenyl-
phenylethyl]amino}-2-butanol  230 74 (2R,3S)-3-amino-4-phenyl-1-{[(1S)-1-phenylethyl]amino}-2-butanol  231 75 (2R,3S)-3-amino-1-{[3,5-bis(trifluoromethyl)benzyl]amino}-4-phenyl-2-butanol  232 76 (2R,3S)-3-amino-4-phenyl-1-{[2-(trifluoromethyl)benzyl]amino}-2-butanol  233 77 (2R,3S)-3-amino-1-{[(1S)-1-(1-naphthyl)ethyl]amino}-4-phenyl-2-butanol  234 78 (2R,3S)-3-amino-1-{[(1R)-1-(1-	000		
230 74 (2R,3S)-3-amino-4-phenyl-1-{[(1S)-1-phenylethyl]amino}-2-butanol  231 75 (2R,3S)-3-amino-1-{[3,5-bis(trifluoromethyl)benzyl]amino}-4-phenyl-2-butanol  232 76 (2R,3S)-3-amino-4-phenyl-1-{[2-(trifluoromethyl)benzyl]amino}-2-butanol  233 77 (2R,3S)-3-amino-1-{[(1S)-1-(1-naphthyl)ethyl]amino}-4-phenyl-2-butanol  234 78 (2R,3S)-3-amino-1-{[(1R)-1-(1-	229	73	
phenylethyl]amino}-2-butanol  231 75  (2R,3S)-3-amino-1-{[3,5-bis(trifluoromethyl)benzyl]amino}-4-phenyl-2-butanol  232 76  (2R,3S)-3-amino-4-phenyl-1-{[2-(trifluoromethyl)benzyl]amino}-2-butanol  233 77  (2R,3S)-3-amino-1-{[(1S)-1-(1-naphthyl)ethyl]amino}-4-phenyl-2-butanol  234 78  (2R,3S)-3-amino-1-{[(1R)-1-(1-	222	7.4	
231 75 (2R,3S)-3-amino-1-{[3,5-bis(trifluoromethyl)benzyl]amino}-4-phenyl-2-butanol  232 76 (2R,3S)-3-amino-4-phenyl-1-{[2-(trifluoromethyl)benzyl]amino}-2-butanol  233 77 (2R,3S)-3-amino-1-{[(1S)-1-(1-naphthyl)ethyl]amino}-4-phenyl-2-butanol  234 78 (2R,3S)-3-amino-1-{[(1R)-1-(1-	230	74	
bis(trifluoromethyl)benzyl]amino}-4-phenyl-2-butanol  232 76 (2R,3S)-3-amino-4-phenyl-1-{[2-(trifluoromethyl)benzyl]amino}-2-butanol  233 77 (2R,3S)-3-amino-1-{[(1S)-1-(1-naphthyl)amino}-4-phenyl-2-butanol  234 78 (2R,3S)-3-amino-1-{[(1R)-1-(1-	024		
butanol  232 76 (2R,3S)-3-amino-4-phenyl-1-{[2-(trifluoromethyl)benzyl]amino}-2-butanol  233 77 (2R,3S)-3-amino-1-{[(1S)-1-(1-naphthyl)ethyl]amino}-4-phenyl-2-butanol  234 78 (2R,3S)-3-amino-1-{[(1R)-1-(1-	231	75	
232 76 (2R,3S)-3-amino-4-phenyl-1-{[2- (trifluoromethyl)benzyl]amino}-2-butanol 233 77 (2R,3S)-3-amino-1-{[(1S)-1-(1- naphthyl)ethyl]amino}-4-phenyl-2-butanol 234 78 (2R,3S)-3-amino-1-{[(1R)-1-(1-			Dis(trifluoromethyl)benzyl]amino}-4-phenyl-2-
(trifluoromethyl)benzyl]amino}-2-butanol  233 77 (2R,3S)-3-amino-1-{[(1S)-1-(1-naphthyl)amino}-4-phenyl-2-butanol  234 78 (2R,3S)-3-amino-1-{[(1R)-1-(1-	222	7.0	
233 77 (2R,3S)-3-amino-1-{[(1S)-1-(1- naphthyl)ethyl]amino}-4-phenyl-2-butanol 234 78 (2R,3S)-3-amino-1-{[(1R)-1-(1-	232	76	
naphthyl)ethyl]amino}-4-phenyl-2-butanol 234 78 (2R,3S)-3-amino-1-{[(1R)-1-(1-	222		(trifiuoromethyl)benzyl]amino}-2-butanol
234   78   (2R, 3S) -3-amino-1-{[(1R)-1-(1-	233	77	
234 /8 (2R,3S)-3-amino-1-{[(1R)-1-(1- naphthyl)ethyl]amino}-4-phenyl-2-butanol	224	70	naphtny1)ethyl]amino}-4-phenyl-2-butanol
naphthy1)ethy1]amino}-4-pheny1-2-butanol	234	78	(2R, 3S) -3-amino-1-{[(1R)-1-(1-
	l		napntny1)ethy1]amino}-4-phenyl-2-butanol

379			·
236   80	235	79	4-({[(2R,3S)-3-amino-2-hydroxy-4-
phenylbutyl]amino)methyl)-1,2-benzenediol   (2R,3s)-3-amino-1-[(3-methoxypropyl)amino]-4-phenyl-2-butanol   (2R,3s)-3-amino-1-{(1S)-2-hydroxy-1-methylethyl]amino}-4-phenyl-2-butanol   (2R,3s)-3-amino-1-{(1R)-2-hydroxy-1-methylethyl]amino}-4-phenyl-2-butanol   (2R,3s)-3-amino-1-{(1R)-2-hydroxy-1-methylethyl]amino}-4-phenyl-2-butanol   (2R,3s)-3-amino-4-phenyl-1-(2-propynylamino)-2-butanol   (2R,3s)-3-amino-1-{(2-(2-fluorophenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3s)-3-amino-1-{(2-(3-fluorophenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3s)-3-amino-1-{(2-(4-fluorophenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3s)-3-amino-1-{(2-(4-bromophenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3s)-3-amino-1-{(2-(3-d)-q)amino}-4-phenyl-2-butanol   (2R,3s)-3-amino-1-{(2-(2,4-d)amino)-4-phenyl-2-butanol   (2R,3s)-3-amino-1-{(2-(2,5-d)amino)-4-phenyl-2-butanol   (2R,3s)-3-amino-1-{(2-(2,5-d)amino)-4-phenyl-2-butanol   (2R,3s)-3-amino-1-{(2-(4-methylphenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3s)-3-amino-1-{(1-(4-methylphenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3s)-3-amino-1-{(1-(4-methylphenyl)ethyl)amino}-4-phenyl-2-butanol   (2R,3s)-3-amino-1-{(1-(4-methylphenyl)ethyl)amino}-4-phenyl-2-butanol   (2R,3s)-3-amino-1-{(1-(4-methylphenyl)ethyl)amino}-4-ph			phenylbutyl]amino}methyl)-2-methoxyphenol
237   81	236	80	4-({[(2R,3S)-3-amino-2-hydroxy-4-
pheny1-2-butanol   (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1-methylethyl]amino}-4-pheny1-2-butanol   (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-methylethyl]amino}-4-pheny1-2-butanol   (2R,3S)-3-amino-4-pheny1-1-(2-propynylamino)-2-butanol   (2R,3S)-3-amino-4-pheny1-1-(2-propynylamino)-2-butanol   (2R,3S)-3-amino-1-{[2-(2-fluorophenyl)ethyl]amino}-4-pheny1-2-butanol   (2R,3S)-3-amino-1-{[2-(3-fluorophenyl)ethyl]amino}-4-pheny1-2-butanol   (2R,3S)-3-amino-1-{[2-(4-fluorophenyl)ethyl]amino}-4-pheny1-2-butanol   (2R,3S)-3-amino-1-{[2-(4-fluorophenyl)ethyl]amino}-4-pheny1-2-butanol   (2R,3S)-3-amino-1-{[2-(3-methoxyphenyl)ethyl]amino}-4-pheny1-2-butanol   (2R,3S)-3-amino-1-{[2-(3-methoxyphenyl)ethyl]amino}-4-pheny1-2-butanol   (2R,3S)-3-amino-1-{[2-(2,4-dichlorophenyl)ethyl]amino}-4-pheny1-2-butanol   (2R,3S)-3-amino-1-{[2-(2,5-dimethoxyphenyl)ethyl]amino}-4-pheny1-2-butanol   (2R,3S)-3-amino-1-{[2-(2,5-dimethoxyphenyl)ethyl]amino}-4-pheny1-2-butanol   (2R,3S)-3-amino-1-{[2-(4-methylphenyl)ethyl]amino}-4-pheny1-2-butanol   (2R,3S)-3-amino-1-{[2-(4-methylphenyl)ethyl]amino}-4-pheny1-2-butanol   (2R,3S)-3-amino-1-{[2-(4-methylphenyl)ethyl]amino}-4-pheny1-2-butanol   (2R,3S)-3-amino-1-{[2-(4-morpholinyl)propyl]amino}-4-pheny1-2-butanol   (2R,3S)-3-amino-1-{[2-(4-morpholinyl)propyl]amino}-4-pheny1-2-butanol   (2R,3S)-3-amino-1-{[2-(4-morpholinyl)pethyl]amino}-4-pheny1-2-butanol   (2R,3S)-3-ami			phenylbutyl]amino}methyl)-1,2-benzenediol
238   82	237	81	(2R,3S)-3-amino-1-[(3-methoxypropyl)amino]-4-
methylethyl]amino}-4-phenyl-2-butanol			phenyl-2-butanol
methylethyl]amino}-4-phenyl-2-butanol	238	82	$(2R,3S)-3-amino-1-\{[(1S)-2-hydroxy-1-$
239   83   (2R,3S)-3-amino-1-{{(1R)-2-hydroxy-1-methylethyl)amino}-4-phenyl-2-butanol   240   84   (2R,3S)-3-amino-4-phenyl-1-(2-propynylamino)-2-butanol   241   85   (2R,3S)-3-amino-1-{{2-(2-fluorophenyl)ethyl]amino}-4-phenyl-2-butanol   242   86   (2R,3S)-3-amino-1-{{2-(3-fluorophenyl)ethyl]amino}-4-phenyl-2-butanol   243   87   (2R,3S)-3-amino-1-{{2-(4-fluorophenyl)ethyl]amino}-4-phenyl-2-butanol   244   88   (2R,3S)-3-amino-1-{{2-(4-bromophenyl)ethyl]amino}-4-phenyl-2-butanol   245   89   (2R,3S)-3-amino-1-{{2-(3-methoxyphenyl)ethyl]amino}-4-phenyl-2-butanol   246   90   (2R,3S)-3-amino-1-{{2-(3-chlorophenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{{2-(3-chlorophenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{{2-(2-(3-chlorophenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{{2-(4-methylphenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{{2-(4-methylphenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{{1-(2-(4-methylphenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{{1-(4-methylphenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{{1-(4-methylphenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{{1-(4-morpholinyl)propyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{{1-(4-morpholinyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{{1-(4-morpholinyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{{1-(4-morpholinyl)ethyl]amino}-1-butanol   (2R,3S)-3-amino-1-{{1-(4-morpholinyl)ethyl]ami			· · ·
methylethyl]amino}-4-phenyl-2-butanol	239	83	<del></del>
240 84 (2R,3S)-3-amino-4-phenyl-1-(2-propynylamino)-2-butanol 241 85 (2R,3S)-3-amino-1-{[2-(2-fluorophenyl)ethyl]amino}-4-phenyl-2-butanol 242 86 (2R,3S)-3-amino-1-{[2-(3-fluorophenyl)ethyl]amino}-4-phenyl-2-butanol 243 87 (2R,3S)-3-amino-1-{[2-(4-fluorophenyl)ethyl]amino}-4-phenyl-2-butanol 244 88 (2R,3S)-3-amino-1-{[2-(4-fluorophenyl)ethyl]amino}-4-phenyl-2-butanol 245 89 (2R,3S)-3-amino-1-{[2-(3-methoxyphenyl)ethyl]amino}-4-phenyl-2-butanol 246 90 (2R,3S)-3-amino-1-{[2-(2,4-dichlorophenyl)ethyl]amino}-4-phenyl-2-butanol 247 91 (2R,3S)-3-amino-1-{[2-(3-chlorophenyl)ethyl]amino}-4-phenyl-2-butanol 248 92 (2R,3S)-3-amino-1-{[2-(4-methylphenyl)ethyl]amino}-4-phenyl-2-butanol 249 93 (2R,3S)-3-amino-1-{[2-(4-methylphenyl)ethyl]amino}-4-phenyl-2-butanol 250 94 (2R,3S)-3-amino-1-{[(1R)-1-benzyl-2-hydroxyethyl]amino}-4-phenyl-2-butanol 251 95 (2R,3S)-3-amino-1-{[3-(4-morpholinyl)propyl]amino}-4-phenyl-2-butanol 252 96 (2R,3S)-3-amino-1-{[2-(4-morpholinyl)ethyl]amino}-4-phenyl-2-butanol 253 97 (2R,3S)-3-amino-1-{[2-(4-morpholinyl)ethyl]amino}-4-phenyl-2-butanol 254 98 (2R,3S)-3-amino-1-{[2-(4-morpholinyl)ethyl]amino}-1-phenyl-2-butanol 255 99 (2R,3S)-3-amino-1-{[2-(4-morpholinyl)ethyl]amino}-1-phenyl-2-butanol 256 100 4-{[(2R,3S)-3-amino-1-{[2-(4-morpholinyl)ethyl]amino}-1-phenyl-2-butanol 257 101 (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-4-phenylbutyl]amino}-1-phenylethyl]amino}-4-phenyl-2-butanol 258 102 (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1-phenylethyl]amino}-4-phenyl-2-butanol 259 103 (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-phenylethyl]amino}-4-phenyl-2-butanol			
butanol   241   85   (2R,3S)-3-amino-1-{[2-(2-fluorophenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[2-(3-fluorophenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[2-(4-fluorophenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[2-(4-bromophenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[2-(4-bromophenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[2-(3-methoxyphenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[2-(2,4-dichlorophenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[2-(3-chlorophenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[2-(4-methylphenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[2-(4-methylphenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[(1R)-1-benzyl-2-hydroxyethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[(1R)-1-benzyl-2-hydroxyethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[(3-(4-morpholinyl)propyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[(2-(4-morpholinyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[(2-(4-morpholinyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[(2-(4-morpholinyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[(2-(4-morpholinyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[(2-(4-morpholinyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[(2-(4-morpholinyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]amino}-1-butanol   (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1-phenylethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1-phenylethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1-phenyl-2-butanol   (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1-phenyl-2-butanol   (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-phenyl-2-butanol   (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-phenyl-2-butanol   (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-phenyl-2-butanol   (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-phenyl-2-butanol   (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-phenyl-2-butanol   (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1	240	84	
241 85			
4-phenyl-2-butanol   (2R, 3S) -3-amino-1-{(2-(3-fluorophenyl)ethyl]amino}-  (4-phenyl-2-butanol)   (2R, 3S) -3-amino-1-{(2-(4-fluorophenyl)ethyl]amino}-  (4-phenyl-2-butanol)   (2R, 3S) -3-amino-1-{(2-(4-fluorophenyl)ethyl]amino}-  (4-phenyl-2-butanol)   (2R, 3S) -3-amino-1-{(2-(3-methoxyphenyl)ethyl)amino}-4-phenyl-2-butanol)   (2R, 3S) -3-amino-1-{(2-(3-methoxyphenyl)ethyl)amino}-4-phenyl-2-butanol)   (2R, 3S) -3-amino-1-{(2-(3-chlorophenyl)ethyl)amino}-4-phenyl-2-butanol)   (2R, 3S) -3-amino-1-{(2-(3-chlorophenyl)ethyl)amino}-4-phenyl-2-butanol)   (2R, 3S) -3-amino-1-{(2-(4-methylphenyl)ethyl)amino}-4-phenyl-2-butanol)   (2R, 3S) -3-amino-1-{(1R)-1-benzyl-2-hydroxyethyl)amino}-4-phenyl-2-butanol)   (2R, 3S) -3-amino-1-{(1R)-1-benzyl-2-hydroxyethyl)amino}-4-phenyl-2-butanol)   (2R, 3S) -3-amino-1-{(3-(4-morpholinyl)propyl)amino}-4-phenyl-2-butanol)   (2R, 3S) -3-amino-1-{(3-(4-morpholinyl)propyl)amino}-4-phenyl-2-butanol)   (2R, 3S) -3-amino-1-{(1S-(4-morpholinyl)propyl)amino}-4-phenyl-2-butanol)   (2R, 3S) -3-amino-1-{(1S-(4-morpholinyl)propyl)amino}-1-phenyl-2-butanol)   (2R, 3S) -3-amino-1-{(1S-(4-morpholinyl)propyl)amino}-1-phenyl-2-butanol   (2R, 3S) -3-amino-1-{(1S-(4-morpholinyl)propyl)amino}-1-phenyl-2-butanol   (2R, 3S) -3-amino-1-{(1S-(4-morpholinyl)propyl)amino}-1-phenyl-2-butanol   (2R, 3S) -3-amino-1-{(1S-(4-morpholinyl)pro	241	85	
242 86 (2R,3S)-3-amino-1-{[2-(3-fluorophenyl)ethyl]amino}- 4-phenyl-2-butanol 243 87 (2R,3S)-3-amino-1-{[2-(4-fluorophenyl)ethyl]amino}- 4-phenyl-2-butanol 244 88 (2R,3S)-3-amino-1-{[2-(4-bromophenyl)ethyl]amino}- 4-phenyl-2-butanol 245 89 (2R,3S)-3-amino-1-{[2-(3-methoxyphenyl)ethyl]amino}-4-phenyl-2-butanol 246 90 (2R,3S)-3-amino-1-{[2-(2,4-dichlorophenyl)ethyl]amino}-4-phenyl-2-butanol 247 91 (2R,3S)-3-amino-1-{[2-(3-chlorophenyl)ethyl]amino}- 4-phenyl-2-butanol 248 92 (2R,3S)-3-amino-1-{[2-(3-chlorophenyl)ethyl]amino}- 4-phenyl-2-butanol 249 93 (2R,3S)-3-amino-1-{[2-(4-methylphenyl)ethyl]amino}- 4-phenyl-2-butanol 250 94 (2R,3S)-3-amino-1-{[(1R)-1-benzyl-2-hydroxyethyl]amino}-4-phenyl-2-butanol 251 95 (2R,3S)-3-amino-1-{[3-(4-morpholinyl)propyl]amino}- 4-phenyl-2-butanol 252 96 (2R,3S)-3-amino-1-(isobutylamino)-4-phenyl-2-butanol 253 97 (2R,3S)-3-amino-1-([2-(4-morpholinyl)ethyl]amino}- 4-phenyl-2-butanol 254 98 (2R,3S)-3-amino-4-phenyl-1-{(2-hydroxybutyl)amino}- 2-butanol 255 99 (2R,3S)-3-amino-4-phenyl-1-{(2-hydroxybutyl)amino}- 2-butanol 256 100 4-{(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]amino}- 1-butanol 257 101 (2R,3S)-3-amino-1-{((1S)-2-hydroxy-1-phenylethyl]amino}-4-phenyl-2-butanol 258 102 (2R,3S)-3-amino-1-{((1R)-2-hydroxy-1-phenylethyl]amino}-4-phenyl-2-butanol 259 103 (2R,3S)-3-amino-1-{((1R)-2-hydroxy-1-phenyl-2-butanol} 259 103 (2R,3S)-3-amino-1-{((1R)-2-hydroxy-1-phenyl-2-butanol}			
4-phenyl-2-butanol	242	86	
243 87 (2R,3S)-3-amino-1-{[2-(4-fluorophenyl)ethyl]amino}- 4-phenyl-2-butanol 244 88 (2R,3S)-3-amino-1-{[2-(4-bromophenyl)ethyl]amino}- 4-phenyl-2-butanol 245 89 (2R,3S)-3-amino-1-{[2-(3- methoxyphenyl)ethyl]amino}-4-phenyl-2-butanol 246 90 (2R,3S)-3-amino-1-{[2-(2,4- dichlorophenyl)ethyl]amino}-4-phenyl-2-butanol 247 91 (2R,3S)-3-amino-1-{[2-(3-chlorophenyl)ethyl]amino}- 4-phenyl-2-butanol 248 92 (2R,3S)-3-amino-1-{[2-(2,5- dimethoxyphenyl)ethyl]amino}-4-phenyl-2-butanol 249 93 (2R,3S)-3-amino-1-{[2-(4-methylphenyl)ethyl]amino}- 4-phenyl-2-butanol 250 94 (2R,3S)-3-amino-1-{[(1R)-1-benzyl-2- hydroxyethyl]amino}-4-phenyl-2-butanol 251 95 (2R,3S)-3-amino-1-{[3-(4-morpholinyl)propyl]amino}- 4-phenyl-2-butanol 252 96 (2R,3S)-3-amino-1-{[3-(4-morpholinyl)ethyl]amino}- 4-phenyl-2-butanol 253 97 (2R,3S)-3-amino-1-{[2-(4-morpholinyl)ethyl]amino}- 4-phenyl-2-butanol 254 98 (2R,3S)-3-amino-1-{[2-(4-morpholinyl)ethyl]amino}- 2-butanol 255 99 (2R,3S)-3-amino-4-phenyl-1-{[2-(2- thienyl)ethyl]amino}-2-butanol 256 100 4-{[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]amino}- 1-butanol 257 101 (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1- phenylethyl]amino}-4-phenyl-2-butanol 258 102 (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1- phenyl-2-butanol 259 103 (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1- phenyl-2-butanol 259 100 (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-			
4-phenyl-2-butanol   244   88   (2R,3S)-3-amino-1-{[2-(4-bromophenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[2-(3-methoxyphenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[2-(2,4-dichlorophenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[2-(3-chlorophenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[2-(3-chlorophenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[2-(2,5-dimethoxyphenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[2-(4-methylphenyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[(1R)-1-benzyl-2-hydroxyethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[3-(4-morpholinyl)propyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[2-(4-morpholinyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[2-(4-morpholinyl)ethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(2-hydroxybutyl)amino]-2-butanol   (2R,3S)-3-amino-4-phenyl-1-[(2-(2-thienyl)ethyl]amino)-2-butanol   (2R,3S)-3-amino-4-phenyl-1-{[2-(2-thienyl)ethyl]amino}-2-butanol   (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1-phenylethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1-phenylethyl]amino}-4-phenyl-2-butanol   (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-phenyl-2-butanol   (2R,3S)-3-amino-1	243	87	
244 88 (2R,3S)-3-amino-1-{[2-(4-bromopheny1)ethyl]amino}- 4-phenyl-2-butanol 245 89 (2R,3S)-3-amino-1-{[2-(3- methoxyphenyl)ethyl]amino}-4-phenyl-2-butanol 246 90 (2R,3S)-3-amino-1-{[2-(2,4- dichlorophenyl)ethyl]amino}-4-phenyl-2-butanol 247 91 (2R,3S)-3-amino-1-{[2-(3-chlorophenyl)ethyl]amino}- 4-phenyl-2-butanol 248 92 (2R,3S)-3-amino-1-{[2-(2,5- dimethoxyphenyl)ethyl]amino}-4-phenyl-2-butanol 249 93 (2R,3S)-3-amino-1-{[2-(4-methylphenyl)ethyl]amino}- 4-phenyl-2-butanol 250 94 (2R,3S)-3-amino-1-{[(1R)-1-benzyl-2- hydroxyethyl]amino}-4-phenyl-2-butanol 251 95 (2R,3S)-3-amino-1-((3-(4-morpholinyl)propyl)amino}- 4-phenyl-2-butanol 252 96 (2R,3S)-3-amino-1-(isobutylamino)-4-phenyl-2- butanol 253 97 (2R,3S)-3-amino-1-{[2-(4-morpholinyl)ethyl]amino}- 4-phenyl-2-butanol 254 98 (2R,3S)-3-amino-4-phenyl-1-[(2-hydroxybutyl)amino]- 255 99 (2R,3S)-3-amino-4-phenyl-1-[(2-(2- thienyl)ethyl]amino)-2-butanol 256 100 4-{[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]amino}- 1-butanol 257 101 (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1- phenylethyl]amino}-4-phenyl-2-butanol 258 102 (2R,3S)-3-amino-1-{[(2,4-dichlorobenzyl)amino]-4- phenyl-2-butanol 259 103 (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-		- '	
4-phenyl-2-butanol   245   89   (2R,3S)-3-amino-1-{[2-(3-methoxyphenyl)ethyl]amino}-4-phenyl-2-butanol   246   90   (2R,3S)-3-amino-1-{[2-(2,4-dichlorophenyl)ethyl]amino}-4-phenyl-2-butanol   247   91   (2R,3S)-3-amino-1-{[2-(3-chlorophenyl)ethyl]amino}-4-phenyl-2-butanol   4-phenyl-2-butanol   248   92   (2R,3S)-3-amino-1-{[2-(2,5-dimethoxyphenyl)ethyl]amino}-4-phenyl-2-butanol   249   93   (2R,3S)-3-amino-1-{[2-(4-methylphenyl)ethyl]amino}-4-phenyl-2-butanol   270   94   (2R,3S)-3-amino-1-{[(1R)-1-benzyl-2-hydroxyethyl]amino}-4-phenyl-2-butanol   270   95   (2R,3S)-3-amino-1-{[(3-(4-morpholinyl)propyl]amino}-4-phenyl-2-butanol   270   96   (2R,3S)-3-amino-1-(isobutylamino)-4-phenyl-2-butanol   270   2	244	88	
245 89			
methoxyphenyl)ethyl]amino}-4-phenyl-2-butanol  (2R, 3S)-3-amino-1-{[2-(2,4-dichlorophenyl)ethyl]amino}-4-phenyl-2-butanol  (2R, 3S)-3-amino-1-{[2-(3,-chlorophenyl)ethyl]amino}-4-phenyl-2-butanol  (2R, 3S)-3-amino-1-{[2-(2,5-dimethoxyphenyl)ethyl]amino}-4-phenyl-2-butanol  (2R, 3S)-3-amino-1-{[2-(4-methylphenyl)ethyl]amino}-4-phenyl-2-butanol  (2R, 3S)-3-amino-1-{[(1R)-1-benzyl-2-hydroxyethyl]amino}-4-phenyl-2-butanol  (2R, 3S)-3-amino-1-{[(3-(4-morpholinyl)propyl]amino}-4-phenyl-2-butanol  (2R, 3S)-3-amino-1-([3-(4-morpholinyl)propyl]amino}-4-phenyl-2-butanol  (2R, 3S)-3-amino-1-{[2-(4-morpholinyl)ethyl]amino}-4-phenyl-2-butanol  (2R, 3S)-3-amino-1-{[2-(4-morpholinyl)ethyl]amino}-4-phenyl-2-butanol  (2R, 3S)-3-amino-4-phenyl-1-[(2-hydroxybutyl)amino]-2-butanol  (2R, 3S)-3-amino-4-phenyl-1-{[2-(2-thienyl)ethyl]amino}-2-butanol  255 99 (2R, 3S)-3-amino-2-hydroxy-4-phenylbutyl]amino}-1-butanol  257 101 (2R, 3S)-3-amino-1-{[(1S)-2-hydroxy-1-phenylethyl]amino}-4-phenyl-2-butanol  258 102 (2R, 3S)-3-amino-1-{[(2,4-dichlorobenzyl)amino]-4-phenyl-2-butanol  259 103 (2R, 3S)-3-amino-1-{[(1R)-2-hydroxy-1-phenyl-2-butanol}	245	89	
246 90 (2R,3S)-3-amino-1-{[2-(2,4-dichlorophenyl)ethyl]amino}-4-phenyl-2-butanol 247 91 (2R,3S)-3-amino-1-{[2-(3-chlorophenyl)ethyl]amino}-4-phenyl-2-butanol 248 92 (2R,3S)-3-amino-1-{[2-(2,5-dimethoxyphenyl)ethyl]amino}-4-phenyl-2-butanol 249 93 (2R,3S)-3-amino-1-{[2-(4-methylphenyl)ethyl]amino}-4-phenyl-2-butanol 250 94 (2R,3S)-3-amino-1-{[(1R)-1-benzyl-2-hydroxyethyl]amino}-4-phenyl-2-butanol 251 95 (2R,3S)-3-amino-1-{[3-(4-morpholinyl)propyl]amino}-4-phenyl-2-butanol 252 96 (2R,3S)-3-amino-1-(isobutylamino)-4-phenyl-2-butanol 253 97 (2R,3S)-3-amino-1-{[2-(4-morpholinyl)ethyl]amino}-4-phenyl-2-butanol 254 98 (2R,3S)-3-amino-4-phenyl-1-[(2-hydroxybutyl)amino]-2-butanol 255 99 (2R,3S)-3-amino-4-phenyl-1-{[2-(2-thienyl)ethyl]amino}-2-butanol 256 100 4-{[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]amino}-1-butanol 257 101 (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1-phenylethyl]amino}-4-phenyl-2-butanol 258 102 (2R,3S)-3-amino-1-[(2,4-dichlorobenzyl)amino]-4-phenyl-2-butanol 259 103 (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-phenyl-2-butanol}			
dichlorophenyl)ethyl]amino}-4-phenyl-2-butanol   247   91	246	90	
247 91 (2R,3S)-3-amino-1-{[2-(3-chlorophenyl)ethyl]amino}- 4-phenyl-2-butanol  248 92 (2R,3S)-3-amino-1-{[2-(2,5-dimethoxyphenyl)ethyl]amino}-4-phenyl-2-butanol  249 93 (2R,3S)-3-amino-1-{[2-(4-methylphenyl)ethyl]amino}- 4-phenyl-2-butanol  250 94 (2R,3S)-3-amino-1-{[(1R)-1-benzyl-2-hydroxyethyl]amino}-4-phenyl-2-butanol  251 95 (2R,3S)-3-amino-1-{[3-(4-morpholinyl)propyl]amino}- 4-phenyl-2-butanol  252 96 (2R,3S)-3-amino-1-(isobutylamino)-4-phenyl-2-butanol  253 97 (2R,3S)-3-amino-1-{[2-(4-morpholinyl)ethyl]amino}- 4-phenyl-2-butanol  254 98 (2R,3S)-3-amino-4-phenyl-1-[(2-hydroxybutyl)amino]- 2-butanol  255 99 (2R,3S)-3-amino-4-phenyl-1-{[2-(2-thienyl)ethyl]amino}-2-butanol  256 100 4-{[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]amino}- 1-butanol  257 101 (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1-phenylethyl]amino}-4-phenyl-2-butanol  258 102 (2R,3S)-3-amino-1-[(2,4-dichlorobenzyl)amino]-4-phenyl-2-butanol			
4-phenyl-2-butanol  248 92 (2R,3S)-3-amino-1-{[2-(2,5-dimethoxyphenyl)ethyl]amino}-4-phenyl-2-butanol  249 93 (2R,3S)-3-amino-1-{[2-(4-methylphenyl)ethyl]amino}-4-phenyl-2-butanol  250 94 (2R,3S)-3-amino-1-{[(1R)-1-benzyl-2-hydroxyethyl]amino}-4-phenyl-2-butanol  251 95 (2R,3S)-3-amino-1-{[3-(4-morpholinyl)propyl]amino}-4-phenyl-2-butanol  252 96 (2R,3S)-3-amino-1-(isobutylamino)-4-phenyl-2-butanol  253 97 (2R,3S)-3-amino-1-{[2-(4-morpholinyl)ethyl]amino}-4-phenyl-2-butanol  254 98 (2R,3S)-3-amino-4-phenyl-1-[(2-hydroxybutyl)amino]-2-butanol  255 99 (2R,3S)-3-amino-4-phenyl-1-{[2-(2-thienyl)ethyl]amino}-2-butanol  256 100 4-{[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]amino}-1-butanol  257 101 (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1-phenylethyl]amino}-4-phenyl-2-butanol  258 102 (2R,3S)-3-amino-1-[(2,4-dichlorobenzyl)amino]-4-phenyl-2-butanol	247	91	<u>, , , , , , , , , , , , , , , , , , , </u>
248 92 (2R,3S)-3-amino-1-{[2-(2,5-dimethoxyphenyl)ethyl]amino}-4-phenyl-2-butanol 249 93 (2R,3S)-3-amino-1-{[2-(4-methylphenyl)ethyl]amino}-4-phenyl-2-butanol 250 94 (2R,3S)-3-amino-1-{[(1R)-1-benzyl-2-hydroxyethyl]amino}-4-phenyl-2-butanol 251 95 (2R,3S)-3-amino-1-{[3-(4-morpholinyl)propyl]amino}-4-phenyl-2-butanol 252 96 (2R,3S)-3-amino-1-(isobutylamino)-4-phenyl-2-butanol 253 97 (2R,3S)-3-amino-1-{[2-(4-morpholinyl)ethyl]amino}-4-phenyl-2-butanol 254 98 (2R,3S)-3-amino-4-phenyl-1-[(2-hydroxybutyl)amino]-2-butanol 255 99 (2R,3S)-3-amino-4-phenyl-1-{[2-(2-thienyl)ethyl]amino}-2-butanol 256 100 4-{[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]amino}-1-butanol 257 101 (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1-phenylethyl]amino}-4-phenyl-2-butanol 258 102 (2R,3S)-3-amino-1-[(2,4-dichlorobenzyl)amino]-4-phenyl-2-butanol 259 103 (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-		-	
dimethoxyphenyl)ethyl]amino}-4-phenyl-2-butanol  (2R, 3S)-3-amino-1-{[2-(4-methylphenyl)ethyl]amino}- 4-phenyl-2-butanol  (2R, 3S)-3-amino-1-{[(1R)-1-benzyl-2- hydroxyethyl]amino}-4-phenyl-2-butanol  (2R, 3S)-3-amino-1-{[3-(4-morpholinyl)propyl]amino}- 4-phenyl-2-butanol  (2R, 3S)-3-amino-1-(isobutylamino)-4-phenyl-2- butanol  (2R, 3S)-3-amino-1-{[2-(4-morpholinyl)ethyl]amino}- 4-phenyl-2-butanol  (2R, 3S)-3-amino-4-phenyl-1-[(2-hydroxybutyl)amino]- 2-butanol  (2R, 3S)-3-amino-4-phenyl-1-{[2-(2- thienyl)ethyl]amino}-2-butanol  (2R, 3S)-3-amino-1-{[(1S)-2-hydroxy-1- phenylethyl]amino}-4-phenyl-2-butanol  (2R, 3S)-3-amino-1-[(2,4-dichlorobenzyl)amino]-4- phenyl-2-butanol  (2R, 3S)-3-amino-1-{[(1R)-2-hydroxy-1-	248	92	
249 93 (2R,3S)-3-amino-1-{[2-(4-methylphenyl)ethyl]amino}- 4-phenyl-2-butanol  250 94 (2R,3S)-3-amino-1-{[(1R)-1-benzyl-2- hydroxyethyl]amino}-4-phenyl-2-butanol  251 95 (2R,3S)-3-amino-1-{[3-(4-morpholinyl)propyl]amino}- 4-phenyl-2-butanol  252 96 (2R,3S)-3-amino-1-(isobutylamino)-4-phenyl-2- butanol  253 97 (2R,3S)-3-amino-1-{[2-(4-morpholinyl)ethyl]amino}- 4-phenyl-2-butanol  254 98 (2R,3S)-3-amino-4-phenyl-1-[(2-hydroxybutyl)amino]- 2-butanol  255 99 (2R,3S)-3-amino-4-phenyl-1-{[2-(2- thienyl)ethyl]amino}-2-butanol  256 100 4-{[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]amino}- 1-butanol  257 101 (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1- phenylethyl]amino}-4-phenyl-2-butanol  258 102 (2R,3S)-3-amino-1-[(2,4-dichlorobenzyl)amino]-4- phenyl-2-butanol			
4-phenyl-2-butanol  250 94 (2R,3S)-3-amino-1-{[(1R)-1-benzyl-2-hydroxyethyl]amino}-4-phenyl-2-butanol  251 95 (2R,3S)-3-amino-1-{[3-(4-morpholinyl)propyl]amino}-4-phenyl-2-butanol  252 96 (2R,3S)-3-amino-1-(isobutylamino)-4-phenyl-2-butanol  253 97 (2R,3S)-3-amino-1-{[2-(4-morpholinyl)ethyl]amino}-4-phenyl-2-butanol  254 98 (2R,3S)-3-amino-4-phenyl-1-[(2-hydroxybutyl)amino]-2-butanol  255 99 (2R,3S)-3-amino-4-phenyl-1-{[2-(2-thienyl)ethyl]amino}-2-butanol  256 100 4-{[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]amino}-1-butanol  257 101 (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1-phenylethyl]amino}-4-phenyl-2-butanol  258 102 (2R,3S)-3-amino-1-[(2,4-dichlorobenzyl)amino]-4-phenyl-2-butanol  259 103 (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-	249	93	
250 94 (2R,3S)-3-amino-1-{[(1R)-1-benzyl-2-hydroxyethyl]amino}-4-phenyl-2-butanol  251 95 (2R,3S)-3-amino-1-{[3-(4-morpholinyl)propyl]amino}-4-phenyl-2-butanol  252 96 (2R,3S)-3-amino-1-(isobutylamino)-4-phenyl-2-butanol  253 97 (2R,3S)-3-amino-1-{[2-(4-morpholinyl)ethyl]amino}-4-phenyl-2-butanol  254 98 (2R,3S)-3-amino-4-phenyl-1-[(2-hydroxybutyl)amino]-2-butanol  255 99 (2R,3S)-3-amino-4-phenyl-1-{[2-(2-thienyl)ethyl]amino}-2-butanol  256 100 4-{[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]amino}-1-butanol  257 101 (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1-phenylethyl]amino}-4-phenyl-2-butanol  258 102 (2R,3S)-3-amino-1-[(2,4-dichlorobenzyl)amino]-4-phenyl-2-butanol  259 103 (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-			
hydroxyethyl]amino}-4-phenyl-2-butanol  251 95 (2R,3S)-3-amino-1-{[3-(4-morpholinyl)propyl]amino}- 4-phenyl-2-butanol  252 96 (2R,3S)-3-amino-1-(isobutylamino)-4-phenyl-2- butanol  253 97 (2R,3S)-3-amino-1-{[2-(4-morpholinyl)ethyl]amino}- 4-phenyl-2-butanol  254 98 (2R,3S)-3-amino-4-phenyl-1-[(2-hydroxybutyl)amino]- 2-butanol  255 99 (2R,3S)-3-amino-4-phenyl-1-{[2-(2- thienyl)ethyl]amino}-2-butanol  256 100 4-{[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]amino}- 1-butanol  257 101 (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1- phenylethyl]amino}-4-phenyl-2-butanol  258 102 (2R,3S)-3-amino-1-[(2,4-dichlorobenzyl)amino]-4- phenyl-2-butanol  259 103 (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-	250	94	(2R,3S)-3-amino-1-{[(1R)-1-benzy1-2-
4-phenyl-2-butanol  (2R,3S)-3-amino-1-(isobutylamino)-4-phenyl-2-butanol  (2R,3S)-3-amino-1-{[2-(4-morpholinyl)ethyl]amino}-4-phenyl-2-butanol  (2R,3S)-3-amino-4-phenyl-1-[(2-hydroxybutyl)amino]-2-butanol  (2R,3S)-3-amino-4-phenyl-1-{[2-(2-thienyl)ethyl]amino}-2-butanol  (2R,3S)-3-amino-2-butanol  256 100 4-{[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]amino}-1-butanol  (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1-phenylethyl]amino}-4-phenyl-2-butanol  (2R,3S)-3-amino-1-[(2,4-dichlorobenzyl)amino]-4-phenyl-2-butanol  (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-phenyl-2-butanol}  (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-phenyl-2-butanol]}			
4-phenyl-2-butanol  (2R,3S)-3-amino-1-(isobutylamino)-4-phenyl-2-butanol  (2R,3S)-3-amino-1-{[2-(4-morpholinyl)ethyl]amino}-4-phenyl-2-butanol  (2R,3S)-3-amino-4-phenyl-1-[(2-hydroxybutyl)amino]-2-butanol  (2R,3S)-3-amino-4-phenyl-1-{[2-(2-thienyl)ethyl]amino}-2-butanol  (2R,3S)-3-amino-2-butanol  256 100 4-{[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]amino}-1-butanol  (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1-phenylethyl]amino}-4-phenyl-2-butanol  (2R,3S)-3-amino-1-[(2,4-dichlorobenzyl)amino]-4-phenyl-2-butanol  (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-phenyl-2-butanol}  (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-phenyl-2-butanol]}	251	95	$(2R,3S)-3-amino-1-\{[3-(4-morpholinyl)propyl]amino\}-$
252 96 (2R,3S)-3-amino-1-(isobutylamino)-4-phenyl-2-butanol 253 97 (2R,3S)-3-amino-1-{[2-(4-morpholinyl)ethyl]amino}- 4-phenyl-2-butanol 254 98 (2R,3S)-3-amino-4-phenyl-1-[(2-hydroxybutyl)amino]- 2-butanol 255 99 (2R,3S)-3-amino-4-phenyl-1-{[2-(2-thienyl)ethyl]amino}-2-butanol 256 100 4-{[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]amino}- 1-butanol 257 101 (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1-phenylethyl]amino}-4-phenyl-2-butanol 258 102 (2R,3S)-3-amino-1-[(2,4-dichlorobenzyl)amino]-4-phenyl-2-butanol 259 103 (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-	-		
butanol  253 97 (2R,3S)-3-amino-1-{[2-(4-morpholinyl)ethyl]amino}- 4-phenyl-2-butanol  254 98 (2R,3S)-3-amino-4-phenyl-1-[(2-hydroxybutyl)amino]- 2-butanol  255 99 (2R,3S)-3-amino-4-phenyl-1-{[2-(2- thienyl)ethyl]amino}-2-butanol  256 100 4-{[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]amino}- 1-butanol  257 101 (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1- phenylethyl]amino}-4-phenyl-2-butanol  258 102 (2R,3S)-3-amino-1-[(2,4-dichlorobenzyl)amino]-4- phenyl-2-butanol  259 103 (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-	252	96	
4-phenyl-2-butanol  254 98 (2R,3S)-3-amino-4-phenyl-1-[(2-hydroxybutyl)amino]- 2-butanol  255 99 (2R,3S)-3-amino-4-phenyl-1-{[2-(2-thienyl)ethyl]amino}-2-butanol  256 100 4-{[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]amino}- 1-butanol  257 101 (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1-phenylethyl]amino}-4-phenyl-2-butanol  258 102 (2R,3S)-3-amino-1-[(2,4-dichlorobenzyl)amino]-4-phenyl-2-butanol  259 103 (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-			butanol
4-phenyl-2-butanol  254 98 (2R,3S)-3-amino-4-phenyl-1-[(2-hydroxybutyl)amino]- 2-butanol  255 99 (2R,3S)-3-amino-4-phenyl-1-{[2-(2-thienyl)ethyl]amino}-2-butanol  256 100 4-{[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]amino}- 1-butanol  257 101 (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1-phenylethyl]amino}-4-phenyl-2-butanol  258 102 (2R,3S)-3-amino-1-[(2,4-dichlorobenzyl)amino]-4-phenyl-2-butanol  259 103 (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-	253	97	$(2R,3S)-3-amino-1-\{[2-(4-morpholinyl)ethyl]amino\}-$
254 98 (2R,3S)-3-amino-4-phenyl-1-[(2-hydroxybutyl)amino]- 2-butanol  255 99 (2R,3S)-3-amino-4-phenyl-1-{[2-(2-thienyl)ethyl]amino}-2-butanol  256 100 4-{[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]amino}- 1-butanol  257 101 (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1-phenylethyl]amino}-4-phenyl-2-butanol  258 102 (2R,3S)-3-amino-1-[(2,4-dichlorobenzyl)amino]-4-phenyl-2-butanol  259 103 (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-			
2-butanol  255 99 (2R,3S)-3-amino-4-phenyl-1-{[2-(2-thienyl)ethyl]amino}-2-butanol  256 100 4-{[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]amino}-1-butanol  257 101 (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1-phenylethyl]amino}-4-phenyl-2-butanol  258 102 (2R,3S)-3-amino-1-[(2,4-dichlorobenzyl)amino]-4-phenyl-2-butanol  259 103 (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-	254	98	(2R,3S)-3-amino-4-phenyl-1-[(2-hydroxybutyl)amino]-
thienyl)ethyl]amino}-2-butanol  256	1		
256 100 4-{[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]amino}- 1-butanol  257 101 (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1- phenylethyl]amino}-4-phenyl-2-butanol  258 102 (2R,3S)-3-amino-1-[(2,4-dichlorobenzyl)amino]-4- phenyl-2-butanol  259 103 (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-	255	99	(2R,3S)-3-amino-4-phenyl-1-{[2-(2-
256 100 4-{[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]amino}- 1-butanol  257 101 (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1- phenylethyl]amino}-4-phenyl-2-butanol  258 102 (2R,3S)-3-amino-1-[(2,4-dichlorobenzyl)amino]-4- phenyl-2-butanol  259 103 (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-			thienyl)ethyl]amino}-2-butanol
257   101   (2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1-phenylethyl]amino}-4-phenyl-2-butanol   258   102   (2R,3S)-3-amino-1-[(2,4-dichlorobenzyl)amino]-4-phenyl-2-butanol   259   103   (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-phenyl-2-butanol   (2R,3S)-3-amino-1-[(1R)-2-butanol   (2R,3S)-3-amino-1-[(1R)-2-butanol   (2R,3S)-3-amino-1-[(1R)-2-butanol   (2R,3S)-3-amino-1-[(1R	256	100	4-{[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]amino}-
phenylethyl]amino}-4-phenyl-2-butanol  258   102   (2R,3S)-3-amino-1-[(2,4-dichlorobenzyl)amino]-4-phenyl-2-butanol  259   103   (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-			1-butanol
258   102   (2R,3S)-3-amino-1-[(2,4-dichlorobenzyl)amino]-4- phenyl-2-butanol 259   103   (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-	257	101	(2R,3S)-3-amino-1-{[(1S)-2-hydroxy-1-
phenyl-2-butanol 259 103 (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-	L		phenylethyl]amino}-4-phenyl-2-butanol
259 103 (2R,3S)-3-amino-1-{[(1R)-2-hydroxy-1-	258	102	(2R,3S)-3-amino-1-[(2,4-dichlorobenzyl)amino]-4-
phenylethyl]amino}-4-phenyl-2-butanol	259	103	
		<u> </u>	phenylethyl]amino}-4-phenyl-2-butanol

260	104	(2P 3C) 2 and 4 (4)
200	, 104	(2R,3S)-3-amino-1-[(4-tert-butylbenzyl)amino]-4-phenyl-2-butanol
261	105	(2R, 3S) - 3-amino-4-phonyl 1 [/1 ]
		(2R,3S)-3-amino-4-phenyl-1-[(1-phenylethyl)amino]-2-butanol
262	106	(1R,2S)-1-{[(2R,3S)-3-amino-2-hydroxy-4-
	_	phenylbutyl]amino}-2,3-dihydro-1H-inden-2-ol
263	107	(2R,3S)-3-amino-1-[(3,4-dimethylbenzyl)amino]-4-
264	108	methyl 7-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-
		2-hydroxybutyl]amino}heptanoate
265	109	2-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-
		hydroxybutyl]amino}-N-isobutylpropanamide
266	110	(2S)-2-{[(2R,3S)-3-amino-4-(3,5-difluoropheny1)-2-
		hydroxybutyl]amino}-N-isobutylpropanamide
267	111	2-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-
		hydroxybutyl]amino}-N-isobutyl-2-methylpropanamide
268	112	2-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-
		hydroxybutyl]amino}-N-isobutylacetamide
269	113	$(2S)-2-\{[(2R,3S)-3-amino,4/2,5]\}$
		(2S)-2-{[(2R,3S)-3-amino-4-(3,5-difluoropheny1)-2-hydroxybuty1]amino}-N-isobuty1butanamide
270	114	$(2R)-2-\{[(2R-3C), 2, 2mins, 4, (2,5,7), 6\}$
		$(2R)-2-\{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxyhutyllaminol N inch.$
271	115	hydroxybutyl]amino}-N-isobutylbutanamide
_		(2R,3S)-3-amino-1-(benzylamino)-4-(3,5-
272	116	difluorophenyl)-2-butanol
	0	(2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-
273	117	(ethylamino) -2-butanol
		(2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-
274	118	(isobutylamino) -2-butanol
_ · -	110	3-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-
275	119	hydroxybutyl]amino}-N-isobutyl-2-methylpropanamide
2.5	117	$(20,35)$ -3-dm1 $\pi$ 0-4- $(3,5$ -difluorophenv1 $)$ -1- $(4$
276	120	(dimethylamino)benzyl]amino}-2-butanol
-, 0	<u> </u>	(2S)-2-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-
277	121	nydroxybutyllamino}-N-isobutyl-3-phenylpropagate
- ' '	2: <u>-</u>	$(20)^{-2}$ ((2x, 35) -3-amino-4-(3, 5-difluorophones) 3
278	122	Tydroxybucy1 alli110 \ -N-150biity1 -3-methy1 but anomide
2,0	144	(2K, 35) - 3 - amino - 4 - (3, 5 - difluorophenyl) - 1 - 1 - 1 - 2 - 3 - 3 - 3 - 3 - 3 - 3 - 3 - 3 - 3
279	123	(dimethylamino)ethyl]amino}-2-butanol
-,,,	ردے۔	(2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-
280	124	pyridinylmethyl)amino]-2-butanol
200	144	(2S)-2-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-
-	1	$mydroxyburyr]amino}-3-(benzyloxy)-M-$
281	125	isobutylpropanamide
201	125	(2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(1-
202	105	methy1-1-pnenylethy1)amino1-2-butano1
282	126	$(2R) - 2 - \{ [(2R, 3S) - 3 - amino - 4 - (3, 5 - diffuore base) \} $
		hydroxybutyl]amino}-N-isobutyl-3-methylbutanamide
	<del></del> +	T TRODUCYT J - INCLIVIDITANAMI do
283	127	(2S)-2-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-N-isobutylpentanamide

hydroxybutyl]amino}-3-hydroxy-N-isobutylpropanamide   285   129   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(2-phenylethyl)amino]-2-butanol   286   130   (2S)-2-{((2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-N-benzylpropanamide   287   131   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-{((1S)-1-phenylpropyl)amino}-N-benzylpropanamide   287   169a   (2S)-2-{((2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-N-ethylpropanamide   288   132   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-N-ethylpropanamide   289   133   (2S)-2-(((2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-(isopentylamino)-N-ethylpropanamide   289   134   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-(isopentylamino)-2-butanol   291   135   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-(isopentylamino)-2-butanol   292   136   (2R,3S)-3-amino-1-(butylamino)-4-(3,5-difluorophenyl)-2-butanol   293   137   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxypropyl)amino]-2-butanol   294   138   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(2-hydroxy2-2-phenylethyl)amino]-2-butanol   295   139   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-((3R,5S)-3,5-dimethoxycyclohexyl)amino]-2-butanol   296   140   dimethyl (1R,3S)-5-{((2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-((3R,5S)-3,5-dimethoxycyclohexyl)amino]-2-butanol   296   141   (1R,3S)-5-{((2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-((1R)-1-phenylpropyl)amino)-2-butanol   297   141   (1R,3S)-5-{((2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-((1R)-1-phenylpropyl)amino)-2-butanol   298   142   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(1R)-1-phenylpropyl)amino]-2-butanol   299   143   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybutyl)amino]-2-butanol   298   142   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol   298   2	284	128	(2S)-2-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-
285   129   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(2-phenylethyl)amino]-2-butanol   (2S)-2-((2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino]-N-benzylpropanamide   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(1S)-1-phenylpropyl]amino]-2-butanol   (2S)-2-((2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino]-N-ethylpropanamide   (2S)-2-((2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-N-ethylpropanamide   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-N-isobutyl-2-phenylethanamide   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-(isopentylamino)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-(isopentylamino)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-(3-difluorophenyl)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxypropyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(2-hydroxy-2-phenylethyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-((3R,5S)-3,5-difluorophenyl)-1-((3R,5S)-3,5-difluorophenyl)-1-((3R,5S)-3,5-difluorophenyl)-1-((3R,5S)-3,5-difluorophenyl)-1-((3R,5S)-3,5-difluorophenyl)-1-((3R,5S)-3,5-difluorophenyl)-1-((3R,5S)-3,5-difluorophenyl)-1-((3R,5S)-3,5-difluorophenyl)-1-((3R,5S)-3,5-difluorophenyl)-1-((3R,5S)-3,5-difluorophenyl)-1-((3R,5S)-3,5-difluorophenyl)-1-((3R,5S)-3,5-difluorophenyl)-1-((3R,5S)-3,5-difluorophenyl)-1-((3R,5S)-3,5-difluorophenyl)-1-((3R,5S)-3,5-difluorophenyl)-1-((3R,5S)-3,5-difluorophenyl)-1-((3R,5S)-3,5-difluorophenyl)-1-((3R,5S)-3-amino-4-(3,5-difluorophenyl)-1-((3R,5S)-3-amino-4-(3,5-difluorophenyl)-1-((3-methoxybenzyl)amino)-2-butanol   (2R,3S)-3-amino-1-((3-chlorobenzyl)amino]-4-(3,5-difluorophenyl)-1-((3-methoxybenzyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-((3-methoxybenzyl)amino)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-((3-methoxybenzyl)amino)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-((3-methoxybenzyl)amino)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-((3-methoxybenzyl)amino)-2-butanol   (2R,3S)-3-amino-4-(3	204	120	
phenylethyl)amino]-2-butano1   (2S)-2-{((2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-M-benzylpropanamide   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-{((1S)-1-phenylpropyl)amino}-M-benzylpropanamide   (2S)-2-{((2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-M-ethylpropanamide   (2S)-2-{((2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-((3-methoxybenzyl)amino)-M-ethylpropanamide   (2S)-2-{((2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-((3-methoxybenzyl)amino)-M-ethylpropanamide   (2S)-2-{((2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-((isopentylamino)-2-butanol   (2R,3S)-3-amino-1-(cyclohexylamino)-4-(3,5-difluorophenyl)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-((3-methoxypropyl)amino)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-((2-hydroxy-2-phenylethyl)amino)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-((3R,5S)-3,5-dimethoxycyclohexyl]amino)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-((3R,5S)-3,5-dimethoxycyclohexyl]amino)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-((3R,5S)-3,5-dimethoxycyclohexyl]amino)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-((3R,5S)-3,5-dimethoxycyclohexyl]amino)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-((3R,5S)-3,5-dimethoxycyclohexyl]amino)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-((3R,5S)-3,5-dimethoxycyclohexyl)-1-((2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-((3R,5S)-3,5-dimethoxycyclohexyl)-1-((3R,5S)-3,5-dimethoxycyclohexyl)-1-((3R,5S)-3,5-dimethoxychyclohexyl)-1-((3R,5S)-3,5-dimethoxychyclohexyl)-1-((3R,5S)-3,5-dimethoxychyclohexyl)-1-((3R,5S)-3,5-dimethoxychyclohexyl)-1-((3R,5S)-3,5-dimethoxychyclohexyl)-1-((3R,5S)-3,5-dimethoxychyclohexyl)-1-((3R,5S)-3,5-dimethoxychyclohexyl)-1-((3R,5S)-3,5-dimethoxychyclohexyl)-1-((3R,5S)-3,5-dimethoxychyclohexyl)-1-((3R,5S)-3,5-dimethoxychyclohexyl)-1-((3R,5S)-3,5-dimethoxychyclohexyl)-1-((3R,5S)-3,5-dimethoxychyclohexyl)-1-((3R,5S)-3,5-dimethoxychyclohexyl)-1-((3R,5S)-3,5-dimethox	205	120	
286   130   (2S)-2-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-N-benzylpropanamide   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-{[(1S)-1-phenylpropyl]amino}-2-butanol   (2S)-2-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-ahydroxybutyl]amino}-N-ethylpropanamide   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol   (2S)-2-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-N-isobutyl-2-phenylethanamide   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-(isopentylamino)-2-butanol   (2R,3S)-3-amino-1-(cyclohexylamino)-4-(3,5-difluorophenyl)-2-butanol   (2R,3S)-3-amino-1-(butylamino)-4-(3,5-difluorophenyl)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxypropyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxypropyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxypropyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-([(3R,5S)-3,5-dimethoxycyclohexyl]amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-([(3R,5S)-3,5-dimethoxycyclohexyl]amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino]-1,3-cyclohexanedicarboxylate   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino]-1,3-cyclohexanedicarboxylate   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-((1R)-1-phenylpropyl]amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-((1R)-1-phenylpropyl]amino]-2-butanol   (2R,3S)-3-amino-1-((1L)-1-biphenyl)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methylbenzyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methylbenzyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methylb	203	129	
hydroxybutyl]amino}-N-benzylpropanamide	206	120	
287   131   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[[(1S)-1-phenylpropyl]amino}-2-butanol     287   169a   (2S)-2-[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-M-ethylpropanamide     288   132   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol     289   133   (2S)-2-[((2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-M-isobutyl-2-phenylethanamide     290   134   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-(isopentylamino)-2-butanol     291   135   (2R,3S)-3-amino-1-(cyclohexylamino)-4-(3,5-difluorophenyl)-2-butanol     292   136   (2R,3S)-3-amino-1-(butylamino)-4-(3,5-difluorophenyl)-2-butanol     293   137   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxypropyl)amino]-2-butanol     294   138   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(2-hydroxy-2-phenylethyl)amino]-2-butanol     295   139   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-((3R,5S)-3,5-dimethoxycyclohexyl]amino]-2-butanol     296   140   dimethyl (1R,3S)-5-([(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino]-1,3-cyclohexanedicarboxylate     297   141   (1R,3S)-5-([(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino]-1,3-cyclohexanedicarboxylate     298   142   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(1R)-1-phenylpropyl]amino]-2-butanol     300   144   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol     301   145   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-butanol     302   146   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-butanol     303   147   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-butanol     303   146   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-butanol     304   146   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-butanol     305   146   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-butanol     306   146   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methylbenzyl)amino]-2-butanol	200	130	
phenylpropyl]amino}-2-butanol   287   169a   (2S)-2-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-N-ethylpropanamide   288   132   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol   289   133   (2S)-2-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-N-isobutyl-2-phenylethanamide   290   134   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-(isopentylamino)-2-butanol   (2R,3S)-3-amino-1-(cyclohexylamino)-4-(3,5-difluorophenyl)-2-butanol   291   135   (2R,3S)-3-amino-1-(butylamino)-4-(3,5-difluorophenyl)-2-butanol   292   136   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxypropyl)amino]-2-butanol   293   137   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxypropyl)amino]-2-butanol   294   138   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(2-hydroxy-2-phenylethyl)amino]-2-butanol   295   139   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3R,5S)-3,5-dimethoxycyclohexyl]amino]-2-butanol   296   140   dimethyl (1R,3S)-5-([(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-1,3-cyclohexanedicarboxylate   297   141   (1R,3S)-5-([(2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[((1R)-1-phenylpropyl)amino]-2-butanol   298   142   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[((1R)-1-phenylpropyl)amino]-2-butanol   299   143   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol   300   144   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol   301   145   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-butanol   302   146   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-butanol   303   147   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methylbenzyl)amino]-2-butanol   303   147   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methylbenzyl)amino]-2-butanol   303   147   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methylbenzyl)amino]-2-butanol   303   147   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methylbenzyl)amino]-2-butanol   303   304   304   305   304   305   304   305   305   305   305   305   305   305   305   305   305   3	207	121	
287 169a (2S)-2-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-N-ethylpropanamide  288 132 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol  289 133 (2S)-2-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-N-isobutyl-2-phenylethanamide  290 134 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-(isopentylamino)-2-butanol  291 135 (2R,3S)-3-amino-1-(cyclohexylamino)-4-(3,5-difluorophenyl)-2-butanol  292 136 (2R,3S)-3-amino-1-(butylamino)-4-(3,5-difluorophenyl)-2-butanol  293 137 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxypropyl)amino]-2-butanol  294 138 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(2-hydroxy-2-phenylethyl)amino]-2-butanol  295 139 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3R,5S)-3,5-dimethoxycyclohexyl]amino]-2-butanol  296 140 dimethyl (1R,3S)-5-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-1,3-cyclohexanedicarboxylate  297 141 (1R,3S)-5-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-1,3-cyclohexanedicarboxylic acid  298 142 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(1R)-1-phenylpropyl]amino]-2-butanol  300 144 (2R,3S)-3-amino-1-[(3-chlorobenzyl)amino]-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol  301 145 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-butanol  302 146 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-butanol  303 147 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methylbenzyl)amino]-2-butanol	28/	131	
a hydroxybutyl]amino}-N-ethylpropanamide  288   132   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol  289   133   (2S)-2-[([2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-N-isobutyl-2-phenylethanamide  290   134   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-	207	1.00-	
288   132   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol   (2S)-2-[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino]-N-isobutyl-2-phenylethanamide   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-(isopentylamino)-2-butanol   (2R,3S)-3-amino-1-(cyclohexylamino)-4-(3,5-difluorophenyl)-2-butanol   (2R,3S)-3-amino-1-(butylamino)-4-(3,5-difluorophenyl)-2-butanol   (2R,3S)-3-amino-1-(butylamino)-4-(3,5-difluorophenyl)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxypropyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(2-hydroxy-2-phenylethyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3R,5S)-3,5-dimethoxycyclohexyl]amino}-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-((3R,5S)-3,5-dimethoxycyclohexyl]amino}-2-butanol   (2R,3S)-5-[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-1,3-cyclohexanedicarboxylate   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-1,3-cyclohexanedicarboxylic   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(1R)-1-phenylpropyl]amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methyl)amino]-4-(3,5-difluorophenyl)-1-[(3-methyl)amino]-4-(3,5-difluorophenyl)-1-[(3-methyl)amino]-4-(3,5-difluorophenyl)-1-[(3-methyl)amino]-4-(3,5-difluorophenyl)-1-[(3-methyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methyl)amino]-2-butanol   (		169a	
methoxybenzyl)amino]-2-butanol   289   133   (2S)-2-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino]-N-isobutyl-2-phenylethanamide   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-(isopentylamino)-2-butanol   (2R,3S)-3-amino-1-(cyclohexylamino)-4-(3,5-difluorophenyl)-2-butanol   (2R,3S)-3-amino-1-(butylamino)-4-(3,5-difluorophenyl)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxypropyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(2-hydroxy-2-phenylethyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3R,5S)-3,5-dimethoxycyclohexyl]amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1,3-cyclohexanedicarboxylate   (1R,3S)-5-[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino]-1,3-cyclohexanedicarboxylate   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(1R)-1-phenylpropyl]amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(1R)-1-phenylpropyl]amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methyl)amino]-4-(3,5-difluorophenyl)-1-[(3-methyl)amino]-4-(3,5-difluorophenyl)-1-[(3-methyl)amino]-4-(3,5-difluorophenyl)-1-[(3-methyl)amino]-4-(3,5-difluorophenyl)-1-[(3-methyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methyl)amino]-2-butan		120	
289   133   (2S)-2-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-N-isobutyl-2-phenylethanamide   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-(isopentylamino)-2-butanol   (2R,3S)-3-amino-1-(cyclohexylamino)-4-(3,5-difluorophenyl)-2-butanol   (2R,3S)-3-amino-1-(butylamino)-4-(3,5-difluorophenyl)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxypropyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(2-hydroxy-2-phenylethyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3R,5S)-3,5-dimethoxycyclohexyl]amino}-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3R,5S)-difluorophenyl)-2-hydroxybutyl]amino}-1,3-cyclohexanedicarboxylate   (1R,3S)-5-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-1,3-cyclohexanedicarboxylic   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(1R)-1-phenylpropyl]amino}-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(1R)-1-phenylpropyl]amino}-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-iodobenzyl)amino]-4-(3,5-difluorophenyl)-1-[(3-iodobenzyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-iodobenzyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-iodobenzy	288	132	, ' = = = = : '
hydroxybutyl]amino}-N-isobutyl-2-phenylethanamide   290		100	
290	289	133	
(isopentylamino) - 2-butanol  (291 135 (2R,3S) - 3-amino - 1 - (cyclohexylamino) - 4 - (3,5-difluorophenyl) - 2-butanol  (282 136 (2R,3S) - 3-amino - 1 - (butylamino) - 4 - (3,5-difluorophenyl) - 2-butanol  (283 137 (2R,3S) - 3-amino - 4 - (3,5-difluorophenyl) - 1 - [(3-methoxypropyl) amino] - 2-butanol  (294 138 (2R,3S) - 3-amino - 4 - (3,5-difluorophenyl) - 1 - [(2-hydroxy - 2-phenylethyl) amino] - 2-butanol  (295 139 (2R,3S) - 3-amino - 4 - (3,5-difluorophenyl) - 1 - [(3R,5S) - 3,5-dimethoxycyclohexyl] amino] - 2-butanol  (296 140 dimethyl (1R,3S) - 5 - [(2R,3S) - 3-amino - 4 - (3,5-difluorophenyl) - 2-hydroxybutyl] amino} - 1,3-cyclohexanedicarboxylate  (297 141 (1R,3S) - 5 - [(2R,3S) - 3-amino - 4 - (3,5-difluorophenyl) - 2-hydroxybutyl] amino} - 1,3-cyclohexanedicarboxylic acid  (298 142 (2R,3S) - 3-amino - 4 - (3,5-difluorophenyl) - 1 - [(1R) - 1-phenylpropyl] amino} - 2-butanol  (299 143 (2R,3S) - 3-amino - 4 - (3,5-difluorophenyl) - 1 - [(3-methoxybenzyl) amino] - 2-butanol  300 144 (2R,3S) - 3-amino - 4 - (3,5-difluorophenyl) - 1 - [(3-methoxybenzyl) amino] - 2-butanol  301 145 (2R,3S) - 3-amino - 4 - (3,5-difluorophenyl) - 2-butanol  302 146 (2R,3S) - 3-amino - 4 - (3,5-difluorophenyl) - 1 - [(3-iodobenzyl) amino] - 2-butanol  303 147 (2R,3S) - 3-amino - 4 - (3,5-difluorophenyl) - 1 - [(3-iodobenzyl) amino] - 2-butanol			
291   135   (2R,3S)-3-amino-1-(cyclohexylamino)-4-(3,5-difluorophenyl)-2-butanol   (2R,3S)-3-amino-1-(butylamino)-4-(3,5-difluorophenyl)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxypropyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(2-hydroxy-2-phenylethyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3R,5S)-3,5-dimethoxycyclohexyl]amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-3-cyclohexanedicarboxylate   (1R,3S)-5-[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino]-1,3-cyclohexanedicarboxylate   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino]-1-[(1R)-1-phenylpropyl]amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(1R)-1-phenylpropyl]amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-iodobenzyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-iodobenzyl)amino]-2-butanol   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methylbenzyl)amino]-2-butanol   (2	290	134	
difluorophenyl)-2-butanol   292			
292   136   (2R,3S) - 3-amino - 1 - (butylamino) - 4 - (3,5 - difluorophenyl) - 2-butanol	291	135	
difluorophenyl)-2-butanol   293   137   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxypropyl) amino]-2-butanol   294   138   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(2-hydroxy-2-phenylethyl) amino]-2-butanol   295   139   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3R,5S)-3,5-dimethoxycyclohexyl]amino}-2-butanol   296   140   dimethyl (1R,3S)-5-[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-1,3-cyclohexanedicarboxylate   297   141   (1R,3S)-5-[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-1,3-cyclohexanedicarboxylic acid   298   142   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(1R)-1-phenylpropyl]amino}-2-butanol   299   143   (2R,3S)-3-amino-1-[(3-chlorobenzyl)amino]-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol   300   144   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol   301   145   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-butanol   302   146   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-iodobenzyl)amino]-2-butanol   303   147   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methylbenzyl)amino]-2-butanol			
293   137   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxypropyl) amino]-2-butanol     294   138   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(2-hydroxy-2-phenylethyl) amino]-2-butanol     295   139   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3R,5S)-3,5-dimethoxycyclohexyl] amino}-2-butanol     296   140   dimethyl (1R,3S)-5-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl] amino}-1,3-cyclohexanedicarboxylate     297   141   (1R,3S)-5-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl] amino}-1,3-cyclohexanedicarboxylic     298   142   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(1R)-1-phenylpropyl] amino]-2-butanol     299   143   (2R,3S)-3-amino-1-[(3-chlorobenzyl) amino]-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl) amino]-2-butanol     300   144   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methyl) amino]-4-(3,5-difluorophenyl)-2-butanol     301   145   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-butanol     302   146   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-iodobenzyl) amino]-2-butanol     303   147   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methylbenzyl) amino]-2-butanol	292	136	
methoxypropyl)amino]-2-butanol  294 138 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(2-hydroxy-2-phenylethyl)amino]-2-butanol  295 139 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-{[(3R,5S)-3,5-dimethoxycyclohexyl]amino}-2-butanol  296 140 dimethyl (1R,3S)-5-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-1,3-cyclohexanedicarboxylate  297 141 (1R,3S)-5-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-1,3-cyclohexanedicarboxylic acid  298 142 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-{[(1R)-1-phenylpropyl]amino}-2-butanol  299 143 (2R,3S)-3-amino-1-[(3-chlorobenzyl)amino]-4-(3,5-difluorophenyl)-2-butanol  300 144 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol  301 145 (2R,3S)-3-amino-1-[([1,1'-biphenyl]-3-ylmethyl)amino]-4-(3,5-difluorophenyl)-2-butanol  302 146 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-iodobenzyl)amino]-2-butanol  303 147 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methylbenzyl)amino]-2-butanol			
138   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(2-hydroxy-2-phenylethyl) amino]-2-butanol     295   139   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3R,5S)-3,5-dimethoxycyclohexyl] amino}-2-butanol     296   140   dimethyl (1R,3S)-5-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl] amino}-1,3-cyclohexanedicarboxylate     297   141   (1R,3S)-5-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl] amino}-1,3-cyclohexanedicarboxylic     acid   298   142   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-{[(1R)-1-phenylpropyl] amino}-2-butanol     299   143   (2R,3S)-3-amino-1-[(3-chlorobenzyl) amino]-4-(3,5-difluorophenyl)-2-butanol     300   144   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl) amino]-2-butanol     301   145   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-butanol     302   146   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-iodobenzyl) amino]-2-butanol     303   147   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methylbenzyl) amino]-2-butanol	293	137	· · · · · · · · · · · · · · · · · · ·
hydroxy-2-phenylethyl)amino]-2-butanol  295 139 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-{[(3R,5S)-3,5-dimethoxycyclohexyl]amino}-2-butanol  296 140 dimethyl (1R,3S)-5-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-1,3-cyclohexanedicarboxylate  297 141 (1R,3S)-5-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-1,3-cyclohexanedicarboxylic acid  298 142 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-{[(1R)-1-phenylpropyl]amino}-2-butanol  299 143 (2R,3S)-3-amino-1-[(3-chlorobenzyl)amino]-4-(3,5-difluorophenyl)-2-butanol  300 144 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol  301 145 (2R,3S)-3-amino-1-[([1,1'-biphenyl]-3-ylmethyl)amino]-4-(3,5-difluorophenyl)-2-butanol  302 146 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-iodobenzyl)amino]-2-butanol  303 147 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methylbenzyl)amino]-2-butanol			
295   139   (2R,3S) -3-amino-4-(3,5-difluorophenyl) -1-{[(3R,5S) - 3,5-dimethoxycyclohexyl]amino} -2-butanol   296   140   dimethyl (1R,3S) -5-{[(2R,3S) -3-amino-4-(3,5-difluorophenyl) -2-hydroxybutyl]amino} -1,3-cyclohexanedicarboxylate   297   141   (1R,3S) -5-{[(2R,3S) -3-amino-4-(3,5-difluorophenyl) -2-hydroxybutyl]amino} -1,3-cyclohexanedicarboxylic   acid   (2R,3S) -3-amino-4-(3,5-difluorophenyl) -1-{[(1R) -1-phenylpropyl]amino} -2-butanol   (2R,3S) -3-amino-1-[(3-chlorobenzyl)amino] -4-(3,5-difluorophenyl) -1-[(3-methoxybenzyl)amino] -2-butanol   301   145   (2R,3S) -3-amino-4-(3,5-difluorophenyl) -1-[(3-ylmethyl)amino] -4-(3,5-difluorophenyl) -2-butanol   302   146   (2R,3S) -3-amino-4-(3,5-difluorophenyl) -1-[(3-iodobenzyl)amino] -2-butanol   303   147   (2R,3S) -3-amino-4-(3,5-difluorophenyl) -1-[(3-methylbenzyl)amino] -2-butanol	294	138	<del>-</del> - <del>-</del>
3,5-dimethoxycyclohexyl]amino}-2-butanol  296			
296	295	139	
difluorophenyl)-2-hydroxybutyl]amino}-1,3- cyclohexanedicarboxylate  297 141 (1R,3S)-5-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)- 2-hydroxybutyl]amino}-1,3-cyclohexanedicarboxylic acid  298 142 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-{[(1R)-1- phenylpropyl]amino}-2-butanol  299 143 (2R,3S)-3-amino-1-[(3-chlorobenzyl)amino]-4-(3,5- difluorophenyl)-2-butanol  300 144 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3- methoxybenzyl)amino]-2-butanol  301 145 (2R,3S)-3-amino-1-[([1,1'-biphenyl]-3- ylmethyl)amino]-4-(3,5-difluorophenyl)-2-butanol  302 146 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3- iodobenzyl)amino]-2-butanol  303 147 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3- methylbenzyl)amino]-2-butanol			
cyclohexanedicarboxylate   297	296	140	
297 141 (1R,3S)-5-{[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-1,3-cyclohexanedicarboxylic acid  298 142 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-{[(1R)-1-phenylpropyl]amino}-2-butanol  299 143 (2R,3S)-3-amino-1-[(3-chlorobenzyl)amino]-4-(3,5-difluorophenyl)-2-butanol  300 144 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol  301 145 (2R,3S)-3-amino-1-[([1,1'-biphenyl]-3-ylmethyl)amino]-4-(3,5-difluorophenyl)-2-butanol  302 146 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-iodobenzyl)amino]-2-butanol  303 147 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methylbenzyl)amino]-2-butanol			
2-hydroxybutyl]amino}-1,3-cyclohexanedicarboxylic acid  298 142 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-{[(1R)-1-phenylpropyl]amino}-2-butanol  299 143 (2R,3S)-3-amino-1-[(3-chlorobenzyl)amino]-4-(3,5-difluorophenyl)-2-butanol  300 144 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol  301 145 (2R,3S)-3-amino-1-[([1,1'-biphenyl]-3-ylmethyl)amino]-4-(3,5-difluorophenyl)-2-butanol  302 146 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-iodobenzyl)amino]-2-butanol  303 147 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methylbenzyl)amino]-2-butanol			
acid	297	141	
298 142 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-{[(1R)-1-phenylpropyl]amino}-2-butanol  299 143 (2R,3S)-3-amino-1-[(3-chlorobenzyl)amino]-4-(3,5-difluorophenyl)-2-butanol  300 144 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol  301 145 (2R,3S)-3-amino-1-[([1,1'-biphenyl]-3-ylmethyl)amino]-4-(3,5-difluorophenyl)-2-butanol  302 146 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-iodobenzyl)amino]-2-butanol  303 147 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methylbenzyl)amino]-2-butanol			
phenylpropyl]amino}-2-butanol  299 143 (2R,3S)-3-amino-1-[(3-chlorobenzyl)amino]-4-(3,5-difluorophenyl)-2-butanol  300 144 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol  301 145 (2R,3S)-3-amino-1-[([1,1'-biphenyl]-3-ylmethyl)amino]-4-(3,5-difluorophenyl)-2-butanol  302 146 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-iodobenzyl)amino]-2-butanol  303 147 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methylbenzyl)amino]-2-butanol			
299 143 (2R,3S)-3-amino-1-[(3-chlorobenzyl)amino]-4-(3,5-difluorophenyl)-2-butanol 300 144 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol 301 145 (2R,3S)-3-amino-1-[([1,1'-biphenyl]-3-ylmethyl)amino]-4-(3,5-difluorophenyl)-2-butanol 302 146 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-iodobenzyl)amino]-2-butanol 303 147 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methylbenzyl)amino]-2-butanol	298	142	
difluorophenyl)-2-butanol   300   144   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol   301   145   (2R,3S)-3-amino-1-[([1,1'-biphenyl]-3-ylmethyl)amino]-4-(3,5-difluorophenyl)-2-butanol   302   146   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-iodobenzyl)amino]-2-butanol   303   147   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methylbenzyl)amino]-2-butanol			
300 144 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol 301 145 (2R,3S)-3-amino-1-[([1,1'-biphenyl]-3-ylmethyl)amino]-4-(3,5-difluorophenyl)-2-butanol 302 146 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-iodobenzyl)amino]-2-butanol 303 147 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methylbenzyl)amino]-2-butanol	299	143	
methoxybenzyl)amino]-2-butanol  301 145 (2R,3S)-3-amino-1-[([1,1'-biphenyl]-3-ylmethyl)amino]-4-(3,5-difluorophenyl)-2-butanol  302 146 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-iodobenzyl)amino]-2-butanol  303 147 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methylbenzyl)amino]-2-butanol			
301 145 (2R,3S)-3-amino-1-[([1,1'-biphenyl]-3-ylmethyl)amino]-4-(3,5-difluorophenyl)-2-butanol 302 146 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-iodobenzyl)amino]-2-butanol 303 147 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methylbenzyl)amino]-2-butanol	300	144	
ylmethyl)amino]-4-(3,5-difluorophenyl)-2-butanol  302			
302   146   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-iodobenzyl)amino]-2-butanol   303   147   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methylbenzyl)amino]-2-butanol	301	145	
iodobenzyl)amino]-2-butanol  303 147 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methylbenzyl)amino]-2-butanol			
303 147 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methylbenzyl)amino]-2-butanol	302	146	
methylbenzyl)amino]-2-butanol			
<u> </u>	303	147	
1204   140   72D 201 2 mino 4 /2 E 315331 4 570			
	304	148	(2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(2-
phenylpropyl)amino]-2-butanol			
305   149   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(1,3-	305	149	
thiazol-5-ylmethyl)amino]-2-butanol			
306   150   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(2-	306	150	
thienylmethyl)amino]-2-butanol	L		thienylmethyl)amino]-2-butanol

307   151   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(5-methoxy-1,2,3,4-tetrahydro-1-naphthalenyl)amino]-butanol   308   152   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(2-pyrazinylmethyl)amino]-2-butanol   (2R,3S)-3-amino-1-[(3,5-difluorobenzyl)amino]-4-(3,5-difluorophenyl)-2-butanol   310   154   (2R,3S)-3-amino-1-[(1,3-benzodioxol-5-ylmethyl)amino]-4-(3,5-difluorophenyl)-2-butanol   311   155   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3,5-difluoropheny
methoxy-1,2,3,4-tetrahydro-1-naphthalenyl)amino]-butanol  308 152 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(2-pyrazinylmethyl)amino]-2-butanol  309 153 (2R,3S)-3-amino-1-[(3,5-difluorobenzyl)amino]-4-(3,5-difluorophenyl)-2-butanol  310 154 (2R,3S)-3-amino-1-[(1,3-benzodioxol-5-ylmethyl)amino]-4-(3,5-difluorophenyl)-2-butanol
Sutanol
pyrazinylmethyl)amino]-2-butanol  309 153 (2R,3S)-3-amino-1-[(3,5-difluorobenzyl)amino]-4- (3,5-difluorophenyl)-2-butanol  310 154 (2R,3S)-3-amino-1-[(1,3-benzodioxol-5- ylmethyl)amino]-4-(3,5-difluorophenyl)-2-butanol
pyrazinylmethyl)amino]-2-butanol  (2R,3S)-3-amino-1-[(3,5-difluorobenzyl)amino]-4- (3,5-difluorophenyl)-2-butanol  (2R,3S)-3-amino-1-[(1,3-benzodioxol-5- ylmethyl)amino]-4-(3,5-difluorophenyl)-2-butanol
309   153   (2R,3S)-3-amino-1-[(3,5-difluorobenzyl)amino]-4- (3,5-difluorophenyl)-2-butanol 310   154   (2R,3S)-3-amino-1-[(1,3-benzodioxol-5- ylmethyl)amino]-4-(3,5-difluorophenyl)-2-butanol
(3,5-difluorophenyl)-2-butanol 310   154   (2R,3S)-3-amino-1-[(1,3-benzodioxol-5-ylmethyl)amino]-4-(3,5-difluorophenyl)-2-butanol
310   154   (2R,3S)-3-amino-1-[(1,3-benzodioxol-5-ylmethyl)amino]-4-(3,5-difluorophenyl)-2-butanol
ylmethyl)amino]-4-(3,5-difluorophenyl)-2-butanol
311   155   (2R, 3S) - 3 - amino - 4 - (3, 5 - difluorophenyl) - 1 - [(3, 5 -
dimethoxybenzyl)amino]-2-butanol
312 156 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-{[3-
(trifluoromethyl)benzyl]amino}-2-butanol
313 157 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(2-
furylmethyl)amino]-2-butanol
314 158 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(7-
methoxy-1,2,3,4-tetrahydro-1-naphthalenyl)amino]-2
butanol butanol
315   159   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-{[3-
(trifluoromethoxy)benzyl]amino}-2-butanol
316   160   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-
fluorobenzyl)amino]-2-butanol
317   161   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-
isopropoxybenzyl)amino]-2-butanol
318   162   (2R,3S)-3-amino-1-[(3-bromobenzyl)amino]-4-(3,5-
difluorophenyl)-2-butanol
319 163 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(5-
methyl-2-furylmethyl)amino]-2-butanol
320   164   (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(5-
methoxy-1,2,3,4-tetrahydro-1-naphthalenyl)amino]-2
butanol

EXAMPLE 587 N¹-{(1S,2R)-1-Benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-N³,N³-dipropyl-1,3,5-benzenetricarboxamide (X)

To a mixture of 3-(aminocarbonyl)-5[(dipropylamino)carbonyl]benzoic acid (IX, PREPARATION 6, 0.18
g, 0.616 mmol) in dry DMF (16 mL) is added EDC (0.182 g, 0.9
mmol), HOBT (0.127 g, 0.9 mmol), triethylamine (0.062 g, 0.616
mol), and (2R,3S)-3-amino-1-[(3-methoxybenzyl)amino]-4-phenyl10 2-butanol (VIII, EXAMPLE 175, 0.185 g, 0.616 mmol). The
mixture is stirred at 20-25 degrees C for 3 days. The mixture
is partitioned between water and ethyl acetate. The phases are
separated and the organic phase is washed three times with

water. The organic phase is dried over anhydrous magnesium sulfate, filtered and concentrated. Column chromatography (silica gel, 75 mL; methanol/methylene chloride, 10/90) gives the title compound, IR (diffuse reflectance) 3306, 3301, 3270, 2962, 1676, 1667, 1663, 1645, 1638, 1627, 1615, 1550, 1537, 1450 and 1439 cm<sup>-1</sup>; NMR (CDCl<sub>3</sub>)  $\delta$  0.645, 0.968, 1.20, 1.43, 1.67, 2.8, 2.97, 3.38, 3.47, 3.73, 3.87, 4.31, 6.78, 6.91, 7.23, 7.72, 7.87, 8.22 and 8.43.

10 EXAMPLE 588 1- tert-butyl (1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-iodobenzyl)amino]propylcarbamate (VII)

tert-Butyl (1S)-2-(3,5-difluorophenyl)-1-[(2S)oxiranyl]ethylcarbamate (V, EXAMPLE 3, 1.75 g, 5.8 mmole) is 15 mixed with isopropanol (30 ml). The reaction flask is charged with 3-iodobenzylamine (VI). The reaction mixture is heated to reflux for 45 minutes, HPLC analysis indicates complete disappearance of the epoxide (V). The reaction mixture is concentrated under reduced pressure and the residue 20 partitioned between ethyl acetate (150 ml) and aqueous hydrochloric acid (3%, 35 ml). The organic phase is separated and washed with aqueous hydrochloric acid (3%, 20 ml), bicarbonate, saline and dried over sodium sulfate. Concentration under reduced pressure gives the title compound, 25 M + H = 535.

EXAMPLE 589 1-9H-fluoren-9-ylmethyl (2R,3S)-3-(3-t-butyloxycarbonyl)amino-4-(3,5-difluorophenyl)-2-hydroxybutyl(3'-iodobenzyl)carbamate hydrochloride (XXXIV)

30

1- tert-butyl (1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-iodobenzyl)amino]propylcarbamate (VII, EXAMPLE 588, 2.5 g, 4.7 mmole) and triethylamine (0.72 ml, 5.1 mmole) in THF (10 ml) are mixed. The reaction is cooled to 0 degrees and treated

with FMOC-Cl (1.2 g, 4.7 mmole) in THF (2 ml) via addition funnel. After 15 minutes HPLC indicates complete disappearance of starting material. The reaction is diluted with ethyl acetate and washed with aqueous potassium bisulfate, saturated aqueous bicarbonate, saline and dried over sodium sulfate. Concentration under reduced pressure gives crude product which is purified by flash chromatography, eluting with ethyl acetate/hexane (20/80) followed by ethyl acetate to give the title compound, M + H = 757.

10

30

5

EXAMPLE 590 1-9H-fluoren-9-ylmethyl (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl(3-iodobenzyl)carbamate hydrochloride (XXXV)

15 1-9H-fluoren-9-ylmethyl (2R,3S)-3-(3-t-butyloxycarbonyl)amino-4-(3,5-difluorophenyl)-2-hydroxybutyl(3'-iodobenzyl)carbamate hydrochloride (XXXIV, EXAMPLE 589, 2.9 g) in hydrochloric acid/dioxane (4N, 10 ml). The mixture is stirred 1 hour then slowly poured into rapidly stirring ether (200 ml). The product is filtered and dried to give the title compound, M + H = 657.

EXAMPLE 591 1-9H-fluoren-9-ylmethyl (2R,3S)-4-(3,5-difluorophenyl)-2-hydroxy-3-{[5-oxo-5-(1-piperidinyl)pentanoyl]amino}butyl(3-iodobenzyl)carbamate (XXXVI)

HOBt (81 mg, 0.6 mmole) and EDC (105 mg, 0.55 mmole) are added to 1-carboxy-5-piperdinylglutaramide (IX, 100 mg, 0.5 mmole) in DMF (2 ml). The acid is activated 60 minutes then treated with 1-9H-fluoren-9-ylmethyl (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl(3-iodobenzyl)carbamate hydrochloride (XXXV, EXAMPLE 590, 300 mg, 0.43 mmole) and NMM (0.19 ml, 1.72 mmole). The reaction is stirred 3 hours then concentrated under reduced pressure. The residue is

partitioned between ethyl acetate and saturated aqueous bicarbonate. The organic phases are washed with aqueous potassium bisulfate, saline, dried over sodium sulfate and finally concentrated under reduced pressure to give crude product. Purification via flash chromatography with ethyl acetate/hexane (50/50) then methanol/ethyl acetate (10/90) gives the title compound, M + H = 838.

5

15

20

EXAMPLE 592 1- N-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-iodobenzyl)amino]propyl}-5-oxo-5-(1piperidinyl)pentanamide trifluroacetate (X)

- 1- $N-\{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-max)-1]$ iodobenzyl)amino]propyl}-5-oxo-5-(1-piperidinyl)pentanamide trifluroacetate (XXXVI, EXAMPLE 591, 240 mg, 0.29 mmole is dissolved in diethylamine (10%, 9 ml) in methylene chloride. The reaction is stirred at 20-25 degrees overnight. The next morning the reaction is concentrated under reduced pressure and the residue is redissolved in methylene chloride and purified by preparative reverse phase HPLC. The appropriate fractions are pooled and concentrated under reduced pressure partitioned between ethyl acetate and saline. The organic phase separated and is dried over sodium sulfate and concentrated to give the title compound, M + H = 614.
- 25 EXAMPLE 593 5-(Aminosulfonyl)- $N^1$ -{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}- $N^3$ , N-dipropylisophthalamide (X)
- O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU, 0.0928 g, 0.244 mmol) is added to a 30 mixture of, 3-(aminosulfonyl)-5-[(dipropylamino)-carbonyl]benzoic acid (XXXIX, PREPARATION 13, 0.0800 g, 0.244 mmol) and (2R,3S)-3-amino-1-[(3-methoxybenzyl)-amino]-4-phenyl-2-butanol (VIII, EXAMPLE 175, 0.0732 g, 0.244 mmol) in dry DMF (3 mL). The mixture is stirred for 18 hours at 20-25 degrees,

and then partitioned between ethyl acetate and water. The organic phase is separated and washed with saline, dried over anhydrous sodium sulfate, filtered and concentrated. The concentrate is column chouromatographed (silica gel; methanol/dichloromethane, 5/95) to give the title compound, MS (ESI+) for  $C_{32}H_{42}N_4O_6S$  m/z (M+H)<sup>+</sup> = 611.5; HRMS (FAB) calculated for  $C_{32}H_{42}N_4O_6S$  +H<sub>1</sub> = 611.2903, found = 611.2904.

EXAMPLE 620 N<sup>1</sup>-{(1S,2R)-1-Benzyl-2-hydroxy-3-[(3-10 methoxybenzyl)amino]propyl}-5-ethyl-N<sup>3</sup>,N<sup>3</sup>-dipropylisophthalamide (X)

Diethyl cyanophosphonate (0.132 mL, 0.870 mmol) is added to a mixture of 3-[(dipropylamino)carbonyl]-5-ethylbenzoic acid (IX, PREPARATION 21, 0.200 g, 0.720 mmol), (2R,3S)-3-15 amino-1-[(3-methoxybenzyl)amino]-4-phenyl-2-butanol (VIII, EXAMPLE 175, 0.216 mg, 0.720 mmol), and triethylamine (0.121 mL, 0.870 mmol) in dichloromethane (3 mL). The mixture was stirred for 1 hour at 20-25 degrees C. Dichloromethane is then removed under reduced pressure. The residue is partitioned 20 between ethyl acetate and water. The organic phase is separated and is washed with saline, dried over anhydrous sodium sulfate, filtered and concentrated. The concentrate is column chouromatographed (silica gel; methanol/dichloromethane, 5/95) to give the title compound, MS (ESI+) for  $C_{34}H_{45}N_3O_4\ \text{m/z}$ 25  $(M+H)^+ = 560.4$ ; HOURMS (FAB) calculated for  $C_{34}H_{45}N_3O_4+H =$ 560.3488, found = 560.3487.

EXAMPLE 629 N-{(1S,2R)-1-Benzyl-2-hydroxy-3-[(3-30 methoxybenzyl)amino]propyl}-3[butyryl(propyl)amino]-5-methylbenzamide (X)

Following the procedure of EXAMPLE 570 and making non-critical variations, diethyl cyanophosphonate (0.0760 mL, 0.550 mmol) is added to a mixture of 3-[butyryl(propyl)amino]-5-

methylbenzoic acid (IX, 0.120 g, 0.460 mmol), (2R,3S)-3-amino-1-[(3-methoxybenzyl)amino]-4-phenyl-2-butanol (VIII, 0.137 g, 0.460 mmol), and triethylamine (0.0760 mL, 0.550 mmol) dichloromethane (5 mL). The mixture is stirred for 1 hour at 20-25 degrees C. Dichloromethane is then removed under reduced pressure. The residue is partitioned between ethyl acetate and The organic is separated, is washed with saline, dried over anhydrous sodium sulfate, filtered and concentrated. The concentrate is column chromatographed (silica gel; methanol/dichloromethane, 5/95) to give the title compound, NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.09, 4.15, 3.80, 3.79, 3.60, 3.02, 2.84, 2.36, 1.94, 1.56, 1.49, 0.87 and 0.81; MS (ESI+) for  $C_{33}H_{43}N_{3}O_{4}$  $(M+H)^+ = 546.3$ ; HRMS (FAB) calculated for  $C_{33}H_{43}N_3O_4+H =$ 546.3331, found = 546.3331.

15

30

10

- EXAMPLE 631 N-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-1-propyl-1H-indole-6-carboxamide (X)
- 20 EXAMPLE 682  $N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-5-ethynyl- <math>N^3,N^3-dipropylisophthalamide, (M+H)^+=590$
- EXAMPLE 739 N<sup>1</sup>-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-5-(cyanomethyl)-N<sup>3</sup>,N<sup>3</sup>-dipropylisophthalamide (X)

A mixture of diethyl 1,3,5-benzenetricarboxylate (5.2 g) and borane methylsulfide complex (6.1 g) is stirred in THF (150 mL) at 20-25 degrees C overnight. The mixture is then treated with methanol, concentrated to dryness, and chouromatographed to (silica gel) give diethyl 5-(hydroxymethyl) isophthalate. Diethyl 5-(hydroxymethyl)isophthalate (3.4 g) is hydroyzed in ethanol and water with lithium hydroxide monohydrate (0.57 g) at 20-25

degrees C for 3.5 hours at which time the solvents are removed under reduced pressure. Water (100 mL) is added and the mixture is acidified to pH = 4 with concentrated hydrochloric acid. The mixture is extracted with ethyl acetate and dried over magnesium sulfate, filtered, and concentrated to give 3-5 (ethoxycarbonyl)-5-(hydroxymethyl)benzoic acid, resolution MS MH+ 225.0769. 3-(Ethoxycarbonyl)-5-(hydroxymethyl)benzoic acid (2.3 g), EDC (3.0 g), 1-HOBT (2.1 g), diisopropylethylamine (2.7 mL), dipropyl amine (2.8 mL), and DMF (50 mL) are stirred at 20-25 degrees C overnight. 10 mixture is then partitioned between ethyl acetate, water, and The organic phase is separated and dried over magnesium sulfate, filtered, and concentrated. Chromatography (silica gel) gives 3-[(dipropylamino)carbonyl]-5ethyl 15 (hydroxymethyl)benzoate, NMR (CDCl<sub>3</sub>)  $\delta$  0.77, 1.0, 1.4, 1.6, 1.7, 3.2, 3.5, 4.4, 4.8, 7.6, 8.0 and 8.1.

Step 2. A mixture of ethyl 3-[(dipropylamino)carbonyl]-5-(hydroxymethyl)benzoate (1.5 g) and phosphorous tribromide (0.95 mL) is stirred in dichloromethane (10 mL) and heated at 50 degrees C for 4 hours and then cooled and partitioned 20 between dichloromethane and water. The organic phase is separated and washed with aqueous sodium bicarbonate and then dried over magnesium sulfate and taken to dryness to give ethyl 3-(bromomethyl)-5-[(dipropylamino)carbonyl]benzoate, 25 resolution MS MH+ = 370.1020. Ethyl 3-(bromomethyl)-5-[(dipropylamino)carbonyl]benzoate (1.4 g) and sodium cyanide (0.2 g) are stirred in dry DMSO (25 mL) at 20--25 degrees C for 3.5 hours and the mixture is then partitioned between ethyl acetate, water and saline. The organic layer is separated and dried over magnesium sulfate and taken to dryness under reduced 30 pressure to give ethyl 3-(cyanomethyl)-5-[(dipropylamino)carbonyl]benzoate. Ethyl 3-(cyanomethyl)-5-[(dipropylamino)carbonyl]benzoate (0.6 g) is hydrolyzed with lithium hydroxide monohydrate (0.1 g) in ethanol and water at

20-25 degrees C overnight and then added to water (50 mL). The pH is adjusted to 4 using concentrated hydrochloric acid and the mixture is partitioned between ethyl acetate, water, and saline. The organic phase is separated and dried over magnesium sulfate and taken to dryness under reduced pressure to give 3-(cyanomethyl)-5-[(dipropylamino)carbonyl]benzoic acid, MS M+H = 287.2.

Step 3. A mixture of 3-(cyanomethyl)-5-[(dipropylamino)carbonyl]benzoic acid (IX, 0.13 g), (2R,3S)-3-amino-1-[(3-methoxybenzyl)amino]-4-phenyl-2-butanol (VIII, 0.14 g), HATU (0.17 g), and dichloromethane (10 mL) is stirred at 40 degrees C overnight. After cooling, the mixture is washed with water and the organic phase is separated and dried over magnesium sulfate and taken to dryness under reduced pressure. Chromatography (silica gel) gives the title compound, M + H = 571.2

10

15

20

25

30

EXAMPLE 740 N<sup>1</sup>-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-5-(hydroxymethyl)-N<sup>3</sup>,N<sup>3</sup>-dipropylisophthalamide (X)

Following the procedure of CHART P and EXAMPLE 739 and making non-critical variations but using 3[(dipropylamino)carbonyl]-5-(hydroxymethyl)benzoic acid (IX)
and (2R,3S)-3-amino-1-[(3-methoxybenzyl)amino]-4-phenyl-2butanol (VIII), the title compound is obtained, HRMS (FAB) =
615.3571.

EXAMPLE 741 N¹-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-5-ethynyl-N³,N³-dipropylisophthalamide (X)

Step 1: A mixture of methyl 3-bromo-5- [(dipropylamino)carbonyl]benzoate (XXI, 200 mg, 0.58 mmol),  $PdCl_2(Ph_3P)_2$  (16 mg, 0.03 mol %) and copper (I) iodide (6 mg, 0.05 mol %) in triethylamine (1.2 mL) is heated to reflux.

(Trimethylsilyl) acetylene (100 microliter, 0.7 mmol) is added, and the mixture stirred for 3 hours, cooled to 20-25 degrees, diluted with water (20 mL), and extracted with chloroform (3 x 15 mL). The combined organic extracts are washed with saline (20 mL), dried over sodium sulfate and concentrated under reduced pressure to give methyl 3-[(dipropylamino)carbonyl]-5-ethynylbenzoate (XXXII, 185.5 mg), NMR (300 MHz, CDCl<sub>3</sub>): δ 7.95, 7.75, 7.43, 3.74, 3.25, 2.95, 1.49, 1.34, 0.79, 0.56 and 0.06.

- Step 2: To a stirred mixture of the protected methyl 3[(dipropylamino)carbonyl]-5-ethynylbenzoate (XXXII, Step 1,
  185.3 mg, 0.49 mmol) in methanol (2.5 mL) is added a mixture of
  potassium hydroxide (2.9 mL of a 1 M mixture in water, 2.9
  mmol). The reaction mixture is stirred for 4 hours diluted with
  chloroform (40 mL), the phases are separated and the organic
  phase is concentrated under reduced pressure to give 3[(dipropylamino)carbonyl]-5-ethynylbenzoic acid, NMR (300 MHz,
  CDCl<sub>3</sub>): δ 8.22, 8.05, 7.71, 3.48, 3.17, 3.16, 1.71, 1.55, 1.00
  and 0.78.
- 20 Step 3: To stirred mixture of 3 – [(dipropylamino)carbonyl]-5-ethynylbenzoic acid (70 mg, 0.24 mmol) in DMF mL) is added (2R,3S)-3-amino-1-[(3-(2.5 methoxybenzyl)amino]-4-phenyl-2-butanol dihydrochloride (VIII, 81 mg, 0.24 mmol), HOBt (36 mg, 0.26 mmol) diisopropylethylamine (170 microliter, 0.96 mmol). 25 To this reaction mixture is added EDC (51mg, 0.26 mmol) and the reaction mixture is stirred overnight. The reaction mixture is diluted with ethyl acetate (30 mL), washed with water (3 x 50  $\,$ mL), hydrochloric acid (1 N, 30 mL), saturated sodium bicarbonate (30 mL), saline (30 mL), dried over sodium sulfate 30 and concentrated under reduced pressure. Purification by flash chromatography (silica, ethyl acetate to methanol/chloroform, 1/10) gives the title compound, IR (KBr): 3276, 2956, 2921, 1610, 1450 and 1264 cm<sup>-1</sup>; ESI-MS (m/z) [M + H]<sup>+</sup> = 556.

EXAMPLE 742 N¹-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-iodobenzyl)amino]propyl}-N³, N³-dipropyl-5-prop-1-ynylisophthalamide (X)

5

10

15

20

Following the general procedure of EXAMPLE 741 and making non-critical variations but using propyne in place of (trimethylsily1) acetylene and using (2R,3S)-3-amino-1-[(3-iodobenzy1)amino]-4-pheny1-2-butanol dihydrochloride (VIII) in place of (2R,3S)-3-amino-1-[(3-methoxybenzy1)amino]-4-pheny1-2-butanol dihydrochloride (VIII), the title compound is obtained, IR (ATR): 3305, 2930, 2872, 1613 and 1537 cm<sup>-1</sup>; ESI-MS (m/z) [M+H]<sup>+</sup> = 666.

EXAMPLE 743 N<sup>1</sup>-((1S,2R)-1-benzyl-2-hydroxy-3-{[3-(trifluoromethyl)benzyl]amino}propyl)-5-ethynyl-N<sup>3</sup>,N<sup>3</sup>-dipropylisophthalamide (X)

Step 1: A mixture of tert-butyl (1S)-1-[(2S)-oxiranyl]-2- phenylethylcarbamate (V, 2.3 g, 8.7 mmol) and 3-(trifluoromethyl) benzylamine (VI, 1.9 mL, 13.1 mmol) in 2-propanol (70 mL) is heated at reflux for 4 hours. The reaction mixture is cooled to 20-25 degrees and concentrated under reduced pressure to give tert-butyl (1S, 2R)-1-benzyl-2-hydroxy-3-(3-(trifluoromethyl)benzyl) amino}propylcarbamate (VII, 3.1 g) as a solid, ESI-MS (m/z)  $[M + H]^+ = 439$ .

Step 2: A mixture of tert-butyl (1S,2R)-1-benzyl-2-hydroxy-3-{[3-(trifluoromethyl)benzyl]amino}propylcarbamate (VII, step 1, 2.5 g, 5.7 mmol) and hydrochloric acid (29 mL of a 4.0 M mixture in dioxane, 114 mmol) is stirred at 20-25 degrees. A precipitate forms and is collected by filtration, washed with ether, and dried under reduced pressure to give (2R,3S)-3-amino-4-phenyl-1-{[3-(trifluoromethyl)benzyl]amino}-2-butanol dihydrochloride (VIII, 2.13 g), ESI-MS (m/z) [M +]+ = 339.

A mixture of 3-[(dipropylamino)carbonyl]-5-3: ethynylbenzoic acid (IX, 231 mg, 0.8 mmol), (2R,3S)-3-amino-4phenyl-1-{[3-(trifluoromethyl)benzyl]amino}-2-butanol dihydrochloride (VIII, Step 2, 493.5 mg, 1.2 mmol) HOBt (162 mg, 1.2 mmol), and diisopropylethylamine (832 Micro Liter, 4.8mmol) is stirred in methylene chloride (4 mL) for 15 minutes EDC (206 mg, 1.2 mmol) is added and the reaction mixture is stirred overnight. The reaction mixture is diluted with water, and extracted with methylene chloride (3 x 25 mL). The organic phase is washed with hydrochloric acid (1N, 25 mL), saturated 10 sodium bicarbonate (25 mL), saline dried over sodium sulfate and concentrated under reduced pressure. Purification by flash column chromatography (silica, 100% ethyl acetate methanol/chloroform, 1/9) gives title compound, IR (ATR): 3302, 2963, 2932 and 1615 cm<sup>-1</sup>; MS (m/z) [M + H]<sup>+</sup> = 549. 15

EXAMPLE 744  $N^1$ -{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-iodobenzyl)amino]propyl}-5-ethynyl- $N^3$ ,  $N^3$ -dipropylisophthalamide (X)

Following the general procedure of EXAMPLE 744 and making non-critical variations but using 3-iodobenzylamine hydrochloride salt (VI), the title compound is obtained, IR (ATR) 3295, 2960, 2927 and 1616 cm<sup>-1</sup>, APCI-MS (m/z) [M + H]<sup>+</sup> = 652.

25

EXAMPLE 745  $N^1-\{(1S,2R)-1-benzyl-3-[(3-fluorobenzyl)amino]-2-hydroxypropyl\}-5-ethynyl-N^3,N^3-dipropylisophthalamide (X)$ 

Following the general procedure of EXAMPLE 744 and making non-critical variations but using 3-fluorobenzylamine (VI), the title compound is obtained, IR (ATR): 3217, 2961, 2918 and 1615 cm<sup>-1</sup>; APCI-MS (m/z)  $[M + H]^+ = 544$ .

EXAMPLE 746 N<sup>1</sup>-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-N<sup>3</sup>,N<sup>3</sup>-dipropyl-5-(8-quinolinyl)isophthalamide (X)

1: Α mixture of Step methyl-3-bromo-5-[(dipropylamino)carbonyl]benzoate (XLVIII, 200 mg, 0.58 mmol), 8-quinolineboronic acid (200.6 mg, 1.2 mmol), sodium carbonate (870 Micro Liter of a 2 M mixture in water, 1.74 mmol) in toluene (6 mL) is degassed under reduced pressure for 15 minutes purged with and argon. Palladium 10 tetrakis(triphenylphosphine) (139 mg, 0.12 mmol) is added and the reaction mixture is degassed under reduced pressure for 15 minutes and purged with argon. The reaction mixture is heated at reflux overnight, cooled to 20-25 degrees C and diluted with chloroform. The organic phase is separated and washed with 15 water (3 x 50 mL), and saline, dried over sodium sulfate and concentrated under reduced pressure. Purification by flash column chromatography (silica, ethyl acetate/hexanes, 1.3/1) gives methyl 3-[(dipropylamino)carbonyl]-5-(8quinolinyl)benzoate (XLIX, 176 mg), NMR (300 MHz, CDCl3): delta 20 8.91, 8.42, 8.21, 8.09, 7.95, 7.86, 7.77, 7.64, 3.94, 3.49, 3.34, 1.64, 0.99 and 0.84.

Step 2: To a mixture of methyl 3 --[(dipropylamino)carbonyl]-5-(8-quinolinyl)benzoate (XLIX, step 1, 175.5 mg, 0.45 mmol) in methanol (2 mL) is added lithium hydroxide (32.3 mg, 1.4 mmol) and water (500 microliter). After stirring overnight, the reaction mixture is partitioned between ethyl acetate (10 mL) and water (10 mL). The aqueous phase is separated and acidified with hydrochloric acid (1N), and extracted with chloroform (3 x 40 mL). The organic phase is washed with saline, dried (sodium sulfate) and concentrated under reduced pressure to give 3-[(dipropylamino)carbonyl]-5-(8-quinoliny1)benzoic acid (IX - L, 130 mg), NMR (300 MHz, CD<sub>3</sub>OD) □ 8.84, 8.39, 8.35, 8.05, 7.96, 7.90, 7.87, 7.79, 7.68, 3.50, 3.37, 1.76-1.61, 0.99 and 0.84.

25

30

Step 3: A mixture of 3-[(dipropylamino)carbonyl]-5-(8-quinolinyl)benzoic acid (IX - L, Step 2, 130 mg, 0.35 mmol), (2R,3S)-3-amino-1-[(3-methoxybenzyl)amino]-4-phenyl-2-butanol dihydrochloride (VIII, 117 mg, 0.35 mmol), HOBt (70 mg, 0.52 mmol) and diisopropylethylamine (241 microliter, 1.4 mmol) in methylene chloride (2 mL) is stirred for 15 minutes EDC (89 mg, 0.52 mmol) is added and the reaction mixture is stirred overnight. The reaction mixture is diluted with water and extracted with methylene chloride (3 x 25 mL). The organic phase is washed with hydrochloric acid (1N, 25 mL), saturated sodium bicarbonate (25 mL), saline, dried (sodium sulfate), and concentrated under reduced pressure. Purification by flash column chromatography (silica; methanol/chloroform, 1/9) gives the title compound, IR (NaCl): 3301, 2916, 2365 and 1613 cm<sup>-1</sup>; APCI-MS (m/z) [M + H]<sup>+</sup> = 659.

10

15

20

25

30

EXAMPLE 747 N³-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-4'-methoxy-N⁵,N⁵-dipropyl[1,1'-biphenyl]-3,5-dicarboxamide hydrochloride (X)

Step 1: A mixture of 4-methoxyphenyl boronic acid (463 mg, 3.05 mmol), 3-bromo-5-[(dipropylamino)carbonyl]benzoic acid (XLVIII, 1.02 g, 3.05 mmol), and potassium phosphate (1.29 g, 6.10 mmol) in 1,2-dimethoxyethane (10 mL) and water (5 mL) is degassed with argon for 15 minutes Bis(triphenylphosphine)palladium (II) chloride (21 mg, 0.03 mmol) is added, the reaction mixture is degassed again with argon, and heated at 85 degrees C overnight. The reaction mixture is cooled to 20-25 degrees C, and passed through a plug of diatomaceous earth.

The filtrate is acidified to pH=4 with hydrochloric acid (1N) and extracted with ethyl acetate. The organic phase is washed with water and saline and dried (magnesium sulfate). The product is purified by flash column chromatography (silical

gel; ethyl acetate/acetic acid, 99/1) to give 5- [(dipropylamino)carbonyl]-4'-methoxy[1,1'-biphenyl]-3- carboxylic acid (IX - L, 667 mg), ESI-MS (m/z) [M + H]<sup>+</sup> = 356.

2: A mixture of 5-[(dipropylamino)carbonyl]-4'methoxy[1,1'-biphenyl]-3-carboxylic acid (IX - L, step 1, 316 5 mg, 0.89 mmol), (2R,3S)-3-amino-1-[(3-methoxybenzyl)amino]-4phenyl-2-butanol dihydrochloride (VIII, 332 mg, 0.89 mmol), HOBt (181 mg, 1.34 mmol), and N-methylmorpholine (0.37 g, 3.56 mmol) in methylene chloride (8 mL) and dimethylformamide (2 mL) 10 is stirred at 20-25 degrees for 15 minutes EDC (257 mg, 1.34 mmol) is added and the reaction mixture is stirred for 4.5 The reaction mixture is partitioned between methylene chloride and water. The organic phase is washed with hydrochloric acid (1N), water, and saline, dried (magnesium sulfate), and concentrated. The concentrate is dissolved in a 15 minimum of methanol, treated with hydrochloric acid (3 mL of a 1.0 M mixture in ether, 3 mmol), and stirred for 10 minutes. More ether is added to precipitate the rest of the product. precipitate is collected by filtration and dried in the The 20 vacuum oven at 50 degrees C to give the title compound, mp =205-209 degrees C; IR (ATR): 2964 and 1649 cm<sup>-1</sup>; APCI-MS (m/z) $[M + H]^{+} = 638.$ 

EXAMPLE 748 N³-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3[(3-methoxybenzyl)amino]propyl}-N⁵,N⁵dipropyl[1,1'-biphenyl]-3,5-dicarboxamide
hydrochloride (X)

25

Step 1: Α mixture of tert-butyl (1S)-2-(3,5difluorophenyl)-1-[(2S)-oxiranyl]ethylcarbamate (V, 500 mg, 30 1.67 mmol) and 3-methoxybenzylamine (VI, 0.34g, 2.51 mmol) in 2-propanol (3 mL) is heated at reflux overnight, allowed to cool to 20-25 degrees C, and concentrated under reduced pressure. The residue is crystallized from ethyl acetate/hexanes and collected by filtration to afford tert-

butyl (1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-methoxybenzyl)amino]propylcarbamate (VII, 575 mg) as a solid: ESI-MS <math>(m/z): 437  $[M + H]^+$ .

Step 2: A mixture of tert-butyl (1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-methoxybenzyl)amino]propylcarbamate (VII, Step 1, 535 mg, 1.23 mmol) in methanol (2 mL) is treated with hydrochloric acid (3.2 mL of a 1.0 M mixture in ether, 3.2 mmol), and stirred at 20-25 degrees C for 30 minutes Ether is added until a precipitate formed. The precipitate is collected by filtration is (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol dihydrochloride (VIII).

Step 3: A mixture of 5-[(dipropylamino)carbonyl][1,1'biphenyl]-3-carboxylic acid (IX, 188 mg, 0.56 mmol), (2R,3S)-3amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-15 butanol dihydrochloride (VIII, Step 2, 230 mg, 0.56 mmol), HOBt (114 mg, 0.84 mmol), and N-methylmorpholine (0.23 g, 2.24 mmol) in methylene chloride (6 mL) and dimethylformamide (1 mL) is stirred at 20-25 degrees C for 15 minutes EDC (161 mg, 0.84 mmol) is added and the reaction mixture is stirred at 20-2520 degrees C overnight. The reaction mixture is washed with water, 1 N hydrochloric acid, water, and saline, dried (sodium sulfate), and concentrated under reduced pressure to give the title compound, mp 230-233degrees C; IR (ATR): 2965, 1651, 1596 and 1267 cm<sup>1</sup>; ESI-MS (m/z) [M + H]<sup>+</sup> = 644. 25

EXAMPLE 749 N<sup>3</sup>-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-N<sup>5</sup>,N<sup>5</sup>-dipropyl[1,1'-biphenyl]-3,5-dicarboxamide hydrochloride (X)

30

Following the general procedure of EXAMPLE 748 and making non-critical variations but using (2R,3S)-3-amino-1-[(3-methoxybenzyl)amino]-4-phenyl-2-butanol dihydrochloride (VIII) in place of (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-

5

10

15

25

30

Step 1: A flask is charged with 1,1'bis(diphenylphosphino)ferrocene- dichloropalladium 1:1 complex
(37 mg, 0.05 mmol), potassium acetate (492 mg, 4.5 mmol) and
bis(pinacolato)diboron (408 mg, 1.6 mmol) and is degassed under
reduced pressure for 15 min and purged with argon. To this
mixture is added a mixture of methyl-3-bromo-5-

[(dipropylamino)carbonyl]benzoate (XXI, 500 mg, 1.5 mmol) in anhydrous dimethyl sulfoxide (9 mL) and the reaction mixture is stirred at 80 degrees C for 4 hours. The reaction mixture is cooled to 20-25 degrees C, diluted with toluene (50 mL), washed with water (3 x 150 mL), saline, dried (magnesium sulfate), and concentrated under reduced pressure to give methyl 3-

Step 2: A mixture of methyl 3-[(dipropylamino)carbonyl]-5-

[(dipropylamino)carbonyl]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate, ESI-MS (m/z) [M + H]<sup>+</sup> =390.

(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (Step 1, 534 mg, 1.4 mmol), 4-bromobenzenedimethyl-sulfonamide (363 mg, 1.4 mmol), and sodium carbonate (2 mL of a 2 M mixture in water, 4.1 mmol) in toluene (10 mL) is degassed under reduced pressure for 15 minutes and then purged with argon. Palladium tetrakis(triphenylphosphine) (40 mg, 0.025 mmol) is added and the reaction mixture is degassed under reduced pressure for 15 minutes and then purged with argon. The reaction mixture is heated at reflux for 4 hours, cooled to 20-25 degrees C, filtered through a plug of diatomaceous earth and sodium sulfate, and the filtrate is concentrated under reduced pressure. Purification by flash column chromatography (silica;

ethyl acetate/hexanes, 1/1) gives methyl 4'[(dimethylamino)sulfonyl]-5-[(dipropylamino)carbonyl][1,1'biphenyl]-3-carboxylate (XXXVIII), ESI-MS (m/z) [M + H]<sup>+</sup> = 447.

Step 3: A mixture of methyl 4'-[(dimethylamino)sulfonyl]5 5-[(dipropylamino)carbonyl][1,1'-biphenyl]-3-carboxylate
(XXXVIII, step 2, 555 mg, 1.24 mmol) in methanol (6 mL) and
sodium hydroxide (2 mL of a 6.0 M mixture in water, 12 mmol)
is stirred at 20-25 degrees C for 4 hours. The reaction
mixture is partitioned between ethyl acetate (40 mL) and water

10 (40 mL). The aqueous phase is acidified to pH = 4 with hydrochloric acid (1N), extracted with ether (3 x 100 mL), and the combined organic phases are concentrated under reduced pressure to give methyl 4'-[(dimethylamino)sulfonyl]-5-

[(dipropylamino)carbonyl][1,1'-biphenyl]-3-carboxylic acid (IX - XXXIX), NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  8.37, 8.12, 7.89, 7.80, 3.51, 3.22, 2.76, 1.74, 1.59, 1.02 and 0.79.

Step 4: A mixture of the acid (IX - XXXIX, Step 3, 150 mg, 0.35 (2R,3S)-3-amino-1-[(3-methoxybenzyl)amino]-4phenyl-2-butanol dihydrochloride (VIII, 129 mg, 0.35 mmol) HOBt 20 (47 mg, 0.35 mmol), and N-methylmorpholine (122  $\square$ L, 1.1 mmol) is stirred in methylene chloride (4 mL) for 15 minutes EDC (107 mg, 0.62 mmol) is added and the reaction mixture is stirred overnight. The reaction mixture is diluted with water, and extracted with methylene chloride (3  $\times$  25 mL). The organic phase is washed with hydrochloric acid (1N, 25 mL), saturated 25 sodium bicarbonate (25 mL), saline, dried (sodium sulfate), and concentrated under reduced pressure. Purification by flash column chromatography (silica; 100% ethyl acetate methanol/chloroform, 1/9) gives the title compound, IR (ATR): 2932, 2837 and 1593 cm<sup>-1</sup>; APCI-MS (m/z) [M + H]<sup>+</sup> = 715. 30

EXAMPLE 751 N<sup>3</sup>-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-iodobenzyl)amino]propyl}-4'[(dimethylamino)sulfonyl]-N<sup>5</sup>,N<sup>5</sup>-dipropyl-1,1'-

biphenyl-3,5-dicarboxamide

(X)

Following the general procedure of EXAMPLE 750 and making non-critical variations but using 2R,3S)-3-amino-1-[(3-iodobenzyl)amino]-4-phenyl-2-butanol dihydrochloride (VIII), the title compound is obtained, IR (ATR): 3303, 2930, 2872 and 1614 cm<sup>-1</sup>; APCI-MS (m/z) [M + H]<sup>+</sup> = 811.

EXAMPLE 752 N<sup>1</sup>-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-N<sup>3</sup>,N<sup>3</sup>-dipropyl-5-(3-thienyl)isophthalamide hydrochloride (X)

10

15

20

25

30

Step 1: To an ice-cold mixture of methyl 3-amino-5-[(dipropylamino)carbonyl]benzoate (XLVIII, 1.0 g, 3.60 mmol) in aqueous hydrogen tetrafluoroborate (48% wt. in  $H_2O$ , 12.9 mmol) is added a cold mixture of aqueous sodium nitrite (0.25 g, 3.60 mmol) dropwise. The mixture is stirred for 10 min and then extracted with ethyl acetate. The organic phase is washed with water, dried over magnesium sulfate, filtered, and concentrated under reduced pressure to give a diazonium salt which is used without further purification, NMR (500 MHz,  $CD_3OD$ ):  $\delta$  9.26, 8.86, 8.71, 4.03, 3.50, 3.22, 1.75, 1.60, 1.01 and 0.79.

Step 2: To a mixture of thiophene-3-boronic acid (1.0 g, 7.82 mmol) in methanol is added a concentrated aqueous mixture of potassium hydrogen difluoride

(2.01 g, 25.8 mmol) dropwise. The reaction mixture is stirred for 10 minutes and concentrated under reduced pressure. The resulting solid is extracted with acetone and concentrated under reduced pressure gives crude material, which is recrystallized from acetone/ether to give potassium trifluoro(3-thienyl)borate salt, ESI-MS (m/z) [M + H]<sup>+</sup> =151.

Step 3: A mixture of potassium trifluoro(3-thienyl)borate salt (step 2, 0.69 g, 1.82 mmol), diazonium salt from (XLVIII, step 1, 0.42 g, 2.19 mmol), and lead acetate (0.02 g, 0.09 mmol) in the dark is purged with argon for 15 minutes. Dioxane (8 mL) is added and the reaction mixture is degassed with argon

and stirred at 20-25 degrees C overnight. The reaction mixture is diluted with ether, washed with saline, dried over magnesium sulfate and concentrated under reduced pressure to give methyl 3-[(dipropylamino)carbonyl]-5-(3-thienyl)benzoate (XLIX) which is purified by flash chromatography (silica; ethyl acetate/hexanes, 1/1), ESI-MS <math>(m/z) [M + H]<sup>+</sup> = 346.

5

10

15

Step 4: A mixture of methyl 3-[(dipropylamino)carbonyl]-5-(3-thienyl)benzoate (XLIX, step 3, 0.31 g, 0.88 mmol) in THF/methanol/sodium hydroxide (3/1/1, 5 mL) is stirred at 40 degrees C for 2 hours. The reaction is cooled to 20-25 degrees C, diluted with water and extracted with ethyl acetate. The aqueous phase is acidified to pH = 4 and extracted with ethyl acetate. The organic phase is washed with water and saline, dried over magnesium sulfate and concentrated under reduced pressure to give 3-[(dipropylamino)carbonyl]-5-(3-thienyl)benzoic acid (IX - L), ESI-MS <math>(m/z)  $[M + H]^+ = 332$ .

Step 5: A mixture of 3-[(dipropylamino)carbonyl]-5-(3thienyl)benzoic acid (IX - L, step 4, 0.26 g, 0.79 mmol), (2R,3S)-3-amino-1-[(3-methoxybenzyl)amino]-4-phenyl-2-butanol dihydrochloride (VIII, 0.26 g, 0.71 mmol), HOBt (0.16 g, 1.18 20 mmol), and triethylamine (0.44 mL, 3.15 mmol) in DMF (4 mL) is stirred at 20-25 degrees C for 10 minutes EDC (0.23 g, 1.18 mmol) is added and the reaction mixture is stirred for 4 hours. The reaction mixture is diluted with water and extracted with ethyl acetate. The organic phase is washed with hydrochloric 25 acid (1 N), water, and saline, dried over magnesium sulfate and concentrated under reduced pressure. Recrystallization (methylene chloride/hexanes, 1/1) gives the title compound, mp = 199-201 degrees C; IR (KBr): 3278, 2961, 2874 and 2837  $cm^{-1}$ ; 30 ESI-MS (m/z)  $[M + H]^+ = 614$ .

EXAMPLE 753 N-{(1R,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3[(3-methoxybenzyl)amino]propyl}-3-methyl-5pentanoylbenzamide (X)

Step 1: To an ice-cold, stirred mixture of oxalyl chloride (733 mg, 5.77 mmol) in methylene chlor0ide (5 mL) is added 3 drops of dimethylformamide. After 10 minutes 3-(methoxycarbonyl)-5-methylbenzoic acid (LXXIII, 560 mg, 2.89 mmol) is added. The reaction mixture is stirred for 1 hour and concentrated under reduced pressure to provide an acid chloride (LXXIV), which is used without further purification.

5

25

30

Step 2: To a -78 degrees C, stirred mixture of acid halide (LXXIV, step 1, 612 mg, 2.89 mmol) and copper (I) bromide (415 10 2.89 mmol) in tetrahydrofuran (5 mL) is added butyl magnesium chloride (1.44)шL of 2.0 M mixture a tetrahydrofuran, 2.89 mmol). The reaction mixture is warmed to 20-25 degrees C, quenched by addition of saturated ammonium chloride, and diluted with ether. The organic phase is 15 separated, washed with saline, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica; hexanes/ethyl acetate, 6.5/1) gives methyl 3-methyl-5pentanoylbenzoate (LXXVI), NMR (300 MHz, CD<sub>3</sub>OD): δ 8.43, 8.05, 20 3.96, 3.01, 1.77, 1.55 and 1.22.

Step 3: A mixture of methyl 3-methyl-5-pentanoylbenzoate (LXXVI, step 2. 133 mg, 0.605 mmol) in methanol (1 mL) is stirred with tetrahydrofuran/methanol/sodium hydroxide (2 N) (3/1/1, 3 mL) for 3 days. The reaction mixture is diluted with ethyl acetate and washed with water. The aqueous phase is separated and acidified with hydrochloric acid (1 N) and extracted with methylene chloride. The organic phase is dried (sodium sulfate), filtered, and concentrated under reduced pressure to give 3-methyl-5-pentanoylbenzoic acid (IX - LXXVII), NMR (300 MHz, CD<sub>3</sub>OD):  $\delta$  8.44, 8.03, 3.10, 2.33, 1.78, 1.64 and 1.34.

Step 4: To a mixture of 3-methyl-5-pentanoylbenzoic acid (IX - LXXVII, 112 mg, 0.589 mmol), (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol

dihydrochloride (VIII, 239 mg, 0.589 mmol), HOBt (80 mg, 0.589 mmol), and N-methylmorpholine (250 mg, 2.47 mmol) in methylene chloride (3 mL) is added EDC (203 mg, 1.06 mmol). The reaction mixture is stirred overnight and then partitioned between ethyl acetate and water. The organic phase is washed with hydrochloric acid (1 N), saturated sodium bicarbonate, saline, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica; methylene chloride/methanol, 12/1) gives the title compound, IR (ATR): 3297, 2957, 1687 and 1628 cm<sup>-1</sup>; APCI-MS (m/z) [M + H]<sup>+</sup> = 539.

EXAMPLE 754 N¹-(4-hydroxybutyl)-N³-{(1S)-2-hydroxy-1-(4-hydroxybenzyl)-3-[(3-methoxybenzyl)amino]propyl}-5-methyl-N¹-propylisophthalamide (X)

10

Step 1: Toa mixture of methyl (2S) - 3 - [4 -(benzyloxy)phenyl]-2-(tert-butoxycarbonyl)aminopropanoate (1.79 g, 4.65 mmol) in a THF/methanol/water (1/2/1, 16 ml) is added lithium hydroxide (340 mg, 13.9 mmol) and the mixture stirred 20 at 20-25 degrees C for 12 hours. The mixture is quenched with citric acid (10%). The resulting mixture is extracted with ethyl acetate (3 x 15 ml). The combined organic extracts are washed three times with water, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give (2S)-25 3-[4-(benzyloxy)phenyl]-2-[(tert-butoxycarbonyl)amino]propanoic acid which is carried on without purification. degrees C, stirred mixture of (2S)-3-[4-(benzyloxy)phenyl]-2-[(tert-butoxycarbonyl)amino]propanoic acid (10.0 g, 27.0 mmol) in THF (200 mL) is added NMM (3.20 mL, 29.0 mmol) and isobutyl 30 chloroformate (3.8 mL, 29.0 mmol). The cold bath is removed, the reaction mixture is stirred for 1 hour, and then filtered. The filtrate is kept cold and used in the next step. ice-cold, stirred mixture of ether (110 mL) and potassium

hydroxide (40%, 35 mL) is slowly added 1-methyl-3-nitro-1nitrosoquanidine (8.40 g, 57.0 mmol). The reaction mixture is stirred until gas evolution ends. The organic phase is separated and slowly added to an ice-cold, stirred mixture of the mixed anhydride filtrate from step 2. After the reaction mixture is stirred for 1 hour, nitrogen is bubbled into the The resulting mixture is concentrated mixture for 10 minutes under reduced pressure, diluted with ethyl acetate (200 mL), and washed with water (100 mL). The organic phase is washed with saturated sodium bicarbonate and saline, dried over sodium 10 sulfate, filtered, and concentrated under reduced pressure to give the diazoketone, which is carried on without purification or characterization. To an ice-cold, stirred mixture of diazoketone in ether (100 mL) is added hydrobromous acid (48%, 4 mL, 73 mmol). The cold bath is removed, the reaction mixture 15 stirred for 30 minutes, and partitioned between ether and The organic phase separated and washed with saturated sodium bicarbonate and saline, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give tert-20 butyl (1S)-1-[4-(benzyloxy)benzyl]-3-bromo-2-oxopropylcarbamate (IV) is which used without further purification characterization. To a -78 degrees C, stirred mixture of tertbutyl (1S)-1-[4-(benzyloxy)benzyl]-3-bromo-2-oxopropylcarbamate (IV) in a isopropanol/THF (2/1, 150 mL) is slowly added sodium borohydride (1.15 g, 30.0 mmol). The reaction mixture is stirred for 30 minutes followed by the addition of water (30 The resulting mixture is warmed to 20-25 degrees C and concentrated under reduced pressure in a water bath not exceeding 30 degrees C. The crude residue is dissolved in ethyl acetate and washed with water and saline. 30 The organic dried magnesium sulfate, phase is over filtered concentrated under reduced pressure to give the bromohydrin as a solid. To an ice-cold, stirred mixture of bromohydrin in ethanol (150 mL) and ethyl acetate (100 ml) is added a

25

potassium hydroxyde (1 N) ethanol mixture (36 mL, 36 mmol). The cold bath is removed and the reaction mixture is stirred for 30 minutes. The resulting mixture is partitioned between ethyl acetate and water. The organic phase is separated and washed with saline, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. Purification by flash chromatography (silica; hexanes/ethyl acetate, 5/1) gives tertbutyl (1s)-2-[4-(benzyloxy)phenyl]-1-[(2s)-oxiranyl]ethylcarbamate (V, as a 8/1 mixture of diastereomers), NMR (500 MHz, CDCl<sub>3</sub>) δ 7.44-7.32, 7.14, 6.93, 5.07, 4.45, 3.61, 3.00-2.60 and 1.39.

Step 2: A mixture of 4-benzyloxybutyric acid (2.69 g, 13.8 mmol), propylamine (0.82 g, 13.8 mmol), HOBt (2.05 g, 15.2 mmol), N-methylmorpholine (1.68 g, 16.6 mmol) and EDC (2.91 g, 15.2 mmol) in DMF (6 mL) is stirred at 20-25 degrees C for 18 hours. The mixture is diluted with ethyl acetate (40 mL) and washed with water (10 mL), hydrochloric acid (1 N, 10 mL), saturated sodium bicarbonate (10 mL), and saline (10 mL). The organic phase is separated, dried over magnesium sulfate, filtered, and concentrated under reduced pressure to provide 4-(benzyloxy)-N-propylbutanamide (2.59 g), APCI-MS (m/z) [M + H]<sup>+</sup> = 236.

10

25

30

Step 3: To an ice-cold, stirred mixture of 4-(benzyloxy)-N-propylbutanamide (2.59 g, 11.0 mmol) in THF (8 mL) is added lithium aluminum hydride (0.54 g, 14.3 mmol). The reaction mixture is heated to 40-50 degrees C for 5 hours. The cooled reaction mixture is quenched with water (0.5 mL), sodium hydroxide (2 N, 1.0 mL), and saline (0.5 mL) then diluted with ether (30 mL). The precipitate that formed is filtered off, and the ether phase dried over magnesium sulfate, filtered, and concentrated under reduced pressure to give N-[4-(benzyloxy)butyl]-N-propylamine (2.41 g), APCI-MS (m/z): 222 [M + H]<sup>+</sup>.

Step 4: A mixture of N-[4-(benzyloxy)butyl]-N-propylamine (2.31 g, 10.44 mmol), 3-(ethoxycarbonyl)-5-methylbenzoic acid 10.44 (2.18 g, mmol), HOBt (1.56 g, 11.49 mmol), methylmorpholine (1.37 mL, 12.52 mmol), and EDC (2.20 g, 11.49 mmol) in DMF (12 mL) is stirred at 20-25 degrees C for 18hours. The reaction mixture is diluted with ethyl acetate (80 mL) and washed with water (2 x 20 mL), hydrochloric acid (1 N,  $\,$ 20 mL), saturated sodium bicarbonate (20 mL) and saline (20 mL), dried over magnesium sulfate, filtered, and concentrated under reduced pressure. Purification by flash chromatography 10 (silica; hexanes/ethyl acetate,1/1) gives ethyl 3-{[[4-(benzyloxy)butyl](propyl)amino]carbonyl}-5-methylbenzoate (1.79 g), NMR (500 MHz, DMSO- $d_6$ ):  $\delta$  7.80, 7.64, 7.40, 7.38-7.16, 4.50-4.43, 4.34-4.29, 3.53-3.30, 3.20-3.06, 2.41-2.36, 1.70-1.40, 1.36-1.29, 0.94-0.84 and 0.82-0.72; APCI-MS (m/z) [M + 15 H] + 412.

Step 5: To a mixture of ethyl 3-{[[4-(benzyloxy)butyl](propyl)amino]carbonyl}-5-methylbenzoate (1.75 g, 4.25 mmol) in THF/ethanol/water (1/2/1, 30 mL) is added lithium hydroxide (0.31 g, 12.76 mmol). The reaction 20 mixture is stirred for 2 h and then acidified to pH = 3 with concentrated hydrochloric acid (0.5 mL). The reaction mixture is extracted with ethyl acetate (2  $\times$  30 mL), dried over magnesium sulfate, filtered, and concentrated under reduced pressure to give 3-{[[4-(benzyloxy)butyl](propyl)amino]carbonyl}-5-methylbenzoic acid (IX, 1.63 g), ESI-MS (m/z) $[M + H]^{+} = 384.$ 

25

Step 6: Α mixture of tert-butyl (1S) - 2 - [4 -(benzyloxy)phenyl]-1-[(2S)-oxiranyl]ethylcarbamate (V, 1.58 g, 4.28 mmol) and 3-methoxybenzylamine (VI, 825 microliter, 6.42 30 mmol) in isopropanol (45 mL) is heated to 90 degrees C for 4hours. Upon cooling to 20-25 degrees C, the reaction mixture is concentrated under reduced pressure. Purification by flash chromatography (silica; methylene chloride/methanol/ammonium

hydroxide 98/1/1 to 95/:4/1) gives tert-butyl (1S,2R)-1-[4-1](benzyloxy)benzyl]-2-hydroxy-3-[(3-

methoxybenzyl)amino]propylcarbamate (VII, 1.97 g), NMR (300 MHz, MeOH- $d_4$ ):  $\delta$  7.41-6.79, 5.05, 4.33-3.33, 3.74, 3.54, 3.03-2.46 and 1.29; ESI-MS (m/z) [M + H]<sup>+</sup> = 507.

5

25

30

tert-Butyl (1S,2R)-1-[4-(benzyloxy)benzyl]-2-Step 7: hydroxy-3-[(3-methoxybenzyl)amino]propylcarbamate (VII, step 6, 2.34 g, 4.62 mmol) in dioxane (10 mL) is treated with hydrochloric acid (12 mL of a 4.0 M mixture in dioxane, 48 mmol) for 2 hours. The precipitate that forms is collected by 10 filtration, washed with ether, and dried under reduced pressure overnight to give (2R,3S)-3-amino-4-[4-(benzyloxy)phenyl]-1-[(3-methoxybenzyl)amino]-2-butanol hydrochloride (VIII), NMR (300 MHz, MeOH- $d_4$ ):  $\delta$  7.44-6.96, 5.05, 4.21, 3.83, 3.65) and 3.21-2.77; ESI-MS (m/z) [M + H]<sup>+</sup> = 407. 15

Step 8: To an ice-cold, stirred mixture of 3-{[[4-(benzyloxy)butyl](propyl)amino]carbonyl}-5-methylbenzoic (IX, 310 mg, 0.809 mmol), (2R, 3S) - 3 - amino - 4 - [4 -(benzyloxy)phenyl]-1-[(3-methoxybenzyl)amino]-2-butanol

20 hydrochloride (VIII, 359 mg, 0.809 mmol), and bromotripyrrolidinophosphonium hexafluorophosphate (415 mg, 0.890 mmol) methylene chloride in (10 mL) is added diisopropylethylamine (285 microL, 1.62 mmol) dropwise. The resulting mixture is stirred at 0 degrees C for 30 minutes and then warmed to 20-25 degrees C. After 4 hours, the reaction is concentrated under reduced pressure and is partitioned between ethyl acetate and water. The aqueous phase is separated and extracted with ethyl acetate (3  $\times$  15 mL), the combined organic phases are dried over magnesium sulfate, and concentrated under reduced pressure. The concentrate is purified by flash chromatography (silica; methylene chloride/methanol/ammonium hydroxide 96/3/0.5) to give  $N^{1}$ -{ (1S, 2R) -1-[4-(benzyloxy)benzyl]-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}- $N^3$ -[4-(benzyloxy)butyl]-5-methyl- $N^3$ -propylisophthalamide (X)

NMR (300 MHz, Acetone- $d_6$ ):  $\delta$  7.99-6.74), 5.01 4.51-4.29, 4.36, 4.01, 3.80, 3.55-3.16, 2.98-2.82, 2.65-2.62, 2.36, 1.85-1.29, 1.01 and 0.68; ESI-MS (m/z) [M + H]<sup>+</sup> = 772.

Step 9. A mixture of  $N^1 - \{(1S, 2R) - 1 - [4 - (benzyloxy)benzyl] - (benzyloxy)benzyl]$ 2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-N<sup>3</sup>-[4-(benzyloxy)butyl]-5-methyl-N<sup>3</sup>-propylisophthalamide (X, 100 mg, 0.130 mmol) and palladium on carbon (10%, 100 mg) in absolute glacial acetic acid (5 mL) is shaken under an atmosphere of hydrogen at 35 psi for 5 hours. The resulting mixture is 10 filtered through diatomaceous earth and washed with methanol. The combined filtrates are concentrated under reduced pressure. The concentrate is purified by flash column chromatography (silica; gradent of dichloromethane/methanol/ammonium hydroxide 97/3/0.05 to 93/7/0.05) to give the title compound: NMR (300) 15 MHz, CD<sub>3</sub>OD):  $\delta$  7.55-6.64, 4.19, 3.99-3.72, 3.63-3.36, 3.21-3.09, 2.79-2.69, 2.39, 1.90-1.40, 1.29 and 1.02-0.6; ESI-MS (m/z)  $[M + H]^+ = 592$ .

EXAMPLE 756 N¹-{(1S,2R)-2-hydroxy-1-(4-hydroxybenzyl)-3-[(3-20 methoxybenzyl)amino]propyl}-5-methyl-N³,N³-dipropylisophthalamide (X)

- Step 1. To a stirred mixture of 3-[(dipropylamino)-carbonyl]-5-methylbenzoic acid (IX, 150 mg, 0.570 mmol), (2R,3S)-3-amino-4-[4-(benzyloxy)phenyl]-1-[(3-
- 25 methoxybenzyl)amino]-2-butanol hydrochloride (VIII, 274 mg, 0.571 mmol), N, N-diisopropylethylamine (400 microliter, 2.28 mmol), and HOBt (116 mg, 0.857 mmol) in dichloromethane (10 mL) is added EDC (165 mg, 0.857 mmol). The resulting mixture is stirred at 20-25 degrees C for 16 hours. The reaction mixture is partitioned between dichloromethane and water. The aqueous 30 phase is separated and extracted with dichloromethane (3  $\times$  15 The combined organic phases are washed with water, dried (magnesium sulfate), and concentrated under reduced pressure. Purification by flash column chromatography (silica;

dichloromethane/methanol/ammonium hydroxide, 97/3/0.05) gives  $N^1-\{(1S,2R)-1-[4-(benzyloxy)benzyl]-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl\}-5-methyl-N^3,N^3-dipropylisophthalamide, ESI-MS <math>(m/z)$   $[M+H]^+=652$ .

Step 2. A mixture of  $N^1-\{(1S,2R)-1-[4-(benzyloxy)benzyl]-$ 5 2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-5-methyl- $N^3$ ,  $N^3$ dipropylisophthalamide (140 mg, 0.215 mmol) and palladium on carbon (10%, 140 mg) in absolute glacial acetic acid (5 mL) is shaken under an atmosphere of hydrogen at 35 psi for 5 hours The resulting mixture is filtered through diatomaceous earth 10 washed with methanol. and The combined filtrates concentrated under reduced pressure. The concentrate is purified by flash column chromatography (silica; methylene chloride/methanol/ammonium hydroxide gradient from 97/3/0.05 to 93/7/0.05) to give the title compound, IR (KBr) 2962, 2931, 15 1611, 1594 and 1263 cm<sup>-1</sup>; ESI-MS (m/z) [M + H]<sup>+</sup> = 562.

EXAMPLE 757  $N^{1}-((1S,2R)-1-benzyl-3-\{[3-(2,4-dimethylphenyl)propyl]amino}-2-hydroxypropyl)-5-methyl-<math>N^{3}$ ,  $N^{3}$ -dipropylisophthalamide (X)

20

25

Step 1: A stirred mixture of tert-butyl (1S)-1-[(2S)oxiranyl]-2-phenylethylcarbamate (V, 247 mg, 0.939 mmol), sodium carbonate (299 mg, 2.82 mmol), and dimethylphenyl)propylamine (VI, 628 mg, 2.82 mmol) is heated at reflux overnight. The reaction mixture is cooled to 20-25degrees Ç and concentrated under reduced pressure. Purification by flash column chromatography (silica; methylene chloride/methanol/ammonium hydroxide, 98/2/1) gives tert-butyl  $(1S, 2R)-1-benzyl-3-\{[3-(2,4-dimethylphenyl)propyl]amino}-2-$ 

30 hydroxypropylcarbamate (VII), NMR (300 MHz, CD<sub>3</sub>OD):  $\delta$  7.22-7.16, 3.81, 3.18, 2.77, 2.54, 2.15, 2.13, 1.89 and 1.23.

Step 2: To a stirred mixture of tert-butyl  $(1S,2R)-1-benzyl-3-\{[3-(2,4-dimethylphenyl)propyl]amino}-2-hydroxypropylcarbamate (VII, 180 mg, 0.423 mmol) in dioxane (2$ 

mL) is added hydrochloric acid (0.32 mL of a 4 N mixture in dioxane, 1.27 mmol). The reaction mixture is stirred overnight and concentrated under reduced pressure to give (2R,3S)-3-amino-1-{[3-(2,4-dimethylphenyl)propyl]amino}-4-phenyl-2-

5 butanol hydrochloride (VIII), NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  7.14, 3.73, 2.70, 2.32 and 1.86.

Step 3: To a stirred mixture of (2R,3S)-3-amino-1-{[3-(2,4-dimethylphenyl)propyl]amino}-4-phenyl-2-butanol

hydrochloride (VIII, 163 mg, 0.411 mmol), 3
[(dipropylamino)carbonyl]-5-methylbenzoic acid (IX, 108 mg, 0.411 mmol), HOBt (55 mg, 0.411 mmol), and N-methylmorpholine (133 mg, 1.32 mmol) in methylene chloride (5 mL) is added EDC (142 mg, 0.740 mmol). The reaction mixture is stirred overnight and then partitioned between ethyl acetate and water.

The organic phase is washed with hydrochloric acid (1 N), saturated sodium bicarbonate, saline, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica; methylene chloride/methanol/ammonium hydroxide, 95/5/1) gives the title compound, IR (ATR): 3299, 2930 and 1614 cm<sup>-1</sup>; APCI-MS (m/z) [M + H]<sup>+</sup> = 572.

EXAMPLE 765  $N^3-\{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl\}-4-methyl-<math>N^1$ ,  $N^1$ -dipropylisophthalamide (X)

25

30

3-Bromo-4-methylbenzoic acid (10.94 43.25 mmol), g, copper(I)cyanide (7.75)g, 86.5 mmol) and pyrrolidinone (75 ml) are heated to 160 degrees C overnight. The mixture is cooled and vacuum distilled to give a residue which is stirred in hydrochloric acid (6N, 60 ml) for 10 minutes. The resulting solid is collected by filtration, washed with water, ether, and dried. The solid is heated to 90 degrees C in sodium hydroxide (2N, 250 ml) for 3 hours and the mixture is then cooled and stirred overnight at 20-25 degrees

The reaction is acidified to about pH 3 with concentrated hydrochloric acid which gives a precipitate. The solids are collected by filtration and washed with water, then triturated in boiling water, filtered and dried in a vacuum oven at 60 The solid is dissolved in methanol (75 ml) and degrees C. concentrated hydrochloric acid (5 ml) is added and the mixture is refluxed overnight. The mixture then is cooled and concentrated under reduced pressure. Chromatography (silica methanol/methylene chloride, 8/92) gives 5-10 (methoxycarbonyl)-2-methylbenzoic acid.

5

To 5-(methoxycarbony1)-2-methylbenzoic acid (250 mg, 1.3 mmol) and triethylamine (0.72 ml, 5.2 mmol) in methylene chloride (14 ml) is added diethylcyanopyrocarbonate (90%, 0.24  $\,$ ml, 1.4 mmol) with stirring. After 1 minute, (2R,3S)-3-amino-1-[(3-methoxybenzyl)amino]-4-phenyl-2-butanol dihydrochloride 15 (VIII, 485 mg, 1.3 mmol) is added and the reaction is stirred overnight. The mixture is concentrated followed chromatography (silica gel; methanol/methylene chloride 8/92) to afford 3-[({(1s,2r)-1-benzy1-2-hydroxy-3-[(3methoxybenzyl)amino]propyl}amino)carbonyl]-4-methylbenzoate. 20

3-[({(1s,2R)-1-benzyl-2-hydroxy-3-[(3methoxybenzyl)amino]propyl}amino) carbonyl]-4-methylbenzoate (200 mg, 0.42 mmol) is treated with lithium hydroxide (39 mg, 0.96 mmol) in tetrahydrofuran/methanol/water (2/1/1, 2 ml), and the mixture stirred overnight at 20-25 degrees C. The mixture 25 is decanted and the supernatant concentrated to give 3-[({(1S,2R)-1-benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl} amino)carbonyl]-4-methylbenzoic acid.

3-[({(1S,2R)-1-benzyl-2-hydroxy-3-[(3-

methoxybenzyl)amino]propyl}amino) carbonyl]-4-methylbenzoic 30 acid (124 mg, 0.27 mmol) is dissolved in triethylamine (0.07 ml, 0.54 mmol) and methylene chloride (3 ml) and treated with diethylcyanopyrocarbonate (90%, 0.06 ml, 0.32 mmol) stirring for 2 minutes. Dipropylamine (0.04 ml, 0.32 mmol) is

added and stirring continued overnight. The organic phase is diluted with methylene chloride and washed with saturated sodium bicarbonate (2 X 50 ml) and saline (50 ml) then dried over anhydrous sodium sulfate, filtered and concentrated. Chromatography (silica gel; methanol/methylene chloride, 8/92) gives the title compound, MS [M+H]<sup>+</sup> = 546.3.

EXAMPLE 766 N-{(1s,2r)-1-benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-3-(2-furyl)-5-methylbenzamide (X)

10

30

 $N-\{(1R, 2R) -1-benzy1-2-hydroxy-3-[(3$ methoxybenzyl)amino]propyl}-3-bromo-5-methylbenzamide (X, EXAMLE 761, 295 mg, 0.59 mmol), 2-furanylboronic acid (133 mg, 1.19 mmol) and sodium carbonate (366 mg, 2.95 mmol) combined in dimethylformamide (5 ml) and sparged under a flow 15 of nitrogen for 15 minutes. Tetrakis(triphenylphosphino) palladium (136 mg, 0.12 mmol) is added and the mixture heated to 100 degrees C overnight. The mixture is cooled to 20-25 degrees C, diluted with chloroform (50 ml) and extracted with water (3  $\times$  100 ml). The organic phase is separated and washed 20 with saturated sodium bicarbonate (2 x 100 ml) and saline (100 ml), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressue. The residue chouromatographed (silica gel; methanol/methylene chloride, 25 8/92) to give the title compound, MS  $[M+H]^+ = 485.3$ .

## EXAMPLE 792 2-Butylcyclopropylamine hydrochloride (VI)

A solution of triethylphosphonoacetate (22.4 g, 0.1 mol) in 13 mL of diglyme is added to a mixture of 13 mL of diglyme and sodium hydride (60%, 5.7 g, 0.12 mol) in mineral oil. When hydrogen evolution ceased, 1,2-epoxyhexane (12 g, 0.12 mol) in diglyme (12 mL) is added. The mixture is stirred for 1 day at 25 degrees C and 3 hours at 140 degrees C. A mixture of sodium hydroxide (15 g in 25 mL of water)

is added in the cold. The mixture is refluxed 15 hours, diluted with cold water (100 mL), and washed with ether (3  $\times$ 50 mL). Acidification to pH = 2 with sulfuric acid (25%), extraction with ether (5 x 25 mL), drying the ether over anhydrous sodium sulfate, filtration and concentration gives 2-butylcyclopropanecarboxylic acid. The acid (5.0 g, 0.035 mmol) in dichloromethane (15 mL) is heated with thionyl chloride (5.1 g, 3.1 mL) for 15 hours at 60 degrees C. reaction mixture is distilled (76 degrees C- 80 degrees C) to give the acid chloride which is dissolved in acetone (15 10 mL), cooled to -10 degrees C and treated with sodium azide (2.2 g, 33.8 mmol) in water (5 mL). The reaction mixture is stirred at -10 degrees C for another 1 hour and then poured onto ice/water, extracted with ether (3x10 mL), dried, and cautiously evaporated to dryness at 20-25 degrees C under 15 reduced pressure. The residue is dissolved in toluene (15 mL) and carefully warmed to 100 degrees C while vigorously stirring for 1 hour. Concentrated hydrochloric acid (7 mL) is added and the reaction mixture is refluxed for 15 minutes. The acidic layer is evaporated to dryness to give 20 the title compound,  $MH^+ = 114.2$ .

## EXAMPLE 793 2-Aminomethyl-3-methylfuran (VI)

3-Methylfuroic acid (4.0 g, 32 mmol) is dissolved in

25 DMF (10 mL) at 20-25 degrees C, and 1,1-carbonyldiimidazole
(5.7 g, 35 mmol) is added. After 15 minutes, ammonia is
bubbled into the mixture for approximately 2 minutes. This
mixture is stirred at 20-25 degrees C for 2 hours then the
mixture is concentrated under reduced pressure. The residue

30 is partitioned between ethyl acetate and 10% aqueous citric
acid. The layers are separated, and the aqueous layer
extracted with additional ethyl acetate (2 x). The combined
organic phases are washed with saturated sodium bicarbonate,
then saline and dried over magnesium sulfate, filtered and

concentrated. Crystals formed upon standing, which are isolated by filtration and washing with a small amount of ethyl acetate/hexanes (80/20), MS(ESI): MH+: 126.1. 3-Methylfuroic amide (317 mg, 2.5 mmol) is dissolved in dry THF (5 mL). Lithium aluminum hydride (230 mg, 6.0 mmol) is added in one portion, and the mixture heated to reflux overnight. The mixture is cooled to 0 degrees C, and quenched by addition of THF/water (50/50). The mixture is then diluted with THF, and filtered through diatomaceous earth. The filtrate is concentrated to give the title compound, MS(ESI): (M-H)+: 109.1.

## EXAMPLE 7944-Aminomethyl-3,5-dimethylisoxazole (VI)

10

25

30

4-Chloromethyl-3,5-dimethylisoxazole (700 mg, 4.8 mmol)

is suspended in concentrated aqueous ammonia at 20-25
degrees C, and vigorously stirred overnight. The reaction
mixture is extracted with isopropyl alcohol/chloroform
(10/90, 2 x). The combined organic phases are concentrated
under nitrogen flow. The residue is purified by flash
chromatography methanol/methylene chloride (5-20%, 1%
triethylamine) to give the title compound, MR (CDCl<sub>3</sub>, 300
MHz) delta3.62, 2.37, 2.29, and 1.44.

EXAMPLE 795 5-Hydroxymethyl-2-(2-methylpropyl) thiazole (VI)

Isovalerothioamide is synthesized according to the procedure in J. Med.Chem. 41, 602-617 (1998).Isovaleramide (10 g, 9.9 mmol) is suspended in dry ether (400 mL), then phosphorous(V) sulfide (4.4 g, 0.99 mmol) is added in portions. This is vigorously stirred at 20-25 degrees C for 2 hours, then filtered. The filtrate is concentrated under reduced pessure and the residue used without further purification: MS(ESI): MH+: 118.1.

Isovalerothioamide (6.0 g, 51 mmol) and ethyl formylchloroacetate (Heterocycles 32 (4), 693-701, (1991), 5.0 g, 33 mmol) are dissolved in dry DMF (20 mL), and heated to 95 degrees C for 4 hours. The reaction is subsequently cooled to 0 degrees C, and cold water (50 mL) is added. The mixture is basified to pH = 8 with solid sodium bicarbonate, then extracted with ether (3  $\times$  35 mL). The combined organic extracts are washed with water, then saline and dried over magnesium sulfate, filtered, and concentrated. The residue is purified by flash chromatography (ethyl acetate/hexanes 10 4-10% elution) to give the desired product. NMR (CDCl3, 300 MHz)  $\delta$  8.27, 4.45-4.30, 3.70-3.50, 3.00-2.80, 2.30-2.10, 1.40-1.20, and 1.10-0.90.

A solution of ethyl 2-(2-methylpropyl)thiazole-5
15 carboxylate (2.05 g, 9.6 mmol) in THF (10 mL) is added dropwise with stirring to a suspension of lithium aluminum hydride (730 mg, 19 mmol) in dry THF (50 mL) at 0 degrees C. Upon complete addition, the reaction mixture is allowed to stir at 20-25 degrees C. The reaction mixture is cooled to 20 0 degrees C, and water (0.75 mL), aqueous sodium hydroxide (15%, 0.75 mL), and water (2.25 mL) is added in succession. This mixture is stirred at 0 degrees C for 1 hour, then filtered through diatomaceous earth, (THF and chloroform). The filtrate is concentrated to give 5-hydroxymethyl-2-(2-25 methylpropyl)thiazole, MS(ESI): MH+: 172.1.

EXAMPLE 796 3-(2-Methylpropyl)-5-aminomethylisoxazole (VI)

Isovaleraldehyde (5.4 mL, 50 mmol) and hydroxylamine hydrochloride (3.5 g, 50.4 mmol) are vigorously stirred in water (6 mL). To this is added a solution of sodium carbonate (2.65 g, 25 mmol) in water (15 mL). This is vigorously stirred overnight. The mixture is extracted with ether. The organic layer is washed with water, then dried over sodium sulfate,

filtered and concentrated. This is used in subsequent reactions without further purification: MS(ESI): MH+: 102.1.

Propargylamine (8.0 mL, 117 mmol) is dissolved in methylene chloride (60 mL), and di-tert-butyl dicarbonate (25 g, 114 mmol) is added. This is stirred overnight, and concentrated to provide the BOC-protected propargylamine, which is used without further purification: MS(ESI): MNa+: 178.0.

5

BOC-propargylamine (6.2 g, 39.7 mmol) and isovaleroxime (3.97 g, 39.3 mmol) is dissolved in methylene chloride (60 mL), and triethylamine (0.55 mL, 3.95 mmol) is added. This is cooled to 0 degrees C, and bleach (5% aqueous solution, 59.1 g) is added dropwise with vigorous stirring. After addition is complete, the mixture is allowed to warm to 20-25 degrees C over 22 hours. The layers are separated, and the aqueous layer is extracted with methylene chloride (2 x). The combined organic extracts are washed with saline, dried over magnesium sulfate, filtered and concentrated. The residue is purified by chromatography (silica gel, ethyl acetate/hexanes 5-10%) to give the BOC-protected title compound, MS(ESI): MH+: 255.3.

BOC-protected 3-(2-methylpropyl)-5-aminomethylisoxazole
(2.4 g, 9.3 mmol) is dissolved in methylene chloride (10 mL)
and treated with trifluoroacetic acid (10 mL) at 20-25 degrees
C. This is stirred at 20-25 degrees C for 70 minutes, then
concentrated. The product is dissolved in methylene chloride,
and washed with aqueous potassium carbonate (1 M) until basic
(pH = 11). The organic layer is isolated, dried over sodium
sulfate, filtered and concentrated to give the title compound:
MS(ESI): MH+: 155.2.

30 EXAMPLE 797 tert-butyl (3R)-2-oxo-1-propylazepanylcarbamate (VI)

To N-t-Boc-D-Lys-OH (10 g, 41.4mmole) in DMF (4 liters) is added benzotriazol-1yloxytripyrrolidino-phosphonium hexafluorophosphate (BOP, 18.3 g, 41.4mmole) and sodium

bicarbonate (17.4 g, 206.8mmole); the reaction is stirred at 20-25 degrees C for 12 hours. The reaction is then concentrated to 50 ml volume and diluted with ethyl acetate and washed with sodium bicarbonate 3x, water, 1M potassium bisulfate and brine, dried and concentrated. Purification by chromatography on silica gel afforded 5.05 g of the tert-butyl (3R)-2-oxoazepanylcarbamate as a solid; the procedure employed is similar to that described in J.Med.Chem. 1999, 4193. M+H-(t-Boc) (m/e=129.2), M+Na (m/e=251.1).

10 To the above lactam (2 g, 8.77mmole) in dry THF (20 ml) is added n-butyllithium /hexane (2.5 M, 5.3 ml, 13.2 mmole ) at -78 degrees C, the reaction is stirred for 1 hour and 1bromopropane (3.2 ml, 35.1 mmole) is added. The reaction is stirred for 1 hour and the cold bath removed and stirring continued for another 16 hours. 15 Tetrabutylammonium iodide (0.49 g, 2.63mmole) is added and the reaction stirred for another 16 hours. The reaction is partitioned between ethyl acetate/hydrochloric acid + ice + water, the mixture is washed with water and saline and concentrated. Purification by chromatography on silica gel afforded the title compound, MS 20 (M+Na+) 293.3.

EXAMPLE 798  $N^{1}$ -{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethynylbenzyl)amino]-2-hydroxypropyl}-5-methyl- $N^{3}$ , $N^{3}$ -dipropylisophthalamide (X)

25

30

Following the procedure described in J. Am. Chem. Soc. 1986, 3150, the trifluoroacetic acid salt of  $N^1$ -{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-iodobenzyl)amino]propyl}-5-methyl- $N^3$ ,  $N^3$ -dipropylisophthalamide (92.9 mg, 0.117 mmol) is dissolved in triethylamine (0.2 M, 0.6 mL) before the addition of  $PdCl_2(PPh_3)_2$  (3.3 mg, 0.005 mmol), and copper (I) iodide (1.1 mg, 0.006 mmol). The reaction is heated to reflux. While the reaction is refluxing, trimethylsilylacetylene (0.02 ml, 0.14

mmol) is added via syringe. The reaction is refluxed for 3 hour under  $N_2$  (g), and the reaction cooled to 20-25 degrees C before partitioning between aqueous sodium bicarbonate and ethyl acetate. The product is extracted with ethyl acetate (3 x), washed with saline, dried over sodium sulfate<sub>4</sub>, and filtered before the removal of solvent under reduced pressure.

The TMS protected acetylene (0.117 mmol) is dissolved in methanol (0.2 M, 0.5 mL) before the addition of potassium hydroxide (1M, 0.7 mL, 0.7 mmol). The reaction is stirred at 20-25 degrees C for 6 hours, at which point the mixture is 10 partitioned between sodium bicarbonate and ethyl acetate. The product is extracted with ethyl acetate (3 x), washed with saline, dried over sodium sulfate, and filtered before the removal of solvent under reduced pressure. Column 15 chromatography (silica gel; 1.5-2 % isopropanol/chloroform under basic conditions; a few drops of ammonium hydroxide per 100 mL of elution solvent) gives the title compound, MS m/z $(M+H)^+ = 576.3$ 

20 EXAMPLE 799 1-phenylcyclopropylamine (VI)

Following the procedure described in N.W. Werner et.al., J. Org. Syn. Coll. Vol. 5, 273-276, sodium azide (0.915g, 14.1 mmol) is slowlyadded to a solution of 1-pheny1cyclopropanecarboxlic acid (1.0 g, 6.1 mmol) in concentrated sulfuric acid (5 ml) and dichloromethane (10 ml). The sodium sulfate precipitated out of solution. The reaction mixture is heated to 50 degrees C for 17 hours and then cooled to 0  $\,$ degrees C. The mixture is basified to pH = 11 with sodium hydroxide (1N) and extracted with dichloromethane (2  $\times$ ). The organic layers are combined, dried over sodium sulfate, filtered and concentrated. The residue is purified by chromatography (silica gel; isopropyl alcohol/chloroform/ ammonium hydroxide 4/95/1) to give the title compound, MS (ESI+) for  $C_9H_{11}N \ m/z \ (M+H)^+ = 134$ .

15

25

30

10

5

EXAMPLE 800 7-methoxy-1,2,3,4-tetrahydro-1-naphthalenamine (VI)

7-Methoxy-1-tetralone (2.0 g, 11.3 mmol), hydroxylamine hydrochloride (1.56 g, 22.6 mmol) and sodium acetate (1.8g, 22.6 mmol) are suspended in ethanol/water (3/1, 40 mL). 20 mixture is heated for 45 min. at 100 degrees C. The mixture is allowed to cool overnight and the precipitate obtained is filtered and washed with water to yield an intermediate oxime, MS (ES) (M+H): 192.1. The oxime is dissolved in glacial acetic acid (25 ml) and palladium/carbon (500 mg) is added and the mixture hydrogenated under 50 psi at 20-25 degrees C overnight. The catalyst is filtered over diatomaceous earth and washed with methanol. The combined filtrates are concentrated. concentrate is triturated with ether to give the title compound, MS (CI) (M+H)+: 178.2.

Examples 1208-1214 and 1226

```
N^{1}-(tert-butyl)-N^{3}-{(1S, 2R)-1-(3, 5-
           1,208
     difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-
     methylisophthalamide
                       5-bromo-N^{1}-(tert-butyl)-N^{3}-((1S,2R)-1-(3,5-
           1,209
     difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
     hydroxypropyl}isophthalamide
           1,210
                       3-\text{tert-butoxy-N-}\{(1S,2R)-1-(3,5-\text{difluorobenzyl})-1-(3,5-\text{difluorobenzyl})-1-(3,5-\text{difluorobenzyl})
     3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}benzamide
                       3-tert-butoxy-N-\{(1S, 2R) - 1 - (3, 5 - difluorobenzyl) - (3, 5 - difluorobenzyl) - (3, 5 - difluorobenzyl)
10
     3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methylbenzamide
           1,212
                       N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
     ethylbenzyl)amino]-2-hydroxypropyl}-3-
     {[(trifluoromethyl)sulfonyl]amino}benzamide
           1,213
                       N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-max)-1]
15
     ethylbenzyl)amino]-2-hydroxypropyl}-3-
     (trifluoromethoxy)benzamide
                      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
     ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-
     (trifluoromethoxy)benzamide
20
                      N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
           1,226
     ethylbenzyl)amino]-2-hydroxypropyl}-5-(4-methyl-1,3-oxazol-2-
     y1)-N^3, N^3-dipropylisophthalamide (M+H)<sup>+</sup> = 647.5
```

The compounds in the table immediately below were prepared essentially using the methods described above and illustrated below in the schemes.

Compounds in this application were named using Chemdraw Ultra version 6.0.2, which is available through Cambridgesoft.co, 100 Cambridge Park Drive, Cambridge, MA 02140, Namepro version 5.09, which is available from ACD labs, 90 Adelaide Street West, Toronto, Ontario, M5H, 3V9, Canada, or were derived from names generated using those programs.

1	0

5

)	
	F HN HN
1260	N-[1-(3,5-Difluoro-benzyl)-2-hydroxy-3-(1- isobutylcarbamoyl-3-methylsulfanyl-propylamino)- propyl]-5-methyl-N',N'-dipropyl-isophthalamide
1261	N-[1-(3,5-Difluoro-benzyl)-3-(1-ethylcarbamoyl-ethylamino)-2-hydroxy-propyl]-5-methyl-N',N'-dipropyl-isophthalamide
1262	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-N'-dimethylcarbamoylmethyl-5,N'-dimethyl-isophthalamide

	OH IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
1263	N-[1-(3,5-Difluoro-benzyl)-2-hydroxy-3-(1-methylcarbamoyl-3-methylsulfanyl-propylamino)-propyl]-5-methyl-N',N'-dipropyl-isophthalamide
1264	N-[3-(1-Benzylcarbamoyl-ethylamino)-1-(3,5- difluoro-benzyl)-2-hydroxy-propyl]-5-methyl- N',N'-dipropyl-isophthalamide
	N-{[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-
1265	benzylamino) -2-hydroxy-propylcarbamoyl]-methyl}- 3-trifluoromethyl-benzamide
	F F F F F F F F F F F F F F F F F F F
1055	N-{[1-(3,5-Difluoro-benzy1)-3-(3-ethyl-benzylamino)-2-hydroxy-propylcarbamoyl]-methyl}-
1266	4-trifluoromethyl-benzamide
1267	3,4-Dichloro-N-{[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propylcarbamoyl]-methyl }-benzamide

	F OH H
1268	N-[3-(1-Carbamoy1-3-methyl-butylamino)-1-(3,5-difluoro-benzyl)-2-hydroxy-propyl]-5-methyl-N',N'-dipropyl-isophthalamide
	OF POH DON
1269	N-{[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propylcarbamoyl]-methyl}-4-methoxy-benzamide
	N={[1-(3, E, Distance   1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,
1270	N-{[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propylcarbamoyl]-methyl}-2,6-difluoro-benzamide
	F NH2
1271	N-[3-(1-Carbamoyl-ethylamino)-1-(3,5-difluoro- benzyl)-2-hydroxy-propyl]-5-methyl-N',N'- dipropyl-isophthalamide
	OF HOLES
1272	N-{[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propylcarbamoyl]-methyl}-2,6-dimethoxy-benzamide

1273	2-{[1-(3,5-Difluoro-benzy1)-3-(3-ethyl-benzylamino)-2-hydroxy-propylcarbamoyl]-methylsulfanyl}-N-(4-oxazol-5-yl-phenyl)-acetamide
	H S H QH H L L
1274	2-{[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propylcarbamoyl]-methylsulfanyl}-N-(5-methyl-isoxazol-3-yl)-acetamide
	O=SOO OH OH
1275	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-4-methanesulfonyl-benzenesulfonamide
	S N H OH
1276	2-Cyano-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-benzenesulfonamide
	F F
1277	2-Chloro-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-4-

	PC 1/US02/360/2
	trifluoromethoxy-benzenesulfonamide
	CI O H H OH
1278	2-Chloro-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-6-methyl-benzenesulfonamide
1279	5-Chloro-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-methoxy-benzenesulfonamide
	CI O S P H OH P
1280	2-Chloro-4-cyano-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-benzenesulfonamide
1281	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-trifluoromethyl-benzenesulfonamide
	HO SO H DH DH
1282	ö 4-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-

	benzylamino) -2-hydroxy-propylsulfamoyl]-benzoic acid
	6-Chloro-pyridine-3-sulfonic acid [1-(3,5-
1283	<pre>difluoro-benzyl)-3-(3-ethyl-benzylamino)-2- hydroxy-propyl] -amide</pre>
	F F F F F F F F F F F F F F F F F F F
1284	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2,5-bis-(2,2,2-trifluoro-ethoxy)-benzenesulfonamide
	N S N H OH
1285	Pyridine-3-sulfonic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide
	CI HA
1286	N-{2-Chloro-4-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propylsulfamoyl}-phenyl}- acetamide

	·
1287	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-trifluoromethoxy-benzenesulfonamide
	F
	S S H H OH H
	N-{5-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-
1288	benzylamino)-2-hydroxy-propylsulfamoyl]- thiophen-2-ylmethyl}-benzamide
	F.
	S O H
	N H OH
	5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonic
1289	1 40 44 [4 (0,0-d111u0ro-penzyl)-3-/3-6+h7
	benzylamino)-2-hydroxy-propyl]-amide
	0, 0 H F
	O N S H OH H T
	N-{5-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-
1290	benzylamino)-2-hydroxy-propylsulfamoyl]-4- methyl-thiazol-2-yl}-acetamide
	F
	O.e.O H
	H A H A
	4-Chloro-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamina) 2 h
1291	20112y tallitilo) -2-nydroxy-propyll-
1731	benzenesulfonamide

	O <sub>CO</sub> O H
	CI S H H OH
	3-Chloro-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-
1292	benzenesulfonamide
	S O H OH OH
1293	N-[1-(3,5-Difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propyl]-2-trifluoromethyl-benzenesulfonamide
	F
	F F
	H H A H
	6-Chloro-pyridine-3-sulfonic acid [1-(3,5-
	difluoro-benzyl)-2-hydroxy-3-(3-methoxy-
1294	benzylamino)-propyl]-amide
	F
	P P
	O S O H
	H H A H
	Pyridine-3-sulfonic acid [1-(3,5-difluoro-
	benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-
1295	propyl]-amide
	Ţ
	O <sub>S,2</sub> O H
	O S S O O OH "
	N-[1-(3,5-Difluoro-benzyl)-2-hydroxy-3-(3-
	methoxy-benzylamino)-propyl]-2-methanesulfonyl-
1296	benzenesulfonamide

	FC1/US02/300/2
1297	3,5-Dichloro-N-[1-(3,5-difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propyl]-benzenesulfonamide
	O S O H OH OH
1298	1,2-Dimethyl-1H-imidazole-4-sulfonic acid [1-(3,5-difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propyl]-amide
1299	N-[1-(3,5-Difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propyl]-3,4-dimethoxy-
1299	FF O S N H F
1300	2-(2,2,2-Trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonic acid [1-(3,5-difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propyl]-amide
	S N H OH N O
1301	c' 5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonic acid [1-(3,5-difluoro-benzyl)-2-hydroxy-3-(3- methoxy-benzylamino)-propyl]-amide

	O, O H F
	AH OH H C
	Ö
	3-{4-[1-(3,5-Difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propylsulfamoyl]-phenyl}-
1302	propionic acid methyl ester
	CI SH H OH H
	3-Chloro-N-[1-(3,5-difluoro-benzyl)-2-hydroxy-3-
1303	(3-methoxy-benzylamino)-propyl]- benzenesulfonamide
	F.
	N O S O H H OH
	3-Cyano-N-[1-(3,5-difluoro-benzyl)-2-hydroxy-3-
1304	(3-methoxy-benzylamino)-propyl]- benzenesulfonamide
	Ţ
	O. O. H
	Н н А Н
	Butane-1-sulfonic acid [1-(3,5-difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propyl]-
1305	amide
	\ \ \ \
	NH OH H
	F A
	\$5.0 \$\frac{1}{2}
	N-{1-(3,5-Difluoro-benzyl)-2-hydroxy-3-[(1-
1306	methanesulfonyl-piperidin-4-ylmethyl)-amino]- propyl}-5-methyl-N',N'-dipropyl-isophthalamide
	E511 2 Weetly 14 '14 Gibrobat-Isobucitatsmide

	T C 17 0502/300 / 2
1307	N-[3-Benzenesulfonylamino-1-(3,5-difluoro-benzyl)-2-hydroxy-propyl]-5-methyl-N',N'-dipropyl-isophthalamide
	F-W
1308	N-[1-(3,5-Difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzoylamino)-propyl]-5-methyl-N',N'-dipropyl-isophthalamide
	N N N N N N N N N N N N N N N N N N N
1309	4-(3,5-Difluoro-phenyl)-3-(2,5-dimethyl-4-nitro- 2H-pyrazol-3-ylamino)-1-(3-methoxy-benzylamino)- butan-2-ol
	NH <sub>2</sub> NH <sub>2</sub> NH H OH H
1310	3-(2-Amino-7H-purin-6-ylamino)-4-(3,5-difluoro-phenyl)-1-(3-methoxy-benzylamino)-butan-2-ol
	CI N H OH H
1311	3-(4-Chloro-pyrimidin-2-ylamino)-4-(3,5-difluoro-phenyl)-1-(3-methoxy-benzylamino)-butan-2-ol

1312	3-(2-Amino-6-methyl-pyrimidin-4-ylamino)-4-(3,5-difluoro-phenyl)-1-(3-methoxy-benzylamino)-butan-2-ol
1314	Dutan-2-01
	CI N F F OOH
1313	3-(2-Chloro-6-methyl-pyrimidin-4-ylamino)-4-(3,5-difluoro-phenyl)-1-(3-methoxy-benzylamino)-butan-2-ol
	CI NH2 P O
1314	3-(2-Amino-6-chloro-pyrimidin-4-ylamino)-4-(3,5-difluoro-phenyl)-1-(3-methoxy-benzylamino)-butan-2-ol
	F OH OH
1315	4-(3,5-Difluoro-phenyl)-1-(3-methoxy-benzylamino)-3-(1-phenyl-1H-tetrazol-5-ylamino)-butan-2-ol
	CI N H OH N OH
1316	3-(2-Chloro-7H-purin-6-ylamino)-4-(3,5-difluoro-phenyl)-1-(3-methoxy-benzylamino)-butan-2-ol

1317	4-(3,5-Difluoro-phenyl)-1-(3-methoxy-benzylamino)-3-[9-(tetrahydro-pyran-2-yl)-9H-purin-6-ylamino]-butan-2-ol
	3-[1-(3,5-Difluoro-benzyl)-2-hydroxy-3-(3,
1318	methoxy-benzylamino)-propylamino]-pyrazine-2-carbonitrile
	4-(3,5-Difluoro-phenyl)-3-(4,6-dimethoxy-
1319	[1,3,5]triazin-2-ylamino)-1-(3-methoxy-benzylamino)-butan-2-ol
	2-[1-(3,5-Difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propylamino]-
1320	nicotinonitrile
	N N N F N OH H OH
1321	4-(3,5-Difluoro-phenyl)-1-(3-methoxy-benzylamino)-3-(7H-purin-6-ylamino)-butan-2-ol

	S F OH DH
1322	3-(Benzothiazol-2-ylamino)-4-(3,5-difluoro- phenyl)-1-(3-methoxy-benzylamino)-butan-2-ol
	F OH DO
1323	4-(3,5-Difluoro-phenyl)-1-(3-methoxy-benzylamino)-3-(2-phenyl-quinolin-4-ylamino)-butan-2-ol
	N N N N N N N N N N N N N N N N N N N
1324	6-[1-(3,5-Difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propylamino]-nicotinonitrile
	F N N N N N N N N N N N
1325	2-[1-(3,5-Difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propylamino]-nicotinic acid ethyl ester
	N N N O N O N O N O N O N O N O N O N O
1326	4-(3,5-Difluoro-phenyl)-1-(3-methoxy- benzylamino)-3-(3-methyl-5-nitro-3H-imidazol-4-

	ylamino)-butan-2-ol
	N N N N N N N N N N N N N N N N N N N
1327	3-(Benzooxazol-2-ylamino)-4-(3,5-difluoro- phenyl)-1-(3-methoxy-benzylamino)-butan-2-ol
	P OH H
1328	4-(3,5-Difluoro-phenyl)-1-(3-methoxy-benzylamino)-3-(quinolin-4-ylamino)-butan-2-ol
	F OH H
1329	4-(3,5-Difluoro-phenyl)-3-(5-ethyl-pyrimidin-2-ylamino)-1-(3-methoxy-benzylamino)-butan-2-ol
	F N N OH N O
1330	4-(3,5-Difluoro-phenyl)-1-(3-methoxy-benzylamino)-3-(4-trifluoromethyl-pyrimidin-2-ylamino)-butan-2-ol
	CI PHOH H
1331	3-(6-Chloro-2-methylsulfanyl-5-phenyl-pyrimidin- 4-ylamino)-4-(3,5-difluoro-phenyl)-1-(3-methoxy- benzylamino)-butan-2-ol

	N CI F ON
1332	3-(3-Chloro-quinoxalin-2-ylamino)-4-(3,5-difluoro-phenyl)-1-(3-methoxy-benzylamino)-butan-2-ol
	F NO OH
1333	4-(3,5-Difluoro-phenyl)-1-(3-methoxy-benzylamino)-3-(8-trifluoromethyl-quinolin-4-ylamino)-butan-2-ol
	CI H N OH
1334	3-(6-Chloro-2,5-diphenyl-pyrimidin-4-ylamino)-4-(3,5-difluoro-phenyl)-1-(3-methoxy-benzylamino)-butan-2-ol
	L CI OH OH
1335	3-(3-Chloro-pyrazin-2-ylamino)-4-(3,5-difluoro-phenyl)-1-(3-methoxy-benzylamino)-butan-2-ol
	4-(3,5-Difluoro-phenyl)-1-(3-methoxy-
1336	benzylamino)-3-(5-trifluoromethyl-pyridin-2-ylamino)-butan-2-ol

	F OH H
1337	4-(3,5-Difluoro-phenyl)-1-(3-methoxy-benzylamino)-3-(quinolin-2-ylamino)-butan-2-ol
	CI N N N OH N O
1338	3-(6-Chloro-pyrazin-2-ylamino)-4-(3,5-difluoro-phenyl)-1-(3-methoxy-benzylamino)-butan-2-ol
	O NO OH H
1339	4-(3,5-Difluoro-phenyl)-1-(3-methoxy-benzylamino)-3-(3-nitro-pyridin-2-ylamino)-butan-2-ol
	F F O O O O O O O O O O O O O O O O O O
1340	4-(3,5-Difluoro-phenyl)-1-(3-methoxy-benzylamino)-3-(pyrimidin-2-ylamino)-butan-2-ol
	P P P P P P P P P P P P P P P P P P P
1341	4-(3,5-Difluoro-phenyl)-1-(3-methoxy-benzylamino)-3-(2-phenyl-quinazolin-4-ylamino)-butan-2-ol

	3-(4,6-Diamino-[1,3,5]triazin-2-ylamino)-4-(3,5-
1342	difluoro-phenyl)-1-(3-methoxy-benzylamino)- butan-2-ol
	F-C
1343	N-{1-(3,5-Difluoro-benzyl)-2-hydroxy-3-[3-(3-hydroxymethyl-piperidine-1-carbonyl)-phenylamino]-propyl}-5-methyl-N',N'-dipropylisophthalamide
	F—————————————————————————————————————
1344	N-[3-(3-Cyclohexyl-1-phenyl-propylamino)-1-(3,5-difluoro-benzyl)-2-hydroxy-propyl]-5-methyl-N',N'-dipropyl-isophthalamide
	2-Methanegul fonylamine everel a A serbandian in
1345	2-Methanesulfonylamino-oxazole-4-carboxylic acid {1-benzyl-3-[N-ethyl-N'-(3-ethyl-benzoyl)-hydrazino]-2-hydroxy-propyl}-amide

	0 H HN O O O O O O O O O O O O O O O O O
1346	2-Methanesulfonylamino-oxazole-4-carboxylic acid {1-benzyl-3-[N-ethyl-N'-(4-methyl-pentanoyl)-hydrazino]-2-hydroxy-propyl}-amide
	OH HN OH HN O
1347	2-Methanesulfonylamino-oxazole-4-carboxylic acid [3-(N'-acetyl-N-ethyl-hydrazino)-1-benzyl-2-hydroxy-propyl]-amide
	2-Methanesulfonylamino-oxazole-4-carboxylic acid
1348	[3-(N'-benzoyl-N-ethyl-hydrazino)-1-benzyl-2-hydroxy-propyl]-amide
	O=S-N OH HN OH HN
1349	2-Methanesulfonylamino-thiazole-4-carboxylic acid {1-benzyl-3-[N-ethyl-N'-(3-ethyl-benzoyl)-hydrazino]-2-hydroxy-propyl}-amide

	<u> </u>
	2-Methanesulfonylamino-thiazole-4-carboxylic acid [3-(N'-acetyl-N-ethyl-hydrazino)-1-benzyl-
1350	2-hydroxy-propyl]-amide
	SN OH HN O
1351	N-{1-Benzyl-3-[N-ethyl-N'-(3-ethyl-benzoyl)-hydrazino]-2-hydroxy-propyl}-2-[4-(2-oxo-pyrrolidin-1-yl)-phenyl]-acetamide
	OH HN O
1352	N-{1-Benzyl-3-[N-ethyl-N'-(4-methyl-pentanoyl)-hydrazino]-2-hydroxy-propyl}-2-[4-(2-oxo-pyrrolidin-1-yl)-phenyl]-acetamide
	H OH HN O
1353	N-[3-(N'-Acetyl-N-ethyl-hydrazino)-1-benzyl-2- hydroxy-propyl]-2-[4-(2-oxo-pyrrolidin-1-yl)- phenyl]-acetamide

	N OH HN O
1354	N-[3-(N'-Benzoyl-N-ethyl-hydrazino)-1-benzyl-2-hydroxy-propyl]-2-[4-(2-oxo-pyrrolidin-1-yl)-phenyl]-acetamide
	HO OH HN O
	ő
1355	N-{1-Benzyl-3-[N-ethyl-N'-(3-ethyl-benzoyl)- hydrazino]-2-hydroxy-propyl}-3-hydroxy-4- (pyrrolidine-1-carbonyl)-benzamide
	HO OH HIN O
1356	N-{1-Benzyl-3-[N-ethyl-N'-(4-methyl-pentanoyl)- hydrazino]-2-hydroxy-propyl}-3-hydroxy-4- (pyrrolidine-1-carbonyl)-benzamide
	HO N OH HN O
1341	N-[3-(N'-Acetyl-N-ethyl-hydrazino)-1-benzyl-2-hydroxy-propyl]-3-hydroxy-4-(pyrrolidine-1-carbonyl)-benzamide

	N <sub>P</sub> H
	OH O F
	<u> </u>
1342	5-Acetylamino-N-[1-(3,5-difluoro-benzyl)-3-(3- ethyl-benzylamino)-2-hydroxy-propyl]-2-hydroxy- benzamide
	S OH H
	F
1343	2-(2,5-Dimethyl-pyrrol-1-yl)-thiophene-3- carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3- ethyl-benzylamino)-2-hydroxy-propyl]-amide
	HŅ✓
	HO HO
	HN
	N-S F
1344	4-Phenyl-[1,2,3]thiadiazole-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide
	F N OH
1345	

	N_[1_/2 F D; 61 1 7
	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-
	benzylamino) -2-hydroxy-propyl]-2-(2,6-dimethyl-
	phenoxy)-propionamide
	Y
	HN
	HO. J
ĺ	Y
	HN
	н , "", ]
	\ \ F \ \ F
ļ	4-Acetylamino-1-methyl-1H-pyrrole-2-carboxylic
	acid [1-/3 5-difluers har-will 2 /2 with
1346	acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-
1310	benzylamino)-2-hydroxy-propyl]-amide
	\
	N-N OH
	F A
	Ţ
	2-Ethyl-5-thiophen-2-yl-2H-pyrazole-3-carboxylic
1347	acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-
1347	benzylamino)-2-hydroxy-propyl]-amide
	VVO OH ✓
	0 \rightarrow_F
	Ĭ
	6 Mohbail A
	6-Methyl-4-oxo-1-phenyl-1,4-dihydro-pyridazine-
1348	3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-
1348	ethyl-benzylamino)-2-hydroxy-propyl]-amide
	(_)
	Jro I on I
	∪
	Ť l
	F
	A 19 1
	4-Methyl-2-phenyl-oxazole-5-carboxylic acid [1-
4.0.0	4-Methyl-2-phenyl-oxazole-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-
1349	4-Methyl-2-phenyl-oxazole-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide

	H H H F F N S 1 N 2 (2 A N A N A N A N A N A N A N A N A N A
	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl- benzylamino)-2-hydroxy-propyl]-2-pyridin-3-yl-
1350	benzamide
	S OH N OH
	2-p-Tolyl-thiazole-4-carboxylic acid [1-(3,5-
1351	difluoro-benzyl)-3-(3-ethyl-benzylamino)-2- hydroxy-propyl]-amide
1331	inydroxy-propyr)-amrde
	2 The second this sole A sechemble sold [1]
	2-Phenoxymethyl-thiazole-4-carboxylic acid [1- (3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-
1352	hydroxy-propyl]-amide
	HO
	S-N OF
	[1,2,5]Thiadiazole-3-carboxylic acid [1-(3,5-
1353	difluoro-benzyl)-3-(3-ethyl-benzylamino)-2- hydroxy-propyl]-amide
	1 7 Broble 1

1354	2-m-Tolyl-thiazole-4-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide
	CI -
	s-J
	₩ N
	F
	OH OH
	E AUL
	F NH
	2-(2-Chloro-phenyl)-thiazole-4-carboxylic acid
10	[1-(3,5-difluoro-benzyl)-3-(3-ethyl-
1355	benzylamino)-2-hydroxy-propyl]-amide
	, oн ,
	N O F
	Ý
	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-
	benzylamino)-2-hydroxy-propyl]-3-phenyl-2-
1356	tetrazol-1-yl-propionamide

1357	4-Chloro-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridine-2-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide
	1
1358	HN HO HN
	5-p-Toly1-3,4-dihydro-2H-pyrazole-3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-
1359	benzylamino) -2-hydroxy-propyl]-amide

	CI S NH OH
1360	2-Acetylamino-5-chloro-thiophene-3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide
	NH OH NH
1361	4-(4-Methoxy-phenyl)-thiophene-2-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide
1362	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-N'-(2-fluoro-5-methanesulfonyl-phenyl)-succinamide
	F-O-NN DH
1363	1-(4-Fluoro-phenyl)-5-methyl-1H-[1,2,4]triazole-3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-

	ethyl-benzylamino)-2-hydroxy-propyl]-amide
	HŅ HŅ
	HO.
	HN
	0 0 0
	F F
	s NH
	N-(2-Acetyl-thiophen-3-yl)-N'-[1-(3,5-difluoro-
	benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-
1364	propyl]-succinamide
	F CI
	F
	F ✓N
	f
	№ " ,он
	I H
	F N
	6-Chloro-4-trifluoromethyl-pyridine-2-carboxylic
	acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-
1365	benzylamino)-2-hydroxy-propyl]-amide
	H OH H
	$N \longrightarrow N \longrightarrow N \longrightarrow N$
	F
	, Y
	F
	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-
1266	benzylamino) -2-hydroxy-propyl] -2-(5,7-dimethyl-
1366	[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-acetamide

·	HO HN F
1367	N-(1-Cyclopropyl-ethyl)-N'-[1-(3,5-difluoro- benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy- propyl]-N-phenyl-succinamide
	F OH OH
1368	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl- benzylamino)-2-hydroxy-propyl]-2-(3,4-dimethoxy- phenylsulfanyl)-acetamide
	OH H
1369	1-Methyl-5-oxo-2-pyridin-3-yl-pyrrolidine-3- carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3- ethyl-benzylamino)-2-hydroxy-propyl]-amide

	HO HN S F
1370	4-Methoxy-thiophene-3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide
	OH H
1371	2,5-Dimethyl-1-pyridin-4-ylmethyl-1H-pyrrole-3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide
	S F OH II
1372	2-Methyl-5-thiophen-2-yl-furan-3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide
	N OH H
1373	4-(4-Benzyl-[1,4]diazepan-1-yl)-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-4-oxo-butyramide

	T
	HO HO F
1374	2-(Benzo[1,2,5]thiadiazol-4-yloxy)-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-acetamide
	S OH H
1375	3-Chloro-5-phenyl-isothiazole-4-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide
1376	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-5-phenylethynyl-nicotinamide
	OH H
1377	4,7-Dimethoxy-benzofuran-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide

	OH III
	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-3-morpholin-4-
1378	ylmethyl-benzamide
	TO THE STATE OF TH
1379	2,2-Dimethyl-4-oxo-chroman-6-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide
	NOH H
1380	[1,6]Naphthyridine-2-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide
	P OH O OH F
1381	8-Cyano-4-hydroxy-quinoline-3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-

	benzylamino)-2-hydroxy-propyl]-amide
	S OH H
1382	2-Pyridin-3-yl-thiazole-4-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide
	NH OH NH
1383	5-Chloro-benzofuran-2-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide
	H QH H
1384	4-Dibenzofuran-2-yl-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-4-oxo-butyramide

	HN HO.
	HN
	NH <sub>E</sub>
	, i
1385	N-{[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propylcarbamoyl]-methyl}-nicotinamide
	NH F
1386	4-tert-Butyl-N-{[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propylcarbamoyl]-methyl}-benzamide
1300	CI P OH DONAL OH DONA
1387	4-Chloro-N-{[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propylcarbamoyl]-methyl}-benzamide
	CI
	N OH OH
	NH F
1388	

4-Chloro-6-methyl-quinoline-2-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide  N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-(2,4-dihydroxy-thiazol-5-yl)-acetamide  2-Methyl-pyrimidine-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide	Γ	
benzylamino)-2-hydroxy-propyl]-amide    N-{1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl}-2-(2,4-dihydroxy-thiazol-5-yl)-acetamide    2-Methyl-pyrimidine-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide    N-{1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide		4-Chloro-6-methyl-quinoline-2-carboxylic acid
N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-(2,4-dihydroxy-thiazol-5-yl)-acetamide  2-Methyl-pyrimidine-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide		[1-(3,5-difluoro-benzyl)-3-(3-ethyl-
N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-(2,4-dihydroxy-thiazol-5-yl)-acetamide  2-Methyl-pyrimidine-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide		benzylamino)-2-hydroxy-propyl]-amide
N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-(2,4-dihydroxy-thiazol-5-yl)-acetamide  2-Methyl-pyrimidine-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide		
N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-(2,4-dihydroxy-thiazol-5-yl)-acetamide  2-Methyl-pyrimidine-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide		
N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-(2,4-dihydroxy-thiazol-5-yl)-acetamide  2-Methyl-pyrimidine-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide  N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide	İ	но он
N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-(2,4-dihydroxy-thiazol-5-yl)-acetamide  2-Methyl-pyrimidine-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide  N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide		
N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-(2,4-dihydroxy-thiazol-5-yl)-acetamide  2-Methyl-pyrimidine-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide  N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide		$N \rightarrow V \rightarrow V \rightarrow V \rightarrow V \rightarrow V \rightarrow V \rightarrow V \rightarrow V \rightarrow V \rightarrow $
N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-(2,4-dihydroxy-thiazol-5-yl)-acetamide  2-Methyl-pyrimidine-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide		S Ö F
benzylamino) -2-hydroxy-propyl] -2-(2,4-dihydroxy-thiazol-5-yl) -acetamide  2-Methyl-pyrimidine-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl] -amide		но
benzylamino) -2-hydroxy-propyl] -2-(2,4-dihydroxy-thiazol-5-yl) -acetamide  2-Methyl-pyrimidine-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl] -amide		
benzylamino) -2-hydroxy-propyl] -2-(2,4-dihydroxy-thiazol-5-yl) -acetamide  2-Methyl-pyrimidine-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl] -amide		ļ į
benzylamino) -2-hydroxy-propyl] -2-(2,4-dihydroxy-thiazol-5-yl) -acetamide  2-Methyl-pyrimidine-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl] -amide		N = [1 - (3.5 - Difluoro - benzy]) - 3 - (3 - o + by)
2-Methyl-pyrimidine-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide  N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-		benzylamino) = 2 - hydroxy - propyl 1 - 2 - 12 / 4 dipoderane
2-Methyl-pyrimidine-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide  N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-	1389	thiazol-5-vl)-acetamide
2-Methyl-pyrimidine-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide  N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-		N N
2-Methyl-pyrimidine-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide  N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-		
2-Methyl-pyrimidine-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide  N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-		N F
2-Methyl-pyrimidine-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide  N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-	1	
2-Methyl-pyrimidine-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide  N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-		1
difluoro-benzyl)-3-(3-ethyl-benzylamino)-2- hydroxy-propyl]-amide  N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-		NH F
difluoro-benzyl)-3-(3-ethyl-benzylamino)-2- hydroxy-propyl]-amide  N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-		
N-[1-(3,5-Difluoro-benzyl)-3-(3-ethy]-		2-Methyl-pyrimidine-5-carboxylic acid [1-(3,5-
N-[1-(3,5-Difluoro-benzyl)-3-(3-ethy)-	1200	difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-
N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-	1390	hydroxy-propyl]-amide
N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-		
N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-		
N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-		
N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-		N F
N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-		
N-[1-(3,5-Difluoro-benzyl)-3-(3-ethy]-		OH
N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-bydroxy-propyll A pincylal 1 1		, NH F
N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-bydroxy-propyll A pincylal 1		
N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-bydroxy-propyll A pincyldia 1		
N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-bydroxy-propyll 4 pincyldia 1	i	
N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-bydrovy-propyll 4 pincyldia 1		( ~
N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-bydroxy-propyll 4 pincyldia 1	[	
benzylamino) = 2 = hydroyy = propyll 4 = i = -1 1 1		N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-
1301 Sent James 2 Nydroxy-propyrj-4-piperidin-1-yi-	1201	benzylamino)-2-hydroxy-propyl]-4-piperidin-1-vl-
1391   benzamide	1391	benzamide
1391 benzamide	1391	benzylamino)-2-hydroxy-propyl]-4-piperidin-1-vl-

	O H OH F
1392	4-Acetylamino-N-[1-(3,5-difluoro-benzyl)-3-(3- ethyl-benzylamino)-2-hydroxy-propyl]-benzamide
	O H F
1393	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl- benzylamino)-2-hydroxy-propyl]-4-methoxy- benzamide
	N OH H
1394	4-Methyl-oxazole-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide
1395	1H-Indole-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide

	HN OH OH
1396	6-Chloro-1H-indole-2-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide
	2-(4-Chloro-2-oxo-benzothiazol-3-yl)-N-[1-(3,5-
1397	difluoro-benzyl)-3-(3-ethyl-benzylamino)-2- hydroxy-propyl]-acetamide
	HO
	F F
	Thiophene-3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide

	HO HN F
1399	2-Methyl-oxazole-4-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide
1400	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-(1-oxy-pyridin-3-yl)-acetamide
	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-
1401	benzylamino)-2-hydroxy-propyl]-2-hydroxy-2- phenyl-2-thiophen-2-yl-acetamide

	HO HO HO HO HO HO HO HO HO HO HO HO HO H
	NH F
1402	6-Hydroxy-2-methylsulfanyl-pyrimidine-4- carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide
	OH II
1403	2,5-Dimethyl-furan-3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide
	HN
	HO HO F
1404	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-nicotinamide
	OH F
1405	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-

	hongral amino) 2 hadrons manual 1 4 /2 mathors
	benzylamino)-2-hydroxy-propyl]-4-(3-methoxy-phenyl)-4-oxo-butyramide
	prenyly 4 one butylande
	O H F F
1406	4-Acetyl-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-benzamide
	HO HO HO HO HO HO HO HO HO HO HO HO HO H
	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-4-hydroxy-3,5-
1407	dimethoxy-benzamide
	но
	F F
1408	Furan-2-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide

1409	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-purin-7-yl)-acetamide
	O H OH F
1410	4-Acetylamino-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2,6-dimethyl-benzamide
	OH H
1411	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-thiophen-2-yl-acetamide
	OH F
1412	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-4-oxo-4-phenyl-butyramide

	1H-Indole-3-carboxylic acid [1-(3,5-difluoro-
1413	benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy- propyl]-amide
	OH BODY
1414	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propionamide
	HN HN F
1415	3-Benzo[1,3]dioxol-5-yl-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-propionamide
	N 11 (2 F D 5)
1416	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-4-morpholin-4-yl-

	PC 1/USU2/360/2
	4-oxo-butyramide
	5
	NH OH
	FNH
1417	[2,3']Bithiophenyl-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide
	F, S
	NH OH
	F NH
	5-Methoxy-thiophene-2-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-
1418	hydroxy-propyl]-amide
٠	
	STATE
	F
	F
	4-Phenyl-thiophene-2-carboxylic acid [1-(3,5-
L <b>41</b> 9	difluoro-benzyl)-3-(3-ethyl-benzylamino)-2- hydroxy-propyl]-amide

	N-N-H-H-H-F
1420	2-(5-Benzo[1,3]dioxol-5-yl-tetrazol-2-yl)-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-acetamide
	ON S F H H D
1421	2-(Benzothiazol-2-ylmethoxy)-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-acetamide
1422	Pyrrolidine-1,2-dicarboxylic acid 1-{[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide} 2-phenylamide
	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-
1423	benzylamino)-2-hydroxy-propyl]-3-(6-ethoxy-1H-benzoimidazol-2-yl)-propionamide

·	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-
1424	benzylamino) -2-hydroxy-propyl] -2-(3-methyl-2-oxo-2,3-dihydro-benzoimidazol-1-yl)-acetamide
	OH H
1425	2-Oxo-2,3-dihydro-benzooxazole-6-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide
	Thieno[3,2-c]pyridine-2-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-
1426	hydroxy-propyl]-amide
	HO
	HN
į.	1-Methyl-1H-indole-3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide

	Benzo[b]thiophene-3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-
1428	hydroxy-propyl]-amide
	ON HOH F
1429	4-Oxy-3-propyl-pyrazine-2-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide
	HO
	1,1,3-Trioxo-2,3-dihydro-1H-116-
	benzo[d]isothiazole-6-carboxylic acid [1-(3,5-
	difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-
1430	hydroxy-propyl]-amide
	HO N S T H
1431	<u> </u>

	N [1 /2 F p/c]
	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamina) 2 hydronylamina)
	benzylamino) -2-hydroxy-propyl] -2-(7-hydroxy-5-
	methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylsulfanyl)-acetamide
	115011011 acecanide
	Ĭ
	N OH
,	
	\ \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
]	F
	2-Hydroxy-6-methyl-quinoline-4-carboxylic acid
	[1-(3,5-difluoro-benzyl)-3-(3-ethyl-
1432	benzylamino)-2-hydroxy-propyl]-amide
ļ	
	F
	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzyl)]
1433	benzylamino) -2-hydroxy-propyl] -2-(2-methyl-2,3-
1433	dihydro-benzofuran-5-yl)-propionamide
	Ĭ,
	3-(Benzooxazol-2-ylsulfanyl)-N-[1-(3,5-difluoro-
	benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-
1434	propyl]-propionamide
	ОН
	N O YF
	Ţ
	N-[1-/3 5-Difluoro bongul) 2 /2 /2
	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-(5-o-tolyl-
1435	tetrazol-2-yl)-acetamide
	2 Jan accountage

	HO HO N N N N N N N N N N N N N N N N N
1436	2-Chloro-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-4-tetrazol-1-yl-benzamide
	HN OH OH
1437	N-(4-tert-Butyl-thiazol-2-yl)-N'-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-succinamide
	HO HO F
1438	N-(5-Cyclopropyl-[1,3,4]thiadiazol-2-yl)-N'-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-

	hydroxy-propyl]-succinamide
	CI OH F
1439	2-(3-Chloro-phenoxy)-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-propionamide
	N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-3-(pyridin-4-
1440	ylmethylsulfanyl)-benzamide

The compounds in the table immediately below were prepared essentially using the methods described above and illustrated below in the schemes.

The following compounds were named using the Advanced

5 Chemistry Development Inc. (ACD) nomenclature program, IUPAC

Name Batch Version 4.5. The website for ACD is

www.acdlabs.com.

	Compound Name (IUPAC Name)
	$N^{1}$ -{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(2-
	hydroxyethyl)amino]sulfonyl}-N3,N3-
1441	dipropylisophthalamide
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[(2-isobuty1-1,3-thiazo1-5-
	y1)methyl]amino}propyl)-5-ethynyl-N <sup>3</sup> ,N <sup>3</sup> -
1442	dipropylisophthalamide
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-[(3-isopropylbenzyl)amino]propyl}-5-
1443	ethynyl-N3,N3-dipropylisophthalamide
	$N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-$
	3-[(3-isopropylbenzyl)amino]propyl}-5-(1,3-
1444	oxazol-2-yl)-N3,N3-dipropylisophthalamide
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(2-
	hydroxy-1,1-dimethylethyl)amino]sulfonyl}-
1445	$N^3$ , $N^3$ -dipropylisophthalamide
	$N^{1}$ -{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-5-(4-
	$methyl-1,3-oxazol-2-yl)-N^3,N^3-$
1446	dipropylisophthalamide
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[(2-isobuty1-1,3-thiazo1-5-
	yl)methyl]amino)propyl)-5-(1,3-oxazo1-2-yl)-
1447	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^{1}$ -{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(3-
	hydroxypropyl)amino]sulfonyl}-N <sup>3</sup> ,N <sup>3</sup> -
1448	dipropylisophthalamide
	$N^1$ -{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-[(3-propylbenzyl)amino]propyl}-5-methyl-
1449	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-$
	ethynylbenzyl)amino]-2-hydroxypropyl}-5-
1451	ethynyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^1$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
1452	3-{[(3-isobutylisoxazol-5-

	PC1/US02/300
	y1)methy1]amino}propy1)-5-ethyny1-N <sup>3</sup> ,N <sup>3</sup> -
	dipropylisophthalamide
	$N^{1}$ -{ (1s, 2r) -1-(3,5-difluorobenzy1) -3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-5-
	[(dimethylamino)sulfonyl]-N <sup>3</sup> ,N <sup>3</sup> -
1453	dipropylisophthalamide
	N <sup>1</sup> -{(15,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-
	oxazol-2-yl)-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide
1454	hydrochloride hydrochloride
	$N^{1}$ -((1S, 2R)-1-(3, 5-difluorobenzyl)-3-{[3-(5-
	formylthien-2-yl)benzyl]amino}-2-
	hydroxypropy1)-5-methyl-N <sup>3</sup> , N <sup>3</sup> -
1455	dipropylicenth-latin
	dipropylisophthalamide
1	5-bromo-N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-2-
1456	hydroxy-3-[(3-iodobenzyl)amino]propyl}-N <sup>3</sup> ,N <sup>3</sup> -
	dipropylisophthalamide
	$N^{1} - \{(1s, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [(3 - chyllograph)]$
	ethylbenzyl)amino -2-hydroxypropyl}-5
	((1K)-2-nydroxy-1-
1457	methylethyl]amino}sulfonyl)-N <sup>3</sup> ,N <sup>3</sup> -
1437	dipropylisophthalamide
	$N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3,3]]$
1450	
1458	IN IN -CIPIODVIISODNINA Lamide
	$N^{-}((1S, 2R) - 1 - (3.5 - difluorobengy))$
1450	[J-1[J-(LIIILUOYOMethy])benzyllaminolphones
1459	Judinynyi-No, No-dipropylisophthalamide
	$N-\{(15, 2K)-1-(3, 5-difluorobenzy1)-3, [/2]$
	ecliyidenzyi)amino -2-hydroxymronyil 2 (((2n)
	2   (methoxymethy1)pvrrolidin-1-villcarbonvill [
1460	I meetry inerradicte nvdroch for ide
	$N^{2} = \{(1S, 2R) - 1 - (3.5 - diffuorobonyul) \}$
	ethylbenzyl)amino]-2-hydroxypropyl}-5-
	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
	methylethyl]amino}sulfonyl)-N <sup>3</sup> ,N <sup>3</sup> -
1461	Qlpropylisophthalamido
	$N^1$ -butyl- $N^3$ -{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-
	[[\J=e\llv1Denzv]]amino]=2=hydxoxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
1462	methyl-N <sup>1</sup> -propylisophthalamide
	$N^1$ , $N^1$ -dibuty1- $N^3$ -{(1S, 2R)-1-(3, 5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
1463	hydroxypropyl}-5-methylisophthalamide
	$N^{1}$ -(/1S 2R)-1-/2 E diff
	N <sup>1</sup> -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy- 3-{[3-(3-hydroxyprop-1-
	Vnvl) benzullamino
1464	ynyl)benzyl]amino}propyl)-5-methyl-N³,N³-dipropylisophthalamide
	$N^{1}$ - $I$
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
1465	ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(2S)-
	2-(hydroxymethyl)pyrrolidin-1-yl]sulfonyl}-

N <sup>3</sup> N <sup>3</sup> -dipr	opylisophthalamide
	3)-1-(3,5-difluorobenzyl)-3-[(3-
1	nzyl)amino]-2-hydroxypropyl}-5-(1,3-
	$(1.5)^{-1.5}$ $(1.5)^{-1.5}$ $(1.5)^{-1.5}$ $(1.5)^{-1.5}$ $(1.5)^{-1.5}$ $(1.5)^{-1.5}$ $(1.5)^{-1.5}$
1467 $0xazol-2-y$ $N^{1}-[(1S, 2F)]$	
	pylamino)benzyl]amino}-1-(3,5-
	enzyl)-2-hydroxypropyl]-5-ethynyl- opylisophthalamide
	opylisophthalamide 3)-1-(3,5-difluorobenzyl)-2-hydroxy-
<b>■</b> • • • • • • • • • • • • • • • • • • •	· · · · · · · · · · · · · · · · · · ·
	en-3-ylbenzyl)amino]propyl}-5- N³-dipropylisophthalamide
1	R) -1-(3,5-difluorobenzyl)-2-hydroxy-
	ifluoromethyl)benzyl]amino}propyl)-
	$azo1-2-y1)-N^3,N^3-$
	sophthalamide
	R)-1-(3,5-difluorobenzyl)-3-[(3-
, , –	y1)amino]-2-hydroxypropy1}-5-
	n-1-ylsulfonyl)-N³,N³-
	sophthalamide R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	()-1-(3,5-diffuorobenzyi)-z-nydroxy-
3-{[1-(3-	l)cyclopropyl]amino}propyl)-5-
	N <sup>3</sup> -dipropylisophthalamide
	R)-3-[(3-sec-butylbenzyl)amino]-1-
	uorobenzyl)-2-hydroxypropyl]-5-
	N <sup>3</sup> -dipropylisophthalamide
	R)-1-(3,5-difluorobenzyl)-3-[(3-
1 ' ' '	yl)amino]-2-hydroxypropyl}-5-(3-
	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
ı	sophthalamide hydrochloride
	R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	isobutylisoxazol-5-
l	ropyl]amino}propyl)-5-(1,3-oxazol-2-
1 1 - 1 - 1	dipropylisophthalamide
	R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
	yl)cyclopropyl]amino}-2-
	opy1) $-5 - (1, 3 - oxazol - 2 - y1) - N^3, N^3 -$
l –	sophthalamide
	R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenz	yl)amino]-2-hydroxypropyl}-6-methyl-
$1478$ $N^2$ , $N^2$ -dipr	opylpyridine-2,4-dicarboxamide
N <sup>1</sup> -{(1S, 2)	R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	hoxybenzyl)amino]propyl}-5-(1,3-
	yl)-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide
, , ,	R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
	enyl)cyclopropyl]amino}-2-
hydroxypr	opy1)-5-(1,3-oxazo1-2-y1)- $N^3,N^3$ -
	sophthalamide
5-(aminos	ulfonyl)- $N^1$ -{(1S,2R)-1-(3,5-
	enzyl)-3-[(3-ethylbenzyl)amino]-2-

	hydroxypropyl}-N³,N³-dipropylisophthalamide
	$N^{1}$ -[(1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-({3-[(1Z)-prop-1-enyl]benzyl}amino)propyl]-
1483	5-methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> ,N <sup>3</sup> -
1484	dipropyl-5-(1H-pyrazol-4-yl)isophthalamide
	$N^{1}$ -((1s,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
	ethylphenyl)-1-methylethyl]amino}-2-
	hydroxypropyl)-5-ethynyl-N <sup>3</sup> , N <sup>3</sup> -
1485	dipropylisophthalamide
	$N^{1}$ -[(1S,2R)-3-[(3-allylbenzyl)amino]-1-(3,5-
	difluorobenzyl)-2-hydroxypropyl]-5-methyl-
1487	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^{1}$ -((1s,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
	ethylphenyl)cyclopropyl]amino}-2-
	hydroxypropyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
1488	dipropylisophthalamide
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
	ethylphenyl)-1-methylethyl]amino}-2-
	hydroxypropyl) $-5-(1,3-oxazo1-2-y1)-N^3,N^3-$
1489	dipropylisophthalamide
	$N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-N3-ethyl-
1490	5-methyl-N <sup>3</sup> -propylisophthalamide
	N <sup>1</sup> -[(1S,2R)-3-{[3-
	(cyclopropylamino)benzyl]amino}-1-(3,5-
	difluorobenzyl)-2-hydroxypropyl]-5-methyl-
1491	$N^3$ , $N^3$ -dipropylisophthalamide
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
	ethynylphenyl)cyclopropyl]amino}-2-
1400	hydroxypropyl)-5-ethynyl-N <sup>3</sup> ,N <sup>3</sup> -
1492	dipropylisophthalamide
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[1-(3-isobutylisoxazol-5-
1493	yl)cyclopropyl]amino}propyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
1433	dipropylisophthalamide
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[3-(5-formyl-4-methylthien-2-yl)benzyl]amino}-2-
	hydroxypropyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
1494	dipropylisophthalamide
	$N^{1}$ -[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-({3-
	[(methylsulfonyl)amino]benzyl}amino)propyl]-
1496	5-methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^1-\{(1S,2R)-1-(3,5-difluorobenzy1)-2-hydroxy-$
	3-[(3-isopentylbenzyl)amino]propyl}-5-methyl-
1498	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
1500	ethynylphenyl)cyclopropyl]amino}-2-

	11 1 mathe 1 N 3 N 3
	hydroxypropyl)-5-methyl-N <sup>3</sup> , N <sup>3</sup> -
	dipropylisophthalamide
	$N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - [ (3 - 3, 5 - difluorobenzy1) - [ (3 - 3, 5 - difluorobenzy1) - [ (3 - 3, 5 - difluorobenzy1) - [ (3 - 3, 5 - difluor$
	ethylbenzyl)amino]-2-hydroxypropyl}-5-({[2-
	(methylamino)ethyllamino}sulfonyl)-N <sup>3</sup> , N <sup>3</sup> -
1501	dipropylisophthalamide dihydrochloride
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[1-(3-isobutylisoxazol-5-
	yl)cyclopropyl]amino}propyl)-5-ethynyl-N <sup>3</sup> ,N <sup>3</sup> -
1502	dipropylisophthalamide
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[1-(2-isobutyl-1,3-thiazol-5-
,	yl)cyclopropyl]amino}propyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
1504	dipropylisophthalamide
	N <sup>1</sup> -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
	ethylphenyl)-1-methylethyl]amino}-2-
	hydroxypropyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
1505	dipropylisophthalamide
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(2-
	hydroxyethyl)amino]sulfonyl}-N3-
1506	propylisophthalamide
	$N^{1}-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> ,5-
1507	dimethyl-N <sup>3</sup> -propylisophthalamide
	$N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-3)]$
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -
	(phenylsulfonyl)-3-[(1-
1508	propylbutyl)sulfonyl]alaninamide
	$N^{1}-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-3)]$
	ethylbenzyl)amino]-2-hydroxypropyl}-N³,N³-
1509	diethyl-5-(1,3-oxazol-2-yl)isophthalamide
	$N^2 - [(benzylamino) carbonyl] - N^1 - {(1S, 2R) - 1 - (3, 5 - 1)}$
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
	hydroxypropyl}-3-[(1-
1510	propylbutyl)sulfonyl]alaninamide
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-[(3-pyridin-3-ylbenzyl)amino]propyl}-5-
1511	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^3 - \{(1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [(3 - 3, 5 - difluorobenzyl)] - [(3 - 3, 5 - difluorobenzyl)] - 3 - [(3 - 3, 5 - difluorobenzyl)] - [(3 - 3, 5 - difluor$
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>5</sup> ,N <sup>5</sup> -
1512	dipropylpyridine-3,5-dicarboxamide 1-oxide
	$N^{1}$ -((1s, 2R)-1-(3,5-difluorobenzyl)-3-{[3-(3-
	formyl-2-furyl)benzyl]amino}-2-
	hydroxypropyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
1513	dipropylisophthalamide
	$N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzyl)]$
	ethylbenzyl)amino]-2-hydroxypropyl}-5-(1-
	methyl-1H-imidazol-2-yl)-N <sup>3</sup> , N <sup>3</sup> -
1514	dipropylisophthalamide

<u></u>	NT (/10 OR) 1 /0 = 5:55
	$N^{1}$ -{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
1515	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> ,N <sup>3</sup> -
1515	diethyl-5-methylisophthalamide
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[3-
	(ethylsulfinyl)benzyl]amino}-2-
1516	hydroxypropyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
1516	dipropylisophthalamide
	3-{[butyl(ethyl)amino]sulfonyl}-N-{(1S,2R)-1-
	(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
1517	
1317	hydroxypropyl}propanamide
	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]propanamide
1519	hydrochloride
1313	$N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> -
1520	isobutyl-N <sup>3</sup> ,5-dimethylisophthalamide
1320	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-[(3-pyridin-2-ylbenzyl)amino]propyl}-5-
1521	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	N <sup>1</sup> -[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-({3-
	[methyl(methylsulfonyl)amino]benzyl)amino)pro
1523	pyl]-5-methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^{I}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -(3-
	phenylpropanoyl)-3-[(1-
ł	propylbutyl)sulfonyl]alaninamide
1524	trifluoroacetate
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[3-
	(ethylsulfonyl)benzyl]amino}-2-
	hydroxypropyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
1525	dipropylisophthalamide
	$N^2$ -[(5-chlorothien-2-yl)sulfonyl]- $N^1$ -{(1S,2R)-
	1-(3,5-difluorobenzyl)-3-[(3-
4505	ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-
1526	propylbutyl)sulfonyl]alaninamide
	$N^{1}$ -[(1S,2R)-3-{[3-(5-acetylthien-2-
	yl)benzyl]amino}-1-(3,5-difluorobenzyl)-2-
1527	hydroxypropyl]-5-methyl-N <sup>3</sup> , N <sup>3</sup> -
1527	dipropylisophthalamide
,	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
1529	ethylbenzyl)amino]-2-hydroxypropyl}-3-(1,3-
1343	oxazol-2-yl)benzamide hydrochloride
	$N^1$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
1530	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> ,5-
1000	dimethyl-N <sup>3</sup> -(2-phenylethyl)isophthalamide
1531	$N^{1}$ - ((1S, 2R) -1 - (3, 5 - diffluorobenzyl) -3 - {[3 - (3, 5 - dimethylic gyrapa] 4 - d)}
T 7 2 T	dimethylisoxazol-4-yl)benzyl]amino}-2-

	[ 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
	hydroxypropyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
	dipropylisophthalamide
	$N^{1}$ -{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> ,5-
1532	dimethyl-N <sup>3</sup> -prop-2-ynylisophthalamide
	$N^{1}$ -{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> -ethyl-
1533	N <sup>3</sup> ,5-dimethylisophthalamide
	$N^{1}$ -benzyl- $N^{3}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-
	3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-
1535	N <sup>1</sup> ,5-dimethylisophthalamide
	$N^{1}$ -(sec-butyl)- $N^{3}$ -{(1S,2R)-1-(3,5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
	hydroxypropyl}-5-methyl-N <sup>1</sup> -
1536	propylisophthalamide
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[3-(4-methylthien-2-
	yl)benzyl]amino}propyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
1537	dipropylisophthalamide
	methyl 3-({[(2R,3S)-4-(3,5-difluorophenyl)-3-
	({3-[(dipropylamino)carbonyl]-5-
	methylbenzoyl}amino)-2-
	hydroxybutyl]amino}methyl)phenyl(methyl)carba
1538	mate
1330	$N^{1}$ -((1S,2R)-2-hydroxy-1-(2,3,5-
	trifluorobenzyl)-3-{[3-
	(trifluoromethyl)benzyl]amino}propyl)-5-
1539	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
1333	$N^{1} - \{ (1S, 2R) - 1 - (3, 5 - \text{difluorobenzy1}) - 3 - [ (3 - 3) - (3 -$
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> ,N <sup>3</sup> -
1540	disobutyl-5-methylisophthalamide
1340	$N^{1} - \{(1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [(3 - (3 - (3 - (3 - (3 - (3 - (3$
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> ,5-
	dimethyl-N <sup>3</sup> -(2-pyridin-2-
1541	ylethyl)isophthalamide
1741	$N^1$ -{(1S,2R)-1-(3-fluoro-5-hydroxybenzyl)-2-
	hydroxy-3-[(3-methoxybenzyl)amino]propyl}-5-
	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
1542	hydrochloride
1344	N-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-[(3-iodobenzyl)amino]propyl}-4-hydroxy-3-
1544	(pyrrolidin-1-ylcarbonyl)benzamide
1344	5-oxo-D-prolyl-N <sup>1</sup> -{(1S, 2R)-1-(3, 5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
	hydroxypropy1}-3-[(1-
1545	propylbutyl)sulfonyl]alaninamide
1545	hydrochloride
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-
1546	{[(trifluoromethyl)sulfonyl]amino}benzamide

	137 (/10 07) 4 /07
	$N^1-\{(1S,2R)-1-(3,5-difluorobenzy1)-2-hydroxy-$
1547	3-[(3-pyridin-4-ylbenzyl)amino]propyl}-5-
1547	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-$
ļ	3-[(6-methoxy-1,2,3,4-tetrahydronaphthalen-1-
	yl)amino]propyl}-5-methyl-N³,N³-
1549	dipropylisophthalamide
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-N2-
	(phenylacetyl)-3-[(1-
1550	propylbutyl)sulfonyl]alaninamide
	methyl $3-(\{[(2R,3S)-4-(3,5-difluorophenyl)-3-$
	({3-[(dipropylamino)carbonyl]-5-
	methylbenzoyl}amino)-2-
1552	hydroxybutyl]amino}methyl)phenylcarbamate
	$5-oxo-L-prolyl-N^1-\{(1S,2R)-1-(3,5-$
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
	hydroxypropyl}-3-[(1-
	propylbutyl)sulfonyl]alaninamide
1553	hydrochloride
	$N^{1}$ -{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-N3-
1554	isobutyl-5-methylisophthalamide
	4-({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}amino)-4-
	oxo-3-{[(1-
t	
	propylbutyl)sulfonyl]methyl}butanoic acid
1555	<pre>propylbutyl)sulfonyl]methyl}butanoic acid trifluoroacetate</pre>
1555	<pre>propylbutyl)sulfonyl]methyl}butanoic acid trifluoroacetate N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-</pre>
	<pre>propylbuty1)sulfony1]methy1}butanoic acid trifluoroacetate N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethy1benzy1)amino]-2-hydroxypropy1}-3-</pre>
1555 1556	<pre>propylbutyl)sulfonyl]methyl}butanoic acid trifluoroacetate  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3- [methyl(methylsulfonyl)amino]benzamide</pre>
	propylbutyl)sulfonyl]methyl}butanoic acid trifluoroacetate  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3- [methyl(methylsulfonyl)amino]benzamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
1556	propylbutyl)sulfonyl]methyl}butanoic acid trifluoroacetate  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3- [methyl(methylsulfonyl)amino]benzamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethyl-
	propylbutyl)sulfonyl]methyl}butanoic acid trifluoroacetate  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3- [methyl(methylsulfonyl)amino]benzamide  N^1-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N^3-ethyl-N^3-isopropyl-5-methylisophthalamide
1556	propylbutyl)sulfonyl]methyl}butanoic acid trifluoroacetate  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[methyl(methylsulfonyl)amino]benzamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethyl-N³-isopropyl-5-methylisophthalamide  N¹-[(1S,2R)-2-hydroxy-3-[(3-
1556	propylbutyl)sulfonyl]methyl}butanoic acid trifluoroacetate  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3- [methyl(methylsulfonyl)amino]benzamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethyl- N³-isopropyl-5-methylisophthalamide  N¹-[(1S,2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(thien-2-
1556 1557	propylbutyl)sulfonyl]methyl}butanoic acid trifluoroacetate  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3- [methyl(methylsulfonyl)amino]benzamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethyl- N³-isopropyl-5-methylisophthalamide  N¹-[(1S,2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(thien-2-ylmethyl)propyl]-5-methyl-N³,N³-
1556	propylbutyl)sulfonyl]methyl}butanoic acid trifluoroacetate  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3- [methyl(methylsulfonyl)amino]benzamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethyl- N³-isopropyl-5-methylisophthalamide  N¹-[(1S,2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(thien-2-ylmethyl)propyl]-5-methyl-N³,N³- dipropylisophthalamide
1556 1557	propylbutyl)sulfonyl]methyl}butanoic acid trifluoroacetate  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3- [methyl(methylsulfonyl)amino]benzamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethyl- N³-isopropyl-5-methylisophthalamide  N¹-[(1S,2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(thien-2-ylmethyl)propyl]-5-methyl-N³,N³- dipropylisophthalamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
1556 1557	propylbutyl)sulfonyl]methyl}butanoic acid trifluoroacetate  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[methyl(methylsulfonyl)amino]benzamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethyl-N³-isopropyl-5-methylisophthalamide  N¹-[(1S,2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(thien-2-ylmethyl)propyl]-5-methyl-N³,N³-dipropylisophthalamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(
1556 1557 1558	propylbutyl)sulfonyl]methyl}butanoic acid trifluoroacetate  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[methyl(methylsulfonyl)amino]benzamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethyl-N³-isopropyl-5-methylisophthalamide  N¹-[(1S,2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(thien-2-ylmethyl)propyl]-5-methyl-N³,N³-dipropylisophthalamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2-hydroxyethyl)(propyl)amino]sulfonyl}propanami
1556 1557	propylbutyl)sulfonyl]methyl}butanoic acid trifluoroacetate  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[methyl(methylsulfonyl)amino]benzamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethyl-N³-isopropyl-5-methylisophthalamide  N¹-[(1S,2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(thien-2-ylmethyl)propyl]-5-methyl-N³,N³-dipropylisophthalamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2-hydroxyethyl)(propyl)amino]sulfonyl}propanamide
1556 1557 1558	propylbutyl)sulfonyl]methyl}butanoic acid trifluoroacetate  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3- [methyl(methylsulfonyl)amino]benzamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethyl- N³-isopropyl-5-methylisophthalamide  N¹-[(1S,2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(thien-2-ylmethyl)propyl]-5-methyl-N³,N³- dipropylisophthalamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2-hydroxyethyl)(propyl)amino]sulfonyl}propanamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]-3-[(3-ethylbenzyl)amino]-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-1-(3,5-difluorobenzyl)-3
1556 1557 1558	propylbutyl)sulfonyl]methyl}butanoic acid trifluoroacetate  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3- [methyl(methylsulfonyl)amino]benzamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethyl- N³-isopropyl-5-methylisophthalamide  N¹-[(1S,2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(thien-2-ylmethyl)propyl]-5-methyl-N³,N³- dipropylisophthalamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(2-hydroxyethyl)(propyl)amino]sulfonyl}propanamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-
1556 1557 1558	propylbutyl)sulfonyl]methyl}butanoic acid trifluoroacetate  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[methyl(methylsulfonyl)amino]benzamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethyl-N³-isopropyl-5-methylisophthalamide  N¹-[(1S,2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(thien-2-ylmethyl)propyl]-5-methyl-N³,N³-dipropylisophthalamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(2-hydroxyethyl)(propyl)amino]sulfonyl}propanamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-isopropyl-N³,5-dimethylisophthalamide
1556 1557 1558	propylbutyl)sulfonyl]methyl}butanoic acid trifluoroacetate  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3- [methyl(methylsulfonyl)amino]benzamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethyl- N³-isopropyl-5-methylisophthalamide  N¹-[(1S,2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(thien-2-ylmethyl)propyl]-5-methyl-N³,N³- dipropylisophthalamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(2-hydroxyethyl)(propyl)amino]sulfonyl}propanamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³- isopropyl-N³,5-dimethylisophthalamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³- isopropyl-N³,5-dimethylisophthalamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³- isopropyl-N³,5-dimethylisophthalamide
1556 1557 1558	propylbutyl)sulfonyl]methyl}butanoic acid trifluoroacetate  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[methyl(methylsulfonyl)amino]benzamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethyl-N³-isopropyl-5-methylisophthalamide  N¹-[(1S,2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(thien-2-ylmethyl)propyl]-5-methyl-N³,N³-dipropylisophthalamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2-hydroxyethyl)(propyl)amino]sulfonyl}propanamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-isopropyl-N³,5-dimethylisophthalamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-
1556 1557 1558 1559	propylbutyl)sulfonyl]methyl}butanoic acid trifluoroacetate  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3- [methyl(methylsulfonyl)amino]benzamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethyl- N³-isopropyl-5-methylisophthalamide  N¹-[(1S,2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(thien-2-ylmethyl)propyl]-5-methyl-N³,N³- dipropylisophthalamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2-hydroxyethyl)(propyl)amino]sulfonyl)propanamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³- isopropyl-N³,5-dimethylisophthalamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2- [(methylsulfonyl)amino]-1,3-thiazole-4-
1556 1557 1558	propylbutyl)sulfonyl]methyl}butanoic acid trifluoroacetate  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[methyl(methylsulfonyl)amino]benzamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethyl-N³-isopropyl-5-methylisophthalamide  N¹-[(1S,2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(thien-2-ylmethyl)propyl]-5-methyl-N³,N³-dipropylisophthalamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2-hydroxyethyl)(propyl)amino]sulfonyl}propanamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-isopropyl-N³,5-dimethylisophthalamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-

	1 2 5 2 5 4 2 5 4 2 7 3 7 3 7 3 7 3 7 3 7 3 7 3 7 3 7 3 7
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
	hydroxypropyl}-5-methylisophthalamide
	N-(3-({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}amino)-3-
	oxo-2-{[(1-
1563	<pre>propylbutyl)sulfonyl]methyl}propyl)benzamide</pre>
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-
1564	(isopentylsulfonyl)propanamide
	$N^{1}$ -((1S, 2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[3-(5-methylthien-2-
ļ	yl)benzyl]amino}propyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
1565	dipropylisophthalamide
	$N^1$ -{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-[(1-methylhexyl)amino]propyl}-5-methyl-
1567	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
1507	N <sup>1</sup> -[(1S, 2R) -3-{[1-
	(aminocarbonyl)cyclohexyl]amino}-1-(3,5-
	difluorobenzyl)-2-hydroxypropyl]-5-methyl-
1568	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
1300	$N^1$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(2E)-
	hex-2-enylamino]-2-hydroxypropyl}-5-methyl-
15.00	1
1569	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
1571	ethylbenzyl)amino]-2-hydroxypropyl}-3-
1571	hydroxyisoxazole-5-carboxamide
	$N^{1}$ -[(1s,2R)-1-(3,5-difluorobenzyl)-3-({3-
	[(1E)-hex-1-enyl]benzyl}amino)-2-
4550	hydroxypropyl]-5-methyl-N <sup>3</sup> , N <sup>3</sup> -
1572	dipropylisophthalamide
	$N^{1}$ -{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> -
1573	isopropyl-5-methylisophthalamide
	$N^{1}$ -[(1S,2R)-2-hydroxy-3-[(3-
	methoxybenzyl)amino]-1-(thien-2-
	ylmethyl)propyl]-N <sup>3</sup> ,N <sup>3</sup> -dipropylbenzene-1,3,5-
1574	tricarboxamide
	2-[3-(2-amino-2-oxoethoxy)phenyl]-N-{(1S,2R)-
	1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-
1575	iodobenzyl)amino]propyl}acetamide
	$N^{1}$ -{(1s,2R)-1-(3-bromobenzyl)-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
1576	dipropylisophthalamide
	$N^{1}$ -{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(2-
	ethylhexyl)amino]-2-hydroxypropyl}-5-methyl-
1577	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[3-(6-methoxypyridin-3-
	yl)benzyl]amino)propyl)-5-methyl-N³,N³-
1578	dipropylisophthalamide
<u> </u>	

	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[3-(2,4-
	dimethoxypyrimidin-5-yl)benzyl]amino}-2- hydroxypropyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
1579	
1379	dipropylisophthalamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
1500	ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-
1580	ethylbutanoyl)benzamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-[(4-
	hydroxypiperidin-1-yl)carbonyl]-5-
1581	methylbenzamide
	$N^{1}$ -{(1S, 2R)-1-(3-bromobenzyl)-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-N3,N3-
1582	dipropylbenzene-1,3,5-tricarboxamide
	4'-[4-({(1S,2R)-1-(3,5-difluorobenzyl)-2-
	hydroxy-3-[(3-iodobenzyl)amino]propyl}amino)-
1583	4-oxobutanoyl]-1,1'-biphenyl-2-carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-[(3-
	hydroxypiperidin-1-yl)carbonyl]-5-
1585	methylbenzamide
	$N^1$ -{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-[(3-hydroxy-1-phenylpropyl)amino]propyl}-5-
1586	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> -[2-
	(dimethylamino)ethyl]-N <sup>3</sup> -ethyl-5-
1587	methylisophthalamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-methyl-
	4H, 6H-pyrrolo[1, 2-a][4,1]benzoxazepine-4-
1588	carboxamide
* ****	2-(5-acetylthien-2-yl)-N-{(1S,2R)-1-(3,5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
1589	hydroxypropyl}acetamide
	$N^1$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-N³, N³-
1591	diisopropyl-5-methylisophthalamide
	N-{(1\$,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-
1592	[(methylsulfonyl)amino]benzamide
	N-{(1s, 2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-[(3-iodobenzyl)amino]propyl}-2-[4-(2-
1594	oxopyrrolidin-1-yl)phenyl]acetamide
	N-{(1S,2R)-1-(3-chloro-5-fluorobenzyl)-2-
	hydroxy-3-[(3-methoxybenzyl)amino]propyl}-3-
1595	[(dipropylamino)sulfonyl]propanamide
	$N^{1}$ -[(1S,2R)-1-(3-chloro-5-fluorobenzyl)-2-
	hydroxy-3-(isopentylamino)propyl]-N <sup>3</sup> , N <sup>3</sup> -
1596	dipropylbenzene-1,3,5-tricarboxamide
	arpropyruemzeme-1,3,5-tf1carboxamide

	27 (/40 07) 4 (2 5 1 5 1 1 1 2 5 /2
	N-{ (1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(1-
	methyl-1H-imidazol-4-
1597	yl)sulfonyl]amino}benzamide trihydrochloride
	$N^1$ -[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-(pentylamino)propyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
1598	dipropylisophthalamide
	$N^{1}$ -{ (1s, 2r) -1- (4-fluorobenzyl) -2-hydroxy-3-
	[(3-methoxybenzyl)amino]propyl}-N <sup>3</sup> ,N <sup>3</sup> -
1599	dipropylbenzene-1,3,5-tricarboxamide
	$N^{1}$ -[(1S, 2R)-3-(benzylamino)-1-(3-chloro-5-
	fluorobenzyl)-2-hydroxypropyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
1600	dipropylisophthalamide
	$N^1$ -cyclohexyl- $N^3$ -{(1S,2R)-1-(3,5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
1601	hydroxypropyl}-N¹-ethyl-5-methylisophthalamide
	2-{[(2R,3S)-4-(3,5-difluorophenyl)-3-({3-
	[(dipropylamino)carbonyl]-5-
	methylbenzoyl}amino)-2- hvdroxvbutvllamino)ethyl 2,4-
1.600	
1602	<pre>difluorophenylcarbamate N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-</pre>
	ethylbenzyl)amino]-2-hydroxypropyl}-3- $\{(2S)$ -
•	2-(methoxymethyl)pyrrolidin-1-yl]carbonyl}-5-
1.602	methylbenzamide hydrochloride
1603	$N^{1}$ -[(1S,2R)-1-(3-bromobenzyl)-2-hydroxy-3-
	(isopentylamino)propyl]-N <sup>3</sup> ,N <sup>3</sup> -dipropylbenzene-
1605	1,3,5-tricarboxamide
1003	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2,8-
1606	dimethylquinoline-3-carboxamide
	$N^1 - \{(1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy-$
	3-[(6-hydroxyhexyl)amino]propyl}-5-methyl-
1607	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^1$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[(2R)-2-hydroxypropyl]amino}propyl)-5-
1608	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	N-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-3-[(1-
1609	propylbutyl)sulfonyl]propanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2-
	hydroxy-1,1-
1610	dimethylethyl)amino]sulfonyl}benzamide
	$N^1$ -{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-[(4-phenylbutyl)amino]propyl}-5-methyl-
1611	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N-\{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-$
1612	3-[(3-iodobenzyl)amino]propyl}-7-(1H- imidazol-1-yl)-5,6-dihydronaphthalene-2-

	carboxamide
	3-(acetylamino)-N-{(1S,2R)-1-(3,5-
1613	difluorobenzyl) -3-[(3-ethylbenzyl)amino]-2-
1013	hydroxypropyl}-4-methylbenzamide
	$N^1-[(1S, 2R)-3-\{[2-(aminosulfonyl)ethyl]amino\}-$
1614	1-(3,5-difluorobenzyl)-2-hydroxypropyl]-5-
1014	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[2-
1615	(ethylthio)ethyl]amino}-2-hydroxypropyl)-5- methyl-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide
1013	M <sup>1</sup> [/1c 2D) 2 [bornel/maramide
	N <sup>1</sup> -[(1S,2R)-3-[benzyl(cyanomethyl)amino]-1-
1617	(3,5-difluorobenzyl)-2-hydroxypropyl]-5-
1017	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^1 - \{(1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy-$
1610	3-[(2-hydroxypropyl)amino]propyl}-5-methyl-
1618	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^{1}$ -[(1S,2R)-3-[(3-butoxypropyl)amino]-1-(3,5-
1619	difluorobenzyl)-2-hydroxypropyl]-5-methyl-
1019	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-{[2-(2-
1620	hydroxyethyl)piperidin-1-yl]carbonyl}-5- methylbenzamide
1020	methyl N-[(2R,3S)-4-(3,5-difluorophenyl)-3-
	({3-[(dipropylamino)carbonyl]-5-
	methylbenzoyl}amino)-2-hydroxybutyl]-beta-
1621	alaninate
	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-(1-
1622	hydroxy-2-propylpentyl)benzamide
	$N^{1}$ = [(1S, 2R) -3 - (benzylamino) -1 - (3-chloro-5-
	fluorobenzyl)-2-hydroxypropyl]-N <sup>3</sup> , N <sup>3</sup> -
1623	dipropylbenzene-1,3,5-tricarboxamide
-	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-
1624	[(methylsulfonyl)amino]butanamide
	$N^{1}$ -[(1S,2R)-3-{[3-(1-benzothien-2-
	yl)benzyl]amino}-1-(3,5-difluorobenzyl)-2-
	hydroxypropyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
1625	dipropylisophthalamide
	3-(benzyloxy)-N-{(1S,2R)-1-(3,5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
1626	hydroxypropyl}isoxazole-5-carboxamide
	2-{[(benzyloxy)carbonyl]amino}-7-
	[(cyclopropylmethyl)amino]-1,2,4,5,7-
	pentadeoxy-5-(3,5-difluorobenzyl)-1-[(1-
	propylbutyl)sulfonyl]-D-threo-hept-3-ulose
1627	trifluoroacetate
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
1629	
1629	ethylbenzyl)amino]-2-hydroxypropyl}-5-(1H-

<u> </u>	pyrazol-1-yl)pentanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-1-(2-
1630	furylmethyl)-5-oxopyrrolidine-3-carboxamide
1030	$N^1$ -{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-[(5-hydroxypentyl)amino]propyl}-5-methyl-
1622	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
1632	3-[({(1s,2r)-1-(3,5-difluorobenzyl)-2-
	hydroxy-3-[(1-methyl-1-
	phenylethyl)amino]propyl}amino)sulfonyl]-N,N-
1633	dipropylbenzamide
1033	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-[(3-methoxybenzyl)amino]propyl}-N <sup>3</sup> , N <sup>3</sup> -
1634	dipropylpiperidine-1,3-dicarboxamide
1034	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-[(3-methoxybenzyl)amino]propyl}-N <sup>3</sup> , N <sup>3</sup> -
1635	diethylpiperidine-1,3-dicarboxamide
1033	5-bromo-N <sup>1</sup> -((1S,2R)-2-hydroxy-1-
	(pentafluorobenzyl)-3-{[3-
	(trifluoromethyl)benzyl]amino}propyl)-N <sup>3</sup> , N <sup>3</sup> -
1636	dipropylisophthalamide
1030	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-
1637	[(methylsulfonyl)amino]benzamide
	N-{(1s,2R)-1-(3-bromobenzyl)-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-3-
1638	[(dipropylamino)sulfonyl]propanamide
	3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-2-
	hydroxy-3-[(3-methoxybenzyl)amino]-1-(thien-
1639	2-ylmethyl)propyl]propanamide
	$N^{1}$ -{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethoxypropyl)amino]-2-hydroxypropyl}-5-
1640	methyl-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide
	$N^{1}$ -[(1S,2R)-3-(benzylamino)-2-hydroxy-1-
	(thien-2-ylmethyl)propyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
1641	dipropylisophthalamide
	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-
1642	hydroxy-4-(phenylsulfonyl)butanamide
	$N^{1}$ -[(1S,2R)-1-(3,5-dichlorobenzyl)-2-hydroxy-
	3-(isopentylamino)propyl]-N <sup>3</sup> , N <sup>3</sup> -
1643	dipropylbenzene-1,3,5-tricarboxamide
	$N^{1}-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3,3-1)]$
1.545	dimethylbutyl)amino]-2-hydroxypropyl}-5-
1645	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^{1}$ -[(1S, 2R)-3-(benzylamino)-1-(3-bromobenzyl)-
1646	2-hydroxypropyl]-N <sup>3</sup> ,N <sup>3</sup> -dipropylbenzene-1,3,5-
1646	tricarboxamide
1645	N <sup>1</sup> -[(1S, 2R)-1-(3-chloro-5-fluorobenzyl)-2-
1647	hydroxy-3-(isopentylamino)propyl]-5-methyl-

	1-3-3-3
	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(1,3-
	diphenylpropyl)amino]-2-hydroxypropyl}-5-
1648	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[(1S)-1-
	(hydroxymethyl)propyl]amino}propyl)-N³,N³-
1649	dipropylisophthalamide
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[(3S)-2-oxoazepan-3-yl]amino}propyl)-5-
1650	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
:	$N^{1}$ -cyclohexyl- $N^{5}$ -{ (1S, 2R)-1-(3,5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
1651	hydroxypropyl}pentanediamide
	$N^{1}$ -[(1S,2R)-2-hydroxy-3-[(3-
	methoxybenzyl)amino]-1-(3-
	methylbenzyl)propyl]-N3,N3-dipropylbenzene-
1652	1,3,5-tricarboxamide
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> -[(2-
1653	<pre>propylpentyl)sulfonyl]-beta-alaninamide</pre>
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-(1,3-
1654	thiazol-2-yl)benzamide dihydrochloride
	$N^{1}$ -[(1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-({3-
1	[methyl(phenyl)amino]propyl}amino)propyl]-5-
1656	methyl-N3,N3-dipropylisophthalamide
	$N^{1}$ -[(1S,2R)-2-hydroxy-3-[(3-
	methoxybenzyl)amino]-1-(4-
1650	methylbenzyl)propyl]-N <sup>3</sup> ,N <sup>3</sup> -dipropylbenzene-
1657	1,3,5-tricarboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
1.650	ethylbenzyl)amino]-2-hydroxypropyl}-5-oxo-1-
1658	(thien-2-ylmethyl)pyrrolidine-3-carboxamide
	4-[(butylthio)methyl]-N-{(1S,2R)-1-(3,5-
1650	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
1659	hydroxypropyl}-5-methyl-2-furamide
	N-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
1660	ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2-
1660	hydroxyethyl)amino]sulfonyl}benzamide
	N <sup>1</sup> -{(1S, 2R)-1-(3, 5-difluorobenzy1)-2-hydroxy-
1661	3-[(3-methylcyclohexyl)amino]propyl}-5-
1001	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	N-{(15,2R)-1-(3,5-difluorobenzyl)-3-[(3-
1662	ethylbenzyl)amino]-2-hydroxypropyl}-4-(2-oxo-
1002	1,3-oxazolidin-3-yl)benzamide
	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
1663	ethylbenzyl)amino]-2-hydroxypropyl}-4-(1H-
1003	pyrrol-1-yl)benzamide

	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-1,3,4,5-
	tetrahydrothiopyrano[4,3-b]indole-8-
1665	carboxamide
_	$N^{1}$ -{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}- $N^4$ -[2-
1666	(trifluoromethyl)phenyl]succinamide
	$N^{1}$ -[(1S,2R)-1-(3-bromobenzyl)-2-hydroxy-3-
	(isopentylamino)propyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
1667	dipropylisophthalamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4,5-
	dimethyl-2-(1H-pyrrol-1-yl)thiophene-3-
1668	carboxamide
1000	$N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(2, 3-$
	dihydroxypropyl)amino]-2-hydroxypropyl}-5-
1669	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
1007	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[(2S)-2-hydroxypropyl]amino}propyl)-5-
1670	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
±070	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[(1R)-1-methylpropyl]amino}propyl)-5-
1671	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
10/1	2-chloro-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-
	[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-
1672	(methylsulfonyl)benzamide
10/2	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-[(2-hydroxyethyl)amino]propyl}-5-methyl-
1673	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
1073	3-[(dipropylamino)sulfonyl]-N-{(1S,2R)-2-
	hydroxy-1-(3-methoxybenzyl)-3-[(3-
1674	methoxybenzyl)amino]propyl}propanamide
10/4	N-{ (1S, 2R) -1- (3, 5-difluorobenzyl) -3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-
	{methyl[(trifluoromethyl)sulfonyl]amino}benza
1675	mide
10/3	$N = \{(1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [(3 - 4)]$
	ethylbenzyl)amino]-2-hydroxypropyl}-3-
	hydroxy-6-(1-hydroxy-2,2-
1676	dimethylpropyl)pyridine-2-carboxamide
1676	$N^{1}$ -[(1S, 2R)-3-[(1,3-dicyclohexylpropyl)amino]-
	1-(3,5-difluorobenzyl)-2-hydroxypropyl]-5-
1677	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
1677	$N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-2,2'-
1670	
1678	bithiophene-5-carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
1.650	ethylbenzyl)amino]-2-hydroxypropyl}-4-(1H-
1679	imidazol-1-yl) butanamide $N^{1}-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-difluorobenzyl)]$
1680	INC 1110 101 1 11

	othylhongyllaminal 2 had
	ethylbenzyl)amino]-2-hydroxypropyl}-2,3-
	dihydroxy-N <sup>4</sup> -(4-methoxyphenyl) succinamide
	$N^{1}$ -{(1s,2R)-2-hydroxy-3-[(3-
	methoxybenzyl)amino]-1-[3-
1.600	(trifluoromethyl)benzyl]propyl}-N <sup>3</sup> ,N <sup>3</sup> -
1682	dipropylbenzene-1,3,5-tricarboxamide
	$N^{1}$ -[(1S,2R)-3-(benzylamino)-2-hydroxy-1-
1.600	(thien-2-ylmethyl)propyl]-N <sup>3</sup> , N <sup>3</sup> -
1683	dipropylbenzene-1,3,5-tricarboxamide
	$N^{1}$ -[(1S,2R)-3-{[2-(aminocarbonyl)-1H-indol-6-
	yl]amino}-1-(3,5-difluorobenzyl)-2-
1.604	hydroxypropyl]-5-methyl-N <sup>3</sup> , N <sup>3</sup> -
1684	dipropylisophthalamide
	$N^{1}$ -[(1S,2R)-3-(benzylamino)-1-(3-bromobenzyl)-
1.605	2-hydroxypropyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
1685	dipropylisophthalamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
1.000	ethylbenzyl)amino]-2-hydroxypropyl}-2-(1-oxo-
1686	1,3-dihydro-2H-isoindol-2-yl)butanamide
	3-chloro-N-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-
1.607	[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-
1687	(methylsulfonyl)thiophene-2-carboxamide
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(1-
1.000	ethylpropyl)amino]-2-hydroxypropyl}-5-methyl-
1688	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^{1}$ -[(1s,2R)-1-(3,5-difluorobenzyl)-3-({[(5R)-
	3-ethyl-2-oxo-1,3-oxazolidin-5-
1600	yl]methyl}amino)-2-hydroxypropyl]-5-methyl-
1689	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-
1690	7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-
1090	2-carboxamide
	N <sup>1</sup> -{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-N <sup>2</sup> -
	[(methylthio)acetyl]-3-[(1-
1691	propylbutyl)sulfonyl]alaninamide
1031	hydrochloride
	$N^{1}$ -{(1s, 2r)-1-(3,5-difluorobenzyl)-3-[(2,3-dimethylogical charal) aminal 2 hadronics
1692	dimethylcyclohexyl)amino]-2-hydroxypropyl}-5- methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
1002	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	$N = \{(15, 2K) - 1 - (5, 5 - \alpha)\}$
1693	ethylbenzyl)amino]-2-hydroxypropyl}-4,5-
	dimethoxy-1-benzothiophene-2-carboxamide  N¹-[(1S,2R)-1-[3-fluoro-5-
	(trifluoromethyl)benzyl]-2-hydroxy-3-
	(isopentylamino)propyl]-N <sup>3</sup> ,N <sup>3</sup> -dipropylbenzene-
1694	1,3,5-tricarboxamide
2073	$N^1$ -[(1S,2R)-1-(3,5-difluorobenzyl)-3-({[(5S)-
1695	N - [(15,2k)-1-(3,5-diffuorobenzyf)-3-({[(5s)-  3-ethyl-2-oxo-1,3-oxazolidin-5-
	J-echyr-z-0x0-1, J-0xaz01101n-5-

	yl]methyl}amino)-2-hydroxypropyl]-5-methyl-
	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^1$ -{(1s,2R)-1-(1,3-benzodioxol-5-ylmethyl)-2-
	hydroxy-3-[(3-methoxybenzyl)amino]propyl}-
1696	N <sup>3</sup> , N <sup>3</sup> -dipropylbenzene-1, 3, 5-tricarboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(3,5-
1697	dioxo-1,2,4-triazolidin-4-yl)benzamide
	N-{ (1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-2-hydroxy-3-[(3-
	methoxyphenyl)sulfonyl]propanamide
1698	hydrochloride
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-[(2-methylcyclohexyl)amino]propyl}-5-
1699	methyl-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide
	$N^{1}-[(1S, 2R)-3-[(2-\{4-[(3-$
	chlorobenzyl)oxy]phenyl}ethyl)amino]-1-(3,5-
•	difluorobenzyl)-2-hydroxypropyl]-5-methyl-
1700	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-
1701	hydroxy-4-oxo-4-thien-3-ylbutanamide
	$N^{1}$ -{(1S,2R)-1-[3-(benzyloxy)-5-fluorobenzyl]-
	2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-
1702	N <sup>3</sup> , N <sup>3</sup> -dipropylbenzene-1,3,5-tricarboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-
	hydroxy-4-oxo-4-[3-
1703	(trifluoromethyl)phenyl]butanamide
	$\mathbb{N}^{1}$ -{(1S,2R)-2-hydroxy-3-(isopentylamino)-1-[3-
	(trifluoromethoxy)benzyl]propyl}-N <sup>3</sup> ,N <sup>3</sup> -
1704	dipropylbenzene-1,3,5-tricarboxamide
	$\mathbb{N}^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[1-(hydroxymethyl)-3-
	(methylthio)propyl]amino}propyl)-5-methyl-
1705	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	2-(1H-1,2,3-benzotriazol-1-yl)-N-{(1S,2R)-1-
	(3,5-difluorobenzyl)-3-[(3-
1706	ethylbenzyl)amino]-2-hydroxypropyl}hexanamide
	$N^1$ -[(1S,2R)-1-(3-fluoro-4-methylbenzyl)-2-
	hydroxy-3-(isopentylamino)propyl]-N <sup>3</sup> , N <sup>3</sup> -
1707	dipropylbenzene-1,3,5-tricarboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-(4,4-
	dimethyl-2,5-dioxoimidazolidin-1-yl)-2-{[(1-
1708	propylbutyl)sulfonyl]methyl}propanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-
1709	{[(trifluoromethyl)sulfonyl]amino}butanamide
1710	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-

	ethylbenzyl)amino]-2-hydroxypropyl}-2-(5-
	methyl-1,3-dioxo-1,3-dihydro-2H-isoindol-2-
	yl)acetamide
	$N^{1}$ -((1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[1-(hydroxymethyl)propyl]amino}propyl)-5-
1712	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^{1}$ -[(1S,2R)-3-(benzylamino)-1-(3,5-
	dichlorobenzyl)-2-hydroxypropyl]-N <sup>3</sup> ,N <sup>3</sup> -
1713	dipropylbenzene-1,3,5-tricarboxamide
	N-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-3-{[(2-
	hydroxyethyl)(propyl)amino]sulfonyl}propanami
1714	de hydrochloride
	5-(benzylthio)-N-{(1S,2R)-1-(3,5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
1715	hydroxypropyl}nicotinamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-1H-
1716	pyrazole-5-carboxamide
	6-chloro-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-
	[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-
	methyl-2-oxo-2,3-dihydro-1,3-benzoxazole-5-
1717	carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-1H-
1718	benzimidazole-2-carboxamide
-	$N^{1}$ -{(1S,2R)-1-(cyclohexylmethyl)-2-hydroxy-3-
	[(3-methoxybenzyl)amino]propyl}-N <sup>3</sup> ,N <sup>3</sup> -
1719	dipropylbenzene-1,3,5-tricarboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-6-
	hydroxy-4,7-dimethoxy-1-benzofuran-5-
1720	carboxamide
	$N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-$
	3-[(4-methylcyclohexyl)amino]propyl}-5-
1721	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-
	hydroxypropyl}[1,2,4]triazolo[4,3-a]pyridine-
1722	6-carboxamide
<del></del>	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-
1723	hydroxy-4-oxo-4-thien-2-ylbutanamide
	$N^{1}$ -[(1S,2R)-3-(benzylamino)-1-(3,5-
	dichlorobenzyl)-2-hydroxypropyl]-5-methyl-
1724	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
_ ,	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(2-
1725	hydroxy-5-methylphenyl)-4-oxobutanamide
1726	
1/40	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-

<i></i>	
	ethylbenzyl)amino]-2-hydroxypropy1}-3-
	phenoxybenzamide
	4-[(aminocarbonyl)amino]-N-{(1S,2R)-1-(3,5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
1727	hydroxypropyl}benzamide
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[(1S)-1-(hydroxymethyl)-3-
	(methylthio)propyl]amino}propyl)-5-methyl-
1728	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-7-
1729	hydroxy-4-oxochromane-2-carboxamide
	$N^{1}$ -((1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[(1S)-1-(hydroxymethyl)-3-
	methylbutyl]amino}propyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
1730	dipropylisophthalamide
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[(1R)-1-
	(hydroxymethyl)propyl]amino}propyl)-N³,N³-
1731	dipropylisophthalamide
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-[(1-methyl-3-phenylpropyl)amino]propyl}-5-
1732	methyl-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-(2,3-
	dihydro-1-benzofuran-5-yl)-1,3-thiazole-4-
1733	carboxamide
	$N^{1}$ -{(1S,2R)-1-[3-(benzyloxy)benzyl]-2-hydroxy-
	3-[(3-methoxybenzyl)amino]propyl}-5-methyl-
1734	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	N-{ (1S, 2R) -1- (4-chlorobenzyl) -2-hydroxy-3-
	[(3-methoxybenzyl)amino]propyl}-3-
1735	[(dipropylamino)sulfonyl]propanamide
	$N^{1}$ -{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> -
1736	pentylmalonamide
	N-{ (1s, 2r) -1- (3, 5-difluorobenzyl) -3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-
1737	(trifluoromethoxy)benzamide
	3-[(dipropylamino)sulfonyl]-N-{(1S,2R)-1-(3-
1,500	fluoro-4-methylbenzyl)-2-hydroxy-3-[(3-
1738	methoxybenzyl)amino]propyl)propanamide
	N-[(1S,2R)-1-(3-chloro-5-fluorobenzy1)-2-
1720	hydroxy-3-(isopentylamino)propyl]-3-
1739	[(dipropylamino)sulfonyl]propanamide
	N-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-(4,4-
	dimethyl-2,5-dioxoimidazolidin-1-yl)-2-{[(1-
1740	propylbutyl)sulfonyl]methyl}propanamide
1741	$N^{1}$ -[4-(acetylamino)phenyl]- $N^{4}$ -{(1S,2R)-1-(3,5-

	4:51,0m0hou - 1) 2 5/2 11 11 12 13 1 2 2 2
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
	hydroxypropyl}succinamide
	3-(1-cyanoethy1)-N-{(1S,2R)-1-(3,5-
4	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
1742	hydroxypropyl}benzamide
	$N^{1}$ -{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>4</sup> -(5-
1743	pheny1-1,3,4-thiadiazol-2-yl)succinamide
	$N^1$ -{(1S,2R)-3-(benzylamino)-2-hydroxy-1-[3-
	(trifluoromethoxy)benzyl]propyl}-N <sup>3</sup> ,N <sup>3</sup> -
1744	dipropylbenzene-1,3,5-tricarboxamide
	$\mathbb{N}^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[2-(2-oxo-2-pyrrolidin-1-
	ylethoxy)phenyl]amino}propyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
1745	dipropylisophthalamide
	$N^{1}$ -[(1S,2R)-1-(4-chlorobenzyl)-2-hydroxy-3-
4846	(isopentylamino)propyl]-N <sup>3</sup> ,N <sup>3</sup> -dipropylbenzene-
1746	1,3,5-tricarboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
40.0	ethylbenzyl)amino]-2-hydroxypropyl}-2-(1,1-
1747	dioxidotetrahydrothien-2-yl)acetamide
	$N^{1}-[(1S, 2R)-3-(benzylamino)-1-(4-$
15.40	chlorobenzy1)-2-hydroxypropy1]-5-methyl-N <sup>3</sup> , N <sup>3</sup> -
1748	dipropylisophthalamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzyl)]$
4840	ethylbenzyl)amino]-2-hydroxypropyl}-5-hex-1-
1749	ynylnicotinamide
	N-[(1S, 2R)-1-(3-bromobenzy1)-2-hydroxy-3-
1750	(isopentylamino)propyl]-3-
1750	[(dipropylamino)sulfonyl]propanamide
	N-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
1751	ethylbenzyl)amino]-2-hydroxypropyl}-3-
1/51	methoxyisoxazole-5-carboxamide
	N-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
1750	ethylbenzyl)amino]-2-hydroxypropyl}-2,3-
1752	dimethyl-1H-indole-7-carboxamide
	4-(3-chlorophenyl)-N-{(1S,2R)-1-(3,5-
1753	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
1/33	hydroxypropyl}-2-hydroxy-4-oxobutanamide N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
1755	ethylbenzyl)amino]-2-hydroxypropyl}-2-(1-
1133	methyl-1H-indol-3-yl)-2-oxoacetamide $N^1$ -[(1S,2R)-1-(3-fluoro-4-methylbenzyl)-2-
	hydroxy-3-(isopentylamino)propyl]-5-methyl-
1756	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
1,30	3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-2-
	hydroxy-3-[(3-methoxybenzyl)amino]-1-(4-
1757	methylbenzyl)propyl]propanamide
1131	$N^{1}$ -[(1S,2R)-3-(benzylamino)-1-(3-fluoro-4-
1758	methylbenzy1)-2-hydroxypropy1]-N <sup>3</sup> , N <sup>3</sup> -
<u> </u>	Tweeriatnerrali-s-matoxabrobatl-M.'M

	lainemalhangana 1 2 Estrigarhayamida
	dipropylbenzene-1,3,5-tricarboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-[5-(4-
1759	methylphenyl)-2H-tetraazol-2-yl]acetamide
	$N-\{(1S,2R)-1-(3,5-dichlorobenzyl)-2-hydroxy-$
	3-[(3-methoxybenzyl)amino]propyl}-3-
1760	[(dipropylamino)sulfonyl]propanamide
	$N^{1}$ -[(1s,2R)-2-hydroxy-3-(isopentylamino)-1-
	(thien-2-ylmethyl)propyl]-N <sup>3</sup> , N <sup>3</sup> -
1761	dipropylbenzene-1,3,5-tricarboxamide
	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-
1762	3-phenylisoxazole-4-carboxamide
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]~2-hydroxypropyl}-N²-
1764	[(methylsulfonyl)acetyl]-N2-pentylglycinamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4~(1H-
1765	indol-3-y1)-4-oxobutanamide
	$N^{1}$ -(5-benzyl-1,3,4-thiadiazol-2-yl)- $N^{4}$ -
	$\{(1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - [(3 - (3 - (3 - (3 - (3 - (3 - (3$
	ethylbenzyl)amino]-2-
1766	hydroxypropyl}succinamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(3-
1767	fluoro-4-methoxyphenyl)-4-oxobutanamide
	ethyl 4-{[(2R,3S)-4-(3,5-difluorophenyl)-3-
	({3~[(dipropylamino)carbonyl]-5-
	methylbenzoyl}amino)-2-
1768	hydroxybutyl]amino)piperidine-1-carboxylate
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-4)]$
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(2-
1769	fluorobenzoyl)-1H-pyrrole-2-carboxamide
ļ	$N^{1}$ -[(1S,2R)-3-(benzylamino)-1-(4-
ŧ	chlorobenzyl)-2-hydroxypropyl]-N <sup>3</sup> , N <sup>3</sup> -
1770	dipropylbenzene-1,3,5-tricarboxamide
	$N^1$ -[(1S,2R)-2-hydroxy-1-(4-hydroxybenzyl)-3-
	(isopentylamino)propyl]-5-methyl-N <sup>3</sup> , N <sup>3</sup> -
1772	dipropylisophthalamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]$
1	ethylbenzyl)amino]-2-hydroxypropyl}-2-(4-
1773	morpholin-4-ylphenyl)acetamide
[	3-[(dipropylamino)sulfonyl]-N-{(1S,2R)-2-
1994	hydroxy-3-[(3-methoxybenzyl)amino]-1-[3-
1774	(trifluoromethoxy)benzyl]propyl}propanamide
	$N^1$ -benzyl- $N^1$ -(1-cyclopropylethyl)- $N^4$ -{(1S, 2R)-
Į.	1-(3,5-difluorobenzyl)-3-[(3-
1555	ethylbenzyl)amino]-2-
1775	hydroxypropyl}succinamide
1776	$N-\{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-$

	12 5/2
	3-[(3-methoxybenzyl)amino]propyl}-3-(2,5-
	dimethylbenzoyl) -5-methylbenzamide
	$N^{1}$ -{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
4 5 5 5	ethylbenzyl)amino]-2-hydroxypropyl}-N4-(2-
1777	methoxy-5-methylphenyl)succinamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-(3-
1778	hydroxyphenyl)acetamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-[(3-methoxybenzyl)amino]propyl}-3-
	[hydroxy(2-methylphenyl)methyl]-5-
1779	methylbenzamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-5-
1780	(ethylthio)nicotinamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-[4-(2-
1781	furoyl)piperazin-1-yl]-4-oxobutanamide
	$N^{1}$ -[(1S,2R)-3-(benzylamino)-1-(3-fluoro-4-
	methylbenzyl) $-2$ -hydroxypropyl] $-5$ -methyl- $N^3$ , $N^3$ -
1782	dipropylisophthalamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-
1783	oxoisoindoline-1-carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-
1784	(ethylthio)benzamide
	$N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-$
	ethylbenzyl)amino]-2-
4505	hydroxypropyl}thieno[2,3-b]quinoline-2-
1785	carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
1706	ethylbenzyl)amino]-2-hydroxypropyl}-3-(4-
1786	methyl-1,3-oxazol-2-yl)benzamide
	$N-\{2-[(\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-k-1)]\}\}$
	ethylbenzyl)amino]-2-
1700	hydroxypropyl}amino)carbonyl]phenyl}-N-
1788	methyl-2-furamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
1700	ethylbenzyl)amino]-2-hydroxypropyl}-2-
1789	hydroxy-4-(3-methoxyphenyl)-4-oxobutanamide
	$N^{1}$ -[(1S, 2R)-3-(cycloheptylamino)-1-(3,5-
1700	difluorobenzyl)-2-hydroxypropyl]-5-methyl-
1790	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^{1}$ -[(1S, 2R)-2-hydroxy-3-(isopentylamino)-1-(4-
1501	methylbenzyl)propyl]-N <sup>3</sup> ,N <sup>3</sup> -dipropylbenzene-
1791	1,3,5-tricarboxamide
	1 3-[(dipropylamino)sulfonyl]-N-{(1S,2R)-1-
1700	(3-fluoro-5-hydroxybenzyl)-2-hydroxy-3-[(3-
1792	methoxybenzyl)amino]propyl}propanamide

	12 (/limenalomina) - 1511 27 (/17 07) 1 /2
	3-[(dipropylamino)sulfonyl]-N-{(1S, 2R)-1-(3-
	fluoro-5-hydroxybenzyl)-2-hydroxy-3-[(3-
4	methoxybenzyl)amino]propyl}propanamide
1793	hydrochloride
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzyl)]$
	ethylbenzyl)amino]-2-hydroxypropyl}-5-
1794	hydroxy-1H-indole-2-carboxamide
	$N-\{(1S, 2R)-1-(3, 5-diffluorobenzy1)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-2,2-
1795	dimethylchromane-8-carboxamide
	6-benzyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-
	[(3-ethylbenzyl)amino]-2-
1796	hydroxypropyl}pyrazine-2-carboxamide 4-oxide
	2-{[({(1s,2R)-1-(3,5-difluorobenzyl)-2-
	hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}amino)carbonyl]ami
1797	no}-N,N-dipropylethanesulfonamide
	$N^1$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[(1R)-1-(hydroxymethyl)-2-
	methylpropyl]amino}propyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
1798	dipropylisophthalamide
	N-[(1S, 2R)-3-(benzylamino)-1-(3-chloro-5-
Ì	fluorobenzyl)-2-hydroxypropyl]-3-
1799	[(dipropylamino)sulfonyl]propanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(4-
1800	methoxyphenyl)-4-oxobutanamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzyl)]$
	ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-
1802	4-oxo-3,4-dihydrophthalazine-1-carboxamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-3,4-
1803	dihydro-2H-1,5-benzodioxepine-7-carboxamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-2-[4-
1804	(2,5-dioxopyrrolidin-1-yl)phenoxy]acetamide
	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-
1.005	4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-6-
1806	carboxamide
1	N <sup>1</sup> -[(1S,2R)-1-(1,3-benzodioxol-5-ylmethyl)-2-
1007	hydroxy-3-(isopentylamino)propyl]-N <sup>3</sup> , N <sup>3</sup> -
1807	dipropylbenzene-1,3,5-tricarboxamide
	$N^1$ -{(1s,2r)-1-(3-chloro-5-fluorobenzyl)-2-
1,000	hydroxy-3-[(3-methoxybenzyl)amino]propyl}-
1808	N <sup>5</sup> , N <sup>5</sup> -dipropylpentanediamide
	N-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
1000	ethylbenzyl)amino]-2-hydroxypropyl}-6-fluoro-
1809	2-hydroxyquinoline-4-carboxamide
1810	N-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-

Γ	
	ethylbenzyl)amino]-2-hydroxypropyl}-4-oxo-4-
	thien-2-ylbutanamide
	$N^3$ -[({(1s,2R)-1-(3,5-difluorobenzyl)-2-
	hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}amino)carbonyl]-
1811	N <sup>1</sup> , N <sup>1</sup> -dipropyl-beta-alaninamide
	$N^{1}$ -{ (1R, 2R) -2-hydroxy-3-[(3-
	methoxybenzyl)amino]-1-
	[(phenylthio)methyl]propyl}-N3,N3-
1812	dipropylbenzene-1,3,5-tricarboxamide
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[(1R,2S)-1-(hydroxymethy1)-2-
	methylbutyl]amino}propyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
1814	dipropylisophthalamide
	$N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-2-
1815	(phenoxymethyl)benzamide
	$N^{1}$ -{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>5</sup> -(2,4-
1816	difluorophenyl) pentanediamide
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>5</sup> -(4,6-
1817	dimethylpyrimidin-2-yl)pentanediamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-[(3-methoxybenzyl)amino]propyl}-3-(3-
1818	methoxybenzoyl)-5-methylbenzamide
	$N^{1}$ -{(1S,2R)-1-[3-(benzyloxy)benzyl]-2-hydroxy-
	3-[(3-methoxybenzyl)amino]propyl}-N³, N³-
1819	dipropylbenzene-1,3,5-tricarboxamide
	4-(3,4-dichlorophenyl)-N-{(1S,2R)-1-(3,5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
1820	hydroxypropyl}-4-oxobutanamide
	methyl $4-\{(2R,3R)-2-(\{3-1\})\}$
	4-{(2R,3R)-2-({3-  [(dipropylamino)carbonyl]-5-
	methylbenzoyl}amino)-3-hydroxy-4-[(3-
1821	methoxybenzyl)amino]butyl}benzoate
	$N^{1}$ -(4-acetylphenyl)- $N^{5}$ -{(1S,2R)-1-(3,5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
1822	hydroxypropyl}pentanediamide
2022	$N^{1}$ -{ (1R, 2R) -2-hydroxy-3-[(3-
	methoxybenzyl)amino]-1-
	[(phenylthio)methyl]propyl}-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
1824	(phenylthio)methyljpropyl}-5-methyl-N°,N°-   dipropylisophthalamide
1024	2-{[3-({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
1825	ethylbenzyl)amino]-2-hydroxypropyl}amino)-3-
1023	oxopropyl]thio}-N-methylbenzamide
	N-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-
1826	methoxybenzyl)amino]propyl}-3-[(1-
1827	propylbutyl) thio]propanamide
1021	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-

	ethylbenzyl)amino]-2-hydroxypropyl}-N4-(4-	
ļ	ethoxyphenyl)succinamide	
	$N^{1}$ -[(1S, 2R)-1-[3-(benzyloxy)-5-fluorobenzyl]	- '
1000	2-hydroxy-3-(isopentylamino)propyl]-N <sup>3</sup> ,N <sup>3</sup> -	
1828	dipropylbenzene-1,3,5-tricarboxamide	
	2-{[(2R,3S)-4-(3,5-difluorophenyl)-3-({3-	
	[(dipropylamino)carbonyl]-5-	
	methylbenzoyl}amino)-2-	
	hydroxybutyl]amino}ethyl	3-
1829	methoxyphenylcarbamate	
	3-(benzyloxy)-N-{(1S,2R)-1-(3,5-	
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-	
1830	hydroxypropyl}benzamide	
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy	
	3-{[(1S)-2-hydroxy-1-	
	methylethyl]amino}propyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -	
1831	dipropylisophthalamide	
-	$N^{1}$ -((1S,2R)-2-hydroxy-1-(pentafluorobenzyl)-	3-
	{[3-(trifluoromethyl)benzyl]amino}propyl)-5-	-
1832	methyl-N3,N3-dipropylisophthalamide	
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(4-	
1833	hydroxyphenyl)-4-oxobutanamide	
	3-[(dipropylamino)sulfonyl]-N-{(1S,2R)-2-	
	hydroxy-3-[(3-methoxybenzyl)amino]-1-[3-	
1834	(trifluoromethyl)benzyl]propyl}propanamide	
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	
	ethylbenzyl)amino]-2-hydroxypropyl}-3-	
1835	(piperidin-3-ylsulfonyl)benzamide	
	6-chloro-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3	<u> </u>
	[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-	•
1836	hydroxyquinoline-2-carboxamide	
2000	N <sup>1</sup> -[(1S,2R)-2-hydroxy-3-[(3-	
	methoxybenzyl)amino]-1-(thien-2-	
1837	ylmethyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> -dipropylpentanediamide	_
1037	$N^{1}$ - ((1S)-1-{(1R)-1-hydroxy-2-[(3-	
	methoxybenzyl)amino]ethyl}-3-methylbutyl)-5-	
1838	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide	_
1030	N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-	
	ethylbenzyl)amino]-2-hydroxypropyl}-2-(6-oxo	
1839	3-phenylpyridazin-1(6H)-yl)acetamide	,-
1033	N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-	
	ethylbenzyl)amino]-2-hydroxypropyl}-3-{4-	
1840	[(methylsulfonyl)amino]phenyl)propanamide	
1040	N <sup>1</sup> -[(1S, 2R)-3-(benzylamino)-2-hydroxy-1-(4-	
1040	methylbenzyl)propyl]-5-methyl-N <sup>3</sup> , N <sup>3</sup> -	
1842	dipropylisophthalamide	
	3-(2-chlorophenoxy)-N-{(1S,2R)-1-(3,5-	
1010	difluorobenzy1)-2-hydroxy-3-[(3-	
1843	iodobenzyl)amino]propyl}propanamide	

1	$N^{1}$ -[(1s, 2r)-1-(4-fluorobenzyl)-2-hydroxy-3-
1	(isopentylamino)propyl]-N <sup>3</sup> ,N <sup>3</sup> -dipropylbenzene-
1844	1,3,5-tricarboxamide
	Change
1845	Structure possibly contains peptides which
1015	are not supported in current version!
<b>{</b>	$N^{-1}(15,2K)-1-13-(benzylovy)-5$
1	fluorobenzyl]-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-3-
1046	[(dipropylamino)sulfonyl]propanamide
1846	nydrochloride
	$N-\{(1S, 2R)-1-[3-(benzyloxy)-5-fluorobenzyl]-$
	2-nydroxy-3-[(3-methoxybenzy])aminolpropyll
	(3-[(dipropylamino)sulfonyl)propanamide
1847	nydrochloride
	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(4-
1848	methylphenyl)-4-oxobutanamide
	$N^{1}-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-difluorobenzyl)]$
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>4</sup> -[3-
1849	(trifluoromethyl)phenyl]succinamide
	$N^{1}$ = { (19 2P) = 1 / (1 2 horses 1) / (15 2P) = 1 / (1 2 horses 1) /
	$N^1$ -{(1s,2R)-1-(1,3-benzodioxol-5-ylmethyl)-2-
1850	hydroxy-3-[(3-methoxybenzyl)amino]propyl}-5-
	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
1851	ethylbenzyl)amino]-2-hydroxypropyl}-2-(5-
1031	pyridin-2-yl-2H-tetraazol-2-yl)acetamide
1050	Structure possibly contains pentides which
1852	are not supported in current version!
	3-1(dipropylamino)sulfonvll-N-((15 2R)-2-
1050	nydroxy-3-1(3-methoxybenzyl)aminol-1-(3-
1853	metnylbenzyl)propyl]propanamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzy)\}-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}isoxazole-
1854	
	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-(3,5-
1855	dimethoxyphenoxy) acetamide
	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(2,5-
1856	dimethyl-1H-pyrrol-1-yl)-3-hydroxybenzamide
	$N^1$ -{(1S,2R)-1-(3-bromobenzy1)-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-N <sup>5</sup> , N <sup>5</sup> -
1857	dipropylpentanediamide
	N <sup>1</sup> -[5-(avalopontylmathyl) 4.2
	$N^{1}$ -[5-(cyclopentylmethyl)-1,3,4-thiadiazol-2-
	yl]-N <sup>4</sup> -{(1s, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
1858	ethylbenzyl)amino]-2-
	hydroxypropyl}succinamide
	$N^{1}$ -{(1s,2R)-3-(benzylamino)-2-hydroxy-1-[3-
1859	(trifluoromethyl)benzyl]propyl}-N <sup>3</sup> ,N <sup>3</sup> -dipropylbenzene-1,3,5-tricarboxamide
	1 0 3 20 30 20 20 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1

<del></del>	1- (45 00) 4 (2 5 1) 51
	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-(3-oxo-
1860	1,2-benzisothiazol-2(3H)-yl)acetamide
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[1-methyl-5-(pyrrolidin-1-ylcarbonyl)-1H-
	pyrrol-3-yl]amino}propyl)-5-methyl- $N^3$ , $N^3$ -
1861	dipropylisophthalamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(3,4-
1862	difluorophenyl)-4-oxobutanamide
	$N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(2-
1863	naphthyl)-4-oxobutanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4,6-
1864	diethoxypyridine-2-carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(5-
1865	methyl-1H-pyrrol-2-yl)-4-oxobutanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-({[2-
	(methylamino)ethyl]amino}sulfonyl)benzamide
1866	dihydrochloride
	$N-\{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-$
	3-[(3-methoxybenzyl)amino]propyl}-3-methyl-5-
1867	(4-methylbenzoyl)benzamide
	$N^1$ -[(1S,2R)-1-(1,3-benzodioxol-5-ylmethyl)-3-
	(benzylamino) $-2$ -hydroxypropyl] $-5$ -methyl- $N^3$ , $N^3$ -
1868	dipropylisophthalamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzyl)]$
	ethylbenzyl)amino]-2-hydroxypropyl}-3-
1869	(piperazin-1-ylsulfonyl)benzamide
	$N^{1}-[(1S,2R)-3-(\{2-[4-$
	(aminosulfonyl)phenyl]ethyl}amino)-1-(3,5-
	difluorobenzyl)-2-hydroxypropyl]-5-methyl-
1870	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[2-hydroxy-1-
	(hydroxymethyl)ethyl]amino}propyl)-5-methyl-
1871	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^{1}$ -[(1S,2R)-1-(4-fluoro-3-methylbenzyl)-2-
	hydroxy-3-(isopentylamino)propyl]-N <sup>3</sup> , N <sup>3</sup> -
1872	dipropylbenzene-1,3,5-tricarboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-(3-oxo-
1873	2,1-benzisothiazol-1(3H)-yl)propanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
]	ethylbenzyl)amino]-2-hydroxypropyl}-2-(2,6-
1874	dihydroxypyrimidin-4-yl)acetamide
1875	$N^{1}-\{(1S, 2R)-2-hydroxy-3-[(3-$
<u> </u>	<u>, 1</u>

	mothorshopped 1 1 52
	methoxybenzyl)amino]-1-[3-
	(trifluoromethyl)benzyl]propyl}-N <sup>5</sup> ,N <sup>5</sup> -
	dipropylpentanediamide
	N-[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4-
1876	hydroxybenzyl)propyl]-3-
1876	[(dipropylamino)sulfonyl]propanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
1877	ethylbenzyl)amino]-2-hydroxypropyl}-4-(3,4-
1077	difluorophenyl)-2-methyl-4-oxobutanamide $N^1$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>5</sup> -(2-
1878	pyridin-2-ylethyl)pentanediamide
1070	$N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-2-[2-(4-
1879	fluorophenyl)-1,3-benzoxazol-5-yl]acetamide
10,7	$N^2$ -(anilinocarbonyl)- $N^1$ -{(1S,2R)-1-(3,5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
1880	hydroxypropyl}glycinamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-(1,3-
1881	dithian-2-y1)-3-furamide
	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-[2-oxo-
1882	2-(propylamino)ethyl]benzamide
	N-[(1S,2R)-3-(benzylamino)-1-(3-bromobenzyl)-
ļ	2-hydroxypropyl]-3-
1883	[(dipropylamino)sulfonyl]propanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-[(3-iodobenzyl)amino]propyl}-3-(2-
1884	fluorophenyl)propanamide
	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-5-
1885	methylthiophene-2-carboxamide
	2-[4-(benzyloxy)phenyl]-N-{(1S,2R)-1-(3,5-
	difluorobenzyl)-2-hydroxy-3-[(3-
1886	iodobenzyl)amino]propyl}acetamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-[(5,7-
4000	dimethyl[1,2,4]triazolo[4,3-a]pyrimidin-3-
1887	yl)thio]acetamide
	$N^{1}$ -(1-acetyl-2,3-dihydro-1H-indol-7-yl)- $N^{4}$ -
	{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
1000	ethylbenzyl)amino]-2-
1888	hydroxypropyl}succinamide
	$N^{1}$ - (3-acetylphenyl) - $N^{5}$ - { (1S, 2R) - 1 - (3, 5 -
1000	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
1889	hydroxypropyl}pentanediamide
	3-(4-chlorophenoxy)-N-{(1S,2R)-1-(3,5-
1000	difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-
1890	hydroxypropyl}-2-hydroxypropanamide

	$N^{1}$ -[(1S, 2R)-3-(benzylamino)-1-(3-fluoro-4-
	methoxybenzyl)-2-hydroxypropyl]-N <sup>3</sup> , N <sup>3</sup> -
4004	
1891	dipropylbenzene-1,3,5-tricarboxamide
	$N^{1}$ -[(1S, 2R)-3-(benzylamino)-2-hydroxy-1-(3-
	methylbenzyl)propyl]-N3,N3-dipropylbenzene-
1892	1,3,5-tricarboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-1H-
1893	indole-7-carboxamide
	$N^{1}$ -[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-(3-
	methylbenzyl)propyl]-N3,N3-dipropylbenzene-
1894	1,3,5-tricarboxamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(1,2,3-
1895	thiadiazol-4-yl)benzamide
	$N-\{(1S,2R)-1-[3-(benzyloxy)-5-fluorobenzyl]-$
	2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-
1896	3-[(dipropylamino)sulfonyl]propanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-(4,4-
	dimethyl-2,5-dioxoimidazolidin-1-yl)-2-{[(1-
1897	propylbutyl)sulfonyl]methyl}propanamide
	$N^{1}$ -[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-(4-
	methylbenzyl)propyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
1898	dipropylisophthalamide
	$N^{1}$ -{(1S,2R)-3-(benzylamino)-1-[3-fluoro-5-
	(trifluoromethyl)benzyl]-2-hydroxypropyl}-5-
1899	methyl-N³,N³-dipropylisophthalamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-[1-
1900	methyl-3-(methylthio)-1H-indol-2-yl]acetamide
	$N^{1}$ -[(1S,2R)-1-(3,5-dichlorobenzyl)-2-hydroxy-
	3-(isopentylamino)propyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
1901	dipropylisophthalamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(2-
1902	furyl)-4-oxobutanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-(3-
1903	pyridin-2-yl-1,2,4-oxadiazol-5-yl)propanamide
	2-[2-(acetylamino)-1,3-thiazol-4-y1]-N-
	{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
1904	ethylbenzyl)amino]-2-hydroxypropyl}acetamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-[(4-
	methyl-4H-1,2,4-triazol-3-yl)thio]-2-
1905	phenylacetamide
	$N^{1}$ -[(1S,2R)-1-(4-chlorobenzyl)-2-hydroxy-3-
	(isopentylamino)propyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
1906	dipropylisophthalamide

	14 /1 2 1
	4-(1,3-benzothiazol-2-yl)-N-{(1S,2R)-1-(3,5-
1005	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
1907	hydroxypropyl}butanamide
1	$N^{1}$ -(3-chloro-4-fluorophenyl)- $N^{4}$ -{(1S,2R)-1-
	(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-
1908	hydroxypropyl}succinamide
	$N^1$ -[(1S,2R)-1-[3-(benzyloxy)-5-fluorobenzyl]-
	2-hydroxy-3-(isopentylamino)propyl]-5-methyl-
1909	N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-[(2-
1910	oxo-2,3-dihydroquinazolin-4-yl)thio]acetamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-$
	3-[(3-methoxybenzyl)amino]propyl}-3-methyl-5-
1911	(2-methylbenzoyl)benzamide
	$N^{1}$ -[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4-
	methylbenzyl)propyl]-N <sup>3</sup> ,N <sup>3</sup> -dipropylbenzene-
1913	1,3,5-tricarboxamide
	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-
1914	propoxybenzamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-1-methyl-
1915	1H-indole-2-carboxamide
	5-chloro-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-
1015	[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(3-
1916	methyl-4H-1,2,4-triazol-4-yl)benzamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
1017	ethylbenzyl)amino]-2-hydroxypropyl}-4-(3,4-
1917	difluorophenyl)-2-methoxy-4-oxobutanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
1010	ethylbenzyl)amino]-2-hydroxypropyl}-2-(3-
1918	thien-2-yl-1H-pyrazol-1-yl)acetamide
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
1010	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>5</sup> -
1919	phenylpentanediamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
1000	ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-
1920	thioxo-1,3-benzothiazol-3(2H)-yl)acetamide
	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
1000	ethylbenzyl)amino]-2-hydroxypropyl}-2-(3-
1923	hydroxy-4-methylphenyl)acetamide
	N <sup>1</sup> -[(1S, 2R)-1-[3-fluoro-5-
	(trifluoromethyl)benzyl]-2-hydroxy-3-
1004	(isopentylamino)propyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
1924	dipropylisophthalamide
	N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
1005	ethylbenzyl)amino]-2-hydroxypropyl}-7-fluoro-
1925	4H-imidazo[5,1-c][1,4]benzoxazine-3-

	carboxamide
	$N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(3,4-
	dihydro-2H-1,5-benzodioxepin-7-yl)-4-
1926	oxobutanamide
2320	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
•	ethylbenzyl)amino]-2-hydroxypropyl}-1-
1927	benzofuran-3-carboxamide
	$N^{1}$ -(3,4-dichlorophenyl)- $N^{3}$ -{(1S,2R)-1-(3,5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
1928	hydroxypropyl}malonamide
	$N^{1}$ -{(1S,2R)-3-(benzylamino)-1-[3-fluoro-5-
	(trifluoromethyl)benzyl]-2-hydroxypropyl}-
1929	$N^3$ , $N^3$ -dipropylbenzene-1, 3, 5-tricarboxamide
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[(1R)-2-hydroxy-1-
	methylethyl]amino}propyl)-5-methyl-N3,N3-
1930	dipropylisophthalamide
	$N^{1}$ -[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(3-
	methylbenzyl)propyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
1931	dipropylisophthalamide
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>5</sup> -
1932	pyridin-3-ylpentanediamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-
1933	4-oxo-4H-chromene-6-carboxamide
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[3-(1H-imidazol-1-yl)propyl]amino}propyl)-
1934	5-methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	3-[(dipropylamino)sulfonyl]-N-{(1S,2R)-1-[3-
4005	fluoro-5-(trifluoromethyl)benzyl]-2-hydroxy-
1935	3-[(3-methoxybenzyl)amino]propyl}propanamide
	3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-2-
1026	hydroxy-1-(4-hydroxybenzyl)-3-
1936	(isopentylamino)propyl]propanamide
	$N^{1}$ -[(1S,2R)-1-(1,3-benzodioxol-5-ylmethyl)-2- hydroxy-3-(isopentylamino)propyl]-5-methyl-
1937	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
1937	3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-2-
	hydroxy-3-(isopentylamino)-1-(thien-2-
1938	ylmethyl)propyl]propanamide
1930	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-[(2,2-
1939	dimethylpropanoyl)amino]-2-hydroxybenzamide
1,555	$N^{1}$ -[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-(3-
	methoxybenzyl)propyl]-5-methyl-N <sup>3</sup> , N <sup>3</sup> -
1940	dipropylisophthalamide
	N-((1S,2R)-1-(4-fluorobenzyl)-2-hydroxy-3-
1941	{[3-(trifluoromethyl)benzyl]amino}propyl)-3-
	, (critingtoweenlibenship demino) broblib

	[[[3-mothowyhongyz]]aminalawlfamilli
	{[(3-methoxybenzyl)amino]sulfonyl}benzamide
	N-[6-({(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
1 1 0 4 2	ethylbenzyl)amino]-2-hydroxypropyl}amino)-6-
1943	oxohexyl]-2-furamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-[(1-
4044	phenyl-4,5-dihydro-1H-tetraazol-5-
1944	y1)thio]acetamide
	4-acetyl-4-amino-N-{(1S,2R)-1-(3,5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
	hydroxypropyl}cyclohexa-1,5-diene-1-
1945	sulfonamide
	N-((1S,2S)-1-benzyl-2-hydroxy-3-{[3-
	(trifluoromethyl)benzyl]amino}propyl)-3-{[(3-
1946	methoxybenzyl)amino]sulfonyl}benzamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(3,4-
1947	dihydro-2H-chromen-6-yl)-4-oxobutanamide
	$N^{1}$ -[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-(3-
	methoxybenzyl)propyl]-N <sup>3</sup> ,N <sup>3</sup> -dipropylbenzene-
1948	1,3,5-tricarboxamide
	$N^1$ -{(1S,2R)-1-(3-fluoro-4-methylbenzyl)-2-
	hydroxy-3-[(3-methoxybenzyl)amino]propyl}-
1949	N <sup>5</sup> , N <sup>5</sup> -dipropylpentanediamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-
1950	hydroxypropyl}indolizine-2-carboxamide
	$N^1$ -{(1S,2R)-3-(benzylamino)-2-hydroxy-1-[3-
	(trifluoromethoxy)benzyl]propyl}-5-methyl-
1951	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
1050	ethylbenzyl)amino]-2-
1952	hydroxypropyl}nicotinamide 1-oxide
II	N-[(1S,2R)-1-[3-(benzyloxy)-5-fluorobenzyl]-
	2-hydroxy-3-(isopentylamino)propyl]-3-
1953	[(dipropylamino)sulfonyl]propanamide
	2-({(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-[(3-iodobenzyl)amino]propyl}amino)-2-
1954	oxoethyl carbamate
	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2,3-
4055	dihydro-1H-cyclopenta[b]quinoline-9-
1955	carboxamide
	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-
1956	1H-pyrazole-5-carboxamide
	N-[5-({(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}amino)-5-
1957	oxopentyl]benzamide
1958	N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-

	ethylbenzyl)amino]-2-hydroxypropyl}-4-
	[(methoxymethyl)thio]benzamide
	3-(1,3-benzothiazol-2-yl)-N-{(1S,2R)-1-(3,5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
1959	hydroxypropyl}-3-methoxypropanamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-3-
	{[(methylamino)carbonyl]amino}-3-thien-3-
1960	ylpropanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-5-
1961	pyridin-2-ylthiophene-2-carboxamide
	$N^{1}$ -{(1S,2R)-3-(benzylamino)-1-[3-(benzyloxy)-
	5-fluorobenzyl]-2-hydroxypropyl}-N <sup>3</sup> ,N <sup>3</sup> -
1962	dipropylbenzene-1,3,5-tricarboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-(5,6-
	dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyridin-
1963	3-yl)acetamide
	$N^{1}$ -[(1S,2R)-1-(3-fluoro-4-methoxybenzyl)-2-
	hydroxy-3-(isopentylamino)propyl]-5-methyl-
1964	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-2-
1965	isobutyl-1,3-dioxoisoindoline-5-carboxamide
	5-(acetylamino)-N-{(1S,2R)-1-(3,5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
1967	hydroxypropyl}-2-furamide
	$N^{1}$ -{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -[(4-
1968	methoxyphenyl)acetyl]glycinamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-
1969	hydroxypropyl}isoquinoline-4-carboxamide
	$N^{1}$ -[(1S,2R)-1-[3-(benzyloxy)benzyl]-2-hydroxy-
	3-(isopentylamino)propyl]-N <sup>3</sup> ,N <sup>3</sup> -
1970	dipropylbenzene-1,3,5-tricarboxamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-2-(4-
1971	hydroxy-3-methoxyphenyl)acetamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-[(4-
1972	phenyl-4H-1,2,4-triazol-3-yl)thio]acetamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-(3,5-
1973	dimethoxyphenyl)acetamide
	N <sup>1</sup> -[(1S, 2R)-3-(benzylamino)-2-hydroxy-1-(3-
	methoxybenzyl)propyl]-5-methyl-N <sup>3</sup> , N <sup>3</sup> -
1974	dipropylisophthalamide
1975	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$

ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-ethyl-4H-[1,2,4]triazolo[1,5-a]benzimidazol-4-yl)acetamide  7-chloro-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1-benzofuran-2-carboxamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propanamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-oxo-2H-1,3-benzoxazin-3(4H)-yl)propanamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(pyrimidin-2-ylthio)acetamide
4-yl)acetamide   7-chloro-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-    [(3-ethylbenzyl)amino]-2-hydroxypropyl}-1-    benzofuran-2-carboxamide   N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propanamide   N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-oxo-2H-1,3-benzoxazin-3(4H)-yl)propanamide   N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-    1980
7-chloro-N-{(1S, 2R) -1-(3, 5-difluorobenzyl) -3- [(3-ethylbenzyl) amino] -2-hydroxypropyl}-1- benzofuran-2-carboxamide  N-{(1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl}-2-(1, 3-dioxo-1, 3-dihydro-2H-isoindol-2-yl)propanamide  N-{(1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl}-3-(2-oxo-2H-1, 3-benzoxazin-3(4H)-yl)propanamide  N-{(1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl}-2- [(3-ethylbenzyl) amino] -2-hydroxypropyl}-2- [(4-ethylbenzyl) amino] -2-hydroxypropyl}-2- [(5-ethylbenzyl) amino] -2-hydroxypropyl}-2- [(5-ethylbenzyl) amino] -2-hydroxypropyl}-2-
[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1- benzofuran-2-carboxamide  N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propanamide  N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-oxo-2H-1,3-benzoxazin-3(4H)-yl)propanamide  N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(pyrimidin-2-ylthio)acetamide
Denzofuran-2-carboxamide   N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propanamide   N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-oxo-2H-1,3-benzoxazin-3(4H)-yl)propanamide   N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(pyrimidin-2-ylthio)acetamide
N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propanamide  N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-oxo-2H-1,3-benzoxazin-3(4H)-yl)propanamide  N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(pyrimidin-2-ylthio)acetamide
ethylbenzyl)amino]-2-hydroxypropyl}-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propanamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-oxo-2H-1,3-benzoxazin-3(4H)-yl)propanamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(pyrimidin-2-ylthio)acetamide
ethylbenzyl)amino]-2-hydroxypropyl}-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propanamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-oxo-2H-1,3-benzoxazin-3(4H)-yl)propanamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(pyrimidin-2-ylthio)acetamide
dioxo-1,3-dihydro-2H-isoindol-2- yl)propanamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-oxo-2H-1,3-benzoxazin-3(4H)-yl)propanamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2- (pyrimidin-2-ylthio)acetamide
N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-oxo-2H-1,3-benzoxazin-3(4H)-yl)propanamide  N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2- (pyrimidin-2-ylthio)acetamide
ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-oxo- 2H-1,3-benzoxazin-3(4H)-yl)propanamide N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2-hydroxypropyl}-2- (pyrimidin-2-ylthio)acetamide
ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-oxo- 2H-1,3-benzoxazin-3(4H)-yl)propanamide N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2-hydroxypropyl}-2- (pyrimidin-2-ylthio)acetamide
1979 2H-1,3-benzoxazin-3(4H)-yl)propanamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-  (pyrimidin-2-ylthio)acetamide
N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(pyrimidin-2-ylthio)acetamide
ethylbenzyl)amino]-2-hydroxypropyl}-2- 1980 (pyrimidin-2-ylthio)acetamide
1980 (pyrimidin-2-ylthio) acetamide
77 50 /
$N^1$ -[3-(aminocarbonyl)-4,5,6,7-tetrahydro-1-
benzothien-2-y1]-N <sup>4</sup> -{ $(1S, 2R)-1-(3.5-$
difluorobenzyl)-3-[(3-ethylbenzyl)aminol-2-
1981 hydroxypropyl}succinamide
$N-\{(1s, 2r)-1-(3, 5-difluorobenzyl)-3-[(3-$
ethylbenzyl)amino]-2-hydroxypropyl}-2-[(5-
phenyl-1,3,4-oxadiazol-2-yl)thiolacetamide
$N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-(3-$
ethylbenzyl)amino]-2-hydroxypropyl}guinoline-
1983 6-carboxamide
N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4-(2.3-
1985   dihydro-1,4-benzodioxin-6-yl)-4-oxobutanamide
$N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-$
ethylbenzyl)amino]-2-hydroxypropyl}-3-(1H-
indol-3-yl)-1H-pyrazole-5-carboxamide
$N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-$
ethylbenzyl)amino]-2-hydroxypropyl}-2-
hydroxy-4-
1987 {[(methylamino)carbonothioyl]amino}benzamide
$6-chloro-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-$
[(3-ethylbenzyl)amino]-2-
1988 hydroxypropyl}nicotinamide
$N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-$
ethylbenzyl)amino]-2-hydroxypropyl}-4-(3-
1989 hydroxyphenyl)-4-oxobutanamide
$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
ethylbenzyl)amino]-2-hydroxypropyl}-2-
1990 (phthalazin-1-ylthio)acetamide
$N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-$
ethylbenzyl)amino]-2-hydroxypropyl}-2-[(1-
1991 oxidopyridin-2-yl)thio]acetamide
$3-(acetylamino)-N-\{(1S,2R)-1-(3,5-$
1992   difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-

	hydroxypropyl}-5-fluoro-1H-indole-2-
	carboxamide
	N-((1S,2S)-1-benzyl-2-hydroxy-3-{[3-
,	(trifluoromethyl)benzyl]amino}propyl)-3-{[(3-
1993	chlorobenzyl)amino]sulfonyl}benzamide
	$N^1$ -[(1S,2R)-1-(1,3-benzodioxol-5-ylmethyl)-3-
	(benzylamino)-2-hydroxypropyl]-N <sup>3</sup> , N <sup>3</sup> -
1995	dipropylbenzene-1,3,5-tricarboxamide
	4-(3,4-dichlorophenyl)-N-{(1S,2R)-1-(3,5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
	hydroxypropy1}-2-hydroxy-3-methyl-4-
1996	oxobutanamide
	3-[(dipropylamino)sulfonyl]-N-{(1S,2R)-2-
	hydroxy-3-(isopentylamino)-1-[3-
1997	(trifluoromethoxy)benzyl]propyl}propanamide
	$N^{1}$ -{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-N4-(5-
1998	methyl-1,3,4-thiadiazol-2-yl)succinamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-
1999	ethyl-1H-benzimidazol-1-yl)acetamide
	$N-\{(1S,2R)-1-(1,3-benzodioxol-5-ylmethyl)-2-$
	hydroxy-3-[(3-methoxybenzyl)amino]propyl}-3-
2000	[(dipropylamino)sulfonyl]propanamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-oxo-
2001	1,3-benzoxazol-3(2H)-yl)propanamide
	N-[(1S, 2R)-1-(3, 5-dichlorobenzyl)-2-hydroxy-
	3-(isopentylamino)propyl]-3-
2002	[(dipropylamino)sulfonyl]propanamide
	$N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-4)]$
	ethylbenzyl)amino]-2-hydroxypropyl}-N4-(6-
2003	methylpyridin-2-yl)succinamide
	ethyl $(4R)-4-[({(1S,2R)-1-(3,5-)}$
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
	hydroxypropyl amino carbonyl ]-1,3-
2004	oxazolidine-3-carboxylate
	N-{(1R, 2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
0005	3-[(3-methoxybenzyl)amino]propyl}-3-
2005	glycylbenzamide dihydrochloride
	N-{(1s, 2r) -1-(3, 5-difluorobenzyl) -3-[(3-
2006	ethylbenzyl)amino]-2-hydroxypropyl}-3-(1-
2006	methyl-1H-imidazol-2-yl)benzamide
	4-(acetylamino)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
2007	hydroxypropyl}butanamide trifluoroacetate
2007	$N^{1}$ -{(1S, 2R) -1-(3, 5-difluorobenzyl)-3-[(3-
	$N^{-}$ (1S, 2R) -1-(3, 5-diffuorobenzy1)-3-(3- ethylbenzy1) amino]-2-hydroxypropy1}- $N^{2}$ -{[(3S)-
	tetrahydrofuran-3-yloxy]carbonyl}-D-
2000	leucinamide
2008	Trencinalitue

	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-
2009	(pyrrolidin-3-ylsulfonyl)benzamide
	$N-\{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-$
	3-[(3-methoxybenzyl)amino]propyl}-3-
	[(dipropylamino)methyl]benzamide
2010	dihydrochloride
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[(1R)-1-(hydroxymethyl)-3-
	methylbutyl]amino}propyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
2011	dipropylisophthalamide
	$N^{1}$ -[(1S,2R)-3-[tert-butyl(cyclohexyl)amino]-1-
	(3,5-difluorobenzyl)-2-hydroxypropyl]-5-
2012	methyl-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide
	$N^1$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[(1S)-1-(hydroxymethyl)-2,2-
	dimethylpropyl]amino}propyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
2013	dipropylisophthalamide
	$N^{1}$ -[(1S,2R)-1-(3,5-difluorobenzyl)-3-({[(2R)-
	1-ethylpyrrolidin-2-yl]methyl}amino)-2-
	hydroxypropyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
2014	dipropylisophthalamide
	N <sup>1</sup> -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[3-
	(dimethylamino)-2,2-dimethylpropyl]amino}-2-
	hydroxypropyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
2015	dipropylisophthalamide
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[2-
	(diisopropylamino)ethyl]amino}-2-
	hydroxypropyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
2016	dipropylisophthalamide
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[(1-
	ethylpyrrolidin-2-yl)methyl]amino}-2-
	hydroxypropyl) - 5-methyl- $N^3$ , $N^3$ -
2017	dipropylisophthalamide
	$N^{1}$ -[(1S,2R)-3-[(1-benzylpyrrolidin-3-
	yl)amino]-1-(3,5-difluorobenzyl)-2-
	hydroxypropyl]-5-methyl-N <sup>3</sup> , N <sup>3</sup> -
2018	dipropylisophthalamide
	$N^1$ -{(1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-[(3-pyrrolidin-1-ylpropyl)amino]propyl}-5-
2019	methyl-N³, N³-dipropylisophthalamide
	$N^{1}$ -((1S, 2R)-1-(3,5-difluorobenzyl)-3-{[3-
	(dimethylamino)propyl]amino)-2-
2020	hydroxypropyl)-5-methyl-N <sup>3</sup> , N <sup>3</sup> -
2020	dipropylisophthalamide $N^{1}-[(1S,2R)-3-\{[2-(acetylamino)ethyl]amino\}-1-$
	(3,5-difluorobenzyl)-2-hydroxypropyl]-5-
2021	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
2021	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
2022	
2022	3-{[2-(6-oxo-1,4,5,6-tetrahydropyridazin-3-

	yl)phenyl]amino}propyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
	dipropylisophthalamide
	N <sup>1</sup> -[(1S,2R)-3-[7-chloro-1-(2-hydroxy-3-
	methoxyphenyl)-3,4-dihydroisoquinolin-2(1H)-
	yl]-1-(3,5-difluorobenzyl)-2-hydroxypropyl]-
2023	5-methyl-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide
	$N^{1}$ -[(1S,2R)-3-{[4-(1-
	cyanocyclopentyl)phenyl]amino}-1-(3,5-
	difluorobenzyl)-2-hydroxypropyl]-5-methyl-
2024	$N^3$ , $N^3$ -dipropylisophthalamide
	$N^{1}-[(1S, 2R)-3-(\{4-[4-$
	(acetylamino)phenoxy)phenyl)amino)-1-(3,5-
	difluorobenzyl)-2-hydroxypropyl]-5-methyl-
2025	$N^3$ , $N^3$ -dipropylisophthalamide
	$N^{1}$ -[(1S,2R)-3-[(4-benzoy1-2,3-
	dimethylphenyl)amino]-1-(3,5-difluorobenzyl)-
	2-hydroxypropyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
2026	dipropylisophthalamide
	$N^{1}-[(1S,2R)-3-[(2-amino-2-oxo-1-$
į	phenylethyl)amino]-1-(3,5-difluorobenzyl)-2-
	hydroxypropyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
2027	dipropylisophthalamide
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{4-[(1-methyl-1H-imidazol-2-
	yl)methyl]piperazin-1-yl}propyl)-5-methyl-
2028	$N^3$ , $N^3$ -dipropylisophthalamide
	$N^{1}$ -((1S,2R)-1-[3,5-
	bis(trifluoromethyl)benzyl]-2-hydroxy-3-{[3-
	(trifluoromethyl)benzyl]amino}propyl)-5-
2029	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$(1S, 2R) - N^1 - [2 - (tert-butylthio)ethyl] - N^2 -$
	{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-
2030	hydroxypropyl}cyclopropane-1,2-dicarboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4,5-
2031	dihydronaphtho[2,1-d]isoxazole-3-carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-1-methyl-
2032	1H-benzo[g]indazole-3-carboxamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzyl)]$
	ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-
2033	1,3-thiazole-4-carboxamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzyl)]$
	ethylbenzyl)amino]-2-hydroxypropyl}-4-
2034	methoxy-1H-pyrrole-3-carboxamide
	$N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-9-oxo-
	1,2,3,9-tetrahydrocyclopenta[b]chromene-7-
2035	carboxamide

]	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
2026	ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-oxo-
2036	2,3-dihydro-1H-benzimidazol-5-yl)acetamide
	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
0005	ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-oxo-
2037	2,3-dihydro-1,3-benzoxazol-5-yl)acetamide
	2-[2-(1,3-benzoxazol-2-yl)phenoxy]-N-
	{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
2038	ethylbenzyl)amino]-2-hydroxypropyl}acetamide
	5-chloro-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-
0000	[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-
2039	morpholin-4-ylbenzamide
	3-(3-chloroisoxazol-5-yl)-N-{(1S,2R)-1-(3,5-
0040	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
2040	hydroxypropyl}propanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
2041	ethylbenzyl)amino]-2-hydroxypropyl}-4-(6-
2041	methoxy-1,1'-biphenyl-3-yl)-4-oxobutanamide
	4-(1-benzofuran-2-yl)-N-{(1S,2R)-1-(3,5-
2042	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
2042	hydroxypropyl}-4-oxobutanamide
	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
2042	ethylbenzyl)amino]-2-hydroxypropyl}-2-oxo-
2043	1,2,3,4-tetrahydroquinoline-3-carboxamide
	2-(1-benzofuran-2-yl)-N-{(15,2R)-1-(3,5-
2044	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
2044	hydroxypropyl}-2-methylpropanamide
	N-{(1s,2r)-1-(3,5-difluorobenzy1)-3-[(3-
2045	ethylbenzyl)amino]-2-hydroxypropyl}-6-
2043	methoxy-1-benzofuran-2-carboxamide
	N-{(1s, 2r)-1-(3, 5-difluorobenzyl)-3-[(3-
2046	ethylbenzyl)amino]-2-hydroxypropyl}-2-[4-(1H-
2040	pyrrol-1-yl)phenyl]propanamide
	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
2047	ethylbenzyl)amino]-2-hydroxypropyl}-1H- imidazo[1,2-b]pyrazole-6-carboxamide
2017	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-[(4-
2048	methyl-1,3-thiazol-2-yl)thio]acetamide
	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-
2049	methoxy-4-(methylthio)benzamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-
2050	hydroxy-4-(propionylamino)benzamide
	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-6-{[(4-
2051	methylphenyl)sulfonyl]amino}-4-oxohexanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
2052	ethylbenzyl)amino]-2-hydroxypropyl}-1H-
	1

	benzimidazole-5-carboxamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-
	2-(1-oxo-1,3-dihydro-2H-isoindol-2-
2053	yl)propanamide
	7-(acetylamino)-N-{(1S,2R)-1-(3,5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
	hydroxypropyl}-2-methylquinoline-5-
2054	carboxamide
	$N^3 - (tert-butoxycarbonyl) - N^1 - \{(1S, 2R) - 1 - (3, 5 - 1)\}$
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
2054A	hydroxypropyl}-b-alaninamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-3-
2055	hydroxy-3-propylhexanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
2056	ethylbenzyl)amino]-2-hydroxypropyl}-2-phenyl-
2056	2-(1H-pyrrol-1-yl)acetamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
2057	ethylbenzyl)amino]-2-hydroxypropyl}-1-methyl-
2057	5-phenyl-1H-pyrazole-3-carboxamide
·	N-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-(3-oxo-
2058	2,3-dihydro-1H-isoindol-1-yl)acetamide
	4-[2-(acetylamino)-4,5-dimethylphenyl]-N-
	{(1S, 2R) -1-(3,5-difluorobenzyl) -3-[(3-
2050	ethylbenzyl)amino]-2-hydroxypropyl}-4-
2059	oxobutanamide 6-chloro-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-
	[(3-ethylbenzyl)amino]-2-
2060	hydroxypropyl}pyrazine-2-carboxamide 4-oxide
2000	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-6-
2061	methoxypyrazine-2-carboxamide 4-oxide
2001	2-(1H,1'H-2,2'-biimidazol-1-yl)-N-{(1S,2R)-1-
	(3,5-difluorobenzyl)-3-[(3-
2062	ethylbenzyl)amino]-2-hydroxypropyl}acetamide
2002	5-chloro-N-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-
	[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2,3-
2063	dihydro-1-benzofuran-7-carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-
	([1,2,4]triazolo[4,3-b]pyridazin-6-
2064	ylthio)acetamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-
	1-pyridin-4-yl-1H-1,2,3-triazole-4-
2065	carboxamide
	2-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-
2066	[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-
<del></del>	

	ovo-3 A-dihydromin
	oxo-3,4-dihydroquinazoline-6-carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
2067	ethylbenzyl)amino]-2-hydroxypropyl}-4-(7-
2067	methoxy-1-benzofuran-2-y1)-4-oxobutanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-[(2-
0000	ethyl-1-oxo-2,3-dihydro-1H-isoindo1-5-
2068	yl)oxy]propanamide
	N-{(1s, 2r)-1-(3, 5-difluorobenzyl)-3-[(3-
0050	ethylbenzyl)amino]-2-hydroxypropyl}pyrazine-
2069	2-carboxamide 4-oxide
	7-chloro-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-
	[(3-ethylbenzyl)amino]-2-
2070	hydroxypropyl}quinoline-2-carboxamide
	2-cyano-N-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-
0.071	[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-
2071	(3,4-dimethoxyphenyl)-2-methylpropanamide
	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
2072	ethylbenzyl)amino]-2-hydroxypropyl}-2-
2072	hydroxy-5-(propionylamino)benzamide
	N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
•	ethylbenzyl)amino]-2-hydroxypropyl}-3-[2-oxo-
0.070	5-(trifluoromethyl)pyridin-1(2H)-
2073	yl]propanamide
	5-(4-chlorophenyl)-N-{(1S,2R)-1-(3,5-
0.054	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
2074	hydroxypropy1}-2-furamide
	4-cyano-N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-
2075	[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-
2075	(1H-pyrrol-1-yl)thiophene-2-carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
2076	ethylbenzyl)amino]-2-hydroxypropyl}-3,5-
2070	bis (methylthio) isothiazole-4-carboxamide
	2-chloro-4-cyano-N-{(1S, 2R)-1-(3, 5-
2077	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
4011	hydroxypropyl}benzamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
2078	ethylbenzyl)amino]-2-hydroxypropyl}-3-
2070	[(methoxyacetyl)amino]-3-phenylpropanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
2079	ethylbenzyl)amino]-2-hydroxypropyl}-3-fluoro-
2013	4-morpholin-4-ylbenzamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
2080	ethylbenzyl)amino]-2-hydroxypropyl}-4-(1-
2000	oxidothiomorpholin-4-yl)butanamide
	4-chloro-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-
	[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1,3-
2081	dimethyl-1H-pyrazolo[3,4-b]pyridine-5- carboxamide
2082	
2002	N-{2-[({(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-

	ethylbenzyl)amino]-2-
	hydroxypropyl amino) carbonyl ] phenyl } -5-
	methyl-2-furamide
	1-(cyanomethyl)-N-{(1S,2R)-1-(3,5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
2083	hydroxypropyl}-1H-pyrrole-2-carboxamide
	$N^{1}$ -(2-chloropyridin-3-yl)- $N^{4}$ -{(1S,2R)-1-(3,5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
2084	hydroxypropyl}succinamide
	3-(cyclopentyloxy)-N-{(1S,2R)-1-(3,5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
2085	hydroxypropyl}-4-methoxybenzamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-(5-
2086	pyrrolidin-1-yl-2H-tetraazol-2-yl)acetamide
2000	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2,5-
2087	dimethyl-1-phenyl-1H-pyrrole-3-carboxamide
2007	1-(4-acetylphenyl)-N-{(1S,2R)-1-(3,5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
2088	hydroxypropyl}piperidine-4-carboxamide
2000	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-
2089	2-(1H-1,2,4-triazol-1-yl)propanamide
2009	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-5-
2090	(piperidin-1-ylmethyl)-2-furamide
2000	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-
	2,3-dihydro-1-benzothiophene-2-carboxamide
2091	1,1-dioxide
2001	2-(2,1,3-benzoxadiazol-5-yl)-N-{(1S,2R)-1-
	(3,5-difluorobenzy1)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-1,3-
2092	thiazole-4-carboxamide
2052	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4,5-
	dihydrofuro[2,3-g][2,1]benzisoxazole-8-
2093	carboxamide
2093	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-[(4-
2094	methyl-1,2,3-thiadiazol-5-yl)thio]acetamide
2034	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-1-(2-
2095	furoyl)-4-hydroxyprolinamide
2033	$N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-4-oxo-
2006	4,5,6,7-tetrahydro-1-benzofuran-3-carboxamide
2096	
2007	4,5-dichloro-N-{(1S,2R)-1-(3,5-
2097	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-

	hydroxymronylligothicaele
	hydroxypropyl}isothiazole-3-carboxamide
	$N^{1}$ -{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
2098	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>5</sup> -(1,3-
2030	thiazol-2-yl)pentanediamide
1	N-acetyl-4-chloro-N-{(1S, 2R)-1-(3, 5-
2099	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
2000	hydroxypropyl}phenylalaninamide
	8-chloro-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-
2100	[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-hydroxycinnoline-3-carboxamide
2200	N-{/1c 2p) 1 /2 5 distance
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-ethylbenzyl)aminol 2 hydroxyllaminol 3 h$
2101	ethylbenzyl)amino]-2-hydroxypropyl}-2,6-
3101	dioxohexahydropyrimidine-4-carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-4-(5-
2102	methyl-4-phenyl-1,3-oxazol-2-yl)benzamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-
2103	phenylimidazo[1,2-a]pyridine-6-carboxamide
	N-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
,	ethylbenzyl)amino]-2-hydroxypropyl}-3-[3-(4-
	methoxyphenyl)-1,2,4-oxadiazol-5-
2104	yl]propanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-(4-
	methyl-1,2,3-thiadiazol-5-yl)-1,3-thiazole-4-
2105	carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-
2106	2-phenyl-2H-1,2,3-triazole-4-carboxamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(3-
2107	pyridin-2-yl-1,2,4-oxadiazol-5-yl)butanamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-1,3-
2100	dimethyl-1H-thieno[2,3-c]pyrazole-5-
2108	carboxamide
•	4-(1,3-benzodioxol-5-yl)-N-{(1S,2R)-1-(3,5-
2109	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
2107	hydroxypropyl}butanamide
	N-{(1s, 2r)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-
2110	5-(4-methyl-1,2,3-thiadiazol-5-yl)isoxazole-4-carboxamide
	N <sup>1</sup> -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[2-
	(dimethylamino)-1-methylethyl]amino}-2-
	hydroxypropyl) -5-methyl-N <sup>3</sup> , N <sup>3</sup> -
2111	dipropylisophthalamide
	N <sup>1</sup> -[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
2112	3-(2-methylmorpholin-4-yl)propyl]-5-methyl-
<del></del>	

1

	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^1$ -((1S, 2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{2-[hydroxy(phenyl)methyl]-4-
0112	methylpiperazin-1-yl}propyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
2113	dipropylisophthalamide
	$N^1$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[(2R)-2-methylbuty1]amino}propyl)-5-
2114	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^{1}$ -[(1S, 2R)-3-{[4-(diethylamino)-1-
	methylbutyl]amino}-1-(3,5-difluorobenzyl)-2-
	hydroxypropyl]-5-methyl- $N^3$ , $N^3$ -
2115	dipropylisophthalamide
	$N^1$ -{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-[(2-hydroxy-1,1-
	dimethylethyl) amino]propyl}-5-methyl- $N^3$ , $N^3$ -
2116	dipropylisophthalamide
-	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[3-(2-methylpiperidin-1-
	y1)propy1]amino)propy1)-5-methy1-N3,N3-
2117	dipropylisophthalamide
	$N^1$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-{[5-(trifluoromethyl)-1,3,4-thiadiazol-2-
	yl]aminopropyl)-5-methyl-N3, N3-
2118	dipropylisophthalamide
	$N^1$ -{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-[(3-methyl-4,5,6,7-tetrahydro-3H-3lambda4-
	[1,3]thiazolo[5,4-c]pyridin-2-
	yl)amino]propyl}-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
2119	dipropylisophthalamide
	$N^1$ -[(1S,2R)-3-[(3-ethylbenzyl)amino]-2-
	hydroxy-1-(1H-pyrazol-1-ylmethyl)propyl]-5-
2120	methyl-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide
	3,5-bis(acetylamino)-N-{(1S,2R)-1-(3,5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
2121	hydroxypropyl}benzamide
	$N^1$ -[4-(aminosulfonyl)phenyl]- $N^4$ -{(1S,2R)-1-
	(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-
2122	hydroxypropyl}succinamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-
2123	[methyl(methylsulfonyl)amino]benzamide
	1-acety1-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-
	[(3-ethylbenzyl)amino]-2-
2124	hydroxypropyl}piperidine-4-carboxamide
	$N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-3-(4-
2125	methoxyphenoxy) propanamide
	$N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-$
2126	ethylbenzyl)amino]-2-hydroxypropyl}-N4-
<u> </u>	

	mothyl quasin - 1
	methylsuccinamide
	$N^{1} - \{(1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - [(3 - difluorobenzy1)] - [(3 - difluorobenzy1)] - 3 - [(3 - difluorobenzy1)] - [(3 - difluorobenzy1)] - [$
2127	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>4</sup> -(2,6-
2127	dimethylphenyl) succinamide
	$N-acetyl-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-$
2128	[(3-ethylbenzyl)amino]-2-hydroxypropyl}-D-
2120	phenylalaninamide
	N-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
2129	ethylbenzyl)amino]-2-hydroxypropyl}-2-[(4-
2129	methylphenyl)sulfonyl]acetamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
2130	ethylbenzyl)amino]-2-hydroxypropyl}-2-
2130	{[(ethylamino)carbonyl]amino}benzamide
	N-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-1-phenyl-
2131	1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-
2131	carboxamide
	4-(cyclopentyloxy)-N-{(1S,2R)-1-(3,5-
2132	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
2132	hydroxypropyl}benzamide
	$N^1 - \{(1S, 2R) - 1 - (3, 5 - \text{difluorobenzyl}) - 3 - [(3 - \text{difluorobenzyl})] - [(3 - \text{difluorobenzyl})] - [(3 - \text{difluorobenzyl})] - [(3 - \text{difluorobenzyl})] - [(3 - \text{difluorobenzyl})] - [(3 - \text{difluorobenzyl})]$
2133	ethylbenzyl)amino]-2-hydroxypropyl}-N4- pyridin-3-ylsuccinamide
	$N^1 - \{(1S, 2R) - 1 - (3, 5 - \text{difluorobenzy1}) - 3 - [(3 - \text{ethylbonzy1}) - 3 - [(3 - \text{ethylbonzy1})] - [(3 - \text{ethylbonzy1})]$
2134	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>4</sup> -phenylsuccinamide
2131	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3,4-
2135	dihydroxybenzamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-5-(1H-
2136	1,2,4-triazol-1-yl)pentanamide
	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-phenyl-
2137	1,3-oxazole-4-carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-7-
	methoxy-4-oxo-1,2,3,4-tetrahydronaphthalene-
2138	2-carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-{4-
	[(methylsulfonyl)amino]phenyl}-4-
2139	oxobutanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-
2140	hydroxy-7-methoxy-1-benzofuran-5-carboxamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-4-
	hydroxy-7-methoxy-1-benzothiophene-5-
2141	carboxamide

$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzyl)]$	
ethylbenzyl)amino]-2-hydroxypropyl}-3,6,6-	
trimethyl-4-oxo-4,5,6,7-tetrahydro-1-	
2142 benzofuran-2-carboxamide	
$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]$	
ethylbenzyl)amino]-2-hydroxypropyl}-5,6-	
dihydro-4H-cyclopenta[b]thiophene-2-	
2143 carboxamide	
$N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-$	
ethylbenzyl)amino]-2-hydroxypropyl}-1,3-	
2144 thiazole-4-carboxamide	
$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$	
ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-	
2145 pyridin-2-yl-1,3-thiazol-4-yl)acetamide	
$N^{1}$ -[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl	. ] –
$N^4 - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - [ (3 - 3) - 3 - 3] \}$	
ethylbenzyl)amino]-2-	
2146 hydroxypropyl}succinamide	
$N-\{(1s, 2r)-1-(3, 5-difluorobenzyl)-3-[(3-mu)]$	
ethylbenzyl)amino]-2-hydroxypropyl}-3-	
2147 hydroxy-6-neopentylpyridine-2-carboxamide	<del></del> .
$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$	
ethylbenzyl)amino]-2-hydroxypropyl}-1-(4-	
fluorophenyl)-1,4,5,6-	
2148 tetrahydrocyclopenta[c]pyrazole-3-carboxam	ide_
$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$	
ethylbenzyl)amino]-2-hydroxypropyl}-2-methy	
5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]azepin	ne-
2149 3-carboxamide	
$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$	
ethylbenzyl)amino]-2-hydroxypropyl}-2-methy	<sub>7</sub> 1-
2150 3-furamide	
N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	
ethylbenzyl)amino]-2-hydroxypropyl}-3-	
2151 furamide	
$N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-$	
ethylbenzyl)amino]-2-hydroxypropyl}-4-(2-	
2152 hydroxyethoxy)benzamide	
$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$	
ethylbenzyl)amino]-2-hydroxypropyl}thiopher	ne-
2153 2-carboxamide	
$N^{1}-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-2)]$	
ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> ,N <sup>2</sup> -	
2154 dimethylphthalamide	
$N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-$	_
ethylbenzyl)amino]-2-hydroxypropyl}-5-methy	y1-
2155 2-phenyl-1,3-oxazole-4-carboxamide	
2155	
2155 2-phenyl-1,3-oxazole-4-carboxamide	-

	1.3.1.1.
	hydroxybutanamide
	2-(2H-1,2,3-benzotriazol-2-yl)-N-{(1S,2R)-1-
2157	(3,5-difluorobenzyl)-3-[(3-
2157	ethylbenzyl)amino]-2-hydroxypropyl}butanamide
	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
2150	ethylbenzyl)amino]-2-hydroxypropyl}-1H-
2158	indazole-3-carboxamide
	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
2159	ethylbenzyl)amino]-2-hydroxypropyl}-3-
2159	hydroxyquinoxaline-2-carboxamide
	2-(acetylamino)-N-{(1S,2R)-1-(3,5-
ļ	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
21.60	hydroxypropyl}-4,5-dimethylthiophene-3-
2160	carboxamide
}	$N^{1}$ -(2-cyanophenyl)- $N^{4}$ -{(1S, 2R)-1-(3, 5-
2161	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
2161	hydroxypropyl}succinamide
	N-{(1s,2R)-1-(3,5-difluorobenzy1)-3-[(3-
2162	ethylbenzyl)amino]-2-hydroxypropyl}-1-ethyl-
2102	1H-indole-2-carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
2163	ethylbenzyl)amino]-2-hydroxypropyl}-1-
2103	benzofuran-2-carboxamide
	1-benzyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-
2164	[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3,5-
2164	dimethyl-1H-pyrazole-4-carboxamide
	$N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-difluorobenzyl)]$
2165	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -[(4-
2103	methylphenyl)sulfonyl]glycinamide
	N-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
2166	ethylbenzyl)amino]-2-hydroxypropyl}-4,8-
2100	dihydroxyquinoline-2-carboxamide
	N-{(1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-
2167	ethylbenzyl)amino]-2-hydroxypropyl}-2-(1,1-
2101	dioxidotetrahydrothien-3-yl)acetamide
	methyl 5-[({(1s,2R)-1-(3,5-difluorobenzyl)-3-
	[(3-ethylbenzyl)amino]-2-
2168	hydroxypropyl amino) carbonyl ] -1H-
2100	benzimidazol-2-ylcarbamate
	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
2169	ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-
	methyl-1,3-benzoxazol-5-yl)acetamide
İ	N-{(1s, 2r)-1-(3, 5-difluorobenzyl)-3-[(3-
İ	ethylbenzyl)amino]-2-hydroxypropyl}-2-
2170	[ethyl(methyl)amino]-4-hydroxypyrimidine-5-carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)-minol 2 hydroxyn   3   2   2   2   2   2   2   2   2   2
2171	ethylbenzyl) amino] -2-hydroxypropyl} -2-(2-
2172	pyridin-4-yl-1,3-benzoxazol-5-yl)acetamide
	$4-[2-(diethylamino)ethoxy]-N-{(1S,2R)-1-(3,5-$

	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
	hydroxypropyl}benzamide
	3-(aminosulfonyl)-4-chloro-N-{(1S,2R)-1-(3,5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
2173	hydroxypropyl}benzamide
	2-(diethylamino)-N-{(1S,2R)-1-(3,5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
	hydroxypropyl}-4-hydroxypyrimidine-5-
2174	carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-5,6,7,8-
	tetrahydro-4H-cyclohepta[c]isoxazole-3-
2175	carboxamide
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-N4,N4-
2176	diphenylsuccinamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-6-
2177	hydroxy-4-methylpyridine-2-carboxamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-2-
2178	phenylimidazo[1,2-a]pyridine-7-carboxamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}quinoline-
2179	4-carboxamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-2-(1,3-
	dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-9H-
2180	purin-9-yl)acetamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-5-
2181	methoxy-1H-indole-2-carboxamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(3,5-
2182	dimethyl-1H-pyrazol-1-yl)benzamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-5-
2183	methylisoxazole-3-carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-
2184	methylisoxazole-5-carboxamide
· .	2-(1-benzothien-4-yl)-N-{(1S,2R)-1-(3,5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
2185	hydroxypropyl}acetamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-
	4-oxo-4,5,6,7-tetrahydro-1H-indole-2-
2186	carboxamide
1	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
2187	ethylbenzyl)amino]-2-hydroxypropyl}-1-

	benzothiophene-2-carboxamide
	N={/1g 2p}_1 /2 5 3451
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
2188	ethylbenzyl)amino]-2-hydroxypropyl}-6-
2100	hydroxynicotinamide
	$N^{1} - \{(1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [(3 - difluorobenzyl)] - 3 - [(3 - difluorobenz$
2189	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> -[(4-
2109	methylphenyl)sulfonyl]-beta-alaninamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzyl)]$
2100	ethylbenzyl)amino]-2-hydroxypropyl}-2-
2190	hydroxyquinoline-4-carboxamide
	N-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
0101	ethylbenzyl)amino]-2-hydroxypropyl}-2-(5-
2191	phenyl-1H-tetraazol-1-yl)acetamide
	4-{[(cyclobutylcarbonyl)amino]methyl}-N-
0100	{(1s, 2r)-1-(3,5-difluorobenzyl)-3-[(3-
2192	ethylbenzyl)amino]-2-hydroxypropyl}benzamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
04.00	ethylbenzyl)amino]-2-hydroxypropyl}-4-(2-oxo-
2193	1,3-benzoxazol-3(2H)-yl)butanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
0101	ethylbenzyl)amino]-2-hydroxypropyl}-2-(1,3-
2194	dioxooctahydro-2H-isoindol-2-yl)butanamide
	$N^{2}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -
2195	(tetrahydrofuran-2-ylmethyl)phthalamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
0.4.0.5	ethylbenzyl)amino]-2-hydroxypropyl}-4-(2,3-
2196	dihydro-1H-indol-1-yl)-4-oxobutanamide
	N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
	ethylbenzyl)amino]-2-
04.00	hydroxypropyl}thieno[3,2-b]pyridine-6-
2197	carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
0400	ethylbenzyl)amino]-2-hydroxypropyl}-2-[(6-
2198	methoxy-1H-benzimidazol-2-yl)thio]acetamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
·	ethylbenzyl)amino]-2-
04.00	hydroxypropyl}thieno[2,3-c]pyridine-2-
2199	carboxamide
	2-(1H-benzimidazol-2-ylthio)-N-{(1S,2R)-1-
	(3,5-difluorobenzyl)-3-[(3-
222	ethylbenzyl)amino]-2-
2200	hydroxypropyl}propanamide
	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
2001	ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2,4-
2201	difluorobenzyl)oxylpropanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-5.6-
2222	dimethyl-4-oxo-3,4-dihydrothieno[2,3-
2202	d]pyrimidine-2-carboxamide

	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-1-(2-
2203	fluorophenyl)-5-oxopyrrolidine-3-carboxamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(5-
2204	methyl-1H-tetraazol-1-yl)benzamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-2-(4,4-
	dimethyl-4,5-dihydro-1,3-oxazol-2-
2205	yl)thiophene-3-carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-5-
2206	(trifluoromethoxy)-1H-indole-2-carboxamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-1-phenyl-
2207	5-propyl-1H-pyrazole-4-carboxamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-5-
2208	[(pyridin-2-ylthio)methyl]-2-furamide
	5-chloro-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-
	[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-
2209	morpholin-4-ylpyrimidine-4-carboxamide
	$5-chloro-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-}$
	[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-
2210	methyl-1-phenyl-1H-pyrazole-4-carboxamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl,}-4-methyl-
2211	1,2,3-thiadiazole-5-carboxamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-2,1,3-
2212	benzoxadiazole-5-carboxamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-2-
0010	[(imidazo[1,2-a]pyridin-2-
2213	ylmethyl)thiolacetamide
	2-(acetylamino)-N-{(1R, 2R)-1-(3,5-
	difluorobenzyl)-2-hydroxy-3-[(3-
2214	iodobenzyl)amino]propyl}-1,3-oxazole-4-
2214	carboxamide
	$N-\{(1S,2R)-1-[3-(cyclohexylmethyl)benzyl]-2-$
2215	hydroxy-3-[(3-
2217	<pre>methoxybenzyl)amino]propyl}acetamide  1    2-{[({(1S,2R)-1-benzyl-2-hydroxy-3-[(3-benz</pre>
	methoxybenzyl)amino]propyl}amino)carbonyl]ami
	no}-N, N-dipropylethanesulfonamide
2216	hydrochloride
2210	2-(3-azabicyclo[3.2.2]non-3-y1)-N-{(15,2R)-1-
	(3,5-difluorobenzyl)-2-hydroxy-3-[(3-
2217	iodobenzyl)amino]propyl}acetamide
2218	2-(4-benzoylphenoxy)-N-{(1S,2R)-1-(3,5-
2210	12 (4 Delizolative Hova) - M- / (12,2K)-1-(3,3-

	12.62
	difluorobenzyl)-2-hydroxy-3-[(3-
	iodobenzyl)amino]propyl}propanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-
	3-[(3-iodobenzyl)amino]propyl}-4-(7-methoxy-
	2,3-dihydro-1-benzofuran-4-yl)-4-
2219	oxobutanamide
	N-{(1S,2R)-1-[3-(cyclohexylmethyl)benzyl]-2-
	hydroxy-3-[(3-methoxybenzyl)amino]propyl}-3-
	{[(trifluoromethyl)sulfonyl]amino}benzamide
2220	hydrochloride
	$N^{1}$ -{(1s,2R)-1-[3-(cyclohexylmethyl)benzyl]-2-
	hydroxy-3-[(3-methoxybenzyl)amino]propyl}-5-
	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
2221	hydrochloride
2221	
	3-chloro-N-((1S, 2R)-1-(4-fluorobenzyl)-2-
	hydroxy-3-{[3-
2222	(trifluoromethyl)benzyl]amino}propyl)benzamid
2222	e
İ	3-chloro-N-{(1S,2R)-1-(4-fluorobenzyl)-2-
	hydroxy-3-[(3-
2223	methoxybenzyl)amino]propyl}benzamide
	3-chloro-N-((1S,2R)-1-(cyclohexylmethyl)-2-
	hydroxy-3-{[3-
	(trifluoromethyl)benzyl]amino}propyl)benzamid
2224	e
	3-chloro-N-{(1S,2R)-1-(cyclohexylmethyl)-2-
	hydroxy-3-[(3-
2225	methoxybenzyl)amino]propyl}benzamide
	N-((1S,2S)-1-benzyl-2-hydroxy-3-{[3-
	(trifluoromethyl)benzyl]amino}propyl)-3-
2226	chlorobenzamide
	N-{(1S,2S)-1-benzyl-2-hydroxy-3-[(3-
2227	methoxybenzyl)amino]propyl}-3-chlorobenzamide
	3-{[(3-chlorobenzyl)amino]sulfonyl}-N-
	//1C 2P) 1 // fluorehammel
	((1S,2R)-1-(4-fluorobenzyl)-2-hydroxy-3-{[3-
2228	(trifluoromethyl)benzyl]amino}propyl)benzamid
2220	e 2 (1/2 chloughou 1) 1 25
	3-{[(3-chlorobenzyl)amino]sulfonyl}-N-
2220	{(1S,2R)-1-(4-fluorobenzyl)-2-hydroxy-3-[(3-
2229	methoxybenzyl)amino]propyl}benzamide
	3-{[(3-chlorobenzyl)amino]sulfonyl}-N-
	((1S,2R)-1-(cyclohexylmethyl)-2-hydroxy-3-
	[3-
	(trifluoromethyl)benzyl]amino}propyl)benzamid
2230	e
	3-{[(3-chlorobenzyl)amino]sulfonyl}-N-
	{(1S,2R)-1-(cyclohexylmethyl)-2-hydroxy-3-
2231	[(3-methoxybenzyl)amino]propyl}benzamide
	N-{(1s,2s)-1-benzyl-2-hydroxy-3-[(3-
2232	methoxybenzyl)amino]propyl}-3-{[(3-
	1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-

	chlorobenzyl)amino]sulfonyl}benzamide
	N-{(1S, 2R)-1-(4-fluorobenzyl)-2-hydroxy-3-
	[(3-methoxybenzyl)amino]propyl}-3-{[(3-
2233	methoxybenzyl)amino]sulfonyl}benzamide
2233	N-((1S, 2R) -1-(cyclohexylmethyl) -2-hydroxy-3-
2224	{[3-(trifluoromethyl)benzyl]amino}propyl)-3-
2234	{[(3-methoxybenzyl)amino]sulfonyl}benzamide
	N-{(1S, 2R)-1-(cyclohexylmethyl)-2-hydroxy-3-
0025	[(3-methoxybenzyl)amino]propyl}-3-{[(3-
2235	methoxybenzyl)amino]sulfonyl}benzamide
:	N-{(1S,2S)-1-benzyl-2-hydroxy-3-[(3-
,	methoxybenzyl)amino]propyl}-3-{[(3-
2236	methoxybenzyl)amino]sulfonyl}benzamide
	$N^{1}$ -[(1R,2S)-2-hydroxy-3-[(3-
	methoxybenzyl)amino]-1-(4-
,	methylbenzyl)propyl]-N <sup>3</sup> ,N <sup>3</sup> -dipropylbenzene-
2237	1,3,5-tricarboxamide
	$N^{1}$ -[(1R,2S)-2-hydroxy-3-(isopentylamino)-1-(4-
	methylbenzyl)propyl]-N <sup>3</sup> ,N <sup>3</sup> -dipropylbenzene-
2238	1,3,5-tricarboxamide
	$N^{1}$ -[(1R,2S)-2-hydroxy-3-[(3-
	methoxybenzyl)amino]-1-(4-
	methylbenzyl)propyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
2239	dipropylisophthalamide
	$N^{1}$ -[(1R,2S)-2-hydroxy-3-(isopentylamino)-1-(4-
•	methylbenzyl)propyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
2240	dipropylisophthalamide
	$N^{1}$ -[(1R,2S)-2-hydroxy-3-[(3-
	methoxybenzyl)amino]-1-(4-
	methylbenzyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> -
2241	dipropylpentanediamide
	$N^{1}$ -[(1R,2S)-2-hydroxy-3-(isopentylamino)-1-(4-
	methylbenzyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> -
2242	dipropylpentanediamide
	3-[(dipropylamino)sulfonyl]-N-[(1R,2S)-2-
	hydroxy-3-[(3-methoxybenzyl)amino]-1-(4-
2243	methylbenzyl)propyl]propanamide
	3-[(dipropylamino)sulfonyl]-N-[(1R,2S)-2-
:	hydroxy-3-(isopentylamino)-1-(4-
2244	methylbenzyl)propyl]propanamide
	$N^{1}$ -[(1S,2R)-2-hydroxy-3-[(3-
	methoxybenzyl)amino]-1-(4-
	methylbenzyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> -
2245	dipropylpentanediamide
	$N^{1}$ -[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4-
	methylbenzyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> -
2246	dipropylpentanediamide
	$N^{1}$ -[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-(4-
	methylbenzyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> -
2247	dipropylpentanediamide

	N-[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4-
10040	methylbenzyl)propyl]-3-
2248	[(dipropylamino)sulfonyl]propanamide
	3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-2-
0040	hydroxy-3-(isopentylamino)-1-(4-
2249	methylbenzyl)propyl]propanamide
	N-{ (1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
2050	methoxybenzyl)amino]propyl}-3-(4,5-dimethyl-
2250	
	N-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-
0054	methoxybenzyl)amino]propyl}-2-hydroxy-3-
2251	(isopentylsulfonyl)propanamide hydrochloride
	N-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-3-{[(2-
2252	methoxyethyl) (propyl) amino] sulfonyl) propanami
2252	de hydrochloride
	$N^{1}$ -{(1R, 2R)-3-(benzylamino)-2-hydroxy-1-
2252	[(phenylthio)methyl]propyl}-N <sup>3</sup> ,N <sup>3</sup> -
2253	dipropylbenzene-1,3,5-tricarboxamide
	$N^1 - \{(1R, 2R) - 2 - \text{hydroxy} - 3 - (\text{isopentylamino}) - 1 - (\text{isopentylamino}) - 1 - (\text{isopentylamino}) - 1 - (\text{isopentylamino}) - 1 - (\text{isopentylamino}) - 1 - (\text{isopentylamino}) - 1 - (\text{isopentylamino}) - 1 - (\text{isopentylamino}) - 1 - (\text{isopentylamino}) - 1 - (\text{isopentylamino}) - 1 - (\text{isopentylamino}) - 1 - (\text{isopentylamino}) - 1 - (\text{isopentylamino}) - 1 - (\text{isopentylamino}) - 1 - (\text{isopentylamino}) - 1 - (\text{isopentylamino}) - 1 - (\text{isopentylamino}) - 1 - (\text{isopentylamino}) - ($
2254	[(phenylthio)methyl]propyl}-N <sup>3</sup> ,N <sup>3</sup> -
2254	dipropylbenzene-1,3,5-tricarboxamide
	$N^{1} - \{(1S, 2R) - 3 - (benzylamino) - 1 - [4 - (benzylamino)] $
2255	(benzyloxy) benzyl]-2-hydroxypropyl}-N <sup>3</sup> ,N <sup>3</sup> -
	dipropylbenzene-1,3,5-tricarboxamide
	$N^1$ -[(1S,2R)-1-[4-(benzyloxy)benzyl]-2-hydroxy-
2256	3-(isopentylamino)propyl]-N <sup>3</sup> ,N <sup>3</sup> -
2230	dipropylbenzene-1,3,5-tricarboxamide N <sup>1</sup> -[(1S,2R)-2-hydroxy-3-[(3-
	methoxybenzyl)amino]-1-(1-
	naphthylmethyl)propyl]-N <sup>3</sup> ,N <sup>3</sup> -dipropylbenzene-
2257	1,3,5-tricarboxamide
	N <sup>1</sup> -[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-(1-
	naphthylmethyl)propyl]-N³,N³-dipropylbenzene-
2259	1,3,5-tricarboxamide
	$N^{1}$ -[(1S,2R)-1-(2-furylmethyl)-2-hydroxy-3-
	(isopentylamino)propyl]-N <sup>3</sup> ,N <sup>3</sup> -dipropylbenzene-
2260	1,3,5-tricarboxamide
	N <sup>1</sup> -{(1S,2R)-3-(benzylamino)-1-[3-
	(benzyloxy) benzyl]-2-hydroxypropyl}-N <sup>3</sup> , N <sup>3</sup> -
2261	dipropylbenzene-1,3,5-tricarboxamide
	$N^{1}$ -[(1S,2R)-2-hydroxy-1-(4-hydroxybenzyl)-3-
	(isopentylamino)propyl]-N <sup>3</sup> ,N <sup>3</sup> -dipropylbenzene-
2262	1,3,5-tricarboxamide
	$N^{1}$ -((1S)-1-{(1R)-1-hydroxy-2-[(3-
	methoxybenzyl)amino]ethyl}but-3-ynyl)-N <sup>3</sup> ,N <sup>3</sup> -
2263	dipropylbenzene-1,3,5-tricarboxamide
	$N^{1}$ -{(1S)-1-[(1R)-2-(benzylamino)-1-
	hydroxyethyl]but-3-ynyl}-N <sup>3</sup> ,N <sup>3</sup> -
2264	dipropylbenzene-1,3,5-tricarboxamide
<del></del>	

	((10) 1 [(10) 1 ]
	-{(1S)-1-[(1R)-1-hydroxy-2-
I -	sopentylamino)ethyl]but-3-ynyl}-N3,N3-
	propylbenzene-1,3,5-tricarboxamide
	-[(1S,2R)-3-(benzylamino)-1-
	yclohexylmethyl)-2-hydroxypropyl]- $N^3$ , $N^3$ -
	propylbenzene-1,3,5-tricarboxamide
	-[(1S,2R)-1-(cyclohexylmethyl)-2-hydroxy-3-
	sopentylamino)propyl]-N3,N3-dipropylbenzene-
	3,5-tricarboxamide
N <sup>1</sup> ·	-((1S)-1-{(1R)-1-hydroxy-2-[(3-
	thoxybenzyl)amino]ethyl}-3-methylbutyl)-
	,N <sup>3</sup> -dipropylbenzene-1,3,5-tricarboxamide
N <sup>1</sup>	-{(1S)-1-[(1R)-1-hydroxy-2-
(i	sopentylamino) ethyl]-3-methylbutyl $\}-N^3,N^3-$
	propylbenzene-1,3,5-tricarboxamide
N <sup>1</sup>	-{(1R,2R)-3-(benzylamino)-2-hydroxy-1-
	phenylthio)methyl]propyl}-5-methyl-N3,N3-
	propylisophthalamide
	-{(1R,2R)-2-hydroxy-3-(isopentylamino)-1-
[[(	phenylthio)methyl]propyl}-5-methyl-N3,N3-
2272 di	propylisophthalamide
N <sup>1</sup>	-{(1S,2R)-3-(benzylamino)-1-[4-
	enzyloxy)benzyl]-2-hydroxypropyl}-5-methyl-
$2273$ $N^3$	,N <sup>3</sup> -dipropylisophthalamide
N <sup>1</sup>	-[(1S,2R)-1-[4-(benzyloxy)benzyl]-2-hydroxy-
	(isopentylamino)propyl]-5-methyl-N3,N3-
2274   di	propylisophthalamide
N <sup>1</sup>	-[(1S,2R)-2-hydroxy-3-[(3-
	ethoxybenzyl)amino]-1-(1-
na	phthylmethyl)propyl]-5-methyl-N³,N³-
	propylisophthalamide
N <sup>1</sup>	-[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-(1-
na	phthylmethyl)propyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
2277 di	propylisophthalamide
N <sup>1</sup>	-[(1S,2R)-1-(2-furylmethyl)-2-hydroxy-3-
(i	sopentylamino)propyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
2278   di	propylisophthalamide
	-{(1S,2R)-3-(benzylamino)-1-[3-
( t	penzyloxy)benzyl]-2-hydroxypropyl}-5-methyl-
	, N <sup>3</sup> -dipropylisophthalamide
i i	
1	-[(1S,2R)-1-[3-(benzyloxy)benzyl]-2-hydroxy-
3-	
2280 di	-[(1S,2R)-1-[3-(benzyloxy)benzyl]-2-hydroxy- (isopentylamino)propyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> - propylisophthalamide
2280 di N <sup>1</sup>	-[(1S,2R)-1-[3-(benzyloxy)benzyl]-2-hydroxy- (isopentylamino)propyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> - propylisophthalamide -[(1S,2R)-1-(4-fluorobenzyl)-2-hydroxy-3-
2280 di N <sup>1</sup>	-[(1S,2R)-1-[3-(benzyloxy)benzyl]-2-hydroxy- (isopentylamino)propyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> - propylisophthalamide
2280 di N <sup>1</sup> (i 2281 di	-[(1S,2R)-1-[3-(benzyloxy)benzyl]-2-hydroxy- (isopentylamino)propyl]-5-methyl-N³,N³- propylisophthalamide -[(1S,2R)-1-(4-fluorobenzyl)-2-hydroxy-3- sopentylamino)propyl]-5-methyl-N³,N³- propylisophthalamide
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	-[(1S,2R)-1-[3-(benzyloxy)benzyl]-2-hydroxy- (isopentylamino)propyl]-5-methyl-N³,N³- .propylisophthalamide -[(1S,2R)-1-(4-fluorobenzyl)-2-hydroxy-3- .sopentylamino)propyl]-5-methyl-N³,N³- .propylisophthalamide -[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	-[(1S,2R)-1-[3-(benzyloxy)benzyl]-2-hydroxy- (isopentylamino)propyl]-5-methyl-N³,N³- propylisophthalamide -[(1S,2R)-1-(4-fluorobenzyl)-2-hydroxy-3- sopentylamino)propyl]-5-methyl-N³,N³- propylisophthalamide
2280 di N <sup>1</sup> (i 2281 di N <sup>1</sup> (t	-[(1S,2R)-1-[3-(benzyloxy)benzyl]-2-hydroxy- (isopentylamino)propyl]-5-methyl-N³,N³- .propylisophthalamide -[(1S,2R)-1-(4-fluorobenzyl)-2-hydroxy-3- .sopentylamino)propyl]-5-methyl-N³,N³- .propylisophthalamide -[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-

	methoxybenzyl)aminolethyl}but-3-ynyl)-5-
ļ	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	N <sup>1</sup> -{(1S)-1-[(1R)-2-(benzylamino)-1-
2284	hydroxyethyl]but-3-ynyl}-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
2204	dipropylisophthalamide
	$N^{1}-\{ (1S)-1-[ (1R)-1-hydroxy-2-$
2205	(isopentylamino)ethyl]but-3-ynyl}-5-methyl-
2285	N', N'-dipropylisophthalamide
	$N^{1}$ -[(1s,2R)-1-(cyclohexylmethyl)-2-hydroxy-3-
2226	(isopentylamino)propyl]-5-methyl-N <sup>3</sup> .N <sup>3</sup> -
2286	dipropylisophthalamide
	$N^{1}$ -{ (1s) -1-[ (1R) -1-hydroxy-2-
0000	(isopentylamino)ethyl]-3-methylbutyl}-5-
2288	methyl-N³,N³-dipropylisophthalamide
	$N^2 - \{ (1R, 2R) - 2 - \text{hydroxy} - 3 - [(3 - \frac{1}{2})] \}$
	methoxybenzyl)amino]-1-
	[(phenylthio)methyl]propyl}-N <sup>5</sup> ,N <sup>5</sup> -
2289	dipropylpentanediamide
	$N^{1}$ -{(1R,2R)-3-(benzylamino)-2-hydroxy-1-
	[ (phenylthio)methyl]propyl}-N <sup>5</sup> , N <sup>5</sup> -
2290	dipropylpentanediamide
	$N^{1}$ -{(1R,2R)-2-hydroxy-3-(isopentylamino)-1-
0004	[ (phenylthio)methyl]propyl}-N <sup>5</sup> , N <sup>5</sup> -
2291	dipropylpentanediamide
	$N^{1}$ -{(1S,2R)-3-(benzylamino)-1-[4-
0000	(benzyloxy)benzyl]-2-hydroxypropyl}-N <sup>5</sup> ,N <sup>5</sup> -
2292	dipropylpentanediamide
	$N^{1}$ -[(1S,2R)-1-[4-(benzyloxy)benzyl]-2-hydroxy-
0000	3-(isopentylamino)propyl]-N <sup>5</sup> ,N <sup>5</sup> -
2293	dipropylpentanediamide
	$N^{1}$ -[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(1-
2205	naphthylmethyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> -
2295	dipropylpentanediamide
	$N^{1}$ -[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-(1-
2025	naphthylmethyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> -
2296	dipropylpentanediamide
0000	$N^{1}$ -[(1S, 2R)-3-(benzylamino)-1-(2-furylmethyl)-
2298	[2-hydroxypropyl]-N°, N°-dipropylpentanediamide
	N <sup>1</sup> -[(1S, 2R)-1-(2-furylmethyl)-2-hydroxy-3-
0000	(isopentylamino)propyl]-N <sup>5</sup> ,N <sup>5</sup> -
2299	dipropylpentanediamide
	$N^1-\{(1S,2R)-1-[3-(benzyloxy)benzyl]-2-hydroxy-$
2200	3-[(3-methoxybenzyl)amino]propyl}-N <sup>5</sup> .N <sup>5</sup> -
2300	dipropylpentanediamide
	$N^{1}-\{(1S,2R)-3-(benzylamino)-1-[3-$
2224	$(benzyloxy)benzyl]-2-hydroxypropyl}-N^5,N^5-$
2301	dipropylpentanediamide
	$N^{1}$ -[(1S,2R)-1-[3-(benzyloxy)benzyl]-2-hydroxy-
2302	3-(isopentylamino)propyl]-N <sup>5</sup> ,N <sup>5</sup> -dipropylpentanediamide

	$N^{1}$ -[(1S,2R)-3-(benzylamino)-1-(4-
	fluorobenzyl)-2-hydroxypropyl]-N <sup>5</sup> , N <sup>5</sup> -
2304	dipropylpentanediamide
2304	$N^{1}$ -[(1S,2R)-1-(4-fluorobenzyl)-2-hydroxy-3-
	(isopentylamino)propyl]-N <sup>5</sup> , N <sup>5</sup> -
2305	dipropylpentanediamide
2303	N <sup>1</sup> -[(1S,2R)-3-(benzylamino)-2-hydroxy-1-
	(thien-2-ylmethyl)propyl]-N <sup>5</sup> , N <sup>5</sup> -
2306	dipropylpentanediamide
2300	N <sup>1</sup> -[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-
	(thien-2-ylmethyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> -
2307	dipropylpentanediamide
2307	$N^{1}$ -[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4-
2200	hydroxybenzyl)propyl]-N <sup>5</sup> , N <sup>5</sup> -
2308	dipropylpentanediamide N <sup>1</sup> -[(1S,2R)-2-hydroxy-1-(4-hydroxybenzyl)-3-
2200	(isopentylamino)propyl]-N <sup>5</sup> , N <sup>5</sup> -
2309	dipropylpentanediamide
	$N^{1}$ - ((1S) -1 - {(1R) -1 - hydroxy -2 - [(3 -
2310	methoxybenzyl)amino]ethyl}but-3-ynyl)-N <sup>5</sup> ,N <sup>5</sup> -dipropylpentanediamide
2310	$N^1$ -{(1S)-1-[(1R)-2-(benzylamino)-1-
·	hydroxyethyl]but-3-ynyl}- $N^5$ , $N^5$ -
2311	dipropylpentanediamide
2311	$N^1$ -{(1S)-1-[(1R)-1-hydroxy-2-
	$(isopentylamino)ethyl]but-3-ynyl}-N^5, N^5-$
2312	dipropylpentanediamide
2312	N <sup>1</sup> -{(1S,2R)-1-(cyclohexylmethyl)-2-hydroxy-3-
	[(3-methoxybenzyl)amino]propyl}-N <sup>5</sup> , N <sup>5</sup> -
2313	dipropylpentanediamide
2323	$N^{1}$ -[(1S,2R)-3-(benzylamino)-1-
	(cyclohexylmethyl) -2-hydroxypropyl] -N <sup>5</sup> , N <sup>5</sup> -
2314	dipropylpentanediamide
	$N^{1}$ -[(1S,2R)-1-(cyclohexylmethyl)-2-hydroxy-3-
	(isopentylamino)propyl]-N <sup>5</sup> , N <sup>5</sup> -
2315	dipropylpentanediamide
	$N^{1}$ - ((1S) -1 - {(1R) -1 - hydroxy -2 - [(3 -
	methoxybenzyl)amino]ethyl}-3-methylbutyl)-
2316	N <sup>5</sup> , N <sup>5</sup> -dipropylpentanediamide
	$N^{1}-\{(1S)-1-[(1R)-2-(benzylamino)-1-$
	hydroxyethyl]-3-methylbutyl}-N <sup>5</sup> , N <sup>5</sup> -
2317	dipropylpentanediamide
	$N^{1}$ -{(1S)-1-[(1R)-1-hydroxy-2-
	(isopentylamino)ethyl]-3-methylbutyl}-N <sup>5</sup> , N <sup>5</sup> -
2318	dipropylpentanediamide
	3-[(dipropylamino)sulfonyl]-N-{(1R,2R)-2-
	hydroxy-3-[(3-methoxybenzyl)amino]-1-
2319	[(phenylthio)methyl]propyl}propanamide
	N-{(1R,2R)-3-(benzylamino)-2-hydroxy-1-
2320	[(phenylthio)methyl]propyl}-3-
Z3ZU	[[(buenyrthio)metnyr)propyr}-3-

	[(dipropylamino)sulfonyl]propanamide
	3-[(dipropylamino)sulfonyl]-N-{(1R,2R)-2-
	hydroxy-3-(isopentylamino)-1-
2321	[(phenylthio)methyl]propyl}propanamide
	N-{(1S,2R)-3-(benzylamino)-1-[4-
	(benzyloxy)benzyl]-2-hydroxypropyl}-3-
2322	[(dipropylamino)sulfonyl]propanamide
	N-[(1S,2R)-1-[4-(benzyloxy)benzyl]-2-hydroxy-
	3-(isopentylamino)propyl]-3-
2323	[(dipropylamino)sulfonyl]propanamide
	N-[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(1-
	naphthylmethyl)propyl]-3-
2324	[(dipropylamino)sulfonyl]propanamide
	3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-2-
İ	hydroxy-3-(isopentylamino)-1-(1-
2325	naphthylmethyl)propyl]propanamide
	N-[(1S,2R)-3-(benzylamino)-1-(2-furylmethyl)-
	2-hydroxypropyl]-3-
2326	[(dipropylamino)sulfonyl]propanamide
	3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-1-(2-
	furylmethyl)-2-hydroxy-3-
2327	(isopentylamino)propyl]propanamide
	$N-\{(1S,2R)-1-[3-(benzyloxy)benzyl]-2-hydroxy-$
	3-[(3-methoxybenzyl)amino]propyl}-3-
2328	[(dipropylamino)sulfonyl]propanamide
	N-{(1S,2R)-3-(benzylamino)-1-[3-
	(benzyloxy)benzyl]-2-hydroxypropyl}-3-
2329	[(dipropylamino)sulfonyl]propanamide
	N-[(1S,2R)-1-[3-(benzyloxy)benzyl]-2-hydroxy-
	3-(isopentylamino)propyl]-3-
2330	[(dipropylamino)sulfonyl]propanamide
	N-[(1S,2R)-3-(benzylamino)-1-(4-
	fluorobenzyl)-2-hydroxypropyl]-3-
2331	[(dipropylamino)sulfonyl]propanamide
	3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-1-(4-
	fluorobenzyl)-2-hydroxy-3-
2332	(isopentylamino)propyl]propanamide
	N-[(1S,2R)-3-(benzylamino)-2-hydroxy-1-
2222	(thien-2-ylmethyl)propyl]-3-
2333	[(dipropylamino)sulfonyl]propanamide
	3-[(dipropylamino)sulfonyl]-N-((1S)-1-{(1R)-
	1-hydroxy-2-[(3-
2334	methoxybenzyl)amino]ethyl}but-3-
2335	ynyl)propanamide
2000	N'-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy- 3-({3-[(1Z)-prop-1-en-1-
	yl]benzyl}amino)propyl]-5-methyl-N,N-
	dipropylisophthalamide
2335	N-{(1S)-1-[(1R)-2-(benzylamino)-1-
	hydroxyethyl]but-3-ynyl}-3-

<u> </u>	[(dipropylamino)sulfonyl]propanamide
	3-[(dipropylamino)sulfonyl]-N-{(1S)-1-[(1R)-
0006	1-hydroxy-2-(isopentylamino)ethyl]but-3-
2336	ynyl}propanamide
	N-{(1S,2R)-1-(cyclohexylmethyl)-2-hydroxy-3-
	[(3-methoxybenzyl)amino]propyl}-3-
2337	[(dipropylamino)sulfonyl]propanamide
	N-[(1S, 2R)-3-(benzylamino)-1-
	(cyclohexylmethyl)-2-hydroxypropyl]-3-
2338	[(dipropylamino)sulfonyl]propanamide
	methyl $[3-(\{[(2R,3S)-4-(3,5-difluorophenyl)-$
	3-({3-[(dipropylamino)carbonyl]-5-
	methylbenzoyl}amino)-2-
	hydroxybutyl]amino}methyl)phenyl]methylcarbam
2339	ate
	N-[(1S,2R)-1-(cyclohexylmethyl)-2-hydroxy-3-
	(isopentylamino)propyl]-3-
2339	[(dipropylamino)sulfonyl]propanamide
	$3-[(dipropylamino)sulfonyl]-N-((1S)-1-{(1R)-}$
	1-hydroxy-2-[(3-methoxybenzyl)amino]ethyl}-3-
2340	methylbutyl)propanamide
	N-{(1S)-1-[(1R)-2-(benzylamino)-1-
0041	hydroxyethyl]-3-methylbutyl}-3-
2341	[(dipropylamino)sulfonyl]propanamide
	3-[(dipropylamino)sulfonyl]-N-{(1S)-1-[(1R)-
2240	1-hydroxy-2-(isopentylamino)ethyl]-3-
2342	methylbutyl}propanamide
	$N^{1}-[(1S, 2R)-3-(benzylamino)-2-hydroxy-1-(3-$
2242	methoxybenzyl)propyl]-N <sup>3</sup> , N <sup>3</sup> -dipropylbenzene-
2343	1,3,5-tricarboxamide
	$N^{1}$ -[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-(4-
2346	isopropylbenzyl)propyl]-N <sup>3</sup> ,N <sup>3</sup> -dipropylbenzene-
4340	1,3,5-tricarboxamide
	N <sup>1</sup> -[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4-methoxybenzyl)propyl]-N <sup>3</sup> , N <sup>3</sup> -dipropylbenzene-
2348	
4340	1,3,5-tricarboxamide $N^{1}$ -[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-(4-
	methoxybenzyl)propyl]-N <sup>3</sup> , N <sup>3</sup> -dipropylbenzene-
2349	
4343	1,3,5-tricarboxamide N <sup>1</sup> -[(1S,2R)-3-(benzylamino)-1-(4-fluoro-3-
	$N^{-}$ ((15,2R)-3-(Denzylamino)-1-(4-fluoro-3- methylbenzyl)-2-hydroxypropyl]- $N^{3}$ , $N^{3}$ -
2350	dipropylbenzene-1,3,5-tricarboxamide
2330	$N^{1}$ -[(1S, 2R)-1-(3-fluoro-4-methoxybenzyl)-2-
	hydroxy-3-(isopentylamino)propyl]-N <sup>3</sup> , N <sup>3</sup> -
2351	dipropylbenzene-1,3,5-tricarboxamide
2351	$N^{1}$ -[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4-
	isopropylbenzyl)propyl]-5-methyl-N <sup>3</sup> , N <sup>3</sup> -
2352	dipropylisophthalamide
2334	$N^{1}$ -[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-(4-
2353	isopropylbenzyl)propyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
4333	TPODTODATMENTATIONAL -2-MGCHAT-M 'M -

	dipropylisophthalamide
	$N^{1}$ -{(1S,2R)-2-hydroxy-3-(isopentylamino)-1-[3-
	(trifluoromethoxy) benzyl]propyl}-5-methyl-
2354	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^{1}$ -[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4-
	methoxybenzyl)propyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
2355	dipropylisophthalamide
	N <sup>1</sup> -[/19 2P)-2-hydrons 2 //
	$N^{1}$ -[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-(4-
2356	methoxybenzyl)propyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide
	N <sup>1</sup> [(10, 2p), 2, (1, 1, 2, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,
	$N^{1}$ -[(1S,2R)-3-(benzylamino)-1-(4-fluoro-3-
2357	methylbenzyl)-2-hydroxypropyl]-5-methyl-N <sup>3</sup> , N <sup>3</sup> -
2337	dipropylisophthalamide
	N'-((1S, 2R)-1-(3,5-difluorobenzyl)-3-{[(4R)-
	2,2-dioxido-3,4-dihydro-1H-2,1-benzothiazin-
2358	4-yl]amino}-2-hydroxypropyl)-5-methyl-N,N-
2336	dipropylisophthalamide
	$N' - ((1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - {[(4S) - 2R]}$
	2,2-dioxido-3,4-dihydro-1H-2,1-benzothiazin-
2359	4-yl]amino}-2-hydroxypropyl)-5-methyl-N,N-
	dipropylisophthalamide
	$N^1-[(1s,2R)-1-(4-fluoro-3-methylbenzyl)-2-$
2358	nydroxy-3-(isopentylamino)propyll-5-methyl-
2338	N',N'-dipropylisophthalamide
	$N^{1}$ -{(1S,2R)-3-(benzylamino)-2-hydroxy-1-[3-
2250	(trifluoromethyl)benzyl]propyl}-5-methyl-
2359	N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide
	$N^1-[(1S, 2R)-2-hydroxy-3-(isopentylamino)-1-(3-$
2360	metnylbenzyl)propyl]-5-methyl-N <sup>3</sup> .N <sup>3</sup> -
2360	dipropylisophthalamide
	$N^1$ -{(1S,2R)-3-(benzylamino)-1-[3-(benzyloxy)-
22.61	5-Iluorobenzyl]-2-hydroxypropyl}-5-methyl-
2361	N', N'-dipropylisophthalamide
	$N^{1}$ -[(1S, 2R)-3-(benzylamino)-1-(3-fluoro-4-
22.62	methoxybenzyl)-2-hydroxypropyl]-5-methyl-
2362	N_,N-dipropylisophthalamide
	$N^2-\{(1S,2R)-2-hydroxy-1-(3-methoxybenzyl)-3-$
00.60	[[(3-methoxybenzyl)amino]propyl}-N <sup>5</sup> .N <sup>5</sup> -
2363	dipropylpentanediamide
	$N^{1}$ -[(1S, 2R)-3-(benzylamino)-2-hydroxy-1-(3-
0264	methoxybenzyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> -
2364	dipropylpentanediamide
	$N^{1}$ -[(1S, 2R)-2-hydroxy-3-(isopentylamino)-1-(3-
22.65	methoxybenzyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> -
2365	dipropylpentanediamide
	N <sup>1</sup> -[(1S, 2R)-3-(benzylamino)-1-(3-chloro-5-
2055	fluorobenzyl)-2-hydroxypropyll-N <sup>5</sup> N <sup>5</sup> -
2366	dipropylpentanediamide
	$N^1$ -[(1S,2R)-1-(3-chloro-5-fluorobenzyl)-2-
2367	hydroxy-3-(isopentylamino)propyl]-N <sup>5</sup> , N <sup>5</sup> -

dipropylpentanediamide	-3-
3-[(3-methoxybenzyl)amino]propyl}-N <sup>5</sup> , N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -[(1S,2R)-3-(benzylamino)-1-(3,5- dichlorobenzyl)-2-hydroxypropyl]-N <sup>5</sup> , N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -[(1S,2R)-1-(3,5-dichlorobenzyl)-2-hydroxy 3-(isopentylamino)propyl]-N <sup>5</sup> , N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -((1S,2R)-2-hydroxy-1-(4-isopropylbenzyl)- [(3-methoxybenzyl)amino]propyl}-N <sup>5</sup> , N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4- isopropylbenzyl)propyl]-N <sup>5</sup> , N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -[(1S,2R)-2-hydroxy-3-(isopentylamino)-1- isopropylbenzyl)propyl]-N <sup>5</sup> , N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-1-[3-fluoro-5- (trifluoromethyl)benzyl]-2-hydroxy-3-[(3- methoxybenzyl)amino]propyl}-N <sup>5</sup> , N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-3-(benzylamino)-1-[3-fluoro-5-	-3-
2368   dipropylpentanediamide   N¹-[(1S,2R)-3-(benzylamino)-1-(3,5-dichlorobenzyl)-2-hydroxypropyl]-N⁵,N⁵-   2369   dipropylpentanediamide   N¹-[(1S,2R)-1-(3,5-dichlorobenzyl)-2-hydroxy   3-(isopentylamino)propyl]-N⁵,N⁵-   dipropylpentanediamide   N¹-{(1S,2R)-2-hydroxy-1-(4-isopropylbenzyl)-[(3-methoxybenzyl)amino]propyl}-N⁵,N⁵-   dipropylpentanediamide   N¹-[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4-isopropylbenzyl)propyl]-N⁵,N⁵-   dipropylpentanediamide   N¹-[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-isopropylbenzyl)propyl]-N⁵,N⁵-   dipropylpentanediamide   N¹-{(1S,2R)-1-[3-fluoro-5-(trifluoromethyl)benzyl]-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-N⁵,N⁵-   dipropylpentanediamide   N¹-{(1S,2R)-3-(benzylamino)-1-[3-fluoro-5-dipropylpentanediamide   N¹-{(1S,2R)-3-(	-3-
N <sup>1</sup> -[(1S,2R)-3-(benzylamino)-1-(3,5-dichlorobenzyl)-2-hydroxypropyl]-N <sup>5</sup> ,N <sup>5</sup> -dipropylpentanediamide	-3-
dichlorobenzyl)-2-hydroxypropyl]-N <sup>5</sup> , N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -[(1S,2R)-1-(3,5-dichlorobenzyl)-2-hydroxy 3-(isopentylamino)propyl]-N <sup>5</sup> , N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-2-hydroxy-1-(4-isopropylbenzyl)- [(3-methoxybenzyl)amino]propyl}-N <sup>5</sup> , N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4-isopropylbenzyl)propyl]-N <sup>5</sup> , N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-isopropylbenzyl)propyl]-N <sup>5</sup> , N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-1-[3-fluoro-5-(trifluoromethyl)benzyl]-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-N <sup>5</sup> , N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-3-(benzylamino)-1-[3-fluoro-5-	-3-
dipropylpentanediamide  N¹-[(1S,2R)-1-(3,5-dichlorobenzyl)-2-hydroxy 3-(isopentylamino)propyl]-N⁵,N⁵-  dipropylpentanediamide  N¹-{(1S,2R)-2-hydroxy-1-(4-isopropylbenzyl)- [(3-methoxybenzyl)amino]propyl}-N⁵,N⁵-  dipropylpentanediamide  N¹-[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4-isopropylbenzyl)propyl]-N⁵,N⁵-  dipropylpentanediamide  N¹-[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-isopropylbenzyl)propyl]-N⁵,N⁵-  dipropylpentanediamide  N¹-{(1S,2R)-1-[3-fluoro-5-(trifluoromethyl)benzyl]-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-N⁵,N⁵-  dipropylpentanediamide  N¹-{(1S,2R)-3-(benzylamino)-1-[3-fluoro-5-	-3-
N <sup>1</sup> -[(1S,2R)-1-(3,5-dichlorobenzyl)-2-hydroxy 3-(isopentylamino)propyl]-N <sup>5</sup> ,N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-2-hydroxy-1-(4-isopropylbenzyl)-[(3-methoxybenzyl)amino]propyl}-N <sup>5</sup> ,N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4-isopropylbenzyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-isopropylbenzyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-1-[3-fluoro-5-(trifluoromethyl)benzyl]-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-N <sup>5</sup> ,N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-3-(benzylamino)-1-[3-fluoro-5-	-3-
3-(isopentylamino)propyl]-N <sup>5</sup> ,N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-2-hydroxy-1-(4-isopropylbenzyl)- [(3-methoxybenzyl)amino]propyl}-N <sup>5</sup> ,N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4-isopropylbenzyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-isopropylbenzyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-1-[3-fluoro-5-(trifluoromethyl)benzyl]-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-N <sup>5</sup> ,N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-3-(benzylamino)-1-[3-fluoro-5-	-3-
dipropylpentanediamide  N¹-{(1S,2R)-2-hydroxy-1-(4-isopropylbenzyl)- [(3-methoxybenzyl)amino]propyl}-N⁵,N⁵-  dipropylpentanediamide  N¹-[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4- isopropylbenzyl)propyl]-N⁵,N⁵-  dipropylpentanediamide  N¹-[(1S,2R)-2-hydroxy-3-(isopentylamino)-1- isopropylbenzyl)propyl]-N⁵,N⁵-  dipropylpentanediamide  N¹-{(1S,2R)-1-[3-fluoro-5- (trifluoromethyl)benzyl]-2-hydroxy-3-[(3- methoxybenzyl)amino]propyl}-N⁵,N⁵-  dipropylpentanediamide  N¹-{(1S,2R)-3-(benzylamino)-1-[3-fluoro-5-	
N <sup>1</sup> -{(1S,2R)-2-hydroxy-1-(4-isopropylbenzyl)- [(3-methoxybenzyl)amino]propyl}-N <sup>5</sup> ,N <sup>5</sup> -  2371 dipropylpentanediamide  N <sup>1</sup> -[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4- isopropylbenzyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> -  2311 dipropylpentanediamide  N <sup>1</sup> -[(1S,2R)-2-hydroxy-3-(isopentylamino)-1- isopropylbenzyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> -  2312 dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-1-[3-fluoro-5- (trifluoromethyl)benzyl]-2-hydroxy-3-[(3- methoxybenzyl)amino]propyl}-N <sup>5</sup> ,N <sup>5</sup> -  2313 dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-3-(benzylamino)-1-[3-fluoro-5-	
[(3-methoxybenzyl)amino]propyl}-N <sup>5</sup> ,N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4- isopropylbenzyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -[(1S,2R)-2-hydroxy-3-(isopentylamino)-1- isopropylbenzyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-1-[3-fluoro-5- (trifluoromethyl)benzyl]-2-hydroxy-3-[(3- methoxybenzyl)amino]propyl}-N <sup>5</sup> ,N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-3-(benzylamino)-1-[3-fluoro-5-	
dipropylpentanediamide  N <sup>1</sup> -[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4-isopropylbenzyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> -  dipropylpentanediamide  N <sup>1</sup> -[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-isopropylbenzyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> -  dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-1-[3-fluoro-5-(trifluoromethyl)benzyl]-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-N <sup>5</sup> ,N <sup>5</sup> -  dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-3-(benzylamino)-1-[3-fluoro-5-	[4-
N <sup>1</sup> -[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4-isopropylbenzyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> -  2311 dipropylpentanediamide  N <sup>1</sup> -[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-isopropylbenzyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> -  2312 dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-1-[3-fluoro-5-(trifluoromethyl)benzyl]-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-N <sup>5</sup> ,N <sup>5</sup> -  2313 dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-3-(benzylamino)-1-[3-fluoro-5-	(4-
isopropylbenzyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -[(1S,2R)-2-hydroxy-3-(isopentylamino)-1- isopropylbenzyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-1-[3-fluoro-5- (trifluoromethyl)benzyl]-2-hydroxy-3-[(3- methoxybenzyl)amino]propyl}-N <sup>5</sup> ,N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-3-(benzylamino)-1-[3-fluoro-5-	(4-
dipropylpentanediamide  N <sup>1</sup> -[(1S,2R)-2-hydroxy-3-(isopentylamino)-1- isopropylbenzyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-1-[3-fluoro-5- (trifluoromethyl)benzyl]-2-hydroxy-3-[(3- methoxybenzyl)amino]propyl}-N <sup>5</sup> ,N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-3-(benzylamino)-1-[3-fluoro-5-	(4-
N <sup>1</sup> -[(1S,2R)-2-hydroxy-3-(isopentylamino)-1- isopropylbenzyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> -  2312 dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-1-[3-fluoro-5- (trifluoromethyl)benzyl]-2-hydroxy-3-[(3- methoxybenzyl)amino]propyl}-N <sup>5</sup> ,N <sup>5</sup> -  2313 dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-3-(benzylamino)-1-[3-fluoro-5-	(4-
isopropylbenzyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-1-[3-fluoro-5- (trifluoromethyl)benzyl]-2-hydroxy-3-[(3- methoxybenzyl)amino]propyl}-N <sup>5</sup> ,N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-3-(benzylamino)-1-[3-fluoro-5-	
dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-1-[3-fluoro-5- (trifluoromethyl)benzyl]-2-hydroxy-3-[(3- methoxybenzyl)amino]propyl}-N <sup>5</sup> ,N <sup>5</sup> -  dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-3-(benzylamino)-1-[3-fluoro-5-	
N <sup>1</sup> -{(1s,2R)-1-[3-fluoro-5- (trifluoromethyl)benzyl]-2-hydroxy-3-[(3- methoxybenzyl)amino]propyl}-N <sup>5</sup> ,N <sup>5</sup> - dipropylpentanediamide N <sup>1</sup> -{(1s,2R)-3-(benzylamino)-1-[3-fluoro-5-	
(trifluoromethyl)benzyl]-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-N <sup>5</sup> ,N <sup>5</sup> - dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-3-(benzylamino)-1-[3-fluoro-5-	
methoxybenzyl)amino]propyl}-N <sup>5</sup> ,N <sup>5</sup> -  2313 dipropylpentanediamide  N <sup>1</sup> -{(1S,2R)-3-(benzylamino)-1-[3-fluoro-5-	
2313 dipropylpentanediamide  N <sup>1</sup> -{(1S, 2R)-3-(benzylamino)-1-[3-fluoro-5-	
N <sup>1</sup> -{(1S,2R)-3-(benzylamino)-1-[3-fluoro-5-	
(trifluoromethyl)benzyl]-2-hydroxypropyl}-	
2314 N <sup>5</sup> , N <sup>5</sup> -dipropylpentanediamide	
N <sup>1</sup> -[(1S, 2R) -1-[3-fluoro-5-	
(trifluoromethyl)benzyl]-2-hydroxy-3-	
(isopentylamino)propyl]-N <sup>5</sup> ,N <sup>5</sup> -	
2315 dipropylpentanediamide	•
$N^{1} - \{(1S, 2R) - 2 - \text{hydroxy} - 3 - [(3 - \frac{1}{2})^{2} - \frac{1}{2} + $	
methoxybenzyl)amino]-1-[3-	
(trifluoromethoxy)benzyl]propyl}-N <sup>5</sup> , N <sup>5</sup> -	
2316 dipropylpentanediamide	
N <sup>1</sup> -{(1S, 2R)-3-(benzylamino)-2-hydroxy-1-[3-	
(trifluoromethoxy)benzyl]propyl}-N <sup>5</sup> , N <sup>5</sup> -	
2317 dipropylpentanediamide	
$N^1 - \{(1S, 2R) - 2 - \text{hydroxy} - 3 - (\text{isopentylamino}) - 1 - (\text{isopentylamino}) - 1 - (\text{isopentylamino}) - 1 - (\text{isopentylamino}) - 1 - (\text{isopentylamino}) - 1 - (\text{isopentylamino}) - (is$	[3-
(trifluoromethoxy)benzyl]propyl}-N <sup>5</sup> ,N <sup>5</sup> -	
2318 dipropylpentanediamide	
N <sup>1</sup> -[(1S, 2R)-3-(benzylamino)-1-(3-fluoro-4-	
methylbenzyl)-2-hydroxypropyl]-N <sup>5</sup> ,N <sup>5</sup> -	
2319 dipropylpentanediamide	
$N^1$ -[(1S,2R)-1-(3-fluoro-4-methylbenzyl)-2-	
hydroxy-3-(isopentylamino)propyl]-N <sup>5</sup> ,N <sup>5</sup> -	
2320 dipropylpentanediamide	
$N^{1}$ -{(1S,2R)-2-hydroxy-1-(4-methoxybenzyl)-3	-
[(3-methoxybenzyl)amino]propyl}-N <sup>5</sup> ,N <sup>5</sup> -	
2321 dipropylpentanediamide	
2322 N <sup>1</sup> -[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4-	

	methoxybenzyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> -
ļ	dipropylpentanediamide
	$N^1$ -[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-(4-
2222	methoxybenzyl)propyl]-N <sup>5</sup> ,N <sup>5</sup> -
2323	dipropylpentanediamide
	$N^1$ -{(1s,2r)-1-(4-chlorobenzyl)-2-hydroxy-3-
2224	[(3-methoxybenzyl)amino]propyl}-N <sup>5</sup> ,N <sup>5</sup> -
2324	dipropylpentanediamide
	$N^{1}-[(1S, 2R)-3-(benzylamino)-1-(4-$
0205	chlorobenzyl)-2-hydroxypropyl]-N <sup>5</sup> ,N <sup>5</sup> -
2325	dipropylpentanediamide
	$N^{1}$ -[(1S,2R)-1-(4-chlorobenzyl)-2-hydroxy-3-
	(isopentylamino)propyl]-N <sup>5</sup> ,N <sup>5</sup> -
2326	dipropylpentanediamide
	$N^{1}$ -{ (1S,2R)-1-(1,3-benzodioxol-5-ylmethyl)-2-
	hydroxy-3-[(3-methoxybenzyl)aminolpropyl}-
2327	N <sup>5</sup> , N <sup>5</sup> -dipropylpentanediamide
	$N^{1}$ -[(1S,2R)-1-(1,3-benzodioxol-5-ylmethyl)-3-
	(benzylamino) $-2$ -hydroxypropyl] $-N^5$ , $N^5$ -
2328	dipropylpentanediamide
	$N^{1}$ -[(1S,2R)-1-(1,3-benzodioxol-5-ylmethyl)-2-
	hydroxy-3-(isopentylamino)propyl]- $N^5$ , $N^5$ -
2329	dipropylpentanediamide
	$N^1$ -{(1S,2R)-1-(4-fluoro-3-methylbenzyl)-2-
	hydroxy-3-[(3-methoxybenzyl)aminolpropyl}-
2330	N <sup>5</sup> , N <sup>5</sup> -dipropylpentanediamide
	$N^{1}$ -[(1S,2R)-3-(benzylamino)-1-(4-fluoro-3-
	methylbenzyl)-2-hydroxypropyl]-N <sup>5</sup> ,N <sup>5</sup> -
2331	dipropylpentanediamide
	$N^{1}$ -[(1S,2R)-1-(4-fluoro-3-methylbenzyl)-2-
	hydroxy-3-(isopentylamino)propyl]-N <sup>5</sup> ,N <sup>5</sup> -
2332	dipropylpentanediamide
	$N^{1}$ -{(1s,2R)-3-(benzylamino)-2-hydroxy-1-[3-
	(trifluoromethyl)benzyl]propyl}-N <sup>5</sup> ,N <sup>5</sup> -
2333	dipropylpentanediamide
	$N^{1}$ -[(1S,2R)-2-hydroxy-3-[(3-
	methoxybenzyl)amino]-1-(3-
	methylbenzyl)propyl]-N <sup>5</sup> , N <sup>5</sup> -
2335	dipropylpentanediamide
	$N^{1}$ -[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(3-
	methylbenzyl)propyl]-N <sup>5</sup> , N <sup>5</sup> -
2336	dipropylpentanediamide
	$N^{1}$ -[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-(3-
	methylbenzyl)propyl]-N <sup>5</sup> , N <sup>5</sup> -
2337	dipropylpentanediamide
	$N^{1}$ -{(1S, 2R)-1-[3-(benzyloxy)-5-fluorobenzyl]-
	2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-
2338	N <sup>5</sup> , N <sup>5</sup> -dipropylpentanediamide
	$N^1$ -{(1S,2R)-3-(benzylamino)-1-[3-(benzyloxy)-
2339	5-fluorobenzy1]-2-hydroxypropy1}-N <sup>5</sup> , N <sup>5</sup> -
	-1-1 - 1-1 cr 21/hr 0h1 1 14 /14 -

	dipropylpentanediamide
	$N^{1}$ -[(1S,2R)-1-[3-(benzyloxy)-5-fluorobenzyl]-
	2-hydroxy-3-(isopentylamino)propyl]-N <sup>5</sup> ,N <sup>5</sup> -
2340	dipropylpentanediamide
2340	$N^1$ -{(1s,2R)-1-(3-fluoro-4-methoxybenzyl)-2-
	hydroxy-3-[(3-methoxybenzyl)amino]propyl}-
2341	N <sup>5</sup> , N <sup>5</sup> -dipropylpentanediamide
2341	$N^{1}$ -[(1S,2R)-3-(benzylamino)-1-(3-fluoro-4-
	methoxybenzyl)-2-hydroxypropyl]-N <sup>5</sup> , N <sup>5</sup> -
2342	dipropylpentanediamide
2342	$N^{1}$ -[(1S,2R)-1-(3-fluoro-4-methoxybenzyl)-2-
	hydroxy-3-(isopentylamino)propyl]-N <sup>5</sup> , N <sup>5</sup> -
2343	dipropylpentanediamide
2343	$N^{1}$ -[(1S,2R)-3-(benzylamino)-1-(3-bromobenzyl)-
2344	2-hydroxypropyl]-N <sup>5</sup> , N <sup>5</sup> -dipropylpentanediamide
2344	$N^{1}$ -[(1S, 2R)-1-(3-bromobenzyl)-2-hydroxy-3-
	(isopentylamino)propyl]-N <sup>5</sup> , N <sup>5</sup> -
2345	dipropylpentanediamide
2343	N-[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(3-
	methoxybenzyl)propyl]-3-
2346	[(dipropylamino)sulfonyl]propanamide
2340	3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-2-
	hydroxy-3-(isopentylamino)-1-(3-
2347	methoxybenzyl)propyl]propanamide
4341	N-[(1S,2R)-3-(benzylamino)-1-(3,5-
•	dichlorobenzyl)-2-hydroxypropyl]-3-
2348	[(dipropylamino)sulfonyl]propanamide
	3-[(dipropylamino)sulfonyl]-N-{(1S,2R)-2-
	hydroxy-1-(4-isopropylbenzyl)-3-[(3-
2349	methoxybenzyl)amino]propyl}propanamide
	N-[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4-
	isopropylbenzyl)propyl]-3-
2350	[(dipropylamino)sulfonyl]propanamide
	3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-2-
	hydroxy-3-(isopentylamino)-1-(4-
2351	isopropylbenzyl)propyl]propanamide
	N-{(1S,2R)-3-(benzylamino)-1-[3-fluoro-5-
	(trifluoromethyl)benzyl]-2-hydroxypropyl}-3-
2352	[(dipropylamino)sulfonyl]propanamide
:	3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-1-[3-
	fluoro-5-(trifluoromethyl)benzyl]-2-hydroxy-
2353	3-(isopentylamino)propyl]propanamide
	N-{(1S,2R)-3-(benzylamino)-2-hydroxy-1-[3-
	(trifluoromethoxy)benzyl]propyl}-3-
2354	[(dipropylamino)sulfonyl]propanamide
	N-[(1S,2R)-3-(benzylamino)-1-(3-fluoro-4-
	methylbenzyl)-2-hydroxypropyl]-3-
2355	[(dipropylamino)sulfonyl]propanamide
	3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-1-(3-
2356	fluoro-4-methylbenzyl)-2-hydroxy-3-

<b> </b>	(isopentylamino)propyl]propanamide
	3-1 (dipropylamino) sulfonvil $-N-1$ (10, 20)
	$\frac{11}{2}$ $\frac{1}{2}$ $\frac{1}{2}$ $\frac{1}{2}$
2357	metnoxybenzyl)aminolpropyl}propanamido
	N-[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4-
2358	methoxypenzyi)propvi]-3-
	[(dipropylamino)sulfonyllpropagamide
	3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-2-
	$\mu_{\text{UV}}$ (1sopentylamino) $\mu_{\text{UV}} = 1$
2359	methoxybenzyl)propyl]propanamide
	N-[(1S,2R)-3-(benzylamino)-1-(4-
	chlorobenzyl)-2-hydroxypropyl]-3-
2360	[(dipropylamino)sulfonyl]propanamide
	N-[(1s, 2r)-1-(4-chlorobenzyl)-2-hydroxy-3-
	(isopentylamino)propyl]-3-
2314	[(dipropylamino)sulfonyl]propanamide
	N-[(1S, 2R)-1-(1, 3-benzodioxol-5-ylmethyl)-3-
	(benzylamino) -2-hydroxypropyl]-3-
2315	[(dipropylamino)sulfonyl]propanamide
	N-[(1S.2R)-1-(1.3 homes discontinuo
	N-[(1s,2r)-1-(1,3-benzodioxol-5-ylmethyl)-2-hydroxy-3-(isopentylamino)propyl]-3-
2316	[(dipropylamino)gulforull
	[(dipropylamino)sulfonyl]propanamide
	3-[(dipropylamino)sulfonyl]-N-{(1S,2R)-1-(4-
2317	fluoro-3-methylbenzyl)-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}propanamide
	N-[(1s,2R)-3-(benzylamino)-1-(4-fluoro-3-
2318	methylbenzyl)-2-hydroxypropyl]-3-
	[(dipropylamino)sulfonyl]propanamide
	3-[(dipropylamino)sulfonyl]-N-[(15,2R)-1-(4-
2319	fluoro-3-methylbenzyl)-2-hydroxy-3-
	(isopentylamino)propyl]propanamide
	N-{(1s,2r)3-(benzylamino)-2-hydroxy-1-[3-
2320	(trifluoromethyl)benzyl]propyl}-3-
	[(dipropylamino)sulfonyl]propanamide
	3-[(dipropylamino)sulfonyl]-N-{(1S,2R)-2-
2321	hydroxy-3-(isopentylamino)-1-[3-
	(trifluoromethyl)benzyl]propyl}propanamide
	N=(15,2R)-3-(benzylamino)-2-hydroxy-1-12
2322	methyrbenzyl)propvl  -3-
	[(dipropylamino)sulfonyl]propanamide
	3-[(dipropylamino)sulfony]]-N-[(1c 2p) 2
323	Hydroxy-3-(isopentylamino)-1-/3-
	methylbenzyl)propyllpropanamide
	$N-\{(1S, 2R) - 3 - (benzylamino) - 1 - (3 - (benzylamino)) - 1 - (3 - (benzylamino)) - (benzylamino) - (benzy$
324	J-Liuolopenzvi -2-hvdroxypropyll 2
J44	[ [ (dipropylamino) sulfonyl lpropagation
	3 - 1  (dipropylamino) sulfonvill-N-1/19 3D) 1 /3
325	[ Ligoro-4-methoxybenzyl ) -2-hydrograp 2 (/2
325	
326	N-[(1s,2R)-3-(benzylamino)-1-(3-fluoro-4-

	methoxybenzyl)-2-hydroxypropyl]-3-
	[(dipropylamino)sulfonyl]propanamide
	3-[(dipropylamino)sulfonyl]-N-[(1S, 2R)-1-(3-
	fluoro-4-methoxybenzyl)-2-hydroxy-3-
2327	(isopentylamino)propyl]propanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-phenyl-
2328	2-(4H-1,2,4-triazol-3-ylthio)acetamide
	1-acetyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-
	[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-
2329	phenylprolinamide

## A compound of the formula:

Compound #	Compound Structure
2330	SN OH H

5

The compounds in the table immediately below were prepared essentially using the methods described above and illustrated below in the schemes.

10

The following compounds were named using the Advanced Chemistry Development Inc. (ACD) nomenclature program, IUPAC Name Batch Version 4.5. The website for ACD is www.acdlabs.com.

2332	$N'-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-$ {[(3R,4S)-3-(hydroxymethyl)-6-isopropyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-
	yl]amino}propyl)-5-methyl-N,N-
	dipropylisophthalamide
2333	$N'-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-\{[(3R,4S)-6-isopropyl-3-methyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}propyl)-5-methyl-N,N-dipropylisophthalamide$
2334	N'-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3- {[(3R,4S)-6-isopropyl-2,2-dioxido-3-propyl-3,4-dihydro-1H-isothiochromen-4-yl]amino}propyl)-5-methyl-N,N-dipropylisophthalamide

2226	
2336	N' - ((1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 2 - hydroxy - 3 -
	$\{[(3S,4R)-3-(hydroxymethyl)-6-isopropyl-2,2-$
ļ	dioxido-3,4-dihydro-1H-isothiochromen-4-
ŀ	yl]amino}propyl)-5-methyl-N,N-
	dipropylisophthalamide
2337	N' - ((1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 -
	{[(3S,4R)-3-(2-hydroxyethyl)-6-isopropyl-2,2-
	dioxido-3,4-dihydro-1H-isothiochromen-4-
	yl]amino}propyl)-5-methyl-N,N-
	dipropylisophthalamide
2339	N' - ((1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 -
	{[(3S,4S)-6-isopropyl-2,2-dioxido-3-propyl-3,4-
	dihydro-1H-isothiochromen-4-yl]amino}propyl)-5-
	methyl-N, N-dipropylisophthalamide
2340	N' - ((1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 -
′	$\{[(3S, 4S) - 6 - isopropyl - 3 - methyl - 2, 2 - dioxido - 3, 4 - \}$
	dihydro-1H-isothiochromen-4-yl]amino}propyl)-5-
	methyl-N, N-dipropylisophthalamide
2341	N' - ((1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 -
	{[(4R)-6-isopropyl-2,2-dioxido-3,4-dihydro-1H-
	isothiochromen-4-yl]amino}propyl)-5-methyl-N, N-
	dipropylisophthalamide

The compounds in the table immediately below were prepared essentially using the methods described above and illustrated below in the schemes.

5

The following compounds were named using the Advanced Chemistry Development Inc. (ACD) nomenclature program, IUPAC Name Batch Version 4.5. The website for ACD is www.acdlabs.com.

22.42	34 6/4 = 0-1
2342	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-[(3-
	methoxypropyl) (methylsulfonyl)amino]benzamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-[(3-
2343	methoxypropyl) (methylsulfonyl)aminolbenzamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-4-[(2-
2344	methoxyethyl)(methylsulfonyl)amino]benzamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-6-[(2-
2345_	methoxyethyl) (methylsulfonyl) amino] nicotinamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-6-[(3-
	hydroxypropyl) (methylsulfonyl) amino] nicotinamid
2346	е

	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
2347	ethylbenzyl)amino]-2-hydroxypropyl}-6-[(2-
2347	hydroxyethyl) (methylsulfonyl) amino]nicotinamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
2348	ethylbenzyl)amino]-2-hydroxypropyl}-6-[(2-
2040	methoxyethyl) (methylsulfonyl) amino] nicotinamide N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-[(2-
	methoxyethyl) (methylsulfonyl) amino] isonicotinam
2349	ide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-5-[(2-
2350	methoxyethyl) (methylsulfonyl) amino]nicotinamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-[(3-
	hydroxypropyl) (methylsulfonyl) amino] isonicotina
2351	mide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-[(2-
	hydroxyethyl) (methylsulfonyl)amino]isonicotinam
2352	ide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-5-[(2-
2353	hydroxyethyl) (methylsulfonyl) amino] nicotinamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ŀ	ethylbenzyl)amino]-2-hydroxypropyl}-5-[(3-
0054	hydroxypropyl) (methylsulfonyl) amino]nicotinamid
2354	e N (/1C 2D) 1 /2 5 3 51 1 1) 2 6/2
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-[(3-
	methorypropyl/mothylgylfonyl/min-lined-selice
2355	<pre>methoxypropyl) (methylsulfonyl) amino] isonicotina mide</pre>
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-5-[(3-
	methoxypropyl) (methylsulfonyl) aminolnicotinamid
2356	e
	N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-1-
2357	(methylsulfonyl)-1H-indole-5-carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
0055	ethylbenzyl)amino]-2-hydroxypropyl}-1-
2358	(methylsulfonyl)indoline-5-carboxamide
•	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
OOEÓ	ethylbenzyl)amino]-2-hydroxypropyl}-1-
2359	(methylsulfonyl)indoline-4-carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
2360	ethylbenzyl)amino]-2-hydroxypropyl}-1-
2300	<pre>(methylsulfonyl)indoline-6-carboxamide N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-</pre>
2361	ethylbenzyl)amino]-2-hydroxypropyl}-1-
2301	ecriving -2-mydroxypropy1}-1-

	(methylgulfonyl) 1 y daniel
	(methylsulfonyl) -1H-indole-4-carboxamide
	N-{(1s, 2r)-1-(3, 5-difluorobenzyl)-3-[(3-
2362	ethylbenzyl)amino]-2-hydroxypropyl}-3-[1-
2502	
	N-{(1s, 2r)-1-(3, 5-difluorobenzyl)-3-[(3-
0000	ethylbenzyl)amino]-2-hydroxypropyl}-4-[1-
2363	metny1-1-(methy1sulfony1)ethy11henzamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzv1)-3-[(3-$
0004	ethylbenzyl)amino]-2-hydroxypropyl}-4-
2364	
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-
2365	(propylsulfonyl)benzamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-
2366	(pentylsulfonyl)benzamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]$
	ethylbenzyl)amino]-2-hydroxypropyl}-4-[(2-
2367	hydroxyethyl)sulfonyl]benzamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-[(2-
2368	methoxyethyl)sulfonyl]benzamide
	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-[(2-
2369	ethoxyethyl)sulfonyl]benzamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-[(3-
2370	hydroxypropyl)sulfonyl]benzamide
	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2,3-
	dihydro-1-benzothiophene-5-carboxamide; 1,1-
2371	dioxide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-1-
2372	benzothiophene-5-carboxamide; 1,1-dioxide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
İ	ethylbenzyl)amino]-2-hydroxypropyl}-2,3-
	dihydro-1-benzothiophene-6-carboxamide; 1,1-
2374	dioxide dioxide; 1,1-
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)aminol 2 bydaning
2375	ethylbenzyl)amino]-2-hydroxypropyl}-1-
2070	benzothiophene-6-carboxamide; 1,1-dioxide
l	N-{(1s, 2r)-1-(3, 5-difluorobenzyl)-3-[(3-
1	ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-
2276	2,3-dihydro-1,2-benzisothiazole-6-carboxamide;
	1,1-dloxide
[	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-
2377	2,3-dinydro-1,2-benzisothiazole-5-carboxamide.
23/71	1,1-dioxide

	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-1-methyl-
	1,3-dihydro-2,1-benzisothiazole-6-carboxamide;
2378	2,2-dioxide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-1-methyl-
	1,3-dihydro-2,1-benzisothiazole-5-carboxamide;
2343	2,2-dioxide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2,2-
2344	dimethylchromane-6-carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2,2-
2345	dimethylchromane-7-carboxamide

The compounds in the table immediately below were prepared essentially using the methods described above and illustrated below in the schemes.

The following compounds were named using the Advanced Chemistry Development Inc. (ACD) nomenclature program, IUPAC Name Batch Version 4.5. The website for ACD is www.acdlabs.com.

	Compound Name(s)
	benzyl (3R)-4-({(1S,2R)-1-benzyl-2-hydroxy-3-
	[(3-methoxybenzyl)amino]propyl}amino)-2,2,3-
2346	trimethyl-4-oxobutanoate
	N-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-4-
2347	(phenylsulfonyl)butanamide
	(3S)-tetrahydrofuran-3-yl (1S,2R)-1-benzyl-2-
	hydroxy-3-[(3-
2348	methoxybenzyl)amino]propylcarbamate
	N <sup>1</sup> -{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-
‡ [	methoxybenzyl)amino]propyl}-N³-(phenylsulfonyl)-
2349	beta-alaninamide
	$N^{1}$ -{ (1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-N³-[(4-
2350	methylphenyl)sulfonyl]-beta-alaninamide
	N <sup>1</sup> -{ (1S, 2R) -1-benzyl-2-hydroxy-3-[ (3-
	methoxybenzyl)amino]propyl}-N³-[(4-
2351	fluorophenyl)sulfonyl]-beta-alaninamide
	$N^{1}$ -{ (1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-N³-[(4-
2352	methoxyphenyl)sulfonyl]-beta-alaninamide

	$N^{1}$ -{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-N <sup>2</sup> -[(4-
2353	
	$N^{1}$ -{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-
	methoxybenzyl) amino] propyl $\}-N^2-[(4-$
2354	1 3 3 - 2 4
	$N^{1}$ -{ (1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}- $N^2$ -[(4-
2355	<del></del>
	N-{ (1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-3-[(4-
2356	chlorophenyl)sulfonyl]propanamide
	$N^{1}$ -{ (1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
ļ	methoxybenzyl)amino]propyl}-N <sup>2</sup> -
2357	(benzylsulfonyl)glycinamide
	N-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-3-[(4-
2358	fluorophenyl)sulfonyl]propanamide
	N <sup>1</sup> -{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-N <sup>3</sup> -[(4-
2359	chlorophenyl)sulfonyl]-beta-alaninamide
	N <sup>1</sup> -{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-N³-(benzylsulfonyl)-
2360	beta-alaninamide
	N-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-3-[(4-
2361	methoxyphenyl)sulfonyl]propanamide
	N-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-3-[(4-
2362	methylphenyl)sulfonyl]propanamide
	$N^{1}$ -benzyl- $N^{4}$ -{ (1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-2,2-
2363	dimethylsuccinamide
	N-{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-3-(1,1-dioxido-3-
2364	oxo-1,2-benzisothiazol-2(3H)-yl)propanamide
	N-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-3-(1,3-dioxo-1,3-
2365	dihydro-2H-isoindol-2-yl)propanamide
	(2R) -N-{ (1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-2-methyl-3-
2366	(phenylsulfonyl)propanamide
	(2S)-N-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-2-methyl-3-
2367	(phenylsulfonyl)propanamide
	$N^{1}$ -benzyl- $N^{5}$ -{ (1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
2368	methoxybenzyl)amino]propyl}pentanediamide
	N-{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-2-
2369	[(phenylsulfonyl)methyl]acrylamide

	$N-\{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-$
	methoxybenzyl)amino]propyl}-2-
2370	[(isopentylsulfonyl)methyl]acrylamide
	$N^{1}$ -{ (1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-N³-
2371	[(dipropylamino)carbonyl]-beta-alaninamide
	$N^{1}$ -{ (1S, 2R)-1-benzy1-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-N2-
2372	[(dipropylamino)carbonyl]glycinamide
	benzyl $(4R)-4-\{[((1S,2R)-1-benzyl-3-\{[3-$
	(dimethylamino)-2,2-dimethylpropyl]amino}-2-
	hydroxypropyl)amino]carbonyl}-1,3-oxazolidine-3-
	carboxylate compound with methyl hydroperoxide
2373	(1:2)
	tert-butyl (2R,3S)-2-hydroxy-3-({2-hydroxy-3-
	[(3-methoxyphenyl)sulfonyl]propanoyl}amino)-4-
2374	
	$N^{1}$ -[(1S,2R)-1-[3-(benzyloxy)-5-fluorobenzyl]-2-
	hydroxy-3-(isopentylamino)propyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
2383	
2000	$N^{1}$ -[(1S,2R)-1-[3-(benzyloxy)-5-fluorobenzyl]-2-
	hydroxy-3-(isopentylamino)propyl]-N <sup>3</sup> , N <sup>3</sup> -
2386	dipropylbenzene-1,3,5-tricarboxamide
2000	N <sup>1</sup> -[(1S,2R)-1-(cyclohexylmethyl)-2-hydroxy-3-
	(isopentylamino)propyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
2405	
2400	$N^{1}$ -[(1S,2R)-3-(benzylamino)-1-
	(cyclohexylmethyl)-2-hydroxypropyl]-5-methyl-
2406	
2400	$N^{1}$ -[(1S,2R)-1-[4-(benzyloxy)benzyl]-2-hydroxy-3-
:	(isopentylamino)propyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
2411	
2711	$N^{1}$ -[(1S,2R)-1-(cyclohexylmethyl)-2-hydroxy-3-
	(isopentylamino)propyl]-N <sup>3</sup> , N <sup>3</sup> -dipropylbenzene-
2/12	1,3,5-tricarboxamide
2413	$N^{1}$ -[(1S,2R)-3-(benzylamino)-1-
	(cyclohexylmethyl)-2-hydroxypropyl]-N <sup>3</sup> ,N <sup>3</sup> -
2/1/	dipropylbenzene-1,3,5-tricarboxamide
2414	$N^{1}$ -[(1S,2R)-1-[4-(benzyloxy)benzyl]-2-hydroxy-3-
	(isopentylamino)propyl]-N <sup>3</sup> ,N <sup>3</sup> -dipropylbenzene-
2419	1,3,5-tricarboxamide
2419	N-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
	[(3-methoxybenzyl)amino]propyl}-3-[hydroxy(2-
2421	methylphenyl)methyl]-5-methylbenzamide
2421	$N^{1}$ -[(1R,2S)-2-hydroxy-3-(isopentylamino)-1-(4-
0400	methylbenzyl)propyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
2426	dipropylisophthalamide
	$N^{1} - [(1R, 2S) - 2 - hydroxy - 3 - [(3 - 1) - 1) - 1]$
0.407	methoxybenzyl)amino]-1-(4-methylbenzyl)propyl]-
2427	$5$ -methyl- $N^3$ , $N^3$ -dipropylisophthalamide

1	$N^{1}$ -[(1R,2S)-2-hydroxy-3-(isopentylamino)-1-(4-
	methylbenzyl)propyl]-N <sup>3</sup> ,N <sup>3</sup> -dipropylbenzene-1,3,5-
2428	tricarboxamide
	N <sup>1</sup> -[(1R,2S)-2-hydroxy-3-[(3-
	methoxybenzyl)amino]-1-(4-methylbenzyl)propyl]-
2429	
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-4-
2440	
	benzyl (2R,3S)-4-(3,5-difluorophenyl)-3-[(3-
	(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-2-
	{[(1-
	propylbutyl)sulfonyl]methyl}propanoyl)amino]-2-
2442	hydroxybutyl(3-ethylbenzyl)carbamate
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
	[(3-iodobenzyl)amino]propyl}-7-(1H-imidazol-1-
2445	yl)-5,6-dihydronaphthalene-2-carboxamide
	2-{[({(1s,2R)-1-benzyl-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}amino)carbonyl]amino}
2446	-N, N-dipropylethanesulfonamide hydrochloride
	benzyl (2R,3S)-4-(3,5-difluorophenyl)-2-hydroxy-
	3-({N-(3-phenylpropanoyl)-3-[(1-
	propylbutyl)sulfonyl]alanyl}amino)butyl(3-
2447	ethylbenzyl)carbamate
	$N^{1}$ -[(1S,2R)-3-[[(benzyloxy)carbonyl](3-
	ethylbenzyl)amino]-1-(3,5-difluorobenzyl)-2-
	hydroxypropyl]-N <sup>2</sup> -{[(3S)-tetrahydrofuran-3-
2448	yloxy]carbonyl}-D-leucinamide
	$N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-2-
2449	([1,3]oxazolo[4,5-b]pyridin-2-ylthio)acetamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-
	[(imidazo[1,2-a]pyridin-2-
2450	ylmethyl)thio]acetamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-[(5,7-
	dimethyl[1,2,4]triazolo[4,3-a]pyrimidin-3-
2451	yl)thio]acetamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2,3-dihydro-
2452	1H-cyclopenta[b]quinoline-9-carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-hydroxy-6-
2453	oxo-1-phenyl-1,6-dihydropyridazine-3-carboxamide
	1817 or N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-1,3-
2454	dioxoisoindoline-5-carboxamide
	· · · · · · · · · · · · · · · · · · ·

_	
	1-benzyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-
	[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1H-
2455	imidazole-2-carboxamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzyl)]$
	ethylbenzyl)amino]-2-hydroxypropyl}-2-(4,4-
	dimethyl-4,5-dihydro-1,3-oxazol-2-yl)thiophene-
2456	3-carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-isobutyl-
2457	1,3-dioxoisoindoline-5-carboxamide
2.07	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-5-oxo-2-
2458	phenylpyrazolidine-3-carboxamide
2700	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-5,6-
	dimethyl-4-oxo-3,4-dihydrothieno[2,3-
2459	<u> </u>
2409	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2,4-
2460	difluorobenzyl)oxy]propanamide
2400	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}thieno[2,3-
0.404	
2461	
	N-{(1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-
0400	ethylbenzyl)amino]-2-hydroxypropyl}-4-(2-methyl-
2463	
	N-{(1s, 2r) -1-(3, 5-difluorobenzy1) -3-[(3-
0.404	ethylbenzyl)amino]-2-hydroxypropyl}-3-(2,5-
2464	
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
0.405	ethylbenzyl)amino]-2-hydroxypropyl}thieno[3,2-
2465	b)pyridine-6-carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(2,3-
2466	
	$N = \{(1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [(3 - 3, 5 - difluorobenzyl) - [(3 - 3, 5 - difluoro$
0.455	ethylbenzyl)amino]-2-hydroxypropyl}-2-(1,3-
2468	
	$N^{1}$ -{(1s, 2r)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> -[(4-
2469	methylphenyl)sulfonyl]-beta-alaninamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(1H-indol-
2470	3-y1)-4-oxobutanamide
	$N^2$ -(anilinocarbonothioyl)- $N^1$ -{(1S,2R)-1-(3,5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
2471	
	$N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-4-
2472	oxo-4,5,6,7-tetrahydro-1H-indole-2-carboxamide

	W (// G 07)
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzyl)]$
	ethylbenzyl)amino]-2-hydroxypropyl}-5,6,7,8-
0.470	tetranydro-4H-cyclohepta[c]isoxazole-3-
2473	Carboxamide
	$N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - [ (3 - difluorobenzy1) - [ (3 - difluorobenzy1) - $
	$[etnylbenzyl]$ amino $[-2-hydroxypropyl]$ $[-N^2-1]$
2475	methylphenyl)sulfonyl]glycinamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzy)\}-3-1/3$
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(3,5-
2477	dioxo-1,2,4-triazolidin-4-yl)benzamide
	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
¥	ethylbenzyl)amino]-2-hydroxypropyl}-4-(2-
2478	hydroxyethoxy) benzamide
	N-{ (10 2P) 1 (2 F 3 c)
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
2479	ethylbenzyl)amino]-2-hydroxypropyl}-2-(1,3-
2713	dithian-2-yl)-3-furamide
	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-
2481	5,6,7,8-tetranydro-4H-pyrazolo[1,5-alazepine-3-
2401	Carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-1-(4-
0.400	rruorophenyl)-1,4,5,6-
2482	tetrahydrocyclopenta[c]pyrazole-3-carboxamide
	$N = \{(15, 2R) - 1 - (3, 5 - difluorobenzy)\} - 3 - [(3, 5 - difluorobenzy)]$
	etnylbenzyl)aminol-2-hydroxypropyll-5 6-dibydra
2484	4n-cyclopenta[b]thlophene-2-carboxamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzy)\} = 3-[/3-1]$
İ	ethylbenzyl)aminol-2-hydroxypropyll-3 6 6
	crimethy1-4-oxo-4,5,6,7-tetrahydro-1-benzofuran-
2485	2-carboxamide
ļ	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-7-methoxy-4-
2486	oxo-1,2,3,4-tetrahydronaphthalene-2-carboxamide
	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2,3-dioxo-
2487	1,2,3,4-tetrahydroquinoxaline-6-carboxamide
	N-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ļ	ethylbenzyl)amino]-2-hydroxypropyl}-4,5,6,7-
2488	tetrahydro-2H-indazole-3-carboxamide
	N-{(1s, 2r)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)aminol-2 bydyssyl)-3-[(3-
1.	ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-4-
2489	oxo-3,4-dihydrothieno[2,3-d]pyrimidine-6- carboxamide
	N-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
2490	ethylbenzyl)amino]-2-hydroxypropyl}-7-fluoro-4H-
2430	IMIUdZO[5,1-C][1,4 benzoxazine-3-carbovamido
1.	$N = \{(15, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - 1/$
1 *	ethylbenzyl)amino]-2-hydroxypropyl}-4-(3-fluoro- 4-methoxyphenyl)-4-oxobutanamide
	4-WECROStanhonsel\

	methyl 4-({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
2.55	ethylbenzyl)amino]-2-hydroxypropyl}amino)-4-
2492	oxobutyl-(dithiocarbamate)
	N-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-
	hydroxypropyl}[1,2,4]triazolo[4,3-a]pyridine-6-
2493	carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-1-phenyl-
	1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-
2494	<del></del>
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-[(4-
2495	methylphenyl)sulfonyl]acetamide
	3-(2-chlorophenyl)-2-cyano-N-{(1S,2R)-1-(3,5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
2496	hydroxypropyl}propanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(4-
2498	methylphenyl)-4-oxobutanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(2-
2499	hydroxy-5-methylphenyl)-4-oxobutanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-(2,5-
2500	dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
0504	ethylbenzyl)amino]-2-hydroxypropyl}-4-oxo-4-
2501	thien-2-ylbutanamide or 2379
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(2,5-
0500	dioxo-2,5-dihydro-1H-pyrrol-1-yl)-2-
2502	
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
0500	ethylbenzyl)amino]-2-hydroxypropyl}-4-(2,5-
2503	dioxopyrrolidin-1-yl)benzamide
	N-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
0507	ethylbenzyl)amino]-2-hydroxypropyl}-4-
2507	[(trifluoroacetyl)amino]butanamide
İ	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
0540	ethylbenzyl)amino]-2-hydroxypropyl}-2-[(1-
2510	hydroxycyclopentyl)thio]acetamide
	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
0544	ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-
2511	oxocyclohexyl)propanamide
	N-{(1s, 2r)-1-(3, 5-difluorobenzyl)-3-[(3-
0510	ethylbenzyl)amino]-2-hydroxypropyl}-4-(2-
2512	naphthyl)-4-oxobutanamide

	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-oxo-2,3-
2513	dihydro-1H-indazole-4-carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-1,3-
2514	dimethyl-1H-thieno[2,3-c]pyrazole-5-carboxamide
	$N^{1}-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -
2515	[(dimethylamino)sulfonyl]valinamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(2-furyl)-
2516	4-oxobutanamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(5-methyl-
2517	4-phenyl-1,3-oxazol-2-yl)benzamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
0.740	ethylbenzyl)amino]-2-hydroxypropyl}-2,6-
2518	dioxohexahydropyrimidine-4-carboxamide
	N-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
0540	ethylbenzyl)amino]-2-hydroxypropyl}-5,7-
2519	dimethoxy-1-oxoindane-2-carboxamide
	$N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 2R) - 2R) - (3 - 2R) -$
0504	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>5</sup> -(2-
2521	pyridin-2-ylethyl)pentanediamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
0500	ethylbenzyl)amino]-2-hydroxypropyl}-4-[4-(2-
2522	furoyl)piperazin-1-yl]-4-oxobutanamide
	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
2522	ethylbenzyl)amino]-2-hydroxypropyl}-4-oxo-
2523	4,5,6,7-tetrahydro-1-benzofuran-3-carboxamide
	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
2524	ethylbenzyl)amino]-2-hydroxypropyl}-5-oxo-1-
2024	(thien-2-ylmethyl)pyrrolidine-3-carboxamide
	2-[(cyanomethyl)thio]-N-{(1S,2R)-1-(3,5-
2525	<pre>difluorobenzy1)-3-[(3-ethylbenzyl)amino]-2- hydroxypropyl}nicotinamide</pre>
2020	N-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-1-(2-
2526	furoy1)-4-hydroxyprolinamide
2020	N-{(1s, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4,5-
	dihydrofuro[2,3-g][2,1]benzisoxazole-8-
2527	carboxamide
	methyl 3-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-
	[(3-ethylbenzyl)amino]-2-
	hydroxypropyl}amino)carbonyl]-5-methylthiophene-
2528	2-sulfenate
	2-(acetylamino)-2-(1H-1,2,3-benzotriazol-1-yl)-
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
2529	ethylbenzyl)amino]-2-hydroxypropyl}acetamide

	1-{[(cyclohexylamino)carbonyl]amino}-N-{(1S,2R)-
	1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-
2530	2-hydroxypropyl}cyclopropanecarboxamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-ethyl-
	4H-[1,2,4]triazolo[1,5-a]benzimidazol-4-
2531	yl)acetamide
	$(2E) - N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 2R) - 2 - (3 - 2R) - ($
	ethylbenzyl) amino] $-2$ -hydroxypropyl $-N^4$ - $[4-(1,3-$
2532	
2002	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-1,3,4,5-
2533	
2555	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(3,4-
	dihydro-2H-1,5-benzodioxepin-7-yl)-4-
2535	
2000	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(1-
0500	
2536	
	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
. 0507	ethylbenzyl)amino]-2-hydroxypropyl}-4-oxo-4-(2-
2537	thioxo-1,3-benzothiazol-3(2H)-yl)butanamide
	N-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
0500	ethylbenzyl)amino]-2-hydroxypropyl}-8H-
2538	thieno[2,3-b]indole-2-carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
0500	ethylbenzyl)amino]-2-hydroxypropyl}-3,4-dihydro-
2539	2H-1,5-benzodioxepine-7-carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
27.12	ethylbenzyl)amino]-2-hydroxypropyl}-4H-
2540	chromeno[3,4-d]isoxazole-4-carboxamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzyl)]$
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(3,4-
2542	
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(3,4-
2543	difluorophenyl)-2-methyl-4-oxobutanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(3,4-
2544	difluorophenyl)-2-methoxy-4-oxobutanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-4-
2545	oxo-4-[3-(trifluoromethyl)phenyl]butanamide
	$N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-4-
2546	oxo-4-thien-2-ylbutanamide

	N (/10 0p) 1 /0
	N-{(1s, 2r)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-[(2-ethyl
	1-0x0-2,3-dinydro-1H-isoindol-5-
2548	1 - 1 - P - I - P - I - I - I - I - I - I - I
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-
2549	oxoisoindoline-1-carboxamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-4-7-
2550	metnoxy-1-benzofuran-2-vl)-4-oxobutanamide
	N-{(1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4H-
2551	chromeno[3,4-d]isoxazole-8-carboxamide
	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-4-
2552	oxo-4H-chromene-6-carboxamide
=======	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-
	([1.2.4]triazolo[4.2.h]
2553	([1,2,4]triazolo[4,3-b]pyridazin-6-ylthio)acetamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
2554	ethylbenzyl)amino]-2-hydroxypropyl}-2-(1,1-
2004	
	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
0555	ethylbenzyl)amino]-2-hydroxypropyl}-4-(3,4-
2555	dinydro-2H-chromen-6-vl)-4-oxobutanamide
	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
0550	etnylbenzyl)amino]-2-hydroxypropyl}-2-ethyl-3-
2556	Oxorsorndorne-1-carboxamide
	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
0==0	ethylbenzyl)amino]-2-hydroxypropyl}-4-(4-
2558	nydroxyphenyl)-4-oxobutanamide
i	2-[(6-chloro[1,2,4]triazolo[4,3-b]pyridazin-3-
	$Y^{1}$ , $OXY$ , $-N-\{(1S, 2R)-1-(3, 5-difluorobenzy)\}-3-[(3-1)]$
2559	ethylbenzyl)amino]-2-hydroxypropyl}acetamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzy)\}-3-[(3-$
ĺ	ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-4-
2560	(3-methoxyphenyl)-4-oxobutanamide
	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-4-
2561	oxo-4-thien-3-ylbutanamide
	3-chlorophenyl 4-({(1S,2R)-1-(3,5-
j	difluorobenzyl) -3-[(3-ethylbenzyl)amino]-2-
2562	hydroxypropyl}amino)-4-oxobutanoate
	4-(4-chloro-2-hydroymba-7)
į	4-(4-chloro-2-hydroxyphenyl)-N-((1S, 2R)-1-(3, 5-difluorobenzyl) 3 [(3, abb-2)]
2563	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
	hydroxypropyl}-4-oxobutanamide
	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
2565	ethylbenzyl)amino]-2-hydroxypropyl}-6-{[(4-
2000	methylphenyl)sulfonyl]amino}-4-oxohexanamide

	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mu)]$
	ethylbenzyl)amino]-2-hydroxypropyl}-2-(6-
	hydroxy-3-oxo-2,3-dihydroimidazo[2,1-
2566	b][1,3]thiazol-2-yl)acetamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-(4,5-
2567	dihydro-1,3-thiazol-2-ylthio)acetamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-1H-
2568	imidazo[1,2-b]pyrazole-6-carboxamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(6-
2570	methoxy-1,1'-biphenyl-3-yl)-4-oxobutanamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(4-
2571	methoxyphenyl)-4-oxobutanamide
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(2,3-
2572	
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-oxo-
2573	2,3-dihydro-1,3-benzoxazol-5-yl)acetamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-oxo-
2574	2,3-dihydro-1H-benzimidazol-5-yl)acetamide
	$N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-9-oxo-
	1,2,3,9-tetrahydrocyclopenta[b]chromene-7-
2575	carboxamide
	$N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-1-methyl-1H-
2576	benzo[g]indazole-3-carboxamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4,5-
2577	
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-2-
2578	(tetraazolo[1,5-b]pyridazin-6-ylthio)acetamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-(5-methyl-
2580	1H-pyrrol-2-yl)-4-oxobutanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-
2581	{[(trifluoromethyl)sulfonyl]amino}butanamide
	N-[(1S,2R)-3-(2-acetyl-1-ethylhydrazino)-1-
	benzyl-2-hydroxypropyl]-2-
	[(methylsulfonyl)amino]-1,3-thiazole-4-
2582	carboxamide

	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-(1-
2583	hydroxy-2-propylpentyl)benzamide
	$N^{2}-[(1S, 2R)-3-[(2-\{4-[(3-$
	chlorobenzyl)oxy]phenyl}ethyl)amino]-1-(3,5-
	difluorobenzyl)-2-hydroxypropyll-5-methyl-N <sup>3</sup> N <sup>3</sup> -
2587	dipropylisophthalamide
	$N^1$ -{(1s,2r)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
	[[(3-morpholin-4-vlpropy])aminolpropy]}_5-mothy]
2589	N -dipropylisophthalamide
	$N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -
2597	[ (methylsulfonyl) acetyl] -N <sup>2</sup> -pentylglycinamide
	N-{ (1s, 2r) -1- (3, 5-difluorobenzyl) -3- [ (3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2R)-2-
	(methoxymethyl)pyrrolidin-1-
2598	yl]sulfonyl}propanamide
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2S)-2-
	(methoxymethyl)pyrrolidin-1-
2599	yl]sulfonyl}propanamide
	ethyl $4-\{[(2R,3S)-3-(\{3-$
	[(dipropylamino)carbonyl]benzov]}amino)-2-
	hydroxy-4-phenylbutyl]amino}piperidine-1-
2600	carboxylate
	$N^{1}$ -((1S, 2R)-1-benzyl-3-{[(3R)-1-
	benzylpyrrolidin-3-yllamino}-2-hydroxypropyll-
2601	N',N'-dipropylisophthalamide
	methyl $(2E)-2-[2-({(1S,2R)-1-benzyl-2-hydroxy-3-}]$
	[(3-methoxybenzyl)amino]propyl}amino)-2-
2602	oxoethyl]-4-methylpent-2-enoate
	$N^{2}-\{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-$
_	methoxybenzyl)amino]propyl}-N <sup>4</sup> -(4-
2603	methoxybenzyl) succinamide
	$N-\{(1S, 2R)-1-benzyl-2-hydroxy-3-1(3-$
	methoxybenzyl)amino]propyl}-3-{[(4-
2604	fluorophenyl)sulfonyl amino}-3-methylbutanamido
ļ	$N = \{(1S, 2R) - 1 - benzyl - 2 - hydroxy - 3 - [(3 - benzyl - 2 - hydroxy - 4 - hydroxy - 4 - hydroxy - 4 - hydroxy - 3 - [(3 - benzyl - 2 - hydroxy - 3 - [(3 - benzyl - 2 - hydroxy - 4 - hydr$
	methoxybenzyl)amino]propyl}-9,10-dioxo-9,10-
2605	dihydroanthracene-2-carboxamide
	$N-\{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-benzyl$
	methoxybenzyl)amino]propyl}-4-
2606	(benzyloxy)benzamide
	N'-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-
	methoxybenzyl)amino]propyl}-N-methyl-N-
2607	phenylurea
	N'-{(1S,2R)-1-benzy1-2-hydroxy-3-[(3-
2608	methoxybenzyl)amino]propyl}-N,N-diisopropylurea
	$N = \{(15, 2R) - 1 - benzy \} - 2 - hydroxy - 3 - [(3 - benzy \} - 1 - be$
2609	methoxybenzyl)amino]propyl}-N,N-diphenylurea

2040	N'-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-
2610	methoxybenzyl)amino]propyl}-N,N-dimethylurea
	methyl 2-{[({(1S,2R)-1-benzyl-2-hydroxy-3-[(3-
0611	methoxybenzyl)amino]propyl}amino)carbonyl]amino}
2611	benzoate
2613	2-methoxyethyl (1S,2R)-1-benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propylcarbamate
2010	phenyl (1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
2612	methoxybenzyl)amino]propylcarbamate
	2-(benzyloxy)ethyl (1S,2R)-1-benzyl-2-hydroxy-3-
2614	[(3-methoxybenzyl)amino]propylcarbamate
	prop-2-ynyl (1S,2R)-1-benzyl-2-hydroxy-3-[(3-
2615	methoxybenzyl)amino]propylcarbamate
	(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl
	(1S,2R)-1-benzyl-2-hydroxy-3-[(3-
2616	methoxybenzyl)amino]propylcarbamate
	pentyl (1S,2R)-1-benzyl-2-hydroxy-3-[(3-
2617	methoxybenzyl)amino]propylcarbamate
0040	neopentyl (1S, 2R)-1-benzyl-2-hydroxy-3-[(3-
2618	methoxybenzyl)amino]propylcarbamate
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
0004	{[(4-oxo-4H-chromen-3-yl)methyl]amino}propyl)-5-
2621	methyl-N³, N³-dipropylisophthalamide
	$N^1-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-$
	[(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)amino]propyl}-5-methyl-N³,N³-
2622	
2022	N-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
	[(3-iodobenzyl)amino]propyl}-4-(3-methyl-5-oxo-
2623	4,5-dihydro-1H-pyrazol-1-yl)benzamide
	$N^{1}$ -[(1S,2R)-3-[(1-acetylpiperidin-3-yl)amino]-1-
	(3,5-difluorobenzyl)-2-hydroxypropyl]-5-methyl-
2625	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> -ethoxy-5-
2627	methylisophthalamide
	$N^{1}$ -(allyloxy)- $N^{3}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-
	3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-
2628	methylisophthalamide
	$N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzyl)]$
2620	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> -
2629	isobutoxy-5-methylisophthalamide
	$N^{1} - \{(1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - [(3 - ethylbonzy1) - minol 2 bydnown more) \} = \frac{1}{2} \text{ mathylbonzy1}$
2630	ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-N³-(2,2,3,3,3-pentafluoropropyl)isophthalamide
2000	ethyl 4-({3-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-
	[(3-ethylbenzyl)amino]-2-
	hydroxypropyl amino) carbonyl ]-5-
2631	methylbenzoyl}amino)butanoate

	N1_(/1C 2D) 1 /2 E 42 E 2
	$N^{1} - \{(1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - [(3 - difluorobenzy1)] - [(3 - difluorobenzy1)] - 3 - [(3 - difluorobenzy1)] - [(3 - difluorobenzy1)] - [(3 - difluorobenzy1)] - [(3 - difluorobenzy1)] - [(3 - difluorobenzy1)] - [(3 - difluorobenzy1)] - [(3 - difluorobenzy1)] - [(3 - difluorobenzy1)] - [(3 - difluorobenzy1)] - $
0000	ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-
2632	
	$N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> -ethyl-N <sup>3</sup> -
	[(1-ethylpiperidin-4-yl)carbonyl]-5-
2633	methylisophthalamide
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> -
	(2,2,3,3,4,4,4-heptafluorobutyl)-5-
2634	
	$N^{1}$ -(1-benzylpyrrolidin-3-yl)- $N^{3}$ -{(1S,2R)-1-(3,5-
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
2635	hydroxypropyl}-N1-ethyl-5-methylisophthalamide
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-N <sup>3</sup> -
2636	(tetrahydrofuran-2-ylmethyl)isophthalamide
	$N^1$ -((1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
	{[(3R)-2-oxoazepan-3-yl]amino}propyl)-5-methyl-
2638	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
	$N^{1}-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(1,1-$
	dioxido-3,4-dihydro-2H-1,2-benzothiazin-4-
	yl)amino]-2-hydroxypropyl}-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
2639	dipropylisophthalamide
2000	$N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-$
	[2-(4-methylpentanoyl)hydrazino]propyl}-5-
2640	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
2040	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-[(3-
2641	ethylphenyl)sulfonyl]propanamide
2041	N <sup>1</sup> ((10.2P) 1 (2.5 differential 2.5 di
	$N^{1} - \{(1S, 2R) - 1 - (3, 5 - diffluor obenzy1) - 3 - [(3 - athylhongy1) - [(3 - athylhongy1) - [(3 - athylho$
2642	ethylbenzyl)amino]-2-hydroxypropyl}-2,2,3,3,4,4-
2042	hexafluoro-N <sup>5</sup> , N <sup>5</sup> -dipropylpentanediamide
	$N^5 - \{(1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [(3 - difluorobenzyl)] - 3 - [(3 - difluorobenzyl$
0040	ethylbenzyl)amino]-2-hydroxypropyl}-2-phenyl-
2643	N <sup>1</sup> , N <sup>1</sup> -dipropylpentanediamide
	N-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-[(3-
2644	hydroxypropyl) (methylsulfonyl) amino]benzamide
	N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-[(2-
2645	hydroxyethyl) (methylsulfonyl) amino] benzamide
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(2R)-2-
	(methoxymethyl)pyrrolidin-1-yl]sulfonyl}-N <sup>3</sup> ,N <sup>3</sup> -
2646	dipropylisophthalamide
	N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
	ethylbenzyl)amino]-2-hydroxypropyl}-4-[(3-
2647	hydroxypropyl) (methylsulfonyl) amino] benzamide

The compounds in the table immediately below were prepared essentially using the methods described above and illustrated below in the schemes.

The following compounds were named using the Advanced

5 Chemistry Development Inc. (ACD) nomenclature program, IUPAC
Name Batch Version 4.5. The website for ACD is
www.acdlabs.com.

	Compound Name(s)	mass
	Composite Hame (b)	spec
	$5-bromo-N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-$	- SP S S
	2-hydroxy-3-[(3-iodobenzyl)amino]propyl}-	
2648	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide	
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	586.
	ethylbenzyl)amino]-2-hydroxypropyl}-3-	1
	{[(trifluoromethyl)sulfonyl]amino}benzamid	_
2649	e	
	$N^{1}-\{(1S,2R)-1-(3,5-dichlorobenzyl)-2-$	643.
	hydroxy-3-[(3-methoxybenzyl)amino]propyl}-	2
2657	N <sup>3</sup> , N <sup>3</sup> -dipropylbenzene-1, 3, 5-tricarboxamide	
	$N^{1}$ -[(1S, 2R)-2-hydroxy-3-[(3-	581.
	methoxybenzyl)amino]-1-(thien-2-	3
	ylmethyl)propyl]-N3,N3-dipropylbenzene-	
2664	1,3,5-tricarboxamide	
	$N^1$ -{(1S,2R)-1-(4-fluorobenzyl)-2-hydroxy-3-	593.
	[(3-methoxybenzyl)amino]propyl}-N <sup>3</sup> ,N <sup>3</sup> -	3
2665	dipropylbenzene-1,3,5-tricarboxamide	
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	647
	ethylbenzyl)amino]-2-hydroxypropyl}-5-(4-	
	$methyl-1,3-oxazol-2-yl)-N^3,N^3-$	
2666	dipropylisophthalamide	
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	649
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> ,N <sup>3</sup> -	
	dipropy1-5-(1,3-thiazol-2-	
2667	yl)isophthalamide	_
	$N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-$	532.
	ethylbenzyl)amino]-2-hydroxypropyl}-3-	2
2668	[(methylsulfonyl)amino]benzamide	
	$N^{1}$ -{ (1S, 2R) -1- (3, 5-difluorobenzyl) -3-[(3-	633
	ethylbenzyl)amino]-2-hydroxypropyl}-5-	
	$(1,3-oxazol-2-yl)-N^3,N^3-$	
2671	dipropylisophthalamide	
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	633.
	ethylbenzyl)amino]-2-hydroxypropyl}-5-	4
	$(1,3-oxazol-2-yl)-N^3,N^3-$	
2672	dipropylisophthalamide hydrochloride	
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-$	553
	ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-	
	propylbutyl)sulfonyl]propanamide	
2675	hydrochloride	

	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzy1)-2-	Tear
	hydroxy-3-[(3-methoxybenzyl)amino]propyl}-	635
	$5-(1,3-\text{oxazol}-2-y1)-N^3,N^3-$	
0677		
2677	dipropylisophthalamide	
	N-{(1S,2R)-1-(3,5-difluorobenzy1)-2-	637.
	hydroxy-3-[(3-iodobenzyl)amino]propyl}-2-	6
0070	[(methylsulfonyl)amino]-1,3-thiazole-4-	
2678		
	$N^{1}$ -[(1S,2R)-1-(3,5-difluorobenzy1)-2-	665
	hydroxy-3-(isopentylamino)propy1]-N <sup>3</sup> ,N <sup>3</sup> -	
	dipropy1-5-	
	{[(trifluoromethyl)sulfonyl]amino}isophtha	
2679		
	N-{ (1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-	525
	ethylbenzyl)amino]-2-hydroxypropyl}-3-	1
2680	(isopentylsulfonyl)propanamide	]
	N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-	598.
	ethylbenzyl)amino]-2-hydroxypropyl}-3-	1
1	{[(1-methyl-1H-imidazol-4-	
	yl)sulfonyl]amino}benzamide	
2681	trihydrochloride	
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-$	586
	ethylbenzyl)amino]-2-hydroxypropyl}-4-	
	{[(trifluoromethyl)sulfonyl]amino}benzamid	
2682	e	
	N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-	556
	ethylbenzyl)amino]-2-hydroxypropyl}-3-	
	{[(2-	
	hydroxyethyl)(propyl)amino]sulfonyl}propan	,
2684	amide	
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	506
	ethylbenzyl)amino]-2-hydroxypropyl}-3-	
2685	(1,3-oxazol-2-yl)benzamide hydrochloride	
	$N^{1}$ -{ (1S, 2R) -1-(3, 5-difluorobenzy1) -3-[(3-	717
]	ethylbenzyl)amino]-2-hydroxypropyl}-5-	
	{[(2-hydroxy-1,1-	
	dimethylethyl)amino]sulfonyl $-N^3$ , $N^3$ -	
2686	dipropylisophthalamide	
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	590
	ethylbenzyl)amino]-2-hydroxypropyl}-3-	
	{[(2-hydroxy-1,1-	
2687	dimethylethyl)amino]sulfonyl}benzamide	İ
	$N^{1}$ -{ (1S, 2R) -1-(3, 5-difluorobenzy1) -3-[(3-	703
	ethylbenzyl)amino]-2-hydroxypropyl}-5-	ļ
·	{[(3-hydroxypropy1)amino]sulfony1}-N³,N³-	
2688	dipropylisophthalamide	l
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	539.
	ethylbenzyl)amino]-2-hydroxypropyl}-2-	1
	[(methylsulfonyl)amino]-1,3-thiazole-4-	
2689	carboxamide	

$N^{1}$ -{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-	686
ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -	000
(phenylacetyl)-3-[(1-	
2690 propylbutyl)sulfonyl]alaninamide	
	700
	702
F,C-COOH	
2691 racemic	
$N^{1}$ -{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-	647
ethylbenzyl)amino]-2-hydroxypropyl}-5-(3-	
methylisoxazol-4-yl)-N <sup>3</sup> ,N <sup>3</sup> -	
2692 dipropylisophthalamide hydrochloride	
	702
ethylbenzyl)amino]-2-hydroxypropyl}-5-	. 02
({[2-(methylamino)ethyl]amino}sulfonyl)-	
2693 N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide hydrochloride	
	689
	089
ethylbenzyl)amino]-2-hydroxypropyl}-5-	
{[(2-hydroxyethyl)amino]sulfonyl}-N³,N³-	
2694 dipropylisophthalamide	
	499
ethylbenzyl)amino]-2-hydroxypropyl}-4-	
2695 [(methylsulfonyl)amino]butanamide	
_ · · · · · · · · · · · · · · · · · · ·	714
ethylbenzyl)amino]-2-hydroxypropyl}-5-	
(piperazin-1-ylsulfonyl)-N <sup>3</sup> ,N <sup>3</sup> -	
2696 dipropylisophthalamide	
N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	546
ethylbenzyl)amino]-2-hydroxypropyl}-3-	
2697 [methyl(methylsulfonyl)amino]benzamide	
	733
{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	
ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> , N <sup>3</sup> -	,
2698 dipropylisophthalamide	
	518.
1	3 3
2699 dimethylquinoline-3-carboxamide	<i>_</i>
	661.
•	
[ ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (	7
methylbenzoyl}amino)-2-	
hydroxybutyl]amino}ethyl 2,4-	
2702 difluorophenylcarbamate	
	632
ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> ,N <sup>3</sup> -	
2704   dipropyl-5-(1H-pyrazol-4-yl)isophthalamide	

	N (/10 OP) 1 /2 5 3153	T
1	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	446.
0700	ethylbenzyl)amino]-2-hydroxypropyl}-3-	2
2706		
	$N^{1}$ -{ (1S, 2R) -1-(3,5-difluorobenzy1) -3-[(3-	646
	ethylbenzyl)amino]-2-hydroxypropyl}-5-(1-	•
	$methyl-1H-imidazol-2-yl)-N^3,N^3-$	1
2707		
	N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-	594.
	ethylbenzyl)amino]-2-hydroxypropyl}-3-	3
	{[(2R)-2-(methoxymethyl)pyrrolidin-1-	Ì
	yl]carbonyl}-5-methylbenzamide	-
2708	hydrochloride	
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	647
	ethylbenzyl)amino]-2-hydroxypropy1}-5-	
	{[(2-hydroxyethyl)amino]sulfonyl}-N3-	
2709	propylisophthalamide	
	$N^{1}$ -{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-	703
	ethylbenzyl)amino]-2-hydroxypropyl}-5-	
	({[(1S)-2-hydroxy-1-	
	methylethyl]amino}sulfonyl)-N3,N3-	
2710	dipropylisophthalamide	
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	605.
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> ,N <sup>3</sup> -	4
2711	diethyl-5-(1,3-oxazol-2-yl)isophthalamide	*
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	594.
	ethylbenzyl)amino]-2-hydroxypropy1}-3-	3
	{[(2S)-2-(methoxymethyl)pyrrolidin-1-	
	yl]carbonyl}-5-methylbenzamide	
2712	hydrochloride	
	$N^{1}$ -{(1s, 2r)-1-(3, 5-difluorobenzyl)-3-[(3-	729
	ethylbenzyl)amino]-2-hydroxypropyl}-5-	' - '
	{[(2S)-2-(hydroxymethyl)pyrrolidin-1-	
2713	yl]sulfonyl}-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide	
	$N^1$ -{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-	703
	ethylbenzyl)amino]-2-hydroxypropyl}-5-	, , ,
	({[(1R)-2-hydroxy-1-	
	methylethyl]amino}sulfonyl)-N <sup>3</sup> ,N <sup>3</sup> -	
2714	dipropylisophthalamide	
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	539.
	ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-	3
2716	ethyl-1-hydroxybutyl)benzamide	
	$N^1$ -{(1S, 2R)-1-(3,5-difluorobenzy1)-3-[(3-	673.
	ethylbenzyl)amino]-2-hydroxypropyl}-5-	1
	[(dimethylamino)sulfonyl]-N <sup>3</sup> , N <sup>3</sup> -	
2717	dipropylisophthalamide	
	N <sup>1</sup> -[(1S,2R)-3-{[2-	569.
	(aminosulfonyl)ethyl]amino}-1-(3,5-	
	difluorobenzyl)-2-hydroxypropyl]-5-methyl-	6
2719	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide	
4/13	14 '14 ATTATOTATE TOTAL	<u> </u>

hydroxy-3-[(4-phenylbutyl) amino]propyl}-5-   5     methyl-N³,N³-dipropylisophthalamide   N¹-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-ethylbenzyl) amino]-2-hydroxypropyl}-N³-   4     ethylbenzyl) amino]-2-hydroxypropyl}-N³-   4     ethylbenzyl) amino]-2-hydroxypropyl}-N³-   4     methyl-5-(1, 3-oxazol-2-yl)-N³-   4     methyl-5-(1, 3-oxazol-2-yl)-N³-   5     methyl-5-(1, 3-oxazol-2-yl)-N³-   6     methyl-5-(1, 3-oxazol-2-yl)-N³-   7     propylisophthalamide   N¹-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-ethylbenzyl) amino]-2-hydroxypropyl}-N³,N³-   6     dipropyl-5- (pyrrolidin-1-ylsuffonyl) isophthalamide   N¹-((1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-(isopentylamino) propyl]-5-((2-hydroxy-1, 1-dimethylethyl) amino] sulfonyl)-   7     2732 N³,N³-dipropylisophthalamide   N¹-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-ethylbenzyl) amino]-2-hydroxypropyl}-5-   (1, 3-oxazol-5-yl)-N³,N³-   2     dipropylisophthalamide hydrochloride   N¹-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-ethynylbenzyl) amino]-2-hydroxypropyl}-5-   (1, 3-oxazol-2-yl)-N³,N³-   2   dipropylisophthalamide hydrochloride   N¹-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-ethynylbenzyl) amino]-2-hydroxypropyl)-N³,N³-   2   dimethyl-5-(1, 3-oxazol-2-yl)-N³,N³-   2   dimethyl-5-(1, 3-oxazol-2-yl)-N³,N³-   2   dimethyl-5-(1, 3-oxazol-2-yl)-N³,N³-   2   dimethyl-5-(1, 3-oxazol-2-yl)-N³,N³-   2   dimethyl-5-(1, 3-oxazol-2-yl)-N³-			
Nt-  (1s, 2R) -1- (3, 5-difluorobenzyl) -3- [(3-ethylbenzyl) amino] -2-hydroxypropyl) -N3-ethyl-N3-methyl-5- (1, 3-oxazol-2-yl) isophthalamide		$N^1$ -{(1S,2R)-1-(3,5-difluorobenzyl)-2-	594.
Nt-  (1s, 2R) -1- (3, 5-difluorobenzyl) -3- [(3-ethylbenzyl) amino] -2-hydroxypropyl) -N3-ethyl-N3-methyl-5- (1, 3-oxazol-2-yl) isophthalamide		hydroxy-3-[(4-phenylbutyl)amino]propyl}-5-	5
ethylbenzyl) amino] -2-hydroxypropyl} -N³- ethyl-N³-methyl-5-(1,3-oxazol-2- yl) isophthalamide  N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3- ethylbenzyl) amino] -2-hydroxypropyl}-N³- methyl-5-(1,3-oxazol-2-yl)-N³- propylisophthalamide  N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3- ethylbenzyl) amino] -2-hydroxypropyl}-N³, N³- dipropyl-5-(pyrrolidin-1- ylsulfonyl) isophthalamide hydrochloride  N¹-[(1S,2R)-1-(3,5-difluorobenzyl)-2- hydroxy-3-(isopentylamino) propyl]-5-[(2- hydroxy-1,1-dimethylethyl) amino] sulfonyl)- N³, N³-dipropylisophthalamide  N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3- ethylbenzyl) amino]-2-hydroxypropyl}-5- (1,3-oxazol-5-yl)-N³, N³- 2733 dipropylisophthalamide hydrochloride  N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3- ethynylbenzyl) amino]-2-hydroxypropyl}-5- (1,3-oxazol-2-yl)-N³, N³- 2734 dipropylisophthalamide hydrochloride  N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3- ethylbenzyl)-3-[(3-ethylbenzyl) amino]- 2-hydroxypropyl}-N¹-methyl-5-(1,3-oxazol-2- yl) isophthalamide  N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3- ethylbenzyl) amino]-2-hydroxypropyl}-N³- ethylbenzyl) amino]-2-hydroxypropyl}-N³- ethylbenzyl) amino]-2-hydroxypropyl)-N³- propylisophthalamide  N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3- ethylbenzyl) amino]-2-hydroxypropyl)-N³- et	2723	methyl-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide	
ethyl-N³-methyl-5-(1,3-oxazol-2- yl)isophthalamide  N¹-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-N³-methyl-5-(1,3-oxazol-2-yl)-N³-propylisophthalamide  N¹-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³, N³-dipropyl-5-(pyrrolidin-1-ylsulfonyl)isophthalamide  N¹-{(1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-(isopentylamino)propyl]-5-{[(2-hydroxy-1,1-dimethylethyl)amino]sulfonyl}-2732 N³,N³-dipropylisophthalamide  N¹-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-oxazol-5-yl)-N³,N³-2733 dipropylisophthalamide hydrochloride  N¹-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethyylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-oxazol-2-yl)-N³,N³-2734 dipropylisophthalamide hydrochloride  N¹-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethyl-N³-((1s,2R)-1-(3,5-difluorobenzyl)amino]-2-hydroxypropyl)-N³-ethyl-N³-(1s,2R)-1-(3,5-difluorobenzyl)amino]-2-hydroxypropyl)-N³-ethyl-bn2l)amino]-2-hydroxypropyl)-N³-ethylbenzyl)amino]-2-hydroxypropyl)-N³-ethylbenzyl)amino]-2-hydroxypropyl)-N³-ethyl-5-(1,3-oxazol-2-yl)isophthalamide  N¹-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-N³-ethyl-5-(1,3-oxazol-2-yl)-N³-ethyl-5-(N³-ethyl-5-(N³-ethyl-5-(N³-ethyl-5-(		$N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-$	591.
ethyl-N³-methyl-5-(1,3-oxazol-2- yl)isophthalamide  N¹-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-N³-methyl-5-(1,3-oxazol-2-yl)-N³-propylisophthalamide  N¹-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³, N³-dipropyl-5-(pyrrolidin-1-ylsulfonyl)isophthalamide  N¹-{(1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-(isopentylamino)propyl]-5-{[(2-hydroxy-1,1-dimethylethyl)amino]sulfonyl}-2732 N³,N³-dipropylisophthalamide  N¹-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-oxazol-5-yl)-N³,N³-2733 dipropylisophthalamide hydrochloride  N¹-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethyylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-oxazol-2-yl)-N³,N³-2734 dipropylisophthalamide hydrochloride  N¹-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethyl-N³-((1s,2R)-1-(3,5-difluorobenzyl)amino]-2-hydroxypropyl)-N³-ethyl-N³-(1s,2R)-1-(3,5-difluorobenzyl)amino]-2-hydroxypropyl)-N³-ethyl-bn2l)amino]-2-hydroxypropyl)-N³-ethylbenzyl)amino]-2-hydroxypropyl)-N³-ethylbenzyl)amino]-2-hydroxypropyl)-N³-ethyl-5-(1,3-oxazol-2-yl)isophthalamide  N¹-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-N³-ethyl-5-(1,3-oxazol-2-yl)-N³-ethyl-5-(N³-ethyl-5-(N³-ethyl-5-(N³-ethyl-5-(			j
2729 y1)isophthalamide		ethyl- $N^3$ -methyl-5-(1,3-oxazol-2-	-
N <sup>1</sup> -((1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl}-N <sup>3</sup> -methyl-5-(1, 3-oxazol-2-yl)-N <sup>3</sup> -propylisophthalamide   N <sup>1</sup> -((1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl)-N <sup>3</sup> , N <sup>3</sup> -dipropyl-5-(pyrrolidin-1-ylsulfonyl) isophthalamide hydrochloride   N <sup>1</sup> -[(1S, 2R) -1-(3, 5-difluorobenzyl) -2-hydroxy-3-(isopentylamino) propyl] -5-[(2-hydroxy-3-(isopentylamino) propyl] -5-[(2-hydroxy-1, 1-dimethylethyl) amino] sulfonyl}-   N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide   N <sup>1</sup> -((1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl}-5-(1, 3-oxazol-5-yl) -N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide hydrochloride   N <sup>1</sup> -((1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-ethynylbenzyl) amino] -2-hydroxypropyl}-5-(1, 3-oxazol-2-yl) -N <sup>3</sup> , N <sup>3</sup> -difluorobenzyl) -3-[(3-ethylbenzyl) -3-[(3-ethylbenzyl) -3-[(3-ethylbenzyl) -3-[(3-ethylbenzyl) -3-[(3-ethylbenzyl) -3-[(3-ethylbenzyl) -3-[(3-ethylbenzyl) -3-[(3-ethylbenzyl) -3-[(3-ethylbenzyl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl) -N <sup>3</sup> -ethyl-5-(1, 3-oxazol-2-yl) isophthalamide   N <sup>1</sup> -((1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl) -N <sup>3</sup> -ethyl-5-(1, 3-oxazol-2-yl) isophthalamide   N <sup>1</sup> -((1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl) -N <sup>3</sup> -ethyl-5-(1, 3-oxazol-2-yl) isophthalamide   N <sup>1</sup> -((1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl) -N <sup>3</sup> -ethyl-5-(1, 3-oxazol-2-yl) isophthalamide   N <sup>1</sup> -((1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl) -N <sup>3</sup> -ethylbenzyl) amino] -2-hydroxypropyl) -N <sup>3</sup> -ethylbenzyl) amino] -2-hydroxypropyl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl) -5-[((2R) -2-(hydroxymethyl) pyrrolidin-1-	2729		
ethylbenzyl)amino]-2-hydroxypropyl}-N³- methyl-5-(1,3-oxazol-2-yl)-N³- propylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³, N³-dipropyl-5-(pyrrolidin-1-ylsulfonyl)isophthalamide hydrochloride  N¹-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-(isopentylamino)propyl]-5-{(2-hydroxy-3-(isopentylamino)propyl]-5-{(2-hydroxy-1,1-dimethylethyl)amino]sulfonyl}-2732 N³-N³-dipropylisophthalamide  N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-oxazol-5-yl)-N³,N³-2733 dipropylisophthalamide hydrochloride  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethynylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-oxazol-2-yl)-N³,N³-2734 dipropylisophthalamide hydrochloride  N¹-butyl-N³-{(1S,2R)-1-(3,5-difluorobenzyl)amino]-2-hydroxypropyl}-N³-methyl-5-(1,3-oxazol-2-yl)-N³-methyl-5-(1,3-oxazol-2-yl)-N³-methyl-5-(1,3-oxazol-2-yl)-N³-methyl-5-(1,3-oxazol-2-yl)-N³-methyl-5-(1,3-oxazol-2-yl)-N³-propylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-N³-ethyl-5-(1,3-oxazol-2-yl)-N³-propylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-N³-ethyl-5-(1,3-oxazol-2-yl)-N³-yropylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-N³-ethyl-5-(1,3-oxazol-2-yl)-N³-yropylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-3-[(1-2738 yl)isophthalamide hydrochloride  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-3-((1-2739 propylbutyl)amino]-2-hydroxypropyl)-3-((1-2739 propylbutyl)amino]-2-hydroxypropyl)-3-((1-274)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-5-((2R)-2-(hydroxymethyl)pyrropidin-1-		$N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 1) - 3 - 1 ] \}$	605
methyl-5-(1,3-oxazol-2-yl)-N³- propylisophthalamide N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)aminol-2-hydroxypropyl}-N³,N³-dipropyl-5-(pyrrolidin-1-ylsulfonyl)isophthalamide hydrochloride N¹-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-(isopentylamino)propyl]-5-{((2-hydroxy-3-(isopentylamino)propyl]-5-{((2-hydroxy-1,1-dimethylethyl)amino]sulfonyl}-N³,N³-dipropylisophthalamide N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-oxazol-5-yl)-N³,N³- 2733 dipropylisophthalamide hydrochloride N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethynylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-oxazol-2-yl)-N³,N³- difluorobenzyl)-3-((3-ethylbenzyl)amino]-2-hydroxypropyl}-N²-methyl-5-(1,3-oxazol-2-yl)isophthalamide N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³,N³- 2736 dimethyl-5-(1,3-oxazol-2-yl)isophthalamide N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethylbenzyl)amino]-2-hydroxypropyl}-N³-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-(3-ethylbenzyl)amino]-2-hyd		ethylbenzyl)aminol-2-hydroxypropyl}-N3-	1
2730   propylisophthalamide   N¹-((1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl) amino]-2-hydroxypropyl}-N³, N³-dipropyl-5-(pyrrolidin-1-ylsulfonyl) isophthalamide hydrochloride   N¹-((1S, 2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-(isopentylamino) propyl]-5-([(2-hydroxy-3-(isopentylamino) propyl]-5-([(2-hydroxy-1,1-dimethylethyl) amino] sulfonyl}-2732   N³, N³-dipropylisophthalamide   N¹-((1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl) amino]-2-hydroxypropyl}-5-(1,3-oxazol-5-yl)-N³, N³-2733   dipropylisophthalamide hydrochloride   N¹-((1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-ethynylbenzyl) amino]-2-hydroxypropyl}-5-(1,3-oxazol-2-yl)-N³, N³-2734   dipropylisophthalamide hydrochloride   N¹-butyl-N³-(1S, 2R)-1-(3,5-difluorobenzyl) amino]-2-hydroxypropyl}-N³, N³-2736   dimethyl-5-(1,3-oxazol-2-yl) isophthalamide   N¹-((1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl) amino]-2-hydroxypropyl}-N³, N³-2736   dimethyl-5-(1,3-oxazol-2-yl) isophthalamide   N¹-((1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl) amino]-2-hydroxypropyl}-N³-2   ethyl-5-(1,3-oxazol-2-yl)-N³-2   propylisophthalamide   N¹-((1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl) amino]-2-hydroxypropyl}-N³-3   (3-ethylbenzyl) amino]-2-hydroxypropyl]-N³-3   (3-ethylbenzyl) amino]-2-hydroxypropyl]-N³-3   (3-ethylbenzyl) amino]-2-hydroxypropyl]-N³-3   (3-ethylbenzyl) amino]-2-hydroxypropyl]-N³-3   (3-ethyl			1
N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³, N³-dipropyl-5-(pyrrolidin-1-ylsulfonyl)isophthalamide hydrochloride   N¹-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-(isopentylamino)propyl]-5-{[(2-hydroxy-1,1-dimethylethyl)amino]sulfonyl}-N³, N³-dipropylisophthalamide   N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-oxazol-5-yl)-N³, N³-2733 dipropylisophthalamide hydrochloride   N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethynylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-oxazol-2-yl)-N³, N³-2734 dipropylisophthalamide hydrochloride   N¹-butyl-N³-{(1S,2R)-1-(3,5-difluorobenzyl)amino]-2-hydroxypropyl}-N³-methyl-5-(1,3-oxazol-2-yl)isophthalamide   N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³, N³-2736 dimethyl-5-(1,3-oxazol-2-yl)isophthalamide   N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-2737 propylisophthalamide   N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-2737 propylisophthalamide   N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethynylbenzyl)amino]-2-hydroxypropyl}-N³, N³-2738   N³-2739 propylisophthalamide   N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³, N³-3-dipropyl-5-(1,3-thiazol-2-yl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-ethylbenzyl)amino]-2-hydroxypropyl]-3-[(1-ethylbenzyl)amino]-2-hydroxypropyl]-3-[(1-ethylbenzyl)amino]-2-hydroxy	2730		
ethylbenzyl)amino]-2-hydroxypropyl}-N³,N³-dipropyl-5-(pyrrolidin-1-2731 ylsulfonyl)isophthalamide hydrochloride   N³-[(1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-(isopentylamino)propyl]-5-{[(2-hydroxy-3-(isopentylamino)propyl]-5-{[(2-hydroxy-1,1-dimethylethyl)amino]sulfonyl}-2732   N³,N³-dipropylisophthalamide   N³-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-oxazol-5-yl)-N³,N³-2733   dipropylisophthalamide hydrochloride   N³-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethynylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-oxazol-2-yl)-N³,N³-2734   dipropylisophthalamide hydrochloride   N³-butyl-N³-{(1s,2R)-1-(3,5-difluorobenzyl)amino]-2-hydroxypropyl}-N³-(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-N³-(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-N³-(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-N³-(1,3-oxazol-2-yl)isophthalamide   N³-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-(1,3-oxazol-2-yl)-N³-(1,3-oxazol	2,00		690
dipropyl-5-(pyrrolidin-1-   ylsulfonyl)isophthalamide hydrochloride			1
2731 ylsulfonyl)isophthalamide hydrochloride  N¹-[(1S,2R)-1-(3,5-difluorobenzyl)-2- hydroxy-3-(isopentylamino)propyl]-5-[(2- hydroxy-1,1-dimethylethyl)amino]sulfonyl)-  2732 N³,N³-dipropylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2-hydroxypropyl}-5- (1,3-oxazol-5-yl)-N³,N³-  2733 dipropylisophthalamide hydrochloride  N³-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3- ethynylbenzyl)amino]-2-hydroxypropyl}-5- (1,3-oxazol-2-yl)-N³,N³-  2734 dipropylisophthalamide hydrochloride  N¹-butyl-N³-{(1S,2R)-1-(3,5- difluorobenzyl)-3-((3-ethylbenzyl)amino]- 2-hydroxypropyl}-N¹-methyl-5-(1,3-oxazol-2- y1)isophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2-hydroxypropyl)-N³- dimethyl-5-(1,3-oxazol-2-yl)isophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2-hydroxypropyl)-N³- ethyl-5-(1,3-oxazol-2-yl)-N³- 2737 propylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3- ethynylbenzyl)amino]-2-hydroxypropyl)- N³,N³,dipropyl-5-(1,3-thiazol-2- yl)isophthalamide hydrochloride  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2-hydroxypropyl)-3-[(3- ethylbe			1
N <sup>1</sup> -[(1S,2R)-1-(3,5-difluorobenzyl)-2-   hydroxy-3-(isopentylamino)propyl]-5-{[(2-   hydroxy-1,1-dimethylethyl)amino]sulfonyl}-   N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide	2721		į
hydroxy-3-(isopentylamino)propyl]-5-{[(2-hydroxy-1,1-dimethylethyl)amino]sulfonyl}- N³, N³-dipropylisophthalamide N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-oxazo1-5-yl)-N³,N³-dipropylisophthalamide hydrochloride N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethynylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-oxazo1-2-yl)-N³,N³-dipropylisophthalamide hydrochloride N¹-butyl-N³-{(1S,2R)-1-(3,5-difluorobenzyl)amino]-2-hydroxypropyl}-N¹-methyl-5-(1,3-oxazo1-2-yl)isophthalamide N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³,N³-dimethyl-5-(1,3-oxazo1-2-yl)isophthalamide N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethyl-5-(1,3-oxazo1-2-yl)isophthalamide N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethyl-5-(1,3-oxazo1-2-yl)-N³-yropylisophthalamide N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{(11-propylbutyl)amino]-2-hydroxypropyl}-3-{(11-propylbutyl)amino]-2-hydroxypropyl}-3-{(11-propylbutyl)amino]-2-hydroxypropyl}-3-{(12-propylbutyl)am	2/01		660
hydroxy-1,1-dimethylethyl)amino]sulfonyl}-  N³, N³-dipropylisophthalamide			009
2732 N³, N³-dipropylisophthalamide  N¹-{(1S, 2R) -1 - (3, 5-difluorobenzyl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl} -5-(1, 3-oxazol-5-yl) -N³, N³-2733 dipropylisophthalamide hydrochloride  N¹-{(1S, 2R) -1 - (3, 5-difluorobenzyl) -3-[(3-ethynylbenzyl) amino] -2-hydroxypropyl} -5-(1, 3-oxazol-2-yl) -N³, N³-2734 dipropylisophthalamide hydrochloride  N¹-butyl-N³-{(1S, 2R) -1 - (3, 5-difluorobenzyl) amino] -2-hydroxypropyl} -N²-difluorobenzyl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl} -N³-methyl-5-(1, 3-oxazol-2-yl) isophthalamide  N¹-{(1S, 2R) -1 - (3, 5-difluorobenzyl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl} -N³, N³-dimethyl -5-(1, 3-oxazol-2-yl) isophthalamide  N¹-{(1S, 2R) -1 - (3, 5-difluorobenzyl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl} -N³-ethyl -5-(1, 3-oxazol -2-yl) -N³-propylisophthalamide  N¹-{(1S, 2R) -1 - (3, 5-difluorobenzyl) -3-[(3-ethynylbenzyl) amino] -2-hydroxypropyl} -N³-ethynylbenzyl) amino] -2-hydroxypropyl} -N³, N³-dipropyl -5-(1, 3-thiazol -2-yl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-[(3-ethylbe		hydroxy-1 1-dimethylethyleminal151	
N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-oxazol-5-yl)-N³,N³-dipropylisophthalamide hydrochloride	2722	N <sup>3</sup> N <sup>3</sup> -dipropulicenthaleside	
ethylbenzyl)amino]-2-hydroxypropyl}-5- (1,3-oxazol-5-yl)-N³,N³- 2733 dipropylisophthalamide hydrochloride  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethynylbenzyl)amino]-2-hydroxypropyl}-5- (1,3-oxazol-2-yl)-N³,N³- 2734 dipropylisophthalamide hydrochloride  N¹-butyl-N³-{(1S,2R)-1-(3,5-difluorobenzyl)amino]-2-hydroxypropyl}-N¹-methyl-5-(1,3-oxazol-2-yl)isophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³,N³- 2736 dimethyl-5-(1,3-oxazol-2-yl)isophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³- ethyl-5-(1,3-oxazol-2-yl)-N³- 2737 propylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethynylbenzyl)amino]-2-hydroxypropyl}-N³,N³-dipropyl-5-(1,3-thiazol-2-yl)-3-[(3-ethynylbenzyl)amino]-2-hydroxypropyl}-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-2739 propylbutyl)amino]-2-hydroxypropyl}-3-[(1-2739 propylbutyl)amino]-2-hydroxypropyl}-5-[(2R)-2-(hydroxymethyl)pyrrolidin-1-	2132		600
(1,3-oxazol-5-yl)-N³,N³-    dipropylisophthalamide hydrochloride		othylbonasillaminal 2 hadron and 3	633
2733 dipropylisophthalamide hydrochloride  N¹-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethynylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-oxazol-2-yl)-N³,N³- 2734 dipropylisophthalamide hydrochloride  N¹-butyl-N³-{(1s,2R)-1-(3,5-difluorobenzyl)amino]-2-hydroxypropyl}-N²-methyl-5-(1,3-oxazol-2-yl)isophthalamide  N¹-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³,N³-dimethyl-5-(1,3-oxazol-2-yl)isophthalamide  N¹-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethyl-5-(1,3-oxazol-2-yl)-N³-propylisophthalamide  N¹-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethynylbenzyl)amino]-2-hydroxypropyl}-N³,N³-dipropyl-5-(1,3-thiazol-2-yl)isophthalamide hydrochloride  N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(1-propylbutyl)amino]sulfonyl}propanamide  N¹-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-			
N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethynylbenzyl) amino]-2-hydroxypropyl}-5-(1,3-oxazol-2-yl)-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide hydrochloride   N <sup>1</sup> -butyl-N <sup>3</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl) amino]-2-hydroxypropyl}-N <sup>1</sup> -methyl-5-(1,3-oxazol-2-yl) isophthalamide   N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl) amino]-2-hydroxypropyl}-N <sup>3</sup> ,N <sup>3</sup> -dimethyl-5-(1,3-oxazol-2-yl) isophthalamide   N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl) amino]-2-hydroxypropyl}-N <sup>3</sup> -ethylbenzyl) amino]-2-hydroxypropyl}-N <sup>3</sup> -ethyl-5-(1,3-oxazol-2-yl)-N <sup>3</sup> -propylisophthalamide   N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethynylbenzyl) amino]-2-hydroxypropyl}-N <sup>3</sup> ,N <sup>3</sup> -dipropyl-5-(1,3-thiazol-2-yl) isophthalamide   N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl) amino]-2-hydroxypropyl}-3-{(1-2739 propylbutyl) amino] sulfonyl} propanamide   N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl) amino]-2-hydroxypropyl}-5-{(12R)-2-(hydroxymethyl) pyrrolidin-1-	0700		
ethynylbenzyl)amino]-2-hydroxypropyl}-5- (1,3-oxazol-2-yl)-N³,N³- 2734 dipropylisophthalamide hydrochloride  N¹-butyl-N³-{(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3-ethylbenzyl)amino]- 2-hydroxypropyl}-N¹-methyl-5-(1,3-oxazol-2- y1)isophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2-hydroxypropyl}-N³,N³- 3 2736 dimethyl-5-(1,3-oxazol-2-yl)isophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2-hydroxypropyl}-N³- ethyl-5-(1,3-oxazol-2-yl)-N³- propylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3- ethynylbenzyl)amino]-2-hydroxypropyl}- N³,N³-dipropyl-5-(1,3-thiazol-2- y1)isophthalamide hydrochloride  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2-hydroxypropyl}-3- {[(1- 2739 propylbutyl)amino]sulfonyl)propanamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2-hydroxypropyl}-5- {[(2R)-2-(hydroxymethyl)pyrrolidin-1-	2/33	dipropylisophthalamide hydrochloride	
(1,3-oxazol-2-yl)-N³,N³-    2734   dipropylisophthalamide hydrochloride			629
2734 dipropylisophthalamide hydrochloride  N¹-butyl-N³-{(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3-ethylbenzyl)amino]- 2-hydroxypropyl}-N¹-methyl-5-(1,3-oxazol-2- yl)isophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2-hydroxypropyl}-N³,N³- dimethyl-5-(1,3-oxazol-2-yl)isophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2-hydroxypropyl}-N³- ethyl-5-(1,3-oxazol-2-yl)-N³- propylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3- ethynylbenzyl)amino]-2-hydroxypropyl}- N³,N³-dipropyl-5-(1,3-thiazol-2- yl)isophthalamide hydrochloride  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2-hydroxypropyl}-3- {[(1- propylbutyl)amino]-2-hydroxypropyl}-3- {[(1- ethylbenzyl)amino]sulfonyl)propanamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2-hydroxypropyl}-5- {[(2R)-2-(hydroxymethyl)pyrrolidin-1-			
N <sup>1</sup> -butyl-N <sup>3</sup> -{(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3-ethylbenzyl)amino]- 2-hydroxypropyl}-N <sup>1</sup> -methyl-5-(1,3-oxazol-2- yl)isophthalamide	0704		
difluorobenzyl) -3-[(3-ethylbenzyl) amino] - 2-hydroxypropyl}-N¹-methyl-5-(1,3-oxazol-2- yl) isophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl) amino]-2-hydroxypropyl}-N³,N³-3 dimethyl-5-(1,3-oxazol-2-yl) isophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl) amino]-2-hydroxypropyl}-N³-4 ethyl-5-(1,3-oxazol-2-yl)-N³-2 propylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethynylbenzyl) amino]-2-hydroxypropyl}-N³,N³-dipropyl-5-(1,3-thiazol-2-yl) isophthalamide hydrochloride  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl) amino]-2-hydroxypropyl}-3-{((1-propylbutyl) amino] sulfonyl) propanamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl) amino]-2-hydroxypropyl}-5-{((2R)-2-(hydroxymethyl) pyrrolidin-1-	2/34		ļ
2-hydroxypropyl)-N¹-methyl-5-(1,3-oxazol-2-yl) isophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³,N³-3  2736 dimethyl-5-(1,3-oxazol-2-yl) isophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-4  ethyl-5-(1,3-oxazol-2-yl)-N³-2  propylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethynylbenzyl)amino]-2-hydroxypropyl}-N³,N³-dipropyl-5-(1,3-thiazol-2-yl)isophthalamide hydrochloride  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(1-2739 propylbutyl)amino]sulfonyl}propanamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-	:		
2735   y1) isophthalamide   N¹-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1}-N³, N³-dimethyl-5-(1,3-oxazol-2-y1) isophthalamide   N¹-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1}-N³-ethyl-5-(1,3-oxazol-2-y1)-N³-propylisophthalamide   N¹-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethynylbenzy1) amino]-2-hydroxypropy1}-N³, N³-dipropyl-5-(1,3-thiazol-2-y1) isophthalamide   N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropyl}-3-{(15,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropyl}-3-{(1-ethylbenzy1) amino] sulfonyl} propanamide   N¹-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropyl}-5-{(12R)-2-(hydroxymethyl) pyrrolidin-1-			4
N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³,N³-3  2736 dimethyl-5-(1,3-oxazol-2-yl)isophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-4  ethyl-5-(1,3-oxazol-2-yl)-N³-propylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethynylbenzyl)amino]-2-hydroxypropyl}-N³,N³-dipropyl-5-(1,3-thiazol-2-yl)isophthalamide hydrochloride  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(1-propyl-5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(1-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(1-ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-	0705		
2736 dimethyl-5-(1,3-oxazol-2-yl)isophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-4  ethyl-5-(1,3-oxazol-2-yl)-N³-2  2737 propylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethynylbenzyl)amino]-2-hydroxypropyl}-N³,N³-dipropyl-5-(1,3-thiazol-2-yl)isophthalamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-ethylbenzyl)amino]sulfonyl)propanamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[(2R)-2-(hydroxymethyl)pyrrolidin-1-	2/35		
2736 dimethyl-5-(1,3-oxazol-2-yl)isophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-619.ethylbenzyl)amino]-2-hydroxypropyl}-N³-4 ethyl-5-(1,3-oxazol-2-yl)-N³- propylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-645-ethynylbenzyl)amino]-2-hydroxypropyl}-N³,N³-dipropyl-5-(1,3-thiazol-2-yl)isophthalamide hydrochloride  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-645-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(1-2739-2739-2739]-2-hydroxypropyl}-3-{(15,2R)-1-(3,5-difluorobenzyl)-3-[(3-645-ethylbenzyl)amino]sulfonyl}propanamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-645-ethylbenzyl)amino]-2-hydroxypropyl}-5-{(12R)-2-(hydroxymethyl)pyrrolidin-1-645-ethylbenzyl)amino]-2-hydroxypropyl}-5-{(12R)-2-(hydroxymethyl)pyrrolidin-1-645-ethylbenzyl)amino]-2-hydroxypropyl}-5-{(12R)-2-(hydroxymethyl)pyrrolidin-1-645-ethylbenzyl)amino]-2-hydroxypropyl}-5-{(12R)-2-(hydroxymethyl)pyrrolidin-1-645-ethylbenzyl)amino]-2-hydroxypropyl}-5-{(12R)-2-(hydroxymethyl)pyrrolidin-1-645-ethylbenzyl)amino]-2-hydroxypropyl}-5-{(12R)-2-(hydroxymethyl)pyrrolidin-1-645-ethylbenzyl)amino]-2-hydroxypropyl}-5-{(12R)-2-(hydroxymethyl)pyrrolidin-1-645-ethylbenzyl)amino]-2-hydroxypropyl}-5-{(12R)-2-(hydroxymethyl)pyrrolidin-1-645-ethylbenzyl)amino]-2-hydroxypropyl}-5-{(12R)-2-(hydroxymethyl)pyrrolidin-1-645-ethylbenzyl)amino]-2-hydroxypropyl}-5-{(12R)-2-(hydroxymethyl)pyrrolidin-1-645-ethylbenzyl)amino]-2-hydroxypropyl}-5-{(12R)-2-(hydroxymethyl)pyrrolidin-1-645-ethylbenzyl)amino]-2-hydroxypropyl}-5-{(12R)-2-(hydroxymethyl)pyrrolidin-1-645-ethylbenzyl)amino]-2-hydroxypropyl}-5-{(12R)-2-(hydroxymethyl)pyrrolidin-1-645-ethylbenzyl)amino]-2-hydroxypropyl}-5-{(12R)-2-(hydroxymethyl)pyrrolidin-1-645-ethylbenzyl)amino]-2-hydroxypropyl}-5-{(12R)-2-(hydroxymethyl)pyrrolidin-1-645-ethylbenzyl)amino]-2-hydroxypropyl}-5-{(12R)-2-(hydroxymethyl)pyrrolidin-1-645-ethylbenzyl)amino]-2-hydroxypropyl}-5-{(12R)-2-(hydroxymethyl)pyrrolidin-1-645-ethylbenzyl)amino]-2-hydroxypropyl}-5-{(12R)-2-(hydroxymethylbenzyl)amino]-2-hydroxypropyl}-5-{(12R)-2-(hydroxymethylbe		$N^{2}-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-4)]$	1
N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethyl-5-(1,3-oxazol-2-yl)-N³-propylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethynylbenzyl)amino]-2-hydroxypropyl}-N³,N³-dipropyl-5-(1,3-thiazol-2-yl)isophthalamide hydrochloride  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(1-ethylbenzyl)amino]sulfonyl}propanamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-	0705		3
ethylbenzyl)amino]-2-hydroxypropyl}-N³- ethyl-5-(1,3-oxazol-2-yl)-N³- propylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethynylbenzyl)amino]-2-hydroxypropyl}- N³,N³-dipropyl-5-(1,3-thiazol-2-yl)isophthalamide hydrochloride  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3- {[(1-2739 propylbutyl)amino]sulfonyl}propanamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5- {[(2R)-2-(hydroxymethyl)pyrrolidin-1-	2/36	<pre>aimetny1-5-(1,3-oxazo1-2-yl)isophthalamide</pre>	
ethyl-5-(1,3-oxazol-2-yl)-N³- propylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethynylbenzyl)amino]-2-hydroxypropyl}- N³,N³-dipropyl-5-(1,3-thiazol-2-yl)isophthalamide hydrochloride  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(1-2739 propylbutyl)amino]sulfonyl}propanamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-			619.
2737 propylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethynylbenzyl)amino]-2-hydroxypropyl}- N³,N³-dipropyl-5-(1,3-thiazol-2-yl)isophthalamide hydrochloride  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(1-ethylbenzyl)amino]sulfonyl)propanamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-			4
N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethynylbenzy1)amino]-2-hydroxypropy1}- N <sup>3</sup> ,N <sup>3</sup> -dipropy1-5-(1,3-thiazo1-2-y1)isophthalamide hydrochloride  N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-3-{[(1-propylbuty1)amino]sulfonyl}propanamide  N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-5-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-			
ethynylbenzyl)amino]-2-hydroxypropyl}- N³,N³-dipropyl-5-(1,3-thiazol-2- yl)isophthalamide hydrochloride  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3- {[(1-propylbutyl)amino]sulfonyl}propanamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5- {[(2R)-2-(hydroxymethyl)pyrrolidin-1-	2737		
N <sup>3</sup> , N <sup>3</sup> -dipropyl-5-(1,3-thiazol-2- yl)isophthalamide hydrochloride  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-68) ethylbenzyl)amino]-2-hydroxypropyl}-3- {[(1-2739 propylbutyl)amino]sulfonyl}propanamide  N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-62) ethylbenzyl)amino]-2-hydroxypropyl}-5- {[(2R)-2-(hydroxymethyl)pyrrolidin-1-62]			645
<pre>2738 y1)isophthalamide hydrochloride  N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-chylbenzy1)amino]-2-hydroxypropy1}-3-{[(1-cylbenzy1)amino]sulfony1}propanamide  N^1-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-chylbenzy1)amino]-2-hydroxypropy1}-5-{[(2R)-2-(hydroxymethy1)pyrrolidin-1-cylbenzy1)amino]-2-hydroxymethy1)pyrrolidin-1-</pre>		ethynylbenzyl)amino]-2-hydroxypropyl}-	ļİ
N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(1-propylbutyl)amino]sulfonyl}propanamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-			
ethylbenzyl)amino]-2-hydroxypropyl}-3- {[(1- 2739 propylbutyl)amino]sulfonyl)propanamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2-hydroxypropyl}-5- {[(2R)-2-(hydroxymethyl)pyrrolidin-1-	2738		
{[(1- 2739 propylbutyl)amino]sulfonyl}propanamide N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2-hydroxypropyl}-5- {[(2R)-2-(hydroxymethyl)pyrrolidin-1-			568
2739 propylbutyl)amino]sulfonyl}propanamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-729) ethylbenzyl)amino]-2-hydroxypropyl}-5- {[(2R)-2-(hydroxymethyl)pyrrolidin-1-			
N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-729 ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-	_		
ethylbenzyl)amino]-2-hydroxypropyl}-5- {[(2R)-2-(hydroxymethyl)pyrrolidin-1-	2739	<pre>propylbutyl)amino]sulfonyl}propanamide</pre>	
{[(2R)-2-(hydroxymethyl)pyrrolidin-1-			729
{[(2R)-2-(hydroxymethyl)pyrrolidin-1- 2740 vllsulfonyl}-N <sup>3</sup> N <sup>3</sup> -dipropylisophthalamide		ethylbenzyl)amino]-2-hydroxypropyl}-5-	
2740   vllsulfonvll-N3 N3-dipropylicophthalamide		{[(2R)-2-(hydroxymethyl)pyrrolidin-1-	
o l 1 - 1 - 2 - 2 - 2 - 1 1 1 1 1	2740	yl]sulfonyl}-N3,N3-dipropylisophthalamide	

	$N^{1}$ -{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-	713
	ecriptive thereby   amino -2-hvdroxvnropy   1-5-	1,13
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	
	dimethylethyl)amino]sulfonyl}-N <sup>3</sup> ,N <sup>3</sup> -	
2741		ŀ
	$N^1-[(1S,2R)-1-(3,5-difluorobenzyl)-2-$	<del></del>
	1 Hydroxy-3-(1Sobiity) amino) prop-31 5 4 5	571
	oxazol-2-yl)-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide	
2742	hydrochloride	
	5-bromo-N <sup>1</sup> -((1s,2R)-1-[3-fluoro-4-	
	(trifluoromothyl) how all a	734
	(trifluoromethyl)benzyl]-2-hydroxy-3-{[3-	1
2743	(trifluoromethyl)benzyl]amino)propyl)-	
2/40		l
	5-bromo-N <sup>1</sup> -((1S,2R)-2-hydroxy-1-(2,3,4-	
	[critiuoropenzyl]-3-{[3-	
0744	(trifluoromethyl)benzyl]amino}propyl)-	
2744	<u>ln</u> ,n -ulpropylisophthalamide	-
	$N-\{(1S, 2R)-1-(3, 5-diffuorobenzyl)-3, 1/3$	551
	ecliyibenzyi)amino -2-hvdroxypropyil 2 /2	3
	echyloutanoy1) -5-methylbenzamide	13
2745	Lnydrochloride	
	N-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-	-
	ethylbenzyl)amino]-2-hydroxypropyl}-3-	606
	methyl-5-[(2-propylpiperidin-1-	3
2746	yl)carbonyl]benzamide hydrochloride	
	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-	
	ethylbenzyl)amino]-2-hydroxypropyl}-3-	564.
	methyl-5-[(2-methylpyrrolidin-1-	4
2747	V1) Carbonyl lbenzami de beste de la la la la la la la la la la la la la	
	N-{(1s, 2r)-1-(3, 5-difluorobenzyl)-3-[(3-	592.
	ethylbenzyl)amino]-2-hydroxypropyl}-3-	3
2748	[(2,6-dimethylpiperidin-1-yl)carbonyl]-5-	
2/40	methylbenzamide hydrochlorido	
	N <sup>1</sup> -{(1s, 2r) -1-(3, 5-difluorobenzyl) -3-[(3-	703
	echylbenzyl)amino]-2-hydroxypropyll-5-	
2749	{[(2-methoxyethyl)amino]sulfonyl}-N <sup>3</sup> ,N <sup>3</sup> -	İ
2/49	dipropylisophthalamide	
1	$N^1$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-	689.
	nydroxy-3-{[3-	6
	(trifluoromethyl)benzyl]amino}propyl)-	
	N, N-dlpropyl-5-(1,3-thiazol-2-	İ
2/50	YI)lsophthalamide dihydrochlorido	
	$N^2 - \{ (1S, 2R) - 1 - (3, 5 - diffluorobenzy) \} = 1/2$	605
	ethynylbenzyl)amino]-2-hydroxypropyl}-5-	685.
j	{[(2-hydroxyethyl)amino]sulfonyl}-N³,N³-	2
2751	dipropylisophthalamide	
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	
	ethylbenzyl)amino]-2-hydroxypropyl}-3-	579.
	methyl-5-(2-propyl-september 2)	3
2752	methyl-5-(2-propylpentanoyl)benzamide hydrochloride	
<b>4/</b> 32 L		

	$N^{1}$ -(sec-butyl)- $N^{3}$ -{(1S,2R)-1-(3,5-	594.
		{
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-	6
	2-hydroxypropyl}-5-methyl-N1-	
2753	propylisophthalamide	
	$N^{1}$ -butyl- $N^{3}$ -{ (1S,2R)-1-(3,5-	594.
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-	6
	2-hydroxypropyl}-5-methyl-N <sup>1</sup> -	
2754	propylisophthalamide	
	$N^1$ -allyl- $N^1$ -cyclopentyl- $N^3$ -{(1S,2R)-1-(3,5-	600.
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-	5
2755	2-hydroxypropyl}-5-methylisophthalamide	
	$N^1, N^1$ -dibutyl- $N^3$ -{(1S, 2R)-1-(3, 5-	608.
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-	6
2756	2-hydroxypropyl}-5-methylisophthalamide	
	$N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$	608.
	ethylbenzyl)amino]-2-hydroxypropyl}-N3,N3-	6
2757	diisobutyl-5-methylisophthalamide	
	$N^{1}$ -[(1S,2R)-1-(3,5-difluorobenzyl)-2-	
	hydroxy-3-({3-[(1Z)-prop-1-	
	enyl]benzyl}amino)propyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -	
2758	1	
2700	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[3-	644.
	(ethylsulfonyl)benzyl]amino}-2-	2
	hydroxypropyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -	~
2759	dipropylisophthalamide	
2139	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-	704.
	hydroxy-3-{[1-(3-	1
	iodophenyl)cyclopropyl]amino}propyl)-5-	*
2760	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide	
2700	meenyi-w, w dipropyiisophenaramide	561.
		2
		4
	Д Н он н о	
2761		<del>                                     </del>
	$N^{1}$ -[(1S,2R)-3-[(1,1'-biphenyl-3-	
	ylmethyl)amino]-1-(3,5-difluorobenzyl)-2-	
	hydroxypropyl]-5-methyl-N <sup>3</sup> , N <sup>3</sup> -	
2762	dipropylisophthalamide	
	$N^1$ -{(1S,2R)-1-(3,5-difluorobenzyl)-2-	593.
	hydroxy-3-[(3-hydroxy-1-	3
	phenylpropyl)amino]propyl}-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -	
2763	dipropylisophthalamide	<u> </u>
	$N^1$ -cyclohexyl- $N^3$ -{(1S,2R)-1-(3,5-	594.
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-	6
	2-hydroxypropyl}-N <sup>1</sup> ,5-	
2764	dimethylisophthalamide	
	$N^{1}$ -cyclohexyl- $N^{3}$ -{ (1S, 2R) -1- (3, 5-	606.
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-	6
	2-hydroxypropyl}-N <sup>1</sup> -ethyl-5-	
2765	methylisophthalamide	1
2703	incomplete and a second	_1

N <sup>1</sup> -[(1S,2R)-3-{[3-(1-benzothien-2-	684.
yl)benzyl]amino}-1-(3,5-difluorobenzyl)-2-	5
nydroxypropyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -	1
$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-	630.
hydroxy-3-{ [3-	2
(trifluoromethyl)benzyl]amino}propyl)-5-	1
ethynyl-N', N'-dipropylisophthalamide	
$N^2 - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 2 - (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 2 - (1S, 2R) - 1 - (1S, 2R) - (1S, 2R) - 1 - (1S, 2R) - ($	633.
hydroxy-3-[(3-thien-3-	0
ylbenzyl)amino]propyl}-5-methyl-N <sup>3</sup> .N <sup>3</sup> -	
dipropylisophthalamide	
$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-	647.
hydroxy-3-{[3-(5-methylthien-2-	047.
yl)benzyl]amino}propyl)-5-methyl-N <sup>3</sup> N <sup>3</sup> -	١٠
dipropylisophthalamide	į
$N^{1}-\{(1S, 2R)-1-(3, 5-diffuorobenzyl)-2-$	629.
hydroxy-3-[(3-pyridin-4-	629.
ylbenzyl)amino]propyl}-5-methyl-N <sup>3</sup> N <sup>3</sup> -	0
dipropylisophthalamide	
$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-	648.
hydroxy-3-{[3-(4-methy]thien-2-	5
yl)benzyl]amino}propyl)-5-methyl-N <sup>3</sup> N <sup>3</sup> -	3
dipropylisophthalamide	
	1
$N^{1}$ - ((1S, 2R) -1 - (3, 5 - difluorobenzyl) -3 - (13	690.
(2,4-dimethoxypyrimidin-5-	6
yl)benzyl]amino}-2-hydroxypropyl}-5-	0
methyl-N', N'-dipropylisophthalamide	
$N^{2}$ ((1S, 2R) -1-(3, 5-difluorobenzyl) -3-(13-	647.
(3,5-dimethylisoxazol-4-vl)benzyllamino}-	6
2-hydroxypropyl)-5-methyl-N <sup>3</sup> .N <sup>3</sup> -	
dipropylisophthalamide	
$N^4 - \{(1S, 2R) - 1 - (3, 5 - diffuorobenzy)\} - 3 - [(3 - 1)]$	581.
ethylbenzyl)aminol-2-hydroxypropyll-6-	3
methyl-N',N'-dipropylpyridine-2,4-	
dicarboxamide	
$N^{1}-[(1S, 2R)-3-\{[3-$	607.
(cyclopropylamino)benzyllamino}-1-(3.5-	3
difluorobenzyl)-2-hydroxypropyll-5-methyl-	
N°,N°-dipropylisophthalamide	
$N^{1}-[(1S, 2R)-3-\{[3-$	617.
/	[ 0 + / • ]
(Cyclopropylamino)benzyllamino}-1-(3 5-	7
(cyclopropylamino)benzyl]amino}-1-(3,5-difluorobenzyl)-2-hydroxypropyl]-5-	3
difluorobenzyl)-2-hydroxypropyl]-5- ethynyl-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamido	3
difluorobenzyl)-2-hydroxypropyl]-5- ethynyl-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamido	
difluorobenzyl)-2-hydroxypropyl]-5- ethynyl-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide N <sup>1</sup> -((1S,2R)-1-(3,5-difluorobenzyl)-2-	641.
difluorobenzyl)-2-hydroxypropyl]-5- ethynyl-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamido	
	N¹-((1s,2R)-1-(3,5-difluorobenzyl)-3-{[3-(3,5-dimethylisoxazol-4-yl)benzyl]amino}-2-hydroxypropyl)-5-methyl-N³,N³-dipropylisophthalamide  N⁴-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-6-methyl-N²,N²-dipropylpyridine-2,4-dicarboxamide  N¹-[(1s,2R)-3-{[3-(cyclopropylamino)benzyl]amino}-1-(3,5-difluorobenzyl)-2-hydroxypropyl]-5-methyl-N³,N³-dipropylisophthalamide  N¹-[(1s,2R)-3-{[3-

N <sup>1</sup> -((1S, 2R) -1-(3, 5-difluorobenzyl) -3-{[1-(3-ethylphenyl) cyclopropyl]amino} -2-hydroxypropyl) -5-(1, 3-oxazol -2-yl) -N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
hydroxypropyl)-5-(1,3-oxazol-2-yl)-N³,N³- dipropylisophthalamide  methyl 3-({[(2R,3S)-4-(3,5- difluorophenyl)-3-({3- [(dipropylamino)carbonyl]-5- methylbenzoyl}amino)-2- hydroxybutyl]amino}methyl)phenyl(methyl)ca  2779 rbamate  N¹-[(1S,2R)-1-(3,5-difluorobenzyl)-2- hydroxy-3-({3- [methyl(methylsulfonyl)amino]benzyl}amino) propyl]-5-methyl-N³,N³-  2780 dipropylisophthalamide  N¹-[(1S,2R)-1-(3,5-difluorobenzyl)-3-({3- [(dimethylamino)sulfonyl]benzyl}amino)-2- hydroxypropyl]-5-methyl-N³,N³-  2781 dipropylisophthalamide  N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-([1- (3-ethylphenyl)cyclopropyl]amino}-2- hydroxypropyl)-5-methyl-N³,N³-  2782 dipropylisophthalamide  N¹-((1S,2R)-1-(3,5-difluorobenzyl)-2- hydroxyp-3-{[(2-isobutyl-1,3-thiazol-5- 2
dipropylisophthalamide
methyl 3-({[(2R,3S)-4-(3,5-difluorophenyl)-3-({3-lifluorophenyl)-3-({3-lifluorophenyl)-5-methylbenzoyl}amino)-2-hydroxybutyl]amino}methyl)phenyl(methyl)ca rbamate
methyl 3-({[(2R,3S)-4-(3,5-difluorophenyl)-3-({3-li(dipropylamino)carbonyl]-5-methylbenzoyl}amino)-2-hydroxybutyl]amino}methyl)phenyl(methyl)carbamate  N¹-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-({3-limethylmino}methyl)amino]benzyl}amino)propyl]-5-methyl-N³,N³-2780 dipropylisophthalamide  N¹-[(1S,2R)-1-(3,5-difluorobenzyl)-3-({3-limethylmino}methylmino)sulfonyl]benzyl}amino)-2-hydroxypropyl]-5-methyl-N³,N³-2781 dipropylisophthalamide  N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-linexilamino}methylmino}mino}mino}mino}mino}mino}mino}mino}
difluorophenyl) -3-({3-   (dipropylamino) carbonyl] -5-   methylbenzoyl amino) -2-   hydroxybutyl] amino   methyl) phenyl (methyl) ca   2779   rbamate
[(dipropylamino)carbonyl]-5- methylbenzoyl}amino)-2- hydroxybutyl]amino}methyl)phenyl(methyl)ca rbamate  N¹-[(1S,2R)-1-(3,5-difluorobenzyl)-2- hydroxy-3-({3- [methyl(methylsulfonyl)amino]benzyl}amino) propyl]-5-methyl-N³,N³- 2780 dipropylisophthalamide  N¹-[(1S,2R)-1-(3,5-difluorobenzyl)-3-({3- [(dimethylamino)sulfonyl]benzyl}amino)-2- hydroxypropyl]-5-methyl-N³,N³- 2781 dipropylisophthalamide  N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1- (3-ethylphenyl)cyclopropyl]amino}-2- hydroxypropyl)-5-methyl-N³,N³- 2782 dipropylisophthalamide  N¹-((1S,2R)-1-(3,5-difluorobenzyl)-2- hydroxyp-3-{[(2-isobutyl-1,3-thiazol-5- 2
methylbenzoyl}amino)-2- hydroxybutyl]amino}methyl)phenyl(methyl)ca  2779 rbamate  N¹-[(1S,2R)-1-(3,5-difluorobenzyl)-2- hydroxy-3-({3- [methyl(methylsulfonyl)amino]benzyl}amino) propyl]-5-methyl-N³,N³- 2780 dipropylisophthalamide  N¹-[(1S,2R)-1-(3,5-difluorobenzyl)-3-({3- [(dimethylamino)sulfonyl]benzyl}amino)-2- hydroxypropyl]-5-methyl-N³,N³- 2781 dipropylisophthalamide  N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1- (3-ethylphenyl)cyclopropyl]amino}-2- hydroxypropyl)-5-methyl-N³,N³- 2782 dipropylisophthalamide  N¹-((1S,2R)-1-(3,5-difluorobenzyl)-2- hydroxy-3-{[(2-isobutyl-1,3-thiazol-5- 2
hydroxybutyl]amino}methyl)phenyl(methyl)ca  2779 rbamate  N¹-[(1S,2R)-1-(3,5-difluorobenzyl)-2- 659. hydroxy-3-({3- 3 [methyl(methylsulfonyl)amino]benzyl}amino) propyl]-5-methyl-N³,N³-  2780 dipropylisophthalamide  N¹-[(1S,2R)-1-(3,5-difluorobenzyl)-3-({3- 659. [(dimethylamino)sulfonyl]benzyl}amino)-2- 3 hydroxypropyl]-5-methyl-N³,N³-  2781 dipropylisophthalamide  N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1- 606. (3-ethylphenyl)cyclopropyl]amino}-2- 3 hydroxypropyl)-5-methyl-N³,N³-  2782 dipropylisophthalamide  N¹-((1S,2R)-1-(3,5-difluorobenzyl)-2- 668. hydroxy-3-{[(2-isobutyl-1,3-thiazol-5- 2
N1-[(1S,2R)-1-(3,5-difluorobenzyl)-2-   659.     hydroxy-3-({3-   3   [methyl (methylsulfonyl) amino] benzyl}amino)   propyl]-5-methyl-N³, N³-     2780   dipropylisophthalamide   N¹-[(1S,2R)-1-(3,5-difluorobenzyl)-3-({3-   659.   (dimethylamino) sulfonyl]benzyl}amino)-2-   3   hydroxypropyl]-5-methyl-N³, N³-     2781   dipropylisophthalamide   N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-   606.   (3-ethylphenyl)cyclopropyl]amino}-2-   3   hydroxypropyl)-5-methyl-N³, N³-   2782   dipropylisophthalamide   N¹-((1S,2R)-1-(3,5-difluorobenzyl)-2-   668.   hydroxy-3-{[(2-isobutyl-1,3-thiazol-5-   2
N¹-[(1S,2R)-1-(3,5-difluorobenzyl)-2-   659.   hydroxy-3-({3-   [methyl (methylsulfonyl) amino] benzyl} amino)   propyl]-5-methyl-N³, N³-   2780   dipropylisophthalamide   N¹-[(1S,2R)-1-(3,5-difluorobenzyl)-3-({3-   659.   [(dimethylamino) sulfonyl] benzyl} amino)-2-   hydroxypropyl]-5-methyl-N³, N³-   2781   dipropylisophthalamide   N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-   606.   (3-ethylphenyl) cyclopropyl] amino}-2-   3   hydroxypropyl)-5-methyl-N³, N³-   2782   dipropylisophthalamide   N¹-((1S,2R)-1-(3,5-difluorobenzyl)-2-   668.   hydroxy-3-{[(2-isobutyl-1,3-thiazol-5-   2
hydroxy-3-({3-
[methyl (methylsulfonyl) amino]benzyl}amino) propyl]-5-methyl-N³,N³-  2780 dipropylisophthalamide  N¹-[(1S,2R)-1-(3,5-difluorobenzyl)-3-({3-659. [(dimethylamino) sulfonyl]benzyl}amino)-2-3 hydroxypropyl]-5-methyl-N³,N³-  2781 dipropylisophthalamide  N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-606.(3-ethylphenyl) cyclopropyl]amino}-2-3 hydroxypropyl)-5-methyl-N³,N³-  2782 dipropylisophthalamide  N¹-((1S,2R)-1-(3,5-difluorobenzyl)-2-668. hydroxy-3-{[(2-isobutyl-1,3-thiazol-5-2668.)
propyl]-5-methyl-N³,N³-    2780   dipropylisophthalamide     N¹-[(1S,2R)-1-(3,5-difluorobenzyl)-3-({3-659.   [(dimethylamino)sulfonyl]benzyl}amino)-2-3     hydroxypropyl]-5-methyl-N³,N³-    2781   dipropylisophthalamide     N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-606.(3-ethylphenyl)cyclopropyl]amino}-2-3     hydroxypropyl)-5-methyl-N³,N³-    2782   dipropylisophthalamide     N¹-((1S,2R)-1-(3,5-difluorobenzyl)-2-3     hydroxy-3-{[(2-isobutyl-1,3-thiazol-5-2688.   hydroxy-3-{[(2-isobutyl-1,3-thiazol-5-2689.   Assumption     10
2780 dipropylisophthalamide  N <sup>1</sup> -[(1S,2R)-1-(3,5-difluorobenzyl)-3-({3-659. [(dimethylamino)sulfonyl]benzyl}amino)-2-3 hydroxypropyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -  2781 dipropylisophthalamide  N <sup>1</sup> -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-606.(3-ethylphenyl)cyclopropyl]amino}-2-3 hydroxypropyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -  2782 dipropylisophthalamide  N <sup>1</sup> -((1S,2R)-1-(3,5-difluorobenzyl)-2-668. hydroxy-3-{[(2-isobutyl-1,3-thiazol-5-269.]  N - (2-isobutyl-1,3-thiazol-5-269.]
N <sup>1</sup> -[(1S,2R)-1-(3,5-difluorobenzyl)-3-({3- [(dimethylamino)sulfonyl]benzyl}amino)-2- hydroxypropyl]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> - 2781 dipropylisophthalamide N <sup>1</sup> -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1- (3-ethylphenyl)cyclopropyl]amino}-2- hydroxypropyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> - 2782 dipropylisophthalamide N <sup>1</sup> -((1S,2R)-1-(3,5-difluorobenzyl)-2- hydroxy-3-{[(2-isobutyl-1,3-thiazol-5-
[(dimethylamino)sulfonyl]benzyl}amino)-2- hydroxypropyl]-5-methyl-N³,N³-  2781 dipropylisophthalamide  N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1- (3-ethylphenyl)cyclopropyl]amino}-2- hydroxypropyl)-5-methyl-N³,N³-  2782 dipropylisophthalamide  N¹-((1S,2R)-1-(3,5-difluorobenzyl)-2- hydroxy-3-{[(2-isobutyl-1,3-thiazol-5- 2
hydroxypropyl]-5-methyl-N³,N³-  2781 dipropylisophthalamide  N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-606.(3-ethylphenyl)cyclopropyl]amino}-2-3 hydroxypropyl)-5-methyl-N³,N³-  2782 dipropylisophthalamide  N¹-((1S,2R)-1-(3,5-difluorobenzyl)-2-668. hydroxy-3-{[(2-isobutyl-1,3-thiazol-5-2
2781 dipropylisophthalamide  N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-606.(3-ethylphenyl)cyclopropyl]amino}-2-3 hydroxypropyl)-5-methyl-N³,N³-  2782 dipropylisophthalamide  N¹-((1S,2R)-1-(3,5-difluorobenzyl)-2-668. hydroxy-3-{[(2-isobutyl-1,3-thiazol-5-2
$ \begin{array}{c} N^1-((1S,2R)-1-(3,5-\text{difluorobenzyl})-3-\{[1-\\ (3-\text{ethylphenyl})\text{cyclopropyl}]\text{amino}\}-2-\\ \text{hydroxypropyl})-5-\text{methyl-N}^3,N^3-\\ 2782 \ \text{dipropylisophthalamide} \\ N^1-((1S,2R)-1-(3,5-\text{difluorobenzyl})-2-\\ \text{hydroxy-3-}\{[(2-\text{isobutyl-1},3-\text{thiazol-5-}\\ 2\end{array} \right. $
(3-ethylphenyl)cyclopropyl]amino}-2- 3 hydroxypropyl)-5-methyl-N³,N³- dipropylisophthalamide  N¹-((1S,2R)-1-(3,5-difluorobenzyl)-2- 668. hydroxy-3-{[(2-isobutyl-1,3-thiazol-5- 2
hydroxypropyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -  2782 dipropylisophthalamide $N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2- hydroxy-3-{[(2-isobutyl-1,3-thiazol-5- 2
2782 dipropylisophthalamide  N <sup>1</sup> -((1S,2R)-1-(3,5-difluorobenzyl)-2- 668. hydroxy-3-{[(2-isobutyl-1,3-thiazol-5- 2
$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2- 668. hydroxy-3-{[(2-isobutyl-1,3-thiazol-5- 2
hydroxy-3-{[(2-isobutyl-1,3-thiazol-5- 2
yl)methyl]amino}propvl)-5-(1.3-oxazol-2-
2783 yl)-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide
$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-618.
(3-ethylphenyl)-1-methylethyl]amino}-2- 3
hydroxypropyl)-5-ethynyl-N <sup>3</sup> ,N <sup>3</sup> -
2785 dipropylisophthalamide
$N^{1}$ -((1S, 2R)-1-(3, 5-difluorobenzyl)-3-{[1- 608.
(3-ethylphenyl)-1-methylethyl]amino}-2- 3
hydroxypropyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -
2786 dipropylisophthalamide
$N^{1}$ -{(1S, 2R) -1-(3, 5-difluorobenzyl) -2- 647.
hydroxy-3-[(3- 2
isopropylbenzyl)amino]propyl}-5-(1,3-
2787 oxazol-2-yl)-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide
$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-661.
(3-ethylphenyl)-1-methylethyl]amino}-2- 3
hydroxypropyl) -5-(1,3-oxazol-2-yl) - $N^3$ , $N^3$ -
2788 dipropylisophthalamide
$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2- 678.
hydroxy-3-{[1-(3-isobutylisoxazol-5- 3
yl)cyclopropyl]amino)propyl)-5-(1,3-
2789 oxazol-2-yl)-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide

	$N^1$ -((1s,2R)-1-(3,5-difluorobenzyl)-2-	635
	nydroxy-3-{[1-(3-isobutylisoxazo]-5-	2
	Y1) Cyclopropyl] amino propyl) -5-ethimyl	1
2790	/ N',N'-dipropviisophthalamide	
	N <sup>1</sup> -[(1S,2R)-1-(3,5-difluorobenzyl)-2-	
	hydroxy-3-({3-	645
	[(methylsulfonyl)amino]benzyl)amino)propyl	2
2791	]-5-methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide	l l
	N <sup>1</sup> -((1S, 2R)-1-(3,5-difluorobenzyl)-2-	
	hydroxy=3-{[1 /2 in-hydroxy=3-	625
	hydroxy-3-{[1-(3-isobutylisoxazol-5-	3
2792	yl)cyclopropyl]amino}propyl)-5-methyl-	
	$N^{1}$ -{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-	629
	ethynylbenzyl)aminol-2-hydroxynropyl}-5-	2
	$(1,3-oxazo1-2-y1)-N^3,N^3-$	
2793	<u> </u>	
	$N^1$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-	673
	nydroxy-3-{[3-	2
	(trifluoromethyl)benzyl]amino}propyl)-5-	4
	$(1,3-\text{oxazol}-2-\text{yl})-N^3,N^3-$	
2794	dipropylisophthalamide	1
	N <sup>1</sup> -[(1S,2R)-3-[(3-cyanobenzyl)amino]-1-	+
	(3,5-difluorobenzyl)-2-hydroxypropyl]-5-	577
2795	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide	2
	diplopylisophthalamide	<del> </del>
	,	649.
		0
	F H HN	
		İ
2796	F	
	$N^{1}$ -((1S, 2R)-1-(3,5-difluorobenzyl)-3-{[1-	655.
	(3-ethynylphenyl)cyclopropyllamino}-2-	3
	hydroxypropyl) -5-(1,3-oxazol-2-yl)- $N^3$ , $N^3$ -	]
2797	dipropylisophthalamide	
	$N^{1}$ -[(1S, 2R)-1-(3,5-difluorobenzyl)-3-({3-	62.4
	[(1E)-hex-1-enyl]benzyl}amino)-2-	634.
	hydroxypropyl]-5-methyl-N <sup>3</sup> , N <sup>3</sup> -	6
2799	dipropylisophthalamide	
	N <sup>1</sup> -[(1S,2R)-3-{[3-(5-acetylthien-2-	
	yl)benzyl]amino}-1-(3,5-difluorobenzyl)-2-	676.
	hydroxypropyl]-5-methyl-N <sup>3</sup> , N <sup>3</sup> -	5
2800	dipropylisophthalamide	
	N <sup>1</sup> -[/1C 2D) 2 [/2 -11-7]	
i	$N^{1}$ -[(1S,2R)-3-[(3-allylbenzyl)amino]-1-	592.
J	Late a TOTAL CONTROL OF THE PROPERTY OF THE PR	6
2004	(3,5-difluorobenzyl)-2-hydroxypropyl]-5-	
2801	methyl-N'.N'-dipropyligophthalamida	
	methyl-N',N'-dipropylisophthalamide $N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-	659.
	methyl-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide N <sup>1</sup> -((1S,2R)-1-(3,5-difluorobenzyl)-2- hydroxy-3-{[3-(6-methoxypyridin-3-	659. 6
	methyl-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide N <sup>1</sup> -((1S,2R)-1-(3,5-difluorobenzyl)-2- hydroxy-3-{[3-(6-methoxypyridin-3- yl)benzyl]amino}propyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -	
	methyl-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide N <sup>1</sup> -((1S,2R)-1-(3,5-difluorobenzyl)-2- hydroxy-3-{[3-(6-methoxypyridin-3-	

	$N^1$ -[(1S,2R)-3-{[(2-tert-butylpyrimidin-4-	610.
	yl)methyl]amino}-1-(3,5-difluorobenzyl)-2-	3
	hydroxypropyl]-5-methyl-N <sup>3</sup> , N <sup>3</sup> -	ر
0000		
2803	dipropylisophthalamide	505
	$N^4 - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 2 - (15, 2R) - 1 - (15, 2R) - 1 - (15, 2R) - 1 - (15, 2R) -$	595.
	hydroxy-3-[(3-	3
	isopropylbenzyl)amino propyl}-6-methyl-	}
2804	N <sup>2</sup> , N <sup>2</sup> -dipropylpyridine-2, 4-dicarboxamide	
	$N^1$ -[(1S,2R)-3-[(3-butylbenzyl)amino]-1-	608.
	(3,5-difluorobenzyl)-2-hydroxypropyl]-5-	6
2805	methyl-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide	
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-2-	622.
	hydroxy-3-[(3-pentylbenzyl)amino]propyl}-	6
2806	5-methyl-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide	
	$N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 2 - $	620.
	hydroxy-3-[(3-pent-4-	6
	enylbenzyl)amino]propyl}-5-methyl-N <sup>3</sup> , N <sup>3</sup> -	
2807		-
	$N^1-[(1S, 2R)-3-[(3-cyclopentylbenzyl)amino]-$	620.
	1-(3,5-difluorobenzyl)-2-hydroxypropyl]-5-	6
2808	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide	~
2000	$N^{1}$ -[(1S, 2R) -3-[(3-cyclohexylbenzyl)amino]-	634.
	1-(3,5-difluorobenzyl)-2-hydroxypropyl]-5-	6
2000	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide	"
2009		640
	$N^{1}-[(1S, 2R)-3-\{[3-(1S, 2R)-3-(1S, 2R)]\}$	648.
	(cyclohexylmethyl)benzyl]amino}-1-(3,5-	6
0040	difluorobenzyl)-2-hydroxypropyl]-5-methyl-	
2810		
	$N^{1}$ -{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-	634.
	hex-5-enylbenzyl)amino]-2-hydroxypropyl}-	6
2811	5-methyl-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide	
	methyl $(2S)-3-[3-(\{[(2R,3S)-4-(3,5-$	
	difluorophenyl)-3-({3-	
	[(dipropylamino)carbonyl]-5-	
	methylbenzoyl}amino)-2-	
	hydroxybutyl]amino}methyl)phenyl]-2-	
2812	methylpropanoate	2812
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-	648.
	hydroxy-3-{[3-(3-methylthien-2-	5
	yl)benzyl]amino}propyl)-5-methyl-N³,N³-	
2813	dipropylisophthalamide	
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-	643.
	hydroxy-3-{[3-(3-methylpyridin-2-	6
	yl)benzyl]amino)propyl)-5-methyl-N³,N³-	
2814		
	$N^1$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-	643.
	hydroxy-3-{[3-(4-methylpyridin-2-	6
	yl)benzyl]amino)propyl)-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -	
2815	- · · · · · · · · · · · · · · · · · ·	
	athrobattematamirae	<u> </u>

	$N^1$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-	643
	nydroxy-3-{[3-(5-methylpyridin-2-	6
	y1) benzyl]amino $propyl)-5-methyl-N3 N3-$	"
2816	dipropylisophthalamide	
	$N^{1}-[(1S, 2R)-3-\{[3-(4-$	642
	chlorobutyl)benzyl]amino}-1-(3,5-	1
	difluorobenzyl)-2-hydroxypropyl]-5-methyl-	6
2817	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide	
	$N^{1}$ -[(1S, 2R)-3-{[3-(3-	
	cyanopropyl)benzyl]amino}-1-(3,5-	619
	difluorohomasi) 2 had	6
2819	difluorobenzyl)-2-hydroxypropyl]-5-methyl-	
2010	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide	1
	$N^{1}$ -[(1S, 2R)-3-{[3-(4-	633.
	cyanobutyl)benzyl]amino}-1-(3,5-	6
	difluorobenzyl) -2-hydroxypropyl] -5-methyl-	
2819	N ,N -dipropylisophthalamide	
	$N^{1}$ -[(1S, 2R)-3-{[3-(6-	661.
	cyanohexyl)benzyllamino}-1-(3 5-	
	difluorobenzyl) -2-hydroxymronyll = 5 mothyl	6
2820	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide	
	N <sup>1</sup> -((1S, 2R)-1-(3, 5-difluorobenzyl)-2-	-
	hydroxy-3-{[3-(6-methylpyridin-2-	643.
	VI) benzyl laminol property 5	6
2821	yl)benzyl]amino}propyl)-5-methyl-N³,N³-dipropylisophthalamide	
	$N^{1}$ / (10 2P) 1 (2.5 1) 62	
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-	619.
	hydroxy-3-{[3-(1,3-oxazol-2-	2
2020	y1)benzyl]amino}propyl)-5-methyl-N³,N³-	1
2822	- I I I I I I I I I I I I I I I I I I I	
	methyl 3-{[((2R,3S)-4-(3,5-	
	difluorophenyl)-3-{[3-	1
	[(dipropylamino)carbonyl]-5-(1,3-oxazol-2-	
	yl)benzoyl]amino}-2-	
	hydroxybutyl)amino]methyl)phenyl(methyl)ca	1
2823	rbamate	
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-	-
	hydroxy-3-{[(1S)-1-	681.
	[(isobutylamino)carbonyl]-3-	0
l.	/mathers 3.5 and Carbony 1 - 3 -	
	(IIIQE DV   Sill fonte   propertion   lambar   l	
2824	(methylsulfonyl)propyl]amino}propyl)-5-	
2824	metnyl-N°,N°-dipropylisophthalamide	
2824	metnyl-N',N'-dipropylisophthalamide $N^1$ -butyl- $N^3$ -{ (1S,2R)-1-(3,5-	580.
2824	N <sup>1</sup> -butyl-N <sup>3</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-	580. 3
	metnyl-N°,N°-dipropylisophthalamide N¹-butyl-N³-{(1S,2R)-1-(3,5- difluorobenzyl)-2-hydroxy-3-[(3- isopropylbenzyl)amino]propyl}-N¹,5-	l
2824	metnyl-N°,N°-dipropylisophthalamide N¹-butyl-N³-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-isopropylbenzyl)amino]propyl}-N¹,5-dimethylisophthalamide	1
	methyl-N°,N°-dipropylisophthalamide N¹-butyl-N³-{(1S,2R)-1-(3,5- difluorobenzyl)-2-hydroxy-3-[(3- isopropylbenzyl)amino]propyl}-N¹,5- dimethylisophthalamide N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-([1-	3
2825	methyl-N°,N°-dipropylisophthalamide N¹-butyl-N³-{(1S,2R)-1-(3,5- difluorobenzyl)-2-hydroxy-3-[(3- isopropylbenzyl)amino]propyl}-N¹,5- dimethylisophthalamide N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1- (3-ethylphenyl)-1-methylethyl]amino}-2-	745.
2825	methyl-N°,N°-dipropylisophthalamide $N^1$ -butyl-N³-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-isopropylbenzyl)amino]propyl}-N¹,5-dimethylisophthalamide $N^1$ -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)-1-methylethyl]amino}-2-hydroxypropyl)-5-{[(2-hydroxy-1,1-	3
2825	methyl-N°,N°-dipropylisophthalamide N¹-butyl-N³-{(1S,2R)-1-(3,5- difluorobenzyl)-2-hydroxy-3-[(3- isopropylbenzyl)amino]propyl}-N¹,5- dimethylisophthalamide N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-([1-	745.

ī		
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-	727
	ethylbenzyl)amino]-2-hydroxypropyl}-5-	
	{methyl[(trifluoromethyl)sulfonyl]amino}-	
2827	$N^3$ , $N^3$ -dipropylisophthalamide	ĺ
	$N^{1}$ -[(1S,2R)-3-(cyclopropylamino)-1-(3,5-	639
1	difluorobenzyl)-2-hydroxypropyl]-5-{[(2-	037
	hydroxar 1 1 dimethylathyllar 25	ł
0000	hydroxy-1,1-dimethylethyl)amino sulfonyl}-	1
2828	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide	
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-	677.
	(3-ethylphenyl)-1-methylethyl]amino}-2-	1
	hydroxypropyl)-N <sup>3</sup> ,N <sup>3</sup> -dipropyl-5-(1,3-	
2829	thiazol-2-yl)isophthalamide	
	$N^{1}$ -{(1s, 2r)-1-(3,5-difluorobenzyl)-3-[(3-	673.
·	ethylbenzyl)amino]-2-hydroxypropyl}-5-	1
		2
	[methyl(methylsulfonyl)amino]-N <sup>3</sup> , N <sup>3</sup> -	
2830	dipropylisophthalamide	
	$N^{1}$ -butyl- $N^{3}$ -((1S,2R)-1-(3,5-	594.
	difluorobenzyl)-3-{[1-(3-ethylphenyl)-1-	3
	methylethyl]amino}-2-hydroxypropyl)-N <sup>1</sup> ,5-	~
2831	dimethylisophthalamide	
2001		
	$N^1$ -((1S,2R)-1-(2,4-difluorobenzyl)-2-	620.
	hydroxy-3-{[3-	2
	(trifluoromethyl)benzyl]amino}propyl)-5-	
2832	methyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide	
	$5-bromo-N^1-((1S,2R)-1-(2,4-difluorobenzyl)-$	684.
l .	1	
1	2-hydroxy-3-{[3-	1
	2-hydroxy-3-{[3- (trifluoromethyl)benzyllaminolpropylla	1
2833	(trifluoromethyl)benzyl]amino}propyl)-	1
2833	(trifluoromethyl)benzyl]amino}propyl)- N³,N³-dipropylisophthalamide	
2833	(trifluoromethyl)benzyl]amino}propyl)- N³,N³-dipropylisophthalamide N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	566
	<pre>(trifluoromethyl)benzyl]amino}propyl)- N³,N³-dipropylisophthalamide N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-</pre>	
2833 2834	<pre>(trifluoromethyl)benzyl]amino}propyl)- N³,N³-dipropylisophthalamide N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-ethylpiperidin-1-yl)sulfonyl]propanamide</pre>	
	(trifluoromethyl)benzyl]amino}propyl)- N³,N³-dipropylisophthalamide N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-ethylpiperidin-1-yl)sulfonyl]propanamide N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-	
	(trifluoromethyl)benzyl]amino}propyl)- N³,N³-dipropylisophthalamide N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-ethylpiperidin-1-yl)sulfonyl]propanamide N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-	566
	(trifluoromethyl)benzyl]amino}propyl)- N³,N³-dipropylisophthalamide N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-ethylpiperidin-1-yl)sulfonyl]propanamide N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-	566
2834	(trifluoromethyl)benzyl]amino}propyl)- N³,N³-dipropylisophthalamide N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-ethylpiperidin-1-yl)sulfonyl]propanamide N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-ethynyl-N³,N³-	566
	(trifluoromethyl)benzyl]amino}propyl)- N³,N³-dipropylisophthalamide N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-ethylpiperidin-1-yl)sulfonyl]propanamide N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-ethynyl-N³,N³-dipropylisophthalamide	566 616. 3
2834	(trifluoromethyl)benzyl]amino}propyl)- N³,N³-dipropylisophthalamide N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-ethylpiperidin-1-yl)sulfonyl]propanamide N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-ethynyl-N³,N³-dipropylisophthalamide N¹-cyclobutyl-N³-{(1S,2R)-1-(3,5-	566 616. 3
2834 2835	(trifluoromethyl)benzyl]amino}propyl)- N³,N³-dipropylisophthalamide N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-ethylpiperidin-1-yl)sulfonyl]propanamide N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-ethynyl-N³,N³-dipropylisophthalamide N¹-cyclobutyl-N³-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-	566 616. 3
2834	(trifluoromethyl)benzyl]amino}propyl)- N³,N³-dipropylisophthalamide N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-ethylpiperidin-1-yl)sulfonyl]propanamide N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-ethynyl-N³,N³-dipropylisophthalamide N¹-cyclobutyl-N³-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methylisophthalamide	566 616. 3
2834 2835	(trifluoromethyl)benzyl]amino}propyl)- N³,N³-dipropylisophthalamide N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-ethylpiperidin-1-yl)sulfonyl]propanamide N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-ethynyl-N³,N³-dipropylisophthalamide N¹-cyclobutyl-N³-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methylisophthalamide N¹-cyclopentyl-N³-{(1S,2R)-1-(3,5-	566 616. 3
2834 2835	(trifluoromethyl)benzyl]amino}propyl)- N³,N³-dipropylisophthalamide N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-ethylpiperidin-1-yl)sulfonyl]propanamide N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-ethynyl-N³,N³-dipropylisophthalamide N¹-cyclobutyl-N³-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methylisophthalamide N¹-cyclopentyl-N³-{(1S,2R)-1-(3,5-	566 616. 3 550. 1
2834 2835 2836	(trifluoromethyl)benzyl]amino}propyl)- N³,N³-dipropylisophthalamide N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-ethylpiperidin-1-yl)sulfonyl]propanamide N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-ethynyl-N³,N³-dipropylisophthalamide N¹-cyclobutyl-N³-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino}-2-hydroxypropyl}-5-methylisophthalamide N¹-cyclopentyl-N³-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino}-2-hydroxypropyl}-3-[(3-ethylbenzyl)amino]-	566 616. 3
2834 2835	(trifluoromethyl)benzyl]amino}propyl)- N³,N³-dipropylisophthalamide N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-ethylpiperidin-1-yl)sulfonyl]propanamide N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-ethynyl-N³,N³-dipropylisophthalamide N¹-cyclobutyl-N³-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino}-2-hydroxypropyl}-5-methylisophthalamide N¹-cyclopentyl-N³-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methylisophthalamide	566 616. 3 550. 1
2834 2835 2836	(trifluoromethyl)benzyl]amino}propyl)- N³,N³-dipropylisophthalamide N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-ethylpiperidin-1-yl)sulfonyl]propanamide N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-ethynyl-N³,N³-dipropylisophthalamide N¹-cyclobutyl-N³-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methylisophthalamide N¹-cyclopentyl-N³-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methylisophthalamide N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methylisophthalamide	566 616. 3 550. 1 564. 1
2834 2835 2836 2837	(trifluoromethyl)benzyl]amino}propyl)- N³,N³-dipropylisophthalamide N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-ethylpiperidin-1-yl)sulfonyl]propanamide N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-ethynyl-N³,N³-dipropylisophthalamide N¹-cyclobutyl-N³-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methylisophthalamide N¹-cyclopentyl-N³-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methylisophthalamide N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methylisophthalamide	566 616. 3 550. 1
2834 2835 2836	(trifluoromethyl)benzyl]amino}propyl)- N³,N³-dipropylisophthalamide N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-ethylpiperidin-1-yl)sulfonyl]propanamide N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-ethynyl-N³,N³-dipropylisophthalamide N¹-cyclobutyl-N³-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methylisophthalamide N¹-cyclopentyl-N³-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methylisophthalamide N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-N³-pentylisophthalamide	566. 566. 1
2834 2835 2836 2837	(trifluoromethyl)benzyl]amino}propyl)- N³,N³-dipropylisophthalamide N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-ethylpiperidin-1-yl)sulfonyl]propanamide N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-ethynyl-N³,N³-dipropylisophthalamide N¹-cyclobutyl-N³-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methylisophthalamide N¹-cyclopentyl-N³-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methylisophthalamide N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-N³-pentylisophthalamide N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-N³-pentylisophthalamide	566 616. 3 550. 1 564. 1
2834 2835 2836 2837	(trifluoromethyl)benzyl]amino}propyl)- N³,N³-dipropylisophthalamide N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-ethylpiperidin-1-yl)sulfonyl]propanamide N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-ethynyl-N³,N³-dipropylisophthalamide N¹-cyclobutyl-N³-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methylisophthalamide N¹-cyclopentyl-N³-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methylisophthalamide N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-N³-pentylisophthalamide N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-N³-pentylisophthalamide	566. 566. 1
2834 2835 2836 2837	(trifluoromethyl)benzyl]amino}propyl)- N³,N³-dipropylisophthalamide N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-ethylpiperidin-1-yl)sulfonyl]propanamide N¹-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-ethynyl-N³,N³-dipropylisophthalamide N¹-cyclobutyl-N³-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methylisophthalamide N¹-cyclopentyl-N³-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methylisophthalamide N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-N³-pentylisophthalamide	566. 566. 566.

	27	
]	$N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - [ (3 - 4) + 3 - 4 + 4 + 4 + 4 + 4 + 4 + 4 + 4 + 4 + 4$	568
1	I COLLY IDELIZATION I DO I - 2 - Prigram 1 3 3	1
00	[ecnyi-N -(2-nydroxvethyl)_5_	-
284	+U methylisophthalamide	- 1
	$N^{1} - \{(1s, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [(3 - ethylboxyl) - [(3 - ethylboxyl) - [(3 - ethy$	568
	1 CC117 TDC117 V T J J J J J J J J J J J J J J J J J J	1 208
284	''  CCHOAYCUIVI)-5-Methylicophehala	1
	$[10] = \{(10, 40) = 1 = (3, 5 = 0) = (3, 5) = ($	<del></del>
	CCIIVIDEIIZV  Amino  _/  hydanaaa	568
284	- 1 m c c c c c c c c c c c c c c c c c c	1
	$\frac{1}{1}$ $\frac{1}$	
	1 C C L V L D C L L O V L D D D D D L D L D L D L D L D L D L	590
284	3 furylmethyl) -N <sup>3</sup> ,5-dimethylisophthalamide	1
	N-{(1S 2P) 1 (2 F 3:5)	
	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-	578
	ethylbenzyl)amino]-2-hydroxypropyl}-3-	1
284	{[(2R,5R)-2,5-dimethylpyrrolidin-1-	
		-
	N <sup>1</sup> -cyclopentyl-N <sup>3</sup> -{(1S, 2R)-1-(3, 5-	578
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-	1
2041	1 2 11 AT OX ADI ODA I 2 10 2 P	-
2043	dimethylisophthalamide	
	$N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-k)]$	580.
0046	I SCHVIDENZVI Jamino I. O breden	1
2846	/   Grimechtyl-N -Dentyligophthalamid-	+
	$N = \{(15, 2R) - 1 - (3, 5 - diffluor observed) \}$	582.
	Convincent 1 amino 1-2-hydrovymrony 1 N3 (c	1
	my droxyechyl -2-methyl -N <sub>2</sub> -	1
2847	propylisophthalamide	1
	$N^{1} - \{ (1S, 2R) - 1 - (3.5 - difluorobongs) \}$	F00
	1 CC11 1 DC112 V 1 1 dm 1 nO 1 = 2 = h37 dx 0 2 2 2 2 2 2 3 2 3	582.
	ecnyr-N - (2-methoxvethv1)_5_	1
2848	Metnylisophthalamide	
	$N^{1} - \{ (1S, 2R) - 1 - (3.5 - difluorobong) \} $	<b> </b>
	ethylbenzyl)amino]-2-hydroxypropyl}-5-	592.
	$methyl-N^3-(2-$	1
		1
2849		ł
2849	methylcyclohexyl) i sophthalamida	
2849	methylcyclohexyl)isophthalamide  N <sup>1</sup> -{(1S,2R)-1-(3.5-difluorehement) 2.5-difluorehement)	596.
2849	methylcyclohexyl)isophthalamide  N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)aminol-2-hydroxypropyll n <sup>3</sup> /2	596. 1
	methylcyclohexyl)isophthalamide  N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> -(2-methoxyethyl)-5-methyl-N <sup>3</sup> -	
2849 2850	methylcyclohexyl)isophthalamide  N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> -(2-methoxyethyl)-5-methyl-N <sup>3</sup> - propylisophthalamide	
	methylcyclohexyl)isophthalamide $N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-N^3-(2-methoxyethyl)-5-methyl-N^3-propylisophthalamide N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-difluorobenzyl)$	
2850	methylcyclohexyl)isophthalamide  N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> -(2-methoxyethyl)-5-methyl-N <sup>3</sup> - propylisophthalamide  N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxymropyl) x3 x3	1
	methylcyclohexyl)isophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³-(2-methoxyethyl)-5-methyl-N³- propylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³,N³- bis(2-methoxyethyl)-5-mothylisophthalamide	612.
2850	methylcyclohexyl)isophthalamide $N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-N^3-(2-methoxyethyl)-5-methyl-N^3-propylisophthalamide N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-N^3,N^3-bis(2-methoxyethyl)-5-methylisophthalamide N^1-allyl-N^1-cyclohexyl-N^3$	612.
2850 2851	methylcyclohexyl)isophthalamide $N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-N^3-(2-methoxyethyl)-5-methyl-N^3-propylisophthalamide N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-N^3,N^3-bis(2-methoxyethyl)-5-methylisophthalamide N^1-allyl-N^1-cyclohexyl-N^3-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)-3-[(3-ethylbenzyl)-3-[(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)-3-[(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)-3-[(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)-3-[(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)-3-[(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)-3-[(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)-3-[(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)-3-[(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)-3-[(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)-3-[(3,5-difluorobenzyl)-3-[(3,5-difluo$	612. 1
2850	methylcyclohexyl)isophthalamide $N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-N^3-(2-methoxyethyl)-5-methyl-N^3-propylisophthalamide N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-N^3,N^3-bis(2-methoxyethyl)-5-methylisophthalamide N^1-allyl-N^1-cyclohexyl-N^3-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-5-methylisophthalamide 2-hydroxypropyl}-5-methylisophthalamide 3-hydroxypropyl]-5-methylisophthalamide 3-hydroxypropyl}-5-methylisophthalamide 3-hydroxypropyl}-5-methylisophthalamide 3-hydroxypropyl}-5-methylisophthalamide 3-hydroxypropyl}-5-methylisophthalamide 3-hydroxypropyl}-5-methylisophthalamino]-$	612.
2850 2851	methylcyclohexyl) isophthalamide $N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-N^3-(2-methoxyethyl)-5-methyl-N^3-propylisophthalamide N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-N^3,N^3-bis(2-methoxyethyl)-5-methylisophthalamide N^1-allyl-N^1-cyclohexyl-N^3-\{(1S,2R)-1-(3,5-difluorobenzyl)amino]-2-hydroxypropyl\}-5-methylisophthalamide N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)amino]-2-hydroxypropyl\}-5-methylisophthalamide N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)amino]-2-hydroxypropyl\}-5-methylisophthalamide$	612. 1 618. 1
2850 2851	methylcyclohexyl)isophthalamide $N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-N^3-(2-methoxyethyl)-5-methyl-N^3-propylisophthalamide N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-N^3,N^3-bis(2-methoxyethyl)-5-methylisophthalamide N^1-allyl-N^1-cyclohexyl-N^3-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)-3-[(3-ethylbenzyl)-3-[(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)-3-[(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)-3-[(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)-3-[(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)-3-[(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)-3-[(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)-3-[(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)-3-[(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)-3-[(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)-3-[(3,5-difluorobenzyl)-3-[(3,5-difluo$	612. 1 618.

	$N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - [ (3 - 4) - 4] \}$	640.
1	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> ,N <sup>3</sup> -	1
2854	bis(2-ethoxyethyl)-5-methylisophthalamide	-
2004	$N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-2-$	655.
	hydroxy-3-[(2-	2
	naphthylmethyl)amino]propyl}-5-(1,3-	4
2855	oxazol-2-yl)-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide	
2000	$N^{1}$ -butyl- $N^{3}$ -((1S, 2R)-1-(3, 5-	500
		592.
	difluorobenzyl)-3-{[1-(3-	3
0050	ethylphenyl)cyclopropyl]amino}-2-	ĺ
2856	hydroxypropyl)-N <sup>1</sup> ,5-dimethylisophthalamide	5.46
1	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-	743.
l	(3-ethylphenyl)cyclopropyl]amino}-2-	2
	hydroxypropyl)-5-{[(2-hydroxy-1,1-	
	dimethylethyl)amino]sulfonyl}-N <sup>3</sup> ,N <sup>3</sup> -	
2857	dipropylisophthalamide	
	$N^{1}-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-$	688
	ethylbenzyl)amino]-2-hydroxypropyl}-5-[(3-	
	hydroxypropyl)sulfonyl]- $N^3$ , $N^3$ -	
2860	dipropylisophthalamide	
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	632
	ethylbenzyl)amino]-2-hydroxypropyl}-5-(1H-	
	imidazol-4-yl)-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide	
2861	trifluoroacetate	
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	633
	ethylbenzyl)amino]-2-hydroxypropyl}-5-	·
2862	isoxazol-3-yl-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide	
	$N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-$	647
	ethylbenzyl)amino]-2-hydroxypropyl}-3-	
	{[(2R)-2-(methoxymethyl)pyrrolidin-1-	
2863	yl]carbonyl}-5-(1,3-oxazol-2-yl)benzamide	
	$N^4 - \{(1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [(3 - 1)]$	577.
	ethynylbenzyl)amino]-2-hydroxypropyl}-6-	2
	$methyl-N^2, N^2-dipropylpyridine-2, 4-$	
2864	dicarboxamide	
	$N^4$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-	621.
	hydroxy-3-{[3-	2
	(trifluoromethyl)benzyl]amino}propyl)-6-	
	methyl-N <sup>2</sup> , N <sup>2</sup> -dipropylpyridine-2, 4-	
2865	dicarboxamide	
	$N^4 - ((1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - {[1 - (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - ([1 - (3, 5 - difluorobenzyl) - ([1 - (3, 5 - difluor$	607.
	(3-ethylphenyl)cyclopropyl]amino}-2-	3
	hydroxypropyl)-6-methyl- $N^2$ , $N^2$ -	
2866	dipropylpyridine-2,4-dicarboxamide	
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-	675.
	(3-ethylphenyl)cyclopropyl]amino}-2-	4
1	hydroxypropyl) $-N^3$ , $N^3$ -dipropyl-5-(1,3-	
2867	thiazol-2-yl)isophthalamide	
	<u> </u>	L

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-5-[methyl(thien-2-ylsulfonyl)amino]-N³,N³-   2868   dipropylisophthalamide	<del></del>		
2872  2872  2873  2874		$N^{1} - \{(1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [(3 - 4)] - [(3 - 4)] - [(3 - $	741
Interty (thien=-2-ylsulfony ) amino] -N³, N³-   dipropylisophthalamide		ethylbenzyl)amino -2-hydroxymronyl   E	
N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-(([(2R)-2-hydroxypropyl]amino]sulfonyl)-2869   N-3-dipropylisophthalamide		[metnyl(thien-2-ylsulfonyl)aminol-N3 N3-	
N1-{(1S, 2R) -1-(3, 5-difluorobenzyl) -3-((3-ethylbenzyl) amino] -2-hydroxypropyl) -5-(([(2R) -2-hydroxypropyl] amino) sulfonyl) - N3, N3-dipropylisophthalamide	2868	)   Cipropylisophthalamide	ł
2872  2874  N-{(1S, 2R) -1 - (3, 5-difluorobenzyl) -3- (3- ethylbenzyl) amino] -2-hydroxypropyl) -3- (3- ethylbenz		$N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-1/3$	702
2872  2874		ethylbenzyl)aminol-2-hydroxymronyll 5	703
2874  N-\(-(1S,2R)-1-(3,5-difluorobenzyl)-2-\) hydroxy-3-\([1-(2-isobutyl-1,3-thiazol-5-\) yl) cyclopropyl] amino\(] propyl) -5-\([1,3-\) 0xazol-2-yl)-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide  N <sup>1-</sup> \((1S,2R)-1-(3,5-difluorobenzyl)-3-\) 2871 hydroxy-N <sup>5</sup> , N <sup>5</sup> -dipropylpentanediamide  2872  2874  N-\((1S,2R)-1-(3,5-difluorobenzyl)-3-\) 1  2875  N-\((1S,2R)-1-(3,5-difluorobenzyl)-3-\) \([(methylsulfonyl) methyl] benzamide  N-\((1S,2R)-1-(3,5-difluorobenzyl)-3-\) \([(methylsulfonyl) methyl] benzamide  N-\((1S,2R)-1-(3,5-difluorobenzyl)-3-\) \([(methylbenzyl) amino]-2-hydroxypropyl\)-3-\([(3-\) ethylbenzyl) amino]-2-hydroxypropyl\)-3-\([(3-\) ethylbenzyl) amino]-2-hydroxypropyl\)-3-\([(3-\) ethylbenzyl) amino]-2-hydroxypropyl\)-3-\([(3-\) ethylbenzyl) amino]-2-hydroxypropyl\)-3-\([(3-\) ethylbenzyl) amino]-2-hydroxypropyl\)-5-\([(\) ((methylsulfonyl) amino]-2-hydroxypropyl\)-3-\([(3-\) ethylbenzyl) amino]-2-hydroxypropyl\)-3-\([(3-\) ethylbenzyl) amino]-2-hydroxypropyl\)-3-\([(3-\) ethylbenzyl) amino]-2-hydroxypropyl\)-3-\([(3-\) ethylbenzyl) amino]-2-hydroxypropyl\)-3-\([(3-\) ethylbenzyl\)		({[(2R)-2-hydroxypropyl]aminolaulfamin)	
N^-((1s, 2R) -1-(3, 5-difluorobenzyl) -2-	2869	N <sup>3</sup> . N <sup>3</sup> -dipropyligophthalamida	
2870  2870  2870  2870  2870  2870  2870  2870  2870  2871   2871  2871  2871  2872  2872  2872  2873  2873  2874  2874  2874  2874  2875  2876  2877  2876  2877  2878  2879  2879  2879  2870		$N^{2}$ - ((1S 2R) - 1 - (3 5 - d) fluored	
2870   0xazol-2-yl) -N³, N³-dipropyl) -5-(1, 3-oxazol-2-yl) -N³, N³-dipropylisophthalamide   N²-((15, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-   1   1   1   1   1   1   1   1   1		hvdroxy-3-{[1 (2 igeh-b-7 1 2 ) -2-	I
2870   Oxazo1-2-y1)-N', N'-dipropylisophthalamide   N'-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-ethylbenzyl) amino]-2-hydroxypropyl}-3-   1   1   1   1   1   1   1   1   1		vi) cyclopropyllaminal and a second s	2
2872  2874  N-{(1s, 2r) -1-(3, 5-diffluorobenzyl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl} -3- [(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl) -4-[(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-[(3-ethylbenzyl)	2870	1 1 1 1 2 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3	
2872   strylbenzyl)amino]-2-hydroxypropyl}-3-hydroxy-N <sup>5</sup> , N <sup>5</sup> -dipropylpentanediamide   534. 1    2872   strylbenzyl)amino]-2-hydroxypropyl}-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-[(methylsulfonyl)methyl)benzamide   S31.    2876   N-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-[(methylsulfonyl)methyl)benzamide   N-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-N <sup>3</sup> , N <sup>3</sup> -[(3-ethylbenzyl)amino]-2-hydroxypropyl]-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]-3-[(1-propylbutyl)sulfonyl]-D-alaninamide   534.   1   1   1   1   1   1   1   1   1	2070	Nazor-z-yr)-N', N'-dipropylisophthalamide	
2872  2872  2873  N-{(1S, 2R) -1 - (3, 5-difluorobenzyl) -3 - [(3-ethylbenzyl) amino] -2-hydroxypropyl} -3-methyl -5 - (2-methylpentanoyl) benzamide  N-{(1S, 2R) -1 - (3, 5-difluorobenzyl) -3 - [(3-ethylbenzyl) amino] -2-hydroxypropyl} -3-methyl -5 - (2-methylpentanoyl) benzamide  N-{(1S, 2R) -1 - (3, 5-difluorobenzyl) -3 - [(3-ethylbenzyl) amino] -2-hydroxypropyl} -3-methyl -5 - (2-methylpentanoyl) benzamide  N^1-{(1S, 2R) -1 - (3, 5-difluorobenzyl) -3 - [(3-ethylbenzyl) amino] -2-hydroxypropyl} -5-[(methylsulfonyl) amino] -2-hydroxypropyl} -5-[(methylsulfonyl) amino] -2-hydroxypropyl} -5-[(methylsulfonyl) amino] -2-hydroxypropyl} -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl} -3-[(1-propylbutyl) sulfonyl] -D-alaninamide		$N = \{(1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [(3 - 1)]$	548.
2872  2872  2873  N-{(1S, 2R) -1 - (3, 5-difluorobenzyl) -3 - [(3-ethylbenzyl) amino] -2-hydroxypropyl} -3-methyl -5 - (2-methylpentanoyl) benzamide  N-{(1S, 2R) -1 - (3, 5-difluorobenzyl) -3 - [(3-ethylbenzyl) amino] -2-hydroxypropyl} -3-methyl -5 - (2-methylpentanoyl) benzamide  N-{(1S, 2R) -1 - (3, 5-difluorobenzyl) -3 - [(3-ethylbenzyl) amino] -2-hydroxypropyl} -3-methyl -5 - (2-methylpentanoyl) benzamide  N^1-{(1S, 2R) -1 - (3, 5-difluorobenzyl) -3 - [(3-ethylbenzyl) amino] -2-hydroxypropyl} -5-[(methylsulfonyl) amino] -2-hydroxypropyl} -5-[(methylsulfonyl) amino] -2-hydroxypropyl} -5-[(methylsulfonyl) amino] -2-hydroxypropyl} -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl} -3-[(1-propylbutyl) sulfonyl] -D-alaninamide	0074	ethylbenzyl)amino]-2-hydroxypropyl}-3-	1
2872  2873  N-{(1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl} -4-[(methylsulfonyl) methyl]benzamide  N-{(1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl} -3-methyl -5-(2-methylpentanoyl) benzamide  N-{(1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl} -3-methyl -5-(2-methylpentanoyl) benzamide  N¹-((1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl} -5-[(methylsulfonyl) amino] -2-hydroxypropyl] -5-[(methylsulfonyl) amino] -2-hydroxypropyl] -5-[(methylsulfonyl) amino] -2-hydroxypropyl] -3-[(1-propylbutyl) sulfonyl] -D-alaninamide	28/1	hydroxy-N³,N³-dipropylpentanediamide	
2872  2873  N-{(1s, 2R) -1 - (3, 5-difluorobenzy1) -3 - [(3-ethylbenzy1) amino] -2-hydroxypropy1} -4-[(methylsulfony1) methyl) benzamide  N-{(1s, 2R) -1 - (3, 5-difluorobenzy1) -3 - [(3-ethylbenzy1) amino] -2-hydroxypropy1} -3-[(3-ethylbenzy1) amino] -2-hydroxypropy1} -3-[(3-ethylbenzy1) amino] -2-hydroxypropy1} -3-[(3-ethylbenzy1) amino] -2-hydroxypropy1} -5-[(methylsulfony1) amino] -2-hydroxypropy1} -5-[(methylsulfony1) amino] -2-hydroxypropy1} -5-[(methylsulfony1) amino] -N³, N³-2  2877 dipropylisophthalamide  N¹-{(1s, 2R) -1 - (3, 5-difluorobenzy1) -3-[(3-ethylbenzy1) amino] -2-hydroxypropy1} -3-[(1-propylbuty1) sulfony1] -D-alaninamide		F	534
2872  2873  N-{(1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl} -4-[(methylsulfonyl) methyl] benzamide  N-{(1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl} -3-methyl -5-(2-methylpentanoyl) benzamide  N-{(1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl} -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl} -5-[(methylsulfonyl) amino] -N, N, N, N, N, N, N, N, N, N, N, N, N, N			1
2873  2874  N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-[(methylsulfonyl)methyl]benzamide  N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-(2-methylpentanoyl)benzamide  N¹-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-N³,N³-2877 dipropylisophthalamide  N¹-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]-D-alaninamide		l l H F	1
2873  2874  N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-[(methylsulfonyl)methyl]benzamide  N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-(2-methylpentanoyl)benzamide  N¹-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-N³,N³-2877 dipropylisophthalamide  N¹-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]-D-alaninamide			1
2873  2874  N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-[(methylsulfonyl)methyl]benzamide  N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-(2-methylpentanoyl)benzamide  N¹-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-N³,N³-2877 dipropylisophthalamide  N¹-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]-D-alaninamide	2872	on V	
2874  N-{(1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl} -4-[(3-ethylbenzyl) amino] -2-hydroxypropyl} -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl} -5-[(methylsulfonyl) amino] -N³, N³-[(3-ethylsulfonyl) amino] -N³, N³-[(3-ethylbenzyl) amino] -2-hydroxypropyl] -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl] -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl] -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl] -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl] -3-[(1-propylbutyl) sulfonyl] -D-alaninamide			
2873  2874  N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-[(methylsulfonyl)methylbenzamide  N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-1-hydroxypropyl}-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]-D-alaninamide			550.
2874  N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-[(methylsulfonyl)methyl]benzamide  N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-(2-methylpentanoyl)benzamide hydrochloride  N¹-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-N³,N³-2877 dipropylisophthalamide  N¹-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]-D-alaninamide			1
2874  N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-[(methylsulfonyl)methyl]benzamide  N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-(2-methylpentanoyl)benzamide hydrochloride  N¹-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-N³,N³-2877 dipropylisophthalamide  N¹-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]-D-alaninamide			
2874  N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-[(methylsulfonyl)methyl]benzamide  N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-(2-methylpentanoyl)benzamide hydrochloride  N¹-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-N³,N³-2877 dipropylisophthalamide  N¹-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]-D-alaninamide		HHOH H	
2874  N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-[(methylsulfonyl)methyl]benzamide  N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-(2-methylpentanoyl)benzamide  N^1-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-N^3,N^3-2877 dipropylisophthalamide  N^1-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]-D-alaninamide	2873	1	
2874  N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-[(methylsulfonyl)methyl]benzamide  N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-(2-methylpentanoyl)benzamide  N^1-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-N^3,N^3-2877 dipropylisophthalamide  N^1-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]-D-alaninamide		F	656
2874  N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-[(methylsulfonyl)methyl]benzamide  N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-(2-methylpentanoyl)benzamide  hydrochloride  N¹-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-N³,N³-2877 dipropylisophthalamide  N¹-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]-D-alaninamide			i i
N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4- [(methylsulfonyl)methyl]benzamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-(2-methylpentanoyl)benzamide hydrochloride  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-N³,N³- [(methylsulfonyl)amino]-N³,N³- 2877 dipropylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]-D-alaninamide		l g (H )	
N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4- [(methylsulfonyl)methyl]benzamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-(2-methylpentanoyl)benzamide hydrochloride  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-N³,N³- [(methylsulfonyl)amino]-N³,N³- 2877 dipropylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]-D-alaninamide			
N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4- [(methylsulfonyl)methyl]benzamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-(2-methylpentanoyl)benzamide hydrochloride  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-N³,N³- [(methylsulfonyl)amino]-N³,N³- 2877 dipropylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]-D-alaninamide			
N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4- [(methylsulfonyl)methyl]benzamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-(2-methylpentanoyl)benzamide hydrochloride  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-N³,N³- [(methylsulfonyl)amino]-N³,N³- 2877 dipropylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]-D-alaninamide	2874	<u>\</u>	
2875 [(methylsulfonyl)methyl]benzamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-(2-methylpentanoyl)benzamide  N^1-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-N^3,N^3-  2877 dipropylisophthalamide  N^1-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-N^3,N^3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]-D-alaninamide	2017	M-1/10 2P) 1 /2 F 3/63	
2875 [(methylsulfonyl)methyl]benzamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-(2-methylpentanoyl)benzamide hydrochloride  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-N³,N³- 2877 dipropylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]-D-alaninamide		[4, 1] $[4, 2]$ $[$	531
N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-(2-methylpentanoyl)benzamide  2876 hydrochloride  N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-N <sup>3</sup> ,N <sup>3</sup> - 2877 dipropylisophthalamide  N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]-D-alaninamide	007E	[/mothed-self-self-self-self-self-self-self-self	
N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-(2-methylpentanoyl)benzamide  2876 hydrochloride  N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-N <sup>3</sup> ,N <sup>3</sup> - 2877 dipropylisophthalamide  N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]-D-alaninamide	2015	I (metnylsulfonyl) methyl] benzamide	
ethylbenzyl)amino]-2-hydroxypropyl}-3- methyl-5-(2-methylpentanoyl)benzamide hydrochloride  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5- [(methylsulfonyl)amino]-N³,N³-  2877 dipropylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]-D-alaninamide		$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]$	551.
methyl-5-(2-methylpentanoyl)benzamide hydrochloride  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-N³,N³- dipropylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]-D-alaninamide		ethylbenzyl)amino]-2-hvdroxvoropyl}-3-	1 [
2876 hydrochloride  N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide  N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]-D-alaninamide	22	methyl-5-(2-methylpentanovl)benzamide	
ethylbenzyl)amino]-2-hydroxypropyl}-5- [(methylsulfonyl)amino]-N³,N³- 2877 dipropylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]-D-alaninamide	2876	nydrochloride	1 1
ethylbenzyl)amino]-2-hydroxypropyl}-5- [(methylsulfonyl)amino]-N³,N³- 2877 dipropylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]-D-alaninamide		$N^{1} - \{(1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - 1(3 - 1)\}$	659
[(methylsulfonyl)amino]-N³, N³- dipropylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]-D-alaninamide	]	ethylbenzyl)amino]-2-hydroxypropyl}-5-	I I
2877 dipropylisophthalamide  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-bylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]-D-alaninamide		[(methylsulfonyl)amino]-N3.N3-	4
N <sup>1</sup> -{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3- 568 ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1- propylbutyl)sulfonyl]-D-alaninamide	2877	dipropylisophthalamide	
ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-  propylbutyl)sulfonyl]-D-alaninamide		$N^{1} - \{ (1S, 2R) - 1 - (3.5 - difluorobergy) \} $ (2)	<del>   </del>
propyrbuty1)sulfonyl]-D-alaninamide		ethylbenzyl)aminol-2-hydrogements a see	568
2878 dihydrochloride		propylbutyl) sulfonyllan alaminania	
J arm at contot the	2878	dihydrochloride	
		1 JOINTOLING	

	$N^{1}-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-$	624
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -	024
	propionyl-3-[(1-propylbutyl)sulfonyl]-D-	
2879	alaninamide	
20,0		658.
	s N	3
		3
		j
2880		1
		-
	\$ <del>\</del>	630.
		3
	i i i	}
0004	7	1
2881	N1 huber N3 (/10 0p) 1 /0 5	<del> </del>
	$N^{1}$ -butyl- $N^{3}$ -{(1S, 2R)-1-(3, 5-	635.
	difluorobenzyl) -3-[(3-ethylbenzyl)amino]-	4
2000	2-hydroxypropyl}-N <sup>1</sup> -methyl-5-(1,3-thiazol-	
2882	2-yl)isophthalamide	ļ
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	590.
	ethylbenzyl)amino]-2-hydroxypropyl}-3-[(3-	2
2000	hydroxypropyl) (methylsulfonyl)amino]benzam	
2883	ide	
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	517.
2884	ethylbenzyl)amino]-2-hydroxypropyl}-4-	2
2004	(methylsulfonyl)benzamide	60.0
		638
	O O HN O OH H	j
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	
2885	as drawn	
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	644
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> ,N <sup>3</sup> -	
2886	dipropyl-5-pyrimidin-2-ylisophthalamide	
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	703
	ethylbenzyl)amino]-2-hydroxypropyl}-5-	
	({[(2S)-2-hydroxypropyl]amino}sulfonyl)-	
2887	$N^3$ , $N^3$ -dipropylisophthalamide	
İ	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	621.
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> -	3
	$methyl-N^3-propyl-5-(1,3-thiazol-2-$	
2888	yl)isophthalamide	
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	604.
	ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-	3
	methylpentanoyl)-5-(1,3-oxazol-2-	
2889	yl)benzamide	

	$N^1$ -[(1S,2R)-1-(3,5-difluorobenzyl)-2-	698.
}	hydroxy-3-({3-	2
	[(methylsulfonyl)amino]benzyl}amino)propyl	
	$1-5-(1,3-oxazo1-2-y1)-N^3,N^3-$	
2890		
	$N^{1}$ -{(1s, 2r)-1-(3,5-difluorobenzyl)-3-[(3-	652
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -	
	(2,2-dimethylpropanoyl)-3-[(1-	
	propylbutyl)sulfonyl]-D-alaninamide	į
2891	hydrochloride	
	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-	743
	ethylbenzyl)amino]-2-hydroxypropyl}-5-	, = 3
	{[(2R)-2-(methoxymethyl)pyrrolidin-1-	
2892	yl]sulfonyl}-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide	
	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-	590.
	ethylbenzyl)amino]-2-hydroxypropyl}-4-[(3-	$\begin{bmatrix} 390. \\ 0 \end{bmatrix}$
	hydroxypropyl) (methylsulfonyl) amino] benzam	
2893	ide	
	$N^2$ -acetyl- $N^1$ -{(1S,2R)-1-(3,5-	610
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-	010
	2-hydroxypropyl}-3-[(1-	
	propylbutyl)sulfonyl]-D-alaninamide	
2894	hydrochloride	
	2-[allyl(methylsulfonyl)amino]-N-{(1S,2R)-	579.
	1-(3,5-difluorobenzyl)-3-[(3-	2
	ethylbenzyl)amino]-2-hydroxypropyl}-1,3-	
2895	thiazole-5-carboxamide	j
	3-(butylsulfonyl)- $N^{1}$ -{(1S, 2R)-1-(3, 5-	526
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-	320
	2-hydroxypropyl}-D-alaninamide	
2896	bis(trifluoroacetate)	
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-	594
	(3-ethylphenyl)cyclopropyl]amino}-2-	334
	hydroxypropyl)-3-[(1-	
	propylbutyl)sulfonyl]-D-alaninamide	
2897	bis(trifluoroacetate)	
	$N^{1}$ -{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-	638
İ	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -	V30
ŀ	isobutyryl-3-[(1-propylbutyl)sulfonyl]-D-	
2898	alaninamide hydrochloride	
		I .

The compounds in the table immediately below were prepared essentially using the methods described above and illustrated below in the schemes.

The following compounds were named using the Advanced Chemistry Development Inc. (ACD) nomenclature program, IUPAC

Name Batch Version 4.5. The website for ACD is www.acdlabs.com.

	Compound Name(s)	mass
		spec
	N-[(1S, 2R)-3-(butylamino)-1-(3,5-	
	difluorobenzyl)-2-hydroxypropyl}-4-	l
2899	(ethylthio)benzamide	
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	540.
	ethylbenzyl)amino]-2-hydroxypropyl}-1-(2-	2
	fluorophenyl)-5-oxopyrrolidine-3-	
2900	carboxamide	
,	$N^{1}$ -(4-tert-butyl-1,3-thiazol-2-yl)- $N^{4}$ -	
	{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	
	ethylbenzyl)amino]-2-	
2901	hydroxypropyl}succinamide	
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$	542.
	ethylbenzyl)amino]-2-hydroxypropyl}-3-	3
	hydroxy-6-(1-hydroxy-2,2-	
2902	dimethylpropyl)pyridine-2-carboxamide	
	N-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-	525.
	ethylbenzyl)amino]-2-hydroxypropyl}-2-	3
2903	{[(ethylamino)carbonyl]amino}benzamide	-
	3-acetyl-N-[(1S,2R)-3-(benzylamino)-1-	
	(3,5-difluorobenzyl)-2-	
2908	hydroxypropyl]benzamide	
	$N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-2-$	
	hydroxy-3-[(7-methoxy-1,2,3,4-	
	tetrahydronaphthalen-1-yl)amino]propyl}-5-	
2909	$methyl-N^3,N^3-dipropylisophthalamide$	
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(2,2-	
	dioxido-3,4-dihydro-1,2-benzoxathiin-4-	
	y1) amino] $-2$ -hydroxypropyl} $-5$ -methyl- $N^3$ , $N^3$ -	
2913		
	$N^{1}-\{(1S, 2R)-1-\{[5-(cyanomethyl)-1H-$	
	imidazol-1-yl]methyl}-3-{(3-	
	ethylbenzyl)amino]-2-hydroxypropyl}-5-	
2916		
	$N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[(2-	
	ethylpyrimidin-4-yl)methyl]amino}-2-	
]	hydroxypropyl) -5-methyl- $N^3$ , $N^3$ -	
2918	dipropylisophthalamide	
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	687.
	ethylbenzyl)amino]-2-hydroxypropyl}-5-	3
	{[ethyl(methyl)amino]sulfonyl}-N³, N³-	
2920	dipropylisophthalamide	

	N-{(1S 2B)-1-(3 5 dif1	<del></del>
	N-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-	575.
	ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-	9
0004	hydroxyethyl) (methylsulfonyl) amino]benzami	
2921	de la companya de la	l
	$5-bromo-N^1-\{(1s,2R)-1-(2,4-difluorobenzyl)-1-(2,4-difluorobenzyl)-1-(2,4-difluorobenzyl)$	646.
	3-[(3-ethylbenzyl)amino]-2-hydroxynropyll-	4
2922	N', N'-dipropylisophthalamide	=
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	590.
	ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-	I -
	methoxyethyl) (methylsulfonyl) amino]benzami	0
2923	de hydrochloride	
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	
	ethylbenzyl\aminol\amin	531.
2924	ethylbenzyl)amino]-2-hydroxypropyl}-3-	2
2324	[(methylsulfonyl)methyl]benzamide	<u></u>
	N <sup>1</sup> -{(1s, 2r)-1-(3, 5-difluorobenzyl)-3-[(3-	702.
	ethylbenzyl)amino]-2-hydroxypropyl}-5-[(4-	4
0005	nydroxybuty1)sulfonvll-N³.N³-	
2925	dipropylisophthalamide hydrochloride	
	$N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]$	589.
	etnylbenzyl)amino]-2-hydroxypropy]}-1-	4
2926	(dipropylamino) isoquinoline-7-carboxamide	•
	N <sup>1</sup> -{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-	703.
	ethylbenzyl)amino]-2-hydroxypropyl}-5-	703. 4
	{[(2-hydroxyethyl)(methyl)amino]sulfonyl}-	4
2927	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide	
	N <sup>1</sup> -{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-	
	ethylbenzyl)amino]-2-hydroxypropyl}-5-	673.
	[(ethylamino)sulfonyl]-N <sup>3</sup> , N <sup>3</sup> -	4
2928	dipropylisophthalamide	
	N <sup>1</sup> -{ (1s, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-	
	ethylbongullaminal 2 to 1	648.
	ethylbenzyl)amino]-2-hydroxypropyl}-5-(5-	4
2929	methyl-1,2,4-oxadiazol-3-yl)-N <sup>3</sup> ,N <sup>3</sup> -	
2323	dipropylisophthalamide hydrochloride	
]	N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-	
	ethylbenzyl)amino]-2-hydroxypropyl}-2-	
2025	[methyl(methylsulfonyl)amino]-1,3-oxazole-	
2930	4-carboxamide	
ſ	3-(butylsulfonyl)-N-{(1S,2R)-1-(3,5-	511
	difluorobenzyl)-3-[(3-ethylbenzyl)aminol-	
2931	2-hydroxypropyl}propanamide	
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> ,N <sup>3</sup> -	
2932	dipropylmalonamide	ŀ
	N <sup>2</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> ,N <sup>3</sup> -	
	dipropylbicyclo[2.2.1]hept-5-ene-2,3-	-
2933	dicarboxamide	j
-	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	
2934	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> ,N <sup>3</sup> -dipropylcyclopentane-1,3-dicarboxamide	
Z 25.04   U	ULDIUDVICVCIODENtano 1 3 digambarania 1	- 1

	$N^2 - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [(3 - 3) - 3] \}$	
	ethylbenzyl)amino]-2-hydroxypropyl}-3,4-	
2005	dimethyl-N <sup>5</sup> , N <sup>5</sup> -dipropylthieno[2,3-	
2935	b]thiophene-2,5-dicarboxamide	
	$N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	
	ethylbenzyl)amino]-2-hydroxypropyl}-2-	
2936	phenyl-N <sup>5</sup> ,N <sup>5</sup> -dipropylpentanediamide	
	$N^2$ -benzyl- $N^1$ -{(1S,2R)-1-(3,5-	
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-	
	2-hydroxypropyl}-N <sup>2</sup> -[2-(dipropylamino)-2-	
2937	oxoethyl]glycinamide	
	3-(4-chlorophenyl)-N <sup>1</sup> -{(1S, 2R)-1-(3, 5-	
	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-	
	2-hydroxypropyl}-N <sup>5</sup> ,N <sup>5</sup> -	
2938	dipropylpentanediamide	
	$(2E)-N^5-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-$	
	[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-	
2939	(methoxyimino) -N <sup>1</sup> , N <sup>1</sup> -dipropylpentanediamide	
	$N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-$	
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -[2-	
	(dipropylamino)-2-oxoethyl]-N2-	
2940	phenylglycinamide	
	$N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-$	
	ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> , N <sup>2</sup> -	
2941	dipropylcyclohexane-1,2-dicarboxamide	
	$N^1$ -[(1S,2R)-3-[(benzyloxy)amino]-1-(3,5-	
	difluorobenzyl)-2-hydroxypropyl]-5-(1,3-	
2942	$[oxazol-2-y1)-N^3,N^3-dipropylisophthalamide]$	
20.12	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	
	ethylbenzyl)amino]-2-hydroxypropyl}-3-	
2943		
25-75	$N^1-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-$	632.
	ethylbenzyl)amino]-2-hydroxypropyl}-5-(1H-	3
2945	imidazol-2-yl)-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide	
2940	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	567.
	ethylbenzyl)amino]-2-hydroxypropyl}-3-(1-	ا ما
2946	hydroxy-2-propylpentyl)benzamide	3
2340	N-{(1R, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-	536.
·	ethylbenzyl)amino]-2-hydroxypropyl}-3-	2
2947	isobutyrylbenzamide hydrochloride	4
2341	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-	565.
	<u> </u>	3
2040	ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-	
2948	propylpentanoyl) benzamide	F 2 77
	N-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-	537.
0040	ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-	3
2949	ethylbutanoyl)benzamide hydrochloride	<u> </u>

The compounds in the table immediately below were prepared essentially using the methods described above and illustrated below in the schemes.

The following compounds were named using the Advanced Chemistry Development Inc. (ACD) nomenclature program, IUPAC Name Batch Version 4.5. The website for ACD is www.acdlabs.com.

	Į.	561.
		2
		-
2951		
2901		
	· 👉 '	623.
		2
2953		
	$N^{1}$ -{(1s, 2r)-1-(3, 5-difluorobenzyl)-3-[(3-	558.
	ethylpenzvl)aminol-2-hydrovamronall 2 2	4
0054	dimethyi-N, N-dipropylcvclopropage_1 2_	-
2954	dicarboxamide	
	$N^{1}$ -{(1s, 2r)-1-(3, 5-difluorobenzyl)-3-[(3-	546.
2056	ethyloenzyl) aminol-2-hydroxymronyll 3	5
2956	Metnyl-N', N'-dipropylpentanediamide	
	$N^{1}$ -{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-	560.
2957	[ethylbenzyl)aminol-2-hydron magazil 2 2	5
2957	dimetnyl-N, N-dipropylpentagediamide	1
	$N = \{(15, 2R) - 1 - (3, 5 - diffluor obenezz)\} - 2 = 1/2$	574.
2958	culyinelizy1)amino -2-hydrovymrony1) 2	5
2936	ethyl-3-methyl-N', N'-dipropylpentanedia-	
	$1^{10} - 1(15, 2R) - 1 - (3, 5 - difluorohenzy) 1 - 3 + (2)$	562.
	[ethylpenzyl)amino]-2-hvdroxypropyll-3-	5
2959	Invaroxy-3-methyl-N3,N3-	
2339		
	2-[allyl(methylsulfonyl)amino]-N-{(1s,2R)-	563.
	1-(3,5-difluorobenzyl)-3-[(3-	2
2960	ethylbenzyl)amino]-2-hydroxypropyl}-1,3- oxazole-4-carboxamide	
2000	$N^{1}$ -[(1S,2R)-3-({2-[bis(2-	<u>L</u> .
	hvdroxyothyl\ominals\\\ 2-	593.
	hydroxyethyl)amino]ethyl)amino)-1-(3,5-	5
2962	difluorobenzyl)-2-hydroxypropyl]-5-methyl-	
2002	N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide	
	$N^{1}$ -[(1S,2R)-3-(cyclopropylamino)-1-(3,5-	
	difluorobenzyl)-2-hydroxypropyl]-3-[(1-	
2963	propylbutyl)sulfonyl]-D-alaninamide dihydrochloride	
	army arount of 106	}

	$N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-difluorobenzyl)]$	536.
	ethylbenzyl)amino]-2-hydroxypropyl}-3-[4-	3
	(hydroxymethyl)-1,3-oxazol-2-yl]benzamide	
2964	hydrochloride	

## EXAMPLE SP-131

- Step 1: A solution of iodide 1 (1.70 g, 4.36 mmol), Pd<sub>2</sub>dba<sub>3</sub> (80 mg, 0.087 mmol), dppf (193 mg, 0.349 mmol), and triethylamine (882 mg, 8.72 mmol) in N-methylpyrrolidine (10 mL) was degassed under nitrogen for 15 min. 3-Mercapto-1-propanol (402 mg, 4.36 mmol) was added and the reaction mixture was heated at 60 °C for 2 h. The reaction mixture was cooled to room temperature and then partitioned between ethyl acetate and saturated sodium chloride. The organic layer was washed (2x) with saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure.
- Purification by flash column chromatography (silica, 1:1 hexanes/ethyl acetate) gave sulfide **2** (880 mg, 57%) as a yellow oil:  $^{1}$ H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ .8.00 (s, 1H), 7.85 (s, 1H), 7.50 (s, 1H), 3.92 (s, 3H), 3.77 (m, 2H), 3.47 (m, 4H),

3.11 (m, 4H), 1.92 (m, 2H), 1.70 (m, 2H), 0.98 (m, 3H), 0.78 (m, 3H); ESI MS m/z 354 [M + H]<sup>+</sup>.

Step 2: To a stirred solution of sulfide 2 (880 mg, 2.49 mmol)
5 in 1:1 acetic acid/water (15 mL) was added excess 30% hydrogen
peroxide. The reaction mixture was stirred overnight and then
partitioned between ethyl acetate and water. The organic
layer was washed with water, dried (sodium sulfate), filtered,
and concentrated under reduced pressure to give a sulfone (912
10 mg, 95%) as a pale yellow oil: ¹H NMR (300 MHz, CDCl<sub>3</sub>) δ.9.51
(s, 1H), 8.28 (s, 1H), 8.11 (s, 1H), 3.99 (s, 3H), 3.71 (m,
2H), 3.55 (m, 2H), 3.44 (m, 2H), 3.38 (m, 2H), 2.11 (m, 2H),
1.88 (m, 2H), 1.78 (m, 2H), 0.77 (m, 3H), 0.56 (m, 3H); APCI
MS m/z 387 [M + H]\*.

15

Step 3: A solution of the sulfone from step 2 (912 mg, 2.36
mmol) in 3:1:1 methanol/tetrahydrofuran/1 N sodium hydroxide
 (20 mL) was stirred at room temperature for 2 h. The reaction
 mixture was partitioned between ethyl acetate and water. The
20 aqueous layer was acidified to pH 3 with 1 N hydrochloric acid
 and extracted with chloroform. The organic layer was dried
 (sodium sulfate), filtered, and concentrated to give acid 3
 (860 mg, 98%) as a white foam: ¹H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.48
 (s, 1H), 8.24 (s, 1H), 8.08 (s, 1H), 4.11 (m, 2H), 3.69 (m,
25 2H), 3.33 (m, 2H), 3.13 (m, 2H), 1.98 (m, 2H), 1.75 (m, 2H),
1.58 (m, 2H), 1.03 (m, 3H), 0.79 (m, 3H).

Step 4: To a stirred solution of acid 3 (630 mg, 1.69 mmol), amine 4 (688 mg, 1.69 mmol), HOBt (251 mg, 1.86 mmol), and N-methylmorpholine (855 mg, 8.45 mmol) in methylene chloride (15 mL) was added EDC (583 mg, 3.04 mmol). The reaction mixture was stirred overnight and then partitioned between ethyl acetate and water. The organic layer was washed with 1 N hydrochloric acid, saturated sodium bicarbonate, and saturated

sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 93:7:1 methylene chloride/methanol/ammonium hydroxide) gave ALB 8198 (5) (400 5 mg, 34%) as a white solid: mp 62-66 □C; IR (ATR) 3293, 2964, 2874, 1614 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ.8.18 (s, 1H), 8.06 (s, 1H), 7.85 (s, 1H), 7.28 (m, 2H), 7.15 (m, 2H), 6.85 (m, 2H), 6.62 (m, 1H), 4.31 (m, 1H), 3.79 (m, 2H), 3.67 (m, 2H), 3.55 (m, 2H), 3.24 (m, 2H), 3.05 (m, 2H), 2.91 (m, 4H), 2.86 10 (m, 1H), 2.60 (m, 2H), 1.95 (m, 2H), 1.73 (m, 2H), 1.56 (m, 2H), 1.22 (m, 3H), 1.03 (m, 3H), 0.72 (m, 3H); APCI MS m/z 688 [M + H]<sup>+</sup>; HPLC: Method A, 8.36 min (>99%, AUC). Anal. Calcd for C<sub>36</sub>H<sub>47</sub>F<sub>2</sub>N<sub>3</sub>O<sub>6</sub>S•0.25H<sub>2</sub>O: C, 62.45; H, 6.92; N, 6.07. Found: C, 62.21; H, 6.69; N, 5.97.

15

## EXAMPLE SP-132

20 **Step 1:** A mixture of benzoate **6** (870 mg, 3.79 mmol) and sodium thiomethoxide (292 mg, 4.18 mmol) was stirred in THF (20 mL) at 40  $\square$ C. After 48 h, the reaction mixture was cooled to room

temperature and then partitioned between ethyl acetate and water. The organic layer was dried (sodium sulfate), filtered, and concentrated under reduced pressure to give sulfide 7 (650 mg, 87%) as a white foam:  $^{1}$ H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ .7.97 (s, 1H), 7.88 (d, J = 8 Hz, 1H), 7.40 (d, J = 8 Hz, 1H), 7.27 (m, 1H), 3.92 (s, 3H), 3.71 (s, 2H), 1.99 (s, 3H).

- Step 2: To a stirred solution of sulfide 7 (650 mg, 3.31 mmol)
  in 1:1 acetic acid/water (25 mL) was added excess 30% hydrogen
  peroxide. The reaction mixture was stirred overnight and then
  partitioned between ethyl acetate and water. The organic
  layer was washed with sodium bicarbonate, water, and saturated
  sodium chloride, dried (sodium sulfate), filtered, and
  concentrated under reduced pressure to give sulfone 8 (540 mg,
  72%) as a clear oil: ¹H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.12 (s, 1H),
  8.04 (d, J = 7 Hz, 1H), 7.74 (d, J = 7 Hz, 1H), 7.54 (m, 1H),
  4.62 (s, 2H), 3.98 (s, 3H), 2.98 (s, 3H).
- Step 3: A mixture of sulfide 8 (540 mg, 2.37 mmol) in 3:1:1
  methanol/THF/2 N sodium hydroxide (10 mL) was stirred
  overnight. The reaction mixture was partitioned between ethyl
  acetate and water. The aqueous layer was acidified to pH 3
  with 1 N HCl and extracted with chloroform. The organic layer
  was dried (sodium sulfate), filtered, and concentrated under
  reduced pressure to provide an acid (406 mg, 80%) as a white
  solid: ¹H NMR (300 MHz, DMSO-d<sub>6</sub>) δ.8.02 (s, 1H), 7.96 (d, J = 7
  Hz, 1H), 7.64 (d, J = 7 Hz, 1H), 7.57 (m, 1H), 4.59 (s, 2H),
  2.92 (s, 3H).

Step 4: To a stirred solution of acid from step 3 (260 mg, 1.21 mmol), HOBt (163 mg, 1.21 mmol), amine 4 (495 mg, 1.21 mmol), and N-methylmorpholine (612 mg, 6.05 mmol) was added EDC (418 mg, 2.18 mmol). The reaction mixture was stirred

overnight and then partitioned between ethyl acetate and water. The organic layer was washed with 1 N hydrochloric acid, saturated sodium bicarbonate, and saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 93:7:1 methylene chloride/methanol/ammonium hydroxide) gave ALB 8653 (9) (308 mg, 48%): mp 147-149  $\square$ C; IR (ATR) 3286, 2961, 1633, 1596 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, DMSO- $d_6$ )  $\delta$  8.39 (d, J = 9 Hz, 1H), 7.77 (s, 1H), 7.72 (d, J = 7 Hz, 1H), 7.54 (d, J = 7 Hz, 1H), 7.48 (m, 10 1H), 7.18 - 6.93 (m, 7H), 5.03 (br s, 1H), 4.51 (s, 2H), 4.18 (br s, 1H), 3.68 (s, 2H), 3.67 (m, 1H), 3.12 (m, 1H), 2.91 (s, 3H), 2.88 (m, 1H), 2.61 (m, 1H), 2.45 (m, 2H), 2.43 (m, 2H), 1.13 (m, 3H); ESI MS m/z 531 [M + H]<sup>+</sup>; HPLC: Method A, 6.81 min (>99%, AUC). Anal. Calcd for  $C_{31}H_{40}F_2N_4O_4 \cdot 0.25H_2O$ : C, 62.85; H, 15 6.12; N, 5.23. Found: C, 62.96; H, 5.83; N, 5.09.

## EXAMPLE SP-133

Step 1: A solution of hydroxide 10 (2.5 g, 11.1 mmol) and POCl<sub>3</sub>
 (10.4 mL, 111 mmol) was stirred at 70 °C for 2.5 h. The

5 reaction mixture was cooled to room temperature, poured into ice water and the solution was stirred overnight. The aqueous mixture was diluted with CHCl<sub>3</sub>, washed with a saturated solution of NaHCO<sub>3</sub>, saturated NaCl, dried (MgSO<sub>4</sub>), filtered, and concentrated under reduced pressure to afford chloride 11

10 (2.3 g, 85%) as a tan solid: ¹H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 8.39-8.36 (m, 2H), 8.09-8.02 (m, 2H), 7.95 (d, J = 6 Hz, 1H).

Step 2: A solution of chloride 11 (500 mg, 2.1 mmol) and
dipropylamine (2.8 mL, 21 mmol) was heated at 150 °C in a

15 sealed tube for 2 d. The reaction mixture was cooled, and the solvent was removed under reduced pressure to provide amine 12
 (400 mg, 63%) as a brown oil: ¹H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 8.55
 (s, 1H), 7.90 (d, J = 6 Hz, 1H), 7.75-7.64 (m, 2H), 6.87 (d, J = 6 Hz, 1H), 3.42 (q, J = 7 Hz, 4H), 1.65 (q, J = 7 Hz, 4H),

20 0.94 (t, J = 7 Hz, 6H).

Step 3: A solution of amine 12 (350 mg, 1.1 mmol) and CuCN (204 mg, 2.2 mmol) in DMF (2 mL) was stirred at reflux for 24 h. The reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (3 x 50 mL). The combined organics were washed with saturated NaCl, dried (MgSO<sub>4</sub>), filtered, and concentrated under reduced pressure to provide a nitrile (279, mg, 100%) as a brown oil, which was used without any further characterization.

30

**Step 4:** A solution of the nitrile from step 4 (279 mg, 1.1 mmol) in concentrated HCl (4 mL) was heated at 150 °C in a sealed tube for 14 h. The reaction mixture was cooled to room temperature, the solvent was removed under reduced pressure,

and the residue was dissolved in a 25%  $NH_4OH/H_2O$  solution and stirred for 1 h. The solution was acidified to pH 4, and extracted with  $CHCl_3$  (3 x 50mL). The combined organics were dried ( $Na_2SO_4$ ), filtered, and concentrated under reduced pressure to provide acid 13 (104 mg, 35%) as a white solid:  $^1H$  NMR (300 MHz,  $CDCl_3$ )  $\delta$  8.85 (s, 1H), 8.15 (d, J = 8 Hz, 1H), 8.01 (d, J = 6 Hz, 1H), 7.79 (d, J = 7 Hz, 1H), 7.21 (d, J = 6 Hz, 1H), 3.47 (m, 4H), 1.68 (m, 4H), 0.83 (m, 6H); ESI MS m/z 273 [M + H] $^+$ .

10

Step 5: To a stirred solution of acid 13 (103 mg, 0.38 mmol), amine  $\mathbf{4}$  (154 mg, 0.38 mmol), HOBt (77 mg, 0.57 mmol), and DIPEA (0.2 mL, 1.1 mmol) in methylene chloride (4 mL) was added HATU (216 mg, 0.57 mmol). The reaction mixture was stirred overnight and then partitioned between methylene 15 chloride and 1 N hydrochloric acid. The organic layer was washed with saturated sodium bicarbonate, saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 9:1 methylene chloride/methanol) gave 20 a ALB 8655 (70 mg, 31): mp: 142-151 °C; IR (ATR): 3222, 1621, 1585, 1114, 848, 700 cm<sup>-1</sup>;  $^{1}$ H NMR (500 MHz, DMSO- $d_6$ )  $\delta$  9.46 (s, 1H), 9.09 (s, 2H), 8.57 (s, 1H), 8.35 (s, 1H), 8.09 (s, 1H), 7.29 (s, 1H), 7.46 (d, J = 6 Hz, 1H), 7.40 (s, 1H), 7.35 (d, J= 7 Hz, 1H), 7.27 (t, J = 7 Hz, 1H), 7.19 (d, J = 7 Hz, 1H), 25 7.04-6.97 (m, 3H), 4.24-4.08 (m, 4H), 3.73 (br s, 4H), 3.54 (br s, 8H), 3.18 (d, J = 8 Hz, 1H), 3.10 (br s, 1H), 3.00 (m, 1H), 2.87 (d, J = 8 Hz, 1H), 2.56-2.50 (m, 2H), 1.75 (d, J = 6Hz, 4H), 1.12 (t, J = 7 Hz, 3H), 0.88 (t, J = 7 Hz, 6H); APCI MS m/z 589 [M + H]<sup>+</sup>; HPLC: Method A, 7.21 min (99%, AUC). 30 Anal. Calcd for  $C_{35}H_{42}F_2N_4O_2 \cdot 2HC1 \cdot 0.5H_2O$ : C, 62.68; H, 6.76; N, 8.35. Found: C, 62.60; H, 6.89; N, 8.29.

EXAMPLE SP-134

Ketones used in this EXAMPLE can be generally prepared as shown in chart  $\mathbf{U}$ .

Step 1.

5

To a stirred solution of the halide (4.68 g, 20 mmol) in anhydrous toluene (10 mL) was added  $(\alpha-ethyoxyvinyl)-$ 10 tributyltin (7.66 ml, 22 mmol) dichlorobis(triphenylphosphine)palladium (0.715 g, 1 mmol). The reaction was heated under nitrogen at 100 °C for 14 hours. After hydrolysis of the reaction mixture with 1N HCl (100 ml), the organic layer was extracted with diethyl ether (100 mL  $_{
m x}$ 2), washed with aqueous potassium fluoride (10%, 100 mL), 15 dried with magnesium sulfate, and concentrated under vacuo. The crude product was purified by flash column chromatography (10 - 20% ethyl acetate: hexane) to afford 2.5 g of 3-Acetyl-5-methyl-benzoic acid methyl ester as a white solid (65% yield). IR (drift) 3090, 3078, 3019, 2998, 2952, 2920, 1716, 20 1681, 1608, 1596, 1448, 1435, 1273, 1237, 1234, 1197, 1118, 893 cm $^{-1}$ ;  $^{1}$ H NMR (CDCl $_{3}$ )  $\delta$  8.44 (s, 1 H), 8.10 (s, 1 H), 8.01 (s, 1 H), 3.99 (s, 3 H), 2.68 (s, 3 H), 2.51 (s, 3 H); HRMS (FAB) calcd for  $C_{11}H_{12}O_3 + H^+= 193.0865$ , found 193.0868.

Step 2.

To a stirred suspension of potassium hydroxide (pellets) (5.0 g, 90.0 mmol) in dimethylsulfoxide (10 mL) was added 3-Acetyl-5-methyl-benzoic acid methyl ester  $(0.8\ \mathrm{g},\ 4.5\ \mathrm{mmol})$  and 1 iodopropane (2.9mL, 36 mmol) at room temperature. The reaction mixture was heated to 50 - 60  $^{\circ}\text{C}$  and stirred for additional 1 hour. After cooled to room temperature, the reaction was poured into 1N aqueous HCl solution (100 mL). The aqueous solution was extracted with diethyl ether (80 mL  $\times$  2). The combined organic layer was washed with brine (80 mL  $\times$  2), dried with magnesium sulfate, and concentrated under vacuo. The crude product was purified by flash column chromatography (30 - 40% ethyl acetate: hexane) to afford 0.316 g of the benzoic acid as a pale yellow solid (30% yield).

#### 15 Step 3

10

To a stirred solution of acid the benzoic acid (138.2 mg, 0.59mmol) in DMF (3 mL) was added HATU (281 mg, 0.74 mmol), diisopropylethylamine (0.31 mL, 1.77 mmol), and then the amine (240 mg, 0.59 mmol) at room temperature. After stirred for 1 20 hour at room temperature, the reaction mixture was poured into 40 mLwater. The aqueous solution was extracted with chloroform x 2), and then organic layers were (50  $\mathtt{mL}$ collected, washed with water (40 mL  $\times$  2), 1N HCl (40 mL  $\times$  2), sat. aq. sodium bicarbonate (40 mL  $\times$  2) and brine (40 mL  $\times$  2), 25 dried over sodium sulfate, and concentrated under vacuo. The crude product was purified by flash column chromatography (10% methanol: dichloromethane) to afford 198 mg of the desired product as a pale yellow solid (61% yield). 30

## EXAMPLE SP-135

Compound 14b (1 equiv, 0.064 mmol, 37.6 mg) was dissolved in EtOAc before the addition of PtO (catalytic) and an  $H_2$  balloon. The reaction was stirred for 4 hours at ambient temperature 5 before LC-MS determined the two products: 15 and 16. The crude mixture was filtered through celite and the solvent was removed in vacuo before isolation by HPLC of each of the products: 15 (13 mg, 34 %,  $M+H^+ = 592.3$ ) and 16 (16 mg, 42 %,  $M+H^{+} = 594.3$ ).

## EXAMPLE SP-136

5

Compound 17 (1 equiv, 0.46 mmol, 0.31 g) was dissolved in  $CH_2Cl_2$  and cooled to 0 °C before the addition of  $Boc_2O$  (1 equiv, 0.46 mmol, 0.1 g) and catalytic DMAP. After the reaction was judged to be done by TLC (4 h), the solvent was simply removed in vacuo and the product was used crude in the next step.

10 The iodo compound (1 equiv, 0.13 mmol, 100 mg), Pd<sub>2</sub>dba<sub>3</sub>(0.02 equiv, 0.002 mmol, 2.4 mg), dppf (0.08 equiv, 0.01 mmol, 5.8 mg), Et<sub>3</sub>N (2 equiv, 0.26 mmol, 0.04 mL), and NMP (0.3 M, 0.4 mL) were added to a sealed tube and flushed / bubbled with N<sub>2</sub> (g) for 15 minutes. Ethanethiol was then added and the tube was sealed and stirred for 3h at 60 °C. At this point the reaction was cooled to ambient temperature, diluted with brine, and extracted 3x with EtOAc. The combined organic extracts were then washed with brine (2x), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and rotovapped to give the crude brown desired thioether. Column chromatography through SiO<sub>2</sub> with 25 % EtOAc

in hexanes gave the purified product (71.5 mg, 0.1 mmol, 77 %).

The thioether (1 equiv, 0.08 mmol, 56.3 mg) was dissolved in AcOH (0.4 mL) and treated with 30 % H2O2 (0.2 mL). The reaction was stirred 2 h. At this point, the crude mixture was partitioned between EtOAc and  $H_2O$ , and the products were extracted 3x with EtOAc. The organic extracts were dried over  $Na_2SO_4$ , filtered, and rotovapped before column chromatography purification through  $SiO_2$  with 50 % EtOAc in hexanes gave the separated Boc protected sulfone and sulfoxide. After TFA deprotection and HPLC purification, the final products 18 (17 mg, 33%,  $M+H^+=644.2$ ) and 19 (18 mg, 35 %,  $M+H^+=628.3$ ) were achieved.

15

10

#### EXAMPLE SP-137

EXAMPLE SP-138

<u>OR</u>

5

EXAMPLE SP-139

The aniline (1 equiv, 8.46 mmol, 1 g) was dissolved in

10 pyridine (1 M, 8.5 mL) and cooled to 0 °C before the addition of methyl chloroformate (1.2 equiv, 10.2 mmol, 0.96 g, 0.78 mL). The reaction was allowed to warm to room temperature overnight with stirring. The reaction mixture was then rotovapped, and H<sub>2</sub>O was added to the residual oil, at which point a white solid precipitated. The white precipitate was

filtered and washed with  ${\rm H}_2{\rm O}$ , and then dried on the vacuum pump overnight to give the clean crude carbamate (1.4 g, 93%)

The carbamate (1 equiv, 3.98 mmol, 0.70 g) was dissolved in THF (8 mL) and cooled to 0 °C before the addition of a 1M THF solution of KOtBu (1.1 equiv, 4.37 mmol, 4.37 mL). Upon addition of KOtBu, the starting material crashed out of solution, and so more THF was added (5 mL) along with dioxane (2 mL). At this point, despite the continued lack of · 10 solubility, MeI (1.1 equiv, 4.37 mmol, 0.62 g, 0.27 mL) was added and the reaction was allowed to warm to room temperature overnight with stirring. After 12 hours, the reaction was still not in solution, and TLC showed incomplete consumption of starting material. Thus, DMF (5 mL) was added and the 15 reaction finally went into solution. After stirring for 5 additional hours at ambient temperature, the reaction was complete. The crude reaction mixture was filtered through celite, rotovapped, partitioned between H2O and EtOAc, extracted 3x with EtOAc, and washed with brine. The organic 20 extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and rotovapped. Purification through a short plug of SiO2 with 30% EtOAc in hexanes gave the desired methylated carbamate which still contained a colored impurity which was undetected by TLC and NMR. (0.76 g, Quantitative)

25

30

The nitrile (1 equiv, 3.98 mmol, 0.76 g) was dissolved in ethanol, and  $N_2$  (g) was bubbled through the solution for 5 minutes before the addition of AcOH (1 equiv, 3.98 mmol, 2.27 mL) and 5% DeGussa Pd/C (1 scoop).  $N_2$  (g) was bubbled again for 5 minutes before shaking on Parr Shaker at 55 psi  $H_2$  overnight. The reaction was filtered through celite and rotovapped to give the acetic acid salt of the desired product. The product was then partitioned between 10% NaOH

(aq) and 20% isopropanol / chloroform, and extracted 3x with 20% isopropanol / chloroform to give the desired free-base.

The crude free-base was used to open the epoxide. The  $M+H^+$  mass of the final product is 639.3.

### EXAMPLE SP-140

The aniline (1 equiv, 16.9 mmol, 2 g) was dissolved in pyridine and cooled to 0 °C before the addition of the sulfonyl chloride (1.5 equiv, 25.4 mmol, 2.91 g, 1.97 mL). Upon addition of the sulfonyl chloride, the reaction turned bright orange. The reaction was allowed to warm to room temperature overnight with stirring. After 12 hours, the reaction mixture was rotovapped, partitioned between CH<sub>2</sub>Cl<sub>2</sub> and NaHCO<sub>3</sub> (aq), and extracted 3x with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic extracts were washed with KHSO<sub>4</sub> (aq) and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and rotovapped to give the clean crude sulfonamide. (3.34 g, Quantitative)

The crude sulfonamide was dissolved in acetone before the addition of  $ground\ Cs_2CO_3$ , followed by  $Me_2SO_4$ . The  $Cs_2CO_3$  did not dissolve completely. The reaction was stirred overnight

at ambient temperature. After 12 h, the brownish reaction mixture was rotovapped in a fume hood, partitioned between EtOAc and  $H_2O$ , and extracted 3x with EtOAc. The combined organic extracts were then washed with  $NaHCO_3$  (aq) and  $KHSO_4$  (aq), dried over  $Na_2SO_4$ , filtered and rotovapped to give the crude methylated sulfonamide. By TLC the  $R_f$  values of the starting sulfonamide and the final product were identical, however the spots were different colors. Quick purification through a plug of  $SiO_2$  with 30% - 40% EtOAc in hexanes gave the desired product. (1.88 q, 93 %)

The nitrile (1 equiv, 8.94 mmol, 1.88 g) was dissolved in methanol, and  $N_2$  (g) was bubbled through the solution for 5 minutes before the addition of AcOH (1 equiv, 8.94 mmol, 0.51 mL) and 5% DeGussa Pd/C (one scoop).  $N_2$  (g) was bubbled again for 5 minutes before shaking on Parr Shaker at 55 psi  $H_2$  for 2 hours. The reaction was filtered through celite and rotovapped to give the acetic acid salt of the desired product. The product was then partitioned between 10% NaOH (aq) and 20% isopropanol / chloroform, and extracted 3x with 20% isopropanol / chloroform to give the desired free-base.

The crude free-base was used to open the epoxide. The  $M+H^+$  mass of the final product is 659.3.

#### EXAMPLE SP-141

5

10

15

20

A 2M solution of dimethylamine in THF (1.2 equiv, 11.88 mmol, 5.94 mL) was dissolved in pyridine and cooled to 0 °C before the addition of the sulfonyl chloride (1 equiv, 9.9 mmol, 2 g). The reaction was allowed to warm to room temperature overnight with stirring. After 12 hours, the reaction mixture was rotovapped, partitioned between CH<sub>2</sub>Cl<sub>2</sub> and NaHCO<sub>3</sub> (aq), and extracted 3x with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic extracts were washed with KHSO<sub>4</sub> (aq) and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and rotovapped to give the clean crude sulfonamide. (2.04 g, 98 %)

The nitrile (1 equiv, 9.7 mmol, 2.04 g) was dissolved in a mixture of ethanol, methanol, and THF until it finally went into solution.  $N_2$  (g) was bubbled through the solution for 5 minutes before the addition of AcOH (1 equiv, 9.7 mmol, 0.56 mL) and 5% DeGussa Pd/C (one scoop).  $N_2$  (g) was bubbled again for 5 minutes before shaking on Parr Shaker at 55 psi  $H_2$  overnight. The reaction was filtered through celite and rotovapped to give the acetic acid salt of the desired product. The product was then partitioned between 10% NaOH (aq) and 20% isopropanol / chloroform, and extracted 3x with 20% isopropanol / chloroform to give the desired free-base.

The crude free-base was used to open the epoxide. The  $M+H^+$  25 mass of the final product is 659.3.

#### EXAMPLE SP-142

15

The aniline (1 equiv, 8.46 mmol, 1 g) was dissolved in pyridine (1 M, 8.5 mL) and cooled to 0 °C before the addition of methyl chloroformate (1.2 equiv, 10.2 mmol, 0.96 g, 0.78 mL). The reaction was allowed to warm to room temperature overnight. The reaction mixture was then rotovapped, and  $H_2O$  was added to the residual oil, at which point a white solid precipitated. The white precipitate was filtered and washed with  $H_2O$ , and then dried on the vacuum pump overnight to give the clean crude carbamate (1.4 g, 93%)

The nitrile (1 equiv, 3.43 mmol, 0.604 g) was dissolved in ethanol, and  $N_2$  (g) was bubbled through the solution for 5 minutes before the addition of AcOH (1 equiv, 3.43 mmol, 0.2 mL) and 5% DeGussa Pd/C (one scoop).  $N_2$  (g) was bubbled again for 5 minutes before shaking on Parr Shaker at 55 psi  $H_2$  overnight. The reaction was filtered through celite and rotovapped to give the acetic acid salt of the desired product. The product was then partitioned between  $H_2O$  with  $NH_4OH$  and 20% isopropanol / chloroform, and extracted 3x with 20% isopropanol / chloroform to give the desired free-base.

The crude free-base was used to open the epoxide. The  $M+H^+$  mass of the final product is 625.2.

# EXAMPLE SP-143

5

10

15

20

The aniline (1 equiv, 16.9 mmol, 2 g) was dissolved in pyridine and cooled to 0 °C before the addition of the sulfonyl chloride (1.5 equiv, 25.4 mmol, 2.91 g, 1.97 mL). Upon addition of the sulfonyl chloride, the reaction turned bright orange. The reaction was allowed to warm to room temperature overnight with stirring. After 12 hours, the reaction mixture was rotovapped, partitioned between CH<sub>2</sub>Cl<sub>2</sub> and NaHCO<sub>3</sub> (aq), and extracted 3x with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic extracts were washed with KHSO<sub>4</sub> (aq) and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and rotovapped to give the clean crude sulfonamide. (3.34 g, Quantitative)

10

The nitrile (1 equiv, 7.40 mmol, 1.45 g) was dissolved in

methanol, and N<sub>2</sub> (g) was bubbled through the solution for 5
minutes before the addition of AcOH (1 equiv, 7.40, 0.42 mL)
and 5% DeGussa Pd/C (one scoop). N<sub>2</sub> (g) was bubbled again for
5 minutes before shaking on Parr Shaker at 55 psi H<sub>2</sub> for 2
hours. The reaction was filtered through celite and
rotovapped to give the acetic acid salt of the desired
product. The product was then partitioned between H<sub>2</sub>O with
NH<sub>4</sub>OH and 20% isopropanol / chloroform, and extracted 3x with
20% isopropanol / chloroform to give the desired free-base.

25 The crude free-base was used to open the epoxide. The  $M+H^+$  mass of the final product is 645.2

#### EXAMPLE SP-144

The aldehyde (1 equiv, 2.29 mmol, 0.3 g) and the amine (1.05 equiv, 2.40 mmol, 0.76 g) were dissolved in 1,2 dichloroethane (40 mL) and treated with molecular sieves (a small scoop) and a few drops of AcOH. The reaction was stirred for 1 h before adding  $Na(OAc)_3BH$  (1.3 equiv, 2.98 mmol, 0.63 g). The reaction was stirred overnight at ambient temperature. After 12 h, the reaction mixture was filtered, and rotovapped. The residue was partitioned between EtOAc and  $H_2O$ , and the product was extracted 3x with EtOAc. The combined organic extracts were dried over  $Na_2SO_4$ , filtered, and rotovapped to give the clean crude desired amine. (Quantitative)

15

10

The crude material was deprotected with TFA and coupled to the N-terminus as usual. The  $M+H^+$  mass of the final product is 577.2.

#### 20 EXAMPLE SP-145

The phenol (1 equiv, 16.8 mmol, 2 g) was taken up in CH<sub>2</sub>Cl<sub>2</sub>, but did not dissolve, thus THF and acetone were added in a failed attempt to solubilize the phenol. The mixture was cooled to 0 °C before the addition of NEt<sub>3</sub> (1 equiv, 16.8 mmol, 1.7 g, 2.3 mL), DMAP (1 equiv, 16.8 mmol, 2.05 g), and dimethylcarbamyl chloride (1 equiv, 16.8 mmol, 1.81 g, 1.55 mL). Upon addition of NEt<sub>3</sub>, the reagents dissolved. The reaction appeared to be complete after stirring for 2 hours, as judged by TLC. However, the reaction was stirred for 2 days. After 2 days, the reaction was partitioned between CH<sub>2</sub>Cl<sub>2</sub> and NaHCO<sub>3</sub> (aq), and extracted 3x with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic extracts were washed with 1 N HCl and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and rotovapped to afford the clean crude carbamate. (3.04 g, 95%)

10

15

20

The nitrile (1 equiv, 16.0 mmol, 3.04 g) was dissolved in ethanol, and  $N_2$  (g) was bubbled through the solution for 5 minutes before the addition of 5% DeGussa Pd/C (one scoop).  $N_2$  (g) was bubbled again for 5 minutes before shaking on Parr Shaker at 55 psi for 1 hour. The reaction was filtered through celite and rotovapped to give the desired free-base.

The crude free-base was used to open the epoxide. The  $M+H^+$  25 mass of the final product is 639.3.

#### EXAMPLE SP-146

Oxazole (3.15 equiv, 1.89 mmol, 0.13 g) was weighed into an oven-dried round-bottom flask, dissolved in THF (3 mL), and cooled to -78 °C before the addition of a 1.6 M solution of nBuLi in hexanes (3.48 equiv, 2.09 mmol, 1.3 mL). After stirring for 30 minutes at -78 °C, a 1.0 M solution of  $\rm ZnCl_2\ in$ THF (9.06 equiv, 5.4 mmol, 5.4 mL) was added dropwise. At this point the stirring stopped due to increased viscosity or stickiness within the reaction vessel. This solution was warmed to 0  $^{\circ}\text{C}$  for 1 hour before the HCl salt of AN 104574-7 (1 equiv, 0.6 mmol, 0.429 g), along with  $Pd(PPh_3)_4$  were added. This mixture was heated to reflux for 1 hour. The reaction was then partitioned between EtOAc and  ${\rm H}_2{\rm O}$ , extracted 3x with EtOAc, washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and rotovapped. Chromatography on  $SiO_2$  with 2 - 5% MeOH /  $CH_2Cl_2$ with a few drops of NH4OH yielded the clean desired product.  $(95\%, 0.35 \text{ g}, \text{M+H}^{+} = 619.2)$ 

20 EXAMPLE SP-147

10

15

### 2-Dipropylcarbamoyl-6-methyl-isonicotinic acid

A solution of 23.7 mmole (1.0eq.) of 2-chloro-6methylisonicotinic acid in 32mL of 30%MeOH/THF was prepared.
To the reaction mixture was added 30.0mmole (1.3eq) of
(trimethylsilydiazo)methane dropwise. The reaction was
complete after stirring at rt overnight. A few drops of
glacial acetic acid were added to the reaction mixture prior
to concentration by rotary evaporation to afford product 2,
quantitatively.

To a dried 100 mL round bottom flask was added 22.0 mmole (1.0eq.) of the methyl ester 2, 0.45mmole (0.02eq.)

tris(dibenzlideneacetone)dipalladium (0), 0.90 (0.04eq.) 1,1-bis(diphenylphosphine)ferrocene, 28.3mmole (0.13eq.) zinc metal dust and 10.7 (0.5eq) zinc cyanide. The reaction flask was flushed with nitrogen gas for 5 min and 45mL N,N-dimethylacetamide was added via syringe. The reaction was complete after refluxing while stirring vigorously for 4 h. The reaction mixture was diluted with EtOAc (50mL) and washed

with 2N NH<sub>4</sub>OH (3 x 50mL) followed by sat. NaCl (50 mL). The combined organic extracts were dried over  $Na_2SO_4$  and vacuum filtered. The filtrate was concentrated by rotary evaporation and purified via column chromatography Hex/EtOAc (8:2) to yield product 3, 34% yield.

A solution of 1.2mmole (1.0eq.) of the nitrile 3 in 5 mL of methanol was prepared. To the reaction mixture was added 6.7mmole (5.7eq) of sodium hydroxide. After 1 h of stirring at rt, 5mL of  $H_2O$  were added to the reaction mixture. The reaction was complete after stirring for an additional 1.5h. The mixture was diluted with CHCl $_3$  and washed with 2NHCl. The organic extracts were collected and dried over  $Na_2SO_4$  and vacuum filtered. The filtrate was concentrated by rotary

10

A solution of 0.7mmole (1.0 eq.) of the carboxylic acid 4 in 6mL of dichloromethane was prepared. To the reaction mixture was added 1.8mmole (2.6eq.) 4-methylmorpholine. The reaction flask was placed on ice to cool prior to addition of 0.8mmole (1.1eq.) HBTU and 0.8mmole (1.2eq.) diproplyamine. The

evaporation to afford product 4, 61% yield.

reaction was complete after allowing to warm to rt overnight while stirring. The reaction mixture was diluted with EtOAc (25 mL) and washed with H<sub>2</sub>O (2 x 25mL) followed by sat. NaHCO<sub>3</sub> (2 x 25mL). The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and vacuum filtered. The filtrate was concentrated by

25 rotary evaporation to afford product **5**, 64% yield.

A solution of 0.5 (1.0eq.) of the isophalate **5** in 2 mL of methanol was prepared. To the reaction mixture was added 4.5mmole (9.3eq) of sodium hydroxide. After 2 h of stirring at rt, 2mL of H<sub>2</sub>O were added to the reaction mixture. The reaction

was complete after stirring for an additional 1.5h. The mixture was diluted with EtOAc and washed with H<sub>2</sub>O (2x) followed by sat. NaHCO<sub>3</sub> (2x). The aqueous extracts were collected and acidified with conc. HCl. A solution of CHCl<sub>3</sub>/iPA (1:3) was utilized for extraction. The organic extracts were

collected washed with sat. NaCl, dried over  $Na_2SO_4$  and vacuum filtered. The filtrate was concentrated by rotary evaporation to afford product  $\bf 6$ .

5

#### EXAMPLE SP-148

HN 
$$\frac{1}{NH_2}$$
 +  $\frac{1}{NH_2}$   $\frac{1}{NAOCH_2CH_3}$  EtOH

MS 211.1 (M+H) MS 165.1 (M+H)

10

Bredereck, H., Sell, R. and Effenberger, F.; Chem. Ber.; 1964, 97, 3407.

#### 15 EXAMPLE SP-149

MS 140.1 (M+H),162.0(M+Na)

### (2-Ethyl-pyrimidin-4-yl)-methylamine

Experimental procedures were utilized in order to yield products 1 through 3 as described in the following references. Burness, D.M.; J. Org. Chem., 1956,21,97.

5 Daves, G.D., O'Brien, D.E., Lewis, L. and Cheng, C.C.; J. Heterocycl. Chem., 1963, 1, 130.

Into a oven-dried 50 mL round bottom flask was added 3.6mmole (1.0eq.) of the halopyrimidine 3, 5.4mmole (1.5eq.)

- tributyl(vinyl)tin, 0.09mmole (0.03eq.)
  bis(triphenylphosphine)palladium (II) chloride, 4.1mmole
  (1.1eq.) tetraethylammonium chloride, 3.8mmole (0.9eq.)
  potassium carbonate and 7.5 mL of dry DMF. The reaction was
  complete after refluxing under condenser with nitrogen inlet
- for 2 hrs. The reaction mixture was diluted with EtOAc (30 mL) and washed with H<sub>2</sub>O (2 x 30 mL) followed by sat. NaCl (30 mL). The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and vacuum filtered. The filtrate was concentrated by rotary evaporation, purified via column chromatography Hex/EtOAc (9:1) to yield
- 20 product 4, 42% yield.

product 5.

In a small vial, a solution of 1.53mmole (1.0eq.) of the styrene 4 was prepared by dissolving in a minimal amount of EtOH. To the reaction mixture was added 0.1 mL of glacial acetic acid followed by a catalytic amount of 10%wt palladium on carbon. The reaction was complete after placement on the hydrogentator for 30 min. at 50psi. The reaction mixture was vacuum filtered through Celite and rinsed with EtOAc. The filtrate was concentrated by rotary evaporation to afford

EXAMPLE SP-150

The starting diamine (~ 18 mgs, ~ 0.05 mmol) and 1 equiv. of sulfonyl chloride were dissolved in 1 ml of pyridine at - 5.0 °C in a 1-dram vial. This mixture was allowed to react for 18 hours. After reaction time, the pyridine was dissolved and the product mixture was prepared for LC-MS analysis using a Hewlett-Packard 1050 Series HPLC coupled to a Thermo-Finnigan LCQ Deca MS. From the LC-MS results, the final product was purified using the Varian Pro Star Preparative HPLC.

# EXAMPLE SP-151 Synthesis of N-terminal dipropylamine replacement

15

5

10

### EXAMPLE SP-152 Synthesis of N-terminal glutarates

PCT/US02/36072 WO 03/040096

From the 11 compounds that were made in this library, 2 were made with the starting dicarboxylic acid and the other 9 were already in the glutaric anhydride form. To prevent the 5 dicarboxylic acids from forming diamides, 0.1 mmol of each acid was reacted with 1 equiv. of EDC in 1 ml of dichloromethane for 1 hour at room temperature. With all of the starting materials in the glutaric anhydride form, 0.1 mmol of each glutaric anhydride was mixed with 0.1 mmol of dipropylamine in 1.5 ml of dichloromethane for 2 hours at room temperature. The resulting acids were then reacted with 1 equiv. of the HEA piece using 1.1 equiv. of HATU as the coupling agent. 3 equiv. of polystyrene-bound diisopropylethylamine was used as the base. These reactions were run in 1.5 ml of DMF for 4 hours at room temperature. The 15 products were then purified via the Varian Pro Star Preparative HPLC.

EXAMPLE SP-153: Representative procedure of CHART Y(R=I)

20

10

NC BrCH<sub>2</sub>CH<sub>2</sub>CI NC ROH, H<sub>2</sub>O<sub>2</sub> H<sub>2</sub>N ReOH R = Me, I, Br 
$$\frac{1}{8}$$
 R = Me, I, Br  $\frac{1}{8}$  Curtius rearrangement Cl Rearr

Preparation of 1-arylcyclopropanecarbonitriles (2) (R = I)
Org. Prep. Proc. Inter. 1995, 27(3), 355-59

5

10

15

20

To a vigorously stirred mixture of the iodobenzyl cyanide  $\underline{1}$  (3g, 12.35 mM), benzyltriethylammonium chloride (TEBAC, 100 mg) and 1-bromo-2-chloroethane (BCE, 15 mL), 50% aq. NaOH solution (20 mL) was added dropwise over 35 min. (temp. 50°C). After addition, the reaction was stirred at 50°C for additional 2 hrs, then at RT for 2 hrs. Added water to 100 mL total and extracted with dichloromethane (3 x 25 mL). Organic extracts were washed with water, 5% aq. HCl, and water, then dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. Purified by Kugelrohr distillation. Yield  $\underline{2}$  - 3.3 g (99%); MH+(CI) 269.9.

Preparation of amide 3. A mixture of  $\underline{2}$  (13.3 mM), 25% aq. KOH (0.34 mL), 30%  $H_2O_2$  (17.5 mL) and MeOH (100 mL) was heated at 55°C for 7 hrs. TLC showed no SM. The reaction mixture was concentrated and dried under vacuum. Yield 95%; MH+(CI) 288.0.

**Hydrolysis of 3.** An amide  $\underline{3}$  ( 14 mM) was dissolved in a small amount of MeOH (5 mL) and 10% aq. NaOH solution (80 mL) and refluxed for 6 hrs. The mixture was cooled down and acidified with 15% HCl to pH $\sim$ 2. The solvent was partially

evaporated and white solid was collected by filtration. Yield of an acid 4 - 85%; MH+(CI) 288.9.

Preparation of acid chloride 5. The reaction mixture: acid 4 (8 mM) and thionyl chloride (2.0 g, 1.23 mL) in  $CH_2Cl_2$  (10 mL) was heated o/n at  $50^{\circ}C$  (reflux). The next day a solvent was stripped on rotavapor and the residue was dried under vacuo. Used immediately without purification.

Curtius rearrangement. An acid chloride <u>5</u> (6.5 mM) was dissolved in acetone (15 mL), cooled to -10°C and treated with sodium azide (1.8 g in 5 mL of water). After stirring for 1 hr at -10°C the reaction mixture was poured into 100 mL of cold water and the azide was extracted into toluene. The toluene layer was washed with water and dried. The toluene solution was partially concentrated (to 15 mL) and the rest was carefully warmed to 100°C for 1 hr. Conc. HCl (8-10 mL) was added and the reaction mixture was refluxed for 15 min. with vigorous stirring. White crystals were decanted and dried under vacuo. Yield 84% of 6 (R = I); MH+(CI) 260.2.

EXAMPLE SP-154: Synthesis of 2-isobutyl-5-(1-

$$H_2N$$
 $S$ 
 $N$ 

aminocycloprop-1-yl)thiazole:

15

20

This procedure was adapted from: Wilk, BK. Synth. Commun. 1993, 23, 2481-4. To a solution of the thiazole methyl alcohol (753 mg, 4.4 mmol) and triphenylphosphine (1.74 g, 6.63 mmol) in dry THF (10 mL) at 0 °C was added diethyl azodicarboxylate

(DEAD, 1.0 mL, 6.4 mmol) dropwise with stirring. After 10 min, acetone cyanohydrin (Aldrich, 0.6 mL, 6.6 mmol) was added dropwise with stirring. The resulting solution was stirred at 0 °C for 10 min, then at rt for 3 h, whereupon the mixture was concentrated under reduced pressure, and the residue purified by flash chromatography (EtOAc/hexanes elution; product  $R_{\rm f}=0.73$  in 60% EtOAc/hexanes) to give a yellow oil (516 mg, 65%) as product.

10

15

20

This procedure was adapted from: Org. Prep. Proc. Int.

1995, 27, 355-9. 50% Sodium hydroxide (aq, 5.0 mL total) was added to a solution of cyanide (516 mg, 2.9 mmol), 1-bromo-2-chloroethane (3.5 mL, 42 mmol), and benzyltriethylammonium chloride (25 mg, 0.09 mmol) at 50 °C. This was maintained at 50 °C for 2 h, then at rt for 2 h. Water was added such that the total volume was 20 mL, and the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 x 10 mL). The combined organic extracts were washed (water, 1 N HCl, water), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (20% EtOAc/hexanes elution) to give the product as an oil (403 mg, 68%); MH+ (CI) 207.1.

NC 
$$\xrightarrow{\text{KOH}}$$
  $\xrightarrow{\text{H}_2\text{O}_2}$   $\xrightarrow{\text{KOH}}$   $\xrightarrow{\text{H}_2\text{N}}$   $\xrightarrow{\text{N}_2\text{N}}$   This procedure was adapted from: Org. Prep. Proc. Int. 1995, 27, 355-9. Cyclopropylarylcyanide (403 mg, 1.96 mmol) was dissolved in MeOH (15 mL), and 30% hydrogen peroxide (2.7 mL) and 25% KOH (aq, 0.05 mL) were added at rt. The solution

was heated to 55 °C for 7 h. The reaction mixture was then concentrated in vacuo and stored in the freezer overnight. This crude product was used in the next reaction without further purification.

The crude amide was dissolved in minimal MeOH (1 mL), and 2.5 N NaOH (aq, 10 mL) was added. This suspension was heated to reflux (bath temp 105 °C) for 6 h, whereupon the mixture was cooled to 0 °C, and acidified to pH 3 using 3 N HCl (aq). This was partially concentrated, then extracted with CHCl<sub>3</sub> (3x). The combined extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated to give a solid (189 mg, 43%); MH+(CI) 226.1.

The carboxylic acid (189 mg, 0.84 mmol) was dissolved in CH2Cl2 (5 mL) and thionyl chloride (0.2 mL, 2.7 mmol) was 15 added at rt. This was heated to reflux (bath temp 55 °C) for 3.5 h, whereupon the mixture was concentrated under reduced pressure. The crude acid chloride was dissolved in acetone (4 mL), and a solution of sodium azide (270 mg, 4.2 mmol) in water (1 mL) was added at -15 °C. After 1 h at -15 °C, water 20 (20 mL) was added, and the acyl azide was extracted into toluene (3x). The combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and partially concentrated (to ca. 30 mL). The solution was then warmed to 100 °C for 1 h. Conc. HCl (ag, 2 mL) was then added, and the mixture was heated to reflux for 25 15 min. The mixture was cooled to 0 °C, basified with 10 N NaOH (aq), then extracted with CHCl3 (3x). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated to give an oil ( $R_f = 0.37$  in 5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>; ninhydrin visualization); MH+ (CI) 197.1.

5

10

### EXAMPLE SP-155 Procedure A: Synthesis of 2:

2,2-Dioxo-1,2,3,4-tetrahydro- $2\lambda^6$ -benzo[c][1,2]thiazin-4-ylamine

5 A solution of 0.58 g (2.7 mmol) of oxime 1 (prepared according to J. Heterocyclic. Chem. 17, 1281 (1980), the identical compound is described in this paper) in 13 ml of aqueous tetrahydrofurane (THF:H2O, 10:1) was stirred under argon atmosphere. Aluminum amalgam (from 0.52 g, 19 mmol, 7eq. of Reynolds heavy-duty aluminum foil), prepared by sequential 10 exposure (10-20 seconds each) of small strips to 1 N KOH, distilled water, 0.5% mercuric chloride, distilled water, and dry THF, was then added to the solution of  ${\bf 1}$  over a period of 3 hours. The reaction mixture was stirred overnight, then filtered on a bed of celite and the solvent evaporated to 15 yield 510 mg of 2 (94%) as an orange oil that slowly solidified. mass spec (CI) (MH+): 199.1

#### EXAMPLE SP-155A

20

The compound of Example SP-155 can be used to open the appropriate boc protected amino epoxide to generate the compound of Example SP-155A. This compound can then be

deprotected using methods well known in the art to generate the free amine, which can then be further manipulated.

EXAMPLE SP-156: Procedure B: Synthesis of 4, 2,2-Dioxo-3,4-dihydro-2H-2 $\lambda^6$ -benzo[e][1,2]oxathiin-4-ylamine

The amine 4 (mass spec (CI) (MH+): 200.0) was prepared according to the procedure A described above starting from 1H-2,1-Benzothiazin-4(3H)-one, oxime, 2,2-dioxide 3.

Oxime 3 was obtained starting from commercially available 1,2-Benzoxathiin-4(3H)-one, 2,2-dioxide [49670-47-5].

#### 15 EXAMPLE SP-156A:

5

20

The compound of Example SP-156 can be used to open the appropriate boc protected amino epoxide to generate the compound of Example SP-156A. This compound can then be deprotected using methods well known in the art to generate the free amine, which can then be further manipulated.

-446-

EXAMPLE SP-156-B

Rc and Rd are independently H, halogen, alkoxy, or alkyl. R<sub>1</sub> is 3,5-difluorobenzene; Z is residue from a group that will couple to an amine, including, for example, carboxylic acid derivates (such as an isophthalamide), sulfonic acid derivatives (such as para-toluenesulfonic acid), haloalkane derivatives (such as iodopentane, and arylhaloalkyl derivatives (such as benzylbromide.)

10

5

EXAMPLE SP-157: Preparation of : tert-butyl (2R,3S)-4-(3,5-difluorophenyl)-2-hydroxy-3-({3-[(1-propylbutyl)sulfonyl]alanyl}amino)butyl(3-ethylbenzyl)carbamate

15

Part A.

A 250 ml round bottom flask equipped with magnetic stir bar 5 and  $N_2$  inlet was charged with 5.0 g (34 mmole) methyl 2acetamidoacrylate, 4.6 g (34 mmole) 4-mercapto heptane in 50 ml methanol. The reaction vessel was charged with 3.6 g (36 mmole) triethylamine and stirred at room temperature for 45 minutes when HPLC indicated complete reaction. The reaction vessel was then treated with 47.2 g (77 mmole) Oxone. After 90 minutes HPLC indicated complete oxidation to the desired sulfone. The reaction was filtered and concentrated in vacuo. The residue was partitioned between ethyl acetate and water and the organic layer was washed with brine, dried over sodium sulfate, and concentrated in vacuo to 9.2 g (86 %) of methyl N-acetyl-3-[(1-propylbutyl)sulfonyl]alaninate as a colorless oil. M + H = 308 g/m.

Part B.

20

10

15

A 250 ml round bottom flask equipped with magnetic stir bar, reflux condenser, and  $N_2$  inlet was charged with 9.2 g methyl Nacetyl-3-[(1-propylbutyl)sulfonyl]alaninate in 50 ml acetic acid and 50 ml conc. HCl. The solution was refluxed for 4 hours then concentrated in vacuo. The residue was chased with toluene (2X ) then vacuum dried overnight to yield 7.8 g of the desired 3-[(1-propylbutyl)sulfonyl]alanine HCl salt.

Part C.

30

25

A 250 ml round bottom flask equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 7.8 g (27 mmole) 3-[(1-propylbutyl)sulfonyl]alanine and 7.4 g (30 mmole) N-Cbz succinamide in 100 ml methylene chloride. The reaction was cooled to 0 °C, and 6.9 g NMM was added dropwise. The reaction was allowed to warm to room temperature and stirred for 4 hours at which point HPLC analysis indicated complete reaction. The reaction was concentrated in vacuo and partitioned between ethyl acetate and 1 N HCl. The organic layer was washed with water, brine, dried over sodium sulfate, and concentrated in vacuo to give 11.4 g of N-[(benzyloxy)carbonyl]-3-[(1-propylbutyl)sulfonyl]alanine that was used without further purification. M + H = 386.

#### 15 Part D.

A 250 ml round bottom flask equipped with magnetic stir bar and  $N_2$  inlet was charged with 4.0 g (10 mmole) N-[(benzyloxy)carbonyl]-3-[(1-propylbutyl)sulfonyl]alanine and 1.2 g (12 mmole) (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-mmole)]20 ethylbenzyl)amino]butan-2-ol dihydrochloride in 50 ml anhydrous methylene chloride. To the reaction mixture was added 5.6 ml (51 mmole) NMM, 1.7 g (13 mmole) hydroxybenzotriazole, and lastly 3.1 g (16 mmole) 1-(3-25 dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride. stirring at room temperature for 3 hours, HPLC analysis indicated complete reaction. The reaction was diluted with methylene chloride and washed with saturated sodium bicarbonate solution, 0.5 M citric acid, and brine. The organic layer was dried over sodium sulfate, filtered, and 30 concentrated in vacuo to give the  $N^2$ -[(benzyloxy)caronyl]- $N^1$ -{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]alaninamide. A 50 ml round bottom flask equipped with magnetic stir bar and  $\ensuremath{\text{N}}_2$ 

inlet was charged with the crude residue in anhydrous methylene chloride. The reaction was cooled to 0°C and added 2.5 g (12 mmole) di-tert-butyl dicarbonate and 1.2 ml (11 mmole) N-methyl morpholine. The reaction was allowed to warm to room temperature and stirred for 18 hours at which point HPLC analysis indicated complete reaction. The reaction was diluted with methylene chloride and washed with saturated sodium bicarbonate solution, and brine. The organic layer was dried over sodium sulfate, filtered, and concentrated in 10 The crude material was purified on silica gel by flash vacuo. chromatography using a gradient solvent of 5-40% ethyl acetate in hexane to give 3.4 g of  $N^2$ -[(benzyloxy-)caronyl]- $N^1$ - $\{(1S,2R)-N-[(t-butyloxy)carbonyl]-1-(3,5-difluorobenzyl)-3-$ [(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1propylbutyl)sulfonyl]-D,L-alaninamide.

15 M+Na = 824.

Part E.

A Fisher-Porter bottle was charged with 3.4 g (4.2 mmole) of 20  $N^2$ -[(benzyloxy)-carbonyl]- $N^1$ -{(1S,2R)- N-[(tbutyloxy)carbonyl]-1-(3,5-difluorobenzyl)-3-[(3ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1propylbutyl)sulfonyl]alaninamide in 50 ml methanol. After 25 degassing with nitrogen, 1.6 g of 5% Pd/C (Degussa E101 50% water) was added. The reaction vessel was purged with 40 psi nitrogen (4X) then pressurized to 50 psi with hydrogen. After 15 minutes, HPLC analysis indicated complete reaction. The catalyst was removed by filtration through celite, and the 30 filtrate concentrated in vacuo to give 2.4 g of  $N^1$ -{(1S,2R)- N-[(t-butyloxy) carbonyl]-1-(3,5-difluorobenzyl)-3-[(3-butyloxy) carbonyl]-1-(3,5-difluorobenzyl)-3-[(3-butyloxy) carbonyl]-1-(3,5-difluorobenzyl)-3-[(3-butyloxy) carbonyl]-1-(3,5-difluorobenzyl)-3-[(3-butyloxy) carbonyl]-1-(3,5-difluorobenzyl)-3-[(3-butyloxy) carbonyl]-1-(3,5-difluorobenzyl)-3-[(3-butyloxy) carbonyl]-1-(3,5-difluorobenzyl)-3-[(3-butyloxy) carbonyl]-1-(3,5-difluorobenzyl)-3-[(3-butyloxy) carbonyl]-1-(3,5-difluorobenzyl)-3-[(3-butyloxy) carbonyl]-1-(3,5-difluorobenzyl)-3-[(3-butyloxy) carbonyl]-1-(3,5-difluorobenzyl)-3-[(3-butyloxy) carbonyl]-1-(3,5-difluorobenzyl)-3-[(3-butyloxy) carbonyl]-1-(3,5-difluorobenzyl)-3-[(3-butyloxy) carbonyl]-1-(3,5-difluorobenzyl)-3-[(3-butyloxy) carbonyl]-1-(3,5-difluorobenzyl)-3-[(3-butyloxy) carbonyl]-1-(3-butyloxy)-1-(3-butylethylbenzyl)amino]-2-hydroxypropyl}-3-[(1propylbutyl)sulfonyl]-D,L-alanine. M+H = 668. EXAMPLE SP-158

## 2,2-Dioxo-1,2,3,4-tetrahydro- $2\lambda^6$ -benzo[c][1,2]thiazin-4-ylamine

2 was prepared according to procedure A of EXAMPLE SP-155. Also, epoxide opening with 2 (see procedure A of EXAMPLE SP-155) was achieved according to the procedure described in Bennett, Frank. Synlett 1993, 703-704. Mass spec (CI) MH+643.7.

#### EXAMPLE SP-159

10

15

20

### 2,2-Dioxo-1,2,3,4-tetrahydro- $2\lambda^6$ -benzo[c][1,2]thiazin-4-ylamine

2 was prepared according to procedure A in EXAMPLE SP-155. Also, epoxide opening with 2 (see procedure A) was achieved according to the procedure described in Bennett, Frank. Synlett 1993, 703-704. Mass spec (CI) MH+ 643.7.

#### EXAMPLE SP-160

### Synthesis of t-Boc-NH-di-F-Phe-Hydroxyethylamine(HEA)-O-Bn

To 2.4g (15 mmole, 3 eq.)of O-benzylhydroxylamine hydrochloride in 20 ml of EtOAc was added 20 ml of 1N KOH with stirring. The organic layer extracted and dried, stripping of solvent and reconstituted with 20 ml of DCM, 1.5 g (5 mmole)of

erythro-di-F-Phe-epoxide and 0.62 g (1mmole, 0.2 eq.) of Ytterbium(III) trifluoromethanesulfonate was added at room temperature. The mixture was stirred overnight and worked up by 1N HCl, bicarb and brine washings, dried, stripping of solvent gave 1.23 g crude which was subject to column purification, it afforded 0.76 g( 1.8 mmole, 36%) of the targeted compound as a pale white solid.

EXAMPLE SP-161

20

25

30

10 N<sup>1</sup>-{(1S,2R)-1-(3,5-Difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-(5-methyl-1,2,4-oxadiazol-3-yl)-N<sup>3</sup>,N<sup>3</sup>-dipropylisophthalamide hydrochloride

Step 1: Methyl 3-[(dipropylamino)carbonyl]-5-(5-methyl-1,2,4-15 oxadiazol-3-yl)benzoate

To a stirred solution of methyl 3-cyano-5-[(dipropylamino)carbonyl]benzoate prepared by the method in EXAMPLE S-2510 (2.3 g, 7.9 mmol) in methanol (26 mL) is added hydroxylamine hydrochloride (1.1 g, 16 mmol) and potassium carbonate (2.2 g, 16 mmol). The resulting reaction mixture is refluxed for 20 h, and then cooled to room temperature. The inorganic salts are filtered, and the filtrate is concentrated under reduced pressure to provide an amidoxime in quantitative yield.

To the amidoxime (1.3 g, 4 mmol), and EDC (1.5 g, 8 mmol) in 2-methoxyethyl ether (8 mL) is added acetic acid (0.21 mL, 4 mmol). The resulting reaction mixture is stirred for 24 h and then refluxed for 3 h. The reaction mixture is cooled to room temperature, diluted with ethyl acetate, washed with water, 1 N hydrochloric acid, saturated sodium bicarbonate,

and brine, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 50% ethyl acetate hexanes) provides the title compound.  $^{1}\text{H}$  NMR (500 MHz, CDCl3)  $\delta$  8.69 (s, 1H), 8.18 (m, 1H), 8.11 (s, 1H), 3.91 (s, 3H), 3.43 (t, J = 7 Hz, 2H), 3.12 (t, J = 7 Hz, 2H), 2.63 (s, 3H), 1.66 (t, J = 7 Hz, 2H), 1.50 (t, J = 7 Hz, 2H), 0.95 (t, J = 7 Hz, 3H), 0.70 (t, J = 7 Hz, 3 H).

#### 10 Step 2

3-[(Dipropylamino)carbonyl]-5-(5-methyl-1,2,4-oxadiazol-3yl)benzoic acid

A stirred solution of methyl 3-[(dipropylamino)carbonyl]-5-(5-methyl-1,2,4-oxadiazol-3-yl)benzoate (629 mg, 1.8 mmol) 15 and lithium iodide (2.4 g, 18 mmol) in pyridine (7 ml) is refluxed for 18 h. The reaction mixture is cooled to room temperature and the solvent is concentrated under reduced The residue is dissolved in water, washed with 20 ethyl acetate, the aqueous layer is acidified to pH 3 with 1 N hydrochloric acid and extracted with chloroform (3 x 100 mL). The organic layer is dried (sodium sulfate), filtered, and concentrated to give the title compound. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  11.11 (br s, 1H), 8.85 (t, J = 1 Hz, 1H), 8.31 (t, J = 1 Hz, 1H), 8.23 (t, J = 1 Hz, 1H), 3.51 (s, 2H), 3.19 (s, 2H), 2.72 (s, 3H), 1.73 (d, J = 7 Hz, 2H), 1.56 (d, J = 7 Hz, 2H), 1.01 (t, J = 7 Hz, 3H), 0.76 (t, J = 7 Hz, 3H).

Step 3

25

 $N^1-\{(1S,2R)-1-(3,5-Difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-5-(5-methyl-1,2,4-oxadiazol-3-yl)-N^3,N^3-dipropylisophthalamide hydrochloride$ 

5 A solution of 3-[(dipropylamino)carbony1]-5-(5-methyl-1,2,4-oxadiazol-3-yl)benzoic acid (209 mg, 0.63 mmol), HATU (359 mg, 0.95 mmol), HOBt (128 mg, 0.95 mmol), and diisopropylethylamine (165  $\square$ L, 0.95 mmol) is stirred in methylene chloride (2.0 mL) for 15 min. A solution of 10 (2R, 3S) - 3 - amino - 4 - (3, 5 - difluorophenyl) - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]]ethylbenzyl)amino]butan-2-ol dihydrochloride prepared by the method in EXAMPLE SP-272 (257 mg, 0.63 mmol) and diisopropylethylamine (165 □L, 0.95 mmol) in methylene chloride (2.0 mL) is added and the reaction mixture is stirred The reaction mixture is diluted with methylene 15 overnight. chloride, washed with 1 N hydrochloric acid (25 mL), saturated sodium bicarbonate (25 mL), and brine, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 20 methanol/chloroform) provides the title compound as the free The solid is dissolved in methanol (1 mL), and treated with hydrochloric acid (0.3 mL of a 1.0 M solution in diethyl ether, 0.3 mmol). The resulting precipitate is collected by filtration to provide the title compound. APCI MS m/z 648.4 [M

EXAMPLE SP-162

+ H]<sup>+</sup>.

25

 $\label{eq:N1-local} $$N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-5-(1H-imidazol-2-yl)-N^3,N^3-dipropylisophthalamide$ 

5 Step 1

Methyl 3-[(dipropylamino)carbonyl]-5-(1H-imidazol-2yl)benzoate

То -70 °C stirred solution of 1-tertbutyldimethylsilylimidazole 10 (602 mg, 3.3 mmol) tetrahydrofuran (10 mL) is added n-butyllithium (1.6 M in hexanes, 2.3 mL, 3.63 mmol). After 30 min, zinc chloride (1 M  $\,$ in diethyl ether, 9.9 mL, 9.9 mmol) is added and the reaction mixture is warmed to 0 °C for 1 h. To this mixture is then 15 added 3-[(dipropylamino)carbonyl]-5-iodobenzoate methyl prepared by the method in EXAMPLE SP-281, step2 (1.17 g, 3mmol) followed by palladium(0) tetrakis(triphenylphosphine) (173 mg, 0.15 mmol). The reaction mixture is heated at reflux for 15 h. The reaction mixture is diluted with ethyl acetate (50 mL), washed with water, and brine, dried (sodium sulfate), 20 filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica gel, 1-5% methanol/methylene chloride) provides the title compound in pure form.  $^{1}\text{H}$  NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.64 (s, 1H), 8.14 (s, 1H), 7.97 (s, 1H), 7.19 (s, 2H), 3.96 (s, 3H), 3.51 (m, 2H), 25 3.32 (m, 2H), 1.73 (m, 2H), 1.57 (m, 2H), 1.01 (m, 3H), 0.73 (m, 3H).

Step 2

30 3-[(Dipropylamino)carbonyl]-5-(1H-imidazol-2-yl)benzoic acid

To a stirred solution of the ester from step 1 (260 mg, 0.79 mmol) in 2:1:1 tetrahydrofuran/methanol/water (8 mL) is added lithium hydroxide (140 mg, 3.3 mmol). The reaction mixture is stirred at room temperature for 2 h, concentrated under reduced pressure. The residue partitioned between water (10 mL) and diethyl ether (10 mL). The aqueous layer is acidified to pH 4 - 5 with 1 N hydrochloric acid and extracted with 3:1 chloroform/2-propanol (3 x 30 mL). The combined organic layers are dried (sodium 10 sulfate), filtered, and concentrated under reduced pressure to provide the title compound.  $^{1}$ H NMR (300 MHz, CD<sub>3</sub>OD)  $\delta$  8.64 (s, 1H), 8.10 (s, 1H), 8.01 (s, 1H), 7.28 (s, 2H), 3.52 (m, 2H), 3.26 (m, 2H), 1.75 (m, 2H), 1.59 (m, 2H), 1.02 (t, J = 7 Hz, 3H), 0.75 (t, J = 7 Hz, 3H). 15

#### Step 3

 $N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-(1H-imidazol-2-yl)- $N^{3}$ ,  $N^{3}$ -

20 dipropylisophthalamide

To a stirred solution of 3-[(dipropylamino)carbonyl]-5-(1H-imidazol-2-yl)benzoic acid (250 mg, 0.79 mmol), diisopropylethylamine (103 mg, 0.8 mmol), and HBTU (330 mg, 0.87 mmol) in methylene chloride (5 mL) is added a mixture of (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-

ethylbenzyl)amino]butan-2-ol prepared by the method of EXAMPLE SP-272 (322 mg, 0.79 mmol) and diisopropylethylamine (206 mg, 1.6 mmol) in methylene chloride (5 mL). The reaction mixture is stirred at room temperature for 4 h and concentrated under reduced pressure. The residue is diluted with ethyl acetate (20 mL), washed with saturated sodium bicarbonate, and brine, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica gel, 5:95 methanol/methylene chloride) provides the title compound in pure form. APCI MS m/z 632.3 [M + H]<sup>+</sup>.

#### EXAMPLE SP-163

 $\label{eq:N1-lem2yl-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl} N^3-methyl-5-(1,3-oxazol-2-yl)-N^3-propylisophthalamide$ 

15

10

Step 1

Methyl 3-iodo-5-{[methyl(propyl)amino]carbonyl}benzoate

To 3-iodo-5-(methoxycarbonyl)benzoic acid (1.0 g, -20 mmol), prepared EXAMPLE as in SP-281, step and diisopropylethylamine (1.7 mL, 9.8 mmol) in DMF (10 mL) is O-(7-Azabenzotriazol-1-yl)-N, N, N', N'-tetramethyluronium hexafluorophosphate (HATU, 1.5 g, 3.9 mmol) methylpropylamine (503  $\mu\text{L}$ , 4.9 mmol). The solution is stirred at room temperature 2 h. The solution is diluted in ethyl 25 acetate and washed with water, saturated sodium bicarbonate, The organic layer is dried over sodium sulfate, and brine. filtered and concentrated under reduced pressure to give the title compound in crude form. This material is purified by flash chromatography (40% ethyl acetate/hexane) to give the 30 purified title compound. MS (ESI)  $[M+H^{+}] = 362.4$ .

Step 2

3-{[Methyl(propyl)amino]carbonyl}-5-(1,3-oxazol-2-yl)benzoic acid

5 To a -70 °C stirred solution of oxazole (330 mg, 4.8 mmol) in tetrahydrofuran (4 mL) is added n-butyllithium (1.6 M in hexanes, 3.3 mL, 5.3 mmol). After 30 min, zinc chloride (1 M in diethyl ether, 14.5 mL, 14.5 mmol) is added and the reaction mixture is warmed to 0 °C for 1 h. To this mixture is 10 added а solution of methyl 3-iodo-5-{[methyl(propyl)amino]carbonyl}benzoate (1.6 g, 4.5 mmol) in anhydrous tetrahydrofuran (3 mL) followed by palladium(0) tetrakis(triphenylphosphine) (221 mg, 0.19 mmol). reaction mixture is heated at reflux for 2 h. The reaction mixture is cooled, diluted with ethyl acetate, washed with 15 water, and brine, dried (sodium sulfate), filtered, concentrated under reduced pressure. Purification by flash column chromatography (silica gel, 60% ethyl acetate/hexane) provides a solid. The solid is redissolved in 1:1:1 20 tetrahydrofuran/methanol/water (9 mL), and lithium hydroxide monohydrate (311 mg, 7.4 mmol) is added and stirred 2 h at room temperature. The reaction is diluted in chloroform and washed with 1N hydrochloric acid (aq), water, and brine, dried (sodium sulfate), filtered and concentrated under reduced 25 pressure to give the title compound. ESI MS m/z 287.3 [M - H]

Step 3

 $N^{1}$ -{(1S,2R)-1-Benzyl-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-30  $N^{3}$ -methyl-5-(1,3-oxazol-2-yl)- $N^{3}$ -propylisophthalamide

3-{[methyl(propyl)amino]carbonyl}-5-(1,3-oxazol-2yl)benzoic acid (206 mg, 0.71 mmol) in DMF (5 mL) is added diisopropylethylamine (174  $\mu\text{L}$ , 1.1 mmol), HATU (323 mg, 0.85 (2R,3S)-3-amino-1-[(3-ethylbenzyl)amino]-4then phenylbutan-2-ol dihydrochloride prepared by the method of EXAMPLE SP-272 (292 mg, 0.79 mmol). The reaction is stirred 4h at room temperature. The reaction is partitioned between chloroform and water. The organic layer is washed with 1 N 10 hydrochloric acid, saturated sodium bicarbonate, and brine, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 8% methanol/chloroform) gives the title compound. ESI MS m/z 569.3 [M + H]<sup>+</sup>. 15

EXAMPLE SP-164

Step 1

N1- Isobutyl-L-alaninamide

20

25

Boc-L-alanine (5.0 g, 26.4 mmol), isobutylamine (2.9 mL, 29.1 mmol), diisopropylethylamine (11.5 mL, 66 mmol), and HOBt (3.6 g, 26.4 mmol) in anhydrous DMF (15 mL) is stirred 15 min. EDC is added, and the reaction is stirred at room temperature 16 h. The reaction is diluted in ethyl acetate and washed with 1 N hydrochloric acid, saturated sodium bicarbonate, and brine, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. The residue is redissolved in 4N hydrochloric acid in dioxane (30 mL) and stirred for 2 h. The

solution is concentrated under reduced pressure, dissolved in chloroform and washed with 1 N NaOH (aq). The aqueous layer is extracted with chloroform, and the pooled organics are dried (sodium sulfate), filtered, and concentrated under reduced pressure to give the title compound. ESI MS m/z 145.2  $[M + H]^+$ .

#### Step 2

[1-(3,5-Difluoro-benzyl)-2-hydroxy-3-(1-isobutylcarbamoyl-10 ethylamino)-propyl]-carbamic acid tert-butyl ester

 $N^1$ - Isobutyl-L-alaninamide (3.8 g, 26 mmol) and tert-butyl (1S)-2-(3,5-difluorophenyl)-1-[(2S)-oxiran-2-yl]ethylcarbamate prepared by the method in EXAMPLE S-3 (3.1 g, 10.4 mmol) in isopropanol (50 mL) are refluxed 4 h. The reaction is cooled and concentrated under reduced pressure. Purification by flash column chromatography (silica, 8% methanol/chloroform) gives the title compound. ESI MS m/z 444.1 [M + H]<sup>+</sup>.

### 20 Step 3

15

 $N^2$ -[(2R,3S)-3-Amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]- $N^1$ -isobutyl-L-alaninamide dihydrochloride

[1-(3,5-Difluoro-benzyl)-2-hydroxy-3-(1-

isobutylcarbamoyl-ethylamino)-propyl]-carbamic acid tert-butyl ester (2.7 g, 6 mmol) is dissolved in excess 4N hydrochloric acid in dioxane, and the reaction is stirred 2 h at room temperature. The solution is concentrated under reduced

pressure to give the title compound. ESI MS m/z 344.3 [M + H]<sup>+</sup>.

Step 4

5 Methyl 3-[(dipropylamino)carbonyl]-5-(1,3-oxazol-2-yl)benzoate

3-[(Dipropylamino)carbonyl]-5-iodobenzoic acid (12 g, 32 mmol) is dissolved in 20% methanol/benzene (480 mL), and 2M  $\,$ trimethylsilyldiazomethane in hexane (19 mL, 38 mmol) is added slowly. Upon completion of the addition, the solution is 10 concentrated under reduced pressure to give methyl [(dipropylamino)carbonyl]-5-iodobenzoate for use without further purification in the following reaction. To a -70 °C stirred solution of oxazole (120 1.7 mmol) mg, tetrahydrofuran (4 mL) is added n-butyllithium (1.6 M in 15 hexanes, 1.2 mL, 1.9 mmol). After 30 min, zinc chloride (1 M  $\,$ in diethyl ether,  $5.2\ \text{mL}$ ,  $5.2\ \text{mmol}$ ) is added and the reaction mixture is warmed to 0  $^{\circ}\text{C}$  for 1 h. To this mixture is added a solution of methyl 3-[(dipropylamino)carbonyl]-5-iodobenzoate (643 mg, 1.6 mmol) in anhydrous tetrahydrofuran (3 mL) 20 followed by palladium(0) tetrakis(triphenylphosphine) (80 mg, 0.07 mmol). The reaction mixture is heated at reflux for 3 h. The reaction mixture is cooled, diluted with ethyl acetate, filtered, washed with saturated sodium bicarbonate, water, and brine, dried (sodium sulfate), filtered, and concentrated 25 under reduced pressure. Purification by flash column chromatography (silica gel, 60% ethyl acetate/hexane) provides the title compound in pure form.  $^{1}H\ NMR\ (400\ MHz,\ CDCl_{3})\ \delta$ 8.77 (s, 1H), 8.27 (s, 1H), 8.14 (s, 1H), 7.80 (s, 1H) 7.32(s, 1H), 3.52 (t, 2H), 3.22 (t, 2H), 1.75 (m, 2H), 1.30 (m, 30 2H), 0.97 (t, 3H), 0.79 (t, 3H).

Step 5

10

15

20

25

N-[1-(3,5-Difluoro-benzyl)-2-hydroxy-3-(1-isobutylcarbamoyl-ethylamino)-propyl]-5-oxazol-2-yl-N',N'-dipropyl-

5 isophthalamide

Methyl 3-[(dipropylamino)carbonyl]-5-(1,3-oxazol-2-yl)benzoate (430 mg, 1.3 mmol) is dissolved in 1:1:1 tetrahydrofuran/methanol/water (9 mL), and lithium hydroxide monohydrate (110 mg, 2.6 mmol) is added and stirred 2 h at room temperature. The reaction is concentrated under reduced pressure and chloroform is added. The solution is washed with 1N hydrochloric acid (aq). The aqueous layer is reextracted with chloroform, and the pooled organics are washed with brine. The solution is concentrated under reduced pressure.

To this residue redissolved in DMF (5 mL) is added diisopropylethylamine (438  $\mu$ L, 2.52 mmol), HATU (289 mg, 0.76  $N^2$ -[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2hydroxybutyl]-N<sup>1</sup>-isobutyl-L-alaninamide dihydrochloride (288 The reaction is stirred 4 h at room mg, 0.69 mmol). temperature. The reaction is partitioned between chloroform and water. The organic layer is washed with 1 N hydrochloric acid, saturated sodium bicarbonate, and brine, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, methanol/chloroform) gives the title compound. ESI MS m/z $642.3 [M + H]^{+}$ .

EXAMPLE SP-165

N-[1-(3,5-Difluoro-benzyl)-2-hydroxy-3-(1-isobutylcarbamoyl-ethylamino)-propyl]-N'-methyl-5-oxazol-2-yl-N'-propyl-isophthalamide

5 3-{[Methyl(propyl)amino]carbonyl}-5-(1,3-oxazol-2yl)benzoic acid prepared by the method in EXAMPLE SP-163 in DMF (5 mL) is added diisopropylethylamine (361  $\mu$ L, 2.1 mmol), HATU (237 mg, 0.62 mmol), then dihydrochloride prepared by the method of EXAMPLE SP-164 (237 mg, 0.57 mmol). The reaction is stirred 2 h at room temperature. The reaction is partitioned 10 between chloroform and water. The organic layer is washed with 1 N hydrochloric acid, saturated sodium bicarbonate, and brine, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 8% methanol/chloroform) gives 15 title compound. ESI MS m/z 614.4 [M + H]<sup>+</sup>.

EXAMPLE SP-166

 $N^1$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[1-(ethoxymethyl)-1H-imidazol-2-yl]- $N^3$ ,  $N^3$ -dipropylisophthalamide

Step 1

Methyl 3-[(dipropylamino)carbonyl]-5-[1-(ethoxymethyl)-1H-25 imidazol-2-yl]benzoate

To a -70 °C stirred solution of 1-ethoxylmethylimidazole (J. Am. Chem. Soc. 1978, 100, 3918) (420 mg, 3.3 mmol) in tetrahydrofuran (10 mL) is added n-butyllithium (1.6 M in hexanes, 2.3 mL, 3.6 mmol). After 30 min, zinc chloride (9.9 mL of a 1 M solution in diethyl ether, 9.9 mmol) is added and the reaction mixture is warmed to 0 °C for 1 h. mixture is then added methyl 3-[(dipropylamino)carbonyl]-5iodobenzoate (1.17 g, 3 mmol) followed by palladium(0) tetrakis(triphenylphosphine) (173 mg,  $0.15 \quad mmol)$ . reaction mixture is heated at reflux for 2 h. The reaction mixture is diluted with ethyl acetate (50 mL), washed with water, and brine, dried (sodium sulfate), filtered, concentrated under reduced pressure. Purification by flash column chromatography (silica gel, 1-5% methanol/methylene chloride) provides the title compound in pure form. H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.52 (s, 1H), 8.10 (s, 1H), 8.03 (s, 1H), 8.19 (s, 2H), 5.28 (s, 2H), 3.95 (s, 3H), 3.59 (q, J = 7 Hz, 2H),3.49 (m, 2H), 3.21 (m, 2H), 1.70 (m, 2H), 1.54 (m, 2H), 1.25 (t, J = 7 Hz, 3H), 0.99 (m, 3H), 0.75 (m, 3H).

20

10

15

#### Step 2

3-[(Dipropylamino)carbonyl]-5-[1-(ethoxymethyl)-1H-imidazol-2-yl]benzoic acid

To a stirred solution of the ester from step 1 (756 mg, 1.95 mmol) in 2:1:1 tetrahydrofuran/methanol/water (12 mL) is added lithium hydroxide (170 mg, 4 mmol). The reaction mixture is stirred at room temperature for 42 h, and concentrated under reduced pressure. The residue is partitioned between water (10 mL) and chloroform (10 mL). The aqueous layer is acidified to pH 4 - 5 with 1 N hydrochloric

acid and extracted with 3:1 chloroform/2-propanol (3 x 30 mL). The combined organic layers are dried (sodium sulfate), filtered, and concentrated under reduced pressure to provide the title compound.  $^{1}H$  NMR (300 MHz, CD<sub>3</sub>OD)  $\delta$  8.51 (s, 1H), 8.06 (s, 1H), 8.00 (s, 1H), 7.49 (s, 1H), 7.17 (s, 1H), 5.39 (s, 2H), 3.62 (q, J = 7 Hz, 2H), 3.51 (m, 2H), 3.27 (m, 2H), 1.72 (m, 2H), 1.59 (m, 2H), 1.21 (t, J = 7 Hz, 3H), 1.00 (m, 3H), 0.75 (m, 3H).

#### 10 Step 3

 $N^1$ -{(1S, 2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-5-[1-(ethoxymethyl)-1H-imidazol-2-yl]- $N^3$ ,  $N^3$ -dipropylisophthalamide

To a stirred solution of 3-[(dipropylamino)carbony1]-5-15 [1-(ethoxymethyl)-1H-imidazol-2-yl]benzoic acid (177 mg, 0.47 mmol), diisopropylethylamine (651 mg, 0.5 mmol), and HBTU (209  $\,$ mg, 0.55 mmol) in methylene chloride (5 mL) is added a mixture of (2R, 3S) - 3 - amino - 4 - (3, 5 - difluorophenyl) - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]] - 1 - [(3 - amino - 4 - amino - 4 - (3 - amino - 4 - amino - 4 - (3 - amino - 4 - amino - 4 - (3 - amino - 4 - amino - 4 - (3 - amino - 4 - amino - 4 - (3 - amino - 4 - amino - 4 - amino - 4 - (3 - amino - 4 - amino - 4ethylbenzyl)amino]butan-2-ol prepared by the method of EXAMPLE 20 SP-272 (196 mg, 0.48 mmol) and diisopropylethylamine (130 mg, 1.0 mmol) in methylene chloride (5 mL). The reaction mixture is stirred at room temperature for 15 h and concentrated under reduced pressure. The residue is diluted with ethyl acetate (20 mL), washed with saturated sodium bicarbonate, and brine, 25 dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica gel, 5:95 methanol/methylene chloride) provides the title compound. APCI MS m/z 690.3 [M + H]<sup>+</sup>.

EXAMPLE SP-168

Methyl 3-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}amino)carbonyl]benzoate

5

hydrogen isophthalate (1.0 g, To methyl 5.6 mmol) DMF/chloroform (1:2, 15 mL) is added disopropylethylamine (3.9 mL, 22 mmol), HATU (2.5 g, 6.7 mmol), then (2R,3S)-3amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-10 ol dihydrochloride prepared by the method of EXAMPLE SP-272 (2.5 g, 6.1 mmol). The reaction is stirred 1 h at room The reaction is partitioned between ethyl temperature. acetate and water. The organic layer is washed with 1 N hydrochloric acid, saturated sodium bicarbonate, and brine, 15 dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 8% methanol/chloroform) gives the title compound. ESI MS m/z 497.3 [M + H]<sup>+</sup>.

20 EXAMPLE SP-169 N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[4-(2-hydroxyethyl)-1,3-oxazol-2-yl]benzamide

Step 1

25 Methyl O-benzyl-N-(tert-butoxycarbonyl)homoserinate

To O-benzyl-N-(tert-butoxycarbonyl)homoserine (5.8 g, 18.9 mmol) in 20% methanol/benzene (72 mL) is added 2M trimethylsilyldiazomethane in hexane (12.3 mL, 24.5 mmol), and the reaction stirred at room temperature 1.5 h. The solution is concentrated under reduced pressure to give the title compound in pure form. ESI MS m/z 324.2 [M + H]<sup>+</sup>.

#### Step 2

tert-Butyl 3-(benzyloxy)-1-(hydroxymethyl)propylcarbamate

10

15


20

5

To an ice-cold solution of methyl O-benzyl-N-(tert-butoxycarbonyl)homoserinate (6 g, 18.6 mmol) in absolute ethanol (100 mL) is added sodium borohydride (2.8 g, 74.2 mmol), and the reaction is refluxed 2 h. The solution is cooled, excess saturated potassium carbonate added, and stirred 16 h at room temperature. The ethanol is removed under reduced pressure, and the aqueous solution is extracted with chloroform. The organic layer is washed with saturated sodium bicarbonate, saturated sodium sulfate, dried (magnesium sulfate), filtered, and concentrated under reduced pressure to give the title compound. ESI MS m/z 296.2 [M + H]<sup>+</sup>.

#### Step 3

2-Amino-4-(benzyloxy)butan-1-ol hydrochloride



25

tert-Butyl 3-(benzyloxy)-1-(hydroxymethyl)propylcarbamate (5 g, 17 mmol) is dissolved in 4 N hydrochloric acid in

dioxane (21 mL) and stirred for 3 h at room temperature. The solution is concentrated under reduced pressure to give the title compound in pure form. ESI MS m/z 196.1 [M + H]<sup>+</sup>.

# 5 Step 4

Methyl

$$3-({[3-(benzyloxy)-1-$$

(hydroxymethyl)propyl]amino}carbonyl)benzoate

Methyl hydrogen isophthalate (1.5 g, 8.2 mmol), 2-amino-4-(benzyloxy)butan-1-ol hydrochloride (2 g, 10 8.6 mmol), diisopropylethylamine (4.2 mL, 24.7 mmol), and HATU (3.8 mg, 9.9 mmol), in DMF (15 mL) are stirred at room temperature 1 h. The reaction is diluted in ethyl acetate and washed with hydrochloric acid (aq), saturated 1N 15 bicarbonate, brine, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica gel, 4% methanol/chloroform) provides the title compound. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.44 (s, 1H), 8.18 (d, 1H, J= 7.9 Hz), 7.86 (d, 1H, J= 7.9 Hz),7.43 (t, 1H, J=7.6 Hz), 7.42-7.35 (m, 5 H), 4.59 (s, 2H), 20 4.33 (m, 1H), 3.96 (s, 3H), 3.88-3.72 (m, 4H), 3.53 (s, 1H), 2.08 (m, 2H).

Step 5

25 Methyl 3-{4-[2-(benzyloxy)ethyl]-1,3-oxazol-2-yl}benzoate

To methyl

3-({[3-(benzyloxy)-1-

(hydroxymethyl)propyl]amino}carbonyl)benzoate (1.3 g, 3.6 mmol) in water-saturated methylene chloride (20 mL) is added sodium bromide (187 mg, 1.8 mmol) and water (2.75 mL), then TEMPO (6 mg, 0.04 mmol) with vigorous stirring. Sodium bicarbonate (115 mg) and 6% sodium hypochlorite (5 mL) is added and stirred 1 h. 6% sodium hypochlorite (1 mL) is added each hour for 3 h.

Excess saturated sodium thiosulfate is added and stirred 30 The mixture is partitioned, and the organic layer is washed with brine, dried (sodium sulfate), filtered and concentrated under reduced. The residue is dissolved in 15 anhydrous tetrahydrofuran (4 mL), and (methoxycarbonylsulfamoyl)triethylammonium hydroxide, inner salt (670 mg, 2.8 mmol). The reaction is microwaved (100 W, 2  $\,$ min) in a sealed vessel, cooled, filtered, and concentrated under reduced pressure. Purification by flash chromatography (silica gel, 40% ethyl acetate/hexanes) gives the title 20 compound. ESI MS m/z 338.3 [M + H]<sup>+</sup>.

Step 6

5

10

 $N-\{\,(1\text{S}\,,2\text{R})\,-1-\,(3\,,5-\text{difluorobenzyl})\,-3-\,[\,(3-\text{ethylbenzyl})\,\text{amino}]\,-2-\,(3-\text{ethylbenzyl})\,\text{amino}]\,-2-\,(3-\text{ethylbenzyl})\,$ 

25 hydroxypropyl}-3-[4-(2-hydroxyethyl)-1,3-oxazol-2-yl]benzamide

Methyl 3-{4-[2-(benzyloxy)ethyl]-1,3-oxazol-2-yl}benzoate (300 mg, 0.9 mmol), 20% palladium(II) hydroxide on carbon (65 mg), and cyclohexene (3 mL) in absolute ethanol (3 mL) are refluxed 1 h. The reaction is cooled, filtered through diatomaceous earth, and concentrated under reduced pressure. The residue is redissolved in 2:1:1 tetrahydrofuran/methanol/water (4 mL) is added lithium hydroxide (75 mg, 1.8 mmol). The reaction mixture is stirred 10 at room temperature for 3 h, and concentrated under reduced The residue is dissolved in DMF (5 mL), diisopropylethylamine (625  $\mu$ L, 3.6 mmol), HATU (540 mg, 1.4 and (2R, 3S) - 3 - amino - 4 - (3, 5 - difluorophenyl) - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]]ethylbenzyl)amino]butan-2-ol dihydrochloride prepared by the 15 method in EXAMPLE SP-272 (407 mg, 1 mmol) are added. reaction stirred at room temperature 16 h. The reaction mixture is diluted with chloroform, washed with water, 1N hydrochloric acid (aq), saturated sodium bicarbonate, brine, dried (sodium sulfate), filtered, and concentrated under 20 reduced pressure. Purification by flash column chromatography (silica, 8% methanol/chloroform) provides the title compound. ESI MS m/z 550.3 [M + H]<sup>+</sup>.

# EXAMPLE SP-170

25 N<sup>1</sup>-{(1S,2R)-1-(3,5-Difluorobenzyl)-2-hydroxy-3-[(3-isopropylbenzyl)amino]propyl}-N<sup>3</sup>,N<sup>3</sup>-dipropyl-5-(1,3-thiazol-2-yl)isophthalamide

Step 1

3-Isopropenylbenzonitrile

To a stirred solution of 3-cyanophenylboronic acid (10.0 68.05 mmol) dissolved in DME (340 mL) g, is added 2bromopropene (6.86 g, 56.7 mmol), and sodium carbonate (62.3 mL of a 2 M solution in water, 124.7 mmol). The reaction mixture is degassed for 20 min with nitrogen. Tetrakis(triphenylphosphine)palladium(0) (2.54 g, 2.2 mmol) is added, the reaction mixture degassed for 10 min, and heated at 10 reflux overnight. The reaction mixture is cooled to room temperature and then partitioned between hexanes and water. The aqueous layer is extracted with hexanes (3  $\times$  75 mL). organic layers are washed with brine, combined (magnesium sulfate), filtered, and concentrated under reduced Purification by flash column chromatography (9:1 pressure. hexanes/ethyl acetate) provides the title compound. (300 MHz, DMSO- $d_6$ )  $\delta$ .7.96 (m, 1H), 7.85 (d, J = 8 Hz, 1H), 7.75 (d, J = 8 Hz, 1H), 7.56 (m, 1H) 5.58 (s, 1H), 5.23 (m, 1H), 2.13 (s, 3H).

20

15

Step 2

3-Isopropylbenzylamine hydrochloride

A solution of 3-isopropenylbenzonitrile (6.0 g, mmol) and 10% Pd/C (600 mg) in ethanol (65 mL) and acetic acid 25 (2.4 mL) is degassed with nitrogen for 15 min, and shaken under an atmosphere of hydrogen at 50 psi for 12 h. reaction mixture is filtered through diatomaceous earth and concentrated under reduced pressure to provide an oil. The oil is dissolved in methanol (5 mL) and hydrochloric acid (15 30  ${\tt mL}$  of a 1 M solution in diethyl ether) is added. The

PCT/US02/36072 WO 03/040096

resulting precipitate is collected by filtration to provide the title compound. APCI MS m/z 149 [M + H]<sup>+</sup>.

Step 3

tert-Butyl (1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-[(3-5 isopropylbenzyl)amino]propylcarbamate

(1S) - 2 - (3, 5 - difluorophenyl) - 1 - [(2S) - oxiran - 2 yl]ethylcarbamate (2.0 g, 6.7 mmol) and 3-isopropylbenzylamine hydrochloride (2.5 g, 13.5 mmol) in isopropanol (60 mL) are refluxed 3 h. The reaction is cooled and stirred 16 h. The solution is concentrated under reduced pressure, redissolved in chloroform, washed with 1N hydrochloric acid, saturated sodium bicarbonate, brine, dried (sodium sulfate), filtered 15 and concentrated under reduced pressure. Purification by flash chromatography (silica, 7% methanol/chloroform) gives the title compound in pure form. ESI MS m/z 449.3 [M + H]<sup>+</sup>.

Step 4

10

20 (2R, 3S) - 3 - amino - 4 - (3, 5 - difluorophenyl) - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]]isopropylbenzyl)amino]butan-2-ol dihydrochloride

(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3tert-Butyl [(3-isopropylbenzyl)amino]propylcarbamate (1.5 g, 3.3 mmol) is 25 dissolved in 4 N hydrochloric acid in dioxane (20 mL), and the reaction is stirred at room temperature 3 h. The mixture is

concentrated under reduced pressure to afford the title compound. ESI MS m/z 349.2 [M + H] $^+$ .

Step 5

5 Methyl 3-[(dipropylamino)carbonyl]-5-(1,3-thiazol-2-yl)benzoate

is added methyl 3-[(dipropylamino)carbonyl]-5-iodobenzoate

(8.6 g, 21.4 mmol) in anhydrous tetrahydrofuran (130 mL)
followed by palladium(0) tetrakis(triphenylphosphine) (2 g,
1.7 mmol). The reaction mixture is heated at reflux for 16 h.
The reaction mixture is diluted with ethyl acetate (50 mL),
washed with water, saturated sodium bicarbonate, and brine,
dried (magnesium sulfate), filtered, and concentrated under
reduced pressure. Purification by flash column chromatography
(silica gel, 35% ethyl acetate/hexanes) provides the title
compound. ESI MS m/z 347.1 [M + H]<sup>+</sup>.

20 Step 6
3-[(Dipropylamino)carbonyl]-5-(1,3-thiazol-2-yl)benzoic acid

Methyl 3-[(dipropylamino)carbonyl]-5-(1,3-thiazol-2-yl)benzoate (4.4 g, 12.8 mmol) is dissolved in 1:1:1

25 tetrahydrofuran/methanol/water (60 mL), and lithium hydroxide monohydrate is added (1.1 g, 25.6 mmol). The reaction is stirred 15 min and is concentrated under reduced pressure. The residue is diluted in chloroform and washed with water,

brine, dried (magnesium sulfate), filtered, and concentrated under reduced pressure to give the title compound. ESI MS m/z 333.1 [M + H]<sup>+</sup>.

5 Step 7

 $N^1$ -{(1S,2R)-1-(3,5-Difluorobenzyl)-2-hydroxy-3-[(3-isopropylbenzyl)amino]propyl}- $N^3$ ,  $N^3$ -dipropyl-5-(1,3-thiazol-2-yl)isophthalamide

10

15

20

25

3-[(Dipropylamino)carbonyl]-5-(1,3-thiazol-2-yl)benzoic acid is dissolved in DMF (8 mL), and diisopropylethylamine (456  $\mu$ L, 2.6 mmol), HATU (342 mg, 0.9 mmol), and (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-

isopropylbenzyl)amino]butan-2-ol dihydrochloride (350 mg, 0.83 mmol) are added. The reaction stirred at room temperature 1 h. The reaction is partitioned between ethyl acetate and water. The organic layer is washed with 1 N hydrochloric acid, saturated sodium bicarbonate, and brine, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 8% methanol/chloroform) provides the title compound as the free base. The residue is dissolved in diethyl ether (5 mL) and 1N hydrochloric acid in diethyl ether (2 mL) is added. The mixture is concentrated under reduced pressure to yield the title compound. ESI MS m/z 663.3 [M + H]\*.

EXAMPLE SP-171

 $N^1-\{(1S,2R)-1-(3,5-Difluorobenzyl)-2-hydroxy-3-[(3-isopropylbenzyl)amino]propyl}-N^3,N^3-dipropyl-5-(1,3-thiazol-2-yl)isophthalamide hydrochloride$ 

5

10


 $N^1$ -{(1S,2R)-1-(3,5-Difluorobenzyl)-2-hydroxy-3-[(3-isopropylbenzyl)amino]propyl}- $N^3$ , $N^3$ -dipropyl-5-(1,3-thiazol-2-yl)isophthalamide (180 mg, 0.27 mmol) is dissolved in diethyl ether (5 mL) and 1N hydrochloric acid in diethyl ether (2 mL) is added. The mixture is concentrated under reduced pressure to yield the title compound. ESI MS m/z 663.3 [M + H]<sup>+</sup>.

EXAMPLE SP-172

Methyl 3-(2-{3-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-15 ethylbenzyl)amino]-2-hydroxypropyl}amino)carbonyl]phenyl}-1,3oxazol-5-yl)propanoate

Step 1

Methyl 3-{[(5-methoxy-2,5-dioxopentyl)amino]carbonyl}benzoate



20

25

Methyl hydrogen isophthalate (1.8 g, 10.2 mmol) is dissolved in methylene chloride (10 mL) and DMF (10 mL), and diisopropylethylamine (4.4 mL, 25.5 mmol), HATU (4.6 g, 12.2 mmol), and 5-aminolevulinic acid methyl ester hydrochloride (2 g, 11.2 mmol) are added. The reaction stirred at room

temperature 1 h. The reaction is partitioned between ethyl acetate and water. The organic layer is washed with 1 N hydrochloric acid, saturated sodium bicarbonate, and brine, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 4% methanol/chloroform) provides the title compound. ESI MS m/z 306.1 [M - H]<sup>-</sup>.

# Step 2

10 Methyl 3-[5-(3-methoxy-3-oxopropyl)-1,3-oxazol-2-yl]benzoate

Methyl

 $3-\{[(5-methoxy-2,5-$ 

dioxopentyl)amino]carbonyl}benzoate (520 mg, 1.7 mmol) is dissolved in anhydrous tetrahydrofuran (4 mL), and (methoxycarbonylsulfamoyl)triethylammonium hydroxide, inner salt (810 mg, 3.4 mmol). The reaction is microwaved (100 W, 2 min) in a sealed vessel, cooled, filtered, and concentrated under reduced pressure. Purification by flash chromatography (silica gel, 40% ethyl acetate/hexanes) gives the title compound. ESI MS m/z 290.1 [M + H] $^+$ .

## Step 3

15

20

3-[5-(2-Carboxyethyl)-1,3-oxazol-2-yl]benzoic acid

To methyl 3-[5-(3-methoxy-3-oxopropyl)-1,3-oxazol-2yl]benzoate (400 mq, 1.3 mmol) in 2:1:1 tetrahydrofuran/methanol/water (8 mL) is added lithium hydroxide monohydrate (112 mg, 2.7 mmol), and the reaction is stirred 2 h at room temperature. More lithium hydroxide monohydrate (225 mg, 5.4 mmol) is added and the reaction is stirred 16 h at room temperature. The reaction is treated with excess concentrated hydrochloric acid resulting in a precipitate. The precipitate is filtered to give the title compound. ESI MS m/z 260.1 [M - H]<sup>-</sup>.

Step 4

5

10

3-[5-(3-Methoxy-3-oxopropyl)-1,3-oxazol-2-yl]benzoic acid

15

20

To 3-[5-(2-carboxyethy1)-1,3-oxazol-2-y1]benzoic acid (317 mg, 1.2 mmol) in methanol (5 mL) is added thionyl chloride (4.4  $\mu$ L, 0.06 mmol), and the reaction is stirred at room temperature 16 h. The solution is concentrated under reduced pressure to give the title compound. ESI MS m/z 274.1 [M - H]<sup>-</sup>.

Step 5

Methyl 3-(2-{3-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}amino)carbonyl]phenyl}-1,3-oxazol-5-yl)propanoate

3-[5-(3-Methoxy-3-oxopropyl)-1,3-oxazol-2-yl]benzoic acid (285 mg, 1.0 mmol) is dissolved in methylene chloride (5 mL) and DMF (5 mL), and diisopropylethylamine (695  $\mu$ L, 4.0 mmol), 1.2 mmol), and (2R, 3S) - 3 - amino - 4 - (3, 5 - 4)(472 g, difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol dihydrochloride prepared by the method of EXAMPLE SP-272 (448 mg, 1.1 mmol) are added. The reaction stirred at room temperature 1 h. The reaction is partitioned between ethyl 10 acetate and saturated sodium bicarbonate. The organic layer is washed with 1 N hydrochloric acid, saturated sodium bicarbonate, and brine, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column (silica, 8% chromatography methanol/chloroform) 15 provides the title compound. ESI MS m/z 591.9 [M + H]<sup>+</sup>.

EXAMPLE SP-173

3-(2-{3-[({(1\$,2R)-1-(3,5-Difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}amino)carbonyl]phenyl}-1,320 oxazol-5-yl)propanoic acid

Methyl  $3-(2-{3-[({(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3$ ethylbenzyl)amino]-2-hydroxypropyl}amino)carbonyl]phenyl}-1,3oxazol-5-yl)propanoate (70 mg, 0.12 mmol) and hydroxide monohydrate (10 mg, 0.24 mmol) in 2:1:1 tetrahydrofuran/methanol/water (6 mL) is stirred at room temperature 1.5 h. The reaction is concentrated under reduced The residue is washed with 1N hydrochloric acid (aq), then chloroform, and the solid is dried under reduced pressure to give the title compound. ESI MS m/z 578.2 [M + H]<sup>+</sup>.

## EXAMPLE SP-174

N-{(1s,2r)-1-(3,5-Difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2hydroxypropyl}-4-(1,3-oxazol-2-yl)benzamide

Step 1

10

Methyl 4-(1,3-oxazol-2-yl)benzoate

To a -70 °C, stirred solution of oxazole (190  $\square$ L, 3.8 20 mmol) in tetrahydrofuran (10 mL) is added n-butyl lithium (2.6 mL of a 1.6 M solution in hexanes, 4.2 mmol). After 30 min, zinc chloride (11.5 mL of a 1.0 M solution in diethyl ether, 11.5 mmol) is added. The reaction mixture is warmed to 0  $^{\circ}\text{C}$ and methyl 4-iodobenzoate (1 g, 3.8 mmol) and palladium(0) 25 tetrakis(triphenylphosphine) (530 mg, 0.4 mmol) are added. The reaction mixture is heated at 70 °C for 20 h under argon, cooled to room temperature, and then partitioned between ethyl acetate and water. The organic layer is washed with water and 30 dried (sodium sulfate), filtered, and concentrated brine, under reduced pressure. Purification by flash column chromatography (3:1 hexanes/ethyl acetate) yields the title

compound. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.14 (s, 4H), 8.07-8.05 (m, 1H), 7.36-7.35 (m, 1H), 3.95 (s, 3H).

Step 2

5 4-(1,3-0xazol-2-yl)benzoic acid

solution of methyl 4-(1,3-oxazol-2-To stirred (690 yl)benzoate mg, 3.4 mmol) in a mixture of tetrahydrofuran/methanol/water (20 mL) is added 10 hydroxide (430 mg, 3 mmol). The reaction mixture is stirred at room temperature for 2 h. The solvent is removed under reduced pressure and the residue is partitioned between diethyl ether and water. The aqueous layer is acidified to pH 1 with 1 N hydrochloric acid and a precipitate is observed. 15 The solid is collected by filtration to afford the title compound.  $^{1}$ H NMR (300 MHz, CD<sub>3</sub>OD)  $\delta$  8.14 (s, 4H), 8.05 (s, 1H), 7.36 (s, 1H).

Step 3

N-{(1S,2R)-1-(3,5-Difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-4-(1,3-oxazol-2-y1)benzamide

To a solution of 4-(1,3-oxazol-2-yl)benzoic acid (105 mg, 0.6 mmol), (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-25 ethylbenzyl)amino]butan-2-ol dihydrochloride (220 mg, 0.6 mmol), and HATU (210 mg, 0.6 mmol) stirring in methylene chloride (5 mL) is added N,N-diisopropylethylamine (340  $\square$ L, 1.9 mmol). The reaction mixture is stirred at room

temperature for 18 h. The reaction mixture is partitioned between methylene chloride and water. The organic layer is washed with water, dried (sodium sulfate), filtered, and concentrated under reduced pressure to afford a crude solid. Purification by flash column chromatography (silica, gradient 96:4 to 93:7 methylene chloride/methanol) provided the title compound. ESI MS m/z 506.2 [M + H]<sup>+</sup>.

## EXAMPLE SP-173

N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-(1,3-thiazol-2-yl)benzamide

# Step 1

Methyl 4-(1,3-thiazol-2-yl)benzoate

15

20

25

30

To a -70  $^{\circ}$ C, stirred solution of thiazole (270  $\Box$ L, 3.8 mmol) in tetrahydrofuran (10 mL) is added n-butyl lithium (2.6 mL of a 1.6 M solution in hexanes, 4.2 mmol). After 30 min, zinc chloride (11.4 mL of a 1.0 M solution in diethyl ether, 11.4 mmol) is added. The reaction mixture is warmed to 0  $^{\circ}\text{C}$ and methyl 4-iodobenzoate (1 g, 3.8 mmol) and palladium(0) tetrakis(triphenylphosphine) (530 mg, 0.4 mmol) are added. The reaction mixture is heated at 70 °C for 20 h under argon, cooled to room temperature, and then partitioned between ethyl acetate and water. The organic layer is washed with water, and brine, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (3:1 hexanes/ethyl acetate) yields the title compound.  $^{1}H$  NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.14-8.03 (m, 4H), 7.93-7.92 (m, 1H), 7.42-7.41 (m, 1H), 3.95 (s, 3H).

Step 2

4-(1,3-Thiazol-2-yl)benzoic acid

stirred solution of methyl 4-(1,3-thiazol-2-To yl)benzoate (560 mg, 2.6 mmol) in a mixture of 2:1:1 5 tetrahydrofuran/methanol/water (20 mL) is added lithium hydroxide (322 mg, 3 mmol). The reaction mixture is stirred at room temperature for 2 h. The solvent is removed under reduced pressure and the residue is partitioned between diethyl ether and water. The aqueous layer is acidified to pH 10 1 with 1 N hydrochloric acid and a precipitate is observed. The solid is collected by filtration to afford the title compound.  $^{1}$ H NMR (300 MHz, CD<sub>3</sub>OD)  $\delta$  8.14-8.05 (m, 4H), 7.95-7.93 (m, 1H), 7.71-7.69 (m, 1H).

# 15 Step 3

 $N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1\}-4-(1,3-thiazol-2-yl)benzamide$ 

To a solution of 4-(1,3-thiazol-2-yl)benzoic acid (110 20 0.6 mmol), (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-mmol), (2R,3S)-3-amino-4-(3,5-difluorophenyl)]ethylbenzyl)amino]butan-2-ol dihydrochloride (220 mmol), and HATU (210 mg, 0.6 mmol) stirring in methylene chloride (5 mL) is added N, N-diisopropylethylamine (340  $\square$ L, 1.9 mmo1). The reaction mixture is stirred at room temperature for 18 h. 25 The reaction mixture is partitioned between methylene chloride and water. The organic layer is washed with water, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash

column chromatography (silica, gradient 95:5 to 92:8 methylene chloride/methanol) provides the title compound. ESI MS m/z 522.2 [M + H]<sup>+</sup>.

# 5 EXAMPLE SP-176

 $N-\{(1s,2R)-1-(3,5-Difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1\}-3-[(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yloxy)methyl]benzamide$ 

To 3-(bromomethyl)benzoic acid (200 mg, 0.93 mmol) and diisopropylethylamine (566 μL, 3.26 mmol) in DMF (5 mL) is added HATU (424 mg, 1.12 mmol), and the reaction is stirred 5 min. To the reaction is added (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol

dihydrochloride prepared by the method in EXAMPLE SP-272 (379 mg, 0.93 mmol), and the reaction stirred 30 min. The reaction mixture is diluted with methylene chloride, washed with 1 N hydrochloric acid (15 mL), saturated sodium bicarbonate (15 mL), and brine. The organic layer is then dried (sodium

sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 8% methanol/chloroform) provides the title compound. ESI MS m/z 587.4 [M + H]<sup>+</sup>.

# 25 EXAMPLE SP-177

N-{(1S,2R)-1-(3,5-Difluorobenzyl)-2-hydroxy-3-[(3-iodobenzyl)amino]propyl}-3-{[(2-hydroxyethyl)(propyl)amino]methyl}-5-methylbenzamidedihydrochloride

30 Step 1

3-Bromo-5-(hydroxymethyl)benzoic acid

ice-cold solution To an of 3-bromo-5-(methoxycarbonyl)benzoic acid prepared by the method Preparation 2 (10.3 g, 40 mmol) in anhydrous tetrahydrofuran (100 mL) is added lithium borohydride (12 g, 550 mmol) portion-wise. The reaction is stirred 4 h at this temperature. Absolute ethanol (20 mL) is added dropwise, and the reaction is stirred 1.5 h. The reaction is slowly poured on ice, and 10 % hydrochloric acid (aq) is added until gas 10 evolution ceased. The aqueous layer is extracted with chloroform, and the organic layer is washed with brine, dried (magnesium sulfate), filtered, and concentrated under reduced pressure to give the title compound. ESI MS m/z 229, 231 [M -15 H]-.

Step 2

Methyl 3-bromo-5-(hydroxymethyl)benzoate

To 3-bromo-5-(hydroxymethyl)benzoic acid (7.0 g, 30 mmol) in 20% methanol/benzene (100 mL) is added trimethylsilyldiazomethane (2M in hexanes), and the reaction is stirred 16 h. The reaction is concentrated under reduced pressure to afford the title compound. ESI MS m/z 244.0 [M + 25 H]<sup>+</sup>.

Step 3

Methyl 3-(hydroxymethyl)-5-methylbenzoate

To stirred solution of methyl 3-bromo-5-(hydroxymethyl)benzoate (3.0 g, 12.2 mmol) in dioxane (27 mL) is added cesium carbonate (4.0 g, 12.2 mmol), potassium carbonate (34 g, 24.4 mmol), and palladium(0) tetrakis(triphenylphosphine) (704 mg, 0.61 mmol), followed by trimethyl boroxine (1.7 mL, 12.2 mmol). The reaction mixture is refluxed for 5 h, cooled to room temperature, and then partitioned between water and ethyl acetate. layer is washed with water, saturated sodium bicarbonate, and brine, dried (magnesium sulfate), filtered, and concentrated reduced pressure. under Purification by flash chromatography (silica, 20% ethyl acetate/hexanes) provides the title compound. ESI MS m/z 181.2 [M + H]<sup>+</sup>.

15

10

5

Step 4

N-{(1S,2R)-1-(3,5-Difluorobenzyl)-2-hydroxy-3-[(3-iodobenzyl)amino]propyl}-3-{[(2-bydroxy-1)]

hydroxyethyl)(propyl)amino]methyl}-5-methylbenzamide

20 dihydrochloride

To a stirred solution of methyl 3-(hydroxymethyl)-5-methylbenzoate (1.25, 7 mmol) in methylene chloride (30 mL) at -30 °C is added methanesulfonyl chloride (752 μL, 9.7 mmol) followed by triethylamine (1.95 mL, 14 mmol). The reaction mixture is stirred for 15 min at 0 °C. The reaction is diluted in diethyl ether and washed with water and cold brine, dried (magnesium sulfate), filtered and concentrated under reduced

pressure to give an oil. The residue is redissolved in anhydrous methylene chloride (22 mL). From this stock solution of added to a 2 mLis solution, N-hydroxyethylpropylamine (115 in μL, 1 mmol) anhydrous methylene chloride (1 mL), and the reaction mixture is stirred at room temperature for 5 h. The reaction mixture is diluted with methylene chloride (10 mL), washed with 1 N hydrochloric and saturated sodium bicarbonate, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 10 The amine methanol/chloroform) provided the amine. dissolved in 1:1:1 tetrahydrofuran/methanol/water (3 mL), and lithium hydroxide monohydrate is added (33 mg, 0.75 mmol). The reaction is stirred 2 h and is concentrated under reduced The residue is redissolved in DMF (3 mL), and 15 pressure. diisopropylethylamine (261  $\mu$ L, 1.5 mmol), HATU (214 mg, 0.56 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3and iodobenzyl)amino]butan-2-ol dihydrochloride (189 mmol) are added. The reaction stirred at room temperature 16 Purification by flash column chromatography (silica, 8% 20 methanol/chloroform) provides the title compound as the free base. The residue is dissolved in diethyl ether (3 mL) and 1N hydrochloric acid in diethyl ether (1 mL) is added. The mixture is concentrated under reduced pressure to yield the title compound. ESI MS m/z 666.2 [M + H]<sup>+</sup>. 25

EXAMPLE SP-178

N-{(1S,2R)-1-(3,5-Difluorobenzyl)-2-hydroxy-3-[(3-iodobenzyl)amino]propyl}-3-{[ethyl(propyl)amino]methyl}-5-methylbenzamide dihydrochloride

30

Analogous to the method described in EXAMPLE SP-177, Step 4, 2 mL of the stock solution is added to a solution of N-  $^{-1}$ ethylpropylamine (143  $\mu L$ , 1 mmol) in anhydrous methylene chloride (1 mL), and the reaction mixture is stirred at room temperature for 5 h. The reaction mixture is diluted with methylene chloride (10 mL), washed with 1 N hydrochloric acid, and saturated sodium bicarbonate, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 10 methanol/chloroform) provided the amine. The amine is dissolved in 1:1:1 tetrahydrofuran/methanol/water (3 mL), and lithium hydroxide monohydrate is added (42 mg, 1 mmol). reaction is stirred 2 h and is concentrated under reduced 15 pressure. The residue is redissolved in DMF (5 mL), and diisopropylethylamine (265  $\mu$ L, 1.5 mmol), (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-iodobenzyl)amino]butan-2-ol dihydrochloride (252 mg, 0.5 mmol), and HATU (237 mg, 0.62 mmol) are added. The reaction stirred at room temperature 16 Purification by flash column chromatography (silica, 10% 20 methanol/chloroform) provides the title compound as the free The residue is dissolved in diethyl ether (3 mL) and 1N  $\,$ hydrochloric acid in diethyl ether (1 mL) is added. mixture is concentrated under reduced pressure to yield the 25 title compound. ESI MS m/z 650.2 [M + H]<sup>+</sup>.

#### EXAMPLE SP-179

 $N-\{(1S, 2R)-1-(3, 5-Difluorobenzyl)-2-hydroxy-3-[(3-iodobenzyl)amino]propyl\}-3-\{[(2-iodobenzyl)amino]propyl}-3-{[(2-iodobenzyl)amino]propyl}-3-{[(3-iodobenz$ 

30 hydroxyethyl)(propyl)amino]methyl}benzamide dihydrochloride

Step 1

Methyl 3-{[(2-hydroxyethyl)(propyl)amino]methyl}benzoate

To 2-propylaminomethanol (505  $\mu L$ , 4.4 mmol) in chloroform (20 mL) is added methyl bromomethylbenzoate (1 g, 4.4 mmol), 5 and the reaction stirred at room temperature 16 h. reaction is washed with saturated sodium bicarbonate and brine. The organic layer is then dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 80% ethyl 10 acetate/hexanes) provides the title compound. ESI MS m/z $252.3 [M + H]^{+}$ .

Step 2

N-{(1S,2R)-1-(3,5-Difluorobenzy1)-2-hydroxy-3-[(3iodobenzy1)amino]propy1}-3-{[(2hydroxyethy1)(propy1)amino]methy1}benzamide dihydrochloride

Methyl 3-{[(2-hydroxyethyl)(propyl)amino]methyl}benzoate 20 (500 mg, 2 mmol) and lithium hydroxide monohydrate (170 mg, 4 mmol) are stirred in 2:1:1 tetrahydrofuran/methanol/water (4 mL) room temperature for 16 h. The reaction concentrated under reduced pressure and redissolved in DMF (15 To this solution is added (2R,3S)-3-amino-4-(3,5mL). 25 difluorophenyl)-1-[(3-iodobenzyl)amino]butan-2-ol dihydrochloride (1 g, 2 mmol), diisopropylethylamine (1.4 mL, 8 mmol), then HATU (1.1 g, 3 mmol), and the reaction stirred 2Purification by flash column chromatography (silica, 10%

methanol/chloroform) provides the title compound as the free base. The residue is dissolved in diethyl ether (5 mL) and 1N hydrochloric acid in diethyl ether (3 mL) is added. The mixture is concentrated under reduced pressure to yield the title compound. ESI MS m/z 652.2 [M + H]<sup>+</sup>.

EXAMPLE SP-180

5

 $N-\{(1S, 2R)-1-(3, 5-Difluorobenzy1)-2-hydroxy-3-[(3-iodobenzy1)amino]propy1\}-3-methy1-5-$ 

10 {[methyl(propyl)amino]methyl}benzamide dihydrochloride

Analogous to the method described in EXAMPLE SP-177, Step. 4, 2 mL of the stock solution is added to a solution of N-methylpropylamine (103  $\mu$ L, 1 mmol) in anhydrous methylene 15 chloride (1 mL), and the reaction mixture is stirred at room temperature for 5 h. The reaction mixture is diluted with methylene chloride (10 mL), washed with 1 N hydrochloric acid, and saturated sodium bicarbonate, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. 20 Purification by flash column chromatography (silica, methanol/chloroform) provided the amine. The dissolved in 1:1:1 tetrahydrofuran/methanol/water (3 mL), and lithium hydroxide monohydrate is added (33 mg, 0.75 mmol). The reaction is stirred 2 h and is concentrated under reduced 25 pressure. The residue is redissolved in DMF (3 mL), and diisopropylethylamine (261  $\mu$ L, 1.5 mmol), HATU (214 mg, 0.56 (2R, 3S) - 3 - amino - 4 - (3, 5 - difluoropheny1) - 1 - [(3 - amino - 4 - (3, 5 - difluoropheny1)] - 1 - [(3 - amino - 4 - (3, 5 - difluoropheny1)] - 1 - [(3 - amino - 4 - (3, 5 - difluoropheny1)] - 1 - [(3 - amino - 4 - (3, 5 - difluoropheny1)] - 1 - [(3 - amino - 4 - (3, 5 - difluoropheny1)] - 1 - [(3 - amino - 4 - (3, 5 - difluoropheny1)] - 1 - [(3 - amino - 4 - (3, 5 - difluoropheny1)] - 1 - [(3 - amino - 4 - (3, 5 - difluoropheny1)] - 1 - [(3 - amino - 4 - (3, 5 - difluoropheny1)]] - 1 - [(3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - ammol), and iodobenzyl)amino]butan-2-ol dihydrochloride (189 ma, mmol) are added. The reaction stirred at room temperature 16 30 Purification by flash column chromatography (silica, 8% h.

methanol/chloroform) provides the title compound as the free base. The residue is dissolved in diethyl ether (3 mL) and 1N hydrochloric acid in diethyl ether (1 mL) is added. The mixture is concentrated under reduced pressure to yield the title compound. ESI MS m/z 636.2  $[M + H]^+$ .

EXAMPLE SP-181

5

10

N-{(1s,2r)-1-(3,5-Difluorobenzyl)-2-hydroxy-3-[(3-iodobenzyl)amino]propyl}-3-[(dipropylamino)methyl]-5-methylbenzamide dihydrochloride

Analogous to the method described in EXAMPLE SP-177, Step 4, 2 mL of the stock solution is added to a solution of dipropylamine (137 µL, 1 mmol) in anhydrous methylene chloride the reaction mixture is 15 stirred and temperature for 5 h. The reaction mixture is diluted with methylene chloride (10 mL), washed with 1 N hydrochloric acid, and saturated sodium bicarbonate, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. 20 Purification by flash column chromatography (silica, methanol/chloroform) provided the amine. The dissolved in 1:1:1 tetrahydrofuran/methanol/water (3 mL), and lithium hydroxide monohydrate is added (33 mg, 0.75 mmol). The reaction is stirred 2 h and is concentrated under reduced 25 pressure. The residue is redissolved in DMF (3 mL), and diisopropylethylamine (261 µL, 1.5 mmol), HATU (214 mg, 0.56 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3mmol), and iodobenzyl)amino]butan-2-ol dihydrochloride (189 mg, mmol) are added. The reaction stirred at room temperature 16 30 Purification by flash column chromatography (silica, 8%

methanol/chloroform) provides the title compound as the free base. The residue is dissolved in diethyl ether (3 mL) and 1N hydrochloric acid in diethyl ether (1 mL) is added. The mixture is concentrated under reduced pressure to yield the title compound. ESI MS m/z 664.2 [M + H]<sup>+</sup>.

## EXAMPLE SP-182

10

3-{[Butyl(methyl)amino]methyl}-N-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-iodobenzyl)amino]propyl}-5-methylbenzamide dihydrochloride

2 HCI

Analogous to the method described in EXAMPLE SP-177 Step 4, 2 mL of the stock solution is added to a solution of Nmethylbutylamine (118  $\mu$ L, 1 mmol) in anhydrous methylene chloride (1 mL), and the reaction mixture is stirred at room 15 temperature for 5 h. The reaction mixture is diluted with methylene chloride (10 mL), washed with 1 N hydrochloric acid, and saturated sodium bicarbonate, dried (magnesium sulfate), filtered. and concentrated under reduced pressure. 20 Purification by flash column chromatography (silica, methanol/chloroform) provided the amine. The amine dissolved in 1:1:1 tetrahydrofuran/methanol/water (3 mL), and lithium hydroxide monohydrate is added (33 mg, 0.75 mmol). The reaction is stirred 2 h and is concentrated under reduced 25 The residue is redissolved in DMF (3 mL), and diisopropylethylamine (261  $\mu L,~1.5$  mmol), HATU (214 mg, 0.56 mmol), (2R, 3S) -3-amino-4-(3,5-difluorophenyl)-1-[(3and iodobenzyl)amino]butan-2-ol dihydrochloride (189 mg, mmol) are added. The reaction stirred at room temperature 16

h. Purification by flash column chromatography (silica, 8% methanol/chloroform) provides the title compound as the free base. The residue is dissolved in diethyl ether (3 mL) and 1N hydrochloric acid in diethyl ether (1 mL) is added. The mixture is concentrated under reduced pressure to yield the title compound. ESI MS m/z 650.2 [M + H]<sup>+</sup>.

## EXAMPLE SP-183

5

3-[(Cyclohexylamino)methyl]-N-{(1S,2R)-1-(3,5-difluorobenzyl)10 2-hydroxy-3-[(3-iodobenzyl)amino]propyl}-5-methylbenzamide
dihydrochloride

2 HCI

Analogous to the method described in EXAMPLE SP-177, Step 4, 2 mL of the stock solution is added to a solution of 1 mmol) in anhydrous methylene cyclohexylamine (114 μL, 15 chloride (1 mL), and the reaction mixture is stirred at room temperature for 5 h. The reaction mixture is diluted with methylene chloride (10 mL), washed with 1 N hydrochloric acid, and saturated sodium bicarbonate, dried (magnesium sulfate), under reduced 20 filtered, and concentrated pressure. Purification by flash column chromatography (silica, methanol/chloroform) provided the amine. The amine is dissolved in 1:1:1 tetrahydrofuran/methanol/water (3 mL), and lithium hydroxide monohydrate is added (33 mg, 0.75 mmol). The reaction is stirred 2 h and is concentrated under reduced 25 The residue is redissolved in DMF (3 mL), and pressure. diisopropylethylamine (261  $\mu$ L, 1.5 mmol), HATU (214 mg, 0.56 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3mmol), and iodobenzyl)amino]butan-2-ol dihydrochloride (189 mg, 0.37

mmol) are added. The reaction stirred at room temperature 16 h. Purification by flash column chromatography (silica, 8% methanol/chloroform) provides the title compound as the free base. The residue is dissolved in diethyl ether (3 mL) and 1N hydrochloric acid in diethyl ether (1 mL) is added. The mixture is concentrated under reduced pressure to yield the title compound. ESI MS m/z 662.2  $[M + H]^+$ .

#### EXAMPLE SP-184

5

15

20

25

30

3-{[benzyl(methyl)amino]methyl}-N-{(1S,2R)-1-(3,5difluorobenzyl)-2-hydroxy-3-[(3-iodobenzyl)amino]propyl}-5methylbenzamide dihydrochloride

Analogous to the method described in EXAMPLE SP-177, a stirred solution of methyl 3-(hydroxymethyl)-5-methylbenzoate (1.0, 5.6 mmol) in methylene chloride (9 mL) at  $-30 \, ^{\circ}\text{C}$  is added methanesulfonyl chloride (600 µL, 7.8 mmol) followed by triethylamine (1.55 mL, 11 mmol). The reaction mixture is stirred for 1 h at 0 °C, then filtered. From this stock solution, 2 mL is added to a solution of N-methylbenzylamine (538  $\mu$ L, 4.2 mmol) in anhydrous methylene chloride (1 mL), and the reaction mixture is stirred at room temperature for 16 h. The reaction mixture is diluted with methylene chloride (10 mL), washed with saturated sodium bicarbonate and brine, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 4% methanol/chloroform) provided the amine. amine is dissolved in 2:1:1 tetrahydrofuran/methanol/water (4 mL), and lithium hydroxide monohydrate is added (90 mg, 2 mmol). The reaction is stirred 16 h and is concentrated under

reduced pressure. The residue is redissolved in DMF (5 mL), and diisopropylethylamine (695 µL, 4 mmol), HATU (570 mg, 1.5 mmol), (2R, 3S) - 3 - amino - 4 - (3, 5 - difluorophenyl) - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]] - [(3 - amino - 4 - (3, 5 - difluorophenyl)]] - [(3 - amino - 4 - (3, 5 - difluorophenyl)]] - [(and iodobenzyl)amino]butan-2-ol dihydrochloride (505 mg, 1 mmol) are added. The reaction stirred at room temperature 16 h. Purification by flash column chromatography (silica, 7% methanol/chloroform) provides the title compound as the free The residue is dissolved in diethyl ether (3 mL) and 1N hydrochloric acid in diethyl ether (1 mL) is added. mixture is concentrated under reduced pressure to yield the title compound. ESI MS m/z 684.2 [M + H]<sup>+</sup>.

EXAMPLE SP-185

10

 $2-Butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-difluorobenzyl)]}$ 

ethylbenzyl)amino]-2-hydroxypropyl}-1,2,3,4tetrahydroisoquinoline-7-carboxamide dihydrochloride
Step 1

2-Butyl-1,2,3,4-tetrahydroisoquinoline-7-carbonitrile

20 To an ice-cold, stirred solution οf 1,2,3,4tetrahydroisoquinoline-7-carbonitrile (J. Med. Chem. 1997, 40, 3997) (485 mg, 3.1 mmol) and triethylamine (0.47 mL, 3.4 mmol) in methylene chloride (5 mL) is added DMAP (37 mg, 0.3 mmol) and bromobutane (0.5 mL, 4.6 mmol). The reaction mixture is 25 stirred for 20 h, diluted with methylene chloride, washed with water, and brine, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 50% ethyl acetate/hexanes) affords the title compound. ESI MS m/z 215 [M + H]<sup>+</sup>.

30

Step 2

2-Butyl-1,2,3,4-tetrahydroisoquinoline-7-carboxylic acid

A sealed tube containing a solution of 2-butyl-1,2,3,4-tetrahydroisoquinoline-7-carbonitrile (480 mg, 2.2 mmol) in concentrated hydrochloric acid (10 mL) is stirred at 90 °C for 16 h. The reaction mixture is cooled to room temperature, concentrated ammonium hydroxide is added, and the precipitate formed is then collected by filtration to provide the title compound. ESI MS m/z 234  $[M + H]^+$ .

10 Step 3
2-Butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1,2,3,4tetrahydroisoquinoline-7-carboxamide dihydrochloride

5

A solution of 2-butyl-1,2,3,4-tetrahydroisoquinoline-7-15 carboxylic acid (190 mg, 0.81 mmol), HATU (465 mg, 1.2 mmol), HOBt (162 mg, 1.2 mmol), and disopropylethylamine (250 AUL, 1.6 mmol) is stirred in methylene chloride (2.0 mL) for 15 A solution of (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol prepared by the method in 20 EXAMPLE SP-272 (332 mg, 0.81 mmol) and disopropylethylamine (250  $\mathcal{A}_{\mathrm{L}}$ , 1.6 mmol) in methylene chloride (2.0 mL) is added, and the reaction mixture is stirred overnight. The reaction mixture is diluted with methylene chloride, washed with 1 N  $\,$ hydrochloric acid (15 mL), saturated sodium bicarbonate (15 25 mL), and brine. The organic layer is then dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, methanol/chloroform) provides the title compound as the free

base. The solid is dissolved in methanol (1 mL), and treated with hydrochloric acid (0.2 mL, 1.0 M diethyl ether, 0.2 mmol). The resulting precipitate was collected by filtration to provide the title compound. ESI MS m/z 550.3 [M + H]<sup>+</sup>.

5

# EXAMPLE SP-186

3-{[Cyclohexyl(methyl)amino]methyl}-N-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-iodobenzyl)amino]propyl}-5-methylbenzamide dihydrochloride

2 HCl

10

15

20

25

Analogous to the method described in EXAMPLE SP-184, 2 mL to a solution of Nthe stock solution is added methylcyclohexylamine (545  $\mu$ L, 4.2 mmol) in anhydrous methylene chloride (1 mL), and the reaction mixture is stirred at room The reaction mixture is diluted with temperature for 16 h. methylene chloride (10 mL), washed with saturated sodium bicarbonate and brine, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 4% methanol/chloroform) The amine is dissolved in provided the amine. tetrahydrofuran/methanol/water (4 mL), and lithium hydroxide The reaction is monohydrate is added (60 mg, 1.4 mmol). stirred 16 h and is concentrated under reduced pressure. (4 mL), and redissolved in DMF is residue diisopropylethylamine (465  $\mu$ L, 2.7 mmol), HATU (380 mg, 1 (2R, 3S) - 3 - amino - 4 - (3, 5 - difluorophenyl) - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenymmol), and iodobenzyl)amino]butan-2-ol dihydrochloride (340 mg, mmol) are added. The reaction stirred at room temperature 16 Purification by flash column chromatography (silica, 7% h.

methanol/chloroform) provides the title compound as the free base. The residue is dissolved in diethyl ether (3 mL) and 1N hydrochloric acid in diethyl ether (1 mL) is added. The mixture is concentrated under reduced pressure to yield the title compound. ESI MS m/z 676.2 [M + H]<sup>+</sup>.

## EXAMPLE SP-187

5

5-{[Butyl(methyl)amino]methyl}-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-


10 hydroxypropyl}thiophene-2-carboxamide dihydrochloride
 Step 1

Methyl 5-(bromomethyl)thiophene-2-carboxylate

To an ice-cold solution ο£ methyl 5-(hydroxymethyl)thiophene-2-carboxylate (375 mg, 2.17 mmol) in 15 methylene chloride (9.0 mL) is added phosphorus tribromide (100  $\Re$ L, 1.08 mmol) and the reaction mixture is stirred at 0 °C for 0.5 h. Saturated sodium bicarbonate (10 mL) is carefully added to the reaction mixture and the phases are 20 separated. The organic phase is washed with water, dried (sodium sulfate), filtered, and concentrated under reduced pressure to yield the title compound in pure form. ESI MS  $\it{m/z}$  $235 [M + H]^{+}$ .

25 Step 2

Methyl 5-{[butyl(methyl)amino]methyl}thiophene-2-carboxylate



To a solution of methyl 5-(bromomethyl)thiophene-2-carboxylate (350 mg, 1.49 mmol) in dry acetone (6.0 mL) is added N-methylbutylamine (533 ML, 4.47 mmol) and the solution stirred at room temperature overnight. The reaction is then

concentrated under reduced pressure, redissolved in methylene chloride, washed with saturated sodium bicarbonate, water, and The organic layer is then dried (sodium sulfate), brine. filtered, and concentrated under reduced pressure to yield the title compound in pure form.  $^1H$  NMR (300 MHz, CDCl3)  $\delta_.7.65$  (d, J = 3 Hz, 1H), 6.88 (d, J = 3 Hz, 1H), 3.86 (s, 3H), 3.69 (s, 2H), 2.41-2.36 (m, 2H), 2.25 (s, 3H), 1.53-1.43 (m, 2H), 1.34-1.25 (m, 2H), 0.91 (t, J = 7 Hz, 3H).

10 Step 3 5-{[Buty1(methyl)amino]methyl}thiophene-2-carboxylic acid

of methyl solution То {[butyl(methyl)amino]methyl}thiophene-2-carboxylate (280 1.16 mmol) in 2:1:1 dioxane/methanol/water (8.0 mL) is added lithium hydroxide monohydrate (146 mg, 3.38 mmol) and the reaction mixture stirred at room temperature overnight. reaction mixture is concentrated under reduced pressure and the solid residue partitioned between ethyl acetate and water The aqueous phase is acidified to pH 1with 1 N hydrochloric 20 acid and extracted several times with 3:1 chloroform/2propanol. The combined organic phase is washed with water, and brine, dried (sodium sulfate), filtered, and concentrated under reduced pressure to provide the title compound in pure form. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD)  $\delta$  7.75 (d, J = 4 Hz, 1H), 7.41 25 (d, J = 4 Hz, 1H), 4.63 (s, 2H), 3.20-3.14 (m, 2H), 2.85 (s, 2H)3H), 1.82-1.72 (m, 2H), 1.42 (tq, J=8, 7 Hz, 2H), 0.99 (t, J= 7 Hz, 3H).

30 Step 4

15

5-{[Butyl(methyl)amino]methyl}-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}thiophene-2-carboxamide dihydrochloride

To a solution 5-{[butyl(methyl)amino]methyl}thiophene-2-

carboxylic acid (171 mg, 0.75 mmol) and N, Ndiisopropylethylamine (250 **瓜**山, 1.43 mmol) in methylene chloride (5.0 mL) is added HBTU (285 mg, 0.75 mmol) and the reaction stirred for 0.5 h. To this is added a solution of 10 (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-mino-4-(3,5-difluorophenyl)ethylbenzyl)amino]butan-2-ol prepared by the method in EXAMPLE SP-272 (306 mg, 0.75 mmol) in methylene chloride (5.0 mL) containing N, N-diisopropylethylamine (250 ML, 1.43 mmol). reaction mixture is stirred then at room temperature 15 The reaction mixture is diluted with methylene overnight. chloride, washed with saturated sodium bicarbonate, and brine. The organic layer is then dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 95:5 chloroform/methanol)

gives the title compound as the free base. The solid is dissolved in methanol (1 mL) and treated with hydrochloric acid (1.0 M diethyl ether). The resulting precipitate was collected by filtration to provide the title compound. ESI MS m/z 544.3 [M + H]<sup>+</sup>.

25

30

20

5

EXAMPLE SP-188

3-{[Butyl(methyl)amino]methyl}-N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-methylbenzamide dihydrochloride
Step 1

Methyl 3-{[butyl(methyl)amino]methyl}-5-methylbenzoate

To methyl 3-(hydroxymethyl)-5-methylbenzoate prepared by the method in EXAMPLE SP-177 (1.1 g, 6.1 mmol), in anhydrous methylene chloride (10 mL) is added methanesulfonyl chloride (663  $\mu$ L, 8.6 mmol) at -30 °C, and the reaction is warmed to 0 °C. The reaction stirred 1 h, then filtered. The filtrate is added to N-methylbutylamine (2.1 mL, 18.3 mmol), and the reaction stirred at room temperature 16 h. The solution is concentrated under reduced pressure. Purification by flash chromatography affords the title compound in pure form. ESI MS m/z 250.2 [M + H]<sup>+</sup>.

## Step 2

5

10

15 3-{[Butyl(methyl)amino]methyl}-N-((1S,2R)-1-(3,5difluorobenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2hydroxypropyl)-5-methylbenzamide dihydrochloride

2 HCI

3-{[butyl(methyl)amino]methyl}-5-methylbenzoate Methvl 20 mmol) is dissolved in (122)mq, 0.49 tetrahydrofuran/methanol/water (4 mL), and lithium hydroxide monohydrate is added (41 mg, 1 mmol), and the reaction stirred 16 h. The solution is concentrated under reduced pressure. The residue is redissolved in DMF (5 mL), 25 diisopropylethylamine (350 µL, 2 mmol), HATU (240 mg, mmol), and  $(2R, 3S) - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3, 5 - diffluor ophenyl) - 1 - \{[1 - (3 - 3)] - 3 - amino - 4 - (3$ ethynylphenyl)cyclopropyl]amino}butan-2-ol dihydrochloride

prepared by the method in EXAMPLE SP-272 (215 mg, 0.5 mmol) are added. The reaction stirred at room temperature 16 h. The reaction mixture is diluted with ethyl acetate, washed with water, saturated sodium bicarbonate, brine, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 8% methanol/methylene chloride) provides the title compound as the free base. The residue is dissolved in diethyl ether (3 mL) and 1N hydrochloric acid in diethyl ether (1 mL) is added.

The mixture is concentrated under reduced pressure to yield the title compound. ESI MS m/z 574.3 [M + H]<sup>+</sup>.

# EXAMPLE SP-189

 $3-\{[Butyl(methyl)amino]methyl\}-N-((1S,2R)-1-(3,5-$ 

difluorobenzyl)-2-hydroxy-3-{[3 (trifluoromethyl)benzyl]amino}propyl)-5-methylbenzamide
 dihydrochloride

Analogous to the method in EXAMPLE SP-188, methyl 3{[butyl(methyl)amino]methyl}-5-methylbenzoate (112 mg, 0.45
mmol) is dissolved in 2:1:1 tetrahydrofuran/methanol/water (4
mL), and lithium hydroxide monohydrate is added (38 mg, 0.9
mmol), and the reaction stirred 16 h. The solution is
concentrated under reduced pressure. The residue is
redissolved in DMF (5 mL), and diisopropylethylamine (350 μL, 2
mmol), HATU (240 mg, 0.63 mmol), and (2R,3S)-3-amino-4-(3,5difluorophenyl)-1-{[1-(3-

ethynylphenyl)cyclopropyl]amino}butan-2-ol dihydrochloride

prepared by the method in EXAMPLE SP-272 (201 mg, 0.44 mmol) are added. The reaction stirred at room temperature 16 h. The reaction mixture is diluted with ethyl acetate, washed with water, saturated sodium bicarbonate, brine, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 8% methanol/methylene chloride) provides the title compound as the free base. The residue is dissolved in diethyl ether (3 mL) and 1N hydrochloric acid in diethyl ether (1 mL) is added. The mixture is concentrated under reduced pressure to yield the title compound. ESI MS m/z 592.3 [M + H]<sup>+</sup>.

#### EXAMPLE SP-190

 $3-Bromo-5-\{[buty1(methy1)amino]methy1\}-N-((1S,2R)-1-(3,5-$ 

15 difluorobenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2hydroxypropyl)benzamide dihydrochloride

Step 1

10

Methyl 3-bromo-5-{[butyl(methyl)amino]methyl}benzoate

To a solution of methyl 3-bromo-5-(hydroxymethyl)benzoate

(4.1 g, 16.8 mmol) in anhydrous methylene chloride (35 mL) at

-30 °C is added methanesulfonyl chloride (1.82 mL, 23.5 mmol)

followed by triethylamine (4.7 mL, 33.6 mmol). The reaction

mixture is stirred for 45 min at 0 °C, and then filtered. The

25 filtrate is added to N-methylbutylamine (6 mL, 50.4 mmol) and

stirred at room temperature for 16 h. The solution is

concentrated under reduced pressure, and the residue is

purified by flash column chromatography (silica, 8% ethyl

acetate/hexanes) to give the title compound. ESI MS m/z 314.1

30 [M + H]<sup>+</sup>.

Step 2

3-Bromo-5-{[buty1(methy1)amino]methy1}-N-((1S,2R)-1-(3,5-difluorobenzy1)-3-{[1-(3-ethynylphenyl)cyclopropy1]amino}-2-hydroxypropy1)benzamide dihydrochloride

2 HCI

5 Methyl 3-bromo-5-{[butyl(methyl)amino]methyl}benzoate (113 mg, 0.36 mmol) is dissolved in tetrahydrofuran/methanol/water (4 mL), and lithium hydroxide monohydrate is added (30 mg, 0.72 mmol), and the reaction stirred 16 h. The solution is concentrated under reduced 10 The residue is redissolved in DMF (5 mL), and pressure. diisopropylethylamine (250  $\mu L,\ 1.44$  mmol), HATU (170 mg, 0.45 mmol),  $(2R,3S)-3-amino-4-(3,5-difluoropheny1)-1-{[1-(3$ and ethynylphenyl)cyclopropyl]amino}-3-methylbutan-2-ol dihydrochloride prepared as in EXAMPLE SP-264 (170 mg, 0.4 mmol) are added. The reaction stirred at room temperature 16 15 Purification by flash column chromatography (silica, 8% methanol/methylene chloride) provides the title compound as the free base. The residue is dissolved in diethyl ether (3 mL) and 1N hydrochloric acid in diethyl ether (1 mL) is added. The mixture is concentrated under reduced pressure to yield 20 the title compound. ESI MS m/z 638.2 [M + H]<sup>+</sup>.

## EXAMPLE SP-191

 $3-\{[Butyl(methyl)amino]methyl\}-N-((1S,2R)-1-(3,5-1))$ 

25 difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2hydroxypropyl)-5-methylbenzamide dihydrochloride

2 HC

Analogous to the method in EXAMPLE SP-188, methyl 3-{[butyl(methyl)amino]methyl}-5-methylbenzoate (132 mg, 0.53 mmol) is dissolved in 2:1:1 tetrahydrofuran/methanol/water (4 mL), and lithium hydroxide monohydrate is added (45 mg, 1.06 mmol), and the reaction stirred 16 h. The solution is concentrated under reduced pressure. The residue redissolved in DMF (5 mL), and diisopropylethylamine (350 µL, 2 mmol), HATU (240 mg, 0.63 mmol), and (2R,3S)-3-amino-4-(3,5-10 difluorophenyl)-1-{[1-(3-ethylphenyl)cyclopropyl]amino}butan-2-ol prepared by the method in EXAMPLE SP-272 (191 mg, 0.5 mmol) are added. The reaction stirred at room temperature 16 The reaction mixture is diluted with ethyl acetate, washed with water, saturated sodium bicarbonate, brine, dried (sodium 15 sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, methanol/methylene chloride) provides the title compound as the free base. The residue is dissolved in diethyl ether (3 mL) and 1N hydrochloric acid in diethyl ether (1 mL) is added. The mixture is concentrated under reduced pressure to yield 20 the title compound. ESI MS m/z 578.4 [M + H]<sup>+</sup>.

## EXAMPLE SP-192

 $3-\{[Butyl(methyl)amino]methyl\}-N-\{(1S,2R)-1-(3,5-1)\}$ 

25 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5methylbenzamide dihydrochloride

2 ....

Analogous to the method in EXAMPLE SP-188, methyl 3-{[butyl(methyl)amino]methyl}-5-methylbenzoate (122 mg, 0.49 mmol) is dissolved in 2:1:1 tetrahydrofuran/methanol/water (4  $\ensuremath{\text{mL}})\,,$  and lithium hydroxide monohydrate is added (41 mg, 1.0 mmol), and the reaction stirred 16 h. The solution is concentrated under reduced pressure. The residue is redissolved in DMF (5 mL), and diisopropylethylamine (350  $\mu\text{L},~2$ mmol), HATU (240 mg, 0.63 mmol), and (2R,3S)-3-amino-4-(3,5-amino-4difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol 10 dihydrochloride prepared by the method in EXAMPLE SP-272 (203 mg, 0.5 mmol) are added. The reaction stirred at room temperature 16 h. The reaction mixture is diluted with ethyl acetate, washed with water, saturated sodium bicarbonate, brine, dried (sodium sulfate), filtered, and concentrated 15 under reduced pressure. Purification by flash column chromatography (silica, 8% methanol/methylene chloride) provides the title compound as the free base. The residue is dissolved in diethyl ether (3 mL) and 1N hydrochloric acid in diethyl ether (1 mL) is added. The mixture is concentrated 20 under reduced pressure to yield the title compound. m/z 552.3 [M + H]<sup>+</sup>.

EXAMPLE SP-193

N-{(1S,2R)-1-(3,5-Difluorobenzyl)-2-hydroxy-3-[(3-iodobenzyl)amino]propyl}-3-{[isopentyl(methyl)amino]methyl}-5-methylbenzamide dihydrochloride

2 HCI

Analogous to the method described in EXAMPLE SP-184, 2 mL to a solution of Nthe stock solution is added isoamylmethylamine (526 µL, 4.2 mmol) in anhydrous methylene chloride (1 mL), and the reaction mixture is stirred at room temperature for 16 h. The reaction mixture is diluted with methylene chloride (10 mL), washed with saturated sodium bicarbonate and brine, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by 10 flash column chromatography (silica, 4% methanol/chloroform) provided the amine. The amine is dissolved in 2:1:1 tetrahydrofuran/methanol/water (4 mL), and lithium hydroxide monohydrate is added (42 mg, 1 mmol). The reaction is stirred 16 h and is concentrated under reduced pressure. The residue 15 is redissolved in DMF (5 mL), and diisopropylethylamine (355  $\mu$ L, 2 mmol), HATU (242 mg, 0.64 mmol), and (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-iodobenzyl)amino]butan-2-ol dihydrochloride (257 mg, 0.5 mmol) are added. The reaction stirred at room temperature 16 h. Purification by flash 20 column chromatography (silica, 7% methanol/chloroform) provides the title compound as the free base. The residue is dissolved in diethyl ether (3 mL) and 1N hydrochloric acid in diethyl ether (1 mL) is added. The mixture is concentrated under reduced pressure to yield the title compound. ESI MS m/z 664.2 [M + H]<sup>+</sup>. 25

#### EXAMPLE SP-194

 $3-\{[Butyl(methyl)amino]methyl\}-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(1-$ 

phenylcyclopropyl)amino]propyl}-5-methylbenzamide
dihydrochloride

2 HCI

Analogous to the method in EXAMPLE SP-188, methyl 3-{[butyl(methyl)amino]methyl}-5-methylbenzoate (170 mg, mmol) is dissolved in 2:1:1 tetrahydrofuran/methanol/water (4  $\mbox{mL}$ ), and lithium hydroxide monohydrate is added (57 mg, 1.4 mmol), and the reaction stirred 2 h. The solution is concentrated under reduced pressure. The residue redissolved in DMF (3 mL), and diisopropylethylamine (472  $\mu L,$ 10 2.7 mmol), HATU (322 mg, 0.85 mmol), and (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(1-phenylcyclopropyl)amino]butan-2-ol dihydrochloride prepared by the method in EXAMPLE S-XYZ (275 mg, 0.68 mmol) are added. The reaction stirred at room temperature 16 h. The reaction mixture is diluted with ethyl 15 acetate, washed with water, saturated sodium bicarbonate, brine, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 88 methanol/methylene chloride) 20 provides the title compound as the free base. The residue is dissolved in diethyl ether (3 mL) and 1N hydrochloric acid in diethyl ether (1 mL) is added. The mixture is concentrated under reduced pressure to yield the title compound. ESI MS m/z 550.3 [M + H]<sup>+</sup>.

25

### EXAMPLE SP-195

3-{[Butyl(methyl)amino]methyl}-N-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-isopropylbenzyl)amino]propyl}-5-methylbenzamide dihydrochloride

2 HCI

Analogous to the method in EXAMPLE SP-188, methyl 3-{[butyl(methyl)amino]methyl}-5-methylbenzoate (50 0.2 mg, mmol) is dissolved in 2:1:1 tetrahydrofuran/methanol/water (4 mL), and lithium hydroxide monohydrate is added (17 mg, 0.4 mmol), and the reaction stirred 16 h. The solution is concentrated under reduced pressure. The residue is redissolved in DMF (2 mL), and diisopropylethylamine (140 μL, 0.8 mmol), HATU (95 mg, 0.25 mmol), and (2R,3S)-3-amino-4-10 (3,5-difluorophenyl)-1-[(3-isopropylbenzyl)amino]butan-2-ol dihydrochloride prepared by the method in EXAMPLE SP-170, Step 4 (85 mg, 0.2 mmol) are added. The reaction stirred at room temperature 16 h. The reaction mixture is diluted with ethyl acetate, washed with water, saturated sodium bicarbonate, 15 brine, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash chromatography (silica, 88 methanol/methylene provides the title compound as the free base. The residue is dissolved in diethyl ether (3 mL) and 1N hydrochloric acid in 20 diethyl ether (1 mL) is added. The mixture is concentrated under reduced pressure to yield the title compound. m/z 566.3 [M + H]<sup>+</sup>.

### EXAMPLE SP-196

3-{[Butyl(methyl)amino]methyl}-N-((1S,2R)-1-(3,5difluorobenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2hydroxypropyl)-5-(1,3-oxazol-2-yl)benzamide dihydrochloride
Step 1


3-(Methoxycarbonyl)-5-(1,3-oxazol-2-yl)benzoic acid

To a -70 °C stirred solution of oxazole (432 mg, 6.3 mmol) in tetrahydrofuran (10 mL) is added n-butyllithium (2.5 M in 5 hexanes, 2.75 mL, 6.9 mmol). After 30 min, zinc chloride (1 M in diethyl ether, 18.75 mL, 18.75 mmol) is added and the reaction mixture is warmed to 0  $^{\circ}\text{C}$  for 1 h. To this mixture is added a solution of 3-iodo-5-(methoxycarbonyl)benzoic acid prepared by the method in EXAMPLE SP-281, step 1 (1.8 g, 6 in anhydrous tetrahydrofuran (10 mL) 10 mmol) followed by palladium(0) tetrakis(triphenylphosphine) (291 mg, 0.25 mmol). The reaction mixture is heated at reflux for 15 h. reaction mixture is cooled, filtered through diatomaceous earth, diluted with ethyl acetate (50 mL), washed with water, and brine, dried (sodium sulfate), filtered, and concentrated 15 under reduced pressure. Purification by flash column chromatography (silica gel, 5% methanol/methylene chloride) provides the title compound in pure form. ESI MS m/z 246.1 [M - H]~.

20

Step 2

Methyl 3-{[butyl(methyl)amino]methyl}-5-(1,3-oxazol-2-yl)benzoate



25

To an ice-cold solution of 3-(methoxycarbonyl)-5-(1,3-0xazol-2-yl) benzoic acid (340 mg, 1.4 mmol) in anhydrous tetrahydrofuran (10 mL) is added lithium borohydride (250 mg,

The reaction is stirred 30 min, 11 mmol) slowly. absolute ethanol (4 mL) is added, and the reaction is stirred The solution is poured onto ice containing excess 1 h. hydrochloric acid and extracted with ethyl acetate. The organic layer is washed with water, brine, dried (sodium sulfate), filtered, and concentrated under reduced pressure. The residue is redissolved in 20% methanol/benzene (50 mL), and 2M trimethylsilyldiazomethane in hexane (0.9 mL, 1.8 mmol) is added. The reaction is stirred 2 h at room temperature, then concentrated under reduced pressure. The residue is redissolved in anhydrous methylene chloride (10 mL), cooled to -30 °C, then methanesulfonyl chloride (150  $\mu$ L, 1.9 mmol) and triethylamine (380  $\mu$ L, 2.7 mmol) are added. The reaction is stirred at 0  $^{\circ}$ C 15 min, then N-methylbutylamine (480  $\mu$ L, 4 mmol) is added, and the reaction is stirred 16 h at room temperature. The solution is concentrated under reduced pressure. Purification by flash column chromatography (silica gel, 40-100% ethyl acetate/hexane gradient) provides the title compound in pure form. ESI MS m/z 303.3 [M + H]<sup>+</sup>.

20


15

5

10

### Step 3

3-{[Butyl(methyl)amino]methyl}-N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-(1,3-oxazol-2-yl)benzamide dihydrochloride



25

Methyl 3-{[butyl(methyl)amino]methyl}-5-(1,3-oxazol-2-yl)benzoate (30 mg, 0.1 mmol) is dissolved in 2:1:1 tetrahydrofuran/methanol/water (4 mL), and lithium hydroxide

monohydrate is added (10 mg, 0.2 mmol), and the reaction stirred 16 h. The solution is concentrated under reduced The residue is redissolved in DMF (1 mL), and pressure. diisopropylethylamine (70  $\mu$ L, 0.4 mmol), HATU (57 mg, 0.15 5 mmol), and  $(2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-{[1-(3$ ethynylphenyl)cyclopropyl]amino}butan-2-ol dihydrochloride (203 mg, 0.5 mmol) are added. The reaction stirred at room The reaction mixture is diluted with ethyl temperature 2 h. acetate, washed with water, saturated sodium bicarbonate, brine, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 9-10% methanol/methylene chloride) provides the title compound as the free base. The residue is dissolved in diethyl ether (3 mL) and 1N hydrochloric acid in 15 diethyl ether (1 mL) is added. The mixture is concentrated under reduced pressure to yield the title compound. ESI MS m/z 627.3 [M + H]<sup>+</sup>.

## EXAMPLE SP-197

10

20  $3-\{[Butyl(methyl)amino]methyl\}-5-cyano-N-((1S,2R)-1-(3,5$ difluorobenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2hydroxypropyl)benzamide dihydrochloride

3-Bromo-5-(methoxycarbonyl)benzoic acid (4 g, 15.4 mmol) 25 and copper(I) cyanide (4.1)g, 89.5 in mmol) methylpyrrolidinone (20 mL) is heated at 175 °C for 4 h. The reaction is cooled, and water is added. The aqueous solution is extracted with methylene chloride, washed with 1N hydrochloric acid (aq), brine, dried (sodium sulfate),

filtered, and concentrated under reduced pressure. The residue is dissolved in tetrahydrofuran (20 mL), cooled in an ice bath, and lithium borohydride (475 mg, 22 mmol) is added slowly. The reaction stirred at this temperature 2 h. Absolute ethanol (4 mL) is added dropwise, and the reaction stirred 30 min. The mixture is poured on ice containing excess hydrochloric acid. After gas evolution ceases, the solution is extracted with methylene chloride and concentrated under reduced pressure.

5

30

10 The residue is dissolved in 20% methanol/benzene (20 mL), and 2M trimethylsilyldiazomethane in hexane (1.3 mL, 2.6 mmol) is added. The reaction stirred at room temperature 2 h and is concentrated under reduced pressure. The residue is then dissolved in anhydrous methylene chloride (10 mL), cooled to 15 -30 °C, then methanesulfonyl chloride (216  $\mu \rm L,~2.8~mmol)$  and triethylamine (556  $\mu$ L, 4 mmol) are added. The reaction is warmed to 0 °C and stirred 15 min, then filtered. is added to N-methylbutylamine (5 mL) and stirred 16 h. solution is concentrated under reduced pressure 20 purification by flash chromatography (silica gel, 40% ethyl acetate/hexane) gives an oil. The oil (107 mg) is dissolved in 2:1:1 tetrahydrofuran/methanol/water (4 mL), and lithium hydroxide monohydrate is added (35 mg, 0.8 mmol), and the reaction stirred 1.5 h. The solution is concentrated under 25 reduced pressure.

The residue is redissolved in DMF (3 mL), and diisopropylethylamine (280 µL, 1.6 mmol), HATU (230 mg, 0.6 and  $(2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-{[1-(3$ ethynylphenyl)cyclopropyl]amino}butan-2-ol dihydrochloride (206 mg, 0.5 mmol) are added. The reaction stirred at room temperature 16 h. The reaction mixture is diluted with ethyl acetate, washed with water, saturated sodium bicarbonate, brine, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column

chromatography (silica, 8% methanol/methylene chloride) provides the title compound as the free base. The residue is dissolved in diethyl ether (3 mL) and 1N hydrochloric acid in diethyl ether (1 mL) is added. The mixture is concentrated under reduced pressure to yield the title compound. ESI MS m/z 585.3 [M + H]<sup>+</sup>.

EXAMPLE SP-198

 $N-\{(1S,2R)-1-(3,5-Difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-(3,5-Difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-(3,5-Difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-(3,5-Difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-(3,5-Difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-(3,5-Difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-(3,5-Difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-(3-ethylbenzy1)-3-$ 

10 hydroxypropy1}-3-{[(2-furylmethyl)(methyl)amino]methyl}-5methylbenzamide dihydrochloride

Step 1

Methyl 3-bromo-5-(hydroxymethyl)benzoate

15 To an ice-cold, stirred solution of 3-bromo-5-(methoxycarbonyl)benzoic acid (5.0 g, 19.3 mmol) in tetrahydrofuran (77.2 mL) is added borane dimethyl sulfide complex (10.6 mL, 2.0 M tetrahydrofuran, 21.1 mmol). reaction mixture is heated at 50 °C for 2 h. The reaction mixture is quenched with methanol (50 mL) and concentrated 20 under reduced pressure. Purification by flash column chromatography (silica, 50% ethyl acetate/hexanes) affords the title compound.  $^{1}H$  NMR (300 MHz, CDCl3)  $\delta_{.}8.03$  (s, 1H), 7.90 (s, 1H), 7.69 (s, 1H), 4.69 (s, 1H), 3.91 (s, 3H), 2.83 (br s, 25 1H).


Step 2

Methyl 3-(hydroxymethyl)-5-methylbenzoate

a stirred solution of methyl 3-bromo-5-To (hydroxymethyl)benzoate (4.53 g, 18.5 mmol) in dioxane (74 mL) is added cesium carbonate (6.0 g, 18.5 mmol), potassium 37 mmol), and palladium(0) (5.1)g, carbonate tetrakis(triphenylphosphine) (2.1 g, 1.85 mmol), followed by trimethyl boroxine (5.1 mL, 37 mmol). The reaction mixture is refluxed for 12 h, cooled to room temperature, and then partitioned between water and ethyl acetate. The organic layer is washed with water and brine, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. The black oil is adsorbed onto silica gel followed by purification by flash column chromatography (silica, 25% ethyl acetate/hexanes) to provide the title compound. 1H NMR (300 MHz,  $CDC1_3$ )  $\delta$ .7.75 (s, 1H), 7.65 (s, 1H), 7.39 (s, 1H), 5.31 (br s, 1H), 4.53 (s, 1H), 3.84 (s, 3H), 2.36 (s, 3H).

Step 3

Methyl 3-{[(2-furylmethyl)(methyl)amino]methyl}-5
methylbenzoate



20

25

30

5

10

15

ice-cold, stirred solution methyl 3of To an (hydroxymethyl)-5-methylbenzoate (200 1.1 mmol) mg, methylene chloride (2.2 mL) is added triethylamine (0.304 mL, 2.2 mmol) followed by methanesulfonyl chloride (0.116 mL, 1.5 The reaction mixture is stirred for 15 min and mmol). N-Methylfurfurylamine (367 mg, 3.3 mmol) is added filtered. to the filtrate and the reaction mixture is stirred at room temperature for 5 h. The reaction mixture is diluted with methylene chloride (10 mL), washed with 1 N hydrochloric acid, and saturated sodium bicarbonate, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 50% ethyl

acetate/hexanes) provided the title compound.  $^{1}H$  NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ .7.76 (d, J = 11 Hz, 2H), 3.79 (d, J = 6 Hz, 2H), 6.32 (d, J = 2 Hz, 1H), 6.21 (d, J = 3 Hz, 1H), 3.90 (s, 3H), 3.59 (s, 3H), 3.53 (s, 2H), 2.39 (s, 3H), 2.23 (s, 3H).

5


### Step 4

3-{[(2-Furylmethyl)(methyl)amino]methyl}-5-methylbenzoic acid

To stirred solution of a methyl 3-{[(2-10 furylmethyl) (methyl) amino]methyl}-5-methylbenzoate (180 0.66 mmol) in methanol (2 mL), tetrahydrofuran (1 mL), and water (1 mL) is added lithium hydroxide (277 mg, 6.6 mmol), and the reaction mixture stirred at room temperature for 2 h. The reaction mixture is concentrated under reduced pressure, 15 dissolved in methylene chloride, filtered, and the filtrate concentrated under reduced pressure to provide the title compound. ESI MS m/z 258 [M + H]<sup>+</sup>.

Step 5

20 N-{(1S,2R)-1-(3,5-Difluorobenzy1)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2-furylmethyl)(methyl)amino]methyl}-5-methylbenzamide dihydrochloride



2 HCl

stirred To solution οf 3-{[(2-25 furylmethyl) (methyl) amino] methyl}-5-methylbenzoic (170 mg, 0.66 mmol) in methylene chloride (3 mL) is added HBTU (375 mg, 0.99 mmol), HOBt (134 mg, 0.99 mmol), and N, N-

diisopropylethylamine (0.334 mL, 1.98 mmol), followed by (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-

ethylbenzyl)amino]butan-2-ol prepared by the method in EXAMPLE SP-272 (269 mg, 0.66 mmol), and the reaction mixture is stirred for 12 h at room temperature. The reaction mixture is diluted with methylene chloride, washed with water, sodium bicarbonate, saturated dried (magnesium sulfate), filtered. and concentrated under reduced pressure. Purification by flash column chromatography (silica, methanol/chloroform) affords the title compound as the free The compound is dissolved in methanol (2 mL), and to base. this solution is added hydrochloric acid (5 mL, 4 N dioxane, 20 mmol). The reaction mixture is stirred for 1 h at room temperature. The reaction mixture is then diluted with ethyl ether (10 mL). The precipitate that is formed is collected by filtration to provide the title compound. ESI MS m/z 576 [M + H]<sup>+</sup>.

### EXAMPLE SP-199

N-{(1S,2R)-1-(3,5-Difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2-methoxyethyl)(methyl)amino]methyl}-5-methylbenzamide dihydrochloride

Step 1

10

15

30

Methyl 3-{[(2-methoxyethyl)(methyl)amino]methyl}-5-

25 methylbenzoate

То an ice-cold stirred solution of methyl 3-(hydroxymethyl)-5-methylbenzoate (200 mg, 1.1 mmol) in methylene chloride (2.2 mL) is added triethylamine (0.304 mL, 2.2 mmol) followed by methanesulfonyl chloride (0.116 mL, mmol). The reaction mixture is stirred for 15 min filtered. 2-Methoxy-N-methyleneamine (0.354 mL, 3.3 mmol) is

added to the filtrate, and the reaction mixture is stirred at room temperature for 5 h. The reaction mixture is diluted with methylene chloride (10 mL), washed with 1 N hydrochloric acid, and saturated sodium bicarbonate, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 50% ethyl acetate/hexanes) provided the title compound.  $^{1}$ H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ .7.75 (d, J = 5 Hz, 2H), 7.37 (s, 3H), 3.90 (s, 1H), 3.56 (s, 2H), 3.52 (t, J = 6 Hz, 2H), 3.34 (s, 3H), 2.61 (t, J = 6 Hz, 2H), 2.39 (s, 3H), 2.26 (s, 3H).

Step 2

5

10

3-{[(2-Methoxyethyl)(methyl)amino]methyl}-5-methylbenzoic acid

15 Tostirred solution of methy1 3-{[(2methoxyethyl) (methyl) amino]methyl}-5-methylbenzoate 0.72 mmol) in methanol (2 mL), tetrahydrofuran (1 mL), water (1 mL) is added lithium hydroxide (302 mg, 7.2 mmol) and the reaction mixture stirred at room temperature for 2 h. 20 reaction mixture is concentrated under reduced pressure, dissolved in methylene chloride, filtered, and the filtrate concentrated under reduced pressure to provide the title compound. ESI MS m/z 238 [M + H]<sup>+</sup>.

25 Step 3

N-{(1S,2R)-1-(3,5-Difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2-methoxyethyl)(methyl)amino]methyl}-5-methylbenzamide dihydrochloride

2 HCI

To a stirred solution of 3-{[(2-methoxyethyl) (methyl) amino] methyl}-5-methylbenzoic acid (140 mg, 0.56 mmol) in methylene chloride (3 mL) is added HBTU (318 mg, 0.84 mmol), HOBt (114 mg, 0.84 mmol), and N,N-diisopropylethylamine (0.284 mL, 1.68 mmol), followed by (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl) amino] butan-2-ol prepared by the method in EXAMPLE

SP-272 (228 mg, 0.56 mmol). The reaction mixture is stirred for 24 h at room temperature, diluted with methylene chloride, washed with water, and saturated sodium bicarbonate, dried (magnesium sulfate), filtered, and concentrated under reduced Purification by flash column chromatography pressure. (silica, 10% methanol/chloroform) affords the title compound The compound is dissolved in methanol (2 as the free base. mL), and to this solution is added hydrochloric acid (5 mL, 4 N dioxane, 20 mmol). The reaction mixture is stirred for 1 h The reaction mixture is then diluted at room temperature. The precipitate that is formed is with ethyl ether (10 mL). collected by filtration to provide the title compound. m/z 554 [M + H]<sup>+</sup>.

### EXAMPLE SP-200

 $3-\{[[2-(Diethylamino)ethyl](methyl)amino]methyl\}-N-\{(1S,2R)-1-(1S,2R)ethyl]\}$ 

25 (3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-

hydroxypropyl}-5-methylbenzamide trihydrochloride

Step 1

5

10

15

20

Methyl 3-{[[2-(diethylamino)ethyl](methyl)amino]methyl}-5-methylbenzoate

То stirred an ice-cold, solution οf methyl 3-(hydroxymethyl)-5-methylbenzoate (200 mg, 1.19 mmol) and triethylamine (241 mg, 2.38 mmol) in methylene chloride (5 mL) is added methanesulfonyl chloride (191 mg, 1.67 mmol). The reaction mixture is stirred for 15 min, the precipitate that formed is removed by filtration, and N, N-diethvl-N'methylethylenediamine (465 mg, 3.57 mmol) was added. reaction mixture is stirred at room temperature for 2 h and then concentrated under reduced pressure. Purification by flash column chromatography (silica, 9:1 chloroform/methanol) gives the title compound.  $^{1}H$  NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.02 (s, 2H), 7.33 (s, 1H), 3.56 (s, 3H), 3.48 (s, 2H), 2.95 (m, 4H), 2.75 (m, 4H), 2.41 (s, 3H), 2.31 (s, 3H), 1.21 (m, 6H).

15

10

Step 2

3-{[[2-(Diethylamino)ethyl](methyl)amino]methyl}-5-methylbenzoic acid

20 Α mixture of methyl 3-{[[2-(diethylamino)ethyl](methyl)amino]methyl}-5-methylbenzoate (296 mg, 1.01 mmol) and 3:1:1 methanol/tetrahydrofuran/2 N sodium hydroxide (10 mL) is stirred overnight and then partitioned between ethyl acetate and water. The aqueous 25 layer is acidified to pH 3 with 1 N hydrochloric acid and extracted with chloroform. The aqueous layer is concentrated under reduced pressure to give the title compound. 1H NMR (300 MHz, DMSO- $d_6$ )  $\delta$ .7.99 (s, 1H), 7.82 (s, 1H), 7.80 (s, 1H), 4.56 (m, 2H), 4.31 (m, 2H), 3.98 (m, 2H), 3.17 (m, 4H), 2.51 (s, 30 3H), 2.50 (s, 3H), 1.27 (m, 6H).

# Step 3

 $3-\{[[2-(Diethylamino)ethyl](methyl)amino]methyl\}-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-$ 

5 hydroxypropyl}-5-methylbenzamide trihydrochloride

3 HCI

To stirred solution of 3-{[[2-(diethylamino)ethyl](methyl)amino]methyl}-5-methylbenzoic acid (267 mg, 0.959 mmol), (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol prepared by the method of 10 EXAMPLE SP-272 (391 mg, 0.959 mmol), HOBt (129 mg, 0.959 mmol), and N, N-diisopropylethylamine (496 mg, 3.84 mmol) in methylene chloride (5 mL) is added EDC (331 mg, 1.73 mmol). The reaction mixture is stirred overnight and then partitioned between ethyl acetate and water. The organic layer is washed 15 with 1 N hydrochloric acid, saturated sodium bicarbonate, and brine, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 9:1:1 methylene 20 chloride/methanol/ammonium hydroxide) gives the title compound. ESI MS m/z 595.4 [M + H]<sup>+</sup>.

#### EXAMPLE SP-201

25

 $N-\{(1S,2R)-1-(3,5-Difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1\}-3-oxoindane-5-carboxamide$ 

To 3-oxoindane-5-carboxylic acid (2.0 g, 11.5 mmol) in DMF (10 mL) is added diisopropylethylamine (8 mL, 46 mmol), HATU (5.5 g, 14.4 mmol), then (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol

dihydrochloride prepared by the method of EXAMPLE SP-272 (5.6 g, 13.8 mmol). The reaction is stirred 1 h at room temperature. The reaction was partitioned between ethyl acetate and water. The organic layer is washed with 1 N hydrochloric acid, saturated sodium bicarbonate, and brine, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 8% methanol/methylene chloride) gives the title compound. ESI MS m/z 493.2 [M + H]<sup>+</sup>.

### 15 EXAMPLE SP-202

10

 $N-\{(1S, 2R)-1-(3, 5-Difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1\}-3-hydroxyindane-5-carboxamide$ 

То ice-cold solution of  $N-\{(1S, 2R)-1-(3, 5-$ 20 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3oxoindane-5-carboxamide prepared by the method in EXAMPLE SP-201 (66 mg, 0.13 mmol) in methanol (3 mL) is added sodium borohydride (20 mg, 0.52 mmol). The reaction stirred at room temperature 3 h. The reaction is concentrated under reduced 25 pressure, redissolved in water (3 mL) and partitioned into ethyl acetate. The organic layer is washed with water, saturated sodium bicarbonate, and brine, dried (sodium sulfate), filtered, and concentrated under reduced pressure to give the title compound. ESI MS m/z 495.2 [M + H]<sup>+</sup>.

30

EXAMPLE SP-203

N-{(1S,2R)-1-(3,5-Difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[isobutyl(methyl)amino]methyl}-5-methylbenzamide hydrochloride
Step 1

5 Methyl 3-{[isobutyl(methyl)amino]methyl}-5-methylbenzoate

ice-cold, stirred solution 3 – of methyl To (hydroxymethyl)-5-methylbenzoate (200 mg, 1.1 mmol) methylene chloride (2.2 mL) is added triethylamine (0.304 mL, 2.2 mmol) followed by methanesulfonyl chloride (0.116 mL, 1.5 10 The reaction mixture is stirred for 15 min and mmol). N-Methylisobutylamine (287 mg, 3.3 mmol) is added filtered. to the filtrate, and the reaction mixture is stirred at room temperature for 5 h. The reaction mixture is diluted with methylene chloride (10 mL), washed with 1 N hydrochloric acid, 15 and saturated sodium bicarbonate, dried (magnesium sulfate), concentrated under reduced pressure. and filtered, Purification by flash column chromatography (silica, 15% ethyl acetate/hexanes) provides the title compound. 1H NMR (300 MHz,  $CDC1_3$ )  $\delta$  7.77 (s, 1H), 7.73 (s, 1H), 7.36 (s, 1H), 3.90 (s, 20 3H), 3.44 (s, 2H), 2.38 (s, 3H), 2.14 (s, 3H), 2.10 (d, J = 8Hz, 2H), 1.81 (m, 1H), 0.90 (d, J = 7 Hz, 6H).

Step 2

30

25 3-{[Isobuty1(methy1)amino]methy1}-5-methylbenzoic acid

To a stirred solution of methyl 3-{[isobutyl(methyl)amino]methyl}-5-methylbenzoate (120 mg, 0.48 mmol) in methanol (2 mL), tetrahydrofuran (1 mL), and water (1 mL) is added lithium hydroxide (200 mg, 4.8 mmol), and the

reaction mixture stirred at room temperature for 2 h. The reaction mixture is concentrated under reduced pressure, dissolved in methylene chloride, filtered, and the filtrate concentrated under reduced pressure to provide the title compound. ESI MS m/z 236  $[M + H]^+$ .

### Step 3

5

 $N-\{(1S, 2R)-1-(3, 5-Difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1\}-3-\{[isobuty1(methyl)amino]methy1\}-5-$ 

10 methylbenzamide hydrochloride

2 HCl

То a stirred solution of 3 – {[isobutyl(methyl)amino]methyl}-5-methylbenzoic acid (110 mg, 0.48 mmol) in methylene chloride (3 mL) is added HBTU (273 mg, 15 0.72 mmol), HOBt (97 mg, 0.72 mmol), and N, Ndiisopropylethylamine (0.243 mL, 1.44 mmol), followed by (2R, 3S) - 3 - amino - 4 - (3, 5 - difluorophenyl) - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]] - 1 - [(3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - aethylbenzyl)amino]butan-2-ol prepared by the method of EXAMPLE SP-272 (196 mg, 0.48 mmol), and the reaction mixture is 20 stirred for 12 h at room temperature. The reaction mixture is diluted with methylene chloride, washed with water, saturated sodium bicarbonate, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 25 methanol/chloroform) affords a clear oil, which is dissolved in methanol (2 mL). To this solution is added hydrochloric acid (5 mL, 4 N dioxane, 20 mmol), and the reaction mixture is stirred for 1 h at room temperature. The reaction mixture is then diluted with ethyl ether (10 mL). The precipitate that

is formed is collected by filtration to provide the title compound. ESI MS m/z 552.5  $[M + H]^+$ .

### EXAMPLE SP-204

5 N-{(1S, 2R)-1-(3,5-Difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-

{[methyl(pentyl)amino]methyl}benzamide dihydrochloride Step 1

Methyl 3-methyl-5-{[methyl(pentyl)amino]methyl}benzoate

10

Toan ice-cold, stirred solution of methyl 3 – (hydroxymethyl)-5-methylbenzoate (200 mg, 1.1 mmol) in methylene chloride (2.2 mL) is added triethylamine (0.304 mL, 2.2 mmol) followed by methanesulfonyl chloride (0.116 mL, 1.5 15 The reaction mixture is stirred for 15 min and N-Methylpentylamine (333 mg, 3.3 mmol) is added to the filtrate, and the reaction mixture is stirred at room temperature for 5 h. The reaction mixture is diluted with methylene chloride (10 mL), washed with 1 N hydrochloric acid, and saturated sodium bicarbonate, dried (magnesium sulfate), 20 filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 15% ethyl acetate/hexanes) provides the title compound.  $^{1}H$  NMR (300 MHz,  $CDCl_3$ )  $\delta.7.75$  (d, J = 4 Hz, 2H), 7.36 (s, 1H), 3.90 (s, 3H), 3.47 (s, 2H), 3.13 (t, J = 9 Hz, 3H), 2.39 (s, 2H), 2.34 (d, J25 = 8 Hz, 2H), 2.18 (s, 3H), 1.45 (m, 5H), 1.32 (m, 2H).

### Step 2

3-Methyl-5-{[methyl(pentyl)amino]methyl}benzoic acid

30

To a stirred solution of methyl 3-methyl-5- $\{[methyl(pentyl)amino]methyl\}$ benzoate (120 mg, 0.46 mmol) in methanol (2 mL), tetrahydrofuran (1 mL), and water (1 mL) is added lithium hydroxide (191 mg, 4.6 mmol), and the reaction mixture stirred at room temperature for 2 h. The reaction mixture is concentrated under reduced pressure, dissolved in methylene chloride, filtered, and the filtrate concentrated under reduced pressure to provide the title compound. ESI MS m/z 250 [M + H]<sup>+</sup>.

10

5

### Step 3

 $N-\{(1S,2R)-1-(3,5-Difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-3-methyl-5-$ 

{[methyl(pentyl)amino]methyl}benzamide dihydrochloride

2 HCI

15

20

25

То stirred solution of 3-methy1-5-{[methyl(pentyl)amino]methyl}benzoic acid (110 mg, 0.44 mmol) in methylene chloride (3 mL) is added HBTU (250 mg, 0.66 mmol), HOBt (90 mg, 0.66 mmol), and N, N-diisopropylethylamine (0.222 mL, 1.32 mmol), followed by (2R,3S)-3-amino-4-(3,5-4)difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol prepared by the method of EXAMPLE SP-272 (180 mg, 0.44 mmol), and the reaction mixture is stirred for 12 h at room temperature. The reaction mixture is diluted with methylene chloride, washed with water, and saturated sodium bicarbonate, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, methanol/chloroform) affords a clear oil, which is dissolved in methanol (2 mL). To this solution is added hydrochloric

acid (5 mL, 4 N dioxane, 20 mmol), and the reaction mixture is stirred for 1 h at room temperature. The reaction mixture is then diluted with ethyl ether (10 mL). The precipitate that is formed is collected by filtration to provide the title compound. ESI MS m/z 566.5 [M + H]<sup>+</sup>.

### EXAMPLE SP-205

5

 $N-\{(1S,2R)-1-(3,5-Diffluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-3-\{[(2R)-2-(methoxymethyl)pyrrolidin-1-hydroxypropyl)-3-(methoxymethyl)-3-(m$ 

10 yl]methyl}-5-methylbenzamide dihydrochloride
 Step 1

Methyl  $3-\{[(2R)-2-(methoxymethyl)pyrrolidin-1-yl]methyl\}-5-methylbenzoate$ 

stirred solution methyl 15 To an ice-cold, of 3-(hydroxymethyl)-5-methylbenzoate (200 mg, 1.1 mmol) in methylene chloride (2.2 mL) is added triethylamine (0.304 mL, 2.2 mmol) followed by methanesulfonyl chloride (0.116 mL, 1.5 mmol). The reaction mixture is stirred for 15 min and 20 filtered. (R)-2-(Methoxymethyl)pyrrolidine (380 mg, 3.3 mmol) is added to the filtrate, and the reaction mixture is stirred at room temperature for 5 h. The reaction mixture is diluted with methylene chloride (10 mL), washed with 1 N hydrochloric acid, and saturated sodium bicarbonate, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. 25 Purification by flash column chromatography (silica, 50% ethyl acetate/hexanes) provides the title compound. 1H NMR (300 MHz,  $CDCl_3$ )  $\delta_1 7.77$  (s, 1H), 7.73 (s, 1H), 7.37 (s, 1H), 4.11 (d, J =13 Hz, 1H), 3.90 (d, J = 6 Hz, 2H), 3.41 (m, 2H), 3.34 (m, 30 3H), 2.89 (m, 1H), 2.71 (m, 1H), 2.38 (s, 3H), 2.19 (m, 1H), 1.93 (m, 2H), 1.54 (m, 3H).

Step 2

3-{[(2R)-2-(Methoxymethyl)pyrrolidin-1-yl]methyl}-5-methylbenzoic acid

5 stirred To a solution of methyl  $3-\{[(2R)-2-$ (methoxymethyl)pyrrolidin-1-yl]methyl}-5-methylbenzoate mg, 0.43 mmol) in methanol (2 mL), tetrahydrofuran (1 mL), and water (1 mL) is added lithium hydroxide (180 mg, 4.3 mmol), and the reaction mixture stirred at room temperature for 2 h. The reaction mixture is concentrated under reduced pressure, 10 dissolved in methylene chloride, filtered, and the filtrate concentrated under reduced pressure to provide the title compound. ESI MS m/z 264 [M + H]<sup>+</sup>.

15 Step 3

 $N-\{(1S,2R)-1-(3,5-Diffluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-3-\{[(2R)-2-(methoxymethyl)pyrrolidin-1-yl]methyl\}-5-methylbenzamide dihydrochloride$ 

2 HCI

20 To stirred a solution of  $3-\{[(2R)-2-$ (methoxymethyl)pyrrolidin-1-yl]methyl}-5-methylbenzoic (113 mg, 0.43 mmol) in methylene chloride (3 mL) is added  ${\tt HBTU}$ (165 mg, 0.66 mmol), HOBt (89 mg, 0.66 mmol), and N, Ndiisopropylethylamine (0.220 mL, 1.30 mmol), followed by 25 ethylbenzyl)amino]butan-2-ol prepared by the method of EXAMPLE

SP-272 (175 mg, 0.43 mmol), and the reaction mixture is stirred for 12 h at room temperature. The reaction mixture is diluted with methylene chloride, washed with water, saturated sodium bicarbonate, dried (magnesium sulfate), 5 filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, methanol/chloroform) affords a clear oil, which was dissolved in methanol (2 mL). To this solution is added hydrochloric acid (5 mL, 4 N dioxane, 20 mmol), and the reaction mixture is 10 stirred for 1 h at room temperature. The reaction mixture is then diluted with ethyl ether (10 mL). The precipitate that is formed is collected by filtration to provide the title compound. ESI MS m/z 580.4 [M + H]<sup>+</sup>.

### 15 EXAMPLE SP-206

3-Bromo-5-{[butyl(methyl)amino]methyl}-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}benzamide dihydrochloride

2 HCI

20 Methyl 3-bromo-5-{[butyl(methyl)amino]methyl}benzoate prepared by the method in EXAMPLE SP-190, Step 1 (170 mg, 0.54) is dissolved in 2:1:1 tetrahydrofuran/methanol/water (4 mL), and lithium hydroxide monohydrate is added (45 mg, 1.1 mmol), and the reaction stirred 16 h. The solution is 25 concentrated under reduced pressure. The residue is redissolved in DMF (5 mL), and diisopropylethylamine (375  $\mu$ L, 2.16 mmol), HATU (256 mg, 0.68 mmol), and (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol dihydrochloride prepared by the method in EXAMPLE SP-272 (265

0.65 mmol) are added. The reaction stirred at room temperature 1 h. The reaction mixture is diluted with methylene chloride, washed with water, and saturated sodium bicarbonate, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 8% methanol/methylene chloride) provides the title compound as the free base. The residue is dissolved in diethyl ether (3 mL) and 1N hydrochloric acid in diethyl ether (1 mL) is added. The mixture is concentrated under reduced pressure to yield the title compound. ESI MS m/z 616.2 [M + H]<sup>+</sup>.

### EXAMPLE SP-207

 $3-[(Butylamino)methyl]-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-$ 

15 [(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methylbenzamide dihydrochloride

Step 1

5

10

Methyl 3-[(butylamino)methyl]-5-methylbenzoate

20 To an ice-cold, stirred solution of methyl 3-(hydroxymethyl)-5-methylbenzoate (200 mg, 1.1 mmol) in methylene chloride (2.2 mL) is added triethylamine (0.304 mL, 2.2 mmol) followed by methanesulfonyl chloride (0.116 mL, mmol). The reaction mixture is stirred for 15 min 25 filtered. Butylamine (0.543 mL, 5.5 mmol) is added to the and the reaction mixture is stirred at filtrate, The reaction mixture is diluted with temperature for 5 h. methylene chloride (10 mL), washed with 1 N hydrochloric acid, and saturated sodium bicarbonate, dried (magnesium sulfate), 30 filtered. and concentrated under reduced pressure. Purification by flash column chromatography (silica, 89:10:1 chloroform/methanol/ammonium hydroxide) provides the title

compound. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ .7.75 (s, 1H), 7.70 (s, 1H), 7.24 (br s, 1H), 4.42 (d, J = 9 Hz, 2H), 3.90 (s, 3H), 3.16 (m, 2H), 2.38 (s, 3H), 1.64 (s, 2H), 1.44 (m, 9H), 1.27 (m, 2H), 0.89 (t, J = 7 Hz, 3H).

5

Step 2

Methyl 3-{[(tert-butoxycarbonyl)(butyl)amino]methyl}-5-methylbenzoate

To a stirred solution of methyl 3-[(butylamino)methyl]-5-10 methylbenzoate (70 mg, 0.30 mmol) in methylene chloride is mmol), triethylamine (0.046 mL, 0.33 and 4dimethylaminopyridine (4.0 mg, 0.03 mmol) followed by di-tertbutyl-dicarbonate (72 mg, 0.30 mmol). The reaction mixture is stirred at room temperature for 24 h, diluted with methylene 15 chloride, washed with 1 N hydrochloric acid, and brine. organic solution is dried (magnesium sulfate), filtered, and concentrated under reduced pressure to afford the title  $^{1}$ H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.75 (s, 1H), 7.70 (s, compound. 1H), 7.24 (br s, 1H), 4.42 (d, J = 9 Hz, 2H), 3.90 (s, 3H), 20 3.16 (m, 2H), 2.38 (s, 3H), 1.64 (s, 2H), 1.44 (m, 9H), 1.27 (m, 2H), 0.89 (t, J = 7 Hz, 3H).

Step 3

3-{[(tert-Butoxycarbonyl)(butyl)amino]methyl}-5-methylbenzoic
acid

To a stirred solution of methyl 3-{[(tert-butoxycarbonyl)(butyl)amino]methyl}-5-methylbenzoate (70 mg,

0.21 mmol) in methanol (2 mL), tetrahydrofuran (1 mL), and water (1 mL) is added lithium hydroxide (88 mg, 2.1 mmol), and the reaction mixture stirred at room temperature for 2 h. The reaction mixture is concentrated under reduced pressure, dissolved in methylene chloride, filtered, and the filtrate concentrated under reduced pressure to provide the title compound.

# Step 4

5

20

25

3-[(Butylamino)methyl]-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methylbenzamide dihydrochloride

2 HCI

To stirred solution of 3-{[(tertbutoxycarbonyl)(butyl)amino]methyl}-5-methylbenzoic acid 15 mg, 0.28 mmol) in methylene chloride (3 mL) is added HBTU (160 mq, 0.42 mmol), HOBt (57 mg, 0.42 mmol), and N, Ndiisopropylethylamine (0.142 mL, 0.84 mmol), followed by (2R, 3S) - 3 - amino - 4 - (3, 5 - difluorophenyl) - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]] - 1 - [(3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 -

ethylbenzyl)amino]butan-2-ol prepared by the method of EXAMPLE SP-272 (114 mg, 0.28 mmol), and the reaction mixture is stirred for 12 h at room temperature. The reaction mixture is diluted with methylene chloride, washed with water, and saturated sodium bicarbonate, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, methanol/chloroform) affords a clear oil, which is dissolved in methanol (2 mL). To this solution is added hydrochloric acid (5 mL, 4 N dioxane, 20 mmol), and the reaction mixture is

stirred for 1 h at room temperature. The reaction mixture is then diluted with ethyl ether (10 mL). The precipitate that is formed is collected by filtration to provide the title compound. ESI MS m/z 538.5 [M + H]<sup>+</sup>.

5

EXAMPLE SP-208

N-{(1S,2R)-1-(3,5-Difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]methyl}-5-methylbenzamide dihydrochloride

10 Step 1

Methyl 3-{[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]methyl}-5-methylbenzoate

To an ice-cold, stirred solution of methyl 3 – 15 (hydroxymethyl)-5-methylbenzoate (200 mg, 1.1 in mmol) methylene chloride (2.2 mL) is added triethylamine (0.304 mL, 2.2 mmol) followed by methanesulfonyl chloride (0.116 mL, The reaction mixture is stirred for 15 min and (S)-(+)-2-(Methoxymethyl) pyrrolidine (380 mg, 20 mmol) is added to the filtrate, and the reaction mixtire is stirred at room temperature for 5 h. The reaction mixture is diluted with methylene chloride (10 mL), washed with 1 N hydrochloric acid, and saturated sodium bicarbonate, dried (magnesium sulfate), filtered, and concentrated under reduced 25 pressure. Purification by flash column chromatography (silica, 15% ethyl acetate/hexanes) provides the title compound.  $^{1}$ H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ .7.77 (s, 1H), 7.73 (s, 1H), 7.37 (s, 1H), 4.12 (d, J = 17 Hz, 1H), 3.90 (s, 3H), 3.85(m, 2H), 3.51 (m, 2H), 3.44 (m, 2H), 3.15 (s, 1H), 2.38 (s, 30 3H), 1.94 (m, 3H), 1.72 (m, 3H).

Step 2

3-{[(2S)-2-(Methoxymethyl)pyrrolidin-1-yl]methyl}-5-methylbenzoic acid

To stirred solution of methyl  $3-\{[(2S)-2-$ 5 (methoxymethyl)pyrrolidin-1-yl]methyl}-5-methylbenzoate mg, 0.50 mmol) in methanol (2 mL), tetrahydrofuran (1 mL), and water (1 mL) is added lithium hydroxide (211 mg, 5.0 mmol), and the reaction mixture stirred at room temperature for 2 h. The reaction mixture is concentrated under reduced pressure, 10 dissolved in methylene chloride, filtered, and the filtrate concentrated under reduced pressure to provide the title compound. ESI MS m/z 264 [M + H]<sup>+</sup>.

Step 3

N-{(1S,2R)-1-(3,5-Difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]methyl}-5-methylbenzamide dihydrochloride

2 HCI

To a stirred solution of 3-{[(2S)-2-20 (methoxymethyl)pyrrolidin-1-yl]methyl}-5-methylbenzoic acid (110 mg, 0.42 mmol) in methylene chloride (3 mL) is added HBTU (240 mg, 0.63 mmol), HOBt (85 mg, 0.63 mmol), and N,N-diisopropylethylamine (0.212 mL, 1.26 mmol), followed by (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-

ethylbenzyl)amino]butan-2-ol prepared by the method of EXAMPLE SP-272 (171 mg, 0.42 mmol). The reaction mixture is stirred

for 12 h at room temperature. The reaction mixture is diluted with methylene chloride, washed with water, and saturated sodium bicarbonate, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash (silica, 10% methanol/chloroform) column chromatography affords a clear oil, which is dissolved in methanol (2 mL). To this solution is added hydrochloric acid (5 mL,4 N dioxane, 20 mmol), and the reaction mixture is stirred for 1 h at room temperature. The reaction mixture is then diluted with ethyl ether (10 mL). The precipitate that is formed was collected by filtration to provide the title compound. ESI MS m/z 580.4  $[M + H]^+$ .

EXAMPLE SP-209

N-{(1S,2R)-1-(3,5-Difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2hydroxypropyl}-3-{[(2-hydroxyethyl) (methyl)amino]methyl}-5methylbenzamide dihydrochloride

Step 1

5

10

Methyl 3-{[(2-hydroxyethyl)(methyl)amino]methyl}-5-

20 methylbenzoate

solution ice-cold stirred of methyl 3 -To (hydroxymethyl)-5-methylbenzoate (200 mg, 1.1 mmol) in methylene chloride (2.2 mL) is added triethylamine (0.304 mL, 2.2 mmol) followed by methanesulfonyl chloride (0.116 mL, 25 The reaction mixture is stirred for 15 min and mmol). filtered. 2-Methoxy-N-methyleneamine (0.354 mL, 3.3 mmol) is added to the filtrate and stirred at room temperature for 5 h. The reaction mixture is diluted with methylene chloride (10 30 mL), washed with 1 N hydrochloric acid, and saturated sodium bicarbonate, dried (magnesium sulfate), filtered, concentrated under reduced pressure. Purification by flash

column chromatography (50% ethyl acetate/hexanes) provides the title compound. ESI MS m/z 238 [M + H]<sup>+</sup>.

Step 2

5 3-{[(2-Hydroxyethyl)(methyl)amino]methyl}-5-methylbenzoic acid

То stirred solution of methyl 3-{[(2hydroxyethyl) (methyl)amino]methyl}-5-methylbenzoate (180 0.72 mmol) in methanol (2 mL), tetrahydrofuran (1 mL), and water (1 mL) is added lithium hydroxide (302 mg, 7.2 mmol), 10 and the reaction mixture is stirred at room temperature for 2 The reaction mixture is concentrated under reduced h. dissolved in methylene chloride, filtered, concentrated under reduced pressure to provide the title compound. ESI MS m/z 224 [M + H]<sup>+</sup>. 15

Step 3

20

25

N-{(1S,2R)-1-(3,5-Difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2-hydroxyethyl)(methyl)amino]methyl}-5-methylbenzamide dihydrochloride

2 HCI

То a stirred solution of 3-{[(2hydroxyethyl) (methyl) amino]methyl}-5-methylbenzoic mg, 0.56 mmol) in methylene chloride (3 mL) is added HBTU (318 0.84 mmol), HOBt (114 0.84 mmol), mg, and diisopropylethylamine (0.284 mL, 1.68 mmol), followed by (2R, 3S) - 3 - amino - 4 - (3, 5 - difluorophenyl) - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]] - 1 - [(3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (

ethylbenzyl)amino]butan-2-ol prepared by the method of EXAMPLE SP-272 (228 mg, 0.56 mmol). The reaction mixture is stirred for 24 h at room temperature, diluted with methylene chloride, washed with water, and saturated sodium bicarbonate, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (10% methanol/chloroform) affords a clear oil, which is dissolved in methanol (2 mL). To this is added hydrochloric acid (5 mL of a 4 N solution in dioxane, 20 mmol), and the reaction mixture is stirred for 1 h at room temperature. The reaction mixture is diluted with ethyl ether (10 mL). The precipitate that is formed is collected by filtration to provide the title compound. ESI MS m/z 540.4 [M + H]<sup>+</sup>.

### 15 EXAMPLE SP-210

10

 $3-Bromo-5-\{[butyl(methyl)amino]methyl\}-N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-\{[3-difluorobenzyl)amino]methyl\}-N-((1S,2R)-1-(3,5-difluorobenzyl)amino]methyl$ 

(trifluoromethyl)benzyl]amino)propyl)benzamide dihydrochloride

2 HCl

Methyl 3-bromo-5-{[butyl(methyl)amino]methyl]benzoate prepared by the method in EXAMPLE SP-190, Step 1 (200 mg, 0.64) is dissolved in 2:1:1 tetrahydrofuran/methanol/water (4 mL), and lithium hydroxide monohydrate is added (60 mg, 1.3 mmol), and the reaction stirred 16 h. The solution is concentrated under reduced pressure. The residue is redissolved in DMF (5 mL), and diisopropylethylamine (445 μL, 2.6 mmol), HATU (304 mg, 0.8 mmol), and (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-{[3-

(trifluoromethyl)benzyl]amino}butan-2-ol dihydrochloride

prepared by the method in EXAMPLE S-2511 (315 mg, 0.7 mmol) The reaction stirred at room temperature 16 h. are added. The reaction mixture is diluted with ethyl acetate, washed with water, and saturated sodium bicarbonate, brine, dried (sodium sulfate), filtered, and concentrated under reduced Purification by flash column pressure. chromatography (silica, 9% methanol/methylene chloride) provides the title compound as the free base. The residue is dissolved in diethyl ether (3 mL) and 1N hydrochloric acid in diethyl ether (2 mL) is added. The mixture is concentrated under reduced pressure to yield the title compound. ESI MS m/z 656.2 [M + H]<sup>+</sup>.

### EXAMPLE SP-211

10

25

30

N-((1S,2R)-1-(3,5-Difluorobenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-3{[isopentyl(methyl)amino]methyl}-5-methylbenzamide
dihydrochloride
Step 1

20 Methyl 3-{[isopentyl(methyl)amino]methyl}-5-methylbenzoate

To methyl 3-(hydroxymethyl)-5-methylbenzoate prepared by the method in EXAMPLE SP-198, Step 2 in anhydrous methylene chloride at -30 °C is added methanesulfonyl chloride (601  $\mu$ L, 7.8 mmol), then triethylamine (1.5 mL, 11.1 mmol), and the reaction is stirred at 0 °C 15 min. The resulting precipitate is filtered, and the filtrate is added to N-methylisoamylamine (2.1 mL, 16.7 mmol). The reaction stirred at room temperature 16 h. The solution is concentrated under reduced pressure, redissolved in ethyl acetate and washed with saturated sodium bicarbonate, brine, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash

column chromatography (silica, 20% ethyl acetate/hexanes) provides the title compound. ESI MS m/z 264.2 [M + H]<sup>+</sup>.

Step 2

5 N-((1S,2R)-1-(3,5-Difluorobenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-3-{[isopentyl(methyl)amino]methyl}-5-methylbenzamide dihydrochloride

2 HCI

10 3-{[isopentyl(methyl)amino]methyl}-5-То methyl (250 0.95 mmol) in mg, methylbenzoate tetrahydrofuran/methanol/water (2:1:1, 8 mL) is added lithium hydroxide monohydrate (80 mg, 1.9 mmol), and the reaction is The room temperature 16 h. solution is stirred at concentrated under reduced pressure, redissolved in DMF (5 15 mL), and diisopropylethylamine (660  $\mu$ L, 3.8 mmol), HATU (540 mg, 1.4 mmol), and (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-{[1-(3-ethynylphenyl)cyclopropyl]amino}-3-methylbutan-2-ol dihydrochloride (450 mg, 1.05 mmol) are added. The reaction stirred at room temperature 2 h. 20 The reaction mixture is diluted with ethyl acetate, washed with water, saturated sodium bicarbonate, brine, dried (sodium sulfate), filtered, Purification by and concentrated under reduced pressure. flash column chromatography (silica, 9% methanol/methylene 25 chloride) provides the title compound as the free base. The dissolved in diethyl ether (3 mL) 1N residue is hydrochloric acid in diethyl ether (2 mL) is added. The mixture is concentrated under reduced pressure to yield the title compound. ESI MS m/z 588.3 [M + H]<sup>+</sup>.

EXAMPLE SP-212

N-((1S,2R)-1-(3,5-Difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-3[isopentyl(methyl)amino]methyl}-5-methylbenzamide
dihydrochloride

2 HCI

To methyl 3-{[isopentyl(methyl)amino]methyl}-5methylbenzoate prepared by the method in EXAMPLE SP-211, Step 10 (160 mg, 0.61 mmol) in tetrahydrofuran/methanol/water (2:1:1, 8 mL) is added lithium hydroxide monohydrate (51 mg, 1.2 mmol), and the reaction is stirred at room temperature 16 h. The solution is concentrated under reduced pressure, redissolved in DMF (5 mL), and diisopropylethylamine (424  $\mu$ L, 2.4 mmol), HATU (290 mg, 0.8 mmol), and (2R,3S)-3-amino-4-15 (3,5-difluorophenyl)-1-{[1-(3-ethylphenyl)cyclopropyl]amino}-3-methylbutan-2-ol dihydrochloride prepared by the method in EXAMPLE SP-272 (291 mg, 0.7 mmol) are added. The reaction stirred at room temperature 2 h. The reaction mixture is 20 diluted with ethyl acetate, washed with water, saturated sodium bicarbonate, brine, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 8% methanol/methylene chloride) provides the title compound as the free base. 25 residue is dissolved in diethyl ether (3 mL) 1N hydrochloric acid in diethyl ether (2 mL) is added. The mixture is concentrated under reduced pressure to yield the title compound. ESI MS m/z 592.3 [M + H]<sup>+</sup>.

EXAMPLE SP-213

10

15

25

1-Butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1H-indole-6-carboxamide

5 Step 1: Methyl 1H-indole-5-carboxylate

To a mixture of indole-5-carboxylic acid (3.0 g) and triethylamine (1.9 g) in dry THF (100 mL) was added 1,1carbonyldiimidazole (3.08 g). The mixture was stirred for 30 minutes at room temperature, at which time methanol (25 mL) was added. The mixture was stirred at room temperature for 1 h, partitioned between water and ethyl acetate. The layers were separated and the organic layer washed twice with water, dried over anhydrous magnesium sulfate, filtered concentrated under reduced pressure. Column chromatography on silica gel (200 mL) using  $CH_2Cl_2$  as eluent to give 0.794 g of the title compound:  ${}^{1}H$  NMR (CDCl<sub>3</sub>)  $\delta$  3.93, 6.66, 7.28, 7.41, 7.91, 8.34, 8.42.

20 Step 2: Methyl 1-butyl-1H-indole-5-carboxylate

To a mixture of methyl 1H-indole-5-carboxylate (6.0 g) in methylsulfoxide (30 mL) was added potassium t-butoxide (3.88 g). The mixture was stirred at room temperature for 10 minutes at which time 1-iodobutane (1.8 mL) was added. The mixture was stirred at room temperature for 5 h then partitioned between water and methylene chloride. The layers

were separated and the organic layer washed three times with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. Column chromatography on silica gel (100 mL) using 10% ethyl acetate in hexanes as eluent to give 6.18 g of the title compound:  $^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  0.923, 1.38, 1.83, 3.9, 4.14, 6.58, 7.15, 7.34, 7.9, 8.39.

Step 3: 1-Butyl-1H-indole-6-carboxylic acid

To a mixture of 1-butyl-1H-indole-6-carboxylic acid (0.52 g) in methanol (25.0 mL) and water (5.0 mL) was added lithium hydroxide monohydrate (2.0 g). The mixture was heated to 60 °C for 6 h, cooled to room temperature, poured into 1N HCl (50mL) and extracted into ethyl acetate. The ethyl acetate extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give 0.496 g (72%) of the title compound: <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.98 (t, J = 7.3 Hz, 3 H), 1.4 (m, 2 H), 1.9 (m, 2 H), 4.2 (m, 2 H), 6.57 (ss, J = 2.6 Hz, 1 H), 7.31 (ss, J = 3.1 Hz, 1 H), 7.68 (d, J = 8.4 Hz, 1 H), 7.89 (dd, J = 1.4, 8.4 Hz, 1 H), 8.24 (s, 1 H).

Step 4: 1-Butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1H-indole-6-carboxamide

To a mixture of 1-butyl-1H-indole-6-carboxylic acid (0.278 g) in methylene chloride (10 mL) was added triethylamine (0.129 g), HOBT (0.175 g) and, HATU (0.486 g).

The mixture was stirred at room temperature for 30 minutes at time (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3which ethylbenzyl)amino]butan-2-ol (0.408 g) was added. The resulting mixture was stirred at room temperature for 18 h then partitioned between water and methylene chloride. layers were separated and the organic layer washed with water followed by brine and dried over anhydrous magnesium sulfate. Column chromatography on silica gel (100 mL) using 3% methanol in methylene chloride as eluent to give 0.256 g of the title compound: MS (ESI+) for  $C_{32}H_{37}F_2N_3O_2$  m/z 542.2 (M+H).

EXAMPLE SP-201

10

1-Butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}indoline-6-carboxamide hydrochloride

Step 1: Methyl 1-butylindoline-6-carboxylate

To a mixture of methyl 1-butyl-1H-indole-6-carboxylate,

(2.1 g) in glacial acetic acid (25 mL) was added sodium cyanoborohydride (2.28 g). The mixture was heated at 40 °C for 3 h then cooled to room temperature, partitioned between water and ethyl acetate and the layers were separated. The organic layer was washed three times with brine, dried over anhydrous sodium sulfate and concentrated to give 1.64 g of the title compound: ¹H NMR (CDCl<sub>3</sub>) δ 0.969, 1.43, 1.59, 2.99, 3.1, 3.4, 3.88, 7.07, 7.34.

Step 2: 1-Butylindoline-6-carboxylic acid

30

To a mixture of Methyl 1-butylindoline-6-carboxylate (1.6 g) in methanol (20 mL) was added 1N NaOH (5.0 mL). The mixture was heated at 60 °C for 2 h then cooled to room temperature, poured into 1N HCl and extracted into ethyl acetate. The ethyl acetate extract was dried over anhydrous magnesium sulfate and concentrated to give 1.16 gof the title compound:  $^1{\rm H}$  NMR (CDCl<sub>3</sub>)  $\delta$  0.974, 1.43, 1.60, 3.01, 3.11, 3.42, 7.1, 7.43.

10

5

Step 3: 1-Butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}indoline-6-carboxamide hydrochloride

15

20

25

To a mixture of 1-butylindoline-6-carboxylic acid (0.2 g) in methylene chloride was added triethylamine (0.0.27 g), HOBT (0.125 g) and, HATU (0.347 g). The mixture was stirred at 40 °C for 15 minutes at which time (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol (0.346 g) was added. The resulting mixture was stirred at 40 °C for 5 h then partitioned between water and methylene chloride. The layers were separated and the organic layer washed with water followed by brine and dried over anhydrous magnesium sulfate. Column chromatography on silica gel (100 mL) using 5% methanol

in methylene chloride as eluent to give 0.100 g of the title compound: MS (ESI+) for  $C_{32}H_{39}F_2N_3O_2$  m/z 535.9  $(M+H)^+$ .

EXAMPLE SP-215

1-Butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1H-indazole-6-carboxamide

Step 1: 3-[(E)-(Tert-butylthio)diazenyl]-4-methylbenzoic acid

10

To a mixture of 3-amino-4-methyl benzoic acid (5.0 g) in water (50 mL) was added concentrated hydrochloric acid (15 mL). The mixture was chilled to 0 °C in an ice/acetone bath.

15 Sodium nitrite (2.28 g) was dissolved in water (10 mL) and slowly added to the mixture at 0 °C. The pH was adjusted to 6 with saturated sodium acetate and 2-methyl-2-propanethiol (1.8 mL) was added. The mixture was stirred for 1 h and the resulting solids were collected by filtration, washed with water and dried under reduced pressure to give 5.7 g of the title compound: ¹H NMR (CDCl<sub>3</sub>) δ 1.61, 2.20, 7.38, 7.55, 9.67.

Step 2: 1H-Indazole-6-carboxylic acid

To a mixture of 3-[(E)-(tert-butylthio)diazenyl]-4-methylbenzoic acid (5.7 g) in nitrogen degassed methylsulfoxide (90 mL) was added potassium t-butoxide (25.0 g). The mixture was stirred at room temperature for 24 h then poured onto ice and acidified to pH 4 with concentrated hydrochloric acid. The mixture was extracted with diethyl

ether and the organic layer washed with brine. The organic layer was dried over anhydrous magnesium sulfate and decolorizing carbon then concentrated under reduced pressure to give 1.2 gof the title compound:  $^{1}\text{H}$  NMR (CDCl<sub>3</sub>)  $\delta$  0.963, 1.36, 1.95, 4.48, 7.81, 7.88, 8.08, 8.29.

Step 3: Methyl 1H-indazole-6-carboxylate

To a mixture of 1H-indazole-6-carboxylic acid (1.0 g) in methylene chloride (15 mL) was added EDC (1.8 g), HOBT (1.27 10 g), and triethylamine (1.29 mL). The mixture was heated to 40 °C for 30 minutes at which time methanol (10.0 mL) was added. The mixture was stirred at 40 °C for 18 h. The mixture was removed from heat, cooled to room temperature and poured into 15 methylene chloride. The mixture was washed twice with water dried over then brine. anhydrous sodium sulfate concentrated under reduced pressure to give 0.955 g of the title compound:  $^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  3.98, 7.81, 7.86, 8.16, 8.29, 10.6.

20

25

5

Step 4: Methyl 1-butyl-1H-indazole-6-carboxylate

To a mixture of methyl 1H-indazole-6-carboxylate (0.95 g) in DMF (10 mL) was added 60% NaH (0.216 g). The mixture was heated to 60 °C and 1-iodobutane (0.61 mL) was added. The mixture was heated at 60 °C for 72 h and 1-iodobutane (0.61 mL) was added every 24 h. The mixture was removed from heat and cooled to room temperature and partitioned between water and ethyl acetate. The layers were separated and the organic

layer washed three times with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. Column chromatography on silica gel (100 mL) using 5% ethyl acetate in hexanes as eluent to give 0.356 g of the title compound:  $^{1}\text{H}$  NMR (CDCl<sub>3</sub>)  $\delta$  0.938, 1.34, 1.92, 3.97, 4.43, 7.73, 7.79, 8.03, 8.18.

Step 5: 1-Butyl-1H-indazole-6-carboxylic acid

10

15

20

5

To a mixture of methyl 1-butyl-1H-indazole-6-carboxylate (0.356 g) in methanol (10 mL) was added saturated sodium bicarbonate (5 mL). The mixture was heated at 60 °C for 2 h at which time 1N NaOH (5 mL) was added and the mixture heated to 80°C for 18 h. The mixture was cooled to room temperature, poured into 1N HCl (50 mL), and extracted with ethyl acetate. The ethyl acetate extract dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give 0.310 g of the title compound:  $^1{\rm H}$  NMR (CDCl3)  $\delta$  0.964, 1.96, 4.48, 7.81, 7.89, 8.29, 8.46.

Step 6: 1-Butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1H-indazole-6-carboxamide

25

To a mixture of 1-butyl-1H-indazole-6-carboxylic acid  $(0.2\ g)$  in methylene chloride  $(20\ mL)$  was added triethylamine  $(0.182\ g)$ , HOBT  $(126\ g)$ , and HATU  $(0.348\ g)$ . The mixture was

stirred at 40 °C for 10 minutes at which time (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol

(0.35 g) was added. The mixture was stirred at 40 °C for 3 h then poured into methylene chloride (50 mL), washed with water then brine, dried over anhydrous magnesium sulfate and concentrated under vacuum. Column chromatography on silica gel (100 mL) using 5% methanol in methylene chloride as eluent to give 0.2 g of the title compound: MS (ESI+) for  $C_{31}H_{36}F_2N_4O_2$  m/z 534.9 (M+H)<sup>+</sup>.

10

EXAMPLE SP-216

1-Butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4[methyl(methylsulfonyl)amino]-1H-indole-6-carboxamide

15

20

25

Step 1: Methyl 4-methyl-3,5-dinitrobenzoate

To a mixture of 3,5 dinitrotoluic acid (16 g) in methanol (10 mL) was added sulfuric acid (15 mL). The mixture was heated to 75 °C for 72 h, removed from heat and cooled to room temperature. The solvents were removed under pressure and the residue was partitioned between water and ethyl acetate. The layers were separated and the organic layer washed with 2 N NaOH followed by water. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated to give 16.28 g (96%) of the title compound:  $^1\text{H NMR } (\text{CDCl}_3) \delta 2.65 \text{ (s, 3 H), 4.02 (s, 3 H), 8.61 (s, 2 H)}$ 

Step 2: Methyl 4-[(E)-2-(dimethylamino)ethenyl]-3,5-30 dimitrobenzoate

To a mixture of methyl 4-methyl-3,5-dinitrobenzoate (5.6 g) in toluene (20 mL) was added dimethylformamide dimethyl acetal (4.17 g) and 5-sulfo salycylic acid hydrate (0.1 g). The mixture was heated to 110 °C for 19 h, removed from heat and cooled to room temperature. The solvents were removed under reduced pressure at which time hexanes was added to the residue and the residue was filtered to give 6.85 g of the title compound:  $^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  2.97, 3.96, 5.54, 6.74, 8.33.

10

15

20

Step3: Methyl 4-amino-1H-indole-6-carboxylate

To a mixture of methyl 4-[(E)-2-(dimethylamino)ethenyl]-3,5-dinitrobenzoate (19.3 g) in ethyl acetate (200 mL) was added 5% palladium on carbon (1.5 g). The mixture was placed under 45 PSI H2 and shaken overnight. The mixture was filtered through celite and concentrated. The residue was dissolved in  $CH_2Cl_2$  to which was added ((1:1)  $H_2O:conc.$  HCl (250 mL)). resulting solids were collected by filtration, dissolved in ethyl acetate and washed with 2N NaOH. The ethyl acetate layer with anhydrous magnesium sulfate, filtered concentrated to give 7.4 g if the title compound: <sup>1</sup>H NMR  $(CDCl_3)$   $\delta$  3.91, 4.01, 6.51, 7.09, 7.27, 8.40.

25 Step 4: Methyl 4-[(methylsulfonyl)amino]-1H-indole-6-carboxylate

To a mixture of methyl 4-amino-1H-indole-6-carboxylate  $(1.0~\rm g)$  in DMF  $(10~\rm mL)$  was added 4-dimethylaminopyridine  $(1.46~\rm g)$  and methanesulfonyl chloride  $(0.6~\rm g)$ . The mixture was heated to  $60~\rm ^{\circ}C$  for 3 h, cooled to room temperature, and partitioned between water and ethyl acetate. The layers were separated and the organic layer washed three times with brine, dried over anhydrous sodium sulfate and concentrated to give  $0.71~\rm g$  of the title compound:  $^{1}\rm H$  NMR  $(CDCl_{3})$   $\delta$  3.02, 3.94, 6.69, 7.42, 7.81, 8.04.

Step 5: Methyl 4-[methyl(methylsulfonyl)amino]-1H-indole-6-carboxylate

10

15 a mixture of Methyl 4-[(methylsulfonyl)amino]-1Hindole-6-carboxylate (0.6 g) in THF (10 mL) was added potassium carbonate (0.309 g) and iodomethane (0.63 mL). mixture was stirred at room temperature for 4 h then heated to 40 °C overnight. Iodomethane (0.3 mL) was added and the mixture heated an additional 3 h. The mixture was cooled to 20 room temperature, partitioned between water and diethyl ether, dried over anhydrous sodium sulfate and concentrated. residue was dissolved in ether and decolorizing carbon (2 g) was added and the mixture refluxed for 5 minutes then filtered 25 through celite while hot. The ether was removed under reduced

pressure to give 0.437 g of the title compound: MS (ESI+) for C12 H14 N2 O4 S1 m/z 321.1 (M+K).

1-Butyl-4-[methyl(methylsulfonyl)amino]-1H-indole-6carboxylic acid

To a mixture of methyl 4-[methyl(methylsulfonyl)amino]-1H-indole-6-carboxylate (0.437 g) in DMF(15 mL) was added potassium hydroxide (0.087 g) and iodobutane (0.34 mL). mixture was heated to 70 °C for 6 h. then stirred at room 10 temperature for 72 h. The mixture was partitioned between water and ethyl acetate, the layers were separated and the organic layer washed three times with water. The organic layer was dried over anhydrous sodium sulfate, filtered and 15 concentrated. The residue was dissolved in methanol (5 mL) to which was added 1N NaOH (2 mL) and the mixture heated to 50 °C for 1 h. The mixture was cooled to room temperature and poured into water and washed with ether. The aqueous layer was acidified to pH 4 with 1N HCl and the product extracted into ethyl acetate which was dried over anhydrous sodium sulfate, filtered and concentrated to dryness to give 0.377 g  $^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  0.973, 1.38, 1.87, of the title compound: 3.01, 3.45, 4.21, 6.71, 7.36, 7.82, 8.18.

25 · Step 7:  $1-Butyl-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-mu)]$ ethylbenzyl)amino]-2-hydroxypropyl}-4-[methyl(methylsulfonyl)amino]-1H-indole-6-carboxamide

20

To a mixture of 1-Butyl-4-[methyl(methylsulfonyl)amino]-1H-indole-6-carboxylic acid (0.2g) in methylene chloride (15 mL) was added triethylamine (0.156 g), HOBT (0.105 g), and HATU (0.293 g). The mixture was stirred at 39 °C for 10 minutes at which time (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol (0.293 g) was added. The mixture was stirred at 40 °C for 4 h then poured into methylene chloride (50 mL), washed with water followed by brine then dried over anhydrous magnesium sulfate and concentrated under reduced pressure. Column chromatography on silica gel (100 mL) using 5% methanol in methylene chloride as eluent to give 0.21 g of the title compound: MS (ESI+) for C34H42F2N4O4S1 m/z 640.8 (M+H).

15

25

10

5

EXAMPLE SP-217

N-{(1S,2R)-1-(3,5-Difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(dipropylamino)isonicotinamide hydrochloride

20 Step 1: 2-Chloroisonicotinonitrile

4-cyanopyridine-N-oxide (10.0 g) was added to phosphorus oxychloride (85 mL) and heated to 110 °C for 2.5 h. mixture was cooled to room temperature and the excess phosphorus oxychloride removed under reduced pressure. The residue was dissolved in water and made basic with concentrated ammonia. The product was extracted into

methylene chloride, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. Column chromatography on silica gel (100 mL) using methylene chloride as eluent to give 7.19 g of the title compound:  $^{1}H$  NMR (CDCl<sub>3</sub>)  $\delta$  7.48, 7.6, 8.6.

5

Step 2: 2-(Dipropylamino)isonicotinonitrile

2-Chloroisonicotinonitrile (1.0 g) and dipropylamine (10 mL) were placed in a sealed heavy wall tube and heated to 100  $^{\circ}$ C for 18 h. The mixture was removed from heat and cooled to room temperature. The dipropylamine was removed under reduced pressure and the residue chromatographed on silica gel using 2% ethyl acetate in hexanes as eluent to give 1.06 g of the title compound: MS (ESI+) for  $C_{12}H_{17}N_3$  m/z 204.1 (M+H) $^{\dagger}$ .

15

20

10

Step 3: 2-(Dipropylamino)isonicotinic acid hydrochloride

2-(Dipropylamino)isonicotinonitrile (1.0 g) was dissolved in concentrated hydrochloric acid (30 mL) and heated at 65 °C for 3 h. The solvents were removed under reduced pressure to give 1.27 g of the title compound: MS (ESI+) for  $C_{13}H_{20}N_2O_2$  m/z 237.3 (M+H)<sup>+</sup>.

Step 4: N-{(1S,2R)-1-(3,5-Difluorobenzyl)-3-[(3-

25 ethylbenzyl)amino]-2-hydroxypropyl}-2-

(dipropylamino) isonicotinamide hydrochloride

To mixture of 2-(Dipropylamino)isonicotinic hydrochloride (0.2g) in methylene chloride (15 mL) was added triethylamine (0.195 g), HOBT (0.105 g), and HATU (0.293 g). The mixture was stirred at 39 °C for 10 minutes at which time 5 (2R, 3S) - 3 - amino - 4 - (3, 5 - difluorophenyl) - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]]] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]]] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]]] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]]] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]]] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]]] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]]] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]]] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]]] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]]] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]]] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]]] - 1 - [(3 - amino - 4 - (3 - aethylbenzyl)amino]butan-2-o1 (0.285 g) was added. The mixture was stirred at 40  $^{\circ}\text{C}$  for 4 h then poured into methylene chloride (50 mL), washed with water then brine, dried over anhydrous magnesium sulfate and concentrated under vacuum. 10 Column chromatography on silica gel (100 mL) using 5% methanol in methylene chloride as eluent and conversion the hydrochloride salt gave 0.105 g of the title compound: MS (ESI+) for  $C_{31}H_{40}F_2N_4O_2$  m/z 539.3 (M+H)<sup>+</sup>.

15

EXAMPLE SP-218

1-Butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-(1,3-oxazol-2-yl)-1H-indole-6-carboxamide

20

25

Step 1: Methyl 4-iodo-1H-indole-6-carboxylate

To a mixture of methyl 4-amino-1H-indole-6-carboxylate (EXAMPLE SP-216, step 3) (3.2 g) in water (50 mL) was added concentrated hydrochloric acid (5 mL). The mixture was chilled to below 5 °C with the addition of ice. To this was added sodium nitrite (1.16 g) dissolved in water (10 mL). The

mixture was stirred chilled for 1 h followed by addition of sodium iodide (3 g) in water (20 mL). The mixture was stirred for 30 minutes, filtered and the solids collected by filtration were washed with water and dried at 50 °C. The solids turned black and gas evolved rapidly upon drying. Column chromatography on silica gel (200 mL) using 20 % hexanes in  $CH_2Cl_2$  as eluent to give 0.82 g of the title compound:  $^1H$  NMR (CDCl<sub>3</sub>)  $\delta$  3.94, 6.55, 7.43, 8.14, 8.22, 8.62.

10 Step 2: Methyl 1-butyl-4-iodo-1H-indole-6-carboxylate

15

20

To a mixture of methyl 4-iodo-1H-indole-6-carboxylate (1.0 g) in DMF (10 mL) was added potassium hydroxide (0.392 g) and 1-iodobutane (0.8 mL). The mixture was heated to 80 °C for 18 h. The mixture was cooled to room temperature and partitioned between water and ethyl acetate. The layers were separated and the organic layer washed twice with water, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. Column chromatography on silica gel (100 mL) using 20% ethyl acetate in hexanes as eluent to give 0.73 g of the title compound: <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.940, 1.32, 1.81, 3.95, 4.15, 6.45, 7.31, 8.09, 8.18.

Step 3: 1-Butyl-4-(1,3-oxazol-2-yl)-1H-indole-6-carboxylic 25 acid

To a -72 °C solution of oxazole (0.069 g) in dry THF (20 mL) was added dropwise 1.6 M N-butyl lithium (0.68 mL). mixture was stirred at -72 °C for 30 minutes at which time 1.0 M zinc chloride (3.3 mL) was added. The mixture was allowed to warm to 0 °C at which time methyl 1-butyl-4-iodo-1H-indole-6-carboxylate (0.37 q) and tetrakis triphenylphosphine palladium (0) (0.07 g) were added and the mixture heated to 85 The mixture was heated at 85 °C for 20 h then cooled to room temperature and partitioned between water and ethyl acetate. The layers were separated and the organic layer washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. Column chromatography was performed on silica gel (100 mL) using 20% ethyl'acetate in hexanes as eluent. The residue was dissolved in methanol (10 mL) and 1N NaOH (3 mL) and heated at 60  $^{\circ}$ C for 2 h. mixture was acidified to pH 4 with 1N HCl and extracted with ethyl acetate. The ethyl acetate extracts were dried over anhydrous sodium sulfate and concentrated to dryness under reduced pressure to give 0.2 g of the title compound: MS (ESI+) for  $C_{16}H_{16}N_2O_3$  m/z 283.16 (M+H)<sup>+</sup>.

Step 4: 1-Butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-(1,3-oxazol-2-yl)-1H-indole-6-carboxamide

25

10

15

20

To a mixture of 1-butyl-4-(1,3-oxazol-2-yl)-1H-indole-6-carboxylic acid (0.2g) in methylene chloride (20 mL) was added 1,1-carbonyldiimidazole (0.114 g). The mixture was stirred at room temperature for 1 h at which time (2R,3S)-3-amino-4-(3,5-

difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol (0.265 g) dissolved in methylene chloride (10 mL) was added. The mixture was stirred at room temperature for 18 h then poured into methylene chloride (50 mL), washed with water followed by brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. Column chromatography on silica gel (100 mL) using 65% methylene chloride, 30% hexanes, and 5% methanol as eluent to give 0.0985 g of the title compound: MS (ESI+) for  $C_{35}H_{38}F_2N_4O_3$  m/z 601.99 (M+H) $^+$ .

10

20

25

## EXAMPLE SP-219

1-Butyl-4-cyano-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1H-indole-6-carboxamide

15 Step 1: Methyl 1-butyl-4-cyano-1H-indole-6-carboxylate

methyl 1-butyl-4-iodo-1H-indole-6-To mixture of carboxylate (EXAMPLE SP-218, Step 4) (1.47 g) in N-methyl pyrrolidinone (15 mL) was added copper (I) cyanide (1.1 g). The mixture was heated to 150 °C for 6 h, removed from heat and cooled to room temperature. The mixture was partitioned between water and ethyl acetate and the layers were separated. The organic layer was washed three times with water, dried over anhydrous sodium sulfate and concentrated under reduced Column chromatography on silica gel (100 mL) using pressure. 20% ethyl acetate as eluent to give 0.5 g of the title compound: <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  0.955, 1.32, 1.85, 3.98, 4.23, 6.76, 7.43, 8.16, 8.30.

30 Step 2: 1-Butyl-4-cyano-1H-indole-6-carboxylic acid

To a mixture of methyl 1-butyl-4-cyano-1H-indole-6-carboxylate (10.5 g) in methanol (15 mL) was added 1N NaOH (3.0 mL). The mixture was heated at 40 °C for 2 h then cooled to room temperature. The mixture was poured into 1N HCl and extracted into ethyl acetate. The ethyl acetate extract was dried over anhydrous magnesium sulfate and concentrated to give 0.45 g of the title compound:  $^1\text{H}$  NMR (CDCl<sub>3</sub>)  $\delta$  0.973, 1.38, 1.88, 4.27, 6.79, 7.48, 8.24, 8.38.

10

Step 3: 1-Butyl-4-cyano-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1H-indole-6-carboxamide

15

20

25

To a mixture of 1-butyl-4-cyano-1H-indole-6-carboxylic acid (0.29 g) in methylene chloride (10 mL) was added 1,1-carbonyldiimidazole (0.194 g) and triethylamine (0.267 g). The mixture was stirred at room temperature for 45 minutes at which time (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol (0.5 g) dissolved in methylene chloride (10 mL) was added. The mixture was stirred at room temperature for 18 h then poured into methylene chloride (50 mL), washed with water followed by brine, dried over anhydrous magnesium sulfate and concentrated under vacuum. Column chromatography on silica gel (100 mL) using 5% methanol in

methylene chloride as eluent to give 0.47 g of the title compound: MS (ESI+) for  $C_{33}H_{36}F_2N_4O_2$  m/z 559.0  $(M+H)^+$ .

EXAMPLE SP-220

4-Butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-8-(1,3-oxazol-2-yl)-3,4-dihydro-2H-1,4-benzoxazine-6-carboxamide

Step 1: Methyl 4-hydroxy-3-iodo-5-nitrobenzoate

10

15

20

To a solution of methyl 4-hydroxy-3-nitrobenzoate (2.0 g) in acetic acid (15 mL) was added iodine monochloride (1.65 mg) in acetic acid, and the mixture was stirred at 100 °C for 1.5 h. After cooling to room temperature, the mixture was poured into water (200mL), and stirred for 30 min. The mixture was filtered and washed with water and hexanes. The yellow powder was collected by filtration and dried in vacuum oven overnight to give 2.99 g of the title compound:  $^1\text{H}$  NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ .11.68, 8.81, 8.72, 3.96.

Step 2: Methyl 3-amino-4-hydroxy-5-iodobenzoate

To a mixture of methyl 4-hydroxy-3-iodo-5-nitrobenzoate (2.99 g) in ethanol (40 mL) was added tin (II) chloride (10 g) portion wise. After stirring for 1 h at reflux, the mixture was cooled to 0 °C and quenched by saturated potassium carbonate (100 mL). The mixture was filtered through

diatomaceous earth and the filtrate was extracted with ethyl acetate (4 x 100 mL). The combined organic extracts were dried (sodium sulfate), filtered, and concentrated under reduced pressure to give 2.5 g of the title compound:  $^{1}\text{H}$  NMR (300 MHz, DMSO- $d_{6}$ )  $\delta$  7.50, 7.24, 3.75.

Step 3: Methyl 8-iodo-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-6-carboxylate

10

15

To an ice-cold, stirred solution of Methyl 3-amino-4-hydroxy-5-iodobenzoate (2.3 g) and sodium bicarbonate (1.5 g) in 1:1 isobutyl methyl ketone/water (80 mL) was added chloroacetyl chloride (1.1 g), and the reaction mixture was stirred for 1 h. The mixture was warmed to room temperature and heated at reflux for 18 h. After overnight, a beige solid formed. The mixture was filtered, and washed with water and hexanes to give 2.4 g of the title compound:  $^1$ H NMR (300 MHz, DMSO- $d_6$ )  $\delta$ .10.98, 7.89, 7.47, 4.79, 3.82.

20

Step 4: Methyl 4-butyl-8-iodo-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-6-carboxylate

To a solution of Methyl 8-iodo-3-oxo-3,4-dihydro-2H-1,4-25 benzoxazine-6-carboxylate (2.64 g) and potassium carbonate (5 g) in DMSO (20 mL) was added bromobutane (5 g), and the reaction mixture was stirred for 1 h at 80 °C. The mixture was cooled to room temperature, diluted with 1:1 ethyl

acetate/hexanes (100 mL) and water (160 mL), and separated. The organic layer was washed with water, and brine, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 1:10 ethyl acetate/hexanes) afforded 2.24 g of the title compound:  $^{1}$ H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ .8.13, 7.63, 4.74, 3.96, 3.92, 1.64, 1.42, 0.97.

Step 5: Methyl 4-butyl-8-iodo-3,4-dihydro-2H-1,4-benzoxazine10 6-carboxylate

A solution of Methyl 4-butyl-8-iodo-3-oxo-3,4-dihydro-2H1,4-benzoxazine-6-carboxylate (680 mg) and 9-BBN (900 mg) in

15 tetrahydrofuran (30 mL) was heated at reflux for 1.5 h. The mixture was cooled to room temperature, ethanolamine (0.22 mL) was added, and the resulting solution was concentrated under reduced pressure. The residue was washed with hexanes, filtered, and the filtrate was concentrated under reduced pressure. Purification by flash column chromatography (silica, 10% ethyl acetate/hexanes) afforded 600 mg of the title compound: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ.7.75, 7.28, 4.34, 3.86, 3.36, 3.28, 1.58, 1.40, 0.96.

25 Step 6: Methyl 4-butyl-8-(1,3-oxazol-2-yl)-3,4-dihydro-2H-1,4-benzoxazine-6-carboxylate

a -70 °C solution of oxazole (227 mg) in tetrahydrofuran (10 mL) was added n-butyllithium (2.5 M in hexanes, 2 mL). After stirred at -70 °C for 30 min, zinc chloride (1 M in ethyl ether, 13 mL) was added. The mixture was warmed to 0 °C for 1 h. To this mixture was then added ethyl 4-butyl-8-iodo-3,4-dihydro-2H-1,4-benzoxazine-6carboxylate (600 mg, 1.6 mmol) in THF (5 mL) followed by tetrakis triphenylphosphine palladium (0) (115 mg). mixture was heated at reflux for 3 h, diluted with ethyl acetate (300 mL) and washed with water followed by brine. The organic solution was dried (sodium sulfate) and concentrated under reduced pressure. Purification by silica gel plug (1:1 acetate/hexanes) provided 363 mg of the title compound:  $^{1}\text{H}$  NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.96, 7.73, 7.40, 7.28, 4.44, 3.90, 3.43, 3.34, 1.61, 1.41, 0.98.

10

15

Step 7: 4-Butyl-8-(1,3-oxazol-2-yl)-3,4-dihydro-2H-1,4-benzoxazine-6-carboxylic acid

20 To a stirred solution of Methyl 4-butyl-8-(1,3-oxazol-2y1)-3,4-dihydro-2H-1,4-benzoxazine-6-carboxylate (474 mg) in methanol (20 mL) was added potassium hydroxide (15 mL of a 1.0 M solution in water). The mixture was stirred at room temperature overnight then concentrated under reduced pressure. The residue was diluted with water and washed with 25 ethyl acetate. The aqueous layer was acidified to pH 4 with 1 N hydrochloric acid and extracted with chloroform (4 x 100  $\,$ The combined organic extracts were dried (sodium sulfate), filtered, and concentrated under reduced pressure to give 450 mg of the title compound: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) 30

 $\delta_{.}11.60$ , 8.08, 7.74, 7.46, 7.37, 4.46, 3.43, 3.34, 1.62, 1.41, 0.98.

Step 8: 4-Butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-8-(1,3-oxazol-2-yl)-3,4-dihydro-2H-1,4-benzoxazine-6-carboxamide

A solution of 4-Butyl-8-(1,3-oxazol-2-yl)-3,4-dihydro-2H-1,4-benzoxazine-6-carboxylic acid (450 mg, HBTU (853 mg), and 10 diisopropylethylamine (580 mg) stirred in methylene was chloride (15 mL) for 15 min. A solution of (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol mg) in methylene chloride (7 mL) was added and the reaction mixture was stirred overnight. The mixture was filtered with chloride, dried (magnesium sulfate), and 15 methylene concentrated under reduced pressure. Purification by flash column chromatography (silica, 1:9 methanol/chloroform) provided 400 mg of the title compound: ESI MS m/z 619 [M + Hl+.

20

## EXAMPLE SP-221

4-Butyl-8-cyano-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3,4-dihydro-2H-1,4-benzoxazine-6-carboxamide

25

Step 1: Methyl 3-bromo-5-(butylamino)-4-methoxybenzoate

To a stirred solution of Pd(OAc)2 (144 mg), BINAP (1.2 g), and cesium carbonate (8.4 g) in toluene (100 mL) was added butylamine (1.6 mL), and the mixture was heated at 80  $^{\circ}\text{C}$  for 15 A solution methyl 3,5-dibromo-4-methoxybenzoate (4.2 g) in toluene (30 mL) was added dropwise over 20 min. mixture was refluxed overnight. The mixture was cooled to room temperature, filtered through diatomaceous earth, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 1:9 ethyl acetate/hexanes) provided 3.5 g of the title compound:  ${}^{1}\text{H}$  NMR (300 MHz, CDCl<sub>3</sub>) δ.7.52, 7.19, 3.90, 3.88, 3.18, 1.66, 1.46, 0.97.

5

10

30

Step 2: Methyl 3-bromo-5-(butylamino)-4-hydroxybenzoate

15 To a -78 °C solution of the Methyl 3-bromo-5-(butylamino)-4-methoxybenzoate (520 mg) in methylene chloride (10 mL) was added  $BBr_3$  (8 ml of 1.0 M solution in methylene chloride) dropwise and the reaction mixture was stirred for 18 h. The mixture was concentrated under reduced pressure, and the residue was dissolved in methylene chloride and saturated 20 sodium bicarbonate was added. The mixture was cooled to 0  ${}^{\circ}\text{C}$ and methanol was added dropwise. After stirring for 30 min, the mixture was stirred at room temperature for 1 h. The solvent was removed, and the residue dissolved in methylene chloride, washed with water, saturated sodium bicarbonate (15 25 and brine, dried (magnesium sulfate), filtered, concentrated under reduced pressure. Purification by flash column chromatography (silica, 1:20, ethyl acetate/hexanes) provided 440 mg of the title compound: 1H NMR (300 MHz, CDCl3)  $\delta.7.52$ , 7.19, 3.88, 3.18, 1.65, 1.46, 0.97.

Step 3: Methyl 8-bromo-4-butyl-3,4-dihydro-2H-1,4-benzoxazine-6-carboxylate

To an ice-cold, stirred solution of Methyl 3-bromo-5
(butylamino)-4-hydroxybenzoate (440 mg) and sodium bicarbonate
(280 mg) in 1:1 isobutyl methyl ketone/water (10 mL) was added
chloroacetyl chloride (226 mg). The mixture was stirred for 1
h, warmed to room temperature, and heated at reflux for 14 h.
The mixture was cooled to room temperature, diluted with
chloroform, and the layer separated. The organic layer was
washed with water, and brine, dried (magnesium sulfate),
filtered, and concentrated under reduced pressure to give a
white solid: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) & 7.94, 7.62, 4.76, 3.98,
3.93, 1.65, 1.43, 0.97, which was used in the next step
without further purification or characterization.

Step 4: A solution of the amide from step 3 and 9-BBN (780 mg) in tetrahydrofuran (10 mL) was heated at reflux for 1.5 h. The mixture was cooled to room temperature, ethanolamine (0.2 mL) was added, and the resulting solution was concentrated under reduced pressure. The residue was washed with hexanes, filtered, and the filtrate was concentrated under reduced pressure. Purification by flash column chromatography (silica, 10% ethyl acetate/hexanes) afforded (330 mg, over 2 steps) of the title compound:  $^1{\rm H}$  NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ .7.55, 7.27, 4.36, 3.87, 3.37, 3.30, 1.60, 1.41, 0.97.

20

25

Step 5: Methyl 4-butyl-8-cyano-3,4-dihydro-2H-1,4-benzoxazine-6-carboxylate

To a flask containing methyl 8-bromo-4-butyl-3,4-dihydro-2H-1,4-benzoxazine-6-carboxylate (0.33 g) was added NMP (7 mL), followed by copper cyanide (0.18 g). The mixture was then heated to 175 °C and stirred overnight. The resulting mixture was cooled to room temperature and poured into 1 N hydrochloric acid. The acidic aqueous layer was extracted with ethyl acetate, washed with 1 N hydrochloric acid (15 mL), saturated sodium bicarbonate (15 mL), and brine, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 1:9 ethyl acetate/hexanes) provided 184 mg of the title compound: ¹H NMR (300 MHz, CDCl<sub>3</sub>) δ.7.55, 7.43, 4.41, 3.89, 3.39, 3.31, 1.58, 1.40, 0.97.

15

10

Step 6: 4-Butyl-8-cyano-3,4-dihydro-2H-1,4-benzoxazine-6-carboxylic acid

To a stirred solution of Methyl 4-butyl-8-cyano-3,420 dihydro-2H-1,4-benzoxazine-6-carboxylate (184 mg) in methanol
(3 mL) was added potassium hydroxide (7 mL of a 1.0 M solution
in water). The mixture was stirred at room temperature
overnight then concentrated under reduced pressure. The
residue was diluted with water and washed with ethyl acetate.
25 The aqueous layer was acidified to pH 4 with 1 N hydrochloric
acid and extracted with chloroform (4 x 100 mL). The combined
organic extracts were dried (sodium sulfate), filtered, and

concentrated under reduced pressure to give 154 mg of the title compound:  $^{1}H$  NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ .7.62, 7.46, 4.44, 3.41, 3.33, 1.60, 1.41, 0.98.

5 Step 7: 4-Butyl-8-cyano-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3,4-dihydro-2H-1,4benzoxazine-6-carboxamide

4-Butyl-8-cyano-3,4-dihydro-2H-1,4solution of 10 benzoxazine-6-carboxylic acid (129 mg), HBTU (284 mg), and diisopropylethylamine (0.26 mL) was stirred in methylene chloride (6 mL) for 15 min. A solution of (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol mg) in methylene chloride (4 mL) was added and the reaction mixture was stirred overnight. The mixture was diluted with 15 methylene chloride, washed with 1 N hydrochloric acid (15 mL), saturated sodium bicarbonate (15 mL), and brine, dried (magnesium sulfate), filtered, and concentrated under reduced Purification by flash column chromatography (silica, 1:9 methanol/chloroform) provided 20 mg of the title 20 compound: ESI MS m/z 577  $[M + H]^+$ .

EXAMPLE SP-222

 $4-Butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-difluorobenzyl)]}$ 

25 ethylbenzyl)amino]-2-hydroxypropyl}-1-(methylsulfonyl)-1,2,3,4-tetrahydroquinoxaline-6-carboxamide

Step 1: Methyl 4-nitro-3-{[(trifluoromethyl)sulfonyl]oxy}benzoate

To an ice-cold, stirred solution of methyl 3-hydroxy-4-nitrobenzoate (1.5 g) and triethylamine (1.1 mL) in methylene chloride (15 mL) was added trifluoromethane sulfonic anhydride (1.4 mL), and the reaction mixture was stirred for 30 min. The mixture was diluted with methylene chloride, washed with saturated sodium bicarbonate, and brine, dried (magnesium sulfate), filtered, and concentrated under reduced pressure provided 2.4 g of the title compound:  $^{1}$ H NMR (300 MHz, DMSO- $d_{6}$ )  $\delta$ .8.47, 8.27, 8.15, 3.99.

Step 2: Methyl 3-(butylamino)-4-nitrobenzoate

$$\underset{\mathsf{H}}{\overset{\mathsf{O_2N}}{\underset{\mathsf{H}}{\bigvee}}} \overset{\mathsf{I}}{\underset{\mathsf{O}}{\bigvee}}$$

To a stirred solution of Pd<sub>2</sub>(dba)<sub>3</sub> (139 mg), BINAP (284 mg), and cesium carbonate (2.0 g) in toluene (50 mL) was added butylamine (0.45 mL), and the reaction mixture was heated at 80 °C for 15 min. A solution of methyl 4-nitro-3-{[(trifluoromethyl)sulfonyl]oxy}benzoate (1.0 g) in toluene (15 mL) was added dropwise over 1 h. The mixture was cooled to room temperature, filtered through diatomaceous earth, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 3:1 ethyl acetate/hexanes) provided 670 mg of the title compound as a yellow oil: ESI MS m/z 550 [M + H]<sup>+</sup>.

25

10

Step 3: Methyl 4-amino-3-(butylamino)benzoate

A solution of methyl 3-(butylamino)-4-nitrobenzoate (1.1 g) and 10% Pd/C (110 mg) in methanol (20 mL) was shaken under an atmosphere of hydrogen at 50 psi for 2 h. The mixture was filtered through diatomaceous earth, and concentrated under reduced pressure to provide 940 mg of the title compound:  $^{1}$ H NMR (300 MHz, DMSO- $d_6$ )  $\delta$ .7.13, 6.94, 6.52, 3.72, 3.02, 1.60, 1.42, 0.93.

Step 4: Methyl 4-butyl-3-oxo-1,2,3,4-tetrahydroquinoxaline-6-10 carboxylate

To an ice-cold, stirred solution of methyl 4-amino-3-(butylamino)benzoate (950 mg) and sodium bicarbonate (862 mg) in 1:1 isobutyl methyl ketone/water (20 mL) was added chloroacetyl chloride (0.41 mL), and the mixture was stirred The mixture was warmed to room temperature and for 1 h. refluxed for 14 h. The mixture was cooled to room temperature, diluted with chloroform, and separated. The organic layer was washed with water, and brine, dried (magnesium sulfate), filtered, and concentrated under reduced Purification by flash pressure. column chromatography (silica, 1:1 ethyl acetate/hexanes) afforded 850 mg of the title compound:  ${}^{1}H$  NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ .7.89, 7.72, 6.80, 3.97, 3.88, 3.30-3.25, 1.68-1.58, 1.47-1.35, 0.94-0.88.

25

15

20

Step 5: Methyl 4-butyl-1,2,3,4-tetrahydroquinoxaline-6-carboxylate

To an ice-cold, stirred solution of methyl 4-butyl-3-oxo-1,2,3,4-tetrahydroquinoxaline-6-carboxylate (840 mg) in tetrahydrofuran (32 mL) was added borane dimethylsulfide complex (3.2 mL, 2.0 M tetrahydrofuran) and the resulting mixture was refluxed for 24 h. The mixture was cooled to room temperature, quenched with methanol, and the solvent was removed under reduced pressure. Purification by flash column chromatography (silica, 1:1 ethyl acetate/hexanes) provided 364 mg of the title compound: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ.7.27, 7.22, 6.41, 3.84, 3.47-3.45, 3.32-3.23, 1.60-1.58, 1.42-1.37, 0.99-0.94.

Step 6: Methyl 4-butyl-1-(methylsulfonyl)-1,2,3,4-tetrahydroquinoxaline-6-carboxylate

15

20

25

10

To an ice-cold, stirred solution of methyl 4-butyl-1,2,3,4-tetrahydroquinoxaline-6-carboxylate (180 mg) and triethylamine (62  $\mu$ L) in methylene chloride (2 mL) was added methanesulfonyl chloride (101  $\mu$ L) and the mixture was stirred for 1 h. The mixture was warmed to room temperature, diluted with methylene chloride, washed with washed with 1 N hydrochloric acid, and brine. The organic layer was then dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 1:3 ethyl acetate/hexanes) provided 150 mg of the title compound: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ .7.57, 7.41, 7.32, 3.90, 3.84, 3.45, 3.38, 1.61, 1.41, 0.98.

Step 7: 4-Butyl-1-(methylsulfonyl)-1,2,3,4-30 tetrahydroquinoxaline-6-carboxylic acid

methyl 4-buty1-1solution οf stirred То a (methylsulfonyl)-1,2,3,4-tetrahydroquinoxaline-6-carboxylate in methanol (1.3 mL) was added 1 M potassium mixture was stirred at The hydroxide (13 mL). 5 temperature for 48 h and concentrated under reduced pressure. The residue was diluted with water and washed with ethyl $\mathfrak l_i$ The aqueous layer was acidified to pH 4 with  $1\ N$ hydrochloric acid and extracted with chloroform (4 x 100 mL). The combined organic extracts were dried (sodium sulfate), 10 filtered, and concentrated under reduced pressure to give 99  $^{1}$ H NMR (300 MHz,  $^{\circ}_{3}$  CDC1<sub>3</sub>)  $\delta$ .7.43, mg of the title compound: 7.39, 7.24, 3.77, 3.39, 3.32, 1.56, 1.33, 0.90.

15 Step 8: 4-Butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1-(methylsulfonyl)1,2,3,4-tetrahydroquinoxaline-6-carboxamide

4-butyl-1-(methylsulfonyl)-1,2,3,4solution of tetrahydroquinoxaline-6-carboxylic acid (99 mg), HATU (181 20 mg), HOBt (64 mg), and diisopropylethylamine (100 何 $oldsymbol{t}$ L) was stirred in methylene chloride (1.0 mL) for 15 min. A solution (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3of ethylbenzyl)amino]butan-2-ol (129 mg) and diisopropylethylamine (100 ML) in methylene chloride (1.0 mL) 25 was added and the mixture was stirred overnight. The mixture

was diluted with methylene chloride, washed with 1 N hydrochloric acid (10 mL), saturated sodium bicarbonate (10 mL), and brine. The organic layer was then dried (magnesium sulfate), filtered, and concentrated under reduced pressure.

5 Purification by flash column chromatography (silica, 1:9 methanol/chloroform) provided a clear solid. The solid was dissolved in methanol (1 mL), and treated with hydrochloric acid (0.5 mL, 1.0 M diethyl ether). The resulting precipitate was collected by filtration to provide 90 mg of the title compound: ESI MS m/z 629 [M + H]<sup>+</sup>.

EXAMPLE SP-223

4-Butyl-N- $\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1,2,3,4-$ 

15 tetrahydroquinoxaline-6-carboxamide hydrochloride

Step 1: 1-Tert-butyl 6-methyl 4-butyl-3-oxo-3,4-dihydroquinoxaline-1,6(2H)-dicarboxylate

20 To an ice-cold, stirred solution of methyl 4-butyl-3-oxo-1,2,3,4-tetrahydroquinoxaline-6-carboxylate (1.1 g), triethylamine (0.9 mL) in methylene chloride (10 mL) was added DMAP (51.3 mg) and di-tert-butyl dicarbonate (1.4 g), and the resulting mixture was stirred for 4 d. The mixture was diluted with methylene chloride, washed with water, and brine. 25 The organic layer was then dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 1:1 ethyl

acetate/hexanes) provided 440 mg of the title compound: ESI MS m/z 363 [M + H]<sup>+</sup>.

Step 2: 1-Tert-butyl 6-methyl 4-butyl-3,4-dihydroquinoxaline-; 1,6(2H)-dicarboxylate

A solution of 1-tert-butyl 6-methyl 4-butyl-3-oxo-3,4dihydroquinoxaline-1,6(2H)-dicarboxylate (440 mg) and 9-BBN dimer (600 mg) in tetrahydrofuran (10 mL) was heated at 65  $^{\circ}\text{C}$ 10 for 10 h. The mixture was cooled to room temperature, ethanolamine (0.15 mL) was added and the resulting solution was concentrated under reduced pressure. The residue was washed with hexanes, filtered, and the filtrate concentrated under reduced pressure. Purification by flash column chromatography (silica, 1:9 ethyl acetate/hexanes) 15 afforded 158 mg of the title compound: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta.7.50$ , 7.34, 7.28, 3.88, 3.77, 3.38-3.30, 1.65-1.51, 1.42-1.34, 0.99-0.94.

20 Step 3: 1-(Tert-butoxycarbonyl)-4-butyl-1,2,3,4-tetrahydroquinoxaline-6-carboxylic acid

To a stirred solution of 1-tert-butyl 6-methyl 4-butyl-3,4-dihydroquinoxaline-1,6(2H)-dicarboxylate (158 mg) in

methanol (1.4 mL) was added 1 M potassium hydroxide (1.4 mL). The mixture was stirred at 40 °C for 12 h and then concentrated under reduced pressure. The residue was diluted with water and washed with ethyl acetate. The aqueous layer was acidified to pH 4 with 1 N hydrochloric acid and extracted with chloroform (4 x 100 mL). The combined organic extracts were dried (sodium sulfate), filtered, and concentrated under reduced pressure to give 120 mg of the title compound:  $^1{\rm H}$  NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ .7.55, 7.40, 7.37, 3.79, 3.38, 3.34, 1.60, 1.53, 1.39, 0.97.

Step 4: 4-Butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1,2,3,4-tetrahydroquinoxaline-6-carboxamide hydrochloride

A solution of 1-(tert-butoxycarbony1)-4-buty1-1,2,3,4-

15

20

25

30

5

10

tetrahydroquinoxaline-6-carboxylic acid (120 mg), HBTU (204 and diisopropylethylamine (100 **M**L) was stirred methylene chloride (2.0 mL) for 15 min. A solution (2R, 3S)-3-amino-4-(3, 5-difluorophenyl)-1-[(3-miethylbenzyl)amino]butan-2-ol (146 mg) and diisopropylethylamine (100 AL) in methylene chloride (2.0 mL) was added and the mixture was stirred overnight. The mixture diluted with methylene chloride, washed with hydrochloric acid (10 mL), saturated sodium bicarbonate (10 mL), and brine. The organic layer was then dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, methanol/chloroform) provided a clear solid. The solid was dissolved in methanol (1 mL), and treated with hydrochloric

acid (0.5 mL, 1.0 M diethyl ether, 0.5 mmol). The resulting precipitate was collected by filtration to provide 45 mg of the title compound: ESI MS m/z 551 [M + H]<sup>+</sup>.

## 5 EXAMPLE SP-224

 $N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1\}-6-[(methylsulfonyl)methyl]nicotinamide$ 

Step 1: Methyl 6-[(acetyloxy)methyl]nicotinate

10

To a solution of methyl 6-methylnicotinate (6.05 g) in methylene chloride (100 mL) was added m-chloroperbenzoic acid (77%, 13.5 g). The reaction mixture was stirred at room temperature for 2 h and then diluted with chloroform (100 mL). 15 The mixture was washed successively with aqueous sodium sulfite, saturated sodium bicarbonate, and brine. The organic later was then dried (sodium sulfate), filtered, and concentrated under reduced pressure to provide 6.21 g of methyl 6-methylnicotinate 1-oxide. A solution of methyl 6-20 methylnicotinate 1-oxide (4.35 g) in acetic anhydride (50 mL) was heated at 120 °C for 2 h and then concentrated under reduced pressure. Purification by flash column chromatography (silica gel, 1:2 to 3:5 ethyl acetate/hexanes) provided 3.3 g of the title compound:  $^{1}H$  NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  9.18, 8.31, 25 7.44, 5.29, 3.96, 2.19.

Step 3: 6-[(Methylsulfonyl)methyl]nicotinic acid

5

10

15

To a solution of methyl 6-[(acetyloxy)methyl]nicotinate (3.0 g) in dry methanol (100 mL) was added potassium carbonate (4.56 g). The mixture was stirred at room temperature for 2 h and then diluted with methylene chloride (200 mL) and water (200 mL). The organic layer was washed with brine, dried (sodium sulfate), filtered, and concentrated under reduced pressure to provide 1.70 g of the alcohol. This material was used without further purification. To an ice-cold solution of 6-(hydroxymethyl)nicotinate (1.6 g) methyl in methylene chloride (40 mL) was added diisopropylethylamine (1.5 g) followed by methanesulfonyl chloride (1.21 g). The mixture was stirred at room temperature for 1 h and then diluted with methylene chloride (100 mL). The mixture was washed successively with 0.5 N potassium hydrogen sulfate, water, and The organic layer was then dried (sodium sulfate), brine. filtered, and concentrated under reduced pressure to provide mesylate 2.34 g. This mesylate was used without further purification.

То а solution of methyl 6-20 {[(methylsulfonyl)oxy]methyl}nicotinate (2.34)g) in N.Ndimethylformamide (10 mL) was added sodium thiomethoxide (850 mg). The mixture was stirred at 50 °C for 15 h. The mixture was diluted with ethyl acetate (100 mL) and washed successively with water, saturated sodium bicarbonate, brine. The organic layer was then dried (sodium sulfate), 25 filtered, and concentrated under reduced pressure to provide 1.61 g of the methyl thioether. This material was used without further purification. To an ice-cold solution of methyl 6-[(methylthio)methyl]nicotinate (1.61 g) in methanol (35 mL) was added a solution of oxone (7.52 g) in water (35 30 mL). The resulting slurry was stirred at room temperature for The resulting mixture was diluted with water (50 mL), and extracted with chloroform  $(3 \times 100 \text{ mL})$ . The combined organic extracts were washed with brine, dried (sodium

sulfate), filtered, and concentrated under reduced pressure to provide 1.77 g of the methyl sulfone, which was used without further purification.

stirred solution οf methyl 6-То a [(methylsulfonyl)methyl]nicotinate (800 mg) in 1:1:1 tetrahydrofuran/methanol/water (30 mL) was added lithium hydroxide (440 mg). The mixture was stirred at room temperature for 1 h, and concentrated under reduced pressure. The residue was partitioned between water (10 mL) The aqueous layer was acidified to pH 4 chloroform (10 mL). and extracted with with N hydrochloric acid chloroform/2-propanol (3 x 30 mL). The combined organic layers were dried (sodium sulfate), filtered, and concentrated under reduced pressure to provide 700 mg of the title  $^{1}$ H NMR (300 MHz, CD<sub>3</sub>OD)  $\delta$ , 9.07, 8.33, 7.65, 4.77, compound: 3.06.

Step 4:  $N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1\}-6-$ 

20 [(methylsulfonyl)methyl]nicotinamide

5

10

15

25

30

solution 6-То a stirred οf (181 [(methylsulfonyl)methyl]nicotinic acid mg), diisopropylethylamine (116 mg), and HBTU (341 mg) in methylene chloride (5 mL) was added a mixture of (2R,3S)-3-amino-4-(3,5difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol (326 and N, N-diisopropylethylamine (233 mg) in methylene chloride (5 mL). The mixture was stirred at room temperature for 15 h The residue was and concentrated under reduced pressure. diluted with ethyl acetate (50 mL), washed with saturated sodium bicarbonate, and brine, dried (sodium sulfate),

filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica gel, 5:95 to 10:90 methanol/methylene chloride) provided 165 mg of the title compound: ESI MS m/z 532 [M + H]<sup>+</sup>.

5

EXAMPLE SP-225

3-Butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1-methyl-1H-indole-5-carboxamide

10

15

20

25


Step 1: Ethyl 4-hydrazinobenzoate hydrochloride

To a 0 °C mixture of 4-ethylaminobenzoate (10.0 g) in water (56 mL) and concentrated hydrochloric acid (20 mL) was added portion wise a solution of sodium nitrite (4.25 g) in water (20 mL). The mixture was stirred at 0 °C for 15 minutes at which time the mixture was poured into a solution of tin (II) chloride (50 gm) in water (34 mL). The resulting mixture was removed from the ice bath and allowed to slowly come to room temperature over 1 h at which time the resulting solids were collected by filtration and washed with chilled concentrated hydrochloric acid (30 mL) followed by ether. The solids were dried under vacuum to give 13 g of the title compound:  $^{1}$ H NMR (DMSO- $d_{6}$ )  $\delta$  1.29, 4.25, 7.03, 7.85, 9.0, 9.06, 10.6.

Step 2: Ethyl 3-butyl-1H-indole-5-carboxylate

To a mixture of ethyl 4-hydrazinobenzoate hydrochloride (10 gm) in ethanol: water (5:1 100 mL) was added hexanal (4.62 gm). The mixture was refluxed at 100 °C for 3 h. The solvents were removed and toluene (100 mL) and p-toluene sulfonic acid (0.1 g) were added. The mixture was refluxed at 120 °C for 18 h, cooled to room temperature and concentrated under reduced pressure. Column chromatography on silica gel (100 mL) using 90:9:1 (hexanes: methylene chloride: ethyl acetate) as eluent to give 0.8 g of the title compound:  ${}^{1}H$  NMR (CDCl<sub>3</sub>)  $\delta$  0.957, 1.44, 1.72, 2.78, 4.40, 7.02, 7.34, 7.90, 8.13, 8.38.

Step 3: Ethyl 3-butyl-1-methyl-1H-indole-5-carboxylate



To a mixture of ethyl 3-butyl-1H-indole-5-carboxylate (0.6 g) in methylsulfoxide (10 mL) was added potassium tbutoxide (0.29 g) and iodomethane (2.0 mL). The mixture was stirred at 50 °C for 18 H, at which time the mixture was pored into water (50 mL). The solution was extracted with ethyl acetate and the organic extracts washed three times with 20 brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. Column chromatography on silica gel (100 mL) using 5% ethyl acetate in hexanes as eluent to give 0.294 g of the title compound:  $^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  0.953, 1.44, 1.69, 2.77, 3.76, 4.40, 6.87, 7.26, 7.91, 8.35.

25

10

15

Step 4: 3-Butyl-1-methyl-1H-indole-5-carboxylic acid

To a mixture of ethyl 3-butyl-1-methyl-1H-indole-5-carboxylate (0.294 g) in methanol (20 mL) was added 1N NaOH (10 mL). The mixture was stirred at 50 °C for 18 h, cooled to room temperature and poured into 1N HCl (50 mL). The mixture was extracted with ethyl acetate and the ethyl acetate extract was dried over anhydrous sodium sulfate and concentrated to dryness under reduced pressure to give 0.234 g (89%) of the title compound:  $^1$ H NMR (CD<sub>3</sub>OD)  $\delta$  0.965, 1.42, 1.69, 2.76, 3.77, 7.02, 7.35, 7.84, 8.29.

10

Step 5: 3-Butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1-methyl-1H-indole-5-carboxamide

15

20

25

To a mixture of 3-Butyl-1-methyl-1H-indole-5-carboxylic acid (0.15 g) in methylene chloride (5 mL) and tetrahydrofuran (10 mL) was added 1,1-carbonyldiimidazole (0.105 g). The mixture was stirred at 40 °C at which time (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol (0.2 g) in methylene chloride (5 mL) was added. The mixture was stirred at 40 °C for 18 h then poured into methylene chloride (50 mL). The mixture was washed with water then brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. Column chromatography on silica gel (100 mL) using 85:10:5 (methylene chloride: hexanes: methanol) as eluent to give 0.102 g of the title compound: MS (ESI+) for  $C_{33}H_{39}F_2N_3O_2$  m/z 547.9 (M+H)<sup>+</sup>.

EXAMPLE SP-226

3-Butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1H-indole-5-carboxamide

Step 1: 3-Butyl-1H-indole-5-carboxylic acid

5

To a mixture of Ethyl 3-butyl-1H-indole-5-carboxylate, EXAMPLE SP-225, step2, (0.4 g) in methanol (15 mL) was added 1N NaOH (5 mL). The mixture was stirred at 50 °C for 18 h, cooled to room temperature and poured into 1N HCl (50 mL). The mixture was extracted with ethyl acetate. The ethyl acetate extract was dried over anhydrous sodium sulfate and concentrated to dryness under reduced pressure to give 0.145 g of the title compound: MS (ESI+) for  $C_{13}H_{15}N_1O_2$  m/z 216.12  $(M+H)^+$ .

15

10

Step 2: 3-Butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1H-indole-5-carboxamide

20

25

To a mixture of 3-Butyl-1H-indole-5-carboxylic acid (0.145g) in methylene chloride (15 mL) was added triethylamine (0.068 g), and HATU (0.255 g). The mixture was stirred at room temperature for 15 minutes at which time (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol (0.224 g) was added. The mixture was stirred at room temperature for 72 h then poured into methylene chloride (50 mL), washed with water then saturated sodium bicarbonate, dried over anhydrous magnesium sulfate and concentrated under

vacuum. Column chromatography on silica gel (100 mL) using 5% methanol in methylene chloride with 0.15% HOAc as eluent to give 0.247 g of the title compound: MS (ESI+) for  $C_{32}H_{37}F_2N_3O_2$ m/z 534.3 (M+H)<sup>+</sup>.

5

EXAMPLE SP-227

 $4-Butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-difluorobenzyl)$ ethylbenzyl)amino]-2-hydroxypropyl}-3,4-dihydro-2H-1,4benzoxazine-6-carboxamide

10

20

25

30

Methyl 4-butyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-6-carboxylate

To an ice-cold, stirred solution of methyl 3-amino-4-15 hydroxybenzoate (3.0 g) and sodium bicarbonate (3.3 g) in 1:1isobutyl methyl ketone/water (40 mL) was added chloroacetyl chloride (1.7 mL), and the mixture was stirred for 1 h. mixture was warmed to room temperature and refluxed for 14 h, cooled to room temperature, diluted with chloroform, separated. The organic layer was washed with water, brine, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 1:9 methanol/chloroform) afforded a phenoxazine 3.2 g as a white solid, which was used without further purification or characterization. To a solution of phenoxazine from step 1 (700 mg) and potassium carbonate (934 mg) in methanol (8 mL) was added bromobutane (1.8 mL), and the mixture was refluxed for 6 d. The mixture was cooled to room temperature, concentrated under reduced pressure, and the residue was partitioned between ethyl acetate and water. organic layer washed with brine, dried (magnesium sulfate),

filtered, and concentrated under reduced pressure to afforded 800 mg of the title compound:  $^1H$  NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ .7.72-7.68, 7.02-6.99, 4.66, 4.00-3.92, 1.69-1.64, 1.46-1.38, 1.01-0.95.

5

Step 2: Methyl 4-butyl-3,4-dihydro-2H-1,4-benzoxazine-6-carboxylate

10 A solution of methyl 4-butyl-3-oxo-3,4-dihydro-2H-1,4benzoxazine-6-carboxylate (800 mg) and 9-BBN (1.6 g) tetrahydrofuran (13 mL) was refluxed for 1.5 h. The mixture was cooled to room temperature, ethanolamine (0.4 mL) was added, and the resulting solution was concentrated under 15 reduced pressure. The residue was washed with hexanes, filtered, and the filtrate was concentrated under reduced Purification by flash column chromatography pressure. (silica, 25% ethyl acetate/hexanes) afforded 607 mg of the title compound:  ${}^{1}H$  NMR (300 MHz, DMSO- $d_{6}$ )  $\delta$  7.21, 7.16, 6.75, 4.24-4.21, 3.78, 3.34-3.24, 1.55-1.47, 1.38-1.30, 0.95-0.90. 20

Step 3: 4-Butyl-3,4-dihydro-2H-1,4-benzoxazine-6-carboxylic acid

25

To a stirred solution of methyl 4-butyl-3,4-dihydro-2H-1,4-benzoxazine-6-carboxylate (412 mg) in methanol (5 mL) was added 1 M potassium hydroxide (17 mL). The mixture was stirred at room temperature for 5 h and concentrated under reduced pressure. The residue was diluted with water and

washed with ethyl acetate. The aqueous layer was acidified to pH 4 with 1 N hydrochloric acid and extracted with chloroform (4 x 50 mL). The combined organic extracts were dried (sodium sulfate), filtered, and concentrated under reduced pressure to provide 384 mg of the title compound: ESI MS m/z 236 [M + H]<sup>+</sup>.

Step 4: 4-Butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3,4-dihydro-2H-1,4-benzoxazine-6-carboxamide

10

15

20

A solution of 4-Butyl-3,4-dihydro-2H-1,4-benzoxazine-6carboxylic acid (43 mg), HATU (104 mg), HOBt (37 mg), and diisopropylethylamine (47 DL) was stirred in methylene chloride (1.0 mL) for 15 min. A solution of (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol dihydrochloride (62 mg) and diisopropylethylamine (47  $\square$ L) in methylene chloride (1.0 mL) was added and the reaction mixture was stirred overnight. The mixture was diluted with methylene chloride, washed with 1 N hydrochloric acid (15 mL), saturațed sodium bicarbonate (15 mL), and brine, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, methanol/chloroform) provided 15 mg of the title compound: APCI MS m/z 552 [M + H]<sup>+</sup>.

25

EXAMPLE SP-228

 $3-acetyl-1-butyl-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-1\\ H-indole-6-carboxamide$ 

30 Step 1. Methyl 1-butyl-1H-indole-6-carboxylate

Methyl 1H-indole-6-carboxylate (4.17g) was dissolved in DMSO (30 mL), and potassium tert-butoxide (2.93 g) was added. The mixture was stirred for ten min at room temperature. Iodobutane (3.0 mL) was added. The mixture was allowed to stir for three additional hours. The mixture was partitioned between ethyl acetate and water and brine, dried over sodium sulfate, filtered, and concentrated to give methyl 1-butyl-1H-indole-6-carboxylate (4.53 g). MS (ESI+) for  $C_{14}H_{17}NO_2+H_1$  m/z 232.12  $(M+H)^+$ .

Step 2. Methyl 3-acetyl-1-butyl-1H-indole-6-carboxylate

10

Methyl 1-butyl-1H-indole-6-carboxylate (4.53) q) 15 dissolved in dichloromethane (25ml). The mixture was cooled to 0 °C. Diethyl aluminum chloride was added dropwise (29.5 mL) and the mixture was allowed to stir at 0 °C for 30 min. A solution of dichloromethane (25 mL) and acetyl chloride (2.1 mL) was added dropwise, and the mixture was stirred for 2 h at 20 0 °C. The mixture was then partitioned between dichloromethane, water, and brine, dried over sodium sulfate, filtered, and concentrated. The concentrate was chromatographed on silica gel using ethyl acetate/heptane methyl 3-acetyl-1-butyl-1H-indole-6-(40/60)to give 25 carboxylate (3.38 g). MS (ESI+) for  $C_{16}H_{19}N_1O_3+H_1$  m/z 274.14  $(M+H)^+$ .

Step 3. 3-acetyl-1-butyl-1H-indole-6-carboxylic acid

Methyl 3-acetyl-1-butyl-1H-indole-6-carboxylate (2.00 g) was dissolved in methanol (100mL). Sodium hydroxide (1N) was added until the mixture became slightly cloudy. Methanol was again added (20 mL) until the solution was clear. 5 hydroxide was again added until the mixture was slightly The mixture was allowed to stir at room temperature cloudy. overnight. The solution was concentrated to half its original volume and hydrochloric acid (2N) was added until the aqueous layer indicated a  $pH_{\pm}$  of about one. The mixture was extracted 10 with dichloromethane and the organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated. The resulting material was chromatographed on silica gel using MeOH/heptane/dichloromethane (4/20/76) to give 3-acety1-1butyl-1H-indole-6-carboxylic acid (1.60 g). 15 MS (ESI+) for  $C_{15}H_{17}N_1O_3+H_1 m/z 260.13 (M+H)^+$ .

Step 4. 3-acetyl-1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1H-indole-6-

20 carboxamide

3-Acetyl-1-butyl-1H-indole-6-carboxylic acid (0.322 g) was dissolved in dichloromethane (15 mL). 1,1'-Carbonyldiimidazole was added (0.171 g). The mixture was stirred for 2 h and then a mixture of (2R,3S)-3-amino-4-(3,5-amino-4)25 difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol in dichloromethane (15 mL) was added. After stirring

the mixture partitioned overnight, was between dichloromethane, water, and brine. The organic layer was dried over sodium sulfate, filtered, and concentrated. The chromatographed on silica gel using MeOH/ residue was dichloromethane (4/96) to give 3-acetyl-1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2hydroxypropyl}-1H-indole-6-carboxamide (0.335 g). for  $C_{34}H_{39}F_2N_3O_3+H_1$  m/z 576.30 (M+H)<sup>+</sup>.

#### 10 EXAMPLE SP-229

25

 $1-butyl-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-N-4)]$ ethylbenzyl)amino]-2-hydroxypropyl}-3-(trifluoroacetyl)-1Hindole-6-carboxamide

15 Step 1. Butyl 1-butyl-1H-indole-6-carboxylate

1-Butyl-1H-indole-6-carboxylic acid (0.450 g) was dissolved in dimethyl sulfoxide (10mL). Potassium tertbutoxide (0.317 g) was added and the mixture was stirred for 20 10 min at room temperature. Iodobutane (0.33 mL) was added and the mixture was allowed to stir at room temperature for 6 h. Water was then added and the mixture was partioned between ethyl acetate, water, and brine, and dried over magnesium sulfate, filtered, and concentrated. Silica gel chromatography using heptane/dichloromethane (30/70) gave butyl 1-butyl-1H-indole-6-carboxylate (0.429 g). MS (ESI+) for  $C_{17}H_{23}NO_2 + H_1 m/z 274.20 (M+H)^+$ .

Step 2. Butyl 1-butyl-3-(trifluoroacetyl)-1H-indole-6-30 carboxylate

Boron trifluoride-methyl sulfide complex (0.238 g) was dissolved in dichloromethane (10 mL). The solution was cooled to -78 °C and a solution of trifluoroacetic anhydride (0.384 g) in dichloromethane (2 mL) was added. The mixture was stirred at -78 °C for 10 min, at which time a solution of butyl 1butyl-1H-indole-6-carboxylate (0.250 g) in dichloromethane (3 mL) was added. The mixture was allowed to stir at -78 °C for 15 min and then allowed to warm to room temperature overnight. The mixture was then poured into aqueous sodium bicarbonate 10 and extracted with dichloromethane. The organic layer was dried over sodium sulfate, filtered, and concentrated and the resulting material was chromatographed on silica gel using ethyl acetate/heptane (20/80) to give butyl 1-buty1-3-(trifluoroacetyl)-1H-indole-6-carboxylate (0.302 15 g). MS (ESI+) for  $C_{19}H_{22}F_3N_1O_3+H_1 m/z 370.16 (M+H)^+$ .

Step 3. 1-butyl-3-(trifluoroacetyl)-1H-indole-6-carboxylic acid

20

25

Butyl 1-butyl-3-(trifluoroacetyl)-1H-indole-6-carboxylate (0.277~g), LiOH•H<sub>2</sub>O (0.040~g), THF (1.5~mL), water (0.5~mL), and methanol (0.5~mL) were stirred overnight at room temperature. The solvents were then removed under reduced pressure and HCl (2N,~0.5mL) was added to the residue. The residue was extracted with ethyl acetate, dried over magnesium sulfate, filtered, and concentrated. Chromatography on silica

gel using methanol/dichloromethane (6/94) gave 1-butyl-3-(trifluoroacetyl)-1H-indole-6-carboxylic acid (0.166 g). MS (ESI+) for  $C_{15}H_{14}F_3N_1O_3+H_1$  m/z 314.10 (M+H)<sup>+</sup>.

5 Step 4. 1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-(trifluoroacetyl)-1H-indole-6-carboxamide

1-Butyl-3-(trifluoroacetyl)-1H-indole-6-carboxylic acid 10 (0.141 g) was dissolved in dichloromethane (10 mL). 1,1'-Carbonyldiimidazole (0.080 g) was added and the mixture was stirred at room temperature for 2 h. A solution of (2R,3S)-3amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2ol (0.166 g) in dichloromethane was added and the mixture was allowed to stir overnight at room temperature. The mixture 15 was then partitioned between dichloromethane and water, dried filtered, and concentrated. over sodium sulfate, methanol/ethyl Chromatography silica gel using on acetate/heptane /dichloromethane (3/10/10/77 to 6/10/10/74)  $1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-difluorobenzyl)]}$ 20 ethylbenzyl)amino]-2-hydroxypropyl}-3-(trifluoroacetyl)-1Hindole-6-carboxamide (0.155 g). MS (ESI+) for  $C_{34}H_{36}F_{5}N_{3}O_{3}+H_{1}$ m/z 630.28 (M+H)<sup>+</sup>.

25 EXAMPLE SP-230

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-2-(dipropylamino)isonicotinamide

2-(Dipropylamino)isonicotinic acid (0.206 g) was dissolved in dichloromethane (10 mL). 1,1'-Carbonyldiimidazole was added (0.142 g) and the mixture was stirred for 2 h at room temperature, at which time (2R,3S)-3 $amino-4-(3,5-difluoropheny1)-1-{[1-(3$ ethynylphenyl)cyclopropyl]amino}butan-2-ol (0.284 g) in dichloromethane was added. The mixture was allowed to stir overnight and then was partitioned between dichloromethane, water, and brine, dried over sodium sulfate, filtered, and 10 concentrated under reduced pressure. The concentrate was chromatographed on silica gel using methanol/dichloromethane (4/96)give  $N-((1S, 2R)-1-(3, 5-difluorobenzy1)-3-{[1-(3$ ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-2-

15 (dipropylamino)isonicotinamide (0.268g). MS (ESI+) for  $C_{33}H_{38}F_2N_4O_2+H_1$  m/z 561.30 (M+H)<sup>+</sup>.

#### EXAMPLE SP-231

 $1-butyl-N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-mu)]}$ 

20 ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-1H-indole-6-carboxamide

In the same manner as for N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2-

25 hydroxypropyl)-2-(dipropylamino)isonicotinamide, 1-butyl-1H-indole-6-carboxylic acid (0.119 g) gave 1-butyl-N-((1S,2R)-1-

 $(3,5-difluorobenzyl)-3-\{[1-(3-ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-1H-indole-6-carboxamide (0.076g). MS (ESI+) for <math>C_{34}H_{35}F_2N_3O_2+H_1$  m/z 556.28  $(M+H)^+$ .

5

## EXAMPLE SP-231

- 3-(allylthio)-N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)benzamide
- 3-Thiobenzoic acid (Aldrich, 4.3g, 28mmol) was dissolved in THF (100mL), cooled to 0°C, and treated with KO-tBu (6.3g, 56mmol), followed by allyl bromide (2.4mL, 28mmol). The solvent was removed from the reaction mixture and the residue was partitioned between 3M HCl and EtOAc. The organic layer was separated, dried (MgSO<sub>4</sub>) and concentrated to give the title compound (5.3g). (LRMS (M-H) m/z 193.2)
- Step 2. 3-(allylthio)-N-((1S,2R)-1-(3,5-difluorobenzyl)
  3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2hydroxypropyl)benzamide
  - 3-(Allylthio)benzoic acid (717mg, 3.69mmol), (2R,3R)-3-amino-4-(3,5-difluorophenyl)-1- $\{[1-(3-$
- 25 ethylphenyl)cyclopropyl]amino}butan-2-ol (247mg, 0.685mmol), and HATU(Aldrich, 2.1g, 5.54mmol) were dissolved dichloromethane (35mL), at ambient temperature, and treated with diisopropylethylamine (1.6mL, 9.225mmol). Upon completion, the reaction mixture was concentrated and 30 chromatographed (SiO2, 2:1 to 1:1 Hexanes: EtOAc) to give the desired compound (650mg). (LRMS (M+H) m/z = 537.8)

EXAMPLE SP-232

 $3-(allylsulfinyl)-N-((1S,2R)-1-(3,5-difluorobenzyl)-3-\{[1-(3-ethylphenyl)\,cyclopropyl]\,amino\}-2-hydroxypropyl)\,benzamide \\$ 

3-(allylthio)-N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)benzamide (325mg, 0.606mmol) was dissolved in  $CH_2Cl_2$  (10mL) and AcOH (1mL) and treated with mCPBA (104mg, 0.606mmol). The reaction mixture was stirred for 2.5h, at which time more mCPBA (20mg, 0.11mmol) was added and stirring continued for 30 min. more. The organic layer was diluted with  $Et_2O$  and washed with 15% sodium thiosulfite solution. The organic was washed with brine, then dried (MgSO<sub>4</sub>) and concentrated to give an oil, which was chromatographed with 25% to 50%EtOAc in hexanes to give the title compound. (LRMS (M+H) m/z 553.8)

15

10

5

EXAMPLE SP-233

3-(allylsulfonyl)-N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)benzamide

5 3-(allylthio)-N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)benzamide (245mg, 0.456mmol) was dissolved in MeOH:H<sub>2</sub>O (9:1, 6mL) and treated with oxone (561mg, 0.913mmol). When the reaction was complete, the mixture was concentrated to 0.5x volume and 10 poured onto EtOAc. This was washed with a 15% sodium thiosulfite solution, dried (MgSO<sub>4</sub>) and concentrated to give the title compound. (LRMS (M+H) m/z 569.8)

EXAMPLE SP-234

N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(dipropylamino)-6-methylisonicotinamide

Step 1. 2-chloro-6-methylisonicotinonitrile

20

Using the method of Org. Prep. Proceed. Intern. (1982) 396, 2-chloro-6-methylisonicotinic acid (0.405 g, 2.36 mmol) was converted to 2-chloro-6-methylisonicotinonitrile (0.241 g).

Step 2. 2-(dipropylamino)-6-methylisonicotinonitrile

$$CI \longrightarrow C \equiv N$$

25

To 2-chloro-6-methylisonicotinonitrile (0.230 g, 1.51 mmol) was added di-n-propylamine (5 mL). The mixture was heated at 80 °C in a sealed, thick-walled glass vessel for 12 h and then at room temperature for 17 h. Excess di-n-

propylamine was removed under reduced pressure and the residue was partitioned between dichloromethane and aq. bicarbonate. After drying over sodium sulfate and concentration, the residue was chromatographed on silica gel using ethyl acetate-hexane (10/90) to give 0.14 g of 2-chloro-6-methylisonicotinonitrile and 0.059 g of 2-(dipropylamino)-6methylisonicotinonitrile. Using the above conditions, chloro-6-methylisonicotinonitrile (0.14 g) was converted to an additional 0.043 g of 2-(dipropylamino)-6methylisonicotinonitrile.

Step 3. 2-(dipropylamino)-6-methylisonicotinic acid hydrochloride

To 2-(dipropylamino)-6-methylisonicotinonitrile (0.094 g, 0.433 mmol) was added 4N HCl (2 mL) and THF (1 mL). 15 mixture was stirred at 100  $^{\circ}\text{C}$  (THF allowed to distill off) for 12 h, then the aqueous layer was removed under reduced pressure and using a toluene azeotrope to give (dipropylamino)-6-methylisonicotinic acid hydrochloride, which was used without further purification in the next step. 20

Step 4. N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(dipropylamino)-6-methylisonicotinamide

25

5

10

To 2-(dipropylamino)-6-methylisonicotinic acid hydrochloride (approx. 0.4 mmol) in THF (3 mL) was added

triethylamine (0.17 mL), followed by dichloromethane (2 mL) and then CDI (0.071 g, 0.44 mmol). After stirring for 1 h, a mixture of (2R, 3S) - 3 - amino - 4 - (3, 5 - difluorophenyl) - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]] - 1 - [(3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 - (3 - amino - 4 ethylbenzyl)amino]butan-2-ol dihydrochloride (0.163 g, 0.400 mmol), triethylamine (0.11 mL), and dichloromethane (approx. 2 mL) was added to the CDI mixture. The mixture was allowed to stir overnight, after which additional an 0.12 mL of triethylamine and 0.045 of (2R,3S)-3-amino-4-(3,5g difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol

10 dihydrochloride was added. After stirring for several more hours, the mixture was partitioned between dichloromethane and aq. sodium bicarbonate. The organic layer was dried with sodium sulfate, concentrated, and the residue was chromatographed on silica gel using MeOH-dichloromethane 15 (5/95) to give 0.04 g of the title compound.

## EXAMPLE SP-235

N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(dipropylamino)-6-methylpyrimidine-4-

20 carboxamide

Step 1. methyl 2-(dipropylamino)-6-methylpyrimidine-4-carboxylate

$$\bigcap_{\text{CI}} \bigcap_{\text{N}} \text{OCH}^3 \longrightarrow \bigcap_{\text{N}} \bigcap_{\text{OCH}^3}$$

A mixture of methyl 2-chloro-6-methylpyrimidine-4-carboxylate (0.411 g, 2.20 mmol), di-n-propylamine (0.668 g, 6.60 mmol), triethylamine (0.267 g, 2.64 mmol), and THF (5 ml) was stirred at room temperature for 55 min and then at reflux for 1.3 h, at which time is was cooled and partitioned between ethyl acetate and a mixture of brine and aq. sodium bicarbonate. The organic layer was dried over magnesium

sulfate and concentrated and then chromatographed on silica gel using ethyl acetate-hexane (90/10) to give methyl 2-(dipropylamino)-6-methylpyrimidine-4-carboxylate (0.457 g) as a pale yellow liquid.

5

Step 2. 35137-ret-135 2-(dipropylamino)-6-methylpyrimidine-4-carboxylic acid

To 2-(dipropylamino)-6-methylpyrimidine-4methyl carboxylate (0.450 g, 1.79 mmol) in MeOH (2 mL), water (1 mL), 10 and THF (1 mL) was added lithium hydroxide monohydrate (0.113 The mixture was stirred at room temperature g, 2.68 mmol). for 1 h and then MeOH and THF were removed under reduced pressure. The pH of the residue was adjusted to approximately 15 5 and the resulting mixture was extracted dichloromethane, dried over sodium sulfate, and concentrated to give 2-(dipropylamino)-6-methylpyrimidine-4-carboxylic acid (0.351 g) as a yellow solid.

20 Step 3. N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(dipropylamino)-6-methylpyrimidine-4-carboxamide

To 2-(dipropylamino)-6-methylpyrimidine-4-carboxylic acid 25 (0.101 g, 0.426 mmol) in THF (0.5 mL) was added 1,1'-carbonyldiimidazole (CDI) (0.076 g, 0.468 mmol). After 50 min the CDI mixture was added to a mixture of (2R,3S)-3-amino-4-

(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol dihydrochloride (0.173 g, 0.425 mmol) and triethylamine (0.18 mL, 1.28 mmol) in THF (6 mL) and dichloromethane (2 mL). After stirring overnight, the solvents were removed under reduced pressure and the residue was partitioned between sodium bicarbonate, and aq. dichloromethane, aq. bicarbonate-brine mixture. The organic layer was dried over concentrated, and the residue sodium sulfate, chromatographed on silica gel using MeOH-dichloromethane (5/95) to give 0.199 g of the title compound as a solid.

#### EXAMPLE SP-236

10

15

3-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}imidazo[1,2-a]pyridine-6-carboxamide

Step 1. 3-butylimidazo[1,2-a]pyridine-6-carboxylic acid

To hexanal (1.02 g, 10.2 mmol) in 15 mL of isopropyl alcohol-water (4:1 v/v) was added  $CuCl_2$  (1.37 g, 10.2 mmol). The mixture was heated at 80 °C for 2.5 h, then cooled. 20 solids were removed by filtration and the filtrate was added to 6-aminonicotinic acid (1.35 g, 10 mmol). The mixture was stirred overnight at room temperature, then heated at reflux 32 h. After cooling, the solvents were removed under reduced pressure and MeOH was added to the residue. The resulting 25 solid was removed by filtration and the filtrate MeOH was again added, and the concentrated to dryness. resulting solid removed by filtration. After concentration of the filtrate, the residue was chromatographed on silica gel using MeOH-dichloromethane (33/67) to give 0.26 g of 3-30 butylimidazo[1,2-a]pyridine-6-carboxylic acid.

3-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}imidazo[1,2-a]pyridine-6-carboxamide

5 Step 2. In the same manner as for N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(dipropylamino)-6-methylpyrimidine-4-carboxamide {EXAMPLE S-SP-235}, Step 3, 3-butylimidazo[1,2-a]pyridine-6-carboxylic acid (0.16 g) was converted to 0.30 g of the title compound.

10

# EXAMPLE SP-237

2-[butyl(methyl)amino]-6-chloro-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}isonicotinamide

15

Step 1. methyl 2-[butyl(methyl)amino]-6-chloroisonicotinate

In the same manner as for N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(dipropylamino)-6-methylisonicotinamide {EXAMPLE SP-234, Step 2,} methyl 2,6-dichloroisonicotinate (1.0 g) was converted to methyl 2-[butyl(methyl)amino]-6-chloroisonicotinate (0.87 g).

Step 2. 2-[butyl(methyl)amino]-6-chloroisonicotinic acid

25

20

for  $N-\{(1S,2R)-1-(3,5-$ In the same manner as difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-5 (dipropylamino) -6-methylpyrimidine-4-carboxamide {EXAMPLE 2435}, Step 2 methyl 2-[butyl(methyl)amino]-6chloroisonicotinate (0.17)converted to g) was [butyl(methyl)amino]-6-chloroisonicotinic acid (0.15 g).

10 Step 3. 2-[butyl(methyl)amino]-6-chloro-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}isonicotinamide

In the same manner as for  $N-\{(1S,2R)-1-(3,5-$ 15 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(dipropylamino)-6-methylpyrimidine-4-carboxamide {EXAMPLE S-2435}, 2-[butyl(methyl)amino]-6-chloroisonicotinic Step 3, acid (0.15 g) was converted to 0.13 g of the title compound.

20 EXAMPLE SP-238

2-[butyl(methyl)amino]-6-cyano-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}isonicotinamide

25 Step 1. methyl 2-[butyl(methyl)amino]-6-cyanoisonicotinate

A flask containing methyl 2-[butyl(methyl)amino]-6-chloroisonicotinate (0.306 g, 1.19 mmol), zinc cyanide (0.0839 g, 0.714 mmol), Pd<sub>2</sub>dba<sub>3</sub> (0.0218 g, 0.024 mmol), dppf (0.0264 g, 0.048 mmol), and zinc dust (0.0093 g, 0.143 g) was flushed with nitrogen. N-Methylpyrrolidinone (2 mL) was added and the mixture was heated at 120 °C for 2 h, at which time it was cooled and partitioned between ethyl acetate and aq. ammonium hydroxide and brine. The organic layer was dried over magnesium sulfate and concentrated, followed by silica get chromatography using ethyl acetate-hexane (10/90) to give 0.161 g of methyl 2-[butyl(methyl)amino]-6-cyanoisonicotinate.

Step 2. 2-[butyl(methyl)amino]-6-cyanoisonicotinic acid

15

20

10

5

In the same manner for as  $N-\{(1S, 2R)-1-(3, 5$ difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(dipropylamino)-6-methylpyrimidine-4-carboxamide {EXAMPLE 2435}, Step 2 ,methyl 2-[butyl(methyl)amino]-6cyanoisonicotinate (0.157 g) was converted to 2-[butyl(methyl)amino]-6-cyanoisonicotinic acid (0.151 g).

Step 3. 2-[butyl(methyl)amino]-6-cyano-N-{(1S,2R)-1-(3,5-25 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}isonicotinamide

In the same manner as for N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(dipropylamino)-6-methylpyrimidine-4-carboxamide {EXAMPLE S-2435}, Step 3, 2-[butyl(methyl)amino]-6-cyanoisonicotinic acid (0.135 g) was converted to the title compound (0.223 g).

## EXAMPLE SP-239

2-cyano-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-10 ethylbenzyl)amino]-2-hydroxypropyl}-6-[methyl(propyl)amino]isonicotinamide

In the same manner as for N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(dipropylamino)-6-methylpyrimidine-4-carboxamide {EXAMPLE S-2435}, Step 3, 2-cyano-6-[methyl(propyl)amino]isonicotinic acid (0.13 g) gave 0.23 g of the title compound.

# 20 EXAMPLE SP-240

Reaction scheme for the preparation of 1-butyl-N- $\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1,2,3,4-tetrahydroquinoline-7-carboxamide$ 

1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1,2,3,4-tetrahydroquinoline-7-carboxamide

5

10

15

Step 1: To an ice-cold, stirred solution of quinolin-7-ol (1.0 g, 6.9 mmol) and triethylamine (1.0 mL, 7.6 mmol) in methylene chloride (14 mL) was added trifluoromethane sulfonic anhydride (1.3 mL, 7.6 mmol), and the mixture was stirred for 30 min. The mixture was diluted with methylene chloride, washed with saturated sodium bicarbonate, and brine, dried (magnesium sulfate), filtered, and concentrated under reduced pressure provided quinolin-7-yl trifluoroacetate (1.5 g): ESI MS m/z 278 [M + H]<sup>+</sup>.

Step 2: To a stirred solution of quinolin-7-yl trifluoroacetate (750 mg, 2.7 mmol),  $PdCl_2(Ph_3P)$  (95 mg, 0.14 mmol), and triethylamine (1.2 mL, 8.4 mmol) in 1:2 DMF/MeOH

(39 mL) was degassed and sparged with CO, and the mixture was heated at 60 °C for 48 h. The mixture was cooled to room through temperature, filtered diatomaceous earth, and concentrated under reduced pressure. The residue was diluted with a 5% solution of LiCl, and washed with CHCl<sub>3</sub> (3 x 250 mL). The combined organics were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, Purification by flash concentrated under reduced pressure. column chromatography (silica, 3:1 ethyl acetate/hexanes) provided methyl quinoline-7-carboxylate (185 mg): ESI MS m/z 10  $188 [M + H]^{+}$ .

- Step 3: A solution of methyl quinoline-7-carboxylate (185 mg, 1.0 mmol) and PtO<sub>2</sub> (20 mg) in methanol (10 mL) was shaken under an atmosphere of hydrogen for 2 h. The reaction mixture was filtered through diatomaceous earth, and concentrated under reduced pressure to provide methyl 1,2,3,4-tetrahydroquinoline-7-carboxylate (189 mg): ESI MS m/z 192 [M+H]<sup>+</sup>.
- of methyl 1,2,3,4-20 stirred solution Step 4: To a tetrahydroquinoline-7-carboxylate (180 mg, 0.94 mmol) cesium bicarbonate (1.5 g, 4.7 mmol) in THF (2 mL) was added n-butyl bromide (1.0 mL, 9.4 mmol), and the reaction mixture was heated at reflux for 48 h. The reaction mixture was cooled to room temperature, and diluted with EtOAc. The 25 organic layer was washed with water, and brine, (magnesium sulfate), filtered, and concentrated under reduced Purification by flash column chromatography pressure. (silica, 1:3 ethyl acetate/hexanes) afforded methyl 1-butyl-1,2,3,4-tetrahydroquinoline-7-carboxylate (156 mg): ESI MS m/z 30  $248 [M + H]^{+}$ .
  - Step 5: To a stirred solution of methyl 1-butyl-1,2,3,4-tetrahydroquinoline-7-carboxylate (156 mg, 0.63 mmol) in

methanol (1.3 mL) was added potassium hydroxide (6.3 mL of a 1 M solution in water, 6.3 mmol). The reaction mixture was stirred at room temperature for 48 h and concentrated under reduced pressure. The residue was diluted with water and washed with ethyl acetate. The aqueous layer was acidified to pH 4 with 1 N hydrochloric acid and extracted with chloroform  $(4 \times 100 \text{ mL}).$ The combined organic extracts were dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 1:9 methanol/chloroform) afforded 1-butyl-1,2,3,4tetrahydroquinoline-7-carboxylic acid (139 mg): ESI MS m/z 234  $[M + H]^+$ .

- Step 6: A solution of 1-butyl-1,2,3,4-tetrahydroquinoline-715 carboxylic acid (134 mg, 0.57 mmol), HBTU (327 mg, 0.86 mmol),
  and diisopropylethylamine (150 μL, 0.86 mmol) was stirred in
  methylene chloride (3.0 mL) for 15 min. A solution of
  (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3ethylbenzyl)amino]butan-2-ol (EXAMPLE SP-272) (234 mg, 0.57
  20 mmol) and diisopropylethylamine (150 μL, 0.86 mmol) in
  methylene chloride (3.0 mL) was added and the reaction mixture
- was stirred overnight. The reaction mixture was diluted with methylene chloride, washed with 1 N hydrochloric acid (10 mL), saturated sodium bicarbonate (10 mL), and brine. The organic 25 layer was then dried (magnesium sulfate), filtered, concentrated under reduced pressure. Purification by flash column (silica, chromatography methanol/chloroform) 1:9 provided  $1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-N-4)]}$ ethylbenzyl)amino]-2-hydroxypropyl}-1,2,3,4-
- 30 tetrahydroquinoline-7-carboxamide (130 mg): ESI MS m/z 550 [M + H]<sup>+</sup>

EXAMPLE SP-241

10

 $N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-3-propyl-1, 2-benzisoxazole-5-carboxamide$ 

General Synthesis of Benzisoxazole

15

Furan 1 was hydrogenated to afford amine 2. Diels-Alder reaction of amine 2 and 1-hexen-3-one afforded ketone 3. 1 Ketone 3 was then treated with p-toluenesulfonic acid to afford diketone 4. Diketone 4 was rearomatized with boron trifluoride to give phenol 5. Phenol 5 was then converted to oxime 6 with hydroxylamine. Oxime 6 was cyclized with thionyl chloride to afford methyl ester 7. Methyl ester 7 was then saponified to acid 8. Coupling of acid 8 and amine 9 in the presence of HATU, provided benzoxazole 10.

Reaction scheme

 $\begin{tabular}{l} N-\{ (1S,2R)-1-(3,5-diffluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1\}-3-propyl-1,2-benzisoxazole-5-carboxamide \end{tabular}$ 

Step 1: A mixture of methyl 5-nitro-2-furoate (13 g, 76 mmol) 5 and 10% Pd/C (1.3 g) in ethanol (150 mL) was shaken under an atmosphere of hydrogen at 40 psi for 18 h. The reaction mixture was filtered through diatomaceous earth and concentrated under reduced pressure to afford a crude oil. 10 Purification by flash column chromatography (silica, hexanes/ethyl acetate) provided methyl 5-amino-2-furoate (5.6 g):  $^{1}\text{H}$  NMR (500 MHz, CDCl<sub>3</sub>)  $\delta7.11\text{--}7.10$  (m, 1H), 5.31-5.29 (m, 1H), 4.31 (br s, 2H), 3.84 (s, 3H).

Step 2: A stirred solution of methyl 5-amino-2-furoate (1.4 g, 10 mmol) and 1-hexen-3-one (7 mL, 60 mmol) in benzene (50 mL) The reaction mixture was was heated to reflux for 2 h. concentrated under reduced pressure to afford a crude oil. Purification by flash column chromatography (silica, 2:1 hexanes/ethyl acetate) provided methyl 4-amino-5-butyryl-1hydroxycyclohexa-2,4-diene-1-carboxylate (1.25 g): <sup>1</sup>H NMR (300 MHz, CDC1<sub>3</sub>):  $\delta$  6.26-6.23 (m, 1H), 6.09-6.05 (m, 1H), 3.80 (s, 3H), 3.02-2.96 (m, 1H), 2.89-2.84 (m, 1H), 2.42-2.37 (m, 2H), 1.64-1.57 (m, 2H), 0.96-0.88 (m, 3H).

5

10

25

Step 3: To a stirred solution of methyl 4-amino-5-butyryl-1hydroxycyclohexa-2,4-diene-1-carboxylate (1.25 g, 5.2 mmol) in a 1:1 mixture of water/tetrahydrofuran (10 mL) was added p-15 toluenesulfonic acid monohydrate (1.1 g, 5.8 mmol). reaction mixture was stirred for 18 h and then partitioned between dichloromethane and water. The organic layer was dried (sodium sulfate), filtered, and concentrated under reduced pressure to afford methyl 5-butyryl-1-hydroxy-4-20 oxocyclohex-2-ene-1-carboxylate which was used without further purification or characterization.

Step 4: To a stirred solution of methyl 5-butyryl-1-hydroxy-4oxocyclohex-2-ene-1-carboxylate in benzene was added BF3·O(Et)2 (1.3 mL, 10 mmol). The mixture was stirred for 0.25 h and then quenched with saturated sodium bicarbonate followed by extraction with dichloromethane. The organic layer was dried (sodium sulfate), filtered, and concentrated under reduced pressure to afford methyl 3-butyryl-4-hydroxybenzoate which 30 was used without further purification or characterization.

5: A stirred solution of methyl 3-butyryl-4-Step hydroxybenzoate, pyridine (3.7 mL, 46 mmol), and hydroxylamine

hydrochloride (3.55 g, 51 mmol) in ethanol (30 mL) was heated reflux for 2 h. The mixture was concentrated under reduced pressure and partitioned between water and ethyl acetate. The organic layer was washed with 1 N hydrochloric acid, saturated sodium bicarbonate, dried (sodium sulfate), filtered, and concentrated under reduced pressure to afford a crude oil. Purification by flash column chromatography (silica, 10:1 hexanes/ethyl acetate) provided methyl 4-hydroxy-3-[(1E)-N-hydroxybutanimidoyl]benzoate (170 mg):  $^1$ H NMR (500 MHz, CD<sub>3</sub>OD):  $^3$  8.30-8.28 (m, 1H), 7.85-7.82 (m, 1H), 6.92-6.89 (m, 1H), 3.88 (s, 3H), 2.87-2.84 (m, 2H), 1.67-1.60 (m, 2H), 1.05-1.00 (m, 3H).

Step 6: To an ice-cold stirred solution of methyl 4-hydroxy-3-[(1E)-N-hydroxybutanimidoyl]benzoate (170 mg, 0.7 mmol) 15 diethyl ether (5 mL) was added a mixture of thionyl chloride (60  $\mu\text{L},~0.8$  mmol) and pyridine (580  $\mu\text{L},~7.2$  mmol) in diethyl ether (5 mL). After 2.5 h the mixture was poured over icewater and acidified to pH = 1 with 1 N hydrochloric acid. mixture was then partitioned between water and ethyl acetate. 20 The organic layer was washed with saturated sodium bicarbonate, dried (sodium sulfate), filtered, and concentrated under reduced pressure to afford a crude oil. Purification by flash column chromatography (silica, 10:1 25 hexanes/ethyl acetate) provided methyl 3-propyl-1,2benzisoxazole-5-carboxylate (90 mg):  $^1\!H$  NMR (300 MHz, CDCl3):  $\delta$ 8.36-8.35 (m, 1H), 8.07-8.04 (m, 1H), 7.52-7.49 (m, 1H), 3.95(s, 3H), 2.96-2.91 (m, 2H), 2.00-1.87 (m, 2H), 1.09-1.04 (m, 3H).

30

10

Step 7: To a solution of methyl 3-propyl-1,2-benzisoxazole-5-carboxylate (90 mg, 0.4 mmol) in a 2:1:1 mixture of tetrahydrofuran, water, and methanol (4 mL) was added lithium hydroxide (50 mg, 1.2 mmol) and the resulting reaction mixture

stirred at room temperature for 2.5 h. The reaction mixture concentrated under reduced pressure, and partitioned was between water and ethyl ether. The aqueous layer was washed twice with ether and acidified to pH 1 with 6 M hydrochloric The resulting aqueous layer was extracted with ethyl acid. dried (sodium sulfate), and concentrated under acetate, to afford 3-propyl-1,2-benzisoxazole-5pressure reduced carboxylic acid (73 mg):  $^{1}$ H NMR (300 MHz, CD<sub>3</sub>OD):  $\delta$  8.28-8.27 (m, 1H), 8.09-8.06 (m, 1H), 7.64-7.61 (m, 1H), 2.99-2.94 (m, 1H)2H), 1.96-1.86 (m, 2H), 1.08-1.02 (m, 3H). 10

Step 8: To a stirred solution of 3-propyl-1,2-benzisoxazole-5carboxylic acid (70 mg, 0.3 mmol) and HATU (130 mg, 0.3 mmol) (5 added mL) was N, Nchloride in methylene diisopropylethylamine (110  $\mu$ L, 0.6 mmol). In a separate flask, 15 N, N-diisopropylethylamine (110  $\mu$ L, 0.6 mmol) was added to (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3ethylbenzyl)amino]butan-2-ol (EXA xxx) (140 mg, 0.3 mmol) in methylene chloride (2 mL). This solution was added to the above solution containing the acid and the resulting reaction 20 mixture was stirred at room temperature for 18 h. The reaction mixture was partitioned between methylene chloride The organic layer was washed with water, dried and water. (sodium sulfate), filtered, and concentrated under reduced pressure to afford a crude oil. Purification by flash column 25 97:3 to 94:6 methylene chromatography (silica, gradient chloride/methanol) provided N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-propyl-1,2benzisoxazole-5-carboxamide (30 mg). ESI-MS m/z 522 [M + H]<sup>+</sup>

30

# EXAMPLE SP-242

 $N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}isoquinoline-7-carboxamide dihydrochloride$ 

Step 1: A solution of 7-bromo-1-chloroisoquinoline (2.50 g, 10.3 mmol) and activated zinc (1.40 g, 21.65 mmol) in acetic acid (20 mL) was heated at reflux for 2 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The resulting residue was partitioned between ethyl acetate and water. The organic layer was washed with saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure to provide 7-bromoisoquinoline (1.86 g): ESI MS m/z 208 [M + H]<sup>+</sup>.

10

15

20

Step 2: A solution of 7-bromoisoquinoline (1.80 g, 8.65 mmol) and cuprous cyanide (1.16 g, 12.97 mmol) in N-methyl pyrrolidinone (17 mL) was heated to 200 °C for 2 h. The reaction mixture was cooled to room temperature and partitioned between ethyl acetate and water. The aqueous phase was back-extracted with additional ethyl acetate and the combined organic layers were washed with saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure to yield 7-cyano-isoquinoline (770 mg): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ 9.35 (s, 1H), 8.70 (d, J = 5 Hz, 1H),

8.40 (s, 1H), 7.95 (d, J = 8 .Hz, 1H), 7.84 (d, J = 8 Hz, 1H), 7.73 (d, J = 5 Hz, 1H); ESI MS m/z 155 [M + H]<sup>+</sup>.

Step 3: A solution of 7-cyanoisoquinoline (770 mg, 5.0 mmol) in concentrated hydrochloric acid (25 mL) was heated in a sealed tube to 150 °C for 18 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was dissolved in water (10 mL) and neutralized to pH 7.0 with concentrated ammonium hydroxide.

10 The solution was vacuum filtered and the filtrate concentrated under reduced pressure to provide isoquinoline-7-carboxylic acid (640 mg): ESI MS m/z 174 [M + H]<sup>+</sup>.

Step 4: To a stirred solution of isoquinoline-7-carboxylic acid (200 mg, 1.15 mmol) and N,N-diisopropyl ethylamine (1.20 mL, 6.88 mmol) in methylene chloride (14.0 mL) was added HBTU (438 mg, 1.15 mmol) and the reaction stirred for 0.5 h. (2R,3S)-3-Amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol (470 mg, 1.15 mmol) was added in

one portion and the reaction mixture was stirred under nitrogen for 18 h. The reaction mixture was then diluted with additional methylene chloride and washed with saturated sodium bicarbonate, saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure.

25 Purification by flash column chromatography (silica, 0-5% methanol/methylene chloride) gave N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-

hydroxypropyl}isoquinoline-7-carboxamide (100 mg) which was characterized as its bis-HCl salt: mp 142-143 °C; ESI MS m/z

 $30 490 [M + H]^+$ 

EXAMPLE SP-243

 $\label{eq:N-sum} $$N-\{(1S,2R)-1-(3,5-diffluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-1-(propylamino)isoquinoline-7-carboxamide dihydrochloride$ 

$$\begin{array}{c|c} & & & \\ \hline \\ \hline \\ DIPEA, CH_2Cl_2 \\ \hline \\ 33\% \\ \hline \\ H_2N \\ \hline \\ F \\ \hline \\ F \\ \hline \\ F \\ \hline \\ F \\ \hline \\ 2HCl \\ \end{array}$$

5

Step 1: A solution of 7-bromo-1-chloroisoquinoline in propylamine (15.0 mL) was heated at 70 °C in a sealed tube overnight. The reaction mixture was concentrated under reduced pressure, then dissolved in chloroform and washed with saturated sodium bicarbonate, saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure to yield 7-bromo-2-(N-propylamino)isoquinoline (820 mg): ESI MS m/z 266 [M + H]<sup>+</sup>.

15

20

10

Step 2: A solution of 7-bromo-2-(N-propylamino)isoquinoline (200 mg, 0.754 mmol) in anhydrous diethyl ether (1.0 mL) was cooled to -65 °C. To this solution sec-butyllithium was added dropwise (1.30 mL of a 1.3 M solution in cyclohexane, 1.69 mmol) and the reaction mixture stirred at -60 °C for 10 min. The reaction mixture was quenched by addition of pulverized dry ice ( $CO_2$ ) and the reaction allowed to slowly warm to room temperature over 1 h. The resulting solution was acidified

with 1 N hydrochloric acid and the reaction mixture extracted with ethyl acetate (3 x 15 mL). The combined organic phase was washed with water, dried (sodium sulfate), filtered, and concentrated under reduced pressure to yield a brown solid. Purification flash column chromatography by 66:20:10:4 ethyl acetate/chloroform/methanol/concentrated ammonium hydroxide) gave 1-(propylamino)isoquinoline-7carboxylic acid (133 mg): ESI MS m/z 231 [M + H]<sup>+</sup>.

10 Step 3: To a stirred solution of 1-(propylamino)isoquinoline-7-carboxylic acid (81 mg, 0.396 mmol) and N,N-diisopropyl ethylamine (3.75  $\mu$ L, 2.16 mmol) in methylene chloride (5.0 mL) was added HBTU (152 mg, 0.396 mmol) and the reaction stirred 0.5 h. (2R,3S)-3-Amino-4-(3,5-difluorophenyl)-1-[(3-15 ethylbenzyl)amino]butan-2-ol (150 mg, 0.36 mmol) was added in one portion and the reaction mixture was stirred under nitrogen for 18 h. The reaction mixture was then diluted with additional methylene chloride and washed with saturated sodium bicarbonate, saturated sodium chloride, dried (sodium 20 sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 0-5% methanol/methylene chloride)  $N-\{(1S, 2R)-1-(3, 5$ gave difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1-(propylamino)isoquinoline-7-carboxamide (67 mg) 25 characterized as its bis-HCl salt: mp 262 °C dec; ESI MS m/z  $547 [M + H]^{+}$ 

## EXAMPLE SP-244

 $N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-(3-ethylbenzy1)$ 

30 hydroxypropyl}-1-(dipropylamino)isoquinoline-7-carboxamide

Step 1: A solution of 7-bromoisoquinolin-1-ol (2.5 g, 11.1 mmol) and POCl<sub>3</sub> (10.4 mL, 111 mmol) was stirred at 70 °C for 2.5 h. The reaction mixture was cooled to room temperature, poured into ice water, and the solution was stirred overnight. The aqueous mixture was diluted with chloroform, washed with a saturated solution of NaHCO<sub>3</sub>, saturated NaCl, dried (MgSO<sub>4</sub>), filtered, and concentrated under reduced pressure to afford 7-bromo-1-chloroisoquinoline (2.3 g): ¹H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 8.39-8.36 (m, 2H), 8.09-8.02 (m, 2H), 7.95 (d, J = 6 Hz, 1H).

10

Step 2: A solution of 7-bromo-1-chloroisoquinoline from step 1
 (500 mg, 2.1 mmol) and dipropylamine (2.8 mL, 21 mmol) was

15 heated at 150 °C in a sealed tube for 2 d. The reaction mixture was cooled, and the solvent was removed under reduced pressure to provide 7-bromo-N,N-dipropylisoquinolin-1-amine (400 mg): ¹H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 8.55 (s, 1H), 7.90 (d, J = 6 Hz, 1H), 7.75-7.64 (m, 2H), 6.87 (d, J = 6 Hz, 1H), 3.42

20 (q, J = 7 Hz, 4H), 1.65 (q, J = 7 Hz, 4H), 0.94 (t, J = 7 Hz, 6H).

Step 3: A solution of 7-bromo-N,N-dipropylisoquinolin-1-amine (350 mg, 1.1 mmol) and CuCN (204 mg, 2.2 mmol) in N,N-dimethylformamide (2 mL) was stirred at reflux for 24 h. The reaction mixture was cooled to room temperature, diluted with water, and extracted with ethyl acetate (3 x 50 mL). The combined organics were washed with saturated sodium chloride, dried (magnesium sulfate), filtered, and concentrated under reduced pressure to provide 1-(dipropylamino)isoquinoline-7-carbonitrile (279 mg, which was used without any further characterization.

10

- 1-(dipropylamino)isoquinoline-7solution of 4: Α carbonitrile from step 3 (279 mg, 1.1 mmol) in concentrated hydrochloric acid (4 mL) was heated at 150 °C in a sealed tube The reaction mixture was cooled to room 15 temperature, the solvent was removed under reduced pressure, dissolved in a 25% and the residue was hydroxide/water solution and stirred for 1 h. The solution was acidified to pH 4 with concentrated hydrochloric acid, and extracted with chloroform (3 x 50 mL). The combined organics 20 were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated under reduced pressure to provide 1-(dipropylamino)isoquinoline-7-carboxylic acid (104 mg): ESI MS m/z 273 [M + H]<sup>+</sup>.
- 1-25 Step 5: To a stirred solution οf (dipropylamino)isoquinoline-7-carboxylic acid (103 mmol), (2R, 3S) - 3 - Amino - 4 - (3, 5 - difluorophenyl) - 1 - [(3 - 4)]ethylbenzyl)amino]butan-2-ol (154 mg, 0.38 mmol), HOBt (77 mg, 0.57 mmol), and DIPEA (0.2 mL, 1.1 mmol) in methylene chloride 30 (4 mL) was added HATU (216 mg, 0.57 mmol). The reaction mixture was stirred overnight and then partitioned between methylene chloride and 1 N hydrochloric acid. layer was washed with saturated sodium bicarbonate, saturated sodium chloride, dried (sodium sulfate), filtered,

concentrated under reduced pressure. Purification by flash column chromatography (silica, 9:1 chloroform/methanol) gave  $N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-1-(dipropylamino)isoquinoline-7-carboxamide (70 mg): mp: 142-151 °C; APCI MS <math>m/z$  589 [M + H]<sup>+</sup>

### EXAMPLE SP-244

5

1-[butyl(methyl)amino]-N- $\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-$ 

10 ethylbenzyl)amino]-2-hydroxypropyl}isoquinoline-7-carboxamide

Step 1: A solution of 7-bromo-1-chloroisoquinoline (750 mg, 3.09 mmol) in N-methylbutylamine (7.0 mL) was heated at 65 °C in a sealed tube for 18 h. The reaction mixture was concentrated under reduced pressure. The residue was diluted with chloroform and washed with saturated sodium bicarbonate, dried (sodium sulfate), filtered, and concentrated under reduced pressure to yield a brown oil. Purification by flash column chromatography (silica, 3:1 hexanes/diethyl ether) provided 7-bromo-N-butyl-N-methylisoquinolin-1-amine (730 mg): ESI MS m/z 293 [M + H]<sup>+</sup>.

25 Step 2: To a -60 °C solution of 7-bromo-N-butyl-N-methylisoquinolin-1-amine (230 mg, 0.78 mmol) in diethyl ether -615-

was added sec-butyllithium (1.00 mL of a 1.3 M solution in cyclohexanes, 1.30 mmol). The solution was stirred at -60 °C for 20 min then excess dry ice (CO<sub>2</sub>) was added and the reaction mixture was allowed to warm to room temperature. The reaction mixture was then acidified with 1 N hydrochloric acid and extracted with ethyl acetate. The aqueous phase concentrated under reduced pressure to yield a yellow oil. Purification by flash column chromatography (silica, 50:30:15:5 ethyl acetate/chloroform/methanol/ammonium hydroxide) provided 1-[butyl(methyl)amino]isoquinoline-7carboxylic acid (90 mg): ESI MS m/z 259 [M + H]<sup>+</sup>.

Step 3: To a solution of 1-[butyl(methyl)amino]isoquinoline-7carboxylic (130 acid mg, 0.5 mmol) 15 diisopropylethylamine (525  $\mu$ L, 3.0 mmol) in methylene chloride (6.25 mL) was added HBTU (190 mg, 0.5 mmol) and the reaction mixture was stirred for 0.5 h. (2R,3S)-3-Amino-4-(3,5difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol 0.42 mmol) was added in one portion and the reaction mixture 20 was stirred at room temperature 18 h. The reaction mixture was diluted with methylene chloride and washed with saturated sodium bicarbonate, and saturated sodium chloride, (sodium sulfate), filtered, and concentrated under reduced Purification by flash chromatography (silica, 1-5% pressure. 25 methanol in chloroform) gave 1-[butyl(methyl)amino]-N-{ (1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-ethylbenzyl)amino]-2hydroxypropyl}isoquinoline-7-carboxamide (101 mg): mp 120-121 °C; ESI MS m/z 575 [M + H]<sup>+</sup>

# 30 EXAMPLE SP-244

10

N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1-[methyl(propyl)amino]isoquinoline-7-carboxamide

was prepared in a manner similar to that outlined above for  $1-[butyl(methyl)amino]-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2hydroxypropyl}isoquinoline-7-carboxamide. ESI MS <math>m/z$  561 [M + H]<sup>+</sup>

5

### EXAMPLE SP-245

1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}isoquinoline-7-carboxamide

$$\begin{array}{c|c} & & & \\ \hline \\ H_2N \\ \hline \\ F \\ \end{array} \begin{array}{c} OH \\ N \\ \hline \\ F \\ \end{array} \begin{array}{c} H \\ OH \\ N \\ \hline \\ F \\ \end{array} \begin{array}{c} OH \\ N \\ \hline \\ F \\ \end{array}$$

10

Step 1: To a refluxing solution of 7-bromo-1chloroisoquinoline (4.85 g, 23.28 mmol) in diethyl ether (75 mL) was added butylmagnesium chloride (17.8 mL, 2.0 M ether, 35.6 mmol) and the reaction maintained at reflux for 2 h. The 15 reaction mixture was cooled to room temperature, carefully diluted with an equal volume of ethyl acetate, washed with saturated sodium bicarbonate, water, and saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure to give an brown oil. Purification by 20 flash column chromatography (silica, 1-10% ether/hexanes) gave the desired 7-bromo-1-butylisoquinoline (1.50 g): ESI MS m/z $264 [M + H]^{+}$ 

25 Step 2: To a -60 °C solution of 7-bromo-1-butylisoquinoline prepared in step 1 (940 mg, 3.55 mmol) in diethyl ether (15-617-

mL) was added sec-butyl lithium (3.0 mL, 1.3 M cyclohexanes, 3.90 mmol) to yield a dark green solution. The reaction mixture was stirred at -60 °C for an additional 15 minutes at which time carbon dioxide gas was bubbled through the solution for 20 minutes with the aid of a gas dispersion tube. to warm to solution was then allowed temperature and concentrated under reduced pressure to yield a pink solid. The residue was partitioned between ethyl acetate and water and then acidified to pH 7 with 1 N hydrochloric The aqueous phase was extracted again with ethyl acid. acetate and the combined organic phases were washed with saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated to yield 1-butylisoquinoline-7-carboxylic acid (299 mg). ESI MS m/z 230 [M + H]<sup>+</sup>.

15

20

25

30

10

Step 3: To a solution of 1-butylisoquinoline-7-carboxylic acid (79 mg, 0.26 mmol) and N,N-diisopropylethylamine (150  $\mu$ L, 0.86 mmol) in methylene chloride (1.8 mL) was added HBTU (100 mg, 0.264 mmol) and the reaction mixture stirred for 0.5 h. solution of (2R,3S)-3-amino-4-(3,5this added a was difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol 0.264 mmol) in methylene chloride (1.8 mL) containing N, Ndiisopropylethylamine (150  $\mu$ L, 0.86 mmol). The reaction mixture was then stirred at room temperature overnight. reaction mixture was diluted with methylene chloride, washed with saturated sodium bicarbonate, and saturated sodium The organic layer was then dried (sodium sulfate), chloride. reduced concentrated under pressure. filtered, and Purification by flash column chromatography (silica, 93:7  $1-butyl-N-\{(1S,2R)-1-(3,5$ chloroform/methanol) gave difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2hydroxypropyl}isoquinoline-7-carboxamide (103 mg): mp 109-110 °C; ESI MS m/z 546 [M + H]<sup>+</sup>.

EXAMPLE SP-246

1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1,2,3,4-tetrahydroisoquinoline-7-carboxamide

5

10

15

20

Step 1: A solution of 1-butylisoquinoline-7-carboxylic acid (325 mg, 1.41 mmol) in methanol (25 mL) containing concentrated sulfuric acid (800  $\mu L$ ) was refluxed overnight. The reaction mixture was then concentrated under reduced pressure, diluted with methylene chloride, washed with water, and saturated sodium chloride. The organic layer was then dried (sodium sulfate), filtered, and concentrated to yield methyl 1-butylisoquinoline-7-carboxylate (350 mg): ESI MS m/z $244 [M + H]^{+}$ ;

Step 2: To a solution of methyl 1-butylisoquinoline-7-carboxylate prepared in step 1 (350 mg, 1.44 mmol) in methanol (6.0 mL) was added platinum(IV) oxide (35 mg) and the reaction mixture stirred under one atmosphere of hydrogen at room temperature overnight. The reaction mixture was concentrated under reduced pressure and redissolved in methylene chloride (15 mL). To this solution was added di-tert-butyl dicarbonate

(350 mg, 1.6 mmol), triethylamine (500  $\mu$ L, 3.11 mmol), 4-dimethylaminopyridine (20 mg, 0.16 mmol), and the reaction mixture stirred at room temperature for 4 h. The reaction mixture was then diluted with methylene chloride, washed with saturated sodium bicarbonate, water, and saturated sodium chloride. The organic layer was then dried (sodium sulfate), filtered, and concentrated under reduced pressure to yield a colorless oil. Purification by flash column chromatography (silica, 85:15 hexanes/ethyl acetate) yielded 2-tert-butyl 7-methyl 1-butyl-3,4-dihydroisoquinoline-2,7(1H)-dicarboxylate (347 mg)l: ESI MS m/z 248 [M + H] $^+$ .

5

10

Step 3: To a solution of 2-tert-butyl 7-methyl 1-butyl-3,4dihydroisoquinoline-2,7(1H)-dicarboxylate prepared in step 2 (347 mg, 1.0 mmol) in 2:1:1 dioxane/methanol/water (6.6 mL) 15 was added lithium hydroxide monohydrate (125 mg, 3.0 mmol) and the reaction mixture stirred 24 h at room temperature. reaction mixture was concentrated under reduced pressure and the solid residue partitioned between ethyl acetate and water. The aqueous phase was acidified with 1 N hydrochloric acid to 20 pH 1 and extracted several times with 3:1 chloroform/2-The combined organic phases were washed with water propanol. sodium chloride, dried (sodium sulfate), saturated filtered, and concentrated under reduced pressure to provide 2-(tert-butoxycarbonyl)-1-butyl-1,2,3,4-25 tetrahydroisoquinoline-7-carboxylic acid (205 mg). ESI MS m/z $332 [M - H]^{-}$ .

Step 4: To a solution of 2-(tert-butoxycarbonyl)-1-butyl-30 1,2,3,4-tetrahydroisoquinoline-7-carboxylic acid (205 mg, 0.61 mmol) and N,N-diisopropylethylamine (150 µL, 0.86 mmol) in methylene chloride (4.0 mL) was added HBTU (233 mg, 0.61 mmol) and the reaction mixture stirred for 0.5 h. To this was added a solution of (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-

ethylbenzyl)amino]butan-2-ol (250 mg, 0.61 mmol) in methylene chloride (4.0 mL) containing N, N-diisopropylethylamine (150  $\mu$ L, The reaction mixture was then stirred at room 0.86 mmol). temperature overnight. The reaction mixture was diluted with methylene chloride, washed with saturated sodium bicarbonate, and saturated sodium chloride. The organic layer was then dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 95:5 chloroform/methanol) gave the desired amide 10 The amide was then dissolved in dioxane (5.0 mL) to product. which was added hydrochloric acid (20 mL, 4.0 M dioxanes, 80 mmol) and the reaction mixture stirred overnight. The reaction mixture was then concentrated to dryness and purified by flash column chromatography (silica, 90:6:3:1 acetate/chloroform/methanol/ammonium hydroxide) to yield a 15 colorless oil. The oil was partitioned between chloroform/2-propanol, washed with water, and saturated sodium chloride. The organic layer was then dried (sodium sulfate), filtered, and concentrated to yield a white solid. The solid 20 was dried under high vacuum at 45  $^{\circ}\text{C}$  in the presence of  $P_2O_5$  to yield  $1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-N-4)]}$ ethylbenzyl)amino]-2-hydroxypropyl}-1,2,3,4tetrahydroisoquinoline-7-carboxamide(140 mg) characterized as a mixture of diastereomers: mp 121-124 °C; ESI MS m/z 550 [M + 25 H] +.

## EXAMPLE SP-247

30

 $N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1\}-3-\{[(2S)-2-ethylpyrrolidin-1-y1]carbony1\}-5-methylbenzamide hydrochloride$ 

$$\begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \\ \\ \end{array} \end{array} \end{array} \end{array} \begin{array}{c} \begin{array}{c} \\ \\ \end{array} \end{array} \begin{array}{c} \\ \\ \end{array} \end{array} \begin{array}{c} \\ \\ \end{array} \begin{array}{c} \\ \\ \end{array} \end{array} \begin{array}{c} \\ \\ \end{array} \begin{array}{c} \\ \\ \end{array} \end{array} \begin{array}{c} \\ \\ \end{array} \begin{array}{c} \\ \\ \end{array} \begin{array}{c} \\ \\ \end{array} \begin{array}{c} \\ \\ \end{array} \begin{array}{c} \\ \\ \end{array} \begin{array}{c} \\ \\ \end{array} \end{array} \begin{array}{c} \\ \\ \\ \end{array} \begin{array}{c} \\ \\ \\ \end{array} \begin{array}{c} \\ \\ \end{array} \begin{array}{c} \\ \\ \\ \end{array} \begin{array}{c} \\ \\ \end{array} \begin{array}{c} \\ \\ \end{array} \begin{array}{c} \\ \\ \\ \end{array} \begin{array}{c} \\ \\ \end{array}$$

Step 1: Di-tert-butyl-dicarbonate (10.8 g, 49 mmol) was added to an ice-cold solution of R-pyrrolidinemethanol (5.0 g, 49 mmol) and triethylamine (7.6 mL, 55 mmol) in 125 mL of CH<sub>2</sub>Cl<sub>2</sub>. The resultant solution was warmed to ambient temperature and solution was then reaction The stirred overnight. concentrated, diluted with EtOAc, washed 2X with 1 M KH2PO4 and 2X with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to (2R)-2-(hydroxymethyl)pyrrolidine-1tert-butyl afford carboxylate (9.9 g).

5

10

15

20

25

Oxalyl chloride (9.0 mL, 100 mmol) was added to a Step 2: solution of DMSO (10.5 mL, 150 mmol) in 80 mL of CH<sub>2</sub>Cl<sub>2</sub> at -78 °C, under a nitrogen atmosphere. The solution was stirred for 20 min at -78 °C, tert-butyl (2R)-2-(hydroxymethyl)pyrrolidine-1-carboxylate (9.9 g, 49 mmol) was added, and the resultant solution stirred at -78 °C for 20 min. Triethylamine (28 mL, 200 mmol) was added to the reaction solution, the dry iceacetone bath was removed, and the resultant solution was allowed to stir for two hours, slowly warming to ambient The reaction solution was quenched with brine, temperature. the phases were separated, and the organic phase was washed with 1 M KH<sub>2</sub>PO<sub>4</sub> and saturated NaHCO<sub>3</sub>. The organic solution was then dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to an orange oil. This oil was then dissolved in heptane, filtered through

a plug of silica gel eluting with heptane, and the filtrate was concentrated to yield tert-butyl (2R)-2-formylpyrrolidine-1-carboxylate (7.87 g).

- Step 3: n-Butyl lithium (1.6 M in hexanes) (27 mL, 43 mmol) was added to ice-cold hexamethyldisilazane (9.2 mL, 44 mmol) under a nitrogen atmosphere. The solution was stirred for 10 min and was then added to a suspension methyl(triphenylphosphonium)bromide (15.5 g, 43 mmol) in 100 10 mL of THF at ambient temperature. After stirring for 1 h, the mixture was cooled to -78 °C and a solution of tert-butyl (2R)-2-formylpyrrolidine-1-carboxylate (7.9 g, 40 mmol) in 50 mL of The cold bath was removed and the mixture THF was added. stirred overnight at ambient temperature. The reaction mixture was then quenched with saturated NH4Cl, the phases were 15 separated, and the organic phase was washed with saturated NH<sub>4</sub>Cl, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give an orange oil. The oil was purified on a Biotage 40M column eluting with heptane to give tert-butyl (2R)-2-20 vinylpyrrolidine-1-carboxylate (5.0 g).
- Step 4: To a suspension of palladium (II) hydroxide on activated carbon (20% by wt, 1.2 g) in 10 mL of ethanol was added tert-butyl (2R)-2-vinylpyrrolidine-1-carboxylate (2.0 g, 10 mmol)as a solution in 15 mL of ethanol and the mixture was placed under 12 psi of H<sub>2</sub> on a parr hydrogenator overnight. The resultant mixture was then filtered and concentrated to give tert-butyl (2S)-2-ethylpyrrolidine-1-carboxylate (1.5 g).

30

Step 5: To a solution of tert-butyl (2S)-2-ethylpyrrolidine-1-carboxylate (1.0 g, 5.0 mmol) in 10 mL of dioxane was added 8 mL of 6N HCl and the resultant solution stirred overnight at ambient temperature. The reaction solution was then

concentrated, turned basic with solid KOH, and extracted with EtOAc. The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give (2S)-2-ethylpyrrolidine hydrochloride (0.30 g).

5

10

15

20

Step 6: A solution of 3-(methoxycarbonyl)-5-methylbenzoic acid (0.48 g, 2.5 mmol), HATU (1.0 g, 2.6 mmol), and HOAt (0.37 g, 2.7 mmol) in 10 mL of dry DMF was stirred for an hour over ice, under a nitrogen atmosphere prior to the of (2R, 3S) -3-amino-4-(3, 5-difluorophenyl) -1-[(3ethylbenzyl)amino]butan-2-ol dihydrochloride (1.0 g, 2.5 mmol) and DIPEA (1.8 mL, 10 mmol). The solution was stirred overnight at ambient temperature. The reaction solution was then quenched with 1 M HCl, diluted with EtOAc, and the phases were separated. The organic phase was washed with 1 M HCl, the combined acid washings were back-extracted with EtOAc, and the organic phases combined. The combined organic phases were then washed with saturated NaHCO3, brine and dried over Na2SO4 The mixture was filtered and concentrated to give the coupled product as an orange oil. This oil was dissolved in 35 mL of MeOH and solid LiOHH2O (0.6 g, 14 mmol) was added with 2 mL of The mixture was stirred overnight at ambient water.

temperature. The solution was concentrated, diluted with water, neutralized with 1 M HCl, and concentrated. The resulting oily residue was purified on a Biotage 40S column eluting with 5% MeOH in  $CH_2Cl_2$  to give a colorless oil. This was dissolved in 10 mL of MeOH and 3 mL of 1 M HCl in ether was added. The solution was concentrated and the residue triturated with heptane to give  $3-[(\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-$ 

hydroxypropyl amino) carbonyl ] -5-methylbenzoic acid

10 hydrochloride (0.65 g).

Step 7: To a solution of 3-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}amino)carbonyl]-5-methylbenzoic acid hydrochloride (0.50 g, 0.94 mmol) and ditert-butyldicarbonate (0.20 g, 0.92 mmol) in 10 mL of methanol and 10 mL of CH<sub>2</sub>Cl<sub>2</sub> was added triethylamine (0.40 mL, 2.9 mmol). The solution was stirred for 2.5 hours at ambient temperature, at which time it was concentrated, partitioned between EtOAc and 1 M KH<sub>2</sub>PO<sub>4</sub>, and the phases were separated.

The organic phase was washed with M KH<sub>2</sub>PO<sub>4</sub>, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated, and triturated with heptane to give 3-({[(1S,2R)-3-[(tert-butoxycarbonyl)(3-ethylbenzyl)amino]-1-(3,5-difluorobenzyl)-2-hydroxypropyl]amino}carbonyl)-5-methylbenzoic acid (0.50 g).

25

Step 8: A solution of 3-({[(1S,2R)-3-[(tert-butoxycarbonyl)(3-ethylbenzyl)amino]-1-(3,5-difluorobenzyl)-2-hydroxypropyl]amino}carbonyl)-5-methylbenzoic acid (0.30 g, 0.50 mmol), HATU (0.19 g, 0.50 mmol) and HOAt (0.07 g, 0.51 mmol) in 5 mL of dry DMF under a nitrogen atmosphere was stirred for 15 minutes. A solution of (2S)-2-ethylpyrrolidine hydrochloride (0.05 g, 0.50 mmol) and DIPEA (0.35 mL, 2.0 mmol) in 5 mL of DMF was added. The solution was stirred overnight at ambient temperature. It was then quenched with 1

M HCl, diluted with EtOAc, and the phases were separated. organic phase was washed with 1 M HCl, saturated NaHCO3, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give an orange-brown This oil was purified on a Biotage 40S column eluting oil. with 200 mL of CH<sub>2</sub>Cl<sub>2</sub>, then 3% MeOH in CH<sub>2</sub>Cl<sub>2</sub>. The yellow oil 5 obtained was dissolved in 4 mL of CH<sub>2</sub>Cl<sub>2</sub> and 4 mL of TFA was After stirring for two hours at ambient temperature added. the reaction solution was concentrated and the residue was purified by reverse phase prep hplc using a 1-inch Kromasil c18 column to give the product as the formic acid salt. This 10 was then converted to the HCl salt by the addition of 2 mL of Upon concentration and trituration with 1 M HCl in ether.  $N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mu)]$ heptane ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2S)-2-

ethylpyrrolidin-1-yl]carbonyl}-5-methylbenzamide hydrochloride was obtained (0.010 g). MS m/z 579.0 [M + H].

EXAMPLE SP-248

The following compounds,

3-{[(2S)-2-butylpyrrolidin-1-yl]carbonyl}-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-

hydroxypropyl}-5-methylbenzamide, MS m/z 606.4 [M + H];

 $N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mu)]$ 

ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-{[(2S)-2-

25 propylpyrrolidin-1-yl]carbonyl}benzamide formic acid salt, MS
 m/z 638.6 [M + H];

 $N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-mu)]$ 

ethylbenzyl) amino]-2-hydroxypropyl}-3- $\{[(2R)-2-(2-1)]$ 

methoxyethyl)pyrrolidin-1-yl]carbonyl}-5-methylbenzamide,

MS

30 m/z 608.6[M + H]; and

ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2S)-2-

ethylpyrrolidin-1-yl]carbonyl}-5-methylbenzamide

hydrochloride; were prepared in a manner similar to that outlined above for EXAMPLE SP-247.

EXAMPLE SP-249

5 The following compounds;

N-{(1S,2R)-1-(3,5-difluorobenzy1)-2-hydroxy-3-[(3-isopropylbenzy1)amino]propyl}-3-{[(2R)-2-(methoxymethyl)pyrrolidin-1-yl]carbonyl}-5-methylbenzamide

10 hydrochloride, MS m/z 608.3 [M + H];

N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethynylbenzyl)amino]-2-hydroxypropyl}-3-{[(2R)-2-(methoxymethyl)pyrrolidin-1-yl]carbonyl}-5-methylbenzamide hydrochloride, MS m/z 590.3 [M + H]; and

15 N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-3-{[(2R)-2-(methoxymethyl)pyrrolidin-1-yl]carbonyl}-5-methylbenzamide hydrochloride, MS m/z 620.3 [M + H]; were also prepared using the methods disclosed herein.

20

EXAMPLE SP-250

Preparation of:  $N-[(1S,2R)-3-\{[1-(3-bromophenyl) cyclopropyl] amino}-1-(3,5-difluorobenzyl)-2-hydroxypropyl] acetamide:$ 

25

Step 1: A stirred solution of N-{(1S)-2-(3,5-difluorophenyl)-1-[(2S)-oxiran-2-yl]ethyl}acetamide (4.96 g) and 1-(3-bromophenyl)cyclopropylamine (8.6 g) in 60 mL of *i*-PrOH was heated to 75 °C for 3 h. The cooled solution was evaporated and the residue re-dissolved in ethyl acetate (200 mL). The organic layer was washed with 10 % aqueous HCl (25 mL x 2). The aqueous washings were extracted once with EtOAc (75 mL) and the combined organic layers washed with a saturated solution of NaCl (100 mL). The organic layers were then dried

over  $Na_2SO_4$  and evaporated to yield a residue that was purified by column chromatography to give 5.0 g of tert-butyl (1S,2R)-3-{[1-(3-bromophenyl)cyclopropyl]amino}-1-(3,5-difluorobenzyl)-2-hydroxypropylcarbamate.

5

10

15

To a suspension of tert-butyl (1S,2R)-3-{[1-(3-Step 2: bromophenyl)cyclopropyl]amino}-1-(3,5-difluorobenzyl)-2hydroxypropylcarbamate (1.3 g) in 5.0 mL of dichloromethane was added 5.0 mL of trifluoroacetic acid at 23 °C. stirring for 1 h, 10.0 mL of toluene was added and the The resulting residue was re-dissolved solution evaporated. in toluene and the solution evaporated. This procedure was repeated once more. After drying under high vacuum for 2 h, the residue was suspended in dichloromethane (10.0 mL) and triethylamine (0.5 g) and acetylimidazole (0.3 g) were added. The solution was stirred for 4 h and concentrated under The residue was purified by column reduced pressure. chromatography to yield 0.90 g of the title compound. ES+ found  $(M+H^{+})$ : 455.

20

## EXAMPLE SP-251

Preparation of N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[1-(3'-methoxy-1,1'-biphenyl-3-yl)cyclopropyl]amino}propyl)acetamide:

25

30

of  $N-[(1S, 2R)-3-\{[1-(3-$ To solution а bromophenyl)cyclopropyl]amino}-1-(3,5-difluorobenzyl)-2hydroxypropyl]acetamide (0.030 g) in DMF (0.75 mL) was added 3-methoxyphenylboronic acid (0.030 g), Cs<sub>2</sub>CO<sub>3</sub> (0.085 g) and Pd(Ph<sub>3</sub>P)<sub>4</sub>. The mixture was heated for 12 h at 90 °C. The cooled solution was diluted with EtOAc (15 mL) and washed with The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, brine  $(10 \text{ mL } \times 2)$ . filtered, and evaporated under reduced pressure. The

resulting residue was purified by column chromatography to give 0.010 g of the title compound. ES+ found (M+H+): 481.

#### EXAMPLE SP-251

- 5 N-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-({1-[3'-(hydroxymethyl)-1,1'-biphenyl-3-yl]cyclopropyl}amino)propyl]acetamide, was prepared by the method of N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[1-(3'-methoxy-1,1'-biphenyl-3-
- 10 yl)cyclopropyl]amino}propyl)acetamide step 1, using 3-(hydroxymethyl)phenylboronic acid (0.036 g) to give 0.008 g of the title compound. ES+ found (M+H<sup>+</sup>):481.

### EXAMPLE SP-252A

N-[(1S,2R)-3-{[1-(2'-acetyl-1,1'-biphenyl-3-yl)cyclopropyl]amino}-1-(3,5-difluorobenzyl)-2-hydroxypropyl]acetamide was prepared by the method of N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[1-(3'-methoxy-1,1'-biphenyl-3-yl)cyclopropyl]amino}propyl)acetamide step 1, using 2-acetylphenylboronic acid (0.032 g) to give 0.012 g of the title compound. ES+ found (M+H<sup>+</sup>):493.

## EXAMPLE SP-252B

N-[(1s,2r)-1-(3,5-difluorobenzyl)-3-({1-[3-(5-formylthien-2-yl)phenyl]cyclopropyl}amino)-2-hydroxypropyl]acetamide was prepared by the method of N-((1s,2r)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[1-(3'-methoxy-1,1'-biphenyl-3-yl)cyclopropyl]amino}propyl)acetamide step 1, using 5-formylthien-2-ylboronic acid (0.030 g) to give 0.005 g of the

30 title compound. ES+ found (M+H+): 484.

EXAMPLES 2453A to 2453D

EXAMPLE SP-253A

 $N^1-\{(1S,2R)-1-(cyclopentylmethy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1\}-5-methyl-N^3,N^3-dipropylisophthalamide hydrochloride;$ 

5 EXAMPLE SP-253B

 $N^1$ -[(1S,2R)-3-[(3-bromobenzyl)amino]-1-(cyclopentylmethyl)-2-hydroxypropyl]-5-methyl- $N^3$ ,  $N^3$ -dipropylisophthalamide hydrochloride;

- 10 EXAMPLE SP-253C
  - $\label{eq:N3-1-(cyclohexylmethyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-N^3, N^3-dipropylisophthalamide hydrochloride;$
- 15 EXAMPLE SP-253D

 $N^{1}$ -[(1S, 2R)-3-[(3-bromobenzyl)amino]-1-(cyclohexylmethyl)-2-hydroxypropyl]-5-methyl- $N^{3}$ ,  $N^{3}$ -dipropylisophthalamide hydrochloride;

20 EXAMPLE SP-254A

N<sup>1</sup>-{(1S,2R)-1-(cyclopentylmethyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-N<sup>3</sup>,N<sup>3</sup>-dipropylisophthalamide hydrochloride (EXAMPLE SP-254) and N<sup>1</sup>-[(1S,2R)-3-[(3-bromobenzyl)amino]-1-(cyclopentylmethyl)-2-hydroxypropyl]-5-methyl-N<sup>3</sup>,N<sup>3</sup>-dipropylisophthalamide hydrochloride (EXAMPLE SI 255)

or CDI

Step 1: Cyclopentyl magnesium bromide (8 mL of 2M ethereal solution) was added to cuprous bromide/dimethylsulfide complex (0.33 g, 1.6 mmol) in 10 mL of dry THF cooled to - 25°C under nitrogen. After 20 min, a solution of tert-butyl (2R)-2-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]aziridine-1-carboxylate (1.95 g, 8 mmol) in 4 mL of dry THF was introduced. The mixture was allowed to warm to ambient temperature overnight. It was quenched with saturated aqueous NH<sub>4</sub>Cl and extracted with ethyl ether. The organic phase was washed with aqueous saturated NH<sub>4</sub>Cl, 1 N NaHCO<sub>3</sub>, and brine. It was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated to 2.38 g of a solid. This material was dissolved in 70 mL of methanol, 12 g of Dowex 50WX2-400 was

added, and the mixture was refluxed for 2 h. The mixture was filtered, washing with methanol and dichloromethane. A clean receiver was attached, and the resin was washed with 100 mL of 1:1 concentrated NH4OH: ethanol. The filtrate was concentrated to 1.16 g of tan crystals. The crystals were dissolved in 30 5 mL of dry THF, and 1.5 g (6.9 mmol) of di-t-butyldicarbonate The mixture was stirred under nitrogen was introduced. overnight. It was concentrated, extracted with ether and the ether was washed with several portions of water and brine. Drying over Na<sub>2</sub>SO<sub>4</sub> and concentration afforded 1.8 g (6.7 mmol, 10 84% from tert-butyl (2R)-2-[(4S)-2,2-dimethyl-1,3-dioxolan-4-(1S, 2S) - 1 yl]aziridine-1-carboxylate) of tert-butyl [cyclopentylmethy] -2, 3-dihydroxypropylcarbamate:  $^{1}H$  NMR (CDCl<sub>3</sub>)  $\delta$  4.5 (d, 1 H, NH), 3.7 (m, 1 H), 3.6-3.49 (m, 2 H), 3.36 (m, 1 H), 3.26 (t, 1 H, OH), 2.76 (d, 1 H, OH), 1.45 (s, 9 H), 1.88-15 1.36 (m, 9 H), 1.17-1.08 (m, 2 H).

Step 2: Toluenesulfonyl imidazole (Ts-Im, 2.22 g, 10 mmol) was tert-butyl (1S, 2S) - 1 - [cyclopentylmethy] - 2, 3 added to dihydroxypropylcarbamate (1.8 g, 6.7 mmol) in 15 mL of dry THF 20 under nitrogen, cooled in an ice bath. To this was added 13.4 mL (13.4 mmol) of a 1M solution of potassium-t-butoxide in THF over 8 min. After 5 min, the ice bath was removed and the orange mixture was stirred for 3 h. It was quenched with 1 N KH2PO4 and diluted with ether. The organic phase was washed 25 with 1 N KH<sub>2</sub>PO<sub>4</sub>, water, and brine. The solution was dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and chromatographed over silica gel, eluting with 5% dichloromethane, 15% ethyl acetate, and 80% heptane. Fraction 4 afforded 900 mg of a 2:1 mixture of tertbutyl (1S)-2-(cyclopentyl)-1-[(2S)-oxiran-2-yl]ethylcarbamate 30 and a side product. Fraction 5 afforded 230 mg of tert-butyl (1S)-2-(cyclopentyl)-1-[(2S)-oxiran-2-yl]ethylcarbamate: <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  4.56 (d, 1 H), 3.45 (m, 1 H), 2.85 (m, 1 H), 2.75 (m,

2 H), 1.91 (m, 1 H), 1.8 (m, 2 H), 1.6-1.4 (m, 6 H), 1.44 (s, 9 H), 1.13-1.07 (m, 2 H).

#### EXAMPLE SP-254B

5  $N^{1}$ -{(1S,2R)-1-(cyclopentylmethyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl- $N^{3}$ , $N^{3}$ -dipropylisophthalamide hydrochloride

Step 3: To tert-butyl (1S)-2-(cyclopentyl)-1-[(2S)-oxiran-2yl]ethylcarbamate (230 mg, 0.9 mmol) was added 260 mg (1.9 10 mmol) of m-ethylbenzylamine in 5 mL of isopropanol. mixture was refluxed for 1.5 h under nitrogen, the solvent was removed in vacuo, and the residue was dissolved in ethyl acetate. It was washed three times with small portions of 10% HCl, and the aqueous phases were back-extracted with ethyl 15 acetate. The combined organic phases were washed with 1 N  $\,$  $NaHCO_3$  and brine, dried over  $Na_2SO_4$ , and concentrated. The residue was partially purified by forming the HCl salt, triturating with pentane, and then neutralizing to the free 20 base (290 mg, 0.74 mmol). To this was added 2 mL of trifluoroacetic acid (TFA) and 2 mL of dichloromethane, and the mixture was stirred under nitrogen for 30 min. It was concentrated to an oil which was dissolved in 2 mL of dry THF and neutralized with 0.2 mL of 4-methyl morpholine. To this mixture was added a solution of 3-[(dipropylamino)carbonyl]-5-25 methylbenzoic acid (0.2 g, 0.76 mmol) and carbonyldiimidazole (CDI, 0.13 g, 0.8 mmol) in 3 mL of dry THF, which had been stirring together for 35 min. The reaction was stirred under nitrogen overnight. To the mixture was added 1 N  $\mbox{KH}_2\mbox{PO}_4$  and 30 ethyl acetate. The organic phase was washed with 1 N  $\mathrm{KH_2PO_4}$ , 1 N NaHCO<sub>3</sub> (2X) and brine, dried over  $Na_2SO_4$ , and concentrated. Chromatography over silica gel, eluting with 6% methanol (containing 1%  $NH_4OH$ ) in dichloromethane afforded 109 mg (0.19  $N^{1}$ -{(1S,2R)-1-(cyclopentylmethyl)-3-[(3mmol) οf

ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl- $N^3$ , $N^3$ -dipropylisophthalamide hydrochloride (EXAMPLE SP-254) after formation of the salt with ethereal HCl: CI MS m/z 536 [M+H] $^+$ .

- 5 EXAMPLE SP-255  $N^{1}-[(1S,2R)-3-[(3-bromobenzyl)amino]-1-(cyclopentylmethyl)-2-hydroxypropyl]-5-methyl-N^{3},N^{3}-dipropylisophthalamide hydrochloride$
- containing tert-butyl 10 Step 3: The fraction (cyclopentyl)-1-[(2S)-oxiran-2-yl]ethylcarbamate (ca. and a side product, described in the above example, was reacted with m-bromobenzylamine (10 mmol) in 12 isopropanol at reflux for 3 h. The solvent was removed and the residue was dissolved in ethyl acetate. This was washed with 15 several portions of 10% HCl, 1 N NaHCO3, and brine, dried (Na<sub>2</sub>SO<sub>4</sub>), concentrated. Chromatography on silica gel, eluting with dichloromethane, then up to 2% of methanol (containing 1%  $NH_4OH$ ) in dichloromethane afforded 523 mg ( 1.19 mmol, 60% based on epoxide) of the oily addition product. This material 20 (0.31 g, 0.7 mmol) was dissolved in 2 mL of dichloromethane, and 1 mL of TFA was added. After 1 h it was concentrated, dissolved in ethyl acetate, neutralized with 1 N NaHCO3, washed with brine, and concentrated to the free base. To this was added 4 mL of dry THF and a pre-mixed (for 2 h) solution of 3-25 [(dipropylamino)carbonyl]-5-methylbenzoic acid (190 mg, 0.72 mmol) and CDI (120 mg, 0.74 mmol) in 3 mL of dry THF. After 2 days the reaction was quenched with 1 N KH2PO4 and dissolved in ethyl acetate.
- 30 The organic phase was washed with 1 N  $KH_2PO_4$ , 1 N NaHCO<sub>3</sub> (2X) and brine, dried over  $Na_2SO_4$ , and concentrated. Chromatography over silica gel, eluting with 5% methanol (containing 1%  $NH_4OH$ ) in dichloromethane afforded 184 mg (0.29 mmol) of  $N^1$ -[(1S,2R)-3-[(3-bromobenzyl)amino]-1-(cyclopentylmethyl)-2-

hydroxypropyl]-5-methyl- $N^3$ ,  $N^3$ -dipropylisophthalamide hydrochloride EXAMPLE SP-255 as a white solid after formation of the salt with ethereal HCl: CI MS m/z 586 [M+H]<sup>+</sup>.

- 5 N¹-{(1S,2R)-1-(cyclohexylmethyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-N³,N³-dipropylisophthalamide
  hydrochloride (EXAMPLE SP-256) and N¹-[(1S,2R)-3-[(3-bromobenzyl)amino]-1-(cyclohexylmethyl)-2-hydroxypropyl]-5-methyl-N³,N³-dipropylisophthalamide hydrochloride (EXAMPLE SP
  10 257)
- Step 1: Cyclohexyl magnesium bromide was prepared by adding cyclohexyl bromide (2.46 mL, 20 mmol) to magnesium turnings (0.97 g, 40 mmol) in dry THF (20 mL) and refluxing for 1.5 h. 15 Following the procedures described in step 1 for the previous EXAMPLE S-tert-butyl (1S, 2S) - 1 - [cyclohexylmethy] - 2,3 dihydroxypropylcarbamate was obtained as 1.66 g (5.8 mmol, 70% from tert-butyl (2R)-2-[(4S)-2,2-dimethyl-1,3-dioxolan-4yl]aziridine-1-carboxylate) of a slightly yellow oil which solidified on standing:  $^{1}\text{H}$  NMR (CDCl3)  $\delta$  4.43 (d, 1 H, NH), 20 3.69 (m, 1 H), 3.59 (m, 2 H), 3.32 (m, 1 H), 3.24 (t, 1 H, OH), 2.70 (d, 1 H, OH), 1.45 (s, 9 H), 1.8-1.13 (m, 11 H), 1.01 (m, 1 H), 0.87 (m, 1 H).
- Step 2: tert-Butyl (1S,2S)-1-[cyclohexylmethy]-2,3-dihydroxypropylcarbamate (1.6 g, 5.5 mmol) was reacted with Ts-Im (1.5 g, 6.75 mmol) and potassium t-butoxide (11 mL of a 1 M solution in THF) in 20 mL of dry THF according to the procedure described in step 2 for the preceding example.
  Chromatography on silica gel, eluting with 5% dichloromethane and 5%, increasing to 15% ethyl acetate in heptane afforded 456 mg 1.7 mmol, of tert-butyl (1S)-2-(cyclohexyl)-1-[(2S)-oxiran-2-yl]ethylcarbamate: ¹H NMR (CDCl<sub>3</sub>) δ 4.41 (m, 1 H),

3.55 (m, 1 H), 2.84 (m, 1 H), 2.75 (m, 2 H), 1.8-1.6 (m, 4 H), 1.45 (s, 9 H), 1.4-1.1 (m, 7 H), 0.98 (m, 1 H), 0.86 (m, 1H).

### EXAMPLE SP-256

 $N^1-\{(1S,2R)-1-(cyclohexylmethyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-5-methyl-N^3,N^3-dipropylisophthalamide hydrochloride$ 

tert-Butyl (1S)-2-(cyclohexyl)-1-[(2S)-oxiran-2-3: Step yl]ethylcarbamate (225 mg, 0.84 mmol) was refluxed with m-10 ethyl benzylamine (254 mg, 1.9 mmol) in 5 mL of isopropanol under nitrogen for 1.5 h, the solvent was removed in vacuo, and the residue was dissolved in ethyl acetate. It was washed three times with small portions of 10% HCl, and the aqueous phases were back-extracted with ethyl acetate. The combined 15 organic phases were washed with 1 N NaHCO3 and brine, dried over  $Na_2SO_4$ , and concentrated. The resulting oil (300 mg) was dissolved in 2 mL of dichloromethane and 2 mL of TFA and stirred for 30 min. It was concentrated, and by weight determined to contain 4 eq. of TFA. This was dissolved in 2 mL 20 of dry THF, and 0.4 mL (3.6 mmol) of 4-methyl morpholine was added. This was cooled to - 30°C, and a mixture of 3-[(dipropylamino)carbonyl]-5-methylbenzoic acid (238 mg, 0.9 mmol) and CDI (165 mg, 1 mmol) in 3 mL of dry THF, which had previously been stirred together for 1 h at room temperature, 25 The mixture was allowed to warm to ambient was added. temperature. After 3 days the reaction was quenched with 1  ${\tt N}$  $\ensuremath{\text{KH}_2\text{PO}_4}$  and dissolved in ethyl acetate. The organic phase was washed with 1 N  $KH_2PO_4$ , 1 N  $NaHCO_3$  (2X) and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. Chromatography over silica gel, 30 eluting with 4% to 10% methanol (containing 1% NH4OH) in dichloromethane afforded 124 mg (0.21 mmol) of  $N^{1}$ -{(1S,2R)-1-(cyclohexylmethyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide hydrochloride (EXAMPLE

SP-256) as a white solid after formation of the salt with ethereal HCl: CI MS m/z 550 [M+H]<sup>+</sup>.

### EXAMPLE SP-257

5 N<sup>1</sup>-[(1S,2R)-3-[(3-bromobenzyl)amino]-1-(cyclohexylmethyl)-2-hydroxypropyl]-5-methyl-N<sup>3</sup>,N<sup>3</sup>-dipropylisophthalamide hydrochloride

Step 3: tert-Butyl (1S)-2-(cyclohexyl)-1-[(2S)-oxiran-2yl]ethylcarbamate (225 mg, 0.84 mmol) was refluxed with m-10 bromobenzylamine (380 mg, 2.0 mmol) in 7 mL of isopropanol under nitrogen for 2 h, the solvent was removed in vacuo, and the residue was dissolved in ethyl acetate. It was washed three times with small portions of 10% HCl, and the aqueous phases were back-extracted with ethyl acetate. The combined 15 organic phases were washed with 1 N NaHCO3 and brine, dried over  $Na_2SO_4$ , and concentrated. The resulting oil (356 mg) was dissolved in 3 mL of dichloromethane and 2 mL of TFA and stirred for 1.5 h. It was concentrated, and by weight determined to contain 3 eq. of TFA. To this was added 2 mL of 20 dry dimethylformamide (DMF) and 0.35 mL (3.2 mmol) of 4-methyl morpholine. To this was added a pre-mixed solution of 3-[(dipropylamino)carbonyl]-5-methylbenzoic acid (240 mg, mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 25 (EDC, 190 mg, 1 mmol), hydroxybenzotriazole hydrate (HOBT, 135 mg, 1 mmol) in 3 mL of dry DMF, which had been stirring together for 1.5 h. . After 3 days the reaction was quenched with 1 N  $\mathrm{KH}_2\mathrm{PO}_4$  and dissolved in ethyl acetate. The organic phase was washed with 1 N  $\mathrm{KH_2PO_4}$ , 1 30 N NaHCO $_3$  (2X) and brine, dried over Na $_2$ SO $_4$ , and concentrated. Chromatography over silica gel, eluting with 5% methanol (containing 1%  $NH_4OH$ ) in dichloromethane afforded 208 mg (0.32  $N^{1}$ -[(1S,2R)-3-[(3-bromobenzyl)amino]-1of (cyclohexylmethyl) - 2 - hydroxypropyl] - 5 - methyl - N<sup>3</sup>, N<sup>3</sup> -

dipropylisophthalamide hydrochloride (EXAMPLE SP-257) after formation of the salt with ethereal HCl: CI MS m/z 600 [M+H]<sup>+</sup>.

#### EXAMPLE SP-258

5 Synthesis of  $N^1$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[({2-[(dimethylamino)methyl]} pyridin-4-yl}methyl)amino]-2-hydroxypropyl} -5-(1,3-oxazol-2-yl)- $N^3$ ,  $N^3$ -dipropylisophthalamide

10

15

Step 1: Trimethyloxonium tetrafluoroborate (2.46 g, 16.7 mmol) was added dropwise at room temperature to a solution of 4-cyanopyridine N-oxide (compound 35, above) (2.0 g, 16.7 mmol) in methylene chloride (260 mL) and the reaction mixture stirred at room temperature overnight. The reaction was concentrated under reduced pressure to give the desired 4-cyanopyridinum N-methoxy tetrafluoroborate: <sup>1</sup>H NMR (300 MHz,

DMSO- $d_6$ )  $\delta$  9.80 (d, J = 6.0 Hz, 2H), 8.87 (d, J = 6.0 Hz, 2H), 4.48 (s, 3H).

Step 2: An aqueous solution of ammonium persulfate (8.3 mL, 5 8.3 mmol) was added to a refluxing solution of the Nmethoxypyridinium salt prepared in step 1 was dissolved in methanol (200 mL). After stirring for 0.5 h, additional 1 M ammonium persulfate was added (4.2 mL, 4.2 mmol) and the reaction mixture was heated at reflux overnight. The reaction 10 mixture was cooled to room temperature and concentrated under reduced pressure. The residue was partitioned between methylene chloride and saturated sodium bicarbonate. The organic layer was separated and washed with water, saturated sodium chloride, dried (sodium sulfate), filtered, and 15 concentrated under reduced pressure to give a white solid. Purification by flash column chromatography (silica, 98:2 methylene chloride/methanol) gave 4-cyano-2hydroxymethylpyridine (36) as a white solid (670 mg, 30%): 1H NMR (300 MHz, CDCl3)  $\delta$  8.75 (d, J = 5.0 Hz, 1H), 7.59 (d, J = 20 0.5 Hz, 1H), 7.46 (dd, J = 5.3, 0.5 Hz, 1H), 4.85 (d, J = 5.3)Hz, 2H), 3.25 (t, J = 5.3 Hz, 1H).

Step 3: Bromine (1.07 mL, 20.8 mmol) was added slowly at 0 °C to a solution of triphenylphosphine (5.53 g, 21.1 mmol) in methylene chloride (97 mL). The solution was warmed to room temperature and a white precipitate was observed. hydroxymethylpyridine 36 (2.61 g, 19.5 mmol) in methylene chloride (20 mL) was added dropwise and the reaction mixture was stirred at room temperature overnight. The reaction mixture was partitioned between water and methylene chloride. The organic layer was washed with saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure to give a white solid. Purification by flash Column chromatography (silica, 99:1 methylene

25

30

chloride/methanol) gave 4-cyano-2-bromomethylpyridine (3.95 g), which was used immediately in the next step without further purification:  $^{1}$ H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.76 (d, J = 5.0 Hz, 1H), 7.7 (s, 1H), 7.46 (dd, J = 5.0, 1.3 Hz, 1H), 4.58 (s, 2H).

5

25

30

Step 4: Dimethylamine hydrochloride (4.78 g, 58.6 mmol) was added to a solution of 4-cyano-2-bromomethylpyridine (3.95 g, 19.5 mmol) and triethylamine (13.58 mL, 97.7 mmol) in acetone (40 mL). The reaction mixture was stirred overnight at room 10 temperature in a sealed tube. The reaction mixture was concentrated under reduced pressure and partitioned between methylene chloride and saturated sodium bicarbonate. organic layer was separated and washed with water, saturated sodium chloride, dried (sodium sulfate), filtered, and 15 concentrated under reduced pressure. Purification by flash methylene chromatography (silica, 99:1 column the desired 4-cvano-2chloride/methanol) gave (dimethylamino)methylpyridine (2.10 g): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.73 (d, J = 5.0 Hz, 1H), 7.71 (s, 1H), 7.41 (dd, J = 5.0, 20 1.2 Hz, 1H), 3.65 (s, 2H), 2.31 (s, 6H); ESI MS m/z 162 [M + H]<sup>+</sup>.

Step 5: A mixture of 4-cyano-2-(dimethylamino)methylpyridine 4.97 mmol), palladium (80 mg, 10% Pd/C) concentrated hydrochloric acid (3 mL) in methanol (30 mL) was shaken under 60 psi of hydrogen overnight. The reaction mixture was filtered through diatomaceous earth and the filter cake rinsed with water and methanol. The filtrate was concentrated under reduced pressure and the residue partitioned between water and methylene chloride. The aqueous layer was made alkaline with 1 N sodium hydroxide and extracted with methylene chloride. The organic layer was washed with saturated sodium chloride, dried (sodium sulfate),

filtered, and concentrated under reduced pressure to give an orange oil. Purification by flash column chromatography (97:3 2-propanol/ammonium hydroxide) gave 4-aminomethyl-2-(dimethylamino) methylpyridine 37 (492 mg):  $^{1}$ H NMR (500 Hz, CDCl<sub>3</sub>)  $\delta$  8.50 (d, J = 5.1 Hz, 1H), 7.37 (s, 1H), 7.15 (d, J = 5.1 Hz, 1H), 3.91 (s, 2H), 3.58 (s, 2H), 2.30 (s, 6H); ESI MS m/z 166 [M + H] $^{+}$ .

Step 6: A mixture of 4-aminomethyl-2-(dimethylamino) 10 methylpyridine 37 (490 mg, 2.98 mmol) and tert-butyl (1S)-2-(3,5-difluorophenyl)-1-[(2S)-oxiran-2-yl] ethylcarbamate mg, 2.98 mmol) in 2-propanol (20 mL) was heated at reflux overnight. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. 15 residue was purified by flash column chromatography (99:1 2propanol/ammonium hydroxide) to give product (590 mg): ESI MS m/z 465 [M + H]<sup>+</sup>.

Step 7: Hydrogen chloride (6.3 mL of a 4 N solution in dioxane, 25 mmol) was added at room temperature to a solution of the yellow solid prepared in step 6 (590 mg, 1.26 mmol) in dioxane (6.3 mL) and the reaction mixture stirred at room temperature for 6 h. The reaction mixture was concentrated under reduced pressure and the residue dissolved in methylene chloride containing N,N-diisopropylethylamine (3 mL). The organic phase was washed with water, and saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure to give the product (523 mg): ESI MS m/z 365 [M + H]<sup>+</sup>

30

Step 8: A solution of 3-[(dipropylamino)carbonyl]-5-(1,3-oxazol-2-yl)benzoic acid  $\bf 38$  (120 mg, 0.38 mmol) in methylene chloride (3.8 mL) containing N,N-diisopropylethylamine (132  $\mu$ L, 0.76 mmol) and HBTU (151 mg, 0.40 mmol) was stirred at

room temperature for 0.5 h. To the above solution was added a solution of the orange oil from step 7 (207 mg, 0.57 mmol) in containing N, N-(3.8) mL) chloride methylene diisopropylethylamine (132  $\mu L$ , 0.76 mmol) and the reaction mixture was stirred at room temperature for 18 h. reaction mixture was then diluted with additional methylene chloride and washed with saturated sodium bicarbonate and saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure to yield an oily residue. Purification by flash column chromatography (silica, 10 90:10 methylene chloride/methanol) gave  $N^1-\{(1S,2R)-1-(3,5-1)\}$ methyl]pyridin-4difluorobenzyl)-3-[({2-(dimethylamino) yl $\mbox{methyl}$ )amino]-2-hydroxypropyl $\mbox{-5-(1,3-oxazol-2-yl)-N}^3, N^3-\mbox{-3-(1,3-oxazol-2-yl)-N}^3$ dipropylisophthalamide (178 mg): mp 63-66 °C; ESI MS m/z 663  $[M + H]^+$ . 15

### EXAMPLE SP-259

Synthesis of  $N^1$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[({4-[(dimethylamino)methyl]} pyridin-2-yl}methyl)amino]-2-20 hydroxypropyl} -5-(1,3-oxazol-2-yl)- $N^3$ ,  $N^3$ -dipropylisophthalamide, compound 94 in scheme 23, below

Synthesis of 2-cyano-4-(dimethylamino)methylpyridine (92)

Step 1: A mixture of 4-(hydroxymethyl)pyridine (17.4 g, 159 5 mmol), t-butyldimethylsilyl chloride (26.36 g, 174.88 mmol), and imidazole (13.31 g, 195.5 mmol) in N, N-dimethyformamide (200 mL) and methylene chloride (20 mL) was stirred overnight at room temperature. The reaction mixture was concentrated under reduced pressure and then partitioned between water and 10 a mixture of ethyl acetate and hexanes (1:1). The organic layer was washed with saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure to give an oil (35.62 g):  $^{1}\text{H}$  NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.43 (d, J = 6 15 Hz, 2H), 7.13 (d, J = 6 Hz, 2H), 4.63 (s, 2H), 0.84 (s, 9H), 0.05 (s, 6H).

Step 2: To a stirred solution of the oil from step 1 (35.62 g, 159 mmol) in dry methylene chloride (470 mL) was added 3-

choloroperoxybenzoic acid (47.03 g, 172.57 mmol). The reaction mixture was stirred at room temperature overnight and then partitioned between water and methylene chloride. The organic layer was washed with saturated sodium sulfite, saturated sodium bicarbonate, 1 N sodium hydroxide, and saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure to give 4-(t-butyldimethylsilyloxy)methylpyridine N-oxide  $\mathbf{91}$  (37.8 g):  $^{1}H$  NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.07 (d, J = 6 Hz, 2H), 7.13 (d, J = 6 Hz, 2H), 4.59 (s, 2H), 0.83 (s, 9H), 0.05 (s, 6H).

10

15

20

25

30

Step 3: A mixture of 4-(t-butyldimethylsilyloxy)methylpyridine N-oxide 91 (30 g, 125 mmol), triethylamine (40 mL), and trimethylsilylcyanide (44 mL, 360 mmol) was refluxed overnight. The black solution was cooled to room temperature and concentrated under reduced pressure to give a black gum. Purification by flash column chromatography (silica, 10:90 ethyl acetate/hexanes) gave an oil (20.3 g):  $^1$ H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.50 (d, J = 5 Hz, 1H), 7.55 (s, 1H), 7.34 (d, J = 5 Hz, 1H), 4.66 (s, 2H), 0.83 (s, 9H), 0.05 (s, 6H).

Step 4: Bromine (1.97 mL, 38.74 mmol) was added slowly at 0 °C to a solution of triphenylphosphine (10.29 g, 39.28 mmol) in methylene chloride (200 mL). The solution was warmed to room temperature and a white precipitate was observed. The brown oil from step 3 (9.0 g, 36.27 mmol) in methylene chloride (50 mL) was added and the reaction mixture was stirred at room temperature overnight. The reaction mixture was partitioned between water and methylene chloride. The organic layer was washed with saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure to give a brown solid. Purification by flash column chromatography (silica, 17:83 ethyl acetate/hexanes) gave a white solid (6.20

g):  $^{1}$ H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.71 (d, J = 3 Hz, 1H), 7.73 (s, 1H), 7.55 (dd, J = 6, 3 Hz, 1H), 4.42 (s, 2H).

Step 5: To a stirred solution of the solid from step 4 (9.1 g, 46.44 mmol) in acetone (90 mL) was added dimethylamine hydrochloride (11.36 g, 139.3 mmol) and trimethylamine (38.73 mL, 278.6 mmol). The reaction mixture was stirred overnight in a sealed bottle. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in water, made alkaline with 1 N sodium hydroxide to pH 10 and extracted with methylene chloride. The organic layer was washed with saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure to give 2-cyano-4-(dimethylamino)methylpyridine 92 (6.2 g): ESI MS m/z 162 [M + 15 H]\*.

EXAMPLE SP-260

 $N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[({4-

[(dimethylamino)methyl]

pyridin-2-yl}methyl)amino]-2-

20 hydroxypropyl}

 $-5-(1,3-oxazol-2-yl)-N^3,N^3-$ 

dipropylisophthalamide

Step 1: A mixture of 2-cyano-4-(dimethylamino)methylpyridine 92 (2.0 g, 12.4 mmol), 10% Pd/C (200 mg) and concentrated hydrochloric acid (8 mL) in methanol (180 mL) was shaken under 60 psi hydrogen overnight. The reaction mixture was filtered through diatomaceous earth and repeatedly washed with water and methanol. Methanol was removed under reduced pressure and the residue partitioned between water and methylene chloride. The aqueous layer was made alkaline with 1 N sodium hydroxide and extracted with methylene chloride. The organic layer was washed with saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure to give an oil (1.07 g): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.53 (d, J = 5 Hz, 1H),

7.25 (s, 1H), 7.13 (d, J = 5 Hz, 1H), 3.98 (s, 2H), 3.42 (s, 2H), 2.26 (s, 6H); ESI MS m/z 166 [M + H]<sup>+</sup>.

Step 2: A mixture of the orange oil from step 1 (500 mg, 3.03 tert-butyl (1S)-2-(3,5-difluorophenyl)-1-[(2S)and 5 oxiran-2-y1]ethylcarbamate (907 mg, 3.03 mmol) in 2-propanol (20 mL) was refluxed overnight. The reaction mixture was cooled to room temperature and concentrated under reduced residue was purified by flash column pressure. The chromatography (silica, 1:99 ammonium hydroxide/2-propanol) to 10 give a solid (1.13 g): ESI MS m/z 465 [M + H]<sup>+</sup>.

Step 3: The yellow solid from step 2 (400 mg, 0.86 mmol) was dissolved in dioxane (4.3 mL) and hydrogen chloride (4.3 mL, 4 M dioxane, 17.22 mmol) was added. The reaction mixture was stirred at room temperature for 6 h. The reaction mixture was concentrated under reduced pressure and methylene chloride and N, N-diisopropylethylamine (3 mL) were added. The organic phase was washed with water, and saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under 20 reduced pressure to give an oil (365 mg): ESI MS m/z 365 [M + H]+

15

25

Step 4: To a stirred solution of 3-[(dipropylamino)carbonyl]-5-(1,3-oxazol-2-yl)benzoic acid 93 (173.6 mg, 0.55 mmol) and N, N-diisopropyl ethylamine (191  $\mu L$ , 1.10 mmol) in methylene chloride (6.0 mL) was added HBTU (218.62 mg, 0.58 mmol) and the reaction mixture stirred for 0.5 h. To the above solution was added a solution of the orange oil from step 3 (300 mg, 0.823 mmol) and N,N-diisopropylethylamine (191  $\mu$ L, 1.10 mmol) 30 in methylene chloride (6.0 mL), and the reaction mixture was The reaction mixture was stirred under nitrogen for 18 h. then diluted with additional methylene chloride and washed with saturated sodium bicarbonate, 0.5 N hydrochloric acid,

and saturated sodium chloride,. The organic layer was then dried (sodium sulfate), filtered, and concentrated under reduced pressure to yield an oily residue. Purification by flash column chromatography (silica, 10:90 methanol/methylene chloride)  $N^{1}$ -{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[({4gave [(dimethylamino)methyl] pyridin-2-yl}methyl)amino]-2hydroxypropyl }  $-5-(1,3-oxazol-2-yl)-N^3,N^3$ dipropylisophthalamide (94) (233 mg): mp 65-68 °C; ESI MS m/z  $663 [M + H]^{+}$ 

10

5

#### EXAMPLE SP-261

Synthesis of  $N^1-\{(1S,2R)-1-(3,5-\text{difluorobenzyl})-3-[(1-\{4-[(\text{dimethylamino})\text{methyl}] pyridin-2-yl\}cyclopropyl)amino}]-2-hydroxypropyl}-5-(1,3-oxazol-2-yl)-N^3,N^3-dipropylisophthalamide)$ 

15

20

25

Step 1: То solution a of 2-cyano-4-(dimethylamino)methylpyridine 92 (prepared as in EXAMPLE SP-259) (500 mg, 3.10 mmol) in tetrahydrofuran (10 mL) was added titanium(IV) isopropoxide (1.01)mL, 3.41 and ethylmagnesium bromide (6.20 mL, 1 N THF, 6.20 mmol). stirring for 0.5 h, boron trifluoride diethyl etherate (786  $\mu L$ , 6.20 mmol) was added in one portion. The reaction mixture was stirred for 1 h at room temperature and 1 N sodium hydroxide was added to adjust the mixture to pH 9-10.

white solid generated was removed by filtration and the filtrate was partitioned between water and methylene chloride. The organic layer was washed with saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure to give a yellow oil. Purification by flash column chromatography (silica, 1:99 to 3:97 ammonium hydroxide/2-propanol) gave an oil (360 mg):  $^{1}$ H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.42 (dd, J = 6, 5 Hz, 1H), 3.41 (s, 2H), 7.02 (dd, J = 6, 5 Hz, 1H), 3.98 (s, 2H), 3.42 (s, 2H), 2.25 (s, 6H), 2.08 (s, 2H), 1.31-1.27 (m, 2H), 1.15-1.11 (m, 2H); ESI MS m/z 192  $[M + H]^{+}$ .

10

15

20

25

30

Step 2: A mixture of the oil from step 1 (350 mg, 1.83 mmol) and tert-butyl (1S)-2-(3,5-difluorophenyl)-1-[(2S)-oxiran-2-yl]ethylcarbamate (496.8 mg, 1.66 mmol) in 2-propanol (13 mL) was refluxed overnight. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica, 1:99 ammonium hydroxide/2-propanol) to give a solid (300 mg): ESI MS m/z 491 [M + H]\*.

Step 3: To a stirred solution of the solid from step 2 (300 mg, 0.61 mmol) in dioxane (6.0 mL) was added hydrochloric acid (6.0 mL, 4 N dioxane, 24.40 mmol). The reaction mixture was stirred at room temperature for 6 h. The reaction mixture was concentrated under reduced pressure and methylene chloride and N, N-diisopropylethylamine (3 mL) were added. The organic layer was washed with water, and saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure to give an oil (269 mg): ESI MS m/z 391 [M + H]<sup>+</sup>.

Step 4: To a stirred solution of 3-[(dipropylamino)carbonyl]-5-(1,3-oxazol-2-yl)benzoic acid 93 (prepared as in EXAMPLE S-

2364, step 5) (124.3 mg, 0.39 mmol) and N, N-diisopropyl ethylamine (139 µL, 0.79 mmol) in methylene chloride (3.0 mL) was added HBTU (156.5 mg, 0.41 mmol) and the reaction mixture stirred for 0.5 h. To the above solution was added a solution of the orange oil from step 3 (269.6 mg, 0.823 mmol) and N,Ndiisopropylethylamine (139 µL, 0.79 mmol) in methylene chloride (3.0 mL), and the reaction mixture was stirred under nitrogen for 18 h. The reaction mixture was then diluted with additional methylene chloride and washed with saturated sodium bicarbonate, and saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure to yield an oily residue. Purification by flash column chromatography (silica, 10:90 methanol/methylene chloride)  $N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(1-{4-[(dimethylamino)methyl] pyridin-2-yl}cyclopropyl)amino]-2hydroxypropyl}-5-(1,3-oxazol-2-yl)-N³,N³-dipropylisophthalamide **(95)** (134 mg): mp 70-72 °C; ESI MS m/z 689 [M + H]<sup>+</sup>.

EXAMPLE SP-262

10

15

Preparation of bromo-cyclopropyl cyanide 2 (modification of procedure from Org. Prep. & Proc. Int., 1995, 27(3), 355)

A mixture of 1-bromo-2-chloroethane (BCE; 120 ml), 3-bromobenzyl cyanide (25 g) and benzyl-triethylammonium chloride (TEBAC, 1.1 g) was stirred at 40°C while base (50% NaOH, 120 g) was added dropwise over 20 min. Temperature has risen to ~80°C within first 15 min. Very vigorous mechanical

stirring was continued while temperature slowly dropped to 50°C (over the next 3 hr). The mixture was deep red at this stage. After 3 hr there was no starting material (TLC). The reaction mixture was cooled down to RT, water (100 ml) was added and stirred for 5 min. Organic layer was separated and aqueous was extracted with dichloromethane (3 x). Combined organic layers were washed with water and dil. aq. HCl. Solution was dried using MgSO<sub>4</sub>, filtered and concentrated yielding deep yellow oil (126 g; still contains some BCE). Product was purified by a high vacuum fractionation using short-path set-up and single receiver. Collected fraction with bp 108-115°C / 0.1-0.05 mmHg as a heavy oily liquid 26.6 g (94%). After cooling to RT this liquid solidified.

### 15 Preparation of bromoamide 3

Bromocyanide 2 (5.9 g; 26.6 mmol) was dissolved in methanol (150 ml). To this solution while stirring KOH (25% aq soln., 0.68 ml) and hydrogen peroxide (30%, 35 ml) was added and the reaction mixture was heated at 55°C for 5 hr. At that time there was no starting material (TLC). Mixture was evaporated yielding solid residue (7.1 g; contains KOH).

## Preparation of bromoacid 4

25

30

20

10

Crude bromoamide 3 from previous reaction was slurried in methanol (10 ml) and NaOH (10% aq, 150 ml) was added. Reaction mixture was refluxed 4.5 hr (TLC control). The mixture was cooled to RT, acidified with 15% HCl (to pH 2) and concentrated. Precipitated white solid was collected by filtration. Yield 6.8 g.

Preparation of acid chloride **5** (slight modification of procedure from Synlett 1999, 11, 1763)

Thionyl chloride (2.73 ml) and benzotriazole (4.47 g) were dissolved in dry dichloromethane (25 ml). Crude bromoacid 4 (6.8 g) was dissolved in dichloromethane (120 ml) and to this stirred solution the prepared above thionyl chloride solution (22.2 ml; 1.25 eq) was added portionwise over a few minutes. Before the addition was complete, benzotriazole hydrochloride started separating out as a white solid. The reaction mixture was stirred for additional 15 min and at the end the solids were filtered off. Filtrate was stirred with anhydrous MgSO<sub>4</sub> (2 g) to destroy an excess of reagent. The solids were filtered off and filtrate was evaporated and dried under high vacuum for 1 hr to give viscous amber oil. Yield 6.6 g.

15

20

25

30

10

### Preparation of bromoamine 6

Crude acid chloride 5 was dissolved in dry acetone (40 ml), cooled to -10°C and treated with sodium azide (4 g in 15 ml of waterl). After stirring for 1 hr at -10°C a mixture was allowed to warm to 0°C and was poured into cold water (300 ml). Azide was extracted into smallest possible amount of toluene (ca. 40 ml). The toluene layer was washed with water and dried. Solids were filtered off and resulting solution was stirred and heated cautiously at 100°C for 1 hr. Conc. HCl (~25 ml) was added through condenser and mixture was refluxed for 15 min. On cooling white crystalline material precipitated and was filtered off. Filtrate was slightly concentrated, cooled down and additional portion of precipitate was collected. Combined solids were dried to give 4.1 g of bromocyclopropylamine 6 as hydrochloride salt.

Preparation of compound 7

Crude bromoamine hydrochloride 6 (2 g; 8 mmol) was dissolved in sat. aq Na<sub>2</sub>CO<sub>3</sub> (20 ml) and extracted with dichloromethane (5 x 10 ml). Combined extracts were dried, evaporated and kept overnight under vacuum. Yield of bromoamine 6 (1.68 g, 7.92 mmol). This amine was dissolved in isopropanol (20 ml) and epoxide (ii; 2.36 g, 7.92 mmol) was added. A mixture was stirred in a sealed tube at 80°C until starting epoxide was not detected by TLC (2-6 hr). Reaction mixture was cooled and solvent was evaporated to give, after drying under vacuum, white solid (3.9 g, 82 % pure).

### Preparation of compound 8

10

Crude BOC bromide 7 (3.9 g; 7.0 mmol; 1 eq) was dissolved 15 in triethylamine (20 ml) and  $PdCl_2(PPh_3)_2$  (0.196 g, 0.28 mmol; 0.04 eq) and CuI (0.068 g; 0.36 mmol; 0.05 eq) were added. Upon addition of CuI a reaction mixture turned yellow then changed color slowly to green. The reaction mixture was heated to reflux, at point which it turned orange-brown. 20 Trimethylsilyl acetylene (0.82 g, 1.2 ml, 8.2 mmol, 1.2 eg) was added via syringe. A black precipitate formed immediately. The reaction mixture was refluxed for 3 hr under nitrogen, then it was cooled to RT before partitioning between aq. sat. Na<sub>2</sub>CO<sub>3</sub> and ethyl acetate. Organic layer was separated and 25 aqueous was extracted with ethyl acetate (3 x 25 ml). Combined extracts were washed with brine, dried and evaporated. The crude product was contaminated by acetylene derived from bromoamine 6.

### 30 Preparation of BOC-acetylene 8a

To a solution of crude silyl-protected acetylene 8 (from previous reaction) in THF (5 ml) the tetrabutylammonium fluoride (1M in THF, 8 ml) was added. Mixture was stirred for

1 hr at RT, solvent was evaporated, residue was dissolved in ether (30 ml), washed with brine, dried and concentrated. Crude product was purified by flash chromatography on silica gel using ethyl acetate/hexane (2:3) mixture to give purified BOC-acetylene 8a (1.54 g, 43% from 6).

Preparation of 9:

1-(3,5-difluorobenzyl)-3-[1-(3-ethynylphenyl)cyclopropylamino)]-2-hydroxypropyl amine dihydrochloride

[1-(3,5-difluorobenzyl)-3-[1-(3-

ethynylphenyl)cyclopropylamino]-2-hydroxypropyl]-carbamic acid tert-butyl ester (2.34 g, 5.13 mmol) was treated with 4N HCl in dioxane (15.8 mL, 63.3. mmol). The resulting heterogeneous mixture was treated with methanol (10 mL) whereupon it became homogeneous over 30 min. The volatiles were evaporated in vacuo. Dioxane (20 mL) was added and the mixture was evaporated in vacuo to produce a white solid (2.33 g, 106%).

20

5

10

15

EXAMPLE SP-263

Preparation of cyclopropyl m-ethylbenzylamine (11)

$$H_2N$$

$$(Boc)_2O$$

$$Boc$$

$$Br$$

$$Br$$

$$1) PddfPdCl_2^{H_2N}$$

$$K_3PO_4, BEt_3$$

$$2) TFA$$

$$0$$

$$11$$

$$11$$

$$11$$

25

30

Preparation of 10.

1-(3-Bromo-phenyl)-cyclopropylamine 6 (25 g, 112 mmol), triethylamine(21.7g, 2170 mmol) were mixed together in  $CH_2Cl_2$  (300 mL). The solution was cooled to 0 °C and boc anhydride (25.07 g, 115 mmol) added in 4 equal portions at 15 minute

intervals. (Gas evolution noted after each addition). Mixture stirred for 30 minutes and then an additional 5 grams of boc anhyrdide was added to drive reaction to completion (GC/MS). Solution worked up with 1 N HCl (2X 100 mL), saturated aq. sodium bicarbonate (2 X 100 mL), and dried over sodium sulfate. Solvent was removed at reduced pressure and product was isolated by crystallization from cold hexanes (about 150 mL). Obtained 20.6 grams of white solid. Reduced volume of hexanes to about 75 ml and second crop was obtained (9.2 g)

10

Preparation of 11.

The Boc-bromobenzyl amine 10 (26.8 g, 94.03 mmol), and PddfPdCl<sub>2</sub> (816 mg, 0.38 mmol, 0.004 eq) were mixed together in 15 anhydrous THF (300 mL) and aqueous  $K_3PO_4$  (100 mL of 2.0 M). To this red solution was added triethylborane (100 ml of 1.0 M in THF, 100 mmol). The solution turned black and was refluxed for 4 hours. GC/MS indicated the reaction was complete. solution was poured into a separatory funnel and the aqueous 20 layer separated. The organic layer was collected and solvent removed to a volume of 100 mL. Ethyl acetate/ hexanes (300 mL of 1:1) were added and the solution was extracted with 1N HCl (1X100 mL), sodium bicarbonate (2X 100 mL) and brine (1X100 mL). The solution was dried over sodium sulfate and vacuum 25 filtered through a bed of silica gel ( 125 ml of silica). The solvent was removed at reduced pressure to afford 20.6 grams of 11 as light yellow oil.

#### EXAMPLE SP-264

Preparation of 6-Methyl-pyridine-2,4-dicarboxylic acid 4-({1-(3,5-difluoro-benzyl)-3-[1-(3-ethynyl-phenyl)-cyclopropylamino]-2-hydroxy-propyl}-amide) 2-dipropylamide

Mol. Wt.: 456.52

The Boc protected amine (prepared as in EXAMPLE SP-262) (0.912 g, 2 mM) was treated with 50% TFA in  $CH_2Cl_2$  (1 hr, RT). Solvents were removed under reduced pressure to form an oil. 5 Added toluene and evaporated; repeated stripping with toluene. After this operation and keeping residue under high vacuum for 1 hr off-white solid was obtained (free amine, most likely as a TFA salt). This amine was dissolved in  $CH_2Cl_2$  (10 mL, slurry), added acid 2 (0.528 g; 2 mM), HOBt (0.297 g; 2.2 mM) 10 and EDC (0.423 g; 2.2 mM). When EDC was added slurry rapidly became clear solution. At the end an excess of NEt3 (2 mL) was added and a reaction mixture was stirred o/n at RT. The next day solvent was stripped and EtOAc solution was washed with 15 ag. saturated solution of Na<sub>2</sub>CO<sub>3</sub> (3x), brine, dried and concentrated. Initially purified by flash chromatography on Biotage (eluted with 20% hexane and 80% EtOAc). Final purification was done by HPLC. The TFA salt was converted into HCl mono salt by addition of 1.25M solution of HCl in MeOH 20 (1.6 mL). Yield 0.971 g (76%).

### EXAMPLE SP-265

25

 $N^{1}$ -((1S, 2R)-1-(3, 5-difluorobenzyl)-3-{[1-(3ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-(1,3-oxazol-2-yl)-N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;

The above identified compound is prepared essentially using the procedure described in EXAMPLE SP-264. M+ 659.3.

5 Carbon NMR (CDCl<sub>3</sub>): 11.00, 11.56, 11.78, 15.37, 20.80, 21.90, 28.71, 35.28, 44.45, 47.26, 49.97, 51.16, 53.75, 69.43, 77.12, 102.12, 112.02, 112.34, 126.23, 126.94, 127.29, 128.01, 128.68, 129.20, 129.51, 133.90, 134.70, 137.56, 139.59, 142.15, 145.53, 160.26, 161.43, 164.73, 166.98, 170.42.

10

### EXAMPLE SP-266

 $N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-(1,3-oxazol-2-yl)- $N^{3}$ ,  $N^{3}$ -dipropylisophthalamide

15

The above identified compound is prepared essentially using the procedure described in EXAMPLE SP-264.

M+ 655.3.

Carbon NMR (CDCl<sub>3</sub>): 11.01, 11.47, 11.58, 11.98, 20.82, 21.91, 35.22, 43.94, 47.28, 50.09, 51.17, 53.77, 69.49, 77.11, 78.63, 82.55, 102.17, 112.05, 123.22, 126.23, 126.82, 128.07, 128.76,

129.49, 130.68, 133.33, 134.50, 137.57, 139.61, 142.17, 160.23, 161.27, 164.56, 167.04, 170.44.

# EXAMPLE SP-267

5 N<sup>4</sup>-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-6-methyl-N<sup>2</sup>,N<sup>2</sup>-dipropylpyridine-2,4-dicarboxamide

The above identified compound is prepared essentially using the procedure described in EXAMPLE SP-264.

Carbon NMR (CDCl<sub>3</sub>): 10.96, 11.06, 11.53, 12.09, 15.43, 20.73, 21.90, 23.96, 28.75, 33.93, 44.32, 47.82, 49.60, 50.90, 53.98, 68.65, 77.11, 101.98, 112.064, 112.39, 117.03, 122.12, 127.25, 129.23, 129.49, 134.06, 142.21, 145.61, 153.63, 158.94, 161.19, 161.36, 164.48, 164.65, 165.65, 169.06.

# EXAMPLE SP-268

M+607.3

 $N^4$ -((1S, 2R)-1-(3, 5-difluorobenzyl)-3-{[1-(3-

20 ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-6-methyl-N²,N²-dipropylpyridine-2,4-dicarboxamide

The above identified compound is prepared essentially using the procedure described in EXAMPLE SP-264. M+ 603.3.

Carbon NMR (CDCl<sub>3</sub>): 10.99, 11.58, 12.29, 20.75, 21.92, 24.03, 33.98, 43.91, 47.91, 49.83, 50.96, 53.95, 68.74, 77.13, 78.72, 82.57, 102.08, 112.08, 112.41, 117.63, 122.16, 123.32, 129.51, 130.66, 133.37, 133.55, 134.63, 142.28, 153.56, 158.96, 161.20, 161.37, 164.66, 165.80.

EXAMPLE SP-269

10 Preparation of 1-(3,5-difluorobenzyl)-3-(3-ethynyl)benzylamino)-2-hydroxypropyl amine dihydrochloride

[1-(3,5-difluorobenzyl)-3-(3-ethynylbenzylamino)-2-hydroxypropyl]-carbamic acid tert-butyl ester (2.73 g, 6.33

mmol) was treated with 4N HCl in dioxane (15.8 mL, 63.3. mmol). The mixture became homogeneous after 5 min and then deposited a precipitate. Diethyl ether (15 mL) was added to aid stirring and the mixture was stirred for 2 h. The volatiles were evaporated in vacuo. Dioxane (20 mL) was added and the mixture was evaporated in vacuo to produce a white solid (2.67 g, 104%).

EXAMPLE SP-270

15

20

 $N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethynylbenzyl)amino]-2-hydroxypropyl}-5-ethynyl- $N^{3}$ ,  $N^{3}$ -dipropylisophthalamide

$$CO_2H$$
  $CO_2H$   $CO_2H$   $CO_2H$ 

5

10

15

20

25

5-Ethynyl-N, N-dipropyl-iso-phthalamic acid (1.73 g, 6.32 mmol) was dissolved in anhydrous DMF (20 ml) under nitrogen. (1.28 g, 9.48 mmol) and 1-Hydroxybenzotriazole dimethylaminopropy)-3-ethylcarbodiimidehydrochloride (1.70 g, 8.85 mmol)) were added in succession. This mixture was stirred for 30 min at RT until homogeneous and then was added in one portion to a rapidly-stirred slurry of amine dihydrochloride (2.67, 6.32 mmol) and N-methylmorpholine ( 2.78 mL, 2.56 g, 25.3 mmol) in DMF (25mL). The resulting mixture was stirred for 2 h before diluting with saturated aq sodium bicarbonate (200 mL). The mixture was extracted with ethyl acetate (3 X 100 mL) and the combined organic extracts were washed with saturated aq sodium bicarbonate (100 mL), water (2 X 100 mL), and brine (100 mL), dried (sodium sulfate), filtered and evaporated in vacuo to give an oil (3.7 g). The product was purified using flash column chromatography on silica gel (Flash 65i cartridge, eluting with 1L 100% ethyl acetate, then 4L 95:5 ethyl acetate/methanol ) to yield a pale yellow oil (2.74 g, 74%). LC-MS (m/e): 586 (M+1); 100% (254 nm). The ELN 152006 free base was dissolved in ethanol (25 mL) and treated with 4N HCl in dioxane (2.0 mL). The resulting mixture was evaporated in vacuo to remove volatiles, re-dissolved in 1:1 ethanol/water (25 mL) and evaporated in vacuo. The resulting solid was slurried in diethyl ether (50 mL), filtered and washed with diethyl ether to produce an off-white solid which

was vacuumed dried to constant weight (2 d) to yield the desired product (2.43 g).

Analysis: for  $C_{35}H_{37}F_2N_3O_3$  +HCl: calcd.: C, 67.57; H, 6.16; N, 6.75; Cl, 5.50; found: C, 67.21; H, 6.04; N, 6.55; Cl, 5.71.

### EXAMPLE SP-271

10

Preparation of  $N^1$ -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-methyl- $N^3$ ,  $N^3$ -dipropylisophthalamide

5-Methyl-N, N-dipropyl-iso-phthalamic acid (1.35 g, 5.13 mmol, was dissolved in anhydrous DMF (15 ml) under nitrogen. 1-Hydroxybenzotriazole (1.04 g, 15 7.69 mmol) and dimethylaminopropy)-3-ethylcarbodiimide hydrochloride (1.38 g, 7.18 mmol)) were added in succession. This mixture was stirred for 30 min at RT until homogeneous and then was added in one portion to a rapidly-stirred slurry of amine dihydrochloride 20 (2.23 g, 5.13 mmol) and N-methylmorpholine ( 2.25 mL, 2.07 g,20.5 mmol) in DMF (20 mL). The resulting mixture was stirred for 3.5 h before diluting with saturated aq sodium bicarbonate The mixture was extracted with ethyl acetate (3 X 100 mL) and the combined organic extracts were washed with saturated aq sodium bicarbonate (100 mL), water (2 X 100 mL), 25 and brine (100 mL), dried (sodium sulfate), filtered and evaporated in vacuo to give an oil (3.0 g). The product was purified using flash column chromatography on silica gel (Flash 65i cartridge, eluting with 2.8L 1:1 ethyl 30 acetate/hexane, 2.5L 2:1 ethyl acetate/hexane, then 2L 100%

ethyl acetate) to yield a clear oil (2.34 g, 76%). LC-MS (m/e): 602 (M+1); 100% (254 nm). The ELN 152227 free base was dissolved in ethanol (25 mL) and treated with 4N HCl in dioxane (2.0 mL). The resulting mixture was evaporated in vacuo to remove volatiles, re-dissolved ethanol (25 mL) and evaporated in vacuo. The resulting solid was slurried in diethyl ether (50 mL) and filtered to produce a hygroscopic solid which was lyophilized to yield ELN 152227-3 (1.93 g). Analysis: for  $C_{36}H_{41}F_2N_3O_3$  +HCl + 0.8  $H_2O$ : calcd.: C, 66.26; H, 6.73; N, 6.44; Cl, 5.43; found: C, 67.21; H 6.40; N, 6.42; Cl, 5.34.

### EXAMPLE SP-272

10

20

25

30

Preparation of (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-15 ethylbenzyl)amino]butan-2-ol dihydrochloride

[1-(3,5-difluorobenzyl)-3-(3of The slurry acid ethylbenzylamino)-2-hydroxypropyl]-carbamic tert-butyl ester (5.25 g, 0.012 m) in anhydrous dioxane (20 ml) was stirred (magnetic bar) at RT under nitrogen atmosphere in an 250 ml round-bottom flask, immersed in a cold water bath. The solution of hydrogen chloride in dioxane (4M, 32 ml) was added in one portion. The reaction mixture, initially homogenous, became a thick slurry within ca. 20 min. Mixture was stirred for 70 min, and was monitored by the TLC (silica gel plates, 5 x 10 cm, eluted with ethyl acetate - methanol 95:5 mixture). Ethyl ether (100 ml) was added, precipitated product was filtered off and rinsed with ether (2  $\times$  50 ml). The filter cake was air-dried for 1 hour then placed in an vacuum oven at

35 °C and the oven evacuated (5 torr). Product was dried to constant mass for 7 hours. Yield was 5.24 g. LC-MS (m/e): 335 (M+1); purity: 100% (254 nm).

### 5 EXAMPLE SP-273

 $N^1$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-ethynyl- $N^3$ ,  $N^3$ -dipropylisophthalamide

10 The 5-ethynyl-N,N-dipropyl-iso-phthalamic acid 0.006m) was dissolved in anhydrous DMF (30 ml) in an roundbottom flask (50 ml) equipped with magnetic stirring bar. Flask was flushed with nitrogen and HOBt (1.23 g, 0.009m, 1.5 eq), followed by EDC (1.63 g, 0.0084m, 1.4 eq) were added. 15 This mixture was stirred for 45 min at RT and then was added in one portion to the stirred solution of amine hydrochloride  $(2.45~\mathrm{g},~0.006\mathrm{m})$  in anhydrous DMF  $(30~\mathrm{ml})$  and NMO  $(5.0~\mathrm{g},$ 0.05m, 8.5 eq). The resulted heterogeneous mixture was vigorously stirred under nitrogen at RT for 2 hr. During that time all solids gradually dissolved, mixture remained however 20 cloudy. Reaction progress was monitored by TLC (silica gel plates, 5 x 10 cm, eluted with ethyl acetate-methanol 95:5mixture). Product was isolated by diluting reaction mixture with sat. aq. sodium bicarbonate (250 ml) and extraction with 25 ethyl acetate (3 x 150 ml). Combined extracts were washed with brine and dried over magnesium sulfate. Solution was filtered and evaporated, yield of crude product was 4.6 g (yellow oil). Product was purified using flash column chromatography on silica gel (Flash 65i cartridge, applied in dichloromethane

solution and eluted with ethyl acetate-methanol 93:7 mixture). Fractions containing product were combined and evaporated to give pale yellow oil, 2.7 g. LC-MS (m/e): 590 (M+1); 100% (254 nm). Purified product was treated with ethanolic hydrogen chloride (1.05 eq), filtered and lyophilized. Yield of final hydrochloride salt was 2.4 g. LC-MS (m/e) 590 (M+1); purity: 100% (254 nm), 100% (280 nm).

<sup>1</sup>H-NMR (MeOH-d4):  $\delta$  0.70 (t, 3H), 1.01 (t, 3H), 1.23 (t, 3H), 1.53 (m, 2H), 1.73 (m, 2H), 2.67 (q, 2H), 2.87 (m, 1H), 3.05-3.35 (m, 8H), 4.00 (s, 1H), 4.01 (m, 1H), 4.25 (m, 3H), 4.91 (s), 6.77 (m, 1H), 6.91 (d, 2H), 7.29-7.38 (m, 4H), 7.56 (d, 2H), 7.79 (s, 1H).

<sup>13</sup>C-NMR: (MeOH-*d4*): 9.73, 10.17, 20.17, 21.33, 46.51-48.32, 49.27, 50.71, 54.04, 68.75, 79.79, 80.94, 101.17 (t), 111.56 (d), 123.26, 124.83, 127.00, 128.73, 129.23, 130.53, 130.95, 132.15, 134.29, 137.46, 142.69, 142.81, 145.17, 161.28 (d), 164.40 (d), 167.13, 170.28.

Analysis: for  $C_{35}H_{42}ClF_2N_3O_3 \times 0.5 H_2O$  calcd.: C, 66.18; H, 6.82; N, 6.62; Cl, 5.58; found: C, 66.07; H 6.85; N, 6.79; Cl, 5.17.

20

10

15

### EXAMPLE SP-274

Preparation of  $N^1-\{(1S,2R)-1-(3,5-\text{difluorobenzyl})-3-[(3-\text{ethylbenzyl})\,\text{amino}]-2-\text{hydroxypropyl}\}-N^3, N^3-\text{dipropyl}-5-(1,3-\text{thiazol}-2-yl)\,\text{isophthalamide}$ 

25

The N,N-dipropyl-5-thiazol-2-yl-iso-phthalamic acid (1.99 g, 0.006m) was dissolved in anhydrous DMF (30 ml) in an round-

bottom flask (50 ml) equipped with magnetic stirring bar. Flask was flushed with nitrogen and HOBt (1.24 g, 0.009m, 1.5 eq), followed by EDC (1.63 g, 0.0084m, 1.4 eq) were added. This mixture was stirred for 45 min at RT and then was added in one portion to the stirred solution of amine hydrochloride (2.45 g, 0.006m) in anhydrous DMF (30 ml) and NMO (5.0 g,0.05m, 8.5 eq). The resulted heterogeneous mixture was vigorously stirred under nitrogen at RT for 2 hr. During that time all solids gradually dissolved, mixture remained however 10 slightly cloudy. Reaction progress was monitored by (silica gel plates, 5 x 10 cm, eluted with ethyl acetatemethanol 95:5 mixture). Product was isolated by diluting reaction mixture with sat. aq. sodium bicarbonate (250 ml) and extraction with ethyl acetate (3 x 150 ml). Combined extracts 15 were washed with brine and dried over magnesium sulfate. Solution was filtered and evaporated, yield of crude product was 4.2 g (pale yellow oil). Product was purified using flash column chromatography on silica gel (Flash 65i cartridge, applied in dichloromethane solution and eluted with ethyl acetate-methanol 9:1 mixture). Fractions containing product 20 were combined and evaporated to give pale yellow oil, 2.75 g. LC-MS (m/e): 649 (M+1); purity: 100% (254 nm). Purified product was treated with ethanolic hydrogen chloride (1.05 eq) and lyophilized (added ethanol to improve solubility before 25 filtration). Yield of final hydrochloride salt was 2.6 g. LC-MS (m/e): 649 (M+1); purity: 100% (254 nm).  $^{1}\text{H-NMR}$  (MeOH-d4):  $\delta$  0.74 (t, 3H), 1.04 (t, 3H), 1.20 (t, 3H), 1.58 (m, 2H), 1.77 (m, 2H), 2.64 (q, 2H), 2.92 (m, 1H), 3.10-3.55 (m, 9H), 4.04 (m, 1H), 4.26 (m, 2H), 4.90 (s), 6.77 (m, 30 1H), 6.96 (d, 2H), 7.23-7.38 (m, 4H), 7.68 (t, 1H), 7.73 (d, 1H), 7.96 (d, 1H), 8.11 (t, 1H), 8.28 (t, 1H).

1H), 7.96 (d, 1H), 8.11 (t, 1H), 8.28 (t, 1H).

<sup>13</sup>C-NMR: (MeOH-d4): 9.76, 10.19, 14.75, 20.21, 21.39, 28.10, 35.38, 46.60-48.31, 50.75, 54.12, 68.78, 101.22 (t), 111.53 (d), 120.48, 125.65, 126.12, 126.97, 128.70, 129.218, 130.56,

133.96, 134.97, 138.00, 142.84, 143.53, 145.16, 161.31 (d), 164.52 (d), 165.96, 167.36, 170.47.

Analysis: for  $C_{36}H_{43}ClF_2N_4O_3S \times 0.5 H_2O$  calcd.: C, 62.28; H, 6.39; N, 8.07; Cl, 5.11; found: C, 62.42; H 6.24; N, 8.03; Cl, 5.10.

### EXAMPLE SP-275

2-Dipropylcarbamoyl-6-methyl-isonicotinic acid

10

15

5

Commercially available, 2-chloro-methylisotinic acid (4.07g, 23.72 mmol) was dissolved in a 30%MeOH/ THF solution (32 ml). (Trimethylsilyl)diazomethane (2.0 M solution in hexanes) was added dropwise. Bubbling was observed and more reagent was added until bubbling ceased (15mL). The reaction mixture was allowed to stir overnight at room temp. Prior to evaporation of solvent, glacial acetic acid was added to the reaction flask dropwise in order to rid of excess amine.

20

#### EXAMPLE SP-276

Reference: Fuqiang, J. and Confalone, N. Tet. Lett., 41, 2000, 3271-3273

Into a R.B flask equipped with a stir bar was added the methylated intermediate, tri(dibenzlideneacetone)dipalladium

(0), 1,1-bis(diphenylphosphine), zinc metal dust and zinc cyanide. The flask was flushed with nitrogen gas for approx. 5 min. N,N-dimethylacetamide was added via syringe. The reaction mixture was refluxed in an oil bath set at 120°C with a condenser under nitrogen atmosphere. Stir vigorously. After 4 h, the reaction mixture was partitioned between ethyl acetate (50 ml) and 2N NH<sub>4</sub>OH (50 ml) Repeat washing with 2N NH<sub>4</sub>OH (2 x 50 ml) followed by brine (50 ml). Organic phases were collected and dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated. Purification by column chromatography was performed with eluting solvent (80:20;Hex/EtOac).

### EXAMPLE SP-277

15

20

10

Dissolve nitrile intermediate (0.206g, 1.170 mmol) in methanol (5 ml). Add sodium hydroxide (0.267g, 6.675 mmol) and continue to stir at room temp. After 90 min add water (5 ml) and continue to stir for an additional 90 min. Partition between chloroform and 2 N HCl (aq). Add NaCl(s) to aqueous phase in order to saturate. Continue extraction with isopropanol:chloroform (1:3). Collect organic phases, dry over NaSO<sub>4</sub>, filter and evaporate.

25

EXAMPLE SP-278

Anhydrous dichloromethane was added to the hydrolyzed intermediate (0.136, 0.697 mmol) followed by 4-methylmorpholine. The flask was placed on an ice bath to cool prior to addition of HBTU and dipropylamine. The mixture was allowed to warm to room temp. over night under nitrogen atmosphere. Partition reaction mixture between ethyl acetate (25 ml) and water (25 ml). Wash with water followed by sat.  $NaHCO_3$  (2 x 25 ml). Organic phase was collected, dried over  $Na_2SO_4$ , filtered and evaporated.

EXAMPLE SP-279

5

10

15  $N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-5-(4-methyl-1,3-oxazol-2-yl)-N^3,N^3-dipropylisophthalamide$ 

20 Step 1: A stirred solution of methyl 3-(aminocarbonyl)-5[(dipropylamino)carbonyl]benzoate (200 mg, 0.65 mmol)
chloroacetone (10 mL, 93 mmol) and potassium carbonate (90 mg,
0.65 mmol) was refluxed for 18 h. The reaction mixture was
cooled to room temperature, diluted with ethyl acetate, washed
25 with 2 N sodium hydroxide (2 x 50 mL), and saturated sodium

chloride, dried (magnesium sulfate), and concentrated under reduced pressure. Purification by flash column chromatography (silica, 1:1 ethyl acetate/hexanes) provided methyl 3-[(dipropylamino)carbonyl]-5-(4-methyl-1,3-oxazol-2-yl)benzoate 5 (119 mg): ¹H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.70 (d, J = 1 Hz, 1H), 8.20 (d, J = 1 Hz, 1H), 8.09 (d, J = 1 Hz, 1H), 7.48 (s, 1H), 3.96 (s, 3H), 3.46 (d, J = 7 Hz, 2H), 3.16 (t, J = 7 Hz, 2H), 2.26 (s, 3H), 1.71 (d, J = 7 Hz, 2H), 1.54 (d, J = 7 Hz, 2H), 1.00 (t, J = 7 Hz, 3H), 0.74 (t, J = 7 Hz, 3H); ESI MS m/z 345 10 [M + H]<sup>+</sup>.

Step 2: A solution of methyl 3-[(dipropylamino)carbonyl]-5-(4methyl-1,3-oxazol-2-yl)benzoate (118 mg, 0.34 mmol) in methanol (1 mL) and potassium hydroxide (1 mL of a 1.0 M  $\,$ 15 solution in water, 1 mmol) was stirred at room temperature for The solvent was removed under reduced pressure, the residue was dissolved in water, extracted with ethyl acetate, the aqueous layer was acidified to pH 4 with 1 N hydrochloric acid, extracted with chloroform (3 x 100 mL), and the combined 20 organics were concentrated under reduced pressure to afford 3-[(dipropylamino)carbonyl]-5-(4-methyl-1,3-oxazol-2-yl)benzoic acid (110 mg):  $^{1}\text{H}$  NMR (300 MHz, CD<sub>3</sub>OD)  $\delta$  8.66 (d, J = 1 Hz, 1H), 8.17 (d, J = 1 Hz, 1H), 8.07 (d, J = 1 Hz, 1H), 7.75 (d, J = 1 Hz, 1H), 3.51 (t, J = 7 Hz, 2H), 3.25 (t, J = 7 Hz, 2H), 25 2.23 (s, 3H), 1.74 (d, J = 7 Hz, 2H), 1.60 (d, J = 7 Hz, 2H), 1.01 (t, J = 7 Hz, 3H), 0.76 (t, J = 7 Hz, 3H).

Step 3: A solution of 3-[(dipropylamino)carbony1]-5-(4-methyl-1,3-oxazol-2-yl)benzoic acid (77.5 mg, 0.23 mmol), (2R,3S)-3-30 amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol dihydrochloride (96 mg, 0.23 mmol), HOBt (32 mg, 0.23 mmol), and N-methylmorpholine (83 µL, 0.75 mmol) was stirred in dimethylformamide (2 mL) for 15 min. EDC (73 mg, 0.42 mmol) was added and the reaction mixture was stirred overnight. The

reaction mixture was diluted with water, and extracted with ethyl acetate (3 x 25 mL). The organic layer was washed with 1 N hydrochloric acid (25 mL), saturated sodium bicarbonate (25 mL), saturated sodium chloride, dried (sodium sulfate), and concentrated under reduced pressure. Purification by flash column chromatography (silica, 1:9 methanol/chloroform)  $N^{1}$ -{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3provided ethylbenzyl)amino]-2-hydroxypropyl}-5-(4-methyl-1,3-oxazol-2 $y1)-N^3$ ,  $N^3$ -dipropylisophthalamide (40 mg): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.20 (br s, 1H, -NH), 8.17 (s, 1H), 8.05 (s, 1H), 7.52 10 (s, 1H), 7.38 (s, 1H), 7.24-7.08 (m, 5H), 7.02 (d, J = 8 Hz,2H), 6.61 (t, J = 8 Hz, 1H), 4.27 (br s, 1H), 3.93 (d, J = 4Hz, 1H), 3.85 (s, 2H), 3.54 (br s, 2H), 3.43 (br s, 2H), 2.84 (d, J = 5 Hz, 2H), 2.63 (q, J = 8 Hz, 2H), 2.18 (s, 3H), 1.74(t, J = 5 Hz, 2H), 1.41 (d, J = 7 Hz, 2H), 1.22 (t, J = 8 Hz,15 3H), 1.03 (t, J = 7 Hz, 3H), 0.64 (t, J = 7 Hz, 3H); ESI MS m/z 647 [M + H]<sup>+</sup>

## EXAMPLE SP-280

20

 $N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}- $N^{3}$ ,  $N^{3}$ -dipropyl-5-(1,3-thiazol-2-yl)isophthalamide

25

Step 1: To a -78 °C solution of thiazole (1.2 g) in THF (25 mL) was added n-butyl lithium (1.6 M in hexanes, 10 mL). The mixture was stirred for 30 min and then allowed to warm to 0 °C

in an ice/water bath. Zinc chloride (1M in ethyl ether, 40 mL) was added and the mixture was stirred for 1 h, at which time methyl 3-[(dipropylamino)carbonyl]-5-iodobenzoate (5.1 g) in THF (20 mL) was added, followed by Pd(PPh<sub>3</sub>)<sub>4</sub> (palladium tetrakis triphenylphosphine) (0.68 g). The mixture was then heated at 80 °C for 2 h, at which time it was allowed to cool and partitioned between ethyl acetate and water. The organic layers were washed with brine, dried (magnesium sulfate), and concentrated. The residue was chromatographed on silica gel using ethyl acetate/heptane (50/50) to give 4.5 g of methyl 3-[(dipropylamino)carbonyl]-5-(1,3-thiazol-2-yl)benzoate.

10

- Step 2: Methyl 3-[(dipropylamino)carbonyl]-5-(1,3-thiazol-2-yl)benzoate (4.5 g) was dissolved in THF (20 mL), methanol (20 mL), and water (20 mL). Lithium hydroxide monohydrate (1.1 g) was added and the mixture was stirred at room temperature for 1.5 h, at which time the organic solvents were removed under reduced pressure. Some ethyl acetate and water were added and the pH was adjusted to about 0 with aq. HCl. The mixture was extracted with ethyl acetate and the organic layers were washed with brine, dried (magnesium sulfate), and concentrated to give 3.8 g of 3-[(dipropylamino)carbonyl]-5-(1,3-thiazol-2-yl)benzoic acid
- Step 3: A solution of 3-[(dipropylamino)carbonyl]-5-(1,3-thiazol-2-yl)benzoic acid (156 mg, 0.47 mmol), (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol dihydrochloride (191 mg, 0.47 mmol), HOBt (64 mg, 0.47 mmol), and N-methylmorpholine (200 µL, 1.5 mmol) was stirred in dimethylformamide (2 mL) for 15 min. EDC (145 mg, 0.84 mmol) was added and the reaction mixture was stirred overnight. The reaction mixture was diluted with water, and extracted with ethyl acetate (3 x 25 mL). The organic layer was washed with 1 N hydrochloric acid (25 mL), saturated sodium bicarbonate

(25 mL), saturated sodium chloride, dried (sodium sulfate), and concentrated under reduced pressure. Purification by flash column chromatography (silica, 1:9 methanol/chloroform)  $N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-4)]$ provided ethylbenzyl)amino]-2-hydroxypropyl}-N3,N3-dipropyl-5-(1,3thiazol-2-yl)isophthalamide (33 mg):  $^{1}\text{H}$  NMR (500 MHz, CDCl3)  $\delta$ 8.40 (br s, 1H, -NH), 8.15 (br s, 1H), 7.94 (br s, 1H), 7.80(d, J = 3 Hz, 1H), 7.51 (br s, 1H), 7.34 (d, J = 3 Hz, 1H),7.27-7.24 (m, 1H), 7.21-7.18 (m, 2H), 7.11-7.10 (m, 1H), 7.00(br s, 1H), 6.62-6.58 (m, 1H), 4.23 (d, J = 5 Hz, 1H), 3.91-10 3.85 (m, 3H), 3.57 (br s, 2H), 3.31 (br s, 2H), 3.05 (d, J = 5)Hz, 4H), 2.83 (d, , J = 6 Hz, 2H), 2.64 (q, J = 8 Hz, 2H), 1.75 (br s, 2H), 1.44 (t, J = 7 Hz, 2H), 1.22 (t, J = 8 Hz, 3H) 1.04 (t, J = 7 Hz, 3H), 0.65 (t, J = 7 Hz, 3H); ESI MS m/z $649 [M + H]^+;$ 15

### EXAMPLE SP-281

25

 $N^1$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-20 hydroxypropyl}-5-(1,3-oxazol-2-yl)- $N^3$ , $N^3$ -dipropylisophthalamide

Step 1. To an ice-cold, stirred solution of 3-amino-5-(methoxycarbonyl)benzoic acid (5.19 g, 26.59 mmol) in a 2 N hydrochloric acid (156 mL) was added a solution of sodium nitrite (1.84 g, 26.67 mmol) in water (10.8 mL). This mixture was then added dropwise to an ice-cold, stirred solution of potassium iodide (8.84 g, 53.25 mmol) in water (26.2 mL).

After stirring for 35 min, the reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with 5% aqueous sodium thiosulfate, saturated sodium chloride, dried (sodium sulfate), and concentrated under reduced pressure. Purification by flash chromatography (silica, 50:50:2 hexanes/ethyl acetate/acetic acid) afforded 3-iodo-5-(methoxycarbonyl)benzoic acid (4.48 g):  $^{1}\text{H}$  NMR (500 MHz, DMSO $d_6$ ):  $\delta$ 13.49 (br s, 1H), 8.45-8.38 (m, 3H), 3.83 (s, 3H); ESI-MS (m/z): 305  $[M + H]^+$ .

Step 2: To a mixture of 3-iodo-5-(methoxycarbonyl)benzoic acid (65.8 g, 0.215 mol), triethylamine (52.2 g, 0.516 mol), and dipropylamine (23.9 g, 0.237 mol) in methylene chloride (950 mL) was added 2-chloro-1-methylpyridinium iodide (65.9 g, 0.258 mol). The reaction mixture was stirred at room temperature for 15 h and then concentrated under reduced pressure. Purification by silica gel plug (3:1 hexanes/ethyl acetate) provided methyl 3-[(dipropylamino)carbonyl]-5-iodobenzoate (66.8 g): \frac{1}{1}NMR (300 MHz, CDCl3) \delta 8.39 (s, 1H), 7.98 (s, 1H), 7.88 (s, 1H), 3.93 (s, 3H), 3.45 (m, 2H), 3.14 (m, 2H), 1.69 (m, 2H), 1.54 (m, 2H), 0.98 (m, 3H), 0.77 (m, 3H).

10

Step 3: A stirred solution of 2-triethylstannyloxazole (Chem. 25 1994, 6, 1023)(1.5 g, 5.5 mmol) and methyl 3-[(dipropylamino)carbonyl]-5-iodobenzoate (1.8 g, 4.6 mmol) in dimethylformamide (12 mL) was degassed under reduced pressure for 15 min and purged with argon. Palladium(0) tetrakis(triphenylphosphine) (158 mg, 0.14 mmol) was added and 30 the reaction mixture was degassed under reduced pressure for 15 min and then purged with argon. The reaction mixture was heated at reflux for 2 d, cooled to room temperature, diluted with ethyl acetate, washed with water (3  $\times$  50 mL), dried

(sodium sulfate), and concentrated under reduced pressure. Purification by flash column chromatography (silica, 1:1 ethyl acetate/hexanes) provided methyl 3-[(dipropylamino)carbonyl]-5-(1,3-oxazol-2-yl)benzoate (423 mg):  $^{1}$ H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.73 (s, 1H), 8.23 (s, 1H), 8.11 (s, 1H), 7.76 (s, 1H), 7.28 (s, 1H), 3.97 (s, 3H), 3.49 (br s, 2H), 3.18 (br s, 2H), 1.72 (d, J = 7 Hz, 2H), 1.55 (d, J = 7 Hz, 2H), 1.00 (t, J = 7 Hz, 3H), 0.75 (t, J = 7 Hz, 3H).

- Step 4: A solution of methyl 3-[(dipropylamino)carbonyl]-5-10 (1,3-oxazol-2-y1) benzoate (315 mg, 0.95 mmol) in methanol (3mL) and potassium hydroxide (3 mL of a 1.0 M solution in water, 3 mmol) was stirred at room temperature for 30 min. The solvent was removed under reduced pressure, the residue was dissolved in water, and extracted with ethyl acetate. 15 aqueous layer was acidified to pH 3 with 1 M hydrochloric acid, extracted with chloroform (3 x 100 mL), and the combined organic layers were concentrated under reduced pressure to afford 3-[(dipropylamino)carbonyl]-5-(1,3-oxazol-2-yl)benzoic acid (265 mg):  $^{1}\text{H}$  NMR (300 MHz, CD<sub>3</sub>OD)  $\delta$  8.71 (s, 1H), 8.08 (s, 20 2H), 8.05 (s, 1H), 7.34 (s, 1H), 3.52 (t, J = 8 Hz, 2H), 3.26(t, J = 8 Hz, 2H), 1.75 (q, J = 8 Hz, 2H), 1.59 (q, J = 8 Hz,2H), 1.02 (t, J = 8 Hz, 3H), 0.74 (t, J = 8 Hz, 3H).
- Step 5: A solution of 3-[(dipropylamino)carbonyl]-5-(1,3-oxazol-2-yl)benzoic acid (133 mg, 0.42 mmol), (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol dihydrochloride (171 mg, 0.42 mmol), HOBt (57 mg, 0.42 mmol), and N-methylmorpholine (148 μL, 1.3 mmol) was stirred in dimethylformamide (2 mL) for 15 min. EDC (130 mg, 0.75 mmol) was added and the reaction mixture was stirred overnight. The reaction mixture was diluted with water, and extracted with ethyl acetate (3 x 25 mL). The organic layer was washed with 1 M hydrochloric acid (25 mL), saturated sodium bicarbonate

(25 mL), saturated sodium chloride, dried (sodium sulfate), and concentrated under reduced pressure. Purification by flash column chromatography (silica, 1:9 methanol/chloroform) provided  $N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-oxazol-2-yl)- $N^3$ , $N^3$ dipropylisophthalamide (62 mg): mp 65-67 °C; <sup>1</sup>H NMR (500 MHz, CDCl $_3$ )  $\delta$  8.21 (br s, 1H), 8.15 (s, 2H), 7.69 (s, 1H), 7.60 (s, 1H), 7.25 (t, J = 8 Hz, 1H), 7.19-7.17 (m, 3H), 7.10 (d, J = 8Hz, 1H), 6.96 (d, J = 8 Hz, 2H), 6.60 (t, J = 8 Hz, 1H), 4.27 (d, J = 8 Hz, 1H), 3.88-3.80 (m, 3H), 3.53 (br s, 2H), 3.44 10 (br s, 2H), 3.09-3.01 (m, 4H), 2.85-2.82 (m, 2H), 2.62 (t, J =8 Hz, 2H), 1.74 (br s, 2H), 1.45 (br s, 2H), 1.21 (t, J=8Hz, 3H), 1.03 (t, J = 7 Hz, 3H), 0.66 (t, J = 7 Hz, 3H); APCI  $MS m/z 633 [M + H]^{+}$ 

15

25

EXAMPLE SP-281

 $N^1$ -{(1S,2R)-1-(3,5-Difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}- $N^3$ -methyl-5-(1,3-oxazol-2-yl)- $N^3$ -

20 propylisophthalamide

To 3-{[Methyl(propyl)amino]carbonyl}-5-(1,3-oxazol-2-yl)benzoic acid (350 mg, 1.2 mmol) in DMF (5 mL) is added disopropylethylamine (835  $\mu$ L, 4.8 mmol), HATU (554 mg, 1.5 mmol), then (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol dihydrochloride prepared by the method of EXAMPLE SP-272 (488 mg, 1.2 mmol). The reaction is stirred for 16 h at room temperature. The reaction is


partitioned between chloroform and water. The organic layer is washed with 1 N hydrochloric acid, saturated sodium bicarbonate, and saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 9% methanol/chloroform) gives the title compound. ESI MS m/z 605.3 [M + H]<sup>+</sup>.

EXAMPLE SP-282

10

Step 1

Methyl 3-{[butyl(methyl)amino]carbonyl}-5-iodobenzoate



3-Iodo-5-(methoxycarbonyl)benzoic acid (1 g, 3.3 mmol) is 15 dissolved in DMF (10 mL), and disopropylethylamine (1.7 mL, 9.8 mmol), HATU (1.5 g, 3.9 mmol), and N-methylbutylamine (581 μL, 4.9 mmol) are added. The reaction stirred at room temperature 2 h. The reaction is partitioned between ethyl acetate and water. The organic layer is washed with saturated sodium bicarbonate, and saturated sodium chloride, dried 20 (sodium sulfate), filtered, and concentrated under reduced Purification by flash column chromatography pressure. title (silica, 40% ethyl acetate/hexane) provides the compound. ESI MS m/z 376.1 [M + H]<sup>+</sup>.

25

Step 2

Methyl 3-{[butyl(methyl)amino]carbonyl}-5-(1,3-oxazol-2-yl)benzoate

To a -70 °C stirred solution of oxazole (167 mg, 2.4 mmol) in tetrahydrofuran (4 mL) is added n-butyllithium (1.6 M in hexanes, 1.7 mL, 2.7 mmol). After 30 min, zinc chloride (1 M in diethyl ether, 7.3~mL, 7.3~mmol) is added and the reaction 5 mixture is warmed to 0  $^{\circ}\text{C}$  for 1 h. To this mixture is added a methyl 3-{[butyl(methyl)amino]carbonyl}-5solution of iodobenzoate (864 mg, 2.3 mmol) in anhydrous tetrahydrofuran (3 mL) followed by palladium(0) tetrakis(triphenylphosphine) (112 mg, 0.10 mmol). The reaction mixture is heated at reflux 10 for 1.5 h. The reaction mixture is cooled, diluted with ethyl acetate, washed with water, and saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica gel, 60% ethyl acetate/hexane) provides the title 15 compound. ESI MS m/z 317.1 [M + H]<sup>+</sup>.

Step 3

3-{[Butyl(methyl)amino]carbonyl}-5-(1,3-oxazol-2-yl)benzoic 20 acid

To methyl 3-{[butyl(methyl)amino]carbonyl}-5-(1,3-oxazol-2-yl)benzoate (660 mg, 2.1 mmol) in tetrahydrofuran/methanol/water (1:1:1, 9 mL) is added lithium by 25 hydroxide monohydrate (175 mg, 4.2 mmol), and the reaction is

stirred at room temperature 16 h. The solution is diluted in chloroform and washed with water and saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure to give the title compound. ESI MS m/z 301.1 [M - H]<sup>-</sup>.

Step 4

N<sup>1</sup>-butyl-N<sup>3</sup>-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>1</sup>-methyl-5-(1,3-oxazol-2-yl)isophthalamide

3-{[Butyl(methyl)amino]carbonyl}-5-(1,3-oxazol-2yl)benzoic acid (237 mg, 0.78 mmol) is dissolved in DMF (5 mL), and diisopropylethylamine (546  $\mu$ L, 3.1 mmol), HATU (358 mg, 0.94 mmol), and (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol dihydrochloride prepared by the method of EXAMPLE SP-272 (319 mg, 0.78 mmol) are added. The reaction stirred at room temperature 5 h. The reaction mixture is diluted with chloroform, washed with water, 1N hydrochloric acid (aq), saturated sodium saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 9% methanol/methylene chloride) provides the title compound. ESI MS m/z 619.3 [M + H]<sup>+</sup>.

EXAMPLE SP-283

5

15

20

25

 $N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}- $N^{3}$ -ethyl-5-(1,3-oxazol-2-yl)- $N^{3}$ propylisophthalamide

### Step 1

5 Methyl 3-{[ethyl(propyl)amino]carbonyl}-5-iodobenzoate

3-Iodo-5-(methoxycarbonyl)benzoic acid (1 g, 3.3 mmol) is dissolved in DMF (10 mL), and dissopropylethylamine (1.7 mL, 9.8 mmol), HATU (1.5 g, 3.9 mmol), and N-ethylpropylamine (572 μL, 4.9 mmol) are added. 10 The reaction stirred at room temperature 16 h. The reaction is partitioned between ethyl acetate and water. The organic layer is washed with saturated sodium bicarbonate, and saturated sodium chloride, (sodium sulfate), filtered, and concentrated under reduced 15 Purification by flash column chromatography pressure. (silica, 40% ethyl acetate/hexane) provides the title compound. ESI MS m/z 376.1 [M + H]<sup>+</sup>.

Step 2

20 Methyl 3-{[ethyl(propyl)amino]carbonyl}-5-(1,3-oxazol-2-yl)benzoate

To a -70 °C stirred solution of oxazole (106 mg, 1.5 mmol) in tetrahydrofuran (4 mL) is added n-butyllithium (1.6 M in hexanes, 1.0 mL, 1.7 mmol). After 30 min, zinc chloride (1 M

in diethyl ether, 4.6 mL, 4.6 mmol) is added and the reaction mixture is warmed to 0 °C for 1 h. To this mixture is added a 3-{[ethyl(propyl)amino]carbonyl}-5of methvl solution iodobenzoate (535 mg, 1.45 mmol) in anhydrous tetrahydrofuran (1.8 mL) followed by palladium(0) tetrakis(triphenylphosphine) 5 (120 mg, 0.10 mmol). The reaction mixture is heated at reflux The reaction mixture is cooled, diluted with ethyl acetate, washed with water, and saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography 10 (silica gel, 60% ethyl acetate/hexane) provides the title compound. ESI MS m/z 317.1 [M + H]<sup>+</sup>.

Step 3

3-{[Ethyl(propyl)amino]carbonyl}-5-(1,3-oxazol-2-yl)benzoic

To methyl 3-{[ethyl(propyl)amino]carbonyl}-5-(1,3-oxazol-1.2 mmol) in 2-y1)benzoate (375 mg, tetrahydrofuran/methanol/water (1:1:1, 9 mL) is added lithium 20 hydroxide monohydrate (100 mg, 2.4 mmol), and the reaction is stirred at room temperature 16 h. The solution is diluted in and saturated sodium chloroform and washed with water chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure to give the title compound. ESI MS 25 m/z 301.1 [M - H].

Step 4

 $N^1-\{(1S,2R)-1-(3,5-Difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-N^3-ethyl-5-(1,3-oxazol-2-yl)-N^3-propylisophthalamide$ 

5

10

15

3-{[Ethyl(propyl)amino]carbonyl}-5-(1,3-oxazol-2yl)benzoic acid (290 mg, 0.96 mmol) is dissolved in DMF (5 mL), and diisopropylethylamine (668  $\mu$ L, 3.8 mmol), HATU (438 mg, 1.15 mmol), and (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol dihydrochloride prepared by the method of EXAMPLE SP-272 (391 mg, 0.96 mmol) are added. The reaction stirred at room temperature 5 h. The reaction mixture is diluted with chloroform, washed with water, 1N hydrochloric acid (aq), saturated sodium bicarbonate, saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 9% methanol/methylene chloride) provides the title compound. ESI MS m/z 619.3 [M + H]<sup>+</sup>.

20

EXAMPLE SP-284

 $N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[3-(trifluoromethyl)benzyl]amino}propyl)- $N^{3}$ , $N^{3}$ -dipropyl-5-(1,3-thiazol-2-yl)isophthalamide

25

Step 1

Methyl 3-[(dipropylamino)carbonyl]-5-(1,3-thiazol-2-yl)benzoate

To 0.5M thiazole zinc bromide (45 mL) is added methyl 3- [(dipropylamino)carbonyl]-5-iodobenzoate (8.6 g, 21.4 mmol) in THF (130 mL), then palladium(0) tetrakis(triphenylphosphine) (2 g, 1.7 mmol) are added. The reaction mixture is heated at reflux for 16 h, cooled to room temperature, and then filtered. The solution is washed with water, saturated sodium bicarbonate, and saturated sodium chloride, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (35% ethyl acetate/hexane) yields the title compound. ESI MS m/z 347.1  $[M + H]^+$ .

15 Step 2
3-[(Dipropylamino)carbonyl]-5-(1,3-thiazol-2-yl)benzoic acid

10

20

25

3-[(dipropylamino)carbonyl]-5-(1,3-thiazol-2-Methyl (4.4 g,12.8 mmol) is dissolved in vl)benzoate tetrahydrofuran/methanol/water (60 mL), and lithium hydroxide monohydrate is added (1.1 g, 25.6 mmol), and the reaction The solution is concentrated under reduced stirred 15 min. The solution is washed pressure and diluted in chloroform. with water and saturated sodium bicarbonate, dried (magnesium sulfate), filtered, and concentrated under reduced pressure to give the title compound. ESI MS m/z 333.1 [M + H]<sup>+</sup>.

Step 3

N<sup>1</sup>-((1S,2R)-1-(3,5-Difluorobenzyl)-2-hydroxy-3-{[3-(trifluoromethyl)benzyl]amino}propyl)-N<sup>3</sup>,N<sup>3</sup>-dipropyl-5-(1,3-thiazol-2-yl)isophthalamide dihydrochloride

3-[(Dipropylamino) carbonyl]-5-(1,3-thiazol-2-yl) benzoic acid is dissolved in DMF (10 mL), and diisopropylethylamine (364  $\mu$ L, 2.1 mmol), HATU (237 mg, 0.62 mmol), (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-{[3-

(trifluoromethyl)benzyl]amino}butan-2-ol dihydrochloride prepared by the method of EXAMPLE SP-311 (250 mg, 0.52 mmol) The reaction stirred at room temperature 4 h. The are added. reaction mixture is diluted with chloroform, washed with water, saturated sodium bicarbonate, saturated chloride, dried (sodium sulfate), filtered, and concentrated reduced pressure. under Purification by flash column chromatography (silica, 88 methanol/methylene chloride) provides the title compound as the free base. The residue is dissolved in diethyl ether (3 mL) and 1N hydrochloric acid in diethyl ether (2 mL) is added. The mixture is concentrated under reduced pressure to yield the title compound. ESI MS m/z 689.3 [M + H]<sup>+</sup>.

## 25 EXAMPLE SP-285

Step 1

5

10

15

20

3-{[Butyl(methyl)amino]carbonyl}-5-(1,3-thiazol-2-yl)benzoic acid

To 0.5M thiazole zinc bromide (4.5 mL) is added methyl 3-5 {[butyl(methyl)amino]carbonyl}-5-iodobenzoate (700 mg, THF (5 mL), then palladium(0) in tetrakis(triphenylphosphine) (175 mg, 0.15 mmol) are added. The reaction mixture is heated at reflux for 16 h, cooled to room temperature, and then filtered. The solution is washed 10 with water, saturated sodium bicarbonate, and saturated sodium dried (magnesium sulfate), filtered, chloride, concentrated under reduced pressure. Purification by flash column chromatography (35% ethyl acetate/hexane) yields the title compound. ESI MS m/z 333.1 [M + H]<sup>+</sup>. 15

Step 2
3-{[Butyl(methyl)amino]carbonyl}-5-(1,3-thiazol-2-yl)benzoic
acid

20

25

3-{[Butyl (methyl) amino] carbonyl}-5-(1,3-thiazol-2-yl) benzoic acid (410 mg, 1.23 mmol) is dissolved in 1:1:1 tetrahydrofuran/methanol/water (9 mL), and lithium hydroxide monohydrate is added (103 mg, 2.5 mmol), and the reaction stirred 16 h. The solution is concentrated under reduced

pressure and diluted in ethyl acetate. The solution is washed with water and saturated sodium bicarbonate, dried (magnesium sulfate), filtered, and concentrated under reduced pressure to give the title compound. ESI MS m/z 319.1 [M + H]<sup>+</sup>.

5

Step 3  $N^1-Butyl-N^3-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-N^1-methyl-5-(1,3-thiazol-2-yl)isophthalamide$ 

10

15

20

25

3-{[Butyl(methyl)amino]carbonyl}-5-(1,3-thiazol-2yl)benzoic acid (125 mg, 0.39 mmol) is dissolved in DMF (3 mL), and diisopropylethylamine (271  $\mu$ L, 1.6 mmol), HATU (178 mg, 0.47 mmol),  $(2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-{[3-$ (trifluoromethyl)benzyl]amino}butan-2-ol dihydrochloride (176 mg, 0.43 mmol) are added. The reaction stirred at room temperature 4 h. The reaction mixture is diluted with chloroform, washed with water, saturated sodium bicarbonate, saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 8% methanol/methylene chloride) provides the title compound as the free base. residue is dissolved in diethyl ether (3 mL) and 1N hydrochloric acid in diethyl ether (2 mL) is added. The mixture is concentrated under reduced pressure to yield the title compound. ESI MS m/z 635.3 [M + H]<sup>+</sup>.

EXAMPLE SP-286

Step 1

Methyl 3-{[methyl(propyl)amino]carbonyl}-5-(1,3-thiazol-2-yl)benzoate

5

10

15

To 0.5M thiazole zinc bromide (4.1 mL) is added methyl 3iodo-5-{[methyl(propyl)amino]carbonyl}benzoate (616 mL), then palladium(0) THF (5 in tetrakis(triphenylphosphine) (158 mg, 0.14 mmol) are added. The reaction mixture is heated at reflux for 16 h, cooled to room temperature, and then filtered. The solution is washed with water, saturated sodium bicarbonate, and saturated sodium (magnesium sulfate), filtered, and chloride, dried concentrated under reduced pressure. Purification by flash column chromatography (35% ethyl acetate/hexane) yields the title compound. ESI MS m/z 319.1 [M + H]<sup>+</sup>.

Step 2  $N^{1}-\{(1S,2R)-1-(3,5-Difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-\\$ 20  $hydroxypropyl\}-N^{3}-methyl-5-(1,3-thiazol-2-yl)-N^{3}-\\ propylisophthalamide$ 

3-{[methyl(propyl)amino]carbonyl}-5-(1,3-thiazol-2-y1) benzoate (390 mg, 1.22 mmol) is dissolved in 1:1:1 tetrahydrofuran/methanol/water (9 mL), and lithium hydroxide monohydrate is added (103 mg, 2.4 mmol), and the reaction stirred 2 h. The solution is concentrated under reduced pressure. The residue is redissolved in DMF (5 mL), diisopropylethylamine (355 µL, 2.0 mmol), HATU (230 mg, 0.61 mmol), (2R, 3S) - 3 - amino - 4 - (3, 5 - difluorophenyl) - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]]ethylbenzyl)amino]butan-2-ol dihydrochloride prepared by the method of EXAMPLE SP-272 (206 mg, 0.51 mmol) are added. reaction stirred at room temperature 16 h. The reaction mixture is diluted with ethyl acetate, washed with water, saturated sodium bicarbonate, saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced Purification by flash pressure. column chromatography (silica, 9% methanol/methylene chloride) provides the title compound. ESI MS m/z 621.3 [M + H]<sup>+</sup>.

### EXAMPLE SP-287

20

5

10

15

{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-dipropyl-5-pyridin-4-ylisophthalamide dihydrochloride

25 Step 1: To a stirred solution of borate ester methyl 3[(dipropylamino)carbonyl]-5-(3,3,4,4-tetramethylborolan-1yl)benzoate dissolved in 1,4-dioxane (9.3 mL) was added sodium
carbonate (2 mL of a 2 M solution in water, 4 mmol), 4bromopyridine hydrochloride (250 mg, 1.3 mmol), and the
30 reaction mixture was degassed for 15 min. The reaction
mixture was flushed with argon and heated to reflux overnight.
The reaction mixture was cooled to room temperature, diluted
with water, extracted with ethyl acetate (3 x 50 mL), dried
(magnesium sulfate), filtered, and concentrated under reduced

pressure. Purification by flash column chromatography (silica, 1:1 ethyl acetate/hexanes) provided methyl 3-[(dipropylamino)carbonyl]-5-pyridin-4-ylbenzoate (240 mg):  $^{1}$ H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.46 (d, J = 7 Hz, 2H), 8.10 (t, J = 3 Hz, 1H), 8.04 (t, J = 3 Hz, 1H), 7.97 (t, J = 3 Hz, 1H), 7.48 (d, J = 6 Hz, 2H), 3.45 (m, 2H), 3.16 (m, 2H), 2.09 (s, 3H), 1.69 (m, 2H), 1.54 (m, 2H), 0.94 (m, 3H), 0.74 (m, 3H).

- of 1-methyl solution stirred To a 2: Step [(dipropylamino)carbonyl]-5-pyridin-4-ylbenzoate (240 mg, 0.7 10 mmol) in methanol (1.5 mL), tetrahydrofuran (0.7 mL), and water (0.7 mL) was added lithium hydroxide (58 mg, 1.4 mmol). The reaction mixture was stirred for 4 h, and concentrated under reduced pressure. The residue was dissolved in water, and extracted with ethyl acetate (3  $\times$  75 mL). The aqueous 15 layer was acidified to pH 5 with 1 N hydrochloric acid and extracted with chloroform (4  $\times$  50 mL). The combined organic extracts were dried (magnesium sulfate), filtered, and concentrated under reduced pressure to provide a pyridine (160 mg):  $^{1}\text{H}$  NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.79 (d, J = 5 Hz, 2H), 8.45 (s, 20 1H), 8.19 (s, 1H), 7.89 (s, 1H), 7.69 (d, J = 6 Hz, 2H), 3.50 (d, J = 7 Hz, 2H), 1.74 (d, J = 7 Hz, 2H), 1.02 (m, 3H), 0.78 (m, 3H).
- 25 Step 3: To a stirred solution of pyridine from step 3 (160 mg, 0.49 mmol) in dichloromethane (1.96 mL) was added DIPEA (190 mg, 1.47 mmol), HATU (278 mg, 0.73 mmol), and HOBt (99 mg, 0.73 mmol), followed by amine 2 (200 mg, 0.49 mmol). The reaction mixture was stirred overnight at room temperature.

  30 The reaction mixture was partitioned between dichloromethane and water. The organic layer was washed with saturated sodium bicarbonate, saturated sodium chloride, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. The resulting oil was dissolved in a minimal amount of

methanol, and precipitated with hydrochloric acid (10 mL of a 1 M solution in diethyl ether, 10 mmol). The precipitate was filtered, washed with diethyl ether, and dried under vacuum to afford the title compound (100 mg): mp 166-169 °C; APCI MS m/z 643  $[M + H]^+$ .

### EXAMPLE SP-288

5

N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-10 hydroxypropyl}-4-[(methylsulfonyl)methyl]piperidine-1carboxamide:

Step 1: To an ice-cold, stirred solution of acid 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (1.0 g, 4.4 mmol)

in tetrahydrofuran (11 mL) was added borane-dimethylsulfide complex (3.4 mL of a 2.0 M solution in tetrahydrofuran, 6.8 mmol). After 2 h, the reaction mixture was quenched with methanol, and concentrated under reduced pressure to provide an alcohol (939 mg): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) & 4.11 (br s, 2H),

3.50 (t, J = 6 Hz, 2H), 2.68 (d, J = 12 Hz, 2H), 1.74-1.65 (m, 3H), 1.45 (s, 9H), 1.31 (t, J = 7 Hz, 1H), 1.14 (dd, J = 12, 4 Hz, 2H).

Step 2: To an ice-cold, stirred solution of the alcohol from step 1 (450 mg, 2.1 mmol) and triethylamine (0.32 mL, 2.3 mmol) in tetrahydrofuran (6 mL) was added methanesulfonyl chloride (0.18 mL, 2.3 mmol). The reaction mixture was stirred for 5 min and then sodium iodide (375 mg, 2.3 mmol) was added. The reaction mixture was warmed to room temperature and filtered. To the collected filtrate was added sodium thiomethoxide (161 mg, 2.3 mmol) and the reaction mixture was heated at reflux for 24 h. The reaction mixture was cooled to room temperature, diluted with ethyl acetate, washed with water, and saturated sodium chloride, dried

(sodium sulfate), filtered, and concentrated under reduced pressure to provide tert-butyl 4- [(methylthio)methyl]piperidine-1-carboxylate (430 mg):  $^{1}$ H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  4.11 (t, J = 7 Hz, 2H), 2.69 (t, J = 12 Hz, 2H), 2.42 (d, J = 7 Hz, 2H), 2.10 (s, 3H), 1.83-1.78 (m, 2H), 1.66-1.59 (m, 2H), 1.45 (s, 9H), 1.26-1.06 (m, 2H).

Step 4: A solution of sulfone from step 3 (390 mg, 1.4 mmol) and hydrochloric acid (4 mL of a 4 M solution in dioxane, 14 mmol) was stirred for 18 h. The resulting precipitate was collected by filtration to provide tert-butyl 4-[(methylsulfonyl)methyl]piperidine-1-carboxylate (220 mg):  $^{1}$ H NMR (300 MHz, DMSO- $d_6$ )  $\delta$  8.94 (br s, 1H), 8.70 (br s, 1H), 25 3.24-3.15 (m, 4H), 3.00 (s, 3H), 2.89 (q, J = 7 Hz, 2H), 2.29-2.18 (m, 1H), 1.97 (d, J = 13 Hz, 2H), 1.57-1.43 (m, 2H).

Step 5: To an ice-cold, stirred solution of triphosgene (108 mg, 0.36 mmol) and diisopropylethylamine (0.6 mL, 3.3 mmol) in methylene chloride (2.0 mL) was added amino sulfone from step 4 (210 mg, 0.98 mmol) in methylene chloride (3.5 mL) dropwise. After 5 min a solution of dihydrochloride of (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol (401 mg, 0.98 mmol) was added and the reaction mixture was warmed

until the solution became homogeneous. The reaction mixture diluted with methylene chloride, washed with 1 N was hydrochloric acid (25 mL), saturated sodium bicarbonate (25 mL), and saturated sodium chloride, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 15:85 methanol/chloroform) provided a clear solid. The solid was dissolved in methanol (1 mL), and treated with hydrochloric acid (0.3 mL of a 1.0 M solution in diethyl ether, 0.3 mmol). The resulting precipitate was collected by filtration to 10 provide the title compound (38 mg): mp 130-134 °C; APCI MS m/z  $538 [M + H]^{+}$ .

### EXAMPLE SP-289

15

N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-[(methylsulfonyl)methyl]cyclohexane carboxamide

20 Step 1: To a stirred solution of dimethyl cyclohexane-1,4dicarboxylate (10.2 g, 51 mmol) in a mixture of 2:1:1 tetrahydrofuran/methanol/water (52 mL) was added lithium hydroxide (2.13 g, 51 mmol). The reaction mixture was stirred at room temperature for 18 h. The solvent was removed under reduced pressure and the residue was partitioned between 25 diethyl ether and water. The aqueous layer was acidified to pH 4 with 1 N hydrochloric acid, and the precipitate collected, and dried under vacuum to afford (methoxycarbonyl)cyclohexanecarboxylic acid (7.4 g): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  3.68 (s, 3H), 2.33-2.27 (m, 2H), 2.11-2.06 30 (m, 4H), 1.50-1.43 (m, 4H).

Step 2: To an ice-cold, stirred solution of acid (3.2 g, 17 mmol) in tetrahydrofuran (40 mL) was added borane-dimethyl

sulfide complex (12 mL, 22 mmol). The reaction mixture was heated at 70 °C for 2 h and a 1:1 mixture of acetic acid/water (10 mL) added. The resulting mixture was concentrated. Purification by flash column chromatography (silica, 1:1 hexanes/ethyl acetate) provided methyl 4 (hydroxymethyl)cyclohexanecarboxylate (1.26 g):  $^1$ H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  3.67 (s, 3H), 3.48-3.46 (m, 2H), 2.26-2.15 (m, 1H), 2.05-1.85 (m, 4H), 1.52-1.42 (m, 3H), 1.02-0.97 (m, 2H).

Step 3: To an ice-cold, stirred solution of the alcohol (365 10 2.12 mmol) and triethylamine (440  $\mu L,\ 4.8$  mmol) in methylene chloride (5 mL) was added mesyl chloride (200  $\mu$ L, 2.6 The reaction mixture was stirred for 20 min and then mmol). partitioned between methylene chloride and water. The organic layer was washed with 1 M hydrochloric acid, and saturated 15 dried (magnesium sulfate), bicarbonate, sodium concentrated under reduced pressure to afford a the desired mesylate, which was carried on without purification or characterization.

20

25

30

Step 4: To a stirred solution of the mesylate from step 3 (2.12 mmol) in tetrahydrofuran (5 mL) was added sodium iodide (640 mg, 4.3 mmol). The reaction mixture was heated to 60 °C for 5 h and then filtered. The reaction mixture was concentrated under reduced pressure, and carried on without purification or characterization.

Step 5: To a stirred solution of the iodide from step 4 (2.12 mmol) in a mixture of N,N-dimethylformamide (10 mL) and tetrahydrofuran (1 mL) was added sodium thiomethoxide (450 mg, 6.4 mmol). The reaction mixture was heated at 70 °C for 15 h. The reaction mixture was allowed to cool to room temperature, the solvents were removed, and the residue was partitioned between ether and water. The aqueous layer was acidified to

pH 1 with 1 N hydrochloric acid, extracted with ethyl acetate, dried (sodium sulfate), filtered, and concentrated under reduced pressure to afford methyl 4-[(methylthio)methyl]cyclohexanecarboxylate (230 mg):  $^{1}$ H NMR (300 MHz, CD<sub>3</sub>OD)  $\delta$  2.40-2.37 (m, 2H), 2.22-2.05 (m, 1H), 2.05 (s, 3H), 2.02-1.93 (m, 4H), 1.48-1.38 (m, 3H), 1.03-0.95 (m, 2H).

5

Step 6: To a stirred solution of the methyl sulfide (240 mg, 1.3 mmol) in sodium hydroxide solution (3.5 mL, 0.5 M  $\,$ 10 solution) was added sodium bicarbonate (870 mg, 10.3 mmol) and acetone (1 mL) followed by the addition of a solution of oxone (1.0 g, 1.7 mmol) in 0.0004 M EDTA (4 mL). The reaction mixture was stirred at room temperature for 2 h and then 15 quenched with sodium bisulfite. The reaction mixture was acidified with hydrochloric acid and extracted with ethyl acetate (3  $\times$  100 mL). The combined organic layers were washed with water, dried (sodium sulfate), filtered, and concentrated under reduced pressure to provide acid 20 [(methylthio)methyl]cyclohexanecarboxylic acid (240 mg): <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD)  $\delta$  3.06-3.04 (m, 2H), 2.96 (s, 3H), 2.28-2.20 (m, 1H), 2.08-1.98 (m, 5H), 1.50-1.40 (m, 2H), 1.21-1.16 (m, 2H).

Step 7: To a stirred solution of the acid (120 mg, 0.6 mmol), (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol (230 mg, 0.6 mmol), and HATU (210 mg, 0.6 mmol) in methylene chloride (5 mL) was added N,N-diisopropylethylamine (340 μL, 1.93 mmol). The reaction mixture was stirred at room temperature for 18 h. The reaction mixture was partitioned between methylene chloride and water. The organic layer was washed with water, dried (sodium sulfate), filtered, and concentrated under reduced pressure to afford a crude oil. Purification by flash column

chromatography (silica, gradient 95:5 to 93:7 methylene chloride/methanol) provided the title compound (35 mg): mp 178-180 °C; ESI MS m/z 537 [M + H]<sup>+</sup>.

# 5 EXAMPLE SP-290

 $N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-5-piperidin-4-yl-N\(u)3\(d),N\(u)3\(d)-dipropylisophthalamide$ 

10

Step 1: To a -70 °C stirred solution of N-Boc-piperidone (500 mg, 2.5 mmol) in tetrahydrofuran (11 mL) was added lithium 2 M solution οf a diisopropylamine (1.37)mLThe reaction mixture was stirred tetrahydrofuran, 2.75 mmol). for 2 h, warmed to 0  $^{\circ}$ C, and N-phenyltriflamide (955 mg, 2.67 15 The solution was allowed to warm to room. mmol) was added. temperature and was stirred for 12 h. The reaction mixture was concentrated under reduced pressure. Purification by (3:1 hexanes/ethyl acetate) flash column chromatography tert-butyl 4-{[(trifluoromethyl)sulfonyl]oxy}-3,6-20 afforded dihydropyridine-1(2H)-carboxylate (240 mg): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ 5.77 (s, 1H), 4.05 (m, 2H), 3.63 (m, 2H), 2.45 (m, 2H), 1.48 (s, 9H).

25 Step 2: To a stirred solution of the triflate (240 mg, 0.72 mmol) and borate ester methyl 3-[(dipropylamino)carbonyl]-5-(3,3,4,4-tetramethylborolan-1-yl)benzoate (280 mg, 0.72 mmol) in dioxane (3 mL) was added sodium carbonate (1.1 mL of a 2 M solution in water, 2.16 mmol). The reaction mixture was flushed with argon, palladium(0) tetrakis(triphenylphosphine) (34 mg, 0.03 mmol) was added, and the reaction mixture was heated at reflux for 12 h. The reaction mixture was cooled to room temperature, filtered through diatomaceous earth, dried (magnesium sulfate), filtered, and concentrated under reduced

pressure. Purification by flash column chromatography (90:10 chloroform/methanol) afforded an acid (160 mg): <sup>1</sup>H NMR (300 MHz,  $CDCl_3$ )  $\delta 8.11$  (s, 1H), 7.95 (s, 1H), 7.58 (s, 1H), 6.15 (br s, 1H), 4.10 (s, 2H), 3.65 (m, 2H), 3.48 (m, 2H), 3.16 (s, 2H), 2.54 (s, 2H), 1.70 (s, 2H), 1.50 (s, 9H), 1.25 (m, 2H), 0.99 (s, 3H), 0.76 (s, 3H).

Step 3: A solution of the acid from step 2 (160 mg, 0.37 mmol) and 10% Pd/C (25 mg) in ethanol (10 mL) was degassed with 10 nitrogen for 15 min, and shaken under an atmosphere of hydrogen at 50 psi for 12 h. The reaction mixture was filtered through diatomaceous earth, and concentrated under reduced pressure give acid to 3-[1-(tertbutoxycarbonyl)piperidin-4-yl]-5-

15 [(dipropylamino)carbonyl]benzoic acid (121 mg), which was carried on without further purification: <sup>1</sup>H NMR (300 MHz,  $CDCl_3$ )  $\delta 7.94$  (d, J = 12 Hz, 2H), 7.44 (s, 1H), 4.27 (br s, 2H), 3.43 (m, 2H), 3.14 (m, 2H), 2.78 (m, 4H), 1.84 (m, 3H), 1.63 (m, 6H), 1.49 (s, 9H), 1.23 (m, 3H), 0.86 (m, 3H), 0.75 (m, 20 3H).

Step 4: To a stirred solution of the acid (120 mg, 0.28 mmol) in methylene chloride (2 mL) added was N, Ndiisopropylethylamine (0.141 mL, 0.84 mmol), HOBt (56 mg, 0.42 mmol), and HATU (160 mg, 0.42 mmol), followed by (2R,3S)-3amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2ol (114 mg, 0.28 mmol). The reaction mixture was stirred for 16 h at room temperature. The reaction mixture was diluted with methylene chloride (25 mL), washed with water, saturated sodium bicarbonate, and saturated sodium chloride, and dried 30 (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (93:7 chloroform/methanol) afforded a piperidine (90 mg): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ 7.61 (s, 1H), 7.54 (s, 1H), 7.43 (s, 1H), 7.14 (m,

25

4H), 6.79 (m, 2H), 6.64 (m, 1H), 4.29 (m, 3H), 3.68 (m, 4H), 3.47 (m, 2H), 3.02 (m, 4H), 2.77 (m, 5H), 2.66 (m, 2H), 1.71 (m, 8H), 1.48 (s, 9H), 1.24 (m, 5H), 0.99 (m, 3H), 0.73 (m, 3H).

5

10

Step 5: A solution of piperidine from step 4 (90 mg, 0.12 mmol) and hydrochloric acid (0.3 mL of a 4.0 M solution in dioxane, 1.2 mmol) was stirred for 30 min at room temperature. The reaction mixture was concentrated under reduced pressure, washed with ether (50 mL), and filtered. Purification by flash column chromatography (89:10:1 chloroform/methanol/ammonium hydroxide) afforded the title compound (35 mg): mp 84-87 °C; ESI MS m/z 649 [M + H]<sup>+</sup>.

#### 15 EXAMPLE SP-291

N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-(1,3-oxazol-2-yl)benzamide hydrochloride

20

25

To an ice-cold, stirred solution of acid (methoxycarbonyl)-5-nitrobenzoic acid (24.6 g, 0.11 mol) tetrahydrofuran (200 mL) was added borane-dimethylsulfide complex (82 mL of a 2.0 M solution in tetrahydrofuran, 0.16 mol) and the reaction mixture was heated at reflux for 24 h. The reaction mixture was cooled to room temperature, quenched with methanol, and the solvent was removed under reduced flash column chromatography pressure. Purification by (silica, 1:1 ethyl acetate/hexanes) provided an alcohol (16 g):  $^{1}$ H NMR (300 MHz, DMSO- $d_{6}$ )  $\delta$ 8.51 (d, J = 1 Hz, 1H), 8.42 (s, 1H), 8.32 (s, 1H), 5.69 (t, J = 6 Hz, 1H), 4.70 (d, J = 6 Hz, 2H), 3.93 (s, 3H).

Step 2: To an ice-cold, stirred solution of the alcohol from step 1 (6.6 g, 32 mmol) in methylene chloride was added phosphorus tribromide (1.5 mL, 16 mmol) and the reaction mixture was stirred for 40 min. The reaction mixture was diluted with methylene chloride, washed with saturated sodium bicarbonate, and saturated sodium chloride, dried (magnesium sulfate), filtered, and concentrated under reduced pressure to give a bromide (8.1 g):  $^{1}$ H NMR (300 MHz, DMSO- $d_6$ )  $\delta$  8.79 (t, J = 2 Hz, 1H), 8.45 (t, J = 2 Hz, 1H), 8.39 (d, J = 2 Hz, 1H), 4.57 (s, 2H), 4.00 (s, 3H).

Step 3: A solution of bromide from step 2 (8.1 g, 32 mmol) and 10% Pd/C (1.0 g) in 13:4:1 methanol/ethyl acetate/acetic acid (90 mL) was shaken under an atmosphere of hydrogen at 45 psi for 24 h. The reaction mixture was filtered through diatomaceous earth, and concentrated under reduced pressure to provide 1 methyl 3-amino-5-methylbenzoate (2.8 g): ESI MS m/z 166 [M + H]<sup>+</sup>.

10

Step 4: To an ice-cold, stirred solution of the aniline (2.8 20 g, 17 mmol) in 2 N hydrochloric acid (48 mL) was added a solution of sodium nitrite (1.2 g, 17 mmol) in water (10 mL), and the reaction mixture was stirred for 30 min. This reaction mixture was added to an ice-cold, stirred solution of potassium iodide (5.6 g, 34 mmol) and copper(I) iodide (1.6 g, 25 8.6 mmol) in water (10 mL). The reaction mixture was warmed to room temperature over 2 h and then diluted with ethyl acetate. The organic layer was washed with a 10% solution of sodium thiosulfate, and saturated sodium chloride, dried (magnesium sulfate), filtered, and concentrated under reduced 30 pressure. Purification by flash column chromatography (silica, 1:9 ethyl acetate/hexanes) provided an iodide (1.4 g):  $^{1}$ H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.16 (s, 1H), 7.80 (d, J = 1 Hz, 1H), 7.72 (d, J = 1 Hz, 1H), 3.90 (s, 3H), 2.35 (s, 3H).

Step 5: To a -70 °C stirred solution of oxazole (174 mg, 2.5 mmol) in tetrahydrofuran (5 mL) was added n-butyllithium (1.7 mL of a 1.6 M solution in hexanes, 2.8 mmol). After 30 min, zinc chloride (7.5 mL of a 1 M solution in diethyl ether, 7.5 mmol) was added and the reaction mixture was warmed to 0 °C for To this mixture was then added iodide from step 4 (695 1 h. mg, 2.5 mmol) followed by palladium(0) tetrakis-(triphenylphosphine) (145 mg, 0.13 mmol). The reaction mixture was heated at reflux for 16 h. The reaction mixture was cooled, and diluted with ethyl acetate (50 mL). organic layer was washed with water, and saturated sodium (magnesium sulfate), chloride, dried filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 1:1 ethyl acetate/hexanes) provided an oxazole (330 mg):  $^{1}$ H NMR (300 MHz, CD<sub>3</sub>OD)  $\delta$  8.45 (s, 1H), 8.08 (d, J = 1 Hz, 1H), 8.01 (s, 1H), 7.97 (d, J = 1)Hz, 1H), 7.32 (s, 1H), 3.95 (s, 3H), 2.48 (s, 3H); ESI MS m/z $218 [M + H]^{+}$ .

20

25

30

10

15

Step 6: To a stirred solution of the ester from step 5 (384 mg, 1.7 mmol) in methanol (5 mL) was added potassium hydroxide (15 mL of a 1.0 M solution in water, 15 mmol). The reaction mixture was stirred at room temperature for 2 h and concentrated under reduced pressure. The residue was diluted with water and washed with ethyl acetate. The aqueous layer was acidified to pH 5 with 1 N hydrochloric acid and extracted with chloroform (4 x 100 mL). The combined organic extracts were dried (sodium sulfate), filtered, and concentrated under reduced pressure to give an acid (358 mg):  $^{1}$ H NMR (300 MHz, DMSO- $d_6$ )  $\delta$  13.2 (br s, 1H), 8.32 (s, 1H), 8.20 (s, 1H), 8.03 (s, 1H), 7.93 (s, 1H), 7.42 (s, 1H), 2.45 (s, 3H).

Step 7: A solution of the acid from step 6 (358 mg, 1.8 mmol), HATU (1.0 g, 2.6 mmol), HOBt (357 mg, 2.6 mmol), and diisopropylethylamine (500  $\mu L$ , 2.6 mmol) was stirred in methylene chloride (2.0 mL) for 15 min. A solution of dihydrochloride of (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol (718 mg, 1.8 mmol) and diisopropylethylamine (500  $\mu L$ , 2.6 mmol) in methylene chloride (2.0 mL) was added and the reaction mixture was stirred The reaction mixture was diluted with methylene overnight. chloride, washed with 1 N hydrochloric acid (20 mL), saturated sodium bicarbonate (20 mL), and saturated sodium chloride, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 1:9 methanol/chloroform) provided a clear solid. solid was dissolved in methanol (2 mL), and treated with hydrochloric acid (0.5 mL of a 1.0 M solution in diethyl ether, 0.5 mmol). The resulting precipitate was collected by filtration to provide the title compound (250 mg): mp 105-107 °C; APCI MS m/z 520 [M + H]<sup>+</sup>.

20

10

15

EXAMPLE SP-292

 $N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-5-[(methylsulfonyl)methyl]thiophene-2- \\$ 

25 carboxamide

Step 1: To a solution of acid 5-(methoxycarbonyl)thiophene-2-carboxylic acid (1.00 g, 5.37 mmol) in tetrahydrofuran (21.5 mL) was added borane-dimethylsulfide complex (3.0 mL of a 2.0 M soltion in tetrahydrofuran, 6.00 mmol). The reaction mixture was heated at reflux for 24 h and then carefully quenched with anhydrous methanol (1.0 mL) and cooled to room temperature. The reaction mixture was acidified with 1 N hydrochloric acid and extracted with ethyl acetate. The

combined organic phases were washed with water, and saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated to yield the desired alcohol (820 mg):  $^{1}\text{H}$  NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.65 (d, J = 4 Hz, 1H), 6.96 (d, J = 4 Hz, 1H), 4.83 (s, 2H), 3.87 (s, 3H).

5

Step 2: To a 0 °C solution of the alcohol prepared in step 1 (805 mg, 4.67) in tetrahydrofuran (31 mL) containing triethylamine (790  $\mu$ L, 5.61 mmol) and dimethylaminopyridine (6 mg) was added methanesulfonyl chloride (400  $\mu$ L, 5.14 mmol) and the reaction mixture was stirred for 0.5 h. The reaction mixture was filtered and the filtrate concentrated under reduced pressure to provide the crude mesylate, which was used in the next step without further purification: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.70 (m, 1H), 7.18 (m, 1H), 5.39 (s, 2H), 3.90 (s, 3H), 2.97 (s, 3H).

Step 3: To the mesylate prepared in step 2 in N, N-dimethylformamide (10 mL) was added sodium thiomethoxide (516 mg, 7.0 mmol) and the reaction mixture was warmed to 50 °C for 18 h. The reaction was diluted with water (200 mL) and extracted with chloroform (4 x 25 mL). The combined organic phases were washed with 5% lithium chloride, water, and saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure to give the desired sulfide (760 mg) which was used without further purification:

1 NMR (300 MHz, CDCl<sub>3</sub>) & 7.64 (d, J = 4 Hz, 1H), 6.93 (d, J = 4 Hz, 1H), 3.89 (m, 5H), 2.08 (s, 3H).

30 Step 4: To a 0 °C solution of the sulfide prepared in step 3 (760 mg, 3.75 mmol) in chloroform (6.25 mL) was added 70% m-CPBA (2.31 g, 9.37 mmol) and the reaction stirred at 0 °C for 2.5 h. The reaction mixture was then diluted with chloroform and washed with 1 N sodium hydroxide, water, and saturated

sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure to provide the desired sulfone (780 mg) which was used without further purification:  $^{1}$ H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.74 (d, J = 4 Hz, 1H), 7.20 (d, J = 4 Hz, 1H), 4.46 (s, 2H), 3.89 (m, 3H), 2.87 (s, 3H).

Step 5: To a solution of the sulfone prepared in step 4 (268 mg, 1.14 mmol) in 2:1:1 dioxane/methanol/water (7.6 mL) was added lithium hydroxide monohydrate (53 mg, 1.14 mmol) and the reaction mixture was stirred for 24 h at room temperature. 10 The reaction mixture was concentrated under reduced pressure and the solid residue was partitioned between ethyl acetate and water. The aqueous phase was acidified with 1 N hydrochloric acid and extracted several times with diethyl 15 ether. The combined ether extracts were washed with water, and saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure to provide 5-[(methylsulfonyl)methyl]thiophene-2-carboxylic acid (115 mg) which was used without further purification: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.73 (d, J = 4 Hz, 1H), 7.20 (d, J = 4 Hz, 1H), 4.52 20 (s, 2H), 2.90 (s, 3H); ESI MS (negative mode) m/z 219 [M - H]<sup>-</sup>.

Step 6: To a solution of acid from step 5 (115 mg, 0.52 mmol) and N,N-diisopropylethylamine (540 µL, 3.12 mmol) in methylene chloride (6.5 mL) was added HBTU (200 mg, 0.52 mmol) and the reaction mixture was stirred for 0.5 h. (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol (211 mg, 0.52 mmol) was added in one portion and the reaction mixture was stirred at room temperature for 18 h. The reaction mixture was diluted with methylene chloride and washed with saturated sodium bicarbonate, and saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure. Purification by flash chromatography

25

30

(silica, 1-5% methanol in chloroform) gave the title compound (45 mg): mp 128-131 °C;; ESI MS m/z 537  $[M+H]^+$ .

# EXAMPLE SP-293

5

 $N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1\}-3-methyl-5-(1,3-thiazol-2-y1)benzamide hydrochloride$ 

Step 1: To a -70 °C stirred solution of thiazole (214 mg, 2.5 10 mmol) in tetrahydrofuran (5 mL) was added n-butyllithium (1.7 mL of a 1.6 M solution in hexanes, 2.8 mmol). After 30 min, zinc chloride (7.5 mL of a 1 M solution in diethyl ether, 7.5 mmol) was added and the reaction mixture was warmed to 0 °C for To this mixture was then added iodide described above 15 1 h. followed by palladium(0) 2.5 mmol) (695 mg, mg, 0.13 The (145 mmol). tetrakis(triphenylphosphine) reaction mixture was heated at reflux for 16 h. The reaction mixture was cooled and diluted with ethyl acetate (50 mL). The organic layer was washed with water, and saturated sodium 20 sulfate), (magnesium filtered, chloride, dried Purification by flash concentrated under reduced pressure. column chromatography (silica, 1:1 ethyl acetate/hexanes) provided a thiazole (208 mg):  $^{1}\text{H}$  NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.38 (s, 1H), 8.02 (d, J = 1 Hz, 1H), 7.92 (s, 1H), 7.88 (d, J = 3)25 Hz, 1H), 7.37 (d, J = 3 Hz, 1H), 3.95 (s, 3H), 2.48 (s, 3H).

Step 2: To a stirred solution of the ester from step 1 (208 mg, 0.89 mmol) in 2:1:1 methanol/tetrahydrofuran/water (4 mL) was added lithium hydroxide (75 mg, 1.8 mmol). The reaction 30 room temperature for at 3 was stirred mixture The residue was diluted concentrated under reduced pressure. with water and washed with ethyl acetate. The aqueous layer was acidified to pH 5 with 1 N hydrochloric acid and extracted

with chloroform (5 x 100 mL). The combined organic extracts were dried (sodium sulfate), filtered, and concentrated under reduced pressure to give an acid (146 mg):  $^{1}$ H NMR (300 MHz, DMSO- $d_6$ )  $\delta$  13.17 (br s, 1H), 8.28 (s, 1H), 8.01 (d, J = 1 Hz, 1H), 7.96 (d, J = 3 Hz, 1H), 7.85 (d, J = 3 Hz, 2H), 2.45 (s, 3H).

Step 3: A solution of the acid from step 2 (140 mg, 0.64 mmol), HATU (364 mg, 0.96 mmol) and diisopropylethylamine (170  $\mu\text{L}\text{, 0.96 mmol)}$  was stirred in methylene chloride (2.0 mL) for 10 15 min. A solution of dihydrochloride (2R,3S)-3-amino-4-(3,5difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol (318 0.64 mmol) and diisopropylethylamine (170  $\mu L$ , 0.96 mmol) in methylene chloride (2.0 mL) was added and the reaction mixture was stirred overnight. The reaction mixture was diluted with 15 methylene chloride, washed with 1 N hydrochloric acid (20 mL), saturated sodium bicarbonate (20 mL), and saturated sodium chloride, dried (magnesium sulfate), filtered, concentrated under reduced pressure. Purification by flash 20 column chromatography (silica, methanol/chloroform) 1:9 provided a clear solid. The solid was dissolved in methanol (1 mL), and treated with hydrochloric acid (0.5 mL of a 1.0 M  $\,$ solution in diethyl ether, 0.5 mmol). The resulting precipitate was collected by filtration to provide the title compound (100 mg): mp 178-180 °C; APCI MS m/z 536 [M + H]<sup>+</sup>. 25

### EXAMPLE SP-293

N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-30 hydroxypropyl}-4-[(methylsulfonyl)methyl]cyclohexanecarboxamide

Step 1: To an ice-cold, stirred solution of cyclohexane-1,4-dicarboxylic acid (3.0 g, 17 mmol) in a mixture of 2:1 tetrahydrofuran/methanol (24 mL) was added trimethylsilyl diazomethane (9 mL of a 2.0 M in hexanes, 18 mmol). The reaction mixture was stirred at room temperature for 2 h. Acetic acid (5 mL) was added and the solvent was removed under reduced pressure. Purification by flash column chromatography (silica, 10:1:0.01 hexanes/ethyl acetate/acetic acid) provided 4-(methoxycarbonyl)cyclohexanecarboxylic acid (1.00 g):  $^{1}$ H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  3.68 (s, 3H), 2.53-2.47 (m, 2H), 1.97-1.89 (m, 4H), 1.74-1.66 (m, 4H).

10

Step 2: To an ice-cold, stirred solution of acid from step 1 (700 mg, 3.8 mmol) in tetrahydrofuran (10 mL) was added borane-dimethyl sulfide complex (2 mL, 4.1 mmol). 15 reaction mixture was warmed to room temperature for 2 h and a 1:1 mixture of acetic acid/water (10 mL) was added. resulting mixture was concentrated under reduced pressure. Purification by flash column chromatography (silica, 1:1 4methyl 20 hexanes/ethyl acetate) provided (hydroxymethyl)cyclohexanecarboxylate (560 mg): <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  3.68 (s, 3H), 3.51-3.46 (m, 2H), 2.59-2.57 (m, 1H), 2.05-2.00 (m, 2H), 1.65-1.55 (m, 5H), 1.31-1.27 (m, 2H).

Step 3: To an ice-cold, stirred solution of alcohol from step 25 2 (300 mg, 1.8 mmol) and triethylamine (370  $\mu$ L, 2.7 mmol) in methylene chloride (5 mL) was added mesyl chloride (170  $\mu$ L, 2.1 The reaction mixture was stirred for 20 min and then partitioned between methylene chloride and water. The organic layer was washed with 1 N hydrochloric acid, and saturated 30 dried (magnesium sulfate), bicarbonate, sodium concentrated under reduced pressure to afford a the desired mesylate, which was carried on without purification or characterization.

Step 4: To a stirred solution of the mesylate from step 3 (1.8 mmol) in tetrahydrofuran (5 mL) was added sodium iodide (530 mg, 3.5 mmol). The reaction mixture was heated at 60 °C for 5 h, cooled to room temperature, and then filtered. The reaction mixture was concentrated under reduced pressure, and carried on without purification or characterization.

Step 5: To a stirred solution of the iodide from step 4 (1.8 10 mmol) in a mixture of N, N-dimethylformamide (10 mL) tetrahydrofuran (1 mL) was added sodium thiomethoxide (375 mg, 5.3 mmol). The reaction mixture was heated at 70  $^{\circ}\text{C}$  for 15 h. The reaction mixture was then cooled to room temperature, the solvents were removed, and the residue partitioned between ether and water. The aqueous layer was acidified to pH 1 with 15 1 N hydrochloric acid, extracted with ethyl acetate, dried (sodium sulfate), filtered, and concentrated under reduced pressure to afford 4-[(methylthio)methyl]cyclohexanecarboxylic acid (50 mg):  $^{1}$ H NMR (300 MHz, CD<sub>3</sub>OD)  $\delta$  2.53-2.51 (m, 1H), 2.43-2.41 (m, 3H), 2.05 (s, 3H), 2.05-1.95 (m, 2H), 1.71-1.5320 (m, 4H), 1.36-1.30 (m, 2H).

Step 6: To a stirred solution of methyl sulfide from step5 (100 mg, 0.5 mmol) in sodium hydroxide solution (1.5 mL, 0.5 M  $\,$ solution in water) was added sodium bicarbonate (360 mg, 4.3 mmol) and acetone (1 mL) followed by the addition of a solution of oxone (430 mg, 0.7 mmol) in 0.0004 M EDTA (2 mL). The reaction mixture was stirred at room temperature for 2 h and then quenched with sodium bisulfite. The reaction mixture was acidified with 1 N hydrochloric acid and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with water, dried (sodium sulfate), filtered, and concentrated under reduced pressure to provide 4-[(methylsulfonyl)methyl]cyclohexanecarboxylic acid (100 mg): <sup>1</sup>H

25

30

NMR (300 MHz, CD<sub>3</sub>OD)  $\delta$  3.11-3.08 (m, 2H), 2.96 (s, 3H), 2.53-2.51 (m, 1H), 2.18-2.16 (m, 1H), 1.99-1.93 (m, 2H), 1.79-1.25 (m, 6H).

Step 7: To a stirred solution of acid from step 6 (100 mg, 0.5 (2R, 3S) - 3 - amino - 4 - (3, 5 - difluorophenyl) - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)] - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]] - [(3 - amino - 4 - (3, 5 - difluorophenyl)]] - [(3 - amino - 4 - (3, 5 - difluorophenyl)]] - [(ethylbenzyl)amino]butan-2-ol (190 mg, 0.5 mmol), and HATU (175 mg, 0.5 mmol) in methylene chloride (5 mL) was added N, N-The reaction mixture diisopropylethylamine (280 µL, 1.6 mmol). was stirred at room temperature for 18 h. The reaction 10 mixture was partitioned between methylene chloride and water. The organic layer was washed with water, dried sulfate), filtered, and concentrated under reduced pressure to oil. Purification by flash column afford a crude gradient 95:5 to 92:8 methylene chromatography (silica, 15 chloride/methanol) provided the title compound (60 mg): mp 45-50 °C; ESI MS m/z 537 [M + H]<sup>+</sup>.

### EXAMPLE SP-293

20

N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-piperidin-3-yl-N,N-dipropylisophthalamidehydrochloride

Step 1: To a stirred solution of 3-bromo-pyridine (205 mg, 1.3 25 3-[(dipropylamino)carbonyl]-5-(3,3,4,4methyl tetramethylborolan-1-yl)benzoate (500 mg, 1.3 mmol) in dioxane (9 mL) was added sodium carbonate (2.0 mL of a 2 M solution in The reaction mixture was flushed with water, 3.9 mmol). argon, palladium(0) tetrakis(triphenylphosphine) (36 mg, 0.052 30 mmol) was added and the reaction mixture was heated at reflux cooled to 12 h. The reaction mixture was room for through diatomaceous earth, dried temperature, filtered (magnesium sulfate), filtered, and concentrated under reduced

pressure. Purification by flash column chromatography (3:2 hexanes/ethyl acetate) afforded a pyridine (200 mg):  $^{1}H$  NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.88 (m, 1H), 8.65 (m, 1H), 8.31 (m, 1H), 8.07 (m, 1H), 7.92 (m, 1H), 7.79 (m, 1H), 7.67 (m, 1H), 3.98 (m, 3H), 3.50 (m, 2H), 3.21 (m, 2H), 1.66 (m, 4H), 1.07 (m, 3H), 0.78 (m, 3H).

Step 2: A solution of the pyridine from step 1 (160 mg, 0.37 mmol) and platinum oxide (15 mg) in ethanol (2.5 mL), water (0.5 mL), and concentrated hydrochloric acid (1.0 mL) was 10 degassed with nitrogen for 15 min, and shaken under an atmosphere of hydrogen at 50 psi for 12 h. The reaction mixture was filtered through diatomaceous concentrated under reduced pressure to afford methyl [(dipropylamino)carbonyl]-5-piperidin-3-ylbenzoate 15 quantitative), which was carried forward without further purification: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ 9.62 (m, 3H), 8.02 (m, 3H), 4.78 (m, 2H), 3.96 (s, 3H), 3.61 (m, 5H), 2.04 (m, 5H), 1.34 (m, 3H), 0.91 (m, 6H).

20

5

Step 3: To a stirred solution of piperidine from step 2 (204 mg, 0.59 mmol) in methylene chloride (1.6 mL) was added Boc anhydride (162 mg, 0.65 mmol) and triethylamine (0.122 mL, 0.88 mmol). The solution was stirred at room temperature for 2 d. The reaction mixture was filtered and concentrated under reduced pressure. Purification by flash column chromatography afforded a Boc-protected piperidine (100 mg): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ 7.93 (t, J = 3 Hz, 1H), 7.88 (t, J = 3 Hz, 1H), 7.42 (t, J = 3 Hz, 1H), 4.16 (m, 2H), 3.93 (s, 3H), 3.46 (m, 2H), 3.13 (m, 2H), 2.78 (m, 3H), 2.03 (d, J = 10 Hz, 1H), 1.70 (m, 7H), 1.48 (m, 9H), 1.00 (m, 3H), 0.75 (m, 3H).

Step 4: To a stirred solution of piperidine from step 3 (100 mg, 0.22 mmol) in methanol (2 mL) was added potassium

hydroxide (2.2 mL of a 1 M solution in water, 2.2 mmol) and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was partitioned between ethyl acetate (50 mL) and water (50 mL). The aqueous layer was acidified to pH 4-5 with 1 N hydrochloric acid and extracted with chloroform (5 x 50 mL). The combined organic layers were dried (magnesium sulfate), filtered, and concentrated under reduced pressure to afford an acid (90 mg)l:  $^{1}$ H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.99 (s, 1H), 7.94 (s, 1H), 7.47 (s, 1H), 4.12 (m, 2H), 3.47 (m, 2H), 3.14 (m, 2H), 2.77 (m, 3H), 2.03 (m, 1H), 1.67 (m, 7H), 1.48 (s, 9H), 0.98 (m, 3H), 0.77 (m, 3H).

10

15

20

25

Step 5: To a stirred solution of piperidine from step 4 (90 mg, 0.21 mmol) in methylene chloride (1 mL) was added N,N-diisopropylethylamine (0.142 mL, 0.84 mmol), HOBt (42 mg, 0.31 mmol), and HATU (118 mg, 0.31 mmol) followed by (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol (86 mg, 0.21 mmol). The reaction was stirred for 16 h at room temperature. The reaction mixture was diluted with methylene chloride (25 mL), washed with water, saturated sodium bicarbonate, and saturated sodium chloride, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (95:5 chloroform/methanol) afforded a piperidine (100 mg) which was carried forward without further characterization.

Step 6: A solution of piperidine from step 5 (100 mg, 0.15 mmol) and hydrochloric acid (0.4 mL of a 4.0 M solution in dioxane, 1.5 mmol) was stirred for 30 min at room temperature.

The reaction mixture was concentrated under reduced pressure and washed with ether (50 mL). The precipitate that formed was collected by filtration to give the title compound (60 mg): mp 145-145 °C; ESI MS m/z 649 [M + H]<sup>+</sup>.

EXAMPLE SP-294

1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-1H-pyrrole-2-carboxamide

Step 1: To a stirred solution of ethanol (54 mL) was added sodium metal (1.29 g, 54.00 mmol). The reaction mixture was 10 stirred for 1 h and then diethyl acetamidomaloante (2.37 g, 10.92 mmol) was added. The reaction mixture was heated at reflux for 1 h and 1,4-dichloro-2-butyne (1.14 mL, 11.64 mmol) was added. The reaction mixture was refluxed for 1 h, cooled to room temperature, and concentrated under reduced pressure. 15 The resulting residue was partitioned between ethyl acetate and water. The organic layer was washed with saturated sodium chloride, dried (sodium sulfate), treated with activated charcoal, filtered through diatomaceous earth, concentrated under reduced pressure to yield ethyl 5-methyl-20 1H-pyrrole-2-carboxylate (1.26 g):  $^{1}$ H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ 8.82 (br s, 1H), 6.81 (s, 1H), 5.95 (s, 1H), 4.31 (q, J = 6Hz, 2H), 2.31 (s, 3H), 1.34 (t, J = 6 Hz, 3H).

Step 2: A mixture of pyrrole from step 1 (240 mg, 1.71 mmol), potassium carbonate (306 mg, 2.21 mmol), and butyl bromide (328 mg, 2.39 mmol) in acetonitrile (10 mL) was heated to 40 °C for 2 d. The reaction mixture was cooled to room temperature and then partitioned between ethyl acetate and water. The organic layer was dried (sodium sulfate), filtered, and concentrated under reduced pressure to give a brown oil. Purification by flash column chromatography (silica, 5.5:1 hexanes/ethyl acetate) gave an ester (232 mg):  $^{1}$ H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  6.91 (d, J = 3 Hz, 1H), 5.88 (d, J = 3 Hz, 1H), 4.24

(m, 4H), 2.26 (s, 3H), 1.65 (m, 2H), 1.37 (m, 5H), 0.99 (m, 3H); ESI MS m/z 210 [M + H]<sup>+</sup>.

Step 3: A mixture of the ester from step 2 (232 mg, 1.11 mmol) and 3:1:1 methanol/tetrahydrofuran/2 N sodium hydroxide (5 mL) was stirred overnight. The reaction was not complete after 24 h. The reaction mixture was heated to 40 °C for 4 h, cooled to room temperature, and then partitioned between ethyl acetate and water. The aqueous layer was acidified to pH 3 with 1 N hydrochloric acid and extracted with chloroform. The organic layer was dried (sodium sulfate), filtered, and concentrated under reduced pressure to give 1-butyl-5-methyl-1H-pyrrole-2-carboxylic acid (110 mg):  $^{1}$ H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.04 (d, J = 3 Hz, 1H), 5.93 (d, J = 3 Hz, 1H), 4.24 (m, 2H), 2.28 (s, 3H), 1.67 (m, 2H), 1.43 (m, 2H), 0.99 (m, 3H).

Step 4: To a stirred solution of (2R,3S)-3-amino-4-(3,5difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol (248 0.608 mmol), acid (110 mg, 0.608 mmol), HOBt (82 mg, 0.608 mmol), and N-methylmorpholine (99 mg, 2.43 mmol) in methylene chloride (5 mL) was added EDC (210 mg, 1.09 mmol). reaction mixture was stirred overnight and then partitioned between ethyl acetate and water. The organic layer was washed with 1 N hydrochloric acid, saturated sodium bicarbonate, and saturated sodium chloride, dried (sodium sulfate), filtered, Purification by and concentrated under reduced pressure. chromatography (silica, 9:1 methylene flash column chloride/methanol) gave the title compound (100 mg): mp 116-121 °C; ESI MS m/z 498 [M + H]<sup>+</sup>.

30

10

15

20

25

EXAMPLE SP-295

 $N-\{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(1H-pyrrol-2-ylmethyl)amino]propyl}-5-methyl-N,N-dipropylisophthalamide$ 

1: A mixture of tert-butyl (1S, 2R)-3-amino-1-(3, 5difluorobenzyl)-2-hydroxypropylcarbamate (170 mg, 0.538 mmol), 1H-pyrrole-2-carbaldehyde (51 mg, 0.538 mmol), triethylamine (60 mg, 0.592 mmol) was stirred in chloroform (10 mL) containing magnesium sulfate for 4 h. The reaction mixture was filtered and concentrated under reduced pressure. The resulting residue was dissolved in 2-propanol (10 mL) and sodium borohydride (26 mg, 0.699 mmol) was added. reaction mixture was stirred overnight and then treated with methanol. The reaction mixture was concentrated under reduced Purification by flash column chromatography pressure. (silica, 9:1 chloroform/methanol) gave tert-butyl (1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(1H-pyrrol-2-

10

- 15 ylmethyl)amino]propylcarbamate (132 mg):  $^1$ H NMR (300 MHz, CD<sub>3</sub>OD)  $\delta$  6.82 (m, 4H), 6.21 (s, 1H), 6.09 (m, 1H), 4.09 (s, 2H), 3.66 (m, 2H), 3.19 (m, 1H), 3.13 (m, 1H), 3.03 (m, 1H), 2.88 (m, 1H), 1.31 (s, 9H).
- 20 Step 2: To a stirred solution of the pyrrole from step 1 (132 mg, 0.334 mmol) in dioxane (3 mL) was added hydrochloric acid (0.33 mL, 4 N dioxane, 1.34 mmol). The reaction mixture was stirred overnight and then concentrated under reduced pressure to give an amine (134 mg, quantitative) as a brown solid, 25 which was used without any further characterization or purification.

Step 3: To a stirred mixture of the amine from step 2 (134 mg, 0.334 mmol), 3-[(dipropylamino)carbonyl]-5-methylbenzoic acid 30 (88 mg, 0.334 mmol), HOBt (45 mg, 0.334 mmol), and N-methylmorpholine (203 mg, 2.00 mmol) in methylene chloride (5 mL) was added EDC (115 mg, 0.601 mmol). After 24 h, the reaction mixture was partitioned between ethylacetate and water. The organic layer was washed with 1 N hydrochloric

acid, saturated sodium bicarbonate, and saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure to give a white solid. Purification by chromatography (silica, 9:1:1 column flash chloride/methanol/ammonium hydroxide) gave the title compound  $(27 \text{ mg}): \text{mp } 63-74 \text{ }^{\circ}\text{C}; \text{ESI MS } m/z 541 \text{ [M + H]}^{+}.$ 

# EXAMPLE SP-296

15

25

 $N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-$ 10 hydroxypropyl}-5-piperazin-1-yl-N,N-dipropylisophthalamide hydrochloride

In a sealed tube, a solution of dimethyl bromoisophthalate (5.0 g, 18.3 mmol), N-benzylpiperazine (4.0 mL, 23.0 mmol), and cesium carbonate (8.4 g, 25.7 mmol) in toluene (36 mL) was degassed with nitrogen at room temperature for 20 minutes. Palladium (II) acetate (225 mg, 0.92 mmol) and BINAP (1.7 g, 2.74 mmol) were quickly added under nitrogen and the solution heated to 80  $^{\circ}\text{C}$  overnight to yield a yellow 20 The reaction mixture was solution with a white suspension. cooled to room temperature, vacuum filtered, and the solid rinsed with fresh toluene. The filtrate was then concentrated under reduced pressure to yield a yellow oil. Purification by flash chromatography (silica, 80:20 hexanes/ethyl acetate) dimethyl 5-(4-benzylpiperazin-1gave the desired yl)isophthalate (4.40 g): ESI MS m/z 369 [M + H]<sup>+</sup>.

Step 2: To a solution of the ester from step 1 (1.0 g, 2.70 mmol) in 2:1:1 dioxane/methanol/water (18 mL) was added 30 lithium hydroxide monohydrate (100 mg, 2.44 mmol) and the reaction mixture stirred for 24 h at room temperature. reaction mixture was concentrated under reduced pressure and the solid residue partitioned between ethyl acetate and water.

The organic layer was set aside and the aqueous phase acidified with 1 N hydrochloric acid and extracted three times with ethyl acetate. The combined ethyl acetate extracts were washed with water, and saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure to provide the desire monoacid (945 mg): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 10.50-10.30 (br s, 1H), 8.19-8.12 (m, 1H), 7.80-7.60 (m, 2H), 7.35-7.26 (m, 5H), 3.91 (s, 3H), 3.73 (s, 2H), 3.36-3.33 (m, 4H), 2.77-2.71 (m, 4H); ESI MS m/z 355 [M + H]<sup>+</sup>.

10

Step 3: To a solution of the monoacid prepared in step 2 (1.2 g, 3.38 mmol) in methylene chloride (22.5 mL) was added triethylamine (940  $\mu$ L, 6.76 mmol), N.N-dipropylamine (554  $\mu$ L, 4.0 mmol), and 2-chloro-1-methylpyridinium iodide (865 mg, 15 3.38 mmol). The reaction mixture was stirred at room temperature overnight. The residue was then diluted with methylene chloride, washed with saturated sodium bicarbonate, water, and saturated sodium chloride. The organic layer was then dried (sodium sulfate), filtered, and concentrated under reduced pressure to yield a yellow oil. Purification by flash 20 column chromatography (silica, 80:20 hexanes/ethyl acetate) gave the desired amide (1.0 g):  $^{1}\text{H}$  NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.59- $7.58 \, (m, 1H), 7.44-7.42 \, (m, 1H), 7.35-7.26 \, (m, 5H), 7.05-7.04$ (m, 1H), 3.89 (s, 3H), 3.56 (s, 2H), 3.50-3.35 (m, 2H), 3.28-25 3.25 (m, 4H), 3.20-3.05 (m, 2H), 2.62-2.58 (m, 4H), 1.70-1.40 (m, 4H), 1.00-0.95 (m, 3H), 0.80-0.70 (m, 3H).

Step 4: To a solution of the amide prepared in step 3 (1.00 g, 2.28 mmol) in absolute ethanol (120 mL) was added palladium(II) hydroxide (100 mg) and the reaction shaken under 55 psi of hydrogen at 60 °C overnight. The reaction was then cooled to room temperature, filtered through diatomaceous earth, and the filter cake rinsed with fresh ethanol. The filtrate was concentrated under reduced pressure and

redissolved in dry acetonitrile (15 mL). To this was added di-tert-butyl dicarbonate (650 mg, 2.96 mmol) and N, Ndiisopropylethylamine (450 uL, 2.50 mmol), and the reaction mixture stirred at room temperature overnight. The reaction concentrated under reduced pressure, was then mixture saturated sodium in chloroform, washed with redissolved bicarbonate, water, and saturated sodium chloride. The organic layer was then dried (sodium sulfate), filtered, and concentrated under reduced pressure to yield a colorless oil. Purification by flash column chromatography (silica, 66:33 hexanes/ethyl acetate) yielded the desired Boc-protected amine (953 mg):  ${}^{1}H$  NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.60-7.59 (m, 1H), 7.48-7.47 (m, 1H), 7.08-7.07 (m, 1H), 3.92 (s, 3H), 3.60-3.51 (m, 4H),3.46-3.44 (m, 2H), 3.22-3.16 (m, 6H), 1.70-1.48 (m, 13H), 1.10-0.98 (m, 3H), 0.78-0.74 (m, 3H); ESI MS m/z 448 [M + H]<sup>+</sup>.

10

15

20

25

30

Step 5: To a solution of Boc-protected amine prepared in step 4 (953 mg, 2.13 mmol) in 2:1:1 dioxane/methanol/water (14.2 mL) was added lithium hydroxide monohydrate (268 mg, 6.39 mmol), and the reaction mixture stirred at room temperature The reaction mixture was concentrated under overnight. reduced pressure and then partitioned between ethyl acetate aqueous phase was acidified with 1 N and water. The hydrochloric acid and extracted three times with ethyl The combined ethyl acetate extracts were washed with water and saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure to provide 3-[4-(tert-butoxycarbonyl)piperazin-1-yl]-5the desired [(dipropylamino)carbonyl]benzoic acid (770 mg): ESI MS m/z 434  $[M + H]^{\dagger}$ .

Step 6: A solution of the acid from step 5 (320 mg, 0.738 mmol) and HBTU (279 mg, 0.738 mmol) in methylene chloride (4.6 mL) containing N,N-disopropylethylamine (770  $\mu$ L, 4.42 mmol)

was stirred at room temperature for 20 minutes. To this was added a solution of (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-o1 (300 mg, 0.738 mmol) and N, Ndiisopropylethylamine (770 µL, 4.42 mmol) in methylene chloride 5 The reaction mixture was stirred at room temperature overnight. The reaction mixture was then concentrated under reduced pressure, diluted with methylene chloride, washed with saturated sodium bicarbonate, water, and saturated sodium chloride. The organic layer was then dried 10 (sodium sulfate), filtered, and concentrated under reduced pressure to yield a yellow syrup. Purification by flash column chromatography (silica, 93:7 chloroform/methanol) gave the desired amide (443 mg): ESI MS m/z 750 [M + H]<sup>†</sup>.

15 Step 7: To a solution of the amide prepared in step 6 (220 mg, 0.293 mmol) in 1,4-dioxane (2.0 mL) was added hydrochloric acid (750 µL, 4 M dioxane, 3.0 mmol) and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was then concentrated under reduced pressure. The residue was 20 taken up in methylene chloride and concentrated again under reduced pressure. This was repeated until a solid remained. No further purification was required. The recovered solid was dried under high vacuum over phosphorus pentoxide at 50 °C for h to give the title compound (120 mq) which was 25 characterized as its dihydrochloride salt: mp 135-136 °C; ESI  $MS m/z 650 [M + H]^+$ .

### EXAMPLE SP-297

N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(3-oxo-4-propylcyclohexyl)acetamide

Step 1: A solution of 2-propylphenol (26.83 g, 197 mmol), potassium carbonate (30.64 g, 221 mmol), methyl iodide (50.0

mL, 800 mmol), and 18-crown-6 (500 mg, 1.9 mmol) in acetone (300 mL) was refluxed for 48 h. The reaction mixture was cooled to room temperature, the solid removed by filtration, and the filtrate concentrated under reduced pressure. The resulting residue was partitioned between methylene chloride and water. The organic layer was washed with 2 N sodium hydroxide, water, and saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure to afford the desired methyl phenyl ether (23.46 g) as an oil, which was used without further purification:  $^{1}$ H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.16-7.11 (m, 2H), 6.90-6.82 (m, 2H), 3.81 (s, 3H), 2.58 (m, 2H), 1.60 (tq, J = 7, 5 Hz, 2H), 0.95 (t, J = 7 Hz, 3H).

10

Step 2: Absolute ethanol (200 mL) followed by tetrahydrofuran 15 (50 mL) was added at -78 °C to a solution of methyl phenyl ether from step 1 (10.0 g, 66.58 mmol) suspended in anhydrous ammonia (700 mL). Lithium metal (2.3 g, 330 mmol) was added at -78 °C in small portions over 0.5 h to yield a deep blue The reaction was stirred at -78 °C until a white 20 solution. solution resulted. The cooling bath was taken away, the flask exposed to the atmosphere, and the ammonia was removed under a stream of nitrogen. The solid residue remaining was dissolved in a minimum amount of water and acidified to pH 3 with 10% hydrochloric acid, and then extracted several times with 25 The combined ether phase was washed with diethyl ether. saturated sodium chloride, dried (sodium sulfate), filtered, and carefully concentrated under reduced pressure at 0 °C to The oil was dissolved in 10% hydrochloric provide an oil. acid (200 mL) and refluxed for 3 h. The reaction mixture was 30 then cooled to room temperature and extracted several times The combined ether extracts were washed with diethyl ether. with saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure to yield an

oil. Purification by flash column chromatography (silica, 89:11 hexanes/ethyl acetate) gave 2-propylcyclohexenone (4.43 g):  $^{1}$ H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  6.95-6.89 (m, 1H), 5.97 (app dt, J = 10, 2 Hz, 1H), 2.39-2.36 (m, 3H), 2.20-2.04 (m, 1H), 1.88-1.63 (m, 2H), 1.50-1.25 (m, 4H), 0.93 (t, J = 7 Hz, 3H).

Step 3: A solution of sodium metal (30 mg, 1.30 mmol) in absolute ethanol (4.0 mL) was stirred at -10 °C for 0.5 h. Diethyl malonate (3.5 mL, 23 mmol) was added at -10 °C followed by addition of a solution of 2-propylcyclohexenone (3.0 g, 21.7 mmol) in absolute ethanol (3.0 mL). The reaction mixture was stirred an additional 12 h at room temperature. The reaction mixture was acidified to pH 3 with 10% hydrochloric acid and then extracted several times with diethyl ether. The combined ether extracts were washed with water, and saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure to yield a Purification by flash column chromatography yellow oil. (silica, 83:17 hexanes/ethyl acetate) gave 2-(3-oxo-4-propylcyclohexyl)-malonic acid diethyl ester (5.07g): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  4.21 (q, J = 7 Hz, 2H), 4.20 (q, J = 7 Hz, 2H), 3.30 (s, 0.5H), 3.28 (s, 0.5H), 2.67-1.55 (m, 8H), 1.43-1.11(m, 10H), 0.90 (t, J = 7 Hz, 1.5H), 0.90 (t, J = 7.0 Hz,1.5H).

25

30

20

5

10

15

Step 4: A solution of the diester from step 2 (2.37 g, 7.94 mmol) in 1 N potassium hydroxide (16.27 mL, 16.27 mmol) was refluxed for 2 h. The reaction mixture was cooled to room temperature, diluted with water, and extracted with methylene chloride. The aqueous phase was acidified to pH 1-2 with 6 N hydrochloric acid and then refluxed for 2 h. The reaction mixture was cooled to room temperature and extracted several times with methylene chloride. The combined organic phase was washed with water, and saturated sodium chloride, dried

(sodium sulfate), filtered, and concentrated under reduced pressure to yield a light yellow oil. Purification by flash column chromatography (silica, 66:33 hexanes/ethyl acetate with 1% glacial acetic acid) gave (3-oxo-4-propyl-cyclohexyl)-acetic acid (1.42 g):  $^{1}$ H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  2.71-1.12 (m, 14H), 1.11-0.82 (m, 3H); ESI MS m/z 197 [M - H] $^{-}$ .

Step 5: To a stirred solution of the acid from step 4 (244 mg, 1.23 mmol) and N, N-diisopropyl ethylamine (214  $\mu$ L, 1.23 mmol) in methylene chloride (7.0 mL) was added HBTU (513 mg, 1.35 10 mmol) and the reaction mixture stirred for 0.5 h. above solution was added a solution of amine (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2-ol (500 mg, 1.35 mmol) and N,N-diisopropylethylamine (428  $\mu$ L, 2.46 mmol) in methylene chloride (7.0 mL) and the reaction mixture 15 was stirred under nitrogen for 18 h. The reaction mixture was then diluted with additional methylene chloride and washed with saturated sodium bicarbonate, 0.5 N hydrochloric acid, and saturated sodium chloride. The organic layer was then dried (sodium sulfate), filtered, and concentrated under 20 reduced pressure to yield an oily residue. Purification by flash column chromatography (silica, 7:93 methanol/methylene chloride) gave the title compound (360 mg): mp 52-54 °C; ESI MS m/z 515 [M + H]<sup>+</sup>.

25

EXAMPLE SP-298

 $N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-2-(3-oxocyclohexyl)acetamide$ 

30

Step 1 (3-Oxo-cyclohexyl)-malonic acid diethyl ester was prepared in 88% yield from cyclohexenone by the method described above for the synthesis of 2-(3-oxo-4-propyl-

cyclohexyl)-malonic acid diethyl ester:  $^{1}$ H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  4.44-4.12 (m, 4H), 2.88-1.22 (m, 16H).

Step 2 (3-Oxo-cyclohexyl)-acetic acid was prepared in 70% yield from 2-(3-oxo-cyclohexyl)-malonic acid diethyl ester by the method described above for the synthesis of (3-oxo-4-propyl-cyclohexyl)-acetic acid: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 2.58-1.92 (m, 7H), 1.80-1.61 (m, 1H), 1.52-1.42 (m, 1H); ESI MS m/z 155 [M - H]<sup>-</sup>.

10

Step 3: N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(3-oxocyclohexyl)acetamide was prepared in 23% yield from (3-Oxocyclohexyl)-acetic acid by the method described for the synthesis of N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(3-oxo-4-propylcyclohexyl)acetamide (EXAMPLE SP-297.)

mp 139.5-149.8 °C;); ESI MS m/z 473 [M + H]<sup>+</sup>.

# 20 EXAMPLE SP-299

3-benzyl-4-(4-butylphenyl)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-oxobutanamide

Step 1: Benzaldehyde (2.81 mL, 27.15 mL) was added at 0 °C to 25 a solution of 4-butyl-acetophenone (5.26 mL, 27.15 mmol) in methanol (7.8 mL) and water (13.0 mL) containing sodium hydroxide (1.39 g, 34.75 mmol). The reaction was warmed to room temperature and stirred 48 h. The reaction mixture was diluted with ethyl acetate and washed with water, saturated 30 dried (sodium sulfate), filtered, and sodium chloride, concentrated to yield a light yellow syrup. Volatile impurities were removed under high vacuum at 120 °C to yield the desired enone (6.3 g): ESI MS m/z 265 [M + H]<sup>+</sup>.

Step 2: A solution of the enone prepared in step 1 (2.0 g, 7.56 mmol) in anhydrous diethyl ether (11 mL) was added at -78 °C to a solution of lithium metal (120 mg, 16.6 mmol) in dry liquid ammonia (11 mL). The reaction was stirred at -78 °C 5 for 0.5 h and excess lithium was quenched with several drops of piperylene to yield a yellow solution. Lithium bromoacetate (2.75 g, 18.9 mmol) was added in one portion and the reaction stirred at -78 °C for 0.5 h then at -33 °C for 2 The reaction was then quenched with NH4Cl and the open 10 h. reaction vessel warmed to room temperature. The residue was partitioned between ethyl acetate and water and the phases separated. The organic phase was washed with water, saturated dried (sodium sulfate), filtered sodium chloride, concentrated to yield a yellow syrup. Purification by flash 15 (silica, 74:25:1 hexanes/ethyl chromatography 3-benzyl-4-(4-butylphenyl)-4acetate/acetic gave acid) oxobutanoic acid (60 mg): ESI MS m/z 325 [M + H]<sup>+</sup>.

Step 3: A solution of 3-benzyl-4-(4-butylphenyl)-4-oxobutanoic 20 acid (60 mg, 0.185 mmol) and HBTU (70 mg, 0.185 mmol) in containing chloride (1.2)mL) methylene diisopropylethylamine (100  $\mu$ L, 0.55 mmol) was stirred at room temperature for 20 minutes. To this was added a solution of (2R, 3S) - 3 - amino - 4 - (3, 5 - difluorophenyl) - 1 - [(3 - amino - 4 - (3, 5 - difluorophenyl)]25 ethylbenzyl)amino]butan-2-ol (75 mg, 0.185 mmol) and N, Ndiisopropylethylamine (100  $\mu$ L, 0.55 mmol) in methylene chloride The reaction mixture was stirred at room (1.2 mL). The reaction mixture was temperature overnight. concentrated under reduced pressure, diluted with methylene 30 chloride, washed with saturated sodium bicarbonate, water and saturated sodium chloride, dried (sodium sulfate), filtered, and concentrated under reduced pressure to yield a colorless syrup. Purification by flash column chromatography (silica,

93:7 chloroform/methanol) gave the title compound (36 mg) (diastereomeric mixture): mp 42-45 °C; ESI MS m/z 641 [M + H]<sup>+</sup>.

EXAMPLE SP-300

5

N-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(1H-indol-6-ylmethyl)amino]propyl}-5-methyl-N<sup>3</sup>,N<sup>3</sup>-dipropylisophthalamide

10

15

Step 1: To a -78 °C, stirred solution of methyl 1H-indole-6-carboxylate (500 mg, 2.85 mmol) in methylene chloride (11.5 mL) was added diisobutylaluminum hydride (5.70 mL, 1.0 M solution in methylene chloride). The reaction mixture was stirred for 2 h at -78 °C, and slowly warmed to room temperature for 10 h. The reaction mixture was quenched with methanol, washed with Rochelle's salt (saturated aqueous

potassium sodium tartrate), dried (magnesium sulfate), and concentrated under reduced pressure. Purification by flash column chromatography (silica, 6:1 ethyl acetate/hexanes) afforded an alcohol (100 mg):  $^1$ H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.21 (br s, 1H), 7.62 (d, J = 9 Hz, 1H), 7.39 (s, 1H), 7.20-7.22 (m, 1H), 7.10-7.13 (m, 1H), 6.54-6.56 (m, 1H), 4.77 (d, J = 3 Hz, 2H), 1.60 (s, 1H).

Step 2: To a stirred solution of alcohol from step 1 (100 mg, 0.68 mmol) in methylene chloride (3 mL) was added magnesium 10 oxide (590 mg, 6.8 mmol) and the reaction mixture was stirred reaction mixture was filtered through for 1 h. The diatomaceous earth and concentrated under reduced pressure to provide 1H-indole-6-carbaldehyde (99 mg) as a solid, which was forward without further purification 15 carried characterization.  $^{1}$ H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ 10.03-10.88 (m, 1H), 8.56 (br s, 1H), 7.96 (s, 1H), 7.74 (d, J = 8 Hz, 1H), 7.64-7.70 (m, 1H), 7.46 (t, J = 3 Hz, 1H), 6.65 (s, 1H).

Step 3: To a stirred solution of 1H-indole-6-carbaldehyde (99 20 tert-butyl (1S, 2R)-3-amino-1-(3, 5-0.68 mmol) and mg, difluorobenzyl)-2-hydroxypropylcarbamate acetate 3 (256 mg, 0.68 mmol) in 2-propanol (3 mL) was added sodium borohydride (30 mg, 0.82 mmol). The reaction mixture was stirred for 12 25 h., quenched with methanol, and concentrated under reduced Purification by flash column chromatography pressure. (silica, 1:1 ethyl acetate/hexanes) provided indole (50 mg): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta 8.41$  (br s, 1H), 7.60 (d, J = 8 Hz, 1H), 7.38 (s, 1H), 7.21 (t, J = 3 Hz, 1H), 7.04 (dd, J = 8, 1 Hz, 1H), 6.71-6.73 (m, 3H), 6.61-6.68 (m, 1H), 6.53 (s, 1H), 30 5.38 (br s, 2H), 4.66 (d, J = 9 Hz, 1H), 3.89 (s, 2H), 3.49-3.54 (m, 1H), 2.91-2.98 (m, 1H), 2.62-2.73 (m, 3H), 1.35 (s, 9H).

Step 4: To a stirred solution of indole from step 3 (50 mg, 0.11 mmol) was added hydrochloric acid (0.27 mL, 4.0 M solution in dioxane). The reaction mixture was stirred for 1 h, diluted with ethyl ether, and concentrated under reduced pressure to provide (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(1H-indol-6-ylmethyl)amino]butan-2-ol hydrochloride 4 (70 mg): ESI MS <math>m/z 346 [M + H]<sup>+</sup>.

Step 5: To a stirred solution of 3-[(dipropylamino)carbonyl]-5-methylbenzoic acid (5) (29 mg, 0.11 mmol) in methylene 10 chloride (3 mL) was added HBTU (64 mg, 0.17 mmol), HOBt (23 mg, 0.17 mmol), and N,N-diisopropylethylamine (0.075 mL, 0.44 mmol), followed by (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(1H-indol-6-ylmethyl)amino]butan-2-ol hydrochloride 4 (70 mg, 0.11 mmol). The reaction mixture was stirred for 12 h, 15 diluted with methylene chloride, washed with water, saturated sodium bicarbonate, dried (magnesium sulfate), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 89:10:1 chloroform/methanol/ammonium hydroxide) provided the title 20 compound (6) (13 mg): mp 135-137 °C; ESI MS m/z 591 [M + H]<sup>+</sup>.

## EXAMPLE SP-301

30

N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-25 hydroxypropyl}-1,3-benzodioxole-5-carboxamide

To a solution of piperonylic acid (0.500g, 3.01 mmol), EDC (0.867g, 4.52 mmol), HOBT (0.611g, 4.52 mmol) in anhydrous DMF (10 mL) was added a solution of TEA (1.67 mL, 12.04 mmol), 3-Amino-4-(3,5-difluoro-phenyl)-1-(3-ethyl-benzylamino)-butan-

2-ol (1.693g, 3.01 mmol), and anhydrous DMF (5 mL). Reaction mixture was stirred under nitrogen overnight. Quenched reaction mixture with 10% sodium bicarbonate (aq.) then extracted with ethyl acetate. Washed organic layer with 1N HCl, followed by a wash with 10% sodium bicarbonate (aq.). Dried organic layer over magnesium sulfate, filtered, then concentrated in vacuo, yielding the product. (ES+: 483.2)

EXAMPLE SP-302

10 tert-butyl (1S,2R)-1-[3-(benzyloxy)-5-fluorobenzyl]-3-[(3-ethylbenzyl)amino]-2-hydroxypropylcarbamate

[2-(3-Benzyloxy-5-fluoro-phenyl)-1-oxiranyl-ethyl]-

15 carbamic acid tert-butyl ester (3.33 g, 8.59 mmol) and m-ethyl benzylamine (2.32 g, 17.19 mmol) were dissolved in isopropyl alcohol (80 ml) and brought to reflux for 2h. Reaction mixture was then concentrated in vacuo to remove isopropyl alcohol. Dissolved yellow liquid in ethyl acetate (30 ml), 20 then washed with 1N HCl (3x100 ml). Aqueous layers were combined then extracted with ethyl acetate (2x100 ml). Organic layers were washed with 10% sodium bicarbonate (aq., 3x100 ml), followed by a brine wash. Organic layer was dried over sodium sulfate, filtered, then concentrated in vacuo, 25 yielding the product (4.31 g). (ES+: 523.9)

EXAMPLE SP-303

5-[((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)amino]-5-

30 oxopentanoic acid

To a solution of 3-Amino-4-(3,5-difluoro-phenyl)-1-[1-(3-mino-4-(3-mino-4-(5 ethyl-phenyl)-cyclopropylamino]-butan-2-ol (0.500g, 1.387 mmol) in chloroform (7 ml) was added TEA (0.58 ml, 4.161 mmol) with stirring under nitrogen for 30 min. To this solution was added glutaric anhydride (0.158g, 1.387 mmol) and reaction was stirred overnight at 50°C. The reaction mixture concentrated in vacuo, yielding the product. (ES+: 475.2)

EXAMPLE SP-304

10

15

4-[((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)amino]-4oxobutanoic acid

To a solution of 3-Amino-4-(3,5-difluoro-phenyl)-1-[1-(3-mino-phenyl)ethyl-phenyl)-cyclopropylamino]-butan-2-ol (0.500g, mmol) in chloroform (7 ml) was added TEA (0.58 ml, 4.161 mmol) with stirring under nitrogen for 30 min. To this solution was added succinic anhydride (0.138g, 1.387 mmol) and reaction was stirred overnight at 50°C. The next morning reaction mixture was concentrated in vacuo, yielding the product. (ES+: 461.2)

25

20

EXAMPLE SP-305

5

formic acid compound with  $N^1$ -[(3S)-1-azabicyclo[2.2.2]oct-3-yl]- $N^5$ -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)pentanediamide (1:1)

To a solution of R-aminoquinuclidine (0.084g, 0.421 mmol)

TEA (0.294 ml, 2.11 mmol), and anhydrous DMF (2.5 ml) was

10 added 5-[((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)amino]-5
oxopentanoic acid (0.200g, 0.421 mmol), EDC (0.121g, 0.632 mmol), HOBT (0.085g, 0.632 mmol) under nitrogen, with stirring at 45°C overnight. Reaction mixture was quenched with 10%

15 sodium bicarbonate (aq.) then extracted with ethyl acetate then concentrated in vacuo, yielding product (0.122g). Prep-HPLC yielded the product as its formate salt. (ES+: 583.3)

EXAMPLE SP-306

formic acid compound with  $N^1$ -[(3R)-1-azabicyclo[2.2.2]oct-3-yl]- $N^5$ -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)pentanediamide (1:1)

25

To a solution of S-aminoquinuclidine (0.084g, 0.421 mmol) TEA (0.294 ml, 2.11 mmol), and anhydrous DMF (2.5 ml) was added  $5-[((1S,2R)-1-(3,5-difluorobenzyl)-3-\{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)amino}-5-$ 

oxopentanoic acid (0.200g, 0.421 mmol), EDC (0.121g, 0.632 mmol), HOBT (0.085g, 0.632 mmol) under nitrogen, with stirring at 45°C overnight. Reaction mixture was quenched with 10% sodium bicarbonate (aq.) then extracted with ethyl acetate then concentrated in vacuo, yielding product (0.065g). Prep-10 HPLC yielded the product as its formate salt. (ES+: 583.3)

## EXAMPLE SP-307

formic acid compound with  $N^1-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-N^4-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-yl]-1-(3-yl]-1-(3-yl)-3-(1-(3-yl)-3-(1-(3-yl)-3$ 

ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)succinamide (1:1)

To a solution of R-aminoquinuclidine (0.086g, 0.434 mmol)

TEA (0.302 ml, 2.17 mmol), and anhydrous DMF (2.5 ml) was added 4-[((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)amino]-4-oxobutanoic acid (0.200g, 0.434 mmol), EDC (0.125g, 0.651 mmol), and HOBT (0.088g, 0.651 mmol) under nitrogen, with stirring at 45°C overnight. Reaction mixture was quenched with 10% sodium bicarbonate (aq.) then extracted with ethyl acetate then concentrated in vacuo, yielding product (0.200g). Prep-HPLC yielded the product as its formate salt. (ES+: 569.3)

EXAMPLE SP-308

To a solution of S-aminoquinuclidine (0.086g, 0.434 mmol)

TEA (0.302 ml, 2.17 mmol), and anhydrous DMF (2.5 ml) was added 4-[((1s,2r)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)amino]-4-oxobutanoic acid (0.200g, 0.434 mmol), EDC (0.125g, 0.651 mmol), and HOBT (0.088g, 0.651 mmol) under nitrogen, with stirring at 45°C overnight. Reaction mixture was quenched with 10% sodium bicarbonate (aq.) then extracted with ethyl acetate then concentrated in vacuo, yielding product (0.093g). Prep-HPLC yielded the product as its formate salt. (ES+: 569.3)

EXAMPLE SP-309

Pd(Ph<sub>3</sub>P)<sub>4</sub>
 1,3-dimethylbarbituric acid
 THF/50°C

2. SCX

MP stands for macroporous resin.

5

10

2: A solution of 1 (2.50g; 5.75mmol) and DIEA (1.20mL; 6.90mmol) in DCM (100mL) was cooled in an ice/water bath. Allyl chloroformate (0.73mL; 6.90mmol) was added, and the reaction was allowed to come to ambient temperature over 4h. The reaction was washed with 10% K<sub>2</sub>CO<sub>3</sub> (100mL), water (100mL), brine (100mL), and dried over Na<sub>2</sub>CO<sub>3</sub>. Flash chromatography on 90g silica gel with 0-30% EtOAc/ heptane afforded 2.88g (5.55mmol; 96%) 2 as a white solid.

3: A solution of 2 (2.88g; 5.55mmol) and Dowex 50WX2 (Aldrich; 8.88g; approx. 44.4mmol) in MeOH (100mL) was heated to 50°C for 5.25h. The reaction was cooled to ambient temperature and filtered. The resin was washed well with MeOH, and the product was eluted with approx. 3.5M ammonia in MeOH. After removal of solvent, 2.11g (5.04mmol; 91%) 3 was collected as an off-white waxy solid.

- 5: The appropriate amines (0.3mmol) were added to vials containing 4-(chlorosulfonyl)benzoic acid 4 (2.0mL of a 0.05M solution of THF) plus 1eq. of DIEA if necessary (to liberate any amine hydrochloride salts). The vials were agitated on an orbital shaker at ambient temperature/250rpm for 18h. MP-15 isocyanate resin (approx. 0.6mmol) was added to each vial, which were heated to 60°C for 5h. The reactions were filtered, the resin washed well with THF, and concentrated.
- The acids 5 were coupled to Alloc-protected TSI 3 using 20 HATU (1.2eq.) and DIEA (2.4eq.) in DMF for 18h at ambient temperature. MP-isocyanate (3eq.) and MP-carbonate (1eq.) were then added, and the reactions rocked for 4h at ambient temperature. The reactions were filtered, the resins washed well with 1,2-dichloroethane, and concentrated. The residues were dissolved in 1,2-dichloroethane (1.5mL), washed with 1M 25 citric acid (1.5mL) and loaded onto 3mL capacity Varian ChemElut Hydromatrix cartridges. After 5 min, the product was eluted with 1,2-dichloroethane (2x6mL), and concentrated in vacuo.

30

7: Alloc intermediates 6 were deprotected using Pd(Ph3P)4 (0.15eq.) and 1,3-dimethylbarbituric acid (20eq.) in THF at 60°C/3h. The reaction vials were concentrated *in vacuo*, and SCX was performed by loading the crude reaction mixture onto

1000mg/3mL SCX cartridges using 5mL MeOH. The cartridges were washed well with MeOH, and the products eluted with approx.

3.5M ammonia in MeOH. If necessary, the final products were purified by high-throughput preparative UV HPLC.

5 The following compounds were prepared using the above described methodology.

EXAMPLE	Structure	Compound Name(s)	OAMS
2965	H N NH F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-phenylpropanamide	467.3
2966	рек не объ	formic acid compound with N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-{[ethyl(methyl)amino] sulfonyl}benzamide (1:1)	560.1
2967	ONS OH IN OH	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-(piperidin-1-ylsulfonyl)benzamide	586.2
2968	H N OH F	2-(2-chlorophenoxy)- N-{(1S,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}acetami de	503.3

	·	- (14 m OP) 1 /2 F	441.2
	N	1 ( ( 1 D ) 2 - 1 ) = ( - ) -	441.2
	$\mathbb{N} \wedge \wedge \mathbb{F}$	difluorobenzyl)-3-	
ľ	$N \rightarrow N \rightarrow N \rightarrow N \rightarrow N \rightarrow N \rightarrow N \rightarrow N \rightarrow N \rightarrow N \rightarrow$	[(3-	
	Ö ///OH	ethylbenzyl)amino]-2-	į
	Ž" OU Ī	hydroxypropyl}pyrazin	1
	NH F	e-2-carboxamide	
	$\downarrow$		Į.
			Ì
2969			'
2505	ОН	N-{(1S,2R)-1-(3,5-	531.2
	Š, N, A	difluorobenzyl)-3-	
		[(3-	
	O ("OH	ethylbenzyl)amino]-2-	
	ŅH Ė	hydroxypropyl}-3-	
		(phenylsulfonyl)propa	
}		namide	-
<u> </u>		Hamitae	
2970			F00 0
		formic acid compound	ן פֿינעטכן
		with $N-\{(1S, 2R)-1-$	] [
	s	(3,5-difluorobenzyl)-	
		3-[(3-	
	Н НСООН	ethylbenzyl)amino]-2-	1
	F	hydroxypropyl}-4-	
		(1,3-thiazolidin-3-	}
		ylsulfonyl)benzamide	i
2971		(1:1)	}
27/1	9, 0	formic acid compound	634.0
	N'S DH DH	with $N-\{(1S,2R)-1-$	
		(3,5-difluorobenzyl)-	
	Ö <b>Ş</b> ✓ <b>√</b> F	3-[(3-	
	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	ethylbenzyl)amino]-2-	
	F HCOOH	hydroxypropyl}-4-	
		(3,4-	
		dihydroisoquinolin-	
		2(1H) -	
		ylsulfonyl)benzamide	
2972		(1:1)	663.0
		N-{(1S, 2R)-1-(3,5-	1003.0
		difluorobenzyl)-3-	
	↓ ↓ F	[(3-	
	· \	ethylbenzyl)amino]-2-	1
	<b> </b>	hydroxypropyl}-4-[(4-	-
		phenylpiperazin-1-	
2973		yl)sulfonyl]benzamide	
	0,0	formic acid compound	
		with $N-\{(1S,2R)-1-$	-
		(3,5-difluorobenzyl)-	-
	F	3-[(3-	
	F HCOOH	ethylbenzyl)amino]-2-	-
2974	нсоон		_L

		hydroxypropyl}-4-{[4-	
	•	(4-	
		fluorophenyl)piperazi	
		n-1-	
		yl]sulfonyl}benzamide	
		(2:1)	
	0, 0	N-{(1S,2R)-1-(3,5-	572
	NIS OH	difluorobenzyl)-3-	3/2
		[(3-	
	) AF	- '	
		ethylbenzyl)amino]-2-	
	Ĭ	hydroxypropyl}-4-	
	ſ ·	(pyrrolidin-1-	
2975		ylsulfonyl)benzamide	
		formic acid compound	572.0
	I ON H OH H ON	with N-{(1S,2R)-1-	
		(3,5-difluorobenzyl)-	
	l o 🏋 F	3-[(3-	
	HCOOH	ethylbenzyl)amino]-2-	
	Fsoci	hydroxypropyl}-4-	
		(pyrrolidin-1-	
f		ylsulfonyl)benzamide	
2976		(1:1)	
	0,0	formic acid compound	731 0
	N'S H OHH	with $N-\{(1S,2R)-1-$	731.0
		(3,5-difluorobenzyl)-	
	CE HCOOH	3-[(3-	
	F HCOOH	ethylbenzyl)amino]-2-	
		hydroxypropyl}-4-({4-	
		[3-	
		(trifluoromethyl)phen	
		yl]piperazin-1-	
2077		yl)sulfonyl)benzamide	
2977		(2:1)	
		N-{(1S,2R)-1-(3,5-	546
	N'S HOHH O	difluorobenzyl)-3-	
		[(3-	
	" F	ethylbenzyl)amino]-2-	
	\\	hydroxypropyl}-4-	
	<b> </b>	[(dimethylamino)sulfo	
2978		nyl]benzamide	
	Q, p	formic acid compound	546.0
	N,S N OH I	with N-{(1S,2R)-1-	
		(3,5-difluorobenzyl)-	
	"	3-[(3-	
	нсоон		
	F	hydroxypropyl}-4-	
	·	[(dimethylamino)sulfo	
2979		nyl]benzamide (1:1)	
		TITATINGHISUMITOE (T:T)	

		formic acid compound	642.0
	N'S H OHH ()	with $4-\{[(4-)]$	
		chlorophenyl) (methyl)	
Ì	0 Y	amino]sulfonyl}-N-	
ļ	нсоон 🍸	{ (1S, 2R) -1- (3, 5-	
	F	difluorobenzyl)-3-	
			į
		[(3-	ļ
		ethylbenzyl)amino]-2-	l
	'	hydroxypropyl}benzami	1
2980		de (1:1)	
		formic acid compound	684.1
	NS OH . OH .	with 4-	į
		{ [benzyl (phenyl) amino	
	Ö 🆴 F	]sulfonyl}-N-	
	₩ нсоон		1
	F	{ (1S, 2R) -1- (3, 5-	
		difluorobenzyl)-3-	
		[(3-	
		ethylbenzyl)amino]-2-	
		hydroxypropyl}benzami	
2981		de (1:1)	
	0,0	formic acid compound	588.1
	OH OH OH	with N-{(1S, 2R)-1-	
		(3,5-difluorobenzyl)-	
		3-[(3-	
	, uncou	1 7 7	
	HCOOH F	ethylbenzyl)amino]-2-	
		hydroxypropyl}-4-	
		(morpholin-4-	1
		ylsulfonyl)benzamide	
2982		(1:1)	
	0,0	formic acid compound	585.0
	N=\N'S\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	with 4-{[(2-	
		cyanoethyl) (methyl) am	
	Ö	ino]sulfonyl}-N-	
	₩ нсоон		
	Ė	{ (1s, 2r) -1- (3, 5-	
		difluorobenzyl)-3-	
		[(3-	'
		ethylbenzyl)amino]-2-	
		hydroxypropyl}benzami	
2983	1	de (1:1)	
	0,0	formic acid compound	614.0
		with 4-	
1		{[cyclohexyl(methyl)a	
		· - = =	
	нсоон	mino]sulfonyl}-N-	
	1.00011	{(1s,2r)-1-(3,5-	
	F	difluorobenzyl)-3-	
		[(3-	
		ethylbenzyl)amino]-2-	
		hydroxypropyl}benzami	
2984		de (1:1)	
,	I .	· · · · · · · · · · · · · · · · · · ·	

	T		
		formic acid compound 63	37.0
	N'S H OHH	with $N-\{(1S, 2R)-1-$	
		(3,5-difluorobenzy1)-	
	N Ö V	3-[(3-	
	НСООН	ethylbenzyl)amino]-2-	
	F HCOOH	hydroxypropyl}-4-	
		{[methyl(2-pyridin-2-	
2985		ylethyl)amino]sulfony	
2505	100	l}benzamide (2:1)	
		formic acid compound 60	8.1
	No H OH H	with $N-\{(1s,2r)-1-$	
		(3,5-difluorobenzyl)-	
	0 \rightarrow F	3-[(3-	
	₩ нсоон	ethylbenzyl)amino]-2-	
	į Ė	hydroxypropyl}-4-	
1		{[methyl(phenyl)amino]	
			İ
2986	1	(1:1)	
	9,9	formic acid compound 62	2 1
	NS OH	7	2.1
		1 - 1	
		{[benzyl(methyl)amino	
	НСООН	]sulfonyl}-N-	-
	F	{(1s, 2r) -1-(3,5-	
ĺ		difluorobenzy1)-3-	
		[(3-	İ
		ethylbenzyl)amino]-2-	
		hydroxypropyl}benzami	ĺ
2987		de (1:1)	
		formic acid compound 63	6.1
	N'S H OH H	with N-{(1S,2R)-1-	
		(3,5-difluorobenzyl)-	
	Ö 🆴 F	3-[(3-	j
	нсоон	ethylbenzyl)amino]-2-	
	F HCOOH	hydroxypropyl}-4-	1
		[methyl(2-	ļ
2988		phenylethyl)amino]sul	l
	0.0	fonyl}benzamide (1:1)	
		formic acid compound 572	2.1
	N T H OH H C	with 4-	-
		{[allyl(methyl)amino]	1
	"	$sulfonyl}-N-{(1S,2R)-}$	
	₩ нсоон	1-(3,5-	- 1
	Ė	difluorobenzyl)-3-	ŀ
		[(3-	
		ethylbenzyl)amino]-2-	1
		hydroxypropyl}benzami	
2989		de (1:1)	
		GC (1.1)	

	0.0	E	C21 1
		formic acid compound	631.1
	N THE SHALL	with 4-{[[2-	
		(diethylamino)ethyl)(	
	HCOOH	methyl)amino]sulfonyl	
	E HCOOH	}-N-{(1S,2R)-1-(3,5-	
	F 1100011	difluorobenzyl)-3-	
		[(3-	
		ethylbenzyl)amino]-2-	
		hydroxypropyl}benzami	
2990		de (2:1)	
	0,0	formic acid compound	574.1
	NS OH OH	with $N-\{(1S, 2R)-1-$	
		(3,5-difluorobenzyl)-	
		3-[(3-	
		ethylbenzyl)amino]-2-	
	т нсоон	hydroxypropyl}-4-	
	<b>'</b> '	{[methyl(propyl)amino	
		]sulfonyl}benzamide	
2001		<del>-</del>	
2991	l	(1:1)	E00 1
		formic acid compound	288.1
	N H DH H L	with 4-	
		{[butyl(methyl)amino]	
	нсоон	$sulfonyl}-N-{(1S,2R)-}$	
	HCOOH	1-(3,5-	
	F	difluorobenzyl)-3-	
		[ (3-	
		ethylbenzyl)amino]-2-	
		hydroxypropyl}benzami	
2992	·	de (1:1)	
	9,0	formic acid compound	602.1
	N'S N DH D	with N-{(1S, 2R)-1-	
		(3,5-difluorobenzyl)-	
		3-[(3-	
1	HCOOH	ethylbenzyl)amino]-2-	
	F	hydroxypropyl}-4-	
		{ [methyl (pentyl) amino	
		]sulfonyl}benzamide	
2993		(1:1)	
	0, 0	formic acid compound	602 1
		with $N-\{(1S, 2R)-1-$	002.1
		(3,5-difluorobenzyl)-	
	↓	3-[(3-	
	Н нсоон	1	
	T F	ethylbenzyl)amino]-2-	
		hydroxypropyl}-4-	
		{[isopentyl(methyl)am	
		ino]sulfonyl}benzamid	
2994	i	e (1:1)	

		745 0
		615.0
NS H OHH	with $N-\{(1S,2R)-1- $	
	(3,5-difluorobenzyl)-	
) <b>\</b> -\	3-[(3-	
у нсоон	ethylbenzyl)amino]-2-	
Ė HCOOH	hydroxypropyl}-4-	
nocon	{[methyl(1-	
	- I	
	<b>3</b>	
0, 0		602.0
VN'S OH ♦	·	
	· · · · · · · · · · · · · · · · · · ·	
Ů ↓ F		
НСООН	* * * *	
F	. – –	
	<del></del>	
	t I	574.0
^ Ŋ ° ¬ H Q H   ↑ I	with 4-	
	[(diethylamino)sulfon	
	yl]-N-{(1S,2R)-1-	
<b>∀</b> ″ нсоон	(3,5-difluorobenzyl)-	
F	3-[(3-	
	ethylbenzyl)aminol-2-	
	HCOOH  HCOOH  HCOOH  P  HCOOH	HCOOH  HC

## EXAMPLE SP-310

N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide

ethyl 2-amino-1,3-oxazole-4-carboxylate

5

10

15

20

To a 250 ml 3-neck round bottom flask was added Step 1. (20g, 0.3332 moles) urea, (150ml) ethanol and (42.42g, 0.2175 moles, 0.65eq) ethylbromopyruvate. The mixture was then heated under agitation to reflux for 16 hours. The reaction solution changed from yellow to red in color. The reaction solution was then evaporated to dryness and the crude product was taken up in (50ml) water and (150ml) ethyl acetate. pH was adjusted from 1 to 10 using 2N sodium hydroxide, changing the biphasic mixture a dark red. The mixture was separated and the aqueous phase was extracted twice with ethyl The organic layers were then combined and washed with water and brine. The resulting yellow solution was concentrated to ~50ml, causing an off-white solid precipitate out. The solid was filtered off and washed with ethanol and diethyl ether. The mother liquor was evaporated to dryness and the resulting oily solid was taken up in (150ml) ethyl acetate and concentrated to ~50ml. off-white solid precipitated out. The mixture was cooled in an ice bath, and the solid was filtered off and washed with

ethanol and diethyl ether to give ethyl 2-amino-1,3-oxazole-4-carboxylate (14.79 g).

ethyl 2-[(methylsulfonyl)amino]-1,3-oxazole-4-carboxylate

5 Step 2. To a 20 ml screw cap vial was added (1g, 5.8069 mmoles) ethyl 2-amino-1,3-oxazole-4-carboxylate, (10ml) dichloromethane and (1.39ml, 7.9797mmoles, 1.25 eq.) N,Ndiisopropylethylamine. To the reaction was then added (0.545ml, 7.0415 mmoles, 1.1 eq.) methanesulfonyl chloride, and the reaction was agitated for 14 hours. The reaction was 10 then evaporated to dryness and purified using a Biotage silica in gel column, resulting (272mg) of ethyl [(methylsulfonyl)amino]-1,3-oxazole-4-carboxylate.

15 ethyl 2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxylate

Step 3. To a 25 ml round bottom flask under  $N_2$  was added

(101.8mg, 0.4346 mmoles) ethyl 2-[(methylsulfonyl)amino]-1,3oxazole-4-carboxylate, (180.2mg, 1.3038 mmoles, 20 potassium carbonate, and (5ml) acetonitrile. The mixture was then agitated at ambient temperature while (33.8µ1, 0.5429 mmoles, 1.25 eq.) iodomethane was added. The reaction was allowed to run at ambient temperature for 3 hours. electrospray mass spec indicated mostly starting material. 25 The  $N_2$  line was removed and an additional (40µ1, 0.6425 mmoles, 1.5 eq.) iodomethane were added. The reaction was left at ambient temperature overnight. The reaction was quenched with (5ml) 1N HCl and was extracted with dichloromethane. organic layer was washed with water and then evaporated to 30 The resulting oil was purified by preparative HPLC, dryness. yielding (70mg) of ethyl 2-[methyl(methylsulfonyl)amino]-1,3oxazole-4-carboxylate.

2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxylic acid To a 50 ml round bottom flask was added (61mg, 2-[methyl(methylsulfonyl)amino]-1,3ethyl mmoles) oxazole-4-carboxylate, (51.5mg, 1.2274 mmoles, 5.0 lithium hydroxide, (2.5ml) tetrahydrofuran and (1.5ml) water. 5 The reaction was agitated at ambient temperature for ~2 hours. The reaction was complete by electrospray mass spec. reaction was worked up by adding (5ml) 1N HCl and then extracting with ethyl acetate. The organic layer was washed with water and brine and then dried with magnesium sulfate. 10 The solution was then evaporated to dryness, leaving (44.6mg) 2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxylic acid.

N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide

To a 7 ml screw cap vial was added (20.9mg, Step 5. 0.0949 mmoles) 2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4carboxylic acid, (36.7mg, 0.1097 mmoles, 1.15 eq.) (2R,3S)-3-20 amino-4-(3,5-difluorophenyl)-1-[(3-ethylbenzyl)amino]butan-2ol and (54.6mg, 0.1436 mmoles, 1.5 eq.) HATU, followed by (1.25ml) N, N-dimethylformamide. The reaction was placed in an orbital shaker and was left at ambient temperature for 2 The reaction was quenched with (2ml) 1N HCl. The 25 clear solution was extracted three times with ethyl acetate and the combined organic layers were washed with saturated sodium carbonate solution and then brine. The solution was then dried with magnesium sulfate and evaporated to a clear oil which was purified by preparative HPLC, resulting N-30 { (1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-ethylbenzyl) amino] -2hydroxypropyl}-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4carboxamide (15.7mg).

EXAMPLE SP-311

methyl 3-cyano-5-[(dipropylamino)carbonyl]benzoate

5

10

Methyl 3-bromo-5-[(dipropylamino)carbonyl]benzoate (Preparation 3) (0.15 g), copper (I) cyanide, and N-methylpyrrolidinone (1 mL) was heated at 150 °C overnight, at which time the mixture was cooled and partitioned between ethyl acetate and aq. HCl (1N). The organic layer was dried (magnesium sulfate), concentrated under reduced pressure, and the residue was chromatographed on silica gel using ethyl acetate-hexane (20/80) to give 0.066 g of the desired product. ms (m + H) 289.2. See also preparation 7 for the preparation of the acid.

EXAMPLE SP-312

(2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-{[3-(trifluoromethyl)benzyl]amino}butan-2-ol dihydrochloride

20

15

A mixture of oxirane (1.0 g) and 3-25 (trifluoromethyl)benzylamine (1.2 g) in isopropyl alcohol (25 mL) was stirred at reflux for 4 h, at which time the mixture was cooled and the solvent was removed under reduced pressure.

The residue was partitioned between ethyl acetate and aq. HCl (1N) and the organic layers were dried (sodium sulfate), concentrated, and chromatographed on silica gel using methanol-dichloromethane (5/95) to give 1.0 g of tert-butyl (1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[3-(trifluoromethyl)benzyl]amino}propylcarbamate.

The carbamate group was then removed essentially using the method described in EXAMPLE SP-272.

## 10 EXAMPLE SP-313

5

15

20

3-[(dipropylamino)carbonyl]-5-ethynylbenzoic acid

27

Step 1: Α solution οf methyl 3-bromo-5-[(dipropylamino)carbonyl]benzoate (25) (200 mg, 0.58 mmol), PdCl<sub>2</sub>(Ph<sub>3</sub>P)<sub>2</sub> (16 mg, 0.03 mol %) and CuI (6 mg, 0.05 mol %) in triethylamine (1.2 mL) was heated to reflux. (Trimethylsilyl) acetylene (100  $\mu$ L, 0.7 mmol) was added, and the bright yellow solution quickly turned orange then went brown within a minute. The reaction mixture was stirred for 3 h, cooled to room temperature, diluted with H2O (20 mL), and extracted with CHCl<sub>3</sub> (3 x 15 mL). The combined organics were washed with

saturated NaCl (20 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated under reduced pressure to give methyl 3-[(dipropylamino)carbonyl]-5-[(trimethylsilyl)ethynyl]benzoate **26** (185.5 mg):  $^{1}$ H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  7.95 (s, 1H), 7.75 (s, 1H), 7.43 (s, 1H), 3.74 (s, 3H), 3.25 (br s, 2H), 2.95 (br s, 2H), 1.49 (br s, 2H), 1.34 (br s, 2H), 0.79 (br s, 3H), 0.56 (br s, 3H), 0.06 (s, 9H).

Step 2: To а stirred solution of methyl 3 – 10 [(dipropylamino)carbonyl]-5-[(trimethylsilyl)ethynyl]benzoate 26 (185.3 mg, 0.49 mmol) in MeOH (2.5 mL) was added a solution of KOH (2.9 mL of a 1 M solution in  $H_2O$ , 2.9 mmol). The resulting homogeneous brown solution turned to a white/brown suspension, then to a clear brown solution. The reaction mixture was stirred for 4 h, diluted with CHCl<sub>3</sub> (40 mL), 15 separated and the organic layer was concentrated under reduced provide 3-[(dipropylamino)carbonyl]-5pressure to ethynylbenzoic acid 27 (141.8 mg):  $^{1}$ H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$ 8.22 (d, J = 1 Hz, 1H), 8.05 (d, J = 1 Hz, 1H), 7.71 (d, J = 1 Hz) 20 Hz, 1H), 3.48 (br s, 2H), 3.17 (s, 1H), 3.16 (br s, 2H), 1.71 (d, J = 7 Hz, 2H), 1.55 (d, J = 7 Hz, 2H), 1.00 (d, J = 7 Hz,3H), 0.78 (d, J = 7 Hz, 3H).

The following compounds were also prepared using the procedures described above and the schemes described below.

EXAMPLE	Structure	Compound Name(s)	Mass Spec
2000	HO NO O H OH H N F F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-hydroxyethyl)(methylsulfonyl)amino]benzamide	*575.3
3000	Br OH H	5-bromo-N <sup>1</sup> -{(1S,2R)-1-(2,4-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide	**644 646
	O H H N HCI	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-methoxyethyl)(methylsulfonyl)amino]benzamidehydrochloride	**590
3001	O H OH H N F F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(methylsulfonyl)methylbenzamide	**531
3003	O S O OH  N O O O O O O O O O O O O O O O O O	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[(4-hydroxybutyl)sulfonyl]-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamidehydrochloride	**702
3004	H OH H N N F F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1-(dipropylamino)isoquinoline-7-carboxamide	**589.4

3005	N-SEO H N N F F F F F F F F F F F F F F F F F	N <sup>1</sup> -{(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-5-{[(2- hydroxyethyl)(methyl)a mino]sulfonyl}-N <sup>3</sup> ,N <sup>3</sup> - dipropylisophthalamide	**703
3006	HZ-S HZ F	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[(ethylamino)sulfonyl]-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide	**673
3007	N H OH H N H CI	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-(5-methyl-1,2,4-oxadiazol-3-yl)-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamidehydrochloride	**648.4
3008	O=S=O O F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide	**** 537.3 (+)
3009	P F P P P P P P P P P P P P P P P P P P	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> ,N <sup>3</sup> -dipropylmalonamide	
	P N = N H H OH H	N <sup>2</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> ,N <sup>3</sup> -dipropylbicyclo[2.2.1]hept-5-ene-2,3-dicarboxamide	
3010			<u> </u>

		E3 (/4 G DP) 4 /2 F	
	<u> </u>	$N^1 - \{ (1S, 2R) - 1 - (3, 5 - 1) \}$	
		difluorobenzyl)-3-[(3-	ŀ
	F F	ethylbenzyl)amino]-2-	l
	l o li [#	hydroxypropyl}-N3,N3-	
	N N N N N N N N N N N N N N N N N N N	dipropylcyclopentane-	
	N OH H	1,3-dicarboxamide	
ļ		İ	
3011			
		$N^2 - \{ (1S, 2R) - 1 - (3, 5 - 1) \}$	
	F	difluorobenzyl)-3-[(3-	1
		ethylbenzyl)amino]-2-	
	0 \ / 0 \>F	hydroxypropyl)-3,4-	
		dimethyl-N <sup>5</sup> , N <sup>5</sup> -	
1	LAN SAS HADEN I	dipropylthieno[2,3-	
1	(	b]thiophene-2,5-	
3012	\	dicarboxamide	
5012	<del>                                      </del>	N <sup>1</sup> -{(1S,2R)-1-(3,5-	
		difluorobenzyl)-3-[(3-	I
	F	ethylbenzyl)amino]-2-	
		hydroxypropyl}-2-	
	N H H OH H	phenyl-N <sup>5</sup> , N <sup>5</sup> -	
	N N N N N N N N N N N N N N N N N N N	dipropylpentanediamide	
3013			
	F	$N^2$ -benzyl- $N^1$ -{(1S,2R)-	
		1-(3,5-	
	F	difluorobenzyl)-3-[(3-	
	9 ) 9 (H	ethylbenzyl)amino]-2-	
	N N N N N N N N N N N N N N N N N N N	hydroxypropyl}-N2-[2-	
	л он п	(dipropylamino)-2-	
3014	'	oxoethyl]glycinamide	
	a f	3-(4-chlorophenyl)-N1-	
		{ (1S, 2R) -1- (3, 5-	
		difluorobenzyl)-3-[(3-	
1		ethylbenzyl)amino]-2-	
	N H H OH H	hydroxypropyl}-N <sup>5</sup> ,N <sup>5</sup> -	
3015		dipropylpentanediamide	
	E	$(2E) - N^5 - \{ (1S, 2R) - 1 -$	
	<u> </u>	(3,5-difluorobenzyl)-	
	F	3-[(3-	
ŀ	l P P B	ethylbenzyl)amino]-2-	
	N N N N N N N N N N N N N N N N N N N	hydroxypropyl}-2-	ļ
	/ Ño ""ŌH" 💚	(methoxyimino) -N1, N1-	
3016	1 1	dipropylpentanediamide	
	_	$N^{1} - \{ (1S, 2R) - 1 - (3, 5 - 1) \}$	
		difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	[
		hydroxypropyl $-N^2-[2-$	
		(dipropylamino) -2-	
	H"ÖHH	$oxoethyl]-N^2-$	
3017		phenylglycinamide	
30-7	_l	ж	<del></del>

			·
		$N^1 - \{ (1S, 2R) - 1 - (3, 5 - 1) \}$	
		difluorobenzyl)-3-[(3-	
	N O O	ethylbenzyl)amino]-2-	
		hydroxypropyl}-N2,N2-	
	H H OH H	dipropylcyclohexane-	
3018	. OH	1,2-dicarboxamide	
		N-{(1S,2R)-1-(3,5-	
ļ	H A A F	difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	
	Ö	hydroxypropyl}-3-	
	OH Y	phenylpropanamide	***467.
	NH È		3
			3
}			
3019			
		$N^1 - \{ (1S, 2R) - 1 - (3, 5 - $	
		difluorobenzyl)-3-	
	H P P H NHO	[(1,1-dioxido-3,4-	
	N S	dihydro-2H-1,2-	
	l e g i h	benzothiazin-4-	
		yl)amino]-2-	
1		hydroxypropyl}-5-	
2020	ļ ¦	$methyl-N^3, N^3-$	
3020		dipropylisophthalamide	
		$N^{1} - \{ (1S, 2R) - 1 - (3, 5 - 1) \}$	
		difluorobenzyl)-3-	
ļ	H OH H NHO	[(1,1-dioxido-3,4-	'
	Ö	dihydro-2H-1,2- benzothiazin-4-	
	F Q J H ( )	yl)amino]-2-	
		hydroxypropyl}-5-	
		$methyl-N^3, N^3-$	
3021	Ė	dipropylisophthalamide	
		$N^{1}-\{(1S, 2R)-1-(3, 5-$	
		difluorobenzyl)-3-	
	N. F.	[(2,2-dioxido-3,4-	
	H P PH H S=0	dihydro-1,2-	
		benzoxathiin-4-	•
	F H ( )	yl)amino]-2-	
		hydroxypropyl}-5-	
		$methyl-N^3, N^3-$	
3022	F	dipropylisophthalamide	
	,	$N^{1}-\{(1S,2R)-1-(3,5-$	
		difluorobenzyl)-3-	
1	N H OU H -S=0	[(2,2-dioxido-3,4-	
1	H <sub>H</sub> OH H S=O	dihydro-1,2-	
		benzoxathiin-4-	
		y1)amino]-2-	
		hydroxypropyl}-5-	
	[	$methyl-N^3,N^3-$	
3023	Г	dipropylisophthalamide	

	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	$N^1 - \{ (1S, 2R) - 1 - (3, 5 - 1) \}$	
		difluorobenzyl)-2-	
	H OH H	hydroxy-3-[(7-methoxy-	
		1,2,3,4-	
Į		tetrahydronaphthalen-	
İ	[ <del>_</del>	1-yl)amino]propyl}-5-	
		$methyl-N^3, N^3-$	
2024	F	dipropylisophthalamide	
3024	•		
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	$N^1 - \{ (1S, 2R) - 1 - (3, 5 - 1) \}$	
		difluorobenzyl)-2-	
	THOM I CO	hydroxy-3-[(7-methoxy-	
	N N N N N N N N N N N N N N N N N N N	1,2,3,4-	
		tetrahydronaphthalen-	
		1-yl)amino]propyl}-5-	
	F-\ /	methyl-N <sup>3</sup> , N <sup>3</sup> -	
3025	F	dipropylisophthalamide	
	HNZN	$N^{1}-\{(1S, 2R)-1-(3, 5-$	[
	1	difluorobenzyl)-3-[(3-	1
	A H OH H	ethylbenzyl)amino]-2-	1
		hydroxypropyl}-5-(1H-	**632.3
1		$imidazol-2-yl)-N^3, N^3-$	1
1		dipropylisophthalamide	
		dipropy ii sopiicii a i ami de	
3026	ļ Ė		
		N-{(1S, 2R)-1-(3,5-	
	H OH H	difluorobenzyl)-3-[(3-	
-		ethylbenzyl)amino]-2-	
		hydroxypropyl}-2-	**522
		propyl-1,3-	322
		F	
	Ė	benzoxazole-6-	
3027		carboxamide	
	+	N-{(1S,2R)-1-(3,5-	
	N H OH H ○	difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	
		hydroxypropyl}-2-	3.3.404
	0 1	methyl-1,3-	**494
1		benzoxazole-6-	
	HCI	carboxamide	
2000	F	1	
3028		hydrochloride	
		5-[(tert-	
	HN	butylamino)sulfonyl]-	
	0=\$=0	$N^{1} - \{ (1S, 2R) - 1 - (3, 5 - 1) \}$	
	н Ри С	difluorobenzyl)-3-[(3-	11504
		ethylbenzyl)amino]-2-	**701
		hydroxypropyl}-N <sup>3</sup> , N <sup>3</sup> -	
		dipropylisophthalamide	
2000		orbrobarraching and inde	
3029	Ė		<b></b>
1	1 1	5-{[tert-	
	N.	butyl(methyl)amino sul	
	) o=\$=0	$fonyl = N^1 - \{ (1S, 2R) - 1 - \}$	
	н онн	(3,5-difluorobenzyl)-	44545
	N N N N N N N N N N N N N N N N N N N	3-[(3-	**715
		ethylbenzyl)amino]-2-	
ļ		hydroxypropyl}-N <sup>3</sup> , N <sup>3</sup> -	
3030		dipropylisophthalamide	
	i ė	MIDIODATIZODHCHGIGHTGWJG6	1

	T		
	N N	N-{(1S,2R)-1-(3,5-	
•		difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	
İ	0 ~ F	hydroxypropyl}-2-	**522
		isopropyl-1,3-	
ļ	Ţ	benzoxazole-6-	1
3031 _	F	carboxamide	
	QHH QHH	(2S)-N-{(1S,2R)-1-	
	6., HH 5., H	(3,5-difluorobenzyl)-	
j	H W W W W W W W W W W W W W W W W W W W	3-[(3-	
	📞 " " " " " " " " " " " " " " " " " "	ethylbenzyl)amino]-2-	ļ
		hydroxypropyl}-2-	
		hydroxy-2-(1-	
3032	F	naphthyl)ethanamide	
	A H H A	(2R)-N-{(1S,2R)-1-	
		(3,5-difluorobenzyl)-	
		3-[(3-	
		ethylbenzyl)amino]-2-	
		hydroxypropyl}-2-	
	F-\	hydroxy-2-(1-	
3033	F	naphthyl)ethanamide	
	F	N-{ (1S, 2R) -1- (3,5-	
ĺ	F	difluorobenzyl)-3-[(3-	
ĺ		ethylbenzyl)amino]-2-	
ļ		hydroxypropyl}isonicot	
		inamide	
		Inamide	
2024	N H H OHH		
3034			
	( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )	$N^1 - \{ (1S, 2R) - 1 - benzyl - $	
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	3-[(3-	1
	н он н	ethylbenzyl)amino]-2-	•
l .		hydroxypropyl}-N3-	**569.3
		methyl-5-(1,3-oxazol-	
2025		$2-y1)-N^3-$	
3035	<u> </u>	propylisophthalamide	
	0 N		
	H OH H O		
			**642.3
3036	ļ ļ		
	√N		
	~~"		
	, н <sub>О</sub> н н О		
	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		**614.4
	H H H		V-1.1
3037	Ţ		
<u></u>	<u> Г</u>	L	

3038	N H H N F F	N <sup>1</sup> -{(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-5-[1- (ethoxymethyl)-1H- imidazol-2-yl]-N <sup>3</sup> ,N <sup>3</sup> - dipropylisophthalamide	**690.3
3039	H OH H	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-propyl-1,3-benzoxazole-5-carboxamidehydrochloride	**522
3040	HOH HOH	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-isopropyl-1,3-benzoxazole-5-carboxamidehydrochloride	**522
3041	O S F F F F F F F F F F F F F F F F F F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[ethyl(methyl)amino]sulfonyl}benzamide	**560
3042	HCI F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-1,3-benzoxazole-5-carboxamidehydrochloride	**494
3043	O-S=O H QH H N F F	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-(methylsulfonyl)-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide	**644

3044	H QH H H H H H H H H H H	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-(methylsulfonyl)-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamidehydrochloride	**645.0 4
3045	N O H OH H OH HCI	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-1,3-benzoxazole-7-carboxamidehydrochloride	**494
3046	H OH H	methyl 3-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}amino)carbonyl]benzoate	**497.3
3047	H OH H	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)amino]propyl}-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide	
3048	H OH N N F	N <sup>1</sup> -{(1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)amino]propyl}-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide	
3049	HO HO N H	ELAN-91970	

		· · · · · · · · · · · · · · · · · · ·	
3050	H H OH H N	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(6-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)amino]propyl}-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide	
3051	H H H N N H N N N N N N N N N N N N N N	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3- [(1S)-2,3-dihydro-1H-inden-1-ylamino]-2-hydroxypropyl}-5- methyl-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide	
3052	N O O H N H OH H	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> ,N <sup>2</sup> -dipropylcyclohexane-1,2-dicarboxamide N-{(1S,2R)-1-(3,5-	
	O=S=O O O O O O O O O O O O O O O O O O	difluorobenzyl) -3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3- {[(2R)-2-(methoxymethyl)pyrrolidin-1-yl]sulfonyl}benzamide	**616
3053	F NO OF S H OH H N N F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-{[ethyl(methyl)amino]sulfonyl}benzamide	.**560
3055	N S P P P P P P P P P P P P P P P P P P	formic acid compound with N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-{[ethyl(methyl)amino]sulfonyl}benzamide(1:1)	***560. 1

ŧ		N-{(1S,2R)-1-(3,5-	
	H OHH	difluorobenzyl)-3-[(3-	
	THO H	ethylbenzyl)amino]-2-	İ
1		hydroxypropyl}-3,5-	]
	Ö ₹''	dimethylbenzamide	ľ
		dimethy ibelizaminge	
	\_}_+		
3056			_
	F	N <sup>1</sup> -butyl-N <sup>3</sup> -((1S,2R)-1-	<del>                                     </del>
		(3,5-difluorobenzyl)-	•
j	L L F	3-{[1-(3-	f
		ethynylphenyl)cyclopro	
	N N N N N N N N N N N N N N N N N N N	pyl]amino}-2-	ĺ
1	H H OH H	F = -	
ĺ		hydroxypropyl) -N1-	
3057	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	methyl-5-(1,3-thiazol-	
P037		2-yl)isophthalamide	
	<u> </u>	$N^1$ -butyl- $N^5$ -{(1s,2R)-1-	
		(3,5-difluorobenzyl)-	
	0 0 × F	3-[(3-	
		ethylbenzyl)amino]-2-	
2050	H H OH H	hydroxypropyl}-N1-	
3058		methylpentanediamide	
	I	N <sup>1</sup> -{ (1S, 2R) -1- (3,5-	
•		difluorobenzyl)-3-[(3-	
1	P P P F	ethylbenzyl)amino]-2-	
	N N N N N N N N N N N N N N N N N N N	hydroxypropyl}-N <sup>5</sup> ,N <sup>5</sup> -	
	H OH H	dipropylpentanediamide	
3059	<b>,</b>		
	F	$(2R) - N^5 - \{ (1S, 2R) - 1 -$	
		(3,5-difluorobenzyl)-	
		3-[(3-	
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	ethylbenzyl)amino]-2-	
ļ.	N HICK N TOTAL N	hydroxypropyl}-2-	
	P H OH H	$methyl-N^1, N^1-$	
3060		dipropylpentanediamide	
	F	$(2S) - N^5 - \{ (1S, 2R) - 1 -$	
		(3,5-difluorobenzyl)-	
		3-[(3-	
] .	N N N N N N N N N N N N N N N N N N N	ethylbenzyl)amino]-2-	
1	N N N N N N N N N N N N N N N N N N N	hydroxypropy1}-2-	j
	✓ ° н н он н 🕡	$methyl-N^1, N^1-$	
3061		dipropylpentanediamide	
	F	$N^{1} - \{ (1S, 2R) - 1 - (3, 5 - 1) \}$	
		difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	
		hydroxypropyl}-N <sup>4</sup> ,N <sup>4</sup> -	
2000	O H OH H H	dipropylsuccinamide	
3062	O OH		
	ļ F	$N^1 - \{ (1S, 2R) - 1 - (3, 5 - 1) \}$	
		difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	
		hydroxypropyl}-N2-[2-	
	I N A N XWH N A	(dipropylamino)-2-	
	OH	oxoethyl]-N <sup>2</sup> -	
3063	'	methylglycinamide	

	l l	$N^1 - \{ (1S, 2R) - 1 - (3, 5 - $	
		difluorobenzyl)-3-[(3-	
	\	ethylbenzyl)amino]-2-	
	J P H P (H ~ F	hydroxypropyl}-N2-[2-	1
		(dipropylamino) -2-	1
	H OH H		
3064		oxoethyl]glycinamide	
	F	N-{(1S,2R)-1-(3,5-	
		difluorobenzyl)-3-[(3-	I
		ethylbenzyl)amino]-2-	
	Q Q (H F	, – –	l
		hydroxypropyl}-5-[2-	i
	H OH H	(methoxymethyl)pyrroli	1
		din-1-yl]-5-	
3065		oxopentanamide	
	F	$N^{1} - \{ (1s, 2R) - 1 - (3, 5 - 1) \}$	
		difluorobenzyl)-3-[(3-	
į.		ethylbenzyl)amino]-2-	
	P P (H F		
	N N N N N N N N N N N N N N N N N N N	hydroxypropyl}-N <sup>5</sup> -(2-	
1	н он п П П П П П П П П П П П П П П П П П П	furylmethyl)-N <sup>5</sup> -	
3066	KZ ,	methylpentanediamide	
	Ę	$N^{1}$ -((1S,2R)-1-(3,5-	
		difluorobenzyl)-3-	
1	1	{[(4-ethylpyridin-2-	
	F		
		yl)methyl]amino}-2-	
	N N N N N N N N N N N N N N N N N N N	hydroxypropyl)-5-	
	J   H OH H   J	methyl-N <sup>3</sup> , N <sup>3</sup> -	
		dipropylisophthalamide	į
3067			
		N <sup>4</sup> -((1S,2R)-1-(3,5-	
		difluorobenzyl)-3-{[1-	i
		(3-	ļ
	L LE	ethynylphenyl)cyclopro	
	P P SH ∇	pyl]amino}-2-	
	N N N N N N N N N N N N N N N N N N N	hydroxypropy1)-6-	
i	Н Н Н Н	$methyl-N^2, N^2-$	
		dipropylpyridine-2,4-	
2000		,	
3068		dicarboxamide	
	$\times$	N-{(1s,2r)-1-(3,5-	
	, jo	difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	
		hydroxypropyl}-2,2-	
	N N N	dimethylchromane-7-	**523
		carboxamide	
		hydrochloride	
	HCI		
3069	Ė Ė		
	н он н	$N-\{(1S,2R)-1-(3,5-$	
		difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	3.4500
	Ö - F '	hydroxypropy1}-2,2-	**523
		dimethylchromane-6-	
0.05	I Y	carboxamide	
3070	ļ Ė		

3071	H OH H	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-1,3-benzoxazole-4-carboxamidehydrochloride	.**494
3072	HOH HOH HCI	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-propyl-1,3-benzoxazole-4-carboxamidehydrochloride	
3073	N. I. OH H. I. OH H. N. I. OH H. I. OH H. N. I. OH H.	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-{[(2R)-2-(methoxymethyl)pyrrolidin-1-yl]sulfonyl}benzamide	**616
3074	HO-S-OHOH  HO-S-OHOH  HO-S-OHOH  F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{dihydroxy[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-lambda <sup>4</sup> -sulfanyl}benzamide	**602
3075	H QH H N F F	1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1H-indole-6-carboxamide	**534
3076	H OH H N III	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1-propyl-1H-indole-6-carboxamide	**520

3077	H OH H	1-buty1-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1H-indole-5-carboxamidehydrochloride	**534
3078	O N OH H N F F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[4-(2-hydroxyethyl)-1,3-oxazol-2-yl]benzamide	**550.3
3079	S N O H H N O F F	N <sup>1</sup> -{(1s,2r)-1-(3,5- difluorobenzyl)-2- hydroxy-3-[(3- isopropylbenzyl)amino] propyl}-N <sup>3</sup> ,N <sup>3</sup> -dipropyl- 5-(1,3-thiazol-2- yl)isophthalamide	**663.3
3080	S N  O H OH H  N  F HO	N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-isopropylbenzyl)amino]propyl}-N³,N³-dipropyl-5-(1,3-thiazol-2-yl)isophthalamidehydrochloride	**663.3
3081	N H H OH H	N <sup>1</sup> -((1S,2R)-1-(3,5difluorobenzyl)-3- {[(4-ethylpyridin-2-yl)methyl]amino}-2- hydroxypropyl)-5-(1,3-oxazol-2-yl)-N <sup>3</sup> ,N <sup>3</sup> - dipropylisophthalamide	
3082	P N H H OH H	N-((1S,2R)-1-(3,5- difluorobenzyl)-3-{[1- (3- ethynylphenyl)cyclopro pyl]amino}-2- hydroxypropyl)-4- (ethoxymethyl)benzamid e	

		·	
3083	H QH H H HCI	1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}indoline-6-carboxamide	**535.9
3084	HN O=S=O H QH H N F	hydrochloride  3-[(tert- butylamino)sulfonyl]- N-{(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}benzamid e	**574
3085	O H OH H OH HCI	N-{(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-2,3- dihydro-1,4- benzodioxine-6- carboxamide hydrochloride	
3086	OH O=S=O H OH N N F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]sulfonyl}benzamide	**602
3087	H-CI H-CI P OH H N N N N N N N N N N N N N N N N N N	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> ,N <sup>3</sup> -dipropyl-5-pyridin-4-ylisophthalamidedihydrochloride	**643.3
3088	H OH H H H CI	N <sup>1</sup> -butyl-N <sup>3</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethynylbenzyl)amino]-2-hydroxypropyl}-N <sup>1</sup> ,5-dimethylisophthalamidehydrochloride	*561

	,	$N-\{(1s,2R)-1-(3,5-$	
	H-CI	difluorobenzyl)-2-	
1	, OH OH	hydroxy-3-[(3-	
		<pre>isopropylbenzyl)amino]</pre>	
		propy1}-3-{[(2R)-2-	**608.3
		(methoxymethyl)pyrroli	
	ľ	din-1-yl]carbonyl}-5-	
	Ĭ	methylbenzamide	
3089	<b>.</b>	hydrochloride	ĺ
-		N-{(1s,2r)-1-(3,5-	
	ı H-CI	difluorobenzyl)-3-[(3-	
	1 1 1-01	ethynylbenzyl)amino]-	1
	Д Н № Н Д	2-hydroxypropyl}-3-	
		{ [(2R)-2-	**590.3
	0	1	1 390.3
•	ľ	(methoxymethyl)pyrroli	
		din-1-yl]carbonyl}-5-	
	· •	methylbenzamide	
3090		hydrochloride	
		3-(1-butyl-1H-pyrazol-	
	H OH H	4-y1)-N-{(1S,2R)-1-	1
		(3,5-difluorobenzyl)-	1
		3-[(3-	
		ethylbenzyl)amino]-2-	1
	Ť	hydroxypropyl}propanam	
3091	<b>,</b>	ide	
<del></del>		N-((1S,2R)-1-(3,5-	T
	·	difluorobenzyl)-3-{[1-	
	H-CI	(3-	ŀ
İ		ethylphenyl)cyclopropy	
		1]amino}-2-	ł
		hydroxypropyl)-3-	**620.3
		[{ [(2R)-2-	020.3
	/ F	(methoxymethyl)pyrroli	
		din-1-yl]carbonyl}-5-	ļ
	ŕ		
2000		methylbenzamide	
3092	<del> </del>	hydrochloride	<del> </del>
	н он н	1-buty1-N-{ (1s, 2R)-1-	
	N N N N N N N N N N N N N N N N N N N	(3,5-difluorobenzyl)-	
1		3-[(3-	
		ethylbenzyl)amino]-2-	
		hydroxypropyl}-1H-	
3093	 	indazole-6-carboxamide	
	\$-7 н ОН н П	N-{ (1s, 2r) -1-(3,5-	
	ST H OF H	difluorobenzyl)-3-[(3-	
	I N I N Y N Y N N N N N N N N N N N N N	ethylbenzyl)amino]-2-	****
	0 -\rightarrow F	hydroxypropyl}-2-	528.2
		thien-2-yl-1,3-	(+)
3094	Ĭ	thiazole-4-carboxamide	
5054	F	5-(aminosulfonyl)-N-	<del>                                     </del>
	O CO LI OH LI	$\{(1S, 2R) - 1 - (3, 5 - 1)\}$	1
			****
	O 1 0 5	difluorobenzyl)-3-[(3-	1
	· · · · · · · · · · · · · · · · · · ·	ethylbenzyl)amino]-2-	521.2
		hydroxypropyl}-1-	(+)
	 	methyl-1H-pyrrole-2- carboxamide	!
3095			

	<del></del>		
		N-{(1S,2R)-1-(3,5-	
	ş¬, н ΩН н 🕥	difluorobenzyl)-3-[(3-	
	N N N N N N N N N N N N N N N N N N N	ethylbenzyl)amino]-2-	****
	0=\$=0 "	hydroxypropyl}-2-{[(2-	604.1
		furylmethyl)sulfonyl]m	(+)
			(+)
2006	Ė	ethyl}-1,3-thiazole-4-	
3096		carboxamide	
		N-{(1S,2R)-1-(3,5-	
]	- OS H OH H	difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	
	0 " " " " F	hydroxypropy1}-2-{[(4-	
		fluorobenzyl)sulfonyl]	
	Ţ	methyl}-1,3-thiazole-	
2007	r		
3097		4-carboxamide	
	\ \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	$1-butyl-N-{(1S,2R)-1-}$	
	N <sub>2</sub> O	(3,5-difluorobenzyl)-	
		3-[(3-	
1	H OH H	ethylbenzyl)amino]-2-	
	N N N N N N N N N N N N N N N N N N N	hydroxypropyl}-4-	**640.8
		[methyl(methylsulfonyl	
		)amino]-1H-indole-6-	
Ì		carboxamide	
3098	<u> </u>	Carboxamide	
		N-((1S,2R)-1-(3,5-	
	Ę	difluorobenzyl)-3-{[1-	
		(3-	
	F	1 '	
		ethynylphenyl)cyclopro	
	H HOH H	pyl]amino}-2-	
	NON H TON H	hydroxypropyl)-4-(2-	
3099		methoxyethyl)benzamide	
		$N^{1}$ -butyl- $N^{3}$ -{ (1S, 2R)-1-	
	N S	(3,5-difluorobenzyl)-	
		2-hydroxy-3-[(1-	
1		phenylcyclopropyl)amin	
		o]propy1}-N <sup>1</sup> -methy1-5-	
[		(1,3-thiazol-2-	
		yl)isophthalamide	
		ут/твориспаташтае	
3100	<i></i>		
2100	F	1 (40 00)	
	N 0	$N^{1} - \{ (1S, 2R) - 1 - (3, 5 - 1) \}$	
		difluorobenzyl)-2-	
	\	hydroxy-3-[(1-	
	THOUSE THE	phenylcyclopropyl)amin	
l	N N N N N N N N N N N N N N N N N N N	o]propyl}-5-(1,3-	
		$oxazol-2-yl)-N^3,N^3-$	
		dipropylisophthalamide	
	/ <b>》</b> −F		
<u></u>	<b> </b>		
3101		· .	

3102	HN OH H OH H	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-[(ethylamino)sulfonyl]benzamide	**546
	HN S O H O H H N N F F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-[(methylamino)sulfonyl]benzamide	**532
3104		(2E) -3-(1-buty1-1H-pyrazol-4-yl)-N- {(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}prop-2-enamide or (2E)-3-(1-butyl-1H-pyrazol-4-yl)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}prop-2-enamide	
3105	H OH H N N F H-CI H-CI	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}isoquinoline-7-carboxamidedihydrochloride	**490.1
3106	H OH H N N N N N N N N N N N N N N N N N	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1-(propylamino)isoquinoline-7-carboxamidedihydrochlorideorN-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1-(propylamino)isoquinoline-7-carboxamidedihydrochloride	**547.3

, <del>,,,,</del>			
3107	OH HN N N N N N N N N N N N N N	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzy1)-2-hydroxy-3-[(3-isopropylbenzy1)amino]propyl}-5-{[(2-hydroxy-1,1-dimethylethyl)amino]sulfonyl}-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide	**730.8
3108	N OH HN F	methyl 3-(2-{3- [({(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}amino)ca rbonyl]phenyl}-1,3- oxazol-5-yl)propanoate	**591.9
3109	HO-O N N N N N N F F	3-(2-{3-[({(15,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}amino)carbonyl]phenyl}-1,3-oxazol-5-yl)propanoicacid	**578.2
3110	HO PE	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1-(3-hydroxypropyl)-1H-indole-6-carboxamide	**536.8
3111	H H O H H N N N N N N N N N N N N N N N	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-ethoxybenzamide	
3112	F O O H H H O H H O H H	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-6-(pyrrolidin-1-ylcarbonyl)isonicotinamide	

		hr1 //10 2D) 1 /2 E	
	· · · · · · · · · · · · · · · · · · ·	N <sup>1</sup> -((1S,2R)-1-(3,5- difluorobenzyl)-3-	
		{[(6-ethylpyridin-2-	
	Q Q H	yl)methyl]amino}-2-	
		hydroxypropyl)-5-	
	J HHOHH N	$methyl-N^3, N^3-$	
		dipropylisophthalamide	İ
3113		V (/10 2D) 1 /2 5	
	1	N-{(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	
	00 0	hydroxypropyl}-3-	
	ト ヘ※	[(dipropylamino)sulfon	
	N N H N N N N N N N N N N N N N N N N N	yl]benzamide	
3114		V1 (/10 0P) 1 /2 5	
		$N^{1}$ -((1S,2R)-1-(3,5-	
[		difluorobenzyl)-3- {[(6-ethylpyridin-2-	
	O O H	y1)methy1]amino}-2-	
		hydroxypropyl)-5-(1,3-	
	H H OH H N	$oxazol-2-yl)-N^3,N^3-$	
		dipropylisophthalamide	
3115	N U		
		tert-butyl (1R)-1-	
	O O OHH	[({(1s,2r)-1-(3,5-	
	NH NH NH	difluorobenzyl)-3-[(3-	****
	O NH E	ethylbenzyl)amino]-2-	582.1
	\ <b>&gt;</b> \( \)	hydroxypropyl}amino)ca rbonyl]-3-	(+)
<u> </u>		(methylsulfinyl)propyl	
3116	r	carbamate	
	^ ^	N-{(1s,2R)-1-(3,5-	
	N H OH H	difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	
	Ö	hydroxypropyl}-2-	
		(dipropylamino) isonico	
3117	· <del> </del>	tinamide or ELAN154894	
2111	NI OIL	N-{(1S,2R)-1-(3,5-	<u> </u>
	N H OH H	difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	**E30 3
		hydroxypropyl}-2-	**539.3
	HCI	(dipropylamino)isonico	
3118	F F	tinamide hydrochloride	_
	O O OHH	(2R)-2-amino-N-	
	\s\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	{ (1S, 2R) -1- (3, 5-	****
	NH <sub>2</sub>	<pre>difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2-</pre>	482.2
		hydroxypropyl}-4-	(+)
		(methylsulfinyl)butana	[ ``'
3119	ļ F	mide	1
<del></del>	<u></u>	<del></del>	<del></del>

		·	
3120	No. Section 1. Section	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[ethyl(methyl)amino]sulfonyl}-5-{[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]carbonyl}benzamide	**701
3121	H OH H N N F F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1-[methyl(propyl)amino]isoquinoline-7-carboxamide or N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1-[methyl(propyl)amino]isoquinoline-7-carboxamide	**561.4
3122	H OH H N F F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-(1,3-oxazol-2-yl)benzamide	**506.2
3123	N H H OH H	N <sup>1</sup> -[(1S,2R)-3-{[1-(3-bromophenyl)cyclopropyl]amino}-1-(3,5-difluorobenzyl)-2-hydroxypropyl]-5-(1,3-oxazol-2-yl)-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide	
3124	N H HOH H HOLD	N <sup>1</sup> -[(1S,2R)-3-{[1-(3-bromophenyl)cyclopropy 1]amino}-1-(3,5- difluorobenzyl)-2- hydroxypropyl]-5-(1,3- oxazol-2-yl)-N <sup>3</sup> ,N <sup>3</sup> - dipropylisophthalamide hydrochloride	**709.2 + 711.2
3125	N N OH H	N <sup>5</sup> -{(1s,2r)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-N <sup>3</sup> ,N <sup>3</sup> - dipropyl-1H-pyrazole- 3,5-dicarboxamide	

		<u> </u>	
	F \	$N^1 - \{ (1S, 2R) - 1 - (3, 5 - 1) \}$	1
		difluorobenzyl)-3-[(3-	Į
	0 0 F	ethylbenzyl)amino]-2-	
		hydroxypropyl}-N <sup>2</sup> ,N <sup>2</sup> -	
l i		dipropylcyclobutane-	
2206	, / OH	1,2-dicarboxamide	
3126	<u> </u>		
	Ī	N-{ (1S, 2R) -1-(3,5-	
		difluorobenzyl)-3-[(3-	
	s o F	ethylbenzyl)amino]-2-	j
		hydroxypropyl}-3-	
		[(dipropylamino)carbon	
3127	OH	othioyl]benzamide	
5127		<del></del>	
	F	3-[(E)-	1
	Ī	(cyanoimino) (dipropyla	
		mino)methyl]-N-	
	N O F	{(1s,2r)-1-(3,5-	
		difluorobenzyl)-3-[(3-	
	N Y N Y N Y N	ethylbenzyl)amino]-2-	
		hydroxypropyl}benzamid	
2120	<b>1</b>		
3128		e	
		$N^1 - \{ (1S, 2R) - 1 - (3, 5 - 1) \}$	
1		difluorobenzyl)-2-	
1	нн он н	hydroxy-3-[(6-	
	N N N N N N N N N N N N N N N N N N N	isopropyl-2,2-dioxido-	
		3,4-dihydro-1H-	
		isothiochromen-4-	
		yl)amino]propyl}-5-	
	' 🖳	methyl-N <sup>3</sup> , N <sup>3</sup> -	
2122	F		
3129	l l	dipropylisophthalamide	
	H	$N-\{(1S,2R)-1-(3,5-$	
		difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	
	Ö 🏋 T	hydroxypropyl}-3-(1-	
1		propylbutoxy) benzamide	
3130_	F F		
	Ę	$N^{1}$ -((1s,2R)-1-(3,5-	
		difluorobenzyl)-3-	
1	L. J. F	{[(5-ethylpyridin-3-	
		yl)methyl]amino}-2-	
	N P P P P P P P P P P P P P P P P P P P	hydroxypropyl)-5-(1,3-	
1	I HADH H		
1		oxazol-2-yl)-N <sup>3</sup> , N <sup>3</sup> -	
1	' N 0	dipropylisophthalamide	
3131			
		$N^{1} - \{ (1S, 2R) - 1 - (3, 5 - $	
	\	difluorobenzyl)-2-	
	HH OH H	hydroxy-3-[(6-	
	l n. 人 L n. t. i. 人 J	isopropyl-2,2-dioxido-	
1	L. L ~ L. L. L.		
	Ŭ Ö Ž " S	3,4-dihydro-1H-	
	/=< 6°°0	isothiochromen-4-	
	F- <b>√</b>	y1)amino]propy1}-5-	
1	`	$methyl-N^3,N^3-$	
3132	<u> </u>	dipropylisophthalamide	

			·
3133	H QH H N F F	N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-1-(2-methoxyethy1)-1H-indole-6-carboxamide	**536
3134	H OH H HCI	N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-3,4-dihydro-2H-1,4-benzoxazine-6-carboxamidehydrochloride	**496
3135	O D D D D D D D D D D D D D D D D D D D	N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-3-{[(2S)-2-(methoxymethyl)pyrrolidin-1-y1]carbony1}-5-{[(2R)-2-(methoxymethyl)pyrrolidin-1-y1]sulfony1}benzamide	**757
3136	S H OH H N N F F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-(1,3-thiazol-2-yl)benzamide	**522.2
3137	H QH H	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4,8-diethoxyquinoline-2-carboxamide	**** 578.3 (+)
3138	O N O H OH H N F H-CI F H-CI	2-(4-buty1-3- oxopiperazin-1-y1)-N- {(1S,2R)-1-(3,5- difluorobenzy1)-3-[(3- ethylbenzy1)amino]-2- hydroxypropy1}acetamid e dihydrochloride	
3139	P P P P P P P P P P P P P P P P P P P	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>3</sup> -[2-(dimethylamino)ethyl]-N <sup>3</sup> ,5-dimethylisophthalamide	

3140	F	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-methylbutandyl)amino]propyl}-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide	
3141	N H H OH H	N <sup>1</sup> -{(1S,2R)-1-(3,5- difluorobenzyl)-2- hydroxy-3-[(4- methylpentanoyl)amino] propyl}-5-methyl-N <sup>3</sup> ,N <sup>3</sup> - dipropylisophthalamide	
	P O N H O H	isobutyl (2R,3S)-4- (3,5-difluorophenyl)- 3-({3- [(dipropylamino)carbon yl]-5- methylbenzoyl}amino)- 2-	
3142		hydroxybutylcarbamate	
	F O H H OH H	ethyl (2R,3S)-4-(3,5-difluorophenyl)-3-({3-[(dipropylamino)carbonyl]-5-methylbenzoyl}amino)-	
3143		hydroxybutylcarbamate N <sup>1</sup> -[(1S,2R)-1-(3,5-	
3144	O O N H N N N H H OH H	difluorobenzyl) -2- hydroxy-3-(pyrimidin- 2-ylamino)propyl]-5- methyl-N³,N³- dipropylisophthalamide	
3145	F N H H H H H H H H H H	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-{(3-ethylbenzyl)amino}-2-hydroxypropyl}-5-methyl-N <sup>3</sup> -[(1S)-1-methylpropyl]isophthalamide	
3146	H O N H N H N H N H N H N H N H N H N H	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-N <sup>3</sup> -[(1R)-1-methylpropyl]isophthalamide	

		$N-\{(1S, 2R)-1-(3, 5-$	
-	N H OH H	difluorobenzyl)-3-[(3-	
İ		ethylbenzyl)amino]-2-	]
i		hydroxypropyl}-2-	**554.4
•	0 TF	1	7 " 3 5 4 . 4
		(dipropylamino)-6-	
ŀ	Y	methylpyrimidine-4-	ļ
3147	F	carboxamide	
		1-	
		[butyl(methyl)amino]-	ļ
		$N-\{(1S,2R)-1-(3,5-$	
	·	difluorobenzyl)-3-[(3-	
Į.		ethylbenzyl)amino]-2-	
	I I I I I I	_	
		hydroxypropyl}isoquino	l
	N Ö T	line-7-carboxamide or	**575.4
		1-	1
ŀ		[butyl(methyl)amino]-	1
	Ė .	N-{(1s,2r)-1-(3,5-	
		difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	
		hydroxypropyl}isoquino	
3148		line-7-carboxamide	
		N-{ (1s, 2r) -1-(3,5-	<del></del>
	9 ~	difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	
	U L AF	hydroxypropyl}-1,3-	**529
		dihydro-2-	323
	HCI	benzothiophene-5-	
	ļ F	carboxamide 2,2-	
3149	·	dioxide hydrochloride	
		N-((1S,2R)-1-(3,5-	
	r r	difluorobenzyl)-3-{[1-	
	<u> </u>	(3-	
		ethynylphenyl)cyclopro	
		pyl]amino}-2-	
		hydroxypropy1)-3-	
	HHOH H	1	
	) Y	{[(2R)-2-	
	<b>९</b>	(methoxymethyl)pyrroli	
2150		din-1-yl]carbonyl}-5-	
3150		methylbenzamide	
		N-((1S,2R)-1-(3,5-	
	F	difluorobenzyl)-3-{[1-	
	<b>)</b>	(3-	
	F	ethynylphenyl)cyclopro	
		pyl]amino}-2-	
1		hydroxypropyl)-3-	
1	HHOHH WOO	{ [ (2R) -2-	
]	1 d 1	(methoxymethyl)pyrroli	
	\ FX -OH	din-1-yl]carbonyl}-5-	
	F´ F		
3151		methylbenzamide	
2131	<del></del>	trifluoroacetate	
	н он н	N-{(1S,2R)-1-(3,5-	
	N N N N N N N N N N N N N N N N N N N	difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	**534.2
[		hydroxypropyl}-1-	
	' <u> </u>	isobutyl-1H-indole-6-	
3152	F	carboxamide	
		<del></del>	

		carboxamide	I
	H OH H	1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-(2,5-dimethyl-1H-pyrrol-1-yl)-1H-indole-6-	**627.8 6
3153	H OH H N N F	carboxamide  1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-methyl-1H-indole-6-carboxamide	**548.9 4
3155	H OH H N HCI	N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-3-oxo-2-propy1-2,3-dihydro-1,2-benzisothiazole-6-carboxamide 1,1-dioxide hydrochloride	**586
3156	H OH H N N N N N N N N N N N N N N N N N	1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-(1,3-oxazol-2-yl)-1H-indole-6-carboxamide	**601.9 9
3157	H QH H N N N N N N N N N N N N N N N N N	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(dipropylamino)-6-methylisonicotinamide	**553
3158	S H OH H	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-2-[(methylsulfonyl)methyl]-1,3-thiazole-4-carboxamide	**** (537.8) (+)
3159	NH2 OH H N HCI	4-amino-1-butyl-N- {(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-1H- indole-6-carboxamide hydrochloride	

		N-{(1S,2R)-1-(3,5-	
	Q,	difluorobenzyl)-3-[(3-	
	H OH H	ethylbenzyl)amino]-2-	
		hydroxypropyl}-2-	
1		ethyl-3-oxo-2,3-	1
	0 - F		
	HCI	dihydro-1,2-	
		benzisothiazole-6-	
	F	carboxamide 1,1-	
3160		dioxide hydrochloride	
	1	3-[(tert-	
1	1,11,1	butylamino)sulfonyl]-	
	HŅ \ O=S=O	N-{(1S,2R)-1-(3,5-	
	0-3-0	difluorobenzyl)-3-[(3-	
i	н он н	ethylbenzyl)amino]-2-	
	N N N N N N N N N N N N N N N N N N N	hydroxypropyl}-5-	1
	10 1 5 F	{ [ (2S) -2-	
	1 7	(methoxymethyl)pyrroli	
		din-1-	
3161	Ė	yl]carbonyl}benzamide	
		3-{[(2S)-2-	
		butylpyrrolidin-1-	
1		yl]carbonyl}-N-	1
		{ (1S,2R) -1-(3,5-	- 1
		difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	
	Ţ	hydroxypropyl}-5-	
3162	F	methylbenzamide	
		4-butyl-N-{(1S,2R)-1-	
İ	H OH H	(3,5-difluorobenzyl)-	
		3-[(3-	1
1		ethylbenzyl)amino]-2-	
		hydroxypropyl}-3,4-	
		dihydro-2H-1,4-	ļ
1	Ţ	benzoxazine-6-	
3163	Į F	carboxamide	- 1
		N-{(1S,2R)-1-(3,5-	
1		difluorobenzyl)-3-[(3-	
ĺ	] 1	othylbongyl\n=i=ol	
	The second secon	ethylbenzyl) amino]-2-	_ ]
		hydroxypropyl}-3-	
	o ö ö F	methyl-5-{[(2R)-2-	
	н-а	(propoxymethyl)pyrroli	
	ļ	din-1-	l
		yl]carbonyl}benzamide	
3164		hydrochloride	
1		2-(1-butyl-2-	
	04	oxopiperidin-4-yl)-N-	İ
]	O O O N I N	{ (1s, 2r) -1- (3, 5-	
	1	difluorobenzyl)-3-[(3-	
	N Ö F	ethylbenzyl)amino]-2-	
		hydroxypropyl}acetamid	
3165	Ĭ	e	
5102	<u> </u>	<u> </u>	I

	<del></del>		
		N-{(1S,2R)-1-(3,5-	
	L. L.	difluorobenzyl)-3-[(3-	
	g (H	ethylbenzyl)amino]-2-	:
		hydroxypropyl}-3-	
3166	H H OH H	pentylbenzamide	
	Ę	N-{(1S,2R)-1-(3,5-	
		difluorobenzyl)-3-[(3-	
	9 J	ethylbenzyl)amino]-2-	
		hydroxypropyl}-3-(2-	
3167	H H OH H	ethylhexyl)benzamide	
		ethyl 5-{3-[({(1S,2R)-	
		1-(3,5-	
		difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	
		hydroxypropyl amino) ca	
	HHOH H	rbonyl]phenyl}-2-	
3168		furoate	
	f,	N-{(1S,2R)-1-(3,5-	
1		difluorobenzyl)-3-[(3-	
	F	ethylbenzyl)amino]-2-	
1	[] I (AH	hydroxypropyl}-1,1'-	
	N N N N N N N N N N N N N N N N N N N	biphenyl-3-carboxamide	
3169	H H OH H		
	F	N-{(1S,2R)-1-(3,5-	
•		difluorobenzyl)-3-[(3-	
	F	ethylbenzyl)amino]-2-	
	[ ] [M	hydroxypropyl}-2'-	
	S H H OH H	(methylthio)-1,1'-	
3170	S " " OH "	biphenyl-3-carboxamide	
		N-{(1S,2R)-1-(3,5-	
ľ		difluorobenzyl)-3-[(3-	
	F 0	ethylbenzyl)amino]-2-	
	NAME OF THE PROPERTY OF THE PR	hydroxypropyl}-3-(2-	
3171		fluorobenzyl)benzamide	
	Ę	N-{(1S,2R)-1-(3,5-	
		difluorobenzyl)-3-[(3-	
	F	ethylbenzyl)amino]-2-	<b></b>
	O CH	hydroxypropyl}-3-(4-	
2170	H H OH H	fluorobenzyl) benzamide	
3172	F		
	<u>.</u> .	ethyl 3'-[({(1S,2R)-1-	
		(3,5-difluorobenzyl)-	
		3-[(3-	
		ethylbenzyl)amino]-2-	
1	TO HHOH H T	hydroxypropyl}amino)ca rbonyl]-1,1'-biphenyl-	
L	10° 70	2-carboxylate	
3173			
	<u></u>	N-{(1S,2R)-1-(3,5-	
	F	difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	ľ
		hydroxypropyl}-3',5'-	
2174	H H OH H	difluoro-1,1'-	
3174	✓ OR ✓	biphenyl-3-carboxamide	

	Ę	N-{(1S,2R)-1-(3,5-	
		difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	
		hydroxypropy1}-2-	
	∏ N (NH	phenylacetamide	
	<b>人人人.火</b> "人人	phenyracetamide	
	HHOH H	1	
	H H OH H		
3175			
	Ę	tert-butyl 4-	
		[({(1S,2R)-1-(3,5-	
	F	difluorobenzyl)-3-[(3-	
	P (₃H		
	H N N N N N	ethylbenzyl)amino]-2-	
	HHOH H	hydroxypropyl}amino)ca	
3176	<u> </u>	rbonyl]benzylcarbamate	
	Ę	(2R)-N-{(1S,2R)-1-	
		(3,5-difluorobenzyl)-	
	[ L_	3-[(3-	
		ethylbenzyl)amino]-2-	
	I CH	_	
		hydroxypropyl}-2-	
2177	HOW H H H HOH H	hydroxy-2-	
3177	- CIT	phenylethanamide	
	<u> </u>	(2S)-N-{(1S,2R)-1-	
		(3,5-difluorobenzyl)-	
	\\_F	3-[(3-	
		ethylbenzyl)amino]-2-	
		hydroxypropyl}-2-	
	N. Y. W. A. A.	hydroxy-2-	
3178	H, OH H H, OH H	phenylethanamide	
	Ę	3-(5-chloropentyl)-N-	
		{(1s,2r)-1-(3,5-	
	CI	difluorobenzyl)-3-[(3-	
	O ComH	ethylbenzyl)amino]-2-	
	T H N H	hydroxypropyl}benzamid	
3179	H H OH H	e	
	Ę F	N-{(1S,2R)-1-(3,5-	
	o F	difluorobenzyl)-3-[(3-	
	F OV F	ethylbenzyl)amino]-2-	
	§ O NH OH.	hydroxypropyl}-3-(1-	
		phenylethyl)benzamide	•
3180	H H OH H U	trifluoroacetate	
7100	F		
	Ĺ	3-(cyclohexylmethyl)-	
		N-{(1S,2R)-1-(3,5-	
		difluorobenzyl)-3-[(3-	
	Y	ethylbenzyl)amino]-2-	
		hydroxypropyl}benzamid	
3181	H H OH H	e	
-	F	3-cyclopentyl-N-	
	<u> </u>		
1		{ (1S, 2R) -1 - (3, 5 -	
		difluorobenzyl)-3-[(3-	
	I I'MH	ethylbenzyl)amino]-2-	
	N N N N	hydroxypropyl}benzamid	
3182	H H OH H	e l	

		<del></del>	
1	ļ ,	N-{(1S,2R)-1-(3,5-	
		difluorobenzyl)-3-[(3-	
	F	ethylbenzyl)amino]-2-	
	° CuH	hydroxypropy1}-3-hex-	
	しっるとだっこっるへ	5-enylbenzamide	
3183		2 (6	
1	] ,,	3-(6-cyanohexyl)-N-	
İ		{ (1S, 2R) -1- (3,5-	
	/_F	difluorobenzyl)-3-[(3-	
İ	₽ («H	ethylbenzyl)amino]-2-	
	しょる 人.だっ.ふるへ	hydroxypropyl}benzamid	
3184	N N N N N N N N N N N N N N N N N N N	e le	
3104	H OH	$N^{1}$ -((1S,2R)-1-(3,5-	
}	F,		
		difluorobenzyl)-3-{[3-	
<u> </u>	F	(2-formylthien-3-	
		yl)benzyl]amino}-2-	
		hydroxypropyl)-5-	
	/ W "Hoh" W of	methyl-N <sup>3</sup> , N <sup>3</sup> -	
3185		dipropylisophthalamide	
	Ę	$N^{1}$ -((1S,2R)-1-(3,5-	
		difluorobenzyl)-3-{[3-	
		(5-formylthien-3-	
	N N N N N N N N N N N N N N N N N N N	yl)benzyl]amino}-2-	
	H H OH H	hydroxypropyl)-5-	
	1 1	methyl-N <sup>3</sup> , N <sup>3</sup> -	
3186		dipropylisophthalamide	
	_	$N^{1}$ -((1s,2R)-1-(3,5-	,
	<u> </u>	difluorobenzyl)-2-	
	F	hydroxy-3-{[3-(6-	
	l e e ch	methoxypyridin-2-	
į	NA NA NA NA NA NA NA NA NA NA NA NA NA N	yl)benzyl]amino}propyl	
	H H OH H	$)-5-methyl-N^3, N^3-$	
3187		dipropylisophthalamide	
5107		$N^{1}$ -[(1S,2R)-3-{[3-(5-	
ľ	F, N		
		cyanopyridin-3-	
		yl)benzyl]amino}-1-	
		(3,5-difluorobenzyl)-	
	N Y N Y N Y N Y Y N	2-hydroxypropy1]-5-	
	H OH!	$methyl-N^3, N^3-$	
3188		dipropylisophthalamide	
	_	N <sup>1</sup> -((1S,2R)-1-(3,5-	
	1	difluorobenzyl)-3-{[3-	
		(6-fluoropyridin-3-	
		yl)benzyl]amino}-2-	
		hydroxypropyl)-5-	
	/ W H #\OH H \U	methyl-N <sup>3</sup> , N <sup>3</sup> ~	
2100		dipropylisophthalamide	
3189		$N^{1} - \{ (1S, 2R) - 1 - (3, 5 - 1) \}$	
	Ę	1	
		difluorobenzyl)-2-	
1	F	hydroxy-3-[(3-	
1		pyrimidin-4-	
1	N N N N N N N N N N N N N N N N N N N	ylbenzyl)amino]propyl}	
	/ "HÖH" W	$-5$ -methyl- $N^3$ , $N^3$ -	
3190	}	dipropylisophthalamide	
( <u> </u>	<u> </u>		

	_	$N^{1}$ -((1S, 2R)-1-(3, 5-	
		difluorobenzyl)-3-{[3-	
l		(5-ethylpyrimidin-2-	
		yl)benzyl]amino}-2-	
		hydroxypropyl)-5-	
	I J H A H U "		
200		methyl-N <sup>3</sup> , N <sup>3</sup> -	
3191		dipropylisophthalamide	
	F	$N^{1}-\{(1S, 2R)-1-(3, 5-$	
İ		difluorobenzyl)-2-	
	L F	hydroxy-3-[(3-	
	P P (NH N)	pyrimidin-2-	
1	NAME OF THE PROPERTY OF THE PR	ylbenzyl)amino]propyl}	
1	H H OH H	-5-methyl-N <sup>3</sup> , N <sup>3</sup> -	
3192		- 1	
5132	F	dipropylisophthalamide	
	J. F	methyl 2-[({(1S,2R)-1-	
	1 ( T'	(3,5-difluorobenzyl)-	
		3-[(3-	
	P P LH	ethylbenzyl)amino]-2-	
		hydroxypropyl amino) ca	
	O TH H OHH	rbonyl]-6-	
3193		methylisonicotinate	
	, E	N <sup>4</sup> -{(1S,2R)-1-(3,5-	
	, F	difluorobenzyl)-3-[(3-	
	N 0 1 1	ethylbenzyl)amino]-2-	
		hydroxypropyl}-6-	
	N H H OHH	$methyl-N^2,N^2-$	
	NH H H OHH	dipropylpyridine-2,4-	
3194		dicarboxamide 1-oxide	
	N III	1-butyl-4-cyano-N-	· · ·
	l "l'	{(1S, 2R)-1-(3,5-	
	04	difluorobenzyl)-3-[(3-	
1	H QH H L I	ethylbenzyl)amino]-2-	
	N N N N N N N N N N N N N N N N N N N	hydroxypropyl}-1H-	
		indole-6-carboxamide	
	11	midore-o-carboxamide	
3195	F		
	N	1-butyl-4-cyano-N-	
1	<b> </b>	{(1s,2r)-1-(3,5-	
1		difluorobenzy1)-3-[(3-	
	H OH H		
1		ethylbenzyl)amino]-2-	
		hydroxypropyl}-1H-	
i	1 ( YY.	indole-6-carboxamide	
		hydrochloride	
	ļ <u></u>		
3196	l trei		
	HCI F	5-(diethylamino)-N <sup>1</sup> -	
		{ (1s, 2r) -1- (3, 5-	
]	Q Q H	difluorobenzyl)-3-[(3-	
1	N N N N N N N N N N N N N N N N N N N	ethylbenzyl)amino]-2-	
1		hydroxypropyl}-N3,N3-	
1		dipropylisophthalamide	
3197			İ
	<u></u>	L	

<u></u>		1 5 (4 5 05) 2 (50	
	Ī	$N^{1}$ -[(1S, 2R)-3-{[3-	
1		(diethylamino)benzyl]a	
ŀ	. ♀ ♀ ♠ ←	mino}-1-(3,5-	
1	N T T T T T T T T T T T T T T T T T T T	difluorobenzyl)-2-	
1	N P OH H	hydroxypropyl]-5-(1,3-	}
	Ĭ	$oxazol-2-yl)-N^3, N^3-$	
3198	N P	dipropylisophthalamide	
3196		$N^1 - \{(1S, 2R) - 1 - (3, 5 - 1)\}$	
	1	•	
		difluorobenzyl)-3-[(3-	
	Q Q F	ethylbenzyl)amino]-2-	
	N N N N N N N N N N N N N N N N N N N	hydroxypropyl}-5-	
	H OH H	(dimethylamino)-N <sup>3</sup> ,N <sup>3</sup> -	
24.00		dipropylisophthalamide	
3199		1	
1	Ţ	$N^{1}$ -((1s,2R)-1-(3,5-	
		difluorobenzyl)-3-	
	∫	{[(2-ethylpyridin-4-	
	P PH	yl)methyl]amino}-2-	
	$\sim$	hydroxypropyl)-5-(1,3-	
	ј ј н нон н ј и	$oxazol-2-yl)-N^3,N^3-$	
		dipropylisophthalamide	:
2200	N O		
3200		ht <sup>2</sup> / h = h	
		N <sup>2</sup> -(tert-	
	, 0 H 0 H H	butoxycarbonyl)-N <sup>1</sup> -	
		{(1S,2R)-1-(3,5-	
	LON NA LINA	difluorobenzyl)-3-[(3-	
	H Ö ₹''	ethylbenzyl)amino]-2-	
		hydroxypropyl}-L-	
	\F	norleucinamide	
3201	F		
		N-{(1S,2R)-1-(3,5-	
	OH L OH L	difluorobenzyl)-3-[(3-	
<u> </u>		ethylbenzyl)amino]-2-	
1		hydroxypropyl}-3-[(3H-	
	I N		
		[1,2,3]triazolo[4,5-	
		b]pyridin-3-	
3202		yloxy)methyl]benzamide	<del></del>
		N-{(1S,2R)-1-(3,5-	
	<b>ОН 1</b>	difluorobenzyl)-2- · · ·	<b>.</b>
		hydroxy-3-[(3-	
1		iodobenzyl)amino]propy	
	L ~^	1}-3-{[(2-	
	0 ~ F	hydroxyethyl)(propyl)a	
		mino]methyl}-5-	
	ļ н—а	methylbenzamide	
2202	·	I = 1	
3203		dihydrochloride	
		N-{(1s,2r)-1-(3,5-	
		difluorobenzyl)-2-	
	C H OH H C	hydroxy-3-[(3-	
	NA NA NA NA NA NA NA NA NA NA NA NA NA N	iodobenzyl)amino]propy	
		1}-3-	
1	~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~	{[ethyl(propyl)amino]m	
1			
	H-Ci	etnyl}-5-	
	H—CI H—CI	ethy1}-5- methylbenzamide	
3204	Y	ethy1}-5- methylbenzamide dihydrochloride	

<del></del>	<b></b>		
3205	ON H OH H N F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1-methyl-1,3-dihydro-2,1-benzisothiazole-5-carboxamide 2,2-dioxide  N¹-{(1S,2R)-1-(3,5-	
	H H H H H H H H H H H H H H H H H H H	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-L-norleucinamide	
3206	<u> </u>		
3207	F H N H OH H	N <sup>1</sup> -((1S,2R)-1-(3,5- difluorobenzyl)-3-{[3- (dimethylamino)benzyl] amino}-2- hydroxypropyl)-5-(1,3- oxazol-2-yl)-N <sup>3</sup> ,N <sup>3</sup> - dipropylisophthalamide	
3208	CI H OH H OH H	2-chloro-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-6-methylisonicotinamide	
3209	OH HOH HOH HOH HOH HOH	N-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-iodobenzyl)amino]propyl}-3-{[(2-hydroxyethyl)(propyl)amino]methyl}benzamidedihydrochloride	
3210	F O H D F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(3-fluoro-4-propoxyphenyl)acetamide	
3211	H OH H	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(3-methoxy-4-propoxyphenyl)acetamide	

		N-{(1S,2R)-1-(3,5-	
		difluorobenzyl)-2-	ļ
	, М н № н М	hydroxy-3-[(3-	Į.
		iodobenzyl)amino]propy	ŀ
ļ			
1	0 \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	1}-3-methy1-5-	1
		[{ [methyl (propyl) amino]	
	<u>Т</u> н—сі	methyl}benzamide	
2010	F	dihydrochloride	
3212			
	, ,	N-{(1s,2R)-1-(3,5-	
		difluorobenzyl)-2-	
		hydroxy-3-[(3-	
		iodobenzyl)amino]propy	į
		1}-3-	
	Y	1 -	
		[(dipropylamino)methyl	
	<u> </u>	]-5-methylbenzamide	]
3213	F	dihydrochloride	1
F		3-	
		{[butyl(methyl)amino]m	l
		ethyl}-N-{(1S,2R)-1-	l
		(3,5-difluorobenzyl)-	
		2-hydroxy-3-[(3-	
		iodobenzyl)amino]propy	
		1}-5-methylbenzamide	
1	на		
3214		hydrochloride	
	0,0	N-{(1S,2R)-1-(3,5-	
}	N.S OH	difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	
}	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	hydroxypropyl}-4-	
	Ö F		
		(piperidin-1-	
2015	Y	ylsulfonyl)benzamide	
3215	F	5/45 05) 4 /2 5	
		N-{(1S,2R)-1-(3,5-	
		difluorobenzyl)-2-	
1	H H ÔH H	hydroxy-3-[(6-	
	N. N. A.	isopropyl-2,2-dioxido-	
		3,4-dihydro-1H-	
	Ö = '' \_	-	
		isothiochromen-4-	
1	[	yl)amino]propyl}-3-	
1.	· · · · · · · · · · · · · · · · · · ·	methylbenzamide	
2216			
3216	<u> </u>		
		7 //10 OD) 1 /2 F	
1		N-((1S,2R)-1-(3,5-	···
	· F	difluorobenzyl)-3-{[1-	
	· F		
	F	difluorobenzyl)-3-{[1-(3-	
	F F	<pre>difluorobenzyl)-3-{[1- (3- ethynylphenyl)cyclopro</pre>	
	N H N T	<pre>difluorobenzyl)-3-{[1- (3- ethynylphenyl)cyclopro pyl]amino}-2-</pre>	
	N H HOH H	difluorobenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-4-(3-	
	O WH N H HOH H	<pre>difluorobenzyl)-3-{[1- (3- ethynylphenyl)cyclopro pyl]amino}-2-</pre>	
3217	N H HOH H	difluorobenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-4-(3-	
3217	P F	difluorobenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-4-(3-methoxypropyl)benzamide	
3217	N H H OH H	difluorobenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-4-(3-methoxypropyl)benzamide 5-amino-N <sup>1</sup> -{(1S, 2R)-1-	
3217	N H H OH H	difluorobenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-4-(3-methoxypropyl)benzamide  5-amino-N¹-{(1S, 2R)-1-(3,5-difluorobenzyl)-	
3217	N H HOH H	difluorobenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-4-(3-methoxypropyl)benzamide  5-amino-N¹-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-	
3217	O N H HOH H	difluorobenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-4-(3-methoxypropyl)benzamide  5-amino-N¹-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-	
3217		difluorobenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-4-(3-methoxypropyl)benzamide  5-amino-N¹-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-	
3217	O N H H OH H NH NH NH NH NH NH NH NH NH NH NH NH	difluorobenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-4-(3-methoxypropyl)benzamide  5-amino-N¹-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-	

3219	N H H OH H	N <sup>1</sup> -[(1S,2R)-1-(3,5- difluorobenzyl)-3-({3- [(dimethylamino)methyl] ]benzyl}amino)-2- hydroxypropyl]-5-(1,3- oxazol-2-yl)-N <sup>3</sup> ,N <sup>3</sup> -	
	,N,	dipropylisophthalamide	
	N H H H H H H H H H H H H H H H H H H H	N-(tert- butoxycarbonyl)-3- butyl-N-{(1S,2R)-1- (3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2-	
3220		hydroxypropyl}-L- histidinamide	
3221	H OH H N N F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1-isopentyl-1H-indole-6-carboxamide	
	N H OH H	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-propyl-2,3-dihydro-1,2-benzisothiazole-6-	
3222	'	carboxamide 1,1- dioxide	
3223	N ON ON ON ON ON ON ON ON ON ON ON ON ON	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-2-ethyl-2,3-dihydro-1,2-benzisothiazole-6-carboxamide 1,1-	
	Br H QH H	dioxide  6-bromo-N-{(1S,2R)-1- (3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-2,2- dimethylchromane-8- carboxamide	-
3224	<del> </del>		
	N N N N N N N N N N N N N N N N N N N	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-[(methylsulfonyl)methy	
3225	F	l]cyclohexanecarboxami de	

	H	$N^1 - \{ (1S, 2R) - 1 - (3, 5 - 1) \}$	i
	\	difluorobenzyl)-3-[(3-	
	$\downarrow$	ethylbenzyl)amino]-2-	,
		hydroxypropyl}-5-	ì
		piperidin-4-yl-N <sup>3</sup> , N <sup>3</sup> -	
Ì		dipropylisophthalamide	
	Ö Ö 📉 F	dipropylisophicharamide	
1			
3226	Ĭ		
3220	) HCi	N-{(1S,2R)-1-(3,5-	
		difluorobenzyl)-3-[(3-	
	H OH H	ethylbenzyl)amino]-2-	
	N Ö F	hydroxypropy1}-3-	
		methyl-5-(1,3-oxazol-	
		2-y1)benzamide	
3227	_ <b>- - - - - - - - - -</b>	hydrochloride	
	_	N-{(1S,2R)-1-(3,5-	
	Д н Он н Оп	difluorobenzyl)-3-[(3-	ļ
1	O S N N N	ethylbenzyl)amino]-2-	
	)	hydroxypropyl}-5-	
	\\ \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	[(methylsulfonyl)methy	
		l]thiophene-2-	
	<u> </u>	1 1	
3228		carboxamide	
		3-	
	н П н он н	[(cyclohexylamino)meth	
	N N N N N N N N N N N N N N N N N N N	y1]-N-{(1s,2R)-1-(3,5-	
		difluorobenzyl)-2-	
	1 YY	hydroxy-3-[(3-	
		iodobenzyl)amino]propy	
	F	1}-5-methylbenzamide	
3229	HCI	hydrochloride	
		2-(2-chlorophenoxy)-N-	
	Н _	{ (1S,2R)-1-(3,5-	
İ	N F	difluorobenzyl)-3-[(3-	
ŀ		ethylbenzyl)aminol-2-	
	CI O MOH	hydroxypropyl acetamid	
			;
	NH F	e	
			i
.			
	\ \`\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		
3230			
	N	N-{(1s,2R)-1-(3,5-	
1		difluorobenzyl)-3-[(3-	
	N N F	ethylbenzyl)amino]-2-	
1	"	hydroxypropyl}pyrazine	
1	O / MOH	-2-carboxamide	
	NH F		
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		
2022	~ ]		
3231		<u> </u>	_

	O H N N OH F	N-{(1s,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-3-(phenylsulfony1)propanamide	
3232			
	H H H N F F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]-6-	
3233	H-Cl	methylisonicotinamide	
3234	HO HO N H N F	3-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}amino)carbonyl]-5-methylbenzoic acidhydrochloride	
	H OH H	6-cyano-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2,2-dimethylchromane-8-carboxamide	
3235	F		
	HCI H QH H N N N N N N N N N N N N N N N N N N	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-(1,3-thiazol-2-yl)benzamide	
3236	ļ F	hydrochloride	İ
3237	H OH H OH	formic acid compound with N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(4-ethoxyphenyl)acetamide(1:1)	

	,		
		formic acid compound	
		with N-{(1S,2R)-1-	
		(3,5-difluorobenzyl)-	
	∕	3-[(3-	
		1	
		ethylbenzyl)amino]-2-	
	Ö Ö 🌄 F	hydroxypropyl}-3-	
	l'	methy1-5-{[(2S)-2-	
	I HYOH	propylpyrrolidin-1-	
	l ö F	yl]carbonyl}benzamide	
2220			
3238		(1:1)	
		N-{(1S,2R)-1-(3,5-	
		difluorobenzyl)-3-[(3-	
	— Пи н он н оп н оп н оп н оп н оп н оп н о	ethylbenzyl)amino]-2-	
		hydroxypropyl}-3-	
		{ [ (2R) -2-(2-	
ļ			
	<b>├</b> ^	methoxyethyl)pyrrolidi	
	Ţ	n-1-yl]carbonyl}-5-	
3239	<u> </u>	methylbenzamide	
		N-{(1S,2R)-1-(3,5-	
	у н он н оп	difluorobenzyl)-3-[(3-	
	W $V$ $V$ $V$ $V$ $V$ $V$ $V$ $V$ $V$		
	l, , , # , , , , ,	ethylbenzyl)amino]-2-	
	0 -\_F	hydroxypropyl}-4-	
		[(methylsulfonyl)methy	
	Ĭ	1]cyclohexanecarboxami	
3240	F F	de	
	,	3-butyl-N-{(1S,2R)-1-	
	N au		
		(3,5-difluorobenzyl)-	
		3-[(3-	
		ethylbenzyl)amino]-2-	
		hydroxypropyl}-1-	
1		methyl-1H-indole-5-	
3241		carboxamide	
		formic acid compound	
1	н он н	with 2-(1-butyl-2-oxo-	
1		1,2-dihydropyridin-4-	
1		yl)-N-{(1s,2R)-1-(3,5-	
	N O TH OH	difluorobenzyl)-3-[(3-	
	\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\	ethylbenzyl)amino]-2-	
		hydroxypropyl}acetamid	
3242			
2044	N	e (1:1)	
	l (")	3-butyl-N-{(1S,2R)-1-	
	N'\ au \	(3,5-difluorobenzyl)-	
	H H OH H	3-[(3-	
	H <sub>2</sub> N H H	ethylbenzyl)amino]-2-	
		hydroxypropyl}-L-	
1		histidinamide	
1	\ <u>_</u>	urscramaniae	
3243	<sub>F</sub>		
	F F	5-	
1		[(diethylamino)methyl]	
l			
1	Q Q (H F	$-N^{1}-\{(1S,2R)-1-(3,5-$	
		difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	
1		hydroxypropyl}-N3,N3-	
1	' \ <u>\</u> \	dipropylisophthalamide	
1	1 19 -	ICTUTUUVII SUUNII NA TAMITIE I	
3244	֓֞֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓	Cipropyrisophcharamide	İ

		N <sup>1</sup> -{(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3-	
	The state of the s	ethylbenzyl)amino]-2- hydroxypropyl}-5-	
	N H H OH H	[(dimethylamino)methyl]-N <sup>3</sup> , N <sup>3</sup> -	
3245	, N	dipropylisophthalamide	
		N-{(1S,2R)-3-[(3-	
	N O	ethylbenzyl)amino]-1-	
	н он н	[3-(hexyloxy)benzyl]- 2-hydroxypropyl}-3-	
	N N N N N N N N N N N N N N N N N N N	(1,3-oxazol-2-	**570.2
	0 11	yl)benzamide	370.2
3246			
	/	formic acid compound	
	H OH H	with N-{(1S,2R)-1- (3,5-difluorobenzyl)-	
	HO N N N	3-[(3-	
	, F	ethylbenzyl)amino]-2-	
		hydroxypropyl}-2-(3- hydroxy-4-	
	H OH I	methoxyphenyl)acetamid	
3247	F	e (1:1)	
	0.0	formic acid compound with N-{(1S,2R)-1-	
	CNS OH	(3,5-difluorobenzyl)-	
		3-[(3-	***589.
	Ö F	ethylbenzyl)amino]-2- hydroxypropyl}-4-(1,3-	9
	н-соон	thiazolidin-3-	
3248	F	ylsulfonyl)benzamide	
2240		(1:1) formic acid compound	
		with N-{(1S,2R)-1-	
		(3,5-difluorobenzyl)- 3-[(3-	
		ethylbenzyl)amino]-2-	***634.
	, F	hydroxypropyl}-4-(3,4-	0
	н-соон	dihydroisoquinolin-	
		2(1H)- ylsulfonyl)benzamide	
3249		(1:1)	
		N-{(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	
		hydroxypropyl}-4-[(4-	***663.
		phenylpiperazin-1- yl)sulfonyl]benzamide	0
3250	ŧ	y - , burrony i penzamide	
	L	<u> </u>	

		3-butyl-N-{(1S,2R)-1-	
	1	(3,5-difluorobenzyl)-	
	, , , , , , , , , , , , , , , , , , , ,	3-[(3-	
		ethylbenzyl)amino]-2-	
· ·		hydroxypropyl}-1H-	
3251	Ĭ	indole-5-carboxamide	
3231	F	1-butyl-N-((1S,2R)-1-	
		(3,5-difluorobenzyl)-	
	Ę	3-{[1-(3-	
		ethynylphenyl)cyclopro	
		pyl]amino}-2-	
		hydroxypropyl)-1H-	
		benzimidazole-6-	
	N Sii	carboxamide or	
3253	;	ELAN155076	
3233	O . N	N-{(1S,2R)-1-(3,5-	-
	1 N	difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	
	. "	hydroxypropyl}-5-	**532
İ		[(methylsulfonyl)methy	
1		l]nicotinamide	
3254	Ė		
	1	$N^{1} - [(1S, 2R) - 3 - (\{3 - 1\})]$	
		[(diethylamino)methyl]	
	O O H	benzyl}amino)-1-(3,5-	
	N H H OU H	difluorobenzyl)-2-	
	/ H OH H	hydroxypropyl]-5-(1,3- oxazol-2-yl)-N <sup>3</sup> ,N <sup>3</sup> -	
	N N		
3255		dipropylisophthalamide	
	0 , 04	N-{(1s,2R)-1-(3,5-	
-	N H H OH H	difluorobenzyl)-3-[(3-	
1		ethylbenzyl)amino]-2-	
}		hydroxypropyl}-2-[1-	
	F	methyl-5-(4-	, , , , , , , , , , , , , , , , , , ,
2256	f f	methylbenzoyl)-1H-	
3256	F	pyrrol-2-yl]acetamide N-{(1S,2R)-1-(3,5-	-
1	F	difluorobenzyl) -3-[(3-	
		ethylbenzyl)amino]-2-	
1	Q (H	hydroxypropyl}-2-	
	N N N N N N N N N N N N N N N N N N N	(dipropylamino)-6-	
	I N I H H OHH []	(1,3-oxazol-2-	
ŀ	/ "Y	v1) isonicotinamide	
	N O		
3257		M (/10 2m) 1 /2 5	
		N-{(1S,2R)-1-(3,5-	
		<pre>difluorobenzy1)-3-[(3- ethylbenzyl)amino]-2-</pre>	
	l Ö (H	hydroxypropyl}-2- methyl-6-(1,3-oxazol-	
		, -	
	N H H OHH	2-yl)isonicotinamide	
	) )		1
	N O		
3258			

	Ę	1-buty1-N-((1S,2R)-1-	
		(3,5-difluorobenzyl)-	1
	F	3-{[1-(3-	
	N S LH V	ethynylphenyl)cyclopro	
	H H OH H	pyl]amino}-2-	
	NOH !!	hydroxypropy1)-1H-	İ
	الم ا	benzimidazole-5-	1
3259	//	carboxamide	
		N-{(1s,2R)-1-(3,5-	<u> </u>
		difluorobenzy1)-2-	ł
	H H OH H	hydroxy-3-[(6-	i
1	N N N	isopropyl-2,2-dioxido-	
		3,4-dihydro-1H-	İ
	0 7 " S		
	∫	isothiochromen-4-	
	F-( )	y1)amino]propy1}-3-	
		methylbenzamide	1
3260	F		
	NH Ha	$N^1 - \{ (1S, 2R) - 1 - (3, 5 - $	
	Y	difluorobenzyl)-3-[(3-	
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	ethylbenzyl)amino]-2-	
1		hydroxypropyl}-5-	**649.6
İ		piperidin-3-yl-N3,N3-	1 ~ 649.6
1		dipropylisophthalamide	i
		hydrochloride	ļ
3261	<u> </u>		
	1	3-	
		{[benzyl(methyl)amino]	
		methyl}-N-{(1S,2R)-1-	ł
	~ ~ ~ ~ \ \	(3,5-difluorobenzyl)-	**684.2
	0 ~~F	2-hydroxy-3-[(3-	^^684.2
Ì		iodobenzyl)amino]propy	
		1}-5-methylbenzamide	
3262	·	dihydrochloride	
		formic acid compound	
1		with N-{(1S,2R)-1-	
	٥٠٥		
	0 0	(3,5-difluorobenzyl)-	
		(3,5-difluorobenzyl)- 3-[(3-	
		(3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2-	<u>*</u> ** <u>*</u> 680.
-		(3,5-difluorobenzyl)- 3-[(3-	<u>*</u> ** <u>*</u> 680.
-	F N N N N N N N N N N N N N N N N N N N	(3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-4-{[4- (4-	
-	ļ.	(3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-4-{[4- (4- fluorophenyl)piperazin	
-	ļ.	(3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-4-{[4- (4- fluorophenyl)piperazin -1-	
3263	ļ.	(3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-4-{[4- (4- fluorophenyl)piperazin -1- yl]sulfonyl}benzamide	
3263	ļ.	(3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-4-{[4- (4- fluorophenyl)piperazin -1- yl]sulfonyl}benzamide (2:1)	
3263	F н-соон	(3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-4-{[4- (4- fluorophenyl)piperazin -1- yl]sulfonyl}benzamide (2:1) N-{(1S,2R)-1-(3,5-	
3263	P HCCOH	(3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-4-{[4- (4- fluorophenyl)piperazin -1- yl]sulfonyl}benzamide (2:1) N-{(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3-	
3263	N S H OOH	(3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-4-{[4- (4- fluorophenyl)piperazin -1- yl]sulfonyl}benzamide (2:1) N-{(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2-	9
3263	N S H OOH	(3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-4-{[4- (4- fluorophenyl)piperazin -1- yl]sulfonyl)benzamide (2:1) N-{(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-4-	
3263	P HOOOH	(3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-4-{[4- (4- fluorophenyl)piperazin -1- yl]sulfonyl}benzamide (2:1) N-{(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-4- (pyrrolidin-1-	9
3263	P HOOOH	(3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-4-{[4- (4- fluorophenyl)piperazin -1- yl]sulfonyl)benzamide (2:1) N-{(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-4-	9

		<del>, , _ ,</del>	
3265	P H-COOM	formic acid compound with N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-(pyrrolidin-1-ylsulfonyl)benzamide (1:1)	**** 572.0
3266	N N S H OH H H H-COOM	formic acid compound with N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-(4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}sulfonyl)benzamide(2:1)	**** 731.0
3267	O O O O O O O O O O O O O O O O O O O	N-{(1s,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-4-[(dimethylamino)sulfony1]benzamide	***546
3268	N P P P P P P P P P P P P P P P P P P P	formic acid compound with N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-[(dimethylamino)sulfonyl]benzamide (1:1)	**** 546.0
3269	S O O H OH H	N-{(1S,2R)-3-[(3-ethylbenzyl)amino]-1-[3-(hexyloxy)benzyl]-2-hydroxypropyl}-2-[(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide	**587.5
3270	OSON H OH H N F F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-6-[(methylsulfonyl)methylnicotinamide	**532
3272	H OH H N N F F	1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-1H-pyrrole-2-carboxamide	**498.4

		<del></del>	
3273	H OH H N N H	N <sup>1</sup> -{(1S,2R)-1-(3,5- difluorobenzyl)-2- hydroxy-3-[(1H-pyrrol- 2- ylmethyl)amino]propyl} -5-methyl-N <sup>3</sup> ,N <sup>3</sup> - dipropylisophthalamide	**541.2
3274	H Z Z H Z F F F F F F F F F F F F F F F	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-piperazin-1-yl-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamidehydrochloride	**650.4
3276	F O O N H H H O H H O H H	N <sup>2</sup> -{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-6-methyl-N <sup>4</sup> ,N <sup>4</sup> -dipropylpyridine-2,4-dicarboxamide	
3277	H '' Ö	N <sup>2</sup> -(tert- butoxycarbonyl)-N <sup>1</sup> - {(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-D- norleucinamide	
	H H OH H	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-D-norleucinamide	
3278	F	formic acid compound	
3281	CI ON S HOOM	with 4-{[(4- chlorophenyl)(methyl)a mino]sulfonyl}-N- {(1s,2r)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}benzamid e (1:1)	*** 642.0

		,
3282	formic acid compound with 4- {[benzyl(phenyl)amino] sulfonyl}-N-{(1S,2R)- 1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}benzamid e (1:1)	*** 684.1
3283	formic acid compound with N-{(1s,2r)-1- (3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-4- (morpholin-4- ylsulfonyl)benzamide (1:1)	***588. 1
3285	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(3-oxo-4-propylcyclohexyl)acetamide	**515.4
3286	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(3-oxocyclohexyl)acetamide	**473.3
3287	N-{(1s,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-1,1-dipropy1-3,4-dihydro-1H-isochromene-7-carboxamide	**579.4
3288	formic acid compound with 4-{[(2-cyanoethyl) (methyl) amino]sulfonyl}-N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}benzamide (1:1)	***585. 0

	o, o formic acid compound	
	with 4-	
	N	1
	ino]sulfonyl}-N-	
•	F {(1S,2R)-1-(3,5-	***614.
	difluorobenzyl)-3-[(3-	0
	H-COOH ethylbenzyl) amino]-2-	1
	hydroxypropyl)benzamid	
3289	e (1:1)	]
		<del> </del>
	formic acid compound	ŀ
1	with N-{(1S, 2R)-1-	
	(3,5-difluorobenzyl)-	
	3-[(3-	***637.
	ethylbenzyl)amino]-2-	0
	hydroxypropyl}-4-	
	[ [metny1(2-pyridin-2-	
	ylethyl)amino]sulfonyl	
3290		
	o, o formic acid compound	
	with N-{(1S,2R)-1-	
	N OH H (3,5-difluorobenzyl)-	
İ	3-[(3-	J
	ethylbenzyl)amino]-2-	***608.
	hydroxypropyl}-4-	1
	H-COOH [[methyl(phenyl)amino]	
	sulfonyl)benzamide	
3291	(1:1)	
	formic acid compound	
	with 4-	
	1 . `C _	i
	H OH H [[benzyl(methyl)amino]	
	sulfonyl}-N-{(1S,2R)-	***622.
	Ö F 1-(3,5-	1
	difluorobenzyl)-3-[(3-	_
	ethylbenzyl)amino]-2-	
2202	hydroxypropyl}benzamid	
3292	e (1:1)	
	o, o formic acid compound	
] .	with N-{(1S,2R)-1-	
1	N р р н (3,5-difluorobenzyl)-	
1	3-[(3-	***636.
	ethylbenzyl)amino]-2-	l . i
	hydroxypropy1}-4-	1
	H-COOH [[methyl(2-	
	phenylethyl)amino]sulf	
3293	onyl}benzamide (1:1)	
	O, O formic acid compound	
	with 4-	
	N gH н [[allyl(methyl)amino]s	ľ
	N N N N N N N 1 (11 C 2D) 1	
	(3,5-difluorobenzyl)-	***572.
	3-[(3-	1
ļ	H-coordethylbenzyl)amino]-2-	ŀ
	F hydron manual 1 have a second and the second and	1
3294	hydroxypropyl}benzamid	j
<del></del>	e (1:1)	

3295	P P P P P P P P P P P P P P P P P P P	N-{(1S,2R)-1-(3,5- difluorobenzv1)-3-[(3-	***631. 1
3296	N S O H S F	formic acid compound with N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-{[methyl(propyl)amino] sulfonyl)benzamide (1:1)	***574. 1
3297	P HOOGH	formic acid compound with 4- {[butyl(methyl)amino]s ulfonyl}-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}benzamide (1:1)	***588. 1
3298	r	formic acid compound with N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-{[methyl(pentyl)amino] sulfonyl)benzamide (1:1)	***602. 1
3299	N QH H-COOCH	formic acid compound with N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-{[isopentyl(methyl)amino]sulfonyl}benzamide(1:1)	***602. 1
3300	H OH H N H-CI H-CI	2-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1,2,3,4-tetrahydroisoquinoline-7-carboxamidedihydrochloride	**550.3

	formic acid compound	
ĺ	\(\sigma_i\) with N-{(1s,2r)-1-	
	(3,5-difluorobenzyl)-	i
		1
	ethylbenzyl)amino]-2-	***615.
	hydroxypropyl}-4-	0
	+coo <sub>H</sub> {[methyl(1-	
•	methylpyrrolidin-3-	
2201	yl)amino]sulfonyl}benz	
3301	amide (2:1)	1
	$\mathbb{N}^{1}$ – ((1s, 2R) –1 – (3, 5 –	
1	difluorobenzyl)-3-{[1-	
[	\/ \( (4-ethylpyridin-2-	[
	yl)cyclopropyl]amino}-	l i
	N 2-hydroxypropy1)-5-	
	H HOH H (1,3-oxazo1-2-y1)-	
	$\mathbb{N}^3, \mathbb{N}^3$	
	dipropylisophthalamide	
3302		
	ELAN-155957	
1	0 0	
ŀ		
		1
	F	ļ
3303	)=/ F	1
	N-((1S,2R)-1-(3,5-	
1	difluorobenzyl)-3-{[1-	
	(3-	
	ethynylphenyl)cyclopro	
	pyl]amino}-2-	1
	hydroxypropy1)-3-(2-	1
3304	methoxyethyl)benzamide	
	1-buty1-N-((1S,2R)-1-	
1	(3,5-difluorobenzyl)-	
1	3-{[1-(3-	
-	ethynylphenyl)cyclopro	
	pyl]amino}-2-	1
	hydroxypropy1)-2-(2-	1
1	methoxyethyl)-1H-	
3305	benzimidazole-6-	
-	carboxamide	
1	Y s L-alpha-glutamyl-L-	
	Valy1-N <sup>1</sup> -{(1S, 2R)-1-	
	HN 2 N 1 N 1 N 1 N 1 N 1 N 1 N 1 N 1 N 1	
	H     H   H   H	
	ethylbenzyl)amino]-2-	
3306	hydroxypropyl}-L-	1
	F methioninamide	

		<u></u>	
	H OH H N F	3- {[cyclohexyl(methyl)am ino]methyl}-N- {(1S,2R)-1-(3,5- difluorobenzyl)-2-	**676.2
		hydroxy-3-[(3- iodobenzyl)amino]propy	
	Ė	1}-5-methylbenzamide	
3307	HCI	hydrochloride	
	н он н	formic acid compound with 2-(4-buty1-2,5-	
	O N N N N N N N N N N N N N N N N N N N	dioxopiperazin-1-yl)-	
	N O F	N-{(1S,2R)-1-(3,5-	
	H OH	difluorobenzyl)-3-[(3-	
	, F O	ethylbenzyl)amino]-2- hydroxypropyl}acetamid	
3809		e (1:1)	
	F	3-bicyclo[2.2.1]hept-	
		2-y1-N-{(1s,2R)-1-	
	F	(3,5-difluorobenzyl)- 3-[(3-	
	A A I IMA	ethylbenzyl)amino]-2-	
	H H OH H	hydroxypropyl}benzamid	
3310	<b>⊘</b> □ OH <b>⊘</b>	e	
	F \	3-(butylamino)-N-	
		((1S,2R)-1-(3,5- difluorobenzyl)-3-{[1-	
	H O WH V	(3-	
	H HOH H	ethynylphenyl)cyclopro	
		py1]amino}-2-	
3311		hydroxypropyl)-4-(2- methoxyethyl)benzamide	
		N-((1s, 2r) -1-(3,5-	
	F	difluorobenzyl)-3-{[1-	
		(3-	
		ethynylphenyl)cyclopro pyl]amino}-2-	
[		hydroxypropyl)-2-	
	."\	(dipropylamino)-6-	
2212	N <sup>∕</sup> O ∥	(1,3-oxazol-2-	
3312		yl)isonicotinamide N-{(1S,2R)-1-(3,5-	
	HHĀ, H	difluorobenzyl)-2-	
	N N N N N N N N N N N N N N N N N N N	hydroxy-3-[(1S)-	
	N H	1,2,3,4-	
		tetrahydronaphthalen-	
		1-ylamino]propyl}-3- methylbenzamide	
3313		an orrania do	
		formic acid compound	
	√N,s H ŌH H U	with N-{(1S,2R)-1-	
		(3,5-difluorobenzyl)- 3-[(3-	***602.
		ethylbenzyl)amino]-2-	0
3314		hydroxypropyl}-4-	
3314	Ė	[[dinronvlamino]sulfon	

		[[ / di	
		[(dipropylamino)sulfon yl]benzamide (1:1)	
2215	N'S OH I	formic acid compound with 4- [(diethylamino)sulfony 1]-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}benzamid	***574. 0
3315 3316	0=\$=0 N H QH H N F	e (1:1)  4-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1-(methylsulfonyl)-1,2,3,4-tetrahydroquinoxaline-6-carboxamide	**629
3317	N F F	1-butyl-N-{(15,2R)-1- (3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}isoquino line-7-carboxamide	**546.3
3318	H QH H H CH H CH H CH H CH H CH H CH H	5- {[butyl(methyl)amino]methyl}-N-{(1S,2R)-1- (3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}thiophene-2-carboxamide dihydrochloride	**544.3
3319	Na Ha	3- {[butyl(methyl)amino]methyl}-N-((15,2R)-1-(3,5-difluorebenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-methylbenzamidehydrochloride	**574.3
3320	HO OH H CFs	3- {[butyl(methyl)amino]methyl}-N-((15,2R)-1- (3,5-difluorobenzyl)- 2-hydroxy-3-{[3- (trifluoromethyl)benzy 1]amino}propyl)-5- methylbenzamide hydrochloride	**592.3

1	₿r	3-bromo-5-	
		{[butyl(methyl)amino]m	
		ethyl}-N-((1S,2R)-1-	1
	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	(3,5-difluorobenzyl)-	
	Ö 🔭 F	3-{[1-(3-	**638.2
			030.2
	<b>Y</b>	ethynylphenyl)cyclopro	
	F	pyl]amino}-2-	
	на	hydroxypropyl)benzamid	
3321		e hydrochloride	
3341			
		3-	
	1	{[butyl(methyl)amino]m	
		ethyl}-N-((1S,2R)-1-	
		(3,5-difluorobenzyl)-	
		3-{[1-(3-	
	Ö ₹	l	**578.4
		ethylphenyl)cyclopropy	
	ľ	l]amino}-2-	
	F	hydroxypropyl)-5-	
	на	methylbenzamide	
2222		hydrochloride	
3322			
		(2R)-2-(4-butyl-3-	
		oxopiperazin-1-yl)-N-	
	H OH H	{ (1S, 2R) -1- (3, 5-	
		difluorobenzyl)-3-[(3-	
	l α .N J U U U A .E		
		ethylbenzyl)amino]-2-	
		hydroxypropyl}propanam	
	l o Ł	ide	
2202	l Å <sup>r</sup>		
3323	H, OH		
	1	3-	
		{[butyl(methyl)amino]m	
		$ethyl}-N-{(1S,2R)-1-}$	
	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	(3,5-difluorobenzyl)-	
	Ö 🎺 F		**552.3
		3-[(3-	352.3
	l Y	ethylbenzyl)amino]-2-	
ļ	F	hydroxypropyl}-5-	
İ	на	methylbenzamide	
3324		hydrochloride	
		N-{(1S,2R)-1-(3,5-	
	N. S		
	. Y	difluorobenzyl)-3-[(3-	* ****
	K	ethylbenzyl)amino]-2-	
	N H H OHH	hydroxypropyl}-2-	
		(dipropylamino)-6-	
	j   NH	(1,3-thiazol-2-	
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		
		yl)isonicotinamide	
3325			
		N-{(1S,2R)-1-(3,5-	
	l i	difluorobenzyl)-2-	
		hydroxy-3-[(3-	l
		<pre>iodobenzyl)amino]propy</pre>	ŀ
	¹ Ö <sup>‡</sup> ✓✓F	1}-3-	**664.2
		{[isopentyl(methyl)ami	
	Ė	no]methyl}-5-	
1	•	methylbenzamide	ŀ
ŀ	на		ļ.
3326	на	hydrochloride	

3327	O O H OH H	N-{(1S,2R)-1-(3-butoxybenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-[(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide	**559.1
3328	N H OH H	3-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}imidazo[1,2-a]pyridine-6-carboxamide	
3329	H H OH H N H F	2- [butyl(methyl)amino]- N-{(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-6-(1,3- oxazol-2- yl)isonicotinamide	
3330	H OH H	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1,3-benzodioxole-5-carboxamide	**483.2
3333	H H OH H	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-[methyl(propyl)amino]-6-(1,3-oxazol-2-yl)isonicotinamide	
3334	F HCI	3- {[butyl(methyl)amino]methyl}-N-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(1-phenylcyclopropyl)amino]propyl}-5- methylbenzamidehydrochloride	**550.3

	,	<del></del>
3335	S-   [butyl(methyl)amino]    ethyl]-N-{(15,2R)-1-   (3,5-difluorobenzyl)-   2-hydroxy-3-[(3-   isopropylbenzyl)amino    propyl}-5-   methylbenzamide   hydrochloride	**566.3
3337	3- {{butyl(methyl)amino}rethyl}-N-((1s,2r)-1- (3,5-difluorobenzyl)- 3-{[1-(3- ethynylphenyl)cyclopro pyl]amino}-2- hydroxypropyl)-5-(1,3- oxazol-2-yl)benzamide hydrochloride	**627.3
3339	3- {[butyl(methyl)amino]rethyl}-5-cyano-N- ((1s,2r)-1-(3,5- difluorobenzyl)-3-{[1-(3- ethynylphenyl)cyclopro pyl]amino}-2- hydroxypropyl)benzamio e hydrochloride	**585.3
3342	N-{(1s,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-3-{[(2-furylmethyl)(methyl)arino]methyl}-5-methylbenzamidehydrochloride	**576 1
3343	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2-methoxyethyl)(methyl)amino]methyl}-5-methylbenzamidehydrochloride	1**551 51
3344	3-{[[2- (diethylamino)ethyl](rethyl)amino]methyl}-N- {(1s, 2r)-1-(3, 5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-5- methylbenzamide hydrochloride	-

r			
3345	H QH H Br	N-[(1S,2R)-3-[(3-bromobenzyl)amino]-1-(3,5-difluorobenzyl)-2-hydroxypropyl]-2-methoxyacetamide	**457
3346	O H OH H N N F F OH OH F F T OH OH T O	formic acid compound with N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-[4-(ethoxymethyl)piperidin-1-yl]pentanamide(2:1)	
3347	H OH H N F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-oxoindane-5-carboxamide	**493.2
3348	HO OH H	N-{(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-3- hydroxyindane-5- carboxamide	**495.2
3349	H OH H OH F	formic acid compound with N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(4-propoxypiperidin-1-yl)acetamide (2:1)	
3350	H-X-H		**614.3
3351	H OH H		**628.3

3352	H OH H	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[isobutyl(methyl)amino]methyl}-5-methylbenzamidehydrochloride	**552.5
3353	H OH H OH H OH H OH H OH H OH H OH H O	formic acid compound with 2-(1-butyl-2-oxopiperidin-4-yl)-N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}acetamide (1:1)	
3354	H OH H OH F	formic acid compound with 2-(4-butylpiperazin-1-yl)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}acetamide (3:1)	
3355	s. A	4-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3,4-dihydro-2H-1,4-benzothiazine-6-carboxamide or ELAN157245	
	H OH H OH H	2-[(2S)-4-buty1-2- methy1-3-oxopiperazin- 1-y1]-N-{(1S,2R)-1- (3,5-difIuorobenzy1)- 3-[(3- ethy1benzy1)amino]-2- hydroxypropy1}acetamid	
3357	H QH H N N N N N N N N N N N N N N N N N	e hydrochloride  2-[(2R)-4-butyl-2- methyl-3-oxopiperazin- 1-yl]-N-{(1S,2R)-1- (3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}acetamid e hydrochloride	

	O H OH H OH H difluorobenzyl)-3-[(3-	
	o N N N Harring 1-3-[(3-ethylbenzyl)amino]-2-	
	hydroxypropy1}-2-(2,3-dioxo-4-	
	,	l
	propylpiperazin-1-	
3359	y1)acetamide	ļ
2339	hydrochloride	ļ. <u></u>
	N	
	H OH H (3,5-difluorobenzyl)-	İ
	3-[(3-	
1	ethylbenzyl)amino]-2-	
	hydroxypropyl}-	**551
	1,2,3,4-	
1	tetrahydroquinoxaline-	
	6-carboxamide	
3360	hydrochloride	
	N-{(1S, 2R)-1-(3,5-	<del> </del>
	і н <sup>QH</sup> н difluorobenzyl)-3-[(3-	
	ethylbenzyl) amino]-2-	]
	hydroxypropyl}-3-	
	methyl-5-	**566.5
	f [[methyl(pentyl)amino]	
	methyl}benzamide	·
3361	hydrochloride	
	0 N-{(1S, 2R)-1-(3, 5-	
	difluorobenzyl)-3-[(3-	
	H OH H ethylbenzyl)amino]-2-	
l	hydroxypropy1}-3-	
	F {{(2R)-2-	
	(methoxymethyl)pyrroli	**580.4
	din-1-yl]methyl}-5-	
	F methylbenzamide	
3362	hydrochloride	
2304		
	N QH H QH H (1S, 2R) -1- (3, 5-	
	人人人人 表	
	(3-	
	ethynylphenyl)cyclopro	•
	/ pyl]amino}-2-	
	hydroxypropyl)-2-	
3363	(dipropylamino)isonico	
3303	tinamide	
	$\mathbb{N}^{1} - \{ (1S, 2R) - 1 - (3, 5 - 1) \}$	
	difluorobenzyl)-3-[(1-	
	[4-	
	O O H [(dimethylamino)methyl	1
	N   pyridin-2-	+600
	H HOH H [V1)cyclopropyl)amino]-	*689
ļ	2-hydroxypropy1}-5-	l
	(1,3-oxazol-2-y1)	[
	$N^3$ , $N^3$	Į
3364	dipropylisophthalamide	

3365	N S H OH H N F F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(dipropylamino)-4-methyl-1,3-thiazole-5-carboxamide	
3367	D-N H N H N H N H N H N H N H N H N H N H	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1-methyl-3-phenyl-1H-thieno[2,3-c]pyrazole-5-carboxamide	
3368	H H OH H N N N N N N N N N N N N N N N N	N-((1S,2R)-1-(3,5-difluorobenzyl)-3- {[(4R)-6-ethyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}-2-hydroxypropyl)-3,5-dimethylbenzamide	**616.2
3370	HCI HCI	3-bromo-5- {[butyl(methyl)amino]methyl}-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}benzamide	
3371	H O H O F F	1-butyl-N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-1H-indole-6-carboxamide	
3372	P P P P P P P P P P P P P P P P P P P	ALB 12052 or N <sup>1</sup> - {(1S,2R)-1-(3,5- difluorobenzyl)-3- [({4- [(dimethylamino)methyl] pyridin-2- yl}methyl)amino]-2- hydroxypropyl}-5-(1,3- oxazol-2-yl)-N <sup>3</sup> ,N <sup>3</sup> - dipropylisophthalamide	*663

3373	Ö È F	3- [(butylamino)methyl]- N-{(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-5- methylbenzamide hydrochloride	**538.5
3374	H N OH H N F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]methyl}-5-methylbenzamidehydrochloride	**580.4
3375	N N N F F N N N N N N N N N N N N N N N	formic acid compound with N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-[4-(2-methoxyethyl)piperidin-1-yl]acetamide (2:1)	
3376	HN OH H	1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1,2,3,4-tetrahydroisoquinoline-7-carboxamide	**550.4
3377	N OH H	N <sup>1</sup> -{(1S, 2R) -1-(3, 5-difluorobenzy1) -3-[(3-ethylbenzy1) amino] -2-hydroxypropy1}-N <sup>1</sup> , 5-dimethyl-N <sup>3</sup> , N <sup>3</sup> -dipropylisophthalamide N <sup>1</sup> -{(1S, 2R) -1-(3, 5-	
3378	F	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[3-(dimethylamino)prop-1-ynyl]-N³,N³-dipropylisophthalamide	

	H OH H	N-{(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-2-(2-	
		phenoxyphenyl)acetamid e	
3379	F		
	H S'H H	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(2,5-dimethylphenyl)acetamide	
3380			
	1 1	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-[2-(trifluoromethoxy)phenyl]acetamide	
3381	F		
	H OHH H	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-ethoxyphenyl)acetamide	
3382	F		
	F H OH H	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-[2-(trifluoromethyl)phenyl]acetamide	
3383			
3384	O H OH H N N F F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-methoxyphenyl)acetamide	
	<u> </u>	I	L

3385	H OHH H N	2-[2- (benzyloxy)phenyl]-N- {(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}acetamid e	
5505		7 ( (1 0 0 0 ) 1 (2 5	
	H OH H N N H N N H N N H N N H N N H N N H N N H N N H N N H N	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-phenylbutanamide	
3386			
2205		N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-mesitylacetamide	
3387	F F		
	H OH H N H N H N F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(2,4-dimethoxyphenyl)acetamide	
3388			
	CI H OHH H N H	2-(2-chlorophenyl)-N- {(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}acetamid e	
3389	,		
3390	H OH H N H N H	2-cyclohexyl-N- {(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}acetamid e	

	Γ	45B303	
	H OHH	ELAN-157393	
	H		
	0 F—()	·	
3391			
	1	ELAN-157394	
	<del>                                     </del>		
	ZOHH PHH		
	TON N THIN		
	Н Д ТР		
	F—〈 〉		
3392	ļ <b>F</b>		
		2-cyclopent-2-en-1-yl-	
		N-{(1S,2R)-1-(3,5-	
		difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	
	o <i>-</i> j	hydroxypropyl}acetamid e	
3393	F		
		N-{ (1S,2R)-1-(3,5-	
	l √ N⊔	difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2- hydroxypropyl}-2-(1-	
	$N \sim N \sim N \sim N \sim N \sim N \sim N \sim N \sim N \sim N \sim$	methyl-5-oxo-2-	
	∥ <u>≛</u> `H	thioxoimidazolidin-4-	
		yl)acetamide	
	F─ <b>⟨</b>	·	
3394			
		N-{ (1S,2R)-1-(3,5-	
		difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	
		hydroxypropyl}-2-(2- fluorophenyl)acetamide	
	F( )		
	`~`{_		
3395	'		
	u OH u	2-cyclopropyl-N-	
}	H OHH H	{ (1s,2R) -1- (3,5-	
		difluorobenzyl)-3-[(3-	
	1 0 7	ethylbenzyl)amino]-2- hydroxypropyl}acetamid	
	F—( )	e	
2206	F		
3396			

	T		
3397	H OHH H N	2-cyclohex-1-en-1-yl- N-{(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}acetamice	
3398	H OHH H N N N N N N N N N N N N N N N N	2-(1-adamanty1)-N- {(1S,2R)-1-(3,5- difluorobenzy1)-3-[(3- ethylbenzy1)amino]-2- hydroxypropy1}acetamic e	
3399	H OHH H N	(2S)-N-{(1S,2R)-1- (3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-2- phenylpropanamide	
3400	H OH H N H	(2R)-N-{(1S,2R)-1- (3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-2- phenylpropanamide	
3401	F( )	2-(2,4- dichlorophenyl)-N- {(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}acetamid	
3402	P H	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(2,3-dimethoxyphenyl)acetamide	

3403	P H H N N N N N N N N N N N N N N N N N	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[3-(dimethylamino)propyl]-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide	
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	N <sup>1</sup> -((1S,2R)-1-(3,5- difluorobenzyl)-3-{[1- (4-ethynylpyridin-2-	
	H HOH H	yl)cyclopropyl]amino}- 2-hydroxypropyl)-5- (1,3-oxazol-2-yl)- N <sup>3</sup> ,N <sup>3</sup> - dipropylisophthalamide	
3406			
3407	OH H N F	4-butyl-N-{(1S,2R)-1- (3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-3,4- dihydro-2H-1,4- benzothiazine-6- carboxamide 1-oxide	
	НО	N-{(1S,2R)-1-(3,5-	
3408	H OH H	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1-heptyl-4-hydroxy-L-prolinamide	
	ÇI	2-	
2400	N OH H	[butyl(methyl)amino]-6-chloro-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}isonicotinamide	
3409	=N	2	
3410	DH H N F F	2- [butyl(methyl)amino]- 6-cyano-N-{(1S,2R)-1- (3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}isonicot inamide	

	· · · · · · · · · · · · · · · · · · ·		
3411	O H HOH H	ALB-12164  N'-{(1s,2r)-1-(3,5-difluorobenzyl)-3- [({2- [(dimethylamino)methyl]pyridin-4-yl}methyl)amino]-2-hydroxypropyl}-5-(1,3-oxazol-2-yl)-N,N-dipropylisophthalamide	*663
3412	O H H N F F	4-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-8-(1,3-oxazol-2-yl)-3,4-dihydro-2H-1,4-benzoxazine-6-carboxamide or 4-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-8-(1,3-oxazol-2-yl)-3,4-dihydro-2H-1,4-benzoxazine-6-carboxamide	**619
3413	H OH H	N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-3-(4-ethyl-1,3-oxazo1-2-y1)-5-(1,3-oxazo1-2-y1)benzamidehydrochloride	**601
3414	HO N HO N HO		**540.4
3415	Br OH HZ F F F		**656.2

		3-benzyl-4-(4- butylphenyl)-N-	
	H QH H	{(1S,2R)-1-(3,5-	
	1 2 5	difluorobenzyl)-3-[(3-	
·	1 11 - 11 - 1	ethylbenzyl)amino]-2-	**641.6
		hydroxypropyl}-4-	1
•	Ţ	oxobutanamide	1
3416	ľ		ļ
5-1-0	O H OH H	2-(4-buty1-2-	
		oxopiperazin-1-yl)-N-	[
		{ (1S,2R)-1-(3,5-	
		difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	
	F H-CI	hydroxypropyl}acetamid	
3417		e dihydrochloride	
		N-{(1S,2R)-1-(3,5-	
,		difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	
		hydroxypropyl}-2-[4-	]
		(ethoxymethyl)piperidi	
2410	ļ Ė	n-1-yl]acetamide	
3418		2-(4-butyl-2,3-	<b></b>
		dioxopiperazin-1-yl)-	
		N-{(1S,2R)-1-(3,5-	
	O N N N N N N N N N N N N N N N N N N N	difluorobenzyl)-3-[(3-	
	N O S	ethylbenzyl)amino]-2-	
		hydroxypropyl}hexanami	
		de hydrochloride	
	F	de nyaroemeerae	
3419	на		
3113	Ę	N <sup>1</sup> -((1s,2R)-1-(3,5-	
	_	difluorobenzyl)-3-{[1-	
	F	(4-ethynylpyridin-2-	
	P P H ∇	yl)cyclopropyl]amino}-	
	N N N N N N N N N N N N N N N N N N N	2-hydroxypropy1)-5-	1
İ	H HOH H	(1,3-oxazol-2-yl)-	
		$N^3, N^3 - \cdots$	
	' N/O	dipropylisophthalamide	
	"		
3421			
	h ôn h	5-[((1s,2R)-1-(3,5-	
		difluorobenzyl)-3-{[1-	
	OH O F	(3-	
	OH Ö	ethylphenyl)cyclopropy	**475.2
		l]amino}-2-	
	Ţ	hydroxypropyl)amino]- 5-oxopentanoic acid	
3422		p-oxopencanoic acid	
	H OH H	1-butyl-N-{(1S,2R)-1-	
		(3,5-difluorobenzyl)-	
	I W. A Junta August Aug	3-[(3-	
		ethylbenzyl)amino]-2-	
		hydroxypropyl}-	
3423	l F	1,2,3,4-	
L	<del></del>	<del></del>	

		tetrahydroquinoline-7-	
		carboxamide or 1-	ľ
		butyl-N-{(1S,2R)-1-	
		(3,5-difluorobenzyl)-	
		_	
		3-[(3-	
		ethylbenzyl)amino]-2-	
Į.		hydroxypropyl}-	
		1,2,3,4-	
		tetrahydroguinoline-7-	
		carboxamide	
		4-[((1S,2R)-1-(3,5-	
	O H OH H		
	l l i i i i i i i i i i i i i i i i i i	difluorobenzyl)-3-{[1-	
-	HO W	(3-	
ļ	l ő t 《 F	ethylphenyl)cyclopropy	**461.2
}		1]amino}-2-	1^^461.2
	\\"	hydroxypropyl)amino]-	
1		4-oxobutanoic acid	
2424		- ONODUCATIOTC, actu	
3424		7 ((10 00) 1 (2 5	
	H OH H	N-{(1s,2R)-1-(3,5-	
		difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	
	Ö F	hydroxypropyl}-3-	
	] / [] ]	propy1-1,2-	
		benzisoxazole-5-	
3425	{ F	carboxamide	
<del>  123                                   </del>		2_	· · · · · · · · · · · · · · · · · · ·
	H OH H	[allyl(methyl)amino]-	
		N-{(1S,2R)-1-[3-	
		(allyloxy)-5-	**547.5
		fluorobenzyl]-3-[(3-	347.3
		ethylbenzyl)amino]-2-	
		hydroxypropyl}isonicot	1
3426	F	inamide	
3420		1 -11:1 N (/10 2D) 1	
	H QH H	1-allyl-N-{(1S,2R)-1-	[
		[4-(allyloxy)-3-	
		fluorobenzyl]-3-[(3-	<u> </u>
	Ö	ethylbenzyl)amino]-2-	
-		hydroxypropyl }-1H-	**556.4
		indole-6-carboxamide	
			<b>j</b>
	_O F		
3427			
		N-((1S,2R)-1-(3,5-	
		difluorobenzyl)-3-{[1-	! !
	N H OH H	(3-	1
	N-COLIN THIN	ethynylphenyl)cyclopro	
	] J A A	pyl]amino}-2-	
		hydroxypropy1)-4-	
		phenyl-2-(1H-pyrrol-1-	
	ŕ	yl)-1,3-thiazole-5-	
3428		carboxamide	
P420	Land or		1

	F F OH H	N-((1S,2R)-1-(3,5- difluorobenzyl)-3-{[1- (3- ethynylphenyl)cyclopro	
	Ö	pyl]amino}-2-	
		hydroxypropyl)-2- (dipropylamino)-4-	
	f f	(trifluoromethyl)-1,3-	
3429	.0.	thiazole-5-carboxamide N-((1S,2R)-1-(3,5-	
	N //	difluorobenzyl)-3-{[1-	
		ethynylphenyl)cyclopro pyl]amino}-2-	
		hydroxypropyl)-2,6-	
	N N OH	dimorpholin-4- ylpyrimidine-4-	
	O HN NH	carboxamide	
	F		
	F		
3432		N-{(1S,2R)-1-(3,5-	
	HCI HCI	difluorobenzyl)-3-[(3-	
	H PH H	ethylbenzyl)amino]-2- hydroxypropyl}-3-	
		{ [ (2S) -2-	
		ethylpyrrolidin-1- yl]carbonyl}-5-	
	F	methylbenzamide	
3433		hydrochloride (2S)-2-(4-butyl-3-	
	OH .	oxopiperazin-1-yl)-N-	
	O H OH H	{ (1s, 2r) -1- (3, 5-	
	N	<pre>difluorobenzy1)-3-[(3- ethylbenzy1)amino]-2-</pre>	
	на	hydroxypropyl}propanam	
3434	F F	ide hydrochloride N-((1S,2R)-1-(3,5-	
	F F	difluorobenzyl)-3-{[1-	
	N H OH H	(3- ethynylphenyl)cyclopro	
	s N HN	pyl]amino}-2-	
	Ö ₹H △	hydroxypropyl)-1-	
		methyl-3- (trifluoromethyl)-1H-	
	F	thieno[2,3-c]pyrazole-	
3451		5-carboxamide	

	T	T	
3452	H OH H N	2- [allyl(methyl)amino]- N-{(1S,2R)-1-[4- (allyloxy)-3- fluorobenzyl]-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}isonicot inamide	**547.4
3453	H OH H N N F F	3-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1,2-benzisoxazole-5-carboxamide	**536
	Pan Han OH H	5-(3-aminopropyl)-N <sup>1</sup> - {(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-N <sup>3</sup> ,N <sup>3</sup> - dipropylisophthalamide	
3454	1.2.4		
3455	P P P P P P P P P P P P P P P P P P P	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[3-(methylamino)propyl]-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide or ELAN157961	
	F H N H H OH H	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[3-(methylamino)prop-1-ynyl]-N <sup>3</sup> ,N <sup>3</sup> -	
3456	HN	dipropylisophthalamide	
3457	P P P P P P P P P P P P P P P P P P P	5-(3-aminoprop-1- ynyl)-N¹-{(1s,2R)-1- (3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-N³,N³- dipropylisophthalamide or ELAN157963	

3458	N O OH	N-((1s,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-pyrrolidin-1-ylpyrazine-2-carboxamide	
3459	O H H OH H	4-butoxy-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}quinoline-2-carboxamide	
3461	N H OH H N F	2-cyano-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-6-[methyl(propyl)amino]isonicotinamide	
3462	O H H H H H H H H H H H H H H H H H H H	3-acetyl-1-butyl-N- {(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-1H- indole-6-carboxamide	
3463	H OH H N N H	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(1H-indol-6-ylmethyl)amino]propyl}-5-methyl-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide	**591.5
3464	NO HOLL NO F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-isobutyl-1,2-benzisoxazole-5-carboxamide	**536

3465	HN H OH H	N-{(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-2- [(2S)-pyrrolidin-2- yl]acetamide	
	F N H OH N H OH	2-[2-({(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}amino)- 2-oxoethyl]-N-(6-methoxypyridin-3-yl)benzamide	
3466	P O H, F N H OH H	2-[2-({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}amino)-2-oxoethyl]-N-(2,4-difluorophenyl)benzamide	
3467	F F N N N N H H OH H	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-pyridin-3-ylacetamide	
3469	NH O H, N N N H H OH H	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(1H-imidazol-5-yl)acetamide	

3470	0 F	2-cyclopenty1-N- {(1S,2R)-1-(3,5- difluorobenzy1)-3-[(3- ethylbenzy1)amino]-2- hydroxypropy1}acetamid e	
3471	OH NH OH H	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-hydroxyphenyl)acetamide	
3472	O H, F N H OH H	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-methylphenyl)acetamide	
3473	F N H OH H	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-iodophenyl)acetamide	
	O H, F N H H OH H	1-(4-chlorophenyl)-N- {(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-5- oxopyrrolidine-3- carboxamide	
3474		4-(2,4- dichlorophenoxy)-N- {(1s,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}butanami de	

		<del></del>
3476	Br H H OH H 4,5-dibromo-N- {(1s,2r)-1-(3,5-difluorobenzy1)-3-[(3ethylbenzy1)amino]-2-hydroxypropyl}thiophele-2-carboxamide	
	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3ethylbenzyl)amino]-2-hydroxypropyl}-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)acetamide	
3477	N-((1s,2R)-1-(3,5-difluorobenzyl)-3-{[1 (3-ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-2,6-bis(dimethylamino)pyrmidine-4-carboxamide	0
3479	4-buty1-8-cyano-N- {(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3ethylbenzyl)amino]-2-hydroxypropy1}-3,4-dihydro-2H-1,4-benzoxazine-6-carboxamide	
3480	H OH H ((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1 (3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)benzamie	**569.8

	н он н	3-(allylthio)-N-		
	L へ L L L L L L L L L L L L L L L L L L	((1S,2R)-1-(3,5-	ļ	
		difluorobenzyl)-3-{[1-		
	∫ F	(3-	**537.8	
		ethylphenyl)cyclopropy	337.0	
		1]amino}-2-		
	Ė	hydroxypropyl)benzamid		
3481	İ	e		
	0	formic acid compound		
	H OH	with $N^1 - [(3S) - 1 -$	1	
	11 0.11	azabicyclo[2.2.2]oct-		
	OH	3-y1]-N <sup>5</sup> -((1S, 2R)-1-	`	
ļ		(3,5-difluorobenzyl)-		
Ì			**583.3	
	I MH Ö	3-{[1-(3-		
}	1/47 T	ethylphenyl)cyclopropy		
	\n'\	l]amino}-2-	Į l	
	Ė	hydroxypropyl)pentaned		
3484		iamide (1:1)		
	o o	formic acid compound		
	H <sup>N</sup> OH	with N <sup>1</sup> -[(3R)-1-	l I	
		azabicyclo[2.2.2]oct-		
	H OH H	$3-y1]-N^5-((1S,2R)-1-$	i I	
		(3,5-difluorobenzyl)-	++500 0	
		3-{[1-(3-	**583.3	
		ethylphenyl)cyclopropy		
		1]amino}-2-		
	F	hydroxypropyl)pentaned		
3485		iamide (1:1)		
2403	0	formic acid compound		
	нЙон	with $N^1 - [(3S) - 1 -$		
	h On	azabicyclo[2.2.2]oct-		
	O OH	$3-y1]-N^4-((1s, 2r)-1-$		
1		(3,5-difluorobenzyl)-		
	MH NH N Y N X N X	3-{[1-(3-	**569.3	
	15) ° <del>F</del>			
	I'N'	ethylphenyl)cyclopropy		
	Ĭ	1]amino}-2-		
	Į F	hydroxypropyl) succinam		
3486	<u> </u>	ide (1:1)		
	0	formic acid compound		
	н^он	with $N^1 - ((3R) - 1 -$		
+		azabicyclo[2.2.2]oct-		
1	O H OH H	3-y1]-N <sup>4</sup> -((1S,2R)-1-		
1	N N N N N N N N N N N N N N N N N N N	(3,5-difluorobenzyl)-	**569.3	1
		3-{[1-(3-	309.3	
	I'N'	ethylphenyl)cyclopropy	-	
		1]amino}-2-		
	F	hydroxypropyl) succinam		1
3487		ide (1:1)		
<del></del>		· <del>·</del>		-

		-1 (/4 0 0 0 ) 4 /0 5	
	\ \ \	$N^{1} - \{ (1S, 2R) - 1 - (3, 5 - 1) \}$	
		difluorobenzyl)-3-[(3-	
	• • •	ethylbenzyl)amino]-2-	
<b>!</b>		hydroxypropyl}-5-[4-	
		(dimethylamino)but-1-	
	l i	$ynyl]-N^3,N^3-$	
	1 1	dipropylisophthalamide	
	₩ \ <u>.</u>	or ELAN158095	
	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		
3490			
	F <sub>3</sub> C/O	1-butyl-N-{(1S,2R)-1-	
	Ь ∕А Н ОН	(3,5-difluorobenzyl)-	
	1 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.	3-[(3-	
		ethylbenzyl)amino]-2-	
	Ö	hydroxypropyl}-3-	
	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	(trifluoroacetyl)-1H-	
	´	indole-6-carboxamide	
	ľ ľ		
2401	F .		
3491		N ( (10 2D) 1 /2 E	
		N-((1S,2R)-1-(3,5-	
	, OH	difluorobenzyl)-3-{[1-	
		(3-	
ŀ		ethynylphenyl)cyclopro	
j		pyl]amino}-2-	**588.3
		hydroxypropyl)-3-	
	ļ Ė	{[isopentyl(methyl)ami	
	1	no]methyl}-5-	
2400		methylbenzamide	
3492		hydrochloride	
	<b>,</b>	N-((1s,2R)-1-(3,5-	
	, , , , он , ,	difluorobenzyl)-3-{[1-	
		(3-	
	$ \downarrow\rangle$	ethylphenyl)cyclopropy	
	1 1 1	1]amino}-2-	**592.3
		hydroxypropyl) -3-	
	ļ ļ	{[isopentyl(methyl)ami	
}	I HUI	no]methyl}-5-	
12.402		methylbenzamide	
3493		hydrochloride	
		N-((1S,2R)-1-(3,5-	
	N H OHH	difluorobenzyl)-3-{[1-	]
		(3-	
		ethynylphenyl)cyclopro	
	1 "F'	pyl]amino}-2-	
1		hydroxypropyl)-4-	
	ļ É	(dipropylamino)-1-	
		methyl-1H-pyrrole-2-	
3494		carboxamide ·	1

		N-((1S,2R)-1-(3,5-	
1		difluorobenzyl)-3-	
	H OH H	{[(4R)-6-ethy1-2,2-	}
	$N \rightarrow N \rightarrow N \rightarrow N \rightarrow N \rightarrow N \rightarrow N \rightarrow N \rightarrow N \rightarrow N \rightarrow$	dioxido-3,4-dihydro-	
		1H-isothiochromen-4-	
	F. S.	yl]amino}-2-	
		hydroxypropyl)-4-(2-	
		methoxyethyl)benzamide	1
	I E	methoxyethy1)behzamice	
3495	· ·		1
333	F	$N^{1}-\{(1S,2R)-1-(3,5-$	
		difluorobenzyl)-3-[(3-	ŀ
1	( L <sub>E</sub>	ethylbenzyl)amino]-2-	
i	Q Q (H		
1		hydroxypropy1}-5-[4-	
	T H HOH H	(dimethylamino)butyl]-	
		$N^3$ , $N^3$ –	1
1	' <b>ノ</b> .	dipropylisophthalamide	
1		or ELAN158113	
3496	\		1
3430		ELAN-158116	
	$  \sim   N \sim      $	ELIAN-130110	Į.
ļ	//		
	N N		
			Ì
	CI_N_OH		
	HŃ NH		
	ì		
	-\_F		
			ļ
3497	<u> </u>		
3491	Cl ///	ELAN-158128	
1	<b>Ι</b>	2,6-dichloro- <i>N</i>	
		•	
		((1S, 2R) - 1 - (3, 5 - 4, 6) - 2 - (6, 1)	
	CI N OH	difluorobenzyl)-3-{[1-	İ
1	HN NH	(3-	
	1114	ethynylphenyl)cyclopro	
i	↓ ∧ .F	pyl]amino}-2-	
i	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	hydroxypropyl)pyrimidi	
	·	ne-4-carboxamide	
	<b>Y</b>		
3500	Ė		
	F F	N-((1S,2R)-1-(3,5-	
	N × F	difluorobenzyl)-3-{[1-	
	H HOH H	(3-	
	IN SAN SAN SAN SAN SAN SAN SAN SAN SAN SA	ethynylphenyl)cyclopro	
		pyl]amino}-2-	
	F	hydroxypropyl)-2-	
		morpholin-4-yl-4-	
	<u> </u>		
	<b>F</b>	(trifluoromethyl)-1,3-	
3503		thiazole-5-carboxamide	


3506			**688
3507	ZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZ	N <sup>1</sup> -[(1S,2R)-1-(3,5- difluorobenzyl)-3- ({[1-(3-ethylphenyl)- 1H-tetraazol-5- yl]methyl}amino)-2- hydroxypropyl]-5- methyl-N <sup>3</sup> ,N <sup>3</sup> - dipropylisophthalamide	**648
3508	H Z L L L L L L L L L L L L L L L L L L	3-(allylsulfinyl)-N- ((1S,2R)-1-(3,5- difluorobenzyl)-3-{[1- (3- ethylphenyl)cyclopropy l]amino}-2- hydroxypropyl)benzamide	**553 <b>.</b> 8
	P P P P P P P P P P P P P P P P P P P	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-[3-(dimethylamino)propyl]-N <sup>3</sup> ,N <sup>3</sup> -dipropylisophthalamide	
3520	HO O H, N H OH H	N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-3'-(hydroxymethy1)-5-(1,3-thiazo1-2-y1)-1,1'-bipheny1-3-carboxamide	
3522	H H OH H	3'-cyano-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-thiazol-2-yl)-1,1'-biphenyl-3-carboxamide	

	O O H	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2'-	
	н н он н	ethoxy-5-(1,3-thiazol- 2-y1)-1,1'-biphenyl-3- carboxamide	
3523			
2524	F O HA N H OH H	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-thiazol-2-yl)-3'-(trifluoromethoxy)-1,1'-biphenyl-3-carboxamide	
3524	F	N-{(1S,2R)-1-(3,5-	
3525	O H. P H	difluorobenzyl) -3-[(3-ethylbenzyl) amino]-2-hydroxypropyl}-4'-propoxy-5-(1,3-thiazol-2-yl)-1,1'-biphenyl-3-carboxamide	
3526	O H H H OH H	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-4'-(dimethylamino)-5-(1,3-thiazol-2-yl)-1,1'-biphenyl-3-carboxamide	
3527	O O H, N N N N N N N N N N N N N N N N N N	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2!	
3527 3528	O H, N H	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3'-propoxy-5-(1,3-thiazol-2-yl)-1,1'-biphenyl-3-carboxamide	

		······································	
3529	O H, N F N N N N N N N N N N N N N N N N N	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3'-ethoxy-5-(1,3-thiazol-2-yl)-1,1'-biphenyl-3-carboxamide	
3530	O H, N H OH H	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4'-ethoxy-5-(1,3-thiazol-2-yl)-1,1'-biphenyl-3-carboxamide	
3531	O H, F N H H OH H	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4'-isopropoxy-5-(1,3-thiazol-2-yl)-1,1'-biphenyl-3-carboxamide	
3532	HO O H, F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4'-(hydroxymethyl)-5-(1,3-thiazol-2-yl)-1,1'-biphenyl-3-carboxamide	
3533	O H, F N-H'OH H	4'-butoxy-N-{(1S,2R)-1-(3,5-,difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-thiazol-2-yl)-1,1'-biphenyl-3-carboxamide	
3534	O H H H OH H	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4'-methoxy-5-(1,3-thiazol-2-yl)-1,1'-biphenyl-3-carboxamide	

3535	F F O H, H OH H	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-thiazol-2-yl)-4'-(trifluoromethoxy)-1,1'-biphenyl-3-carboxamide	
3536	O H, N H N N H N S	4'-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-thiazol-2-yl)-1,1'-biphenyl-3-carboxamide	
3537	P H H N H N H N H N H N H N H N H N H N	3'-butoxy-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-thiazol-2-yl)-1,1'-biphenyl-3-carboxamide	
3538	H, N H OH	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3'-isopropyl-5-(1,3-thiazol-2-yl)-1,1'-biphenyl-3-carboxamide	-
3539	O H, N H H O H H	3'-(acetylamino)-N- {(1S,2R)-1-(3,5- difluorobenzyl)-3-[-(3- ethylbenzyl)amino]-2- hydroxypropyl}-5-(1,3- thiazol-2-yl)-1,1'- biphenyl-3-carboxamide	
3540	O H, N H OH H	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2'-methyl-5-(1,3-thiazol-2-yl)-1,1'-biphenyl-3-carboxamide	

3541	O H, N H OH H	2'-acetyl-N-{(1S,2R)- 1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-5-(1,3- thiazol-2-yl)-1,1'- biphenyl-3-carboxamide	
3542	HO O H, F N H H OH H	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4'-hydroxy-5-(1,3-thiazol-2-yl)-1,1'-biphenyl-3-carboxamide	
3543	HN NH NH NH NH NH NH NH NH NH NH NH NH N	4'-(acetylamino)-N- {(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-5-(1,3- thiazol-2-yl)-1,1'- biphenyl-3-carboxamide	
	P N H H H H O H H O H H	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-(1H-pyrrol-2-yl)-5-(1,3-thiazol-2-yl)benzamide	
3544	F N H H OH H	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(E)-2-(4-fluorophenyl)ethenyl]-5-(1,3-thiazol-2-yl)benzamide	
3546	F	N-((1S,2R)-1-(3,5- difluorobenzyl)-3-{[1- (3- ethynylphenyl)cyclopro pyl]amino}-2- hydroxypropyl)pyrimidi ne-4-carboxamide	



\* means M/Z (EI)

\*\* means M+H (CI)

\*\*\* means OAMS

\*\*\*\* means MS Data

5

### **CHART B**

$$PG \xrightarrow{R_1} R_2 R_3 \xrightarrow{R_2 R_3} (VI) \xrightarrow{R_1} PG \xrightarrow{R_1} R_2 R_3 \qquad PG \xrightarrow{R_1} R_2 R_3 \qquad (VII)$$

PG = protecting group X<sub>1</sub> is a leaving group

5

#### <u>CHART C</u>

$$PG \xrightarrow{H} R_{1} R_{2} R_{3} \longrightarrow PG \xrightarrow{H} R_{1} R_{2} R_{3} \longrightarrow PG \xrightarrow{N} R_{1} R_{2} R_{3} \xrightarrow{N} R_{2} R_{3}$$

$$(V) \qquad (XII) \qquad (XIII) \qquad (VIII) \qquad (VIII)$$

PG = Protecting Group

## CHART D

### **CHART E**

$$Z = H, \text{ alkyl or benzyl}$$

$$HO \longrightarrow Q$$

$$Z = H, \text{ alkyl or benzyl}$$

$$HO \longrightarrow Q$$

$$Z = H, \text{ alkyl or benzyl}$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A = Q$$

$$A =$$

5

## **CHART F**

# CHART G

5

$$\begin{array}{c|c} & & & \\ \hline R_{N\alpha} \\ R_{N\beta} \\ \hline \end{array} \\ \begin{array}{c} R_{N\alpha} \\ \hline \\ \end{array} \\ \begin{array}{c} R_{N\alpha} \\ \\ \end{array} \\$$

## **CHART I**

## **CHART J**

$$\begin{array}{c|c} & & & & & & & \\ R_{N\alpha} & & & & & & \\ R_{N\beta} & & & & & \\ R_{N\beta} & & & & & \\ R_{N\beta} & & & & & \\ R_{N\beta} & & & & \\ R_{N\beta} & & & & \\ R_{N\beta} & & & & \\ R_{N\alpha} & & & & \\ R_{N\alpha} & & & & \\ R_{N\alpha} & & & & \\ R_{N\alpha} & & & & \\ R_{N\alpha} & & & & \\ R_{N\beta} & & & & \\ R_{N\alpha} & & & & \\ R_{N\beta} & & & & \\ R_{N\alpha} & & & \\ R_{N\alpha} & & & \\ R_{N\alpha} & & & \\ R_{N\alpha} & & & \\ R_{N\alpha} & & & \\ R_{N\alpha} & & & \\$$

## **CHART K**

## CHART L

$$CO_2H$$

$$O_2N$$

$$(XLII)$$

$$O_2N$$

$$(XLIII)$$

$$O_2N$$

$$(XLIII)$$

$$O_2N$$

$$(XLIII)$$

$$O_2N$$

$$(XLIII)$$

$$O_2N$$

$$(XLIII)$$

$$O_2N$$

$$(XLIII)$$

$$O_2N$$

$$(XLIII)$$

$$O_2N$$

$$(XLIII)$$

$$O_2N$$

$$(XLIII)$$

$$O_2N$$

$$(XLIV)$$

$$O_3N$$

$$(XLIV)$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O_4N$$

$$O$$

5

## **CHART M**

## **CHART N**

### **CHART O**

$$(C_1 \cdot C_4) \text{alkyl} - O + (C_1 \cdot C_4) \text{alkyl} + O + (C_1 \cdot C_4) \text{alkyl$$

# CHART Q

## **CHART R**

$$(alkyl) - O \qquad (alkyl) - O \qquad$$

### **CHARTS**

$$\begin{array}{c} OH \\ H_2N/m, CH \\ R_1 \\ R_2 \\ R_3 \\ R_4 \\ R_5 \\ R_6 \\ R_6 \\ R_7 \\ R_8 \\ R_8 \\ R_8 \\ R_8 \\ R_9 \\ R_{1} \\ R_{2} \\ R_{3} \\ R_{3} \\ R_{4} \\ R_{5} \\ R_{1} \\ R_{2} \\ R_{3} \\ R_{5} \\ R_{1} \\ R_{2} \\ R_{3} \\ R_{5} \\ R_{6} \\ R_{1} \\ R_{2} \\ R_{3} \\ R_{5} \\ R_{6} \\ R_{1} \\ R_{2} \\ R_{3} \\ R_{5} \\ R_{6} \\ R_{1} \\ R_{2} \\ R_{3} \\ R_{5} \\ R_{6} \\ R_{1} \\ R_{2} \\ R_{3} \\ R_{5} \\ R_{6} \\ R_{1} \\ R_{2} \\ R_{3} \\ R_{5} \\ R_{6} \\ R_{6} \\ R_{1} \\ R_{2} \\ R_{3} \\ R_{5} \\ R_{6} \\ R_{6} \\ R_{1} \\ R_{2} \\ R_{3} \\ R_{5} \\ R_{6} \\ R_{6} \\ R_{1} \\ R_{2} \\ R_{3} \\ R_{5} \\ R_{6} \\ R_{6} \\ R_{1} \\ R_{2} \\ R_{3} \\ R_{5} \\ R_{6} \\ R_{6} \\ R_{1} \\ R_{2} \\ R_{3} \\ R_{5} \\ R_{6} \\ R_{6} \\ R_{1} \\ R_{2} \\ R_{3} \\ R_{5} \\ R_{6} \\ R_{6} \\ R_{1} \\ R_{2} \\ R_{3} \\ R_{5} \\ R_{6} \\ R_{6} \\ R_{1} \\ R_{2} \\ R_{3} \\ R_{5} \\ R_{6} \\$$

$$\begin{array}{c} \text{CHART T} \\ \\ \text{NH}_2 \\ \\ \text{NR}_{Na} \\ \text{NR}_{Na} \\ \text{RN}_{b} \\ \\ \text{(IXXVIII)} \end{array}$$

### **CHART U**

Halogen

O-C<sub>1</sub>-C<sub>4</sub> alkyl

Base 
$$<$$
2eq. Alkyl'-LG

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

Alkyl'

5

CHART U details a method for the preparation of ketones used in the invention. The preferred halogen is bromine or

iodine. A commercially available halogenated benzoate is coupled with  $(\alpha-\text{ethoxyvinyl})$ -tributyl in the presence of a catalyst, for example a palladium catalyst like dichlorobis (triphenylphosphine)palladium, yielding a methylketonesubstituted benzoate ester after hydrolytic workup. In a 5 preferred embodiment of the invention, this reaction is conducted in an anhydrous organic solvent. In a further more preferred embodiment of the invention, this reaction is conducted in anhydrous toluene. (Kosugi and Migita, Bull. Chem. 10 Soc., Jpn., 1987, 60, 767-768). Base-catalyzed nucleophilic addition to a stoichiometric excess of alkyl'-LG (or alkyl"-LG) yields a symmetric dialkylated productthat, depending on the strength of the base, may be directly converted to the equivalent benzoate. Alternatively, the methylketone-15 substituted benzoate ester may be reacted with a lower excess of alkyl'-LG, yielding a mono-substituted derivative. Said derivative may be further alkylated by base-catalyzed reaction with alkyl"-LG. It is understood that LG is Leaving Group as defined above. It is understood by one skilled in the art how 20 to perform alkylations. In a preferred embodiment of the invention, said alkylations are catalyzed by sodium hydroxide or potassium hydroxide. In an additional preferred embodiment of the invention, the alkylations are conducted in a dipolar aprotic solvent, e.g. dimethylsulfoxide.

## <u>CHART V</u>

CHART V. Synthesis of 3-substituted cyclopropylbenzylamines and related heteroaryl amines (Y.6 in Chart V). A commercially available 3-substituted benzylonitrile is reacted with 1-bromo-2-chloroethanein the presence of an aqueous base and a phase transfer catalyst to yield the a cyclopropanated benzylnitrile (Y.2). The cyanide (Y.2) is converted to amide (Y.3), which is treated with aqueous base, yielding acid (Y.4) after acidic workup. Acid (Y.4) is converted to acyl chloride (Y.5), which is reacted

5

10

with azide, yielding an intermediate which undergoes rearrangement and decomposition to give product(Y.6). (Y.6) is then reacted according to Chart JJ to yield inhibitor (X). Representative procedures are provided in Example 2353.

5




Chart Z. Reaction of epoxide I with an aromatic hydrazine in isopropanol produces the selective alkylation of the unsubstituted hydrazine nitrogen, yielding hydrazine II (M.

Nakakata, Tetrahedron Letters 1993, 6095-6098). Acylation of one of the hydrazine nitrogens with an acylating agent, e.g. benzyloxycarbonyl, yields III and reduces the reactivity of this moiety to further acylation irrespective of which bydrazine nitrogen is the first to undergo acylation (B. Gisin, Helv. Chim. Acta 1970, vol 53, 1030-1043. S. Shinagawa, Chem. Pharm. Bull. 1981, vol 29, 3630-3638). Removal of the tert-butoxycarbonyl protecting group of III yields free amine IV, which is coupled to isophthalic acid (XIV)using carbodimide or other known coupling agents. Deacylation of the hydrazine nitrogen yields compound V.

# **CHART AA** EDC, HOBt, Et<sub>3</sub>N NH<sub>2</sub> ĊНз (VI) (VII) (l) ...HCl H<sub>2</sub>N ОН ÓН (VIII) (VII) isophthalic acid, EDC, HOBt, Et<sub>3</sub>N Н ÓН (VIII) (IX)

CHART AA procedure:

15

Selective acylation of methylhydrazine on the substituted nitrogen (D. Butler, J. Medicinal Chemistry 1971, vol. 14, 1052-1054) yields acylhydrazine VI, which is reacted withwith

epoxide I in isopropanol to form adduct VII (S. Wang, J. Medicinal Chemistry 1997, vol 40, 937-941. G. Bold, J. Medicinal Chemistry 1998, vol 41, 3387-3401). Removal of the tert-butoxycarbonyl protecting group, followed by coupling to isophthalic acid (XIV) yields final product IX.

### 10 Chart BB procedure:

5

15

Epoxide X is reacted with 0-benzylhydroxylamine to yield adduct XI (S. Rosenberg, J. Medicinal Chemistry 1990, vol 33, 1582-1590). Removal of the tert-butoxycarbonyl protecting group, followed by acylation with isophthallic acid XIV yields target compound XIII.

### CHART CC

Chart CC. Aniline XXXI is acylated with acyl chlorides or anhydrides or sulfonated with sulfonyl halides or sulfonyl anhydrides to yield sulfonamide-I using methods well known to those skilled in the art. Sulfonamide-I is alkylated with RX, wherein X is a leaving group, for example Cl, Br, tosylate, or mesylate, in the presence of a base, e.g. trialkylamine, sodium hydride, pyridine, or potassium t-butoxide, to yield sulfonamide-II.

10

#### **CHART DD**

Chart DD. Amine-a is acylated with acyl chlorides or anhydrides or sulfonated with sulfonyl halides or sulfonyl anhydrides to yield sulfonamide-I using methods known to those skilled in the art. Sulfonamide-Ia is alkylated with RX, wherein X is a leaving group, for example Cl, Br, tosylate, or mesylate, in the presence of a base, e.g. trialkylamine, sodium hydride, pyridine, or potassium t-butoxide, to yield sulfonamide-IIa.

### CHART EE

15

5

10

Chart EE. Iodo amide (I) is coupled to a thiol RSH in the presence of a catalyst, for example a palladium (0) catalyst like bis(dibenzylideneacetone) palladium (0), an additive, preferably 1,1'-bis (diphenylphosphino) ferrocene, and a base, e.g. a trialkyamine, in an organic solvent, for example N-methylpyrrolidinone (NMP) or DMF, at a temperature ranging from room temperature to reflux temperature to yield sulfide (II). Sulfide (II) is oxidized with hydrogen peroxide in the presence of an acid or with a peracid, e.g. mchloroperoxybenzoic acid to yield sulfone (III). Other methods of oxidation are reported in references like Smith and March, Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th Ed., Wiley Interscience, 2001. If sulfone (III) is an ester, it is further hydrolyzed to yield a carboxylic acid (IV, not shown) by basic hydrosolisis with a base like lithium, sodium, or potassium hydroxide, followed by acidic workup. Acid (IV) is then coupled to an amine to yield the final target product.

20

5

10

15

#### CHART FF

$$R_{N-a}O$$
 $X$ 
 $RSY$ 
 $Y=Li$ ,  $Na$ ,  $K$ 
 $R_{N-a}O$ 
 $X=CI$ ,  $Br$ ,  $I$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_{N-a}O$ 
 $R_$ 

Chart FF. A halogenated benzyl-derivative of structure(1). (1)
25 is reacted with thiolate, for example a lithium, sodium or
potassium thiolate, in an organic solvent, for example THF,
toluene, or acetonitrile, at temperatures ranging from room
temperature to reflux, yielding a sulfanyl derivative of
structure(2). (2) is peroxidated with an oxidant, for example
30 hydrogen peroxide in the presence of an acid like acetic acid

or m-chloroperoxybenzoic acid, in an organic solvent like dichloromethane to yield methylene sulfone (3). Other methods of oxidation are reported in references like Smith and March, Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5<sup>th</sup> Ed., Wiley Interscience, 2001. If necessary, sulfone (3) is hydrolyzed to its acid derivative by methods known to those skilled in the art, or is used directly if already a carboxylic acid; coupling of said acid with amine yields the target product.

10

5

### **CHART GG**

Chart GG. Isoquinoline (1) is reacted with phosphorus oxychloride or phosphorus oxybromide at temperatures ranging 15 from room temperature to about 150 °C to yield haloisoquinoline (2). Halo-isoquinoline (2) is reacted with an amine at temperatures ranging from room temperature to 200 °C to yield amino-isoquinoline (3). This reaction may be carried out in the presence of an organic solvent such as THF, 20 acetonitrile, DMF, or NMP. Alternatively, the amine can be used as solvent, and a sealed reaction vessel may be used to contain volatile amine at high temperatures. Aminoisoquinoline (3) is reacted with copper (I) cyanide in an organic solvent, for example DMF or NMP (N-25 methylpyrrolidinone) at temperatures ranging from about 120 °C

to reflux, followed by hydrolysis with an aqueous acid, for example aqueous HCl, to yield isoquinoline carboxylic acid (4). Additional methods for converting amino-isoquinoline (3) to isoguinoline carboxylic acid (4) are known to those skilled in the art and include, for example, reacting (3) with carbon monoxide and an alcohol in the presence of a catalyst, for example a palladium catalyst such as palladium acetate or palladium(0) tetrakis(triphenylphosphine), and an additive, for example1,1'-bis (diphenylphosphino) ferrocene or 1,3-bis (diphenylphosphino) propane, in an organic solvent, example DMF or NMP, and in the presence of a base, for example a trialkylamine or aqueous sodium or potassium carbonate or sodium or potassium hydrogen carbonate, at temperatures ranging from about 50 to about 150 °C, followed by hydroysis of the ester product to isoquinoline carboxylic acid (4). Isoquinoline carboxylic acid (4) is then coupled to an amine to yield the final target product.

20

15

10

## **CHART HH**

5

10

### CHART II

Charts HH and II. Chart HH discloses the synthesis of a set of racemic  $\alpha$ -amino sulfones while Chart II discloses the synthesis of the active enantiomer. The Michael addition of a thiol to a protected dehydroalanine methyl ester yields a sulfanyl intermediate. The sulfanyl derivative is peroxidated to the corresponding sulfone according to one of the abovementioned methods. Hydrolysis of the ester and protecting group may be carried out with a strong aqueous acid, for example 6N HCl, or acetic acid, optionally at high temperature to yield the free amino acid salt. A protecting group for

example Cbz or Boc, may be added to the amine group. Standard peptide coupling to the unprotected diamine preferentially affords the product with an unreacted N-Rc moiety which is then orthogonally protected to yield the diprotected diamine. Selective removal of the Rn protecting group affords a free 5 This amine can be converted according one of the above-mentioned methods into amides, carbamates,. Alternatively, it may be reacted with an isocyanate to yield a urea, or with a sulfonyl chloride to yield a sulfonamide. The 10 removal of the Rc protecting yields the targetcompounds. Chart II is identical to chart HH with an additional isomer separation step which may be carried out chemically, enzymatically, or by chiral chromatography, yielding the single isomer acid which is transformed into the target

#### **CHART JJ**

15

product as described above.

#### ChartKK

Pyridine 1 is reacted with an amine 2 in an organic solvent, for example THF, at reflux or by warming to a temperature ranging from about 80 °C to about 130 °C in a sealed vessel, to yield pyridine ester 3. Pyridine ester 3 is hydrolyzed using methods known to those skilled in the art to yield chloro-acid 4. Chloro-acid 4 is coupled to amine (VIII) using methods discussed above and known to those skilled in the art to yield final product (X).

5

10

15

Alternatively, ester pyridine 3 is cyanated as taught in Tet. Lett. 2000, 41, 3271 to yield nitrile ester 5. Additional methods of preparing nitrile ester 5 include but are not limited to treatment of ester pyridine 3 with copper cyanide in organic solvents, for example N-methylpyrrolidinone, DMF at temperatures ranging from about 80 °C to about 180 °C. The ester moiety of 5 is converted to acid 6 via methods known

to those skilled in the art. Acid **5** is then coupled to amine (VIII) using methods that are discussed above or known to those skilled in the art to give final product (X).

5

10

#### Chart LL

Dinitro acid 1 is esterified with an alcohol and an acid catalyst or by methods known to those skilled in the art to yield dinitro ester 2. Dinitro ester 2 is reacted with a

protected aldehyde, for example an acetal or a ketal, in an organic solvent, for example toluene, at temperatures from about 50 to 150 °C and in the presence of an acid catalyst, for example concentrated sulfuric acid or sulfosalicylic acid, yielding dinitro amine 3. Dinitro amine 3 is treated with a palladium catalyst such as palladium on carbon in an organic solvent, for example methanol, ethanol, ethyl acetate, and acetonitrile, in the presence of an acid such as formic or acetic acid to yield amino-indole 4. Amino-indole 4 is reacted with sodium nitrite and aqueous hydrochloric or sulfuric acid, followed by potassium iodide, to give iodo-indole 5. Iodoindole 5 is reacted with copper cyanide in an organic solvent, for example N-methylpyrrolidinone at temperatures from about 100 to about 200 °C to yield nitrile-indole 6. Nitrile-indole 6 is then alkylated with an alkyl halide, for example propyl or butyl iodide, bromide, or chloride in the presence of a base, for example sodium hydride or potassium tert-butoxide, preferably potassium tert-butoxide, in an organic solvent, for example THF, DMF or DMSO, preferably DMSO, at room temperature to 100 °C, to yield ester indole 7.

5

10

15

20

25

30

Alternatively, amino-indole 4 may be reacted with an aqueous mineral acid and sodium nitrite, followed by neutralization with a base, for example sodium bicarbonate, and then reacted with potassium cyanide and copper cyanide to yield nitrile-indole 6. Ester indole 7 is then hydrolyzed to indole acid 8 using methods known to those skilled in the art. Indole 8 is then coupled to amine (VIII) using methods known to those skilled in the art and previously disclosed in this document.

Alternatively, iodo indole 5 is reacted with an alkyl halide, for example as propyl or butyl iodide, bromide, or chloride in the presence of a base, for example sodium hydride or potassium tert-butoxide, more preferably potassium tert-butoxide, in an organic solvent, for example THF, DMF or DMSO,

preferrably DMSO, at a temperature from room temperature to about 100 °C, to yield iodo alkyl 9. An Oxazole or a thiazole in an organic solvent, for example dialkyl ether or THF, at a temperature from about 0 to about -78 °C is reacted with a base, preferably butyl lithium and optionally left stirring for from about 15 to about 60 min.Zinc chloride is then added and the mixture is allowed to warm to 0-30 °C, at which time iodo alkyl 9 is added, followed by tetrakis triphenylphosphine palladium. The mixture is then optionally left stirring at a temperature from room temperature to about 80 °C to yield oxazole/thiazole indole 10. The hydrolysis of 10 by methods known to those skilled in the art yields oxazole/thiazole acid 11 is coupled to amine (VIII) using methods known to those skilled in the art.

15

10

5

Indole acid 1 is converted to indole ester 2 by methods known to those skilled in the art. Indole ester 2 is then alkylated with an alkyl halide, for example propyl or butyl iodide, bromide, or chloride, in the presence of a base, for

example sodium hydride or potassium tert-butoxide, preferably potassium tert-butoxide, in an organic solvent, for example THF, DMF or DMSO, preferrably DMSO, at room temperature to about 100 °C to yield alkyl indole 3. Alternatively, indole acid 1 may be converted directly to alkyl indole 3 by reaction with an alkyl halide, for example propyl or butyl iodide, bromide, or chloride in the presence of a base, for example sodium hydride or potassium tert-butoxide, preferably potassium tert-butoxide, in an organic solvent, for example THF, DMF or DMSO, preferrably DMSO at room temperature to about 100 °C. Alkyl indole 3 is then treated by the method disclosed in Org. Lett. (2000) 1485 and references cited therein, Tet. Lett. (1995) 4005 and references cited therein, and Org. Lett. (2001) 1005 and references cited therein to yield acylindole 4. Acylindole 4 is hydrolyzed to indole acid 5 using methods known to those skilled in the art, and indole acid 5 is coupled to amine (VIII) using methods known to those skilled in the artto yield (X).

#### 20 BIOLOGICAL EXAMPLES

Example A
Enzyme Inhibition Assay

5

10

15

The compounds of the invention are analyzed for inhibitory activity by use of the MBP-C125 assay. This assay determines the relative inhibition of beta-secretase cleavage of a model APP substrate, MBP-C125SW, by the compounds assayed as compared with an untreated control. A detailed description of the assay parameters can be found, for example, in U.S. Patent No. 5,942,400. Briefly, the substrate is a fusion peptide formed of maltose binding protein (MBP) and the carboxy terminal 125 amino acids of APP-SW, the Swedish mutation. The beta-secretase enzyme is derived from human

brain tissue as described in Sinha et.al, 1999, Nature 40:537-540) or recombinantly produced as the full-length enzyme (amino acids 1-501), and can be prepared, for example, from 293 cells expressing the recombinant cDNA, as described in WO00/47618.

Inhibition of the enzyme is analyzed, for example, by immunoassay of the enzyme's cleavage products. One exemplary ELISA uses an anti-MBP capture antibody that is deposited on precoated and blocked 96-well high binding plates, followed by incubation with diluted enzyme reaction supernatant, incubation with a specific reporter antibody, for example, biotinylated anti-SW192 reporter antibody, and further incubation with streptavidin/alkaline phosphatase. In the assay, cleavage of the intact MBP-C125SW fusion protein results in the generation of a truncated amino-terminal fragment, exposing a new SW-192 antibody-positive epitope at the carboxy terminus. Detection is effected by a fluorescent substrate signal on cleavage by the phosphatase. ELISA only detects cleavage following Leu 596 at the substrate's APP-SW 751 mutation site.

#### Specific Assay Procedure:

5

10

15

20

25

30

35

Compounds are diluted in a 1:1 dilution series to a sixpoint concentration curve (two wells per concentration) in one
96-plate row per compound tested. Each of the test compounds
is prepared in DMSO to make up a 10 millimolar stock solution.
The stock solution is serially diluted in DMSO to obtain a
final compound concentration of 200 micromolar at the high
point of a 6-point dilution curve. Ten (10) microliters of
each dilution is added to each of two wells on row C of a
corresponding V-bottom plate to which 190 microliters of 52
millimolar NaOAc, 7.9% DMSO, pH 4.5 are pre-added. The NaOAc
diluted compound plate is spun down to pellet precipitant and
20 microliters/well is transferred to a corresponding flatbottom plate to which 30 microliters of ice-cold enzyme-

substrate mixture (2.5 microliters MBP-C125SW substrate, 0.03 microliters enzyme and 24.5 microliters ice cold 0.09% TX100 per 30 microliters) is added. The final reaction mixture of 200 micromolar compound at the highest curve point is in 5% DMSO, 20 millimolar NaAc, 0.06% TX100, at pH 4.5.

Warming the plates to 37 degrees C starts the enzyme reaction. After 90 minutes at 37 degrees C, 200 microliters/well cold specimen diluent is added to stop the reaction and 20 microliters/well is transferred to a corresponding anti-MBP antibody coated ELISA plate for capture, containing 80 microliters/well specimen diluent. This reaction is incubated overnight at 4 degrees C and the ELISA is developed the next day after a 2 hours incubation with anti-192SW antibody, followed by Streptavidin-AP conjugate and fluorescent substrate. The signal is read on a fluorescent plate reader.

Relative compound inhibition potency is determined by calculating the concentration of compound that showed a fifty percent reduction in detected signal ( $IC_{50}$ ) compared to the enzyme reaction signal in the control wells with no added compound. In this assay, the compounds of the invention exhibited an  $IC_{50}$  of less than or equal to 20 micromolar.

#### Example B

10

15

20

30

#### 25 Cell Free Inhibition Assay Utilizing a Synthetic APP Substrate

A synthetic APP substrate that can be cleaved by betasecretase and having N-terminal biotin and made fluorescent by the covalent attachment of oregon green at the Cys residue is used to assay beta-secretase activity in the presence or absence of the inhibitory compounds of the invention. Useful substrates include the following:

Biotin-SEVNL-DAEFR[oregon green]KK

[SEQ ID NO: 1]

Biotin-SEVKM-DAEFR[oregon green]KK [SEQ ID NO: 2]
Biotin-GLNIKTEEISEISY-EVEFRC[oregon green]KK [SEQ ID NO: 3]
Biotin-ADRGLTTRPGSGLTNIKTEEISEVNL-DAEF[oregon green]KK [SEQ ID NO: 4]

5 Biotin-FVNQHLCoxGSHLVEALY-LVCoxGERGFFYTPKA[oregon green]KK
[SEQ ID NO: 5]

The enzyme (0.1 nanomolar) and test compounds (0.001 -100 micromolar) are incubated in pre-blocked, low affinity, black plates (384 well) at 37 degrees C for 30 minutes. The reaction is initiated by addition of 150 millimolar substrate 10 to a final volume of 30 microliter per well. The final assay conditions are: 0.001 - 100 micromolar compound inhibitor; 0.1 molar sodium acetate (pH 4.5); 150 nanomolar substrate; 0.1 nanomolar soluble beta-secretase; 0.001% Tween 20, and 2% DMSO. The assay mixture is incubated for 3 hours at 37 15 degrees C, and the reaction is terminated by the addition of a saturating concentration of immunopure streptavidin. After incubation with streptavidin at room temperature for 15 minutes, fluorescence polarization is measured, for example, using a LJL Acqurest (Ex485 nm/ Em530 nm). The activity of 20 the beta-secretase enzyme is detected by changes in the fluorescence polarization that occur when the substrate is cleaved by the enzyme. Incubation in the presence or absence of compound inhibitor demonstrates specific inhibition of 25 beta-secretase enzymatic cleavage of its synthetic APP substrate. In this assay, compounds of the invention exhibited an IC50 of less than 20 micromolar.

#### Example C

### 30 Beta-secretase inhibition: P26-P4'SW assay

Synthetic substrates containing the beta-secretase cleavage site of APP are used to assay beta-secretase activity, using the methods described, for example, in

published PCT application WO00/47618. The P26-P4'SW substrate is a peptide of the sequence:

(biotin)CGGADRGLTTRPGSGLTNIKTEEISEVNLDAEF [SEQ ID NO: 6]
The P26-P1 standard has the sequence:

5 (biotin)CGGADRGLTTRPGSGLTNIKTEEISEVNL [SEQ ID NO: 7]

Briefly, the biotin-coupled synthetic substrates are incubated at a concentration of from about 0 to about 200 micromolar in this assay. When testing inhibitory compounds, a substrate concentration of about 1.0 micromolar is preferred. Test compounds diluted in DMSO are added to the reaction mixture, with a final DMSO concentration of 5%. Controls also contain a final DMSO concentration of 5%. The concentration of beta secretase enzyme in the reaction is varied, to give product concentrations with the linear range of the ELISA assay, about 125 to 2000 picomolar, after dilution.

10

15

20

25

30

The reaction mixture also includes 20 millimolar sodium acetate, pH 4.5, 0.06% Triton X100, and is incubated at 37 degrees C for about 1 to 3 hours. Samples are then diluted in assay buffer (for example, 145.4 nanomolar sodium chloride, 9.51 millimolar sodium phosphate, 7.7 millimolar sodium azide, 0.05% Triton X405, 6g/liter bovine serum albumin, pH 7.4) to quench the reaction, then diluted further for immunoassay of the cleavage products.

Cleavage products can be assayed by ELISA. Diluted samples and standards are incubated in assay plates coated with capture antibody, for example, SW192, for about 24 hours at 4 degrees C. After washing in TTBS buffer (150 millimolar sodium chloride, 25 millimolar Tris, 0.05% Tween 20, pH 7.5), the samples are incubated with strepavidin-AP according to the manufacturer's instructions. After a one hour incubation at room temperature, the samples are washed in TTBS and incubated with fluorescent substrate solution A (31.2 g/liter 2-amino-2-methyl-1-propanol, 30 mg/liter, pH 9.5). Reaction with

streptavidin-alkaline phosphate permits detection by fluorescence. Compounds that are effective inhibitors of beta-secretase activity demonstrate reduced cleavage of the substrate as compared to a control.

5

#### Example D

### Assays using Synthetic Oligopeptide-Substrates

Synthetic oligopeptides are prepared that incorporate the 10 known cleavage site of beta-secretase, and optionally detectable tags, such as fluorescent or chouromogenic moieties. Examples of such peptides, as well as their production and detection methods are described in U.S. Patent No: 5,942,400, herein incorporated by reference. Cleavage products can be detected using high performance liquid 15 chromatography, or fluorescent or chromogenic detection methods appropriate to the peptide to be detected, according to methods well known in the art. By way of example, one such peptide has the sequence SEVNL-20 DAEF [SEQ ID NO: 8], and the cleavage site is between residues 5 and 6. Another preferred substrate has the sequence ADRGLTTRPGSGLTNIKTEEISEVNL-DAEF [SEQ ID NO: 9], and the cleavage site is between residues 26 and 27. These synthetic APP substrates are incubated in the 25 presence of beta-secretase under conditions sufficient to result in beta-secretase mediated cleavage of the substrate.

30

#### Example E

### Inhibition of beta-secretase activity - cellular assay

the compound's inhibitory activity.

Comparison of the cleavage results in the presence of the compound inhibitor to control results provides a measure of

An exemplary assay for the analysis of inhibition of beta-secretase activity utilizes the human embryonic kidney cell line HEKp293 (ATCC Accession No. CRL-1573) transfected with APP751 containing the naturally occurring double mutation Lys651Met52 to Asn651Leu652 (numbered for APP751), commonly called the Swedish mutation and shown to overproduce A beta (Citron et.al., 1992, Nature 360:672-674), as described in USPN 5,604,102.

The cells are incubated in the presence/absence of the inhibitory compound (diluted in DMSO) at the desired concentration, generally up to 10 micrograms/ml. At the end of the treatment period, conditioned media is analyzed for beta-secretase activity, for example, by analysis of cleavage fragments. A beta can be analyzed by immunoassay, using specific detection antibodies. The enzymatic activity is 15 measured in the presence and absence of the compound inhibitors to demonstrate specific inhibition of betasecretase mediated cleavage of APP substrate.

#### 20 Example F

25

30

10

## Inhibition of Beta-Secretase in Animal Models of AD

Various animal models can be used to screen for inhibition of beta-secretase activity. Examples of animal models useful in the invention include, but are not limited to, mouse, guinea pig, dog, and the like. The animals used can be wild type, transgenic, or knockout models. In addition, mammalian models can express mutations in APP, such as APP695-SW and the like described herein. Examples of transgenic non-human mammalian models are described in U.S. Patent Nos. 5,604,102, 5,912,410 and 5,811,633.

PDAPP mice, prepared as described in Games et.al., 1995, Nature 373:523-527 are useful to analyze in vivo suppression of A beta release in the presence of putative inhibitory

compounds. As described in USPN 6,191,166, 4 month old PDAPP mice are administered compound formulated in vehicle, such as corn oil. The mice are dosed with compound (1-30 mg/ml; preferably 1-10 mg/ml). After time, e.g., 3-10 hours, the animals are sacrificed, and brains removed for analysis.

Transgenic animals are administered an amount of the compound inhibitor preferably formulated in a carrier suitable for the chosen mode of administration. Control animals are untreated, treated with vehicle, or treated with an inactive compound. Administration can be acute, i.e., single dose or multiple doses in one day, or can be chronic, i.e., dosing is repeated daily for a period of days. Beginning at time 0, brain tissue or cerebral fluid is obtained from selected animals and analyzed for the presence of APP cleavage peptides, including A beta, for example, by immunoassay using specific antibodies for A beta detection. At the end of the test period, animals are sacrificed and brain tissue or cerebral fluid is analyzed for the presence of A beta and/or beta-amyloid plaques. The tissue is also analyzed for necrosis.

Animals administered the compound inhibitors of the invention are expected to demonstrate reduced A beta in brain tissues or cerebral fluids and reduced beta amyloid plaques in brain tissue, as compared with non-treated controls.

25

30

20

10

15

#### Example G

### Inhibition of A beta production in human patients

Patients suffering from Alzheimer's Disease (AD) demonstrate an increased amount of A beta in the brain. AD patients are administered an amount of the compound inhibitor formulated in a carrier suitable for the chosen mode of administration. Administration is repeated daily for the duration of the test period. Beginning on day 0, cognitive and memory tests are performed, for example, once per month.

patients administered the compound inhibitors are expected to demonstrate slowing or stabilization of disease progression as analyzed by changes in one or more of the following disease parameters: A beta present in CSF or plasma; brain or hippocampal volume; A beta deposits in the brain; amyloid plaque in the brain; and scores for cognitive and memory function, as compared with control, non-treated patients.

#### 10 Example H

15

20

25

30

### Prevention of A beta production in patients at risk for AD

Patients predisposed or at risk for developing AD are identified either by recognition of a familial inheritance pattern, for example, presence of the Swedish Mutation, and/or by monitoring diagnostic parameters. Patients identified as predisposed or at risk for developing AD are administered an amount of the compound inhibitor preferably formulated in a carrier suitable for the chosen mode of administration.

Administration is repeated daily for the duration of the test period. Beginning on day 0, cognitive and memory tests are performed, for example, once per month.

Patients administered the compound inhibitors are expected to demonstrate slowing or stabilization of disease progression as analyzed by changes in one or more of the following disease parameters: A beta present in CSF or plasma; brain or hippocampal volume; amyloid plaque in the brain; and scores for cognitive and memory function, as compared with control, non-treated patients.

While this invention has been described with respect to various specific examples and embodiments, it is to be understood that the invention is not limited thereby and should only be construed by interpretation of the scope of the appended claims.

The following compounds were prepared using the above described methodology.

			Mass
Example	Structure	Compound Name(s)	Spec +H <sup>+</sup>
3552	F-W-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-	N'-[(1S,2S)-3- (benzylamino)-1-(3,5- difluorobenzyl)-2- hydroxypropyl]-5- methyl-N,N- dipropylisophthalamid e	552.2
3553	O HO H	N'-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-ethynyl-N,N-dipropylisophthalamide	590.3
3554		N'-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-({3-[(1E)-prop-1-en-1-yl]benzyl}amino)propyl]-5-methyl-N,N-dipropylisophthalamide	592.3
3555	ZH ZH ZH ZH ZH ZH ZH ZH ZH ZH ZH ZH ZH Z	N'-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-isopropylbenzyl)amino-]propyl}-5-(1,3-oxazol-2-yl)-N,N-dipropylisophthalamide	647.2
3556		methyl (3-{[((2R,3S)-4-(3,5-difluorophenyl)-3-{[3-[(dipropylamino)carbonyl]-5-(1,3-oxazol-2-yl)benzoyl]amino}-2-hydroxybutyl)amino]methyl}phenyl)methylcarbamate	692.2

N'-[(1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-(3-[(methylsulfonyl) amino olbenzyl) amino) propyl   1-5-(1,3-0xazol-2-y1)-N,N-dipropylbenzyl) amino   propyl-N,N-dipropylpyridine-3,5-dicarboxamide   N'-((1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl) amino] -2-hydroxy-propyl-N,N-dipropylpyridine-3,5-dicarboxamide   N'-((1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl) amino] -2-hydroxy-propyl-N,N-dipropylpyridine-3,5-dicarboxamide   N'-((1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl) amino] -2-hydroxy-propyl-5-ethynyl-N,N-dipropylisophthalamid   N'-((1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethynyl-N,N-dipropylisophthalamid   N'-((1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-ethynyl-N,N-dipropylisophthalamid   N'-((1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-ethynyl-N,N-dipropylisophthalamid   N'-((1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-ethynyl-N,N-dipropylisophthalamid   N'-((1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-ethynyl-N,N-dipropylisophthalamid   N'-((1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-ethynyl-N,N-dipropylisophthalamid   N'-((1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-ethynyl-N,N-dipropylisophthalamid   N'-((1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-ethynyl-N,N-dipropylisophthalamid   N'-((1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-ethynyl-N,N-dipropylisophthalamid   N'-((1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-ethynyl-N,N-dipropylisophthalamid   N'-((1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-ethynyl-N,N-dipropylisophthalamid   N'-((1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-ethynyl-N,N-dipropylisophthalamid   N'-((1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-ethynyl-N,N-dipropylisophthalamid   N'-((1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-ethynyl-N,N-dipropylisophthalamid   N'-((1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-ethynyl-N,N-dipropylisophthalamid   N'-((1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-ethynyl-N,N-dipropylisophthalamid   N'-((1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-ethynyl-N,N-dipropylisophthalamid   N'-((1s,2R)-1-(3,5-d		<u> </u>		
difluorobenzy1)-2-hydroxy-3-[(3-isopropylbenzy1)amino]propyl-N,N-dipropylpyridine-3,5-dicarboxamide   MS 584 (M+H).	3557		difluorobenzyl)-2- hydroxy-3-({3- [(methylsulfonyl)amin o]benzyl}amino)propyl ]-5-(1,3-oxazol-2- yl)-N,N- dipropylisophthalamid e	698.2
difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-N,N- dipropylpyridine-3,5- dicarboxamide 1-oxide  N'-((1s,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]- 2-hydroxypropyl}-5- ethynylbenzyl)amino]- 2-hydroxypropyl}-5- ethynyl-N,N- dipropylisophthalamid e  N^4-{(1s,2R)-1-(3,5- difluorobenzyl)-2- hydroxy-3-[(3-  MS 595 (M+H).	3558		<pre>difluorobenzy1)-2- hydroxy-3-[(3- isopropylbenzy1)amino ]propy1}-N,N- dipropylpyridine-3,5-</pre>	1
difluorobenzyl)-3- [(3- ethynylbenzyl)amino]- 2-hydroxypropyl}-5- ethynyl-N,N- dipropylisophthalamid e  N <sup>4</sup> -{(1s,2r)-1-(3,5- difluorobenzyl)-2- hydroxy-3-[(3-  MS 595 (M+H).			<pre>difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-N,N- dipropylpyridine-3,5-</pre>	
$N^4 - \{ (1S, 2R) - 1 - (3, 5 - MS 595) \}$ $0  0  F$ $N^4 - \{ (1S, 2R) - 1 - (3, 5 - MS 595) \}$ 0  0  0  MS 595 0  0  MS 595 0  0  MS 595 0  0  MS 595	3560		difluorobenzyl)-3- [(3- ethynylbenzyl)amino]- 2-hydroxypropyl}-5- ethynyl-N,N- dipropylisophthalamid	1
]propyl}-6-methyl- N <sup>2</sup> ,N <sup>2</sup> - dipropylpyridine-2,4- dicarboxamide		F OH I	difluorobenzyl)-2- hydroxy-3-[(3- isopropylbenzyl)amino ]propyl}-6-methyl- N <sup>2</sup> ,N <sup>2</sup> - dipropylpyridine-2,4-	
N'-[(1s,2r)-3-{[(2-tert-butylpyrimidin-4-y1)methyl]amino}-1-(3,5-difluorobenzyl)-2-hydroxypropyl]-5-methyl-n,n-dipropylisophthalamide	3562	~\n'\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	tert-butylpyrimidin- 4-y1)methyl]amino}-1- (3,5-difluorobenzy1)- 2-hydroxypropyl]-5- methyl-N,N- dipropylisophthalamid	610

		<del></del>	
3563	P OH N N	N'-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[(2-ethylpyrimidin-4-yl)methyl]amino}-2-hydroxypropyl)-5-methyl-N,N-dipropylisophthalamide	583 605 (M+Na)
3564	NHH NH NH NH NH NH NH NH NH NH NH NH NH	N'-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(1S)-1-[(isobutylamino)carbonyl]-3-(methylsulfonyl)propyl]amino}propyl)-5-methyl-N,N-dipropylisophthalamide	681.3
3565	NHH ONH HOH NH OH	N'-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-hydroxy-1-phenylpropyl)amino]propyl}-5-methyl-N,N-dipropylisophthalamide	596.3
3566	O NH H OH NH F	N'-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-ylamino)propyl]-5-methyl-N,N-dipropylisophthalamide	606.3

3567	O NHH H OH NH	N'-((1S,2S)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{((1R)-6-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl]amino}propyl)-5-methyl-N,N-dipropylisophthalamide	Mass spec (CI) MH+- OMe- tetrali ne 462.2
3568	N NH H H OH NH F	N'-((1S,2R)-1-(3,5- difluorobenzyl)-2- hydroxy-3-{[(1R)-6- methoxy-1,2,3,4- tetrahydronaphthalen- 1-yl]amino}propyl)-5- methyl-N,N- dipropylisophthalamid e	Mass spec (CI) MH+- OMe- tetrali ne 462.2
3569	OH H Z H	N'-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(1S)-2-oxo-1-methyl-2-(methylamino)ethyl]amino}propyl)-5-methyl-N,N-dipropylisophthalamide	547.4
3570	P P P P P P P P P P P P P P P P P P P	N'-[(1S,2R)-3-{[(1S)-1-benzy1-2-oxo-2-(methylamino)ethyl]amino}-1-(3,5-difluorobenzy1)-2-hydroxypropyl]-5-methyl-N,N-dipropylisophthalamide	
3571		N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N²-{oxo[3-(trifluoromethyl)phenyl]methyl}glycinamide	

	HO HO F	2-{[2-({(1S,2R)-1- (3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}amino)- 2-oxoethyl]thio}-N- (5-methylisoxazol-3- yl)acetamide	
3572	, o		
	H OH H N NH NH NH	N'-((1S,2R)-1-(3,5- difluorobenzyl)-2- hydroxy-3-{[(1S)-1- [oxo(methylamino)meth yl]-3- (methylthio)propyl]am ino}propyl)-5-methyl- N,N- dipropylisophthalamid	
3573		e	
3574	H OH H OH N ON NH F	N'-((1S,2R)-1-(3,5- difluorobenzy1)-2- hydroxy-3-{[(1R)-1- (hydroxymethy1)-2- oxo-2- (methylamino)ethyl]am ino}propy1)-5-methyl- N,N- dipropylisophthalamid e	
	H OH H N O NH <sub>2</sub>	N'-[(1S,2R)-3-({(1S)- 1-[amino(oxo)methy1]- 3-methylbutyl}amino)- 1-(3,5- difluorobenzyl)-2- hydroxypropyl]-5- methyl-N,N- dipropylisophthalamid	
3575		e	
3576	H OH H O NH <sub>2</sub>	N'-[(1S,2R)-3-[(2- amino-2-oxo-1- methylethyl)amino]-1- (3,5-difluorobenzyl)- 2-hydroxypropyl]-5- methyl-N,N- dipropylisophthalamid	

	,		
3577	F CH CH CH CH CH CH CH CH CH CH CH CH CH	tert-butyl (1S,2R)-1- (3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropylcarbamat e	
3578	as drawn	tert-butyl (1S,2R)-3- (cyclopropylamino)-1- (3,5-difluorobenzyl)- 2- hydroxypropylcarbamat e	
3579	as drawn	tert-butyl (1S,2R)-3- [(cyclopropylmethyl)a mino]-1-(3,5- difluorobenzyl)-2- hydroxypropylcarbamat e	
3580	O O OH H O HN NH	tert-butyl ((1S,2R)- 1-(3,5- difluorobenzyl)-2- hydroxy-3-{[2-oxo-2- (isobutylamino)-1- methylethyl]amino}pro pyl)carbamate	416.1
3581	\$\$	benzyl (1S,2R)-1- benzyl-3-[(3- ethylbenzyl)amino]-2- hydroxypropylcarbamat e	
3582	H <sub>2</sub> N HCI	(2R,3S)-3-amino-4- (3,5-difluorophenyl)- 1-{[1-(3- ethynylphenyl)cyclopr opyl]amino}butan-2-ol hydrochloride	357.2
3583	P H N N N N N N N N N N N N N N N N N N	tert-butyl [(1S,2R)-3-{[(1S)-2-(benzylamino)-2-oxo-1-methylethyl]amino}-1-(3,5-difluorobenzyl)-2-hydroxypropyl]carbamate	478.1

H <sub>2</sub> N	CF <sub>3</sub> COOH CF <sub>3</sub> COOH	N <sup>2</sup> -[(2R,3S)-3-amino- 4-(3,5- difluorophenyl)-2- hydroxybutyl]-N <sup>1</sup> - benzyl-L-alaninamide bis(trifluoroacetate) (salt)	
3584	·		
3584	CF₃COOH		1
	F	<del>                                     </del>	
3585	S H OH H	tert-butyl ((1S,2R)- 1-(3,5- difluorobenzyl)-2- hydroxy-3-{[1-(2- isobutyl-1,3-thiazol- 5- yl)cyclopropyl]amino) propyl)carbamate	496.2
H <sub>2</sub> N	F N OH H	(2R,3S)-3-amino-4- (3,5-difluorophenyl)- 1-{[1-(2-isobutyl- 1,3-thiazol-5- yl)cyclopropyl]amino} butan-2-ol bis(trifluoroacetate) (salt)	·
3506	CF₃COOH		
3586	CF <sub>3</sub> COOH  F ON N ON H OH H ON N	tert-butyl ((1S,2R)- 1-(3,5- difluorobenzyl)-2- hydroxy-3-{[1-(3- isobutylisoxazol-5- yl)cyclopropyl]amino} propyl)carbamate	480.2
H <sub>2</sub> N	F OH H OF <sub>3</sub> COOH	(2R,3S)-3-amino-4- (3,5-difluorophenyl)- 1-{[1-(3- isobutylisoxazol-5- yl)cyclopropyl]amino} butan-2-ol bis(trifluoroacetate) (salt)	

			125 2
3589	H OH H N	tert-butyl ((1S,2R)- 1-(3,5- difluorobenzyl)-3- {[(2-ethylpyrimidin- 4-yl)methyl]amino}-2- hydroxypropyl)carbama te	437.3
3590	OH H N H <sub>2</sub> N CF <sub>3</sub> COOH CF <sub>3</sub> COOH	(2R,3S)-3-amino-4- (3,5-difluorophenyl)- 1-{[(2- ethylpyrimidin-4- yl)methyl]amino}butan -2-ol bis(trifluoroacetate) (salt)	
3591	NH H OH HNboc	tert-butyl {(1S,2R)- 1-(3,5- difluorobenzyl)-2- hydroxy-3-[(7- methoxy-1,2,3,4- tetrahydronaphthalen- 1- yl)amino]propyl}carba mate	477.5
3592	NH OH H COD F	tert-butyl [(1S,2R)- 1-(3,5- difluorobenzyl)-2- hydroxy-3-(6,7,8,9- tetrahydro-5H- benzo[7]annulen-5- ylamino)propyl]carbam ate	461.2
3593	OH NH OH	tert-butyl {(1S,2R)- 1-(3,5- difluorobenzyl)-2- hydroxy-3-[(3 hydroxy-1- phenylpropyl)amino]pr opyl}carbamate	451.2
3594	N O H H NH boc	tert-butyl ((1S,2R)- 1-(3,5- difluorobenzyl)-2- hydroxy-3-{[(1S)-1- [oxo(isobutylamino)me thyl]-3- (methylthio)propyl]am ino)propyl)carbamate	504.3

	\	tert-butyl ((1S,2R)-	536.2
		1-(3,5-	
	\	difluorobenzyl)-2-	
	NH	hydroxy-3-{[(1S)-1-	-
9	U≕\ ,,,, oH	[(isobutylamino)carbo	
	→NH ĜŢ	ny1]-3-	
	O. NH	(methylsulfonyl)propy	
	SO E H boc	l]amino}propyl)carbam	
		ate	
3595	<u> </u>		
3333	F	took butsel (/10 2D)	400 1
	O F F	tert-butyl {(1S,2R)- 1-(3,5-	499.1
		difluorobenzyl)-3-	
}		[(2,2-dioxido-3,4-	
	Y NH > H ]	dihydro-1,2-	
	OH)	benzoxathiin-4-	
	HNHboc	yl)amino]-2-	
	141,000	hydroxypropyl}carbama	
3596		te	
	0.0	tert-butyl {(1S,2R)-	498.1
	F F	1-(3,5-	
	HN-S	difluorobenzyl)-3-	
		[(2,2-dioxido-3,4-	
}	NH XH	dihydro-1H-2,1-	
	OH	benzothiazin-4-	
	H NHboc	yl)amino]-2-	ĺ
}		hydroxypropyl}carbama	
3597		te	
	Ę	tert-butyl ((1S,2R)-	461.3
		1-(3,5-	
	Ĺ \L_F	difluorobenzyl)-3-	
	/ Q	{[1-(3-	
	TONN NICON	ethylphenyl)cycloprop	
	' H OH H L J	yl]amino}-2-	
3500		hydroxypropyl)carbama	
3598		te	
	· · F	tert-butyl ((1S,2R)	457.2
		1-(3,5-	
	∫ Je⁄F	difluorobenzyl)-3-	
1		{[1-(3-	
	TONN N	ethynylphenyl)cyclopr	
}	H OHH L	opyl]amino}-2-	
3599	<b>\</b>	hydroxypropyl)carbama te	
3333	F	tert-butyl ((1S,2R)-	447.2
	<u>'</u> _	1-(3,5-	##1.4
		difluorobenzyl)-2-	
	) Jef	hydroxy-3-{[1-(3-	
		methylphenyl)cyclopro	
		pyl]amino)propyl)carb	
3600	Г Н ОНН 📗	amate	
12000			

	<u></u>		
	F	tert-butyl ((1S,2R)- 1-(3,5- difluorobenzyl)-2- hydroxy-3-{[1-(3-	558.4
3601	H OH H	<pre>iodophenyl)cyclopropy l]amino}propyl)carbam ate</pre>	
3602	F H N N N N N N N N N N N N N N N N N N	tert-butyl [(1S,2R)-3-{[3- (cyclopropylamino)ben zyl]amino}-1-(3,5- difluorobenzyl)-2- hydroxypropyl]carbama	462.2
3602	F O OMe	methyl 3-({[(2R,3S)-3-[(tert-butoxycarbonyl)amino]-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}me	465.1
3603	ÓН Н 🤍	thyl)benzoate	
3604	BocHN OH H	methyl [3-({[(2R,3S)-3-[(tert-butoxycarbonyl)amino]-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}methyl)phenyl]carbamate	480.1
3004	F	methyl [3-({[(2R,3S)-	494.1
	BocHN OH H	3-[(tert-butoxycarbonyl)amino] -4-(3,5-difluorophenyl)-2-hydroxybutyl]amino)methyl)phenyl]methylcar	474.1
3605	·	bamate	
	BocHN OH H	tert-butyl [(1S,2R)- 1-(3,5- difluorobenzyl)-3- ({3- [(dimethylamino)sulfonyl]benzyl}amino)-2- hydroxypropyl]carbama	514.1
3606		te	
3607	BocHN OH H	tert-butyl [(1s,2R)- 1-(3,5- difluorobenzyl)-2- hydroxy-3-({3- [(methylsulfonyl)amin o]benzyl}amino)propyl ]carbamate	500.1

			400 4
		tert-butyl [(1S,2R)-	432.1
		3-[(3-	
	<u> </u>	cyanobenzyl)amino]-1-	
	F	(3,5-difluorobenzyl)-	
	BocHN	2-	
	OH H	hydroxypropyl]carbama	
3608	011	te	
	F	3-({[(2R,3S)-3-	494.1
		[(tert-	
		butoxycarbonyl)amino]	
	F	-4-(3,5-	
		difluorophenyl)-2-	
	BocHN Y N Y Y	hydroxybutyl]amino}me	
	OH '' 💙 0	thyl)phenyl	
3609		dimethylcarbamate	
	F	tert-butyl [(2R,3S)-	612.3
1		4-(3,5-	014.3
		difluorophenyl)-3-	
		({3-	
	N Y N Y N Y N	[(dipropylamino)carbo	
	H ÖH Boc	nyl]-5-	
	' '	• =	
		methylbenzoyl}amino)-	
		2-hydroxybutyl][3-	
2610		(ethylthio)benzyl]car	
3610		bamate	
İ	ŌH H	tert-butyl {(1S,2R)-	433.2
	BocHN N.,	1-(3,5-	<u> </u>
		difluorobenzyl)-3-	
		[(1R)-2,3-dihydro-1H-	1
	F-(-)	inden-1-ylamino]-2-	
		hydroxypropyl}carbama	
3611	F	te	İ
	OH H	tert-butyl {(1S,2R)-	433.2
		1-(3,5-	#33.4
	BocHN	difluorobenzyl)-3-	1
		[(1S)-2,3-dihydro-1H-	
		inden-1-ylamino]-2-	1
	F-	, –	1
	· · <u>                               </u>	hydroxypropyl}carbama	1
3612	F	te	
***	OH	tert-butyl ((1S,2R)-	449.2
	BocHN N,	1-(3,5-	}
		difluorobenzyl)-2-	1
	ラー- 人)	hydroxy-3-{[(1S,2R)-	
		2-hydroxy-2,3-	
	F—( )	dihydro-1H-inden-1-	
1		yl]amino)propyl)carba	
3613	F	mate	
	L		1

			440 4
	BocHN OH	tert-butyl ((1S,2R)- 1-(3,5- difluorobenzyl)-2- hydroxy-3-{[(1R,2S)-	449.4
	F—	2-hydroxy-2,3- dihydro-1H-inden-1- yl]amino}propyl)carba	
3614	r .	mate	
3615	BocHN N, NH	tert-butyl ((1S,2R)- 1-(3,5- difluorobenzyl)-2- hydroxy-3-{[(3S)-2- oxoazepan-3- yl]amino}propyl)carba mate	428.2
3616	BocHN NH NH	tert-butyl ((1S,2R)- 1-(3,5- difluorobenzyl)-2- hydroxy-3-{[(3R)-2- oxoazepan-3- yl]amino}propyl)carba mate	428.2
	BocHN N O	tert-butyl [(1S,2R)- 1-(3,5- difluorobenzyl)-3- ({[(5S)-3-ethyl-2- oxo-1,3-oxazolidin-5- yl]methyl}amino)-2- hydroxypropyl]carbama te	444.2
3617	F		
	BocHN N N O	tert-butyl [(1S,2R)- 1-(3,5- difluorobenzyl)-3- ({[(5R)-3-ethyl-2- oxo-1,3-oxazolidin-5- yl]methyl}amino)-2- hydroxypropyl]carbama te	444.2
3618	F		
	BocHN PN N	tert-butyl ((1S,2R)- 1-(3,5- difluorobenzyl)-3- {[1-(3-ethylphenyl)- 1-methylethyl]amino}- 2-	475.2
	F	hydroxypropyl)carbama	
3619	F	te	<u> </u>

2600	BocHN EN N	tert-butyl {(1S,2R)- 1-(3,5- difluorobenzyl)-2- hydroxy-3-[(2- naphthylmethyl)amino] propyl}carbamate	463.3
3620	BocHN N N N H	tert-butyl ((1S,2R)- 1-(3,5- difluorobenzyl)-2- hydroxy-3-{[2-oxo-2- (isobutylamino)-1,1- dimethylethyl]amino}p ropyl)carbamate	458.2
3622	OH H BocHN N O	tert-butyl [(1S,2R)- 3-[(benzyloxy)amino]- 1-(3,5- difluorobenzyl)-2- hydroxypropyl]carbama te	423.1
3623	YOUNG OH OH OH OF S	tert-butyl 4- [({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}amino)carbonyl]piperidine-1-carboxylatetrifluoroacetate	
	F OH F	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-4- fluoro-1-naphthamide	-
3624	OH HN O	N-[(1S,2R)-1-benzyl-3-(2-butyryl-1-ethylhydrazino)-2-hydroxypropyl]-2-(3-methylisoxazol-5-yl)acetamide	
3625			

		N'-{(1S,2R)-1-(3,5-	
		difluorobenzyl)-3-	
		[(3-	
·		ethylbenzyl)amino]-2-	
	1, , , , ,	hydroxypropyl}-N-	
		hexyl-N,5-	
3626		dimethylisophthalamid	
3020		e	
	\ \ \ H.OHH \	N'-{(1S,2R)-1-(3,5-	
		difluorobenzyl)-2-	
	I H H	hydroxy-3-[(3-	
		methoxybenzoyl)amino]	
		propyl}-5-methyl-N,N-	
3627	F	dipropylisophthalamid	
3027		e N (/1c 2p) 1 /2 5	
	NOH	N-{(1S,2R)-1-(3,5-	
		difluorobenzyl)-3-	
1		ethylbenzyl)amino]-2-	
	CH,	hydroxypropyl}-1-	
		methyl-1H-imidazole-	
	ļ.	2-carboxamide	
3628	single enantiomer		
	^ 1/	$N^{1}-\{(1S,2R)-1-(3,5-$	
	OH OH	difluorobenzyl)-3-	
		[(3-	
	°°°	ethylbenzyl)amino]-2-	
1		hydroxypropyl}-3,3-	
		dimethyl-N <sup>2</sup> , N <sup>2</sup> -	
	single diastereomer	dipropylcyclopropane-	
3629		1,2-dicarboxamide	
	XI.	tert-butyl 2-	
	Y H	[({(1S,2R)-1-(3,5-	
	O N N OH	difluorobenzyl)-3-	
		[(3-	
		ethylbenzyl)amino]-2-	
	- Y-	hydroxypropyl}amino)c	
		arbonyl]-1-methyl-1H-	
·	F	imidazol-4-	
3630	single enantiomer	ylcarbamate	
3030		$N^5 - \{ (1S, 2R) - 1 - (3, 5 - 1) \}$	
	F I	difluorobenzy1)-3-	
		[(3-	
	````````````````	ethylbenzyl)amino]-2-	
		hydroxypropyl}-2,2-	
	/ HH OH H	dimethyl-N <sup>1</sup> , N <sup>1</sup> -	i
		dipropylpentanediamid	
3631		e e	
JUJ1		<u> </u>	

r			
ŀ		N-{(1S,2R)-1-benzyl-	
	- 0 CH	2-hydroxy-3-[(2-	
	HO CH <sub>3</sub>	morpholin-4-	
		ylethyl)amino]propyl}	
	CH3 OH CH3 OH	-2-(4-chlorophenoxy)-	ļ
	CI	2-methylpropanamide	
	, Ň,	compound with methyl	
3632		hydroperoxide (1:2)	
3032		N-[(1S,2R)-3-	
		(benzylamino)-1-(3,5-	
	OH Y	difluorobenzyl)-2-	
	HN, 🙏 🕠	hydroxypropyl]-4-	
	· · · · · · · · · · · · · · · · · · ·	fluoro-1-naphthamide	
	HN O		
		,	
2622	Ĭ		
3633	F		
	CH <sub>3</sub>	3-	
	CH <sub>3</sub>	[(dipropylamino)sulfo	
	U Uris	nyl]-N-[(1S,2R)-2-	
	o 🚫	hydroxy-3-	
İ	O L L VOH	(isopentylamino)-1-	
	\S; \N \\'	(4-	
	H W	isopropylbenzyl)propy	
	ĊH₃ CH₃ NH	1]propanamide	
		_,p	
	<u> </u>		
3634	CH <sub>3</sub> CH <sub>3</sub>		
	СН <sub>28</sub>	3-	
	Ĭ	[(dipropylamino)sulfo	
		nyl]-N-[(1S,2R)-2-	
		hydroxy-3-	
	O CH <sub>3</sub>	(isopentylamino)-1-	
	HO. A. L.	(3-	
	I Y N Y S.N.Z	methoxybenzyl)propyl]	
	H $O'$ N	propanamide	
	HN CH <sub>3</sub>	<b>P</b>	
	/		
3635	CH₃ CH₃		
13033	CH <sub>3</sub>	N <sup>1</sup> -[(1S,2R)-1-(3,5-	
	1		
	, J	dichlorobenzyl)-2-	
	ĊI Ņ	hydroxy-3-	,
	CH <sub>3</sub>	(isopentylamino)propy	
		1]-N <sup>5</sup> , N <sup>5</sup> -	
1		dipropylpentanediamid	
1		е	,
	CH <sub>3</sub> HO NO		
	CH <sub>3</sub> ···		
		1	ı
3636	H		

		$N^1 - [(1S, 2R) - 3 -$	- [
		(benzylamino)-2-	-
1	Ϋ́	hydroxy-1-(4-	
	1101	methoxybenzyl)propyl]	
	HŅ	$-5$ -methyl- $N^3$ , $N^3$ -	
	OH	dipropylisophthalamid	
<u> </u>		e	
	CH <sub>3</sub>		1
	H		- 1
			ļ
			- 1
			ļ.
2627	ĊH <sub>3</sub> CH <sub>3</sub> Ö <sub>CH<sub>3</sub></sub>		
3637	On <sub>3</sub>	N <sup>1</sup> -[(1S,2R)-3-	$\dashv$
	( ) au		
	ÇH₃	(benzylamino)-2-	
	NH O	hydroxy-1-(4-	l
		methoxybenzyl)propyl]	
ŀ	HO! (	$-N^3, N^3-$	
	"\/	dipropylbenzene-	
	HN	1,3,5-tricarboxamide	ŀ
	CH <sub>3</sub> _N		
	1		
2620	NH <sub>2</sub>		Ì
3638	CH₃′ Ő	22 (/10 07) 0	
:	CH₃	$N^1 - \{ (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - 2 - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) - (1S, 2R) -$	
	ρ	hydroxy-1-(4-	
		isopropylbenzyl)-3-	
		[(3-	
		methoxybenzyl)amino]p	
		ropyl}-N <sup>3</sup> ,N <sup>3</sup> -	i
	HN OH	dipropylbenzene-	Į
		1,3,5-tricarboxamide	
	\ <b>&gt;</b> '''\		
	HN		
	<b>/=</b> 0(′)	- · · - · ·	
			Ì
	→ CH <sub>3</sub>		
	N CH₃		
	\NH <sub>2</sub>		
3639	CH <sub>3</sub> CH <sub>3</sub> O		
	CH III	3-	]
	U _ Q CH₃	[(dipropylamino)sulfo	
	HO NO S	nyl]-N-((1S)-1-{(1R)-	
	I O O O O O O	1-hydroxy-2-[(3-	ļ
	CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	methoxybenzyl)amino]e	
	"	thy1}but-3-	
3640		ynyl)propanamide	

		·	
		N <sup>1</sup> -[(1S,2R)-1-(2- furylmethyl)-2- hydroxy-3-	
	HO N CH CH	(isopentylamino)propy	
	HN CH <sub>3</sub> CH <sub>3</sub>	dipropylpentanediamid	
		е	
3641	CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	N <sup>1</sup> -[(1S,2R)-1-(2-	
	CH <sub>3</sub>	furylmethyl)-2- hydroxy-3-	
	NH	(isopentylamino)propy	
	O HOH	1]-5-methyl-N <sup>3</sup> ,N <sup>3</sup> - dipropylisophthalamid	
	CH <sub>3</sub> N,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	е	
3642	CH <sub>3</sub> CH <sub>3</sub>		
	ÇH₃ ⇔ O	N <sup>1</sup> -[(1s,2R)-2- hydroxy-3-[(3-	
		methoxybenzyl)amino]-	
	HN	naphthylmethyl)propyl	;
	OH	]-5-methyl-N³,N³- dipropylisophthalamid	
	CH <sub>3</sub> N	е	
	NO		
3643	CH <sub>3</sub> CH <sub>3</sub>		
	CH₃ O	N <sup>1</sup> -((1S)-1-{(1R)-1- hydroxy-2-[(3-	
-		methoxybenzyl)amino]e thyl}-3-methylbutyl)-	
		N <sup>3</sup> ,N <sup>3</sup> -dipropylbenzene- 1,3,5-tricarboxamide	
	HN OHCH <sub>3</sub> CH <sub>3</sub>		
	>111/		
	HN O		
3644	CH <sub>3</sub> CH <sub>3</sub> O		

	CH₃	$N^{1}-[(1S,2R)-1-(2-$	.
	$\rightarrow$	furylmethyl)-2-	
1	CH <sub>3</sub> \—NH OH ⟨ ¬	hydroxy-3-	
	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	(isopentylamino)propy	•
	>.11/	$1]-N^3, N^3-$	
	HN	dipropylbenzene-	
	·	1,3,5-tricarboxamide	
		1,3,5 (11001200101111100	Ì
1			
' i			ļ
1	NH <sub>2</sub>		
3645	`CH <sub>3</sub> С'H <sub>3</sub> О'		
	CH <sub>3</sub>	$N^{1}$ -[(1S,2R)-2-	
	Ò.	hydroxy-3-[(3-	
	·(	methoxybenzyl)amino]-	
	( )	1-(1-	
		naphthylmethyl)propyl	
	\	]-N <sup>3</sup> , N <sup>3</sup> -	ļ
	UN OH -	dipropylbenzene-	
	HN OH	1,3,5-tricarboxamide	
		1,3,3-cricarboxamide	
	<i>)</i> .:!/		
	HN		
	<b>=</b> 0		
	Q /≕< .		:
	<b>&gt;</b>		
	√Ni		
	⟨		
3646	`CH₃ ĆH₃ Ő		
3040		N-{(1S,2R)-1-benzyl-	
		2-hydroxy-3-[(3-	
	ÇH₃	methoxybenzyl)amino]p	
	HO. J. J. A.P.	ropy1}-3-{[(2-	
l i	T H os N	methoxyethyl)(propyl)	
	HCI NH	amino]sulfonyl}propan	
!	O_CH <sub>3</sub>	amide hydrochloride	
	0		[
3647	CH <sub>3</sub>	(46.6.00)	
		N-{(1S,2R)-1-benzyl-	1
		2-hydroxy-3-[(3-	
		methoxybenzyl)amino]p	
	O. L. VOH	ropy1}-3-(4,5-	
		dimethyl-2-furoyl)-5-	
		methylbenzamide	
	CH <sub>3</sub> CH <sub>3</sub>		
	CH <sub>3</sub> CH <sub>3</sub>		
Ì			
	CH₃		
3648			L
	<u></u>		

3649	CH <sub>3</sub> OH CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> F	3- [(dipropylamino) sulfo nyl]-N-[(1S,2R)-2- hydroxy-3- (isopentylamino)-1- (4- methylbenzyl)propyl]p ropanamide  1 3-	
	HO HO CH <sub>3</sub>	[(dipropylamino)sulfo nyl]-N-{(1S,2R)-1-(3- fluoro-5- hydroxybenzyl)-2- hydroxy-3-[(3- methoxybenzyl)amino]p ropyl}propanamide	
3650	Ó <sub>`CH₃</sub>		
	HN OH F	N-{(1S,2R)-1-(3,5-difluorobenzy1)-2-hydroxy-3-[(3-iodobenzy1)amino]propy1}-1,3-benzothiazole-2-carboxamide	
3651	F		
	FHO CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	N-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-iodobenzyl)amino]propyl}-5-(2,5-dimethylphenoxy)-2,2-dimethylpentanamide	
		-	
3652			
3653	F HO N HO CH <sub>3</sub>	N-[(1s,2r)-3-amino-1- (3,5-difluorobenzyl)- 2-hydroxypropyl]-3- (isopentylsulfonyl)pr opanamide trifluoroacetate	
3654	CH <sub>3</sub> OH HN OH CH <sub>3</sub> OH OH	N-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-2-hydroxy-5-methylbenzamide	471.4
1			

		<u></u>
		4-amino-N-{(1S,2R)-1-
		(3,5-difluorobenzyl)-
	F	3-[(3-
	HO N N N N N N N N N N N N N N N N N N N	ethylbenzyl)amino]-2-
	NH F Ton F Ton	hydroxypropyl}butanam
		ide
		bis(trifluoroacetate)
3655	l [	Dis(critituoloacetate)
3033	CH <sub>3</sub>	
1	F I	N-{(1s,2R)-1-(3,5-
		difluorobenzyl)-3-
		[(3-
	N O F	ethylbenzyl)amino]-2-
	S, J, J, OH	hydroxypropyl}-3-
	ן או אף ווי	[(pyridin-4-
	H/	ylmethyl)thio]benzami
	HN'	de
1	CH3 Y	
2656	J	
3656		
1	N,	N-{(1S,2R)-1-(3,5-
	0, 1, 1, 0	difluorobenzyl)-3-
1	Y 💙 N	[(3-
	FNH	ethylbenzyl)amino]-2-
		hydroxypropyl}-2,1,3-
*	HO N CH <sub>3</sub>	benzoxadiazole-5-
3657	F	carboxamide
	F	N-{(1S,2R)-1-(3,5-
	]	difluorobenzyl)-3-
		[(3-
		ethylbenzyl)amino]-2-
	F ~ _ 0	hydroxypropyl}-4-
	HO I	methyl-1,2,3-
•	N S	
	H   ,N	thiadiazole-5-
	NH CH <sub>3</sub> N	carboxamide
	\_ ~ ~	
1	I I	
3658	· · · · · · · CH <sub>a</sub> - · · ·	
3030	U13	N (/10 2p) 1 /2 5
		N-{(1S, 2R) -1-(3,5-
1	N=/	difluorobenzyl)-3-
	,,,,	[(3-
	) <sup>S</sup>	ethylbenzyl)amino]-2-
		hydroxypropyl}-5-
	<i> </i>	[(pyridin-2-
		ylthio)methyl]-2-
	CH <sub>3</sub>	furamide
	HN F	
	H Y Y	
	1 L L N J. L J	
2550	OH Y	
3659	<u> </u>	

		N-{(1S,2R)-1-(3,5-
ļ	CH <sub>3</sub>	difluorobenzyl)-3-
	N	[(3-
	lau N. II	ethylbenzyl)amino]-2-
	CH <sub>3</sub> NO	hydroxypropyl}-1-
	HN A F	phenyl-5-propyl-1H- pyrazole-4-
	H"YYY	carboxamide
	N	Carpoxamide
3660	OH T	
3000	CH <sub>3</sub> \	N (/10 0P) 1 (0
Ì		N-{(1S,2R)-1-(3,5- difluorobenzyl)-3-
1		[(3-
	HN-\	ethylbenzyl)amino]-2-
	H →OH F	hydroxypropy1}-5-
	N HN-	(trifluoromethoxy)-
		1H-indole-2-
	0 4	carboxamide
3661	F F	
	F	N-{(1S,2R)-1-(3,5-
	Ì	difluorobenzyl)-3-
		[(3-
}		ethylbenzyl)amino]-2-
	OH NOH	hydroxypropyl}-4-(5-
	UM3 II Y IN )	methyl-1H-tetraazol-
İ		1-yl)benzamide
	N HN	
	N=N CH <sub>3</sub>	
3662		
	CH <sub>3</sub>	N-{(1S,2R)-1-(3,5-
	CH <sub>3</sub> N	difluorobenzyl)-3-
		[(3-
	0	ethylbenzyl)amino]-2-
	F NH	hydroxypropy1}-2,8-
		dimethylquinoline-3-
,	HO N CH <sub>3</sub>	carboxamide
3663	F	
	F	2-(3-chlorophenoxy)-
		N-{(1S,2R)-1-(3,5-
		difluorobenzyl)-3-
	F 0	[(3-
	HO CH <sub>3</sub>	ethylbenzyl)amino]-2-
		hydroxypropyl}propana mide
	NH, O	MIGE
	CI CI	
3664	\	
2004	CH <sub>3</sub>	

2-chloro-N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-(13-ethylbenzy1) amino]-2-hydroxypropy1)-4-(1H-tetraazol-1-1-y1) benzamide			
Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   Action   A		F	T I
3665  CH <sub>3</sub> (3-ethylbenzyl) amino] -2-hydroxypropyl) -4-(1H-tetrazol-1-yl) benzamide  N-((1S, 2R) -1-(3, 5-difluorobenzyl) -3-[3-difluorobenzyl) -2H-tetrazol-2-ylthio] -N-((1S, 2R) -1-(3, 5-difluorobenzyl) -2H-tetrazol-2-ylthio] -N-((1S, 2R) -1-(3, 5-difluorobenzyl) -3-[3-(3-ethylbenzyl) amino] -2-hydroxypropyl) propana mide  N-((1S, 2R) -1-(3, 5-difluorobenzyl) -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -2-hydroxypropyl] -2-hydroxypropyl] -2-hydroxypropyl] -2-hydroxypropyl] -2-hydroxypropyl] -3-gifluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-difluorobenzyl] -3-[4-dif			1-(3,3-
according to the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of t			
3665  CH <sub>3</sub> N-{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-2-Lyhdroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-3	}		
## Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Section 2   Sec		↓ ↓ \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	hydroxypropyl}-4-(1H-
3665  CH <sub>3</sub> N-((1S,2R)-1-(3,5-difluorobenzyl)-3-(3-ethylbenzyl)amino]-2-hydroxypropyl)-2-(5-(2-methylphenyl)-2H-tetrazol-2-yllacetamide  3666  F  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-benzoxazol-2-yllacetamide)  3-(1,3-be			
3665  CH <sub>3</sub> N=(1(S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-2-(5-(2-methylphenyl)-2H-tetraazol-2-ylthio)-N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-yropana mide  3667  CH <sub>3</sub> N=(1(S,2R)-1-(3,5-difluorobenzyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-2-hydroxypropyl)-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)-3-(13-ethylbenzyl)a		LIM!	
3665  CH <sub>3</sub> N-((1s,2R)-1-(3,5-difluorobenzyl)-3-ethylbenzyl) amino]-2-hydroxypropyl)-2-[5-(2-methylphenyl)-2H-tetrazzol-2-yllnio)-N-((1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl) amino]-2-hydroxypropyl) propana mide  N-((1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxypropyl)-2-hydroxypropyl)-2-hydroxy-6-methylquinoline-4-carboxamide  N-((1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenzyl)-3-(1s,2R)-1-(3,5-difluorobenz			
N-((15,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1)-2-[5-(2-methylpheny1)-2H-tetraazo1-2-ythio)-N-((15,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1)propana mide		N° '' CH₃ \	
N-((15,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1)-2-[5-(2-methylpheny1)-2H-tetraazo1-2-yllnio)-N-((15,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1)propana mide	3665		
CH <sub>3</sub>		CH <sub>3</sub>	
#N			
Note			
3666    HO	•		
3666    CH3			
3666  F  3-(1,3-benzoxazo1-2-ylthio)-N-{(1s,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1)-2-hydroxypropy1)-2-hydroxypropy1)-2-hydroxypropy1)-2-hydroxypropy1)-2-hydroxypropy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1)-3-propylpyrazine-2-carboxamide		CII	
3666  F  3-(1,3-benzoxazol-2-ylthio)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-(13-ethylbenzyl)amino]-2-hydroxypropyl)propana mide  N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-2-hydroxypropyl)-2-hydroxypropyl)-2-hydroxypropyl)-2-hydroxypropyl)-3-methylquinoline-4-carboxamide  N-((1S,2R)-1-(3,5-difluorobenzyl)-3-(13,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-3-propylpyrazine-2-carboxamide 4-oxide		Ni l	
3666  F  3-(1,3-benzoxazo1-2- ylthio)-N-((1S,2R)-1- (3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl)propana mide  N-((1S,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-2- hydroxypropyl)-2- hydroxypropyl)-2- hydroxy-6- methylquinoline-4- carboxamide  OH  CH3  N-((1S,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)			111000000000000000000000000000000000000
3667  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  HO		N=N 0 $N=N$	
3667  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  HO			
3667  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  N  HO  HO		Ť	
Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   Second   S	3666	F	3_/1 3_benzovazol-2-
(3,5-difluorobenzyl) - 3-[(3-ethylbenzyl) amino] -2-hydroxypropyl) propana mide  N-{(15,2R)-1-(3,5-difluorobenzyl)-3[(3-ethylbenzyl) amino] -2-hydroxypropyl) -2-hydroxypropyl) -2-hydroxy-6-methylquinoline-4-carboxamide  N-((15,2R)-1-(3,5-difluorobenzyl) -3-li(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-li(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-li(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-li(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-li(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-li(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-li(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-li(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-li(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-li(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-li(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-li(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-li(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-li(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-li(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-li(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-li(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-li(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-li(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-li(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-li(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-li(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-li(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-li(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-li(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-li(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-li(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-li(3-ethylbenzyl) amino] -2-hydroxypropyl) -3-li(3-ethylbenzyl) amino] -3-li(3-ethylbenzyl) -3-li(3-ethylbenzyl) amino] -3-li(3-ethylbenzyl) -3-li(3-ethylbenzyl) -3-li(3-ethylbenzyl) -3-li(3-ethylbenzyl) -3-li(3-ethylbenzyl) -3-li(3-ethylbenzyl) -3-li(3-ethylbenzyl) -3-li(3-ethylbenzyl) -3-li(3-ethylbenzyl) -3-li(3-ethylbenzyl) -3-li(3-ethylbenzyl) -3-li(3-ethylbenzyl) -3-li(3-ethylbenzyl) -3-li(3-ethylbenzyl) -3-li(3-ethylbenzyl) -3-li(3-ethylbenzyl) -3-li(3-ethylbenzyl) -3-li(3-ethylbenzyl) -3-li(3-ethylbenzyl) -3-li(3-ethylbenzyl) -3-l			v1thio) = N={(1S.2R)-1-
3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)propana mide  N-((1s,2R)-1-(3,5-difluorobenzyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxypropyl}-2-hydroxypropyl}-2-hydroxypropyl}-2-hydroxypropyl}-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl}-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)amino]-2-hydroxypropyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl)amino]-2-hydroxypropyl)amino]-2-hydroxypropyl)amino]-2-hydroxypropyl)amino]-2-hydroxypropyl)amino]-2-hydroxypropyl)amino]-2-hydroxypropyl)amino]-2-			(3.5-difluorobenzyl)-
ethylbenzyl)amino]-2- hydroxypropyl}propana mide  N-{(1S,2R)-1-(3,5- difluorobenzyl)-3{(3- ethylbenzyl)amino]-2- hydroxypropyl}-2- hydroxypropyl}-2- hydroxypropyl}-2- hydroxypropyl}-2- hydroxyofe- methylquinoline-4- carboxamide  N-{(1S,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-3- propylpyrazine-2- carboxamide 4-oxide			
hydroxypropyl}propana mide  N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylpenzyl)amino]-2-hydroxypropyl}-2-hydroxypropyl)-3-[(3-ethylpenzyl)amino]-2-hydroxypropyl)-3-[(3-ethylpenzyl)amino]-2-hydroxypropyl)-3-propylpyrazine-2-carboxamide		F	ethylbenzyl)amino]-2-
3667  CH <sub>3</sub> N-{(1s,2r)-1-(3,5-difluorobenzy1)-3('(3ethylbenzy1) amino]-2-hydroxy-6-methylquinoline-4-carboxamide  N-{(1s,2r)-1-(3,5-difluorobenzy1)-3-((3-ethylbenzy1) amino]-2-hydroxy-formula filluorobenzy1)-3-((3-ethylbenzy1) amino]-2-hydroxy-formula filluorobenzy1)-3-propylpyrazine-2-carboxamide 4-oxide			hydroxypropyl}propana
3667  CH <sub>3</sub> N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3ethylbenzy1)amino]-2-hydroxypropy1}-2-hydroxypropy1}-2-hydroxy-6-methylquinoline-4-carboxamide  N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3ethylbenzy1)amino]-2-hydroxypropy1}-3-propylpyrazine-2-carboxamide 4-oxide			mide
N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-(-(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxymide  N-{(1s,2r)-1-(3,5-difluorobenzyl)-2-hydroxymide}  N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-propylpyrazine-2-carboxamide 4-oxide		NH .	
N-{(1s,2r)-1-(3,5-difluorobenzy1)-3-(-(3ethylbenzy1)amino]-2-hydroxypropy1}-2-hydroxymide  N-{(1s,2r)-1-(3,5-difluorobenzy1)amino]-2-hydroxymide}  N-{(1s,2r)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-3-propylpyrazine-2-carboxamide 4-oxide			
N-{(1s,2r)-1-(3,5-difluorobenzy1)-3-(-(3ethylbenzy1)amino]-2-hydroxypropy1}-2-hydroxymide  N-{(1s,2r)-1-(3,5-difluorobenzy1)amino]-2-hydroxymide}  N-{(1s,2r)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-3-propylpyrazine-2-carboxamide 4-oxide			
N-{(1s,2r)-1-(3,5-difluorobenzy1)-3-(-(3ethylbenzy1)amino]-2-hydroxypropy1}-2-hydroxymide  N-{(1s,2r)-1-(3,5-difluorobenzy1)amino]-2-hydroxymide}  N-{(1s,2r)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-3-propylpyrazine-2-carboxamide 4-oxide			
difluorobenzyl)-3- [(3	3667	CH <sub>3</sub>	
CH <sub>3</sub> ONH HN  OH  CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-propylpyrazine-2-carboxamide 4-oxide		HON	N-{(1S, 2R) -1-(3, 5-
ethylbenzyl)amino]-2- hydroxypropyl}-2- hydroxypropyl}-2- hydroxypropyl-2- hydroxymide  N-{(1s,2r)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-3- propylpyrazine-2- carboxamide 4-oxide			
hydroxypropyl}-2- hydroxy-6- methylquinoline-4- carboxamide  N-{(1s,2r)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-3- propylpyrazine-2- carboxamide 4-oxide		CH₃	othylbenzyllaminol-2-
hydroxy-6- methylquinoline-4- carboxamide  N-{(1s,2r)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-3- propylpyrazine-2- carboxamide 4-oxide	ĺ	O NILLLIN'	
methylquinoline-4- carboxamide  N-{(1S,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-3- propylpyrazine-2- carboxamide 4-oxide		O NA HIN	
OH CH <sub>3</sub> carboxamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-propylpyrazine-2-carboxamide 4-oxide	· ·		methylquinoline-4-
3668  F  CH <sub>3</sub> N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-propylpyrazine-2-carboxamide 4-oxide		∫ он	
CH <sub>3</sub> N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-propylpyrazine-2-carboxamide 4-oxide	[	`CH₃	
CH <sub>3</sub> N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-propylpyrazine-2-carboxamide 4-oxide	3668	F \\F	
difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-3- propylpyrazine-2- carboxamide 4-oxide		CH <sub>3</sub> \	N-{(1s,2R)-1-(3,5-
HN—OH F ethylbenzyl)amino]-2- hydroxypropyl}-3- propylpyrazine-2- carboxamide 4-oxide			
OH F hydroxypropyl}-3- propylpyrazine-2- carboxamide 4-oxide			[(3-
propylpyrazine-2- carboxamide 4-oxide			ethylbenzyl)aminol-2-
carboxamide 4-oxide		1	
			carboxamide 4-oxide
3669 0 F		N+	Carbonamico i onico
	3669	0 \ \ F	

	CH₃ \	$N-\{(1S,2R)-1-(3,5-$	T
3670	S NH HN OH F	difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-1- benzothiophene-3- carboxamide	
3671	CH <sub>3</sub> CH <sub>3</sub> OH F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-1-methyl-1H-indole-3-carboxamide	
3672	CH <sub>3</sub> HN OH F CH <sub>3</sub> CH <sub>3</sub> F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-6-methoxy-1,3-benzothiazole-2-carboxamide	
	CH <sub>3</sub> N HN H O H O F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-ef(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-[(6-methoxy-1H-benzimidazol-2-yl)thio]acetamide	

<del></del>			
	CH <sub>3</sub> ′	$N-\{(1S,2R)-1-(3,5-$	
		difluorobenzyl)-3-	
		[(3-	
	HN	ethylbenzyl)amino]-2-	
	<b>)</b> →OH F	hydroxypropyl}-4-	ł
	HN-!	phenylthiophene-2-	İ
		carboxamide	
	s o		
3674	F F		
	CH₃\	$N-\{(1s,2R)-1-(3,5-$	
		difluorobenzyl)-3-	•
	HN	[(3-	
	\ \ \	ethylbenzyl)amino]-2-	
	OH F	hydroxypropyl}-5-	
	HN-	methoxythiophene-2-	
		carboxamide	
	o's o —		
3675	ĊH₃		
	<b>√ √</b> \$	N-{(1S,2R)-1-(3,5-	
		difluorobenzyl)-3-	
		[(3-	,
	E NH NH	ethylbenzyl)amino]-2-	
	CH <sub>3</sub>	hydroxypropyl}-2,3'-	
	HO	bithiophene-5-	
3676	<u> </u>	carboxamide	
	F	N-{(1S,2R)-1-(3,5-	
		difluorobenzyl)-3-	
		[(3-	
	F O	ethylbenzyl)amino]-2-	
		hydroxypropyl}-4-	
	HONN	morpholin-4-yl-4-	
		oxobutanamide	
	ŅΗ		
			-
3.677	CH₃		
	CH₃	N-{(1s,2R)-1-(3,5-	
	<i>)</i>	difluorobenzyl)-3-	
	н (<	[(3-	
		ethylbenzyl)amino]-2-	
1		hydroxypropyl}-1H-	
		indole-3-carboxamide	
	NH HN		
	( NH )		
	Kri. ~		
	∫ о́н		
	\\F		
3678	F -		
	l	L	<u> </u>

3679	CH <sub>3</sub> O F  CH <sub>3</sub> O H  CH <sub>3</sub> HN  CH <sub>3</sub> HN	4-(acetylamino)-N- {(1S,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-2,6- dimethylbenzamide
3680	CH <sub>3</sub> HN ONH HO'S	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-furamide
3681	F HO, N H CH <sub>3</sub> HO CH <sub>3</sub>	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-hydroxy-3,5-dimethoxybenzamide
3682	CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	4-acetyl-N-{(1S,2R)- 1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)aminol-2- hydroxypropyl}benzami de

		27 (/4 5 0D) 1 /2 5	$\neg$
		N-{(1S, 2R) -1-(3, 5-	
	1	difluorobenzyl)-3-	
,		[(3-	
		ethylbenzyl)amino]-2-	
	~ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	hydroxypropyl}nicotin	
	N HN	amide	
	N OH		
	<u>-</u>		
	0 - F		١
		·	- [
3683	ļ F		ļ
	CH <sub>3</sub>	N-{(1S,2R)-1-(3,5-	$\neg$
	, N. OH	difluorobenzyl)-3-	
		[(3-	
		ethylbenzyl)amino]-2-	
	~ ~	hydroxypropyl}-2-	- 1
	ONH HN	hydroxyquinoline-4-	١
		carboxamide	
	,,,,,		l
	ЬOH		
	011		ı
			ı
3684	F F	((10,00) 1, (2,5	$\dashv$
	CH <sub>3</sub>	N-{(1s,2R)-1-(3,5-	-
		difluorobenzyl)-3-	ŀ
		[(3-	
		ethylbenzyl)amino]-2-	
	)	hydroxypropyl}-6-	
	HO HN	hydroxynicotinamide	
		`	
	N N OH		
	\ \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		
2665	Ţ		
3685	F	77 (/10 OP) 1 /2 5	$\dashv$
	CH <sub>3</sub> \	N-{(1S,2R)-1-(3,5-	
		difluorobenzyl)-3-	
		[(3-	
	HN—OU E	ethylbenzyl)amino]-2-	
	OH F	hydroxypropyl}-1-	
1	S HN-	benzothiophene-2-	
		carboxamide	
3686			
3000	N CI	7-chloro-N-{(1S,2R)-	_
1		1-(3,5-	
		difluorobenzyl)-3-	
1	]_	[(3-	
	F, NH OH	ethylbenzyl)amino]-2-	
1	l U J J N 人 人 CHa	hydroxypropyl}-4-	
	HO NO NO NO NO NO NO NO NO NO NO NO NO NO	hydroxyquinoline-3-	
3607	Ė.	carboxamide	
3687		Cathoxamine	

	CH₃	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-
	CH <sub>3</sub> N	ethylbenzyl)amino]-2-
		hydroxypropyl}-3- methylisoxazole-5-
	NH HN	carboxamide
	O' L'	
	hο	
	F	
3688	F	N-{(1s,2R)-1-(3,5-
		difluorobenzyl)-3-
		[(3-   ethylbenzyl)amino]-2-
	HO.	hydroxypropyl}-5- methylisoxazole-3-
	N N N	carboxamide
	NH CH <sub>3</sub>	
3689	CH <sub>3</sub>	
		N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-
		[(3- ethylbenzyl)amino]-2-
	O F	hydroxypropyl}-4-
	, , , , , , , , , , , , , , , , , , ,	(3,5-dimethyl-1H-pyrazol-1-
	CH <sub>3</sub> NN HN	yl)benzamide
	CH <sub>3</sub>	·
		-
3690	CH₃ CH₃∖	N-{(1S,2R)-1-(3,5-
	21.13	difluorobenzyl)-3-
	HN	[(3- ethylbenzyl)amino]-2-
	H OH F	hydroxypropyl}-5- methoxy-1H-indole-2-
		carboxamide
3691	CH <sub>3</sub> F	
	<u> </u>	

3692	H OH H N F F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2,5-dimethyl-3-furamide	
	S N H N H N H F F N H N H F N H N H F N H N H	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-6-hydroxy-2-(methylthio)pyrimidine-4-carboxamide	
3693		y (/10 2P) 1 /2 F	,
	HO HN	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-1,3-oxazole-4-carboxamide	
3694	HN OF F		
	HO, HN	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3methyl-1H-pyrazole-5-carboxamide	
3695	H HN N N F		

		N-{ (1S, 2R) -1-(3,5-	•
		difluorobenzyl)-3-	1
		[(3-	
	/	ethylbenzyl)amino]-2-	1
į.	uo HN ⊂	hydroxypropyl}thiophe	
	HO, I'IV	ne-3-carboxamide	
	<i>[</i>		1
	HN		l
			ļ
			Ì
	3 .		ŀ
2505			i
3696	F	Cablere N. (/1C 2P)	
	CI <sub>\</sub>	6-chloro-N-{(1S,2R)-	
		1-(3,5-	
	\	difluorobenzyl)-3-	
	<b>)</b> – (	[(3-	ļ
	HN ∕	ethylbenzyl)amino]-2-	1
	<b> </b>	hydroxypropyl}-1H-	
	ONH	indole-2-carboxamide	-
	OH		
'			
	ا <sup>۲</sup>		ŀ
	ŅH		İ
		j	
	<i>\\</i>		
3697			
		N-{(1S,2R)-1-(3,5-	
	H	difluorobenzyl)-3-	
	N H OH H	[(3-	
	N N N	ethylbenzyl)amino]-2-	
	II	hydroxypropyl}-1H-	
	Ö	indole-5-carboxamide	ļ
3698	F		
	.го н ОН н	N-{(1S,2R)-1-(3,5-	
		difluorobenzyl)-3-	
		[(3-	
	/ F	ethylbenzyl-)amino]-2-	
		hydroxypropyl}-4-	
		methyl-1,3-oxazole-5-	
3699	<u> </u>	carboxamide	
3033	100	N-{(1S,2R)-1-(3,5-	
1	H	difluorobenzyl)-3-	
		[(3-	
		ethylbenzyl)amino]-2-	
	Ö	hydroxypropyl}-4-	
	OH Y	methoxybenzamide	
	NH F	Incertoxy bett 2 militue	
		1	
2700			
3700			

			<del></del>
	H O. N. A	4-(acetylamino)-N- {(1S,2R)-1-(3,5-	
		difluorobenzyl)-3-	
	$N \longrightarrow F$	[(3-	
		ethylbenzyl)amino]-2-	
	NH F	hydroxypropyl}benzami de	
·			
3701			
		N-{(1S,2R)-1-(3,5-	
	N	difluorobenzyl)-3- [(3-	
	H	ethylbenzyl)amino]-2-	,
		hydroxypropyl}-4-	
	OOH	piperidin-1- ylbenzamide	
	/NH F	yibelizaliide	
		·	
·		•	
3702	N	N-{(1S,2R)-1-(3,5-	
·	YN H	difluorobenzyl)-3-	
	N F	[(3-	·
	Ö 👆	ethylbenzyl)amino]-2-	
	NH F	hydroxypropyl}-2- methylpyrimidine-5-	
	INFI F	carboxamide	
3703			
	CH₃	N-{(1S,2R)-1-(3,5-	
	N N	difluorobenzyl)-3-	
-		ethylbenzyl)amino]-2-	
-		hydroxypropyl}quinoli	
	O NH HN	ne-4-carboxamide	
	""\		
	Он		
2701			
3704	F´ 🍑 `F		<u> </u>

<del></del>		Y ( (10 07) 1 /2 5	<del></del>
		N-{ (1S, 2R) -1-(3,5-	
	F. N.	difluorobenzyl)-3-	
		[(3-	
		ethylbenzyl)amino]-2-	
	)=/	hydroxypropyl}-2-	
	f HO⊷	phenylimidazo[1,2-	
	∕−NH / <del>−</del> √	a]pyridine-7-	
	\_\( \rangle \)	carboxamide	1
3705	<u></u> СН₃		
	CH₃\	$N-\{(1S,2R)-1-(3,5-$	
		difluorobenzyl)-3-	
	<b>(</b> )	[(3-	
	HN—	ethylbenzyl)amino]-2-	
	CH₃	hydroxypropyl}-6-	
	HN-!	hydroxy-4-	
		methylpyridine-2-	
2706	N O	carboxamide	
3706	HO F	N <sup>1</sup> -{(1S,2R)-1-(3,5-	
		difluorobenzyl)-3-	
		[(3-	
	, N ,	ethylbenzyl)amino]-2-	
	O CH <sub>3</sub>	hydroxypropyl}-N <sup>4</sup> ,N <sup>4</sup> -	
	F. NH	diphenylsuccinamide	
	H N	diphenyisuccinamice	
	HO		
3707	<u>Ė</u>	-	
	Ę	$N-\{(1S,2R)-1-(3,5-$	
		difluorobenzyl)-3-	
	OH ()—F	[(3-	
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	ethylbenzyl)amino]-2-	
	/_NH>···/	hydroxypropy1}-2-	
	HN O	[ethyl(methyl)amino]-	
	HO FO	4-hydroxypyrimidine-	
	CH₃	5-carboxamide	
	N , ,		
3708	CH <sub>3</sub> CH <sub>3</sub>		
3700	F CH <sub>3</sub> CH <sub>3</sub>	N-{(1S,2R)-1-(3,5-	<del></del>
-	\	difluorobenzyl)-3-	
		[(3-	
		ethylbenzyl)amino]-2-	
	F O OH	hydroxypropyl}-4,8-	
	HO	dihydroxyquinoline-2-	
		carboxamide	
	NH NH	Carboxamirae	Į.
	NI		
			ļ
	ľ		
3709	CH₃		
3103	UFI3	<u> </u>	L

	CH <sub>3</sub> \	N-{(1S,2R)-1-(3,5- difluorobenzyl)-3-	
-		[(3-	
	HN—OH F	ethylbenzyl)amino]-2-	
	O HN	hydroxypropyl}-1- benzofuran-2-	
		carboxamide	•
3710	» ö		
3/10	CH <sub>3</sub>	N-{(1S,2R)-1-(3,5-	
	( "	difluorobenzyl)-3-	
1		[(3-	
		ethylbenzyl)amino]-2- hydroxypropyl}-1-	
		ethyl-1H-indole-2-	
İ	CH <sub>3</sub> HN	carboxamide	•
	N HN F		
3711	i i		
3/11	Ę Ę	2-(acetylamino)-N-	
	F	{(1s,2R)-1-(3,5-	
	OH C	difluorobenzyl)-3-	
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	[(3-   ethylbenzyl)amino]-2-	
	/ NH / HN -	hydroxypropyl}-4,5-	
		dimethylthiophene-3-	
	CH <sub>3</sub> NH	carboxamide	,
	CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>		
3712	CI 13 0	77 (410 07) 1 42 5	
		N-{(1S,2R)-1-(3,5- difluorobenzyl)-3-	
		[(3-	
	F O	ethylbenzyl)amino]-2-	
	HO N	hydroxypropyl}-3- hydroxyquinoxaline-2-	
		carboxamide	<u>.</u> .
	NH HO N	•	
		,	
3713	CH <sub>3</sub>	N-{(1S,2R)-1-(3,5-	
	<u></u>	difluorobenzyl)-3-	
		[(3-	
	NH \	ethylbenzyl)amino]-2- hydroxypropyl}-1H-	
	HN.	indazole-3-	
	<b>│                                    </b>	carboxamide	
	CH <sub>3</sub> N=		
	HN		
3714			

3715	CH <sub>3</sub> O CH <sub>3</sub>	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-2-phenyl-1,3-oxazole-4-carboxamide	
	HO NH CH <sub>3</sub>	1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-6- methylquinoline-2- carboxamide	
3716	CH <sub>3</sub> CH <sub>3</sub> NHO HO F	N <sup>1</sup> -{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> ,N <sup>2</sup> -dimethylphthalamide	
3717	CH <sub>3</sub> OH F	N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}thiophe-ne-2-carboxamide	
3718	F HO NH NH	N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-3-furamide	
3719	CH <sub>3</sub>		

			<del></del>
	F O CH <sub>3</sub>	N-{(1s,2k)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-3-furamide	
3720	NH CH <sub>3</sub>	•	
3721	CH <sub>3</sub> HN  OH  F  CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-hydroxy-6-neopentylpyridine-2-carboxamide	
3722	F HO NH CH <sub>3</sub>	N-{(1S,2R)-1-(3,5-difluorobenzy1)-3- [(3-ethylbenzy1)amino]-2-hydroxypropy1}-1,3-thiazole-4-carboxamide	
3723	CH <sub>3</sub> S O H O H CH <sub>3</sub> CH <sub>3</sub>	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-hydroxy-7-methoxy-1-benzothiophene-5-carboxamide	
3724	CH <sub>3</sub> O O O O O O O O O O O O O O O O O O O	N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-4-hydroxy-7-methoxy-1-benzofuran-5-carboxamide	

		N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-	
2725	HO CH <sub>3</sub>	hydroxypropyl}-2- phenyl-1,3-oxazole-4- carboxamide	
3725	<del>F</del> F	N-{(1S, 2R)-1-(3,5-	
)	~	difluorobenzy1)-3-	
·	CH <sub>3</sub> N N	[(3-	1
		ethylbenzyl)amino]-2-	1
	HN "/ V F	hydroxypropyl}-3,4-	ţ
}		dihydroxybenzamide	
<b>\</b>			
	но		
3726	\ \		
		$N^{1}-\{(1S, 2R)-1-(3, 5-$	
		difluorobenzyl)-3-	ĺ
	NH H	[(3-	
	↓ ∧ N ∧ ∧ Æ	ethylbenzyl)amino]-2-	Ì
	0, ~ 1, 1, 1, 1, 1	hydroxypropyl}-N4-	
	Ö /,′он (	phenylsuccinamide	
Ì			
1	NH F		
ì			
1		]	
	ČH₃		
3727		1 . (0 5 0 7 )	
		$N^1 - \{ (1S, 2R) - 1 - (3, 5 - 1) \}$	
		difluorobenzyl)-3-	
	NH H	[(3-	
	N. A. F	ethylbenzyl)amino]-2-	
		hydroxypropyl}-N4-	
:	O / OH	pyridin-3- ylsuccinamide	
	NH F	Arangginamirae	
1	1		
			ł
3728	CH <sub>3</sub>		
3/40	J		

3729	CH <sub>3</sub> NH  CH <sub>3</sub> NH  CH <sub>3</sub> O  NH  F	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>4</sup> -(2,6-dimethylphenyl)succinamide	
	CH <sub>3</sub> CH <sub>3</sub> N H H H H H H H H H H H H H H H H H H	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>4</sup> -methylsuccinamide	
3730	F CH <sub>3</sub>	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-(4-methoxyphenoxy)propanamide	
3732	CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-hydroxy-7-methoxyquinoline-3-carboxamide	
3733	CH <sub>3</sub> N H N OH F F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-[methyl(methylsulfonyl)amino]benzamide	

	HN O O O O O O O O O O O O O O O O O O O	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl}-3- (pyrrolidin-3-ylsulfonyl)benzamide	572.2
3734	F NH CH <sub>3</sub> NH CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-(4-methyl-1,2,3-thiadiazol-5-yl)isoxazole-4-	
3735	CH <sub>3</sub> N O N O CH <sub>3</sub>	carboxamide  N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-2-phenyl-2H-1,2,3-triazole-4-	
3736	F  O  NH  CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	carboxamide  N-{(15,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(4-methyl-1,2,3-thiadiazol-5-yl)-1,3-thiazole-4-carboxamide	
3738	O NH HN HN F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-phenylimidazo[1,2-a]pyridine-6-carboxamide	

	F HO HN S	N <sup>1</sup> -{(1S,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-N <sup>5</sup> - (1,3-thiazol-2- yl)pentanediamide	
3739	CH <sub>3</sub>	W (// G OD) 1 /2 F	
3740	CH <sub>3</sub> S S S S S S S S S S S S S S S S S S S	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-[(4-methyl-1,2,3-thiadiazol-5-yl)thio]acetamide	
3741	CH <sub>3</sub> HN F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-(piperidin-1-ylmethyl)-2-furamide	
3742	HO CH <sub>3</sub> CH <sub>3</sub>	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl}-2,5-dimethyl-1-phenyl-1H-pyrrole-3-carboxamide	

	Ę	N-{(1S,2R)-1-(3,5-
		difluorobenzyl)-3-
		[(3-
		ethylbenzyl)amino]-2-
	F Q	hydroxypropyl}-5-
	HO. A. L. N	
		methyl-1-phenyl-1H-
	H	pyrazole-3-
	ŃΗ	carboxamide
	Û CH₃	
	l Ý	
	L	·
3743	CH₃	
	F	N-{(1S,2R)-1-(3,5-
1	<u> </u>	difluorobenzyl)-3-
		[(3-
		ethylbenzyl)amino]-2-
	F, J, J, OH	hydroxypropyl}-3-
1	I Y Y N )	fluoro-4-morpholin-4-
		ylbenzamide
	HŅ,	·
	l °✓ CH₃ $\Upsilon$ $\Upsilon$	
3744		
3/44	0	N-{(1s,2r)-1-(3,5-
	CH <sub>3</sub> N	
	l s	difluorobenzyl)-3-
		[(3-
		ethylbenzyl)amino]-2-
	F NH S-CH <sub>3</sub>	hydroxypropyl}-3,5-
		bis(methylthio)isothi
	HONN	azole-4-carboxamide
3745	ĊH₃	
3,33	CH <sub>3</sub> ,,	N-{(1S,2R)-1-(3,5-
	0113 N	
		difluorobenzyl)-3-
	0	[(3-
	F	ethylbenzyl)amino]-2-
	F NHF	hydroxypropyl}-3-
	HF	methyl-5-
	HO N	(trifluoromethyl)isox
		azole-4-carboxamide
	✓ \	
3746	, CH <sub>3</sub>	
		<del></del>

	, O	N-{(1S,2R)-1-(3,5-	
	CH₃∖ )—NH	difluorobenzyl)-3-	
	CH <sub>3</sub>	[(3-	
		ethylbenzyl)amino]-2-	
	<b>`</b> ─/ jnh	hydroxypropy1}-2-	
1	√ HN—√ OH	hydroxy-5-	
	<u></u>	(propionylamino)benza	
	HO )	mide	
		mide	
	// <b>\</b>		
	'/		
3747		1	
3/4/	<u> </u>	27 (/1G OP) 1 /2 F	
		N-{(1S,2R)-1-(3,5-	
	// \\F	difluorobenzyl)-3-	
	OH (/	[(3-	
		ethylbenzyl)amino]-2-	
	/ >··\'	hydroxypropyl}-1-	
	MN A	phenyl-1H-pyrrole-2-	
	\( \nabla \)	carboxamide	
			•
3748	CH <sub>3</sub>		
	CH <sub>3</sub> \	N-{(1S,2R)-1-(3,5-	
		difluorobenzyl)-3-	
	( )	[(3-	
	HN—	ethylbenzyl)amino]-2-	
	<b>├</b> ──OH ,F	hydroxypropyl}pyrazin	
	NHN	e-2-carboxamide 4-	
		oxide	
3749	O F		
	<u></u> ⊢N	N-{(1S,2R)-1-(3,5-	
		difluorobenzyl)-3-	
		[(3-	
	CH <sub>3</sub> _N	ethylbenzyl)amino]-2-	
	l "N	hydroxypropy1}-5-	
	O N	methyl-1-pyridin-4-	
	NH NH	yl-1H-1,2,3-triazole-	
	F CH <sub>3</sub>	4-carboxamide	
:			
2750	НО О		
3750	F		<del></del>
	CH <sub>3</sub> (	N-{(1S,2R)-1-(3,5-	
		difluorobenzyl)-3-	
		[(3-	
	HN— HN—	ethylbenzyl)amino]-2-	
	CH <sub>Q</sub> OH F	hydroxypropyl}-6-	
	>=N HN-! /=<	methoxypyrazine-2-	
		carboxamide 4-oxide	
2751	N=- 0 (_		
3751	J 0 F		

	FHO NH N-CH <sub>3</sub>	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1-methyl-5-phenyl-1H-pyrazole-3-carboxamide
3752	CH₃	
	CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-hydroxy-3-propylhexanamide
3753	CH₃	N-{(1S,2R)-1-(3,5-
3754	F HO N H CH3	difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-1H- benzimidazole-5- carboxamide
3734	CH <sub>3</sub> N OH F	N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-4-(propionylamino)benza
3755	Н	mide

S-chloro-N-{(1s, 2R) - 1-(3, 5-difluorobenzy1) - 3-(13-benzofuran-2-carboxamide				
3756    A		Cl <sub>\</sub>		
3756    A			1-(3,5-	ĺ
Note		1 ( )		
## OH H    Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship   Ship	1			
Note		d I		
No			ethylbenzyl)amino]-2-	
S	}	F \	hvdroxypropyl}-1-	
3756  S				
N-((1s, 2r)-1-(3, 5-difluorobenzy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-2-pyridin-3-yl-1, 3-thiazole-4-carboxamide   8-cyano-N-((1s, 2r)-1-(3, 5-difluorobenzy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-4-hydroxypropy1)-4-hydroxypropy1)-4-hydroxypropy1)-4-hydroxypropy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-1, 6-naphthyridine-2-carboxamide   N-((1s, 2r)-1-(3, 5-difluorobenzy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-1, 6-naphthyridine-2-carboxamide   N-((1s, 2r)-1-(3, 5-difluorobenzy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1)-2, 2-dimethyl-4-oxochromane-6-		HO, TO A		
3756  N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-2-pyridin-3-yl-1,3-thiazole-4-carboxamide  8-cyano-N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-4-hydroxypropyl)-4-hydroxypropyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-1,6-naphthyridine-2-carboxamide  3759  N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-1,6-naphthyridine-2-carboxamide  N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-2,2-dimethyl-4-oxochromane-6-			carboxamide	
3756  N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-2-pyridin-3-yl-1,3-thiazole-4-carboxamide  8-cyano-N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-4-hydroxypropyl)-4-hydroxypropyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-1,6-naphthyridine-2-carboxamide  3759  N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-1,6-naphthyridine-2-carboxamide  N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-2,2-dimethyl-4-oxochromane-6-				
N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-pyridin-3-yl-1,3-thiazole-4-carboxamide   S-cyano-N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-4-hydroxyquinoline-3-carboxamide   N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-1,6-naphthyridine-2-carboxamide   N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-1,6-naphthyridine-2-carboxamide   N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-2,2-dimethyl-4-oxocchromane-6-	'	F NH		
N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-pyridin-3-yl-1,3-thiazole-4-carboxamide   S-cyano-N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-4-hydroxyquinoline-3-carboxamide   N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-1,6-naphthyridine-2-carboxamide   N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-1,6-naphthyridine-2-carboxamide   N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-2,2-dimethyl-4-oxocchromane-6-				
N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-pyridin-3-yl-1,3-thiazole-4-carboxamide   S-cyano-N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-4-hydroxyquinoline-3-carboxamide   N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-1,6-naphthyridine-2-carboxamide   N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-1,6-naphthyridine-2-carboxamide   N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-2,2-dimethyl-4-oxocchromane-6-		\		
N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-pyridin-3-yl-1,3-thiazole-4-carboxamide   S-cyano-N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-4-hydroxyquinoline-3-carboxamide   N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-1,6-naphthyridine-2-carboxamide   N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-1,6-naphthyridine-2-carboxamide   N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-2,2-dimethyl-4-oxocchromane-6-				
N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-pyridin-3-yl-1,3-thiazole-4-carboxamide   S-cyano-N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-4-hydroxyquinoline-3-carboxamide   N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-1,6-naphthyridine-2-carboxamide   N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-1,6-naphthyridine-2-carboxamide   N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-2,2-dimethyl-4-oxocchromane-6-	2756	\		
N	3/30			
3758  H OH H   [(3-ethylbenzyl) amino] - 2-hydroxypropyl) - 2-pyridin-3-yl-1, 3-thiazole-4-carboxamide  8-cyano-N-{(1s,2R)-1-(3,5-difluorobenzyl) - 3-[(3-ethylbenzyl) amino] - 2-hydroxypropyl) - 4-hydroxypropyl) - 4-hydroxypropyl) - 4-hydroxypropyl) - 3-[(3-ethylbenzyl) amino] - 2-hydroxypropyl) - 1, 6-naphthyridine-2-carboxamide  N-{(1s,2R)-1-(3,5-difluorobenzyl) - 3-[(3-ethylbenzyl) amino] - 2-hydroxypropyl) - 1, 6-naphthyridine-2-carboxamide  N-{(1s,2R)-1-(3,5-difluorobenzyl) - 3-[(3-ethylbenzyl) amino] - 2-hydroxypropyl) - 2, 2-dimethyl - 4-oxochromane - 6-			N-{(1S,2R)-1-(3,5-	
3758  H OH H   [(3-ethylbenzyl) amino] - 2-hydroxypropyl) - 2-pyridin-3-yl-1, 3-thiazole-4-carboxamide  8-cyano-N-{(1s,2R)-1-(3,5-difluorobenzyl) - 3-[(3-ethylbenzyl) amino] - 2-hydroxypropyl) - 4-hydroxypropyl) - 4-hydroxypropyl) - 4-hydroxypropyl) - 3-[(3-ethylbenzyl) amino] - 2-hydroxypropyl) - 1, 6-naphthyridine-2-carboxamide  N-{(1s,2R)-1-(3,5-difluorobenzyl) - 3-[(3-ethylbenzyl) amino] - 2-hydroxypropyl) - 1, 6-naphthyridine-2-carboxamide  N-{(1s,2R)-1-(3,5-difluorobenzyl) - 3-[(3-ethylbenzyl) amino] - 2-hydroxypropyl) - 2, 2-dimethyl - 4-oxochromane - 6-			difluorobenzvl)-3-	
## OH H    OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H   OH H		I H OHH		
3757    hydroxypropyl   -2-pyridin -3-yl - 1, 3-thiazole -4-carboxamide   8-cyano - N - ((15, 2R) - 1-(3, 5-difluorobenzyl) - 3-[(3-ethylbenzyl) amino] - 2-hydroxypropyl) - 4-hydroxypropyl) - 4-hydroxypropyl) - 3-carboxamide   (3-ethylbenzyl) amino] - 2-hydroxypropyl) - 1, 6-naphthyridine - 2-carboxamide   N - ((15, 2R) - 1 - (3, 5-difluorobenzyl) - 3-[(3-ethylbenzyl) amino] - 2-hydroxypropyl) - 1, 6-naphthyridine - 2-carboxamide   N - ((15, 2R) - 1 - (3, 5-difluorobenzyl) - 3-[(3-ethylbenzyl) amino] - 2-hydroxypropyl) - 2, 2-dimethyl - 4-oxochromane - 6-		1 / LNLNL		
3757    Part		N Y Y V V V		
## State		'`		
## State		l T	pyridin-3-yl-1,3-	
3757    Carboxamide   8-cyano-N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-4-hydroxyquinoline-3-carboxamide   N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-1,6-naphthyridine-2-carboxamide   N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-1,6-naphthyridine-2-carboxamide   N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-2,2-dimethyl-4-oxochromane-6-				
8-cyano-N-{(15,2R)-1- (3,5-difluorobenzy1)- 3-[(3- ethylbenzy1)amino]-2- hydroxypropy1)-4- hydroxyquinoline-3- carboxamide  N-{(15,2R)-1-(3,5- difluorobenzy1)-3- [(3- ethylbenzy1)amino]-2- hydroxypropy1)-1,6- naphthyridine-2- carboxamide  N-{(15,2R)-1-(3,5- difluorobenzy1)-3- [(3- ethylbenzy1)amino]-2- hydroxypropy1)-3- [(3- ethylbenzy1)amino]-2- hydroxypropy1)-2,2- dimethy1-4- oxochromane-6-	3757	ļ	ł .	
3758  NH OH H NH F  NH F  NH OH H NH N NH F  NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H NH OH H N	<del>  '' '</del>	N F		
3758  N-{(1s, 2r) -1 - (3, 5-difluorobenzyl) -3- [(3-ethylbenzyl) amino] -2-hydroxygropyl) -3- [(3-ethylbenzyl) amino] -2-hydroxypropyl) -1, 6-naphthyridine-2-carboxamide  N-{(1s, 2r) -1 - (3, 5-difluorobenzyl) -3- [(3-ethylbenzyl) amino] -2-hydroxypropyl) -1, 6-naphthyridine-2-carboxamide  N-{(1s, 2r) -1 - (3, 5-difluorobenzyl) -3- [(3-ethylbenzyl) amino] -2-hydroxypropyl) -2, 2-dimethyl -4-oxochromane-6-		IV   III		
ethylbenzyl)amino]-2- hydroxypropyl}-4- hydroxyquinoline-3- carboxamide  N-{(1s,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-1,6- naphthyridine-2- carboxamide  N-{(1s,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-2,2- dimethyl-4- oxochromane-6-		"		
ethylbenzyl)amino]-2- hydroxypropyl}-4- hydroxyquinoline-3- carboxamide  N-{(1s,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-1,6- naphthyridine-2- carboxamide  N-{(1s,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-2,2- dimethyl-4- oxochromane-6-		l ↓ N	3-[(3-	
hydroxypropyl)-4- hydroxyquinoline-3- carboxamide  NH PH H OH H NN N		(		
3758  N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1,6-naphthyridine-2-carboxamide  N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2,2-dimethyl-4-oxochromane-6-				
3758  NH OH H NH F  N-{(1S, 2R) -1- (3, 5- difluorobenzyl) -3- [(3- ethylbenzyl) amino] -2- hydroxypropyl} -1, 6- naphthyridine-2- carboxamide  N-{(1S, 2R) -1- (3, 5- difluorobenzyl) -3- [(3- ethylbenzyl) amino] -2- hydroxypropyl) -3- [(3- ethylbenzyl) amino] -2- hydroxypropyl) -2, 2- dimethyl -4- oxochromane -6-				
3758  N-{(1s, 2r)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-1,6-naphthyridine-2-carboxamide  N-{(1s, 2r)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-2,2-dimethyl-4-oxochromane-6-				
3758  N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-1,6-naphthyridine-2-carboxamide  N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-2,2-dimethyl-4-oxochromane-6-		I OH O	carboxamide	
3758  N-{(1s,2r)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-1,6-naphthyridine-2-carboxamide  N-{(1s,2r)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-2,2-dimethyl-4-oxochromane-6-				
N-{(1s,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-1,6-naphthyridine-2-carboxamide  N-{(1s,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-2,2-dimethyl-4-oxochromane-6-		NH F		
N-{(1s,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-1,6-naphthyridine-2-carboxamide  N-{(1s,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-2,2-dimethyl-4-oxochromane-6-				
N-{(1s,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-1,6-naphthyridine-2-carboxamide  N-{(1s,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-2,2-dimethyl-4-oxochromane-6-				
N-{(1s,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-1,6-naphthyridine-2-carboxamide  N-{(1s,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-2,2-dimethyl-4-oxochromane-6-				
N-{(1s,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-1,6-naphthyridine-2-carboxamide  N-{(1s,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-2,2-dimethyl-4-oxochromane-6-				ļ
N-{(1s,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-1,6-naphthyridine-2-carboxamide  N-{(1s,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-2,2-dimethyl-4-oxochromane-6-	3758			
difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-1,6- naphthyridine-2- carboxamide  N-{(1s,2r)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-2,2- dimethyl-4- oxochromane-6-			7 (/10 00) 1 (0 7	
H OH H (1s, 2r) -1-(3,5-difluorobenzyl) amino] -2-hydroxypropyl} -3-[(3-ethylbenzyl) amino] -2-hydroxymide  N-{(1s, 2r) -1-(3,5-difluorobenzyl) -3-[(3-ethylbenzyl) amino] -2-hydroxypropyl} -2,2-dimethyl -4-oxochromane -6-	1			
ethylbenzyl)amino]-2- hydroxypropyl}-1,6- naphthyridine-2- carboxamide  N-{(1S,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-2,2- dimethyl-4- oxochromane-6-			difluorobenzyl)-3-	
ethylbenzyl)amino]-2- hydroxypropyl}-1,6- naphthyridine-2- carboxamide  N-{(1S,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-2,2- dimethyl-4- oxochromane-6-		ĺΝ˙ ϓ Ϡ Η ΟΗ Η 🧪 Ι	_	
hydroxypropyl)-1,6- naphthyridine-2- carboxamide  N-{(1s,2r)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-2,2- dimethyl-4- oxochromane-6-				`
naphthyridine-2- carboxamide  N-{(1s,2r)-1-(3,5- difluorobenzy1)-3- [(3- ethylbenzy1)amino]-2- hydroxypropy1}-2,2- dimethy1-4- oxochromane-6-		~ N. J., ~ ~		
Carboxamide  N-{(1s,2r)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-2,2-dimethyl-4-oxochromane-6-		Ö		
3759    N-{(1s,2r)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-2,2-dimethyl-4-oxochromane-6-		<b>Y Y</b> .		
N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2,2-dimethyl-4-oxochromane-6-		· L	carboxamide	
N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2,2-dimethyl-4-oxochromane-6-	1.	<b>Y</b>		
difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-2,2- dimethyl-4- oxochromane-6-	3759	F		
difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-2,2- dimethyl-4- oxochromane-6-			N-{(1S,2R)-1-(3.5-	
H OH H [(3- ethylbenzyl)amino]-2- hydroxypropyl}-2,2- dimethyl-4- oxochromane-6-	1			
ethylbenzyl)amino]-2- hydroxypropyl)-2,2- dimethyl-4- oxochromane-6-				
hydroxypropyl}-2,2- dimethyl-4- oxochromane-6-	1			
dimethyl-4- oxochromane-6-			ethylbenzyl)amino]-2-	
dimethyl-4- oxochromane-6-	<b>[</b>		hydroxypropyl}-2.2-	'
oxochromane-6-	1			
· · · · · · · · · · · · · · · · · · ·				
3/60 F Carboxamide	27.50	<b>Y</b>		
	3760		carboxamide	

A			
N-{(1s, 2r) -1-(3, 5-difluorobenzyl) -3-(3-ethylbenzyl) amino] -2-hydroxypropyl) -4, 7-dimethoxy-1-benzofuran-5-carboxamide   N-(1s, 2r) -1-(3, 5-difluorobenzyl) -3-(3-ethylbenzyl) amino] -2-hydroxypropyl) -5-phenylisothiazole-4-carboxamide   2-(2, 1, 3-benzothiadiazol-4-yloxy) -N-(1s, 2r) -1-(3, 5-difluorobenzyl) -3-(3-ethylbenzyl) amino] -2-hydroxypropyl) acetamide   N-((1s, 2r) -1-(3, 5-difluorobenzyl) -3-(3-ethylbenzyl) amino] -2-hydroxypropyl) acetamide   N-((1s, 2r) -1-(3, 5-difluorobenzyl) -3-(3-ethylbenzyl) amino] -2-hydroxypropyl) -2-methoxy-4-(methylthio) benzamide   N-((1s, 2r) -1-(3, 5-difluorobenzyl) -2-methoxy-4-(methylthio) benzamide   N-((1s, 2r) -1-(3, 5-difluorobenzyl) -2-methoxy-4-(methylthio) benzamide   N-((1s, 2r) -1-(3, 5-difluorobenzyl) -2-methoxy-4-(methylthio) benzamide   N-((1s, 2r) -1-(3, 5-difluorobenzyl) -2-methoxy-4-(methylthio) benzamide   N-((1s, 2r) -1-(3, 5-difluorobenzyl) -2-methoxy-4-(methylthio) benzamide   N-((1s, 2r) -1-(3, 5-difluorobenzyl) -2-methoxy-4-(methylthio) benzamide   N-((1s, 2r) -1-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl) -3-(3, 5-difluorobenzyl		H OH H	[(3- ethylbenzyl)amino]-2- hydroxypropyl}-3- (morpholin-4-
N-{(1s, 2r) -1-(3, 5-difluorobenzyl) -3-(3-ethylbenzyl) amino] -2-hydroxypropyl) -4, 7-dimethoxy-1-benzofuran-5-carboxamide   S-chloro-N-{(1s, 2r) -1-(3, 5-difluorobenzyl) -3-(3-ethylbenzyl) amino] -2-hydroxypropyl) -5-phenylisothiazole-4-carboxamide   2-(2, 1, 3-benzothiadiazol-4-yloxy) -N-{(1s, 2r) -1-(3, 5-difluorobenzyl) -3-(3-ethylbenzyl) amino] -2-hydroxypropyl) acetamide   N-{(1s, 2r) -1-(3, 5-difluorobenzyl) -3-(3-ethylbenzyl) amino] -2-hydroxypropyl) acetamide   N-{(1s, 2r) -1-(3, 5-difluorobenzyl) -3-(3-ethylbenzyl) amino] -2-hydroxypropyl) -2-methoxy-4-(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benzamide   N-{(methylthio) benza	3761	Į	
1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-5- phenylisothiazole-4- carboxamide  2-(2,1,3- benzothiadiazol-4- yloxy)-N-{(1S,2R)-1- (3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}acetami de  N-{(1S,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-2- methoxy-4- (methylthio)benzamide		H OH H N N N F	difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-4,7- dimethoxy-1- benzofuran-5-
benzothiadiazol-4- yloxy)-N-{(1S,2R)-1- (3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}acetami de  N-{(1S,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-2- methoxy-4- (methylthio)benzamide	3763	S H OH H	1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-5- phenylisothiazole-4-
The second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of th		HO	benzothiadiazol-4- yloxy)-N-{(1S,2R)-1- (3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}acetami
CH <sub>3</sub> O F [(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-methoxy-4-(methylthio)benzamide	3764	1 - 1 1 1	
13765   CH <sub>2</sub>	3765	S N N N N N N N N N N N N N N N N N N N	difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-2- methoxy-4-

	011	(/45 05) 4 /0 5
	CH <sub>3</sub>	N-{(1S, 2R) -1-(3, 5-
		difluorobenzyl)-3-
		[(3-
		ethylbenzyl)amino]-2-
	. ]	hydroxypropyl}-2-[(4-
	HŃ	methyl-1,3-thiazol-2-
	H \	yl)thio]acetamide
	S OH	
	l l l l l l l l l l l l l l l l l l l	
	s n Y	
27.66		
3766	F	77 (/10 02) 1 /2 5
	CH <sub>3</sub>	N-{(1s,2r)-1-(3,5-
		difluorobenzyl)-3-
	\	[(3-
	HN— →OH F	ethylbenzyl)amino]-2-
	1 0 / /	hydroxypropyl)-6-
	CH <sub>3</sub>	methoxy-1-benzofuran-
1		2-carboxamide
3767		
3707	ÇH <sub>3</sub>	5-chloro-N-{(1S,2R)-
	0113	1-(3,5-
		difluorobenzyl)-3-
1		[(3-
	`N´ O	ethylbenzyl)amino]-2-
	NH HN	hydroxypropyl}-2-
1		morpholin-4-
		ylbenzamide
	l di 🗼 ÖH	7120112011
3768	F F	
3700	F F	N-{(1S,2R)-1-(3,5-
	1 1	difluorobenzyl)-3-
		[(3-
İ	1=4.4	ethylbenzyl)amino]-2-
	HO.	hydroxypropyl}-4-
	1	methoxy-1H-pyrrole-3-
	N NH	carboxamide
	NH NH	
	1 7	
	CH <sub>3</sub>	
	ľ	
3769	CH <sub>3</sub>	
3109	_S	N-{(1S,2R)-1-(3,5-
	0 ∫ CH3	N-{(15,2R)-1-(3,5-   difluorobenzyl)-3-
	N 01.13	[(3-
	E & // NH &	ethylbenzyl)amino]-2-
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	hydroxypropy1}-2-
	HO N CH <sub>3</sub>	methyl-1,3-thiazole-
3770		4-carboxamide
3,,0	<u> </u>	1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2

[	<del></del>	37 (/10 0D) 1 /2 F
	у № н ОН Н	N-{ (1S, 2R) -1- (3, 5-
	N N N N N N N N N N N N N N N N N N N	difluorobenzyl)-3-
		[(3-
	~ YY'	ethylbenzyl)amino]-2-
	$\checkmark$	hydroxypropyl}-2-
	<u> </u>	methyl-5-(2-thienyl)-
3771	•	3-furamide
		N-{(1S,2R)-1-(3,5-
		difluorobenzyl)-3-
	Y 1	[(3-
		ethylbenzyl)amino]-2-
	Ĭ	hydroxypropyl}-4-
	HN F	=
	1	methoxythiophene-3-
	HO.	carboxamide
	O HN	
	ľľ	
	0	
3772	و ا	
3772	3	N-{(1s,2R)-1-(3,5-
		difluorobenzyl)-3-
		[(3-
	HN HN	ethylbenzyl)amino]-2-
	HO. ''' F	hydroxypropyl}-N'-
		(3,5-dimethylpyrazin-
	HŅ	2-y1)succinamide
	F	
	0 0 .	
	N. Ju	
	NH	
3773	N	
3.,5	<u> </u>	N-{(1S,2R)-1-(3,5-
	Ų	difluorobenzyl)-3-
	0	[(3-
		ethylbenzyl)amino]-2-
		hydroxypropyl}-2-
		, = ,
		[(3,4-
		dimethoxyphenyl)thio]
	O ŅH	acetamide
	OH.	
	NH	
	F F	
	'''	
3774		

	,	N-(1-	
		cyclopropylethyl)-N'-	
		{ (1S,2R)-1-(3,5-	
	$\Gamma$	difluorobenzyl)-3-	:
	HO, HN F	[(3-	
		ethylbenzyl)amino]-2-	
	HN	hydroxypropyl}-N-	
		phenylsuccinamide	ŀ
	o O F		
	N.		
3775			
	Ę	6-chloro-N-{(1S,2R)-	
	► F.F	1-(3,5-	]
		difluorobenzyl)-3-	
	F LNY T	[(3-	
	N OH H CI	ethylbenzyl)amino]-2-	1
	H OH CI	hydroxypropyl}-4-	
3776		(trifluoromethyl)pyri dine-2-carboxamide	
3776		N-(2-acetyl-3-	
		thienyl)-N'-{(1S,2R)-	
		1-(3,5-	
		difluorobenzyl)-3-	.
		[(3-	
	HŅ	ethylbenzyl)amino]-2-	·
	HO	hydroxypropyl}succina	
		mide	
	HŅ		
	0 0 10		
	F		
	NH		
3777			
	_ >N H OH H ()	N-{(1S,2R)-1-(3,5-	
	I SH SH SH SH SH SH SH SH SH SH SH SH SH	difluorobenzyl)-3-	
	N Y N S	[(3-	
	\ \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	ethylbenzyl)amino]-2-	
	Y	hydroxypropyl}-1-(4- fluorophenyl)-5-	
:	F	methyl-1H-1,2,4-	
		triazole-3-	
3778		carboxamide	
	ГО НОНН	N-{(1s,2r)-1-(3,5-	
		difluorobenzyl)-3-	
	O H O F	[(3-	
	$\vee$	ethylbenzyl)amino]-2-	
	F	hydroxypropyl}-N'-[2- fluoro-5-	
		(methylsulfonyl)pheny	
3779		1] succinamide	
,		1 •	

,	<u> </u>	N-{ (1S, 2R) -1- (3,5-
	)	difluorobenzyl)-3-
		[(3-
		ethylbenzyl)amino]-2-
		hydroxypropyl}-4-(4-
		methoxyphenyl)thiophe
		ne-2-carboxamide
	F T	
	NH	
	HO, "," OH	
	F NH	
İ		
3780		
	<u> </u>	N-{(1S,2R)-1-(3,5-
	0=S(	difluorobenzyl)-3-
		[(3-
		ethylbenzyl)amino]-2-
	/\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	hydroxypropyl}-4-[5-
		(methylsulfinyl)-2,3-
		dihydro-1H-indol-1-
	F \	yl]-4-oxobutanamide
	ONH OH	1 1 0x00dcdilatite
	F NH	
2701	7	
3781		
	Cl_s _	2-(acetylamino)-5-
		chloro-N-{(1S,2R)-1-
		(3,5-difluorobenzyl)-
	NH	3-[(3-  ethylbenzyl)amino]-2-
	HO, Ö NI ÖH	
		hydroxypropyl}thiophe ne-3-carboxamide
	F NH	TIE-3-Cat Doxamit de
3782		
	1	N-{(1s,2R)-1-(3,5-
		difluorobenzyl)-3-
		[(3-
	\times	ethylbenzyl)amino]-2-
	HO HN	hydroxypropyl}-2-
	HO, ""	propyltetrahydro-2H-
	T	pyran-4-carboxamide
-	HŅ	
	Q	
	T F-	
	F	
3783	1/	

		4-chloro-N-{(1S,2R)-	
	0	1-(3,5-	
		difluorobenzyl)-3-	
	N H	[(3-	
	CI	ethylbenzyl)amino]-2-	
		hydroxypropyl}-7,7-	
	OH	dimethyl-7,8-dihydro-	
	NH F	5H-pyrano[4,3-	
	[ [	b]pyridine-2- carboxamide	
		carboxamide	
3784			
		2-(2-chlorophenyl)-N-	
	CI—	{(1s,2r)-1-(3,5-	
		difluorobenzyl)-3-	
	S N	[(3-	
	₩ N	ethylbenzyl)amino]-2-	
	F \	hydroxypropyl}-1,3- thiazole-4-	
	NH OH	carboxamide	
	10 JUH	Carbonalitue	
	L VIII	·	
	F NH		
3785	<u>L</u>		
3703	S H OH H	N-{(1S,2R)-1-(3,5-	
	THO HH L	difluorobenzyl)-3-	
	) N Y S F	[(3-	
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	ethylbenzyl)amino]-2-	
		hydroxypropy1}-2-(3-	
	Ė	methylphenyl)-1,3-	
		thiazole-4-	
3786		carboxamide	
		N-{(1s,2R)-1-(3,5-	
		difluorobenzyl)-3-	
		[(3- ethylbenzyl)amino]-2-	
	LIG HN	hydroxypropyl}-1,2,5-	
	HQ T	thiadiazole-3-	
		carboxamide	
	HN		
	N ]		
	S-N Ö		
	F		
3787	F		
	√-0 S OU △	N-{(1S,2R)-1-(3,5-	
	H OH H OH H	difluorobenzyl)-3-	
	N Y V V V V	[(3-	
	J \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	ethylbenzyl)amino]-2-	
	\ \ \	hydroxypropyl}-2-	
	F	(phenoxymethyl)-1,3-	
3788		thiazole-4-	
	1	carboxamide	

			$\overline{}$
	→ S¬ H OHH ↑	N-{(1S,2R)-1-(3,5-	
	$\rightarrow N \setminus N \setminus N \setminus N \setminus N \setminus N \setminus N \setminus N \setminus N \setminus N $	difluorobenzyl)-3-	- 1
	"	[(3-	
	Y Y .	ethylbenzyl)amino]-2-	- 1
	$\sim$	hydroxypropyl}-2-(4-	ŀ
1	Ė	methylphenyl)-1,3-	- [
		thiazole-4-	
2000			
3789		carboxamide	
		N-{(1s,2R)-1-(3,5-	
		difluorobenzyl)-3-	
		[(3-	- 1
	\ \ N. ∧ ∧ F	ethylbenzyl)amino]-2-	l
		hydroxypropy1}-2-	
	Ö	pyridin-3-ylbenzamide	Ì
	OH Y		ŀ
,	∠NH F		
,			
			1
3790			
		N-{(1s,2R)-1-(3,5-	ļ
1		difluorobenzyl)-3-	
	7	[(3-	
	H OHH	ethylbenzyl)amino]-2-	-
	N N N N N N N N N N N N N N N N N N N	hydroxypropyl}-4-	
	/	methyl-2-phenyl-1,3-	
	Ι ΥΥ.	oxazole-5-carboxamide	
3791	ļ Ļ		1
1	,	N-{(1S,2R)-1-(3,5-	
	N-N' H OH H	difluorobenzyl)-3-	
	N-N H OH H	[(3-	
	I S	ethylbenzyl)amino]-2-	
	0 *\rightarrow F	hydroxypropyl}-1-	
		ethyl-3-(2-thienyl)-	
	Ţ	1H-pyrazole-5-	
2702	F	carboxamide	
3792	<u> </u>	<u></u>	—
	F	4-(acetylamino)-N-	
		{ (1s, 2R) -1 - (3, 5 -	
		difluorobenzyl)-3-	
	₽ <b>(***</b> F	[(3-	
		ethylbenzyl)amino]-2-	
	OHN HOHH	hydroxypropyl}-1-	
	1 \ 211 \	methyl-1H-pyrrole-2-	
3793		carboxamide	

3794	F NH OH NH	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(2,6-dimethylphenoxy)propanamide
3795	HO HO F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-phenyl-1,2,3-thiadiazole-5-carboxamide
3796	S H OH H N F F	N-{(1s,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-2- (2,5-dimethyl-1H- pyrrol-1- yl)thiophene-3- carboxamide
3797	O NH H OH H OH O	5-(acetylamino)-N- {(1S,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-2- hydroxybenzamide
3798	FHO NH F OH	4-(acetylamino)-N- {(1S,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}butanam ide trifluoroacetate

	_O \\S_\\	N-{(1S,2R)-1-benzyl- 3-[1-ethyl-2-(4- methylpentanoyl)hydra zino]-2- hydroxypropyl}-2- [(methylsulfonyl)amin o]-1,3-oxazole-4- carboxamide	
3799	CH <sub>3</sub>	N-{(1s,2R)-1-(3,5-	519
	CH <sub>3</sub> OH F	difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-3-(1- methyl-1H-imidazol-2- yl)benzamide	
3800	H OH H N	N'-[(1S,2R)-3-{[(1R)-3-cyclohexyl-1-phenylpropyl]amino}-1-(3,5-difluorobenzyl)-2-hydroxypropyl]-5-methyl-N,N-dipropylisophthalamid	
3801	HCI CH <sub>3</sub> N OH CH <sub>3</sub> F F	e  N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl}-N³,N³-dipropyl-5-pyridin-3-ylisophthalamidehydrochloride	
3802	OH HN O CH <sub>3</sub> F	N-{(1s,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-4-fluoro-1-naphthamide	

	F	N-cyclohexyl-N'-	
		$\{(1s, 2R) - 1 - (3, 5 -$	
	0 0 × F	difluorobenzyl)-3-	
		[(3-	
	N X X N X N X X	ethylbenzyl)amino]-2-	
	Д ₩"ОН Н 🚫	hydroxypropyl}-N,5-	
		dimethylisophthalamid	
3804	~	e	
	ÇH₃	N-{(1S,2R)-1-(3,5-	443.2
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	difluorobenzyl)-3-	·
		[(3-	
		ethylbenzyl)amino]-2-	
		hydroxypropyl}-1-	
	NUN )	methyl-1H-imidazole-	
	CH <sub>3</sub> HN	2-carboxamide	
	NH'"		
	) OH		
	)		
	)=/ TF		
3805	<u> </u>		
		$N^1$ -{(1S,2R)-1-benzy1-	
	н нн Фн н	2-hydroxy-3-[(3-	
İ	N N N N N N N N N N N N N N N N N N N	methoxybenzyl)amino]p	
		ropy1}-N <sup>3</sup> -	
		[oxo(phenyl)methyl]-	
3806		D-alaninamide	
	O HHOHH	$N^1$ -{(1S,2R)-1-benzyl-	
	N T N	2-hydroxy-3-[(3-	
		methoxybenzyl)amino]p	
		ropy1}-N2-	
		[imino(phenyl)methyl]	
3807		glycinamide	
		$N^{1}-\{(1s, 2r)-1-(3, 5-$	
	Į. Ę	difluorobenzyl)-3-	1
		[(3-	
	1、	ethylbenzyl)amino]-2-	
	)	hydroxypropyl}-N3-(2-	
	N N N N N N N N N N N N N N N N N N N	propylpentanimidoyl)-	
	→ н о̀н	□-alaninamide	
3808			
3000	<u> </u>	6-(4-benzylpiperazin-	
		1-y1)-N-{(1S,2R)-1-	
		(3,5-difluorobenzyl)-	
	H OH H	2-hydroxy-3-[(3-	
	N N N N N	iodobenzyl)amino]prop	
	0 \ F	yl}nicotinamide	
		y : ) iii cocinami de	
3809	F		<u> </u>

	F	N-{(1S, 2R)-1-(3,5-
		difluorobenzyl)-3-
		[(3-
		ethylbenzyl)amino]-2-
	S	hydroxypropyl}-3-[(3-
	o'o H OHH 🔰	methoxyphenyl) sulfony
	as drawn	
3810		1]propanamide
		N-{(1S,2R)-1-(3,5-
	\	difluorobenzy1)-3-
	<i>&gt;</i> −N	[(3-
	\	ethylbenzyl)amino]-2-
		hydroxypropyl}-5-
	F I I I	
	' 0 •	methyl-7-
		(trifluoromethyl)pyra
	Y	zolo[1,5-
	F	a]pyrimidine-2-
3811		carboxamide
7011		N-((1S,2R)-1-(3,5-
		difluorobenzyl)-3-
		1
	N-NO HOHH	[(3-
	1 ) SLULVIN N	ethylbenzyl)amino]-2-
	) H	hydroxypropy1}-N'-(5-
1	· · · · · · · · · · · · · · · · · · ·	phenyl-1,3,4-
	$\downarrow$	thiadiazol-2-
3812	ļ Ė	yl)succinamide
3012	`	N-(5-cyclopropyl-
	,	1,3,4-thiadiazol-2-
	/	
		y1)-N'-{(1S,2R)-1-
		(3,5-difluorobenzyl)-
		3-[(3-
		ethylbenzyl)amino]-2-
	HQ HN	hydroxypropyl}succina
	no_	mide
	/	l milde
	HN	}
	0, / 0,	
	N FEW	
	N' NH '	
	F F	
3813		
		N-{(1S,2R)-1-(3,5-
		difluorobenzy1)-3-
		[(3-
	O M H OH H	ethylbenzyl)amino]-2-
		1
		hydroxypropyl}-3-(3-
	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	methyl-5-oxo-4,5-
	I T'N	dihydro-1H-pyrazol-1-
	'	yl)benzamide
	Ĭ	-
3814	· <b>F</b>	1

		N-{(1S,2R)-1-(3,5-	
		difluorobenzyl)-3-	Ì
		[(3-	
		ethylbenzyl)amino]-2-	
	/	hydroxypropyl}thieno[	
ļ	HO. HN	2,3-b]quinoline-2-	
	ПО	carboxamide	
	N S HN		
	F		
3815	`F		
		N-{(1S,2R)-1-(3,5-	
		difluorobenzyl)-3-	
	0	[(3-	
	у н Он н С	ethylbenzyl)amino]-2-	
	) H OH H	hydroxypropyl}-1-	
		methyl-5-oxo-2-	
		phenylprolinamide	
		priory iprovince	
	<b>Y</b>		
3816	į Ė		
	0 1	N-{(1S,2R)-1-(3,5-	
	H OHH	difluorobenzyl)-3-	
	N N N	[(3-	
	Vol.	ethylbenzyl)amino]-2-	
	F	hydroxypropyl}-4-	ı
		methyl-4H,6H-	
	l É	pyrrolo[1,2-	
		a][4,1]benzoxazepine-	
3817		4-carboxamide	
002.		N-{(1S,2R)-1-(3,5-	
		difluorobenzyl)-3-	
	N H OH H	[(3-	
	HO NS Y	ethylbenzyl)amino]-2-	
	Ö <b>\rightarrow</b> F	hydroxypropy1)-2-[(7-	
		hydroxy-5-	
	<u> </u>		
	•	methyl[1,2,4]triazolo	
2010	·	[1,5-a]pyrimidin-2-	
3818		yl)thio]acetamide	
	_	N-{(1s,2R)-1-(3,5-	
		difluorobenzyl)-3-	
		[(3-	
		ethylbenzyl)amino]-2-	
	1	hydroxypropyl}-3-oxo-	
	HN	2,3-dihydro-1,2-	
	HO, J	benzisothiazole-6-	
		carboxamide 1,1-	
	LINI	dioxide	
	HŅ		
	10 1 0 1		
	F		
	HN-S≥O F		
3819	<u> </u>		
<u> </u>		<del> </del>	

		<u> </u>	
		N-{(1s,2R)-1-(3,5-	
	/	difluorobenzyl)-3-	
	N=	[(3-	- [
		ethylbenzyl)amino]-2-	ļ
	H QHH []		- 1
		hydroxypropyl}thieno[	ı
		3,2-c]pyridine-2-	
	0 * <b>\</b> F	carboxamide	ı
	<u>L</u>		
3820	<u> </u>		긕
		$N-\{(1S,2R)-1-(3,5-$	
	H	difluorobenzyl)-3-	
	N H OHH	[(3-	
	○一人人 点 ぎ 点 人人 /	ethylbenzyl)amino]-2-	
	1 0 ~ J\ ~\ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	hydroxypropy1}-2-oxo-	
[	0 <b>\F</b>		
	l l	2,3-dihydro-1,3-	
		benzoxazole-6-	
3821	F	carboxamide	
	Ę	N-{(1S,2R)-1-(3,5-	
		difluorobenzyl)-3-	
	0	[(3-	
		ethylbenzyl)amino]-2-	
	-N 7.	hydroxypropyl}-1-	
1			
	OH OH	[oxo(phenoxy)methyl]p	
	∕~ н У <u>~</u> О	rolinamide	
	<b> </b>	·	
3822			
		6-chloro-N-{(1S,2R)-	
	0	1-(3,5-	
	1 N	difluorobenzyl)-3-	
	l o l	[(3-	
	H QH H	ethylbenzyl)amino]-2-	
	I I I , , , , ,	hydroxypropyl}-3-	
	CIO F	methy1-2-oxo-2,3-	
		dihydro-1,3-	
		benzoxazole-5-	
3823	j F	carboxamide	
1	· · · · · · · · · · · · · · · · · · ·	N-{(1S,2R)-1-(3,5-	
		difluorobenzyl)-3-	
	⟨	[(3-	
	)		
	HO HN-	ethylbenzyl)amino]-2-	
	<i>&gt;</i> -/ <i>&gt;</i> -	hydroxypropyl}-2-[4-	
	O HN-	(2,5-dioxopyrrolidin-	
		1-	
1	\\ \' \\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	yl)phenoxy]acetamide	
3824	l "b		

		22 (/10 07) 1 /2 5
	_	$N^2 - \{ (1S, 2R) - 1 - (3, 5 - 4) \}$ difluorobenzyl) - 3 - 4
	ή _	[(3-
		ethylbenzyl)amino]-2-
		hydroxypropyl}-N <sup>1</sup> -
		phenylpyrrolidine-
	NH OH ONH	1,2-dicarboxamide
	/-NH OH NIT	1,2-dicarboxamide
3825		
		2-(1,3-benzothiazol-
	н онн 🔿	2-ylmethoxy)-N-
	N N N N	{(1s,2R)-1-(3,5-
	T'S OLAF	difluorobenzyl)-3-
		[(3-
	<u> </u>	ethylbenzyl)amino]-2-
	F	hydroxypropyl}acetami
3826		de
		N-{(1s,2R)-1-(3,5-
		difluorobenzyl)-3-
		[(3-
	♥	ethylbenzyl)amino]-2-
	I N. A. F	hydroxypropyl}-3-
		methyl-4-oxo-3,4-
	OH	dihydrophthalazine-1-
	NH F	carboxamide
	INIT I	
1		
3827		
		N-{(1S,2R)-1-(3,5-
		difluorobenzyl)-3-
	N H OH H	[(3-
	N/N/N/N/N/N/N/N/N/N/N/N/N/N/N/N/N/N/N/	ethylbenzyl)amino]-2-
	Ů √F	hydroxypropyl}indoliz
		ine-2-carboxamide
1		
3828	Ė	
		N-{(1s,2R)-1-(3,5-
	Q H	difluorobenzyl)-3-
	$N \sim F$	[(3-
		ethylbenzyl) amino]-2-
	OH	hydroxypropyl}-4-oxo-
	NH F	4-phenylbutanamide
	[ [	
3829		

			<del></del>
	O N O H OH H	N-{(1s,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2-	
	N N F	hydroxypropyl \ -2- (1,3-dimethyl-2,6- dioxo-1,2,3,6-	
3830	Ė	tetrahydro-7H-purin- 7-yl)acetamide	
	HO N F	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-	
	NH F	hydroxypropyl}-4-(3- hydroxyphenyl)-4- oxobutanamide	
3831			
3031	O H N OH F	N-{(1S,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-4-(3-	
3832	NH F	methoxyphenyl)-4- oxobutanamide	
3032	н онн	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-	
	N N F	hydroxypropy1}-3',4'- dihydro-1'H- spiro[1,3-dioxolane- 2,2'-naphthalene]-8'- carboxamide	
3833		N-{(1S,2R)-1-(3,5-	
	H OH H N N N F	<pre>difluorobenzy1)-3- [(3- ethylbenzy1)amino]-2- hydroxypropy1}-3',4'- dihydro-1'H- spiro[1,3-dioxolane- 2,2'-naphthalene]-7'-</pre>	
3834	F F	carboxamide	

		$N^{1}-\{(1S,2R)-1-(3,5-$	
	S # H	difluorobenzyl)-3-	
	$N \sim F$	[(3-	
		ethylbenzyl)amino]-2- hydroxypropyl}-N <sup>2</sup> -	
	,, oh	[mercapto(methylthio)	l l
	/NH F	methyl]-D-alaninamide	
	l ·	-	:
			į
			1
3835			
		$N^2 - [(4 -$	
	P H PH H	chlorophenyl) (oxo) met hyl] $-N^1-\{(1S, 2R)-1-$	
		(3,5-difluorobenzyl)-	
	CI H O F	3-[(3-	
		ethylbenzyl)amino]-2-	ļ
	j F	hydroxypropyl}glycina	ł
3836		mide	
		N <sup>2</sup> -[(4-tert-	
	O H	butylphenyl)(oxo)meth $y1]-N^1-\{(1S,2R)-1-$	1
	N N N N N N N N N N N N N N N N N N N	(3,5-difluorobenzyl)-	
	H Ö COH	3-[(3-	
	NH F	ethylbenzyl)amino]-2-	
		hydroxypropyl}glycina	
		mide	}
3837			
3637	1	N <sup>1</sup> -{(1S, 2R)-1-(3,5-	
	1	difluorobenzyl)-3-	
		[(3-	
		ethylbenzyl)amino]-2-	
		hydroxypropyl}-N <sup>2</sup> - [oxo(pyridin-3-	
	HN F	yl)methyl]glycinamide	
	HO.		
	HŅ		
	O NH		
3838	NIA NIA	<u></u>	

2-{[2-(((1s,2R)-1-3,5-difluorobenzyl)-3-(3-difluorobenzyl)-3-(3-ethylbenzyl) aminol-2-hydroxypropyl)aminol-2-hydroxypropyl)aminol-2-hydroxypropyl)aminol-2-hydroxypropyl)aminol-2-hydroxypropyl)-3-(3-ethylbenzyl)aminol-2-hydroxypropyl)-D-alaninamide  3840  OHOM HON FOR THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF TH			
3840  O  HO HN  F  HN  HN  HN  HN  HN  HN  HN  HN  H			
## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO HN  ## HO		/	· ·
3840  3840  CC  N <sup>2</sup> -[(4- chlorophenyl) (oxo)met hyl]-N <sup>2</sup> -[(3, 2R)-1- (3, 5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl]-D- alaninamide  N <sup>2</sup> -[(3, 4- dichlorophenyl) (oxo)met hyl]-N <sup>2</sup> -((15, 2R)-1- (3, 5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl]glycina mide N <sup>2</sup> -((18, 2R)-1- (3, 5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl]glycina mide N <sup>2</sup> -((18, 2R)-1-(3, 5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl]-4- (5a, 9a- dihydrodibenzo [b, d] fu ran-2-yl)-4- oxobutanamide N <sup>3</sup> -((18, 2R)-1-(3, 5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl]-N <sup>2</sup> - (oxo[4- (trifluoromethyl)phen yl]methyl)glycinamide	ŀ	<u> </u>	
2-oxoethyl]thio)-N- [4-(1,3-oxazol-5- yl)phenyl]acetamide  N²-[(4- chlorophenyl) (oxo)met hyl]-N²-((1s,2R)-1- (3,5-difluorobenzyl)- 3-(13- ethylbenzyl)amino]-2- hydroxypropyl)-D- alaninamide  3841  N²-[(3,4- dichlorophenyl) (oxo)m ethyl]-N²-((1s,2R)-1- (3,5-difluorobenzyl)- 3-(13- ethylbenzyl)amino]-2- hydroxypropyl)glycina mide N-((1s,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-4- (5a,9a- dihydrodibenzo[b,d]fu ran-2-yl)-4- (5a,9a- dihydrodibenzo[b,d]fu ran-2-yl)-4- (5a,9a- dihydrodibenzo[b,d]fu ran-2-yl)-4- (5a,9a- dihydrodibenzo[b,d]fu ran-2-yl)-4- (5a,9a- dihydrodibenzo[b,d]fu ran-2-yl)-4- (5a,9a- dihydrodibenzo[b,d]fu ran-2-yl)-4- (5a,9a- dihydrodibenzo[b,d]fu ran-2-yl)-4- (5a,0a- dihydrodibenzo[b,d]fu ran-2-yl)-4- (5a,0a- dihydrodibenzo[b,d]fu ran-2-yl)-4- (5a,0a- dihydrodibenzo[b,d]fu ran-2-yl)-4- (5a)0a- (5a)0a- (5a)0a- (5a)0a- (5a)0a- (5a)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6x)0a- (6		<b>( )</b>	
A		<b>&gt;</b>	
3839  N2-[(4- chlorophenyl) (oxo) met hyl]-N <sup>1</sup> -((1s, 2R)-1- (3, 5-difluorobenzyl) all mino]-2- hydroxypropyl)-D- alaninamide  N2-[(3, 4- dichlorophenyl) (oxo) met hyl]-N <sup>1</sup> -((1s, 2R)-1- (3, 5-difluorobenzyl)-D- alaninamide  N1-[(3, 4- dichlorophenyl) (oxo) met hyl]-N <sup>1</sup> -((1s, 2R)-1- (3, 5-difluorobenzyl)- 3-[(3- ethylbenzyl) amino]-2- hydroxypropyl)glycina mide N-[(1s, 2R)-1-(3, 5- difluorobenzyl)-3- [(3- ethylbenzyl) amino]-2- hydroxypropyl)-4- (5a, 9a- dihydrodibenzo[b, d] fu ran-2-yl)-4- oxobutanamide N1-((1s, 2R)-1-(3, 5- difluorobenzyl)-3- [(3- ethylbenzyl) amino]-2- hydroxypropyl)-N <sup>2</sup> - (oxo[4- (trifluoromethyl)phen yl]methyl)glycinamide		HQ HN	
3840  O  HO  HN  F  HN  HN  HN  HN  HN  HN  HN  HN			
N <sup>2</sup> -[(4-  Chlorophenyl) (oxo)methyl]-N <sup>1</sup> -((1S, 2R) -1-  (3, 5-difluorobenzyl) -3-[(3-  ethylbenzyl) amino] -2-  hydroxypropyl) -D-  alaninamide   (3, 5-difluorobenzyl) -3-[(3-  ethylbenzyl) amino] -2-  hydroxypropyl) -D-  alaninamide   (3, 5-difluorobenzyl) -3-[(3-  ethylbenzyl) amino] -2-  hydroxypropyl) glycinamide   N-((1S, 2R) -1-(3, 5-  difluorobenzyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -4-  (oxolbanamide   N-((1S, 2R) -1-(3, 5-  difluorobenzyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) -3-  ((3-  ethylbenzyl) -3-  ((3-  ethylbenzyl) -3-  ((3-  ethylbenzyl) -3-  ((3-  ethylbenzyl) -3-  ((3-  ethylbenzyl) -3-  ((3-  ethylbenzyl) -3-  ((3-  ethylbenzyl) -3-  ((3-  ethylbenzyl) -3-  ((3-  ethylbenzyl) -3-		riv -	yl)phenyl]acetamide
N <sup>2</sup> -[(4-  Chlorophenyl) (oxo)methyl]-N <sup>1</sup> -((1S, 2R) -1-  (3, 5-difluorobenzyl) -3-[(3-  ethylbenzyl) amino] -2-  hydroxypropyl) -D-  alaninamide   (3, 5-difluorobenzyl) -3-[(3-  ethylbenzyl) amino] -2-  hydroxypropyl) -D-  alaninamide   (3, 5-difluorobenzyl) -3-[(3-  ethylbenzyl) amino] -2-  hydroxypropyl) glycinamide   N-((1S, 2R) -1-(3, 5-  difluorobenzyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -4-  (oxolbanamide   N-((1S, 2R) -1-(3, 5-  difluorobenzyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) amino] -2-  hydroxypropyl) -3-  ((3-  ethylbenzyl) -3-  ((3-  ethylbenzyl) -3-  ((3-  ethylbenzyl) -3-  ((3-  ethylbenzyl) -3-  ((3-  ethylbenzyl) -3-  ((3-  ethylbenzyl) -3-  ((3-  ethylbenzyl) -3-  ((3-  ethylbenzyl) -3-  ((3-  ethylbenzyl) -3-  ((3-  ethylbenzyl) -3-		_s′ b	
N <sup>2</sup> -[(4- chlorophenyl) (oxo)methology   N <sup>2</sup> -[(1s, 2R) -1- (3, 5-difluorobenzyl) - 3-[(3- ethylbenzyl) amino] -2- hydroxypropyl) -D- alaninamide   N <sup>2</sup> -[(1s, 2R) -1- (3, 5-difluorobenzyl) - 3-[(3- ethylbenzyl) amino] -2- hydroxypropyl) glycinamide   N-((1s, 2R) -1- (3, 5-difluorobenzyl) - 3-[(3- ethylbenzyl) amino] -2- hydroxypropyl) glycinamide   N-((1s, 2R) -1- (3, 5- difluorobenzyl) -3- [(3- ethylbenzyl) amino] -2- hydroxypropyl) -4- (5a, 3a- dihydrodibenzo [b, d] furan -2-yl) -4- oxobutanamide   N <sup>2</sup> -((1s, 2R) -1- (3, 5- difluorobenzyl) -3- [(3- ethylbenzyl) amino] -2- hydroxypropyl) -N <sup>2</sup> - (oxo[4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -((1s, 2R) -1- (3, 5- difluorobenzyl) -3- ((3- ethylbenzyl) amino] -2- hydroxypropyl) -N <sup>2</sup> - (oxo[4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -((sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]methyl]methyl]methyl]methyl]methylliginamide   N <sup>2</sup> -(sx) (4- (trifluoromethylliginamide		HN-√ F	
N <sup>2</sup> -[(4- chlorophenyl) (oxo)methology   N <sup>2</sup> -[(1s, 2R) -1- (3, 5-difluorobenzyl) - 3-[(3- ethylbenzyl) amino] -2- hydroxypropyl) -D- alaninamide   N <sup>2</sup> -[(1s, 2R) -1- (3, 5-difluorobenzyl) - 3-[(3- ethylbenzyl) amino] -2- hydroxypropyl) glycinamide   N-((1s, 2R) -1- (3, 5-difluorobenzyl) - 3-[(3- ethylbenzyl) amino] -2- hydroxypropyl) glycinamide   N-((1s, 2R) -1- (3, 5- difluorobenzyl) -3- [(3- ethylbenzyl) amino] -2- hydroxypropyl) -4- (5a, 3a- dihydrodibenzo [b, d] furan -2-yl) -4- oxobutanamide   N <sup>2</sup> -((1s, 2R) -1- (3, 5- difluorobenzyl) -3- [(3- ethylbenzyl) amino] -2- hydroxypropyl) -N <sup>2</sup> - (oxo[4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -((1s, 2R) -1- (3, 5- difluorobenzyl) -3- ((3- ethylbenzyl) amino] -2- hydroxypropyl) -N <sup>2</sup> - (oxo[4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -((sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]methyl]methyl]methyl]methyl]methylliginamide   N <sup>2</sup> -(sx) (4- (trifluoromethylliginamide		<sub>r</sub> √ δ	
N <sup>2</sup> -[(4- chlorophenyl) (oxo)methology   N <sup>2</sup> -[(1s, 2R) -1- (3, 5-difluorobenzyl) - 3-[(3- ethylbenzyl) amino] -2- hydroxypropyl) -D- alaninamide   N <sup>2</sup> -[(1s, 2R) -1- (3, 5-difluorobenzyl) - 3-[(3- ethylbenzyl) amino] -2- hydroxypropyl) glycinamide   N-((1s, 2R) -1- (3, 5-difluorobenzyl) - 3-[(3- ethylbenzyl) amino] -2- hydroxypropyl) glycinamide   N-((1s, 2R) -1- (3, 5- difluorobenzyl) -3- [(3- ethylbenzyl) amino] -2- hydroxypropyl) -4- (5a, 3a- dihydrodibenzo [b, d] furan -2-yl) -4- oxobutanamide   N <sup>2</sup> -((1s, 2R) -1- (3, 5- difluorobenzyl) -3- [(3- ethylbenzyl) amino] -2- hydroxypropyl) -N <sup>2</sup> - (oxo[4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -((1s, 2R) -1- (3, 5- difluorobenzyl) -3- ((3- ethylbenzyl) amino] -2- hydroxypropyl) -N <sup>2</sup> - (oxo[4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -((sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]methyl]methyl]methyl]methyl]methylliginamide   N <sup>2</sup> -(sx) (4- (trifluoromethylliginamide		<b>\_</b> \(\)	
N <sup>2</sup> -[(4- chlorophenyl) (oxo)methology   N <sup>2</sup> -[(1s, 2R) -1- (3, 5-difluorobenzyl) - 3-[(3- ethylbenzyl) amino] -2- hydroxypropyl) -D- alaninamide   N <sup>2</sup> -[(1s, 2R) -1- (3, 5-difluorobenzyl) - 3-[(3- ethylbenzyl) amino] -2- hydroxypropyl) glycinamide   N-((1s, 2R) -1- (3, 5-difluorobenzyl) - 3-[(3- ethylbenzyl) amino] -2- hydroxypropyl) glycinamide   N-((1s, 2R) -1- (3, 5- difluorobenzyl) -3- [(3- ethylbenzyl) amino] -2- hydroxypropyl) -4- (5a, 3a- dihydrodibenzo [b, d] furan -2-yl) -4- oxobutanamide   N <sup>2</sup> -((1s, 2R) -1- (3, 5- difluorobenzyl) -3- [(3- ethylbenzyl) amino] -2- hydroxypropyl) -N <sup>2</sup> - (oxo[4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -((1s, 2R) -1- (3, 5- difluorobenzyl) -3- ((3- ethylbenzyl) amino] -2- hydroxypropyl) -N <sup>2</sup> - (oxo[4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -((sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]methyl]methyl]methyl]methyl]methylliginamide   N <sup>2</sup> -(sx) (4- (trifluoromethylliginamide			
N <sup>2</sup> -[(4- chlorophenyl) (oxo)methology   N <sup>2</sup> -[(1s, 2R) -1- (3, 5-difluorobenzyl) - 3-[(3- ethylbenzyl) amino] -2- hydroxypropyl) -D- alaninamide   N <sup>2</sup> -[(1s, 2R) -1- (3, 5-difluorobenzyl) - 3-[(3- ethylbenzyl) amino] -2- hydroxypropyl) glycinamide   N-((1s, 2R) -1- (3, 5-difluorobenzyl) - 3-[(3- ethylbenzyl) amino] -2- hydroxypropyl) glycinamide   N-((1s, 2R) -1- (3, 5- difluorobenzyl) -3- [(3- ethylbenzyl) amino] -2- hydroxypropyl) -4- (5a, 3a- dihydrodibenzo [b, d] furan -2-yl) -4- oxobutanamide   N <sup>2</sup> -((1s, 2R) -1- (3, 5- difluorobenzyl) -3- [(3- ethylbenzyl) amino] -2- hydroxypropyl) -N <sup>2</sup> - (oxo[4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -((1s, 2R) -1- (3, 5- difluorobenzyl) -3- ((3- ethylbenzyl) amino] -2- hydroxypropyl) -N <sup>2</sup> - (oxo[4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -((sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]glycinamide   N <sup>2</sup> -(sx) (4- (trifluoromethyl) phen yl]methyl]methyl]methyl]methyl]methyl]methylliginamide   N <sup>2</sup> -(sx) (4- (trifluoromethylliginamide		9-1	
chlorophenyl) (oxo)met hyl]-N <sup>-</sup> ((IS,2R)-1- (3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-D-alaninamide  N <sup>2</sup> -[(3,4-dichlorophenyl) (oxo)methyl]-N <sup>1</sup> -((1S,2R)-1- (3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)glycinamide  N <sup>-</sup> ((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-4- (5a,9a-dihydrodibenzo[b,d]furan-2-yl)-4- oxobutanamide  N <sup>-</sup> ((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-N <sup>2</sup> - (oxo(4-(trifluoromethyl)phenyl)methyl)glycinamide	3839	N	
hyl]-N <sup>1</sup> -{(1s,2R)-1-(3,5-difluorobenzyl)-3,-[(3-ethylbenzyl) amino]-2-hydroxypropyl}-D-alaninamide  N <sup>2</sup> -[(3,4-dichlorophenyl) (oxo) methyl]-N <sup>1</sup> -{(1s,2R)-1-(3,5-difluorobenzyl)-3,-[(3-ethylbenzyl) amino]-2-hydroxypropyl}glycinamide  N-((1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl) amino]-2-hydroxypropyl}-4-(5a,9a-dihydrodibenzo[b,d]furan-2-yl)-4-oxobutanamide  N <sup>1</sup> -((1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl) amino]-2-hydroxypropyl}-N <sup>2</sup> -(oxo(4-(trifluoromethyl)phenyl)methyl)glycinamide			
3840  O  HO  HN  F  A  O  HO  H  HO  HN  F  O  H  HO  H  H  H  H  H  H  H  H  H  H		/ /	
3840  Cl  HN  HN  A  Cl  H OH H  Cl  H OH H  Cl  H OH H  Cl  H OH H  Cl  H OH H  Cl  H OH H  Cl  H OH H  Cl  H OH H  Cl  H OH H  Cl  H OH H  Cl  H OH H  Cl  H OH H  Cl  H OH H  Cl  H OH H  Cl  H OH H  Cl  H OH H  Cl  H OH H  Cl  H OH H  Cl  A  Cl  H OH H  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A  Cl  A			
3840  CO  H OH H  CO  H OH H  CO  H OH H  CO  H OH H  CO  H OH H  CO  H OH H  CO  H OH H  CO  H OH H  CO  H OH H  CO  H OH H  CO  H OH H  CO  H OH H  CO  H OH H  CO  H OH H  CO  H OH H  CO  H OH H  CO  H OH H  CO  H OH H  CO  H OH H  CO  H OH H  CO  H OH H  CO  H OH H  CO  H OH H  CO  H OH H  CO  H OH H  CO  H OH H  CO  H OH H  CO  H OH H  CO  CO  H OH H  CO  H OH H  CO  CO  H OH H  CO  CO  H OH H  CO  CO  H OH H  CO  CO  CO  H OH H  CO  CO  CO  CO  CO  CO  CO  CO  CO  C		HO HN-	
hydroxypropy1}-D-   alaninamide     hydroxypropy1}-D-   alaninamide     hydroxypropy1}-D-   alaninamide     hydroxypropy1}-D-   alaninamide     hydroxypropy1}-1-   (3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}glycina   mide   hydroxypropy1}-d-   (5a,9a-dihydrodibenzo[b,d]fu   ran-2-y1)-4-   (5a,9a-dihydrodibenzo[b,d]fu   ran-2-y1)-4-   (5a,9a-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-N²-   (oxo[4-(trifluoromethyl)phen   y1]methy1}glycinamide   hydroxypropy1}-N²-   (oxo[4-(trifluoromethyl)phen   y1]methy1}glycinamide   hydroxypropy1}-N²-   (oxo[4-(trifluoromethyl)phen   y1]methy1}glycinamide   hydroxypropy1-N²-   (oxo[4-(trifluoromethyl)phen   y1]methy1}glycinamide   hydroxypropy1-N²-   (oxo[4-(trifluoromethyl)phen   y1]methy1}   hydroxypropy1-N²-   (oxo[4-(trifluoromethyl)phen   y1]methy1}   hydroxypropy1-N²-   (oxo[4-(trifluoromethyl)phen   y1]methy1}   hydroxypropy1-N²-   (oxo[4-(trifluoromethyl)phen   y1]methy1}   hydroxypropy1-N²-   (oxo[4-(trifluoromethyl)phen   y1]methy1}   hydroxypropy1-N²-   (oxo[4-(trifluoromethyl)phen   y1]methy1-N²-   (oxo[4-(trifluoromethyl)phen   y1]methy1-N²-   (oxo[4-(trifluoromethyl)phen   y1]methy1-N²-   (oxo[4-(trifluoromethyl)phen   y1]methy1-N²-   (oxo[4-(trifluoromethyl)phen   y1]methy1-N²-   (oxo[4-(trifluoromethyl)phen   y1]methy1-N²-   (oxo[4-(trifluoromethyl)phen   y1]methy1-N²-   (oxo[4-(trifluoromethyl)phen   y1]methy1-N²-   (oxo[4-(trifluoromethyl)phen   y1]methy1-N²-   (oxo[4-(trifluoromethyl)phen   y1]methy1-N²-   (oxo[4-(trifluoromethyl)phen   (oxo[4-(trifluoromethyl)phen   (oxo[4-(trifluoromethyl)phen   (oxo[4-(trifluoromethyl)phen   (oxo[4-(trifluoromethyl)phen   (oxo[4-(trifluoromethyl)phen   (oxo[4-(trifluoromethyl)phen   (oxo[4-(trifluoromethyl)phen   (oxo[4-(trifluoromethyl)phen   (oxo[4-(trifluoromethyl)phen   (oxo[4-(trifluoromethyl)phen   (oxo[4-(trifluoromethyl)phen   (oxo[4-(trifluoromethyl)phen   (oxo[4-(trifluoromethyl)phen   (oxo[4-(trifluoromethyl)phen   (ox		) F	
3840  CI  N <sup>2</sup> -[(3,4- dichlorophenyl)(oxo)m ethyl]-N <sup>1</sup> -((1s,2R)-1- (3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl)glycina mide  N-{(1s,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-4- (5a,9a- dihydrodibenzo[b,d]fu ran-2-yl)-4- oxobutanamide  N <sup>1</sup> -((1s,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl)-3- [(3- ethylbenzyl)-3- ((5a,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3- ((3- ethylbenzyl)-3		<b>\</b> HŅ⟨ /=-⟨	, ,
C			
N <sup>2</sup> -[(3,4-    dichlorophenyl) (0x0) m     ethyl]-N <sup>1</sup> -{(1s,2R)-1-    (3,5-    difluorobenzyl) -     3-[(3-    ethylbenzyl) amino]-2-    hydroxypropyl}-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl}-4-    (5a,9a-    dihydrodibenzo[b,d] fu     ran-2-yl)-4-    0x0butanamide     N <sup>1</sup> -{(1s,2R)-1-(3,5-    difluorobenzyl)-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl}-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl]-4-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl]-N <sup>2</sup> -    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl]-N <sup>2</sup> -    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl]-N <sup>2</sup> -    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl]-N <sup>2</sup> -    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl]-N <sup>2</sup> -    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl]-N <sup>2</sup> -    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl]-N <sup>2</sup> -    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl]-N <sup>2</sup> -    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5		NH O \(\frac{1}{2}\)	alaninamide '
N <sup>2</sup> -[(3,4-    dichlorophenyl) (0x0) m     ethyl]-N <sup>1</sup> -{(1s,2R)-1-    (3,5-    difluorobenzyl) -     3-[(3-    ethylbenzyl) amino]-2-    hydroxypropyl}-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl}-4-    (5a,9a-    dihydrodibenzo[b,d] fu     ran-2-yl)-4-    0x0butanamide     N <sup>1</sup> -{(1s,2R)-1-(3,5-    difluorobenzyl)-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl}-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl]-4-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl]-N <sup>2</sup> -    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl]-N <sup>2</sup> -    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl]-N <sup>2</sup> -    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl]-N <sup>2</sup> -    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl]-N <sup>2</sup> -    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl]-N <sup>2</sup> -    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl]-N <sup>2</sup> -    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl]-N <sup>2</sup> -    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5		F	
N <sup>2</sup> -[(3,4-    dichlorophenyl) (0x0) m     ethyl]-N <sup>1</sup> -{(1s,2R)-1-    (3,5-    difluorobenzyl) -     3-[(3-    ethylbenzyl) amino]-2-    hydroxypropyl}-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl}-4-    (5a,9a-    dihydrodibenzo[b,d] fu     ran-2-yl)-4-    0x0butanamide     N <sup>1</sup> -{(1s,2R)-1-(3,5-    difluorobenzyl)-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl}-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl]-4-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl]-N <sup>2</sup> -    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl]-N <sup>2</sup> -    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl]-N <sup>2</sup> -    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl]-N <sup>2</sup> -    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl]-N <sup>2</sup> -    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl]-N <sup>2</sup> -    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl]-N <sup>2</sup> -    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (3-    ethylbenzyl) amino]-2-    hydroxypropyl]-N <sup>2</sup> -    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5-    difluorobenzyl)-3-    (xis,2R)-1-(3,5			
dichlorophenyl)(oxo)m ethyl]-N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)glycina mide N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-(5a,9a-dihydrodibenzo[b,d]fu ran-2-yl)-4-oxobutanamide N¹-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N²-{oxo[4-(trifluoromethyl)phenyl]methyl}glycinamide	3840	cı'	
ethyl]-N <sup>1</sup> -{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}glycina mide  N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-(5a,9a-dihydrodibenzo[b,d]furan-2-yl)-4-oxobutanamide  N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -{oxobutanamide}  N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -{oxobutanamide}  N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -{oxobutanamide}  N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -{oxobutanamide}  N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -{oxobutanamide}  N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -{oxobutanamide}  N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -{oxobutanamide}  N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -{oxobutanamide}  N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -{oxobutanamide}  N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -{oxobutanamide}  N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -{oxobutanamide}  N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -{oxobutanamide}  N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -{oxobutanamide}  N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -{oxobutanamide}  N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -{oxobutanamide}  N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -{oxobutanamide}  N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -{oxobutanamide}-N <sup>2</sup> -{oxobutanamide}-N <sup>2</sup> -{oxobutanamide}-N <sup>2</sup> -{oxobutanamide}-N <sup>2</sup> -{oxobutanamide}-N <sup>2</sup> -{oxobutanamide}-N <sup></sup>			1 - 1
(3,5-difluorobenzyl) - 3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)glycina mide  N-((1s,2R)-1-(3,5-difluorobenzyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl}-4- (5a,9a-dihydrodibenzo[b,d]fu ran-2-yl)-4- oxobutanamide  N-((1s,2R)-1-(3,5-difluorobenzyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl}-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl}-N²- (oxo[4-(trifluoromethyl)phen yl]methyl)glycinamide		о нонн 🗥	dichlorophenyl)(oxo)m
3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)glycina mide  N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-(5a,9a-dihydrodibenzo[b,d]fu ran-2-yl)-4-oxobutanamide  N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N^2-(oxo[4-(trifluoromethyl)phen yl]methyl}glycinamide		CI N N N N N N N N N N N N N N N N N N	
as41    Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Solution   Sol		H O VF	
hydroxypropyl}glycina mide   N-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-(5a,9a-dihydrodibenzo[b,d]fu ran-2-yl)-4-oxobutanamide   N^1-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N^2-(oxo[4-(trifluoromethyl)phenyl]methyl}glycinamide   N   N   N   N   N   N   N   N   N		[ ]	1 = ·
## mide  N-{(1s,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1}-4-(5a,9a-dihydrodibenzo[b,d]furan-2-y1)-4-oxobutanamide  N-{(1s,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1}-3-[(3-ethylbenzy1) amino]-2-hydroxypropy1}-N^2-(oxo[4-(trifluoromethyl)pheny1]methy1)glycinamide		Ţ	
N-{(1s,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-4-(5a,9a-dihydrodibenzo[b,d]furan-2-y1)-4-oxobutanamide  N-{(1s,2R)-1-(3,5-difluorobenzy1)amino]-2-hydroxypropy1}-4-(5a,9a-dihydrodibenzo[b,d]furan-2-y1)-4-oxobutanamide  N-{(1s,2R)-1-(3,5-dihydroxypropy1)-4-(sa,9a-dihydroxypropy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-N^2-(oxo[4-(trifluoromethyl)pheny1]methyl)glycinamide			
difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-4- (5a,9a- dihydrodibenzo[b,d]fu ran-2-yl)-4- oxobutanamide  N¹-{(1s,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-N²- {oxo[4- (trifluoromethyl)phen yl]methyl}glycinamide	3841		
[(3- ethylbenzyl)amino]-2- hydroxypropyl}-4- (5a,9a- dihydrodibenzo[b,d]fu ran-2-yl)-4- oxobutanamide N¹-{(1S,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-N²- {oxo[4- (trifluoromethyl)phen yl]methyl}glycinamide			'''
ethylbenzyl)amino]-2- hydroxypropyl}-4- (5a,9a- dihydrodibenzo[b,d]fu ran-2-yl)-4- oxobutanamide  N¹-{(1s,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-N²- {oxo[4- (trifluoromethyl)phen yl]methyl}glycinamide		l H OH H	t i
hydroxypropy1}-4- (5a,9a- dihydrodibenzo[b,d]fu ran-2-y1)-4- oxobutanamide  N¹-{(1S,2R)-1-(3,5- difluorobenzy1)-3- [(3- ethylbenzy1)amino]-2- hydroxypropy1}-N²- {oxo[4- (trifluoromethyl)phen y1]methy1}glycinamide			
(5a,9a-dihydrodibenzo[b,d]fu ran-2-yl)-4-oxobutanamide  N¹-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N²-{oxo[4-(trifluoromethyl)phenyl]methyl}glycinamide			
dihydrodibenzo[b,d]fu ran-2-yl)-4- oxobutanamide  N¹-{(1S,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-N²- {oxo[4- (trifluoromethyl)phen yl]methyl}glycinamide		\ \	
ran-2-yl)-4- oxobutanamide  N¹-{(1S,2R)-1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-N²- {oxo[4- (trifluoromethyl)phen yl]methyl}glycinamide		Ė	
oxobutanamide  N¹-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-N²-{oxo[4-(trifluoromethyl)phenyl]methyl}glycinamide			
N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -{oxo[4-(trifluoromethyl)phenyl]methyl}glycinamide	3042		· - · · · · · · · · · · · · · · · · · ·
difluorobenzy1)-3- [(3- ethylbenzy1)amino]-2- hydroxypropy1}-N²- {oxo[4- (trifluoromethyl)phen y1]methyl}glycinamide	3042		
HO HN  HO HN  HN  ONH  ONH  F  [(3- ethylbenzyl)amino]-2- hydroxypropyl}-N²- {oxo[4- (trifluoromethyl)phen y1]methyl}glycinamide			
HO HN F HN STATE OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPER		\ \ \_	- !
hydroxypropyl}-N²- {oxo[4- (trifluoromethyl)phen yl]methyl}glycinamide		\ \—'	
HN- (trifluoromethyl)phen yl]methyl)glycinamide		HO HN	
ONH O F (trifluoromethyl)phen yl]methyl}glycinamide		HN-\(\sigma\)	
F John Tool			
3843 F F			yl]methyl}glycinamide
3843 F F	1	/= \	
3843 F F	1	\_ <b>\_</b>	
3843   f <sup>T</sup>		F	
	3843	f <sup>}</sup>	

	<del></del>	<del>- 1 - 7 - 7 - 7 - 7 - 7 - 7 - 7 - 7 - 7 </del>	
-		$N^1 - \{ (1S, 2R) - 1 - (3, 5 - 1) \}$	
	FO HOHH	difluorobenzyl)-3-	
		[(3-	
		ethylbenzyl)amino]-2-	
	~~ F'' 0 ~~ ~~ L	hydroxypropyl}-N2-	
		[(2,6-	
	<u></u>	difluorophenyl)(oxo)m	
3844	į	ethyl]glycinamide	
2044		$N^1 - \{ (1S, 2R) - 1 - (3, 5 - 1) \}$	
		difluorobenzyl)-3-	
		1 '	
		[(3-	
1	H O V	ethylbenzyl)amino]-2-	
ļ		hydroxypropyl}-N2-	
	Ī	[oxo(4-	
	'	methoxyphenyl)methyl]	
3845		glycinamide	
	·	N-{(1S,2R)-1-(3,5-	
		difluorobenzyl)-3-	
	O H OHH	[(3-	
		ethylbenzyl)amino]-2-	
		hydroxypropyl}-4-(2-	
	0 <b>F</b>	oxo-1,3-oxazolidin-3-	
		yl)benzamide	
3846	Y	y 17 benzami de	
3640	F	N (/10 2P) 1 /2 5	
		N-{(1S,2R)-1-(3,5-	
	H OHH	difluorobenzyl)-3-	
İ	N N N	[(3-	•
	O √F	ethylbenzyl)amino]-2-	
		hydroxypropyl}-5-	
	Y	(phenylethynyl)nicoti	
3847	F	namide	
	İ	N <sup>1</sup> -{(1S,2R)-1-(3,5-	
ļ		difluorobenzyl)-3-	
		[(3-	
		ethylbenzyl)amino]-2-	
	1	hydroxypropyl}-N3-	
	uo HN√ ⊏	[oxo(1H-1,2,4-	
	HO, "F	triazol-5-yl)methyl]-	
		D-alaninamide	
	HN		
	/ ~O		
ł	H HN		
	N-IN		
3848	O "_j.'		
70±0	IN	2-{[2-({(1S,2R)-1-	
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	(3,5-difluorobenzyl)-	
		3-[(3-	
	HQ_HN—	ethylbenzyl)amino]-2-	
1	HN—	hydroxypropyl amino) -	
		2-oxoethyl]thio}-N-	
	-S D -S	(pyridin-4-	
2046	HN— F	ylmethyl)acetamide	
3849			

		$N-\{(1S,2R)-1-(3,5-$	
	,	difluorobenzyl)-3-	
	/ 1	[(3-	
		ethylbenzyl)amino]-2-	
	( / )	hydroxypropyl}-4-	ŀ
Ì		[(methoxymethyl)thio]	
	/ /		į
	uo HN − E	benzamide	į
	HO, ''j' F		Į.
			Ì
	HN		
	S -		
3850	۱ ۲		
3030		N-{(1S,2R)-1-(3,5-	
	_		
	оо н ОН н 🔿	difluorobenzyl)-3-	
[		[(3-	
		ethylbenzyl)amino]-2-	
	- N-/ A A,	hydroxypropyl}-4-	
	·		
	 	(1,5-dimethyl-3-oxo-	
	·	2-pheny1-2,3-dihydro-	
		1H-pyrazol-4-yl)-4-	
		oxobutanamide	
3851			
		4-(4-benzy1-1,4-	
		diazepan-1-yl)-N-	l
		{(1S,2R)-1-(3,5-	
	о н он 🕥	difluorobenzyl)-3-	
	$N \rightarrow N \rightarrow N \rightarrow N \rightarrow N \rightarrow N \rightarrow N \rightarrow N \rightarrow N \rightarrow N \rightarrow$	1	
		[(3-	
		ethylbenzyl)amino]-2-	
	$\langle \cdot \rangle$	hydroxypropyl}-4-	
		oxobutanamide	
3852			
		N-{(1S,2R)-1-(3,5-	
		difluorobenzy1)-3-	
	→ н онн →	[(3-	
		ethylbenzyl)amino]-2-	
	( ) ' O <b>\</b> F	hydroxypropy1}-2,5-	
	N==	dimethyl-1-(pyridin-	
1		4-ylmethyl)-1H-	1
2052	ļ Ė	pyrrole-3-carboxamide	}
3853	•		<del> </del>
		N-	1
	НО Н	[(dimethylamino)sulfo	
	ONI ANA AF	nyl]glycyl-N <sup>1</sup> -	
	\.\.\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	{ (1s, 2R) -1-(3,5-	
	NO HOLA		
	T OH Y	difluorobenzyl)-3-	
	NH F	[(3-	
	\ \( \tag{\cdots} \)	ethylbenzyl)amino]-2-	
		hydroxypropyl}glycina	
		·	1
		mide	
3854			1
3034			

		N-{(1S,2R)-1-(3,5-
	Ę	difluorobenzyl)-3-
		[(3-
	[	ethylbenzyl)amino]-2-
	F Q	hydroxypropyl}-4-
		hydroxy-1-[(1R,2R)-2-
	Y N Y N Y OH	
	H OH H N-/ "	hydroxycyclohexyl]pro
	17	linamide
3855	ОН	
		(2S,3S)-N-{(1S,2R)-1-
		(3,5-difluorobenzyl)-
	<b>N QU \</b>	3-[(3-
1	HOHH	ethylbenzyl)amino]-2-
		hydroxypropyl}-1-
		methyl-5-oxo-2-
	N	pyridin-3-
	Y	ylpyrrolidine-3-
3856	Ė	carboxamide
		N-{(1S,2R)-1-(3,5-
		difluorobenzyl)-3-
	· (	[(3-
	о Л н ОН н Л	ethylbenzyl)amino]-2-
ļ		
		hydroxypropy1}-3-
	\d \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	(2,5-dioxopyrrolidin-
		1-yl)benzamide
2057	Ţ	
3857	<u> </u>	N-(2-cyano-4,5,6,7-
		tetrahydro-1-
	<b></b>	benzothien-3-yl)-N'-
	HQ HN-	{(1s,2r)-1-(3,5-
	) F	difluorobenzyl)-3-
	HN-{(	[(3-
		ethylbenzyl)amino]-2-
	D F	hydroxypropyl}succina
	S	mide
		mide
3858	N	
		N-{(1S,2R)-1-(3,5-
		difluorobenzyl)-3-
		[(3-
		ethylbenzyl)amino]-2-
	O H OHH	hydroxypropy1}-2-
	$N \sim N \sim N$	
1	HN T I	(2,5-
	NH O F	dioxoimidazolidin-4-
	0	yl)acetamide
3859	į į	
L		······································

		<del></del>
		N-{(1S,2R)-1-(3,5-
		difluorobenzyl)-3-
	<u></u>	[ (3-
	н Онн	ethylbenzyl)amino]-2-
1	$N \sim N \sim N \sim N \sim N \sim N \sim N \sim N \sim N \sim N \sim$	hydroxypropyl}-2-
	N-V III II A F	(5,7-
		dimethyl[1,2,4]triazo
		lo[1,5-a]pyrimidin-2-
3860	Ė	yl)acetamide
		N-{(1s,2R)-1-(3,5-
		difluorobenzy1)-3-
	() (	[(3-
	H OH H	ethylbenzyl)amino]-2-
	N N	, – –
ļ l	l F	hydroxypropyl}-1-(2-
	, TT.	furylmethyl)-5-
	$\checkmark$	oxopyrrolidine-3-
3861	ļ ļ	carboxamide
		N-{(1s,2R)-1-(3,5-
	О Н	difluorobenzyl)-3-
		[(3-
		ethylbenzyl)amino]-2-
	HN O O	hydroxypropyl}-4-oxo-
	NH F	4-(5-oxo-1,4-
	IND F	diazepan-1-
		yl)butanamide
		71,220
3862		
	\	N-{(1S,2R)-1-(3,5-
		difluorobenzyl)-3-
	💙	[(3-
	\	ethylbenzyl)amino]-2-
	H OHH	hydroxypropyl}-3-(4-
	"N\\N\\N\\	methylphenyl)-4,5-
	HOLE	dihydro-1H-pyrazole-
		5-carboxamide
3863	Ī	
13003	F	N-{(1s,2r)-1-(3,5-
		difluorobenzyl)-3-
	1.0	[(3-
	N <sup>†</sup>	ethylbenzyl)amino]-2-
	N OH H	hydroxypropyl}-2,1,3-
	N N N N N N N N N N N N N N N N N N N	benzoxadiazole-5-
	Ů Å ∧ F	carboxamide 1-oxide
	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	Carboxamide 1-oxide
3064	Ī	
3864	<u> </u>	

		N-{(1S,2R)-1-(3,5-
1		difluorobenzyl)-3-
	THOM H	[(3-
ŀ		ethylbenzyl)amino]-2-
		hydroxypropyl}-3-(2-
		pyridin-3-
	<b>Y</b>	ylpiperidin-1-
2005	Ė	
3865		yl)propanamide
		N-{(1s,2R)-1-(3,5-
	,	difluorobenzyl)-3-
	(	[(3-
		ethylbenzyl)amino]-2-
		hydroxypropyl}-4-oxo-
	7	4-(2-propyl-1H-
	LINI	imidazol-1-
	HO, HN F	
	i	yl)butanamide
	HN \	
		ļ.
	`F	
		·
	Γ	
	Ń	
	1 >	
3866	N-//	
		N-{(1S,2R)-1-(3,5-
1		difluorobenzyl)-3-
į		[(3-
	H OHH	ethylbenzyl)amino]-2-
	H QH H	hydroxypropyl}-4a,9a-
İ		dihydro-9H-carbazole-
		9-carboxamide
	<u>l</u>	
3867	<u> </u>	
		N-{(1S,2R)-1-(3,5-
1		difluorobenzyl)-3-
	H OH H	[(3-
	N.N. N. N. N. N. N. N. N. N. N. N. N. N.	F = -
		ethylbenzyl)amino]-2-
	\ \ \ \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	hydroxypropyl}-6-
		methyl-4-oxo-1-
	<b>Y</b>	phenyl-1,4-
	į Ė	
		dihydropyridazine-3-
3868		carboxamide
	0 .	N'-((1S,2R)-1-(3,5-
1	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	difluorobenzyl)-2-
	N √ ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` `	,
		hydroxy-3-{[1-methyl-
	H QH Y	5-(pyrrolidin-1-
	N N NH	ylcarbonyl)-1H-
		pyrrol-3-
		, - <del>-</del>
		yl]amino}propyl)-5-
	<b> </b>	methyl-N,N-
	) F	dipropylisophthalamid
3869		
13807	!	e

_			
		N'-((1S,2R)-1-(3,5-	- 1
į į	$\cap$	difluorobenzyl)-2-	- 1
	0~N~/	hydroxy-3-{[2-(2-oxo-	
		2-pyrrolidin-1-	-
1	l H ÔH H Ô	ylethoxy)phenyl]amino	
	N	}propyl)-5-methyl-	Ì
	ä ö į 💛 l		- 1
į l		N,N-	1
	F-{ }	dipropylisophthalamid	
3870		e	
		$N' - \{ (1S, 2R) - 1 - (3, 5 - 1) \}$	
	I HOME P	difluorobenzyl)-2-	١
	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	hydroxy-3-[(3-{[3-	
		(hydroxymethyl)piperi	
	F-{ }	din-1-	
	F		
		yl]carbonyl)phenyl)am	I
		ino]propyl}-5-methyl-	
		N,N-	
	•	dipropylisophthalamid	
3871		е	
		$N^{1}-\{(1S,2R)-1-(3,5-$	
	о нонн 🦳	difluorobenzyl)-3-	
		[(3-	
	S N JUS S	ethylbenzyl)amino]-2-	
	0	hydroxypropy1}-N2-[3-	ļ
		(methylthio)-1-	
		oxopropyl]-N <sup>2</sup> -	
2000	'		
3872		pentylglycinamide	
	P H QH H	$N^{1} - \{ (1S, 2R) - 1 - (3, 5 - 1) \}$	
	SON NOT NOT NOT NOT NOT NOT NOT NOT NOT N	difluorobenzyl)-3-	
	S N F	[(3-	
		ethylbenzyl)amino]-2-	
		hydroxypropyl}-N <sup>2</sup> -[3-	
	' F	(methylsulfonyl)-1-	
		oxopropyl]-N <sup>2</sup> -	
3873		pentylglycinamide	
		N-{(1S,2R)-1-benzyl-	
		2-hydroxy-3-[(3-	
		methoxybenzyl)amino]p	
	I O H	ropy1}-3-	
		(phenylsulfonyl)propa	
		namide	
	O (""OH	Tam-ue	
1	, NH		
	[""		
		1	
3874			
30/4			

3875	O H HÖH H	N'-{(1S,2R)-1-(3,5-difluorobenzy1)-2-hydroxy-3-[(7-oxabicyclo[2.2.1]hept-2-ylmethyl)amino]propyl}-5-methyl-N,N-dipropylisophthalamide	
3876	HH H H H H H H H H H H H H H H H H H H	N'-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(3R)-2-oxo-1-propylazepan-3-yl]amino}propyl)-5-methyl-N,N-dipropylisophthalamide	
	H H H H H N N N N N N N N N N N N N N N	N'-[(1S,2R)-3-[(1- acetylpiperidin-4- yl)amino]-1-(3,5- difluorobenzyl)-2- hydroxypropyl]-5- methyl-N,N- dipropylisophthalamid e	·
3877	<b>├</b> 0		
3878	N N N N N N N N N N N N N N N N N N N	N'-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N-[2-(dimethylamino)-2-oxoethyl]-N,5-dimethylisophthalamide	
3879	N N H OH H	N'-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N-[2-(dimethylamino)ethyl]-N-ethyl-5-methylisophthalamide N-benzyl-N'-{(1S,2R)-	
3880	O O O O O O O O O O O O O O O O O O O	1-(3,5- difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-N,5- dimethylisophthalamid	

			<del></del> -
		$N-\{(1S, 2R)-1-(3, 5-$	
	F I	difluorobenzyl)-3-	
	OH 📄	[(3-	ŀ
·	で	ethylbenzyl)amino]-2-	l
		hydroxypropyl}-3-{[2-	
	N N N N N N N N N N N N N N N N N N N	(2-	
	HHOHH A	hydroxyethyl)piperidi	
	1	n-1-yl]carbonyl}-5-	
		methylbenzamide	
3881		N'-{(1S,2R)-1-(3,5-	
	_		
]	į l	difluorobenzyl)-3-	
		[(3-	
	9 9 (H F	ethylbenzyl)amino]-2-	
	N N N N N N N N N N N N N N N N N N N	hydroxypropyl}-N,5-	
	г (√) н но́н н (√)	dimethy1-N-(2-	
	l	phenylethyl)isophthal	
3882		amide	
3002		N'-((1S,2R)-1-(3,5-	
	F	difluorobenzy1)-3-	
	<u> </u>	{[3-(3-formy1-2-	
	长儿-	furyl)benzyl]amino}-	
	O OH.		
	~\n'\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	2-hydroxypropy1)-5-	
	\rightarrow \langle \text{H.OH.} \rightarrow \langle \text{A.OH.}	methyl-N,N-	
	, ,	dipropylisophthalamid	
3883		e	
		N'-((1S,2R)-1-(3,5-	
	F	difluorobenzyl)-3-	
		{[3-(5-formyl-2-	
	0 0 F 5-	thienyl)benzyl]amino}	
		-2-hydroxypropyl)-5-	
1	I J W HHOHH W	methyl-N,N-	
		dipropylisophthalamid	
2004		e	
3884		N'-{(1S,2R)-1-(3,5-	
		difluorobenzy1)-3-	
		_	
	O O CH	[(3-	
	NI NI NI NI NI NI NI NI NI NI NI NI NI N	ethylbenzyl)amino]-2-	
	HOHH ()	hydroxypropy1}-N,5-	
		dimethyl-N-(2-	
		pyridin-2-	
	1 し リ	ylethyl) isophthalamid	
3885		e	
3003		N'-[(1S,2R)-1-(3,5-	
	,	difluorobenzyl)-2-	
		hydroxy-3-({[1-	
		(methylsulfonyl)piper	
Ì	HHOH H	(methylsullonyl)piper	
	O NIN N		
1	F Q JH ( )	yl]methyl}amino)propy	
1	I YY	1]-5-methyl-N,N-	
		dipropylisophthalamid	
3886	Ė	e	

	F	N <sup>1</sup> -{(1S,2R)-1-(3,5- difluorobenzyl)-2-
	Ţ	hydroxy-3-[(3-
	1 0 0 F	methoxybenzyl)amino]p
		ropyl}-N³,N³-
	N Y N NHY N Y Y	diethylpiperidine-
3887	/	1,3-dicarboxamide
	_	$N^{1} - \{ (1S, 2R) - 1 - (3, 5 - 1) \}$
	<u> </u>	difluorobenzyl)-2-
		hydroxy-3-[(3-
	) 0 0 () F	methoxybenzyl)amino]p
		ropyl}-N <sup>3</sup> ,N <sup>3</sup> -
	J L J HAGH H L J	dipropylpiperidine-
3888		1,3-dicarboxamide
		N'-((1S,2R)-1-(3,5-
	F	difluorobenzyl)-3-
		{[3-(5-formyl-4-
	0 0 F S	methy1-2-
	NI	thienyl)benzyl]amino}
	У ГР Н° В Н ГР ГР ГР	-2-hydroxypropyl)-5-
	1	methyl-N,N-
		dipropylisophthalamid
3889		le l
		N'-((1S,2R)-1-(3,5-
	F	difluorobenzyl)-2-
		hydroxy-3-{[3-(1-
ŀ	9 9H	phenylvinyl)benzyl]am
	NATION NATIONAL DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DEL CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTION DE LA CONTRACTIO	ino}propyl)-5-methyl-
	J V H OHH V V	N, N-
	l l	dipropylisophthalamid
3890		е
		N'-[(1S,2R)-3-[(3-
	F	bicyclo[2.2.1]hept-2-
		ylbenzyl)amino]-1-
	0 0 F	(3,5-difluorobenzyl)-
	H.I.	2-hydroxypropyl]-5-
		methyl-N,N-
		dipropylisophthalamid
3891		e
		ethyl 3-[3-
	Ţ	({[(2R,3S)-4-(3,5-
		difluorophenyl)-3-
	I A DEL TE	({3-
	I S I HOUH ()	[(dipropylamino)carbo
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	ny1]-5-
		methylbenzoyl}amino)-
		2-
		hydroxybutyl]amino}me
2000		thyl)phenyl]propanoat
3892		e

PCT/US02/36072

### ### ### ### ### ### ### ### ### ##				
Methyl (2R) -3-[3-    ([(2R,3s)-4-(3,5-    difluorophenyl)-3-((3-    (dipropylamino) carbon     yl]-5-    methylpenyl]-2-    methylpenyl]-2-    methylpenyl]-3- ((3,5-    (3,5-  difluorophenyl)-    3-((3-    (3)propylamino) carbon     yl]-5-    methylpenyl]-3-    (dipropylamino) carbon     yl]-5-    methylpenyl]-3-    (dipropylamino) carbon     yl]-5-    methylpenyl]-3-    (dipropylamino) -2-    hydroxybutyl]amino)-2-    hydroxybutyl]amino)-2-    hydroxybutyl]amino]-2-    hydroxypropyl) amino]-2-    hydroxypropyl) amino]-2-    hydroxypropyl) amino]-2-    hydroxypropyl]-3-[(3-    ethylbenzyl) amino]-2-    hydroxypropyl]-3-[(3-    ethylbenzyl) amino]-2-    hydroxypropyl]-3-[(1-    propylbutyl) ymino]-3-    hydroxypropyl)-3-[(1-    propylbutyl) sulfonyl]-    hydroxypropyl)-3-[(1-    propylbutyl) sulfonyl]-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hydroxypropyl)-3-[(1-    hy		H	<pre>({[(2R,3S)-4-(3,5- difluorophenyl)-3- ({3- [(dipropylamino)carbo nyl]-5- methylbenzoyl}amino)- 2- hydroxybutyl]amino}me</pre>	
({[(2R,3S)-4-(3,5-difluorophenyl)-3-((3-lidipropylamino) carbon yl]-5-methylbenzoyl}amino) - 2-hydroxybutyl]amino}methylphenyl)-2-methylpropanoate   ethyl 3'-([(2R,3S)-4-(3,5-difluorophenyl)-3-((3-lidipropylamino) carbon yl]-5-methylpropanoate   ethyl 3'-(([(2R,3S)-4-(3,5-difluorophenyl)-3-((3-lidipropylamino) carbon yl]-5-methylbenzoyl)amino} - 2-hydroxybutyl]amino) methylbiphenyl-2-carboxylate   2-(1-[2-(((1S,2R)-1-(3,5-difluorobenzyl)-3-(3-ethylbenzyl) amino)-2-hydroxypropyl)amino) - 2-coxoethyl]cyclopentyl}-N,N-dipropylacetamide   N²-	3893	N O		
ethyl 3'-({[(2R,3S)-4-(3,5-difluorophenyl)-3-({3-(3-difluorophenyl)-3-({3-(3-difluorophenyl)-3-({3-(3-difluorophenyl)-3-(3-difluorophenyl)-3-(3-difluorobenzyl)-3-[(3-difluorobenzyl)-3-(3-difluorobenzyl)-3-(3-difluorobenzyl)-3-(3-difluorobenzyl)-3-(3-difluorobenzyl)-3-(3-difluorobenzyl)-3-(3-difluorobenzyl)-3-(3-difluorobenzyl)-3-(3-difluorobenzyl)-3-(3-difluorobenzyl)-3-(3-difluorobenzyl)-3-(3-difluorobenzyl)-3-(3-difluorobenzyl)-3-(3-difluorobenzyl)-3-(3-difluorobenzyl)-3-(3-difluorobenzyl)-3-(3-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorobenzyl)-3-(1-difluorob		O H. F O H. N H O H H O H H	<pre>({[(2R,3S)-4-(3,5- difluorophenyl)-3-({3- [(dipropylamino)carbon y1]-5- methylbenzoyl}amino)- 2- hydroxybutyl]amino}met hyl)phenyl]-2-</pre>	
carboxylate  2-{1-[2-({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)amino]-2-hydroxypropyl)amino]-2-oxoethyl]cyclopentyl}-N,N-dipropylacetamide  NP-[(benzyloxy)carbonyl]-N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)-3-[(1-propylbutyl)sulfonyl]-D,L-alaninamide trifluoroacetate  3897    CH3	0024	N ON HOUSE	ethyl 3'-({[(2R,3S)-4-(3,5-difluorophenyl)-3-({3-[(dipropylamino)carbonyl]-5-methylbenzoyl}amino)-2-hydroxybutyl]amino}met	
CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>		N H H OH H	carboxylate  2-{1-[2-({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}amino)-2-oxoethyl]cyclopentyl}-	
		ONHOSO FFO	N <sup>2</sup> - [(benzyloxy)carbonyl]- N <sup>1</sup> -{(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-3-[(1- propylbutyl)sulfonyl]- D,L-alaninamide	702
-927-	3891	F		

	CH <sub>3</sub> ONH OSOCH <sub>3</sub> OHO NH F	N <sup>2</sup> - [(benzyloxy)carbonyl]- N <sup>1</sup> -{(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- methylbutyl)amino]-2- hydroxypropyl}-3-[(1- propylbutyl)sulfonyl]- D,L-alaninamide	654
3000	CH₃∕ CH₃		
3898	CH <sub>3</sub> CH <sub>3</sub> O S O CH <sub>3</sub> O NH O O O	N <sup>2</sup> - [(benzyloxy)carbonyl]- N <sup>1</sup> -{(1S,2R)-1-(3,5- difluorobenzyl)-3- (cyclopropylamino)-2- hydroxypropyl}-3-[(1- propylbutyl)sulfonyl]- D,L-alaninamide trifluoroacetate	624
3899	F F OH		
3900	CH <sub>3</sub> OHN F F OH	N <sup>2</sup> - [(benzyloxy)carbonyl]- N <sup>1</sup> -{(1S,2R)-1-(3,5- difluorobenzyl)-3- [(cyclopropylmethyl)am ino]-2-hydroxypropyl}- 3-[(1- propylbutyl)sulfonyl]- D,L-alaninamide trifluoroacetate	638
3901	CH <sub>3</sub> OHN OH F OH OH OH OH OH OH OH OH OH OH OH OH OH	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-	682

		1	600
		$N^{1} - \{ (1s, 2R) - 1 - (3, 5 - 1) \}$	682
		difluorobenzyl)-3-[(3-	
ار	H <sub>3</sub> HN- F	ethylbenzyl)amino]-2-	
١	OH F - OH	hydroxypropyl}-N2-	
	}-ÿ-\ HN-! /=\ F \	{ [ (3S) -	
		tetrahydrofuran-3-	
	CH <sub>3</sub> HN O	yloxy]carbonyl}-3-[(1-	
		propylbutyl)sulfonyl]-	
	$\sqrt{-0}$	D-alaninamide	
2002		trifluoroacetate	ļ
3902	CH	$N^{1}-\{(1S,2R)-1-(3,5-$	682
	CH <sub>3</sub>	difluorobenzy1)-3-[(3-	1002
	CH <sub>3</sub> HN-	ethylbenzyl)amino]-2-	
'	`` '	hydroxypropyl}-N2-	
		{ [ (3S) -	
	O HN HN	tetrahydrofuran-3-	
		yloxy]carbony1}-3-[(1-	
	) HN O	propylbutyl)sulfonyl]-	
	ĆH₃	D,L-alaninamide	
	9/_	trifluoroacetate	İ
	<b>\</b> 0 ' <b>\</b> \oH		
	, f 📗		
3903	0	N <sup>1</sup> -{(1S,2R)-1-(3,5-	682
1	CH <sub>3</sub>		002
Į Į		difluorobenzyl)-3-[(3-	
	<b>(</b> )	ethylbenzyl)amino]-2-	
	CH₃	hydroxypropyl}-N2-	
	OH F	{[(3R) -	
	}————————————————————————————————————	tetrahydrofuran-3-	ļ
	S-HN-	yloxy]carbonyl}-3-[(1-	
'	⟩ HNį Ö ——́(	propylbutyl)sulfonyl]-	
	ĆH₃ >≕O `F	D,L-alaninamide	
	ó <u>-</u>	trifluoroacetate	
	► F. F.		]
	OH S		
3904	0	$3N^{1}-\{(1S,2R)-1-benzyl-3\}$	- 648
			10.20
		[(3-	
	HN—	methoxybenzyl)amino]-	
	ÇH₃ ⟨	2-hydroxypropyl}-N2-	1
	\он	{[(3s)-	
	HCI O HN HN	tetrahydrofuran-3-	
	1 - 4 " "	yloxy]carbonyl}-3-[(1-	·
	N HN O	propylbutyl)sulfonyl]-	·
	С́н₃	D,L-alaninamide	1
	1 ~~~	hydrochloride	1
3905	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		1
14905			

		1	7
			730
	HN-	(3,5diflurobenzyl)-3-	
		[(3-	
		ethylbenzyl)amino]-2-	ŀ
		hydroxypropyl}-N <sup>2</sup> -	ŀ
	7 2 1 0 1 F H I	{ [ (3S) -1,1-	
	NH <sub>O</sub> S F Ö		ŀ
	CH <sub>3</sub>	dioxidotetrahydrothien	Ī
	CH <sub>3</sub>	-3-yloxy]carbony1}-3-	
	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	[(1-	
		propylbutyl)sulfonyl]-	l
		D,L-alaninamide	
2006		trifluoroacetate	
3906			698
	Ţ	$N^{1}$ -{ (1s,2R)-1-(3,5-	698
		difluorobenzyl)-3-[(3-	
		ethylbenzyl)amino]-2-	
		hydroxypropyl}-N2-	
	HO NHCH <sub>3</sub> S	{ [ (3S) -	
		tetrahydrothiophen-3-	
	NH S F OH	yloxy]carbonyl}-3-[(1-	
	l l	propylbutyl)sulfonyl]-	
	ĊH <sub>3</sub>	D, L-alaninamide	
3907	CH <sub>3</sub>	trifluoroacetate	
3307		$N^{1}-\{(1S,2R)-1-(3,5-$	696
		difluorobenzyl)-3-[(3-	
	F, O=<	11 11 11 1 0	
	O NHCH₃ F OH		
		hydroxypropyl}-N2-	
E	NH —S—	{[tetrahydropyran-4-	
	F HO-NH CH3	yloxy]carbonyl}-3-[(1-	
1	'\'\_\_\	propylbutyl)sulfonyl]-	ļ.
		D, L-alaninamide	
3908	_сн <sub>3</sub>	trifluoroacetate	
3300	_ 0	$N^{1}-\{(1S,2R)-1-(3,5-$	773
1	O—( N-\$CH₃	diflourobenzyl)-3-[(3-	
	ξ		
	NHCH <sub>3</sub> \ F	ethylbenzyl)amino]-2-	
	\\   \_\\\   \_\\\\\   \_\\\\\\\\\\	hydroxypropyl}-N2-{[1-	
	F HO=-	(methylsulfonyl)piperi	]
	NH CH <sub>8</sub>	din-4-yloxy]carbonyl}-	
1		3-[(1-	-
	V—CH₃	propylbutyl) sulfonyl]-	
1		D,L-alaninamide	
3909		trifluoroacetate	
בטפנן		N <sup>2</sup> -{[1-acetylpiperidin-	727
1	F, OH		1/3/
		A-Arovalcarpoutari-n -	1
	)—сн₃ 'ö	{ (1S,2R)-1-(3,5-	}
	N	difluorobenzyl)-3-[(3-	
1	— CH₃	ethylbenzyl)amino]-2-	1
	o che	hydroxypropyl}-3-[(1-	
1	>-NH S.	propylbutyl)sulfonyl]-	
	CH <sub>3</sub>	D, L-alaninamide	
	) o=( ( )-/ ·		
	NH )	trifluoroacetate	
	/''\\HN		
	F— HO		
	\{}		
3910	'F		I

	CH <sub>3</sub>	$N^{1}-\{(1S,2R)-1-(3,5-$	709
		difluorobenzyl)-3-[(3-	
	ĆH³ ⊢N-	ethylbenzyl)amino]-2-	
	V— OH F	hydroxypropyl}-N <sup>2</sup> -	
	}ṣ"-\ HN!, /=-{		
	( ö., )—( )	{[[(3R)-5-	
	CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	oxopyrrolidin-3-	
		yl]methyl]carbonyl}-3-	
l i	,	[(1-	
	NH E OU	propylbutyl)sulfonyl]-	
	Ĭ , 5 \ 04	D,L-alaninamide	
3911	Ö	trifluoroacetate	
3911			
	<u> </u>	$N^{1}-\{ (1S, 2R)-1-benzyl-3-$	668
		[ (3-	
	HCI O-	methoxybenzyl)amino]-	
	2 /	2-hydroxypropyl}-N2-	
	0=	[(benzyloxy)carbonyl]-	
	O NHCH₃\	3-[(1-	
1			
		propylbutyl)sulfonyl]-	
	но⊷	D,L-alaninamide	
		hydrochloride	
	/—NH		
	p= <b>(</b>		
3912	CH₃		
	ÇH₃	$N^2$ -	718
	^0	[(benzyloxy)carbonyl]-	
1		$N^{1}$ -((1s,2R)-1-(3,5-	
		difluorobenzyl)-2-	
	F F	hydroxy-3-{[2-(3-	
	CH <sub>3</sub> HN F OH		E 1
	OH F F O	methoxyphenyl)ethyl]am	
	) - S - HN - S - O	ino}propyl)-3-[(1-	
	HN	propylbutyl)sulfonyl]-	
	CH <sub>3</sub> =0 F	D,L-alaninamide	
	<b>,</b> _6	trifluoroacetate	
3913			
	F	$N^{1}-\{(1S,2R)-1-(3,5-$	562
	OH OH	difluorobenzyl)-3-[(3-	502
	CH <sub>3</sub> Y N Y N		
	HN "/ F F	ethylbenzyl)amino]-2-	
		hydroxypropyl}-N <sup>2</sup> -	
	CH₃ HÑ O F II	{ [ (3s) -	1
	ľ	tetrahydrofuran-3-	
	٧,٠	yloxy]carbonyl}-D-	
		leucinamide	
3914		trifluoracetate	
<del></del>	0.	$N^1-\{(1S,2R)-1-benzy1-2-$	548
			040
		hydroxy-3-[(3-	
	HN 1/2	methoxybenzyl)amino]pr	
	HCI CH <sub>3</sub>	opyl}-N2-	
	Ch my O	[(benzyloxy)carbonyl]-	
	ĊH <sub>3</sub> HÑ O	L-leucinamide	
i			
3915	l	hydrochloride	

		<b></b> 2	660
	CH <sub>3</sub> S O CH <sub>3</sub> CH <sub>3</sub> O CH <sub>3</sub> O CH <sub>3</sub> O CH <sub>3</sub> O CH <sub>3</sub> O CH <sub>3</sub>	N <sup>2</sup> - [(benzyloxy)carbonyl]- N <sup>1</sup> -((1S)-1-{(1R)-2- [ethyl(isobutylsulfonyl)amino]-1- hydroxyethyl}-3- methylbutyl)-3-[(1- propylbutyl)sulfonyl]- D.L-alaninamide	662
3916			
3917	NH CH <sub>3</sub> F OH CH <sub>3</sub>	N <sup>2</sup> - [(benzyloxy)carbonyl]- N <sup>1</sup> -{(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-N <sup>5</sup> ,N <sup>5</sup> - dipropyl-L-glutamamide trifluoroacetate	681
3918		N <sup>2</sup> - [(benzyloxy)carbonyl]- N <sup>1</sup> -{(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-N <sup>5</sup> ,N <sup>5</sup> - dipropyl-D-glutamamide	681
3919	HCI  HCI  N  N  N  N  N  CH <sub>3</sub> CH <sub>3</sub>	N <sup>1</sup> -{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -[(1H-pyrazol-4-yl)carbonyl]-3-[(1-propylbutyl)sulfonyl]-D,L-alaninamidehydrochloride	662

3920	HCI CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	N <sup>2</sup> -[(6-chloropyridin-3-yl)carbonyl]-N <sup>1</sup> - {(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]-D,L-alaninamidehydrochloride	707
3921	HCI  N  NHCH <sub>3</sub> O  NHCH <sub>3</sub> O  CH <sub>3</sub> CH <sub>3</sub>	N <sup>1</sup> -{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -[(pyridin-2-yl)carbonyl]-3-[(1-propylbutyl)sulfonyl]-D,L-alaninamidehydrochloride	673
3922	HCI CH <sub>3</sub> F O NHCH <sub>3</sub> O NHCH <sub>3</sub> O CH <sub>3</sub> CH <sub>3</sub>	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -(2-methylbenzoyl)-3-[(1-propylbutyl)sulfonyl]-D,L-alaninamidehydrochloride	686
3923	HCI OH F  HN OH F  HN OH F  CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -(3-methylbenzoyl)-3-[(1-propylbutyl)sulfonyl]-D,L-alaninamidehydrochloride	686

	HCI  O  NHCH <sub>3</sub> O  S  F  HO  NH  CH <sub>3</sub>	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -(4-methylbenzoyl)-3-[(1-propylbutyl)sulfonyl]-D,L-alaninamidehydrochloride	686
3924	HCI OH F HN OH F HN OH F CH3 CH3 CH3	N <sup>2</sup> -(3-chlorobenzoyl)- N <sup>1</sup> -{(15,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-3-[(1- propylbutyl)sulfonyl]- D,L-alaninamide hydrochloride	706
3926	FHCI HO HN NH NH OCH <sub>3</sub> CH <sub>3</sub>	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino}-2-hydroxypropyl}-N <sup>2</sup> -(4-methoxybenzoyl)-3-[(1-propylbutyl)sulfonyl]-D,L-alaninamidehydrochloride	702
3927	FHCI HCI HN NH FF NH OCH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -(4-triflluoromethylbenzoy1)-3-[(1-propylbutyl)sulfonyl]-D,L-alaninamidehydrochloride	740

l li	HCI	N <sup>2</sup>	678
	CH <sub>0</sub> CH <sub>3</sub>	(cyclohexylcarbonyl) - N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]-D,L-alaninamidehydrochloride	
3928	F	2 /2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	650
	CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	N <sup>2</sup> (benzoyl)-N <sup>1</sup> - {(1S,2R)-1-(3,5- difluorobenzyl)-3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-3-[(1- propylbutyl)sulfonyl]- D,L-alaninamide	672
3929	F	N <sup>1</sup> -{(1S, 2R)-1-(3, 5-	686
3930	O NH CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N²-(phenylacetyl)-3-[(1-propylbutyl)sulfonyl]-D,L-alaninamide	
3330	F	N <sup>1</sup> -{(1S,2R)-1-(3,5-	700
3931	CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N²-(3-phenylpropanoyl)-3-[(1-propylbutyl)sulfonyl]-D,L-alaninamidetrifluoroacetate	
	СНФ	$N^{1}$ -{ (1S, 2R) -1-benzy1-2-	616
	HCI CH <sub>3</sub> HN OH HN O	hydroxy-3-[(3- methoxybenzyl)amino]pr opyl}-N²- (cyclopropylacetyl)-3- [(1- propylbutyl)sulfonyl]- D,L-alaninamide	
3932		hydrochloride	<u> </u>

			1 44 - 00 4 1 - 1 0 1	C F 4
	CH		$N^{1} - \{ (1S, 2R) - 1 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benzyl - 2 - benz$	654
•	CH <sub>s</sub>		hydroxy-3-[(3-	
	\ \``\`	"\ HN	methoxybenzyl)amino]pr	
	(	о >-он>-он	opyl}-N2-	
	сн₃ }-	−ÿ─\ HN─॔; /─\ 「	[(methylsulfonyl)acety	
		OHN O	1]-3-[(1-	
	İ	0 =0	propylbutyl)sulfonyl]-	
ŀ	Ci		D, L-alaninamide	
		Ö	trifluoroacetate	
3933				
!	1	CHĐ	$N^{1}$ -{ (1S, 2R) -1-benzy1-2-	622
	1		hydroxy-3-[(3-	
		CH <sub>3</sub>	methoxybenzyl)amino]pr	
		) HN-	opy1}-N <sup>2</sup> -	
	HCI	CH <sub>3</sub> -S - HN - OH	[(methylthio)acetyl]-	
		CH <sub>3</sub> -S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - S - HN - HN	3-[(1-	
		_ 0 <sub>HN</sub>	propylbutyl)sulfonyl]-	
		` `	D,L-alaninamide	
2024		CH <sub>3</sub> C	hydrochloride	, [
3934	<u> </u>	CHO	$N^1-\{(1S,2R)-1-benzy1-2-$	624
		CHĐ		034
	1		hydroxy-3-[(3-	
		CH3 HN-	methoxybenzyl)amino]pr	
	нсі		opyl}-N²-(4-hydroxy-4-	
	Inci	O HN-: OH	oxobutanoy1)-3-[(1-	
			propylbutyl)sulfonyl]-	
1		CHN 0	D,L-alaninamide	
	1	>=0	hydrochloride	
		⟨ OH		
1	1	$\searrow$		
3935		,		
		СНФ	$N^{1}$ -{(1S,2R)-1-benzy1-2-	647
			hydroxy-3-[(3-	
		/ a	methoxybenzyl)amino]pr	
		CH₃ Q HN—OH	opy1}- $N^2$ -[4-	
	HCI	O HN OH	(methylamino)-4-	
-			oxobutanoy1]-3-[(1-	
[		CHN	propylbutyl)sulfonyl]-	
1		~~~ <u>~</u>	D,L-alaninamide	
	1	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	· ·	
		ÇH₃ 〉	hydrochloride	
		HN−-{		
3936	<u> </u>			540
	1	CH <sub>S</sub>	$N^{1}$ -{(1S,2R)-1-benzy1-2-	648
	1		hydroxy-3-[(3-	
	1	CH <sub>3</sub> HN	methoxybenzyl)amino]pr	
	HCI	CH₃	opyl $-N^2$ -(4-methoxy-4-	
	1,101	\ HN/	oxobutanoy1)-3-[(1-	
	1		propylbutyl) sulfonyl]-	
		CHB O	D, L-alaninamide	
		° <b>≻</b> o	hydrochloride	
	1	<		
		CH³ 〉		
2027	1	o-4_		
3937	ı	0	<u> </u>	<u> </u>

3938	HCI  CH <sub>3</sub> HN  OH  OH  OH  OH  OH  OH  OH  OH  OH	N- (methylsulfonyl)glycyl -N¹-{(1S,2R)-1-benzyl- 2-hydroxy-3-[(3- methoxybenzyl)amino]pr opyl}-3-[(1- propylbutyl)sulfonyl]- D,L-alaninamide hydrochloride	669
3939		N <sup>2</sup> -acetyl-N <sup>1</sup> -{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-3-(phenylsulfonyl)-D,L-alaninamidehydrochloride	554
3940	HCI NH HN O	(2S)-2-(4-methoxy-4-oxobutanoy1)amino-N- {(1S,2R)-1-benzy1-2-hydroxy-3-[(3-methoxybenzy1)amino]propy1}-5-oxo-5-piperidin-1-ylpentanamidehydrochloride	611
	NH HN O O O O O O O O O O O O O O O O O	(2R)-2- {[(benzyloxy)carbonyl]amino}-N-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-5-oxo-5-piperidin-1-ylpentanamidehydrochloride	631
3941	HCI		<u> </u>

3942	HCI HO CH <sub>3</sub>	(2R)-2-(3-ethoxy-3-oxopropanoyl)amino-N-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-5-oxo-5-piperidin-1-ylpentanamidehydrochloride	611
3943	HCI CH <sub>3</sub> N HN O CH <sub>3</sub> HN O CH <sub>3</sub> O CH <sub>3</sub>	N¹-{(1S,2R)-1-benzyl- 3-[(3- methoxybenzyl)amino]- 2-hydroxypropyl}-N²- (4-methoxy-4- oxobutanoyl)-N⁵,N⁵- dipropyl-D- glutamamide hydrochloride	627
3944	HCI  HCI  HCI  HCI  HCI  HCI  HCI  HCI	(2R)-2-(4-methoxy-4-oxobutanoy1)amino-N-{(1S,2R)-1-benzy1-2-hydroxy-3-[(3-methoxybenzy1)amino]propy1}-5-oxo-5-piperidin-1-ylpentanamidehydrochloride	611
3945	HCI NH HN O CH <sub>3</sub> CH <sub>3</sub>	(2R)-2-(5-methoxy-5-oxopentanoyl)amino-N-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-5-oxo-5-piperidin-1-ylpentanamidehydrochloride	625
3946	CH <sub>3</sub> HN  OH  F  HN  OF  CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	N <sup>2</sup> -[(5-chlorothien-2-yl)sulfonyl]-N <sup>1</sup> - {(1S,2R)-1-(3,5-difluorobenzyl)-3- [(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-propylbutyl)sulfonyl]-D,L-alaninamide	748

F=			
3947	O CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	N <sup>1</sup> -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N <sup>2</sup> -(phenylsulfonyl)-3-[(1-propylbutyl)sulfonyl]-D,L-alaninamide	708
3948	CH <sub>3</sub> O=S-OH F HN OH F HN OH F HN OH F	N <sup>2</sup> - [(benzylamino)carbony 1]-N <sup>1</sup> -{(1S,2R)-1- (3,5-difluorobenzyl)- 3-[(3- ethylbenzyl)amino]-2- hydroxypropyl}-3-[(1- propylbutyl)sulfonyl] -D,L-alaninamide	701
3949	HCI HO HO HO	4-({(1S,2R)-1-benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}amino)-3-[(isopentylsulfonyl)methyl]-4-oxobutanoicacid hydrochloride	549
3950	CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> HN HCI HCI OH	methyl 4-({(1S,2R)-1-benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}amino]-3-[(isopentylsulfonyl)methyl]-4-oxobutanoatehydrochloride	563

3951	HCI  CH <sub>3</sub> O  CH <sub>3</sub> O  CH <sub>3</sub> HN  O  CH <sub>3</sub> CH <sub>3</sub>	N¹-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-2-[(isopentylsulfonyl)methyl]succinamidehydrochloride	548
3952	HCI CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	N¹-{(1S,2R)-1-benzyl- 2-hydroxy-3-[(3- methoxybenzyl)amino]p ropyl}-2- [(isopentylsulfonyl)m ethyl]-N⁴- methylsuccinamide hydrochloride	562
3953	HCI  HN  NHO=S=O CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	N¹-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-2-[(isopentylsulfonyl)methyl]-N⁴,N⁴-dimethylsuccinamidehydrochloride	576
3954	F HO, O CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-2-{[(1-propylbutyl)sulfonyl]methyl}propanamide	693
3955	HCI  N  N  N  N  N  N  N  N  CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	N-{(1S,2R)-1-benzyl- 2-hydroxy-3-[(3- methoxybenzyl)amino]p ropyl}-3- (ethylsulfonyl)-2- {[(isobutylsulfonyl)a mino]methyl}propanami de hydrochloride	598

			· · · · · · · · · · · · · · · · · · ·
3956	HCI  HCI  HCI  HCI  HCI  HCI  N  N  S  H  NH  NH  O=S=O  CH <sub>3</sub> CH <sub>3</sub>	N-{(1S,2R)-1-benzyl- 2-hydroxy-3-[(3- methoxybenzyl)amino]p ropyl}-3-(ethylthio)- 2- {[(isobutylsulfonyl)a mino]methyl}propanami de hydrochloride	566
	HCI HO CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	ropyl}-2- [(isopentylsulfonyl)a mino]-4-	598
3957	CH₃		
3958	HCI CH3 O NH HN OH	N <sup>1</sup> -{(1S,2R)-1-benzyl- 2-hydroxy-3-[(3- methoxybenzyl)amino]p ropyl}-N <sup>2</sup> - (isopentylsulfonyl)- L-methioninamide hydrochloride	566
2050	CH <sub>3</sub> CH <sub>3</sub> O O=S=O HO HN H S HCI	S-{3-({(1S,2R)-1-benzy1-2-hydroxy-3-[(3-methoxybenzy1)amino]propyl}amino]-2-[(isopentylsulfony1)methyl]-3-oxopropyl}ethanethioatehydrochloride	579
3959	CĤ₃ CĤ₃	N (/1C 2D) 4 3	
3960	HO CH <sub>3</sub> O CH <sub>3</sub> O CH <sub>3</sub>	N-{(1S,2R)-1-benzyl- 2-hydroxy-3-[(3- methoxybenzyl)amino]p ropyl}-2-hydroxy-3- [(1- propylbutyl)sulfonyl] propanamide	535
		···	

	<del>,</del>		T
	HO ON OH OH	N-{(1S,2R)-1-(3,5-difluorobenzyl)-3- [(3- ethylbenzyl)amino]-2- hydroxypropyl}-2- hydroxy-4- (phenylsulfonyl)butan amide	561
3961	CH <sub>3</sub>		
3962	HCI NH OH CH3	N-{(1S,2R)-1-benzyl- 2-hydroxy-3-[(3- methoxybenzyl)amino]p ropyl}-2-hydroxy-4- (isopentylsulfonyl)bu tanamide hydrochloride	521
3302	CH <sub>3</sub>	N-{(1S,2R)-1-benzyl-	597
3963	HCI CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-4-(isopentylsulfonyl)-2-phenoxybutanamidehydrochloride	557
3964	HCI CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	N-{(1S,2R)-1-benzyl- 2-hydroxy-3-[(3- methoxybenzyl)amino]p ropyl}-4- (isopentylsulfonyl)- 2-(3- methoxyphenoxy)butana mide hydrochloride	627
3704	O <sub>CH3</sub>	3-[1-[({(1S,2R)-1-	641
3965	HO O CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	benzyl-2-hydroxy-3- [(3- methoxybenzyl)amino]p ropyl}amino)carbonyl] -3- (isopentylsulfonyl)pr opoxy]benzoic acid trifluoroacetate	OÆT

	ÇH₃	methyl 3-[1-	ICE E
	0 1 1	[({(1S,2R)-1-benzyl-	655
	O S CH <sub>2</sub> H <sub>3</sub>	2-hydroxy-3-[(3-	j
	O NH HN	methoxybenzyl)amino]p	
		ropyl amino ) carbonyl ]	
	CH3 N	-3-	
	ŎH	<pre>(isopentylsulfonyl)pr opoxy]benzoate</pre>	
3966	HCI HCI	hydrochloride	
3300		N-{(1S,2R)-1-benzyl-	505
		2-hydroxy-3-[(3-	527
		methoxybenzyl)amino]p	
	HO N S	ropyl}-2-hydroxy-4-	
	HCI HOH OH	(phenylsulfonyl)butan	
	NH CII	amide hydrochloride	
			:
3967	o <sub>`cH³</sub>		
		N-{(1S,2R)-1-benzyl-	495
		2-hydroxy-3-[(3-	
		methoxybenzyl)amino]p	
	HO S S	ropyl}-2-hydroxy-4-	
	HCI LIH OH	(phenylthio)butanamid e hydrochloride	
	HCI NH OH	c nyarochioriae	
	Ĭ		
3968	U_CH₃		
		N-{(1S,2R)-1-benzyl-	541
		2-hydroxy-3-[(3- methoxybenzyl)amino]p	
	HO	ropyl}-2-methoxy-4-	
	HCI H O CU	(phenylsulfonyl)butan	
	NH CH <sub>3</sub>	amide hydrochloride	
]			
3969	O <sub>CH3</sub>		
	OF13	N-{(1S,2R)-1-benzyl-	509
]		2-hydroxy-3-[(3-	
		methoxybenzyl)amino]p	
	HO S S	ropyl}-2-methoxy-4-	
	LIGI H O	(phenylthio)butanamid e hydrochloride	
	HCI NH O CH3	e nyarochroride	
		Í	
	Ĭ l		
3970	O_CH₃		

			•
3971	HCI HO O O S O CH <sub>3</sub>	N-{(1S,2R)-1-benzyl- 2-hydroxy-3-[(3- methoxybenzyl)amino]p ropyl}-4- (phenylsulfonyl)-2- propoxybutanamide hydrochloride	569
3972	HCI NH OCH3	N-{(1S,2R)-1-benzyl- 2-hydroxy-3-[(3- methoxybenzyl)amino]p ropyl}-2-(benzyloxy)- 4- (phenylsulfonyl)butan amide hydrochloride	617
3973	HCI HO'N N S CH <sub>3</sub>	N-{(1S,2R)-1-benzyl- 2-hydroxy-3-[(3- methoxybenzyl)amino]p ropyl}-N²- [(benzyloxy)carbonyl]-D,L-methioninamide hydrochloride	566
3974	HO N N N N N N N N N N N N N N N N N N N	(2S)-2-amino-N- {(1S,2R)-1-benzyl-2- hydroxy-3-[(3- methoxybenzyl)amino]p ropyl}-5-oxo-5- piperidin-1- ylpentanamide dihydrochloride	497

3975	HCI HCI HCI HCI	(2S)-2-(2-ethoxy-2-oxoethanyl)amino-N- {(1S,2R)-1-benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-5-oxo-5-piperidin-1-ylpentanamidedihydrochloride	569
3976	HO NH2 HCI HCI HCI OCH3	(2R)-2-amino-N- {(1S,2R)-1-benzyl-2- hydroxy-3-[(3- methoxybenzyl)amino]p ropyl}-5-oxo-5- piperidin-1- ylpentanamide dihydrochloride	497
3977	CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> O NH H N NH N NH N NH N NH N NH N NH N	(2R)-2-(2-ethoxy-2-oxoethany1)amino-N- {(1S,2R)-1-benzy1-2-hydroxy-3-[(3-methoxybenzy1)amino]propy1}-5-oxo-5-piperidin-1-ylpentanamidedihydrochloride	583
3978	FOH HONNIN	(2R)-2-(4-ethoxy-4-oxobutanyl)amino-N-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-5-oxo-5-piperidin-1-ylpentanamideditrifluoroacetate	611
3979	HCI OHON	N <sup>1</sup> -{(1S,2R)-1-benzyl- 2-hydroxy-3-[(3- methoxybenzyl)amino]p ropyl}-N <sup>2</sup> - [(benzyloxy)carbonyl] -L-aspartamide hydrochloride	549

HCI 3980	CH <sub>3</sub> OH OH OH OH OH OH OH OH OH OH OH OH OH	N <sup>1</sup> -{(1S,2R)-1-benzyl- 2-hydroxy-3-[(3- methoxybenzyl)amino]p ropyl}-N <sup>2</sup> - [(tertbutyloxy)carbon yl]-L-aspartamide hydrochloride	515
-------------	--------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----

What is claimed is:

10

1. A compound of the formula

or a pharmaceutically acceptable salt thereof wherein where  $R_1$  is:

- (I)  $C_1$ - $C_6$  alkyl, optionally substituted with one, two or three substituents selected from the group consisting of  $C_1$ - $C_3$  alkyl,  $C_3$ - $C_8$  cycloalkyl (optionally substituted with  $C_1$ - $C_3$  alkyl  $C_1$ - $C_3$  alkoxy), -F, -Cl, -Br, -I, -OH, -SH, -C=N, -CF<sub>3</sub>,  $C_1$ - $C_3$  alkoxy, -NR<sub>1-a</sub>R<sub>1-b</sub>, and -OC=O-NR<sub>1-a</sub>R<sub>1-b</sub>, where R<sub>1-a</sub> and R<sub>1-b</sub> are independently at each occurence-H or  $C_1$ - $C_6$  alkyl,
  - (II)  $-CH_2-S(O)_{0-2}-(C_1-C_6 \text{ alky}^1)$ ,
  - (III)  $-CH_2-CH_2-S(O)_{0-2}-(C_1-C_6 \text{ alkyl})$ ,
- (IV)  $C_2$ - $C_6$  alkenyl with one or two double bonds, optionally substituted with one, two or three substituents selected from the group consisting of -F, -Cl, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>,  $C_1$ - $C_3$  alkoxy, -NR<sub>1-a</sub>R<sub>1-b</sub> where R<sub>1-a</sub> and R<sub>1-b</sub> are -H or  $C_1$ - $C_6$  alkyl,
- (V)  $C_2$ - $C_6$  alkynyl with one or two triple bonds, optionally substituted with one, two or three substituents selected from the group consisting of -F, -Cl, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, -NR<sub>1-a</sub>R<sub>1-b</sub> where R<sub>1-a</sub> and R<sub>1-b</sub> are -H or C<sub>1</sub>-C<sub>6</sub> alkyl,
- (VI) - $(CH_2)_{n1}$ - $(R_{1-aryl})$  where  $n_1$  is zero or one and where  $R_{1-aryl}$  is phenyl, naphthyl, indanyl, indenyl, dihydronaphthayl, or tetralinyl each of which is optionally substituted with one, two, three, four, or five of the following substituents on the aryl ring:
  - (A)  $C_1$ - $C_6$  alkyl optionally substituted with one, two or three substituents selected from the group consisting of  $C_1$ - $C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -NR<sub>1-a</sub>R<sub>1-b</sub>, -C $\equiv$ N, -CF<sub>3</sub>, and  $C_1$ - $C_3$  alkoxy,

-947-

(B)  $C_2$ - $C_6$  alkenyl optionally substituted with one, two or three substituents selected from the group consisting of -F, -Cl, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>,  $C_1$ - $C_3$  alkoxy, and -NR<sub>1-a</sub>R<sub>1-b</sub>,

- (C)  $C_2$ - $C_6$  optionally substituted with one, two or three substituents selected from the group consisting of -F, -C1, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>,  $C_1$ - $C_3$  alkoxy, and -NR<sub>1-a</sub>R<sub>1-b</sub>,
  - (D) -F, Cl, -Br and -I,
  - (E)  $-C_1-C_6$  haloalkoxy
  - (F)  $-C_1-C_6$  alkoxy
- 10 (G)  $-NR_{N-2}R_{N-3}$ ,

- (H) -OH,
- (I) -C≡N,
- (J)  $C_3-C_7$  cycloalkyl, optionally substituted with one, two or three substituents independently selected from the group consisting of -F, -Cl, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, and -NR<sub>1-a</sub>R<sub>1-b</sub>,
  - (K)  $-CO-(C_1-C_4 \text{ alkyl})$ ,
  - (L)  $-SO_2-NR_{1-a}R_{1-b}$ ,
  - (M)  $-CO-NR_{1-a}R_{1-b}$ ,
- 20 (N)  $-SO_2-(C_1-C_4 \text{ alkyl})$ ,
  - $(\text{VII}) \ (\text{CH}_2)_{\text{nl}} (\text{R}_{\text{l-heteroaryl}}) \ \text{where} \ \text{R}_{\text{l-heteroaryl}} \ \text{is selected from}$  the group consisting of pyridinyl, pyrimidinyl, quinolinyl, benzothienyl, indolyl, indolinyl, pryidazinyl, pyrazinyl, isoindolyl, isoquinolyl, quinazolinyl, quinoxalinyl,
- phthalazinyl, imidazolyl, isoxazolyl, pyrazolyl, oxazolyl, thiazolyl, indolizinyl, indazolyl, benzothiazolyl, benzimidazolyl, benzofuranyl, furanyl, thienyl, pyrrolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, oxazolopyridinyl, imidazopyridinyl, isothiazolyl,
- naphthyridinyl,cinnolinyl,carbazolyl, beta-carbolinyl, isochromanyl, chromanyl, tetrahydroisoquinolinyl, isoindolinyl, isobenzotetrahydrofuranyl, isobenzotetrahydrothienyl, isobenzothienyl, benzoxazolyl, pyridopyridinyl, benzotetrahydrofuranyl, benzotetrahydrothienyl, purinyl,

benzodioxolyl, triazinyl, phenoxazinyl, phenothiazinyl, pteridinyl, benzothiazolyl, imidazopyridinyl, imidazothiazolyl, dihydrobenzisoxazinyl, benzisoxazinyl, benzoxazinyl, dihydrobenzisothiazinyl, benzopyranyl, benzothiopyranyl,

- 5 coumarinyl, isocoumarinyl, chromonyl, chromanonyl, tetrahydroquinolinyl, dihydroquinolinyl, dihydroquinolinonyl, dihydroisoquinolinonyl, dihydrocoumarinyl, dihydroisocoumarinyl, isoindolinonyl, benzodioxanyl, benzoxazolinonyl, pyridinyl-N-oxide, pyrrolyl N-oxide,
- 10 pyrimidinyl N-oxide, pyridazinyl N-oxide, pyrazinyl N-oxide, quinolinyl N-oxide, indolyl N-oxide, indolinyl N-oxide, isoquinolyl N-oxide, quinazolinyl N-oxide, quinoxalinyl N-oxide, phthalazinyl N-oxide, imidazolyl N-oxide, isoxazolyl N-oxide, oxazolyl N-oxide, thiazolyl N-oxide, indolizinyl N-
- oxide, indazolyl N-oxide, benzothiazolyl N-oxide, benzimidazolyl N-oxide, pyrrolyl N-oxide, oxadiazolyl N-oxide, thiadiazolyl N-oxide, triazolyl N-oxide, benzothiopyranyl S-oxide, and benzothiopyranyl S,S-dioxide,

where the  $R_{1\text{-heteroary1}}$  group is bonded to  $-(CH_2)_{n1}$ - by any ring atom of the parent  $R_{N\text{-heteroary1}}$  group substituted by hydrogen such that the new bond to the  $R_{1\text{-heteroary1}}$  group replaces the hydrogen atom and its bond, where heteroaryl is optionally substituted with one, two, three, four, or five of:

- (1)  $C_1-C_6$  alkyl optionally substituted with one, two or three substituents selected from the group consisting of  $C_1-C_3$  alkyl, -F, -Cl, -Br, -I, -OH,
  - -SH,  $-NR_{1-a}R_{1-b}$ ,  $-C\equiv N$ ,  $-CF_3$ , and  $C_1-C_3$  alkoxy,
  - (2)  $C_2$ - $C_6$  alkenyl with one or two double bonds, optionally substituted with one, two or three substituents selected from the group consisting of -F, -Cl, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>,  $C_1$ - $C_3$  alkoxy, and -NR<sub>1-a</sub>R<sub>1-b</sub>,
    - (3)  $C_2-C_6$  alkynyl with one or two triple bonds, optionally substituted with one, two or three substituents

selected from the group consisting of -F, -Cl, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, and -NR<sub>1-a</sub>R<sub>1-b</sub>,

- (4) -F, -Cl, -Br and -I,
- (5)  $-C_1-C_6$  haloalkoxy,
- (6)  $-C_1-C_6$  alkoxy
- (7)  $-NR_{N-2}R_{N-3}$ ,
- (8) OH,

5

(9) -C≡N,

(10)  $C_3-C_7$  cycloalkyl, optionally substituted with one, two or three substituents independently selected from the group consisting of -F, -Cl, -OH, -SH, -C $\equiv$ N, -CF $_3$ , C $_1$ -C $_3$  alkoxy, and -NR $_{1-a}$ R $_{1-b}$ ,

- (11)  $-CO-(C_1-C_4 \text{ alkyl})$ ,
- (12)  $-SO_2-NR_{1-a}R_{1-b}$ ,
- 15 (13)  $-CO-NR_{1-a}R_{1-b}$ ,

 $(14) \ -\text{SO}_2\text{--}(\text{C}_1\text{--}\text{C}_4 \ \text{alkyl}) \,, \ \text{with the proviso that when } n_1$  is zero  $R_{1\text{--heteroaryl}}$  is not'bonded to the carbon chain by nitrogen,

(VIII) -(CH<sub>2</sub>)<sub>n1</sub>-(R<sub>1-heterocycle</sub>) where n<sub>1</sub> is as defined above and R<sub>1-heterocycle</sub> is selected from the group consisting of morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S,S-dioxide, piperazinyl, homopiperazinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl, piperidinyl, tetrahydrofuranyl, tetrahydrothienyl, homopiperidinyl,

- homomorpholinyl, homothiomorpholinyl, homothiomorpholinyl S,S-dioxide, oxazolidinonyl, dihydropyrazolyl, dihydropyrrolyl, dihydropyrazinyl, dihydropyridinyl, dihydropyrimidinyl, dihydrofuryl, dihydropyranyl, tetrahydrothienyl S-oxide, tetrahydrothienyl S,S-dioxide, homothiomorpholinyl S-oxide,
- dithianyl, pyranyl, dihydrofuranyl, pyrrolidinonyl, imidazolidinonyl, imidazolidinondionyl, wherein each of the above is optionally fused to a benzene, pyridine, or pyrimidine ring, and

where the  $R_{1-heterocycle}$  group is bonded by any atom of the parent  $R_{1-heterocycle}$  group substituted by hydrogen such that the new bond to the  $R_{1-heterocycle}$  group replaces the hydrogen atom and its bond, where heterocycle is optionally substituted with one, two, three or four:

- (1)  $C_1-C_6$  alkyl optionally substituted with one, two or three substituents independently selected from the group consisting of  $C_1-C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -NR<sub>1-a</sub>R<sub>1-b</sub>, -C $\equiv$ N, -CF<sub>3</sub>, and  $C_1-C_3$  alkoxy,
- 10 (2)  $C_2-C_6$  alkenyl optionally substituted with one, two or three substituents selected from the group consisting of -F, -C1, -OH, -SH,  $-C\equiv N$ ,  $-CF_3$ ,  $C_1-C_3$  alkoxy,  $-NR_{1-a}R_{1-b}$ ,
- (3)  $C_2$ - $C_6$  alkynyl optionally substituted with one, two or three substituents independently selected from the group consisting of -F, -Cl, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, and -NR<sub>1-a</sub>R<sub>1-b</sub>,
  - (4) -F, -Cl, -Br and -I,
  - (5)  $C_1-C_6$  alkoxy,
  - (6)  $-C_1-C_6$  haloalkoxy,
- $20 (7) -NR_{N-2}R_{N-3},$ 
  - (8) OH,
  - (9) -C≡N,
- (10)  $C_3$ - $C_7$  cycloalkyl, optionally substituted with one, two or three substituents independently selected from the group consisting of -F, -Cl, -OH, -SH
  - $-C \equiv N$ ,  $-CF_3$ ,  $C_1-C_3$  alkoxy, and  $-NR_{1-a}R_{1-b}$ ,
    - (11)  $-CO-(C_1-C_4 \text{ alkyl})$ ,
    - (12)  $-SO_2-NR_{1-a}R_{1-b}$ ,
    - (13)  $-CO-NR_{1-a}R_{1-b}$ ,
- 30 (14)  $-SO_2-(C_1-C_4 \text{ alkyl})$ ,
  - (15) =0, with the proviso that when  $n_1$  is zero  $R_{1-}$  heterocycle is not bonded to the carbon chain by nitrogen; where  $R_2$  is selected from the group consisting of:
    - (I)-H,

(II)  $C_1-C_6$  alkyl, optionally substituted with one, two or three substituents independently selected from the group consisting of  $C_1-C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>,  $C_1-C_3$  alkoxy, and -NR<sub>1-a</sub>R<sub>1-b</sub>,

- 5 (III) -(CH<sub>2</sub>)<sub>0-4</sub>-R<sub>30</sub> where R<sub>30</sub> is R<sub>1-aryl</sub>, R<sub>1-heteroaryl</sub>, or R<sub>1-heterocycle</sub>
  - (IV)  $C_2$ - $C_6$  alkenyl with one or two double bonds, optionally substituted with one, two or three substituents independently selected from the group consisting of
- 10 -F, -Cl, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, and -NR<sub>1-a</sub>R<sub>1-b</sub>,
  - (V)  $C_2$ - $C_6$  alkynyl optionally substituted with one, two or three substituents independently selected from the group consisting of -F, -Cl, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, and -NR<sub>1-a</sub>R<sub>1-b</sub>,
- 15 (VI)  $-(CH_2)_{0-4}-C_3-C_7$  cycloalkyl, optionally substituted with one, two or three substituents independently selected from the group consisting of -F, -Cl, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, and -NR<sub>1-a</sub>R<sub>1-b</sub>,

where R<sub>3</sub> is selected from the group consisting of:

20 (I)-H,

- (II)  $C_1$ - $C_6$  alkyl, optionally substituted with one, two or three substituents selected from the group consisting of  $C_1$ - $C_3$  alkyl, -F, -Cl, -Br, -I, -OH,
- -SH, -C=N, -CF<sub>3</sub>,  $C_1$ - $C_3$  alkoxy, and -NR<sub>1-a</sub>R<sub>1-b</sub>,
- 25 (III)  $-(CH_2)_{0-4}-R_{30}$ ,
  - (IV)  $C_2-C_6$  alkenyl,
  - (V)  $C_2-C_6$  alkynyl,
- (VI)  $-(CH_2)_{0-4}$   $C_3$ - $C_7$  cycloalkyl, optionally substituted with one, two or three substituents independently selected from the group consisting of -F, -Cl, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub>

alkoxy, and  $-NR_{1-a}R_{1-b}$ ,

or  $R_2$  and  $R_3$  are taken together with the carbon to which they are attached to form a carbocycle of three, four, five, six,

and seven carbon atoms, optionally where one carbon atom is replaced by a heteroatom selected from the group consisting of -O-, -S-,  $-SO_2-$ ,  $-NR_{N-2}-$ ;

R<sub>N</sub> is:

25

30

5 (I)  $R_{N-1}-X_{N}-$  where  $X_{N}$  is selected from the group consisting of:

- (A) -CO-,
- (B)  $-SO_2-$ ,
- (C)  $-(CR'R'')_{1-6}$  wherein

10 R' and R" at each occurrence are the same or different and are -H,  $C_1-C_4$  alkyl, phenyl, or pyridyl

(D) -CO-(CR'R")  $_{1-6}-X_{N-1}$  wherein  $X_{N-1}$  is selected from the group consisting of -O-, -S- and -NR'-,

- (E) a single bond, and
- 15 (F)  $-CO-(CR'R'')_{1-6}$

where  $R_{N-1}$  is selected from the group consisting of:

- (A)  $R_{N-aryl}$  wherein  $R_{N-aryl}$  at each occurrence is independently phenyl; naphthyl; tetralinyl; indanyl; indenyl; dihydronaphthyl; or 6,7,8,9-tetrahydro-5H-
- benzo[a]cycloheptenyl; each of which is optionally substituted
  with 1, 2, or 3 groups that at each occurrence are
  independently:
  - $\label{eq:consisting} \mbox{(1) $C_1$-$C_6$ alkyl, optionally substituted with one, two or three substituents selected from the group consisting of $C_1$-$C_3$ alkyl, -F, -Cl, -Br, -I, \end{tabular}$

-OH, -SH, -C $\equiv$ N, -CF $_3$ , C $_1$ -C $_3$  alkoxy, and -NR $_{1-a}$ R $_{1-b}$ , wherein R $_{1-a}$  and R $_{1-b}$  at each occurrence are independently H or C $_1$ -C $_6$  alkyl,

- (2) -OH,
- $(3) -NO_2$ ,
- (4) -F, -Cl, -Br, -I,
- (5) -CO<sub>2</sub>H,
- (6) -C≡N,

 $(7) \ - (\text{CH}_2)_{\,0-4} - \text{CO-NR}_{N-2} R_{N-3} \text{ wherein at each}$  occurence  $R_{N-2}$  and  $R_{N-3}$  are the same or different and are selected from the group consisting of:

(a) -H,

5 (b)  $-C_1-C_8$  alkyl optionally substituted with one substituent selected from the group consisting of:

- (i) -OH,
- (ii) -NR'R"
- (iii) phenyl,

10 (c)  $-C_1-C_8$  alkyl optionally substituted with 1, 2, or 3 groups that are independently -F, -Cl, -Br, or -I,

- (d)  $-C_3-C_8$  cycloalkyl,
- (e)  $-(C_1-C_2 \text{ alkyl})-(C_3-C_8 \text{ cycloalkyl})$ ,
- (f)  $-(C_1-C_6 \text{ alkyl})-O-(C_1-C_3 \text{ alkyl})$ ,
- (g)  $-C_2-C_6$  alkenyl,
- (h)  $-C_2-C_6$  alkynyl,
- $\mbox{(i) $-C_1$-$C_6$ alkyl chain with one double bond} \\ \mbox{and one triple bond,}$

 $(j) -R_{1-aryl},$ 

15

- (k) -R<sub>1-heteroaryl</sub>,
- (1)  $-R_{1-heterocyle}$ , or

(m) R<sub>N-2</sub>, R<sub>N-3</sub> and the nitrogen to which they are attached form a 5, 6, or 7 membered heterocycloalkyl or 25 heteroaryl group, wherein said heterocycloalkyl or heteroaryl group is optionally fused to a benzene, pyridine, or pyrimidine ring, and said groups are unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that at each occurrence are independently C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, halogen, halo C<sub>1</sub>-C<sub>6</sub> alkyl, halo C<sub>1</sub>-C<sub>6</sub> alkoxy, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>6</sub> alkyl), N(C<sub>1</sub>-C<sub>6</sub> alkyl)(C<sub>1</sub>-C<sub>6</sub> alkyl), -OH, -C(O)NH<sub>2</sub>, -C(O)NH(C<sub>1</sub>-C<sub>6</sub> alkyl), -C(O)N(C<sub>1</sub>-C<sub>6</sub> alkyl)(C<sub>1</sub>-C<sub>6</sub> alkyl), C<sub>1</sub>-C<sub>6</sub> alkyl), C<sub>1</sub>-C<sub>6</sub> alkyl;

 $(8) - (CR'R'')_{0-4}CO-OR'$ 

(B)  $-R_{N\text{-}heteroaryl}$  where  $R_{N\text{-}heteroaryl}$  is selected from the group consisting of pyridinyl, pyrimidinyl, quinolinyl, benzothienyl, indolyl, indolinyl, pryidazinyl, pyrazinyl, isoindolyl, isoquinolyl, quinazolinyl, quinoxalinyl, phthalazinyl, imidazolyl, isoxazolyl, pyrazolyl, oxazolyl, 5 thiazolyl, indolizinyl, indazolyl, benzisothiazolyl, benzimidazolyl, benzofuranyl, furanyl, thienyl, pyrrolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, oxazolopyridinyl, imidazopyridinyl, isothiazolyl, naphthyridinyl, cinnolinyl, carbazolyl, beta-carbolinyl, 10 isochromanyl, chromanyl, tetrahydroisoquinolinyl, isoindolinyl, isobenzotetrahydrofuranyl, isobenzotetrahydrothienyl, isobenzothienyl, benzoxazolyl, pyridopyridinyl, benzotetrahydrofuranyl, benzotetrahydrothienyl, purinyl, benzodioxolyl, triazinyl, henoxazinyl, phenothiazinyl, 15 pteridinyl, benzothiazolyl, imidazothiazolyl, dihydrobenzisoxazinyl, benzisoxazinyl, benzoxazinyl, dihydrobenzisothiazinyl, benzopyranyl, benzothiopyranyl, coumarinyl, isocoumarinyl, chromonyl, chromanonyl, tetrahydroquinolinyl, dihydroquinolinyl, dihydroquinolinonyl, 20 dihydroisoquinolinonyl, dihydrocoumarinyl, dihydroisocoumarinyl, isoindolinonyl, benzodioxanyl, benzoxazolinonyl, pyridinyl-N-oxide, pyrrolyl N-oxide, pyrimidinyl N-oxide, pyridazinyl N-oxide, pyrazinyl N-oxide, quinolinyl N-oxide, indolyl N-oxide, indolinyl N-oxide, 25 isoquinolyl N-oxide, quinazolinyl N-oxide, quinoxalinyl Noxide, phthalazinyl N-oxide, imidazolyl N-oxide, isoxazolyl Noxide, oxazolyl N-oxide, thiazolyl N-oxide, indolizinyl Noxide, indazolyl N-oxide, benzothiazolyl N-oxide, benzimidazolyl N-oxide, pyrrolyl N-oxide, oxadiazolyl N-oxide, 30 thiadiazolyl N-oxide, triazolyl N-oxide, tetrazolyl N-oxide, benzothiopyranyl S-oxide, benzothiopyranyl S,S-dioxide, imidazopyrazolyl, quinazolinonyl, pyrazopyridyl, benzooxadiazolyl, dihydropyrimidinonyl, and

dihydrobenzfuranonyl, where each of the above is optionally fused to a benzene, pyridine, or pyrimidine ring,

where the  $R_{N\text{-}heteroaryl}$  group is bonded by any atom of the parent  $R_{N\text{-}heteroaryl}$  group substituted by hydrogen such that the new bond to the  $R_{N\text{-}heteroaryl}$  group replaces the hydrogen atom and its bond, where heteroaryl is optionally substituted with one, two, three, or four of:

(1) C<sub>1</sub>-C<sub>6</sub> alkyl, optionally substituted with one, two or three substituents independently selected from the 10 group consisting of C<sub>1</sub>-C<sub>3</sub> alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C≡N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, and -NR<sub>1-a</sub>R<sub>1-b</sub>,

- (2) OH,
- (3) -NO<sub>2</sub>,
- (4) -F, -C1, -Br, -I,
- 15  $(5) CO_2H$ ,

20

- (6) -C≡N,
- (7)  $-(CH_2)_{0-4}-CO-NR_{N-2}R_{N-3}$ ,
- (8)  $-(CH_2)_{0-4}-CO-(C_1-C_{12} \text{ alkyl})$ ,
- (9)  $-(CH_2)_{0-4}-CO-(C_2-C_{12} \text{ alkenyl})$ ,
- (10) (CH<sub>2</sub>)<sub>0-4</sub>-CO-(C<sub>2</sub>-C<sub>12</sub> alkynyl),
  - (11)  $-(CH_2)_{0-4}-CO-(C_3-C_8 \text{ cycloalkyl})$ ,
  - (12)  $-(CH_2)_{0-4}-CO-R_{1-aryl}$ ,
  - (13)  $-(CH_2)_{0-4}-CO-R_{1-heteroaryl}$ ,
  - (14) -(CH<sub>2</sub>)<sub>0-4</sub>-CO-R<sub>1-heterocycle</sub>,
- 25  $(15) (CH_2)_{0-4} CO R_{N-4}$ 
  - (16)  $-(CH_2)_{0-4}-CO_2-R_{N-5}$
  - (17)  $-(CH_2)_{0-4}-SO_2-NR_{N-2}R_{N-3}$ ,
  - (18)  $-(CH_2)_{0-4}-SO-(aryl C_1-C_8 alkyl)$ ,
  - (19) (CH<sub>2</sub>)<sub>0-4</sub> SO<sub>2</sub> (C<sub>1</sub> C<sub>12</sub> alkyl),
  - (20)  $-(CH_2)_{0-4}-SO_2-(C_3-C_8 \text{ cycloalkyl})$ ,
  - (21)  $-(CH_2)_{0-4}-N(H \text{ or } R_{N-5})-CO-O-R_{N-5}$ ,
  - (22)  $-(CH_2)_{0-4}-N(H \text{ or } R_{N-5})-CO-N(R_{N-5})_2$ ,
  - (23)  $-(CH_2)_{0-4}-N-CS-N(R_{N-5})_2$ ,
  - (24) (CH<sub>2</sub>)<sub>0-4</sub> N(-H or R<sub>N-5</sub>) CO-R<sub>N-2</sub>,

```
(25) - (CH<sub>2</sub>)<sub>0-4</sub> - NR<sub>N-2</sub>R<sub>N-3</sub>,
                                   (26) - (CH<sub>2</sub>)<sub>0-4</sub> - R<sub>N-4</sub>,
                                   (27) - (CH<sub>2</sub>)<sub>0-4</sub>-O-CO-(C<sub>1</sub>-C<sub>6</sub> alky1),
                                  (28) -(CH_2)_{0-4}-O-P(O)-(OR_{100})_2,
                                   (29) -(CH_2)_{0-4}-O-CO-N(R_{N-5})_2,
 5
                                   (30) -(CH_2)_{0-4}-O-CS-N(R_{N-5})_2,
                                   (31) -(CH_2)_{0-4}-O-(R_{N-5}),
                                   (32) -(CH_2)_{0-4}-O-(R_{N-5})-COOH,
                                   (33) -(CH_2)_{0-4}-S-(R_{N-5}),
                                   (34) - (CH<sub>2</sub>)<sub>0-4</sub> - O - (C<sub>1</sub> - C<sub>6</sub> alkyl optionally
10
       substituted with one, two, three, four, or five of -F),
                                   (35) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
                                   (36) C2-C6 alkenyl optionally substituted with
       C_1-C_3 alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C\equivN, -CF<sub>3</sub>, C_1-C_3
15
       alkoxy, or -NR_{1-a}R_{1-b},
                                   (37) C2-C6 alkynyl optionally substituted with
        C_1-C_3 alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C\equivN, -CF<sub>3</sub>, C_1-C_3
        alkoxy, or -NR_{1-a}R_{1-b},
                                   (38) -(CH_2)_{0-4}-N(-H \text{ or } R_{N-5})-SO_2-R_{N-2},
                                   (39) - (CH<sub>2</sub>)<sub>1-4</sub> - C<sub>3</sub> - C<sub>8</sub> cycloalky1,
20
                          (C) R_{N-aryl}-W-R_{N-aryl},
                          (D) R<sub>N-aryl</sub>-W-R<sub>N-heteroaryl</sub>,
                          (E) R_{N-aryl}-W-R_{1-heterocycle},
                          (F) R<sub>N-heteroaryl</sub>-W-R<sub>N-aryl</sub>,
25
                          (G) R<sub>N-heteroaryl</sub>-W-R<sub>N-heteroaryl</sub>,
                          (H) R<sub>N-heteroaryl</sub>-W-R<sub>1-heterocycle</sub>,
                          (I) R<sub>N-heterocycle</sub>-W-R<sub>N-aryl</sub>,
                          (J) R<sub>N-heterocycle</sub>-W-R<sub>N-heteroaryl</sub>,
                           (K) R<sub>N-heterocycle</sub>-W-R<sub>1-heterocycle</sub>,
30
                                   where W is
  (1) - (CH<sub>2</sub>)<sub>1-4</sub>-,
  (2)
   -0-,
   -S(O)<sub>0-2</sub>-,
  (3)
  (4)
   -N(R_{N-5})-
```

```
(5) -CO-; or
```

- (6) a bond;
- (II)  $-CO-(C_1-C_{10} \text{ alkyl})$  wherein the alkyl is optionally substituted with one two or three substituents independently selected from the group consisting of:
  - (A) -OH,

- (B)  $-C_1-C_6$  alkoxy,
- (C)  $-C_1-C_6$  thioalkoxy,
- (D)  $-CO_2-R_{N-8}$  where  $R_{N-8}$  at each occurrence is
- independently -H,  $C_1$ - $C_6$  alkyl or -phenyl which is optionally substituted with 1 or 2 groups that are independently halogen,  $C_1$ - $C_4$  alkoxy,  $C_1$ - $C_4$  alkyl or -C(0)NH<sub>2</sub>,
  - (E)  $-CO-NR_{N-2}R_{N-3}$ ,
  - (F)  $-CO-R_{N-4}$ ,
- 15 (G)  $-SO_2-(C_1-C_8 \text{ alkyl})$ ,
  - (H)  $-SO_2-NR_{N-2}R_{N-3}$ ,
  - (I)  $-NH-CO-(C_1-C_6 \text{ alkyl})$ ,
  - (J)  $-NH-CO-O-R_{N-8}$ ,
  - $(K) -NR_{N-2}R_{N-3},$
- 20 (L)  $-R_{N-4}$ ,
  - (M) -O-CO-( $C_1$ - $C_6$  alkyl),
  - (N)  $-O-CO-NR_{N-8}R_{N-8}$ ,
  - (0)  $-0-(C_1-C_5 \text{ alkyl})-COOH$ ,
  - (P)  $-0-(C_1-C_6)$  alkyl optionally substituted with one,
- 25 two, or three groups that are independently -F, -CI, -Br, or -I),
  - (Q)  $-NH-SO_2-(C_1-C_6 \text{ alkyl})$ ,
  - (R) halogen,
  - (S)  $-N(H \text{ or } R_{N-5})-SO_2-R_{N-2}$ ,
- 30 (T)  $-N(H \text{ or } R_{N-5})-CO-(R_{N-2})$ , and
  - $(U) -SO_2-R_{N-2},$
  - (V) R<sub>N-aryl</sub>;

(III)  $-CO-(C_1-C_6 \text{ alkyl})-O-(C_1-C_6 \text{ alkyl})$  wherein each alkyl is unsubstituted or independently substituted with one, two, or three substituents selected from the group consisting of :

(A) -OH,

5

- (B)  $-C_1-C_6$  alkoxy,
- (C)  $-C_1-C_6$  thioalkoxy,
- (D)  $-CO-O-R_{N-8}$ ,
- (E)  $-CO-NR_{N-2}R_{N-3}$ ,
- (F)  $-CO-R_{N-4}$ ,

10

- (G)  $-SO_2-(C_1-C_8 \text{ alkyl})$ ,
- (H)  $-SO_2-NR_{N-2}R_{N-3}$ ,
- (I)  $-NH-CO-(C_1-C_6 \text{ alkyl})$ ,
- (J)  $-NH-CO-O-R_{N-8}$ ,
- (K)  $-NR_{N-2}R_{N-3}$ ,

15

- (L)  $-R_{N-4}$ ,
- (M) -O-CO-( $C_1$ - $C_6$  alkyl),
- (N)  $-O-CO-NR_{N-8}R_{N-8}$ ,
- (O)  $-O-(C_1-C_5 \text{ alky1})-CO_2H$ ,
- (P) -O-(C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with
- one, two, or three groups that are independently -F, -CI, -Br, or -I),
  - (Q) -NH-SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub> alkyl),
  - (R) halogen,
  - (S)  $-N(H \text{ or } R_{N-5})-SO_2-R_{N-2}$ ,

- (T)  $-N(H \text{ or } R_{N-5})-CO-(R_{N-2})$ ,
- (U)  $-SO_2-R_{N-2}$ , and
- (V) R<sub>N-aryl</sub>;
- (IV) -CO-(C<sub>1</sub>-C<sub>6</sub> alkyl)-S-(C<sub>1</sub>-C<sub>6</sub> alkyl) wherein each alkyl is unsubstituted or substituted with one, two, or three of substituents independently selected from the group consisting of:
  - (A) -OH,
  - (B)  $-C_1-C_6$  alkoxy,
  - (C)  $-C_1-C_6$  thioalkoxy,

```
(D) -CO-O-R_{N-B},
                    (E) -CO-NR_{N-2}R_{N-3},
                    (F) -CO-R_{N-4},
                    (G) -SO_2-(C_1-C_8 \text{ alkyl}),
                    (H) -SO_2-NR_{N-2}R_{N-3},
 5
                    (I) -NH-CO-(C_1-C_6 \text{ alkyl}),
                    (J) -NH-CO-O-R_{N-8},
                    (K) -NR_{N-2}R_{N-3},
                    (L) -R_{N-4},
                     (M) -O-CO-(C_1-C_6 alkyl),
10
                     (N) -O-CO-NR_{N-8}R_{N-8},
                     (0) -O-(C_1-C_5 \text{ alkyl})-COOH,
                     (P) -O-(C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with one,
      two, or three groups that are independently -F, -Cl, -Br, or -
15
      I),
                     (Q) -NH-SO_2-(C_1-C_6 \text{ alkyl}),
                     (R) halogen,
                     (S) -N(H \text{ or } R_{N-5})-SO_2-R_{N-2},
                     (T) -N(H \text{ or } R_{N-5})-CO-(R_{N-2}),
20
                     (U) -SO_2-R_{N-2}, and
                     (V) R<sub>N-aryl</sub>;
             (V) -CO-CH(-(CH_2)_{0-2}-O-R_{N-10})-(CH_2)_{0-2}-(R_{N-aryl} \text{ or } R_{N-heteroaryl}))
      wherein
                    R_{N-10} is selected from the group consisting of:
25
                            (1) -H,
                            (2) C_1-C_6 alkyl,
                            (3) C_3-C_8 cycloalkyl,
                            (4) C_2-C_6 alkenyl,
                            (5) C_2-C_6 alkynyl,
                            (6) R<sub>1-aryl</sub>,
30
                            (7) R<sub>N-heteroaryl</sub>,
                            (8) R<sub>N-heterocycle</sub>,
```

(VI)  $-CO-(C_3-C_8$  cycloalkyl) where the cycloalkyl group is optionally substituted with one or two substituents independently selected from the group consisting of:

(A) 
$$-(CH_2)_{0-4}-OH$$
,

5

(B) 
$$-(CH_2)_{0-4}-C_1-C_6$$
 alkoxy,

(C) 
$$-(CH_2)_{0-4}-C_1-C_6$$
 thioalkoxy,

(D) 
$$-(CH_2)_{0-4}-CO-O-R_{N-8}$$
,

(E) 
$$-(CH_2)_{0-4}-CO-NR_{N-2}R_{N-3}$$
,

(F) 
$$-(CH_2)_{0-4}-CO-R_{N-4}$$
,

10

(G) 
$$-(CH_2)_{0-4}-SO_2-(C_1-C_8 \text{ alkyl})$$
,

(H) 
$$-(CH_2)_{0-4}-SO_2-NR_{N-2}R_{N-3}$$
,

(I) 
$$-(CH_2)_{0-4}-NH-CO-(C_1-C_6 \text{ alkyl})$$
,

(J) 
$$-NH-CO-O-R_{N-8}$$
,

(K) 
$$-(CH_2)_{0-4}-NR_{N-2}R_{N-3}$$
,

15

(L) 
$$-(CH_2)_{0-4}-R_{N-4}$$
,

$$(M)$$
 -O-CO- $(C_1-C_6 \text{ alkyl})$ ,

(N) 
$$-O-CO-NR_{N-8}R_{N-8}$$
,

(O) 
$$-O-(C_1-C_6 \text{ alkyl})-CO_2H$$
,

(P)  $-0-(C_1-C_6)$  alkyl optionally substituted with one,

20 two, or three groups that are independently selected from -F, -Cl, -Br, and -I),

(Q) 
$$-NH-SO_2-(C_1-C_6 \text{ alkyl})$$
,

- (R) halogen,
- (S)  $-N(H \text{ or } R_{N-5})-SO_2-R_{N-2}$ ,

25 (T) -N(

- (T)  $-N(H \text{ or } R_{N-5})-CO-(R_{N-2})$ ,
- (U)  $-SO_2-R_{N-2}$ , and
- (V) R<sub>N-aryl</sub>;

where Rc is:

(I)  $-C_1-C_{10}$  alkyl optionally substituted with one, two or three substituents selected from the group consisting of  $C_1-C_3$  alkyl, -F, -Cl, -Br, -I, -OH,

-SH, -C=N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkoxy, -O-phenyl, -NR<sub>1-a</sub>R<sub>1-b</sub>, -OC=O NR<sub>1-a</sub>R<sub>1-b</sub>, -S(=O)<sub>0-2</sub> R<sub>1-a</sub>, - NR<sub>1-a</sub>C=O NR<sub>1-a</sub>R<sub>1-b</sub>, -C=O NR<sub>1-a</sub>R<sub>1-b</sub>, and - S(=O)<sub>2</sub> NR<sub>1-a</sub>R<sub>1-b</sub>,

- (II) -(CH<sub>2</sub>)<sub>0-3</sub>-(C<sub>3</sub>-C<sub>8</sub>) cycloalkyl where cycloalkyl can be
  optionally substituted with one, two or three substituents
  independently selected from the group consisting of C<sub>1</sub>-C<sub>3</sub>
  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C≡N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkoxy, -Ophenyl, -CO<sub>2</sub>H, -CO<sub>2</sub>-(C<sub>1</sub>-C<sub>4</sub> alkyl), and -NR<sub>1-a</sub>R<sub>1-b</sub>,
- (III) -(CR<sub>C-x</sub>R<sub>C-y</sub>)<sub>0-4</sub>-R<sub>C-aryl</sub> at each occurrence is

  10 independently phenyl; naphthyl; tetralinyl; indanyl; indenyl;
  dihydronaphthyl; or 6,7,8,9-tetrahydro-5Hbenzo[a]cycloheptenyl; each of which is optionally substituted
  with 1, 2, or 3 groups that at each occurrence are
  independently:
- 15 (1)  $C_1$ - $C_6$  alkyl, optionally substituted with one, two or three substituents selected from the group consisting of  $C_1$ - $C_3$  alkyl, -F, -Cl, -Br, -I,
  - -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, and -NR<sub>1-a</sub>R<sub>1-b</sub>,
    - (2) OH,
- 20
- (3) -NO<sub>2</sub>,
- (4) -F, -Cl, -Br, -I,
- (5)  $-CO_2H$ ,
- (6)  $-C \equiv N$ , and
- (7)  $-(CH_2)_{0-4}-CO-NR_{N-2}R_{N-3}$ ;
- where  $R_{\text{C-x}}$  and  $R_{\text{C-y}}$  are independently  $_{-\text{H}\text{,}}$

 $C_1\text{-}C_4$  alkyl optionally substituted with one or two - OH,

 $C_1-C_4$  alkoxy optionally substituted with 1, 2, or 3 -

30 F,

-( $CH_2$ )<sub>0-4</sub>- $C_3$ - $C_8$  cycloalkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl, and phenyl,

or  $R_{C-x}$  and  $R_{C-y}$  are taken together with the carbon to which they are attached to form a carbocycle of three, four, five, six and seven carbon atoms, optionally where one carbon atom is replaced by a heteroatom selected from the group consisting of -O-, -S-,  $-SO_2-$ ,  $-NR_{N-2}-$  and  $R_{C-aryl}$  is defined as is defined above:

- above; (IV) -(CR<sub>C-x</sub>R<sub>C-y</sub>) $_{0-4}$ -R<sub>C-heteroaryl</sub> where R<sub>C-heteroaryl</sub> at each occurrence is independently selected from the group consisting of pyridinyl, pyrimidinyl, quinolinyl, benzothienyl, indolyl, indolinyl, pryidazinyl, pyrazinyl, isoindolyl, isoquinolyl, 10 quinazolinyl, quinoxalinyl, phthalazinyl, imidazolyl, isoxazolyl, pyrazolyl, oxazolyl, thiazolyl, indolizinyl, indazolyl, benzoisothiazolyl, benzimidazolyl, benzofuranyl, furanyl, thienyl, pyrrolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, oxazolopyridinyl, isothiazolyl, 15 naphthyridinyl, cinnolinyl, carbazolyl, beta-carbolinyl, isochromanyl, chromanyl, tetrahydroisoquinolinyl, isoindolinyl, isobenzotetrahydrofuranyl, isobenzotetrahydrothienyl, isobenzothienyl, benzoxazolyl, pyridopyridinyl, benzotetrahydrofuranyl, benzotetrahydrothienyl, purinyl, 20 benzodioxolyl, triazinyl, henoxazinyl, phenothiazinyl, pteridinyl, benzothiazolyl, imidazopyridinyl, imidazothiazolyl, dihydrobenzisoxazinyl, benzisoxazinyl, benzoxazinyl, dihydrobenzisothiazinyl, benzopyranyl, benzothiopyranyl, coumarinyl, isocoumarinyl, chromonyl, chromanonyl, 25 tetrahydroquinolinyl, dihydroquinolinyl, dihydroquinolinonyl, dihydroisoquinolinonyl, dihydrocoumarinyl, dihydroisocoumarinyl, isoindolinonyl, benzodioxanyl, benzoxazolinonyl, imidazopyrazolyl, quinazolinonyl,
- pyrazopyridyl, benzooxadiazolyl, dihydropyrimidinonyl, dihydrobenzofuranonyl, pyridinyl-N-oxide, pyrrolyl N-oxide, pyrimidinyl N-oxide, pyridazinyl N-oxide, pyrazinyl N-oxide, quinolinyl N-oxide, indolyl N-oxide, indolinyl N-oxide, isoquinolyl N-oxide, quinazolinyl N-oxide, quinoxalinyl N-

oxide, phthalazinyl N-oxide, imidazolyl N-oxide, isoxazolyl N-oxide, oxazolyl N-oxide, thiazolyl N-oxide, indolizinyl N-oxide, indazolyl N-oxide, benzothiazolyl N-oxide, benzimidazolyl N-oxide, pyrrolyl N-oxide, oxadiazolyl N-oxide, thiadiazolyl N-oxide, triazolyl N-oxide, tetrazolyl N-oxide, benzothiopyranyl S-oxide, and benzothiopyranyl S,S-dioxide,

where the  $R_{C\text{-heteroaryl}}$  group is bonded by any atom of the parent  $R_{C\text{-heteroaryl}}$  group substituted by hydrogen such that the new bond to the  $R_{C\text{-heteroaryl}}$  group replaces the hydrogen atom and its bond, where heteroaryl is optionally substituted 1, 2, 3, or 4 groups that are independently:

(1)  $C_1$ - $C_6$  alkyl, optionally substituted with 1, 2, or 3 groups independently selected from the group consisting of  $C_1$ - $C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>,  $C_1$ - $C_3$  alkoxy, and -NR<sub>1-a</sub>R<sub>1-b</sub>,

- (2) OH,
- (3) -NO<sub>2</sub>,
- (4) -F, -Cl, -Br, -I,
- (5) -CO-OH,
- 20 (6) -C≡N,

5

10

- (7)  $-(CH_2)_{0-4}-CO-NR_{N-2}R_{N-3}$ ,
- (8)  $-(CH_2)_{0-4}-CO-(C_1-C_{12} \text{ alkyl})$ ,
- (9)  $-(CH_2)_{0-4}-CO-(C_2-C_{12} \text{ alkenyl})$ ,
- (10)  $-(CH_2)_{0-4}-CO-(C_2-C_{12} \cdot alkynyl)$ ,
- 25  $(11) (CH_2)_{0-4} CO (C_3 C_7 \text{ cycloalkyl}),$ 
  - (12)  $-(CH_2)_{0-4}-CO-R_{1-aryl}$ ,
  - (13)  $-(CH_2)_{0-4}-CO-R_{1-heteroaryl}$ ,
  - (14) -(CH<sub>2</sub>)<sub>0-4</sub>-CO-R<sub>1-heterocycle</sub>,
  - (15)  $-(CH_2)_{0-4}-CO-R_{N-4}$ ,
- 30 (16)  $-(CH_2)_{0-4}-CO-O-R_{N-5}$ ,
  - (17)  $-(CH_2)_{0-4}-SO_2-NR_{N-2}R_{N-3}$ ,
  - (18)  $-(CH_2)_{0-4}-SO-(C_1-C_8 \text{ alkyl})$ ,
  - (19)  $-(CH_2)_{0-4}-SO_{2-}(C_1-C_{12} \text{ alkyl})$ ,
  - (20)  $-(CH_2)_{0-4}-SO_2-(C_3-C_7 \text{ cycloalkyl})$ ,

```
(21) -(CH_2)_{0-4}-N(H \text{ or } R_{N-5})-CO-O-R_{N-5},
                        (22) -(CH_2)_{0-4}-N(H \text{ or } R_{N-5})-CO-N(R_{N-5})_2,
                        (23) - (CH<sub>2</sub>)<sub>0-4</sub>-N-CS-N(R<sub>N-5</sub>)<sub>2</sub>,
                        (24) - (CH<sub>2</sub>)<sub>0-4</sub>-N(-H or R<sub>N-5</sub>)-CO-R<sub>N-2</sub>,
                        (25) -(CH_2)_{0-4}-NR_{N-2}R_{N-3},
 5
                        (26) - (CH<sub>2</sub>)<sub>0-4</sub> - R<sub>N-4</sub>,
                        (27) - (CH<sub>2</sub>)<sub>0-4</sub>-O-CO-(C<sub>1</sub>-C<sub>6</sub> alky1),
                        (28) - (CH<sub>2</sub>)<sub>0-4</sub>-O-P(O)-(OR<sub>100</sub>)<sub>2</sub>,
                        (29) - (CH<sub>2</sub>)<sub>0-4</sub>-O-CO-N(R<sub>N-5</sub>)<sub>2</sub>,
                        (30) - (CH<sub>2</sub>)<sub>0-4</sub>-O-CS-N(R<sub>N-5</sub>)<sub>2</sub>,
10
                        (31) - (CH<sub>2</sub>)<sub>0-4</sub>-O-(R<sub>N-5</sub>),
                         (32) -(CH_2)_{0-4}-O-(R_{N-5})-COOH,
                         (33) -(CH_2)_{0-4}-S-(R_{N-5}),
                         (34) - (CH<sub>2</sub>)<sub>0-4</sub>-O-(C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted
       with one, two, three, four, or five of -F),
                         (35) C_3-C_8 cycloalkyl,
                         (36) C_2-C_6 alkenyl optionally substituted with C_1-C_3
       alkyl, -F, -C1, -Br, -I, -OH, -SH, -C\equivN, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, or
        -NR_{1-a}R_{1-b},
                         (37) C_2-C_6 alkynyl optionally substituted with C_1-C_3
20
        alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C\equivN, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, or
        -NR_{1-a}R_{1-b},
                         (38) -(CH_2)_{0-4}-N(-H \text{ or } R_{N-5})-SO_2-R_{N-2}, and
                         (39) - (CH<sub>2</sub>)<sub>1-4</sub> - (C<sub>3</sub> - C<sub>8</sub> cycloalky1),
25
                         (V) - (CR_{C-x}R_{C-y})_{0-4} - R_{C-aryl} - R_{C-aryl}
                         (VI) - (CR_{C-x}R_{C-y})_{0-4} - R_{C-aryl} - R_{C-heteroaryl}
                         (VII) -(CR_{C-x}R_{C-y})_{0-4}-R_{C-heteroaryl}-R_{C-aryl},
                          (VIII) - (CR<sub>C-x</sub>R<sub>C-y</sub>)<sub>0-4</sub>-R<sub>C-heteroaryl</sub>-R<sub>C-heteroaryl</sub>,
                          (IX) -(CR_{C-x}R_{C-y})_{0-4}-R_{C-aryl}-R_{C-heterocycle}, wherein
        R_{\text{C-heterocycle}} is selected from the group consisting of
        morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide,
        thiomorpholinyl S,S-dioxide, piperazinyl, homopiperazinyl,
        pyrrolidinyl, pyrrolinyl, tetrahydropyranyl, piperidinyl,
        tetrahydrofuranyl, tetrahydrothienyl, homopiperidinyl,
```

homomorpholinyl, homothiomorpholinyl, homothiomorpholinyl S,S-dioxide, oxazolidinonyl, dihydropyrazolyl, dihydropyrrolyl, dihydropyrazinyl, dihydropyridinyl, dihydropyrimidinyl, dihydrofuryl, dihydropyranyl, tetrahydrothienyl S-oxide, tetrahydrothienyl S,S-dioxide, homothiomorpholinyl S-oxide, dithianyl, pyranyl, dihydrofuranyl, pyrrolidinonyl, imidazolidinonyl, imidazolidinondionyl, wherein each of the above is optionally fused to a benzene, pyridine, or pyrimidine ring, and

- where the  $R_{1\text{-heterocycle}}$  group is bonded by any atom of the parent  $R_{1\text{-heterocycle}}$  group substituted by hydrogen such that the new bond to the  $R_{1\text{-heterocycle}}$  group replaces the hydrogen atom and its bond, where heterocycle is optionally substituted with one, two, three or four:
- 15 (1)  $C_1$ - $C_6$  alkyl optionally substituted with one, two or three substituents independently selected from the group consisting of  $C_1$ - $C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -NR<sub>1-a</sub>R<sub>1-b</sub>, -C $\equiv$ N, -CF<sub>3</sub>, and  $C_1$ - $C_3$  alkoxy,
- (2)  $C_2$ - $C_6$  alkenyl optionally substituted with one, 20 two or three substituents selected from the group consisting of -F, -Cl, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>,  $C_1$ - $C_3$  alkoxy, -NR<sub>1-a</sub>R<sub>1-b</sub>,
  - (3)  $C_2$ - $C_6$  alkynyl optionally substituted with one, two or three substituents independently selected from the group consisting of -F, -Cl, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, and -NR<sub>1-a</sub>R<sub>1-b</sub>,
    - (4) -F, -Cl, -Br and -I,
    - (5)  $C_1-C_6$  alkoxy,
    - (6)  $-C_1-C_6$  haloalkoxy,
    - $(7) NR_{N-2}R_{N-3}$
  - (8) -OH,

25

- (9) -C≡N,
- (10)  $C_3$ - $C_7$  cycloalkyl, optionally substituted with one, two or three substituents independently selected from the group consisting of -F, -Cl, -OH, -SH

 $-C\equiv N$ ,  $-CF_3$ ,  $C_1-C_3$  alkoxy, and  $-NR_{1-a}R_{1-b}$ ,

- (11)  $-CO-(C_1-C_4 \text{ alkyl})$ ,
- (12)  $-SO_2-NR_{1-a}R_{1-b}$ ,
- (13)  $-CO-NR_{1-a}R_{1-b}$ ,
- 5  $(14) -SO_2 (C_1 C_4 \text{ alkyl}),$ 
  - (15) =0, with the proviso that when  $n_1$  is zero  $R_{1-}$  heterocycle is not bonded to the carbon chain by nitrogen;
    - (X)  $-(CR_{C-x}R_{C-y})_{0-4}-R_{C-heteroaryl}-R_{C-heterocycle}$ ,
    - (XI)  $-(CR_{C-x}R_{C-y})_{0-4}-R_{C-heterocycle}-R_{C-aryl}$ ,
- 10 (XII)  $-(CR_{C-x}R_{C-y})_{0-4}-R_{C-heterocycle}-R_{C-heteroaryl}$ ,
  - (XIII) (CR<sub>C-x</sub>R<sub>C-y</sub>)<sub>0-4</sub>-R<sub>C-heterocycle</sub>-R<sub>C-heterocycle</sub>,
  - (XIV) (CR<sub>C-x</sub>R<sub>C-y</sub>)<sub>0-4</sub>-R<sub>C-heterocycle</sub>,
  - (XV) -[C( $R_{C-1}$ )( $R_{C-2}$ )]<sub>1-3</sub>-CO-N-( $R_{C-3}$ )<sub>2</sub> where  $R_{C-1}$  and  $R_{C-2}$  are the same or different and are selected from the group consisting of:
  - /3·\ \*

- (A) -H,
- (B)  $-C_1-C_6$  alkyl, optionally substituted with one, two or three substituents selected from the group consisting of  $C_1-C_3$  alkyl, -F, -Cl, -Br, -I, -OH,
- 20 -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkoxy, -O-phenyl, and -NR<sub>1-a</sub>R<sub>1</sub>,
  - (C)  $C_2$ - $C_6$  alkenyl optionally substituted with one, two or three substituents selected from the group consisting of  $C_1$ - $C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C $\equiv$ N, -CF $_3$ ,  $C_1$ - $C_6$  alkoxy, -O-phenyl, and -NR $_{1-a}$ R $_{1-b}$ ,
- 25 (D)  $C_2$ - $C_6$  alkynyl optionally substituted with one, two or three substituents selected from the group consisting of  $C_1$ - $C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C $\equiv$ N, -CF $_3$ ,  $C_1$ - $C_6$  alkoxy, -O-phenyl, and -NR $_{1-a}$ R $_{1-b}$ ,
  - (E)  $-(CH_2)_{1-2}-S(O)_{0-2}-(C_1-C_6 \text{ alkyl})$ ,
- 30 (F)  $-(CH_2)_{0-4}-C_3-C_8$  cycloalkyl, optionally substituted with one, two or three substituents selected from the group consisting of  $C_1-C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>,  $C_1-C_6$  alkoxy, -O-phenyl, and -NR<sub>1-a</sub>R<sub>1-b</sub>
  - (G)  $-(C_1-C_4 \text{ alkyl})-R_{C-aryl}$ ,

- (H)  $-(C_1-C_4 \text{ alkyl})-R_{C-heteroarvl}$ ,
- (I)  $-(C_1-C_4 \text{ alkyl})-R_{C-\text{heterocycle}}$ ,
- (J) -R<sub>C-heteroaryl</sub>,
- (K) -R<sub>C-heterocycle</sub>,
- 5 (M)  $-(CH_2)_{1-4}-R_{C-4}-(CH_2)_{0-4}-R_{C-aryl}$  where  $R_{C-4}$  is -O-, -S-

or

 $-NR_{C-5}$ - where  $R_{C-5}$  is  $C_1$ - $C_6$  alkyl,

- (N)  $-(CH_2)_{1-4}-R_{C-4}-(CH_2)_{0-4}-R_{C-heteroaryl}$ ,
- $(0) -R_{C-aryl}$ ,
- 10 and where  $R_{C-3}$  at each occurrence is the same or different and is:
  - (A) -H,
  - (B)  $-C_1-C_6$  alkyl optionally substituted with one, two or three substituents independently selected from the group
- 15 consisting of  $C_1$ - $C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>,  $C_1$ - $C_6$  alkoxy, -O-phenyl, and -NR<sub>1-a</sub>R<sub>1-b</sub>,
  - (C)  $C_2$ - $C_6$  alkenyl with one or two double bonds, optionally substituted with one, two or three substituents independently selected from the group consisting of  $C_1$ - $C_3$
- 20 alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C=N, -CF<sub>3</sub>,  $C_1$ -C<sub>6</sub> alkoxy, -O-phenyl, and -NR<sub>1-a</sub>R<sub>1-b</sub>,
  - (D)  $C_2-C_6$  alkynyl optionally substituted with one, two or three substituents independently selected from the group consisting of  $C_1-C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C $\equiv$ N, -
- 25 CF<sub>3</sub>,  $C_1$ - $C_6$  alkoxy, -O-phenyl, and -NR<sub>1-a</sub>R<sub>1-b</sub>,
  - (E)  $-(CH_2)_{0-4}-C_3-C_8$  cycloalkyl, optionally substituted with one, two or three substituents independently selected from the group consisting of  $C_1-C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>,  $C_1-C_6$  alkoxy, -O-phenyl, -NR<sub>1-a</sub>R<sub>1-b</sub>,
- 30

- (F) -R<sub>C-aryl</sub>,
- (G) -R<sub>C-heteroarvl</sub>,
- (H) -R<sub>C-heterocycle</sub>,
- (I)  $-(C_1-C_4 \text{ alkyl})-R_{C-aryl}$ ,
- J)  $-(C_1-C_4 \text{ alkyl})-R_{C-heteroaryl}$ ,

```
(K) -(C_1-C_4 \text{ alkyl})-R_{C-heterocycle}
```

(XVI)  $-CH(R_{C-aryl})_2$ ,

5

10

15

(XVII) -CH(R<sub>C-heteroaryl</sub>)<sub>2</sub>,

(XVIII) -CH(R<sub>C-aryl</sub>)(R<sub>C-heteroaryl</sub>),

(XIX) -cyclopentyl, -cyclohexyl, or -cycloheptyl ring fused to  $R_{C-aryl}$  or  $R_{C-heteroaryl}$  or  $R_{C-heterocycle}$ , where one carbon of cyclopentyl, cyclohexyl, or -cycloheptyl is optionally replaced with NH,  $NR_{N-5}$ , O,  $S(=0)_{0-2}$ , and where cyclopentyl, cyclohexyl, or -cycloheptyl can be optionally substituted with one or two -  $C_1$ - $C_3$  alkyl, -F, -OH, -SH, -C $\equiv$ N, -CF $_3$ ,  $C_1$ - $C_6$  alkoxy, =O, and -  $NR_{1-a}R_{1-b}$ ,

(XX)  $C_2$ - $C_{10}$  alkenyl optionally substituted with one, two or three substituents selected from the group consisting of  $C_1$ - $C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>,  $C_1$ - $C_6$  alkoxy, -O-phenyl, and -NR<sub>1-a</sub>R<sub>1-b</sub>,

(XXI)  $C_2-C_{10}$  alkynyl optionally substituted with one, two or three substituents selected from the group consisting of  $C_1-C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C $\equiv$ N, -CF $_3$ ,  $C_1-C_6$  alkoxy, -O-phenyl, and -NR $_{1-a}$ R $_{1-b}$ ,

20 (XXI)  $-(CH_2)_{0-1}-CHR_{C-6}-(CH_2)_{0-1}-R_{C-aryl}$  where  $R_{C-6}$  is  $-(CH_2)_{0-6}-CH_2$ 

 $(XXII) - (CH_2)_{0-1} - CHR_{C-6} - (CH_2)_{0-1} - R_{C-heteroaryl}, \\ (XXIII) - CH(-R_{C-aryl} \text{ or } R_{C-heteroaryl}) - CO_2(C_1 - C_4 \text{ alkyl}), \\ (XXIV) - CH(-CH_2 - OH) - CH(-OH) - NO_2, \\ (XXV) (C_1 - C_6 \text{ alkyl}) - O - (C_1 - C_6 \text{ alkyl}) - OH, \\ (XXVII) - CH_2 - NH - CH_2 - CH(-O - CH_2 - CH_3)_2, \\ (XXVIII) - H, \\ (XXIX) - (CH_2)_{0-6} - C(=NR_{1-a})(NR_{1-a}R_{1-b});$ 

 $R_{25}$  at each occurrence is independently selected from the group consisting of hydrogen,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  alkyl, hydroxy  $C_1$ - $C_6$  alkyl, halo  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkanoyl, each of which is unsubstituted or substituted with 1, 2, 3, or 4 groups independently selected from halogen, alkyl, hydroxy, alkoxy, and NH<sub>2</sub>, and - $R_{26}$ - $R_{27}$ , wherein

 $R_{26}$  is selected from the group consisting of -C(0)-, -SO<sub>2</sub>-, -CO<sub>2</sub>-, -C(0)NH-, and -C(0)N(C<sub>1</sub>-C<sub>6</sub> alkyl)-;

 $R_{27}$  is selected from the group consisting of  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy, aryl  $C_1$ - $C_6$  alkyl, heterocycloalkyl, and heteroaryl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, halogen, haloalkyl, hydroxyalkyl, -  $C(0)NH_2$ ,  $NH_2$ ,  $NH(C_1$ - $C_6$  alkyl),  $N(C_1$ - $C_6$  alkyl)  $(C_1$ - $C_6$  alkyl), -  $C(0)NH(C_1$ - $C_6$  alkyl), - $C(0)N(C_1$ - $C_6$  alkyl)  $(C_1$ - $C_6$  alkyl).

## 10 2. A compound of the formula

20

25

Z51

and pharmaceutically acceptable salts thereof wherein m is 0-5;

15 B is aryl or heteroaryl optionally substituted with one or two groups independently selected from  $R_6$ ,  $R^{\prime}{}_6$ ,  $R^{\prime}{}_6$ , and  $R^{\prime}{}_{}^{\prime}{}_6$ , or

B is cycloalkyl or heterocycloalkyl optionally substituted with one, two, three, four, five, six, seven or eight groups independently selected from  $R_{6a}$ ,  $R_{6b}$ ,  $R'_{6a}$ ,  $R'_{6b}$ ,  $R''_{6a}$ ,  $R''_{6b}$ ,  $R'''_{6a}$  and  $R''''_{6b}$ ;

 $C_1-C_8$  alkyl,  $C_2-C_7$  alkenyl or  $C_2-C_7$  alkynyl, each of which is optionally substituted with one, two or three groups selected from -NRR', -SR, -CN, -OCF<sub>3</sub>, -CF<sub>3</sub>, -CONRR', -CO<sub>2</sub>R, -SO<sub>2</sub>NRR', -O-P(=O)(OR)(OR'), -N(R)-C(=O)(R'), -N(R)(SO<sub>2</sub>R'), -SO<sub>2</sub>R, -C(=O)R, -NO<sub>2</sub>, halogen, -(CH<sub>2</sub>)<sub>0-4</sub>-aryl, and -(CH<sub>2</sub>)<sub>0-4</sub>-heteroaryl, or

R and R' independently are -H,  $-(C_1-C_{10})$  alkyl,  $-(CH_2)_{0-4}-R_{aryl}$ ,  $-(CH_2)_{0-4}-R_{heterocyclyl}$ , or

30  $C_2$ - $C_7$  alkenyl or  $C_2$ - $C_7$  alkynyl, each of which is optionally substituted with one, two or three substituents selected from the group consisting of halogen, -OH,

5

10

20

-SH,  $-C\equiv N$ ,  $-CF_3$ ,  $C_1-C_3$  alkoxy, amino, mono- or dialkylamino, and  $C_1-C_6$  alkyl, or

- -(CH<sub>2</sub>)<sub>0-4</sub>- C<sub>3</sub>-C<sub>7</sub> cycloalkyl optionally substituted with one, two or three substituents selected from the group consisting of halogen, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, amino, mono- or dialkylamino, and C<sub>1</sub>-C<sub>6</sub> alkyl;
- benzyl where the phenyl ring is optionally substituted with 1-3 groups independently selected from halogen,
  -OH, -SH, -C≡N, mono or dialkylamino, C₁-C6 alkoxy,
  or trifluoromethyl;
- $R_6$ ,  $R''_6$ ,  $R'''_6$ ,  $R_{6a}$ ,  $R_{6b}$ ,  $R'_{6a}$ ,  $R'_{6b}$ ,  $R''_{6a}$ ,  $R''_{6b}$ ,  $R'''_{6a}$  and  $R'''_{6b}$  independently are -OR,  $-NO_2$ , halogen,  $-CO_2R$ ,  $-C\equiv N$ , -NRR', -SR,  $-SO_2R$ , -C(=O)R,  $-OCF_3$ ,  $-CF_3$ , -CONRR',  $-SO_2NRR'$ , -O-P(=O)(OR)(OR'), -N(R)(COR'),  $-N(R)(SO_2R')$ ,  $-(CH_2)_{0-4}-CO-NRR'$
- 25 H or  $R_{11}$ )-CO- $R_7$ , -(CH<sub>2</sub>)<sub>0-4</sub>-NR<sub>7</sub>R'<sub>7</sub>, -(CH<sub>2</sub>)<sub>0-4</sub>-R<sub>10</sub>, -(CH<sub>2</sub>)<sub>0-4</sub>-O-CO-CO-(C<sub>1</sub>-C<sub>6</sub> alkyl), -(CH<sub>2</sub>)<sub>0-4</sub>-O-P(O)-(O- $R_{aryl}$ )<sub>2</sub>, -(CH<sub>2</sub>)<sub>0-4</sub>-O-CO-N( $R_{11}$ )<sub>2</sub>, -(CH<sub>2</sub>)<sub>0-4</sub>-O-CS-N( $R_{11}$ )<sub>2</sub>, -(CH<sub>2</sub>)<sub>0-4</sub>-O-( $R_{11}$ ), -(CH<sub>2</sub>)<sub>0-4</sub>-O-
  - $(R_{11})$ -COOH,  $-(CH_2)_{0-4}$ -S- $(R_{11})$ ,  $C_3$ -C<sub>7</sub> cycloalkyl,  $-(CH_2)_{0-4}$ -N(-H or  $R_{11}$ )-SO<sub>2</sub>-R<sub>7</sub>, or  $-(CH_2)_{0-4}$   $C_3$ -C<sub>7</sub> cycloalkyl, or
- 30  $C_1-C_8$  alkyl optionally substituted with one, two or three groups independently selected from  $C_1-C_6$  alkyl, -F,  $C_1$ , -Br, -I, -OR, -NO<sub>2</sub>, -F, -Cl, -Br, -I, -CO<sub>2</sub>R,  $C_2$ R, -NRR', -SR, -SO<sub>2</sub>R, -C(=O)R, -OCF<sub>3</sub>, -CF<sub>3</sub>, -CONRR', -SO<sub>2</sub>NRR', -O-P(=O)(OR)(OR'), -N(R)(COR'), -

```
N(R)(SO_2R'), -(CH_2)_{0-4}-CO-NR_7R'_7, -(CH_2)_{0-4}-CO-(C_1-C_{12})_{0-4}
                       alkyl), -(CH_2)_{0-4}-CO-(C_2-C_{12} \text{ alkenyl}), -(CH_2)_{0-4}-CO-(C_2-C_{12} \text{ alkenyl})
                       C_{12} alkynyl), -(CH_2)_{0-4}-CO-(C_3-C_7) cycloalkyl), -(CH_2)_{0-4}
                       _{4}-R<sub>aryl</sub>, -(CH<sub>2</sub>)<sub>0-4</sub>-R<sub>heteroaryl</sub>, -(CH<sub>2</sub>)<sub>0-4</sub>-R<sub>heterocyclyl</sub>, -(CH<sub>2</sub>)<sub>0-</sub>
 5
                       _{4}-CO-R_{aryl}, -(CH<sub>2</sub>)<sub>0-4</sub>-CO-R_{heteroaryl}, -(CH<sub>2</sub>)<sub>0-4</sub>-CO-
                       R_{heterocyclyl}, -(CH<sub>2</sub>)<sub>0-4</sub>-CO-R<sub>10</sub>, -(CH<sub>2</sub>)<sub>0-4</sub>-CO-O-R<sub>11</sub>, -(CH<sub>2</sub>)<sub>0-4</sub>
                       _{4}-SO_{2}-NR_{7}R'_{7}, -(CH_{2})_{0-4}-SO_{-}(C_{1}-C_{8} \text{ alkyl}), -(CH_{2})_{0-4}-SO_{2}-
                       (C_1-C_{12} \text{ alkyl}), -(CH_2)_{0-4}-SO_2-(C_3-C_7 \text{ cycloalkyl}),
                       -(CH_2)_{0-4}-N(H \text{ or } R_{11})-CO-O-R_{11}, -(CH_2)_{0-4}-N(H \text{ or } R_{11})-CO-
10
                       N(R_{11})_2, -(CH_2)_{0-4}-N(H \text{ or } R_{11})-CS-N(R_{11})_2, -(CH_2)_{0-4}-N(-H
                       or R_{11})-CO-R_7, -(CH<sub>2</sub>)<sub>0-4</sub>-NR<sub>7</sub>R'<sub>7</sub>, -(CH<sub>2</sub>)<sub>0-4</sub>-R<sub>10</sub>, -(CH<sub>2</sub>)<sub>0-4</sub>-
                       O-CO-(C_1-C_6 \text{ alkyl}), -(CH_2)_{0-4}-O-P(O)-(O-R_{aryl})_2, -(CH_2)_{0-4}-O-P(O)
                       _{4}-O-CO-N(R<sub>11</sub>)<sub>2</sub>, -(CH<sub>2</sub>)<sub>0-4</sub>-O-CS-N(R<sub>11</sub>)<sub>2</sub>, -(CH<sub>2</sub>)<sub>0-4</sub>-O-(R<sub>11</sub>),
                       -(CH_2)_{0-4}-O-(R_{11})-COOH, -(CH_2)_{0-4}-S-(R_{11}), C_3-C_7
15
                       cycloalkyl, -(CH_2)_{0-4}-N(-H \text{ or } R_{11})-SO_2-R_7, or -(CH_2)_{0-4}-
                       C<sub>3</sub>-C<sub>7</sub> cycloalkyl, or
                       C2-C7 alkenyl or C2-C7 alkynyl, each of which is
                                optionally substituted with one, two or three
                                groups independently selected from halogen or -
20
                                OH, or
               C_2-C_7 alkenyl or C_2-C_7 alkynyl, each of which is optionally
                       substituted with one, two or three groups
                       independently selected from halogen, C1-C3 alkyl,
   -C\equiv N, -CF_3, C_1-C_3 alkoxy, amino, and mono-
                       -OH, -SH,
25
                       or dialkylamino, or
               -(CH_2)_{0-4}-O-(C_1-C_6 \text{ alkyl}), where the alkyl portion is
                       optionally substituted with one, two, three, four, or
                       five of halogen, or
       any two of R_{6a}, R_{6b}, R'_{6a}, R'_{6b}, R''_{6a}, R'''_{6b}, R''''_{6a} and R'''_{6b}
30
               together are oxo;
       R_7 and R'_7 are the same or different and represent -H, -C<sub>3</sub>-C<sub>7</sub>
               cycloalkyl, -(C_1-C_2 \text{ alkyl})-(C_3-C_7 \text{ cycloalkyl}), -(C_1-C_6 \text{ cycloalkyl})
               alky1)-0-(C_1-C_3 alky1), -C_2-C_6 alkeny1, -C_2-C_6 alkyny1, -C_1-
```

C6 alkyl chain with one double bond and one triple bond, -C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with -OH or -NH<sub>2</sub>; or; -C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with one, two or three groups independently selected from halogen; or 5 heterocyclyl optionally substituted with halogen, amino, mono- or dialkylamino, -OH, -C≡N, -SO<sub>2</sub>-NH<sub>2</sub>, -SO<sub>2</sub>-NH- $C_1-C_6$  alkyl,  $-SO_2-N(C_1-C_6$  alkyl)<sub>2</sub>,  $-SO_2-(C_1-C_4$  alkyl), - $CO-NH_2$ ,  $-CO-NH-C_1-C_6$  alkyl, oxo and  $-CO-N(C_1-C_6)$ 10 alkyl)2; or C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with one, two or three groups independently selected from C1-C3 alkyl, halogen, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, amino, and mono- or dialkylamino; or C2-C6 alkenyl or C2-C6 alkynyl, each of which is 15 optionally substituted with one, two or three groups independently selected from  $C_1\text{-}C_3$  alkyl, halogen, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, amino, and mono- or dialkylamino; or C<sub>1</sub>-C<sub>6</sub> alkoxy optionally substituted with one, two or 20 three of halogen; aryl or heteroaryl, each of which is optionally substituted with halogen, amino, mono- or dialkylamino, -OH,  $-C \equiv N$ ,  $-SO_2 - NH_2$ ,  $-SO_2 - NH - C_1 - C_6$ alkyl,  $-SO_2-N(C_1-C_6 \text{ alkyl})_2$ ,  $-SO_2-(C_1-C_4 \text{ alkyl})$ , -CO-25  $NH_2$ ,  $-CO-NH-C_1-C_6$  alkyl, and  $-CO-N(C_1-C_6$  alkyl)<sub>2</sub>; or C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with one, two or three groups independently selected from C1-C3 alkyl, halogen, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> 30 alkoxy, amino, and mono- or dialkylamino; or C2-C6 alkenyl or C2-C6 alkynyl, each of which is optionally substituted with one, two or three groups independently selected from C1-C3 alkyl,

halogen, -OH, -SH, -C $\equiv$ N, -CF $_3$ , C $_1$ -C $_3$  alkoxy, amino, and mono- or dialkylamino; or C $_1$ -C $_6$  alkoxy optionally substituted with one, two or three of halogen;

- 5 R<sub>10</sub> is heterocyclyl optionally substituted with one, two, three or four groups independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl;

  R<sub>11</sub> is C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>7</sub>

  cycloalkyl, -(CH<sub>2</sub>)<sub>0-2</sub>-R<sub>aryl</sub>, or -(CH<sub>2</sub>)<sub>0-2</sub>-R<sub>heteroaryl</sub>;
- $R_{aryl}$  is aryl optionally substituted with halogen, amino, mono-or dialkylamino, -OH, -C $\equiv$ N, -SO<sub>2</sub>-NH<sub>2</sub>, -SO<sub>2</sub>-NH-C<sub>1</sub>-C<sub>6</sub> alkyl, -SO<sub>2</sub>-N(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>2</sub>, -SO<sub>2</sub>-(C<sub>1</sub>-C<sub>4</sub> alkyl), -CO-NH<sub>2</sub>, -CO-NH-C<sub>1</sub>-C<sub>6</sub> alkyl, or -CO-N(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>2</sub>; or
  - C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with one, two or three groups independently selected from C<sub>1</sub>-C<sub>3</sub> alkyl,

halogen, -OH, -SH, -C $\equiv$ N, -CF $_3$ , C $_1$ -C $_3$  alkoxy, amino, and mono- or dialkylamino; or

15

- $C_2$ - $C_6$  alkenyl or  $C_2$ - $C_6$  alkynyl, each of which is optionally substituted with one, two or three groups independently selected from  $C_1$ - $C_3$  alkyl, halogen, OH, -SH, -C $\equiv$ N, -CF $_3$ ,  $C_1$ - $C_3$  alkoxy, amino, and monoor dialkylamino; or
- $C_1$ - $C_6$  alkoxy optionally substituted with one, two or three of halogen;
- $R_{\rm heteroaryl}$  is heteroaryl, each of which is optionally substituted with halogen, amino, mono- or dialkylamino, -OH, -C $\equiv$ N, -SO<sub>2</sub>-NH<sub>2</sub>, -SO<sub>2</sub>-NH-C<sub>1</sub>-C<sub>6</sub> alkyl, -SO<sub>2</sub>-N(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>2</sub>, -SO<sub>2</sub>-(C<sub>1</sub>-C<sub>4</sub> alkyl), -CO-NH<sub>2</sub>, -CO-NH-C<sub>1</sub>-C<sub>6</sub> alkyl, or -CO-N(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>2</sub>; or
- $C_1-C_6$  alkyl optionally substituted with one, two or three groups independently selected from  $C_1-C_3$  alkyl, halogen, -OH, -SH, -C $\equiv$ N, -CF $_3$ ,  $C_1-C_3$  alkoxy, amino, and mono- or dialkylamino; or

 $C_2-C_6$  alkenyl or  $C_2-C_6$  alkynyl, each of which is optionally substituted with one, two or three groups independently selected from  $C_1-C_3$  alkyl, halogen, - OH, -SH, -C $\equiv$ N, -CF $_3$ ,  $C_1-C_3$  alkoxy, amino, and monoor dialkylamino; or

 $C_1$ - $C_6$  alkoxy optionally substituted with one, two or three of halogen;

Rheterocyclyl is heterocyclyl optionally substituted with halogen, amino, mono- or dialkylamino, -OH, -C=N, -SO<sub>2</sub>-NH<sub>2</sub>, -SO<sub>2</sub>-NH-C<sub>1</sub>-C<sub>6</sub> alkyl, -SO<sub>2</sub>-N(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>2</sub>, -SO<sub>2</sub>-(C<sub>1</sub>-C<sub>4</sub> alkyl), -CO-NH<sub>2</sub>, -CO-NH-C<sub>1</sub>-C<sub>6</sub> alkyl, =O or -CO-N(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>2</sub>; or C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with one, two or three groups independently selected from C<sub>1</sub>-C<sub>3</sub> alkyl, halogen, -OH, -SH, -C=N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, amino, and mono- or dialkylamino; or

- $C_2$ - $C_6$  alkenyl or  $C_2$ - $C_6$  alkynyl, each of which is optionally substituted with one, two or three groups independently selected from  $C_1$ - $C_3$  alkyl, halogen, OH, -SH, -C=N, -CF<sub>3</sub>,  $C_1$ - $C_3$  alkoxy, amino, and monoor dialkylamino; or
- $C_1$ - $C_6$  alkoxy optionally substituted with one, two or three of halogen;

R<sub>2</sub> and R<sub>3</sub> are independently hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl; or
R<sub>2</sub> and R<sub>3</sub> taken together with the carbon atom to which they are attached form a 3 or 4-membered ring;
R<sub>C</sub> is hydrogen or phenyl optionally substituted with C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkynyl, trifluoromethyl, or C<sub>1</sub>-C<sub>2</sub> alkoxy.

## 3. A compound of the formula

or a pharmaceutically acceptable salt thereof, wherein

`

30

5

20

R<sub>30</sub> is selected from the group consisting of phenyl, pyrazolopyrimidinyl, oxa-aza-benzoazulenyl, isoxazolyl, triazolopyridinyl, pyrrolidinonyl, tetrahydrothia-azafluorenyl, pyridyl, piperidinyl, 5 dihydrocyclopentaquinolinyl, furyl, naphthothienyl, phthalazinonyl, thiadiazolyl, thienopyrimidinonyl, oxadiaza-cyclopentanaphthalenyl, dihydrobenzodioxepinyl, chromanonyl, chromenonyl, oxazolidinyl, benzophenone, pyrazinyl mono N-oxide, benzofuranyl, pyrazolyl, 10 -isoxazolyl-phenyl, phenyl-triazolyl, benzimidazolyl, indolyl, phenyl-pyrrolyl, chromanyl, isoquinolinyl, thienyl-thienyl, benzothienyl, -phenyl-thiadiazolyl, chromanonyl, quinolinyl, -pyrrolyl-C(0)-phenyl, -phenyl-Ophenyl, -phenyl-oxazolyl, -pyrrolidinonyl-phenyl, -phenyl-15 pyrimidinyl, -phenyl-oxadiazolyl, bicyclo[2.2.1]heptenyl, cyclopentyl, thieno[2,3-b]thiophene, cyclohexyl, -phenylimidazolyl, benzoxazole; dihydro-1H-indolyl; 2,3-dihydrobenzo[b]thiophene 1,1-dioxide; benzo[b]thiophene 1,1dioxide; 2,3-dihydro-benzo[d]isothiazole 1,1-dioxide; -20 phenyl-thiazolyl; -phenyl-pyrazolyl, -phenyl-C(0)piperidyl, -phenyl-C(0)-pyrrolidinyl, -phenyl-isoxazolyl, isoindolyl, purinyl, oxazolyl, thiazolyl, pyridazinonyl, thiazolyl, pyranyl, dihydropyranopyridinyl, diazepanyl, azepanyl, cyclopropyl, dihydronaphthoisoxazolyl, 25 benzoindazolyl, dihydrocyclopentachromenonyl, imidazopyrazolyl, tetrahydrocyclopentachromenonyl, dihydroquinolinonyl, pyridyl N-oxide, isochromanyl, quinazolinonyl, pyrazolopyridinyl, dihydrobenzothiophene dioxide, dihydrofurobenzoisoxazolyl, dihydropyrimidine 30 dionyl, thienopyrazolyl, oxazolyl, tetrahydrocyclopentapyrazolyl, dihydronaphthalenonyl, dihydrobenzofuranonyl, dihydrocyclopentathienyl, tetrahydrocyclopentapyrazolyl, tetrahydropyrazoloazepinyl, indazolyl, tetrahydrocycloheptaisoxazolyl,

tetrahydroindolonyl, pyrrolidinyl, thienopyridinyl, dioxodihydrobenzoisothiazolonyl, triazolopyrimidinyl, thienyl, dihydrothienopyrimidinonyl, benzooxadiazolyl, carbazolyl, chromeno[3,4-d]isoxazolyl, chromanonyl, 5 triazolopyridazinyl, oxazolidinyl, -pyrrolyl-(C1-C6 alkyl)-pyridyl, -pyrrolyl-cyclohexyl, pyrrolidinonyl, dihydropyrazolyl, benzooxadiazolyl mono N-oxide, 1-Hpyridazinonyl, -phenyl-dihydro-1-H-pyrazolidinonyl, phenyl-pyrrolidinyl dione, thienoindolyl, 10 thioxobenzothiazolyl, pyrazolopyridinyl, thiomorpholinyl S-oxide, dihydrofurylbenzisoxazolyl, benzoisothiazolinonyl 1,1-dioxide; tetrahydropyrimidinyl dione, tetrahydrothiopyranylindolyl, benzodioxepinyl, -phenylpyrrazolidinonyl, dihydronaphthyl, tetrahydronaphthyl, 15 isoindolinyl dione, -imidazole-benzyl, -thienedihydrooxazolyl, thienoquinolinyl, -pyrrolidine-phenyl, benzooxazolidinonyl, pyrrolopyridinyl, indanonyl, 1-Himidazo[1,2-b]pyrazolyl, dihydrocyclopenta[b]thienyl, dihydroindazolonyl, tetrahydropyrazoloazepinyl, 20 tetrahydrobenzofuranonyl, thienopyrazolyl, cyclopenta[c]pyrazolyl, tetrahydrocyclopenta[c]pyrazolyl, tetrahydroquinoxalinyl dione, tetrahydroindazolyl, imidazobenzoxazinyl, -phenyl-dihydropyrrolyl dione, -phenyl-O-benzyl, -phenyl-benzyl, 3',4'-dihydro-1'H-25 spiro[[1,3]dioxolane-2,2'-naphthalenyl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently selected from the group consisting of  $C_1-C_{10}$  alkyl optionally substituted with 1 phenyl or 1 CN;

 $C_1-C_{10}$  alkyl optionally substituted with 1 phenyl or 1 CN; OH, hydroxy  $C_1-C_{10}$  alkyl optionally substituted with phenyl or  $(C_1-C_4$  alkyl)phenyl,  $C_1-C_6$  alkoxy optionally substituted with 1 or 2 groups that are independently hydroxy or phenyl; haloalkyl, haloalkoxy,  $(CH_2)_{0-4}$   $C(0)NR_{31}R_{32}$ ,  $-NR_{31}-SO_2-(C_1-C_6$  alkyl) wherein the alkyl

group is optionally substituted with 1, 2, or 3 groups that are independently halogen or R<sub>33</sub>, -SO<sub>2</sub>- $NH(C_1-C_6 \text{ alkyl})$  wherein the alkyl group is optionally substituted with 1 or 2 groups that are independently 5 halogen, OH, alkoxy, or  $R_{33}$ ;  $-(C_1-C_6 \text{ alkyl})-SO_2-(C_1-C_6)$ alkyl) wherein the alkyl group is optionally substituted with 1 or 2 groups that are independently halogen, OH,  $C_1-C_4$  alkoxy, or  $R_{33}$ ;  $-SO_2-(C_1-C_6$  alkyl) wherein the alkyl group is optionally substituted 10 with 1 or 2 groups that are independently OH or C1-C4 alkoxy,  $-SO_2-N(C_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl})$  wherein each alkyl group is optionally substituted with 1 or 2 groups that are independently halogen, OH or R33;  $-SO_2-NH(C_1-C_6 \text{ alkyl})$ -phenyl wherein the phenyl is 15 optionally substituted with 1 or 2 groups that are independently  $C_1-C_4$  alkoxy or halogen,  $-(C_1-C_6$  alkyl)-O-phenyl,  $-(C_1-C_6 \text{ alkyl})-O-(C_1-C_6 \text{ alkyl})$ -phenyl, triazolidine-3,5-dione, halogen, -NHC(0)NH<sub>2</sub>, -NHC(O)NH( $C_1$ - $C_6$  alkyl), -NHC(O)N( $C_1$ - $C_6$  alkyl)( $C_1$ - $C_6$ 20 alkyl),  $-N(C_1-C_6 \text{ alkyl})C(O)NH_2$ ,  $-N(C_1-C_6 \text{ alkyl})C(O)NH_2$  $alkyl)C(O)NH(C_1-C_6 \ alkyl)$ ,  $-N(C_1-C_6 \ alkyl)C(O)N(C_1-C_6$ alkyl)  $(C_1-C_6 \text{ alkyl})$ ,  $-(C_1-C_6 \text{ alkyl})$  thienyl,  $-(C_1-C_6 \text{ alkyl})$ alkyl) furanyl,  $-S-(C_1-C_6 \text{ alkyl})$  phenyl,  $-SO_2NR_{31}R_{32}$ , - $C(0)-NR_{31}R_{32}$ ,  $-NR_{31}R_{32}$ , dithiane,  $-NHC(S)NH_2$ , 25 -NHC(S)NH( $C_1$ - $C_6$  alkyl), -NHC(S)N( $C_1$ - $C_6$  alkyl) ( $C_1$ - $C_6$ alkyl),  $-CO_2(C_1-C_6 \text{ alkyl})$ , tetrahydropyran, phenyl optionally substituted with 1 or 2 groups that are independently F, Cl or Br; pyridine, -C2-C4 alkynylphenyl,  $-O-C_3-C_8$  cycloalkyl,  $-O-(C_1-C_6$  alkyl) $-R_{33}$ ; 30 pyrrole optionally substituted with one or two methyl groups; 2,3-dihydro-benzofuran; benzo[1,2,5]oxadiazole,  $-C(0)-(C_1-C_{10} \text{ alkyl})$  wherein the alkyl group is optionally substituted with NH2,  $N(C_1-C_6 \text{ alkyl})$ , or  $N(C_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl})$ ; -

C(0)NH-phenyl,  $-C(0)N(C_1-C_6 \text{ alkyl})$ -phenyl, 4,4dimethyl-4,5-dihydro-oxazole, -(C<sub>1</sub>-C<sub>6</sub> alkyl)-Spyridine,  $-(C_1-C_6 \text{ alkyl})-SO_2$ -pyridine,  $-(C_1-C_6)$ thioalkoxy)-pyridine, thiazole optionally substituted with 1 or 2 methyl groups, pyrazole,  $-S-(C_1-C_6 \text{ alkyl})$ 5 wherein the alkyl group is optionally substituted with 1 or 2 groups that are independently CN or OH; indole,  $(C_1-C_6 \text{ thioalkoxy})-(C_1-C_6 \text{ alkyl})$ ,  $C_2-C_8$ alkynyl,  $-(CH_2)_{0-4}-SO_2-(C_1-C_{10} \text{ alkyl})$  wherein the alkyl group is optionally substituted with OH; -10 NHC(O)NH( $C_3$ - $C_8$  cycloalkyl), -N( $C_1$ - $C_6$  alkyl)C(O)NH( $C_3$ - $C_8$ cycloalkyl),  $-N(C_1-C_6 \text{ alkyl})C(0)N(C_1-C_6 \text{ alkyl})(C_3-C_8)$ cycloalkyl),  $-NHC(O)N(C_1-C_6 \text{ alkyl})(C_3-C_8 \text{ cycloalkyl})$ ,  $-(C_1-C_6 \text{ alkoxy})-(C_1-C_6 \text{ thioalkoxy}); -CO_2-(C_1-C_6 \text{ alkyl})$ wherein the alkyl group is optionally substituted 15 with phenyl; -C(0)-furan; and imidazolyl; wherein R<sub>31</sub> and R<sub>32</sub> at each occurrence are independently selected from the group consisting of hydrogen, C1-C8 alkyl, C2-C8 alkenyl, hydroxy C1-C6 alkyl, C1-C6 20 haloalkyl,  $C_1$ - $C_6$  alkoxy  $C_1$ - $C_6$  alkyl,  $-(CH_2)_{0-4}$ - $SO_2$ - $(C_1$ -C<sub>6</sub> alkyl) wherein the alkyl is optionally substituted with 1, 2, 3 or 4 independently selected halogen atoms;  $-(CH_2)_{0-4}-SO_2-imidazolyl$ ,  $-(C_1-C_6 alkyl) C(0)NH_2$ ,  $-(C_1-C_6 \text{ alkyl})-C(0)NH(C_1-C_6 \text{ alkyl})$ ,  $-(C_1-C_6)$  $alkyl)-C(0)N(C_1-C_6 \ alkyl)(C_1-C_6 \ alkyl), -(C_1-C_6 \ alkyl)-$ 25  $NH_2$ ,  $-(C_1-C_6 \text{ alkyl})-NH(C_1-C_6 \text{ alkyl})$ ,  $-(C_1-C_6 \text{ alkyl}) N(C_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl}), -(C_1-C_6 \text{ alkyl})$ phenyl,  $-(C_1-C_6 \text{ alkyl}) \text{ pyridyl}, -C(0) \text{ furanyl}, (C_1-C_6 \text{ alkyl})$ tetrahydrofuran, cyclopropyl, cyclobutyl, 30 cyclopentyl, cyclohexyl, -CO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub> alkyl), -(C<sub>1</sub>-C<sub>6</sub> alkyl)-furanyl, -(CH<sub>2</sub>)<sub>0-4</sub>-SO<sub>2</sub>-thienyl, -pyrrolidinylbenzyl,  $-(C_1-C_6 \text{ thioalkoxy})-(C_1-C_6 \text{ alkyl})$ ,  $-C(0)-(C_1-C_6)$  $C_6$  alkyl),  $(C_1-C_6$  alkoxy),  $-(C_2-C_6$  alkenyloxy),  $-(C_1-C_6)$ 

5

10

15

20

25

30

alkyl)-CO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub> alkyl), and -C(0)-piperidinyl optionally substituted with C<sub>1</sub>-C<sub>6</sub> alkyl; wherein the phenyl and pyridyl groups are unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxy, C<sub>1</sub>-C<sub>4</sub> alkoxy, halogen, or

R<sub>31</sub>, R<sub>32</sub> and the nitrogen to which they are attached form a 5, 6, or 7 membered heterocycloalkyl or a 6 membered heteroaryl ring, each of which is optionally fused to a benzene, pyridine or pyrimidine ring and each of which is optionally substituted with C<sub>1</sub>-C<sub>6</sub> alkoxy, hydroxy, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl, -C(0)NH<sub>2</sub>, -C(0)NH-(C<sub>1</sub>-C<sub>6</sub> alkyl)-phenyl;

 $R_{33}$  at each occurrence is independently, H,  $NH_2$ ,  $NH(C_1-C_6$  alkyl),  $N(C_1-C_6$  alkyl)( $C_1-C_6$  alkyl),  $N(C_1-C_6$  alkyl)( $C_1-C_6$  alkyl)( $C_1-C_6$  alkyl);

R<sub>35</sub> is phenyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, -S-phenyl, benzodioxole, thienyl, C<sub>1</sub>-C<sub>6</sub> alkyl, furanyl, imidazolyl, each of which is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, OH, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, halogen, halo C<sub>1</sub>-C<sub>6</sub> alkyl, halo C<sub>1</sub>-C<sub>6</sub> alkoxy, -O-(C<sub>1</sub>-C<sub>6</sub> alkyl)-phenyl, -CO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub> alkyl), -(C<sub>1</sub>-C<sub>4</sub> alkyl)-(C<sub>5</sub>-C<sub>6</sub> cycloalkyl), or (CH<sub>2</sub>)<sub>0-4</sub>CN;

R<sub>40</sub> is phenyl, -phenyl-pyridyl, biphenyl, -phenyl-benzothienyl, -phenyl-thienyl, -phenyl-furanyl, -phenyl-pyrimidinyl, -phenyl-isoxazolyl, -C(0)-pyridyl, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-O-C(0)NH-phenyl wherein the phenyl is optionally substituted with 1, 2, or 3 halogen atoms; -(C<sub>1</sub>-C<sub>4</sub> alkyl)-O-C(0)N(C<sub>1</sub>-C<sub>6</sub> alkyl)-phenyl, -(C<sub>1</sub>-C<sub>6</sub> alkyl)-phenyl, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-SO<sub>2</sub>NH<sub>2</sub>, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-SO<sub>2</sub>NH(C<sub>1</sub>-C<sub>6</sub> alkyl), -(C<sub>1</sub>-C<sub>4</sub> alkyl)-SO<sub>2</sub>N(C<sub>1</sub>-C<sub>6</sub> alkyl)(C<sub>1</sub>-C<sub>6</sub> alkyl), -SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NH(C<sub>1</sub>-C<sub>6</sub> alkyl), -SO<sub>2</sub>N(C<sub>1</sub>-C<sub>6</sub> alkyl)(C<sub>1</sub>-C<sub>6</sub> alkyl), CN, -(CH<sub>2</sub>)<sub>0-4</sub>-(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -(C<sub>1</sub>-C<sub>4</sub> alkyl)-C(0)O-(C<sub>1</sub>-C<sub>4</sub> alkyl), -(C<sub>1</sub>-C<sub>4</sub> alkyl)-R<sub>33</sub>, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-NHC(0)-(C<sub>1</sub>-C<sub>4</sub> alkyl), -

 $(CH_2)_{0-4}-C(O)NH_2$ ,  $-(CH_2)_{0-4}-C(O)NH(C_1-C_6 alkyl)$ ,  $-(CH_2)_{0-4} C(0)N(C_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl}), \text{ naphthyl},$ tetrahydronaphthyl, dihydronaphthyl,  $-(CH_2)_{0-4}$ -imidazolyl, -(CH<sub>2</sub>)<sub>0-4</sub>-pyrrolidinyl, oxazolidinone 3,4-dihydro-5 benzo[e][1,2]oxathiine 2,2-dioxide, pyrimidinyl, 3,4dihydro-2H-benzo[e][1,2]thiazine 1,1-dioxide, pyridyl, or pyrimidyl, alkoxyalkyl, -phenyl-benzothienyl, -phenylcyclohexyl, -phenyl-cyclopentyl, -phenyl-(C1-C6 alkyl)cyclopentyl, -phenyl-(C1-C6 alkyl)-cyclohexyl, -phenyl-10 oxazolyl, furanyl, tetrahydrofuranyl, 7-oxabicyclo[2.2.1]heptyl; -dihydro-1-H-pyrazolidinone-phenyl; -phenyl-bicyclo[2.2.1] heptyl; imidazo[2,1b][1,3]thiazolyl; azepanonyl; piperidinyl,  $-(C_1-C_6 \text{ alkyl})$ piperidinyl; bicyclo[2.2.1] heptyl; chromanonyl, -(C1-C6 15 alkyl)-morpholinyl; -phenyl-C(0)-piperidinyl; tetrahydrothiazolopyridinyl, -pyrrolo-C(0)-pyrrolidinyl; phenyl-C(0) -phenyl; -phenyl-O-phenyl; -phenyl-O-benzyl; phenyl-tetrahydropyridazinonyl; and -phenyldihydropyridazinonyl; 20 wherein each of the above is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C<sub>1</sub>-C<sub>8</sub> alkyl optionally substituted with 1 or two groups that are independently CN or OH; C1-C6 alkoxy, halo  $(C_1-C_8 \text{ alkyl})$ , halo  $(C_1-C_4 \text{ alkoxy})$ , -0-25  $(C_1-C_4 \text{ alkyl})$ -phenyl wherein the phenyl is optionally substituted with 1 or 2 halogens, CN, -CHO, C1-C4 thioalkoxy,  $-NHSO_2-(C_1-C_6 \text{ alkyl})$ ,  $-N(C_1-C_4 \text{ alkyl})SO_2 (C_1-C_4 \text{ alkyl})$  wherein the alkyl groups are optionally substituted with 1, 2, or 3 halogens; OH; -SO<sub>2</sub>R<sub>33</sub>; 30 R<sub>33</sub>; C<sub>2</sub>-C<sub>8</sub> alkynyl; C<sub>2</sub>-C<sub>8</sub> alkenyl; thioalkoxyalkyl; - $SO_2-(C_1-C_{10} \text{ alkyl}); -NR_{31}R_{32}; -C(0)-NR_{31}R_{32}; -OC(0)R_{33};$  $C_1-C_8$  alkanoyl; and  $-(C_1-C_6$  alkyl) $-C(0)-(C_1-C_6$  alkoxy),  $-C(0) - (C_1-C_6 \text{ alkoxy}); -O-(C_1-C_6 \text{ alkyl}) - C(0)NR_{31}R_{32}; CO_2$ -( $C_1$ - $C_6$  alkyl);

 $R_{41a}$  and  $R_{41}$  are independently H, cyclohexyl, phenyl, or  $C_1$ - $C_6$  alkyl optionally substituted with 1 or 2 groups that are phenyl, hydroxy,  $C_1$ - $C_4$  thioalkoxy,  $C_1$ - $C_6$  alkyl; or  $-C_1$ - $C_6$  alkyl- $SO_2$ - $C_1$ - $C_6$  alkyl;

5 R<sub>40</sub>, R<sub>41</sub>, and the atom to which they are attached form a C<sub>3</sub>-C<sub>8</sub> cycloalkyl ring which is optionally substituted with C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, halogen, -CO<sub>2</sub>NH<sub>2</sub>, -CO<sub>2</sub>NH(C<sub>1</sub>-C<sub>6</sub> alkyl), or -CO<sub>2</sub>N(C<sub>1</sub>-C<sub>6</sub> alkyl) (C<sub>1</sub>-C<sub>6</sub> alkyl); a thiazolyl ring which is optionally substituted with C<sub>1</sub>-C<sub>6</sub> alkyl; isoxazolyl ring which is optionally substituted with C<sub>1</sub>-C<sub>6</sub> alkyl; phenyl which is optionally substituted with 1, 2, or 3 groups that are independently halogen or C<sub>1</sub>-C<sub>6</sub> alkyl; pyrrolidinyl-benzyl; piperidinyl optionally substituted with 1 or 2 groups that are independently -CO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub> alkyl) or -C(0)-(C<sub>1</sub>-C<sub>6</sub> alkyl);

and

20

- $R_{42}$  is H,  $C_1$ - $C_6$  alkyl optionally substituted with OH; benzyl; NHC(O)-( $C_1$ - $C_6$  alkyl); -NHC(O)-phenyl wherein the phenyl is optionally substituted with 1 or 2 alkyl groups; - $CO_2$ -( $C_1$ - $C_6$  alkyl); - $CO_2$ -(benzyl); or -C(O)-( $C_1$ - $C_6$  alkyl).
  - 4. A compound according to claim 3 of the formula

$$(R_{51})_{1-3}$$
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{51})_{1-3}$ 
 $(R_{$ 

or a pharmaceutically acceptable salt thereof, wherein

R<sub>51</sub> at each occurrence is independently C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub>

alkoxy, -NHSO<sub>2</sub>-(C<sub>1</sub>-C<sub>4</sub> alkyl) wherein the alkyl group is

optionally substituted with 1, 2, or 3 halogens, -SO<sub>2</sub>-NH
(C<sub>1</sub>-C<sub>6</sub> alkyl)-NH<sub>2</sub>, -SO<sub>2</sub>-NH-(C<sub>1</sub>-C<sub>6</sub> alkyl)-NH(C<sub>1</sub>-C<sub>4</sub> alkyl), 
SO<sub>2</sub>-NH-(C<sub>1</sub>-C<sub>6</sub> alkyl)-N(C<sub>1</sub>-C<sub>4</sub> alkyl)(C<sub>1</sub>-C<sub>4</sub> alkyl),

[1,2,4]triazolidine-3,5-dione, -NHC(O)NH<sub>2</sub>, -NHC(O)NH(C<sub>1</sub>-C<sub>6</sub>

alkyl), -NHC(O)N(C<sub>1</sub>-C<sub>6</sub> alkyl)(C<sub>1</sub>-C<sub>6</sub> alkyl), -N(C<sub>1</sub>-C<sub>6</sub>

alkyl)C(O)NH<sub>2</sub>, -N(C<sub>1</sub>-C<sub>6</sub> alkyl)C(O)NH(C<sub>1</sub>-C<sub>6</sub> alkyl), -N(C<sub>1</sub>-C<sub>6</sub>

5

10

15

20

25

30

alkyl)C(0)N(C<sub>1</sub>-C<sub>6</sub> alkyl)(C<sub>1</sub>-C<sub>6</sub> alkyl), halogen, -CF<sub>3</sub>, OH, -SO<sub>2</sub>NR<sub>31</sub>R<sub>32</sub>, -C(0)NR<sub>31</sub>R<sub>32</sub>, -NR<sub>31</sub>R<sub>32</sub>, hydroxy C<sub>1</sub>-C<sub>10</sub> alkyl optionally substituted with phenyl or (C<sub>1</sub>-C<sub>4</sub> alkyl)phenyl, -O-(C<sub>1</sub>-C<sub>4</sub> alkyl)-phenyl, -NHC(S)NH<sub>2</sub>, -NHC(S)NH(C<sub>1</sub>-C<sub>6</sub> alkyl), -NHC(S)N(C<sub>1</sub>-C<sub>6</sub> alkyl)(C<sub>1</sub>-C<sub>6</sub> alkyl), (C<sub>1</sub>-C<sub>4</sub> alkyl)-O-phenyl, -C(0)-(C<sub>1</sub>-C<sub>6</sub> alkyl) wherein the alkyl group is optionally substituted with NH<sub>2</sub>, N(C<sub>1</sub>-C<sub>6</sub> alkyl), or N(C<sub>1</sub>-C<sub>6</sub> alkyl)(C<sub>1</sub>-C<sub>6</sub> alkyl); -O-C<sub>3</sub>-C<sub>6</sub> cycloalkyl, oxazole optionally substituted with 1, or 2 groups that are independently C<sub>1</sub>-C<sub>4</sub> alkyl or phenyl, hydroxy C<sub>1</sub>-C<sub>4</sub> alkoxy, aminoalkoxy, NH(C<sub>1</sub>-C<sub>6</sub>alkyl)-alkoxy, N(C<sub>1</sub>-C<sub>6</sub>alkyl)(C<sub>1</sub>-C<sub>6</sub>alkyl)-alkoxy,

wherein R<sub>31</sub> and R<sub>32</sub> at each occurrence are independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, -(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(0)NH<sub>2</sub>, -(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(0)NH(C<sub>1</sub>-C<sub>6</sub> alkyl), -(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(0)N(C<sub>1</sub>-C<sub>6</sub> alkyl)(C<sub>1</sub>-C<sub>6</sub> alkyl), -(C<sub>1</sub>-C<sub>6</sub> alkyl)-NH<sub>2</sub>, -(C<sub>1</sub>-C<sub>6</sub> alkyl)-NH(C<sub>1</sub>-C<sub>6</sub> alkyl), -(C<sub>1</sub>-C<sub>6</sub> alkyl)-N(C<sub>1</sub>-C<sub>6</sub> alkyl)(C<sub>1</sub>-C<sub>6</sub> alkyl), -(C<sub>1</sub>-C<sub>6</sub> alkyl)phenyl, -(C<sub>1</sub>-C<sub>6</sub> alkyl)pyridyl, -C(0)furanyl, (C<sub>1</sub>-C<sub>6</sub> alkyl)-tetrahydrofuran, wherein the phenyl and pyridyl groups are unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxy, C<sub>1</sub>-C<sub>4</sub>

wherein at each occurrence R<sub>31</sub>, R<sub>32</sub> and the nitrogen to which they are attached independently form a pyrrolidinyl, piperazinyl, piperidinyl, azepanyl, pyridinyl, or pyrimidinyl ring, each of which is optionally fused to a benzene, pyridine or pyrimidine ring and each of which is optionally substituted with C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> alkyl, hydroxy, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl, -C(0)NH<sub>2</sub>, or -C(0)NH-(C<sub>1</sub>-C<sub>6</sub> alkyl)-phenyl.

alkoxy, halogen, or

5. A compound according to claim 4 wherein  $R_{41}$  and  $R_{42}$  are both hydrogen.

- 6. A compound according to claim 4 wherein
  R<sub>35</sub> is phenyl, cyclohexyl, -S-phenyl, benzodioxole, thienyl, C<sub>3</sub>-C<sub>6</sub> alkyl, furanyl, each of which is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, OH, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, halogen, halo C<sub>1</sub>-C<sub>6</sub> alkyl, halo C<sub>1</sub>-C<sub>6</sub> alkoxy, -O-(C<sub>1</sub>-C<sub>6</sub> alkyl)-phenyl, -CO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub> alkyl), -(C<sub>1</sub>-C<sub>4</sub> alkyl)-(C<sub>5</sub>-C<sub>6</sub> cycloalkyl).
- 7. A compound according to claim 3 wherein

  15. R<sub>35</sub> is phenyl, cyclohexyl, -S-phenyl, benzodioxole, thienyl, C<sub>3</sub>-C<sub>6</sub> alkyl, furanyl, each of which is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, OH, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, halogen, halo C<sub>1</sub>-C<sub>6</sub> alkyl, halo C<sub>1</sub>-C<sub>6</sub> alkoxy, -O-(C<sub>1</sub>-C<sub>6</sub> alkyl)-phenyl, -CO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub> alkyl), -(C<sub>1</sub>-C<sub>4</sub> alkyl)-(C<sub>5</sub>-C<sub>6</sub> cycloalkyl);
- R<sub>40</sub> is phenyl, -phenyl-pyridine, biphenyl, -phenylbenzothienyl, -phenyl-thienyl, -phenyl-furanyl, -phenylpyrimidinyl, -phenyl-isooxazolyl, -C(O)-pyridyl, -(C<sub>1</sub>-C<sub>4</sub>

  alkyl)-O-C(O)NH-phenyl, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-O-C(O)N(C<sub>1</sub>-C<sub>6</sub>

  alkyl)-phenyl, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-phenyl, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-SO<sub>2</sub>NH<sub>2</sub>,
  -(C<sub>1</sub>-C<sub>4</sub> alkyl)-SO<sub>2</sub>NH(C<sub>1</sub>-C<sub>6</sub> alkyl), -(C<sub>1</sub>-C<sub>4</sub> alkyl)-SO<sub>2</sub>N(C<sub>1</sub>-C<sub>6</sub>

  alkyl)(C<sub>1</sub>-C<sub>6</sub> alkyl), CN, -(CH<sub>2</sub>)<sub>0-4</sub>-(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -(C<sub>1</sub>-C<sub>4</sub> alkyl)-C(O)O-(C<sub>1</sub>-C<sub>4</sub> alkyl), -(C<sub>1</sub>-C<sub>4</sub> alkyl)-R<sub>33</sub>, C<sub>1</sub>-C<sub>8</sub>

  alkyl, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-NHC(O)-(C<sub>1</sub>-C<sub>4</sub> alkyl), -(CH<sub>2</sub>)<sub>0-4</sub>-C(O)N(C<sub>1</sub>-C<sub>6</sub>

  alkyl)(C<sub>1</sub>-C<sub>6</sub> alkyl), tetrahydronapthyl, dihydronaphthyl,
  wherein each of the above is unsubstituted or substituted
  with 1, 2, 3, 4, or 5 groups that are independently

halogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, halo  $(C_1$ - $C_4$  alkyl), -0- $(C_1$ - $C_4$  alkyl)-phenyl wherein the phenyl is optionally substituted with 1 or 2 halogens, -CHO,  $C_1$ - $C_4$  thioalkoxy, -NHSO<sub>2</sub>- $(C_1$ - $C_4$  alkyl), -N( $C_1$ - $C_4$  alkyl)SO<sub>2</sub>- $(C_1$ - $C_4$  alkyl) wherein the alkyl groups are optionally substituted with 1, 2, or 3 halogens; OH, SO<sub>2</sub>R<sub>33</sub>, R<sub>33</sub>;

- $R_{41}$  is H, cyclohexyl, phenyl, or  $C_1\text{-}C_6$  alkyl optionally substituted with 1 or 2 groups that are phenyl, hydroxy, or  $C_1\text{-}C_4$  thioalkoxy; and
- 10 R<sub>42</sub> is hydrogen or -CH<sub>2</sub>CN.

5

- 8. A compound according to claim 6 wherein
   R<sub>35</sub> is phenyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, -S-phenyl, benzodioxole, thienyl, C<sub>3</sub>-C<sub>6</sub> alkyl, furanyl, each of which is
   unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, OH, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, halogen, CF<sub>3</sub>, OCF<sub>3</sub>, -Obenzyl, -CO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub> alkyl), -(C<sub>1</sub>-C<sub>4</sub> alkyl)-(C<sub>5</sub>-C<sub>6</sub> cycloalkyl);
- R<sub>40</sub> is phenyl, -phenyl-pyridine, biphenyl, -phenyl-20 benzothienyl, -phenyl-thienyl, -phenyl-furanyl, -phenylpyrimidinyl, -phenyl-isoxazolyl, -C(0)-pyridyl, -( $C_1$ - $C_4$ alkyl) -0-C(0) NH-phenyl,  $-(C_1-C_4)$  alkyl) -0-C(0) N( $C_1-C_6$ alkyl)-phenyl,  $-(C_1-C_4 \text{ alkyl})$ -phenyl,  $-(C_1-C_4 \text{ alkyl})-SO_2NH_2$ ,  $-\left(\text{C}_{1}-\text{C}_{4} \text{ alkyl}\right)-\text{SO}_{2}\text{NH}\left(\text{C}_{1}-\text{C}_{6} \text{ alkyl}\right), -\left(\text{C}_{1}-\text{C}_{4} \text{ alkyl}\right)-\text{SO}_{2}\text{N}\left(\text{C}_{1}-\text{C}_{6} \text{ alkyl}\right)$ 25 alkyl)  $(C_1-C_6 \text{ alkyl})$ , CN,  $-(C_1-C_4 \text{ alkyl})-(C_3-C_6 \text{ cycloalkyl})$ ,  $-(C_1-C_4 \text{ alkyl})-C(0)O-(C_1-C_4 \text{ alkyl}), -(C_1-C_4 \text{ alkyl})-R_{33}, C_1-C_8$ alkyl,  $-(C_1-C_4 \text{ alkyl})-NHC(0)-(C_1-C_4 \text{ alkyl})$ ,  $-C(0)NH_2$ , wherein each of the above rings is unsubstituted or substituted with 1, 2, or 3 groups that are independently 30 halogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy,  $CF_3$ , -0-( $C_1$ - $C_4$  alkyl)phenyl wherein the phenyl is optionally substituted with 1 or 2 halogens, -CHO, -NHSO<sub>2</sub>-( $C_1$ - $C_4$  alkyl), -N( $C_1$ - $C_4$

substituted with 1, 2, or 3 halogens,

alkyl) $SO_2$ -( $C_1$ - $C_4$  alkyl) wherein the alkyl is optionally

 $R_{41}$  is H, cyclohexyl, phenyl, or  $C_1\text{--}C_6$  alkyl optionally substituted with 1 or 2 groups that are phenyl, hydroxy, or  $C_1\text{--}C_4$  thioalkoxy; and

R<sub>42</sub> is hydrogen or -CH<sub>2</sub>CN;

15

25

30

5 R<sub>51</sub> at each occurrence is independently  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy, -NHSO<sub>2</sub>-( $C_1$ - $C_4$  alkyl) wherein the alkyl group is optionally substituted with 1, 2, or 3 halogens, -SO<sub>2</sub>-NH-( $C_1$ - $C_6$  alkyl)-NH<sub>2</sub>, -SO<sub>2</sub>-NH-( $C_1$ - $C_6$  alkyl)-NH( $C_1$ - $C_4$  alkyl), -SO<sub>2</sub>-NH-( $C_1$ - $C_6$  alkyl)-N( $C_1$ - $C_4$  alkyl),

 $\begin{aligned} & [1,2,4] \text{triazolidine-3,5-dione, -NHC(0)NH}_2, \text{ -NHC(0)NH}(C_1-C_6 \\ & \text{alkyl}), \text{ -NHC(0)N(C}_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl}), \text{ -N(C}_1-C_6 \\ & \text{alkyl})C(0)\text{NH}_2, \text{ -N(C}_1-C_6 \text{ alkyl})C(0)\text{NH}(C_1-C_6 \text{ alkyl}), \text{ -N(C}_1-C_6 \\ & \text{alkyl})C(0)\text{N(C}_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl}), \text{ halogen, -CF}_3, \text{ OH, } \\ & -\text{SO}_2\text{NR}_{31}\text{R}_{32}, \text{ -C(0)NR}_{31}\text{R}_{32}, \text{ -NR}_{31}\text{R}_{32}, \text{ hydroxy } C_1-C_{10} \text{ alkyl} \end{aligned}$ 

C<sub>6</sub> alkyl); -O-C<sub>3</sub>-C<sub>6</sub> cycloalkyl, oxazole optionally substituted with 1, or 2 groups that are independently C<sub>1</sub>-C<sub>4</sub> alkyl or phenyl, hydroxy C<sub>1</sub>-C<sub>4</sub> alkoxy, aminoalkoxy, NH(C<sub>1</sub>-C<sub>6</sub>alkyl)-alkoxy, N(C<sub>1</sub>-C<sub>6</sub>alkyl)(C<sub>1</sub>-C<sub>6</sub>alkyl)-alkoxy, wherein R<sub>31</sub> and R<sub>32</sub> at each occurrence are independently

selected from the group consisting of hydrogen,  $C_1$ - $C_6$  alkyl, hydroxy  $C_1$ - $C_6$  alkyl, -( $C_1$ - $C_6$  alkyl)-C(0)N( $C_1$ - $C_6$  alkyl)( $C_1$ - $C_6$  alkyl), -( $C_1$ - $C_6$  alkyl)-NH( $C_1$ - $C_6$  alkyl), -( $C_1$ - $C_6$  alkyl))-N( $C_1$ - $C_6$  alkyl)( $C_1$ - $C_6$  alkyl), -( $C_1$ - $C_6$  alkyl)phenyl, -( $C_1$ - $C_6$  alkyl)pyridyl, -C(0)furanyl, ( $C_1$ - $C_6$  alkyl)-tetrahydrofuran, wherein

the phenyl group is unsubstituted or substituted with 1, 2, or 3 groups that are independently  $C_1-C_4$  alkoxy, or halogen,

wherein at each occurrence R<sub>31</sub>, R<sub>32</sub> and the nitrogen to which they are attached independently form a pyrrolidinyl, piperazinyl, piperidinyl, or azepanyl, each of which is optionally fused to a benzene, pyridine or pyrimidine ring and each of which is optionally substituted with hydroxy, C<sub>1</sub>-C<sub>6</sub> alkyl, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl, - C(0)NH<sub>2</sub>, or -C(0)NH-benzyl.

9. A compound according to claim 8 wherein

R<sub>35</sub> is phenyl; halophenyl, dihalophenyl; trihalophenyl;

tetrahalophenyl; pentahalophenyl; halo, benzyloxyphenyl;

halo, alkylphenyl; benzyloxyphenyl; cyclohexyl; (C<sub>1</sub>-C<sub>4</sub>

alkoxy)carbonylphenyl; (C<sub>1</sub>-C<sub>4</sub> alkoxy)phenyl; -S-phenyl, or

benzodioxole;

 $R_{41}$  is H, cyclohexyl, phenyl, or  $C_1\text{--}C_6$  alkyl optionally substituted with 1 or 2 groups that are phenyl, hydroxy, or  $C_1\text{--}C_4$  thioalkoxy; and

R<sub>42</sub> is hydrogen or -CH<sub>2</sub>CN.

20

5

10. A compound according to claim 9 wherein  $R_{35}$  is 3,5-dihalophenyl;

Page 13 phenyl, -phenyl-pyridine, biphenyl, -phenyl-benzothienyl, -phenyl-thienyl, -phenyl-furanyl, -phenyl-pyrimidinyl, -phenyl-isoxazolyl, -(C1-C4 alkyl)-O-C(0)NH-phenyl, -(C1-C4 alkyl)-O-C(0)N(C1-C6 alkyl)-phenyl, -(C1-C4 alkyl)-SO2NH2, CN, -(C1-C4 alkyl)-(C3-C6 cycloalkyl), -(C1-C4 alkyl)-C(0)O-(C1-C4 alkyl), -(C1-C4 alkyl)-R33, or C1-C8 alkyl, wherein each of the above is unsubstituted or substituted with 1, 2, or 3 groups that are independently halogen, C1-C4 alkyl, C1-C4 alkoxy, CF3, -O-(C1-C4 alkyl)-phenyl wherein the phenyl is optionally substituted with 1 or 2 halogens, -CHO, or -NHSO2-(C1-C4 alkyl).

11. A compound according to claim 10 wherein  $R_{35}$  is 3,5-difluorophenyl; 3,5-dichlorophenyl; or 3-chloro,5-fluorophenyl; and

- R<sub>40</sub> is phenyl which is unsubstituted or substituted with 1, 2, or 3 groups that are independently fluoro, chloro, bromo, iodo, methyl, ethyl, methoxy, ethoxy, CF<sub>3</sub>, or -Obenzyl wherein the phenyl is optionally substituted with 1 or 2 groups that are independently halogen, or -NHSO<sub>2</sub>CH<sub>3</sub>.
- 10 12. A compound according to claim 11 wherein  $R_{51}$  at each occurrence is independently  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$ alkoxy,  $-NHSO_2CH_3$ ,  $-SO_2-NH-(ethyl)$ - $NH(CH_3), [1,2,4]$  triazolidine-3,5-dione, -NHC(O)NH<sub>2</sub>, -CF<sub>3</sub>, OH,  $-SO_2NR_{31}R_{32}$ ,  $-C(O)NR_{31}R_{32}$ , hydroxyoctyl, -CH(OH)-2methylphenyl, -Obenzyl, or -NHC(S)NH(CH<sub>3</sub>); 15 wherein R<sub>31</sub> and R<sub>32</sub> at each occurrence are independently selected from the group consisting of hydrogen; C1-C6 alkyl; hydroxy  $C_1-C_6$  alkyl;  $-(CH_2)C(O)N(CH_3)_2$ ; -CH<sub>2</sub>CH<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>; benzyl which is optionally substituted 20 with 1 or 2 groups that are independently  $C_1-C_4$ alkyl,  $C_1$ - $C_4$  alkoxy or halogen; phenethyl; -CH<sub>2</sub>CH<sub>2</sub>pyridyl; or -C(0) furanyl; or at each occurrence R<sub>31</sub>, R<sub>32</sub> and the nitrogen to which they are attached independently form a pyrrolidinyl, 25 piperazinyl, piperidinyl, or azepanyl, each of which is optionally substituted with hydroxymethyl,
- 30 13. A compound according to claim 12 wherein  $R_{40}$  is 3-ethylphenyl or 3-methoxyphenyl; and  $R_{42}$  is hydrogen.
  - 14. A compound according to claim 12 wherein

hydroxyethyl, methoxymethyl, or  $-C(0)NH_2$ .

```
R<sub>51</sub> at each occurrence is independently H, -SO<sub>2</sub>NH-propyl-OH, -
           SO_2NH-ethyl-OH, -SO_2NH-ethyl-OCH_3, -SO_2NH-CH(CH_3)_2-CH_2OH, -
           SO_2NH-(CH_2CH(OH)CH_3), -SO_2NH-ethyl-NH(CH_3), -
           SO_2NH(CH_2CH_2OH)_2, -SO_2NHCH(CH_3)CH_2OH, -SO_2N(CH_3)_2, -
 5
           SO_2NH(CH_2CH(OH)CH_3), -SO_2-pyrrolidine, -SO_2-(2,6-
           dimethylpiperidine), -SO<sub>2</sub>-(2-propylpiperidine), -SO<sub>2</sub>-
           (hydroxypropyl), -C(O)-(2-methoxymethylpyrrolidine), -
          C(0)-(2-methylpyrrolidine), -C(0)-(2,6-
           dimethylpyrrolidine),-C(0)-(2-hydroxymethylpyrrolidine),
10
           -C(0)N(methyl)(ethyl), -C(0)N(methyl)(propyl),
           -C(O)N(methyl)(butyl), -C(O)N(propyl)(butyl),
           -C(O)N(allyl)(cyclopentyl), -C(O)N(allyl)(cyclohexyl),
           -C(O)N(methyl)(methyl), -C(O)N(ethyl)(ethyl),
           -C(0)N(butyl)(butyl), -C(0)N(isopropyl)(isopropyl),
15
           -C(0)N(propyl)(propyl), -C(0)N(methyl)(cyclohexyl),
           -C(0)N(ethyl)(cyclohexyl), -C(0)NH(cyclobutyl),
           -C(0)NH(cyclopentyl), -C(0)N(CH<sub>3</sub>)(cyclopentyl), -C(0)NH(2-
          methylcyclohexyl), -C(0)NH(pentyl),
           -C(0)N(pentyl)(pentyl), -C(0)NH(isopentyl), -
20
           C(0)NH(ethoxyethyl), -C(0)N(CH<sub>3</sub>)(methoxyethyl),
           -C(O)N(propyl)(methoxyethyl),
           -C(0)N(methoxyethyl) (methoxyethyl),
           -C(0)N(ethoxyethyl)(ethoxyethyl),
           -C(O)N(ethyl)(methoxyethyl), -C(O)N(propyl)(hydroxyethyl),
25
           -C(O)N(hydroxyethyl)(ethyl), ethynyl, methyl, bromo,
           -N(CH_3)SO_2(CH_3), -N(CH_3)SO_2-thienyl, -
          N(hydroxypropyl)SO_2CH_3, -CH_2)-SO_2-(CH_3), or -C(0)-
          CH (CH<sub>3</sub>) CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>.
```

- 30 15. A compound according to claim 14 wherein there are two  $R_{51}$  groups.
  - 16. A compound according to claim 15 wherein the  $R_{51}$  groups are at the 3 and 5 positions of the phenyl group.

17. A compound according to claim 11 wherein

R<sub>51</sub> at each occurrence is independently C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub>

alkoxy, -C(0)NR<sub>31</sub>R<sub>32</sub>, -C(0)CH<sub>2</sub>NH<sub>2</sub>, cyclopentyloxy, 
NHC(0)NH(ethyl), oxazole optionally substituted with 1 or

2 groups that are independently C<sub>1</sub>-C<sub>4</sub> alkyl or phenyl,

hydroxyethoxy, diethylaminoethoxy,

wherein R<sub>31</sub> and R<sub>32</sub> at each occurrence are independently

selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub>

alkyl, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, -CH<sub>2</sub>-tetrahydrofuran.

- 18. A compound according to claim 9 wherein  $R_{35}$  is cyclohexyl.
- 15 19. A compound according to claim 15 wherein R<sub>40</sub> is phenyl, or C<sub>1</sub>-C<sub>8</sub> alkyl, wherein each is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, halo (C<sub>1</sub>-C<sub>4</sub> alkyl); and
- 20  $R_{42}$  and  $R_{41}$  are both hydrogen.

- 20. A compound according to claim 16 wherein

  R<sub>40</sub> is phenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3ethoxyphenyl, 4-ethoxyphenyl, 3-trifluoromethylphenyl, 4trifluoromethylphenyl, 2-methylphenyl, 3-methylphenyl, 2ethylphenyl, 3-ethylphenyl, or C<sub>3</sub>-C<sub>6</sub> alkyl; and

  R<sub>51</sub> at each occurrence is independently C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub>
  alkoxy, or halogen,
- wherein  $R_{31}$  and  $R_{32}$  at each occurrence are independently selected from the group consisting of hydrogen,  $C_1$ - $C_6$  alkyl, hydroxy  $C_1$ - $C_6$  alkyl, and -( $C_1$ - $C_6$  alkyl)phenyl wherein the phenyl group is unsubstituted or substituted with 1, 2, or 3 groups that are independently  $C_1$ - $C_4$  alkoxy, or halogen,

wherein at each occurrence R<sub>31</sub>, R<sub>32</sub> and the nitrogen to
which they are attached independently form a
pyrrolidinyl, piperazinyl, piperidinyl, or azepanyl,
each of which is optionally fused to a benzene,
pyridine or pyrimidine ring and each of which is
optionally substituted with hydroxy, hydroxy C<sub>1</sub>-C<sub>6</sub>
alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl, -C(O)NH<sub>2</sub>, or -C(O)NHbenzyl.

- 10 21. A compound according to claim 9 wherein R<sub>35</sub> is 3-halo, 5-benzyloxyphenyl; 3-benzyloxyphenyl; or 4-benzyloxyphenyl;
- R<sub>41</sub> is H, cyclohexyl, phenyl, or C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with 1 or 2 groups that are phenyl, hydroxy, or C<sub>1</sub>-C<sub>4</sub> thioalkoxy; and R<sub>42</sub> is hydrogen or -CH<sub>2</sub>CN.
- 22. A compound according to claim 21 wherein

  R<sub>40</sub> is phenyl, -phenyl-pyridine, biphenyl, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-O
  C(O)NH-phenyl, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-O-C(O)N(C<sub>1</sub>-C<sub>6</sub> alkyl)-phenyl,
  -(C<sub>1</sub>-C<sub>4</sub> alkyl)-SO<sub>2</sub>NH<sub>2</sub>, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-(C<sub>3</sub>-C<sub>6</sub> cycloalkyl), 
  (C<sub>1</sub>-C<sub>4</sub> alkyl)-C(O)O-(C<sub>1</sub>-C<sub>4</sub> alkyl), -(C<sub>1</sub>-C<sub>4</sub> alkyl)-R<sub>33</sub>, or C<sub>1</sub>
  C<sub>8</sub> alkyl, wherein each of the above is unsubstituted or substituted with 1, 2, or 3 groups that are independently halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, CF<sub>3</sub>, -Obenzyl wherein the phenyl is optionally substituted with 1 or 2 halogens, -CHO, or -NHSO<sub>2</sub>-(C<sub>1</sub>-C<sub>4</sub> alkyl).
- 23. A compound according to claim 22 wherein

  30 R<sub>40</sub> is phenyl or C<sub>1</sub>-C<sub>8</sub> alkyl, wherein each of the above is
  unsubstituted or substituted with 1, 2, or 3 groups that
  are independently halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, CF<sub>3</sub>,

  -Obenzyl wherein the phenyl is optionally substituted with
  1 or 2 halogens, -CHO, or -NHSO<sub>2</sub>-(C<sub>1</sub>-C<sub>4</sub> alkyl); and

 $R_{41}$  is hydrogen or  $C_1$ - $C_6$  alkyl optionally substituted with 1 or 2 groups that are phenyl, hydroxy, or  $C_1$ - $C_4$  thioalkoxy;  $R_{42}$  is hydrogen; and

R<sub>51</sub> at each occurrence is independently C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy,  $-NHSO_2-(C_1-C_4 \text{ alkyl})$  wherein the alkyl group is 5 optionally substituted with 1, 2, or 3 halogens, -SO<sub>2</sub>-NH- $(C_1-C_6 \text{ alkyl})-NH_2$ ,  $-SO_2-NH-(C_1-C_6 \text{ alkyl})-NH(C_1-C_4 \text{ alkyl})$ , - $SO_2$ -NH-( $C_1$ - $C_6$  alkyl)-N( $C_1$ - $C_4$  alkyl)( $C_1$ - $C_4$  alkyl),  $-NHC(O)NH_2$ ,  $-NHC(O)NH(C_1-C_6 alkyl)$ ,  $-NHC(O)N(C_1-C_6)$ 10 alkyl)( $C_1-C_6$  alkyl),  $-N(C_1-C_6$  alkyl) $C(O)NH_2$ ,  $-N(C_1-C_6)$  $alkyl)C(O)NH(C_1-C_6 \ alkyl), -N(C_1-C_6 \ alkyl)C(O)N(C_1-C_6)$ alkyl) ( $C_1-C_6$  alkyl), halogen,  $-CF_3$ , OH,  $-SO_2NR_{31}R_{32}$ , - $C(0)NR_{31}R_{32}$ ,  $-NR_{31}R_{32}$ , hydroxy  $C_1-C_{10}$  alkyl, -Obenzyl, - $NHC(S)NH_2$ ,  $-NHC(S)NH(C_1-C_6 alkyl)$ ,  $-NHC(S)N(C_1-C_6 alkyl)(C_1-C_6 alkyl)$ 15  $C_6$  alkyl),  $(C_1-C_4$  alkyl)-O-phenyl,  $-C(0)-(C_1-C_6$  alkyl), -Ocyclopentyl, -0-cyclohexyl, hydroxy  $C_1$ - $C_4$  alkoxy, aminoalkoxy, NH( $C_1$ - $C_6$ alkyl)-alkoxy, N( $C_1$ - $C_6$ alkyl)( $C_1$ - $C_6$ alkyl)-alkoxy,

wherein R<sub>31</sub> and R<sub>32</sub> at each occurrence are independently

selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub>

alkyl, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, -(C<sub>1</sub>-C<sub>6</sub> alkyl)-NH(C<sub>1</sub>-C<sub>6</sub>

alkyl), -(C<sub>1</sub>-C<sub>6</sub> alkyl)-N(C<sub>1</sub>-C<sub>6</sub> alkyl)(C<sub>1</sub>-C<sub>6</sub> alkyl), and

benzyl wherein the phenyl group is unsubstituted or

substituted with 1, or 2 groups that are

independently C<sub>1</sub>-C<sub>4</sub> alkoxy, or halogen,

wherein at each occurrence  $R_{31}$ ,  $R_{32}$  and the nitrogen to which they are attached independently form a pyrrolidinyl, piperazinyl, or piperidinyl, each of which is optionally substituted with hydroxy, hydroxy  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_4$  alkoxy  $C_1$ - $C_6$  alkyl, -C(0)NH<sub>2</sub>, or -C(0)NH-benzyl.

24. A compound according to claim 23 wherein

 $R_{40}$  is phenyl or  $C_1$ - $C_8$  alkyl, wherein each of the above is unsubstituted or substituted with 1, 2, or 3 groups that are independently halogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, or  $CF_3$ ; and

- 5 R<sub>51</sub> at each occurrence is independently  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy, -NHSO<sub>2</sub>CH<sub>3</sub>, -NHSO<sub>2</sub>CF<sub>3</sub>, halogen, -CF<sub>3</sub>, OH, -SO<sub>2</sub>NR<sub>31</sub>R<sub>32</sub>, -C(0)NR<sub>31</sub>R<sub>32</sub>, -NR<sub>31</sub>R<sub>32</sub>, hydroxy  $C_1$ - $C_{10}$  alkyl, hydroxy  $C_1$ - $C_4$  alkoxy, aminoalkoxy, NH( $C_1$ - $C_6$ alkyl)-alkoxy, N( $C_1$ - $C_6$ alkyl)( $C_1$ - $C_6$ alkyl)-alkoxy,
- wherein R<sub>31</sub> and R<sub>32</sub> at each occurrence are independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, and benzyl wherein the phenyl group is unsubstituted or substituted with 1 or 2 groups that are independently methoxy, ethoxy, or halogen, or
  - wherein at each occurrence  $R_{31}$ ,  $R_{32}$  and the nitrogen to which they are attached independently form a pyrrolidinyl, piperazinyl, or piperidinyl ring each of which is optionally substituted with hydroxy, hydroxy  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_4$  alkoxy  $C_1$ - $C_6$  alkyl, or-C(0)  $NH_2$ .
- 25. A compound according to claim 24 wherein  $R_{35}$  is 3-fluoro, 5-benzyloxyphenyl or 3-chloro, 5-benzyloxyphenyl.

- 26. A compound according to claim 9 wherein

  R<sub>35</sub> is -S-phenyl, benzo[1,3]dioxole, furanyl, or thienyl;

  R<sub>41</sub> is H, cyclohexyl, phenyl, or C<sub>1</sub>-C<sub>6</sub> alkyl optionally

  substituted with 1 or 2 groups that are phenyl, hydroxy, or C<sub>1</sub>-C<sub>4</sub> thioalkoxy; and

  R<sub>42</sub> is hydrogen or -CH<sub>2</sub>CN.
  - 27. A compound according to claim 26 wherein

 $R_{40} \text{ is phenyl, -phenyl-pyridine, biphenyl, -phenyl-pyrimidinyl, } \\ -(C_1-C_4 \text{ alkyl})-O-C(O)NH-phenyl, -(C_1-C_4 \text{ alkyl})-O-C(O)N(C_1-C_6 \text{ alkyl})-phenyl, -(C_1-C_4 \text{ alkyl})-SO_2NH_2, -(C_1-C_4 \text{ alkyl})-(C_3-C_6 \text{ cycloalkyl}), -(C_1-C_4 \text{ alkyl})-C(O)O-(C_1-C_4 \text{ alkyl}), -(C_1-C_4 \text{ alkyl})-R_{33}, \text{ or } C_1-C_8 \text{ alkyl, wherein each of the above is unsubstituted or substituted with 1, 2, or 3 groups that are independently halogen, <math>C_1-C_4 \text{ alkyl, } C_1-C_4 \text{ alkoxy, } CF_3, -Obenzyl \text{ wherein the phenyl is optionally substituted with 1 or 2 halogens, -CHO, or -NHSO_2-(C_1-C_4 \text{ alkyl), -NHSO_2CF_3.}$ 

10

15

5

28. A compound according to claim 27 wherein  $R_{51}$  at each occurrence is independently selected from the group consisting of

C(0)NH(alkoxya -C(0)N(alkoxya (alkoxyalkyl),

-C(0)N(alkoxyalkyl) (alkoxyalkyl), -C(0)N( $C_1$ - $C_6$  alkyl) (alkoxyalkyl), -C(0)N( $C_1$ - $C_6$  hydroxyalkyl)(alkyl), -NHSO<sub>2</sub>CF<sub>3</sub>, -N( $C_1$ - $C_6$  alkyl)-SO<sub>2</sub>-thienyl, -N( $C_1$ - $C_6$  hydroxyalkyl)SO<sub>2</sub>-( $C_1$ - $C_6$  alkyl), -NHC(0)C<sub>1</sub>- $C_4$  alkyl, oxazolyl optionally substituted with 1 or 2 methyl

groups, thiazolyl optionally substituted with 1 or 2 methyl groups, pyrazolyl optionally substituted with 1 or 2 methyl groups, imidazolyl optionally

1 or 2 methyl groups, imidazolyl optionally substituted with 1 or 2 methyl groups, isoxazolyl optionally substituted with 1 or 2 methyl groups, pyrimidinyl optionally substituted with 1 or 2 methyl or halogen groups, -NHSO<sub>2</sub>CH<sub>3</sub>, -NHSO<sub>2</sub>-imidazolyl wherein the imidazole ring is optionally substituted

-994-

with 1 or 2 methyl groups,  $-N(C_1-C_6 \text{ alkyl})SO_2(C_1-C_6)$ 

30

alkyl), -SO<sub>2</sub>NH-C<sub>1</sub>-C<sub>6</sub> hydroxyalkyl, -SO<sub>2</sub>NH-C<sub>1</sub>-C<sub>6</sub> alkyl-NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -SO<sub>2</sub>-piperazinyl optionally substituted with 1 or 2 methyl groups, -SO<sub>2</sub>-pyrrolidine optionally substituted with 1 or 2 methyl groups, -SO<sub>2</sub>-piperidine optionally substituted with 1 or 2 C<sub>1</sub>-C<sub>4</sub> alkyl groups, -SO<sub>2</sub>N(C<sub>1</sub>-C<sub>4</sub> hydroxyalkyl)(C<sub>1</sub>-C<sub>4</sub> hydroxyalkyl), -SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>N(C<sub>1</sub>-C<sub>6</sub> alkyl)(C<sub>1</sub>-C<sub>6</sub> alkyl), C<sub>2</sub>-C<sub>6</sub> alkynyl, -SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub> hydroxyalkyl), -SO<sub>2</sub>NH(C<sub>1</sub>-C<sub>6</sub> hydroxyalkyl), -SO<sub>2</sub>N(C<sub>1</sub>-C<sub>6</sub> alkyl)(C<sub>1</sub>-C<sub>6</sub> hydroxyalkyl), -(C<sub>1</sub>-C<sub>4</sub> alkyl)-SO<sub>2</sub>-(C<sub>1</sub>-C<sub>4</sub> alkyl), or -C(0)-(C<sub>1</sub>-C<sub>10</sub> alkyl).

29. A compound according to claim 28 wherein

```
R_{51} at each occurrence is independently selected from the group
          consisting of -SO2NH-propyl-OH, -SO2NH-ethyl-OH, -SO2NH-
15
          ethyl-OCH<sub>3</sub>, -SO_2NH-CH(CH_3)_2-CH_2OH, -SO_2NH-(CH_2CH(OH)CH_3), -
          SO_2NH-ethyl-NH(CH_3), -SO_2NH(-CH_2CH_2OH)_2, -SO_2NHCH(CH_3)CH_2OH,
          -SO_2N(CH_3)_2, -SO_2NH(CH_2CH(OH)CH_3), -SO_2-pyrrolidine, -SO_2-
           (2,6-dimethylpiperidine), -SO<sub>2</sub>-(2-propylpiperidine), -SO<sub>2</sub>-
           (hydroxypropyl), -C(0)-(2-methoxymethylpyrrolidine), -
20
          C(0)-(2-methylpyrrolidine), -C(0)-(2,6-
           dimethylpyrrolidine),-C(0)-(2-hydroxymethylpyrrolidine),
           -C(O)N(methyl)(ethyl), -C(O)N(methyl)(propyl),
           -C(O)N(methyl)(butyl), -C(O)N(propyl)(butyl),
           -C(O)N(allyl)(cyclopentyl), -C(O)N(allyl)(cyclohexyl),
25
           -C(0)N(methyl)(methyl), -C(0)N(ethyl)(ethyl),
           -C(O)N(butyl)(butyl), -C(O)N(isopropyl)(isopropyl),
           -C(O)N(propyl)(propyl), -C(O)N(methyl)(cyclohexyl),
           -C(0)N(ethyl)(cyclohexyl), -C(0)NH(cyclobutyl),
           -C(O)NH(cyclopentyl), -C(O)N(CH<sub>3</sub>)(cyclopentyl), -C(O)NH(2-C)NH(2-C)
30
           methylcyclohexyl), -C(O)NH(pentyl),
           -C(O)N(pentyl)(pentyl), -C(O)NH(isopentyl), -
           C(0)NH(ethoxyethyl), -C(0)N(CH<sub>3</sub>)(methoxyethyl),
           -C(0)N(propyl) (methoxyethyl),
```

```
-C(0)N(methoxyethyl) (methoxyethyl),
-C(0)N(ethoxyethyl) (ethoxyethyl),
-C(0)N(ethyl) (methoxyethyl), -C(0)N(propyl) (hydroxyethyl),
-C(0)N(hydroxyethyl) (ethyl), ethynyl, methyl, bromo,

-N(CH<sub>3</sub>)SO<sub>2</sub>(CH<sub>3</sub>), -N(CH<sub>3</sub>)SO<sub>2</sub>-thienyl, -
N(hydroxypropyl)SO<sub>2</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)-SO<sub>2</sub>-(CH<sub>3</sub>), or -C(0)-
CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>.
```

- 30. A compound according to claim 27 wherein
- 10 R<sub>40</sub> is phenyl or C<sub>1</sub>-C<sub>8</sub> alkyl, wherein each of the above is unsubstituted or substituted with 1, 2, or 3 groups that are independently halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, CF<sub>3</sub>, -Obenzyl wherein the phenyl is optionally substituted with 1 or 2 halogens, -CHO, or -NHSO<sub>2</sub>-(C<sub>1</sub>-C<sub>4</sub> alkyl); and
- 15 R<sub>41</sub> is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with 1 or 2 groups that are phenyl, hydroxy, or C<sub>1</sub>-C<sub>4</sub> thioalkoxy; and;

 $R_{51}$  at each occurrence is independently  $C_1-C_6$  alkyl,  $C_1-C_6$ 

R<sub>42</sub> is hydrogen; and

20 alkoxy,  $-NHSO_2-(C_1-C_4 \text{ alkyl})$  wherein the alkyl group is optionally substituted with 1, 2, or 3 halogens, -SO<sub>2</sub>-NH- $(C_1-C_6 \text{ alkyl})-NH_2$ ,  $-SO_2-NH-(C_1-C_6 \text{ alkyl})-NH(C_1-C_4 \text{ alkyl})$ , - $SO_2-NH-(C_1-C_6 \text{ alkyl})-N(C_1-C_4 \text{ alkyl})(C_1-C_4 \text{ alkyl}),$  $-NHC(O)NH_2$ ,  $-NHC(O)NH(C_1-C_6 alkyl)$ ,  $-NHC(O)N(C_1-C_6)$ 25 alkyl)  $(C_1-C_6 \text{ alkyl})$ ,  $-N(C_1-C_6 \text{ alkyl})C(O)NH_2$ ,  $-N(C_1-C_6 \text{ alkyl})C(O)NH_2$  $alkyl)C(O)NH(C_1-C_6 alkyl)$ ,  $-N(C_1-C_6 alkyl)C(O)N(C_1-C_6)$ alkyl)( $C_1-C_6$  alkyl), halogen,  $-CF_3$ , OH,  $-SO_2NR_{31}R_{32}$  $-C(0)NR_{31}R_{32}$ ,  $-NR_{31}R_{32}$ , hydroxy  $C_1-C_{10}$  alkyl, -Obenzyl, - $NHC(S)NH_2$ ,  $-NHC(S)NH(C_1-C_6 alkyl)$ ,  $-NHC(S)N(C_1-C_6 alkyl)(C_1-C_6 alkyl)$ 30  $C_6$  alkyl),  $(C_1-C_4$  alkyl)-0-phenyl,  $-C(0)-(C_1-C_6$  alkyl), -0cyclopentyl, -O-cyclohexyl, hydroxy C<sub>1</sub>-C<sub>4</sub> alkoxy, aminoalkoxy,  $NH(C_1-C_6 \text{ alkyl})-alkoxy$ ,  $N(C_1-C_6 \text{ alkyl})(C_1-C_6)$ alkyl)-alkoxy,

5

10

wherein  $R_{31}$  and  $R_{32}$  at each occurrence are independently selected from the group consisting of hydrogen,  $C_1$ - $C_6$  alkyl, hydroxy  $C_1$ - $C_6$  alkyl, -( $C_1$ - $C_6$  alkyl)-NH( $C_1$ - $C_6$  alkyl), -( $C_1$ - $C_6$  alkyl)-N( $C_1$ - $C_6$  alkyl)( $C_1$ - $C_6$  alkyl), and benzyl wherein the phenyl group is unsubstituted or substituted with 1, or 2 groups that are independently  $C_1$ - $C_4$  alkoxy, or halogen,

wherein at each occurrence R<sub>31</sub>, R<sub>32</sub> and the nitrogen to which they are attached independently form a pyrrolidinyl, piperazinyl, or piperidinyl, each of which is optionally substituted with hydroxy, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl, -C(0)NH<sub>2</sub>, or -C(0)NH-benzyl.

- 31. A compound according to claim 30 wherein R<sub>40</sub> is phenyl or C<sub>1</sub>-C<sub>8</sub> alkyl, wherein each of the above is unsubstituted or substituted with 1, 2, or 3 groups that are independently halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, or CF<sub>3</sub>; and
- 20 R<sub>51</sub> at each occurrence is independently C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, -NHSO<sub>2</sub>CH<sub>3</sub>, -NHSO<sub>2</sub>CF<sub>3</sub>, halogen, -CF<sub>3</sub>, OH, -SO<sub>2</sub>NR<sub>31</sub>R<sub>32</sub>, -C(O)NR<sub>31</sub>R<sub>32</sub>, -NR<sub>31</sub>R<sub>32</sub>, hydroxy C<sub>1</sub>-C<sub>10</sub> alkyl, hydroxy C<sub>1</sub>-C<sub>4</sub> alkoxy, aminoalkoxy, NH(C<sub>1</sub>-C<sub>6</sub>alkyl)-alkoxy, N(C<sub>1</sub>-C<sub>6</sub>alkyl)(C<sub>1</sub>-C<sub>6</sub>alkyl)-alkoxy,
- wherein R<sub>31</sub> and R<sub>32</sub> at each occurrence are independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, and benzyl wherein the phenyl group is unsubstituted or substituted with 1 or 2 groups that are independently methoxy, ethoxy, or halogen, or
  - wherein at each occurrence  $R_{31}$ ,  $R_{32}$  and the nitrogen to which they are attached independently form a pyrrolidinyl, piperazinyl, or piperidinyl ring each of which is optionally substituted with hydroxy,

hydroxy  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_4$  alkoxy  $C_1$ - $C_6$  alkyl, or-C(0) NH<sub>2</sub>.

## 32. A compound of the formula:

R<sub>30</sub> H OH R<sub>42</sub> N R<sub>55</sub>

5

or a pharmaceutically acceptable salt thereof, wherein R<sub>30</sub> is selected from the group consisting of phenyl, pyrazolopyrimidinyl, oxa-aza-benzoazulenyl, isoxazolyl, triazolopyridinyl, pyrrolidinonyl, tetrahydrothia-aza-10 fluorenyl, pyridyl, piperidinyl, dihydrocyclopentaquinolinyl, furyl, naphthothienyl, phthalazinonyl, thiadiazolyl, thienopyrimidinonyl, oxadiaza-cyclopentanaphthalenyl, dihydrobenzodioxepinyl, chromanonyl, chromenonyl, oxazolidinyl, purinyl, oxaxolyl, 15 thiazolyl, pyridazinonyl, thiazolyl, pyranyl, dihydropyranopyridinyl, diazepanyl, cyclopropyl, dihydronaphthoisoxazolyl, benzoindazole, dihydrocyclopentachromenonyl, imidazopyrazolyl, tetrahydrocyclopentachromenonyl, dihydroquinolinonyl, 20 pyridyl, isochromanyl, quinazolinonyl, pyrazolopyridinyl, dihydrobenzothiophene dioxide, dihydrofurobenzoisoxazolyl, dihydropyrimidine dionyl, thienopyrazolyl, oxazolyl, tetrahydrocyclopentapyrazolyl, dihydronaphthalenonyl, dihydrobenzofuranonyl, dihydrocyclopentathienyl, 25 tetrahydrocyclopentapyrazolyl, tetrahydropyrazoloazepinyl, indazolyl, tetrahydrocycloheptaisoxazolyl, tetrahydroindolonyl, pyrrolidinyl, thienopyridinyl, dioxodihydrobenzoisothiazolonyl, triazolopyrimidinyl, thienyl, dihydrothienopyrimidinonyl, and benzooxadiazolyl, 30 wherein each of the above is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently selected from the group consisting of

-998-

 $C_1-C_{10}$  alkyl optionally substituted with phenyl, hydroxy, hydroxy C<sub>1</sub>-C<sub>10</sub> alkyl optionally substituted with phenyl or  $(C_1-C_4 \text{ alkyl})$  phenyl,  $C_1-C_6 \text{ alkoxy optionally}$ substituted with 1 or 2 hydroxy groups, -C(0) NR<sub>31</sub>R<sub>32</sub>,  $-NR_{31}-SO_2-(C_1-C_6 \text{ alkyl})$  wherein the alkyl group is 5 optionally substituted with 1, 2, or 3 R<sub>33</sub> groups, - $SO_2-NH(C_1-C_6 \text{ alkyl})$  wherein the alkyl group is optionally substituted with 1 or 2 R<sub>33</sub> groups, -SO<sub>2</sub>- $N(C_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl})$  wherein each alkyl group is optionally substituted with 1 or 2 R<sub>33</sub> groups, -10  $SO_2-NH(C_1-C_6 \text{ alkyl})$ -phenyl wherein the phenyl is optionally substituted with 1 or 2 groups that are independently C<sub>1</sub>-C<sub>4</sub> alkoxy or halogen, -O-(C<sub>1</sub>-C<sub>6</sub> alkyl)-phenyl,  $-(C_1-C_6 \text{ alkyl})-O-\text{phenyl}$ ,  $-(C_1-C_6 \text{ alkyl})$ alkyl)-0-(C1-C6 alkyl)-phenyl, triazolidine-3,5-15 dione, halogen,  $-NHC(0)NH_2$ ,  $-N(C_1-C_6 alkyl)C(0)NH_2$ ,  $-N(C_1-C_6 \text{ alkyl})C(O)NH(C_1-C_6 \text{ alkyl}), -N(C_1-C_6)$  $alkyl)C(0)N(C_1-C_6 \ alkyl)(C_1-C_6 \ alkyl), -(C_1-C_6 \ alkyl)$ thienyl,  $-(C_1-C_6 \text{ alkyl}) \text{ furanyl}, -S-(C_1-C_6 \text{ alkyl})$ phenyl,  $-SO_2NR_{31}R_{32}$ , -C(0)  $-NR_{31}R_{32}$ ,  $-NR_{31}R_{32}$ , dithiane, 20 -NHC(S)NH<sub>2</sub>, -NHC(S)NH( $C_1$ - $C_6$  alkyl), -NHC(S)N( $C_1$ - $C_6$ alkyl)  $(C_1-C_6 \text{ alkyl})$ ,  $-CO_2(C_1-C_6 \text{ alkyl})$ , tetrahydropyran, phenyl optionally substituted with 1 or 2 groups that are independently F, Cl or Br, pyridine, -C2-C4 alkynyl-phenyl, -O-C3-C6 cycloalkyl, 25  $-O-(C_1-C_6 \text{ alkyl})-R_{33}$ , benzo[1,2,5]oxadiazole, -C(0)- $(C_1-C_6 \text{ alkyl})$  wherein the alkyl group is optionally substituted with  $NH_2$ ,  $N(C_1-C_6 \text{ alkyl})$ , or  $N(C_1-C_6$ alkyl)  $(C_1-C_6 \text{ alkyl})$ ; -C(0)NH-phenyl, -C(0)N $(C_1-C_6)$ 30 alkyl)-phenyl, 4,4-Dimethyl-4,5-dihydro-oxazole, - $(C_1-C_6 \text{ alkyl})-S-pyridine, -(C_1-C_6 \text{ alkyl})-SO_2-pyridine,$  $-(C_1-C_6 \text{ thioalkoxy})-pyridine,$ 

wherein  $R_{31}$  and  $R_{32}$  at each occurrence are independently selected from the group consisting of hydrogen,  $C_1\text{-}C_6$ 

5

10

15

20

alkyl, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, -(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(0)NH<sub>2</sub>, -(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(0)NH(C<sub>1</sub>-C<sub>6</sub> alkyl), -(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(0)N(C<sub>1</sub>-C<sub>6</sub> alkyl) (C<sub>1</sub>-C<sub>6</sub> alkyl), -(C<sub>1</sub>-C<sub>6</sub> alkyl)-NH<sub>2</sub>, -(C<sub>1</sub>-C<sub>6</sub> alkyl)-NH(C<sub>1</sub>-C<sub>6</sub> alkyl), -(C<sub>1</sub>-C<sub>6</sub> alkyl)-N(C<sub>1</sub>-C<sub>6</sub> alkyl) (C<sub>1</sub>-C<sub>6</sub> alkyl), -(C<sub>1</sub>-C<sub>6</sub> alkyl)phenyl, -(C<sub>1</sub>-C<sub>6</sub> alkyl)pyridyl, -C(0)furanyl, (C<sub>1</sub>-C<sub>6</sub> alkyl)-tetrahydrofuran, wherein the phenyl and pyridyl groups are unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxy, C<sub>1</sub>-C<sub>4</sub> alkoxy, halogen, or

R<sub>31</sub>, R<sub>32</sub> and the nitrogen to which they are attached form a 5, 6, or 7 membered heterocycloalkyl or a 6 membered heteroaryl ring, each of which is optionally fused to a benzene, pyridine or pyrimidine ring and each of which is optionally substituted with C<sub>1</sub>-C<sub>6</sub> alkoxy, hydroxy, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl, -C(0)NH<sub>2</sub>, -C(0)NH-(C<sub>1</sub>-C<sub>6</sub> alkyl)-phenyl;

 $R_{33}$  at each occurrence is independently, H,  $NH_2$ ,  $NH(C_1-C_6$  alkyl),  $N(C_1-C_6$  alkyl)( $C_1-C_6$  alkyl),  $N(C_1-C_6$  alkyl);

R<sub>35</sub> is phenyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, -S-phenyl, benzodioxole, thienyl, C<sub>1</sub>-C<sub>6</sub> alkyl, furanyl, each of which is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, OH, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, halogen, halo C<sub>1</sub>-C<sub>6</sub> alkyl, halo C<sub>1</sub>-C<sub>6</sub> alkyl, -O-(C<sub>1</sub>-C<sub>6</sub> alkyl)-phenyl, -CO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub> alkyl), -(C<sub>1</sub>-C<sub>4</sub> alkyl)-(C<sub>5</sub>-C<sub>6</sub> cycloalkyl);

 $R_{42}$  is H,  $C_1$ - $C_6$  alkyl, benzyl, -NHC(0)-( $C_1$ - $C_6$  alkyl), or -NHC(0)-30 phenyl wherein the phenyl is optionally substituted with 1 or 2 alkyl groups,

R<sub>55</sub> is cyclohexyl; cyclopentyl; azepanone; phenyl; piperidinyl; -SO<sub>2</sub>-phenyl; pyrrolidinyl; or 4,5,6,7-tetrahydro-thiazolo[5,4-c]pyridine; wherein each is optionally

substituted with  $-C(0)NH_2$ ;  $-C(0)NH(C_1-C_6 \text{ alkyl})$ ;  $-C(0)N(C_1-C_6)$  $C_6$  alkyl) ( $C_1$ - $C_6$  alkyl);  $C_1$ - $C_6$  alkoxycarbonyl; -0-( $C_1$ - $C_6$  $alkyl)-C(0)NR_{31}R_{32}$ ;  $-(C_1-C_6 alkyl)-phenyl$ ; 4,5-dihydro-2Hpyridazin-3-one; C<sub>5</sub>-C<sub>6</sub> cycloalkyl which is optionally substituted with one CN group, phenyloxy wherein the phenyl group is optionally substituted with -NHC(O)C1-C6 alkyl,  $-N(C_1-C_6 \text{ alkyl})-C(0)C_1-C_6 \text{ alkyl}$ , wherein  $R_{31}$ ,  $R_{32}$  and the nitrogen to which they are attached form a pyrrolidine, piperidine, piperazine, morpholine, or thiamorpholine ring, wherein each ring is unsubstituted or substituted with 1, 2, or 3 groups that are independently OH, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy,  $-(C_1-C_6 \text{ alkyl})$ -imidazole wherein the imidazole is optionally substituted with 1 or 2 C<sub>1</sub>-C<sub>4</sub> alkyl groups, or hydroxy (C<sub>1</sub>-C<sub>6</sub> alkyl) wherein the alkyl group is optionally substituted with 1 phenyl ring,

or

5

10

15

R<sub>42</sub>, R<sub>55</sub> and the nitrogen to which they are attached form a tetrahydroisoquinolinyl, dihydroisoquinolinyl, or isoquinolinyl group which is optionally substituted by 1, 2, 3, or 4 groups that are independently halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, CN, OH, and phenyl, wherein the phenyl is optionally substituted with halogen, hydroxyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, and C<sub>1</sub>-C<sub>4</sub> alkyl.

25

30

33. A compound according to claim 32 wherein

R<sub>30</sub> is selected from the group consisting of phenyl,
pyrrolidinonyl, pyridyl, piperidinyl, furyl, cyclopropyl,
and thienyl, wherein each of the above is unsubstituted or
substituted with 1, 2, 3, 4, or 5 groups that are
independently selected from the group consisting of
C<sub>1</sub>-C<sub>10</sub> alkyl, hydroxy, hydroxy C<sub>1</sub>-C<sub>10</sub> alkyl C<sub>1</sub>-C<sub>6</sub> alkoxy,
-NR<sub>31</sub>-SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub> alkyl), -SO<sub>2</sub>-NH(C<sub>1</sub>-C<sub>6</sub> alkyl), -SO<sub>2</sub>N(C<sub>1</sub>-C<sub>6</sub> alkyl)(C<sub>1</sub>-C<sub>6</sub> alkyl), halogen, -NHC(O)NH<sub>2</sub>,

 $-N(C_1-C_6 \text{ alkyl})C(O)NH_2$ ,  $-N(C_1-C_6 \text{ alkyl})C(O)NH(C_1-C_6)$ alkyl),  $-N(C_1-C_6 \text{ alkyl})C(0)N(C_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl})$ ,  $-SO_2NR_{31}R_{32}$ , -C(O)  $-NR_{31}R_{32}$ ,  $-NR_{31}R_{32}$ ,  $-C_2-C_4$  alkynylphenyl,  $-0-C_3-C_6$  cycloalkyl,  $-0-(C_1-C_6 \text{ alkyl})-R_{33}$ , 5 benzo[1,2,5]oxadiazole,  $-C(0)-(C_1-C_6 \text{ alkyl};$ wherein R<sub>31</sub> and R<sub>32</sub> at each occurrence are independently selected from the group consisting of hydrogen, C1-C6 alkyl, hydroxy  $C_1-C_6$  alkyl,  $C_1-C_6$  haloalkyl,  $-(C_1-C_6)$  $alkyl) - C(0)NH_2$ ,  $-(C_1-C_6 alkyl) - C(0)NH(C_1-C_6 alkyl)$ , -10  $(C_1-C_6 \text{ alkyl})-C(0)N(C_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl}), -(C_1-C_6)$  $alkyl)-NH_2$ ,  $-(C_1-C_6 \ alkyl)-NH(C_1-C_6 \ alkyl)$ ,  $-(C_1-C_6 \ alkyl)$  $alkyl)-N(C_1-C_6 \ alkyl)(C_1-C_6 \ alkyl)$ , benzyl, and -C(0) furanyl, wherein the phenyl and pyridyl groups are unsubstituted or substituted with 1, 2, or 3, groups that are 15 independently  $C_1-C_4$  alkyl, hydroxy,  $C_1-C_4$  alkoxy, or halogen, or  $R_{31},\ R_{32}$  and the nitrogen to which they are attached form a 5, 6, or 7 membered heterocycloalkyl or a 6 membered 20 heteroaryl ring, each of which is optionally substituted with  $C_1$ - $C_6$  alkoxy, hydroxy, hydroxy  $C_1$ - $C_6$ alkyl,  $C_1-C_4$  alkoxy  $C_1-C_6$  alkyl, or  $-C(0)NH_2$ ;  $R_{35}$  is phenyl,  $C_3-C_6$  cycloalkyl, or -S-phenyl, each of which is unsubstituted or substituted with 1, 2, or 3 groups that 25 are independently  $C_1-C_4$  alkyl,  $C_1-C_4$  alkoxy,  $CF_3$ ,  $OCF_3$ , halogen, -Obenzyl,  $-CO_2-(C_1-C_6 alkyl)$ ,  $-(C_1-C_4 alkyl)-(C_5-C_6)$ cycloalkyl);  $R_{42}$  is H,  $C_1$ - $C_6$  alkyl, benzyl, -NHC(0)-( $C_1$ - $C_6$  alkyl), or -NHC(0)phenyl wherein the phenyl is optionally substituted with 1 30 or 2 alkyl groups, R<sub>55</sub> is cyclohexyl; azepanone; phenyl; piperidinyl; -SO<sub>2</sub>-phenyl; pyrrolidinyl; or 4,5,6,7-tetrahydro-thiazolo[5,4-

c]pyridine; wherein each is optionally substituted with -  $C(0)NH_2$ ;  $C_1-C_6$  alkoxycarbonyl;  $-O-(C_1-C_6$  alkyl)- $C(0)NR_{31}R_{32}$ ;

-( $C_1$ - $C_6$  alkyl)-phenyl; 4,5-dihydro-2H-pyridazin-3-one; cyclopentyl which is optionally substituted with one CN group, phenyloxy wherein the phenyl group is optionally substituted with -NHC(0) $C_1$ - $C_6$  alkyl, wherein

R<sub>31</sub>, R<sub>32</sub> and the nitrogen to which they are attached form a pyrrolidine, piperidine, piperazine, or morpholine ring, wherein each ring is unsubstituted or substituted with 1, 2, or 3 groups that are independently OH, -(C<sub>1</sub>-C<sub>6</sub> alkyl)-imidazole wherein the imidazole is optionally substituted with 1 or 2 C<sub>1</sub>-C<sub>4</sub> alkyl groups, or hydroxy (C<sub>1</sub>-C<sub>6</sub> alkyl) wherein the alkyl group is optionally substituted with 1 phenyl ring,

or

5

- 15 R<sub>42</sub>, R<sub>55</sub> and the nitrogen to which they are attached form a tetrahydroisoquinolinyl, group which is optionally substituted by 1, 2, 3, or 4 groups that are independently halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, CN, OH, and phenyl, wherein the phenyl is optionally substituted with halogen, hydroxyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, and C<sub>1</sub>-C<sub>4</sub> alkyl.
- 34. A compound according to claim 33 wherein R<sub>30</sub> is selected from the group consisting of phenyl, pyridyl, or piperidinyl wherein each of the above is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently selected from the group consisting of C<sub>1</sub>-C<sub>10</sub> alkyl, hydroxy, hydroxy C<sub>1</sub>-C<sub>10</sub> alkyl C<sub>1</sub>-C<sub>6</sub> alkoxy, halogen, -SO<sub>2</sub>NR<sub>31</sub>R<sub>32</sub>, -C(O) -NR<sub>31</sub>R<sub>32</sub>, -NR<sub>31</sub>R<sub>32</sub>, -O-C<sub>3</sub>-C<sub>6</sub> cycloalkyl, -C(O)-(C<sub>1</sub>-C<sub>6</sub> alkyl);
- wherein  $R_{31}$  and  $R_{32}$  at each occurrence are independently selected from the group consisting of hydrogen,  $C_1$ - $C_6$  alkyl, hydroxy  $C_1$ - $C_6$  alkyl, -( $C_1$ - $C_6$  alkyl)-NH( $C_1$ - $C_6$  alkyl), -( $C_1$ - $C_6$  alkyl)-N( $C_1$ - $C_6$

alkyl)( $C_1$ - $C_6$  alkyl), benzyl, and -C(0)furanyl, wherein

the phenyl group is unsubstituted or substituted with 1, 2, or 3, groups that are independently  $C_1$ - $C_4$  alkyl, hydroxy,  $C_1$ - $C_4$  alkoxy, or halogen, or

 $R_{31}$ ,  $R_{32}$  and the nitrogen to which they are attached form a pyrrolidinyl, piperidinyl, morpholinyl, pyridinyl, or pyrimidinyl ring, each of which is optionally substituted with  $C_1$ - $C_6$  alkoxy, hydroxy, hydroxy  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_4$  alkoxy  $C_1$ - $C_6$  alkyl, or - $C(0)NH_2$ ;

R<sub>35</sub> is phenyl, cyclohexyl, cyclopentyl, or -S-phenyl, each of which is unsubstituted or substituted with 1, 2, or 3 groups that are independently C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, CF<sub>3</sub>, OCF<sub>3</sub>, halogen, -Obenzyl, -CO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub> alkyl), -(C<sub>1</sub>-C<sub>4</sub> alkyl)-(C<sub>5</sub>-C<sub>6</sub> cycloalkyl).

## 35. A compound of the formula

5

10

15

30

$$R_{60}$$
 $R_{52}$ 
 $R_{52}$ 
 $R_{40}$ 
 $R_{40}$ 
 $R_{35}$ 

or a pharmaceutically acceptable salt thereof, wherein

R<sub>35</sub> is phenyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, -S-phenyl, benzodioxole,
thienyl, C<sub>1</sub>-C<sub>6</sub> alkyl, furanyl, each of which is
unsubstituted or substituted with 1, 2, 3, 4, or 5 groups
that are independently C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, OH,
hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, halogen, halo C<sub>1</sub>-C<sub>6</sub> alkyl, halo C<sub>1</sub>-C<sub>6</sub>

alkoxy, -O-(C<sub>1</sub>-C<sub>6</sub> alkyl)-phenyl, -CO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub> alkyl), -(C<sub>1</sub>-C<sub>4</sub>
alkyl)-(C<sub>5</sub>-C<sub>6</sub> cycloalkyl);

R<sub>40</sub> is phenyl, -phenyl-pyridine, biphenyl, -phenylbenzothienyl, -phenyl-thienyl, -phenyl-furanyl, -phenylpyrimidinyl, -phenyl-isooxazolyl, -C(0)-pyridyl, -(C<sub>1</sub>-C<sub>4</sub>
alkyl)-O-C(0)NH-phenyl, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-O-C(0)N(C<sub>1</sub>-C<sub>6</sub>
alkyl)-phenyl, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-phenyl, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-SO<sub>2</sub>NH<sub>2</sub>,
-(C<sub>1</sub>-C<sub>4</sub> alkyl)-SO<sub>2</sub>NH(C<sub>1</sub>-C<sub>6</sub> alkyl), -(C<sub>1</sub>-C<sub>4</sub> alkyl)-SO<sub>2</sub>N(C<sub>1</sub>-C<sub>6</sub>

alkyl)  $(C_1-C_6 \text{ alkyl})$ , CN,  $-(C_1-C_4 \text{ alkyl})-(C_3-C_7 \text{ cycloalkyl})$ ,  $-(C_1-C_4 \text{ alkyl})-C(0)O-(C_1-C_4 \text{ alkyl}, -(C_1-C_4 \text{ alkyl})-R_{33}, C_1-C_8)$ alkyl,  $-(C_1-C_4 \text{ alkyl})-NHC(0)-(C_1-C_4 \text{ alkyl})$ ,  $-C(0)NH_2$ , wherein each of the above rings is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are 5 independently halogen, C1-C4 alkyl, C1-C4 alkoxy, halo (C1- $C_4$  alkyl), -O-( $C_1$ - $C_4$  alkyl)-phenyl wherein the phenyl is optionally substituted with 1 or 2 halogens, -CHO, -NHSO2- $(C_1-C_4 \text{ alkyl})$ ,  $-N(C_1-C_4 \text{ alkyl})SO_2-(C_1-C_4 \text{ alkyl})$  wherein the alkyl is optionally substituted with 1, 2, or 3 halogens, 10 R<sub>42</sub> is H, C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with OH; benzyl; - $NHC(0)-(C_1-C_6 \text{ alkyl}); -NHC(0)-phenyl wherein the phenyl is$ optionally substituted with 1 or 2 alkyl groups; -CO<sub>2</sub>-(C<sub>1</sub>- $C_6$  alkyl);  $-CO_2$ -(benzyl); or -C(0)-( $C_1$ - $C_6$  alkyl);  $R_{52}$  is H, phenyl, -NHC(O)-( $C_1$ - $C_6$  alkyl)-( $C_1$ - $C_6$  thioalkoxy), -15  $N(C_1-C_6 \text{ alkyl})C(0)-(C_1-C_6 \text{ alkyl})-(C_1-C_6 \text{ thioalkoxy}), OH, C_1-C_6 \text{ alkyl}$  $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy, mono or di( $C_1$ - $C_6$  alkyl)amino,  $-NHC(0)-(C_1-C_6 \text{ alkyl})$  wherein the alkyl group is optionally substituted with a phenyl, -N(C<sub>1</sub>-C<sub>6</sub> alkyl)C(O)-20  $(C_1-C_6 \text{ alkyl})$  wherein the alkyl groups are each optionally substituted with a phenyl,  $-(CH_2)_{0-4}-SO_2-(C_1-C_{10} \text{ alkyl})$ , - $NHCO_2$ -benzyl, or  $-NH_2$ , and  $R_{60}$  is -L-V- $R_{65}$ ,  $C_1$ - $C_8$  alkyl, or hydroxy  $C_1$ - $C_8$  alkyl, wherein the alkyl or hydroxyalkyl groups are optionally substituted with 1 25 or 2 L-V-R<sub>65</sub> groups, wherein L is absent, -C(0)-,  $-CO_2$ -, -C(0)NH-,  $-C(0)N(C_1$ - $C_6$  alkyl)-, -NHC(O) -,  $-N(C_1-C_6 \text{ alkyl}) - C(O) -$ ,  $-(CH_2)_{0-4} - SO_2 - (CH_2)_{0-4} -$ ,  $-(CH_2)_{0-4}-O-(CH_2)_{0-4}-$ ,  $-(CH_2)_{0-4}-S-(CH_2)_{0-4}-$ , -NHC(O)NH-,  $-N(C_1-C_6 \text{ alkyl})C(O)NH-$ ,  $-N(C_1-C_6 \text{ alkyl})C(O)N(C_1-C_6)$ 30 alkyl) -,  $-NHC(O)N(C_1-C_6 alkyl)$  -, -NH -, -N(benzyl) -, -N(phenyl) -, -(CH<sub>2</sub>)<sub>0-4</sub>-NHSO<sub>2</sub>-(CH<sub>2</sub>)<sub>0-4</sub>-, <math>-N(C<sub>1</sub>-C<sub>6</sub> $alkyl)SO_2-$ ,  $-SO_2NH-$ ,  $-SO_2N(C_1-C_6 alkyl)-$ , or  $C_2-C_6$ alkenyl; or

```
V is absent, -(CH_2)_{0-4}-C(0)NH_{-}, -(CH_2)_{0-4}-C(0)N(C_1-C_6 \text{ alkyl})-
                , cyclopropyl optionally substituted with 1 or 2 C<sub>1</sub>-
               C_4 alkyl groups, =NH, =NOH, =N-alkoxy, C_1-C_8 alkyl
               optionally substituted with 1 or 2 OH; or
 5
               -CH(phenyl) - wherein the phenyl is optionally
               substituted with 1, 2, 3, 4, or 5 groups that are
                independently halogen or OH; cyclopentyl; cyclohexyl;
               or -CH(phenyl)-;
          R<sub>65</sub> is cyclohexyl; cyclopentyl; phenyl; -(C<sub>1</sub>-C<sub>6</sub> alkyl)-
10
               phenyl; NH_2; mono or di(C_1-C_{10} alkyl)amino wherein the
               alkyl group or groups are optionally substituted with
               1 or 2 groups that are independently cyclopropyl,
               phenyl or OH; oxadiazolyl; triazolopyrimidinyl;
               triazolyl; thiadiazolyl; 3H-quinazolin-2-onyl;
15
               pyrimidinyl; pyridyl; pyridyl N-oxide; -(C1-C6
               alkyl)-pyridyl; piperazinyl; phthalazinyl;
               tetrahydro-thiophenyl 1,1-dioxide; tetrazolyl; C<sub>3</sub>-C<sub>6</sub>
               cycloalkyl-C_1-C_6 alkyl; -(C_1-C_4 alkyl)-SO_2-(C_1-C_4
               alkyl); -SO_2-(C_1-C_6 \text{ alkyl}); benzothiazolyl; hexahydro-
20
               isoindole-1,3-dionyl; benzimidazolyl; benzoxazolyl;
                [1,2,4]triazolo[1,5-a]pyrimidinyl;
                [1,2,4]triazolo[4,3-a]pyrimidinyl, thiazolyl;
               thiadiazolyl; imidazo[1,2-a]pyridine; 3-aza-
               bicyclo[3.2.2]nonane; pyrrolidinonyl; diazepanyl;
25
               benzo[1,2,5]thiadiazolyl; -NHSO2-(4-methylphenyl);
                [1,2,4] triazolo[4,3-b] pyridazinyl,
               benzopyrrolidinonyl; morpholinyl; thiomorpholinyl;
               thiomorpholinyl S-oxide; thiomorpholinyl S,S-dioxide;
               2,3-dihydro-benzo[b]thiophene 1,1-dioxide;
30
               pyrrolidinyl; [1,2,4]oxadiazole; C<sub>1</sub>-C<sub>10</sub> alkyl;
               isoxazolyl; 2,3-dihydro-1H-indolyl; quinazolinonyl;
               quinazolinyl; piperidyl; -CO2-(C1-C6 alkyl);
               dibenzofuranyl; dihydroindolinonyl;
               triazolobenzimidazolyl; benzotriazolyl;
```

```
tetrahydrobenzofuranonyl; benzofuranyl;
                dihydrobenzofuranyl, tetrahydrofuranyl; furanyl;
                oxazolopyridinyl; tetrahydrobenzothienyl;
                dihydropurinyl dione; indolyl; thienyl; imidazolyl;
                cyclohexanonyl; naphthyl; tetrahydrothienyl S,S-
5
                dioxide; chromanyl; isoindolinonyl;
                [1,2,4]triazolo[4,3-a]pyrimidinyl; -phenyl-
                oxazolidinonyl; 3-oxo-2,3-dihydroimidazo[2,1-
                b][1,3]thiazolyl; dihydrothiazolyl; benzodioxinyl;
                2,3 dihydrobenzimidazolidinonyl;
10
                tetrahydrocyclopenta[b]chromenonyl; 1-H-
                benzo[g]indazolyl; 4,5-dihydronaphtho[2,1-
                dlisoxazolyl; tetraazolo[1,5-b]pyridazinyl; pyrrolyl;
                dihydropyrazolidinonyl; -NHSO2NH2; -N(C1-C6
                alkyl) SO_2NH_2; -N(C_1-C_6 alkyl) SO_2NH(C_1-C_6 alkyl); -N(C_1-C_6)
15
                C_6 alkyl) SO_2N(C_1-C_6 alkyl) (C_1-C_6 alkyl); -NHSO_2NH(C_1-C_6)
                alkyl); -NHSO_2N(C_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl});
                tetrahydrobenzothienyl; imidazolidinyl dione;
                diazepanonyl; or dihydroanthracenyl dione; wherein
                each of the above is optionally substituted with 1,
20 .
                2, 3, 4, or 5 groups that are independently
                C_1-C_6 alkyl, CF_3, halogen, phenyl, -(C_1-C_4 alkyl)-
                      phenyl, -C(0) phenyl, pyrrolidine-dione, C1-C6
                      alkoxy, -C(0)-furan, -C(0)NH_2, -C(0)NH(C_1-C_6)
                      alkyl), -C(0)N(C_1-C_6 \text{ alkyl})(C_1-C_6)
25
                      alkyl), cyclopropyl, -(CH_2)_{0-4}-cyclopentyl,
                      benzoxazolyl, pyridine, -NHC(0)-(C_1-C_6 alkyl),
                      -N(C_1-C_6 \text{ alkyl})C(O)-(C_1-C_6 \text{ alkyl}), -C(O)C_1-C_6
                      alkyl, -CO_2H, -NHSO_2-(C_1-C_8 \text{ alkyl}), -N(C_1-C_6)
                      \verb"alkyl") SO_2-(C_1-C_8 \ alkyl") \,, \ (C_1-C_6 \ alkoxy) \,, \ OH\,,
30
                      oxazolyl, (C_1-C_6 \text{ thioalkoxy}), or CN.
```

36. A compound according to claim 35 wherein

R<sub>35</sub> is phenyl, cyclohexyl, -S-phenyl, or benzodioxole, each of which is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently methyl, ethyl, methoxy, ethoxy, OH, halogen, CF<sub>3</sub>, OCF<sub>3</sub>, -Obenzyl, -CO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub> alkyl), -(C<sub>1</sub>-C<sub>4</sub> alkyl)-(C<sub>5</sub>-C<sub>6</sub> cycloalkyl);

5

- $$\label{eq:R40} \begin{split} R_{40} \ \ &\text{is phenyl, -phenyl-pyridine, biphenyl, -(C$_1$-C$_4$ alkyl)$-SO$_2NH$_2,} \\ &-(C_1$-C_4$ alkyl)$-SO$_2NH$(C$_1$-C$_6$ alkyl), -(C$_1$-C$_4$ alkyl)$-SO$_2N$(C$_1$-C$_6$ alkyl), -(C$_1$-C$_4$ alkyl)$-(cyclopentyl), -(C$_1$-C$_4$ alkyl)$-C$(0)O$-(C$_1$-C$_4$ alkyl, C$_1$-C$_8$ alkyl, -(C$_1$-C$_4$ alkyl)$-$$
- NHC(0)-( $C_1$ - $C_4$  alkyl), -C(0)NH<sub>2</sub>, wherein each of the above rings is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently halogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, halo ( $C_1$ - $C_4$  alkyl), -Obenzyl wherein the phenyl is optionally substituted with 1 or 2 halogens,
- 15  $R_{42}$  is H,  $C_1$ - $C_6$  alkyl, or benzyl;  $R_{52}$  is H, -NHC(O)-( $C_1$ - $C_6$  alkyl)-( $C_1$ - $C_6$  thioalkoxy), -N( $C_1$ - $C_6$  alkyl)-( $C_1$ - $C_6$  thioalkoxy), OH,  $C_1$ - $C_4$  alkyl, and
- $R_{60}$  is -L-V- $R_{65}$ ,  $C_1$ - $C_8$  alkyl, or hydroxy  $C_1$ - $C_8$  alkyl, wherein the alkyl or hydroxyalkyl groups are optionally substituted with 1 or 2 L-V- $R_{65}$  groups, wherein
- L is absent, -C(0)-,  $-CO_2$ -, -C(0)NH-,  $-C(0)N(C_1$ - $C_6$  alkyl)-, -NHC(0)-,  $-N(C_1$ - $C_6$  alkyl)--C(0)-,  $-SO_2$ -,  $-(CH_2)_{0-4}$ -O-  $(CH_2)_{0-4}$ -,  $-(CH_2)_{0-4}$ -S- $(CH_2)_{0-4}$ -, -NHC(0)NH-,  $-N(C_1$ - $C_6$  alkyl) $-C(0)N(C_1$ - $-C_6$  alkyl) $-C(0)N(C_1$ - $-C_6$  alkyl)-,  $-NHC(0)N(C_1$ - $-C_6$  alkyl)-, -NH-, -N(benzyl)-,  $-(CH_2)_{0-4}$   $-NHSO_2$ - $-(CH_2)_{0-4}$ -,  $-N(C_1$ - $-C_6$  alkyl)-, and
- V is absent, -C(0)NH-, -C(0)N(C<sub>1</sub>-C<sub>6</sub> alkyl)-, cyclopropyl,

  R<sub>65</sub> is cyclohexyl; cyclopentyl; phenyl; -(C<sub>1</sub>-C<sub>6</sub> alkyl)phenyl; NH<sub>2</sub>; mono or di(C<sub>1</sub>-C<sub>6</sub> alkyl)amino wherein the
  alkyl group or groups are optionally substituted with
  1 or 2 groups that are independently cyclopropyl,
  phenyl or OH; oxadiazolyl; triazolopyrimidinyl;

PCT/US02/36072 WO 03/040096

triazolyl; thiadiazolyl; 3H-quinazolin-2-onyl; pyrimidinyl; pyridyl; pyridyl N-oxide; -(C1-C6 alkyl)-pyridyl; piperazinyl; phthalazinyl; tetrahydro-thiophenyl 1,1-dioxide; tetrazolyl; C3-C6 5 cycloalkyl- $C_1$ - $C_6$  alkyl; -( $C_1$ - $C_4$  alkyl)- $SO_2$ -( $C_1$ - $C_4$ alkyl)-; benzothiazole; hexahydro-isoindole-1,3dionyl; benzimidazolyl; benzoxazolyl; [1,2,4]triazolo[1,5-a]pyrimidinyl; thiazolyl; thiadiazolyl; imidazo[1,2-a]pyridine; C<sub>1</sub>-C<sub>6</sub> alkyl; 3aza-bicyclo[3.2.2]nonane; pyrrolidinonyl; diazepanyl; 10 benzo[1,2,5]thiadiazolyl; -NHSO<sub>2</sub>-(4-methylphenyl); [1,2,4]triazolo[4,3-b]pyridazinyl, benzopyrrolidinonyl; thiomorpholinyl S-oxide; 2,3dihydro-benzo[b]thiophene 1,1-dioxide; pyrrolidinyl; 15 [1,2,4]oxadiazole;  $C_1$ - $C_{10}$  alkyl; isoxazolyl; 2,3dihydro-1H-indolyl; wherein each of the above is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently  $C_1-C_6$  alkyl,  $CF_3$ , halogen, phenyl,  $-(C_1-C_4$  alkyl)-phenyl, 20 -C(0)phenyl, pyrrolidine-dione,  $C_1$ - $C_6$  alkoxy, -C(0)furan,  $-C(0)NH_2$ ,  $-C(0)NH(C_1-C_6 alkyl)$ ,  $-C(0)N(C_1-C_6)$ alkyl)  $(C_1-C_6 \text{ alkyl})$ , cyclopropyl, benzoxazole, pyridine,  $-NHC(0) - (C_1-C_6 \text{ alkyl})$ ,  $-N(C_1-C_6 \text{ alkyl})C(0)$ - $(C_1-C_6 \text{ alkyl})$ ,  $-C(0)C_1-C_6 \text{ alkyl}$ . 25 37. A compound according to claim 36 wherein

30

R<sub>35</sub> is phenyl, cyclohexyl, -S-phenyl, benzodioxole, furanyl, or thienyl, each of which is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently

methyl, ethyl, methoxy, ethoxy, OH, halogen, CF3, OCF3, -Obenzyl,  $-CO_2-(C_1-C_4 \text{ alkyl})$ ,  $-(C_1-C_2 \text{ alkyl})-(C_5-C_6)$ cycloalkyl);

 $R_{40}$  is phenyl,  $-(C_1-C_4 \text{ alkyl})-SO_2NH_2$ ,  $-(C_1-C_4 \text{ alkyl})-SO_2NH(C_1-C_6)$ alkyl),  $-(C_1-C_4 \text{ alkyl})-SO_2N(C_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl}), -(C_1-C_6 \text{ alkyl})$ 

 $C_4$  alkyl)-(cyclopentyl),  $C_1$ - $C_8$  alkyl, -( $C_1$ - $C_4$  alkyl)-NHC(0)-( $C_1$ - $C_4$  alkyl), -C(0)NH<sub>2</sub>, wherein each of the above rings is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently halogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, halo ( $C_1$ - $C_4$  alkyl), -Obenzyl wherein the phenyl is optionally substituted with 1 or 2 halogens,

 $R_{42}$  is H,  $C_1$ - $C_6$  alkyl, or benzyl;

5

10

15

30

 $R_{52}$  is H, -NHC(O)-(C<sub>1</sub>-C<sub>6</sub> alkyl)-(C<sub>1</sub>-C<sub>6</sub> thioalkoxy), -N(C<sub>1</sub>-C<sub>6</sub> alkyl)C(O)-(C<sub>1</sub>-C<sub>6</sub> alkyl)-(C<sub>1</sub>-C<sub>6</sub> thioalkoxy), OH, C<sub>1</sub>-C<sub>4</sub> alkyl, and

 $R_{60}$  is -L-R  $_{65},$  or  $C_1-C_6$  alkyl optionally substituted with 1 or 2 L-R  $_{65}$  groups, wherein

L is absent, -C(0)-, -C(0)NH-,  $-C(0)N(C_1-C_6 \text{ alkyl})$ -, -NHC(0)-,  $-N(C_1-C_6 \text{ alkyl})$ -C(0)-,  $-SO_2$ -,  $-(CH_2)_{0-4}$ -O-  $(CH_2)_{0-4}$ -, -S-, -NHC(0)NH-, -NH-, -N(benzyl)-,  $-(CH_2)_{0-4}$ - $-NHSO_2$ - $-(CH_2)_{0-4}$ -,  $-N(C_1-C_6 \text{ alkyl})SO_2$ -,  $-SO_2NH$ -,  $-SO_2N(C_1-C_6 \text{ alkyl})$ -.

- 38. A compound according to claim 32 wherein R<sub>35</sub> is phenyl; halophenyl, dihalophenyl; trihalophenyl; tetrahalophenyl; pentahalophenyl; phenyl substituted with one halogen and one benzyloxygroup; phenyl substituted with one halogen and one alkyl group; benzyloxyphenyl; cyclohexyl; (C<sub>1</sub>-C<sub>4</sub> alkoxy)carbonylphenyl; (C<sub>1</sub>-C<sub>4</sub> alkoxy)phenyl; -S-phenyl, or benzodioxole;
  - $R_{40}$  is phenyl, or  $-(C_1-C_4 \text{ alkyl})-SO_2NH_2$ , wherein each of the above is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, methyl, ethyl, methoxy, ethoxy, or -Obenzyl wherein the phenyl is optionally substituted with 1 or 2 halogens,  $R_{42}$  is H.
    - 39. A compound according to claim 38 wherein

 $R_{35}$  is a halophenyl, dihalophenyl, trihalophenyl, phenyl substituted with one halogen and one benzyloxygroup; phenyl substituted with one halogen and one alkyl group; benzyloxyphenyl, or  $(C_1-C_4$  alkoxy)phenyl.

5

10

15

20

25

30

A compound according to claim 3 wherein  $R_{30}$  is pyridyl or pyrimidyl wherein each is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently selected from the group consisting of  $C_1-C_{10}$  alkyl optionally substituted with 1 phenyl or 1 CN; OH, hydroxy C<sub>1</sub>-C<sub>10</sub> alkyl optionally substituted with phenyl or  $(C_1-C_4 \text{ alkyl})$  phenyl,  $C_1-C_6 \text{ alkoxy}$  optionally substituted with 1 or 2 groups that are independently hydroxy or phenyl; haloalkyl, haloalkoxy,  $(CH_2)_{0}$  $_4$ C(O)NR $_{31}$ R $_{32}$ ,  $_-$ NR $_{31}$ -SO $_2$ -(C $_1$ -C $_6$  alkyl) wherein the alkyl group is optionally substituted with 1, 2, or 3 groups that are independently halogen or R33, -SO2- $NH(C_1-C_6 \text{ alkyl})$  wherein the alkyl group is optionally substituted with 1 or 2 groups that are independently halogen, OH, alkoxy, or  $R_{33}$ ; -( $C_1$ - $C_6$  alkyl)- $SO_2$ -( $C_1$ - $C_6$ alkyl) wherein the alkyl group is optionally substituted with 1 or 2 groups that are independently halogen, OH,  $C_1$ - $C_4$  alkoxy, or  $R_{33}$ ; -SO<sub>2</sub>-( $C_1$ - $C_6$  alkyl) wherein the alkyl group is optionally substituted with 1 or 2 groups that are independently OH or C1-C4 alkoxy,  $-SO_2-N(C_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl})$  wherein each alkyl group is optionally substituted with 1 or 2 groups that are independently halogen, OH or R33;  $-SO_2-NH(C_1-C_6 \text{ alkyl})-phenyl wherein the phenyl is$ optionally substituted with 1 or 2 groups that are independently  $C_1-C_4$  alkoxy or halogen,  $-(C_1-C_6$  alkyl)-O-phenyl,  $-(C_1-C_6 \text{ alkyl})-O-(C_1-C_6 \text{ alkyl})-phenyl,$ triazolidine-3,5-dione, halogen, -NHC(0)NH2,

-1011-

-NHC(0)NH( $C_1$ - $C_6$  alkyl), -NHC(0)N( $C_1$ - $C_6$  alkyl)( $C_1$ - $C_6$ 

alkyl),  $-N(C_1-C_6 \text{ alkyl})C(0)NH_2$ ,  $-N(C_1-C_6 \text{ alkyl})$  $alkyl)C(O)NH(C_1-C_6 \ alkyl)$ ,  $-N(C_1-C_6 \ alkyl)C(O)N(C_1-C_6 \ alkyl)$ alkyl)  $(C_1-C_6 \text{ alkyl})$ ,  $-(C_1-C_6 \text{ alkyl})$  thienyl,  $-(C_1-C_6 \text{ alkyl})$ alkyl) furanyl,  $-S-(C_1-C_6 \text{ alkyl})$  phenyl,  $-SO_2NR_{31}R_{32}$ , -5  $C(0)-NR_{31}R_{32}$ ,  $-NR_{31}R_{32}$ , dithiane,  $-NHC(S)NH_2$ ,  $-NHC(S)NH(C_1-C_6 \text{ alkyl}), -NHC(S)N(C_1-C_6 \text{ alkyl}) (C_1-C_6)$ alkyl),  $-CO_2(C_1-C_6 \text{ alkyl})$ , tetrahydropyran, phenyl optionally substituted with 1 or 2 groups that are independently F, Cl or Br; pyridine, -C2-C4 alkynylphenyl,  $-0-C_3-C_8$  cycloalkyl,  $-0-(C_1-C_6 \text{ alkyl})-R_{33}$ ; 10 pyrrole optionally substituted with one or two methyl groups; 2,3-dihydro-benzofuran; benzo[1,2,5]oxadiazole,  $-C(0)-(C_1-C_{10} \text{ alkyl})$  wherein the alkyl group is optionally substituted with NH2, 15  $N(C_1-C_6 \text{ alkyl})$ , or  $N(C_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl})$ ; -C(0)NH-phenyl,  $-C(0)N(C_1-C_6 \text{ alkyl})$ -phenyl, 4,4dimethyl-4,5-dihydro-oxazole,  $-(C_1-C_6 \text{ alkyl})-S$ pyridine,  $-(C_1-C_6 \text{ alkyl})-SO_2$ -pyridine,  $-(C_1-C_6)$ thioalkoxy)-pyridine, thiazole optionally substituted 20 with 1 or 2 methyl groups, pyrazole, -S-(C<sub>1</sub>-C<sub>6</sub> alkyl) wherein the alkyl group is optionally substituted with 1 or 2 groups that are independently CN or OH; indole,  $(C_1-C_6 \text{ thioalkoxy})-(C_1-C_6 \text{ alkyl})$ ,  $C_2-C_8$ alkynyl,  $-(CH_2)_{0-4}-SO_2-(C_1-C_{10} \text{ alkyl})$  wherein the alkyl 25 group is optionally substituted with OH; -NHC(O)NH( $C_3$ - $C_8$  cycloalkyl), -N( $C_1$ - $C_6$  alkyl)C(O)NH( $C_3$ - $C_8$ cycloalkyl),  $-N(C_1-C_6 \text{ alkyl})C(0)N(C_1-C_6 \text{ alkyl})(C_3-C_8)$ cycloalkyl),  $-NHC(O)N(C_1-C_6 alkyl)(C_3-C_8 cycloalkyl)$ ,  $-(C_1-C_6 \text{ alkoxy})-(C_1-C_6 \text{ thioalkoxy}); -CO_2-(C_1-C_6 \text{ alkyl})$ 30 wherein the alkyl group is optionally substituted with phenyl; -C(0)-furan; and imidazolyl; wherein R<sub>31</sub> and R<sub>32</sub> at each occurrence are independently selected from the group consisting of hydrogen,  $C_1-C_8$ alkyl,  $C_2$ - $C_8$  alkenyl, hydroxy  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$ 

haloalkyl,  $C_1$ - $C_6$  alkoxy  $C_1$ - $C_6$  alkyl,  $-(CH_2)_{0-4}$ - $SO_2$ - $(C_1$ -C<sub>6</sub> alkyl) wherein the alkyl is optionally substituted with 1, 2, 3 or 4 independently selected halogen atoms;  $-(CH_2)_{0-4}-SO_2-imidazolyl$ ,  $-(C_1-C_6 alkyl) C(0)NH_2$ ,  $-(C_1-C_6 \text{ alkyl})-C(0)NH(C_1-C_6 \text{ alkyl})$ ,  $-(C_1-C_6 \text{ alkyl})$ 5  $alkyl) - C(0)N(C_1-C_6 \ alkyl)(C_1-C_6 \ alkyl), -(C_1-C_6 \ alkyl) NH_2$ ,  $-(C_1-C_6 \text{ alkyl})-NH(C_1-C_6 \text{ alkyl})$ ,  $-(C_1-C_6 \text{ alkyl}) N(C_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl}), -(C_1-C_6 \text{ alkyl})$ phenyl,  $-(C_1-C_6 \text{ alkyl})$ pyridyl, -C(0)furanyl,  $(C_1-C_6 \text{ alkyl})$ -10 tetrahydrofuran, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,  $-CO_2-(C_1-C_6 \text{ alkyl})$ ,  $-(C_1-C_6 \text{ alkyl})$ alkyl)-furanyl, -(CH<sub>2</sub>)<sub>0-4</sub>-SO<sub>2</sub>-thienyl, -pyrrolidinylbenzyl,  $-(C_1-C_6 \text{ thioalkoxy})-(C_1-C_6 \text{ alkyl})$ ,  $-C(0)-(C_1-C_6 \text{ alkyl})$  $C_6$  alkyl),  $(C_1-C_6$  alkoxy),  $-(C_2-C_6$  alkenyloxy),  $-(C_1-C_6)$ alkyl)- $CO_2$ -( $C_1$ - $C_6$  alkyl), and -C(0)-piperidinyl 15 optionally substituted with C1-C6 alkyl; wherein the phenyl and pyridyl groups are unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxy, C<sub>1</sub>-C<sub>4</sub> 20 alkoxy, halogen, or  $R_{31}$ ,  $R_{32}$  and the nitrogen to which they are attached form a 5, 6, or 7 membered heterocycloalkyl or a 6 membered heteroaryl ring, each of which is optionally fused to a benzene, pyridine or pyrimidine ring and each of 25

heteroaryl ring, each of which is optionally fused to a benzene, pyridine or pyrimidine ring and each of which is optionally substituted with C<sub>1</sub>-C<sub>6</sub> alkoxy, hydroxy, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl, -C(0)NH<sub>2</sub>, -C(0)NH-(C<sub>1</sub>-C<sub>6</sub> alkyl)-phenyl; and R<sub>33</sub> at each occurrence is independently, H, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>6</sub> alkyl), N(C<sub>1</sub>-C<sub>6</sub> alkyl), N(C<sub>1</sub>-C<sub>6</sub> alkyl), N(C<sub>1</sub>-C<sub>6</sub>

alkyl)(phenyl), N(C<sub>1</sub>-C<sub>6</sub> alkyl)(benzyl);.

41. A compound according to claim 40 wherein R<sub>35</sub> is phenyl; halophenyl, dihalophenyl; trihalophenyl; tetrahalophenyl; pentahalophenyl; phenyl substituted with

one halogen and one benzyloxy group; phenyl substituted with one halogen and one alkyl group; benzyloxyphenyl; cyclohexyl;  $(C_1-C_4 \text{ alkoxy})$  carbonylphenyl;  $(C_1-C_4 \text{ alkoxy})$  phenyl; -S-phenyl, or benzodioxole.

5

30

- 42. A compound according to claim 41 wherein

  R<sub>40</sub> is phenyl, -phenyl-pyridine, biphenyl, -phenyl
  benzothienyl, -phenyl-thienyl, -phenyl-furanyl, -phenyl
  pyrimidinyl, -phenyl-isoxazolyl, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-O-C(O)NH
  phenyl, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-O-C(O)N(C<sub>1</sub>-C<sub>6</sub> alkyl)-phenyl, -(C<sub>1</sub>-C<sub>4</sub>

  alkyl)-SO<sub>2</sub>NH<sub>2</sub>, CN, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-(C<sub>3</sub>-C<sub>6</sub> cycloalkyl), -(C<sub>1</sub>-C<sub>4</sub>

  alkyl)-C(O)O-(C<sub>1</sub>-C<sub>4</sub> alkyl), -(C<sub>1</sub>-C<sub>4</sub> alkyl)-R<sub>33</sub>, C<sub>1</sub>-C<sub>8</sub> alkyl,

  pyridyl, or pyrimidyl, wherein each of the above is

  unsubstituted or substituted with 1, 2, or 3 groups that

  are independently halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, CF<sub>3</sub>,

  -O-(C<sub>1</sub>-C<sub>4</sub> alkyl)-phenyl wherein the phenyl is optionally

  substituted with 1 or 2 halogens, -CHO, or -NHSO<sub>2</sub>-(C<sub>1</sub>-C<sub>4</sub>

  alkyl).
- 43. A compound according to claim 42 wherein

  R<sub>30</sub> is pyridyl or pyrimidyl wherein each of the above is

  unsubstituted or substituted with 1, 2, or 3 groups that

  are independently selected from the group consisting of

  -SO<sub>2</sub>NR<sub>31</sub>R<sub>32</sub>, -C(O)-NR<sub>31</sub>R<sub>32</sub>, -NR<sub>31</sub>R<sub>32</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, halogen, C<sub>1</sub>
  25 C<sub>4</sub> alkoxy,

C<sub>6</sub> alkyl), -(C<sub>1</sub>-C<sub>6</sub> alkyl)-NH<sub>2</sub>, -(C<sub>1</sub>-C<sub>6</sub> alkyl)-NH(C<sub>1</sub>-C<sub>6</sub> alkyl), -(C<sub>1</sub>-C<sub>6</sub> alkyl)-N(C<sub>1</sub>-C<sub>6</sub> alkyl)(C<sub>1</sub>-C<sub>6</sub> alkyl), -(C<sub>1</sub>-C<sub>6</sub> alkyl)phenyl, and -(C<sub>1</sub>-C<sub>6</sub> alkyl)pyridyl, wherein

R<sub>31</sub> and R<sub>32</sub> at each occurrence are independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl,

C<sub>2</sub>-C<sub>6</sub> alkenyl, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl,

C<sub>1</sub>-C<sub>6</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl, -(CH<sub>2</sub>)<sub>0-4</sub>-SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub> alkyl)-,

(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(O)NH<sub>2</sub>, -(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(O)NH(C<sub>1</sub>-C<sub>6</sub> alkyl),

-( $C_1$ - $C_6$  alkyl)-NH<sub>2</sub>, -( $C_1$ - $C_6$  alkyl)-NH( $C_1$ - $C_6$  alkyl), -( $C_1$ - $C_6$  alkyl)-N( $C_1$ - $C_6$  alkyl)( $C_1$ - $C_6$  alkyl), -( $C_1$ - $C_6$  alkyl)phenyl, -( $C_1$ - $C_6$  alkyl)pyridyl, -C(0)furanyl, ( $C_1$ - $C_6$  alkyl)-tetrahydrofuran, or

- R<sub>31</sub>, R<sub>32</sub> and the nitrogen to which they are attached form a pyrrolidinyl, piperidinyl, piperazinyl, pyridyl, or pyrimidyl ring each of which is optionally fused to a benzene, pyridine or pyrimidine ring and each of which is optionally substituted with C<sub>1</sub>-C<sub>6</sub> alkoxy, hydroxy, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl, -C(0)NH<sub>2</sub>, -C(0)NH-(C<sub>1</sub>-C<sub>6</sub> alkyl)-phenyl.
- 44. A compound according to claim 43 wherein  $R_{40}$  is phenyl, pyridyl, or pyrimidyl, wherein each of the above is unsubstituted or substituted with 1, 2, or 3 groups that are independently halogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy,  $CF_3$ , -O- $(C_1$ - $C_4$  alkyl)-phenyl wherein the phenyl is optionally substituted with 1 or 2 halogens, -CHO, or -NHSO<sub>2</sub>- $(C_1$ - $C_4$  alkyl).

20

- 45. A compound according to claim 44 wherein  $R_{35}$  is phenyl; halophenyl, or dihalophenyl.
- 46. A compound according to claim 45 wherein
  25 R<sub>30</sub> is pyridyl which is unsubstituted or substituted with 1 or
  2 groups that are independently selected from the group
  consisting of
- C<sub>1</sub>-C<sub>4</sub> alkyl, -C(0)N(C<sub>1</sub>-C<sub>6</sub> alkyl)(C<sub>1</sub>-C<sub>6</sub> alkyl), -C(0)NH<sub>2</sub>,
  -C(0)N(C<sub>2</sub>-C<sub>6</sub> alkenyl)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -C(0)NH(C<sub>3</sub>-C<sub>8</sub>
  cycloalkyl), -C(0)NH(C<sub>1</sub>-C<sub>6</sub> alkyl), C(0)-(pyrrolidine)
  optionally substituted with 1 or two groups that are
  independently alkoxyalkyl or hydroxy, halogen, C(0)N(C<sub>1</sub>-C<sub>6</sub> hydroxyalkyl)(C<sub>1</sub>-C<sub>6</sub> alkyl), C(0)NH(alkoxyalkyl),

5

10

15

20

25

-C(0)N(alkoxyalkyl)(alkoxyalkyl), -C(0)N(C<sub>1</sub>-C<sub>6</sub> alkyl)(alkoxyalkyl),  $-C(0)N(C_1-C_6 \text{ hydroxyalkyl})$  (alkyl),  $-NHSO_2CF_3$ ,  $-N(C_1-C_6 \text{ alkyl})-SO_2-thienyl$ ,  $-N(C_1-C_6)$ hydroxyalkyl) $SO_2-(C_1-C_6 \text{ alkyl})$ , -NHC(0) $C_1-C_4 \text{ alkyl}$ , oxazolyl optionally substituted with 1 or 2 methyl groups, thiazolyl optionally substituted with 1 or 2 methyl groups, pyrazolyl optionally substituted with 1 or 2 methyl groups, imidazolyl optionally substituted with 1 or 2 methyl groups, isoxazolyl optionally substituted with 1 or 2 methyl groups, pyrimidinyl optionally substituted with 1 or 2 methyl or halogen groups, -NHSO<sub>2</sub>CH<sub>3</sub>, -NHSO<sub>2</sub>-imidazolyl wherein the imidazole ring is optionally substituted with 1 or 2 methyl groups,  $-N(C_1-C_6 \text{ alkyl})SO_2(C_1-C_6)$ alkyl), -SO<sub>2</sub>NH-C<sub>1</sub>-C<sub>6</sub> hydroxyalkyl, -SO<sub>2</sub>NH-C<sub>1</sub>-C<sub>6</sub> alkyl- $NH(C_1-C_4 \text{ alkyl})$ ,  $-SO_2$ -piperazinyl optionally substituted with 1 or 2 methyl groups, -SO<sub>2</sub>pyrrolidine optionally substituted with 1 or 2 methyl groups, -SO<sub>2</sub>-piperidine optionally substituted with 1 or 2  $C_1-C_4$  alkyl groups,  $-SO_2N(C_1-C_4$  hydroxyalkyl)  $(C_1-C_4)$  $C_4$  hydroxyalkyl),  $-SO_2NH_2$ ,  $-SO_2N(C_1-C_6$  alkyl)( $C_1-C_6$ alkyl),  $C_2-C_6$  alkynyl,  $-SO_2-(C_1-C_6$  hydroxyalkyl), - $SO_2NH(C_1-C_6 \text{ hydroxyalkyl}), -SO_2N(C_1-C_6 \text{ alkyl})(C_1-C_6)$ hydroxyalkyl),  $-(C_1-C_4 \text{ alkyl})-SO_2-(C_1-C_4 \text{ alkyl})$ , or - $C(0) - (C_1 - C_{10} \text{ alkyl})$ .

47. A compound according to claim 46 wherein

R<sub>30</sub> is pyridyl which is unsubstituted or substituted with at least one group which is -SO<sub>2</sub>NH-propyl-OH, -SO<sub>2</sub>NH-ethyl
OH, -SO<sub>2</sub>NH-ethyl-OCH<sub>3</sub>, -SO<sub>2</sub>NH-CH(CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>OH, -SO<sub>2</sub>NH
(CH<sub>2</sub>CH(OH)CH<sub>3</sub>), -SO<sub>2</sub>NH-ethyl-NH(CH<sub>3</sub>), -SO<sub>2</sub>NH(-CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>,

-SO<sub>2</sub>NHCH(CH<sub>3</sub>)CH<sub>2</sub>OH, -SO<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>, -SO<sub>2</sub>NH(CH<sub>2</sub>CH(OH)CH<sub>3</sub>), -SO<sub>2</sub>
pyrrolidine, -SO<sub>2</sub>-(2,6-dimethylpiperidine), -SO<sub>2</sub>-(2-propylpiperidine), -SO<sub>2</sub>-(hydroxypropyl), -C(0)-(2-

```
methoxymethylpyrrolidine), -C(0)-(2-methylpyrrolidine),
          -C(0)-(2,6-dimethylpyrrolidine),-C(0)-(2-
          hydroxymethylpyrrolidine), -C(O)N(methyl)(ethyl),
          -C(O)N(methyl)(propyl), -C(O)N(methyl)(butyl),
          -C(O)N(propyl)(butyl), -C(O)N(allyl)(cyclopentyl),
5
          -C(O)N(allyl)(cyclohexyl), -C(O)N(methyl)(methyl),
          -C(O)N(ethyl)(ethyl), -C(O)N(butyl)(butyl),
          -C(O)N(isopropyl)(isopropyl), -C(O)N(propyl)(propyl),
          -C(0)N(methyl)(cyclohexyl), -C(0)N(ethyl)(cyclohexyl),
          -C(O)NH(cyclobutyl), -C(O)NH(cyclopentyl),
10
          -C(0)N(CH_3) (cyclopentyl), -C(0)NH(2-methylcyclohexyl),
          -C(O)NH(pentyl), -C(O)N(pentyl)(pentyl),
          -C(O)NH(isopentyl), -C(O)NH(ethoxyethyl),
          -C(O)N(CH<sub>3</sub>) (methoxyethyl), -C(O)N(propyl) (methoxyethyl),
          -C(O)N(methoxyethyl)(methoxyethyl),
15
          -C(O)N(ethoxyethyl)(ethoxyethyl),
          -C(O)N(ethyl)(methoxyethyl), -C(O)N(propyl)(hydroxyethyl),
          -C(O)N(hydroxyethyl)(ethyl), ethynyl, methyl, bromo,
          -N(CH_3)SO_2(CH_3), -N(CH_3)SO_2-thienyl, -
20
          N(hydroxypropy1)SO_2CH_3, -(CH_2)-SO_2-(CH_3), or -C(O)-
          CH (CH<sub>3</sub>) CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>.
```

48. A compound of the formula wherein

$$R_{60} \xrightarrow{X_{10}} \stackrel{H}{\underset{N}{\bigvee}} \stackrel{QH}{\underset{N}{\bigvee}} \stackrel{R_{42}}{\underset{N}{\bigvee}} R_{40}$$

R<sub>35</sub> is phenyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, -S-phenyl, benzodioxole,

thienyl, C<sub>1</sub>-C<sub>6</sub> alkyl, furanyl, each of which is
unsubstituted or substituted with 1, 2, 3, 4, or 5 groups
that are independently C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, OH,

hydroxy  $C_1$ - $C_6$  alkyl, halogen, halo  $C_1$ - $C_6$  alkyl, halo  $C_1$ - $C_6$  alkoxy, -0-( $C_1$ - $C_6$  alkyl)-phenyl, - $CO_2$ -( $C_1$ - $C_6$  alkyl), -( $C_1$ - $C_4$  alkyl)-( $C_5$ - $C_6$  cycloalkyl);

R<sub>40</sub> is phenyl, -phenyl-pyridine, biphenyl, -phenyl
benzothienyl, -phenyl-thienyl, -phenyl-furanyl, -phenyl
pyrimidinyl, -phenyl-isooxazolyl, -C(0)-pyridyl, -(C<sub>1</sub>-C<sub>4</sub>

alkyl)-O-C(0)NH-phenyl, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-O-C(0)N(C<sub>1</sub>-C<sub>6</sub>

alkyl)-phenyl, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-phenyl, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-SO<sub>2</sub>NH<sub>2</sub>,

-(C<sub>1</sub>-C<sub>4</sub> alkyl)-SO<sub>2</sub>NH(C<sub>1</sub>-C<sub>6</sub> alkyl), -(C<sub>1</sub>-C<sub>4</sub> alkyl)-SO<sub>2</sub>N(C<sub>1</sub>-C<sub>6</sub>

alkyl)(C<sub>1</sub>-C<sub>6</sub> alkyl), CN, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-(C<sub>3</sub>-C<sub>7</sub> cycloalkyl),

-(C<sub>1</sub>-C<sub>4</sub> alkyl)-C(0)O-(C<sub>1</sub>-C<sub>4</sub> alkyl, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-R<sub>33</sub>, C<sub>1</sub>-C<sub>8</sub>

alkyl, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-NHC(0)-(C<sub>1</sub>-C<sub>4</sub> alkyl), -C(0)NH<sub>2</sub>,

wherein each of the above rings is unsubstituted or

substituted with 1, 2, 3, 4, or 5 groups that are

independently halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, halo (C<sub>1</sub>-C<sub>4</sub> alkyl), -0-(C<sub>1</sub>-C<sub>4</sub> alkyl)-phenyl wherein the phenyl is optionally substituted with 1 or 2 halogens, -CHO, -NHSO<sub>2</sub>-(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(C<sub>1</sub>-C<sub>4</sub> alkyl)SO<sub>2</sub>-(C<sub>1</sub>-C<sub>4</sub> alkyl) wherein the alkyl is optionally substituted with 1, 2, or 3 halogens,

20  $R_{42}$  is H,  $C_1$ - $C_6$  alkyl, benzyl, -NHC(O)-( $C_1$ - $C_6$  alkyl), or -NHC(O)-phenyl wherein the phenyl is optionally substituted with 1 or 2 alkyl groups;

 $R_{52}$  is H, phenyl,  $-NHC(O)-(C_1-C_6 \ alkyl)-(C_1-C_6 \ thioalkoxy)$ ,  $-N(C_1-C_6 \ alkyl)C(O)-(C_1-C_6 \ alkyl)-(C_1-C_6 \ thioalkoxy)$ , OH,  $C_1-C_6 \ alkyl$ , mono or  $di(C_1-C_6 \ alkyl)$ amino,  $-NHC(O)-(C_1-C_6 \ alkyl)$  wherein the alkyl group is optionally substituted with a phenyl,  $-N(C_1-C_6 \ alkyl)C(O)-(C_1-C_6 \ alkyl)$  wherein the alkyl groups are each optionally substituted with a phenyl,  $-(CH_2)_{O-4}-SO_2-(C_1-C_{10} \ alkyl)$ ,  $-NHCO_2$ -benzyl, or  $-NH_2$ , and

 $R_{60}$  is -L-V- $R_{65}$ ,  $C_1$ - $C_8$  alkyl, or hydroxy  $C_1$ - $C_8$  alkyl, wherein the alkyl or hydroxyalkyl groups are optionally substituted with 1 or 2 L-V- $R_{65}$  groups, wherein

```
L is absent, -C(0)-, -CO_2-, -C(0)NH-, -C(0)N(C_1-C_6 alky1)-,
                 -NHC(O) -, -N(C_1-C_6 \text{ alkyl}) - C(O) -, -(CH_2)_{0-4} - SO_2 - (CH_2)_{0-4} -
                 (CH_2)_{0-4}-O-(CH_2)_{0-4}-, -(CH_2)_{0-4}-S-(CH_2)_{0-4}-, -NHC(O)NH-
                 , -N(C_1-C_6 \text{ alkyl})C(0)NH-, -N(C_1-C_6 \text{ alkyl})C(0)N(C_1-C_6)
                 alkyl)-, -NHC(O)N(C<sub>1</sub>-C<sub>6</sub> alkyl)-, -NH-, -N(benzyl)-, -
 5
                 N(phenyl) - , -(CH<sub>2</sub>)<sub>0-4</sub> - NHSO<sub>2</sub> - (CH<sub>2</sub>)<sub>0-4</sub> - , -N(C<sub>1</sub> - C<sub>6</sub>
                 alkyl)SO_2-, -SO_2NH-, -SO_2N(C_1-C_6 alkyl)-, or
           V is absent, -(CH_2)_{0-4}-C(O)NH_{-}, -(CH_2)_{0-4}-C(O)N(C_1-C_6 \text{ alkyl})-C_6
                 , cyclopropyl optionally substituted with 1 or 2 C_{1}-
                 C<sub>4</sub> alkyl groups, =NH, =NOH, =N-alkoxy, C<sub>3</sub>-C<sub>8</sub> alkyl
10
                 optionally substituted with 1 or 2 OH, or
                 -CH(phenyl) - wherein the phenyl is optionally
                 substituted with 1, 2, 3, 4, or 5 groups that are
                 halogen or OH;
           R_{65} is cyclohexyl; cyclopentyl; phenyl; -(C_1-C_6 \text{ alkyl})-
15
                 phenyl; NH_2; mono or di(C_1-C_{10} alkyl) amino wherein the
                 alkyl group or groups are optionally substituted with
                 1 or 2 groups that are independently cyclopropyl,
                 phenyl or OH; oxadiazolyl; triazolopyrimidinyl;
20
                 triazolyl; thiadiazolyl; 3H-quinazolin-2-onyl;
                 pyrimidinyl; pyridyl; pyridyl N-oxide; -(C1-C6
                 alkyl)-pyridyl; piperazinyl; phthalazinyl;
                  tetrahydro-thiophenyl 1,1-dioxide; tetrazolyl; C3-C6
                  cycloalkyl-C_1-C_6 alkyl; -(C_1-C_4 alkyl)-SO_2-(C_1-C_4
25
                  alkyl)-; benzothiazole; hexahydro-isoindole-1,3-
                  dionyl; benzimidazolyl; benzoxazolyl;
                  [1,2,4]triazolo[1,5-a]pyrimidinyl; thiazolyl;
                  thiadiazolyl; imidazo[1,2-a]pyridine; C<sub>1</sub>-C<sub>6</sub> alkyl; 3-
                  aza-bicyclo[3.2.2]nonane; pyrrolidinonyl; diazepanyl;
                  benzo[1,2,5]thiadiazolyl; -NHSO<sub>2</sub>-(4-methylphenyl);
30
                  [1,2,4]triazolo[4,3-b]pyridazinyl,
                  benzopyrrolidinonyl; morpholinyl; thiomorpholinyl;
                  thiomorpholinyl S-oxide; thiomorpholinyl S,S-dioxide;
                  2,3-dihydro-benzo[b]thiophene 1,1-dioxide;
```

pyrrolidinyl; [1,2,4]oxadiazole; C<sub>1</sub>-C<sub>10</sub> alkyl; isoxazolyl; 2,3-dihydro-1H-indolyl; quinazolinonyl, quinazolinyl, piperidyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, -O-(C<sub>1</sub>-C<sub>6</sub> alkyl)-phenyl, or  $C_2$ - $C_6$  alkynyl; 5 wherein each of the above is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently C<sub>1</sub>-C<sub>6</sub> alkyl, CF<sub>3</sub>, halogen, phenyl, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-phenyl, -C(0)phenyl, pyrrolidinedione,  $C_1-C_6$  alkoxy, -C(0)-furan,  $-C(0)NH_2$ , -10  $C(0)NH(C_1-C_6 \text{ alkyl})$ ,  $-C(0)N(C_1-C_6 \text{ alkyl})(C_1-C_6)$ alkyl), cyclopropyl,  $-(CH_2)_{0-4}$ -cyclopentyl, benzoxazolyl, pyridine,  $-NHC(0)-(C_1-C_6 \text{ alkyl})$ ,  $-N(C_1-C_6 \text{ alkyl})C(0)-(C_1-C_6 \text{ alkyl}), -C(0)C_1-C_6$ alkyl,  $-CO_2H$ ,  $-NHSO_2-(C_1-C_8 \text{ alkyl})$ ,  $-N(C_1-C_6)$ 

### 49. A compound of the formula wherein

15

 $alkyl)SO_2-(C_1-C_8 alkyl)$ ,  $-CO_2-(C_1-C_6 alkyl)$ .

or a pharmaceutically acceptable salt thereof, wherein  $X_{10}$  is -O-, -S-, -NH-, -N(C<sub>1</sub>-C<sub>6</sub> alkyl);  $R_{35}$  is phenyl,  $C_3$ -C<sub>8</sub> cycloalkyl, -S-phenyl, benzodioxole, thienyl,  $C_1$ -C<sub>6</sub> alkyl, furanyl, each of which is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently  $C_1$ -C<sub>4</sub> alkyl,  $C_1$ -C<sub>4</sub> alkoxy, OH, hydroxy  $C_1$ -C<sub>6</sub> alkyl, halogen, halo  $C_1$ -C<sub>6</sub> alkyl, halo  $C_1$ -C<sub>6</sub> alkyl)-phenyl, -CO<sub>2</sub>-( $C_1$ -C<sub>6</sub> alkyl), -( $C_1$ -C<sub>4</sub> alkyl)-( $C_5$ -C<sub>6</sub> cycloalkyl);

R<sub>40</sub> is phenyl, -phenyl-pyridine, biphenyl, -phenyl
benzothienyl, -phenyl-thienyl, -phenyl-furanyl, -phenyl
pyrimidinyl, -phenyl-isooxazolyl, -C(0)-pyridyl, -(C<sub>1</sub>-C<sub>4</sub>

alkyl)-O-C(0)NH-phenyl, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-O-C(0)N(C<sub>1</sub>-C<sub>6</sub>

alkyl)-phenyl,  $-(C_1-C_4 \text{ alkyl})$ -phenyl,  $-(C_1-C_4 \text{ alkyl})-SO_2NH_2$ ,  $-(C_1-C_4 \text{ alkyl})-SO_2NH(C_1-C_6 \text{ alkyl}), -(C_1-C_4 \text{ alkyl})-SO_2N(C_1-C_6)$ alkyl)  $(C_1-C_6 \text{ alkyl})$ , CN,  $-(C_1-C_4 \text{ alkyl})-(C_3-C_7 \text{ cycloalkyl})$ ,  $-(C_1-C_4 \text{ alkyl})-C(0)O-(C_1-C_4 \text{ alkyl}, -(C_1-C_4 \text{ alkyl})-R_{33}, C_1-C_8)$ alkyl,  $-(C_1-C_4 \text{ alkyl}) - \text{NHC}(O) - (C_1-C_4 \text{ alkyl}), -C(O) \text{NH}_2$ , 5 wherein each of the above rings is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently halogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, halo ( $C_1$ - $C_4$  alkyl),  $-O-(C_1-C_4$  alkyl)-phenyl wherein the phenyl is optionally substituted with 1 or 2 halogens, -CHO, -NHSO2-10  $(C_1-C_4 \text{ alkyl})$ ,  $-N(C_1-C_4 \text{ alkyl})SO_2-(C_1-C_4 \text{ alkyl})$  wherein the alkyl is optionally substituted with 1, 2, or 3 halogens,  $R_{42}$  is H,  $C_1$ - $C_6$  alkyl, benzyl, -NHC(0)-( $C_1$ - $C_6$  alkyl), or -NHC(0)phenyl wherein the phenyl is optionally substituted with 1 or 2 alkyl groups; 15

R<sub>52</sub> is H, phenyl,  $-NHC(O)-(C_1-C_6 \ alkyl)-(C_1-C_6 \ thioalkoxy)$ ,  $-N(C_1-C_6 \ alkyl)C(O)-(C_1-C_6 \ alkyl)-(C_1-C_6 \ thioalkoxy)$ , OH, C<sub>1</sub>-C<sub>6</sub> alkyl, mono or di(C<sub>1</sub>-C<sub>6</sub> alkyl)amino,  $-NHC(O)-(C_1-C_6 \ alkyl)$  wherein the alkyl group is optionally substituted with a phenyl,  $-N(C_1-C_6 \ alkyl)C(O)-(C_1-C_6 \ alkyl)$  wherein the alkyl groups are each optionally substituted with a phenyl,  $-(CH_2)_{O-4}-SO_2-(C_1-C_{10} \ alkyl)$ ,  $-NHCO_2$ -benzyl, or  $-NH_2$ , and

20

 $R_{60}$  is -L-V- $R_{65}$ ,  $C_1$ - $C_8$  alkyl, or hydroxy  $C_1$ - $C_8$  alkyl, wherein the alkyl or hydroxyalkyl groups are optionally substituted with 1 or 2 L-V- $R_{65}$  groups, wherein

L is absent, -C(0)-,  $-CO_2$ -, -C(0)NH-,  $-C(0)N(C_1$ - $C_6$  alkyl)-, -NHC(0)-,  $-N(C_1$ - $C_6$  alkyl)-C(0)-,  $-(CH_2)_{0-4}$ - $SO_2$ - $(CH_2)_{0-4}$ -,  $-(CH_2)_{0-4}$ -O- $(CH_2)_{0-4}$ -,  $-(CH_2)_{0-4}$ -S- $(CH_2)_{0-4}$ -, -NHC(0)NH-,  $-N(C_1$ - $C_6$  alkyl)C(0)NH-,  $-N(C_1$ - $C_6$  alkyl) $C(0)N(C_1$ - $C_6$  alkyl)-, -NH-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N(benzyl)-, -N

V is absent,  $-(CH_2)_{0-4}-C(O)NH_{-}$ ,  $-(CH_2)_{0-4}-C(O)N(C_1-C_6 \text{ alkyl})$ 

```
, cyclopropyl optionally substituted with 1 or 2 C1-
               C<sub>4</sub> alkyl groups, =NH, =NOH, =N-alkoxy, C<sub>3</sub>-C<sub>8</sub> alkyl
               optionally substituted with 1 or 2 OH, or
 5
               -CH(phenyl) - wherein the phenyl is optionally
               substituted with 1, 2, 3, 4, or 5 groups that are
               halogen or OH;
          R_{65} is cyclohexyl; cyclopentyl; phenyl; -(C_1-C_6 \text{ alkyl}) -
               phenyl; NH_2; mono or di (C_1-C_{10} \text{ alkyl}) amino wherein the
10
               alkyl group or groups are optionally substituted with
               1 or 2 groups that are independently cyclopropyl,
               phenyl or OH; oxadiazolyl; triazolopyrimidinyl;
               triazolyl; thiadiazolyl; 3H-quinazolin-2-onyl;
               pyrimidinyl; pyridyl; pyridyl N-oxide; -(C1-C6
15
               alkyl)-pyridyl; piperazinyl; phthalazinyl;
               tetrahydro-thiophenyl 1,1-dioxide; tetrazolyl; C3-C6
               cycloalkyl-C_1-C_6 alkyl; -(C_1-C_4 alkyl)-SO_2-(C_1-C_4
               alkyl)-; benzothiazole; hexahydro-isoindole-1,3-
               dionyl; benzimidazolyl; benzoxazolyl;
20
               [1,2,4]triazolo[1,5-a]pyrimidinyl; thiazolyl;
               thiadiazolyl; imidazo[1,2-a]pyridine; C<sub>1</sub>-C<sub>6</sub> alkyl; 3-
               aza-bicyclo[3.2.2] nonane; pyrrolidinonyl; diazepanyl;
               benzo[1,2,5]thiadiazolyl; -NHSO_2-(4-methylphenyl);
               [1,2,4]triazolo[4,3-b]pyridazinyl,
25
               benzopyrrolidinonyl; morpholinyl; thiomorpholinyl;
               thiomorpholinyl S-oxide; thiomorpholinyl S,S-dioxide;
               2,3-dihydro-benzo[b]thiophene 1,1-dioxide;
               pyrrolidinyl; [1,2,4] oxadiazole; C_1-C_{10} alkyl;
               isoxazolyl; 2,3-dihydro-1H-indolyl; quinazolinonyl,
30
               quinazolinyl, piperidyl, wherein each of the above is
               optionally substituted with 1, 2, 3, 4, or 5 groups
               that are independently
               C_1-C_6 alkyl, CF_3, halogen, phenyl, -(C_1-C_4 alkyl)-
                     phenyl, -C(0)phenyl, pyrrolidine-dione, C1-C6
```

alkoxy, -C(0)-furan,  $-C(0)NH_2$ ,  $-C(0)NH(C_1-C_6$  alkyl),  $-C(0)N(C_1-C_6$  alkyl)( $C_1-C_6$  alkyl), cyclopropyl,  $-(CH_2)_{0-4}$ -cyclopentyl, benzoxazolyl, pyridine,  $-NHC(0)-(C_1-C_6$  alkyl),  $-N(C_1-C_6$  alkyl) $C(0)-(C_1-C_6$  alkyl),  $-C(0)C_1-C_6$  alkyl,  $-CO_2H$ ,  $-NHSO_2-(C_1-C_8$  alkyl),  $-N(C_1-C_6$  alkyl)SO<sub>2</sub>-( $C_1-C_8$  alkyl).

# 50. A compound of the formula

H OH R<sub>42</sub> N R<sub>41a</sub> O<sub>2</sub> R<sub>35</sub> R<sub>41</sub> R<sub>40</sub>

10

5

or a pharmaceutically acceptable salt thereof, wherein  $R_{30}$  is selected from the group consisting of phenyl, pyrazolopyrimidinyl, oxa-aza-benzoazulenyl, isoxazolyl, triazolopyridinyl, pyrrolidinonyl, tetrahydrothia-azafluorenyl, pyridyl, piperidinyl, 15 dihydrocyclopentaguinolinyl, furyl, naphthothienyl, phthalazinonyl, thiadiazolyl, thienopyrimidinonyl, oxadiaza-cyclopentanaphthalenyl, dihydrobenzodioxepinyl, chromanonyl, chromenonyl, oxazolidinyl, benzophenone, pyrazinyl mono N-oxide, benzofuranyl, pyrazolyl, 20 -isoxazolyl-phenyl, phenyl-triazolyl, benzimidazolyl, indolyl, phenyl-pyrrolyl, chromanyl, isoquinolinyl, thienyl-thienyl, benzothienyl, -phenyl-thiadiazolyl, chromanonyl, quinolinyl, -pyrrolyl-C(0)-phenyl, -phenyl-O-25 phenyl, -phenyl-oxazolyl, -pyrrolidinonyl-phenyl, -phenylpyrimidinyl, -phenyl-oxadiazolyl, bicyclo[2.2.1]heptenyl, cyclopentyl, thieno[2,3-b]thiophene, cyclohexyl, -phenylimidazolyl, benzoxazole; dihydro-1H-indolyl; 2,3-dihydrobenzo[b]thiophene 1,1-dioxide; benzo[b]thiophene 1,1-30 dioxide; 2,3-dihydro-benzo[d]isothiazole 1,1-dioxide; phenyl-thiazolyl; -phenyl-pyrazolyl, -phenyl-C(0)piperidyl, -phenyl-C(O)-pyrrolidinyl, -phenyl-isoxazolyl,

isoindolyl, purinyl, oxaxolyl, thiazolyl, pyridazinonyl, thiazolyl, pyranyl, dihydropyranopyridinyl, diazepanyl, cyclopropyl, dihydronaphthoisoxazolyl, benzoindazole, dihydrocyclopentachromenonyl, imidazopyrazolyl, 5 . tetrahydrocyclopentachromenonyl, dihydroquinolinonyl, pyridyl N-oxide, isochromanyl, quinazolinonyl, pyrazolopyridinyl, dihydrobenzothiophene dioxide, dihydrofurobenzoisoxazolyl, dihydropyrimidine dionyl, thienopyrazolyl, oxazolyl, tetrahydrocyclopentapyrazolyl, 10 dihydronaphthalenonyl, dihydrobenzofuranonyl, dihydrocyclopentathienyl, tetrahydrocyclopentapyrazolyl, tetrahydropyrazoloazepinyl, indazolyl, tetrahydrocycloheptaisoxazolyl, tetrahydroindolonyl, pyrrolidinyl, thienopyridinyl, dioxodihydrobenzoisothiazolonyl, triazolopyrimidinyl, 15 thienyl, dihydrothienopyrimidinonyl, and benzooxadiazolyl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently selected from the group consisting of 20  $C_1-C_{10}$  alkyl optionally substituted with 1 phenyl or 1 CN; OH, hydroxy  $C_1$ - $C_{10}$  alkyl optionally substituted with phenyl or  $(C_1-C_4 \text{ alkyl})$  phenyl,  $C_1-C_6 \text{ alkoxy optionally}$ substituted with 1 or 2 groups that are independently hydroxy or phenyl; haloalkyl, haloalkoxy, (CH2)0-25  $_{4}C(0)NR_{31}R_{32}$ ,  $_{-NR_{31}-SO_{2}-(C_{1}-C_{6} \text{ alkyl})}$  wherein the alkyl group is optionally substituted with 1, 2, or 3 groups that are independently halogen or R<sub>33</sub>, -SO<sub>2</sub>- $NH(C_1-C_6 \text{ alkyl})$  wherein the alkyl group is optionally substituted with 1 or 2 groups that are independently 30 halogen, OH, alkoxy, or  $R_{33}$ ;  $-(C_1-C_6 \text{ alkyl})-SO_2-(C_1-C_6)$ alkyl) wherein the alkyl group is optionally substituted with 1 or 2 groups that are independently halogen, OH,  $C_1-C_4$  alkoxy, or  $R_{33}$ ;  $-SO_2-(C_1-C_6$  alkyl) wherein the alkyl group is optionally substituted

with 1 or 2 groups that are independently OH or  $C_1\text{-}C_4$ alkoxy,  $-SO_2-N(C_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl})$  wherein each alkyl group is optionally substituted with 1 or 2 groups that are independently halogen, OH or R33;  $-SO_2-NH(C_1-C_6 \text{ alkyl})-phenyl wherein the phenyl is$ 5 optionally substituted with 1 or 2 groups that are independently  $C_1$ - $C_4$  alkoxy or halogen, -0-( $C_1$ - $C_6$ alkyl)-phenyl,  $-(C_1-C_6 \text{ alkyl})-O-phenyl, -(C_1-C_6)$ alkyl)-0-( $C_1$ - $C_6$  alkyl)-phenyl, triazolidine-3,5dione, halogen,  $-NHC(O)NH_2$ ,  $-NHC(O)NH(C_1-C_6 alkyl)$ , 10  $-NHC(O)N(C_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl}), -N(C_1-C_6)$  $alkyl)C(0)NH_2$ ,  $-N(C_1-C_6 alkyl)C(0)NH(C_1-C_6 alkyl)$ ,  $-N(C_1-C_6 \text{ alkyl})C(O)N(C_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl}), -(C_1-C_6)$ alkyl) thienyl,  $-(C_1-C_6 \text{ alkyl})$  furanyl,  $-S-(C_1-C_6 \text{ alkyl})$ alkyl) phenyl,  $-SO_2NR_{31}R_{32}$ ,  $-C(O)-NR_{31}R_{32}$ ,  $-NR_{31}R_{32}$ , 15 dithiane,  $-NHC(S)NH_2$ ,  $-NHC(S)NH(C_1-C_6 alkyl)$ , -NHC(S)N( $C_1$ - $C_6$  alkyl) ( $C_1$ - $C_6$  alkyl), - $CO_2$ ( $C_1$ - $C_6$  alkyl), tetrahydropyran, phenyl optionally substituted with 1 or 2 groups that are independently F, Cl or Br; pyridine,  $-C_2-C_4$  alkynyl-phenyl,  $-O-C_3-C_8$  cycloalkyl, 20 -O-(C<sub>1</sub>-C<sub>6</sub> alkyl)-R<sub>33</sub>; pyrrole optionally substituted with one or two methyl groups; 2,3-dihydrobenzofuran; benzo[1,2,5]oxadiazole,  $-C(0)-(C_1-C_{10})$ alkyl) wherein the alkyl group is optionally substituted with  $NH_2$ ,  $N(C_1-C_6 \text{ alkyl})$ , or  $N(C_1-C_6$ 25 alkyl)( $C_1$ - $C_6$  alkyl); -C(O)NH-phenyl, -C(O)N( $C_1$ - $C_6$ alkyl)-phenyl, 4,4-dimethyl-4,5-dihydro-oxazole, - $(C_1-C_6 \text{ alkyl})-S-pyridine, -(C_1-C_6 \text{ alkyl})-SO_2-pyridine,$  $-(C_1-C_6 \text{ thioalkoxy})$ -pyridine, thiazole optionally substituted with 1 or 2 methyl groups, pyrazole, S-30  $(C_1-C_6 \text{ alkyl})$ , indole,  $(C_1-C_6 \text{ thioalkoxy})-(C_1-C_6 \text{ thioalkoxy})$ alkyl),  $C_2-C_8$  alkynyl,  $-CO_2-(C_1-C_6$  alkyl),  $C_1-C_{10}$ alkanoyl;  $-(CH_2)_{0-4}-SO_2-(C_1-C_{10} \text{ alkyl})$  wherein the alkyl group is optionally substituted with OH;

wherein R<sub>31</sub> and R<sub>32</sub> at each occurrence are independently selected from the group consisting of hydrogen, C1-C8 alkyl, C2-C8 alkenyl, hydroxy C1-C6 alkyl, C1-C6 haloalkyl,  $C_1$ - $C_6$  alkoxy  $C_1$ - $C_6$  alkyl,  $-(CH_2)_{0-4}$ - $SO_2$ - $(C_1$ -5 C<sub>6</sub> alkyl) wherein the alkyl is optionally substituted with 1, 2, 3 or 4 independently selected halogen atoms;  $-(CH_2)_{0-4}-SO_2-imidazolyl$ ,  $-(C_1-C_6 alkyl) C(0)NH_2$ ,  $-(C_1-C_6 \text{ alkyl})-C(0)NH(C_1-C_6 \text{ alkyl})$ ,  $-(C_1-C_6)$  $alky1) - C(0)N(C_1 - C_6 \ alky1) (C_1 - C_6 \ alky1), - (C_1 - C_6 \ alky1) - C_1 - C_2 - C_3 - C_4 - C_4 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5 - C_5$ 10  $NH_2$ ,  $-(C_1-C_6 \text{ alkyl})-NH(C_1-C_6 \text{ alkyl})$ ,  $-(C_1-C_6 \text{ alkyl}) N(C_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl}), -(C_1-C_6 \text{ alkyl})$ phenyl,  $-(C_1-C_6 \text{ alkyl})$ pyridyl, -C(0) furanyl,  $(C_1-C_6 \text{ alkyl})$ tetrahydrofuran, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,  $-CO_2-(C_1-C_6 \text{ alkyl})$ ,  $-(C_1-C_6 \text{ alkyl})$ , alkyl)-furanyl,  $-(CH_2)_{0-4}-SO_2$ -thienyl, wherein 15 the phenyl and pyridyl groups are unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently C1-C4 alkyl, hydroxy, C1-C4 alkoxy, halogen, or 20  $R_{31}$ ,  $R_{32}$  and the nitrogen to which they are attached form a 5, 6, or 7 membered heterocycloalkyl or a 6 membered heteroaryl ring, each of which is optionally fused to a benzene, pyridine or pyrimidine ring and each of which is optionally substituted with C1-C6 alkoxy, 25 hydroxy, hydroxy  $C_1-C_6$  alkyl,  $C_1-C_4$  alkoxy  $C_1-C_6$  alkyl,  $-C(0)NH_2$ ,  $-C(0)NH-(C_1-C_6 alkyl)-phenyl$ ;

 $R_{33}$  at each occurrence is independently, H,  $NH_2$ ,  $NH(C_1-C_6$  alkyl),  $N(C_1-C_6$  alkyl)( $C_1-C_6$  alkyl),  $N(C_1-C_6$  alkyl)(phenyl),  $N(C_1-C_6$  alkyl)(benzyl);

30 R<sub>35</sub> is phenyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, -S-phenyl, benzodioxole, thienyl, C<sub>1</sub>-C<sub>6</sub> alkyl, furanyl, imidazolyl, each of which is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, OH, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, halogen, halo C<sub>1</sub>-C<sub>6</sub> alkyl, halo

 $C_1-C_6$  alkoxy,  $-O-(C_1-C_6$  alkyl)-phenyl,  $-CO_2-(C_1-C_6$  alkyl),  $-CO_2-(C_1-C_6)$  $(C_1-C_4 \text{ alkyl})-(C_5-C_6 \text{ cycloalkyl})$ , or  $(CH_2)_{0-4}CN$ ; R<sub>40</sub> is phenyl, -phenyl-pyridyl, biphenyl, -phenyl-benzothienyl, -phenyl-thienyl, -phenyl-furanyl, -phenyl-pyrimidinyl, phenyl-isoxazolyl, -C(0)-pyridyl, -(C1-C4 alkyl)-O-C(0)NH-5 phenyl wherein the phenyl is optionally substituted with 1, 2, or 3 halogen atoms;  $-(C_1-C_4 \text{ alkyl})-O-C(O)N(C_1-C_6)$ alkyl)-phenyl,  $-(C_1-C_6 \ alkyl)-phenyl$ ,  $-(C_1-C_4 \ alkyl)-SO_2NH_2$ ,  $-(C_1-C_4 \text{ alkyl})-SO_2NH(C_1-C_6 \text{ alkyl}), -(C_1-C_4 \text{ alkyl})-SO_2N(C_1-C_6 \text{ alkyl})$ alkyl)( $C_1$ - $C_6$  alkyl), -SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NH( $C_1$ - $C_6$  alkyl), -SO<sub>2</sub>N( $C_1$ -10  $C_6$  alkyl) ( $C_1$ - $C_6$  alkyl), CN, -( $CH_2$ )<sub>0-4</sub>-( $C_3$ - $C_8$  cycloalkyl), - $(C_1-C_4 \text{ alkyl})-C(0)0-(C_1-C_4 \text{ alkyl}), -(C_1-C_4 \text{ alkyl})-R_{33}, C_1-C_{10}$ alkyl,  $C_2$ - $C_8$  alkenyl, -( $C_1$ - $C_4$  alkyl)-NHC(0)-( $C_1$ - $C_4$  alkyl), - $(CH_2)_{0-4}-C(O)NH_2$ ,  $-(CH_2)_{0-4}-C(O)NH(C_1-C_6 alkyl)$ ,  $-(CH_2)_{0-4}-C(CH_2)_{0-4}$  $C(0)N(C_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl}), \text{ naphthyl},$ 15 tetrahydronapthyl, dihydronaphthyl,  $-(CH_2)_{0-4}$ -imidazolyl, -(CH<sub>2</sub>)<sub>0-4</sub>-pyrrolidinyl, oxazolidinone 3,4-dihydrobenzo[e][1,2]oxathiine 2,2-dioxide, pyrimidinyl, 3,4dihydro-2H-benzo[e][1,2]thiazine 1,1-dioxide, pyridyl, or pyrimidyl, alkoxyalkyl, -phenyl-benzothienyl, -phenyl-20 cyclohexyl, -phenyl-cyclopentyl, -phenyl-(C<sub>1</sub>-C<sub>6</sub> alkyl)cyclopentyl, -phenyl- $(C_1-C_6 \text{ alkyl})$ -cyclohexyl, -phenyloxazolyl, furanyl, tetrahydrofuranyl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently halogen,  $C_1$ - $C_8$  alkyl 25 optionally substituted with 1 or two groups that are independently CN or OH;  $C_1-C_6$  alkoxy, halo  $(C_1-C_8$  alkyl), halo  $(C_1-C_4 \text{ alkoxy})$ ,  $-0-(C_1-C_4 \text{ alkyl})$ -phenyl wherein the phenyl is optionally substituted with 1 or 2 halogens, CN, -CHO,  $C_1$ - $C_4$  thioalkoxy, -NHSO<sub>2</sub>-( $C_1$ - $C_6$  alkyl), -N( $C_1$ - $C_4$ 30 alkyl)SO<sub>2</sub>-(C<sub>1</sub>-C<sub>4</sub> alkyl) wherein the alkyl groups are optionally substituted with 1, 2, or 3 halogens; OH; - $SO_2R_{33}$ ;  $R_{33}$ ;  $C_2-C_8$  alkynyl;  $C_2-C_8$  alkenyl; thioalkoxyalkyl; -

 $SO_2-(C_1-C_{10} \text{ alkyl})$ ;  $-NR_{31}R_{32}$ ;  $-C(0)-NR_{31}R_{32}$ ;  $-OC(0)R_{33}$ ;  $C_1-C_8$  alkanoyl;  $-(C_1-C_6 \text{ alkyl})-C(0)-(C_1-C_6 \text{ alkoxy})$ ;

- $R_{41a}$  and  $R_{41}$  are independently H, cyclohexyl, phenyl, or  $C_1$ - $C_6$  alkyl optionally substituted with 1 or 2 groups that are phenyl, hydroxy,  $C_1$ - $C_4$  thioalkoxy,  $C_1$ - $C_4$  thioalkoxy  $C_1$ - $C_6$  alkyl; or  $-C_1$ - $C_6$  alkyl- $SO_2$ - $C_1$ - $C_6$  alkyl;
- $R_{40}$ ,  $R_{41}$ , and the atom to which they are attached form a  $C_3$ - $C_8$  cycloalkyl ring which is optionally substituted with  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, halogen,  $-CO_2NH_2$ ,  $-CO_2NH(C_1$ - $C_6$  alkyl),  $-CO_2N(C_1$ - $C_6$  alkyl)( $C_1$ - $C_6$  alkyl), thiazolyl optionally substituted with  $C_1$ - $C_6$  alkyl, isoxazolyl optionally substituted with  $C_1$ - $C_6$  alkyl, or phenyl which is optionally substituted with 1, 2, or 3 groups that are
- 15 and

5

. 10

 $R_{42}$  is H,  $C_1$ - $C_6$  alkyl optionally substituted with OH; benzyl; - NHC(O)-( $C_1$ - $C_6$  alkyl); -NHC(O)-phenyl wherein the phenyl is optionally substituted with 1 or 2 alkyl groups.

independently halogen or C<sub>1</sub>-C<sub>6</sub> alkyl;

20 A compound according to claim 50 wherein R<sub>30</sub> is selected from the group consisting of pyrazolopyrimidinyl, oxa-aza-benzoazulenyl, isoxazolyl, triazolopyridinyl, pyrrolidinonyl, tetrahydrothia-azafluorenyl, pyridyl, piperidinyl, thiazolyl, thiadiazolyl 25 or thienyl, each of which is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently  $C_1-C_4$  alkyl,  $-C(0)N(C_1-C_6$  alkyl)( $C_1-C_6$  alkyl),  $-C(0)NH_2$ ,  $-C(0)N(C_2-C_6 \text{ alkenyl})(C_3-C_8 \text{ cycloalkyl}), -C(0)NH(C_3-C_8)$ cycloalkyl),  $-C(0)NH(C_1-C_6 \text{ alkyl})$ , C(0)-(pyrrolidine)30 optionally substituted with 1 or two groups that are independently alkoxyalkyl or hydroxy, halogen, - $C(0)N(C_1-C_6 \text{ hydroxyalkyl})(C_1-C_6 \text{ alkyl}), -$ C(0)NH(alkoxyalkyl), -C(0)N(alkoxyalkyl)(alkoxyalkyl), -C(0)N(C<sub>1</sub>-C<sub>6</sub> alkyl)

(alkoxyalkyl),  $-C(0)N(C_1-C_6 \text{ hydroxyalkyl})$  (alkyl),  $-NHSO_2CF_3$ ,  $-N(C_1-C_6 \text{ alkyl})-SO_2-thienyl$ ,  $-N(C_1-C_6 \text{ alkyl})$ hydroxyalkyl) $SO_2-(C_1-C_6 \text{ alkyl})$ ,  $-NHC(0)C_1-C_4 \text{ alkyl}$ , oxazolyl optionally substituted with 1 or 2 methyl groups, thiazolyl optionally substituted with 1 or 2 methyl groups, pyrazolyl optionally substituted with 1 or 2 methyl groups, imidazolyl optionally substituted with 1 or 2 methyl groups, isoxazolyl optionally substituted with 1 or 2 methyl groups, pyrimidinyl optionally substituted with 1 or 2 methyl or halogen groups, -NHSO<sub>2</sub>CH<sub>3</sub>, -NHSO<sub>2</sub>-imidazolyl wherein the imidazole ring is optionally substituted with 1 or 2 methyl groups,  $-N(C_1-C_6 \text{ alkyl})SO_2(C_1-C_6)$ alkyl),  $-SO_2NH-C_1-C_6$  hydroxyalkyl,  $-SO_2NH-C_1-C_6$  alkyl- $NH(C_1-C_4 \text{ alkyl})$ ,  $-SO_2$ -piperazinyl optionally substituted with 1 or 2 methyl groups, -SO<sub>2</sub>pyrrolidine optionally substituted with 1 or 2 methyl groups, -SO<sub>2</sub>-piperidine optionally substituted with 1 or 2  $C_1-C_4$  alkyl groups,  $-SO_2N(C_1-C_4$  hydroxyalkyl)  $(C_1-C_4)$  $C_4$  hydroxyalkyl),  $-SO_2NH_2$ ,  $-SO_2N(C_1-C_6$  alkyl)( $C_1-C_6$ alkyl),  $C_2$ - $C_6$  alkynyl,  $-SO_2$ - $(C_1$ - $C_6$  hydroxyalkyl), - $SO_2NH(C_1-C_6 \text{ hydroxyalkyl}), -SO_2N(C_1-C_6 \text{ alkyl})(C_1-C_6)$ hydroxyalkyl),  $-(C_1-C_4 \text{ alkyl})-SO_2-(C_1-C_4 \text{ alkyl})$ , or - $C(0) - (C_1 - C_{10} \text{ alkyl})$ .

25

5

10

15

20

52. A compound according to claim 51 wherein

R<sub>30</sub> is pyridyl which is unsubstituted or substituted with at least one group which is -SO<sub>2</sub>NH-propyl-OH, -SO<sub>2</sub>NH-ethyl-OH, -SO<sub>2</sub>NH-ethyl-OH, -SO<sub>2</sub>NH-ethyl-OCH<sub>3</sub>, -SO<sub>2</sub>NH-CH(CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>OH, -SO<sub>2</sub>NH
(CH<sub>2</sub>CH(OH)CH<sub>3</sub>), -SO<sub>2</sub>NH-ethyl-NH(CH<sub>3</sub>), -SO<sub>2</sub>NH(-CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, -SO<sub>2</sub>NHCH(CH<sub>3</sub>)CH<sub>2</sub>OH, -SO<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>, -SO<sub>2</sub>NH(CH<sub>2</sub>CH(OH)CH<sub>3</sub>), -SO<sub>2</sub>-pyrrolidine, -SO<sub>2</sub>-(2,6-dimethylpiperidine), -SO<sub>2</sub>-(2-propylpiperidine), -SO<sub>2</sub>-(hydroxypropyl), -C(0)-(2-methylpyrrolidine),

```
-C(0)-(2,6-dimethylpyrrolidine),-C(0)-(2-dimethylpyrrolidine)
          hydroxymethylpyrrolidine), -C(O)N(methyl)(ethyl),
          -C(O)N(methyl)(propyl), -C(O)N(methyl)(butyl),
          -C(O)N(propyl)(butyl), -C(O)N(allyl)(cyclopentyl),
5
          -C(O)N(allyl)(cyclohexyl), -C(O)N(methyl)(methyl),
          -C(O)N(ethyl)(ethyl), -C(O)N(butyl)(butyl),
          -C(O)N(isopropyl)(isopropyl), -C(O)N(propyl)(propyl),
          -C(O)N(methyl)(cyclohexyl), -C(O)N(ethyl)(cyclohexyl),
          -C(O)NH(cyclobutyl), -C(O)NH(cyclopentyl),
          -C(O)N(CH<sub>3</sub>)(cyclopentyl), -C(O)NH(2-methylcyclohexyl),
10
          -C(O)NH(pentyl), -C(O)N(pentyl)(pentyl),
          -C(O)NH(isopentyl), -C(O)NH(ethoxyethyl),
          -C(O)N(CH<sub>3</sub>) (methoxyethyl), -C(O)N(propyl) (methoxyethyl),
          -C(O)N(methoxyethyl)(methoxyethyl),
          -C(O)N(ethoxyethyl)(ethoxyethyl),
15
          -C(O)N(ethyl)(methoxyethyl), -C(O)N(propyl)(hydroxyethyl),
          -C(0)N(hydroxyethyl)(ethyl), ethynyl, methyl, bromo,
          -N(CH_3)SO_2(CH_3), -N(CH_3)SO_2-thienyl, -
          N(hydroxypropyl)SO_2CH_3, -(CH_2)-SO_2-(CH_3), or -C(0)-
20
          CH (CH<sub>3</sub>) CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>.
```

## 53. A compound of the formula

or a pharmaceutically acceptable salt thereof, wherein

R<sub>30</sub> is selected from the group consisting of phenyl,

pyrazolopyrimidinyl, oxa-aza-benzoazulenyl, isoxazolyl,

triazolopyridinyl, pyrrolidinonyl, tetrahydrothia-aza
fluorenyl, pyridyl, piperidinyl,

dihydrocyclopentaquinolinyl, furyl, naphthothienyl,

phthalazinonyl, thiadiazolyl, thienopyrimidinonyl, oxa
diaza-cyclopentanaphthalenyl, dihydrobenzodioxepinyl,

chromanonyl, chromenonyl, oxazolidinyl, benzophenone,

pyrazinyl mono N-oxide, benzofuranyl, pyrazolyl, -isoxazolyl-phenyl, phenyl-triazolyl, benzimidazolyl, indolyl, phenyl-pyrrolyl, chromanyl, isoquinolinyl, thienyl-thienyl, benzothienyl, -phenyl-thiadiazolyl, 5 chromanonyl, quinolinyl, -pyrrolyl-C(0)-phenyl, -phenyl-Ophenyl, -phenyl-oxazolyl, -pyrrolidinonyl-phenyl, -phenylpyrimidinyl, -phenyl-oxadiazolyl, bicyclo[2.2.1]heptenyl, cyclopentyl, thieno[2,3-b]thiophene, cyclohexyl, -phenylimidazolyl, benzoxazole; dihydro-1H-indolyl; 2,3-dihydro-10 benzo[b]thiophene 1,1-dioxide; benzo[b]thiophene 1,1dioxide; 2,3-dihydro-benzo[d]isothiazole 1,1-dioxide; phenyl-thiazolyl; -phenyl-pyrazolyl, -phenyl-C(0)piperidyl, -phenyl-C(0)-pyrrolidinyl, -phenyl-isoxazolyl, isoindolyl, purinyl, oxaxolyl, thiazolyl, pyridazinonyl, 15 thiazolyl, pyranyl, dihydropyranopyridinyl, diazepanyl, cyclopropyl, dihydronaphthoisoxazolyl, benzoindazole, dihydrocyclopentachromenonyl, imidazopyrazolyl, tetrahydrocyclopentachromenonyl, dihydroquinolinonyl, pyridyl N-oxide, isochromanyl, quinazolinonyl, 20 pyrazolopyridinyl, dihydrobenzothiophene dioxide, dihydrofurobenzoisoxazolyl, dihydropyrimidine dionyl, thienopyrazolyl, oxazolyl, tetrahydrocyclopentapyrazolyl, dihydronaphthalenonyl, dihydrobenzofuranonyl, dihydrocyclopentathienyl, tetrahydrocyclopentapyrazolyl, 25 tetrahydropyrazoloazepinyl, indazolyl, tetrahydrocycloheptaisoxazolyl, tetrahydroindolonyl, pyrrolidinyl, thienopyridinyl, dioxodihydrobenzoisothiazolonyl, triazolopyrimidinyl, thienyl, dihydrothienopyrimidinonyl, and benzooxadiazolyl, 30 wherein each of the above is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently selected from the group consisting of  $C_1-C_{10}$  alkyl optionally substituted with 1 phenyl or 1 CN; OH, hydroxy  $C_1$ - $C_{10}$  alkyl optionally substituted with

5

10

15

20

25

30

phenyl or  $(C_1-C_4 \text{ alkyl})$  phenyl,  $C_1-C_6 \text{ alkoxy optionally}$ substituted with 1 or 2 groups that are independently hydroxy or phenyl; haloalkyl, haloalkoxy, (CH2)0- $_{4}C(0)NR_{31}R_{32}$ ,  $-NR_{31}-SO_{2}-(C_{1}-C_{6} \text{ alkyl})$  wherein the alkyl group is optionally substituted with 1, 2, or 3 groups that are independently halogen or R<sub>33</sub>, -SO<sub>2</sub>- $NH(C_1-C_6 \text{ alkyl})$  wherein the alkyl group is optionally substituted with 1 or 2 groups that are independently halogen, OH, alkoxy, or  $R_{33}$ ;  $-(C_1-C_6 \text{ alkyl})-SO_2-(C_1-C_6)$ alkyl) wherein the alkyl group is optionally substituted with 1 or 2 groups that are independently halogen, OH,  $C_1$ - $C_4$  alkoxy, or  $R_{33}$ ;  $-SO_2$ - $(C_1$ - $C_6$  alkyl) wherein the alkyl group is optionally substituted with 1 or 2 groups that are independently OH or C1-C4 alkoxy,-SO<sub>2</sub>-N( $C_1$ - $C_6$  alkyl)( $C_1$ - $C_6$  alkyl) wherein each alkyl group is optionally substituted with 1 or 2 groups that are independently halogen, OH or R33;  $-SO_2-NH(C_1-C_6 \text{ alkyl})$ -phenyl wherein the phenyl is optionally substituted with 1 or 2 groups that are independently  $C_1-C_4$  alkoxy or halogen,  $-0-(C_1-C_6)$ alkyl)-phenyl,  $-(C_1-C_6 \text{ alkyl})-O-\text{phenyl}$ ,  $-(C_1-C_6 \text{ alkyl})$ alkyl)-O-( $C_1$ - $C_6$  alkyl)-phenyl, triazolidine-3,5dione, halogen,  $-NHC(0)NH_2$ ,  $-NHC(0)NH(C_1-C_6 alkyl)$ ,  $-NHC(0)N(C_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl}), -N(C_1-C_6)$  $alkyl)C(0)NH_2$ ,  $-N(C_1-C_6 alkyl)C(0)NH(C_1-C_6 alkyl)$ ,  $- N \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \text{C} \left( \text{O} \right) N \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right), \ - \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right), \ - \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alkyl} \right) \left( \text{C}_1 - \text{C}_6 \text{ alk$ alkyl) thienyl,  $-(C_1-C_6 \text{ alkyl})$  furanyl,  $-S-(C_1-C_6)$ alkyl) phenyl,  $-SO_2NR_{31}R_{32}$ ,  $-C(O)-NR_{31}R_{32}$ ,  $-NR_{31}R_{32}$ , dithiane,  $-NHC(S)NH_2$ ,  $-NHC(S)NH(C_1-C_6 alkyl)$ ,  $-NHC(S)N(C_1-C_6 \text{ alkyl}) (C_1-C_6 \text{ alkyl}), -CO_2(C_1-C_6 \text{ alkyl}),$ tetrahydropyran, phenyl optionally substituted with 1 or 2 groups that are independently F, Cl or Br; pyridine, -C<sub>2</sub>-C<sub>4</sub> alkynyl-phenyl, -O-C<sub>3</sub>-C<sub>8</sub> cycloalkyl, -O-(C<sub>1</sub>-C<sub>6</sub> alkyl)-R<sub>33</sub>; pyrrole optionally substituted

5

10

15

20

25

30

with one or two methyl groups; 2,3-dihydrobenzofuran; benzo[1,2,5]oxadiazole,  $-C(0)-(C_1-C_{10})$ alkyl) wherein the alkyl group is optionally substituted with  $NH_2$ ,  $N(C_1-C_6 \text{ alkyl})$ , or  $N(C_1-C_6)$ alkyl)( $C_1-C_6$  alkyl); -C(0)NH-phenyl,  $-C(0)N(C_1-C_6)$ alkyl)-phenyl, 4,4-dimethyl-4,5-dihydro-oxazole, - $(C_1-C_6 \text{ alkyl})-S-pyridine, -(C_1-C_6 \text{ alkyl})-SO_2-pyridine,$ -(C<sub>1</sub>-C<sub>6</sub> thioalkoxy)-pyridine, thiazole optionally substituted with 1 or 2 methyl groups, pyrazole, S- $(C_1-C_6 \text{ alkyl})$ , indole,  $(C_1-C_6 \text{ thioalkoxy})-(C_1-C_6)$ alkyl),  $C_2-C_8$  alkynyl,  $-CO_2-(C_1-C_6$  alkyl),  $C_1-C_{10}$ alkanoyl;  $-(CH_2)_{0-4}-SO_2-(C_1-C_{10} \text{ alkyl})$  wherein the alkyl group is optionally substituted with OH; wherein R<sub>31</sub> and R<sub>32</sub> at each occurrence are independently selected from the group consisting of hydrogen, C1-C8 alkyl,  $C_2$ - $C_8$  alkenyl, hydroxy  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$ haloalkyl,  $C_1$ - $C_6$  alkoxy  $C_1$ - $C_6$  alkyl,  $-(CH_2)_{0-4}$ - $SO_2$ - $(C_1$ - $C_6$  alkyl) wherein the alkyl is optionally substituted with 1, 2, 3 or 4 independently selected halogen atoms;  $-(CH_2)_{0-4}-SO_2-imidazolyl$ ,  $-(C_1-C_6 alkyl) C(0)NH_2$ ,  $-(C_1-C_6 \text{ alkyl})-C(0)NH(C_1-C_6 \text{ alkyl})$ ,  $-(C_1-C_6)$  $\verb"alkyl") - C(O) \, \texttt{N} \, (C_1 - C_6 \ \, \verb"alkyl") \, (C_1 - C_6 \ \, \verb"alkyl") \, , \quad - \, (C_1 - C_6 \ \, \verb"alkyl") \, - \, (C_1 - C_6 \ \, \verb"alkyl") \, - \, (C_1 - C_6 \ \, \verb"alkyl") \, - \, (C_1 - C_6 \ \, \verb"alkyl") \, - \, (C_1 - C_6 \ \, \verb"alkyl") \, - \, (C_1 - C_6 \ \, \verb"alkyl") \, - \, (C_1 - C_6 \ \, \verb"alkyl") \, - \, (C_1 - C_6 \ \, \verb"alkyl") \, - \, (C_1 - C_6 \ \, \verb"alkyl") \, - \, (C_1 - C_6 \ \, \verb"alkyl") \, - \, (C_1 - C_6 \ \, \verb"alkyl") \, - \, (C_1 - C_6 \ \, \verb"alkyl") \, - \, (C_1 - C_6 \ \, \verb"alkyl") \, - \, (C_1 - C_6 \ \, \verb"alkyl") \, - \, (C_1 - C_6 \ \, \verb"alkyl") \, - \, (C_1 - C_6 \ \, \verb"alkyl") \, - \, (C_1 - C_6 \ \, \verb"alkyl") \, - \, (C_1 - C_6 \ \, \verb"alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, - \, (C_1 - C_6 \ \, alkyl") \, -$  $NH_2$ ,  $-(C_1-C_6 \text{ alkyl})-NH(C_1-C_6 \text{ alkyl})$ ,  $-(C_1-C_6 \text{ alkyl}) N(C_1-C_6 \text{ alkyl})(C_1-C_6 \text{ alkyl}), -(C_1-C_6 \text{ alkyl})$ phenyl,  $-(C_1-C_6 \text{ alkyl})$  pyridyl, -C(0) furanyl,  $(C_1-C_6 \text{ alkyl})$  tetrahydrofuran, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,  $-CO_2-(C_1-C_6 \text{ alkyl})$ ,  $-(C_1-C_6 \text{ alkyl})$ , alkyl)-furanyl, -(CH $_2$ ) $_{0-4}$ -SO $_2$ -thienyl , wherein the phenyl and pyridyl groups are unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxy, C<sub>1</sub>-C<sub>4</sub> alkoxy, halogen, or

 $R_{31}$ ,  $R_{32}$  and the nitrogen to which they are attached form a 5, 6, or 7 membered heterocycloalkyl or a 6 membered

heteroaryl ring, each of which is optionally fused to a benzene, pyridine or pyrimidine ring and each of which is optionally substituted with  $C_1$ - $C_6$  alkoxy, hydroxy, hydroxy  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_4$  alkoxy  $C_1$ - $C_6$  alkyl, -C(0)NH<sub>2</sub>, -C(0)NH-( $C_1$ - $C_6$  alkyl)-phenyl;

 $R_{33}$  at each occurrence is independently, H,  $NH_2$ ,  $NH(C_1-C_6$  alkyl),  $N(C_1-C_6$  alkyl)( $C_1-C_6$  alkyl),  $N(C_1-C_6$  alkyl)(benzyl);

R<sub>35</sub> is phenyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, -S-phenyl, benzodioxole,

thienyl, C<sub>1</sub>-C<sub>6</sub> alkyl, furanyl, imidazolyl, each of which
is unsubstituted or substituted with 1, 2, 3, 4, or 5
groups that are independently C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy,

OH, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, halogen, halo C<sub>1</sub>-C<sub>6</sub> alkyl, halo

C<sub>1</sub>-C<sub>6</sub> alkoxy, -O-(C<sub>1</sub>-C<sub>6</sub> alkyl)-phenyl, -CO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub> alkyl), 
(C<sub>1</sub>-C<sub>4</sub> alkyl)-(C<sub>5</sub>-C<sub>6</sub> cycloalkyl), or (CH<sub>2</sub>)<sub>0-4</sub>CN;

 $R_{42}$  is H,  $C_1$ - $C_6$  alkyl optionally substituted with OH; benzyl; - NHC(O)-( $C_1$ - $C_6$  alkyl); -NHC(O)-phenyl wherein the phenyl is optionally substituted with 1 or 2 alkyl groups; and  $R_{48}$  is -C(O) $R_{49}$ ,

wherein  $R_{49}$  is phenyl, or  $C_1-C_8$  alkyl, each of which is optionally substituted with halogen,  $C_1-C_4$  alkoxy,  $C_1-C_4$  alkyl, or  $R_{33}$ .

### 54. A compound of the formula

R<sub>60</sub> H OH R<sub>42</sub> N N R<sub>48</sub> H

25

30

5

or a pharmaceutically acceptable salt thereof, wherein R<sub>35</sub> is phenyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, -S-phenyl, benzodioxole, thienyl, C<sub>1</sub>-C<sub>6</sub> alkyl, furanyl, imidazolyl, each of which is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, OH, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, halogen, halo C<sub>1</sub>-C<sub>6</sub> alkyl, halo

 $C_1-C_6$  alkoxy,  $-O-(C_1-C_6$  alkyl)-phenyl,  $-CO_2-(C_1-C_6$  alkyl), - $(C_1-C_4 \text{ alkyl})-(C_5-C_6 \text{ cycloalkyl}), \text{ or } (CH_2)_{0-4}CN;$ R<sub>42</sub> is H, C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with OH; benzyl; - $NHC(0)-(C_1-C_6 \text{ alkyl})$ ; -NHC(0)-phenyl wherein the phenyl is5 optionally substituted with 1 or 2 alkyl groups; and  $R_{48}$  is  $-C(0)R_{49}$ , wherein  $R_{49}$  is phenyl, or  $C_1$ - $C_8$  alkyl, each of which is optionally substituted with halogen, C1-C4 alkoxy, C1- $C_4$  alkyl, or  $R_{33}$ ; 10  $R_{52}$  is H, phenyl, -NHC(0)-( $C_1$ - $C_6$  alkyl)-( $C_1$ - $C_6$  thioalkoxy), - $N(C_1-C_6 \text{ alkyl})C(0)-(C_1-C_6 \text{ alkyl})-(C_1-C_6 \text{ thioalkoxy}), OH, C_1-C_6$  $C_6$  alkyl, mono or  $di(C_1-C_6$  alkyl) amino, -NHC(0)-( $C_1-C_6$ alkyl) wherein the alkyl group is optionally substituted with a phenyl,  $-N(C_1-C_6 \text{ alkyl})C(0)-(C_1-C_6 \text{ alkyl})$  wherein 15 the alkyl groups are each optionally substituted with a phenyl,  $-(CH_2)_{0-4}-SO_2-(C_1-C_{10} \text{ alkyl})$ ,  $-NHCO_2-benzyl$ , or  $-NH_2$ , and  $R_{60}$  is  $-L-V-R_{65}$ ,  $C_1-C_8$  alkyl, or hydroxy  $C_1-C_8$  alkyl, wherein the alkyl or hydroxyalkyl groups are optionally substituted 20 with 1 or 2 L-V-R<sub>65</sub> groups, wherein L is absent, -C(0)-,  $-CO_2$ -, -C(0)NH-,  $-C(0)N(C_1$ - $C_6$  alkyl)-, -NHC(O) -,  $-N(C_1-C_6 \text{ alkyl}) - C(O) -$ ,  $-(CH_2)_{0-4} - SO_2 - (CH_2)_{0-4} (CH_2)_{0-4}-O-(CH_2)_{0-4}-$ ,  $-(CH_2)_{0-4}-S-(CH_2)_{0-4}-$ , -NHC(O)NH-,  $-N(C_1-C_6 \text{ alkyl})C(O)NH-$ ,  $-N(C_1-C_6 \text{ alkyl})C(O)N(C_1-C_6)$ 25 alkyl)-, -NHC(O)N(C<sub>1</sub>-C<sub>6</sub> alkyl)-, -NH-, -N(benzyl)-, -N(pheny1) -, -(CH<sub>2</sub>)<sub>0-4</sub>-NHSO<sub>2</sub>-(CH<sub>2</sub>)<sub>0-4</sub>-, -N(C<sub>1</sub>-C<sub>6</sub> $alkyl)SO_2-$ ,  $-SO_2NH-$ ,  $-SO_2N(C_1-C_6 alkyl)-$ , or V is absent,  $-(CH_2)_{0-4}-C(O)NH_{-}$ ,  $-(CH_2)_{0-4}-C(O)N(C_1-C_6 \text{ alkyl})$ -, cyclopropyl optionally substituted with 1 or 2 C<sub>1</sub>-30  $C_4$  alkyl groups, =NH, =NOH, =N-alkoxy,  $C_1$ - $C_8$  alkyl optionally substituted with 1 or 2 OH, or -CH(phenyl) - wherein the phenyl is optionally substituted with 1, 2, 3, 4, or 5 groups that are

halogen or OH;

```
R<sub>65</sub> is cyclohexyl; cyclopentyl; phenyl; -(C<sub>1</sub>-C<sub>6</sub> alkyl)-
                 phenyl; NH_2; mono or di(C_1-C_{10} \text{ alkyl}) amino wherein the
                 alkyl group or groups are optionally substituted with
                 1 or 2 groups that are independently cyclopropyl,
 5
                 phenyl or OH; oxadiazolyl; triazolopyrimidinyl;
                 triazolyl; thiadiazolyl; 3H-quinazolin-2-onyl;
                 pyrimidinyl; pyridyl; pyridyl N-oxide; -(C<sub>1</sub>-C<sub>6</sub>
                 alkyl)-pyridyl; piperazinyl; phthalazinyl;
                 tetrahydro-thiophenyl 1,1-dioxide; tetrazolyl; C<sub>3</sub>-C<sub>6</sub>
10
                 cycloalkyl-C_1-C_6 alkyl; -(C_1-C_4 alkyl)-SO_2-(C_1-C_4
                 alkyl); -SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub> alkyl); benzothiazole; hexahydro-
                 isoindole-1,3-dionyl; benzimidazolyl; benzoxazolyl;
                 [1,2,4]triazolo[1,5-a]pyrimidinyl;
                 [1,2,4]triazolo[4,3-a]pyrimidinyl, thiazolyl;
15
                 thiadiazolyl; imidazo[1,2-a]pyridine; C<sub>1</sub>-C<sub>6</sub> alkyl; 3-
                 aza-bicyclo[3.2.2]nonane; pyrrolidinonyl; diazepanyl;
                 benzo[1,2,5]thiadiazolyl; -NHSO<sub>2</sub>-(4-methylphenyl);
                 [1,2,4]triazolo[4,3-b]pyridazinyl,
                 benzopyrrolidinonyl; morpholinyl; thiomorpholinyl;
20
                 thiomorpholinyl S-oxide; thiomorpholinyl S,S-dioxide;
                 2,3-dihydro-benzo[b]thiophene 1,1-dioxide;
                 pyrrolidinyl; [1,2,4]oxadiazole; C<sub>1</sub>-C<sub>10</sub> alkyl;
                 isoxazolyl; 2,3-dihydro-1H-indolyl; quinazolinonyl,
                 quinazolinyl, piperidyl, wherein each of the above is
25
                 optionally substituted with 1, 2, 3, 4, or 5 groups
                 that are independently
                 C_1-C_6 alkyl, CF_3, halogen, phenyl, -(C_1-C_4 alkyl)-
                       phenyl, -C(0) phenyl, pyrrolidine-dione, C_1-C_6
                       alkoxy, -C(0)-furan, -C(0)NH_2, -C(0)NH(C_1-C_6)
30
                       alkyl), -C(0)N(C_1-C_6 \text{ alkyl})(C_1-C_6)
                       alkyl), cyclopropyl, -(CH_2)_{0-4}-cyclopentyl,
                       benzoxazolyl, pyridine, -NHC(0)-(C_1-C_6 \text{ alkyl}),
                       -N(C_1-C_6 \text{ alkyl})C(O)-(C_1-C_6 \text{ alkyl}), -C(O)C_1-C_6
```

alkyl,  $-CO_2H$ ,  $-NHSO_2-(C_1-C_8 \text{ alkyl})$ ,  $-N(C_1-C_6 \text{ alkyl})SO_2-(C_1-C_8 \text{ alkyl})$ .

## 55. A compound of the formula

5

20

25

or a pharmaceutically acceptable salt thereof, wherein n, p, and q are independently 0, 1 or 2; a dashed line represents a single or double bond;  $R_1$ ,  $R_2$ ,  $R_3$ , and  $R_4$  are independently selected from

- hydrogen, halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkoxy,
  halo(C<sub>1</sub>-C<sub>6</sub>) alkyl, hydroxy(C<sub>1</sub>-C<sub>6</sub>) alkyl, halo(C<sub>1</sub>C<sub>6</sub>) alkoxy, thio(C<sub>1</sub>-C<sub>6</sub>) alkyl, (C<sub>1</sub>-C<sub>6</sub>) alkoxy(C<sub>1</sub>-C<sub>6</sub>) alkyl,
  amino(C<sub>1</sub>-C<sub>6</sub>) alkyl, mono(C<sub>1</sub>-C<sub>6</sub>) alkylamino(C<sub>1</sub>-C<sub>6</sub>) alkyl,
  di(C<sub>1</sub>-C<sub>6</sub>) alkylamino(C<sub>1</sub>-C<sub>6</sub>) alkyl,
- 15  $-(CH_2)_{0-4}$ -aryl or  $-(CH_2)_{0-4}$ -heteroaryl,
  - C<sub>2</sub>-C<sub>6</sub> alkenyl or C<sub>2</sub>-C<sub>6</sub> alkynyl, each of which is optionally substituted with one, two or three substituents independently selected from the group consisting of halogen, hydroxy, -SH, cyano, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, amino, mono (C<sub>1</sub>-C<sub>6</sub>) alkylamino, and di(C<sub>1</sub>-C<sub>6</sub>) alkylamino,
    - -(CH<sub>2</sub>)<sub>0-4</sub>- C<sub>3</sub>-C<sub>7</sub> cycloalkyl, where the cycloalkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halogen, hydroxy, -SH, cyano, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, amino, mono(C<sub>1</sub>-C<sub>6</sub>)alkylamino, and di(C<sub>1</sub>-C<sub>6</sub>)alkylamino;

 $R_z$ ,  $R_z'$ ,  $R_z''$ , and  $R_z'''$  independently represent

 $C_1$ - $C_6$  alkyl, optionally substituted with one, two or three substituents independently selected from  $C_1$ - $C_3$  alkyl,

5

10

15

20

halogen, -OH, -SH, -C $\equiv$ N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkoxy, amino, mono(C<sub>1</sub>-C<sub>6</sub>)alkylamino, and di(C<sub>1</sub>-C<sub>6</sub>)alkylamino, hydroxy, nitro, halogen, -CO<sub>2</sub>H, cyano,

- -(CH<sub>2</sub>)<sub>0-4</sub>-CO-NR<sub>142</sub>R<sub>144</sub> where R<sub>142</sub> and R<sub>144</sub> independently represent hydrogen,  $C_1$ -C<sub>6</sub> alkyl, hydroxyl( $C_1$ -C<sub>6</sub>)alkyl, amino( $C_1$ -C<sub>6</sub>)alkyl, haloalkyl,  $C_3$ -C<sub>7</sub> cycloalkyl, -( $C_1$ -C<sub>2</sub> alkyl)-( $C_3$ -C<sub>7</sub> cycloalkyl), -( $C_1$ -C<sub>6</sub> alkyl)-O-( $C_1$ -C<sub>3</sub> alkyl), -C<sub>2</sub>-C<sub>6</sub> alkenyl with one or two double bonds, -C<sub>2</sub>-C<sub>6</sub> alkynyl with one or two triple bonds, -C<sub>1</sub>-C<sub>6</sub> alkyl chain with one double bond and one triple bond, -R<sub>1-aryl</sub> where R<sub>1-aryl</sub> is as defined above, or -R<sub>1-heteroaryl</sub> where R<sub>1-heteroaryl</sub>,
- -(CH<sub>2</sub>)<sub>0-4</sub>-CO-(C<sub>1</sub>-C<sub>12</sub> alkyl), -(CH<sub>2</sub>)<sub>0-4</sub>-CO-(C<sub>2</sub>-C<sub>12</sub> alkenyl),  $\text{CH}_{2})_{0-4}\text{-CO-}(C_{2}\text{-C}_{12}) \text{alkynyl}, -(CH<sub>2</sub>)_{0-4}\text{-CO-}(C_{3}\text{-C}_{7}$   $\text{cycloalkyl}), -(CH<sub>2</sub>)_{0-4}\text{-CO-}R_{1-\text{aryl}} \text{ where } R_{1-\text{aryl}} \text{ is as }$   $\text{defined above, } -(CH<sub>2</sub>)_{0-4}\text{-CO-}R_{1-\text{heteroaryl}} \text{ where } R_{1-\text{heteroaryl}}$  is as defined above,  $-(CH_{2})_{0-4}\text{-CO-}R_{1-\text{heterocycle}}, -(CH_{2})_{0-4}\text{-CO-}R_{1-\text{heterocycle}}, -(CH_{2})_{0-4}\text{-CO-}R_{146}$  where  $R_{146}$  is heterocycloalkyl, where the heterocycloalkyl is optionally substituted with 1-4 of  $C_{1}$ - $C_{6}$  alkyl,
  - -(CH<sub>2</sub>)<sub>0-4</sub>-CO-O-R<sub>148</sub> where R<sub>148</sub> is selected from the group consisting of:  $C_1$ -C<sub>6</sub> alkyl, -(CH<sub>2</sub>)<sub>0-2</sub>-(R<sub>1-aryl</sub>),  $C_2$ -C<sub>6</sub> alkenyl,  $C_2$ -C<sub>6</sub> alkynyl,  $C_3$ -C<sub>7</sub> cycloalkyl, and -(CH<sub>2</sub>)<sub>0-2</sub>-(R<sub>1-heteroaryl</sub>),
- 25  $-(CH_2)_{0-4}-SO_2-N \ R_{142}R_{144}, \ -(CH_2)_{0-4}-SO_-(C_1-C_8 \ alkyl), \ -(CH_2)_{0-4}-SO_2-(C_1-C_{12} \ alkyl), \ -(CH_2)_{0-4}-SO_2-(C_3-C_7 \ cycloalkyl), \ -(CH_2)_{0-4}-N(H \ or \ R_{148})-CO_-C_{148}, \ -(CH_2)_{0-4}-N(H \ or \ R_{148})-CO_-R_{148}, \ -(CH_2)_{0-4}-N(H \ or \ R_{148})_2, \ -(CH_2)_{0-4}-N(-H \ or \ R_{148})_2, \ -(CH_2)_{0-4}-N(-H \ or \ R_{148})_2, \ -(CH_2)_{0-4}-R_{146} \ where \ R_{N-4} \ is as defined above,$ 
  - -(CH<sub>2</sub>)<sub>0-4</sub>-O-CO-(C<sub>1</sub>-C<sub>6</sub> alkyl), -(CH<sub>2</sub>)<sub>0-4</sub>-O-P(O)-(OR<sub>150</sub>)<sub>2</sub> where each R<sub>150</sub> is independently hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl, (CH<sub>2</sub>)<sub>0-4</sub>-O-CO-N(R<sub>148</sub>)<sub>2</sub>, -(CH<sub>2</sub>)<sub>0-4</sub>-O-CS-N(R<sub>148</sub>)<sub>2</sub> -(CH<sub>2</sub>)<sub>0-4</sub>-O-(R<sub>148</sub>)<sub>2</sub>, -(CH<sub>2</sub>)<sub>0-4</sub>-O-(R<sub>148</sub>)<sub>2</sub>-CO<sub>2</sub>H, -(CH<sub>2</sub>)<sub>0-4</sub>-S-(R<sub>148</sub>)<sub>2</sub>,

-(CH<sub>2</sub>)<sub>0-4</sub>-O-halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, -(CH<sub>2</sub>)<sub>0-4</sub>-O-(C<sub>1</sub>-C<sub>6</sub>)alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl,

- $C_2-C_6$  alkenyl or  $C_2-C_6$  alkynyl, each of which is optionally substituted with  $C_1-C_3$  alkyl, halogen, hydroxy, -SH, cyano, -CF<sub>3</sub>,  $C_1-C_3$  alkoxy, amino, mono( $C_1-C_6$ ) alkylamino, and di( $C_1-C_6$ ) alkylamino,
- -(CH<sub>2</sub>)<sub>0-4</sub>-N(-H or R<sub>148</sub>)-SO<sub>2</sub>-R<sub>142</sub>, or -(CH<sub>2</sub>)<sub>0-4</sub>- C<sub>3</sub>-C<sub>7</sub> cycloalkyl;

5

- R<sub>35</sub> is phenyl, cyclohexyl, -S-phenyl, benzodioxole, thienyl, C<sub>3</sub>-C<sub>6</sub> alkyl, furanyl, each of which is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, OH, hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, halogen, halo C<sub>1</sub>-C<sub>6</sub> alkyl, halo C<sub>1</sub>-C<sub>6</sub> alkoxy, -O-(C<sub>1</sub>-C<sub>6</sub> alkyl)-phenyl, -CO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub> alkyl), or -(C<sub>1</sub>-C<sub>4</sub> alkyl)-15 (C<sub>5</sub>-C<sub>6</sub> cycloalkyl);
  - X and Y are independently selected from O, NR5, C(O), CR1R2, SO2, and S,
- where R<sub>5</sub> is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, SO<sub>2</sub>R<sub>5</sub>', C(O)R<sub>5</sub>' where R<sub>5</sub>'
  is hydrogen, halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, hydroxy, C<sub>1</sub>-C<sub>6</sub>

  alkoxy, halo(C<sub>1</sub>-C<sub>6</sub>) alkyl, halo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, thio(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy(C<sub>1</sub>-C<sub>6</sub>)alkyl, amino(C<sub>1</sub>-C<sub>6</sub>)alkyl,
  mono(C<sub>1</sub>-C<sub>6</sub>)alkylamino(C<sub>1</sub>-C<sub>6</sub>)alkyl, di(C<sub>1</sub>-C<sub>6</sub>)alkylamino(C<sub>1</sub>-C<sub>6</sub>)alkyl,
  - -( $CH_2$ )<sub>0-4</sub>-aryl or -( $CH_2$ )<sub>0-4</sub>-heteroaryl,
- C2-C6 alkenyl or C2-C6 alkynyl, each of which is optionally substituted with one, two or three substituents independently selected from the group consisting of halogen, hydroxy, -SH, cyano, -CF3, C1-C3 alkoxy, amino, mono (C1-C6) alkylamino, and di(C1-C6) alkylamino,
  - -(CH<sub>2</sub>)<sub>0-4</sub>- C<sub>3</sub>-C<sub>7</sub> cycloalkyl, where the cycloalkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halogen, hydroxy, -SH, cyano, -CF<sub>3</sub>, C<sub>1</sub>-

 $C_3$  alkoxy, amino, mono( $C_1$ - $C_6$ )alkylamino, and di( $C_1$ - $C_6$ )alkylamino;

R<sub>140</sub> represents phenyl or naphthyl, each of which is optionally substituted with 1-5 groups independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, optionally substituted with one, two or three substituents selected from the group consisting of C<sub>1</sub>-C<sub>3</sub> alkyl, -halogen, hydroxy, -SH, cyano, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, amino, mono(C<sub>1</sub>-C<sub>6</sub>)alkylamino, and di(C<sub>1</sub>-C<sub>6</sub>)alkylamino,

10 hydroxy, nitro, halogen, -CO<sub>2</sub>H, cyano,

15

30

- -(CH<sub>2</sub>)<sub>0-4</sub>-CO-NR<sub>142</sub>R<sub>144</sub> where R<sub>142</sub> and R<sub>144</sub> independently represent hydrogen,  $C_1$ -C<sub>6</sub> alkyl, hydroxyl( $C_1$ -C<sub>6</sub>)alkyl, amino( $C_1$ -C<sub>6</sub>)alkyl, haloalkyl,  $C_3$ -C<sub>7</sub> cycloalkyl, -( $C_1$ -C<sub>2</sub> alkyl)-( $C_3$ -C<sub>7</sub> cycloalkyl), -( $C_1$ -C<sub>6</sub> alkyl)-O-( $C_1$ -C<sub>3</sub> alkyl), -C<sub>2</sub>-C<sub>6</sub> alkenyl with one or two double bonds, -C<sub>2</sub>-C<sub>6</sub> alkynyl with one or two triple bonds, -C<sub>1</sub>-C<sub>6</sub> alkyl chain with one double bond and one triple bond, -R<sub>1-aryl</sub> or -R<sub>1-heteroaryl</sub>,
- -(CH<sub>2</sub>)<sub>0-4</sub>-CO-(C<sub>1</sub>-C<sub>12</sub> alkyl), -(CH<sub>2</sub>)<sub>0-4</sub>-CO-(C<sub>2</sub>-C<sub>12</sub> alkenyl),

  CH<sub>2</sub>)<sub>0-4</sub>-CO-(C<sub>2</sub>-C<sub>12</sub>)alkynyl, -(CH<sub>2</sub>)<sub>0-4</sub>-CO-(C<sub>3</sub>-C<sub>7</sub>

  cycloalkyl), -(CH<sub>2</sub>)<sub>0-4</sub>-CO-R<sub>1-aryl</sub> where R<sub>1-aryl</sub> is as defined above, -(CH<sub>2</sub>)<sub>0-4</sub>-CO-R<sub>1-heteroaryl</sub> where R<sub>1-heteroaryl</sub> is as defined above, -(CH<sub>2</sub>)<sub>0-4</sub>-CO-R<sub>1-heterocycle</sub>, -(CH<sub>2</sub>)<sub>0-4</sub>-CO-R<sub>146</sub> where R<sub>146</sub> is heterocycloalkyl, where the heterocycloalkyl is optionally substituted with 1-4 of C<sub>1</sub>-C<sub>6</sub> alkyl,
  - -(CH<sub>2</sub>)<sub>0-4</sub>-CO-O-R<sub>148</sub> where R<sub>148</sub> is selected from the group consisting of:  $C_1$ -C<sub>6</sub> alkyl, -(CH<sub>2</sub>)<sub>0-2</sub>-(R<sub>1-aryl</sub>),  $C_2$ -C<sub>6</sub> alkenyl,  $C_2$ -C<sub>6</sub> alkynyl,  $C_3$ -C<sub>7</sub> cycloalkyl, and -(CH<sub>2</sub>)<sub>0-2</sub>-(R<sub>1-heteroaryl</sub>),

 $R_{148}$ )-CO- $R_{142}$ , -(CH<sub>2</sub>)<sub>0-4</sub>-NR<sub>142</sub>R<sub>144</sub>, -(CH<sub>2</sub>)<sub>0-4</sub>-R<sub>146</sub> where  $R_{N-4}$  is as defined above,

- (CH<sub>2</sub>)<sub>0-4</sub>-O-CO-(C<sub>1</sub>-C<sub>6</sub> alkyl), (CH<sub>2</sub>)<sub>0-4</sub>-O-P(O)-(OR<sub>150</sub>)<sub>2</sub> where each R<sub>150</sub> is independently hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl, (CH<sub>2</sub>)<sub>0-4</sub>-O-CO-N(R<sub>148</sub>)<sub>2</sub>, (CH<sub>2</sub>)<sub>0-4</sub>-O-CS-N(R<sub>148</sub>)<sub>2</sub> (CH<sub>2</sub>)<sub>0-4</sub>-O-(R<sub>148</sub>)<sub>2</sub>, (CH<sub>2</sub>)<sub>0-4</sub>-O-(R<sub>148</sub>)<sub>2</sub>-CO<sub>2</sub>H, (CH<sub>2</sub>)<sub>0-4</sub>-S-(R<sub>148</sub>)<sub>2</sub>, (CH<sub>2</sub>)<sub>0-4</sub>-O-halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, (CH<sub>2</sub>)<sub>0-4</sub>-O-(C<sub>1</sub>-C<sub>6</sub>)alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl,
- $C_2$ - $C_6$  alkenyl or  $C_2$ - $C_6$  alkynyl, each of which is optionally substituted with  $C_1$ - $C_3$  alkyl, halogen, hydroxy, -SH, cyano, -CF<sub>3</sub>,  $C_1$ - $C_3$  alkoxy, amino, mono( $C_1$ - $C_6$ ) alkylamino, and di( $C_1$ - $C_6$ ) alkylamino, and -( $C_1$ - $C_6$ ) alkylamino, and -( $C_1$ - $C_1$ - $C_2$ - $C_3$ - $C_4$ - $C_3$ - $C_4$ - $C_3$ - $C_4$ - $C_3$ - $C_4$ - $C_5$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_7$ - $C_$

15

10

5

- 56. A compound according to claim 55, wherein q is 1.
- 57. A compound according to claim 56, wherein two or three of R<sub>z</sub>, R<sub>z</sub>', R<sub>z</sub>'', and R<sub>z</sub>''' is hydrogen, and 20 the other one or two of R<sub>z</sub>, R<sub>z</sub>', R<sub>z</sub>'', and R<sub>z</sub>''' is hydroxy, nitro, halogen, -CO<sub>2</sub>H, cyano, or C<sub>1</sub>-C<sub>6</sub> alkyl, where the alkyl is optionally substituted with one, two or three substituents independently selected from C<sub>1</sub>-C<sub>3</sub> alkyl, halogen, -OH, -SH, -C≡N, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkoxy, amino, mono(C<sub>1</sub>-C<sub>6</sub>) alkylamino, and di(C<sub>1</sub>-C<sub>6</sub>) alkylamino.
  - 58. A compound according to claim 57, wherein three of  $R_z$ ,  $R_z{'}$ ,  $R_z{'}{'}$ , and  $R_z{'}{'}{'}$  is hydrogen and the other is  $(C_1-C_6)$  alkyl, halogen, or  $(C_1-C_6)$  alkoxy.

30

 $59\,.\,$  A compound according to claim  $58\,,$  wherein  $R_{140}$  is phenyl substituted with 1, 2, or 3 groups independently selected from

5

25

 $C_1-C_6$  alkyl, optionally substituted with one, two or three groups independently selected from  $C_1-C_3$  alkyl, - halogen, hydroxy, -SH, cyano, -CF<sub>3</sub>,  $C_1-C_3$  alkoxy, amino, mono( $C_1-C_6$ ) alkylamino, and di( $C_1-C_6$ ) alkylamino, hydroxy, nitro, halogen, -CO<sub>2</sub>H, cyano,

- -(CH<sub>2</sub>)<sub>0-4</sub>-CO-NR<sub>142</sub>R<sub>144</sub> where R<sub>142</sub> and R<sub>144</sub> independently represent hydrogen,  $C_1$ -C<sub>6</sub> alkyl, hydroxy( $C_1$ -C<sub>6</sub>)alkyl, amino( $C_1$ -C<sub>6</sub>)alkyl, and  $C_3$ -C<sub>7</sub> cycloalkyl.
- 10 60. A compound according to claim 59, wherein R<sub>140</sub> is phenyl substituted with one of hydroxy, nitro, halogen, -CO<sub>2</sub>H, cyano, or C<sub>1</sub>-C<sub>6</sub> alkyl where the alkyl is optionally substituted with one, two or three groups independently selected from C<sub>1</sub>-C<sub>3</sub> alkyl, halogen, hydroxy, -SH, cyano, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, amino, mono(C<sub>1</sub>-C<sub>6</sub>)alkylamino, and di(C<sub>1</sub>-C<sub>6</sub>)alkylamino; and one of -(CH<sub>2</sub>)<sub>0-4</sub>-CO-NR<sub>142</sub>R<sub>144</sub>.
- 61. A compound according to claim 60, wherein  $R_{140}$  is 20 phenyl substituted with one of  $-C(0)NR_{142}R_{144}$  and  $R_{142}$  and  $R_{144}$  are independently hydrogen or  $C_1-C_6$  alkyl.
  - 62. A compound according to claim 61, wherein  $R_{142}$  and  $R_{144}$  are the same and are propyl.
  - 63. A compound according to claim 60, wherein  $R_{140}$  is phenyl substituted one  $(C_1-C_6)$  alkyl and with one  $-C(0)NR_{142}R_{144}$  where  $R_{142}$  and  $R_{144}$  are independently hydrogen or  $C_1-C_6$  alkyl.
- 30 64. A compound according to claim 61, wherein  $R_{142}$  and  $R_{144}$  are the same and are propyl.
  - 65. A compound according to claim 57, wherein  $R_{35}$  is phenyl substituted with 1-5 halogen, or substituted with 1, 2,

or 3 groups independently selected from  $(C_1-C_6)$  alkyl, hydroxy, halogen,  $(C_1-C_6)$  alkoxy, amino, mono $(C_1-C_6)$  alkylamino, and di $(C_1-C_6)$  alkylamino.

- 5 66. A compound according to claim 65, wherein  $R_{35}$  is phenyl substituted with 2 halogens.
  - 67. A compound according to claim 66, wherein  $R_{35}$  is 3,5-difluorophenyl.

10

- 68. A compound according to claim 65, wherein  $R_{140}$  is phenyl substituted with
- one of hydroxy, nitro, halogen, -CO<sub>2</sub>H, cyano, or C<sub>1</sub>-C<sub>6</sub> alkyl where the alkyl is optionally substituted with one, two or three groups independently selected from C<sub>1</sub>-C<sub>3</sub> alkyl, halogen, hydroxy, -SH, cyano, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> alkoxy, amino, mono(C<sub>1</sub>-C<sub>6</sub>)alkylamino, and di(C<sub>1</sub>-C<sub>6</sub>)alkylamino; and one of -(CH<sub>2</sub>)<sub>0-4</sub>-CO-NR<sub>142</sub>R<sub>144</sub>.
- 69. A compound according to claim 68, wherein  $R_{140}$  is phenyl substituted with one of  $-C(0)NR_{142}R_{144}$  and  $R_{142}$  and  $R_{144}$  are independently hydrogen or  $C_1-C_6$  alkyl.
- 70. A compound according to claim 69, wherein  $R_{142}$  and  $R_{144}$  25 are the same and are propyl.
  - 71. A compound according to any of claims 55-70, wherein n is 1 and p is 0.
- 72. A compound according to claim 71, wherein the dashed lines all represent single bonds.
  - 73. A compound according to claim 72, wherein  $R_1$  is hydrogen and X is  $SO_2$ .

74. A compound according to claim 73, wherein Y is methylene.

- 5 75. A compound according to claim 74, wherein Z' is 2-propyl.
  - 76. A compound according to claim 74, wherein  $R_2$  is hydrogen, hydroxy( $C_1$ - $C_3$ )alkyl, or ( $C_1$ - $C_3$ )alkyl.

10

- 77. A compound according to claim 75, wherein  $\ensuremath{R_2}$  is methyl.
- 78. A compound according to claim 72, wherein  $R_1$  is hydrogen;

X is  $SO_2$  and Y is  $NR_5$ , or X is  $NR_5$  and Y is  $SO_2$ , where each  $R_5$  is hydrogen,  $(C_1-C_6)$  alkyl, or hydroxy $(C_1-C_6)$  alkyl.

79. A compound according to claim 72, wherein  $R_1$  is 20 hydrogen;

X is C(0) and Y is  $NR_5$ , or X is  $NR_5$  and Y is C(0), where each  $R_5$  is hydrogen,  $(C_1-C_6)$  alkyl, or hydroxy( $C_1-C_6$ ) alkyl.

80. A compound according to claim 55, which is 25 represented by the formula

81. A compound according to claim 55, which is represented by the formula

82. A compound according to claim 69, which is represented by the formula

5

83. A compound according to claim 69, which is represented by the formula

10

- 84. A compound according to claim 82, wherein  $R_2$  is ( $C_1$   $C_3$ )alkyl.
- $$85\,$  A compound according to claim  $82\,,$  wherein  $R_2$  is  $$15\,$  methyl.
  - 86. A compound according to claim 82, wherein  $R_2$  is hydroxy( $C_1-C_3$ )alkyl.
- 20 87. A compound according to claim 83, wherein  $R_2$  is  $(C_1-C_3)$  alkyl.
  - 88. A compound according to claim 83, wherein  $\ensuremath{R_2}$  is methyl.

89. A compound according to claim 83, wherein  $R_2$  is hydroxy( $C_1$ - $C_3$ )alkyl.

```
90. A compound according to claim 55 which is

N'-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(4S)-6-isopropyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}propyl)-5-methyl-N,N-dipropylisophthalamide;

N'-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
{[(3R,4S)-3-(hydroxymethyl)-6-isopropyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}propyl)-5-methyl-N,N-
```

dipropylisophthalamide;

N'-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3- { [(3R,4S)-6-isopropyl-3-methyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}propyl)-5-methyl-N,N-dipropylisophthalamide;

N'-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3- {[(3R,4S)-6-isopropyl-2,2-dioxido-3-propyl-3,4-dihydro-1H-isothiochromen-4-yl]amino}propyl)-5-methyl-N,N-dipropylisophthalamide;

N'-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3- { [(3S,4R)-3-(hydroxymethyl)-6-isopropyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}propyl)-5-methyl-N,N-dipropylisophthalamide;

N'-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3- { [(3S,4R)-3-(2-hydroxyethyl)-6-isopropyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}propyl)-5-methyl-N,N-dipropylisophthalamide;

N'-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3- { [(3S,4S)-3-(2-hydroxyethyl)-6-isopropyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}propyl)-5-methyl-N,N-dipropylisophthalamide;

N'-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3- { [(3S,4S)-6-isopropyl-2,2-dioxido-3-propyl-3,4-dihydro-1H-isothiochromen-4-yl]amino}propyl)-5-methyl-N,N-dipropylisophthalamide;

 $N'-((1S,2R)-1-(3,5-difluorobenzy1)-2-hydroxy-3-\{[(3S,4S)-6-isopropy1-3-methy1-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-y1]amino\}propy1)-5-methy1-N,N-dipropylisophthalamide; and$ 

 $N'-((1S,2R)-1-(3,5-\text{difluorobenzyl})-2-\text{hydroxy}-3-\{[(4R)-6-\text{isopropyl}-2,2-\text{dioxido}-3,4-\text{dihydro}-1H-\text{isothiochromen}-4-yl]amino}$ propyl)-5-methyl-N,N-dipropylisophthalamide; or a pharmaceutically acceptable salt thereof.

#### 91. A compound of the formula:

wherein

5  $R_{100}$  is H,  $C_1$ - $C_8$  alkoxycarbonyl, phenyl  $C_1$ - $C_6$  alkyl, or phenyl  $C_1$ - $C_6$  alkoxycarbonyl;

 $R_{110}$  is phenyl  $C_1$ - $C_6$  alkyl, thienyl, -S-phenyl, furanyl, or benzodioxolyl, wherein each is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen,

C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, or phenyl C<sub>1</sub>-C<sub>6</sub> alkoxy; and

R<sub>120</sub> is H, phenyl C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl optionally

substituted with C<sub>1</sub>-C<sub>6</sub> alky or phenyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl C<sub>1</sub>
C<sub>4</sub> alkyl, or C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with

-C(0)NR<sub>121</sub>R<sub>122</sub>, wherein each of the above is optionally

substituted with 1, 2, or 3 groups that are independently

C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, halogen, or C<sub>1</sub>-C<sub>6</sub>

 $R_{121}$  and  $R_{122}$  are independently H, or  $C_1$ - $C_6$  alkyl.

20 92. A compound according to claim 91 wherein

alkoxy; wherein

 $R_{100}$  is tertiary butoxy carbonyl.

5

10

93. A compound according to claim 91 wherein  $R_{110}$  is phenyl  $C_1$ - $C_6$  alkyl optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, or phenyl  $C_1$ - $C_6$  alkoxy.

- 94. A compound according to claim 91 wherein  $R_{110}$  is monohalophenyl, dihalophenyl, or trihalophenyl.
- 95. A compound according to claim 91 wherein R<sub>110</sub> is thienyl, or -S-phenyl each of which is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, benzyloxy.
- 96. A compound according to claim 91 wherein

  R<sub>110</sub> is furanyl, or benzodioxolyl each of which is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, benzyloxy.
- 97. A compound according to claim 91 wherein R<sub>120</sub> is benzyl optionally substituted with 1, 2, or 3 groups that are independently C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, halogen, or C<sub>1</sub>-C<sub>6</sub> alkoxy.
- 98. A compound according to claim 91 wherein R<sub>120</sub> is cyclopropyl optionally substituted with C<sub>1</sub>-C<sub>6</sub> alky or phenyl; or cyclopropyl C<sub>1</sub>-C<sub>4</sub> alkyl, wherein each of the above is optionally substituted with 1, 2, or 3 groups that are independently C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, halogen, or C<sub>1</sub>-C<sub>6</sub> alkoxy.

99. A compound according to claim 92 wherein

- $R_{110}$  is phenyl  $C_1$ - $C_6$  alkyl optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, or phenyl  $C_1$ - $C_6$  alkoxy; and
- 5  $R_{120}$  is H or benzyl optionally substituted with 1, 2, or 3 groups that are independently  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl, halogen, or  $C_1$ - $C_6$  alkoxy.
  - 100. A compound according to claim 92 wherein
- 10  $R_{110}$  is phenyl  $C_1$ - $C_6$  alkyl optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, or phenyl  $C_1$ - $C_6$  alkoxy; and
  - R<sub>120</sub> is cyclopropyl optionally substituted with C<sub>1</sub>-C<sub>6</sub> alky or phenyl; or cyclopropyl C<sub>1</sub>-C<sub>4</sub> alkyl, wherein each of the above is optionally substituted with 1, 2, or 3 groups that are independently C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, halogen, or C<sub>1</sub>-C<sub>6</sub> alkoxy.

15

- 101. A compound according to claim 92 wherein
  20 R<sub>110</sub> is thienyl, or -S-phenyl each of which is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, benzyloxy; and
- $R_{120}$  is H or benzyl optionally substituted with 1, 2, or 3 groups that are independently  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl, halogen, or  $C_1$ - $C_6$  alkoxy.
- 102. A compound according to claim 92 wherein R<sub>110</sub> is thienyl, or -S-phenyl each of which is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, benzyloxy; and
  - $R_{120}$  is cyclopropyl optionally substituted with  $C_1$ - $C_6$  alky or phenyl; or cyclopropyl  $C_1$ - $C_4$  alkyl, wherein each of the

above is optionally substituted with 1, 2, or 3 groups that are independently  $C_1-C_6$  alkyl,  $C_2-C_6$  alkenyl,  $C_2-C_6$  alkynyl, halogen, or  $C_1-C_6$  alkoxy.

- 5 103. A compound according to claim 92 wherein R<sub>110</sub> is furanyl, or benzodioxolyl each of which is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, or benzyloxy.
- 10  $R_{120}$  is H or benzyl optionally substituted with 1, 2, or 3 groups that are independently  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl, halogen, or  $C_1$ - $C_6$  alkoxy.
  - 104. A compound according to claim 92 wherein
- 15 R<sub>110</sub> is furanyl, or benzodioxolyl each of which is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, or benzyloxy;
- R<sub>120</sub> is cyclopropyl optionally substituted with C<sub>1</sub>-C<sub>6</sub> alky or phenyl; or cyclopropyl C<sub>1</sub>-C<sub>4</sub> alkyl, wherein each of the above is optionally substituted with 1, 2, or 3 groups that are independently C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, halogen, or C<sub>1</sub>-C<sub>6</sub> alkoxy.
- 25 105. A compound of the formula

or a pharmaceutically acceptable salt thereof, wherein  $R_1$  is  $C_1$ - $C_4$  alkyl,  $C_2$ - $C_4$  alkynyl, or  $CF_3$ ;  $R_2$  and  $R_3$  are both hydrogen; or

 $R_2$  and  $R_3$  and the carbon to which they are attached form a cyclopropyl ring;

 $R_4$  is oxazolyl optionally substituted with methyl, thiazolyl,  $C_2-C_4$  alkynyl, or  $C_1-C_4$  alkyl;

5  $R_5$  is  $C_1-C_4$  alkyl;

 $R_6$  is  $C_1-C_4$  alkyl;

X and Y are independently halogen;

Z is CH or N.

10 106. A compound according to claim 105, wherein Z is CH.

107. A compound according to claim 106, wherein  $\ensuremath{R_2}$  and  $\ensuremath{R_3}$  are both H.

15 108. A compound according to claim 107 of the formula:

109. A compound according to claim 108 wherein,  $R_1$  is ethyl, ethynyl or  $CF_3$ ; and

20  $R_4$  is 2-oxazolyl optionally substituted with methyl, 2-thiazolyl, ethynyl, or methyl.

110. A compound according to claim 109, wherein  $\ensuremath{R_5}$  is propyl; and  $\ensuremath{R_6}$  is propyl.

25

111. A compound according to claim 110, wherein  $R_1$  is ethyl;

 $R_4$  is 2-oxazolyl optionally substituted with methyl; and X and Y are both F.

112. A compound according to claim 109, wherein  $R_1$  is ethyl, or  $CF_3$ ; and  $R_4$  is 2-thiazolyl.

- 5 113. A compound according to claim 112, wherein  $R_5$  is propyl; and  $R_6$  is propyl; or  $R_5$  is methyl; and  $R_6$  is propyl or butyl; and  $R_6$  and  $R_6$  are both  $R_6$ .
- 10 114. A compound according to claim 113, wherein  $R_1$  is ethyl.
  - 115. A compound according to claim 112, wherein  $R_1$  is  $CF_3$ ;  $R_5$  is propyl; and  $R_6$  is propyl.

116. A compound according to claim 109, wherein  $R_{1}$  is

ethynyl; and R4 is ethynyl, methyl, or 2-oxazolyl.

propyl; and R<sub>6</sub> is propyl; and X and Y are both F.

15

20

- 117. A compound according to claim 116, wherein  $R_{\text{5}}$  is
  - 118. A compound according to claim 117, wherein  $R_4$  is ethynyl or methyl.
- 25 119. A compound according to claim 106 of the formula:

120. A compound according to claim 119, wherein  $R_1$  is ethyl or ethynyl;  $R_4$  is methyl or 2-oxazolyl.

121. A compound according to claim 120, wherein  $R_5$  and  $R_6$  are both propyl; X and Y are both F.

- 5 122. A compound according to claim 121, wherein Z is N; and  $R_4$  is methyl.
  - 123. A compound according to claim 121, wherein Z is CH; and  $R_4$  is methyl or 2-oxazolyl.

10

- 124. A compound according to claim 105 wherein  $R_4$  is 2-oxazolyl.
  - 125. A compound of the formula

15

- or a pharmaceutically acceptable salt thereof, wherein
- $R_1$  is  $C_2-C_3$  alkyl;
- R2 and R3 are both hydrogen; or
- $R_{\text{f}}$  and  $R_{\text{g}}$  are independently halogen;
- 20  $R_5$  is  $C_1-C_2$  alkyl sulfonyl;
  - R<sub>6</sub> is hydroxyethyl or methoxyethyl.
    - 126. A compound of the formula

25 or a pharmaceutically acceptable salt thereof, wherein

 $R_1$  is  $C_2-C_3$  alkyl;

25

R2 and R3 are both hydrogen; or

R<sub>f</sub> and R<sub>g</sub> are independently halogen;

R<sub>5</sub> and R<sub>6</sub> are independently C<sub>3</sub>-C<sub>4</sub> alkyl; or

- $R_5$  is H and  $R_6$  is  $C_3$  alkyl; or
  - $R_5$ ,  $R_6$ , and the nitrogen to which they are attached form a pyrrolidinyl ring optionally substituted with methoxymethyl; and
- R<sub>s</sub> is C<sub>1</sub>-C<sub>2</sub> alkyl, hydroxy(C<sub>2</sub>-C<sub>4</sub>)alkyl, N-[hydroxy(C<sub>2</sub>-C<sub>4</sub>) alkyl]N-(C<sub>1</sub>-C<sub>2</sub>)alkylamino, N-methyl-N-(C<sub>4</sub> (t-butyl)alkyl)amino,
  -NH(C<sub>1</sub>-C<sub>4</sub> hydroxyalkyl), -N(C<sub>1</sub>-C<sub>3</sub> hydroxyalkyl)(C<sub>1</sub>-C<sub>3</sub>
  hydroxyalkyl), -N(C<sub>1</sub>-C<sub>2</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl), pyrrolidin-1yl optionally substituted with hydroxymethyl or
  methoxymethyl, C<sub>1</sub>-C<sub>2</sub> alkoxy C<sub>2</sub>-C<sub>3</sub> alkyl, 1-piperazinyl,
  -NH<sub>2</sub>, -NH(C<sub>2</sub>-C<sub>3</sub> alkyl-NH(C<sub>1</sub>-C<sub>2</sub> alkyl)), or C<sub>1</sub>-C<sub>4</sub> (C<sub>2</sub>)
  alkylamino.
- 127. A compound according to claim 126, wherein  $R_s$  is N-[hydroxy(C<sub>4</sub>-alkyl]-N-methylamino, -N(C<sub>1</sub>-C<sub>3</sub> hydroxyalkyl)(C<sub>1</sub>-C<sub>3</sub> hydroxyalkyl), or -NH(C<sub>1</sub>-C<sub>4</sub> hydroxyalkyl).
  - 128. A compound according to claim 127, wherein the hydroxyalkyl is 2-hydroxy-1,1-dimethylethyl; 2-hydroxyethyl; 3-hydroxypropyl; 1(R)-2-hydroxy-1-methylethyl; 1(S)-2-hydroxy-1-methylethyl; 2(R)-2-hydoxypropyl; or 2(S)-2-hydoxypropyl.
  - 129. A compound according to claim 126, wherein  $R_s$  is 3-hydroxypropyl, or 4-hydroxybutyl.
- 130. A compound according to claim 126, wherein R<sub>s</sub> is 2(R)-2-methoxymethylpyrrolidin-1-yl, 2(R)-2-hydroxymethylpyrrolidin-1-yl, 2(S)-2-hydroxymethylpyrrolidin-1-yl, pyrrolidin-1-yl, or 1-piperazinyl,

131. A compound according to claim 126, wherein  $R_5$ ,  $R_6$ , and the nitrogen to which they are attached form a 2(S)-2-methoxymethyl)pyrrolidin-1-yl.

- 5 132. A compound according to claim 131, wherein  $R_s$  is -NH(tert-butyl), -N(CH<sub>3</sub>)(CH<sub>2</sub>CH<sub>3</sub>), or 2(S)-2-methoxymethylpyrrolidin-1-yl.
- 10 133. A compound of the formula

or a pharmaceutically acceptable salt thereof, wherein

 $R_1$  is  $C_2-C_3$  alkyl;

 $R_2$  and  $R_3$  are both hydrogen; or

15  $R_f$  and  $R_g$  are independently halogen;

 $\ensuremath{\text{R}_{\text{5}}}$  and  $\ensuremath{\text{R}_{\text{6}}}$  are independently  $\ensuremath{\text{C}_{\text{1}}\text{-}\text{C}_{\text{4}}}$  alkyl; and

 $R_d$  is  $C_1-C_2$  alkyl,  $N-hydroxy\,(C_2-C_3)\,alkyl-N-\,(C_1-C_2)\,alkylamino,$  or  $C_1-C_2$  alkylamino.

20 134. A compound of the formula

or a pharmaceutically acceptable salt thereof, wherein

- X is nitrogen or CH;
- $R_1$  is  $C_2-C_3$  alkyl, amino, mono( $C_1-C_3$ )alkylamino, di( $C_1-C_3$ ) alkylamino, amino( $C_1-C_3$ )alkyl, mono( $C_1-C_3$ )alkylamino( $C_1-C_3$ )alkyl, or di( $C_1-C_3$ )alkylamino( $C_1-C_3$ )alkyl;
- 5 R<sub>2</sub> and R<sub>3</sub> are both hydrogen; or
  - $R_f$  and  $R_g$  are both hydrogen or independently halogen;
  - $R_5$  and  $R_6$  are independently methyl or  $C_2\text{-}C_3\text{-}C_4$  alkyl, where at least one of  $R_5$  and  $R_6$  is not methyl.
- 10 135. A compound according to claim 134, wherein X is CH.
  - 136. A compound according to claim 135, wherein  $R_1$  is di( $C_1-C_2$ )alkylamino.
- 15 137. A compound according to claim 136, wherein at least one of  $R_5$  and  $R_6$  is propyl.
  - 138. A compound according to claim 134, wherein X is nitrogen.

20

- 139. A compound according to claim 138, wherein both of  $R_{\rm 5}$  and  $R_{\rm 6}$  are not methyl.
- 140. A compound according to claim 135, wherein  $R_1$  is di( $C_1-C_2$ )alkylamino( $C_1-C_2$ )alkyl.
  - 141. A compound of the formula

or a pharmaceutically acceptable salt thereof, wherein

 $R_1$  is  $C_2-C_3$  alkyl;

 $R_2$  and  $R_3$  are both hydrogen; or

 $R_f$  and  $R_g$  are independently halogen;

 $R_5$  and  $R_6$  are independently  $C_3-C_4$  alkyl; and

5  $R_j$  is hydrogen or  $C_1-C_2$  alkoxymethyl.

### 142. A compound of the formula

or a pharmaceutically acceptable salt thereof, wherein

10  $R_1$  is  $C_2-C_4$  alkynyl,  $C_2-C_4$  alkyl, or trifluoromethyl;

 $R_2$  and  $R_3$  are both hydrogen; or

 $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached;

 $R_{\text{f}}$  and  $R_{\text{g}}$  are independently halogen; and

- 15  $R_5$  and  $R_6$  are independently  $C_3-C_4$  alkyl; or one of  $R_5$  and  $R_6$  is methyl or ethyl and the other is  $C_3-C_4$  alkyl.
- 143. A compound according to claim 142, wherein  $R_1$  is ethyl, n-propyl, isopropyl, or trifluoromethyl.
  - 144. A compound according to claim 143, wherein  $R_5$  is methyl or ethyl and  $R_6$  is  $C_3$   $C_4$  alkyl.
- 25 145. A compound according to claim 142, wherein  $R_5$  is methyl or propyl.
  - 146. A compound according to claim 145, wherein  $R_{\rm f}$  and  $R_{\rm g}$  are both chloro or fluoro.

147. A compound according to claim 146, wherein both of  $R_2$  and  $R_3$  are hydrogen; and  $R_1$  is  $C_2{-}C_3$  alkynyl.

5

- 148. A compound according to claim 1151, wherein  $R_5$  and  $R_6$  are independently propyl or butyl.
- $$149.\ A$$  compound according to claim 1156, wherein both of  $$R_2$$  and  $$R_3$$  are hydrogen.
  - 150. A compound according to claim 1157, wherein  $R_{\rm f}$  and  $R_{\rm g}$  are both chloro or fluoro.
- 15 151. A compound according to claim 1157, wherein  $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached.

### 152. A compound of the formula

20

or a pharmaceutically acceptable salt thereof, wherein one of X or  $X_1$  is nitrogen or  $N^+-0^-$  while the other is CH;  $R_1$  is  $C_2-C_4$  alkynyl, cyano, or  $C_1-C_3$  alkyl;

R<sub>2</sub> and R<sub>3</sub> are both hydrogen; or

 $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached;

R<sub>f</sub> and R<sub>g</sub> are independently halogen;

 $R_p$  is hydrogen,  $C_1$ - $C_2$  alkyl, or oxazolyl; and

 $R_5$  and  $R_6$  are independently  $C_3-C_4$  alkyl.

153. A compound according to claim 152, wherein X is nitrogen;  $R_1$  is  $C_2$ - $C_3$  alkynyl;  $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached; and  $R_p$  is  $C_1$ - $C_2$  alkyl.

- 154. A compound according to claim 152, wherein X is nitrogen; and  $R_1$  is  $C_2$  alkynyl.
- 10 155. A compound according to claim 152, wherein X is nitrogen;  $R_1$  is  $C_1-C_2$  alkyl;  $R_2$  and  $R_3$  are hydrogen; and  $R_p$  is hydrogen,  $C_1-C_2$  alkyl, or oxazol-2-yl.
- 156. A compound according to claim 152, wherein X is nitrogen;  $R_1$  is  $C_1-C_2$  alkyl;  $R_2$  and  $R_3$  are hydrogen; and  $R_p$  is cyano.
- 157. A compound according to claim 152, wherein X is nitrogen; R<sub>1</sub> is C<sub>2</sub>-C<sub>3</sub> alkyl; R<sub>2</sub> and R<sub>3</sub> together form a 3
  20 membered ring with the carbon atom to which they are attached; and R<sub>p</sub> is C<sub>1</sub>-C<sub>2</sub> alkyl.
  - 158. A compound according to any of claims 153-157, wherein  $R_{\rm f}$  and  $R_{\rm g}$  are both chloro or fluoro.
  - 159. A compound according to any of claims 153-157, wherein  $R_5$  and  $R_6$  are independently propyl or butyl.
    - 160. A compound of the formula

25

or a pharmaceutically acceptable salt thereof, wherein  $R_{\text{\scriptsize C}}$  is a group of the formula

 $\underset{X,\ldots,X'}{\overset{\mathcal{S}^{2}}{\bigvee}}R_{1}$ 

where one of X and X' is nitrogen and the other is CH and  $R_1$  is  $C_2-C_4$  alkyl or  $-(C_1-C_2$  alkyl) $-N(C_1-C_2$  alkyl);

R<sub>f</sub> and R<sub>g</sub> are independently halogen;

 $R_p$  is  $C_1-C_2$  alkyl; and

 $\mbox{R}_{5}$  and  $\mbox{R}_{6}$  are independently hydrogen or  $\mbox{C}_{3}\mbox{-}\mbox{C}_{4}$  (sec butyl) alkyl.

10

5

- 161. A compound according to claim 160, wherein X is nitrogen; X' is CH; and  $R_{\rm 5}$  and  $R_{\rm 6}$  are independently propyl or butyl.
- 15 162. A compound according to claim 160, wherein X is CH; X' is nitrogen; and  $R_5$  and  $R_6$  are independently propyl or butyl.
- 163. A compound according to claim 162, wherein 20  $R_1$  is  $-CH_2N(CH_3)CH_3$ .
  - 164. A compound of the formula

or a pharmaceutically acceptable salt thereof, wherein

 $R_s$  is methylamino, ethylamino,  $C_3$  alkylamino, di( $C_3$ -alkyl)amino, or a group of the formula

$$\begin{tabular}{lll} $ & & \\ $N_q$ \\ \hline & & \\ $W$ where $R_q$ is $C_1-C_2$ alkoxy($C_1-C_2$)$ alkyl; \\ \end{tabular}$$

 $R_1$  is  $C_2-C_3$  alkyl;

 $R_2$  and  $R_3$  are both hydrogen; and  $R_f$  and  $R_g$  are independently halogen.

## 165. A compound of the formula

$$\begin{array}{c|c} R_{1} & O & R_{2} & R_{3} \\ Z & N & OH & H \end{array}$$

10 or a pharmaceutically acceptable salt thereof, wherein

Z is CH when the dashed line represents a single bond or a carbon atom or nitrogen atom when the dashed line represents a double bond;

 $R_1$  is  $C_2-C_3$  alkyl;

15  $R_2$  and  $R_3$  are both hydrogen;

 $R_{\text{f}}$  and  $R_{\text{g}}$  are independently halogen;

 $R_p$  is hydrogen, cyano,  $C_1-C_3$  alkyl, amino,  $N-(C_1-C_3$  alkylsulfonyl)- $N-((C_1-C_3)$  alkyl) amino, 2-oxazolyl, or 1-pyrrolyl optionally substituted in the 2 and 5 positions with  $C_1-C_2$  alkyl; and

 $R_j$  is  $C_1-C_5$  alkyl.

20

25

166. A compound according to claim 165, wherein  $R_{\rm j}$  is methyl; and  $\rm Z_1$  is hydrogen.

167. A compound according to claim 165, where Z is CH and  $R_p$  is  $N-(C_1-C_2)$  alkylsulfonyl)- $N-((C_1-C_2)$  alkyl) amino; and  $R_j$  is  $C_3-C_4$  alkyl.

168. A compound according to claims 165, wherein  $R_{\text{p}}$  is 2-oxazolyl and Z is CH.

- 5 169. A compound according to claims 165, wherein  $R_p$  is cyano; Z is CH; and  $R_i$  is  $C_3$ - $C_4$  (buty1) alky1.
- 170. A compound according to claim 167, wherein Rp is  $-N(CH_3)SO_2(C_1-C_2 \text{ alkyl})$ ; and 10 R<sub>1</sub> is ethyl.
  - 171. A compound of the formula

or a pharmaceutically acceptable salt thereof, wherein

- 15 both of X and X' are CH, or one of X and X' is nitrogen and the other is CH;
  - $R_1$  is  $C_2-C_3$  alkynyl,  $C_{1,2}-C_3$  alkyl, amino, mono( $C_1-C_3$ ) alkylamino, or  $di(C_1-C_3)$  alkylamino, aminoalkyl, mono( $C_1-C_3$ ) alkylamino( $C_1-C_2$ ) alkyl,  $di(C_1-C_3)$  alkylamino( $C_1-C_2$ ) alkyl,
- 20  $CF_3$ ,  $C_1-C_2$  alkoxy, halogen,  $-NHSO_2(C_1-C_2 \text{ alkyl})$ ;

R<sub>2</sub> and R<sub>3</sub> are both hydrogen; or

 $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached;

 $R_f$  and  $R_g$  are both hydrogen or independently halogen;

25  $R_5$  and  $R_6$  are independently  $C_1-C_4$  alkyl; or one of  $R_5$  and  $R_6$  is methyl or ethyl and the other is  $C_3$  or  $C_4$  alkyl.

172. A compound according to claim 171, wherein  $R_1$  is  $C_2 - C_3$  alkyl.

- 173. A compound according to claim 171, wherein  $R_1$  is  $\text{di}(C_1-C_3)$  alkylamino and both of  $R_f$  and  $R_g$  are chloro or fluoro.
  - 174. A compound according to claim 171, wherein  $R_1$  is  $di(C_1-C_3)alkylamino(C_1-C_2)alkyl$ , and both of  $R_f$  and  $R_g$  are chloro or fluoro.

10

175. A compound according to claim 171, wherein X is nitrogen;  $R_f$  and  $R_g$  are both fluoro;  $R_1$  is  $C_1$ - $C_3$  alkyl; and  $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached.

15

- 176. A compound according to claim 172, wherein both X and X' are CH; and  $R_{\rm f}$  and  $R_{\rm g}$  are both chloro or fluoro.
- 177. A compound according to claim 176, wherein one of  $R_5$  and  $R_6$  is methyl or ethyl and the other is  $C_3$  or  $C_4$  alkyl.
  - 178. A compound according to claim 176, wherein  $R_5$  and  $R_6$  are independently  $C_{2,3}\text{-}C_4$  alkyl.
- 25 179. A compound according to claim 178, wherein  $R_5$  is  $C_2$ - $C_4$  alkyl and  $R_6$  is ethyl.
  - 180. A compound according to claim 176, wherein one of  $R_5$  and  $R_6$  is methyl and the other is  $C_3$  or  $C_4$  alkyl.

30

181. A compound according to claim 176, wherein  $R_5$  and  $R_6$  are independently propyl or butyl.

182. A compound according to claim 171, wherein  $R_1$  is  $C_2$  alkynyl.

- 183. A compound according to claim 182, wherein
- 5 X is nitrogen and X' is CH; and
  - $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached.
- 184. A compound according to claim 182, wherein both X and 10  $\,$  X' are CH; and R<sub>f</sub> and R<sub>g</sub> are both chloro or fluoro.
  - 185. A compound according to claim 176, wherein  $R_{\rm 5}$  and  $R_{\rm 6}$  are independently propyl or butyl.
- 15 186. A compound according to any of claims 176-185, wherein  $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached.
  - 187. A compound according to claim 171, wherein
- 20 R<sub>1</sub> is CF<sub>3</sub>, or -NHSO<sub>2</sub>CH<sub>3</sub>;

 $R_2$  and  $R_3$  are both H;

 $R_5$  and  $R_6$  are independently  $C_3$  or  $C_4$  alkyl.

- 188. A compound according to claim 172, wherein 25 X is CH and X' is nitrogen.
  - 189. A compound according to claim 188, wherein  $R_2$ ,  $R_3$ , and the carbon to which they are attached form a cyclopropyl ring.

30

- 190. A compound according to claim 186, wherein  $R_1$  is bromo or chloro.
  - 191. A compound of the formula

$$\begin{array}{c|c} R_1 & R_2 \\ \hline \\ R_2 & R_3 \\ \hline \\ OH & H \end{array}$$

or a pharmaceutically acceptable salt thereof, wherein

 $R_1$  is  $C_2-C_3$  alkyl;

R<sub>2</sub> and R<sub>3</sub> are both hydrogen;

5  $R_f$  and  $R_g$  are independently halogen;

R<sub>s</sub> is C<sub>3</sub>-C<sub>4</sub> alkyl, thiazolinyl or thiazolidinyl.

192. A compound according to claim 191, wherein  $R_{\rm S}$  is 2-thiazolidinyl or 2-thiazolinyl.

10

### 193. A compound of the formula

or a pharmaceutically acceptable salt thereof, wherein

 $R_1$  is  $C_2$ - $C_3$  alkyl,  $CF_3$ , or -NH( $C_3$ - $C_6$  cycloalkyl);

15 R<sub>2</sub> and R<sub>3</sub> are both hydrogen; or

 $R_2$  and  $R_3$  together with the carbon atom to which they are attached form a 3-membered ring;

 $R_p$  is pyridyl, piperazinyl, amino, amino( $C_1$ - $C_5$ )alkyl, mono( $C_1$ - $C_2$ )alkylamino( $C_1$ - $C_5$ )alkyl, di( $C_1$ - $C_2$ )alkylamino( $C_1$ - $C_5$ )alkyl,

mono  $(C_1-C_3)$  alkylamino, di  $(C_1-C_3)$  alkylamino, amino  $(C_3-C_4)$  alkynyl, mono  $(C_1-C_2)$  alkylamino  $(C_3-C_4)$  alkynyl, di  $(C_1-C_2)$  alkylamino  $(C_3-C_5)$  alkynyl,  $-N(C_1-C_2)$  alkyl)  $-SO_2(C_1-C_2)$  alkyl),  $-NH-SO_2(C_1-C_2)$  alkyl),  $-N(C_1-C_2)$  alkyl)  $-SO_2$ -thienyl,

 $-N(C_1-C_2 \text{ alkyl})-SO_2(C_1-C_2 \text{ haloalkyl}), \text{ di}(C_1-C_2 \text{ haloalkyl})$ 

C<sub>2</sub>)alkylamino( $C_3-C_4$ )alkynyl, pyrimidinyl, pyrazolyl, imidazolyl, or  $C_2-C_4$  alkynyl;

 $R_{f}$  and  $R_{g}$  are independently halogen;  $R_{5}$  and  $R_{6}$  are independently  $C_{3}$ - $C_{4}$  alkyl.

- 194. A compound according to claim 193, wherein  $R_p$  is 4-pyridyl, 2-pyrimidinyl, 4-pyrazolyl, or 4-imidazolyl.
  - 195. A compound according to claim 193, wherein  $R_{\rm p}$  is diethylamino or dimethylamino.
- 10 196. A compound according to claim 193, wherein  $R_p$  is amino or  $C_1$ - $C_6$  alkylamino.
  - 197. A compound according to claim 193 where  $R_p$  is 1-piperazinyl.

15

198. A compound according to claim 193 where  $R_p$  is amino( $C_2-C_4$ )alkyl where the amino is optionally mono substituted with  $C_1-C_2$  alkyl; or where  $R_p$  is  $-N(CH_3)-SO_2CH_3$ ,  $-NH-SO_2CH_3$ ,  $-N(CH_3)-SO_2-thien-2-yl$ , or  $-N(CH_3)-SO_2CF_3$ .

20

199. A compound according to claim 193 where  $R_p$  is 3-  $(mono(C_1-C_2)alkylamino)propyn-1-y1$ , 3- $(di(C_1-C_2)alkylamino)propyn-1-y1$ , or 4- $(di(C_1-C_2)alkylamino)propyn-1-y1$ .

25

- 200. A compound according to any of claims 194 to 199, wherein  $R_5$  and  $R_6$  are both  $C_3$  alkyl.
- 201. A compound according to any of claims 194 to 199, 30 wherein  $R_2$  and  $R_3$  are hydrogen.
  - 202. A compound according to any of claims 194 to 199, wherein  $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached.

203. A compound according to claim 193 where  $R_p$  is di(C1-C2)alkylamino(C3-C5)alkyl; and  $R_5$  and  $R_6$  are both C3 alkyl.

5

- 204. A compound according to claim 193 where  $R_p$  is  $C_2\text{--}C_3$  alkynyl,  $C_1\text{--}C_2$  alkyl, or -NH(cyclopropyl); and  $R_2$  and  $R_3$  are both H.
- 205. A compound according to claim 193 where  $R_p$  is  $C_2$ - $C_3$  alkynyl,  $C_1$ - $C_2$  alkyl, or -NH(cyclopropyl); and  $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached.
- 15 206. A compound of the formula

or a pharmaceutically acceptable salt thereof, wherein  $R_1$  is  $C_2\text{-}C_3$  alkynyl;  $R_2$  and  $R_3$  are both hydrogen;

20  $R_p$  is  $C_1-C_3$  alkyl;

 $R_f$  and  $R_g$  are independently halogen;  $R_5$  and  $R_6$  are independently  $C_3-C_4$  alkyl; or one of  $R_5$  and  $R_6$  is methyl and the other is  $C_3$  or  $C_4$  alkyl.

- 25 207. A compound according to claim 206, wherein  $R_{\text{p}}$  is methyl.
  - 208. A compound of the formula

or a pharmaceutically acceptable salt thereof, wherein

 $R_1$  is  $C_1-C_2$  alkyl,  $C_2-C_4$  alkynyl or  $C_3-C_4$  alkyl;

R2 and R3 are both hydrogen; or

5  $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached;

 $R_f$  and  $R_g$  are independently halogen;

 $R_p$  is  $C_1$ - $C_3$  alkyl or a group of the formula:

 $R_sSO_2$ - where  $R_s$  is

10

 $R_{51}R_{61}N$ - and  $R_{51}$  and  $R_{61}$  independently represent hydrogen or  $C_1$ - $C_4$  alkyl groups; or a group of the formula:

R<sub>t</sub>

where  $R_t$  is  $C_1-C_2$  alkoxy( $C_1-C_2$ )alkyl; and

 $R_q$  is  $C_1-C_3$  alkoxy  $(C_1-C_2)$  alkyl,  $C_1-C_4$  alkyl, -C(0)  $NH_2$ , or H.

15

209. A compound according to claim 1240, wherein  $R_1$  is  $C_2$  alkynyl;  $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached; and  $R_p$  is  $R_sSO_2$ - where

$$R_s$$
 is  $N$ 

20

- 210. A compound according to claim 208, wherein  $R_1$  is  $C_1-C_2$  alkyl;  $R_2$  and  $R_3$  are hydrogen; and  $R_p$  is  $R_sSO_2-$  where  $R_s$  is  $C_3-C_4$  t-butyl amino.
- 25 211. A compound according to claim 208, wherein  $R_1$  is  $C_1-C_2$  alkyl;  $R_2$  and  $R_3$  are hydrogen;  $R_p$  is  $C_1-C_2$  alkyl; and  $R_q$  is  $C_2-C_4$  alkyl.

212. A compound according to claim 208, wherein  $R_1$  is  $C_1-C_2$  alkyl;  $R_2$  and  $R_3$  are hydrogen;  $R_p$  is  $C_1-C_2$  alkyl; and  $R_q$  is propoxy( $C_1-C_2$ )alkyl.

5

- 213. A compound according to claim 208, wherein  $R_1$  is  $C_1-C_2$  alkyl;  $R_2$  and  $R_3$  are hydrogen;  $R_p$  is  $C_1-C_2$  alkyl; and  $R_q$  is methoxy( $C_1-C_2$ )alkyl.
- 10 214. A compound according to claim 208, wherein  $R_1$  is  $C_1$ - $C_2$  alkyl;  $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached;  $R_p$  is  $C_1$ - $C_2$  alkyl; and  $R_q$  is  $C_1$ - $C_2$  alkyl.
- 15 215. A compound according to claim 208, wherein  $R_1$  is  $C_1-C_2$  alkyl;  $R_2$  and  $R_3$  are hydrogen;  $R_p$  is  $C_1-C_2$  alkyl; and  $R_q$  is  $C_1-C_2$  alkyl.
- 216. A compound according to claim 208, wherein
  20 R<sub>q</sub> is (R)-methoxymethyl, methyl, propyl, (S)-propyl, (R)propyl, butyl, (R)-butyl, (S)-butyl, (R)-2-methoxymethyl, (R)2-methoxyethyl,

### 217. A compound of the formula

25

or a pharmaceutically acceptable salt thereof, wherein Z is oxygen, nitrogen, or sulfur;  $R_1 \ \text{is chloro, bromo, hydrogen or $C_1$-$C_2 alkyl;}$ 

 $R_f$  and  $R_g$  are independently halogen; and

 $R_5$  and  $R_6$  are independently  $C_3-C_4$  alkyl; or one of  $R_5$  and  $R_6$  is methyl and the other is  $C_3$  or  $C_4$  alkyl.

218. A compound according to claim 217, wherein  $R_1$  is 5 bromo, and Z is oxygen.

219. A compound according to claim 217, wherein Z is nitrogen; and  $R_1$  is  $C_1-C_3$  alkyl.

10

220. A compound according to claim 217, wherein Z is sulfur; and  $R_1$  is  $C_1\text{-}C_3$  alkyl.

15 221. A compound of the formula

$$\begin{array}{c|c} & & & & \\ & & & \\ & & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ &$$

or a pharmaceutically acceptable salt thereof, wherein  $\mbox{R}_1$  is  $\mbox{C}_1\mbox{-}\mbox{C}_2\mbox{-}\mbox{C}_3$  alkyl;

 $R_2$  and  $R_3$  are both hydrogen; or

20  $R_p$  is  $C_1-C_2$  alkyl;

 $R_f$  and  $R_g$  are both hydrogen or independently halogen; and  $R_5$  and  $R_6$  are independently  $C_3-C_4$  alkyl.

222. A compound according to claim 221, wherein  $R_1$  is ethyl.

223. A compound of the formula

or a pharmaceutically acceptable salt thereof, wherein one of X and X' is nitrogen and the other is CH or  $CR_1$ ;  $R_1$  is  $C_1-C_2-C_3$  alkyl

- 5 R<sub>2</sub> and R<sub>3</sub> are both hydrogen;  $R_p \text{ is } C_1\text{-}C_2 \text{ alkyl;}$   $R_f \text{ and } R_g \text{ are independently halogen; and}$
- 10 224. A compound according to claim 223, wherein X is CH and X' is nitrogen.

### 225. A compound of the formula

 $R_5$  and  $R_6$  are independently  $C_3-C_4$  alkyl.

or a pharmaceutically acceptable salt thereof, wherein  $R_1$  is a group of the formula:

one of  $R_{\rm s11}$  and  $R^\prime{}_{\rm s11}$  is hydrogen and the other is  $C_1 C_3$  acyl,  $C_1-C_2$  alkyl or CHO; or

one of  $R_{\text{s}11}$  and  $R'_{\text{s}11}$  is methyl and the other is CHO or methyl,

each  $R_{\rm s21}$  is  $C_1-C_3$  alkoxy, halogen, H,  $C_1-C_2$  alkyl or cyano; or

- $R_1$  is cyclopentyl, cyclohexyl, oxazolyl, isoxazolyl optionally substituted with one or two  $C_1\text{-}C_2$  alkyl groups, phenyl,
- thien-2-yl optionally substituted with CHO, unsubstituted thien-3-yl;
  - R<sub>2</sub> and R<sub>3</sub> are both hydrogen;
  - $R_p$  is  $C_1-C_2$  alkyl;
  - $R_{\text{f}}$  and  $R_{\text{g}}$  are independently halogen; and
- 10  $R_5$  and  $R_6$  are independently  $C_3-C_4$  alkyl.
  - 226. A compound according to claim 226, wherein  $R_1$  is 6-( $C_1$ - $C_2$ )alkoxypyridin-2-yl.
- 15 227. A compound according to claim 225, wherein  $R_1$  is 2-formylthien-3-yl.
  - 228. A compound according to claim 225, wherein  $R_1$  is 5-formylthien-3-yl.

20

- 229. A compound according to claim 225, wherein  $R_{\text{s21}}$  is cyano.
- 230. A compound according to claim 225, wherein  $R_1$  is 5-25 cyanopyrid-3-yl.
  - 231. A compound according to claim 225, wherein  $R_1$  is 6-halopyrid-3-yl.
- 232. A compound according to any one of claims 226 to 1285, wherein the halogen is fluoro or chloro.
  - 233. A compound according to claim 225, wherein,  $R_1$  is a substituted or unsubstituted thienyl group.

# 234. A compound of the formula

or a pharmaceutically acceptable salt thereof, wherein

 $R_s$   $R_s$  N N N N

 $R_1$  is  $C_1$ - $C_3$  alkyl or halogen;

 $R_2$  and  $R_3$  are both hydrogen;


 $R_S$  is  $C_1-C_3$  alkylsulfonyl,  $C_1-C_3$  alkylsulfonyl( $C_1-C_3$ ) alkyl,  $-NHSO_2\left(C_1-C_2\text{ alkyl}\right),\text{ or }-N\left(C_1-C_2\text{ alkyl}\right)SO_2\left(C_1-C_2\text{ alkyl}\right);\text{ and }\\ 10 \quad R_f\text{ and }R_g\text{ are independently halogen.}$ 

235. A compound according to claim 234, wherein  $R_1$  is ethyl; and

Z is Sylv

15

# 236. A compound of the formula



or a pharmaceutically acceptable salt thereof, wherein  $R_1$  is  $C_2\text{--}C_3$  alkyl;

20  $R_2$  and  $R_3$  are both hydrogen;

 $R_5$  and  $R_6$  independently represent (a)  $C_1\text{-}C_3$  alkyl optionally substituted with phenyl and (b) phenyl optionally substituted with halogen; and

 $R_f$  and  $R_g$  are independently halogen.

237. A compound according to claim 236, wherein  $R_5$  is methyl optionally substituted with phenyl and  $R_6$  is phenyl.

5 238. A compound according to claim 236, wherein  $R_5$  is  $C_1$ - $C_2$  alkyl and  $R_6$  is 4-halophenyl.

### 239. A compound of the formula

10 or a pharmaceutically acceptable salt thereof, wherein

X is nitrogen or N+-O;

 $R_1$  is  $C_2-C_4$  alkynyl or  $C_1-C_3$  alkyl;

 $R_2$  and  $R_3$  are both hydrogen; or

 $\ensuremath{R_2}$  and  $\ensuremath{R_3}$  together form a 3-membered ring with the carbon atom

15 to which they are attached;

R<sub>f</sub> and R<sub>g</sub> are independently halogen;

 $R_p$  is hydrogen or  $C_1$ - $C_2$  alkyl; and

 $R_5$  and  $R_6$  are independently  $C_3-C_4$  alkyl.

20 240. A compound according to claim 239, wherein X is nitrogen;  $R_p$  is  $C_1$ - $C_2$  alkyl; and  $R_1$  is ethyl.

### 241. A compound of the formula

25 or a pharmaceutically acceptable salt thereof, wherein

 $R_1$  is hydrogen or  $C_1-C_3$  alkyl;

R<sub>2</sub> and R<sub>3</sub> are both hydrogen;

 $R_p$  is  $C_1-C_2$  alkyl;

R<sub>f</sub> and R<sub>g</sub> are independently halogen; and

5  $R_5$  and  $R_6$  are independently  $C_3-C_4$  alkyl.

#### 242. A compound of the formula

or a pharmaceutically acceptable salt thereof, wherein

10  $R_s$  is  $NR_{s31}R_{s41}$  where

15

 $R_{S31}$  is  $C_1-C_2$  alkyl; and

 $R_{S41}$  is  $C_1-C_6$  alkyl, allyl, cyano( $C_1-C_3$ ) alkyl, ( $C_4-$ 

 $C_7$ ) cycloalkyl, pyridyl ( $C_1-C_3$ ) alkyl, phenyl, phenyl ( $C_1-$ 

 $C_3$ ) alkyl, amino  $(C_1-C_3)$  alkyl, mono  $(C_1-C_3)$  alkylamino  $(C_1-C_3)$ 

 $C_2$ ) alkyl, or di( $C_1$ - $C_3$ ) alkylamino( $C_1$ - $C_2$ ) alkyl; or

 $R_s$  is  $CH_3$ ,  $-N(C_1-C_2$  alkyl)phenyl, or  $-N(C_2-C_3$  alkyl)( $C_3-C_4$  alkyl);

 $R_1$  is  $C_2-C_3$  alkyl;

R<sub>2</sub> and R<sub>3</sub> are both hydrogen; and

20  $R_f$  and  $R_g$  are independently halogen.

243. A compound according to claim 242, wherein  $R_{\text{S}}$  is (2-cyanoethyl) (methyl) amino.

25 244. A compound according to claim 242, wherein  $R_{\rm S}$  is (cyclohexyl) (methyl)amino.

245. A compound according to claim 242, wherein  $R_{S41}$  is  $C_1$ -  $C_6$  alkyl, allyl, cyano( $C_1$ - $C_3$ )alkyl, ( $C_4$ - $C_7$ )cycloalkyl,

30 pyridyl( $C_1-C_3$ ) alkyl, phenyl, or phenyl( $C_1-C_3$ ) alkyl.

246. A compound according to claim 242, wherein  $R_{\rm 541}$  is phenyl or cyclohexyl.

- 5 247. A compound according to claim 242, wherein  $R_s$  is  $-N(CH_3)$  phenyl, or  $-N(ethyl)(C_3-C_4$  alkyl)
  - 248. A compound of the formula

- or a pharmaceutically acceptable salt thereof, wherein  $R_1$  is  $C_2$ - $C_3$  alkynyl or  $C_1$ - $C_3$  alkyl;  $R_f$  and  $R_g$  are independently halogen;  $R_5$  and  $R_6$  are independently  $C_1$ - $C_4$  alkyl.
- 15 249. A compound according to claim 248, wherein  $R_5$  and  $R_6$  are  $C_3$  alkyl.
  - $250.\ A$  compound according to claim 248, wherein  $R_5$  is methyl and  $R_6$  is  $C_3$  alkyl.
    - 251. A compound of the formula

20

or a pharmaceutically acceptable salt thereof, wherein

 $R_s$  is  $C_1-C_4$  alkyl;

 $R_m$  is  $C_1-C_4$  alkyl;

 $R_1$  is  $C_2$ - $C_3$  alkyl;

 $R_2$  and  $R_3$  are both hydrogen; and

 $R_{\text{f}}$  and  $R_{\text{g}}$  are independently halogen.

5 252. A compound of the formula

$$\begin{array}{c|c} R_{m} & O & R_{2} & R_{3} \\ \hline R_{M} & O & N & N & N \\ \hline R_{2} & R_{3} & R_{1} \\ \hline R_{2} & R_{3} & R_{1} \\ \hline \end{array}$$

or a pharmaceutically acceptable salt thereof, wherein

 $R_m$  is  $C_1-C_4$  alkyl;

 $R_1$  is  $C_2-C_3$  alkyl;

- 10  $R_2$  and  $R_3$  are both hydrogen; and  $R_f$  and  $R_g$  are independently halogen; Z is S, S(O), S(O)<sub>2</sub>, or O .
- 253. A compound according to claim 252, where Z is S or S(O).

### 254. A compound of the formula

or a pharmaceutically acceptable salt thereof, wherein one of X and X' is CH and the other is N;

R<sub>1</sub> is C<sub>2</sub>-C<sub>4</sub> alkynyl; amino(C<sub>1</sub>-C<sub>3</sub>)alkyl, mono(C<sub>1</sub>-C<sub>3</sub>)alkylamino(C<sub>1</sub>-C<sub>2</sub>)alkyl, or di(C<sub>1</sub>-C<sub>3</sub>)alkylamino(C<sub>1</sub>-C<sub>2</sub>)alkyl;

R<sub>2</sub> and R<sub>3</sub> are both hydrogen; or

 $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached;

 $R_f$  and  $R_g$  are independently halogen;

 $R_5$  and  $R_6$  are independently  $C_1-C_3-C_4$  alkyl.

5


255. A compound according to claim 254, wherein  $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached; X is N; and X' is CH.

- 10 256. A compound according to claim 254, wherein  $R_2$  and  $R_3$  are hydrogen; X' is N; and X is CH.
  - 257. A compound according to claim 255, wherein  $R_1$  is  $C_2$  alkynyl.

15

- 258. A compound according to claim 256 or 257, wherein  $R_1$  is di( $C_1$ - $C_3$ )alkylamino( $C_1$ - $C_3$ )alkyl.
- 259. A compound according to claim 256 or 257, wherein  $R_1$  20 is dimethylamino( $C_1$ - $C_2$ )alkyl.

#### 260. A compound of the formula



or a pharmaceutically acceptable salt thereof, wherein

25  $R_1$  is  $C_2-C_3$  alkyl;

 $R_2$  and  $R_3$  are both hydrogen;

 $R_f$  and  $R_g$  are independently halogen;

 $R_p$  is hydrogen, cyano,  $C_1-C_3$  alkyl, amino,  $N-(C_1-C_3$  alkylsulfonyl)- $N-((C_1-C_3)$  alkyl) amino, 2-oxazolyl, or 1-

pyrrolyl optionally substituted in the 2 and 5 positions with  $C_1-C_2$  alkyl;

 $R_a$  is  $C_1\text{-}C_3$  alkyl, H or trifluoromethyl; and  $R_{\tt j}$  is  $C_1\text{-}C_5$  alkyl.

5

- 261. A compound according to claim 260, wherein  $R_j$  is methyl or ethyl and  $R_p$  is hydrogen, methyl, or ethyl.
- 262. A compound according to claim 260, wherein  $R_{\rm j}$  is 10 methyl or butyl; and  $R_{\rm p}$  is hydrogen.

### 263. A compound of the formula

$$\begin{array}{c|c} R_{5} & O & R_{2} R_{3} \\ R_{6} & N & OH & H \end{array}$$

or a pharmaceutically acceptable salt thereof, wherein

15 X is nitrogen or N<sup>+</sup>-O<sup>-</sup>;

 $R_1$  is  $C_2$ - $C_4$  alkynyl, cyano,  $C_1$ - $C_3$  alkyl, or  $CF_3$ ;

R<sub>2</sub> and R<sub>3</sub> are both hydrogen; or

 $R_2$  and  $R_3$  together form a 3-membered ring with the carbon atom to which they are attached;

- 20  $R_f$  and  $R_g$  are independently halogen;
  - $R_p$  is hydrogen, cyano or  $C_1\text{-}C_2$  alkyl; and

 $\mbox{R}_{5}$  and  $\mbox{R}_{6}$  are independently  $\mbox{C}_{1}\mbox{-}\mbox{C}_{4}$  alkyl.

- 25 264. A compound according to claim 263, wherein X is N.
  - 265. A compound according to claim 264, wherein  $R_{\rm p}$  is cyano.

266. A compound according to claim 265, wherein  $R_5$  is methyl and  $R_6$  is  $C_2\text{-}C_4$  alkyl.

- 267. A compound according to claim 266, wherein  $R_6$  is propyl.
  - 268. A compound according to claim 264, wherein  $\ensuremath{R_1}$  is  $C_2\text{--}C_3$  alkyl;

R<sub>p</sub> is methyl; and

- 10  $R_5$  and  $R_6$  are independently  $C_3-C_4$  alkyl.
  - 269. A compound according to claim 268, wherein  $R_2$  and  $R_3$  are both hydrogen.
- 15 270. A compound according to claim 264, wherein  $R_1$  is  $C_2$ - $C_3$  alkynyl, or  $C_2$  alkyl; and  $R_p$  is methyl.
- $$271.\ A$$  compound according to claims 264, wherein \$20\$  $R_1$  is  $CF_3.$ 
  - 272. A compound of the formula

$$\begin{array}{c|c} & & & & \\ & & & \\ & & & \\ & & & \\ R_6 & & \\ & & & \\ & & \\ R_p & & \\ \end{array}$$

- or a pharmaceutically acceptable salt thereof, wherein  $R_1$  is hydrogen or methyl;
  - R<sub>2</sub> and R<sub>3</sub> are both hydrogen; or
  - $R_2$  and  $R_3$  together with the carbon atom to which they are attached form a 3-membered ring;

 $R_p$  is  $C_2-C_3$  alkynyl or  $C_1-C_3$  alkyl;

 $R_{\text{f}}$  and  $R_{\text{g}}$  are independently halogen;

 $R_5$  and  $R_6$  are independently  $C_3-C_4$  alkyl, or

 $R_5$  is methyl and  $R_6$  is  $C_3-C_4$  alkyl.

5

273. A compound according to claim 272, wherein  $R_1$  is hydrogen and  $R_2$  and  $R_3$  are both hydrogen.

- 274. A compound according to claim 272, wherein  $R_1$  is hydrogen and  $R_2$  and  $R_3$  together with the carbon atom to which they are attached form a 3-membered ring.
  - 275. A compound according to either claim 273 or 274, wherein  $R_{\text{f}}$  and  $R_{\text{g}}$  are both chloro or fluoro.

15

276. A compound according to either claim 273 or 274, wherein  $R_f$  and  $R_g$  are both fluoro and are in the 3 and 5 positions with respect to the point of attachment of the phenyl group.

20

## 277. A compound of the formula:

wherein

 $R_1$  is  $C_2$ - $C_3$  alkyl;

25 R<sub>2</sub> and R<sub>3</sub> are both methyl or

 $R_2$ ,  $R_3$ , and the carbon to which they are attached form a cyclopropyl ring;

 $R_f$  and  $R_g$  are independently halogen;

 $R_5$  and  $R_6$  are independently  $C_3-C_4$  alkyl; and

 $R_s$  is  $-NH(C_1-C_4$  hydroxyalkyl).

278. A compound according to claim 277, wherein the hydroxyalkyl group is 2-hydroxy-1,1,dimethylethyl.

5

279. A compound of the formula:

wherein

 $R_1$  is  $C_2$ - $C_3$  alkynyl;

10  $R_2$  and  $R_3$  are both hydrogen; or  $R_f$  and  $R_g$  are independently halogen;  $R_5$  and  $R_6$  are independently  $C_3$ - $C_4$  alkyl; and

 $R_s$  is  $-NH(C_2-C_4$  hydroxyalkyl).

15 280. A compound according to claim 279, wherein the hydroxyalkyl group is 2-hydroxy-1,1,dimethylethyl; or 2-hydroxyethyl.

281. A compound of the formula:

20

wherein,

 $R_c$  is  $C_4-C_5$  alkyl; cyclopropyl; tetrahydronaphthylenyl; -CH( $C_2$  alkyl-S-( $C_1-C_2$ ) alkyl)C(0)NH( $C_4$  alkyl); -CH( $C_2$  alkyl-SO<sub>2</sub>-( $C_1-C_2$ ) alkyl)C(0)NH( $C_4$  alkyl); pyrimidyl optionally

substituted with  $C_3-C_4$  alkyl; thiochroman 1,1-dioxide; -CH<sub>2</sub>-thiazolyl optionally substituted with  $C_3-C_4$  alkyl;  $R_f$  and  $R_g$  are independently halogen;

 $\mbox{R}_{\mbox{\scriptsize p}}$  is  $\mbox{-NHSO}_2\mbox{CF}_3$  ,  $\mbox{-SO}_2\mbox{NH}(\mbox{C}_3\mbox{-}\mbox{C}_4$  hydroxyalkyl),  $\mbox{-NHSO}_2\mbox{CH}_3$  ; oxazol-2-yl, and

 $\ensuremath{\text{R}}_5$  and  $\ensuremath{\text{R}}_6$  are independently  $\ensuremath{\text{C}}_3\text{--}\ensuremath{\text{C}}_4$  alkyl.

- 282. A compound according to claim 281, wherein

  R<sub>c</sub> is isobutyl; or 1,2,3,4-tetrahydronaphthylen-1-yl,

  -CH(CH<sub>2</sub>CH<sub>2</sub>-S-CH<sub>3</sub>)C(O)NH(isobutyl), 2-tert butylpyrimidin-4yl.
  - 283. A compound according to claim 281, wherein  $R_p$  is  $-SO_2NH(2-hydroxy-1,1-dimethylethyl)$ .
- 15 284. A compound according to claim 282 or 283, wherein  $R_5$  and  $R_6$  are both  $C_3$  alkyl.
  - 285. A compound according to claim 281, wherein  $R_p$  is oxazol-2-yl; and  $R_c$  is -CH<sub>2</sub>-(2-isobutylthiazol-5-yl).

286. A compound of the formula:

wherein

5

20

25  $R_1$  is  $C_2$ - $C_3$  alkyl, or halogen;

 $R_2$  and  $R_3$  are both hydrogen;

 $R_{\text{f}}$  and  $R_{\text{g}}$  are independently halogen; and

 $R_m$  is  $-NH-SO_2CF_3$ , oxazol-2-yl,  $-N(CH_3)SO_2CH_3$ ,  $-N(C_3-C4)$  hydroxyalkyl) $SO_2(C_1-C_2)$  alkyl), and  $R_p$  is H; or

30  $R_m$  is H and  $R_p$  is  $-NH-SO_2CF_3$ ,  $-CH_2SO_2(C_1-C_2 \text{ alkyl})$ ; or

 $R_m$  is -C(0) pyrrolidinyl and  $R_p$  is OH.

### 287. A compound of the formula:

#### 5 wherein

10 R<sub>2</sub> and R<sub>3</sub> are both hydrogen;

R<sub>f</sub> and R<sub>g</sub> are independently halogen;

 $R_p$  is  $C_1-C_2$  alkyl;

 $R_5$  and  $R_6$  are independently  $C_3-C_5$  alkyl,  $C_1-C_2$  alkoxy  $C_1-C_2,_3$  alkyl, or

15 R<sub>5</sub> is H and R<sub>6</sub> is  $C_{4,5}$ - $C_6$  alkyl or  $(C_1$ - $C_2$  alkoxy)- $(C_2$ - $C_3$  alkyl); R<sub>5</sub> is ethyl and R<sub>6</sub> is  $C_2$ - $C_3$  hydroxyalkyl or - $(C_1$ - $C_2$  alkyl)- $N(C_1$ - $C_2$  alkyl); or

 $R_5$  is  $CH_3$  and  $R_6$  is  $C_4-C_5$  alkyl, cyclohexyl,  $-(C_1-C_2$  alkyl) - phenyl,  $-(C_1-C_2$  alkyl)-pyridyl, or  $-CH_2$ -furyl; or

20  $R_5$  is methyl or ethyl and  $R_6$  is  $(C_1-C_2 \text{ alkoxy})-(C_2-C_3 \text{ alkyl})$ , or  $R_5$ ,  $R_6$ , and the nitrogen to which they are attached form a piperidinyl ring optionally substituted with  $C_3-C_4$  alkyl or OH, azepanyl, pyrrolidine-2-carboxylic acid amide, 3-hydroxypiperidin-1-yl.

25

288. A compound according to claim 287, wherein  $\ensuremath{R_1}$  is  $C_2\text{--}C_3$  alkyl.

289. A compound according to claim 288, wherein

 $R_5$  and  $R_6$  are simultaneously ethoxyethyl or  $R_5$  is propyl and  $R_6$  is butyl.

- 290. A compound according to claim 288, wherein  $R_5$ ,  $R_6$ , and the nitrogen to which they are attached form a 2-propyl piperidin-1-yl ring.
- 291. A compound according to claim 287, wherein

  R<sub>1</sub> is cyclopentyl, cyclohexyl, propenyl, allyl, or -(C<sub>3</sub>-C<sub>6</sub>

  alkyl)-CN, C<sub>2</sub>-C<sub>5</sub> alkyl, 4-chlorobutyl, 3-pyridyl, methyl

  2-methylpropanoate, hex-5-enyl, CN, -N(CH<sub>3</sub>)SO<sub>2</sub>CH<sub>3</sub>,

  -SO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, 3-methylpyrid-2-yl, oxazol-2-yl, 3,5
  dimethylisoxazol-4-yl, 3-methylthien-2-yl, 2-pyridyl, 4
  carbaldehydefuran-5-yl, and 2-carbaldehydethien-5-yl, 2
  carbaldehyde-3-methylthien-5-yl, 2-methoxypyridin-4-yl,

  -NH-cyclopropyl, -NHSO<sub>2</sub>CH<sub>3</sub>; and

  R<sub>p</sub> is methyl.
- $292.\ A$  compound according to claim 291, wherein 20  $\ R_5$  and  $R_6$  are both  $C_3$  alkyl.
  - 293. A compound of the formula:

wherein

25  $R_1$  is  $C_2$ - $C_3$  alkyl, halogen, -NH(cyclopropyl),  $R_f$  and  $R_g$  are independently halogen;  $R_p$  is  $C_1$ - $C_2$  alkyl, oxazolyl, thiazolyl, or  $C_2$ - $C_3$  alkynyl;  $R_2$ ,  $R_3$ , and the carbon to which they are attached form a cyclopropyl ring; or

 $R_2$  and  $R_3$  are both methyl;  $R_5$  and  $R_6$  are independently  $C_3-C_4$  alkyl; or  $R_5$  is methyl and  $R_6$  is  $C_3-C_5$  alkyl.

5 294. A compound according to claim 293, wherein  $R_2$  and  $R_3$  are both methyl; and  $R_5$  and  $R_6$  are independently  $C_3$ - $C_4$  alkyl.

295. A compound according to claim 294, wherein 10  $R_p$  is oxazol-2-yl or thiazol-2-yl.

296. A compound according to claim 294, wherein  $R_p$  is  $C_2\hbox{-} C_3$  alkynyl; and  $R_5$  and  $R_6$  are independently  $C_3\hbox{-} C_4$  alkyl.

15

### 297. A compound of the formula:

wherein

Rc is isoxazolyl optionally substituted with C3-C5 alkyl,

thiazolyl optionally substituted with  $C_3-C_4$  alkyl, or  $-C_1-C_3$  alkyl- $C(0)NH(C_1-C_3$  alkyl);

R<sub>f</sub> and R<sub>g</sub> are independently halogen;

 $R_p$  is  $C_1 - C_2$  alkyl, oxazolyl, thiazolyl, or  $C_2 - C_4$  alkynyl;

 $R_5$  and  $R_6$  are independently  $C_3$ - $C_4$  alkyl.

25

298. A compound according to claim 297, wherein  $R_p$  is oxazol-2-yl or thiazol-2-yl;

299. A compound according to claim 298, wherein

 $R_c$  is 3-isobutylisoxazol-5-yl or N-isobutyl-2-methylpropion-2-yl amide; and  $R_f$  and  $R_g$  are independently Cl or F.

300. A compound according to claim 298, wherein  $R_c$  is 2-isobutylthiazol-2-yl; and  $R_f$  and  $R_g$  are independently Cl or F.

301. A compound according to claim 297, wherein

10 R<sub>c</sub> is 3-isobutylisoxazol-5-yl or N-isobutyl-2-methylpropion-2yl amide;

 $R_{\text{f}}$  and  $R_{\text{g}}$  are independently C1 or F; and  $R_{\text{p}}$  is  $C_2\text{--}C_3$  alkynyl.

15 302. A compound of the formula:

wherein

Hal is a halogen;

 $R_1$  is  $C_1-C_2$  alkyl, or halogen;

20  $R_2$  and  $R_3$  are both hydrogen;

 $R_{\text{f}}$  and  $R_{\text{g}}$  are independently halogen;

 $R_z$  is  $C_1-C_2$  alkyl;

 $\mbox{R}_{5}$  and  $\mbox{R}_{6}$  are independently  $\mbox{C}_{3}\mbox{-}\mbox{C}_{4}$  alkyl.

- 303. A compound according to claim 302, wherein Hal is bromo or chloro.
  - 304. A compound according to claim 303, wherein  $\ensuremath{R_1}$  is methyl, ethyl, bromo or iodo.

30

305. A compound of the formula:

n is 0 or 1;

 $R_1$  is  $C_1-C_2$  alkyl;

5  $R_2$  and  $R_3$  are both hydrogen;

 $R_{\text{f}}$  and  $R_{\text{g}}$  are independently halogen;

 $R_s$  is  $(C_1-C_2)$  alkoxy $(C_1-C_2)$  alkyl.

306. A compound according to claim 305, wherein  $R_2$  is methoxymethyl.

307. A compound of the formula:

$$\begin{array}{c|c} & & & & \\ & & & \\ & & & \\ & & & \\ R_{6} & & \\ & & \\ R_{p} & & \\ \end{array}$$

wherein

15  $R_1$  is  $C_1-C_2$  alkyl;

 $R_2$  and  $R_3$  are both hydrogen;

 $R_{\text{f}}$  and  $R_{\text{g}}$  are independently halogen;

 $\ensuremath{R_{\text{p}}}$  is isoxazole optionally substituted with  $\ensuremath{\text{C}_{1}\text{--}\text{C}_{2}}$  alkyl;

 $\mbox{R}_{5}$  and  $\mbox{R}_{6}$  are independently  $\mbox{C}_{3}\mbox{-}\mbox{C}_{4}$  alkyl.

20

308. A compound according to claim 307, wherein  $R_p$  is 3-methylisoxazol-4-yl, 5-oxazolyl, 3-oxazolyl, 3-methyloxazol-2-yl, 3-ethyloxazol-2-yl.

# 309. A compound which is

- N-[1-(3,5-Difluoro-benzyl)-2-hydroxy-3-(1-isobutylcarbamoyl-3-methylsulfanyl-propylamino)-propyl]-5-methyl-N',N'-dipropyl-isophthalamide;
- $N^4$ -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-6-methyl- $N^2$ ,  $N^2$ -dipropylpyridine-2,4-dicarboxamide;
- $N^1$ -butyl-N3-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}- $N^1$ -methyl-5-(1,3-thiazol-2-yl)isophthalamide;
- $N^1-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1\}-N^3-methyl-N^3-propyl-5-(1,3-thiazol-2-yl)isophthalamide;$
- $N^{1}-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-N^{3}-methyl-5-(1,3-oxazol-2-y1)-N^{3}-propylisophthalamide;$
- $N^1$ -butyl-N3-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}- $N^1$ -methyl-5-(1,3-oxazol-2-yl)isophthalamide;
- $N^{1}-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-N^{3}-ethyl-5-(1,3-oxazol-2-yl)-N^{3}-propylisophthalamide;$
- N-[1-(3,5-Difluoro-benzyl)-3-(1-ethylcarbamoyl-ethylamino)-2-hydroxy-propyl]-5-methyl-N',N'-dipropyl-isophthalamide;
- $\label{eq:N-lambda} $$N-[1-(3,5-Diffluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-N'-dimethylcarbamoylmethyl-5,N'-dimethyl-isophthalamide;$
- N-[1-(3,5-Difluoro-benzyl)-2-hydroxy-3-(1-methylcarbamoyl-3-methylsulfanyl-propylamino)-propyl]-5-methyl-N',N'-dipropyl-isophthalamide;
- N-[3-(1-Benzylcarbamoyl-ethylamino)-1-(3,5-difluoro-benzyl)-2-hydroxy-propyl]-5-methyl-N',N'-dipropyl-isophthalamide;
- N-{[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propylcarbamoyl]-methyl}-3-trifluoromethyl-benzamide;
- N-{[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propylcarbamoyl]-methyl}-4-trifluoromethyl-benzamide;
- 3,4-Dichloro-N-{[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propylcarbamoyl]-methyl}-benzamide;
- N-[3-(1-Carbamoy1-3-methy1-buty1amino)-1-(3,5-difluoro-benzy1)-2-hydroxy-propy1]-5-methy1-N',N'-dipropy1-isophthalamide;
- N-{[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propylcarbamoyl}-methyl}-4-methoxy-benzamide;
- N-{[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propylcarbamoyl]-methyl}-2,6-difluoro-benzamide;
- N-[3-(1-Carbamoyl-ethylamino)-1-(3,5-difluoro-benzyl)-2-hydroxy-propyl]-5-methyl-N',N'-dipropyl-isophthalamide;

```
N-\{[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propylcarbamoyl]-methyl\}-2,6-dimethoxy-benzamide;
```

- 2-{[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propylcarbamoyl]-methylsulfanyl}-N-(4-oxazol-5-yl-phenyl)-acetamide;
- 2-{[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propylcarbamoyl]-methylsulfanyl}-N-(5-methyl-isoxazol-3-yl)-acetamide;
- N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-4-methanesulfonyl-benzenesulfonamide;
- 2-Cyano-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-benzenesulfonamide;
- 2-Chloro-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-4-trifluoromethoxy-benzenesulfonamide;
- 2-Chloro-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-6-methyl-benzenesulfonamide;
- 5-Chloro-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-methoxy-benzenesulfonamide;
- 2-Chloro-4-cyano-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-benzenesulfonamide;
- N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-trifluoromethyl-benzenesulfonamide;
- 4-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propylsulfamoyl]-benzoic acid;
- 6-Chloro-pyridine-3-sulfonic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2,5-bis-(2,2,2-trifluoro-ethoxy)-benzenesulfonamide;
- Pyridine-3-sulfonic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- N-{2-Chloro-4-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propylsulfamoyl]-phenyl}-acetamide;
- N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-trifluoromethoxy-benzenesulfonamide;
- N-{5-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propylsulfamoyl]-thiophen-2-ylmethyl}-benzamide;
- 5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- N-{5-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propylsulfamoyl]-4-methyl-thiazol-2-yl}-acetamide;
- 4-Chloro-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-benzenesulfonamide;
- 3-Chloro-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-benzenesulfonamide;
- N-[1-(3,5-Difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propyl]-2-trifluoromethyl-benzenesulfonamide;

```
6-Chloro-pyridine-3-sulfonic acid [1-(3,5-difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propyl]-amide;
```

- Pyridine-3-sulfonic acid [1-(3,5-difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propyl]-amide;
- N-[1-(3,5-Difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propyl]-2-methanesulfonyl-benzenesulfonamide;
- 3,5-Dichloro-N-[1-(3,5-difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propyl]-benzenesulfonamide;
- 1,2-Dimethyl-1H-imidazole-4-sulfonic acid [1-(3,5-difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propyl]-amide;
- N-[1-(3,5-Difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propyl]-3,4-dimethoxy-benzenesulfonamide;
- 2-(2,2,2-Trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonic acid [1-(3,5-difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propyl]-amide;
- 5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonic acid [1-(3,5-difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propyl]-amide;
- 3-{4-[1-(3,5-Difluoro-benzy1)-2-hydroxy-3-(3-methoxy-benzylamino)-propylsulfamoyl]-phenyl}-propionic acid methyl ester:
- 3-Chloro-N-[1-(3,5-difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propyl]-benzenesulfonamide;
- 3-Cyano-N-[1-(3,5-difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propyl]-benzenesulfonamide;
- Butane-1-sulfonic acid [1-(3,5-difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propyl]-amide;
- $N-\{1-(3,5-Difluoro-benzyl)-2-hydroxy-3-[(1-methanesulfonyl-piperidin-4-ylmethyl)-amino]-propyl\}-5-methyl-N',N'-dipropyl-isophthalamide;$
- N-[3-Benzenesulfonylamino-1-(3,5-difluoro-benzyl)-2-hydroxy-propyl]-5-methyl-N',N'-dipropyl-isophthalamide;
- N-[1-(3,5-Difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzoylamino)-propyl]-5-methyl-N',N'-dipropyl-isophthalamide;
- 4-(3,5-Difluoro-phenyl)-3-(2,5-dimethyl-4-nitro-2H-pyrazol-3-ylamino)-1-(3-methoxy-benzylamino)-butan-2-ol;
- 3-(2-Amino-7H-purin-6-ylamino)-4-(3,5-difluoro-phenyl)-1-(3-methoxy-benzylamino)-butan-2-ol;
- 3-(4-Chloro-pyrimidin-2-ylamino)-4-(3,5-difluoro-phenyl)-1-(3-methoxy-benzylamino)-butan-2-ol;
- 3-(2-Amino-6-methyl-pyrimidin-4-ylamino)-4-(3,5-difluoro-phenyl)-1-(3-methoxy-benzylamino)-butan-2-ol;
- 3-(2-Chloro-6-methyl-pyrimidin-4-ylamino)-4-(3,5-difluoro-phenyl)-1-(3-methoxy-benzylamino)-butan-2-ol;
- 3-(2-Amino-6-chloro-pyrimidin-4-ylamino)-4-(3,5-difluoro-phenyl)-1-(3-methoxy-benzylamino)-butan-2-ol;
- 4-(3,5-Difluoro-phenyl)-1-(3-methoxy-benzylamino)-3-(1-phenyl-1H-tetrazol-5-ylamino)-butan-2-ol;

3-(2-Chloro-7H-purin-6-ylamino)-4-(3,5-difluoro-phenyl)-1-(3-methoxy-benzylamino)-butan-2-ol;

- 4-(3,5-Difluoro-phenyl)-1-(3-methoxy-benzylamino)-3-[9-(tetrahydro-pyran-2-yl)-9H-purin-6-ylamino]-butan-2-ol;
- 3-[1-(3,5-Difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propylamino]-pyrazine-2-carbonitrile;
- 4-(3,5-Difluoro-phenyl)-3-(4,6-dimethoxy-[1,3,5]triazin-2-ylamino)-1-(3-methoxy-benzylamino)-butan-2-ol;
- 2-[1-(3,5-Difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propylamino]-nicotinonitrile;
- 4-(3,5-Difluoro-phenyl)-1-(3-methoxy-benzylamino)-3-(7H-purin-6-ylamino)-butan-2-ol;
- 3-(Benzothiazol-2-ylamino)-4-(3,5-difluoro-phenyl)-1-(3-methoxy-benzylamino)-butan-2-ol;
- 4-(3,5-Difluoro-phenyl)-1-(3-methoxy-benzylamino)-3-(2-phenyl-quinolin-4-ylamino)-butan-2-ol;
- 6-[1-(3,5-Difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propylamino]-nicotinonitrile;
- 2-[1-(3,5-Difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propylamino]-nicotinic acid ethyl ester;
- 4-(3,5-Difluoro-phenyl)-1-(3-methoxy-benzylamino)-3-(3-methyl-5-nitro-3H-imidazol-4-ylamino)-butan-2-ol;
- 3-(Benzooxazol-2-ylamino)-4-(3,5-difluoro-phenyl)-1-(3-methoxy-benzylamino)-butan-2-ol;
- .4-(3,5-Difluoro-phenyl)-1-(3-methoxy-benzylamino)-3-(quinolin-4-ylamino)-butan-2-ol;
- 4-(3,5-Difluoro-phenyl)-3-(5-ethyl-pyrimidin-2-ylamino)-1-(3-methoxy-benzylamino)-butan-2-ol;
- 4-(3,5-Difluoro-phenyl)-1-(3-methoxy-benzylamino)-3-(4-trifluoromethyl-pyrimidin-2-ylamino)-butan-2-ol;
- 3-(6-Chloro-2-methylsulfanyl-5-phenyl-pyrimidin-4-ylamino)-4-(3,5-difluoro-phenyl)-1-(3-methoxy-benzylamino)-butan-2-ol;
- 3-(3-Chloro-quinoxalin-2-ylamino)-4-(3,5-difluoro-phenyl)-1-(3-methoxy-benzylamino)-butan-2-ol;
- 4-(3,5-Difluoro-phenyl)-1-(3-methoxy-benzylamino)-3-(8-trifluoromethyl-quinolin-4-ylamino)-butan-2-ol;
- 3-(6-Chloro-2,5-diphenyl-pyrimidin-4-ylamino)-4-(3,5-difluoro-phenyl)-1-(3-methoxy-benzylamino)-butan-2-ol;
- 3-(3-Chloro-pyrazin-2-ylamino)-4-(3,5-difluoro-phenyl)-1-(3-methoxy-benzylamino)-butan-2-ol;
- 4-(3,5-Difluoro-phenyl)-1-(3-methoxy-benzylamino)-3-(5-trifluoromethyl-pyridin-2-ylamino)-butan-2-ol;
- 4-(3,5-Difluoro-phenyl)-1-(3-methoxy-benzylamino)-3-(quinolin-2-ylamino)-butan-2-ol;
- 3-(6-Chloro-pyrazin-2-ylamino)-4-(3,5-difluoro-phenyl)-1-(3-methoxy-benzylamino)-butan-2-ol;

4-(3,5-Difluoro-phenyl)-1-(3-methoxy-benzylamino)-3-(3-nitro-pyridin-2-ylamino)-butan-2-ol;

- 4-(3,5-Difluoro-phenyl)-1-(3-methoxy-benzylamino)-3-(pyrimidin-2-ylamino)-butan-2-ol;
- 4-(3,5-Difluoro-phenyl)-1-(3-methoxy-benzylamino)-3-(2-phenyl-quinazolin-4-ylamino)-butan-2-ol;
- N-[3-(N'-Acetyl-N-ethyl-hydrazino)-1-benzyl-2-hydroxy-propyl]-3-hydroxy-4-(pyrrolidine-1-carbonyl)-benzamide;
- 3-(4,6-Diamino-[1,3,5]triazin-2-ylamino)-4-(3,5-difluoro-phenyl)-1-(3-methoxy-benzylamino)-butan-2-ol;
- 5-Acetylamino-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-hydroxy-benzamide;
- 2-(2,5-Dimethyl-pyrrol-1-yl)-thiophene-3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- $N-\{1-(3,5-Difluoro-benzyl)-2-hydroxy-3-[3-(3-hydroxymethyl-piperidine-1-carbonyl)-phenylamino]-propyl\}-5-methyl-N',N'-dipropyl-isophthalamide;$
- 4-Phenyl-[1,2,3]thiadiazole-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- N-[3-(3-Cyclohexyl-1-phenyl-propylamino)-1-(3,5-difluoro-benzyl)-2-hydroxy-propyl]-5-methyl-N',N'-dipropyl-isophthalamide;
- 2-Methanesulfonylamino-oxazole-4-carboxylic acid {1-benzyl-3-[N-ethyl-N'-(3-ethyl-benzoyl)-hydrazino]-2-hydroxy-propyl}-amide;
- N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-(2,6-dimethyl-phenoxy)-propionamide;
- 2-Methanesulfonylamino-oxazole-4-carboxylic acid {1-benzyl-3-[N-ethyl-N'-(4-methyl-pentanoyl)-hydrazino]-2-hydroxy-propyl}-amide;
- 4-Acetylamino-1-methyl-1H-pyrrole-2-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- 2-Ethyl-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- 2-Methanesulfonylamino-oxazole-4-carboxylic acid [3-(N'-acetyl-N-ethyl-hydrazino)-1-benzyl-2-hydroxy-propyl]-amide;
- 2-Methanesulfonylamino-oxazole-4-carboxylic acid [3-(N'-benzoyl-N-ethyl-hydrazino)-1-benzyl-2-hydroxy-propyl]-amide;
- 6-Methyl-4-oxo-1-phenyl-1,4-dihydro-pyridazine-3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- 2-Methanesulfonylamino-thiazole-4-carboxylic acid {1-benzyl-3-[N-ethyl-N'-(3-ethyl-benzoyl)-hydrazino]-2-hydroxy-propyl}-amide;

4-Methyl-2-phenyl-oxazole-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide:

- 2-Methanesulfonylamino-thiazole-4-carboxylic acid [3-(N'-acetyl-N-ethyl-hydrazino)-1-benzyl-2-hydroxy-propyl]-amide;
- N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-pyridin-3-yl-benzamide;
- 2-p-Tolyl-thiazole-4-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- N-{1-Benzyl-3-[N-ethyl-N'-(3-ethyl-benzoyl)-hydrazino]-2-hydroxy-propyl}-2-[4-(2-oxo-pyrrolidin-1-yl)-phenyl]-acetamide;
- 2-Phenoxymethyl-thiazole-4-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide:
- $\begin{tabular}{ll} N-\{1-Benzyl-3-[N-ethyl-N'-(4-methyl-pentanoyl)-hydrazino]-2-hydroxy-propyl\}-2-[4-(2-oxo-pyrrolidin-1-yl)-phenyl]-acetamide; \end{tabular}$
- [1,2,5]Thiadiazole-3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- N-[3-(N'-Acetyl-N-ethyl-hydrazino)-1-benzyl-2-hydroxy-propyl]-2-[4-(2-oxo-pyrrolidin-1-yl)-phenyl]-acetamide;
- 2-m-Tolyl-thiazole-4-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- N-[3-(N'-Benzoyl-N-ethyl-hydrazino)-1-benzyl-2-hydroxy-propyl]-2-[4-(2-oxo-pyrrolidin-1-yl)-phenyl]-acetamide;
- 2-(2-Chloro-phenyl)-thiazole-4-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- N-{1-Benzyl-3-[N-ethyl-N'-(3-ethyl-benzoyl)-hydrazino]-2-hydroxy-propyl}-3-hydroxy-4-(pyrrolidine-1-carbonyl)-benzamide;
- N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-3-phenyl-2-tetrazol-1-yl-propionamide;
- N-{1-Benzyl-3-[N-ethyl-N'-(4-methyl-pentanoyl)-hydrazino]-2-hydroxy-propyl}-3-hydroxy-4-(pyrrolidine-1-carbonyl)-benzamide;
- 4-Chloro-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridine-2-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- 2-Propyl-tetrahydro-pyran-4-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- 5-p-Tolyl-3,4-dihydro-2H-pyrazole-3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- 2-Acetylamino-5-chloro-thiophene-3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;

4-(4-Methoxy-phenyl)-thiophene-2-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;

- N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-N'-(2-fluoro-5-methanesulfonyl-phenyl)-succinamide;
- 1-(4-Fluoro-phenyl)-5-methyl-1H-[1,2,4]triazole-3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- N-(2-Acetyl-thiophen-3-yl)-N'-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-succinamide;
- 6-Chloro-4-trifluoromethyl-pyridine-2-carboxy; ic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- N-[1-(3,5-Difluoro-benzy1)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-acetamide;
- N-(1-Cyclopropyl-ethyl)-N'-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-N-phenyl-succinamide;
- N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-(3,4-dimethoxy-phenylsulfanyl)-acetamide;
- 1-Methyl-5-oxo-2-pyridin-3-yl-pyrrolidine-3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- 4-Methoxy-thiophene-3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- 2,5-Dimethyl-1-pyridin-4-ylmethyl-1H-pyrrole-3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- 2-Methyl-5-thiophen-2-yl-furan-3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- 4-(4-Benzyl-[1,4]diazepan-1-yl)-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-4-oxo-butyramide;
- 2-(Benzo[1,2,5]thiadiazol-4-yloxy)-N-[1-(3,5-difluorobenzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-acetamide;
- 3-Chloro-5-phenyl-isothiazole-4-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- N-[1-(3,5-Difluoro-benzy1)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-5-phenylethynyl-nicotinamide;
- 4,7-Dimethoxy-benzofuran-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-3-morpholin-4-ylmethyl-benzamide;
- 2,2-Dimethyl-4-oxo-chroman-6-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;

```
[1,6]Naphthyridine-2-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
```

- 8-Cyano-4-hydroxy-quinoline-3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide:
- 2-Pyridin-3-yl-thiazole-4-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide:
- 5-Chloro-benzofuran-2-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- 4-Dibenzofuran-2-yl-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-4-oxo-butyramide;
- N-{[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propylcarbamoyl]-methyl}-nicotinamide;
- 4-tert-Butyl-N-{[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propylcarbamoyl]-methyl}-benzamide;
- 4-Chloro-N-{[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propylcarbamoyl]-methyl}-benzamide;
- 4-Chloro-6-methyl-quinoline-2-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-(2,4-dihydroxy-thiazol-5-yl)-acetamide;
- 2-Methyl-pyrimidine-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-4-piperidin-1-yl-benzamide;
- 4-Acetylamino-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-benzamide;
- N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-4-methoxy-benzamide;
- 4-Methyl-oxazole-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- 1H-Indole-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- 6-Chloro-1H-indole-2-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- 2-(4-Chloro-2-oxo-benzothiazol-3-yl)-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-acetamide;
- Thiophene-3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- 2-Methyl-oxazole-4-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-(1-oxy-pyridin-3-yl)-acetamide;
- N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-hydroxy-2-phenyl-2-thiophen-2-yl-acetamide;

6-Hydroxy-2-methylsulfanyl-pyrimidine-4-carboxylic aci [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;

- 2,5-Dimethyl-furan-3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-nicotinamide;
- N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-4-(3-methoxy-phenyl)-4-oxo-butyramide;
- 4-Acetyl-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-benzamide;
- N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-4-hydroxy-3,5-dimethoxy-benzamide;
- Furan-2-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-purin-7-yl)-acetamide;
- 4-Acetylamino-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2,6-dimethyl-benzamide;
- N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-thiophen-2-yl-acetamide;
- N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-4-oxo-4-phenyl-butyramide;
- 1H-Indole-3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propionamide;
- 3-Benzo[1,3]dioxol-5-yl-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-propionamide;
- N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-4-morpholin-4-yl-4-oxo-butyramide;
- [2,3']Bithiophenyl-5-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- 5-Methoxy-thiophene-2-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- 4-Phenyl-thiophene-2-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- 2-(5-Benzo[1,3]dioxol-5-yl-tetrazol-2-yl)-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-acetamide;
- 2-(Benzothiazol-2-ylmethoxy)-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-acetamide;
- Pyrrolidine-1,2-dicarboxylic acid 1-{[1-(3,5-difluorobenzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide} 2-phenylamide;

```
N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-3-(6-ethoxy-1H-benzoimidazol-2-yl)-propionamide;
```

- N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-(3-methyl-2-oxo-2,3-dihydro-benzoimidazol-1-yl)-acetamide;
- 2-0xo-2,3-dihydro-benzooxazole-6-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- Thieno[3,2-c]pyridine-2-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- 1-Methyl-1H-indole-3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- Benzo[b]thiophene-3-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- 4-0xy-3-propyl-pyrazine-2-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- 1,1,3-Trioxo-2,3-dihydro-1H-116-benzo[d]isothiazole-6-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-(7-hydroxy-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylsulfanyl)-acetamide;
- 2-Hydroxy-6-methyl-quinoline-4-carboxylic acid [1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-amide;
- N-[1-(3,5-Difluoro-benzy1)-3-(3-ethy1-benzy1amino)-2-hydroxy-propy1]-2-(2-methy1-2,3-dihydro-benzofuran-5-y1)-propionamide;
- 3-(Benzooxazol-2-ylsulfanyl)-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-propionamide;
- N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-2-(5-o-tolyl-tetrazol-2-yl)-acetamide;
- 2-Chloro-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-4-tetrazol-1-yl-benzamide;
- N-(4-tert-Butyl-thiazol-2-yl)-N'-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-succinamide;
- N-(5-Cyclopropyl-[1,3,4]thiadiazol-2-yl)-N'-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-succinamide;
- 2-(3-Chloro-phenoxy)-N-[1-(3,5-difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-propionamide;
- N-[1-(3,5-Difluoro-benzyl)-3-(3-ethyl-benzylamino)-2-hydroxy-propyl]-3-(pyridin-4-ylmethylsulfanyl)-benzamide;
- $N^{1}$ -{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(2-hydroxyethyl)amino]sulfonyl}- $N^{3}$ ,  $N^{3}$ -dipropylisophthalamide;

```
N^{1}-((1S, 2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(2-
isobutyl-1,3-thiazol-5-yl)methyl]amino}propyl)-5-ethynyl-N3,N3-
dipropylisophthalamide;
           N^{1}-{ (1s, 2r) -1-(3, 5-difluorobenzyl) -2-hydroxy-3-[(3-
isopropylbenzyl)amino]propyl}-5-ethynyl-N³,N³-
dipropylisophthalamide;
           N^{1}-{ (1S, 2R) -1- (3, 5-difluorobenzyl) -2-hydroxy-3-[(3-
isopropylbenzyl)amino]propyl}-5-(1,3-oxazol-2-yl)-N3,N3-
dipropylisophthalamide;
           N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(2-hydroxy-1,1-
dimethylethyl)amino]sulfonyl}-N3,N3-dipropylisophthalamide;
           N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - [(3 - 3) - 3] \}
ethylbenzyl)amino]-2-hydroxypropyl}-5-(4-methyl-1,3-oxazol-2-
yl) -N^3, N^3-dipropylisophthalamide;
           N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(2-
isobutyl-1,3-thiazol-5-yl)methyl]amino}propyl)-5-(1,3-oxazol-2-
yl)-N3,N3-dipropylisophthalamide;
           N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(3-
hydroxypropyl)amino]sulfonyl}-N3,N3-dipropylisophthalamide;
           methyl [3-({[(2R,3S)-4-(3,5-difluorophenyl)-3-({3-
[(dipropylamino)carbonyl]-5-methylbenzoyl}amino)-2-
hydroxybutyl]amino}methyl)phenyl]methylcarbamate;
           N' - ((1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - \{ [(4R) - 2, 2 - dioxido - 2, 2 - diox
3,4-dihydro-1H-2,1-benzothiazin-4-yl]amino}-2-hydroxypropyl)-5-
methyl-N,N-dipropylisophthalamide
           N' - ((1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - \{[(4S) - 2, 2 - dioxido-
3,4-dihydro-1H-2,1-benzothiazin-4-yl]amino}-2-hydroxypropyl)-5-
methyl-N, N-dipropylisophthalamide
           N^{1} = \{ (1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - [(3 - 3) - 3] \}
ethylbenzyl)amino]-2-hydroxypropyl}-3,3-dimethyl-N2,N2-
dipropylcyclopropane-1,2-dicarboxamide
           N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>2</sup>-(2,2-dimethylpropanoyl)-
3-[(1-propylbutyl)sulfonyl]-D-alaninamide
           N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzyl)]
ethylbenzyl)amino]-2-hydroxypropyl}-N3,N3-dipropyl-5-pyrimidin-
2-ylisophthalamide
           N^{1}-{ (1S, 2R) -1-(3,5-difluorobenzyl) -2-hydroxy-3-[(3-
propylbenzyl)amino]propyl}-5-methyl-N3,N3-
dipropylisophthalamide;
            N^{1}-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
 ethynylbenzyl)amino]-2-hydroxypropyl}-5-ethynyl-N<sup>3</sup>,N<sup>3</sup>-
 dipropylisophthalamide;
            N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(3-
 isobutylisoxazol-5-yl)methyl]amino}propyl)-5-ethynyl-N3,N3-
 dipropylisophthalamide;
            N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-5-
 [(dimethylamino)sulfonyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
```

```
N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-oxazol-2-yl)-N^3, N^3-
dipropylisophthalamide;
           N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[3-(5-formylthien-2-
yl) benzyl] amino} -2 -hydroxypropyl) -5 -methyl -N^3, N^3 -
dipropylisophthalamide;
           5-bromo-N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
[(3-iodobenzyl)amino]propyl}-N3,N3-dipropylisophthalamide;
           N^{1}-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-({[(1R)-2-hydroxy-1-
methylethyl]amino}sulfonyl)-N3,N3-dipropylisophthalamide;
           N^{1}-{ (1S, 2R) -1- (3, 5-difluorobenzyl) -2-hydroxy-3-[(3-
isobutylbenzyl) amino [propyl] -5-methyl-N3, N3-
dipropylisophthalamide;
           N^{1}-((1S, 2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[3-
(trifluoromethyl)benzyl]amino}propyl)-5-ethynyl-N3,N3-
dipropylisophthalamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2R)-2-
 (methoxymethyl)pyrrolidin-1-yl]carbonyl}-5-methylbenzamide;
           N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-({[(1S)-2-hydroxy-1-
methylethyl]amino}sulfonyl)-N³,N³-dipropylisophthalamide;
           N^{1}-butyl-N^{3}-{ (1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-N<sup>1</sup>-
propylisophthalamide;
           N^{1}, N^{1}-dibuty1-N^{3}-{ (1S, 2R) -1-(3, 5-difluorobenzy1) -3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-methylisophthalamide;
           N^{1}-((1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-{[3-(3-
hydroxyprop-1-ynyl)benzyl]amino)propyl)-5-methyl-N3,N3-
dipropylisophthalamide;
           N^{1}-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(2S)-2-
(hydroxymethyl)pyrrolidin-1-yl]sulfonyl}-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalamide;
           N^{1} - \{(1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [(3 - 3, 5 - difluorobenzyl)] - 3 - [(3 - 3, 5
ethynylbenzyl) amino] -2-hydroxypropyl-5-(1,3-oxazol-2-yl) -N^3, N^3-
dipropylisophthalamide;
           N^{1}-[(1S, 2R)-3-\{[3-(cyclopropylamino)benzyl]amino\}-1-(3, 5-
difluorobenzyl)-2-hydroxypropyl]-5-ethynyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalamide;
           \mathbb{N}^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-thien-
3-ylbenzyl)amino]propyl}-5-methyl-N3,N3-dipropylisophthalamide;
           N^{1}-((1S, 2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[3-
(trifluoromethyl)benzyl]aminoppropyl)-5-(1,3-oxazol-2-yl)-N<sup>3</sup>,N<sup>3</sup>-
dipropylisophthalamide;
           N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-(piperazin-1-ylsulfonyl)-
N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
```

```
N^{1}-((1S, 2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[1-(3-
iodophenyl)cyclopropyl]amino}propyl)-5-methyl-N3,N3-
dipropylisophthalamide;
      N^{1}-[(1S, 2R)-3-[(3-sec-butylbenzyl)amino]-1-(3, 5-
difluorobenzyl)-2-hydroxypropyl]-5-methyl-N3,N3-
dipropylisophthalamide;
      N^{1}-{ (1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-(3-methylisoxazol-4-yl)-
N^3, N^3-dipropylisophthalamide;
      N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[1-(3-
isobutylisoxazol-5-yl)cyclopropyl]amino}propyl)-5-(1,3-oxazol-
2-yl)-N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
      N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-(1,3-oxazol-
2-yl)-N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
      N^4 - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - [(3 - 3)] \}
ethylbenzyl)amino]-2-hydroxypropyl}-6-methyl-N2,N2-
dipropylpyridine-2,4-dicarboxamide;
      N^{1}-(cyclopropylmethyl)-N^{3}-{(1S,2R)-1-(3,5-difluorobenzyl)-
3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-N<sup>1</sup>-
propylisophthalamide;
      N^{1}-{ (1S, 2R) -1- (3, 5-difluorobenzyl) -2-hydroxy-3-[(3-
methoxybenzyl) amino [propyl] -5 - (1, 3 - oxazol - 2 - yl) - N^3, N^3 -
dipropylisophthalamide;
      N^{1}-((1S, 2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-(1,3-
oxazol-2-yl)-N3,N3-dipropylisophthalamide;
      5-(aminosulfony1)-N^1-{(1S,2R)-1-(3,5-difluorobenzy1)-3-
[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>3</sup>,N<sup>3</sup>-
dipropylisophthalamide;
      N^{1}-[(1S, 2R)-1-(3, 5-difluorobenzy1)-2-hydroxy-3-({3-[(1Z)-
prop-1-enyl]benzyl}amino)propyl]-5-methyl-N<sup>3</sup>,N<sup>3</sup>-
dipropylisophthalamide;
      N^{1}-{ (1S, 2R) -1-(3,5-difluorobenzy1) -3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N3,N3-dipropyl-5-(1H-
pyrazol-4-yl) isophthalamide;
      N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)-
1-\text{methylethyl}] amino\}-2-\text{hydroxypropyl})-5-\text{ethynyl}-N^3, N^3-
dipropylisophthalamide;
      N^{1}-[(1S, 2R)-3-[(3-allylbenzyl)amino]-1-(3, 5-
difluorobenzyl)-2-hydroxypropyl]-5-methyl-N3,N3-
dipropylisophthalamide;
      N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-methyl-N3,N3-
dipropylisophthalamide;
      N^{1}-((1S, 2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)-
1-\text{methylethyl} amino -2-\text{hydroxypropyl} -5-(1,3-\text{oxazol}-2-\text{yl})-\text{N}^3,\text{N}^3-\text{var}
dipropylisophthalamide;
```

```
N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N3-ethyl-5-methyl-N3-
propylisophthalamide;
      N^{1}-[(1S, 2R)-3-{[3-(cyclopropylamino)benzyl]amino}-1-(3, 5-
difluorobenzyl)-2-hydroxypropyl]-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalamide;
      N^{1}-((1S, 2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-ethynyl-
N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
      N^{1}-((1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-{[1-(3-
isobutylisoxazol-5-yl)cyclopropyl]amino}propyl)-5-methyl-N3,N3-
dipropylisophthalamide;
      N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[3-(5-formyl-4-
methylthien-2-yl)benzyl]amino}-2-hydroxypropyl)-5-methyl-N3,N3-
dipropylisophthalamide;
      N^{1}-[(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-({3-
[(methylsulfonyl)amino]benzyl}amino)propyl]-5-methyl-N³,N³-
dipropylisophthalamide;
      N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-
isopentylbenzyl)amino]propyl}-5-methyl-N3,N3-
dipropylisophthalamide;
      N^{1}-[(1S, 2R)-3-[(1,1'-biphenyl-3-ylmethyl)amino]-1-(3,5-
difluorobenzyl)-2-hydroxypropyl]-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalamide;
      N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-methyl-
N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
      N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-({[2-
(methylamino)ethyl]amino}sulfonyl)-N³, N³-dipropylisophthalamide;
      N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[1-(3-
isobutylisoxazol-5-yl)cyclopropyl]amino}propyl)-5-ethynyl-N3,N3-
dipropylisophthalamide;
      N^{1}, N^{1}-dially1-N^{3}-{ (1S, 2R) -1-(3, 5-difluorobenzy1) -3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-methylisophthalamide;
      N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[1-(2-
isobutyl-1,3-thiazol-5-yl)cyclopropyl]amino}propyl)-5-methyl-
N^3, N^3-dipropylisophthalamide;
      N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)-
1-methylethyl]amino}-2-hydroxypropyl)-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalamide;
      N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [(3 - 1)] \}
ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(2-
hydroxyethyl)amino]sulfonyl}-N3-propylisophthalamide;
      N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [(3 - 1)] \}
ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>3</sup>,5-dimethyl-N<sup>3</sup>-
propylisophthalamide;
      N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-difluorobenzy1)]
```

ethylbenzyl) amino] -2-hydroxypropyl $-N^2$ -(phenylsulfonyl) -3-[(1-

propylbutyl) sulfonyl lalaninamide;

```
N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-N3,N3-diethyl-5-(1,3-oxazol-
2-y1) isophthalamide;
           N^2 - [(benzylamino) carbonyl] - N^1 - {(1S, 2R) - 1 - (3, 5 - 1)}
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-
[(1-propylbutyl)sulfonyl]alaninamide;
           N^{1}-{ (1S, 2R) -1- (3, 5-difluorobenzyl) -2-hydroxy-3-[(3-
pyridin-3-ylbenzyl)amino]propyl}-5-methyl-N<sup>3</sup>,N<sup>3</sup>-
dipropylisophthalamide;
           N^{1}-((1s, 2R)-1-(3, 5-difluorobenzyl)-3-{[3-(3-formyl-2-
furyl)benzyl]amino}-2-hydroxypropyl)-5-methyl-N3,N3-
dipropylisophthalamide;
           N^{1} - \{ (1S, 2R) - 1 - (3, 5 - diffluorobenzyl) - 3 - [ (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - (3
ethylbenzyl)amino]-2-hydroxypropyl}-5-(1-methyl-1H-imidazol-2-
yl)-N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
           N^{1}-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N3,N3-diethyl-5-
methylisophthalamide;
           N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[3-
(ethylsulfinyl)benzyl]amino}-2-hydroxypropyl)-5-methyl-N<sup>3</sup>,N<sup>3</sup>-
dipropylisophthalamide;
            3-\{[butyl(ethyl)amino]sulfonyl\}-N-\{(1S,2R)-1-(3,5-1)\}
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl }propanamide;
            N^{1}-[(1S, 2R)-3-[(3-cyanobenzyl)amino]-1-(3,5-
difluorobenzyl)-2-hydroxypropyl]-5-methyl-N3,N3-
dipropylisophthalamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-
propylbutyl) sulfonyl]propanamide;
            N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N³-isobutyl-N³,5-
dimethylisophthalamide;
            N^{1}-{ (1S, 2R) -1-(3, 5-difluorobenzyl) -2-hydroxy-3-[(3-
pyridin-2-ylbenzyl)amino]propyl}-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalamide;
            N^{1}-[(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-({3-
 [methyl (methylsulfonyl) amino] benzyl amino) propyl] -5-methyl-
N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
            N^{1}-{(1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-
ethylbenzyl) amino] -2-hydroxypropyl-N^2-(3-phenylpropanoyl) -3-
 [(1-propylbutyl)sulfonyl]alaninamide trifluoroacetate;
            N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[3-
 (ethylsulfonyl)benzyl]amino}-2-hydroxypropyl)-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalamide;
            N^2-[(5-chlorothien-2-yl)sulfonyl]-N^1-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-
 [(1-propylbutyl)sulfonyl]alaninamide;
```

```
N^{1}-[(1S,2R)-3-{[3-(5-acetylthien-2-yl)benzyl]amino}-1-
 (3,5-difluorobenzyl)-2-hydroxypropyl]-5-methyl-N<sup>3</sup>,N<sup>3</sup>-
dipropylisophthalamide;
                N^{1}-(sec-butyl)-N^{3}-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-methylisophthalamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino}-2-hydroxypropyl}-3-(1,3-oxazol-2-
yl)benzamide;
                N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>3</sup>,5-dimethyl-N<sup>3</sup>-(2-
phenylethyl)isophthalamide;
                N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[3-(3,5-
dimethylisoxazol-4-yl)benzyl]amino}-2-hydroxypropyl)-5-methyl-
N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
                N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - [ (3 - 3) - 3 - (3 - 3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) -
ethylbenzyl)amino]-2-hydroxypropyl}-N3,5-dimethyl-N3-prop-2-
ynylisophthalamide;
                N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-N3-ethyl-N3,5-
 dimethylisophthalamide;
                 3-(\{[(2R,3S)-4-(3,5-difluorophenyl)-3-(\{3-a,5-difluorophenyl)-3-(\{3-
 [(dipropylamino)carbonyl]-5-methylbenzoyl}amino)-2-
hydroxybutyl]amino}methyl)phenyl dimethylcarbamate;
                 N^{1}-benzyl-N^{3}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-N1,5-
 dimethylisophthalamide;
                 N^{1}-(sec-butyl)-N^{3}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-N<sup>1</sup>-
 propylisophthalamide;
                 N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[3-(4-
 methylthien-2-yl)benzyl]amino}propyl)-5-methyl-N3,N3-
 dipropylisophthalamide;
                 [(dipropylamino)carbonyl]-5-methylbenzoyl}amino)-2-
 hydroxybutyl]amino}methyl)phenyl(methyl)carbamate;
                 N^{1}-((1S,2R)-2-hydroxy-1-(2,3,5-trifluorobenzyl)-3-{[3-
 (trifluoromethyl)benzyl]amino}propyl)-5-methyl-N3,N3-
 dipropylisophthalamide;
                 N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>3</sup>, N<sup>3</sup>-diisobutyl-5-
 methylisophthalamide;
                 N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-N3,5-dimethyl-N3-(2-pyridin-
 2-ylethyl)isophthalamide;
                 N^{1}-{(1S,2R)-1-(3-fluoro-5-hydroxybenzyl)-2-hydroxy-3-[(3-
 methoxybenzyl)amino]propyl}-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
 dipropylisophthalamide;
                 N^1-{(1S,2R)-1-(3-chloro-5-fluorobenzyl)-2-hydroxy-3-[(3-
 methoxybenzyl)amino]propyl}-N3,N3-dipropylbenzene-1,3,5-
 tricarboxamide;
```

```
N-\{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-1)]
iodobenzyl) amino]propyl}-4-hydroxy-3-(pyrrolidin-1-
ylcarbonyl)benzamide;
           5-oxo-D-prolyl-N^1-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-difluor
ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-
propylbutyl) sulfonyl]alaninamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-
{[(trifluoromethyl)sulfonyl]amino}benzamide;
           N^{1}-{ (1S, 2R) -1- (3, 5-difluorobenzyl) -2-hydroxy-3-[(3-
pyridin-4-ylbenzyl)amino]propyl}-5-methyl-N3,N3-
dipropylisophthalamide;
           N^{1}-[(1S,2R)-1-(3,5-difluorobenzyl)-3-({3-
[(dimethylamino)sulfonyl]benzyl}amino)-2-hydroxypropyl]-5-
methyl-N3, N3-dipropylisophthalamide;
           N^{1}-{ (1S, 2R) -1-(3, 5-difluorobenzyl) -2-hydroxy-3-[(6-
methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)amino]propyl}-5-
methyl-N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
           N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N2-(phenylacetyl)-3-[(1-
propylbutyl) sulfonyl] alaninamide;
           methyl 3-(\{(2R,3S)-4-(3,5-difluorophenyl)-3-(\{3-difluorophenyl)\})
 [(dipropylamino)carbonyl]-5-methylbenzoyl)amino)-2-
hydroxybutyl]amino}methyl)phenylcarbamate;
            5-oxo-L-prolyl-N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-\{(3-a)\}
ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-
propylbutyl)sulfonyl]alaninamide;
           N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N3-isobutyl-5-
methylisophthalamide;
            4-({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-4)]}
ethylbenzyl)amino]-2-hydroxypropyl}amino)-4-oxo-3-{[(1-
propylbutyl)sulfonyl]methyl}butanoic acid trifluoroacetate;
            N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
 ethylbenzyl)amino]-2-hydroxypropyl}-3-
 [methyl(methylsulfonyl)amino]benzamide;
            N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-N3-ethyl-N3-isopropyl-5-
methylisophthalamide;
            N^{1}-[(1S,2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(thien-
 2-ylmethyl)propyl]-5-methyl-N³,N³-dipropylisophthalamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2-
 hydroxyethyl) (propyl) amino] sulfonyl) propanamide;
            N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 3) - 3 - 3] \}
 ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>3</sup>-isopropyl-N<sup>3</sup>,5-
 dimethylisophthalamide;
            N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-[(methylsulfonyl)amino]-
 1,3-thiazole-4-carboxamide;
```

```
N^{1}-allyl-N^{1}-cyclopentyl-N^{3}-{ (1s, 2R) -1- (3, 5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-
methylisophthalamide;
     N-(3-({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}amino)-3-oxo-2-{[(1-
propylbutyl)sulfonyl]methyl}propyl)benzamide;
     N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-
(isopentylsulfonyl)propanamide;
     N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[3-(5-
methylthien-2-yl)benzyl]amino}propyl)-5-methyl-N^3,N^3-
dipropylisophthalamide;
     N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(1-
methylhexyl)amino]propyl}-5-methyl-N3,N3-dipropylisophthalamide;
     N^{1}-[(1S, 2R)-3-{[1-(aminocarbonyl)cyclohexyl]amino}-1-(3,5-
difluorobenzyl)-2-hydroxypropyl]-5-methyl-N3,N3-
dipropylisophthalamide;
      N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(2E)-hex-2-
enylamino]-2-hydroxypropyl}-5-methyl-N3,N3-
dipropylisophthalamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-hydroxyisoxazole-5-
carboxamide;
      N^{1}-[(1S, 2R)-1-(3, 5-difluorobenzyl)-3-({3-[(1E)-hex-1-
enyl]benzyl}amino)-2-hydroxypropyl]-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalamide;
      N^{1}-{ (1s, 2r) -1-(3,5-difluorobenzyl) -3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N3-isopropyl-5-
methylisophthalamide;
      N^{1}-[(1S,2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(thien-
2-ylmethyl)propyl]-N3,N3-dipropylbenzene-1,3,5-tricarboxamide;
      2-[3-(2-amino-2-oxoethoxy)] -N-{(1S,2R)-1-(3,5-
difluorobenzyl)-2-hydroxy-3-[(3-
iodobenzyl)amino]propyl}acetamide;
      N^{1}-{(1S,2R)-1-(3-bromobenzyl)-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-5-methyl-N3,N3-
dipropylisophthalamide;
      N^{1}-{ (1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(2-
ethylhexyl)amino]-2-hydroxypropyl}-5-methyl-N³,N³-
dipropylisophthalamide;
      N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[3-(6-
methoxypyridin-3-yl)benzyl]amino}propyl)-5-methyl-N3,N3-
dipropylisophthalamide;
      N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[3-(2,4-
dimethoxypyrimidin-5-yl)benzyl]amino}-2-hydroxypropyl)-5-
methyl-N3, N3-dipropylisophthalamide;
      N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-
ethylbutanovl)benzamide;
```

```
N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-influorobenzy1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-[(4-hydroxypiperidin-1-
yl)carbonyl]-5-methylbenzamide;
                    N^{1}-\{(1S, 2R)-1-(3-bromobenzy1)-2-hydroxy-3-[(3-abromobenzy1)-2-[(3-abro
methoxybenzyl) amino [propyl] - N^3, N^3-dipropylbenzene-1, 3, 5-
tricarboxamide;
                     4'-[4-({(15,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-
iodobenzyl)amino]propyl}amino)-4-oxobutanoyl]-1,1'-biphenyl-2-
carboxamide;
                     1-\{3-[(\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-4)]\}\}]
ethylbenzyl)amino]-2-hydroxypropyl}amino)carbonyl]-5-
methylbenzoyl}-L-prolinamide;
                    N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-3-[(3-hydroxypiperidin-1-
yl)carbonyl]-5-methylbenzamide;
                    N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-
hydroxy-1-phenylpropyl)amino]propyl}-5-methyl-N3,N3-
dipropylisophthalamide;
                     N^{1}-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N3-[2-
(dimethylamino) ethyl] -N<sup>3</sup>-ethyl-5-methylisophthalamide;
                     N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-methyl-4H,6H-pyrrolo[1,2-
a][4,1]benzoxazepine-4-carboxamide;
                      2-(5-acetylthien-2-yl)-N-((1s,2r)-1-(3,5-difluorobenzyl)-
3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}acetamide;
                     N^{1}-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>3</sup>,N<sup>3</sup>-diisopropyl-5-
methylisophthalamide;
                     N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-difluorobenzy1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-
 [(methylsulfonyl)amino]benzamide;
                     N-\{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(
iodobenzyl)amino]propyl}-2-[4-(2-oxopyrrolidin-1-
yl)phenyl]acetamide;
                    N-\{(1S, 2R)-1-(3-chloro-5-fluorobenzyl)-2-hydroxy-3-[(3-fluorobenzyl)-2-[(3-fluorobenzyl)-2-[(3-fluorobenzyl)-2-[(3-fluorobenzyl)-2-[(3-fluorobenzyl)-2-[(
methoxybenzyl)amino]propyl}-3-
[(dipropylamino)sulfonyl]propanamide;
                     N^{1}-[(1S,2R)-1-(3-chloro-5-fluorobenzyl)-2-hydroxy-3-
(isopentylamino)propyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylbenzene-1, 3, 5-
tricarboxamide;
                     N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-difluorobenzy1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(1-methyl-1H-imidazol-
4-yl)sulfonyl]amino}benzamide tri;
                     N^{1}-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
 (pentylamino)propyl]-5-methyl-N3, N3-dipropylisophthalamide;
                    N^{1}-{(1S,2R)-1-(4-fluorobenzyl)-2-hydroxy-3-[(3-
methoxybenzyl)amino[propyl]-N3,N3-dipropylbenzene-1,3,5-
tricarboxamide;
                    N^{1}-[(1S,2R)-3-(benzylamino)-1-(3-chloro-5-fluorobenzyl)-2-
```

```
hydroxypropyl]-5-methyl-N3, N3-dipropylisophthalamide;
                N^{1}-cyclohexyl-N^{3}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N1-ethyl-5-
methylisophthalamide;
                2-\{(2R,3S)-4-(3,5-difluorophenyl)-3-(\{3-4\})\}
[(dipropylamino)carbonyl]-5-methylbenzoyl}amino)-2-
hydroxybutyl]amino}ethyl 2,4-difluorophenylcarbamate;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2S)-2-
 (methoxymethyl)pyrrolidin-1-yl]carbonyl}-5-methylbenzamide;
                N^{1}-[(1S,2R)-1-(3-bromobenzyl)-2-hydroxy-3-
 (isopentylamino)propyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylbenzene-1, 3, 5-
tricarboxamide:
                N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2,8-dimethylquinoline-3-
carboxamide:
                N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(6-
hydroxyhexyl)amino]propyl}-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalamide;
                N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(2R)-2-
hydroxypropyl]amino}propyl)-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalamide;
                N-\{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-3-[(1-
propylbutyl) sulfonyl]propanamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzyl)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2-hydroxy-1,1-
dimethylethyl) amino] sulfonyl}benzamide;
                N^{1}-{(1s,2r)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(4-
phenylbutyl)amino]propyl}-5-methyl-N3,N3-dipropylisophthalamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-[(3-max)-1-(3-max)-1-(3-ma
iodobenzyl)amino]propyl}-7-(1H-imidazol-1-yl)-5,6-
dihydronaphthalene-2-carboxamide;
                 3-(acetylamino)-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-acetylamino)-N-(3-acetylam
ethylbenzyl)amino]-2-hydroxypropyl}-4-methylbenzamide;
                N^{1}-[(1S, 2R)-3-\{[2-(aminosulfonyl)ethyl]amino\}-1-(3, 5-
difluorobenzyl)-2-hydroxypropyl]-5-methyl-N3, N3-
dipropylisophthalamide;
                N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[2-
 (ethylthio) ethyl] amino} -2-hydroxypropyl) -5-methyl-N^3, N^3-
dipropylisophthalamide;
                N^{1}-[(1S, 2R)-3-[benzyl(cyanomethyl)amino]-1-(3,5-
difluorobenzyl)-2-hydroxypropyl]-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalamide;
                N^{1}-{ (1s, 2r) -1-(3, 5-difluorobenzyl) -2-hydroxy-3-[(2-
hydroxypropyl)amino]propyl}-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalamide;
                N^{1}-[(1S, 2R)-3-[(3-butoxypropyl)amino]-1-(3, 5-
difluorobenzyl)-2-hydroxypropyl]-5-methyl-N3,N3-
dipropylisophthalamide;
```

```
N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-max)-1]
ethylbenzyl)amino]-2-hydroxypropyl}-3-{[2-(2-
hydroxyethyl)piperidin-1-yl]carbonyl}-5-methylbenzamide;
                     methyl N-[(2R,3S)-4-(3,5-difluorophenyl)-3-({3-}
[(dipropylamino)carbonyl]-5-methylbenzoyl}amino)-2-
hydroxybutyl]-beta-alaninate;
                     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mu)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-(1-hydroxy-2-
propylpentyl) benzamide;
                     N^{1}-[(1S,2R)-3-(benzylamino)-1-(3-chloro-5-fluorobenzyl)-2-
hydroxypropyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylbenzene-1, 3, 5-tricarboxamide;
                     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-
[(methylsulfonyl)amino]butanamide;
                     N^{1}-[(1S,2R)-3-{[3-(1-benzothien-2-y1)benzy1]amino}-1-(3,5-
difluorobenzyl)-2-hydroxypropyl]-5-methyl-N3,N3-
dipropylisophthalamide;
                      3-(benzyloxy)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-benzyloxy)-1-(3,5-difluorobenzyl)-3-[(3-benzyloxy)-1-(3,5-difluorobenzyl)-3-[(3-benzyloxy)-1-(3,5-difluorobenzyl)-3-[(3-benzyloxy)-1-(3,5-difluorobenzyl)-3-[(3-benzyloxy)-1-(3,5-difluorobenzyl)-3-[(3-benzyloxy)-1-(3,5-difluorobenzyl)-3-[(3-benzyloxy)-1-(3,5-difluorobenzyl)-3-[(3-benzyloxy)-1-(3,5-difluorobenzyl)-3-[(3-benzyloxy)-1-(3,5-difluorobenzyl)-3-[(3-benzyloxy)-1-(3,5-difluorobenzyl)-3-[(3-benzyloxy)-1-(3,5-difluorobenzyl)-3-[(3-benzyloxy)-1-(3,5-difluorobenzyl)-3-[(3-benzyloxy)-1-(3,5-difluorobenzyl)-3-[(3-benzyloxy)-1-(3,5-difluorobenzyl)-3-[(3-benzyloxy)-1-(3,5-difluorobenzyl)-3-[(3-benzyloxy)-1-(3-benzyloxy)-3-[(3-benzyloxy)-1-(3-benzyloxy)-3-[(3-benzyloxy)-1-(3-benzyloxy)-3-[(3-benzyloxy)-1-(3-benzyloxy)-3-[(3-benzyloxy)-1-(3-benzyloxy)-3-[(3-benzyloxy)-1-(3-benzyloxy)-3-[(3-benzyloxy)-1-(3-benzyloxy)-3-[(3-benzyloxy)-1-(3-benzyloxy)-3-[(3-benzyloxy)-1-(3-benzyloxy)-3-[(3-benzy
ethylbenzyl)amino]-2-hydroxypropyl}isoxazole-5-carboxamide;
                      2-{[(benzyloxy)carbonyl]amino}-7-
 [(cyclopropylmethyl)amino]-1,2,4,5,7-pentadeoxy-5-(3,5-
difluorobenzyl)-1-[(1-propylbutyl)sulfonyl]-D-threo-hept-3-
ulose trifluoroacetate;
                      1-\{3-[(\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-i)]\}\}]
ethylbenzyl)amino]-2-hydroxypropyl}amino)carbonyl]-5-
methylbenzoyl}-D-prolinamide;
                      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-(1H-pyrazol-1-
yl)pentanamide;
                      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{(3-1)-1, (3-1)-1
ethylbenzyl)amino]-2-hydroxypropyl}-1-(2-furylmethyl)-5-
oxopyrrolidine-3-carboxamide;
                     N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(5-
hydroxypentyl)amino]propyl}-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalamide;
                       3-[({(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(1-
methyl-1-phenylethyl)amino]propyl}amino)sulfonyl]-N,N-
dipropylbenzamide;
                     N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N<sup>3</sup>,N<sup>3</sup>-dipropylpiperidine-1,3-
                      N^{1}-{ (1S, 2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N³,N³-diethylpiperidine-1,3-
dicarboxamide;
                       5-bromo-N^1-((1S,2R)-2-hydroxy-1-(pentafluorobenzyl)-3-{[3-
 (trifluoromethyl)benzyl]amino}propyl)-N3,N3-
 dipropylisophthalamide;
                      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
 ethylbenzyl)amino]-2-hydroxypropyl}-4-
 [(methylsulfonyl)amino]benzamide;
```

```
N-\{(1S, 2R)-1-(3-bromobenzyl)-2-hydroxy-3-[(3-bromobenzyl)-2-[(3-bromobe
methoxybenzyl)amino]propyl}-3-
[(dipropylamino)sulfonyl]propanamide;
           3-[(dipropylamino)sulfonyl]-N-[(1S, 2R)-2-hydroxy-3-[(3-
methoxybenzyl)amino]-1-(thien-2-ylmethyl)propyl]propanamide;
           N^{1}-{(1S, 2R)-1-(3,5-difluorobenzy1)-3-[(3-
ethoxypropyl) amino] -2-hydroxypropyl}-5-methyl-N^3, N^3-
dipropylisophthalamide;
           N^{1}-[(1S, 2R)-3-(benzylamino)-2-hydroxy-1-(thien-2-
ylmethyl)propyl]-5-methyl-N3,N3-dipropylisophthalamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-4-
(phenylsulfonyl)butanamide;
           N^{1}-[(1S,2R)-1-(3,5-dichlorobenzy1)-2-hydroxy-3-
(isopentylamino)propyl]-N3,N3-dipropylbenzene-1,3,5-
tricarboxamide;
           N^{1}-{(1s, 2r)-1-(3,5-difluorobenzyl)-3-[(3,3-
dimethylbutyl)amino]-2-hydroxypropyl}-5-methyl-N<sup>3</sup>,N<sup>3</sup>-
dipropylisophthalamide;
           N^{1}-[(1S, 2R)-3-(benzylamino)-1-(3-bromobenzyl)-2-
hydroxypropyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylbenzene-1, 3, 5-tricarboxamide;
           N^{1}-[(1S, 2R)-1-(3-chloro-5-fluorobenzyl)-2-hydroxy-3-
(isopentylamino)propyl]-5-methyl-N3,N3-dipropylisophthalamide;
           N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(1,3-
diphenylpropyl) amino] -2-hydroxypropyl} -5-methyl-N^3, N^3-
dipropylisophthalamide;
           N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(1S)-1-
(hydroxymethyl)propyl]amino}propyl)-N<sup>3</sup>,N<sup>3</sup>-
dipropylisophthalamide;
           N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(3S)-2-
oxoazepan-3-yl]amino}propyl)-5-methyl-N3,N3-
dipropylisophthalamide;
           N^1-cyclohexyl-N^5-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}pentanediamide;
          N^{1}-[(1S, 2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(3-
methylbenzyl)propyl]-N3,N3-dipropylbenzene-1,3,5-tricarboxamide;
          N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [(3 - 1)] \}
ethylbenzyl) amino] -2-hydroxypropyl-N^3-[(2-
propylpentyl)sulfonyl]-beta-alaninamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-(1,3-thiazol-2-
yl)benzamide;
          N^{1}-[(1S, 2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-({3-
[methyl(phenyl)amino]propyl}amino)propyl]-5-methyl-N^3, N^3-
dipropylisophthalamide;
          N^{1}-[(1S,2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(4-
methylbenzyl)propyl]-N3,N3-dipropylbenzene-1,3,5-tricarboxamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-oxo-1-(thien-2-
ylmethyl)pyrrolidine-3-carboxamide;
```

```
4-[(butylthio)methyl]-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-
3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-2-furamide;
     N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2-
hydroxyethyl)amino]sulfonyl}benzamide;
     N^{1}-{ (1S, 2R) -1- (3, 5-difluorobenzyl) -2-hydroxy-3-[(3-
methylcyclohexyl)amino]propyl}-5-methyl-N3,N3-
dipropylisophthalamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(2-oxo-1,3-oxazolidin-3-
yl)benzamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(1H-pyrrol-1-
y1) benzamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-1,3,4,5-
tetrahydrothiopyrano[4,3-b]indole-8-carboxamide;
     N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N4-[2-
(trifluoromethyl)phenyl]succinamide;
     N^{1}-[(1S, 2R)-1-(3-bromobenzyl)-2-hydroxy-3-
(isopentylamino)propyl]-5-methyl-N3,N3-dipropylisophthalamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-4,5-dimethyl-2-(1H-pyrrol-
1-yl) thiophene-3-carboxamide;
      N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(2,3-
dihydroxypropyl)amino]-2-hydroxypropyl}-5-methyl-N3,N3-
dipropylisophthalamide;
      N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(2S)-2-
hydroxypropyl]amino}propyl)-5-methyl-N<sup>3</sup>,N<sup>3</sup>-
dipropylisophthalamide;
      N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(1R)-1-
methylpropyl]amino}propyl)-5-methyl-N3,N3-
dipropylisophthalamide;
      2-chloro-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4-
(methylsulfonyl)benzamide;
      N^{1}-{ (1S, 2R) -1- (3, 5-difluorobenzyl) -2-hydroxy-3-[(2-
hydroxyethyl)amino]propyl}-5-methyl-N3,N3-
dipropylisophthalamide;
      3-[(dipropylamino)sulfonyl]-N-{(1S,2R)-2-hydroxy-1-(3-
methoxybenzy1)-3-[(3-methoxybenzy1)amino]propy1}propanamide;
      N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-3-
{methyl[(trifluoromethyl)sulfonyl]amino}benzamide;
      N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-3-hydroxy-6-(1-hydroxy-2,2-
dimethylpropyl)pyridine-2-carboxamide;
```

```
N^{1}-[(1S, 2R)-3-[(1, 3-dicyclohexylpropyl)amino]-1-(3, 5-
difluorobenzyl)-2-hydroxypropyl]-5-methyl-N3,N3-
dipropylisophthalamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2,2'-bithiophene-5-
carboxamide:
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(1H-imidazol-1-
yl)butanamide;
     N^{1}-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2,3-dihydroxy-N4-(4-
methoxyphenyl) succinamide;
     N^{1}-[(1S, 2R)-3-(benzylamino)-2-hydroxy-1-(4-
hydroxybenzyl)propyl]-5-methyl-N3,N3-dipropylisophthalamide;
     N^1-{(1S, 2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-[3-
(trifluoromethyl)benzyl]propyl}-N3,N3-dipropylbenzene-1,3,5-
tricarboxamide;
     N^{1}-[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(thien-2-
ylmethyl)propyl]-N3,N3-dipropylbenzene-1,3,5-tricarboxamide;
     N^{1}-[(1S, 2R)-3-\{[2-(aminocarbonyl)-1H-indol-6-yl]amino\}-1-
(3,5-difluorobenzyl)-2-hydroxypropyl]-5-methyl-N<sup>3</sup>,N<sup>3</sup>-
dipropylisophthalamide;
     N^{1}-[(1S,2R)-3-(benzylamino)-1-(3-bromobenzyl)-2-
hydroxypropyl]-5-methyl-N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mu)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(1-oxo-1,3-dihydro-2H-
isoindol-2-yl)butanamide;
      3-chloro-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4-
(methylsulfonyl)thiophene-2-carboxamide;
     N^{1}-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(1-
ethylpropyl) amino] -2-hydroxypropyl} -5-methyl-N^3, N^3-
dipropylisophthalamide;
      N^{1}-[(1S, 2R)-1-(3,5-difluorobenzyl)-3-({[(5R)-3-ethyl-2-
oxo-1,3-oxazolidin-5-yl]methyl}amino)-2-hydroxypropyl]-5-
methyl-N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzyl)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-7-
(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;
      N^{1}-{ (1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl) amino] propyl - N^2 - [(methylthio) acetyl] - 3 - [(1 -
propylbutyl) sulfonyl]alaninamide;
      N^{1}-{ (1S, 2R) -1- (3,5-difluorobenzyl) -3-[(2,3-
dimethylcyclohexyl)amino]-2-hydroxypropyl}-5-methyl-N^3, N^3-
dipropylisophthalamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4,5-dimethoxy-1-
benzothiophene-2-carboxamide;
```

```
N^{1}-[(1S,2R)-1-[3-fluoro-5-(trifluoromethyl)benzyl]-2-
hydroxy-3-(isopentylamino)propyl]-N3,N3-dipropylbenzene-1,3,5-
tricarboxamide;
      N^{1}-[(1S, 2R)-1-(3,5-difluorobenzyl)-3-({[(5S)-3-ethyl-2-
oxo-1,3-oxazolidin-5-yl]methyl}amino)-2-hydroxypropyl]-5-
methyl-N3, N3-dipropylisophthalamide;
      N^{1}-{ (1S, 2R) -1- (1, 3-benzodioxol-5-ylmethyl) -2-hydroxy-3-
[(3-methoxybenzyl)amino]propyl}-N<sup>3</sup>,N<sup>3</sup>-dipropylbenzene-1,3,5-
tricarboxamide;
      N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(3,5-dioxo-1,2,4-
triazolidin-4-yl) benzamide;
      N-\{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-2-hydroxy-3-[(3-
methoxyphenyl)sulfonyl]propanamide;
      N^{1} - \{(1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 - [(2 - 1)]
methylcyclohexyl)amino]propyl}-5-methyl-N3,N3-
dipropylisophthalamide;
      N^{1}-[(1S, 2R)-3-[(2-{4-[(3-
chlorobenzyl)oxy]phenyl}ethyl)amino]-1-(3,5-difluorobenzyl)-2-
hydroxypropyl]-5-methyl-N3,N3-dipropylisophthalamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-4-oxo-4-thien-3-
ylbutanamide;
      N^{1}-{(1S, 2R)-1-[3-(benzyloxy)-5-fluorobenzyl]-2-hydroxy-3-
[(3-methoxybenzyl)amino]propyl}-N³,N³-dipropylbenzene-1,3,5-
tricarboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-4-oxo-4-[3-
(trifluoromethyl)phenyl]butanamide;
      N^1-{(1S,2R)-2-hydroxy-3-(isopentylamino)-1-[3-
(trifluoromethoxy)benzyl]propyl}-N3,N3-dipropylbenzene-1,3,5-
tricarboxamide:
      N^{1}-((1S, 2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[1-
(hydroxymethyl)-3-(methylthio)propyl]amino)propyl)-5-methyl-
N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
      2-(1H-1,2,3-benzotriazol-1-yl)-N-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl } hexanamide;
      N^{1}-[(1S, 2R)-1-(3-fluoro-4-methylbenzyl)-2-hydroxy-3-
(isopentylamino)propyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylbenzene-1, 3, 5-
tricarboxamide;
      N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-(4,4-dimethyl-2,5-
dioxoimidazolidin-1-yl)-2-{[(1-
propylbutyl)sulfonyl]methyl)propanamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mu)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-
{[(trifluoromethyl)sulfonyl]amino}butanamide;
```

```
N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(5-methyl-1,3-dioxo-1,3-
dihydro-2H-isoindol-2-yl)acetamide;
          N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[1-
(hydroxymethyl)propyl]amino}propyl)-5-methyl-N3,N3-
dipropylisophthalamide;
          N^{1}-[(1S,2R)-3-(benzylamino)-1-(3,5-dichlorobenzyl)-2-
hydroxypropyl]-N^3, N^3-dipropylbenzene-1, 3, 5-tricarboxamide;
          N-\{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-3-{[(2-
hydroxyethyl) (propyl) amino] sulfonyl) propanamide;
          5-(benzylthio)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-benzylthio)]}
ethylbenzyl)amino]-2-hydroxypropyl}nicotinamide;
          N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-1H-pyrazole-5-carboxamide;
           6-chloro-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzy
ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-2-oxo-2,3-dihydro-
1,3-benzoxazole-5-carboxamide;
          N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-1H-benzimidazole-2-
carboxamide;
          N^1-{ (1S, 2R) -1-(cyclohexylmethyl) -2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N<sup>3</sup>,N<sup>3</sup>-dipropylbenzene-1,3,5-
tricarboxamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-6-hydroxy-4,7-dimethoxy-1-
benzofuran-5-carboxamide;
          N^{1}-{ (1S, 2R) -1-(3, 5-difluorobenzyl) -2-hydroxy-3-[(4-
methylcyclohexyl)amino]propyl}-5-methyl-N3,N3-
dipropylisophthalamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}[1,2,4]triazolo[4,3-
a]pyridine-6-carboxamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-4-oxo-4-thien-2-
ylbutanamide;
          \mathbb{N}^{1}-[(1S,2R)-3-(benzylamino)-1-(3,5-dichlorobenzyl)-2-
hydroxypropyl]-5-methyl-N3, N3-dipropylisophthalamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{(3-4)\}
ethylbenzyl)amino]-2-hydroxypropyl}-4-(2-hydroxy-5-
methylphenyl)-4-oxobutanamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-phenoxybenzamide;
           4-[(aminocarbonyl)amino]-N-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}benzamide;
           N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(1S)-1-
 (hydroxymethyl)-3-(methylthio)propyl]amino)propyl)-5-methyl-
N^3, N^3-dipropylisophthalamide;
```

```
N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-7-hydroxy-4-oxochromane-2-
carboxamide;
           N^{1}-((1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-{[(1S)-1-
(hydroxymethyl)-3-methylbutyl]amino}propyl)-5-methyl-N3,N3-
dipropylisophthalamide;
           N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(1R)-1-
(hydroxymethyl)propyl]amino}propyl)-N3,N3-
dipropylisophthalamide;
           N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(1-methyl-
3-phenylpropyl)amino]propyl}-5-methyl-N3,N3-
dipropylisophthalamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(2,3-dihydro-1-
benzofuran-5-yl)-1,3-thiazole-4-carboxamide;
           N^{1}-{ (1S, 2R) -1-[3-(benzyloxy)benzyl] -2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalamide;
           N-\{(1S, 2R)-1-(4-chlorobenzyl)-2-hydroxy-3-[(3-chlorobenzyl)]
methoxybenzyl)amino]propyl}-3-
[(dipropylamino)sulfonyl]propanamide;
           N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N3-pentylmalonamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-
 (trifluoromethoxy) benzamide;
            3-[(dipropylamino)sulfonyl]-N-{(1S,2R)-1-(3-fluoro-4-
methylbenzyl)-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}propanamide;
           N-[(1S,2R)-1-(3-chloro-5-fluorobenzyl)-2-hydroxy-3-
 (isopentylamino)propyl]-3~[(dipropylamino)sulfonyl]propanamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-(4,4-dimethyl-2,5-
dioxoimidazolidin-1-yl)-2-{[(1-
propylbutyl)sulfonyl]methyl}propanamide;
           N^{1}-[4-(acetylamino)phenyl]-N^{4}-{(1S, 2R)-1-(3, 5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl)succinamide;
            3-(1-cyanoethyl)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-difluor
 ethylbenzyl)amino]-2-hydroxypropyl}benzamide;
            N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-N4-(5-phenyl-1,3,4-
 thiadiazol-2-yl)succinamide;
            N^{1}-{ (1S, 2R) -3 - (benzylamino) -2-hydroxy-1-[3-
 (trifluoromethoxy)benzyl]propyl}-N³,N³-dipropylbenzene-1,3,5-
 tricarboxamide;
            N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[2-(2-oxo-
 2-pyrrolidin-1-ylethoxy)phenyl]amino}propyl)-5-methyl-N3,N3-
 dipropylisophthalamide;
```

```
N^{1}-[(1S,2R)-1-(4-chlorobenzyl)-2-hydroxy-3-
(isopentylamino)propyl]-N3, N3-dipropylbenzene-1, 3, 5-
tricarboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{(3-4)\}
ethylbenzyl)amino]-2-hydroxypropyl}-2-(1,1-
dioxidotetrahydrothien-2-yl)acetamide;
      N^{1}-[(1S,2R)-3-(benzylamino)-1-(4-chlorobenzyl)-2-
hydroxypropyl]-5-methyl-N3, N3-dipropylisophthalamide;
      N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-hex-1-ynylnicotinamide;
      N-[(1S, 2R)-1-(3-bromobenzy1)-2-hydroxy-3-
(isopentylamino)propyl]-3-[(dipropylamino)sulfonyl]propanamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-a)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-methoxyisoxazole-5-
carboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2,3-dimethyl-1H-indole-7-
carboxamide;
      4-(3-\text{chlorophenyl})-N-\{(1S,2R)-1-(3,5-\text{difluorobenzyl})-3-
[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-4-
oxobutanamide:
      N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(1-methyl-1H-indol-3-yl)-
2-oxoacetamide;
      N^{1}-[(1S,2R)-1-(3-fluoro-4-methylbenzyl)-2-hydroxy-3-
(isopentylamino)propyl]-5-methyl-N3, N3-dipropylisophthalamide;
      3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-2-hydroxy-3-[(3-
methoxybenzyl)amino]-1-(4-methylbenzyl)propyl]propanamide;
      N^{1}-[(1S,2R)-3-(benzylamino)-1-(3-fluoro-4-methylbenzyl)-2-
hydroxypropyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylbenzene-1, 3, 5-tricarboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-[5-(4-methylphenyl)-2H-
tetraazol-2-yl]acetamide;
      N-\{(1S, 2R)-1-(3, 5-dichlorobenzyl)-2-hydroxy-3-[(3-1)]
methoxybenzyl)amino]propyl}-3-
[(dipropylamino)sulfonyl]propanamide;
      N^{1}-[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-(thien-2-
ylmethyl)propyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylbenzene-1,3,5-tricarboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-3-phenylisoxazole-
4-carboxamide;
      N^{1}-[(1S, 2R)-3-(benzylamino)-1-(4-fluorobenzyl)-2-
hydroxypropyl]-5-methyl-N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
      N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>2</sup>-
[(methylsulfonyl)acetyl]-N<sup>2</sup>-pentylglycinamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(1H-indol-3-yl)-4-
oxobutanamide;
```

```
N^{1}-(5-benzyl-1,3,4-thiadiazol-2-yl)-N^{4}-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}succinamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(3-fluoro-4-
methoxyphenyl)-4-oxobutanamide;
                 ethyl 4-\{[(2R,3S)-4-(3,5-difluorophenyl)-3-(\{3-4\}-4-\{1,2\}-4-(3,3)-4-(3,5-difluorophenyl)-3-(\{3-4\}-4-(3,3)-4-
 [(dipropylamino)carbonyl]-5-methylbenzoyl}amino)-2-
hydroxybutyl]amino}piperidine-1-carboxylate;
                 N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance]]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(2-fluorobenzoyl)-1H-
pyrrole-2-carboxamide;
                N^{1}-[(1S,2R)-3-(benzylamino)-1-(4-chlorobenzyl)-2-
hydroxypropyl]-N^3, N^3-dipropylbenzene-1, 3, 5-tricarboxamide;
                N^1-{(1S, 2R)-2-hydroxy-3-(isopentylamino)-1-[3-
 (trifluoromethyl)benzyl]propyl}-N<sup>3</sup>,N<sup>3</sup>-dipropylbenzene-1,3,5-
tricarboxamide:
                N^{1}-[(1S,2R)-2-hydroxy-1-(4-hydroxybenzyl)-3-
 (isopentylamino)propyl]-5-methyl-N3, N3-dipropylisophthalamide;
                N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(4-morpholin-4-
ylphenyl)acetamide;
                 3-[(dipropylamino)sulfonyl]-N-{(1S,2R)-2-hydroxy-3-[(3-
methoxybenzyl)amino]-1-[3-
 (trifluoromethoxy)benzyl]propyl}propanamide;
                N^{1}-benzyl-N^{1}-(1-cyclopropylethyl)-N^{4}-{(1S, 2R)-1-(3, 5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}succinamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-2-hydroxy-3-[(3-4)]
methoxybenzyl)amino]propyl}-3-(2,5-dimethylbenzoyl)-5-
methylbenzamide;
                N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [(3 - 3)] \}
ethylbenzyl)amino]-2-hydroxypropyl}-N4-(2-methoxy-5-
methylphenyl) succinamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-i)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(3-
hydroxyphenyl)acetamide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-3-[hydroxy(2-methylphenyl)methyl]-
5-methylbenzamide;
                N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-instance of the content 
ethylbenzyl)amino]-2-hydroxypropyl}-5-(ethylthio)nicotinamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-[4-(2-furoyl)piperazin-1-
yl]-4-oxobutanamide;
                N^{1}-[(1S,2R)-3-(benzylamino)-1-(3-fluoro-4-methylbenzyl)-2-
hydroxypropyl]-5-methyl-N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-oxoisoindoline-1-
carboxamide;
```

```
N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-(ethylthio)benzamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}thieno[2,3-b]quinoline-2-
carboxamide:
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-(4-methyl-1,3-oxazol-2-
yl)benzamide;
           N^{1}-[(1S,2R)-3-(benzylamino)-1-(4-fluorobenzyl)-2-
hydroxypropyl]-N^3, N^3-dipropylbenzene-1, 3, 5-tricarboxamide;
           N-\{2-[(\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-i)]\}\}]
ethylbenzyl)amino]-2-hydroxypropyl}amino)carbonyl]phenyl}-N-
methyl-2-furamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-4-(3-
methoxyphenyl)-4-oxobutanamide;
           N^{1}-[(1S,2R)-3-(cycloheptylamino)-1-(3,5-difluorobenzyl)-2-
hydroxypropyl]-5-methyl-N3,N3-dipropylisophthalamide;
           N^{1}-[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-(4-
methylbenzyl)propyl]-N<sup>3</sup>,N<sup>3</sup>-dipropylbenzene-1,3,5-tricarboxamide;
            1 3-[(dipropylamino)sulfonyl]-N-{(1S,2R)-1-(3-fluoro-5-
hvdroxybenzyl)-2-hvdroxy-3-[(3-
methoxybenzyl)amino]propyl}propanamide;
            3-[(dipropylamino)sulfonyl]-N-{(1S,2R)-1-(3-fluoro-5-
hydroxybenzyl)-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}propanamide;
            N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-hydroxy-1H-indole-2-
carboxamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-2,2-dimethylchromane-8-
carboxamide;
            6-benzyl-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{(3-difluorobenzyl)-3-(3-difluorobenzyl)-3-(3-difluorobenzyl)-3-(3-difluorobenzyl)-3-(3-difluorobenzyl)-3
ethylbenzyl)amino]-2-hydroxypropyl}pyrazine-2-carboxamide 4-
oxide;
            2-\{[(\{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-i)]\}\}]
methoxybenzyl) amino]propyl}amino)carbonyl]amino}-N, N-
dipropylethanesulfonamide;
            N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(1R)-1-
 (hydroxymethyl) -2-methylpropyl] amino propyl) -5-methyl-N3, N3-
 dipropylisophthalamide;
            N-[(1S, 2R)-3-(benzylamino)-1-(3-chloro-5-fluorobenzyl)-2-
hydroxypropyl]-3-[(dipropylamino)sulfonyl]propanamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-4-(4-methoxyphenyl)-4-
 oxobutanamide;
            N^1-[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4-
hydroxybenzyl)propyl]-N<sup>3</sup>,N<sup>3</sup>-dipropylbenzene-1,3,5-
```

tricarboxamide:

```
N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{(3-4)\}
ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-4-oxo-3,4-
dihydrophthalazine-1-carboxamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3,4-dihydro-2H-1,5-
benzodioxepine-7-carboxamide;
                N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-[4-(2,5-dioxopyrrolidin-
1-yl)phenoxy]acetamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{(3-1)\}
ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-4-oxo-3,4-
dihydrothieno[2,3-d]pyrimidine-6-carboxamide;
                N^{1}-[(1S,2R)-1-(1,3-benzodioxol-5-ylmethyl)-2-hydroxy-3-
(isopentylamino)propyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylbenzene-1, 3, 5-
tricarboxamide;
                N^{1}-{(1S, 2R)-1-(3-chloro-5-fluorobenzyl)-2-hydroxy-3-[(3-
methoxybenzyl) amino [propyl]-N^5, N^5-dipropylpentanediamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-instance of the second of th
ethylbenzyl)amino]-2-hydroxypropyl}-6-fluoro-2-
hydroxyquinoline-4-carboxamide;
                N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-oxo-4-thien-2-
ylbutanamide;
                N^{3}-[({(1s, 2R) -1-(3, 5-difluorobenzyl) -2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}amino)carbonyl]-N1,N1-dipropyl-beta-
alaninamide;
                N^{1}-{(1R, 2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-
[(phenylthio)methyl]propyl}-N³,N³-dipropylbenzene-1,3,5-
tricarboxamide;
                N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(1R,2S)-
1-(hydroxymethyl)-2-methylbutyl]amino}propyl)-5-methyl-N³,N³-
dipropylisophthalamide;
                 N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-instance]]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(phenoxymethyl)benzamide;
                N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-k)]
ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>5</sup>-(2,4-
difluorophenyl) pentanediamide;
                 N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>5</sup>-(4,6-dimethylpyrimidin-
2-yl)pentanediamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-[(3-max)-1-(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-
methoxybenzyl)amino]propyl}-3-(3-methoxybenzoyl)-5-
                 N^{1}-{ (1s, 2r)-1-[3-(benzyloxy)benzyl]-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N3,N3-dipropylbenzene-1,3,5-
tricarboxamide;
                 4-(3,4-dichlorophenyl)-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-
3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-oxobutanamide;
```

```
methyl 4-\{(2R,3R)-2-(\{3-[(dipropylamino)carbonyl]-5-
methylbenzoyl amino) -3-hydroxy-4-[(3-
methoxybenzyl)amino]butyl}benzoate;
           N^{1}-(4-acetylphenyl)-N^{5}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-
 [(3-ethylbenzyl)amino]-2-hydroxypropyl}pentanediamide;
           N^{1}-{ (1R, 2R) -2-hydroxy-3-[(3-methoxybenzyl)amino]-1-
 [(phenylthio)methyl]propyl}-5-methyl-N<sup>3</sup>,N<sup>3</sup>-
dipropylisophthalamide;
           2-\{[3-(\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-k)]\}\}
ethylbenzyl)amino]-2-hydroxypropyl}amino)-3-oxopropyl]thio}-N-
methylbenzamide;
           N-\{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-3-[(1-propylbutyl)thio]propanamide;
           N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N4-(4-
ethoxyphenyl) succinamide;
           N^1-[(1S,2R)-1-[3-(benzyloxy)-5-fluorobenzyl]-2-hydroxy-3-
 (isopentylamino)propyl]-N3,N3-dipropylbenzene-1,3,5-
tricarboxamide;
            2-\{[(2R,3S)-4-(3,5-difluorophenyl)-3-(\{3-4\})\}\}
 [(dipropylamino)carbonyl]-5-methylbenzoyl}amino)-2-
hydroxybutyl]amino}ethyl 3-methoxyphenylcarbamate;
            3-(benzyloxy)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}benzamide;
           N^{1}-((1S, 2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(1S)-2-
hydroxy-1-methylethyl]amino}propyl)-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalamide;
           N^{1}-((1S,2R)-2-hydroxy-1-(pentafluorobenzyl)-3-{[3-
 (trifluoromethyl)benzyl]amino}propyl)-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-4-(4-hydroxyphenyl)-4-
 oxobutanamide;
            3-[(dipropylamino)sulfonyl]-N-{(1S,2R)-2-hydroxy-3-[(3-
methoxybenzyl)amino]-1-[3-
 (trifluoromethyl)benzyl]propyl}propanamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-3-(piperidin-3-
ylsulfonyl)benzamide;
            6-chloro-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzy
 ethylbenzyl)amino]-2-hydroxypropyl}-4-hydroxyquinoline-2-
 carboxamide;
            N^{1}-[(1S,2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(thien-
 2-ylmethyl)propyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
            N^{1}-((1S)-1-{(1R)-1-hydroxy-2-{(3-
methoxybenzyl) amino ] ethyl] -3-methylbutyl) -5-methyl-N^3, N^3-
 dipropylisophthalamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-4)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-(6-oxo-3-phenylpyridazin-
 1(6H)-yl)acetamide;
```

```
N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-{4-
[(methylsulfonyl)amino]phenyl}propanamide;
     N^{1}-[(1S, 2R)-3-(benzylamino)-2-hydroxy-1-(4-
methylbenzyl)propyl]-5-methyl-N3,N3-dipropylisophthalamide;
      3-(2-chlorophenoxy)-N-\{(1s,2r)-1-(3,5-difluorobenzyl)-2-
hydroxy-3-[(3-iodobenzyl)amino]propyl}propanamide;
     N^1-[(1S, 2R)-1-(4-fluorobenzyl)-2-hydroxy-3-
(isopentylamino)propyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylbenzene-1, 3, 5-
tricarboxamide;
      Structure possibly contains peptides which are not
supported in current version!;
      1 N-\{(1S, 2R)-1-[3-(benzyloxy)-5-fluorobenzyl]-2-hydroxy-
3-[(3-methoxybenzyl)amino]propyl}-3-
[(dipropylamino)sulfonyl]propanamide;
     N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(4-methylphenyl)-4-
oxobutanamide:
     N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl) amino] -2-hydroxypropyl} -N^4-[3-
(trifluoromethyl)phenyl]succinamide;
     N^{1}-{ (1s, 2r) -1- (1, 3-benzodioxol-5-ylmethyl) -2-hydroxy-3-
[(3-methoxybenzyl)amino]propyl}-5-methyl-N^3, N^3-
dipropylisophthalamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(5-pyridin-2-yl-2H-
tetraazol-2-yl)acetamide;
      Structure possibly contains peptides which are not
supported in current version!;
      3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-2-hydroxy-3-[(3-
methoxybenzyl)amino]-1-(3-methylbenzyl)propyl]propanamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-a)]
ethylbenzyl)amino]-2-hydroxypropyl}isoxazole-5-carboxamide;
      N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(3,5-
dimethoxyphenoxy) acetamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4-(2,5-dimethyl-1H-pyrrol-
1-yl)-3-hydroxybenzamide;
      N^{1}-{(1S, 2R)-1-(3-bromobenzy1)-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N^5, N^5-dipropylpentanediamide;
      N^{1}-[5-(cyclopentylmethyl)-1,3,4-thiadiazol-2-yl]-N^{4}-
{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}succinamide;
      N^{1}-{ (1S, 2R) -3- (benzylamino) -2-hydroxy-1-[3-
(trifluoromethyl)benzyl]propyl}-N3,N3-dipropylbenzene-1,3,5-
tricarboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(3-oxo-1,2-
benzisothiazol-2(3H)-yl)acetamide;
```

```
N^{1}-((15,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[1-methyl-
5-(pyrrolidin-1-ylcarbonyl)-1H-pyrrol-3-yl]amino}propyl)-5-
methyl-N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(3,4-difluorophenyl)-4-
oxobutanamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(2-naphthyl)-4-
oxobutanamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-4,6-diethoxypyridine-2-
carboxamide:
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(5-methyl-1H-pyrrol-2-
v1)-4-oxobutanamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-({[2-
 (methylamino)ethyl]amino}sulfonyl)benzamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-mu)]
methoxybenzyl)amino]propyl}-3-methyl-5-(4-
methylbenzoyl)benzamide;
           N^{1}-[(1S,2R)-1-(1,3-benzodioxol-5-ylmethyl)-3-
 (benzylamino) -2-hydroxypropyl]-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-(piperazin-1-
ylsulfonyl)benzamide;
           N^{1}-[(1S, 2R)-3-({2-[4-(aminosulfonyl)phenyl]ethyl}amino)-1-
 (3,5-difluorobenzyl)-2-hydroxypropyl]-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalamide;
            N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[2-
hydroxy-1-(hydroxymethyl)ethyl]amino)propyl)-5-methyl-N3,N3-
dipropylisophthalamide;
            N^{1}-[(1S,2R)-1-(4-fluoro-3-methylbenzyl)-2-hydroxy-3-
 (isopentylamino)propyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylbenzene-1, 3, 5-
tricarboxamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-(3-oxo-2,1-
benzisothiazol-1(3H)-yl)propanamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(2,6-dihydroxypyrimidin-
4-y1)acetamide;
            N^{1} - \{ (1S, 2R) - 2 - hydroxy - 3 - [ (3 - methoxybenzyl) amino ] - 1 - [ 3 - methoxybenzyl) amino ] - 1 - [ 3 - methoxybenzyl) amino ] - 1 - [ 3 - methoxybenzyl) amino ] - 1 - [ 3 - methoxybenzyl) amino ] - 1 - [ 3 - methoxybenzyl) amino ] - 1 - [ 3 - methoxybenzyl) amino ] - 1 - [ 3 - methoxybenzyl) amino ] - 1 - [ 3 - methoxybenzyl) amino ] - 1 - [ 3 - methoxybenzyl) amino ] - 1 - [ 3 - methoxybenzyl) amino ] - 1 - [ 3 - methoxybenzyl) amino ] - 1 - [ 3 - methoxybenzyl) amino ] - 1 - [ 3 - methoxybenzyl) amino ] - 1 - [ 3 - methoxybenzyl) amino ] - 1 - [ 3 - methoxybenzyl] amino ] - 1 - [ 3 - methoxybenzyl] amino ] - 1 - [ 3 - methoxybenzyl] amino ] - 1 - [ 3 - methoxybenzyl] amino ] - 1 - [ 3 - methoxybenzyl] amino ] - 1 - [ 3 - methoxybenzyl] amino ] - 1 - [ 3 - methoxybenzyl] amino ] - 1 - [ 3 - methoxybenzyl] amino ] - 1 - [ 3 - methoxybenzyl] amino ] - 1 - [ 3 - methoxybenzyl] amino ] - 1 - [ 3 - methoxybenzyl] amino ] - 1 - [ 3 - methoxybenzyl] amino ] - 1 - [ 3 - methoxybenzyl] amino ] - 1 - [ 3 - methoxybenzyl] amino ] - 1 - [ 3 - methoxybenzyl] amino ] - 1 - [ 3 - methoxybenzyl] amino [ 3 - met
 (trifluoromethyl)benzyl]propyl}-N<sup>5</sup>,N<sup>5</sup>-dipropylpentanediamide;
            N-[(1S, 2R)-3-(benzylamino)-2-hydroxy-1-(4-
hydroxybenzyl)propyl]-3-[(dipropylamino)sulfonyl]propanamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4-(3,4-difluorophenyl)-2-
methyl-4-oxobutanamide;
```

-1122-

 $N^{1}$ -{ (1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-

```
ethylbenzyl)amino]-2-hydroxypropyl}-N5-(2-pyridin-2-
ylethyl)pentanediamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-[2-(4-fluorophenyl)-1,3-
benzoxazol-5-yl]acetamide;
           N^2-(anilinocarbonyl)-N^1-{(1S,2R)-1-(3,5-difluorobenzyl)-3-
[(3-ethylbenzyl)amino]-2-hydroxypropyl}glycinamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-(1,3-dithian-2-yl)-3-
furamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-[2-oxo-2-
 (propylamino) ethyl] benzamide;
           N-[(1S,2R)-3-(benzylamino)-1-(3-bromobenzyl)-2-
hydroxypropyl]-3-[(dipropylamino)sulfonyl]propanamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-[(3-max)-1-(3-max)-2-(3-ma
iodobenzyl)amino]propyl}-3-(2-fluorophenyl)propanamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-difluorobenzyl)]
 ethylbenzyl)amino]-2-hydroxypropyl}-5-methylthiophene-2-
 carboxamide:
            2-[4-(benzyloxy)phenyl]-N-{(1S,2R)-1-(3,5-)}
 difluorobenzyl)-2-hydroxy-3-[(3-
 iodobenzyl)amino]propyl}acetamide;
            N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-2-[(5,7-
 dimethyl[1,2,4]triazolo[4,3-a]pyrimidin-3-yl)thio]acetamide;
            N^{1}-(1-acetyl-2,3-dihydro-1H-indol-7-yl)-N^{4}-{(1S,2R)-1-
 (3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
 hydroxypropyl}succinamide;
            N^{1}-(3-acetylphenyl)-N^{5}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-
 [(3-ethylbenzyl)amino]-2-hydroxypropyl}pentanediamide;
            3-(4-chlorophenoxy)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-}
 [(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxypropanamide;
            N^{1}-[(1S,2R)-3-(benzylamino)-1-(3-fluoro-4-methoxybenzyl)-
 2-hydroxypropyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylbenzene-1,3,5-tricarboxamide;
            N^{1}-[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(3-
 methylbenzyl)propyl]-N^3, N^3-dipropylbenzene-1,3,5-tricarboxamide;
            N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-1H-indole-7-carboxamide;
            N^{1}-[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-(3-
 methylbenzyl)propyl]-N^3,N^3-dipropylbenzene-1,3,5-tricarboxamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-4-(1,2,3-thiadiazol-4-
 yl)benzamide;
            N-\{(1S,2R)-1-[3-(benzyloxy)-5-fluorobenzyl]-2-hydroxy-3-
  [(3-methoxybenzyl)amino]propyl}-3-
  [(dipropylamino)sulfonyl]propanamide;
```

```
N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance of the stance of th
ethylbenzyl)amino]-2-hydroxypropyl}-3-(4,4-dimethyl-2,5-
dioxoimidazolidin-1-yl)-2-{[(1-
propylbutyl)sulfonyl]methyl)propanamide;
           N^{1}-[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-(4-
methylbenzyl)propyl]-5-methyl-N³,N³-dipropylisophthalamide;
           N^{1}-{(1S, 2R)-3-(benzylamino)-1-[3-fluoro-5-
(trifluoromethyl)benzyl]-2-hydroxypropyl}-5-methyl-N3,N3-
dipropylisophthalamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-[1-methyl-3-(methylthio)-
1H-indol-2-yl]acetamide;
           N^{1}-[(1S,2R)-1-(3,5-dichlorobenzyl)-2-hydroxy-3-
 (isopentylamino)propyl]-5-methyl-N3,N3-dipropylisophthalamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(2-furyl)-4-
oxobutanamide;
       N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-(3-pyridin-2-yl-1,2,4-
oxadiazol-5-yl)propanamide;
            2-[2-(acetylamino)-1,3-thiazol-4-yl]-N-{(1s,2r)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}acetamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-2-[(4-methyl-4H-1,2,4-
 triazol-3-yl)thio]-2-phenylacetamide;
           N^{1}-[(1S,2R)-1-(4-chlorobenzyl)-2-hydroxy-3-
 (isopentylamino)propyl]-5-methyl-N3,N3-dipropylisophthalamide;
            4-(1,3-benzothiazol-2-yl)-N-{(1S,2R)-1-(3,5-
 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
 hydroxypropyl}butanamide;
            N^{1}-(3-chloro-4-fluorophenyl)-N^{4}-{(1S,2R)-1-(3,5-
 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
 hydroxypropyl}succinamide;
            N^{1}-[(1S,2R)-1-[3-(benzyloxy)-5-fluorobenzyl]-2-hydroxy-3-
 (isopentylamino)propyl]-5-methyl-N3,N3-dipropylisophthalamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-[(2-oxo-2,3-
 dihydroquinazolin-4-yl)thio]acetamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-[(3-1)]
 methoxybenzyl)amino]propyl}-3-methyl-5-(2-
 methylbenzoyl)benzamide;
            N^{1}-[(1S, 2R)-3-(benzylamino)-2-hydroxy-1-(4-
 methylbenzyl)propyl]-N³,N³-dipropylbenzene-1,3,5-tricarboxamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-4-propoxybenzamide;
            N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-1-methyl-1H-indole-2-
 carboxamide;
```

```
5-chloro-N-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-(3-methyl-4H-1,2,4-
triazol-4-yl)benzamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(3,4-difluorophenyl)-2-
methoxy-4-oxobutanamide;
     N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-(3-thien-2-yl-1H-pyrazol-
1-yl)acetamide;
     N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>5</sup>-phenylpentanediamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-thioxo-1,3-
benzothiazol-3(2H)-yl)acetamide;
     N^{1}-[(1S,2R)-3-(benzylamino)-1-(cyclohexylmethyl)-2-
hydroxypropyl]-5-methyl-N3,N3-dipropylisophthalamide;
      N^{1}-{ (1S, 2R) -2-hydroxy-1-(4-methoxybenzyl) -3-[(3-
methoxybenzyl)amino]propyl}-N³,N³-dipropylbenzene-1,3,5-
tricarboxamide;
      N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(3-hydroxy-4-
methylphenyl) acetamide;
      N^{1}-[(1S,2R)-1-[3-fluoro-5-(trifluoromethyl)benzyl]-2-
hydroxy-3-(isopentylamino)propyl]-5-methyl-N^3, N^3-
dipropylisophthalamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-7-fluoro-4H-imidazo[5,1-
c][1,4]benzoxazine-3-carboxamide;
      N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(3,4-dihydro-2H-1,5-
benzodioxepin-7-yl)-4-oxobutanamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-benzofuran-3-carboxamide;
      N^{1}-(3,4-dichlorophenyl)-N^{3}-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl } malonamide;
      N^{1}-{(1S, 2R)-3-(benzylamino)-1-[3-fluoro-5-
(trifluoromethyl)benzyl]-2-hydroxypropyl}-N3,N3-dipropylbenzene-
1,3,5-tricarboxamide;
      N^{1}-((1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-{[(1R)-2-
hydroxy-1-methylethyl]aminopropyl -5-methyl-N^3, N^3-
dipropylisophthalamide;
      N^{1}-[(1S, 2R)-3-(benzylamino)-2-hydroxy-1-(3-
methylbenzyl)propyl]-5-methyl-N3,N3-dipropylisophthalamide;
      N^{1}-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N5-pyridin-3-
ylpentanediamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-4-oxo-4H-chromene-
6-carboxamide;
```

```
N^{1}-((1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-{[3-(1H-
imidazol-1-yl)propyl]amino}propyl)-5-methyl-N<sup>3</sup>,N<sup>3</sup>-
dipropylisophthalamide;
     3-[(dipropylamino)sulfonyl]-N-{(1S,2R)-1-[3-fluoro-5-
(trifluoromethyl)benzyl]-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}propanamide;
     3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-2-hydroxy-1-(4-
hydroxybenzyl)-3-(isopentylamino)propyl]propanamide;
     N^{1}-[(1S,2R)-1-(1,3-benzodioxol-5-ylmethyl)-2-hydroxy-3-
(isopentylamino)propyl]-5-methyl-N3, N3-dipropylisophthalamide;
     3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-2-hydroxy-3-
(isopentylamino)-1-(thien-2-ylmethyl)propyl]propanamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4-[(2,2-
dimethylpropanoyl)amino]-2-hydroxybenzamide;
     N^{1}-[(1S, 2R)-2-hydroxy-3-(isopentylamino)-1-(3-
methoxybenzyl)propyl]-5-methyl-N3,N3-dipropylisophthalamide;
     N-((1S, 2R)-1-(4-fluorobenzyl)-2-hydroxy-3-{[3-
(trifluoromethyl)benzyl]amino)propyl)-3-{[(3-
methoxybenzyl)amino]sulfonyl}benzamide;
     N^{1}-{(1S,2R)-2-hydroxy-3-(isopentylamino)-1-[3-
(trifluoromethyl)benzyl]propyl}-5-methyl-N3,N3-
dipropylisophthalamide;
     N-[6-({(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}amino)-6-oxohexyl]-2-
furamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-[(1-phenyl-4,5-dihydro-
1H-tetraazol-5-yl)thio]acetamide;
      4-acetyl-4-amino-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}cyclohexa-1,'5-diene-1-
sulfonamide;
     N-((1S, 2S)-1-benzyl-2-hydroxy-3-{[3-
(trifluoromethyl)benzyl]amino}propyl)-3-{[(3-
methoxybenzyl)amino]sulfonyl}benzamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(3,4-dihydro-2H-chromen-
6-yl)-4-oxobutanamide;
     N^{1}-[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-(3-
methoxybenzyl)propyl]-N3,N3-dipropylbenzene-1,3,5-
tricarboxamide;
     N^1-{(1S,2R)-1-(3-fluoro-4-methylbenzyl)-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N<sup>5</sup>,N<sup>5</sup>-dipropylpentanediamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}indolizine-2-carboxamide;
     N^{1}-{ (1S, 2R) -3- (benzylamino) -2-hydroxy-1-[3-
(trifluoromethoxy) benzyl]propyl}-5-methyl-N3, N3-
dipropylisophthalamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}nicotinamide 1-oxide;
```

- ---

```
N-[(1S, 2R)-1-[3-(benzyloxy)-5-fluorobenzyl]-2-hydroxy-3-
(isopentylamino)propyl]-3-[(dipropylamino)sulfonyl]propanamide;
     2-({(1S,2R)-1-(3,5-difluorobenzy1)-2-hydroxy-3-[(3-
iodobenzyl)amino]propyl}amino)-2-oxoethyl carbamate;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mu)]
ethylbenzyl)amino]-2-hydroxypropyl}-2,3-dihydro-1H-
cyclopenta[b]quinoline-9-carboxamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-mu)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-1H-pyrazole-5-
carboxamide;
     N-[5-({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}amino)-5-
oxopentyl]benzamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-
[(methoxymethyl)thio]benzamide;
      3-(1,3-benzothiazol-2-yl)-N-{(1S,2R)-1-(3,5-)}
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-
methoxypropanamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-3-
{[(methylamino)carbonyl]amino}-3-thien-3-ylpropanamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzyl)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-pyridin-2-ylthiophene-2-
carboxamide;
      \mathbb{N}^{1}-{(1S,2R)-3-(benzylamino)-1-[3-(benzyloxy)-5-
fluorobenzyl]-2-hydroxypropyl}-N3,N3-dipropylbenzene-1,3,5-
tricarboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-(5,6-dimethyl-2,4-dioxo-
1,2,3,4-tetrahydropyridin-3-yl)acetamide;
      N^{1}-[(1S,2R)-1-(3-fluoro-4-methoxybenzyl)-2-hydroxy-3-
 (isopentylamino)propyl]-5-methyl-N3,N3-dipropylisophthalamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-isobutyl-1,3-
dioxoisoindoline-5-carboxamide;
      3-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}amino)sulfonyl]benzoic acid;
      5-(acetylamino)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-furamide;
      N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N2-[(4-
methoxyphenyl)acetyl]glycinamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}isoquinoline-4-carboxamide;
      N^{1}-[(1S,2R)-1-[3-(benzyloxy)benzyl]-2-hydroxy-3-
 (isopentylamino)propyl]-N3,N3-dipropylbenzene-1,3,5-
 tricarboxamide:
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-2-(4-hydroxy-3-
```

```
methoxyphenyl)acetamide;
               N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-[(4-phenyl-4H-1,2,4-
triazol-3-yl)thio]acetamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(3,5-
dimethoxyphenyl)acetamide;
                N^{1}-[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(3-
methoxybenzyl)propyl]-5-methyl-N³, N³-dipropylisophthalamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-ethyl-4H-
 [1,2,4]triazolo[1,5-a]benzimidazol-4-yl)acetamide;
                N^{1}-[(1S, 2R)-3-(benzylamino)-1-(2-furylmethyl)-2-
hydroxypropyl]-5-methyl-N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
                 7-chloro-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-difluorobenzyl)
ethylbenzyl)amino]-2-hydroxypropyl}-1-benzofuran-2-carboxamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-a)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-(1,3-dioxo-1,3-dihydro-
 2H-isoindol-2-yl)propanamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-oxo-2H-1,3-benzoxazin-
 3(4H)-yl)propanamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-(pyrimidin-2-
ylthio)acetamide;
                N<sup>1</sup>-[3-(aminocarbonyl)-4,5,6,7-tetrahydro-1-benzothien-2-
y1]-N^4-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}succinamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-[(5-phenyl-1,3,4-
oxadiazol-2-yl)thio]acetamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}quinoline-6-carboxamide;
                N^{1}-[(1S, 2R)-3-(benzylamino)-1-(2-furylmethyl)-2-
hydroxypropyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylbenzene-1,3,5-tricarboxamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-4-(2,3-dihydro-1,4-
benzodioxin-6-yl)-4-oxobutanamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-(1H-indol-3-yl)-1H-
pyrazole-5-carboxamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-4-
 {[(methylamino)carbonothioyl]amino}benzamide;
                 6-chloro-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzy
 ethylbenzyl)amino]-2-hydroxypropyl}nicotinamide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-4-(3-hydroxyphenyl)-4-
 oxobutanamide;
```

```
N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-(phthalazin-1-
vlthio)acetamide;
                 N-\{(1S, 2R) -1 - (3, 5-difluorobenzyl) -3 - [(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-[(1-oxidopyridin-2-
yl)thio]acetamide;
                  3-(acetylamino)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-fluoro-1H-indole-2-
carboxamide;
                 N-((1S,2S)-1-benzyl-2-hydroxy-3-{[3-
 (trifluoromethyl)benzyl]amino}propyl)-3-{[(3-
 chlorobenzyl)amino]sulfonyl}benzamide;
                 N^{1}-[(1S, 2R)-1-(1,3-benzodioxol-5-ylmethyl)-3-
 (benzylamino) -2-hydroxypropyl]-N3, N3-dipropylbenzene-1,3,5-
 tricarboxamide;
                  4-(3,4-dichlorophenyl)-N-((1S,2R)-1-(3,5-difluorobenzyl)-
 3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-3-methyl-4-
 oxobutanamide;
                  3-[(dipropylamino)sulfonyl]-N-{(1S, 2R)-2-hydroxy-3-
  (isopentylamino)-1-[3-
  (trifluoromethoxy)benzyl]propyl}propanamide;
                  N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-N4-(5-methyl-1,3,4-
 thiadiazol-2-yl) succinamide;
                  N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-ethyl-1H-benzimidazol-
  1-y1)acetamide;
                  N-\{(1S,2R)-1-(1,3-benzodioxol-5-ylmethyl)-2-hydroxy-3-
  [(3-methoxybenzyl)amino]propyl}-3-
  [(dipropylamino)sulfonyl]propanamide;
                   N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
  ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-oxo-1,3-benzoxazol-
  3(2H)-yl)propanamide;
                   N-[(1S, 2R)-1-(3, 5-dichlorobenzyl)-2-hydroxy-3-
   (isopentylamino)propyl]-3-[(dipropylamino)sulfonyl]propanamide;
                   N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
  ethylbenzyl)amino]-2-hydroxypropyl}-N^4-(6-methylpyridin-2-
  yl) succinamide;
                    ethyl (4R)-4-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
  ethylbenzyl)amino]-2-hydroxypropyl}amino)carbonyl]-1,3-
  oxazolidine-3-carboxylate;
                   N-\{(1R, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-[(3-max)-1-(3-max)-2-
  methoxybenzyl)amino]propyl}-3-glycylbenzamide;
                    N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
   ethylbenzyl)amino]-2-hydroxypropyl}-3-(1-methyl-1H-imidazol-2-
   yl) benzamide;
                    4-(acetylamino)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-difluoro
```

ethylbenzyl)amino]-2-hydroxypropyl}butanamide trifluoroacetate;

```
N<sup>1</sup>-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>2</sup>-{[(3S)-tetrahydrofuran-3-yloxy]carbonyl}-D-leucinamide;
N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-(pyrrolidin-3-ylsulfonyl)benzamide;
N-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-ethylbenzyl)amino]-2-hydroxy-3-[(3-ethylbenzyl)amino]-2-hydroxy-3-[(3-ethylbenzyl)amino]-2-hydroxy-3-[(3-ethylbenzyl)amino]-2-hydroxy-3-[(3-ethylbenzyl)amino]-2-hydroxy-3-[(3-ethylbenzyl)amino]-2-hydroxy-3-[(3-ethylbenzyl)amino]-2-hydroxy-3-[(3-ethylbenzyl)amino]-2-hydroxy-3-[(3-ethylbenzyl)amino]-2-hydroxy-3-[(3-ethylbenzyl)amino]-1-(3-ethylbenzyl)amino]-2-hydroxy-3-[(3-eth
```

- N-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-3-[(dipropylamino)methyl]benzamide;
- $N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino}propyl)-5-methyl- $N^{3}$ ,  $N^{3}$ -dipropylisophthalamide;
- $N^{1}-[(1S,2R)-3-[tert-butyl(cyclohexyl)amino]-1-(3,5-difluorobenzyl)-2-hydroxypropyl]-5-methyl-N^{3},N^{3}-dipropylisophthalamide;$
- $N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(1S)-1-(hydroxymethyl)-2,2-dimethylpropyl]amino}propyl)-5-methyl- $N^{3}$ ,  $N^{3}$ -dipropylisophthalamide;
- $N^{1}-[(1S,2R)-1-(3,5-difluorobenzyl)-3-({[(2R)-1-ethylpyrrolidin-2-yl]methyl}amino)-2-hydroxypropyl]-5-methyl-<math>N^{3}$ ,  $N^{3}$ -dipropylisophthalamide;
- $N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-3-([3-(dimethylamino)-2,2-dimethylpropyl]amino}-2-hydroxypropyl)-5-methyl- $N^{3}$ ,  $N^{3}$ -dipropylisophthalamide;
- $N^{1}$ -((1S, 2R)-1-(3,5-difluorobenzyl)-3-{[2-(diisopropylamino)ethyl]amino}-2-hydroxypropyl)-5-methyl- $N^{3}$ ,  $N^{3}$ -dipropylisophthalamide;
- $N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[(1-ethylpyrrolidin-2-yl)methyl]amino}-2-hydroxypropyl)-5-methyl- $N^{3}$ ,  $N^{3}$ -dipropylisophthalamide;
- $N^{1}-[(1S,2R)-3-[(1-benzylpyrrolidin-3-y1)amino]-1-(3,5-difluorobenzyl)-2-hydroxypropyl]-5-methyl-<math>N^{3}$ ,  $N^{3}$ -dipropylisophthalamide;
- $N^1$ -{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-pyrrolidin-1-ylpropyl)amino]propyl}-5-methyl- $N^3$ ,  $N^3$ -dipropylisophthalamide;
- $N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-3-{[3-(dimethylamino)propyl]amino}-2-hydroxypropyl)-5-methyl- $N^{3}$ ,  $N^{3}$ -dipropylisophthalamide;
- $N^{1}-[(1S,2R)-3-\{[2-(acetylamino)ethyl]amino\}-1-(3,5-difluorobenzyl)-2-hydroxypropyl]-5-methyl-<math>N^{3}$ ,  $N^{3}$ -dipropylisophthalamide;
- $N^{1}$ -((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[2-(6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl]amino}propyl)-5-methyl- $N^{3}$ ,  $N^{3}$ -dipropylisophthalamide;
- $N^{1}$ -[(1S,2R)-3-[7-chloro-1-(2-hydroxy-3-methoxyphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-1-(3,5-difluorobenzyl)-2-hydroxypropyl]-5-methyl- $N^{3}$ ,  $N^{3}$ -dipropylisophthalamide;
- $N^{1}$ -[(1S,2R)-3-{[4-(1-cyanocyclopentyl)phenyl]amino}-1-(3,5-difluorobenzyl)-2-hydroxypropyl]-5-methyl- $N^{3}$ ,  $N^{3}$ -dipropylisophthalamide;

```
N^{1}-[(1S, 2R)-3-({4-[4-(acetylamino)phenoxy]phenyl}amino)-1-
(3,5-difluorobenzyl)-2-hydroxypropyl]-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalamide;
           N^{1}-[(1S, 2R)-3-[(4-benzoyl-2, 3-dimethylphenyl)amino]-1-
(3,5-difluorobenzyl)-2-hydroxypropyl]-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalamide;
           N^{1}-[(1S,2R)-3-[(2-amino-2-oxo-1-phenylethyl)amino]-1-(3,5-
difluorobenzyl)-2-hydroxypropyl]-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalamide;
           N^{1}-((1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-{4-[(1-
methyl-1H-imidazol-2-yl)methyl]piperazin-1-yl}propyl)-5-methyl-
N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
           N^{1}-((1S,2R)-1-[3,5-bis(trifluoromethyl)benzyl]-2-hydroxy-
3-{[3-(trifluoromethyl)benzyl]amino}propyl)-5-methyl-N³, N³-
dipropylisophthalamide;
            (1S, 2R) - N^{1} - [2 - (tert-butylthio) ethyl] - N^{2} - { (1S, 2R) - 1 - (3, 5 - 1) - (3, 5 
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}cyclopropane-1,2-dicarboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-4,5-dihydronaphtho[2,1-
d]isoxazole-3-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-methyl-1H-
benzo[g]indazole-3-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-1,3-thiazole-4-
carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-methoxy-1H-pyrrole-3-
carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-9-oxo-1,2,3,9-
 tetrahydrocyclopenta[b]chromene-7-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-a)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-oxo-2,3-dihydro-1H-
benzimidazol-5-yl)acetamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-oxo-2,3-dihydro-1,3-
benzoxazol-5-yl)acetamide;
            2-[2-(1,3-benzoxazol-2-yl)phenoxy]-N-{(1s,2r)-1-(3,5-
 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl acetamide;
            5-chloro-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mathemathem)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-morpholin-4-ylbenzamide;
            3-(3-chloroisoxazol-5-yl)-N-{(1S,2R)-1-(3,5-
 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
 hydroxypropyl)propanamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-4)]
 ethylbenzyl)amino]-2-hydroxypropyl}-4-(6-methoxy-1,1'-biphenyl-
 3-y1)-4-oxobutanamide;
```

```
4-(1-benzofuran-2-y1)-N-\{(1s,2r)-1-(3,5-difluorobenzy1)-
3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-oxobutanamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-oxo-1,2,3,4-
tetrahydroguinoline-3-carboxamide;
            2-(1-benzofuran-2-y1)-N-{(1S,2R)-1-(3,5-difluorobenzy1)-}
3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-methylpropanamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-6-methoxy-1-benzofuran-2-
carboxamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-[4-(1H-pyrrol-1-
yl)phenyl]propanamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-1H-imidazo[1,2-b]pyrazole-
6-carboxamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-[(4-methyl-1,3-thiazol-2-
yl)thio]acetamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-\{(3-1)-1,2R\}\}
ethylbenzyl)amino]-2-hydroxypropyl}-2-methoxy-4-
 (methylthio) benzamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance of the content 
ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-4-
 (propionylamino) benzamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-6-{[(4-
methylphenyl)sulfonyl]amino}-4-oxohexanamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mu)]
ethylbenzyl)amino]-2-hydroxypropyl}-1H-benzimidazole-5-
carboxamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-2-(1-oxo-1,3-
dihydro-2H-isoindol-2-yl)propanamide;
            7-(acetylamino)-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-methylquinoline-5-
carboxamide;
           N^3-(tert-butoxycarbonyl)-N^1-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-b-
alaninamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-hydroxy-3-
propylhexanamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-phenyl-2-(1H-pyrrol-1-
yl)acetamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-methyl-5-phenyl-1H-
pyrazole-3-carboxamide;
```

```
N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(3-oxo-2,3-dihydro-1H-
isoindol-1-yl)acetamide;
          4-[2-(acetylamino)-4,5-dimethylphenyl]-N-{(1S,2R)-1-(3,5-
difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-4-
oxobutanamide;
          ethylbenzyl)amino]-2-hydroxypropyl}pyrazine-2-carboxamide 4-
oxide:
          N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-6-methoxypyrazine-2-
carboxamide 4-oxide;
          2-(1H,1'H-2,2'-biimidazol-1-yl)-N-{(1S,2R)-1-(3,5-1)}
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl acetamide;
          5-chloro-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-\{(3-4)\}
ethylbenzyl)amino]-2-hydroxypropyl}-2,3-dihydro-1-benzofuran-7-
carboxamide:
          N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-([1,2,4]triazolo[4,3-
b]pyridazin-6-ylthio)acetamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-1-pyridin-4-yl-1H-
1,2,3-triazole-4-carboxamide;
          2-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-((3-difluorobenzyl))}
ethylbenzyl)amino]-2-hydroxypropyl}-4-oxo-3,4-
dihydroquinazoline-6-carboxamide;
          N-\{(1s, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(7-methoxy-1-benzofuran-
2-y1)-4-oxobutanamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-[(2-ethyl-1-oxo-2,3-
dihydro-1H-isoindol-5-yl)oxy]propanamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{(3-4)\}
ethylbenzyl)amino]-2-hydroxypropyl}pyrazine-2-carboxamide 4-
oxide;
           7-chloro-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-difluorobenzyl)
ethylbenzyl)amino]-2-hydroxypropyl}quinoline-2-carboxamide;
           2-cyano-N-{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-difluorobenzy1)]}
ethylbenzyl)amino]-2-hydroxypropyl}-3-(3,4-dimethoxyphenyl)-2-
methylpropanamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-5-
(propionylamino)benzamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-[2-oxo-5-
(trifluoromethyl)pyridin-1(2H)-yl]propanamide;
           5-(4-\text{chlorophenyl})-N-\{(1S,2R)-1-(3,5-\text{difluorobenzyl})-3-
[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-furamide;
```

```
4-cyano-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-(1H-pyrrol-1-
v1) thiophene-2-carboxamide;
                     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-3,5-
bis (methylthio) isothiazole-4-carboxamide;
                     2-chloro-4-cyano-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-difluor
ethylbenzyl)amino]-2-hydroxypropyl}benzamide;
                     N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-a)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-[(methoxyacetyl)amino]-3-
phenylpropanamide;
                     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-fluoro-4-morpholin-4-
ylbenzamide;
                     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(1-oxidothiomorpholin-4-
yl)butanamide;
                     4-chloro-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4-chloro-N-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-1,3-dimethyl-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide;
                     N-\{2-[(\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-4)]\}\}]
ethylbenzyl)amino]-2-hydroxypropyl}amino)carbonyl]phenyl}-5-
methyl-2-furamide;
                      1-(cyanomethyl)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-difluoro
ethylbenzyl)amino]-2-hydroxypropyl}-1H-pyrrole-2-carboxamide;
                     N^{1}-(2-chloropyridin-3-yl)-N^{4}-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}succinamide;
                      3-(cyclopentyloxy)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-}
 [(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-methoxybenzamide;
                     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(5-pyrrolidin-1-yl-2H-
tetraazol-2-yl)acetamide;
                     N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2,5-dimethyl-1-phenyl-1H-
pyrrole-3-carboxamide;
                      1-(4-acetylphenyl)-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-
 [(3-ethylbenzyl)amino]-2-hydroxypropyl}piperidine-4-
 carboxamide;
                     N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-2-(1H-1,2,4-
 triazol-1-yl)propanamide;
                     N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-instance of the stance of th
 ethylbenzyl)amino]-2-hydroxypropyl}-5-(piperidin-1-ylmethyl)-2-
 furamide:
                     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{(3-4)\}
ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-2,3-dihydro-1-
benzothiophene-2-carboxamide 1,1-dioxide;
```

```
2-(2,1,3-benzoxadiazol-5-yl)-N-{(1S,2R)-1-(3,5-1)}
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1,3-
thiazole-4-carboxamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4,5-dihydrofuro[2,3-
g][2,1]benzisoxazole-8-carboxamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-[(4-methyl-1,2,3-
thiadiazol-5-yl)thio]acetamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-(2-furoyl)-4-
hydroxyprolinamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-oxo-4,5,6,7-tetrahydro-1-
benzofuran-3-carboxamide;
      4,5-dichloro-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance]]
ethylbenzyl)amino]-2-hydroxypropyl}isothiazole-3-carboxamide;
     N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>5</sup>-(1,3-thiazol-2-
yl) pentanediamide;
     N-acetyl-4-chloro-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-
[(3-ethylbenzyl)amino]-2-hydroxypropyl}phenylalaninamide;
      8-chloro-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-hydroxycinnoline-3-
carboxamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2,6-
dioxohexahydropyrimidine-4-carboxamide;
     N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(5-methyl-4-phenyl-1,3-
oxazol-2-yl)benzamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-phenylimidazo[1,2-
a]pyridine-6-carboxamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-[3-(4-methoxyphenyl)-
1,2,4-oxadiazol-5-yl]propanamide;
     N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(4-methyl-1,2,3-
thiadiazol-5-yl)-1,3-thiazole-4-carboxamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-2-phenyl-2H-1,2,3-
triazole-4-carboxamide;
     N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(3-pyridin-2-yl-1,2,4-
oxadiazol-5-yl)butanamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-1,3-dimethyl-1H-thieno[2,3-
c]pyrazole-5-carboxamide;
```

```
4-(1,3-benzodioxol-5-yl)-N-{(1s,2r)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}butanamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-(4-methyl-1,2,3-
thiadiazol-5-yl)isoxazole-4-carboxamide;
          N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[2-(dimethylamino)-
1-methylethyl]amino}-2-hydroxypropyl)-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalamide;
          N^{1}-[(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-(2-
methylmorpholin-4-yl)propyl]-5-methyl-N3,N3-
dipropylisophthalamide;
          N^{1}-((1S, 2R) -1-(3, 5-difluorobenzyl) -2-hydroxy-3-{2-
[hydroxy(phenyl)methyl]-4-methylpiperazin-1-yl)propyl)-5-
methyl-N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
          N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(2R)-2-
methylbutyl]amino)propyl)-5-methyl-N3, N3-dipropylisophthalamide;
           N^{1}-[(1S, 2R)-3-{[4-(diethylamino)-1-methylbutyl]amino}-1-
(3,5-difluorobenzyl)-2-hydroxypropyl]-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalamide;
           N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(2-
hydroxy-1,1-dimethylethyl)amino]propyl}-5-methyl-N3,N3-
dipropylisophthalamide;
           N^{1}-((1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-{[3-(2-
methylpiperidin-1-yl)propyl]amino}propyl)-5-methyl-N3,N3-
dipropylisophthalamide;
           N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[5-
(trifluoromethyl)-1,3,4-thiadiazol-2-yl]amino}propyl)-5-methyl-
N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
           N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-methyl-
4,5,6,7-tetrahydro-3H-3lambda4-[1,3]thiazolo[5,4-c]pyridin-2-
yl)amino]propyl}-5-methyl-N³,N³-dipropylisophthalamide;
          N^{1}-[(1S,2R)-3-[(3-ethylbenzyl)amino]-2-hydroxy-1-(1H-
pyrazol-1-ylmethyl)propyl]-5-methyl-N3,N3-
dipropylisophthalamide;
           3,5-bis(acetylamino)-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-
[(3-ethylbenzyl)amino]-2-hydroxypropyl}benzamide;
          N^{1}-[4-(aminosulfonyl)phenyl]-N^{4}-{(1S, 2R)-1-(3, 5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl } succinamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-
[methyl (methyl sulfonyl) amino] benzamide;
           1-acetyl-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{(3-acetyl-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{(3-acetyl-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-((3-acetyl-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-((3-acetyl-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-((3-acetyl-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-((3-acetyl-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-((3-acetyl-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-((3-acetyl-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-((3-acetyl-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-((3-acetyl-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-((3-acetyl-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-((3-acetyl-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-((3-acetyl-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-((3-acetyl-N-\{(1S, 2R)-1-(3-acetyl-N-(1S, 2R)-1-(3-acetyl-N-(1S, 2R)-1-(3-acetyl-N-(1S, 2R)-1-(3-acetyl-N-(1S, 2R)-1-(3-acetyl-N-(1S, 2R)-1-(3-acetyl-N-(1S, 2R)-1-(3-acetyl-N-(1S, 2R)-1-(3-acetyl-N-(1S, 2R)-(3-acetyl-N-(1S, 2R)-1-(3-acetyl-N-(1S, 2R)-1-(3-acetyl-N-(1S, 2R)-1-(3-acetyl-N-(1S, 2R)-1-(3-acetyl-N-(1S, 2R)-1-(3-acetyl-N-(1S, 2R)-1-(3-acetyl-N-(1S, 2R)-1-(3-acetyl-N-(1S, 2R)-1-(3-acetyl-N-(1S, 2R)-1-(3-acetyl-N-(1S, 2R)-1-(3-acetyl-N-(1S, 2R)-1-(3-acetyl-N-(1S, 2R)-1-(3-acetyl-N-(1S, 2R)-1-(3-acetyl-N-(1S, 2R)-(3-acetyl-N-(1S, 2R)-1-(3-acetyl-N-(1S, 2R)-1-(3-acetyl-N-(1S, 2R
ethylbenzyl)amino]-2-hydroxypropyl}piperidine-4-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-(4-
methoxyphenoxy) propanamide;
          N^{1}-{(1s, 2r)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N4-methylsuccinamide;
```

```
N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N4-(2,6-
dimethylphenyl) succinamide;
     N-acetyl-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-acetyl-N-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-D-phenylalaninamide;
     N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-[(4-
methylphenyl) sulfonyl]acetamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-mu)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-
{[(ethylamino)carbonyl]amino}benzamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-phenyl-1,4,5,6-
tetrahydrocyclopenta[c]pyrazole-3-carboxamide;
      4-(cyclopentyloxy)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-}
[(3-ethylbenzyl)amino]-2-hydroxypropyl}benzamide;
     N^{1}-{(1s, 2r)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N4-pyridin-3-ylsuccinamide;
     N^{1}-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>4</sup>-phenylsuccinamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-3,4-dihydroxybenzamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-(1H-1,2,4-triazol-1-
yl) pentanamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-phenyl-1,3-oxazole-4-
carboxamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-7-methoxy-4-oxo-1,2,3,4-
tetrahydronaphthalene-2-carboxamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-{4-
[(methylsulfonyl)amino]phenyl}-4-oxobutanamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-hydroxy-7-methoxy-1-
benzofuran-5-carboxamide:
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-hydroxy-7-methoxy-1-
benzothiophene-5-carboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3,6,6-trimethyl-4-oxo-
4,5,6,7-tetrahydro-1-benzofuran-2-carboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mathemathem)]
ethylbenzyl)amino]-2-hydroxypropyl}-5,6-dihydro-4H-
cyclopenta[b]thiophene-2-carboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-1,3-thiazole-4-carboxamide;
```

```
N-\{(1S, 2R)-1-(3, 5-diffluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-pyridin-2-yl-1,3-
thiazol-4-yl)acetamide;
            N^{1}-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]-N^{4}-{(1S,2R)-
1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}succinamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-hydroxy-6-
neopentylpyridine-2-carboxamide;
           N-\{(1S, 2R) -1 - (3, 5 - difluorobenzyl) -3 - [(3 - 3) - (3, 2R) -1 - (3, 5 - difluorobenzyl) -3 - [(3 - 3) -1 - (3, 5 - difluorobenzyl) -3 - [(3 - 3) -1 - (3, 5 - difluorobenzyl) -3 - [(3 - 3) -1 - (3, 5 - difluorobenzyl) -3 - [(3 - 3) -1 - (3, 5 - difluorobenzyl)]]
ethylbenzyl)amino]-2-hydroxypropyl}-1-(4-fluorophenyl)-1,4,5,6-
tetrahydrocyclopenta[c]pyrazole-3-carboxamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-5,6,7,8-
tetrahydro-4H-pyrazolo[1,5-a]azepine-3-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-3-furamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]\}
ethylbenzyl)amino]-2-hydroxypropyl}-3-furamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(2-
hydroxyethoxy) benzamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-a)]
ethylbenzyl)amino]-2-hydroxypropyl}thiophene-2-carboxamide;
            N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl)-N2, N2-dimethylphthalamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-2-phenyl-1,3-
oxazole-4-carboxamide;
            N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(1,3-dioxo-1,3-dihydro-
2H-isoindol-2-yl)-2-hydroxybutanamide;
            2-(2H-1,2,3-benzotriazol-2-y1)-N-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}butanamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-i)]
ethylbenzyl)amino]-2-hydroxypropyl}-1H-indazole-3-carboxamide;
            N-\{(1S, 2R) -1 - (3, 5 - difluorobenzyl) -3 - [(3 - 3) - 3 - 3] \}
ethylbenzyl)amino]-2-hydroxypropyl}-3-hydroxyquinoxaline-2-
carboxamide;
            2-(acetylamino)-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-\{(3-acetylamino)-N-\{(3-acetylamino)
ethylbenzyl)amino]-2-hydroxypropyl}-4,5-dimethylthiophene-3-
carboxamide;
            N^{1}-(2-cyanophenyl)-N^{4}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-
 [(3-ethylbenzyl)amino]-2-hydroxypropyl}succinamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-ethyl-1H-indole-2-
carboxamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mathemathem)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-benzofuran-2-carboxamide;
```

```
1-\text{benzyl-N-}\{(1S,2R)-1-(3,5-\text{difluorobenzyl})-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-3,5-dimethyl-1H-pyrazole-4-
carboxamide;
           N^{1}-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N2-[(4-
methylphenyl)sulfonyl]glycinamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4,8-dihydroxyquinoline-2-
carboxamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(1,1-
dioxidotetrahydrothien-3-yl)acetamide;
           methyl 5-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-methyl 5-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-methyl 5-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-methyl 5-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-methyl 5-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-methyl 5-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-methyl 5-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-methyl 5-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-methyl 5-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-methyl 5-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-methyl 5-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-methyl 5-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-methyl 5-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-methyl 5-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-methyl 5-[({(1S,2R)-1-(2)(3)(3-(2)(3-(2)(3-(2)(3-(2)(3-(2)(3-(2)(3-(2)(3-(2)(3-(2)(3-(2)(3-(2)(3)(3-(2)(
ethylbenzyl)amino]-2-hydroxypropyl}amino)carbonyl]-1H-
benzimidazol-2-ylcarbamate;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mathemathem)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-methyl-1,3-benzoxazol-
5-yl)acetamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-[ethyl(methyl)amino]-4-
hydroxypyrimidine-5-carboxamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-pyridin-4-yl-1,3-
benzoxazol-5-yl)acetamide;
            4-[2-(diethylamino)ethoxy]-N-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}benzamide;
            3-(aminosulfonyl)-4-chloro-N-{(1S,2R)-1-(3,5-)}
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}benzamide;
            2-(diethylamino)-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mathematical field)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-hydroxypyrimidine-5-
carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5,6,7,8-tetrahydro-4H-
cyclohepta[c]isoxazole-3-carboxamide;
           N^{1}-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N4,N4-diphenylsuccinamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-6-hydroxy-4-methylpyridine-
 2-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzyl)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-phenylimidazo[1,2-
 a]pyridine-7-carboxamide;
            ethylbenzyl)amino]-2-hydroxypropyl}quinoline-4-carboxamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-(1,3-dimethyl-2,6-dioxo-
 1,2,3,6-tetrahydro-9H-purin-9-yl)acetamide;
```

```
N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-methoxy-1H-indole-2-
 carboxamide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(3,5-dimethyl-1H-pyrazol-
 1-v1)benzamide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-methylisoxazole-3-
carboxamide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-methylisoxazole-5-
carboxamide;
                  2-(1-benzothien-4-yl)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-}
 3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}acetamide;
                 N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance of the content 
 ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-4-oxo-4,5,6,7-
 tetrahydro-1H-indole-2-carboxamide;
                  N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-1-benzothiophene-2-
 carboxamide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
 ethylbenzyl)amino]-2-hydroxypropyl}-6-hydroxynicotinamide;
                  N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - \{ (3 - 1) - 1 - (3, 5 - 2) \} 
ethylbenzyl)amino]-2-hydroxypropyl}-N3-[(4-
methylphenyl) sulfonyl]-beta-alaninamide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxyquinoline-4-
                  N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-(5-phenyl-1H-tetraazol-1-
yl)acetamide;
                  4-{[(cyclobutylcarbonyl)amino]methyl}-N-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}benzamide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(2-oxo-1,3-benzoxazol-
3(2H)-yl)butanamide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mathemathem)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(1,3-dioxooctahydro-2H-
 isoindol-2-yl)butanamide;
                 N^{1}-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N2-(tetrahydrofuran-2-
ylmethyl) phthalamide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance of the content of the conten
ethylbenzyl)amino]-2-hydroxypropyl}-4-(2,3-dihydro-1H-indol-1-
yl)-4-oxobutanamide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}thieno[3,2-b]pyridine-6-
carboxamide;
```

```
N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mathemathem)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-[(6-methoxy-1H-
benzimidazol-2-yl)thio]acetamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}thieno[2,3-c]pyridine-2-
carboxamide;
           2-(1H-benzimidazol-2-ylthio)-N-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl }propanamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2,4-
difluorobenzyl)oxy]propanamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-5,6-dimethyl-4-oxo-3,4-
dihydrothieno[2,3-d]pyrimidine-2-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-1-(2-fluorophenyl)-5-
oxopyrrolidine-3-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(5-methyl-1H-tetraazol-1-
yl)benzamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(4,4-dimethyl-4,5-
dihydro-1,3-oxazol-2-yl)thiophene-3-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-(trifluoromethoxy)-1H-
indole-2-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-phenyl-5-propyl-1H-
pyrazole-4-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-[(pyridin-2-
ylthio)methyl]-2-furamide;
           5-chloro-N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-morpholin-4-ylpyrimidine-
4-carboxamide;
           5-chloro-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-1-phenyl-1H-
pyrazole-4-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-methyl-1,2,3-thiadiazole-
5-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-influorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2,1,3-benzoxadiazole-5-
carboxamide:
           N-\{(1s, 2r)-1-(3, 5-difluorobenzy1)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-[(imidazo[1,2-a]pyridin-
2-ylmethyl)thio]acetamide;
```

```
2-(acetylamino)-N-\{(1R,2R)-1-(3,5-difluorobenzyl)-2-
hydroxy-3-[(3-iodobenzyl)amino]propyl}-1,3-oxazole-4-
carboxamide;
                          N-\{(1S, 2R)-1-[3-(cyclohexylmethyl)benzyl]-2-hydroxy-3-
 [(3-methoxybenzyl)amino]propyl}acetamide;
                           1 2-{[({(1s,2R)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}amino)carbonyl]amino}-N,N-
dipropylethanesulfonamide;
                           2-(3-azabicyclo[3.2.2]non-3-yl)-N-{(1S,2R)-1-(3,5-azabicyclo[3.2]non-3-yl)-N-{(1S,2R)-1-(3,5-azabicyclo[3.2]non-3-yl)-N-{(1S,2R)-1-(3,5-azabicyclo[3.2]non-3-yl)-N-{(1S,2R)-1-(3,5-azabicyclo[3.2]non-3-yl)-N-{(1S,2R)-1-(3,5-azabicyclo[3.2]non-3-yl)-N-{(1S,2R)-1-(3,5-azabicyclo[3.2]non-3-yl)-N-{(1S,2R)-1-(3,5-azabicyclo[3.2]non-3-yl)-N-{(1S,2R)-1-(3,5-azabicyclo[3.2]non-3-yl)-N-{(1S,2R)-1-(3,5-azabicyclo[3.2]non-3-yl)-N-{(1S,2R)-1-(3,5-azabicyclo[3.2]non-3-(3,5-azabicyclo[3
difluorobenzyl)-2-hydroxy-3-[(3-
iodobenzyl)amino]propyl}acetamide;
                           2-(4-benzoylphenoxy)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-2-}
hydroxy-3-[(3-iodobenzyl)amino]propyl}propanamide;
                          N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-[(3-1)]
 iodobenzyl)amino]propyl}-4-(7-methoxy-2,3-dihydro-1-benzofuran-
 4-yl)-4-oxobutanamide;
                          N-\{(1S, 2R)-1-[3-(cyclohexylmethyl)benzyl]-2-hydroxy-3-
 [(3-methoxybenzyl)amino]propyl}-3-
 {[(trifluoromethyl)sulfonyl]amino}benzamide;
                          N^{1}-{(1S,2R)-1-[3-(cyclohexylmethyl)benzyl]-2-hydroxy-3-
 [(3-methoxybenzyl)amino]propyl}-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalamide;
                           3-\text{chloro-N-}((1S,2R)-1-(4-\text{fluorobenzyl})-2-\text{hydroxy-}3-\{[3-
 (trifluoromethyl)benzyl]amino}propyl)benzamide;
                           3-chloro-N-\{(1S,2R)-1-(4-fluorobenzyl)-2-hydroxy-3-[(3-fluoroben
methoxybenzyl)amino]propyl}benzamide;
                           3-chloro-N-((1S,2R)-1-(cyclohexylmethyl)-2-hydroxy-3-{[3-
 (trifluoromethyl)benzyl]amino}propyl)benzamide;
                           3-chloro-N-\{(1S,2R)-1-(cyclohexylmethyl)-2-hydroxy-3-[(3-mathyl)-2-[(3-mathy
methoxybenzyl)amino]propyl}benzamide;
                          N-((1S, 2S)-1-benzyl-2-hydroxy-3-{[3-
 (trifluoromethyl)benzyl]amino)propyl)-3-chlorobenzamide;
                           N-\{(1S, 2S)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-3-chlorobenzamide;
                           3-\{[(3-\text{chlorobenzyl}) \text{ amino}] \text{ sulfonyl}\}-N-((1S,2R)-1-(4-1))
 fluorobenzyl)-2-hydroxy-3-{[3-
 (trifluoromethyl)benzyl]amino)propyl)benzamide;
                           3-\{[(3-\text{chlorobenzyl}) \text{ amino}] \text{ sulfonyl}\}-N-\{(1S,2R)-1-(4-1S)\}
 fluorobenzyl)-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}benzamide;
                            3-{[(3-chlorobenzyl)amino]sulfonyl}-N-((1S,2R)-1-
 (cyclohexylmethyl) -2-hydroxy-3-{[3-
 (trifluoromethyl)benzyl]amino}propyl)benzamide;
                            3-{[(3-chlorobenzyl)amino]sulfonyl}-N-{(1S,2R)-1-
 (cyclohexylmethyl) -2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}benzamide;
                           N-\{(1S, 2S)-1-benzyl-2-hydroxy-3-[(3-benzyl
methoxybenzyl)amino]propyl}-3-{[(3-
 chlorobenzyl)amino]sulfonyl}benzamide;
```

```
N-\{(1S, 2R)-1-(4-fluorobenzyl)-2-hydroxy-3-[(3-fluorobenzyl)]
methoxybenzyl)amino]propyl}-3-{[(3-
methoxybenzyl)amino]sulfonyl}benzamide;
      N-((1S, 2R)-1-(cyclohexylmethyl)-2-hydroxy-3-{[3-
(trifluoromethyl)benzyl]amino}propyl)-3-{[(3-
methoxybenzyl)amino]sulfonyl}benzamide;
      N-\{(1S, 2R)-1-(cyclohexylmethyl)-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-3-{[(3-
methoxybenzyl)amino]sulfonyl}benzamide;
      N-\{(1S, 2S)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-3-{[(3-
methoxybenzyl)amino]sulfonyl}benzamide;
      N^{1}-[(1R,2S)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(4-
methylbenzyl)propyl]-N3,N3-dipropylbenzene-1,3,5-tricarboxamide;
      N^{1}-[(1R,2S)-2-hydroxy-3-(isopentylamino)-1-(4-
methylbenzyl)propyl]-N3,N3-dipropylbenzene-1,3,5-tricarboxamide;
      N^{1}-[(1R,2S)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(4-
methylbenzyl)propyl]-5-methyl-N³,N³-dipropylisophthalamide;
      N^{1}-[(1R,2S)-2-hydroxy-3-(isopentylamino)-1-(4-
methylbenzyl)propyl]-5-methyl-N3,N3-dipropylisophthalamide;
      N^{1}-[(1R,2S)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(4-
methylbenzyl)propyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
      N^{1}-[(1R,2S)-2-hydroxy-3-(isopentylamino)-1-(4-
methylbenzyl)propyl]-N<sup>5</sup>,N<sup>5</sup>-dipropylpentanediamide;
      3-[(dipropylamino)sulfonyl]-N-[(1R,2S)-2-hydroxy-3-[(3-
methoxybenzyl)amino]-1-(4-methylbenzyl)propyl]propanamide;
      3-[(dipropylamino)sulfonyl]-N-[(1R,2S)-2-hydroxy-3-
(isopentylamino)-1-(4-methylbenzyl)propyl]propanamide;
      N^{1}-[(1S,2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(4-
methylbenzyl)propyl]-N5,N5-dipropylpentanediamide;
      N^{1}-[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4-
methylbenzyl)propyl]-N5,N5-dipropylpentanediamide;
      N^{1}-[(1S, 2R)-2-hydroxy-3-(isopentylamino)-1-(4-
methylbenzyl)propyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
      N-[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4-
methylbenzyl)propyl]-3-[(dipropylamino)sulfonyl]propanamide;
      3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-2-hydroxy-3-
 (isopentylamino)-1-(4-methylbenzyl)propyl]propanamide;
      N-\{(1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-3-(4,5-dimethyl-2-furoyl)-5-
methylbenzamide;
      N-\{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-2-hydroxy-3-
 (isopentylsulfonyl)propanamide;
      N-\{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-3-{[(2-
methoxyethyl)(propyl)amino]sulfonyl}propanamide;
```

```
N^1-{ (1R, 2R) -3- (benzylamino) -2-hydroxy-1-
[(phenylthio)methyl]propyl}-N<sup>3</sup>,N<sup>3</sup>-dipropylbenzene-1,3,5-
tricarboxamide:
      N^{1}-{ (1R, 2R)-2-hydroxy-3-(isopentylamino)-1-
[(phenylthio)methyl]propyl}-N3,N3-dipropylbenzene-1,3,5-
tricarboxamide;
      N^1-{ (1S, 2R)-3-(benzylamino)-1-[4-(benzyloxy)benzyl]-2-
hydroxypropyl\}-N^3, N^3-dipropylbenzene-1, 3, 5-tricarboxamide;
      N^{1}-[(1S,2R)-1-[4-(benzyloxy)benzyl]-2-hydroxy-3-
(isopentylamino)propyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylbenzene-1, 3, 5-
tricarboxamide;
      N^{1}-[(1S,2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(1-
naphthylmethyl)propyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylbenzene-1, 3, 5-
tricarboxamide;
      N^{1}-[(1S, 2R)-3-(benzylamino)-2-hydroxy-1-(1-
naphthylmethyl)propyl]-N3,N3-dipropylbenzene-1,3,5-
tricarboxamide;
      N^{1}-[(1S, 2R)-2-hydroxy-3-(isopentylamino)-1-(1-
naphthylmethyl)propyl]-N3,N3-dipropylbenzene-1,3,5-
      N^{1}-[(1S, 2R)-1-(2-furylmethyl)-2-hydroxy-3-
(isopentylamino)propyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylbenzene-1, 3, 5-
tricarboxamide:
      N^{1} - \{ (1S, 2R) - 3 - (benzylamino) - 1 - [3 - (benzyloxy)benzyl] - 2 - (benzyloxy)benzyl \}
hydroxypropyl}-N<sup>3</sup>, N<sup>3</sup>-dipropylbenzene-1, 3, 5-tricarboxamide;
      N^{1}-[(1S,2R)-2-hydroxy-1-(4-hydroxybenzy1)-3-
(isopentylamino)propyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylbenzene-1, 3, 5-
tricarboxamide:
      N^{1}-((1S)-1-{(1R)-1-hydroxy-2-[(3-
methoxybenzyl)amino]ethyl}but-3-ynyl)-N3,N3-dipropylbenzene-
1,3,5-tricarboxamide;
      N^{1}-{(1S)-1-[(1R)-2-(benzylamino)-1-hydroxyethyl]but-3-
yny1}-N^3, N^3-dipropylbenzene-1, 3, 5-tricarboxamide;
      N^{1}-{(1S)-1-[(1R)-1-hydroxy-2-(isopentylamino)ethyl]but-3-
ynyl}-N<sup>3</sup>, N<sup>3</sup>-dipropylbenzene-1, 3, 5-tricarboxamide;
      N^{1}-[(1S,2R)-3-(benzylamino)-1-(cyclohexylmethyl)-2-
hydroxypropyl]-N^3,N^3-dipropylbenzene-1,3,5-tricarboxamide;
      N^{1}-[(1S,2R)-1-(cyclohexylmethyl)-2-hydroxy-3-
(isopentylamino)propyl]-N3,N3-dipropylbenzene-1,3,5-
tricarboxamide;
      N^{1}-((1S)-1-{(1R)-1-hydroxy-2-[(3-
methoxybenzyl)amino]ethyl}-3-methylbutyl)-N3,N3-dipropylbenzene-
1,3,5-tricarboxamide;
      N^{1}-\{(1S)-1-[(1R)-1-hydroxy-2-(isopentylamino)ethyl]-3-
methylbutyl}-N<sup>3</sup>, N<sup>3</sup>-dipropylbenzene-1, 3, 5-tricarboxamide;
      N^1-{ (1R, 2R) -3-(benzylamino) -2-hydroxy-1-
[(phenylthio)methyl]propyl}-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
```

dipropylisophthalamide;

```
N^{1}-{(1R.2R)-2-hydroxy-3-(isopentylamino)-1-
[(phenylthio)methyl]propyl}-5-methyl-\bar{N}^3, N^3-
dipropylisophthalamide;
      N^{1}-{(1S,2R)-3-(benzylamino)-1-[4-(benzyloxy)benzyl]-2-
\label{eq:hydroxypropyl} \verb|-5-methyl-N^3,N^3-dipropylisophthalamide; \\
      N^{1}-[(1S,2R)-1-[4-(benzyloxy)benzyl]-2-hydroxy-3-
(isopentylamino)propyl]-5-methyl-N3,N3-dipropylisophthalamide;
      N^{1}-[(1S,2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(1-
naphthylmethyl)propyl]-5-methyl-N3,N3-dipropylisophthalamide;
      N^{1}-[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(1-
naphthylmethyl)propyl]-5-methyl-N^3, N^3-dipropylisophthalamide;
      N^{1}-[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-(1-
naphthylmethyl) propyl]-5-methyl-N^3, N^3-dipropylisophthalamide;
      N^{1}-[(1S,2R)-1-(2-furylmethyl)-2-hydroxy-3-
(isopentylamino)propyl]-5-methyl-N3,N3-dipropylisophthalamide;
      \mathbb{N}^{1}-{ (1S,2R)-3-(benzylamino)-1-[3-(benzyloxy)benzyl]-2-
hydroxypropyl}-5-methyl-N3,N3-dipropylisophthalamide;
       N^{1}-[(1S,2R)-1-[3-(benzyloxy)benzyl]-2-hydroxy-3-
(isopentylamino)propyl]-5-methyl-N^3, N^3-dipropylisophthalamide;\\
       N^1-[(1S,2R)-1-(4-fluorobenzyl)-2-hydroxy-3-
(isopenty lamino) propyl] - 5 - methyl - N^3, N^3 - dipropylisophthalamide; \\
       N^{1}-[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-(thien-2-
ylmethyl)propyl]-5-methyl-N3,N3-dipropylisophthalamide;
       N^{1}-((1S)-1-{(1R)-1-hydroxy-2-[(3-
methoxybenzyl) amino]ethyl}but-3-ynyl)-5-methyl-\mathbb{N}^3, \mathbb{N}^3-
dipropylisophthalamide;
       \mathbb{N}^{1}-{ (1S)-1-[(1R)-2-(benzylamino)-1-hydroxyethyl]but-3-
ynyl}-5-methyl-N3,N3-dipropylisophthalamide;
       \mathbb{N}^{1}-{ (1S)-1-[(1R)-1-hydroxy-2-(isopentylamino)ethyl]but-3-
yny1}-5-methyl-N^3, N^3-dipropylisophthalamide;
       N^{1}-[(1S,2R)-1-(cyclohexylmethyl)-2-hydroxy-3-
 (isopentylamino)propyl]-5-methyl-N3,N3-dipropylisophthalamide;
       N^{1}-{(1S)-1-[(1R)-1-hydroxy-2-(isopentylamino)ethyl]-3-
methylbutyl}-5-methyl-N3,N3-dipropylisophthalamide;
       N^{1}-{(1R,2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-
 [(phenylthio)methyl]propyl}-N<sup>5</sup>,N<sup>5</sup>-dipropylpentanediamide;
       N^1-{ (1R, 2R) -3- (benzylamino) -2-hydroxy-1-
 [(phenylthio)methyl]propyl}-N<sup>5</sup>,N<sup>5</sup>-dipropylpentanediamide;
       N^{1}-{ (1R,2R)-2-hydroxy-3-(isopentylamino)-1-
 [(phenylthio)methyl]propyl}-N^5, N^5-dipropylpentanediamide;
       N^{1}-{(1S, 2R)-3-(benzylamino)-1-[4-(benzyloxy)benzyl]-2-
hydroxypropyl}-N<sup>5</sup>,N<sup>5</sup>-dipropylpentanediamide;
       N^{1}-[(1S,2R)-1-[4-(benzyloxy)benzyl]-2-hydroxy-3-
 (isopentylamino)propyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
       N^{1}-[(1S,2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(1-
 naphthylmethyl)propyl]-N5,N5-dipropylpentanediamide;
       N^{1}-[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(1-
 naphthylmethyl)propyl]-N<sup>5</sup>,N<sup>5</sup>-dipropylpentanediamide;
```

```
N^{1}-[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-(1-
naphthylmethyl)propyl]-N5,N5-dipropylpentanediamide;
      N^{1}-[(1S,2R)-3-(benzylamino)-1-(2-furylmethyl)-2-
hydroxypropyl]-N5,N5-dipropylpentanediamide;
      N^{1}-[(1S,2R)-1-(2-furylmethyl)-2-hydroxy-3-
(isopentylamino)propyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
      methoxybenzyl)amino]propyl}-N5,N5-dipropylpentanediamide;
      N^{1}-{(1S,2R)-3-(benzylamino)-1-[3-(benzyloxy)benzyl]-2-
hydroxypropyl}-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
      N^{1}-[(1S,2R)-1-[3-(benzyloxy)benzyl]-2-hydroxy-3-
(isopentylamino)propyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
      N^{1}-[(1S,2R)-3-(benzylamino)-1-(4-fluorobenzyl)-2-
hydroxypropyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
      N^{1}-[(1S,2R)-1-(4-fluorobenzyl)-2-hydroxy-3-
(isopentylamino)propyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
      N^{1}-[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(thien-2-
ylmethyl)propyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
      N^{1}-[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-(thien-2-
ylmethyl)propyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
      N^{1}-[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4-
hydroxybenzyl)propyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
      N^{1}-[(1S,2R)-2-hydroxy-1-(4-hydroxybenzyl)-3-
(isopentylamino)propyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
      N^{1}-((1S)-1-{(1R)-1-hydroxy-2-[(3-
methoxybenzyl)amino]ethyl}but-3-ynyl)-N<sup>5</sup>,N<sup>5</sup>-
dipropylpentanediamide;
       N^{1}-[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4-
isopropylbenzyl)propyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
      N^{1}-{(1S)-1-[(1R)-2-(benzylamino)-1-hydroxyethyl]but-3-
ynyl}-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
      N^{1}-[(1S, 2R)-2-hydroxy-3-(isopentylamino)-1-(4-
isopropylbenzyl)propyl]-N5,N5-dipropylpentanediamide;
       N^{1}-{(1S)-1-[(1R)-1-hydroxy-2-(isopentylamino)ethyl]but-3-
yny1}-N^5, N^5-dipropylpentanediamide;
       N^1-{(1S,2R)-1-(cyclohexylmethyl)-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N5,N5-dipropylpentanediamide;
       N^{1}-{(1S,2R)-1-[3-fluoro-5-(trifluoromethyl)benzyl]-2-
hydroxy-3-[(3-methoxybenzyl)amino]propyl}-\mathbb{N}^5, \mathbb{N}^5-
dipropylpentanediamide;
       N-[(1S,2R)-1-(4-chlorobenzyl)-2-hydroxy-3-
(isopentylamino)propyl]-3-[(dipropylamino)sulfonyl]propanamide;
       N^{1}-[(1S, 2R)-3-(benzylamino)-1-(cyclohexylmethyl)-2-
hydroxypropyl] -N^5, N^5-dipropylpentanediamide;
       N^{1}-{ (1S, 2R) -3-(benzylamino) -1-[3-fluoro-5-
 (trifluoromethyl)benzyl]-2-hydroxypropyl}-N<sup>5</sup>,N<sup>5</sup>-
dipropylpentanediamide;
```

```
N-[(1S, 2R)-1-(1, 3-benzodioxol-5-ylmethyl)-3-
(benzylamino) -2-hydroxypropyl] -3-
[(dipropylamino)sulfonyl]propanamide;
      N^{1}-[(1S,2R)-1-(cyclohexylmethyl)-2-hydroxy-3-
(isopentylamino)propyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
      N^{1}-[(1S,2R)-1-[3-fluoro-5-(trifluoromethyl)benzyl]-2-
hydroxy-3-(isopentylamino)propyl]-N^5, N^5-dipropylpentanediamide;
      N-[(1S, 2R)-1-(1, 3-benzodioxol-5-ylmethyl)-2-hydroxy-3-
(isopentylamino)propyl]-3-[(dipropylamino)sulfonyl]propanamide;
      N^{1}-((1S)-1-{(1R)-1-hydroxy-2-[(3-
methoxybenzyl)amino]ethyl}-3-methylbutyl)-N^5, N^5-
dipropylpentanediamide;
      N^{1}-{(1S,2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-[3-
(trifluoromethoxy) benzyl]propyl}-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
      3-[(dipropylamino)sulfonyl]-N-{(1S,2R)-1-(4-fluoro-3-
methylbenzyl)-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl)propanamide;
      N^{1}-{(1S)-1-[(1R)-2-(benzylamino)-1-hydroxyethyl]-3-
methylbutyl}-N<sup>5</sup>,N<sup>5</sup>-dipropylpentanediamide;
      N^{1}-{(1S, 2R)-3-(benzylamino)-2-hydroxy-1-[3-
(trifluoromethoxy)benzyl]propyl}-N<sup>5</sup>,N<sup>5</sup>-dipropylpentanediamide;
      N-[(1S, 2R)-3-(benzylamino)-1-(4-fluoro-3-methylbenzyl)-2-
hydroxypropyl]-3-[(dipropylamino)sulfonyl]propanamide;
      N^1-{(1S)-1-[(1R)-1-hydroxy-2-(isopentylamino)ethyl]-3-
methylbutyl}-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
      N^1-{(1S,2R)-2-hydroxy-3-(isopentylamino)-1-[3-
(trifluoromethoxy)benzyl]propyl}-N<sup>5</sup>,N<sup>5</sup>-dipropylpentanediamide;
      3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-1-(4-fluoro-3-
methylbenzyl)-2-hydroxy-3-(isopentylamino)propyl]propanamide;
      3-[(dipropylamino)sulfonyl]-N-{(1R,2R)-2-hydroxy-3-[(3-
methoxybenzyl)amino]-1-[(phenylthio)methyl]propyl}propanamide;
      N^{1}-[(1S,2R)-3-(benzylamino)-1-(3-fluoro-4-methylbenzyl)-2-
hydroxypropyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
      N-\{(1R,2R)-3-(benzylamino)-2-hydroxy-1-
[(phenylthio)methyl]propyl}-3-
[(dipropylamino)sulfonyl]propanamide;
      N-\{(1S, 2R)-3-(benzylamino)-2-hydroxy-1-[3-
(trifluoromethyl)benzyl]propyl}-3-
[(dipropylamino)sulfonyl]propanamide;
      N^{1}-[(1S,2R)-1-(3-fluoro-4-methylbenzyl)-2-hydroxy-3-
(isopentylamino)propyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
      3-[(dipropylamino)sulfonyl]-N-{(1R,2R)-2-hydroxy-3-
(isopentylamino) -1-[(phenylthio)methyl]propyl}propanamide;
      3-[(dipropylamino)sulfonyl]-N-{(1S,2R)-2-hydroxy-3-
(isopentylamino)-1-[3-
(trifluoromethyl)benzyl]propyl}propanamide;
      N^{1}-{(1S,2R)-2-hydroxy-1-(4-methoxybenzyl)-3-[(3-
methoxybenzyl)amino]propyl}-N<sup>5</sup>,N<sup>5</sup>-dipropylpentanediamide;
```

```
N-[(1S, 2R)-3-(benzylamino)-2-hydroxy-1-(3-
methylbenzyl)propyl]-3-[(dipropylamino)sulfonyl]propanamide;
     N-\{(1S, 2R)-3-(benzylamino)-1-[4-(benzyloxy)benzyl]-2-
hydroxypropyl}-3-[(dipropylamino)sulfonyl]propanamide;
     N^{1}-[(1S, 2R)-3-(benzylamino)-2-hydroxy-1-(4-
methoxybenzyl)propyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
      3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-2-hydroxy-3-
(isopentylamino) -1-(3-methylbenzyl) propyl] propanamide;
     N-[(1S, 2R)-1-[4-(benzyloxy)benzyl]-2-hydroxy-3-
(isopentylamino)propyl]-3-[(dipropylamino)sulfonyl]propanamide;
     N^{1}-[(1S, 2R)-2-hydroxy-3-(isopentylamino)-1-(4-
methoxybenzyl)propyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
     N-[(1S, 2R)-3-(benzylamino)-2-hydroxy-1-(1-
naphthylmethyl)propyl]-3-[(dipropylamino)sulfonyl)propanamide;
     N-\{(1S, 2R)-3-(benzylamino)-1-[3-(benzyloxy)-5-
fluorobenzyl]-2-hydroxypropyl}-3-
[(dipropylamino)sulfonyl]propanamide;
      N^{1}-{ (1S, 2R) -1- (4-chlorobenzyl) -2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N<sup>5</sup>,N<sup>5</sup>-dipropylpentanediamide;
      3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-2-hydroxy-3-
(isopentylamino) -1-(1-naphthylmethyl)propyl]propanamide;
      3-[(dipropylamino)sulfonyl]-N-{(1S,2R)-1-(3-fluoro-4-
methoxybenzyl)-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}propanamide;
      N^{1}-[(1S,2R)-3-(benzylamino)-1-(4-chlorobenzyl)-2-
hydroxypropyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
     N-[(1S, 2R)-3-(benzylamino)-1-(2-furylmethyl)-2-
hydroxypropyl]-3-[(dipropylamino)sulfonyl]propanamide;
      N-[(1S, 2R)-3-(benzylamino)-1-(3-fluoro-4-methoxybenzyl)-
2-hydroxypropyl]-3-[(dipropylamino)sulfonyl]propanamide;
      N^{1}-[(1S, 2R)-1-(4-chlorobenzyl)-2-hydroxy-3-
(isopentylamino)propyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
      3-[(dipropylamino)sulfonyl]-N-[(15,2R)-1-(2-furylmethyl)-
2-hydroxy-3-(isopentylamino)propyl]propanamide;
      3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-1-(3-fluoro-4-
methoxybenzyl)-2-hydroxy-3-(isopentylamino)propyl]propanamide;
     N^1-{(1S,2R)-1-(1,3-benzodioxol-5-ylmethyl)-2-hydroxy-3-
[(3-methoxybenzyl)amino]propyl}-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
       N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-phenyl-2-(4H-1,2,4-
triazol-3-ylthio)acetamide;
      N^{1}-[(1S, 2R)-1-(1,3-benzodioxol-5-ylmethyl)-3-
(benzylamino) -2-hydroxypropyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
       1-acetyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-phenylprolinamide;
      N-\{(1S, 2R)-3-(benzylamino)-1-[3-(benzyloxy)benzyl]-2-
hydroxypropyl}-3-[(dipropylamino)sulfonyl]propanamide;
```

 $N^{1}$ -[(1S,2R)-1-(1,3-benzodioxol-5-ylmethyl)-2-hydroxy-3-(isopentylamino)propyl]- $N^{5}$ ,  $N^{5}$ -dipropylpentanediamide;

N-[(1S,2R)-1-[3-(benzyloxy)benzyl]-2-hydroxy-3-(isopentylamino)propyl]-3-[(dipropylamino)sulfonyl]propanamide;

 $N^{1}$ -{(1S,2R)-1-(4-fluoro-3-methylbenzyl)-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}- $N^{5}$ ,  $N^{5}$ -dipropylpentanediamide;

N-[(1S,2R)-3-(benzylamino)-1-(4-fluorobenzyl)-2-hydroxypropyl]-3-[(dipropylamino)sulfonyl]propanamide;

 $N^{1}$ -[(1S,2R)-3-(benzylamino)-1-(4-fluoro-3-methylbenzyl)-2-hydroxypropyl]- $N^{5}$ ,  $N^{5}$ -dipropylpentanediamide;

3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-1-(4-fluorobenzyl)-2-hydroxy-3-(isopentylamino)propyl]propanamide;

 $N'-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-\{[(3R,4S)-3-(hydroxymethyl)-6-isopropyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino\}propyl)-5-methyl-N,N-dipropylisophthalamide;$ 

 $N^{1}$ -[(1S, 2R)-1-(4-fluoro-3-methylbenzyl)-2-hydroxy-3-(isopentylamino)propyl]- $N^{5}$ ,  $N^{5}$ -dipropylpentanediamide;

N'-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(3R,4S)-6-isopropyl-3-methyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}propyl)-5-methyl-N,N-dipropylisophthalamide;

N-[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(thien-2-ylmethyl)propyl]-3-[(dipropylamino)sulfonyl]propanamide;

 $N^{1}$ -{(1S,2R)-3-(benzylamino)-2-hydroxy-1-[3-(trifluoromethyl)benzyl]propyl}- $N^{5}$ ,  $N^{5}$ -dipropylpentanediamide;

3-[(dipropylamino)sulfonyl]-N-((1S)-1-{(1R)-1-hydroxy-2-[(3-methoxybenzyl)amino]ethyl}but-3-ynyl)propanamide;

N'-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(3R,4S)-6-isopropyl-2,2-dioxido-3-propyl-3,4-dihydro-1H-isothiochromen-4-yl]amino}propyl)-5-methyl-N,N-dipropylisophthalamide;

 $N^{1}$ -{(1S,2R)-2-hydroxy-3-(isopentylamino)-1-[3-(trifluoromethyl)benzyl]propyl}- $N^{5}$ ,  $N^{5}$ -dipropylpentanediamide;

 $N-\{(1S)-1-[(1R)-2-(benzylamino)-1-hydroxyethyl]but-3-ynyl\}-3-[(dipropylamino)sulfonyl]propanamide;$ 

 $N^{1}-[(1S,2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(3-methylbenzyl)propyl]-N^{5}, N^{5}-dipropylpentanediamide;$ 

3-[(dipropylamino)sulfonyl]-N-{(1S)-1-[(1R)-1-hydroxy-2-(isopentylamino)ethyl]but-3-ynyl}propanamide;

N'-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(3S,4R)-3-(hydroxymethyl)-6-isopropyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}propyl)-5-methyl-N,N-dipropylisophthalamide;

 $N^{1}$ -[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(3-methylbenzyl)propyl]- $N^{5}$ ,  $N^{5}$ -dipropylpentanediamide;

```
N' - ((1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 - {[(3S, 4R) - 1]}
3-(2-hydroxyethyl)-6-isopropyl-2,2-dioxido-3,4-dihydro-1H-
isothiochromen-4-yl]amino}propyl)-5-methyl-N,N-
dipropylisophthalamide;
      N-\{(1S, 2R)-1-(cyclohexylmethyl)-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-3-
[(dipropylamino)sulfonyl]propanamide;
      N^{1}-[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-(3-
methylbenzyl)propyl]-N<sup>5</sup>,N<sup>5</sup>-dipropylpentanediamide;
      N-[(1S, 2R)-3-(benzylamino)-1-(cyclohexylmethyl)-2-
hydroxypropyl]-3-[(dipropylamino)sulfonyl]propanamide;
      N^{1}-{(1S, 2R)-1-[3-(benzyloxy)-5-fluorobenzyl]-2-hydroxy-3-
[(3-methoxybenzyl)amino]propyl}-N<sup>5</sup>,N<sup>5</sup>-dipropylpentanediamide;
      N' - ((1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 - {[(3S, 4S) - 1]}
6-isopropyl-2,2-dioxido-3-propyl-3,4-dihydro-1H-isothiochromen-
4-yl]amino}propyl)-5-methyl-N, N-dipropylisophthalamide;
      N-[(1S,2R)-1-(cyclohexylmethyl)-2-hydroxy-3-
(isopentylamino)propyl]-3-[(dipropylamino)sulfonyl]propanamide;
      N^{1}-{ (1S, 2R) -3- (benzylamino) -1- [3- (benzyloxy) -5-
fluorobenzyl]-2-hydroxypropyl}-N^5, N^5-dipropylpentanediamide;
      3-[(dipropylamino)sulfonyl]-N-((1S)-1-{(1R)-1-hydroxy-2-}
[(3-methoxybenzyl)amino]ethyl}-3-methylbutyl)propanamide;
      N'-((1S, 2R)-1-(3, 5-difluorobenzy1)-2-hydroxy-3-{((3S, 4S)-1)}
6-isopropyl-3-methyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-
4-yl]amino}propyl)-5-methyl-N,N-dipropylisophthalamide;
      N^{1}-[(1S,2R)-1-[3-(benzyloxy)-5-fluorobenzyl]-2-hydroxy-3-
(isopentylamino)propyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
      N'-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(4R)-6-
isopropy1-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-
yl]amino}propyl)-5-methyl-N, N-dipropylisophthalamide;
      N-\{(1S)-1-[(1R)-2-(benzylamino)-1-hydroxyethyl]-3-
methylbutyl}-3-[(dipropylamino)sulfonyl]propanamide;
      N^1-{(1S,2R)-1-(3-fluoro-4-methoxybenzyl)-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N<sup>5</sup>,N<sup>5</sup>-dipropylpentanediamide;
      3-[(dipropylamino)sulfonyl]-N-{(1S)-1-[(1R)-1-hydroxy-2-
(isopentylamino)ethyl]-3-methylbutyl)propanamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-[(3-
methoxypropyl) (methylsulfonyl) amino]benzamide;
      N^{1}-[(1S, 2R)-3-(benzylamino)-1-(3-fluoro-4-methoxybenzyl)-
2-hydroxypropyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-[(3-
methoxypropyl) (methylsulfonyl) amino] benzamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mu)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-methyl-1,3-dihydro-2,1-
benzisothiazole-5-carboxamide 2,2-dioxide;
      N^{1}-[(1S,2R)-1-(3-fluoro-4-methoxybenzyl)-2-hydroxy-3-
(isopentylamino)propyl]-N5,N5-dipropylpentanediamide;
```

```
N^{1}-[(1S, 2R)-3-(benzylamino)-2-hydroxy-1-(3-
methoxybenzyl) propyl] -N^3, N^3-dipropylbenzene-1, 3, 5-
tricarboxamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-[(2-
methoxyethyl) (methylsulfonyl) amino] benzamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2,2-dimethylchromane-6-
carboxamide:
           N^{1}-[(1S, 2R)-3-(benzylamino)-1-(3-bromobenzyl)-2-
hydroxypropyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-6-[(2-
methoxyethyl) (methylsulfonyl) amino]nicotinamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-2,2-dimethylchromane-7-
carboxamide:
           N^{1}-[(1S,2R)-1-(3-bromobenzyl)-2-hydroxy-3-
 (isopentylamino)propyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
           N^{1}-[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4-
isopropylbenzyl)propyl]-N3,N3-dipropylbenzene-1,3,5-
tricarboxamide;
            benzyl (3R)-4-({(1S,2R)-1-benzyl-2-hydroxy-3-[(3-benzyl-2-hydroxy-
methoxybenzyl)amino]propyl}amino)-2,2,3-trimethyl-4-
oxobutanoate;
           N-[(1S, 2R)-3-(benzylamino)-2-hydroxy-1-(3-
methoxybenzyl)propyl]-3-[(dipropylamino)sulfonyl]propanamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-6-[(3-
hydroxypropyl) (methylsulfonyl) amino]nicotinamide;
            N^{1}-[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-(4-
 isopropylbenzyl)propyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylbenzene-1, 3, 5-
 tricarboxamide:
            3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-2-hydroxy-3-
 (isopentylamino) -1-(3-methoxybenzyl)propyl]propanamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-6-[(2-
 hydroxyethyl) (methylsulfonyl) amino]nicotinamide;
            N-\{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-a)]
methoxybenzyl) amino]propyl}-4-(phenylsulfonyl) butanamide;
             (3S)-tetrahydrofuran-3-yl (1S,2R)-1-benzyl-2-hydroxy-3-
 [(3-methoxybenzyl)amino]propylcarbamate;
            N-[(1S,2R)-3-(benzylamino)-1-(3,5-dichlorobenzyl)-2-
 hydroxypropyl]-3-[(dipropylamino)sulfonyl]propanamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-6-[(2-
 methoxyethyl) (methylsulfonyl) amino] nicotinamide;
            N^{1}-[(1S, 2R)-3-(benzylamino)-2-hydroxy-1-(4-
 methoxybenzyl)propyl]-N3,N3-dipropylbenzene-1,3,5-
 tricarboxamide;
```

```
3-[(dipropylamino)sulfonyl]-N-{(1s,2r)-2-hydroxy-1-(4-
isopropylbenzyl)-3-[(3-methoxybenzyl)amino]propyl}propanamide;
     N-\{(1S, 2R) -1 - (3, 5-difluorobenzyl) -3 - [(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-[(2-
methoxyethyl) (methylsulfonyl) amino] isonicotinamide;
     N^{1}-[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-(4-
methoxybenzyl)propyl]-N3,N3-dipropylbenzene-1,3,5-
tricarboxamide;
     N^{1}-{ (1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N3-(phenylsulfonyl)-beta-
alaninamide;
     N-[(1S, 2R)-3-(benzylamino)-2-hydroxy-1-(4-
isopropylbenzyl)propyl]-3-[(dipropylamino)sulfonyl)propanamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{(3-4)\}
ethylbenzyl)amino]-2-hydroxypropyl}-5-[(2-
methoxyethyl) (methylsulfonyl) amino]nicotinamide;
     \mathbb{N}^{1}-[(1S,2R)-3-(benzylamino)-1-(4-fluoro-3-methylbenzyl)-2-
hydroxypropyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylbenzene-1, 3, 5-tricarboxamide;
     N^{1}-{ (1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N3-[(4-methylphenyl)sulfonyl]-beta-
alaninamide;
      3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-2-hydroxy-3-
(isopentylamino)-1-(4-isopropylbenzyl)propyl]propanamide;
     N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-[(3-
hydroxypropyl) (methylsulfonyl) amino] isonicotinamide;
     N^{1}-[(1S,2R)-1-(3-fluoro-4-methoxybenzyl)-2-hydroxy-3-
(isopentylamino)propyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylbenzene-1, 3, 5-
tricarboxamide;
     N^{1}-{ (1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N3-[(4-fluorophenyl)sulfonyl]-beta-
alaninamide;
     N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-[(2-
hydroxyethyl) (methylsulfonyl) amino]isonicotinamide;
     N-{ (1S, 2R) -3- (benzylamino) -1-[3-fluoro-5-
(trifluoromethyl)benzyl]-2-hydroxypropyl}-3-
[(dipropylamino)sulfonyl]propanamide;
     N^{1}-[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4-
isopropylbenzyl)propyl]-5-methyl-N3,N3-dipropylisophthalamide;
     N^{1}-{ (1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N³-[(4-methoxyphenyl)sulfonyl]-
beta-alaninamide;
      3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-1-[3-fluoro-5-
(trifluoromethyl)benzyl]-2-hydroxy-3-
(isopentylamino)propyl]propanamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-[(2-
hydroxyethyl) (methylsulfonyl) amino] nicotinamide;
```

```
N^{1}-[(1S, 2R)-2-hydroxy-3-(isopentylamino)-1-(4-
isopropylbenzyl)propyl]-5-methyl-N3,N3-dipropylisophthalamide;
           N^{1}-{ (1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N2-[(4-
methylphenyl)sulfonyl]glycinamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-instance of the content of the conten
ethylbenzyl)amino]-2-hydroxypropyl}-5-[(3-
hydroxypropyl) (methylsulfonyl) amino]nicotinamide;
           N-\{(1S, 2R)-3-(benzylamino)-2-hydroxy-1-[3-
(trifluoromethoxy)benzyl]propyl}-3-
[(dipropylamino)sulfonyl]propanamide;
           N^{1}-{ (1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N2-[(4-
fluorophenyl) sulfonyl] glycinamide;
           N^{1}-{ (1S, 2R) -2-hydroxy-3-(isopentylamino) -1-[3-
(trifluoromethoxy) benzyl]propyl}-5-methyl-N3, N3-
dipropylisophthalamide;
           N-[(1S, 2R)-3-(benzylamino)-1-(3-fluoro-4-methylbenzyl)-2-
hydroxypropyl]-3-[(dipropylamino)sulfonyl]propanamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-[(3-
methoxypropyl) (methylsulfonyl) amino] isonicotinamide;
           N^{1}-[(1S, 2R)-3-(benzylamino)-2-hydroxy-1-(4-
methoxybenzyl)propyl]-5-methyl-N3,N3-dipropylisophthalamide;
           N^{1}-{ (1S, 2R) -1-benzy1-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl-N^2-[(4-
methoxyphenyl)sulfonyl]glycinamide;
           3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-1-(3-fluoro-4-
methylbenzyl)-2-hydroxy-3-(isopentylamino)propyl]propanamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-[(3-
methoxypropyl) (methylsulfonyl) amino]nicotinamide;
           N-\{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-3-[(4-
chlorophenyl)sulfonyl]propanamide;
           N^{1}-[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-(4-
methoxybenzyl)propyl]-5-methyl-N3,N3-dipropylisophthalamide;
           3-[(dipropylamino)sulfonyl]-N-{(15,2R)-2-hydroxy-1-(4-
methoxybenzy1)-3-[(3-methoxybenzy1)amino]propy1}propanamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino}-2-hydroxypropyl}-1-(methylsulfonyl)-1H-
indole-5-carboxamide;
           N^{1}-[(1S,2R)-3-(benzylamino)-1-(4-fluoro-3-methylbenzyl)-2-
hydroxypropyl]-5-methyl-N3,N3-dipropylisophthalamide;
           N^{1}-{ (1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N2-(benzylsulfonyl)glycinamide;
           N-\{(1S, 2R)-3-(benzylamino)-2-hydroxy-1-(4-
methoxybenzyl)propyl]-3-[(dipropylamino)sulfonyl]propanamide;
```

```
N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-(methylsulfonyl)indoline-
5-carboxamide;
     N-\{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-3-[(4-
fluorophenyl)sulfonyl]propanamide;
     N^{1}-[(1S,2R)-1-(4-fluoro-3-methylbenzyl)-2-hydroxy-3-
(isopentylamino)propyl]-5-methyl-N3,N3-dipropylisophthalamide;
     3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-2-hydroxy-3-
(isopentylamino)-1-(4-methoxybenzyl)propyl]propanamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-1-(methylsulfonyl)indoline-
4-carboxamide;
     N^{1}-\{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N3-[(4-chlorophenyl)sulfonyl]-beta-
alaninamide;
      N^1-{(1S,2R)-3-(benzylamino)-2-hydroxy-1-[3-
(trifluoromethyl)benzyl]propyl}-5-methyl-N<sup>3</sup>,N<sup>3</sup>-
dipropylisophthalamide;
     N-[(1S,2R)-3-(benzylamino)-1-(4-chlorobenzyl)-2-
hydroxypropyl]-3-[(dipropylamino)sulfonyl]propanamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-(methylsulfonyl)indoline-
6-carboxamide;
      N^{1}-[(1S,2R)-2-hydroxy-3-(isopentylamino)-1-(3-
methylbenzyl)propyl]-5-methyl-N3, N3-dipropylisophthalamide;
      N^{1}-{ (1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N3-(benzylsulfonyl)-beta-
alaninamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-1-(methylsulfonyl)-1H-
indole-4-carboxamide;
      N-\{(1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino[propyl]-3-[(4-
methoxyphenyl)sulfonyl]propanamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-3-[1-methyl-1-
(methylsulfonyl)ethyl]benzamide;
      N-\{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-3-[(4-
methylphenyl)sulfonyl]propanamide;
      N^{1}-[(1S,2R)-3-(benzylamino)-1-(3-fluoro-4-methoxybenzyl)-
2-hydroxypropyl]-5-methyl-N3,N3-dipropylisophthalamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mathemathem)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-[1-methyl-1-
(methylsulfonyl)ethyl]benzamide;
      N^{1}-{(1S,2R)-2-hydroxy-1-(3-methoxybenzyl)-3-[(3-
methoxybenzyl)amino]propyl}-N5,N5-dipropylpentanediamide;
      N^{1}-benzy1-N^{4}-{ (1S, 2R) -1-benzy1-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-2,2-dimethylsuccinamide;
```

```
N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4-(ethylsulfonyl)benzamide;
                N-\{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-3-(1,1-dioxido-3-oxo-1,2-
benzisothiazol-2(3H)-yl)propanamide;
                 N^{1}-[(1S, 2R)-3-(benzylamino)-2-hydroxy-1-(3-
methoxybenzyl)propyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
                 N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4-
 (propylsulfonyl)benzamide;
                 N-\{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-3-(1,3-dioxo-1,3-dihydro-2H-
isoindol-2-yl)propanamide;
                N^{1}-[(1S, 2R)-2-hydroxy-3-(isopentylamino)-1-(3-
methoxybenzyl)propyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
                  (2R) - N - \{ (1S, 2R) - 1 - benzyl - 2 - hydroxy - 3 - [ (3 - abs) - 2 - benzyl - 2 - hydroxy - 3 - [ (3 - abs) - 2 - benzyl - 2 - hydroxy - 3 - [ (3 - abs) - 2 - benzyl - 2 - hydroxy - 3 - [ (3 - abs) - 2 - benzyl - 2 - hydroxy - 3 - [ (3 - abs) - 2 - benzyl - 2 - hydroxy - 3 - [ (3 - abs) - 2 - benzyl - 2 - hydroxy - 3 - [ (3 - abs) - 2 - benzyl - 2 - hydroxy - 3 - [ (3 - abs) - 2 - benzyl - 2 - hydroxy - 3 - [ (3 - abs) - 2 - benzyl - 2 - hydroxy - 3 - [ (3 - abs) - 2 - benzyl - 2 - hydroxy - 3 - [ (3 - abs) - 2 - benzyl - 2 - hydroxy - 3 - [ (3 - abs) - 2 - benzyl - 2 - hydroxy - 3 - [ (3 - abs) - 2 - benzyl - 2 - hydroxy - 3 - [ (3 - abs) - 2 - benzyl - 2 - hydroxy - 2 - hydroxy - 3 - [ (3 - abs) - 2 - benzyl - 2 - hydroxy -
methoxybenzyl)amino]propyl}-2-methyl-3-
(phenylsulfonyl)propanamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4-
 (pentylsulfonyl)benzamide;
                 N^{1}-[(1S,2R)-3-(benzylamino)-1-(3-chloro-5-fluorobenzyl)-2-
hydroxypropyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
                  (2S) -N - \{ (1S, 2R) -1 -benzyl -2 - hydroxy -3 - [ (3 - 1) -benzyl -2 - hydroxy -3 - [ (3 - 1) -benzyl -2 - hydroxy -3 - [ (3 - 1) -benzyl -2 - hydroxy -3 - [ (3 - 1) -benzyl -2 - hydroxy -3 - [ (3 - 1) -benzyl -2 - hydroxy -3 - [ (3 - 1) -benzyl -2 - hydroxy -3 - [ (3 - 1) -benzyl -3 - [ (3 - 1) -benzyl -2 - hydroxy -3 - [ (3 - 1) -benzyl -3 - [ (3 - 1) -benzyl -3 - [ (3 - 1) -benzyl -3 - [ (3 - 1) -benzyl -3 - [ (3 - 1) -benzyl -3 - [ (3 - 1) -benzyl -3 - [ (3 - 1) -benzyl -3 - [ (3 - 1) -benzyl -3 - [ (3 - 1) -benzyl -3 - [ (3 - 1) -benzyl -3 - [ (3 - 1) -benzyl -3 - [ (3 - 1) -benzyl -3 - [ (3 - 1) -benzyl -3 - [ (3 - 1) -benzyl -3 - [ (3 - 1) -benzyl -3 - [ (3 - 1) -benzyl -3 - [ (3 - 1) -benzyl -3 - [ (3 - 1) -benzyl -3 - [ (3 - 1) -benzyl 
methoxybenzyl)amino]propyl}-2-methyl-3-
(phenylsulfonyl)propanamide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-[(2-
hydroxyethyl) sulfonyl]benzamide;
                N^{1}-[(1S,2R)-1-(3-chloro-5-fluorobenzyl)-2-hydroxy-3-
(isopentylamino)propyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-difluorobenzy1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-[(2-
methoxyethyl)sulfonyl]benzamide;
                N^{1}-{(1S,2R)-1-(3,5-dichlorobenzyl)-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N<sup>5</sup>,N<sup>5</sup>-dipropylpentanediamide;
                N^{1}-benzyl-N^{5}-{ (1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}pentanediamide:
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mathemathem)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-[(2-
ethoxyethyl) sulfonyl]benzamide;
                N-\{(1S, 2R)-1-benzyl-2-hydroxy-3-\{(3-abs)\}
methoxybenzyl)amino]propyl}-2-
[(phenylsulfonyl)methyl]acrylamide;
                N^{1}-[(1S, 2R)-3-(benzylamino)-1-(3,5-dichlorobenzyl)-2-
hydroxypropyl]-N5,N5-dipropylpentanediamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-[(3-
hydroxypropyl)sulfonyl]benzamide;
```

```
N-\{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-2-
[(isopentylsulfonyl)methyl]acrylamide;
          N^{1}-[(1S, 2R)-1-(3, 5-dichlorobenzyl)-2-hydroxy-3-
(isopentylamino)propyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2,3-dihydro-1-
benzothiophene-5-carboxamide 1,1-dioxide;
           N^{1}-{ (1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N3-[(dipropylamino)carbonyl]-beta-
alaninamide;
           N^{1}-{(1S, 2R)-2-hydroxy-1-(4-isopropylbenzyl)-3-[(3-
methoxybenzyl) amino] propyl\}-N^5, N^5-dipropylpentanediamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-benzothiophene-5-
carboxamide 1,1-dioxide;
           N^{1}-{ (1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N2-
 [(dipropylamino)carbonyl]glycinamide;
           benzyl (4R)-4-\{[((1S,2R)-1-benzyl-3-\{[3-(dimethylamino)-1-benzyl-3-(binzyl-3-benzyl-3-(binzyl-3-benzyl-3-benzyl-3-(binzyl-3-benzyl-3-benzyl-3-benzyl-3-(binzyl-3-benz
2,2-dimethylpropyl]amino}-2-hydroxypropyl)amino]carbonyl}-1,3-
oxazolidine-3-carboxylate compound with methyl hydroperoxide
 (1:2);
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2,3-dihydro-1-
benzothiophene-6-carboxamide 1,1-dioxide;
           tert-butyl (2R,3S)-2-hydroxy-3-({2-hydroxy-3-[(3-
methoxyphenyl)sulfonyl]propanoyl}amino)-4-phenylbutyl(3-
methoxybenzyl) carbamate;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-1-benzothiophene-6-
carboxamide 1,1-dioxide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-2,3-dihydro-1,2-
benzisothiazole-6-carboxamide 1,1-dioxide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-2,3-dihydro-1,2-
benzisothiazole-5-carboxamide 1,1-dioxide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-methyl-1,3-dihydro-2,1-
benzisothiazole-6-carboxamide 2,2-dioxide;
           N^{1}-[(1S, 2R)-1-[3-(benzyloxy)-5-fluorobenzyl]-2-hydroxy-3-
 (isopentylamino)propyl]-5-methyl-N3,N3-dipropylisophthalamide;
           N^{1}-{(1S, 2R)-3-(benzylamino)-1-[3-(benzyloxy)-5-
fluorobenzyl]-2-hydroxypropyl}-5-methyl-N3,N3-
dipropylisophthalamide;
           N^{1}-[(1S,2R)-1-[3-(benzyloxy)-5-fluorobenzyl]-2-hydroxy-3-
 (isopentylamino)propyl]-N<sup>3</sup>,N<sup>3</sup>-dipropylbenzene-1,3,5-
 tricarboxamide;
```

```
N-\{(1S, 2R)-1-[3-(benzyloxy)benzyl]-2-hydroxy-3-[(3-(benzyloxy)benzyloxy]-2-[(3-(benzyloxy)
methoxybenzyl)amino]propyl}-3-
 [(dipropylamino)sulfonyl]propanamide;
                N^{1}-[(1S,2R)-1-(cyclohexylmethyl)-2-hydroxy-3-
 (isopentylamino)propyl]-5-methyl-N3, N3-dipropylisophthalamide;
                N^1-[(1S,2R)-1-[4-(benzyloxy)benzyl]-2-hydroxy-3-
 (isopentylamino)propyl]-5-methyl-N3,N3-dipropylisophthalamide;
                N^{1}-[(1S,2R)-1-(cyclohexylmethyl)-2-hydroxy-3-
 (isopentylamino)propyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylbenzene-1, 3, 5-
tricarboxamide:
                N^{1}-[(1S,2R)-3-(benzylamino)-1-(cyclohexylmethyl)-2-
hydroxypropyl]-N^3, N^3-dipropylbenzene-1,3,5-tricarboxamide;
                N^1-{(1S,2R)-3-(benzylamino)-1-[3-(benzyloxy)benzyl]-2-
hydroxypropyl}-N<sup>3</sup>, N<sup>3</sup>-dipropylbenzene-1, 3, 5-tricarboxamide;
                N^{1}-[(1S,2R)-1-[4-(benzyloxy)benzyl]-2-hydroxy-3-
 (isopentylamino)propyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylbenzene-1, 3, 5-
tricarboxamide;
                N-\{(1S,2R)-1-(3,5-difluorobenzy1)-2-hydroxy-3-[(3-max)-1-(3-max)-1-(3-max)-2-[(3-max)-
methoxybenzyl)amino]propyl}-3-[hydroxy(2-methylphenyl)methyl]-
5-methylbenzamide;
                N^{1}-[(1R,2S)-2-hydroxy-3-(isopentylamino)-1-(4-
methylbenzyl)propyl]-5-methyl-N3,N3-dipropylisophthalamide;
                N^{1}-[(1R,2S)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(4-
methylbenzyl)propyl]-5-methyl-N3,N3-dipropylisophthalamide;
                N^{1}-[(1R,2S)-2-hydroxy-3-(isopentylamino)-1-(4-
methylbenzyl)propyl]-N<sup>3</sup>,N<sup>3</sup>-dipropylbenzene-1,3,5-tricarboxamide;
               N^{1}-[(1R,2S)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(4-
methylbenzyl)propyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylbenzene-1, 3, 5-tricarboxamide;
                3-chloro-N-{(1S,2R)-1-(cyclohexylmethyl)-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}benzamide;
                3-chloro-N-((1S,2R)-1-(cyclohexylmethyl)-2-hydroxy-3-{[3-
 (trifluoromethyl) benzyl] amino propyl) benzamide;
               benzyl (2R,3S)-4-(3,5-difluorophenyl)-3-[(3-(4,4-
dimethyl-2,5-dioxoimidazolidin-1-yl)-2-{[(1-
propylbuty1) sulfony1]methy1}propanoy1) amino]-2-hydroxybuty1(3-
ethylbenzyl)carbamate;
               N-\{(1S,2R)-1-(3,5-difluorobenzy1)-2-hydroxy-3-[(3-
iodobenzyl)amino]propyl}-7-(1H-imidazol-1-yl)-5,6-
dihydronaphthalene-2-carboxamide;
                   2-\{[(\{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-i)\})\}]\}
methoxybenzyl) amino]propyl}amino) carbonyl]amino}-N, N-
dipropylethanesulfonamide;
               benzyl (2R,3S)-4-(3,5-difluorophenyl)-2-hydroxy-3-({N-(3-1)})
phenylpropanoyl)-3-[(1-
propylbutyl)sulfonyl]alanyl}amino)butyl(3-
ethylbenzyl) carbamate;
               N^{1}-[(1S,2R)-3-[[(benzyloxy)carbonyl](3-ethylbenzyl)amino]-
1-(3,5-difluorobenzyl)-2-hydroxypropyl]-N^2-{[(3S)-}
tetrahydrofuran-3-yloxy]carbonyl}-D-leucinamide;
```

```
N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{(3-1)-1, (3-1)-1
ethylbenzyl)amino]-2-hydroxypropyl}-2-([1,3]oxazolo[4,5-
b]pyridin-2-ylthio)acetamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-[(imidazo[1,2-a]pyridin-
2-ylmethyl)thio]acetamide;
           N-\{(1S, 2R)-1-(3, 5-diffluorobenzyl)-3-[(3-diffluorobenzyl)-3-[(3-diffluorobenzyl)]\}
ethylbenzyl)amino]-2-hydroxypropyl}-2-[(5,7-
dimethyl[1,2,4]triazolo[4,3-a]pyrimidin-3-yl)thio]acetamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2,3-dihydro-1H-
cyclopenta[b]quinoline-9-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-hydroxy-6-oxo-1-phenyl-
1,6-dihydropyridazine-3-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzyl)]
ethylbenzyl)amino]-2-hydroxypropyl}-1,3-dioxoisoindoline-5-
carboxamide;
           1-\text{benzyl-N-}\{(1S,2R)-1-(3,5-\text{difluorobenzyl})-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-1H-imidazole-2-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-(4,4-dimethyl-4,5-
dihydro-1,3-oxazol-2-yl)thiophene-3-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-isobutyl-1,3-
dioxoisoindoline-5-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-oxo-2-phenylpyrazolidine-
3-carboxamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-5,6-dimethyl-4-oxo-3,4-
dihydrothieno[2,3-d]pyrimidine-2-carboxamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2,4-
difluorobenzyl)oxy]propanamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}thieno[2,3-c]pyridine-2-
carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4-(2-methyl-1H-
benzimidazol-1-yl)-4-oxobutanamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-(2,5-dioxopyrrolidin-1-
yl)-4-methylbenzamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}thieno[3,2-b]pyridine-6-
carboxamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(2,3-dihydro-1H-indol-1-
yl)-4-oxobutanamide;
```

```
N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethvlbenzyl)amino]-2-hydroxypropyl}-2-(1,3-dioxooctahydro-2H-
isoindol-2-yl)butanamide;
           N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N3-[(4-
methylphenyl) sulfonyl]-beta-alaninamide:
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(1H-indol-3-yl)-4-
oxobutanamide;
           N^2-(anilinocarbonothioy1)-N^1-{(1S, 2R)-1-(3, 5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}glycinamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-4-oxo-4,5,6,7-
tetrahydro-1H-indole-2-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-5,6,7,8-tetrahydro-4H-
cyclohepta[c]isoxazole-3-carboxamide;
           4-[2-(diethylamino)ethoxy]-N-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}benzamide;
           N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl) amino] -2-hydroxypropyl\}-N^2-[(4-
methylphenyl)sulfonyl]glycinamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(3,5-dioxo-1,2,4-
triazolidin-4-yl)benzamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(2-
hydroxyethoxy) benzamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(1,3-dithian-2-yl)-3-
furamide;
           4-(3-chlorophenyl)-N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-}
[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-4-
oxobutanamide
                                or 2479;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-5,6,7,8-
tetrahydro-4H-pyrazolo[1,5-a]azepine-3-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance of the stance of th
ethylbenzyl)amino]-2-hydroxypropyl}-1-(4-fluorophenyl)-1,4,5,6-
tetrahydrocyclopenta[c]pyrazole-3-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5,6-dihydro-4H-
cyclopenta[b]thiophene-2-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-3,6,6-trimethyl-4-oxo-
4,5,6,7-tetrahydro-1-benzofuran-2-carboxamide;
```

```
N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-\{(3-1)-1, (3, 5-difluorobenzy1)-3-\{(3-1)-1, (3, 5-difluorobenzy1)-3-\{(3-1)-1, (3, 5-difluorobenzy1)-3-\{(3-1)-1, (3, 5-difluorobenzy1)-3-\{(3-1)-1, (3, 5-difluorobenzy1)-3-\{(3-1)-1, (3, 5-difluorobenzy1)-3-\{(3-1)-1, (3, 5-difluorobenzy1)-3-\{(3-1)-1, (3, 5-difluorobenzy1)-3-\{(3-1)-1, (3, 5-difluorobenzy1)-3-\{(3-1)-1, (3, 5-difluorobenzy1)-3-\{(3-1)-1, (3, 5-difluorobenzy1)-3-\{(3-1)-1, (3, 5-difluorobenzy1)-3-\{(3-1)-1, (3, 5-difluorobenzy1)-3-\{(3-1)-1, (3, 5-difluorobenzy1)-3-\{(3-1)-1, (3, 5-difluorobenzy1)-3-\{(3-1)-1, (
ethylbenzyl)amino]-2-hydroxypropyl}-7-methoxy-4-oxo-1,2,3,4-
tetrahydronaphthalene-2-carboxamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2,3-dioxo-1,2,3,4-
tetrahydroquinoxaline-6-carboxamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4,5,6,7-tetrahydro-2H-
indazole-3-carboxamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-4-oxo-3,4-
dihydrothieno[2,3-d]pyrimidine-6-carboxamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-7-fluoro-4H-imidazo[5,1-
c][1,4]benzoxazine-3-carboxamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-i)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(3-fluoro-4-
methoxyphenyl)-4-oxobutanamide;
                methyl 4-({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-methyl 4-((3-methyl 4-(3,5-difluorobenzyl)-3-[(3-methyl 4-(3,5-difluorobenzyl)-3-[(3-methyl 4-(3,5-difluorobenzyl)-3-[(3-methyl 4-(3,5-difluorobenzyl)-3-[(3-methyl 4-(3,5-difluorobenzyl)-3-[(3-methyl 4-(3,5-difluorobenzyl)-3-[(3-methyl 4-(3,5-difluorobenzyl)-3-[(3-methyl 4-(3,5-difluorobenzyl)-3-[(3-methyl 4-(3,5-difluorobenzyl)-3-[(3-methyl 4-(3,5-difluorobenz)
ethylbenzyl)amino]-2-hydroxypropyl}amino)-4-oxobutyl-
 (dithiocarbamate);
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}[1,2,4]triazolo[4,3-
a]pyridine-6-carboxamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-a)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-phenyl-1,4,5,6-
tetrahydrocyclopenta[c]pyrazole-3-carboxamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{(3-1)\}
ethylbenzyl)amino]-2-hydroxypropyl}-2-[(4-
methylphenyl)sulfonyl]acetamide;
                3-(2-chlorophenyl)-2-cyano-N-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}propanamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(4-methylphenyl)-4-
oxobutanamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(2-hydroxy-5-
methylphenyl)-4-oxobutanamide;
                N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-(2,5-dioxo-2,5-dihydro-
1H-pyrrol-1-yl)benzamide;
                N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-oxo-4-thien-2-
ylbutanamide or 2379;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4-(2,5-dioxo-2,5-dihydro-
1H-pyrrol-1-yl)-2-hydroxybenzamide;
```

```
N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(2,5-dioxopyrrolidin-1-
yl) benzamide;
            4-[(aminocarbonyl)amino]-N-{(1S, 2R)-1-(3, 5-
difluorobenzyl) -3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}benzamide;
            N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-
[(trifluoroacetyl)amino]butanamide;
            5-bromo-N^1-((1S,2R)-2-hydroxy-1-(pentafluorobenzyl)-3-{[3-
(trifluoromethyl)benzyl]amino}propyl)-N3,N3-
dipropylisophthalamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-[(1-
hydroxycyclopentyl)thio]acetamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-
oxocyclohexyl)propanamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(2-naphthyl)-4-
oxobutanamide;
            N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-oxo-2,3-dihydro-1H-
indazole-4-carboxamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-1,3-dimethyl-1H-thieno[2,3-
c]pyrazole-5-carboxamide;
            N^{1}-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instantial)]
ethylbenzyl)amino]-2-hydroxypropyl}-N2-
[(dimethylamino)sulfonyl]valinamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(2-furyl)-4-
oxobutanamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(5-methyl-4-phenyl-1,3-
oxazol-2-yl) benzamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2,6-
dioxohexahydropyrimidine-4-carboxamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5,7-dimethoxy-1-oxoindane-
2-carboxamide;
            N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{(3-4)\}
\verb|ethylbenzy1|| amino] - 2 - hydroxypropy1| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - pyridin - 2 - hydroxypropy1)| - N^5 - (2 - hydroxypropy1)| - N^5 - (2 - hydroxypropy1)| - N^5 - (2 - hydroxypropy1)| - N^5 - (2 - hydroxypropy1)| - N^5 - (2 - hydroxypropy1)| - N^5 - (2 - hydroxypropy1)| - N^5 - (2 - hydroxypropy1)| - N^5 - (2 - hydroxypropy1)| - N^5 - (2 - hydroxypropy1)| - N^5 - (2 - hydroxypropy1)| - N^5 - (2 - hydroxypropy1)| - N^5 - (2 - hydroxypropy1)| - N^5 - (2 - hydro
ylethyl)pentanediamide;
            N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-[4-(2-furoyl)piperazin-1-
yl]-4-oxobutanamide;
```

```
N' - [(1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 2 - hydroxy - 3 - ({3 - [(1Z) - 1]})
prop-1-en-1-yl]benzyl}amino)propyl]-5-methyl-N,N-
dipropylisophthalamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-oxo-4,5,6,7-tetrahydro-1-
benzofuran-3-carboxamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-oxo-1-(thien-2-
ylmethyl)pyrrolidine-3-carboxamide;
      2-[(cyanomethyl)thio]-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-
3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}nicotinamide;
      N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-(2-furoyl)-4-
hydroxyprolinamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4,5-dihydrofuro[2,3-
g][2,1]benzisoxazole-8-carboxamide;
      methyl 3-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl)amino)carbonyl]-5-
methylthiophene-2-sulfenate;
      2-(acetylamino)-2-(1H-1,2,3-benzotriazol-1-yl)-N-
\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}acetamide;
      1-{[(cyclohexylamino)carbonyl]amino}-N-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}cyclopropanecarboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-ethyl-4H-
[1,2,4]triazolo[1,5-a]benzimidazol-4-yl)acetamide;
       (2E) - N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluor obenzy 1) - 3 - [ (3 - 3) - 1] \}
ethylbenzyl)amino]-2-hydroxypropyl}-N^4-[4-(1,3-oxazol-5-
yl)phenyl]but-2-enediamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-1,3,4,5-
tetrahydrothiopyrano[4,3-b]indole-8-carboxamide;
      4-chloro-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-1,3-dimethyl-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(3,4-dihydro-2H-1,5-
benzodioxepin-7-yl)-4-oxobutanamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(1-oxidothiomorpholin-4-
yl) butanamide;
      N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-oxo-4-(2-thioxo-1,3-
benzothiazol-3(2H)-yl)butanamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-8H-thieno[2,3-b]indole-2-
carboxamide;
```

```
N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-3,4-dihydro-2H-1,5-
benzodioxepine-7-carboxamide;
               N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-instance of the content 
ethylbenzyl)amino]-2-hydroxypropyl}-4H-chromeno[3,4-
dlisoxazole-4-carboxamide;
                 4-(3,4-dichlorophenyl)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-}
3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-oxobutanamide;
               N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mathemathem)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(3,4-difluorophenyl)-4-
oxobutanamide;
               N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(3,4-difluorophenyl)-2-
methyl-4-oxobutanamide;
               N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(3,4-difluorophenyl)-2-
methoxy-4-oxobutanamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-4-oxo-4-[3-
(trifluoromethyl)phenyl]butanamide;
               N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-instance of the stance of th
ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-4-oxo-4-thien-2-
vlbutanamide:
                 4-(3,4-dichlorophenyl)-N-((1S,2R)-1-(3,5-difluorobenzyl)-
3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-3-methyl-4-
oxobutanamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-[(2-ethyl-1-oxo-2,3-
dihydro-1H-isoindol-5-yl)oxy]propanamide;
               N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mathemathem)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-oxoisoindoline-1-
carboxamide;
               N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(7-methoxy-1-benzofuran-
2-y1)-4-oxobutanamide;
               N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{(3-4)\}
ethylbenzyl)amino]-2-hydroxypropyl}-4H-chromeno[3,4-
d]isoxazole-8-carboxamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-i)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-4-oxo-4H-chromene-
6-carboxamide;
               N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-([1,2,4]triazolo[4,3-
b]pyridazin-6-ylthio)acetamide;
               N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-\{(3-4)\}
ethylbenzyl)amino]-2-hydroxypropyl}-2-(1,1-
dioxidotetrahydrothien-2-yl)acetamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4-(3,4-dihydro-2H-chromen-
6-yl)-4-oxobutanamide;
```

```
N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-ethyl-3-oxoisoindoline-1-carboxamide;

4-[2-(acetylamino)-4,5-dimethylphenyl]-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-oxobutanamide;
```

- N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-4-(4-hydroxypheny1)-4-oxobutanamide;
- $2-[(6-\text{chloro}[1,2,4]\text{triazolo}[4,3-b]\text{pyridazin-3-yl})\text{oxy}]-N-\{(1S,2R)-1-(3,5-\text{difluorobenzyl})-3-[(3-\text{ethylbenzyl})\text{amino}]-2-hydroxypropyl}acetamide;$
- N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-4-(3-methoxyphenyl)-4-oxobutanamide;
- N- $\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1\}-2-hydroxy-4-oxo-4-thien-3-ylbutanamide;$
- 3-chlorophenyl 4-({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}amino)-4-oxobutanoate;
- 4-(4-chloro-2-hydroxyphenyl)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-oxobutanamide;
- N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-6-{[(4-methylphenyl)sulfonyl]amino}-4-oxohexanamide;
- N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(6-hydroxy-3-oxo-2,3-dihydroimidazo[2,1-b][1,3]thiazol-2-yl)acetamide;
- N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(4,5-dihydro-1,3-thiazol-2-ylthio)acetamide;
- N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1H-imidazo[1,2-b]pyrazole-6-carboxamide;
- 4-(1-benzofuran-2-yl)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-oxobutanamide;
- N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-(6-methoxy-1,1'-biphenyl-3-yl)-4-oxobutanamide;
- N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-(4-methoxyphenyl)-4-oxobutanamide;
- N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-oxobutanamide;
- N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)acetamide;

```
N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-oxo-2,3-dihydro-1H-
benzimidazol-5-yl)acetamide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-9-oxo-1,2,3,9-
 tetrahydrocyclopenta[b]chromene-7-carboxamide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
 ethylbenzyl)amino]-2-hydroxypropyl}-1-methyl-1H-
benzo[g]indazole-3-carboxamide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-4,5-dihydronaphtho[2,1-
d]isoxazole-3-carboxamide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(tetraazolo[1,5-
b]pyridazin-6-ylthio)acetamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(5-methyl-1H-pyrrol-2-
yl)-4-oxobutanamide;
                N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-
 {[(trifluoromethyl)sulfonyl]amino}butanamide;
                N-[(1S, 2R)-3-(2-acetyl-1-ethylhydrazino)-1-benzyl-2-
hydroxypropyl]-2-[(methylsulfonyl)amino]-1,3-thiazole-4-
carboxamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-instance of the content of the conten
ethylbenzyl)amino]-2-hydroxypropyl}-3-(1-hydroxy-2-
propylpentyl)benzamide;
                N^{1}-[(1S, 2R)-3-[(2-\{4-[(3-
chlorobenzyl)oxy]phenyl}ethyl)amino]-1-(3,5-difluorobenzyl)-2-
hydroxypropyl]-5-methyl-N3,N3-dipropylisophthalamide;
                N^{1}-{(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-[(3-
morpholin-4-ylpropyl)amino]propyl}-5-methyl-N3,N3-
dipropylisophthalamide;
                [(dipropylamino)carbonyl]-5-methylbenzoyl}amino)-2-
hydroxybutyl]amino}piperidine-1-carboxylate;
                N^{1}-{(1S, 2R)-1-(3,5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>2</sup>-
[(methylsulfonyl)acetyl]-N<sup>2</sup>-pentylglycinamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2R)-2-
 (methoxymethyl)pyrrolidin-1-yl]sulfonyl}propanamide;
               N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-instance of the content of the conten
ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2S)-2-
(methoxymethyl)pyrrolidin-1-yl]sulfonyl)propanamide;
                ethyl 4-\{[(2R,3S)-3-(\{3-
[(dipropylamino)carbonyl]benzoyl}amino)-2-hydroxy-4-
phenylbutyl]amino}piperidine-1-carboxylate;
               N^1-((1S,2R)-1-benzyl-3-{[(3R)-1-benzylpyrrolidin-3-
yl]amino}-2-hydroxypropyl)-N³, N³-dipropylisophthalamide;
```

```
methyl (2E)-2-[2-({(1S,2R)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}amino)-2-oxoethyl]-4-methylpent-2-
enoate;
                     N^{1}-{ (1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl) amino]propyl}-N4-(4-methoxybenzyl) succinamide;
                     N-\{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-benzyl-2-hydrox-3-[(3-benzyl-2-hydroxy-3-[(3-benzyl-2-hydroxy-3-[(3-benzyl-2
methoxybenzyl)amino]propyl}-3-{[(4-
 fluorophenyl) sulfonyl]amino}-3-methylbutanamide;
                     N-{ (1S, 2R) -1-benzy1-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-9,10-dioxo-9,10-dihydroanthracene-
 2-carboxamide;
                      N-\{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-4-(benzyloxy)benzamide;
                      N' - \{ (1S, 2R) - 1 - benzyl - 2 - hydroxy - 3 - [ (3 - a) - [ (3 - a) - [ (3 -
methoxybenzyl)amino]propyl}-N-methyl-N-phenylurea
                      N' - \{ (1S, 2R) - 1 - benzyl - 2 - hydroxy - 3 - [ (3 - 1) - 1] \}
methoxybenzyl)amino]propyl}-N,N-diisopropylurea
                      N' - \{ (1S, 2R) - 1 - benzyl - 2 - hydroxy - 3 - [ (3 - 1) - 1] \}
 methoxybenzyl)amino]propyl}-N,N-diphenylurea
                      N' - \{ (1S, 2R) - 1 - benzyl - 2 - hydroxy - 3 - [ (3 - 1) - 1] \}
 methoxybenzyl)amino]propyl}-N,N-dimethylurea
                      methyl 2-\{[(\{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-benzyl-2-hydroxy-3-[
 methoxybenzyl)amino]propyl}amino)carbonyl]amino}benzoate;
                      phenyl (1S,2R)-1-benzyl-2-hydroxy-3-[(3-
 methoxybenzyl)amino]propylcarbamate;
                       2-methoxyethyl (1S,2R)-1-benzyl-2-hydroxy-3-[(3-
 methoxybenzyl)amino]propylcarbamate;
                       2-(benzyloxy)ethyl (1S,2R)-1-benzyl-2-hydroxy-3-[(3-
 methoxybenzyl)amino]propylcarbamate;
                      prop-2-ynyl (1S,2R)-1-benzyl-2-hydroxy-3-[(3-
 methoxybenzyl)amino]propylcarbamate;
                            (1R, 2S, 5R) -2-isopropyl-5-methylcyclohexyl (1S, 2R) -1-
 benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propylcarbamate;
                      pentyl (1S, 2R) -1-benzyl -2-hydroxy-3-[(3-
 methoxybenzyl)amino]propylcarbamate;
                       neopentyl (1S,2R)-1-benzyl-2-hydroxy-3-[(3-
 methoxybenzyl)amino]propylcarbamate;
                      N^{1}-[(1S, 2R)-3-{[(6-chloroimidazo[2,1-b][1,3]thiazol-5-
 y1)methyl]amino}-1-(3,5-difluorobenzyl)-2-hydroxypropyl]-5-
 methyl-N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
                       N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(4-oxo-
  4H-chromen-3-yl)methyl]amino}propyl)-5-methyl-N³,N³-
  dipropylisophthalamide;
                       N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(1,7,7-
  trimethylbicyclo[2.2.1]hept-2-yl)amino]propyl}-5-methyl-N3,N3-
  dipropylisophthalamide;
                       N-\{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-mu)]
  iodobenzyl)amino]propyl}-4-(3-methyl-5-oxo-4,5-dihydro-1H-
  pyrazol-1-yl)benzamide;
```

```
N^{1}-[(1S,2R)-3-[(1-acetylpiperidin-3-yl)amino]-1-(3,5-
difluorobenzyl)-2-hydroxypropyl]-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalamide;
                N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethoxy-5-
methylisophthalamide;
                N^{1}-(allyloxy)-N^{3}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-methylisophthalamide;
                N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>3</sup>-isobutoxy-5-
methylisophthalamide;
                N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-N^3-(2,2,3,3,3-
pentafluoropropyl) isophthalamide;
                ethyl 4-({3-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}amino)carbonyl]-5-
methylbenzoyl}amino)butanoate;
                N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-N³,N³-bis(2,2,2-
 trifluoroethyl)isophthalamide;
                N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
 ethylbenzyl)amino]-2-hydroxypropyl}-N3-ethyl-N3-[(1-
 ethylpiperidin-4-yl)carbonyl]-5-methylisophthalamide;
                N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [(3 - 3, 5 - difluorobenzyl)] - 3 - [(3 - 3, 
ethylbenzyl)amino]-2-hydroxypropyl}-N^3-(2,2,3,3,4,4,4-
heptafluorobutyl)-5-methylisophthalamide;
                N^{1}-(1-\text{benzylpyrrolidin}-3-\text{yl})-N^{3}-\{(1S,2R)-1-(3,5-
 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N^1-
 ethyl-5-methylisophthalamide;
                N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-N3-
 (tetrahydrofuran-2-ylmethyl) isophthalamide;
                N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(3R)-2-
 oxoazepan-3-yl]amino}propyl)-5-methyl-N3,N3-
 dipropylisophthalamide;
                N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(1,1-dioxido-3,4-
dihydro-2H-1,2-benzothiazin-4-yl)amino]-2-hydroxypropyl}-5-
methyl-N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
                N^{1}-{ (1S, 2R) -1-(3,5-difluorobenzyl) -2-hydroxy-3-[2-(4-
methylpentanoyl)hydrazino]propyl}-5-methyl-N<sup>3</sup>,N<sup>3</sup>-
dipropylisophthalamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-3-[(3-
 ethylphenyl)sulfonyl]propanamide;
                N^{1}-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2,2,3,3,4,4-hexafluoro-
N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
                N^5 - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 3) - 3 - (3 - 3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3)
 ethylbenzyl) amino] -2-hydroxypropyl} -2-phenyl-N^1, N^1-
dipropylpentanediamide;
```

```
N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-[(3-
hydroxypropyl) (methylsulfonyl) amino] benzamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-[(2-
hydroxyethyl) (methylsulfonyl) amino]benzamide;
          N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(2R)-2-
(methoxymethyl)pyrrolidin-1-yl]sulfonyl}-N3,N3-
dipropylisophthalamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-[(3-
hydroxypropyl) (methylsulfonyl) amino] benzamide;
           5-bromo-N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
[(3-iodobenzyl)amino]propyl}-N³,N³-dipropylisophthalamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-
{[(trifluoromethyl)sulfonyl]amino}benzamide;
           N^{1}-[(1S,2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(thien-
2-ylmethyl)propyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylbenzene-1,3,5-tricarboxamide;
          N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-(4-methyl-1,3-oxazol-2-
yl) -N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
           N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - [ (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - (3 
ethylbenzyl)amino]-2-hydroxypropyl}-N3,N3-dipropyl-5-(1,3-
thiazol-2-yl)isophthalamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-3-
[(methylsulfonyl)amino]benzamide;
           4-({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}amino)-4-oxo-3-{[(1-
propylbutyl)sulfonyl]methyl}butanoic acid trifluoroacetate;
           N^{1}-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
(isopentylamino)propyl]-5-[(methylsulfonyl)amino]-N3,N3-
dipropylisophthalamide;
           N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - [ (3 - 3) - 3 - 3] \}
ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-oxazol-2-yl)-N3,N3-
dipropylisophthalamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-
propylbutyl)sulfonyl]propanamide;
           N^{1}-{ (1S, 2R) -1-(3, 5-difluorobenzyl) -2-hydroxy-3-[(3-
methoxybenzyl) amino [propyl] -5 - (1, 3 - oxazol - 2 - yl) - N^3, N^3 -
dipropylisophthalamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzy1)-2-hydroxy-3-[(3-1)]
iodobenzyl)amino]propyl}-2-[(methylsulfonyl)amino]-1,3-
thiazole-4-carboxamide;
           N^{1}-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
 (isopentylamino)propyl]-N3,N3-dipropyl-5-
 {[(trifluoromethyl)sulfonyl]amino}isophthalamide;
```

```
N-\{(1s, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-instance of a second o
 ethylbenzyl)amino]-2-hydroxypropyl}-3-
 (isopentylsulfonyl)propanamide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
 ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(1-methyl-1H-imidazol-
 4-yl)sulfonyl]amino}benzamide tri;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-max)]
 ethylbenzyl)amino]-2-hydroxypropyl}-4-
 {[(trifluoromethyl)sulfonyl]amino}benzamide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
 ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2-
 hydroxyethyl) (propyl) amino] sulfonyl} propanamide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-3-(1,3-oxazol-2-
yl)benzamide;
                N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(2-hydroxy-1,1-
 dimethylethyl) amino | sulfonyl | -N3, N3-dipropylisophthalamide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-instance of the content of the conten
 ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2-hydroxy-1,1-
 dimethylethyl)amino]sulfonyl}benzamide;
                N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(3-
hydroxypropyl)amino]sulfonyl}-N3,N3-dipropylisophthalamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-[(methylsulfonyl)amino]-
1,3-thiazole-4-carboxamide;
                N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N2-(phenylacetyl)-3-[(1-
propylbutyl) sulfonyl]alaninamide;
                N^{1}-{(1R,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl) amino] -2-hydroxypropyl}-N^2-benzyloxycarbonyl-3-[(1-
propylbutyl)sulfonyl]alaninamide trifluoroacetate;
                N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-(3-methylisoxazol-4-yl)-
N3, N3-dipropylisophthalamide;
                N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-({[2-
 (methylamino)ethyl]amino}sulfonyl)-N3,N3-
dipropylisophthalamide;;
                N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(2-
hydroxyethyl)amino]sulfonyl}-N³,N³-dipropylisophthala;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4-
[(methylsulfonyl)amino]butanamide;
                N^{1}-{ (1S, 2R) -1-(3,5-difluorobenzyl) -3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-(piperazin-1-ylsulfonyl)-
N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
```

```
N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-
[methyl(methylsulfonyl)amino]benzamide;
          5-{[bis(2-hydroxyethyl)amino]sulfonyl}-\mathbb{N}^1-{(1S,2R)-1-(3,5-
difluorobenzyl) -3-[(3-\text{ethylbenzyl}) \text{ amino}] -2-\text{hydroxypropyl}\}-N^3, N^3-
dipropylisophthalamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2,8-dimethylquinoline-3-
carboxamide;
          2-\{[(2R,3S)-4-(3,5-difluorophenyl)-3-(\{3-4\})\}
[(dipropylamino)carbonyl]-5-methylbenzoyl}amino)-2-
hydroxybutyl]amino}ethyl 2,4-difluorophenylcarbamate;
           5-(aminosulfonyl)-N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-
[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N3,N3-
dipropylisophthalamide;
          N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N3,N3-dipropyl-5-(1H-
pyrazol-4-yl)isophthala;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-3-hydroxyisoxazole-5-
carboxamide;
           N^{1} - \{ (1S, 2R) - 1 - (3, 5 - diffuorobenzy1) - 3 - [(3 - 3) - 3] \}
ethylbenzyl)amino]-2-hydroxypropyl}-5-(1-methyl-1H-imidazol-2-
yl)-N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-a)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2R)-2-
 (methoxymethyl)pyrrolidin-1-yl]carbonyl}-5-methylbenzamide;
           N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(2-
hydroxyethyl)amino]sulfonyl}-N3-propylisophthalamide;
           N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3)
ethylbenzyl)amino]-2-hydroxypropyl}-5-({[(1S)-2-hydroxy-1-
methylethyl]amino}sulfonyl)-N3,N3-dipropylisophthalamide;
           N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N3,N3-diethyl-5-(1,3-oxazol-
2-yl)isophthalamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2S)-2-
 (methoxymethyl)pyrrolidin-1-yl]carbonyl}-5-methylbenzamide;
           N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(2S)-2-
 (hydroxymethyl)pyrrolidin-1-yl]sulfonyl}-N<sup>3</sup>, N<sup>3</sup>-
 dipropylisophthalammide;
           N^{1}-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-5-({[(1R)-2-hydroxy-1-
methylethyl]amino}sulfonyl)-N³,N³-dipropylisophthalammide;
            N^{1}-((1S,2R)-2-hydroxy-1-(2,3,5-trifluorobenzyl)-3-{[3-
 (trifluoromethyl)benzyl]amino}propyl)-5-methyl-N3,N3-
 dipropylisophthalammide;
```

```
N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-ethyl-1-
hydroxybutyl)benzammide;
      N^{1}-{ (1S, 2R) -1- (3, 5-difluorobenzyl) -3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-
[(dimethylamino)sulfonyl]-N³, N³-dipropylisophthalammide;
      N^{1}-[(1S,2R)-3-\{[1-(aminocarbonyl)cyclohexyl]amino\}-1-(3,5-
difluorobenzyl)-2-hydroxypropyl]-5-methyl-N3,N3-
dipropylisophthalammide;
      N^{1}-[(1S,2R)-3-\{[2-(aminosulfonyl)ethyl]amino\}-1-(3,5-
difluorobenzyl)-2-hydroxypropyl]-5-methyl-N3,N3-
dipropylisophthalammide;
      N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(1-
methylhexyl)amino]propyl}-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalammide;
      N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(2-
hydroxypropyl)amino]propyl}-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalammide;
      N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(2-
ethylhexyl)amino]-2-hydroxypropyl}-5-methyl-N3,N3-
dipropylisophthalammide;
      N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(4-
phenylbutyl)amino]propyl}-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalammide;
      N^{1}-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
(pentylamino)propyl]-5-methyl-N3, N3-dipropylisophthalammide;
      N^{1}-{ (1S, 2R) -1- (3, 5-difluorobenzyl) -2-hydroxy-3-[(5-
hydroxypentyl) amino]propyl}-5-methyl-N^3, N^3-
dipropylisophthalammide;
      N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-(6-
hydroxyhexyl)amino]propyl}-5-methyl-N3,N3-
dipropylisophthalammide;
     N^{1}-[(1S, 2R)-3-[(3-butoxypropyl)amino]-1-(3, 5-
difluorobenzyl)-2-hydroxypropyl]-5-methyl-N3,N3-
dipropylisophthalammide:
     N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(2R)-2-
hydroxypropyl]amino}propyl)-5-methyl-N<sup>3</sup>,N<sup>3</sup>-
dipropylisophthalammide;
     N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl) amino] -2-hydroxypropyl} -N^3-ethyl-N^3-methyl-5-(1,3-
oxazo1-2-yl)isophthalammide;
     N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N3-methyl-5-(1,3-oxazol-2-
yl)-N<sup>3</sup>-propylisophthalammide;
      N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N3,NA-dipropyl-5-
(pyrrolidin-1-ylsulfonyl) isophthalamide hydrochlormide;
     N^{1}-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
(isopentylamino)propyl]-5-{[(2-hydroxy-1.1-
dimethylethyl) amino] sulfonyl}-N³, N³-dipropylisophthalammide;
```

```
N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-oxazol-5-yl)-N3,N3-
dipropylisophthalamide hydrochlormide;
     N^{1}-{ (1S, 2R) -1- (3, 5-difluorobenzyl) -3- [(3-
ethynylbenzyl) amino] -2-hydroxypropyl} -5-(1, 3-oxazol-2-yl) -N^3, N^3-
dipropylisophthalamide hydrochlormide;
      N^{1}-butyl-N^{3}-{ (1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>1</sup>-methyl-5-(1,3-oxazol-2-
yl) isophthalammide;
      N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl) amino] -2-hydroxypropyl}-N<sup>3</sup>, N<sup>3</sup>-dimethyl-5-(1,3-
oxazol-2-yl)isophthalammide;
     N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N3-ethyl-5-(1,3-oxazol-2-
yl) -N<sup>3</sup>-propylisophthalammide;
      N^{1}-{ (1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethynylbenzyl)amino]-2-hydroxypropyl}-N<sup>3</sup>, N<sup>3</sup>-dipropyl-5-(1,3-
thiazol-2-yl)isophthalamide hydrochlormide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(1-
propylbutyl)amino]sulfonyl}propanammide;
      N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(2R)-2-
(hydroxymethyl)pyrrolidin-1-yl]sulfonyl)-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalammide;
      N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethynylbenzyl)amino]-2-hydroxypropyl}-5-{[(2-hydroxy-1,1-
dimethylethyl)amino]sulfonyl}-N3,N3-dipropylisophthalammide;
      N^{1}-[(1S, 2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
(isobutylamino)propyl]-5-(1,3-oxazol-2-yl)-N^3,N^3-
dipropylisophthalamide hydrochlormide;
      5-bromo-N^1-((1S,2R)-1-[3-fluoro-4-
(trifluoromethyl)benzyl]-2-hydroxy-3-{[3-
(trifluoromethyl)benzyl]amino}propyl)-N3,N3-
dipropylisophthalammide;
      5-bromo-N^1-((1S,2R)-2-hydroxy-1-(2,3,4-trifluorobenzyl)-3-
{[3-(trifluoromethyl)benzyl]amino}propyl)-N³,N³-
dipropylisophthalammide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mu)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-ethylbutanoyl)-5-
methylbenzamide hydrochlormide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mathemathem)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-[(2-
propylpiperidin-1-yl)carbonyl]benzamide hydrochlormide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-[(2-
methylpyrrolidin-1-yl)carbonyl]benzamide hydrochlormide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2,6-dimethylpiperidin-
1-yl)carbonyl]-5-methylbenzamide hydrochlormide;
```

```
N^{1}-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
   ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(2-
   methoxyethyl) amino] sulfonyl}-N^3, N^3-dipropylisophthalammide;
                        N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[3-
   (trifluoromethyl)benzyl]aminopropyl-N^3, N^3-dipropyl-5-(1,3
   thiazol-2-yl)isophthalamide dihydrochlormide;
                       N^{1}-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
   ethynylbenzyl)amino]-2-hydroxypropyl}-5-{[(2-
  hydroxyethyl)amino]sulfonyl}-N3,N3-dipropylisophthalammide;
                       N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
   ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-(2-
  propylpentanoyl)benzamide hydrochlormide;
                       N^{1}-(sec-butyl)-N^{3}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
  ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-N1-
  propylisophthalammide:
                       N^{1}-butyl-N^{3}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
  ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-N^1-
  propylisophthalammide;
                       N^{1}-allyl-N^{1}-cyclopentyl-N^{3}-{ (1S, 2R) -1- (3, 5-
 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-
  methylisophthalammide;
                      N^{1}, N^{1}-dibutyl-N^{3}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
  ethylbenzyl)amino]-2-hydroxypropyl}-5-methylisophthalammide;
                       N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
  ethylbenzyl)amino]-2-hydroxypropyl}-N3,N3-diisobutyl-5-
 methylisophthalammide:
                      N^{1}-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-({3-[(1Z)-
prop-1-enyl]benzyl\}amino)propyl]-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
 dipropylisophthalammide;
                      N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[3-
  (ethylsulfonyl)benzyl]amino}-2-hydroxypropyl)-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
 dipropylisophthalammide;
                     N^{1}-((1S,2R)-1-(3,5-difluorobenzy1)-2-hydroxy-3-{[1-(3-
 iodophenyl)cyclopropyl]amino}propyl)-5-methyl-N^3, N^3-
dipropylisophthalammide;
                     N'-(1-(3,5-difluorobenzyl)-3-\{[2-(ethylamino)-1-methyl-2-(ethylamino)-1-meth
oxoethyl]amino}-2-hydroxypropyl)-5-methyl-N,N-
dipropylisophthalammide;
                     N^{1}-[(1s,2R)-3-[(1,1'-biphenyl-3-ylmethyl)amino]-1-(3,5-
difluorobenzyl)-2-hydroxypropyl]-5-methyl-N^3, N^3-
dipropylisophthalammide;
                     N^{1}-{ (1S, 2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-
\label{local_propyl} \verb|hydroxy-1-phenylpropyl| amino| propyl| -5-methyl-N^3, N^3-methyl-N^3,
dipropylisophthalammide;
                    N^{1}-cyclohexyl-N^{3}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>1</sup>,5-
dimethylisophthalammide;
                    N^1-cyclohexyl-N^3-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N^1-ethyl-5-
methylisophthalammide;
```

```
N^{1}-[(1S,2R)-3-{[3-(1-benzothien-2-yl)benzyl]amino}-1-(3,5-
difluorobenzyl)-2-hydroxypropyl]-5-methyl-N<sup>3</sup>,N<sup>3</sup>-
dipropylisophthalammide;
          N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[3-
(trifluoromethyl)benzyl]amino}propyl)-5-ethynyl-N3,N3-
dipropylisophthalammide;
          N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-thien-
3-ylbenzyl)amino]propyl}-5-methyl-N³,N³-dipropylisophthalammide;
          N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[3-(5-
methylthien-2-yl)benzyl]amino}propyl)-5-methyl-N3,N3-
dipropylisophthalammide;
           N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-
pyridin-4-ylbenzyl)amino]propyl}-5-methyl-N3,N3-
dipropylisophthalammide;
           N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[3-(4-
methylthien-2-yl)benzyl]amino}propyl)-5-methyl-N3,N3-
dipropylisophthalammide;
           N^{1}-((1S, 2R)-1-(3,5-difluorobenzyl)-3-{[3-(2,4-
dimethoxypyrimidin-5-yl)benzyl]amino}-2-hydroxypropyl)-5-
methyl-N3,N3-dipropylisophthalammide;
           N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[3-(3,5-
dimethylisoxazol-4-yl)benzyl]amino}-2-hydroxypropyl)-5-methyl-
N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalammide;
           N^4 - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - [ (3 - 3) - 3 - 3] \}
ethylbenzyl)amino]-2-hydroxypropyl}-6-methyl-N^2, N^2-
dipropylpyridine-2,4-dicarboxammide;
           N^{1}-[(1S,2R)-3-{[3-(cyclopropylamino)benzyl]amino}-1-(3,5-
difluorobenzyl)-2-hydroxypropyl]-5-methyl-N3,N3-
dipropylisophthalammide;
           N^{1}-[(1S, 2R)-3-{[3-(cyclopropylamino)benzyl]amino}-1-(3, 5-
difluorobenzyl)-2-hydroxypropyl]-5-ethynyl-N3, N3-
dipropylisophthalammide;
           N^{1}-((1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-{[1-(2-
isobutyl-1,3-thiazol-5-yl)cyclopropyl]amino}propyl)-5-methyl-
N^3, N^3-dipropylisophthalammide;
           N^{1}-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-{[1-(3-
ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-(1,3-oxazol-
2-y1)-N3,N3-dipropylisophthalammide;
           methyl 3-(\{(2R,3S)-4-(3,5-difluorophenyl)-3-(\{3-a,5-difluorophenyl)-
 [(dipropylamino)carbonyl]-5-methylbenzoyl}amino)-2-
hydroxybutyl]amino}methyl)phenyl(methyl)carbamate;
           N^{1}-[(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-({3-
 [methyl (methylsulfonyl) amino] benzyl amino) propyl] -5-methyl-
N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalammide;
           N^{1}-[(1S,2R)-1-(3,5-difluorobenzyl)-3-({3-
 [(dimethylamino)sulfonyl]benzyl}amino)-2-hydroxypropyl]-5-
methyl-N3,N3-dipropylisophthalammide;
           N^{1}-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-{[1-(3-
```

ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-methyl- $N^3$ ,  $N^3$ -

dipropylisophthalammide;

```
N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(2-
isobuty1-1,3-thiazol-5-yl)methyl]amino}propyl)-5-(1,3-oxazol-2-
y1)-N^3,N^3-dipropylisophthalammide;
           N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)-
1-methylethyl]amino}-2-hydroxypropyl)-5-ethynyl-N³, N³-
dipropylisophthalammide;
           N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)-
1-methylethyl]amino}-2-hydroxypropyl)-5-methyl-N3,N3-
dipropylisophthalammide;
           N^{1}-{ (1S, 2R) -1-(3, 5-difluorobenzyl) -2-hydroxy-3-[(3-
isopropylbenzyl) amino]propyl}-5-(1,3-oxazol-2-yl)-N^3, N^3-
dipropylisophthalammide;
           N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)-
1-\text{methylethyl} amino} -2-\text{hydroxypropyl}) -5-(1,3-\text{oxazol}-2-\text{yl})-N^3,N^3-
dipropylisophthalammide;
           N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[1-(3-
isobutylisoxazol-5-yl)cyclopropyl]amino}propyl)-5-(1,3-oxazol-
2-yl)-N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalammide;
           N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[1-(3-
isobutylisoxazol-5-yl)cyclopropyl]amino}propyl)-5-ethynyl-N<sup>3</sup>,N<sup>3</sup>-
dipropylisophthalammide;
           N^{1}-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-({3-
[(methylsulfonyl)amino]benzyl}amino)propyl]-5-methyl-N³, N³-
dipropylisophthalammide;
           N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[1-(3-
isobutylisoxazol-5-yl)cyclopropyl]amino)propyl)-5-methyl-N3,N3-
dipropylisophthalammide;
           N^{1}-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethynylbenzyl) amino] -2-hydroxypropyl} -5-(1, 3-oxazol-2-yl) -N^3, N^3-
dipropylisophthalammide;
           N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[3-
 (trifluoromethyl) benzyl] aminopropyl)-5-(1,3-oxazol-2-yl)-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalammide;
           N^{1}-[(1S,2R)-3-[(3-cyanobenzyl)amino]-1-(3,5-
difluorobenzyl) -2-hydroxypropyl] -5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalammide;
           N' - ((1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 - { [(1S) - 1 - (1S) - 1 - (1S) - (
 [(isobutylamino)(oxo)methyl]-3-
 (methylthio)propyl]amino}propyl)-5-methyl-N,N-
dipropylisophthalammide;
           N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-(1,3-
oxazol-2-yl)-N3, N3-dipropylisophthalammide;
           N^{1}-[(1S,2R)-1-(3,5-difluorobenzyl)-3-({3-[(1E)-hex-1-
enyl]benzyl}amino)-2-hydroxypropyl]-5-methyl-N3,N3-
dipropylisophthalammide;
           N^{1}-[(1S, 2R)-3-{[3-(5-acetylthien-2-yl)benzyl]amino}-1-
 (3,5-difluorobenzyl)-2-hydroxypropyl]-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
```

dipropylisophthalammide;

```
N^{1}-[(1S, 2R)-3-[(3-allylbenzyl)amino]-1-(3,5-
difluorobenzyl)-2-hydroxypropyl]-5-methyl-N3,N3-
dipropylisophthalammide;
      N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[3-(6-
methoxypyridin-3-yl)benzyl]amino}propyl)-5-methyl-N3,N3-
dipropylisophthalammide;
      N-[(1S,2R)-3-{[(2-tert-butylpyrimidin-4-yl)methyl]amino}-
1-(3,5-difluorobenzyl)-2-hydroxypropyl]-5-methyl-N<sup>3</sup>,N<sup>3</sup>-
dipropylisophthalammide;
      N^4-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-
isopropylbenzyl)amino]propyl}-6-methyl-N2,N2-dipropylpyridine-
2,4-dicarboxammide;
      N^{1}-[(1S, 2R)-3-[(3-butylbenzyl)amino]-1-(3, 5-
difluorobenzyl)-2-hydroxypropyl]-5-methyl-N3,N3-
dipropylisophthalammide;
      N^{1}-{(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-[(3-
pentylbenzyl)amino]propyl}-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalamide;
      N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-pent-4-
enylbenzyl)amino]propyl}-5-methyl-N³,N³-dipropylisophthalamide;
      N^{1}-[(1S, 2R)-3-[(3-cyclopentylbenzyl)amino]-1-(3, 5-
difluorobenzyl)-2-hydroxypropyl]-5-methyl-N3,N3-
dipropylisophthalamide;
      N^{1}-[(1S, 2R)-3-[(3-cyclohexylbenzyl)amino]-1-(3, 5-
difluorobenzyl)-2-hydroxypropyl]-5-methyl-N3,N3-
dipropylisophthalamide;
      N^{1}-[(1S, 2R)-3-{[3-(cyclohexylmethyl)benzyl]amino}-1-(3,5-
difluorobenzyl)-2-hydroxypropyl]-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalamide;
      N^{1}-{ (1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-hex-5-
enylbenzyl)amino]-2-hydroxypropyl}-5-methyl-N3,N3-
dipropylisophthalammide;
      methyl (2S)-3-[3-({[(2R,3S)-4-(3,5-difluorophenyl)-3-({3-
[(dipropylamino)carbonyl]-5-methylbenzoyl}amino)-2-
hydroxybutyl]amino}methyl)phenyl]-2-methylpropanoate;
      N^{1}-((1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-{[3-(3-
methylthien-2-yl)benzyl]amino}propyl)-5-methyl-N3,N3-
dipropylisophthalammide;
      N^{1}-((1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-{[3-(3-
methylpyridin-2-yl)benzyl]amino}propyl)-5-methyl-N3,N3-
dipropylisophthalammide;
      N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[3-(4-
methylpyridin-2-yl)benzyl]amino)propyl)-5-methyl-N3,N3-
dipropylisophthalammide;
      N^{1}-((1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-{[3-(5-
methylpyridin-2-yl)benzyl]amino}propyl)-5-methyl-N3,N3-
dipropylisophthalammide;
      N^{1}-[(1S,2R)-3-{[3-(4-chlorobutyl)benzyl]amino}-1-(3,5-
difluorobenzyl)-2-hydroxypropyl]-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
```

dipropylisophthalammide;

```
N^{1}-[(1S,2R)-3-\{[3-(3-cyanopropyl)benzyl]amino\}-1-(3,5-
difluorobenzyl)-2-hydroxypropyl]-5-methyl-N3,N3-
dipropylisophthalammide;
           N^{1}-[(1S,2R)-3-\{[3-(4-cyanobutyl)benzyl]amino}-1-(3,5-
difluorobenzyl) -2-hydroxypropyl] -5-methyl-N^3, N^3-
dipropylisophthalammide;
           N^{1}-[(1S, 2R)-3-{[3-(6-cyanohexyl)benzyl]amino}-1-(3,5-
difluorobenzyl) -2-hydroxypropyl] -5-methyl-N^3, N^3-
dipropylisophthalammide;
           N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[3-(6-
methylpyridin-2-yl)benzyl]amino}propyl)-5-methyl-N3,N3-
dipropylisophthalammide;
           N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[3-(1,3-
oxazol-2-yl)benzyl]aminopropyl)-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalammide;
           methyl 3-\{[((2R,3S)-4-(3,5-difluorophenyl)-3-\{[3-
 [(dipropylamino)carbonyl]-5-(1,3-oxazol-2-yl)benzoyl]amino}-2-
hydroxybutyl)amino]methyl}phenyl(methyl)carbamate;
           N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(1S)-1-
[(isobutylamino)carbonyl]-3-
 (methylsulfonyl)propyl]amino}propyl)-5-methyl-N3,N3-
dipropylisophthalammide;
           N^{1}-butyl-N^{3}-{ (1s, 2r)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
[(3-isopropylbenzyl)amino]propyl}-N1,5-dimethylisophthalammide;
           N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)-
1-methylethyl]amino}-2-hydroxypropyl)-5-{[(2-hydroxy-1,1-
dimethylethyl)amino]sulfonyl}-N³,N³-dipropylisophthalammide;
           N^{1}-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-
\{methyl [(trifluoromethyl)sulfonyl]amino\}-N^3, N^3-
dipropylisophthalammide;
           N^1-[(1S,2R)-3-(cyclopropylamino)-1-(3,5-difluorobenzyl)-2-
hydroxypropyl]-5-{[(2-hydroxy-1,1-
dimethylethyl)amino]sulfonyl}-N3, N3-dipropylisophthalammide;
          N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)-
1-methylethyl] amino \} -2-hydroxypropyl) -N^3, N^3-dipropyl-5-(1,3-methylethyl] amino \} -2-hydroxypropyl) -N^3, N^3-dipropyl-5-(1,3-methylethylethyl) -N^3, N^3-dipropyl-5-(1,3-methylethylethyl) -N^3, N^3-dipropyl-5-(1,3-methylethylethylethyl) -N^3, N^3-dipropyl-5-(1,3-methylethylethylethylethylethyll) -N^3, N^3-dipropyl-5-(1,3-methylethylethylethyll) -N^3, N^3-dipropyl-5-(1,3-methylethyll) -N^3, N^3-dipropyl-5-(1,3-methylethyll) -N^3, N^3-dipropyl-5-(1,3-methylethyll) -N^3, N^3-dipropyl-5-(1,3-methyllethyll) -N^3, N^3-dipropyl-5-(1,3-methylleth
thiazol-2-yl) isophthalammide;
          N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-
[methyl(methylsulfonyl)amino]-N3, N3-dipropylisophthalammide;
          N^{1}-butyl-N^{3}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
ethylphenyl) -1-methylethyl] amino} -2-hydroxypropyl) -N^1, 5-
dimethylisophthalammide;
          N^{1}-((1S,2R)-1-(2,4-difluorobenzyl)-2-hydroxy-3-{[3-
(trifluoromethyl)benzyl]aminopropyl)-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalammide;
           5-bromo-N^1-((1s,2R)-1-(2,4-difluorobenzyl)-2-hydroxy-3-
{[3-(trifluoromethyl)benzyl]amino}propyl)-N^3, N^3-
dipropylisophthalammide;
```

```
N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-ethylpiperidin-1-
v1) sulfonyl]propanammide;
     N^{1}-((1S, 2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-ethynyl-N3,N3-
dipropylisophthalammide;
     N^{1}-cyclobuty1-N^{3}-{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-methylisophthalammide;
     N^1-cyclopentyl-N^3-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-methylisophthalammide;
     N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-N3-
pentylisophthalammide;
      N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-kg)]
ethylbenzyl)amino]-2-hydroxypropyl}-N3-isopentyl-5-
methylisophthalammide;
      N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N3-ethyl-N3-(2-
hydroxyethyl) -5-methylisophthalammide;
      N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - [(3 - 3) - 3] \}
ethylbenzyl)amino]-2-hydroxypropyl}-N³-(2-ethoxyethyl)-5-
methylisophthalammide;
      N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N3-(2-methoxyethyl)-N3,5-
dimethylisophthalammide;
      N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N3-(2-furylmethyl)-N3,5-
dimethylisophthalammide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2R,5R)-2,5-
dimethylpyrrolidin-1-yl]carbonyl}-5-methylbenzammide;
      N^1-cyclopentyl-N^3-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>1</sup>,5-
dimethylisophthalammide;
      N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N3,5-dimethyl-N3-
pentylisophthalammide;
      N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N3-(2-hydroxyethyl)-5-
methyl-N3-propylisophthalammide;
      N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N³-ethyl-N³-(2-
methoxyethyl)-5-methylisophthalammide;
      N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl) amino] -2-hydroxypropyl} -5-methyl-N^3-(2-
methylcyclohexyl) isophthalammide;
      N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N3-(2-methoxyethyl)-5-
methyl-N<sup>3</sup>-propylisophthalammide;
```

```
N^{1}-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl) amino] -2-hydroxypropyl} -N^3, N^3-bis(2-methoxyethyl) -5-
 methylisophthalammide;
        N^{1}-allyl-N^{1}-cyclohexyl-N^{3}-{ (1S,2R)-1-(3,5-difluorobenzyl)-
 3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-
 methylisophthalammide;
        N^{1}-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-\bar{5}-methyl-\mathbb{N}^3, \mathbb{N}^3-
 dipentylisophthalammide;
        N^{1}-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl) amino] -2-hydroxypropyl} -\bar{N}^3, N^3-bis(2-ethoxyethyl)-5-
 methylisophthalammide;
       N^{1}-{(1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(2-
 naphthylmethyl)amino]propyl)-5-(1,3-oxazol-2-y1)-N^3,N^3-
 dipropylisophthalammide;
       N^{1}-butyl-N^{3}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
 ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-N^1,5-
 dimethylisophthalammide;
       N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
 ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-{[(2-hydroxy-
 1,1-dimethylethyl)amino]sulfonyl}-N3,N3-dipropylisophthalammide;
        \label{eq:normalized} \mathbb{N}^1 - \{\, (\text{1S}, 2\mathbb{R}) - 1 - (3\,, 5 - \text{difluorobenzyl}) - 2 - \text{hydroxy} - 3 - [\, (1S) - 1] \, \} 
 1,2,3,4-tetrahydronaphthalen-1-ylamino]propyl}-5-methyl-\mathbb{N}^3,\mathbb{N}^3-
 dipropylisophthalammide;
       \mathbb{N}^{1}-((1s,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(2s)-
 tetrahydrofuran-2-ylmethyl]amino}propyl)-5-methyl-N^3,N^3-
 dipropylisophthalammide;
       N^{1}-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-5-[(3-
hydroxypropyl)sulfonyl]-N3,N3-dipropylisophthalammide;
       N^{1}-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl) amino] -2-hydroxypropyl) -5-(1H-imidazol-4-yl) -N^3, N^3-
dipropylisophthalamide trifluoroacetate;
       N^{1}-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-isoxazol-3-yl-N^3, N^3-
dipropylisophthalammide;
      N-\{(1s, 2r)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2R)-2-
(methoxymethyl)pyrrolidin-1-yl]carbonyl}-5-(1,3-oxazol-2-
yl)benzammide;
      N^4-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethynylbenzyl)amino]-2-hydroxypropyl}-6-methyl-\mathbb{N}^2, \mathbb{N}^2-
dipropylpyridine-2,4-dicarboxammide;
      N^4-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[3-
(trifluoromethyl)benzyl]amino}propyl)-6-methyl-N<sup>2</sup>, N<sup>2</sup>-
dipropylpyridine-2,4-dicarboxammide;
      N^4-((1s,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-6-methyl-N^2, N^2-
dipropylpyridine-2,4-dicarboxammide;
```

```
N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-N3,N3-dipropyl-
5-(1,3-thiazol-2-yl)isophthalammide;
                    N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - [ (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - (3 
ethylbenzyl)amino]-2-hydroxypropyl}-5-[methyl(thien-2-
ylsulfonyl)amino]-N3,N3-dipropylisophthalammide;
                    N^{1}-{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-({[(2R)-2-
hydroxypropyl]amino}sulfonyl)-N3,N3-dipropylisophthalammide;
                    N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[1-(2-
isobutyl-1,3-thiazol-5-yl)cyclopropyl]amino}propyl)-5-(1,3-
oxazol-2-yl)-N^3, N^3-dipropylisophthalammide;
                    N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3)
ethylbenzyl)amino]-2-hydroxypropyl}-3-hydroxy-N5,N5-
dipropylpentanediammide;
                     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-a)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-dipropylamine-2-
oxoethoxy)acetammide;
                     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-[(2-dipropylamine-2-
 oxoethyl)thio]acetammide;
                     N' - ((1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 - {[2 - (3, 5 - difluorobenzyl] - 4 - hydroxy - 3 - {[2 - (3, 5 - difluorobenzyl] - 4 - hydroxy - 3 - {[2 - (3, 5 - difluorobenzyl] - 4 - hydroxy - 4 - hydroxy - 3 - hydroxy - 4 -
 (isobutylamino)-1,1-dimethyl-2-oxoethyl]amino)propyl)-5-(1,3-
 oxazol-2-yl)-N,N-dipropylisophthalammide;
                     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-4-
 [(methylsulfonyl)methyl]benzammide;
                     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-(2-
 methylpentanoyl)benzamide hydrochlormide;
                     N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-5-[(methylsulfonyl)amino]-
 N^3, N^3-dipropylisophthalammide;
                      N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-
 propylbutyl)sulfonyl]-D-alaninamide dihydrochlormide;
                      N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-N2-propionyl-3-[(1-
 propylbutyl) sulfonyl]-D-alaninammide;
                      N' - ((1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 - {[(1S) - 2 - 1]}
  (isobutylamino)-1-methyl-2-oxoethyl]amino}propyl)-N, N-dipropyl-
 5-(1,3-thiazol-2-yl)isophthalammide;
                      N' - ((1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 - { [(1S) - 2 - 1]}
   (isobutylamino)-1-methyl-2-oxoethyl]amino}propyl)-N-methyl-N-
 propyl-5-(1,3-thiazol-2-yl)isophthalammide;
                      N^{1}-buty1-N^{3}-{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-N¹-methyl-5-(1,3-thiazol-2-
 yl)isophthalammide;
```

```
N-\{(1s, 2r)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
     ethylbenzyl)amino]-2-hydroxypropyl}-3-[(3-
    hydroxypropyl) (methylsulfonyl)amino]benzammide;
                  N-\{(1s,2R)-1-(3,5-difluorobenzy1)-3-[(3-
    ethylbenzyl)amino]-2-hydroxypropyl}-4-
     (methylsulfonyl)benzammide;
                 N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
    ethylbenzyl)amino]-2-hydroxypropyl}-\bar{N}^2-(1-oxobutyl)-3-[(1-
    propylbutyl)sulfonyl]-D-alaninamide hydrochlormide;
                 N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
   ethylbenzyl) amino] -2-hydroxypropyl\}-N^3, N^3-dipropyl-5-pyrimidin-
   2-ylisophthalammide:
                 N^{1}-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
   ethylbenzyl)amino]-2-hydroxypropyl}-5-({[(2S)-2-
   hydroxypropyl]amino}sulfonyl)-N3,N3-dipropylisophthalammide;
                N^{1}-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
   ethylbenzyl)amino]-2-hydroxypropyl}-\overline{N}^3-methyl-N^3-propyl-5-(1,3-
   thiazol-2-yl)isophthalammide;
                N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-max)-1]
   ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-methylpentanoyl)-5-
   (1,3-oxazol-2-yl)benzammide;
                N^{1}-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-({3-
   [(methylsulfonyl)amino]benzyl}amino)propyl]-5-(1,3-oxazol-2-
  yl)-N3,N3-dipropylisophthalammide;
                N^{1}-{ (1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
  ethylbenzyl)amino]-2-hydroxypropyl}-N^2-(2,2-dimethylpropanoyl)-
  3-[(1-propylbutyl)sulfonyl]-D-alaninamide hydrochlormide;
               N^{1}-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
  ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(2R)-2-
  (\texttt{methoxymethyl}) \, \texttt{pyrrolidin-1-yl}] \, \texttt{sulfonyl} \, \} \, - \, \mathbb{N}^3 \, - \, \mathbb{N
 dipropylisophthalammide;
               N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-4-[(3-
 hydroxypropyl) (methylsulfonyl)amino]benzammide;
              N^2-acetyl-N^1-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-
propylbutyl)sulfonyl]-D-alaninamide hydrochlormide;
              2-[allyl(methylsulfonyl)amino]-N-\{(1S, 2R)-1-(3, 5-1)\}
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1,3-
thiazole-5-carboxammide;
              3-(butylsulfonyl)-N^1-((1S,2R)-1-(3,5-difluorobenzyl)-3-
 [(3-ethylbenzyl)amino]-2-hydroxypropyl}-D-alaninamide
bis(trifluoroacetate);
             N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-3-[(1-
propylbuty1)sulfony1]-D-alaninam; bis(trifluoroacetate);
             N^{1}-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-\overline{N}^2-isobutyryl-3-[(1-
propylbutyl)sulfonyl]-D-alaninamide hydrochlormide;
```

```
N-[(1S, 2R)-3-(butylamino)-1-(3, 5-difluorobenzyl)-2-
hydroxypropyl]-4-(ethylthio)benzammide;
                    N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-(2-fluorophenyl)-5-
oxopyrrolidine-3-carboxammide;
                        N^{1}-(4-tert-butyl-1,3-thiazol-2-yl)-N^{4}-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}succinammide;
                    N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-hydroxy-6-(1-hydroxy-2,2-
dimethylpropyl)pyridine-2-carboxammide;
                    N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzyl)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-
 {[(ethylamino)carbonyl]amino}benzammide;
                     3-(1-cyanoethyl)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-difluor
 ethylbenzyl)amino]-2-hydroxypropyl}benzammide;
                     1-(cyanomethyl)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-difluoro
 ethylbenzyl)amino]-2-hydroxypropyl}-1H-pyrrole-2-carboxammide;
                     N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[3-(1H-
 imidazol-1-yl) propyl lamino propyl) -5-methyl-N^3, N^3-
 dipropylisophthalammide;
                     N^{1}-[(1S,2R)-1-(3,5-difluorobenzyl)-3-({[(2R)-1-
 ethylpyrrolidin-2-yl]methyl}amino)-2-hydroxypropyl]-5-methyl-
N^3, N^3-dipropylisophthalammide;
                     3-acetyl-N-[(1S,2R)-3-(benzylamino)-1-(3,5-
 difluorobenzyl)-2-hydroxypropyl]benzammide;
                     N^{1}-{(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-[(7-
methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)amino]propyl}-5-
methyl-N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalammide;
                    N^{1}-{ (1S, 2R) -1- (3, 5-difluorobenzyl) -3-[(2E) -hex-2-
enylamino]-2-hydroxypropyl}-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalammide;
                     N^{1}-[(1S,2R)-1-(3,5-difluorobenzyl)-3-({[(5R)-3-ethyl-2-
oxo-1,3-oxazolidin-5-yl]methyl}amino)-2-hydroxypropyl]-5-
methyl-N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalammide;
                     N^{1}-[(1S, 2R)-1-(3, 5-difluorobenzyl)-3-({[(5S)-3-ethyl-2-
oxo-1,3-oxazolidin-5-yl]methyl)amino)-2-hydroxypropyl]-5-
methyl-N3, N3-dipropylisophthalammide;
                    N^{1}-{(1s, 2r)-1-(3, 5-difluorobenzyl)-3-[(2, 2-dioxido-3, 4-
dihydro-1,2-benzoxathiin-4-yl)amino]-2-hydroxypropyl}-5-methyl-
N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalammide;
                     N^{1}-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(1, 1-dioxido-3, 4-
dihydro-2H-1,2-benzothiazin-4-y1)amino]-2-hydroxypropyl}-5-
methyl-N3, N3-dipropylisophthalammide;
                     N^5 - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 3) - 3 - (3, 5) - (3, 5) - (3,
 ethylbenzyl) amino] -2-hydroxypropyl} -2-phenyl-N^1, N^1-
 dipropylpentanediammide;
                     N^{1}-{(1S,2R)-1-{[5-(cyanomethyl)-1H-imidazol-1-yl]methyl}-
 3-[(3-\text{ethylbenzyl}) \text{ amino}]-2-\text{hydroxypropyl}-5-\text{methyl-}N^3, N^3-
 dipropylisophthalammide;
```

```
N^{1}-{(1s, 2r)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-N3,N3-dipropyl-5-pyrimidin-
 2-ylisophthalammide;
            N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[(2-ethylpyrimidin-
 4-y1) methyl]amino}-2-hydroxypropyl)-5-methyl-N^3, N^3-
 dipropylisophthalammide;
            N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
 ethylbenzyl) amino] -2-hydroxypropyl}-N^2-(2,2-dimethylpropanoyl) -
 3-[(1-propylbutyl)sulfonyl]-D-alaninamide hydrochlormide;
           N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-5-
 {[ethyl(methyl)amino]sulfonyl}-N3,N3-dipropylisophthalammide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-
hydroxyethyl) (methylsulfonyl) amino]benzammide;
            5-bromo-N^1-\{(1S,2R)-1-(2,4-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalammide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-
methoxyethyl) (methylsulfonyl) amino] benzamide hydrochlormide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mu)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-
 [(methylsulfonyl)methyl]benzammide;
           N^{1}-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-[(4-
hydroxybutyl)sulfonyl]-N3,N3-dipropylisophthalamide
hydrochlormide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-1-
 (dipropylamino)isoquinoline-7-carboxammide;
           N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(2-
hydroxyethyl) (methyl) amino] sulfonyl}-N3, N3-
dipropylisophthalammide;
           N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-[(ethylamino)sulfonyl]-
N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalammide;
          N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-(5-methyl-1,2,4-
oxadiazol-3-yl)-N3,N3-dipropylisophthalamide hydrochlormide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance of the stance of th
ethylbenzyl)amino]-2-hydroxypropyl}-2-
[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxammide;
           3-(butylsulfonyl)-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-
[(3-ethylbenzyl)amino]-2-hydroxypropyl}propanammide;
          N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl\}-N^3, N^3-dipropylmalonammide;
```

```
N^2 - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 3) - 3 - (3 - 3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - (
ethylbenzyl) amino] -2-hydroxypropyl\}-N^3, N^3-
dipropylbicyclo[2.2.1]hept-5-ene-2,3-dicarboxammide;
                N^{1}-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N3,N3-dipropylcyclopentane-
1,3-dicarboxammide;
                 N^2 - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 3) - 3 - 3] \}
ethylbenzyl)amino]-2-hydroxypropyl}-3,4-dimethyl-N<sup>5</sup>,N<sup>5</sup>-
dipropylthieno[2,3-b]thiophene-2,5-dicarboxammide;
                 N^{1}-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-phenyl-N5,N5-
dipropylpentanediammide;
                 N^2-benzyl-N^1-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N2-[2-(dipropylamino)-2-
oxoethyl]qlycinammide;
                 3-(4-\text{chlorophenyl})-N^{1}-\{(1S,2R)-1-(3,5-\text{difluorobenzyl})-3-(4-\text{chlorophenyl})-N^{1}-\{(1S,2R)-1-(3,5-\text{difluorobenzyl})-3-(4-\text{chlorophenyl})-N^{1}-\{(1S,2R)-1-(3,5-\text{difluorobenzyl})-3-(4-\text{chlorophenyl})-N^{1}-\{(1S,2R)-1-(3,5-\text{difluorobenzyl})-3-(4-\text{chlorophenyl})-N^{1}-\{(1S,2R)-1-(3,5-\text{difluorobenzyl})-3-(4-\text{chlorophenyl})-N^{1}-\{(1S,2R)-1-(3,5-\text{difluorobenzyl})-3-(4-\text{chlorophenyl})-N^{1}-\{(1S,2R)-1-(3,5-\text{difluorobenzyl})-3-(4-\text{chlorophenyl})-N^{1}-\{(1S,2R)-1-(3,5-\text{difluorobenzyl})-3-(4-\text{chlorophenyl})-N^{1}-\{(1S,2R)-1-(3,5-\text{difluorobenzyl})-3-(4-\text{chlorophenyl})-N^{1}-\{(1S,2R)-1-(3,5-\text{difluorobenzyl})-3-(4-\text{chlorophenyl})-N^{1}-\{(1S,2R)-1-(3,5-\text{difluorobenzyl})-3-(4-\text{chlorophenyl})-N^{1}-\{(1S,2R)-1-(3,5-\text{difluorobenzyl})-3-(4-\text{chlorophenyl})-N^{1}-\{(1S,2R)-1-(3,5-\text{difluorobenz
[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>5</sup>, N<sup>5</sup>-
dipropylpentanediammide;
                  (2E) - N^5 - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - [ (3 - 1) - 1] \}
ethylbenzyl)amino]-2-hydroxypropyl}-2-(methoxyimino)-N1,N1-
dipropylpentanediammide;
                 N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-N2-[2-(dipropylamino)-2-
oxoethyl]-N2-phenylglycinammide;
                 N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N2, N2-dipropylcyclohexane-
1,2-dicarboxammide;
                 N^{1}-[(1S, 2R)-3-[(benzyloxy)amino]-1-(3,5-difluorobenzyl)-2-
hydroxypropyl]-5-(1,3-oxazol-2-yl)-N^3,N^3-
dipropylisophthalammide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-phenylpropanammide;
                 N^{1}-{(1s, 2r)-1-(3,5-difluorobenzyl)-3-[(1,1-dioxido-3,4-
dihydro-2H-1,2-benzothiazin-4-yl)amino]-2-hydroxypropyl}-5-
methyl-N3, N3-dipropylisophthalammide;
                 N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-(1H-imidazol-2-yl)-N<sup>3</sup>,N<sup>3</sup>-
dipropylisophthalammide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-(1-hydroxy-2-
propylpentyl)benzammide;
                 N-\{(1R, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-isobutyrylbenzammide;
hydrochlormide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-
propylpentanoyl) benzammide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-mathemathem)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-
ethylbutanoyl)benzamide hydrochlormide;
```

```
N^3 - [(1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 - (1, 2, 3, 4 - 1)]
 tetrahydronaphthalen-1-ylamino)propyl]-N5,N5-
 diisopropylpyridine-3,5-dicarboxammide;
             N' - ((1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - \{ (1S) - 2 - (1S) - 2 - (1S) - 3 - (1S) - (1S) - 3 - (1S) -
 (ethylamino)-1-methyl-2-oxoethyl]amino}-2-hydroxypropyl)-5-
 methyl-N,N-dipropylisophthalammide;
            N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-
hydroxy-1-phenylpropyl)amino]propyl}-5-methyl-N3,N3-
 dipropylisophthalammide;
            N'-[(1S, 2R)-3-\{[(1S)-2-(benzylamino)-1-methyl-2-
 oxoethyl]amino}-1-(3,5-difluorobenzyl)-2-hydroxypropyl]-5-
methyl-N, N-dipropylisophthalammide;
            N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
 ethylbenzyl) amino] -2-hydroxypropyl} -3, 3-dimethyl-N^2, N^2-
 dipropylcyclopropane-1, 2-dicarboxammide:
            N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-3,3-dimethyl-N2,N2-
 dipropylcyclopropane-1,2-dicarboxammide;
            N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-N^5, N^5-
dipropylpentanediammide;
            N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl) amino] -2-hydroxypropyl} -3, 3-dimethyl-N^5, N^5-
dipropylpentanediammide;
            N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-3-ethyl-3-methyl-N<sup>5</sup>,N<sup>5</sup>-
dipropylpentanediammide;
            N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-hydroxy-3-methyl-N<sup>5</sup>,N<sup>5</sup>-
dipropylpentanediammide:
            2-[allyl(methylsulfonyl)amino]-N-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1,3-
oxazole-4-carboxammide;
           N^{1}-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-{[2-
 (dimethylamino) ethyl]amino}-2-hydroxypropyl)-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalammide;
           N^1-[(1S, 2R)-3-(\{2-[bis(2-hydroxyethyl)amino]ethyl\}amino)-
1-(3,5-difluorobenzyl)-2-hydroxypropyl]-5-methyl-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalammide;
           N^{1}-[(1S,2R)-3-(cyclopropylamino)-1-(3,5-difluorobenzyl)-2-
hydroxypropyl]-3-[(1-propylbutyl)sulfonyl]-D-alaninamide
dihydrochlormide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-[4-(hydroxymethyl)-1,3-
oxazol-2-yl]benzamide hydrochlormide;
```

or a pharmaceutically acceptable salt thereof.

310. A compound of the formula:

wherein

 $R_a$  and  $R_d$  are independently  $C_1 L C_6$  alkyl;

X is O or S;

- 5  $R_b$  and  $R_c$  are independently hydrogen or halogen;  $R_e$  is  $C_1$ - $C_6$  alkyl or an optionally substituted phenyl.
  - 311. A compound according to claim 310, wherein  $R_{\text{a}}$  is methyl and  $R_{\text{d}}$  is ethyl.
- 10 312. A compound according to claim 311, wherein X is O.
  - 313. A compound according to claim 312, wherein  $R_{\text{b}}$  and  $R_{\text{c}}$  are F.
    - 314. A compound according to claim 312, wherein  $R_{\text{b}}$  and  $R_{\text{c}}$  are hydrogen.
- 315. A compound according to claim 314, wherein  $R_e$  is meta-substituted ethyl phenyl group.
  - 316. A compound according to claim 314, wherein  $R_{\rm e}$  is -CH<sub>2</sub>CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>.
- 317. A compound according to claim 314, wherein  $R_{\rm e}$  is 20 methyl.
  - 318. A compound according to claim 314, wherein  $R_{\rm e}$  is phenyl.
    - 319. A compound according to claim 311, wherein X is S.
- 320. A compound according to claim 319, wherein  $R_{\text{b}}$  and  $R_{\text{c}}$  25 are F.
  - 321. A compound according to claim 319, wherein  $R_{\text{b}}$  and  $R_{\text{c}}$  are hydrogen.
  - 322. A compound according to claim 321, wherein  $R_{\rm e}$  is meta-substituted ethyl phenyl group.

323. A compound according to claim 321, wherein  $R_{\text{\rm e}}$  is methyl.

324. A compound of the formula:

5 wherein

Ya is

or  $-N(CH_2CH_2CH_3)_2$ ;

 $R_{\rm f}$  and  $R_{\rm g}$  are both hydrogen or together with the carbon to which they are attached form a carbonyl;

X<sub>a</sub> is a covalent bond or a carbonyl;

10  $R_n$  is hydrogen or hydroxy;

 $R_i$  and  $R_j$  are independently hydrogen or a halogen;

 $R_k$  is  $C_{1}$ - $C_6$  alkyl;

 $R_1$  is  $C_1\hbox{-} C_6$  alkyl or an optionally substituted phenyl; and m is 0 or 1.

15

325. A compound according to claim 324, wherein  $R_{\rm f}$  and  $R_{\rm g},$  taken together with the carbon to which they are attached, are a carbonyl.

326. A compound according to claim 4325, wherein  $X_a$  is a 20 covalent bond.

327. A compound according to claim 326, wherein  $R_{\text{h}}$  is hydrogen.

328. A compound according to claim 327, wherein m is 1.

329. A compound according to claim 328, wherein  $R_{\rm i}$  and  $R_{\rm j}$  25  $\,$  are F.

330. A compound according to claim 328, wherein  $R_{\rm i}$  and  $R_{\rm j}$  are hydrogen.

331. A compound according to claim 330, wherein  $R_{\boldsymbol{k}}$  is ethyl.

332. A compound according to claim 330, wherein  $R_{\rm e}$  is meta-substituted ethyl phenyl group.

- 333. A compound according to claim 330, wherein  $R_{\rm e}$  is -CH<sub>2</sub>CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>.
- 5 334. A compound according to claim 330, wherein  $R_{\rm e}$  is methyl.
  - 335. A compound according to claim 330, wherein  $R_{\rm e}$  is phenyl.
- $\,$  336. A compound according to claim 324, wherein  $R_{\rm f}$  and  $R_{\rm g}$  10  $\,$  are hydrogen.
  - 337. A compound according to claim 336, wherein  $X_{a}$  is a carbonyl.
  - 338. A compound according to claim 337, wherein  $R_{\rm h}$  is hydroxyl.
- 15 339. A compound according to claim 338, wherein  $R_i$  and  $R_j$  are F.
  - 340. A compound according to claim 338, wherein  $R_{\rm i}$  and  $R_{\rm j}$  are hydrogen.
- 341. A compound according to claim 338, wherein  $R_{\boldsymbol{k}}$  is 20 ethyl.
  - 342. A compound according to claim 338, wherein  $R_{\rm e}$  is meta-substituted ethyl phenyl group.
  - 343. A compound according to claim 338, wherein  $R_{\rm e}$  is  $-\text{CH}_2\text{CH}_2\text{CH}_3)_2.$
- 25 344. A compound according to claim 338, wherein  $R_{\rm e}$  is methyl.

## 345. A compound which is:

N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-hydroxyethyl)(methylsulfonyl)amino]benzamide;

 $5-bromo-N^1-\{(1S,2R)-1-(2,4-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-N^3,N^3-dipropylisophthalamide;$ 

N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(2-methoxyethyl)(methylsulfonyl)amino]benzamide;

```
N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-
 [(methylsulfonyl)methyl]benzamide;
                     N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3- \cdot)
ethylbenzyl)amino]-2-hydroxypropyl}-5-[(4-
hydroxybutyl)sulfonyl]-N3,N3-dipropylisophthalamide;
                      N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-
 (dipropylamino) isoquinoline-7-carboxamide;
                      N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-{[(2-
hydroxyethyl) (methyl) amino]sulfonyl}-N<sup>3</sup>, N<sup>3</sup>-
dipropylisophthalamide;
                      N^{1}-{ (1S, 2R) -1- (3, 5-difluorobenzy1) -3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-[(ethylamino)sulfonyl]-
N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
                      N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-a)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-(5-methyl-1,2,4-
oxadiazol-3-yl)-N^3, N^3-dipropylisophthalamide;
                      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-
 [methyl (methylsulfonyl) amino] -1, 3-oxazole-4-carboxamide;
                      N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-N3,N3-dipropylmalonamide;
                      N^2 - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - [(3 - 3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 
ethylbenzyl)amino]-2-hydroxypropyl}-N3,N3-
dipropylbicyclo[2.2.1]hept-5-ene-2,3-dicarboxamide;
                      N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{(3-4)\}
ethylbenzyl)amino]-2-hydroxypropyl}-N3,N3-dipropylcyclopentane-
1,3-dicarboxamide;
                      N^2 - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [(3 - 1)] \}
ethylbenzyl)amino]-2-hydroxypropyl}-3,4-dimethyl-N<sup>5</sup>,N<sup>5</sup>-
dipropylthieno[2,3-b]thiophene-2,5-dicarboxamide;
                      N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-phenyl-N<sup>5</sup>,N<sup>5</sup>-
dipropylpentanediamide;
                      N^2-benzyl-N^1-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N2-[2-(dipropylamino)-2-
oxoethyl]glycinamide;
                      3-(4-chlorophenyl)-N^{1}-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-(3,5-di
 [(3-ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>5</sup>, N<sup>5</sup>-
dipropylpentanediamide;
                       (2E) - N^5 - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - [ (3 - 3) - 3 - (3 - 3) - (3 - 3) 
ethylbenzyl) amino] -2-hydroxypropyl} -2- (methoxyimino) -N^1, N^1-
dipropylpentanediamide;
                      N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N2-[2-(dipropylamino)-2-
oxoethyl]-N2-phenylglycinamide;
                      N^{1}-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-a)]
ethylbenzyl)amino]-2-hydroxypropyl}-N2,N2-dipropylcyclohexane-
```

```
1.2-dicarboxamide;
               N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-3-phenylpropanamide;
               N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(2,2-dioxido-3,4-
dihydro-1,2-benzoxathiin-4-yl)amino]-2-hydroxypropyl}-5-methyl-
N3, N3-dipropylisophthalamide;
                N^{1} = \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [(2, 2 - dioxido - 3, 4 - dioxido 
dihydro-1,2-benzoxathiin-4-yl)amino]-2-hydroxypropyl}-5-methyl-
N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
               N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(7-
methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)amino]propyl}-5-
methyl-N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
                N^{1}-{ (1S, 2R) -1- (3,5-difluorobenzyl) -2-hydroxy-3-[(7-
methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)amino]propyl}-5-
methyl-N3, N3-dipropylisophthalamide;
                N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-5-(1H-imidazol-2-yl)-N3,N3-
 dipropylisophthalamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{(3-a)\}
 ethylbenzyl)amino]-2-hydroxypropyl}-2-propyl-1,3-benzoxazole-6-
 carboxamide:
                N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-4)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-1,3-benzoxazole-6-
 carboxamide;
                 5-[(tert-butylamino)sulfonyl]-N^1-\{(1S,2R)-1-(3,5-
 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-
 N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
               N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{(3-difluorobenzyl)-3-((3-difluorobenzyl)-3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-oxazol-2-yl)-N3,N3-
dipropylisophthalamide;
               N^4-((1S, 2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-6-methyl-N2,N2-
dipropylpyridine-2,4-dicarboxamide;
               N^4-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-6-methyl-
N^2, N^2-dipropylpyridine-2, 4-dicarboxamide;
               N^{1}-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-ethynyl-N3,N3-
dipropylisophthalamide;
               N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethynylbenzyl)amino]-2-hydroxypropyl}-5-ethynyl-N3,N3-
dipropylisophthalamide;
               N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-methyl-
N3, N3-dipropylisophthalamide;
               N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>3</sup>, N<sup>3</sup>-dipropyl-5-(1,3-
thiazol-2-yl)isophthalamide;
               N^{1}-butyl-N^{3}-{ (1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N1-methyl-5-(1,3-thiazol-2-
yl) isophthalamide;
               N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-N^3-methyl-N^3-propyl-5-(1,3-
```

```
thiazol-2-yl) isophthalamide;
          N^{1}-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-(4-methyl-1,3-oxazol-2-
y1)-N^3,N^3-dipropylisophthalamide:
          N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl) amino] -2-hydroxypropyl}-N^3-methyl-5-(1, 3-oxazol-2-
yl)-N<sup>3</sup>-propylisophthalamide;
          N^{1}-butyl-N^{3}-{ (1S, 2R) -1- (3, 5-difluorobenzyl) -3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>1</sup>-methyl-5-(1,3-oxazol-2-
yl)isophthalamide;
          N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N3-ethyl-5-(1,3-oxazol-2-
yl)-N<sup>3</sup>-propylisophthalamide;
          N^{1}-((1S, 2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[3-
(trifluoromethyl)benzyl]amino}propyl)-N3,N3-dipropyl-5-(1,3-
thiazol-2-yl) isophthalamide; and
          N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-(1,3-oxazol-
2-yl)-N3,N3-dipropylisophthalamide;
          N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-(1,3-
oxazol-2-yl)-N^3, N^3-dipropylisophthalamide;
           5-{[tert-butyl(methyl)amino]sulfonyl}-N^1-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-
N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-isopropyl-1,3-
benzoxazole-6-carboxamide;
            ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-2-(1-
naphthyl)ethanamide;
            (2R)-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-kg)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-2-(1-
naphthyl)ethanamide:
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}isonicotinamide;
           N^1-\{(1S,2R)-1-benzyl-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl\}-N^3-methyl-5-(1,3-oxazol-2-yl)-N^3-
propylisophthalamide:
          N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{(3-1)\}
ethylbenzyl)amino]-2-hydroxypropyl}-5-[1-(ethoxymethyl)-1H-
imidazol-2-yl]-N^3, N^3-dipropylisophthalamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-instance of the stance of th
ethylbenzyl)amino]-2-hydroxypropyl}-2-propyl-1,3-benzoxazole-5-
carboxamide:
          N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-isopropyl-1,3-
benzoxazole-5-carboxamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-3-
{[ethyl(methyl)amino]sulfonyl}benzamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
```

```
ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-1,3-benzoxazole-5-
carboxamide;
     N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-(methylsulfonyl)-N3,N3-
dipropylisophthalamide;
     N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-(methylsulfonyl)-N3,N3-
dipropylisophthalamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-1,3-benzoxazole-7-
carboxamide;
     ethylbenzyl)amino]-2-hydroxypropyl}amino)carbonyl]benzoate;
     N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(5-
methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)amino]propyl}-5-
methyl-N3, N3-dipropylisophthalamide;
     N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(5-
methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)amino]propyl}-5-
methyl-N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
     N^{1}-{ (1S, 2R) -1-(3,5-difluorobenzyl) -3-[(1S) -2,3-dihydro-1H-
inden-1-ylamino]-2-hydroxypropyl}-5-methyl-N3, N3-
dipropylisophthalamide;
     N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-kg)]
ethylbenzyl)amino]-2-hydroxypropyl}-N2,N2-dipropylcyclohexane-
1,2-dicarboxamide:
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2R)-2-
(methoxymethyl)pyrrolidin-1-yl]sulfonyl}benzamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4-
{[ethyl(methyl)amino]sulfonyl}benzamide;
      formic acid compound with N-\{(1S,2R)-1-(3,5-1)\}
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-
{[ethyl(methyl)amino]sulfonyl}benzamide (1:1);
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3,5-dimethylbenzamide;
     N^{1}-butvl-N^{3}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-N1-methyl-5-
(1,3-thiazol-2-yl)isophthalamide;
     N^{1}-butyl-N^{5}-{ (1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>1</sup>-methylpentanediamide;
     N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>5</sup>,N<sup>5</sup>-
dipropylpentanediamide;
      (2R) - N^5 - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - [ (3 - 1) - 1] \}
ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-N1,N1-
dipropylpentanediamide;
      (2S)-N^5-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-N^1, N^1-
dipropylpentanediamide;
```

```
N^{1}-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N4,N4-dipropylsuccinamide;
      N^{1}-{ (1S, 2R) -1- (3, 5-difluorobenzyl) -3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N2-[2-(dipropylamino)-2-
oxoethyl]-N2-methylglycinamide;
      N^{1}-{ (1S, 2R) -1-(3, 5-difluorobenzyl) -3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N2-[2-(dipropylamino)-2-
oxoethyl]glycinamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-[2-
(methoxymethyl)pyrrolidin-1-yl]-5-oxopentanamide;
      N^{1}-{ (1S, 2R) -1-(3, 5-difluorobenzy1) -3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N^5-(2-furylmethyl)-N^5-
methylpentanediamide;
      N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[(4-ethylpyridin-2-
yl) methyl] amino}-2-hydroxypropyl)-5-methyl-N3, N3-
dipropylisophthalamide;
      N^4-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-6-methyl-
N<sup>2</sup>, N<sup>2</sup>-dipropylpyridine-2, 4-dicarboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2,2-dimethylchromane-7-
carboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2,2-dimethylchromane-6-
carboxamide:
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-1,3-benzoxazole-4-
carboxamide:
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-propyl-1,3-benzoxazole-4-
carboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4-{[(2R)-2-
(methoxymethyl)pyrrolidin-1-yl]sulfonyl}benzamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-{dihydroxy[(2S)-2-
(hydroxymethyl)pyrrolidin-1-yl]-lambda4-sulfanyl}benzamide;
      1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-N-4)]}
ethylbenzyl)amino]-2-hydroxypropyl}-1H-indole-6-carboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-1-propyl-1H-indole-6-
carboxamide;
      1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-N-4)]}
ethylbenzyl)amino]-2-hydroxypropyl}-1H-indole-5-carboxamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-[4-(2-hydroxyethyl)-1,3-
oxazol-2-yl]benzamide;
     N^{1}-{ (1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-
isopropylbenzyl)amino]propyl}-N³,N³-dipropyl-5-(1,3-thiazol-2-
```

```
yl) isophthalamide;
          N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-
isopropylbenzyl)amino]propyl}-N3,N3-dipropyl-5-(1,3-thiazol-2-
yl) isophthalamide;
          N^{1}-((15,2R)-1-(3,5-difluorobenzyl)-3-{[(4-ethylpyridin-2-...
yl)methyl]amino}-2-hydroxypropyl)-5-(1,3-oxazol-2-yl)-\mathbb{N}^3, \mathbb{N}^3-
dipropylisophthalamide;
          N-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{(1-(3-
ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-4-
(ethoxymethyl)benzamide;
           1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-difluorobenzyl)]}
ethylbenzyl)amino]-2-hydroxypropyl}indoline-6-carboxamide;
           3-[(tert-butylamino)sulfonyl]-N-{(1S,2R)-1-(3,5-)}
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}benzamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-2,3-dihydro-1,4-
benzodioxine-6-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2R)-2-
(hydroxymethyl)pyrrolidin-1-yl]sulfonyl)benzamide;
           N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-N3,N3-dipropyl-5-pyridin-4-
ylisophthalamide;
          N^{1}-butyl-N^{3}-{ (1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethynylbenzyl) amino] -2-hydroxypropyl} -N^1, 5-
dimethylisophthalamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-\{(3-1)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-\{(3-1)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-\{(3-1)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-\{(3-1)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-\{(3-1)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-\{(3-1)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-\{(3-1)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-\{(3-1)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-\{(3-1)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-\{(3-1)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-\{(3-1)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-\{(3-1)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-\{(3-1)-(3-
isopropylbenzyl)amino]propyl}-3-{[(2R)-2-
(methoxymethyl)pyrrolidin-1-yl]carbonyl}-5-methylbenzamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethynylbenzyl)amino]-2-hydroxypropyl}-3-{[(2R)-2-
(methoxymethyl)pyrrolidin-1-yl]carbonyl}-5-methylbenzamide;
           3-(1-butyl-1H-pyrazol-4-yl)-N-{(1S,2R)-1-(3,5-1)}
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl }propanamide;
           N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-3-{[(2R)-2-
(methoxymethyl)pyrrolidin-1-yl]carbonyl}-5-methylbenzamide;
           1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-N-4)]}
ethylbenzyl)amino]-2-hydroxypropyl}-1H-indazole-6-carboxamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-thien-2-yl-1,3-thiazole-
4-carboxamide;
           5-(aminosulfonyl)-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-
[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1-methyl-1H-pyrrole-2-
carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-{[(2-
furylmethyl)sulfonyl]methyl}-1,3-thiazole-4-carboxamide;
```

```
N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-{[(4-
fluorobenzyl)sulfonyl]methyl}-1,3-thiazole-4-carboxamide;
      1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-N-4)]}
ethylbenzyl)amino]-2-hydroxypropyl}-4-
[methyl (methyl sulfonyl) amino] -1H-indole-6-carboxamide;
     N-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-{[1-(3-
ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-4-(2-
methoxyethyl) benzamide;
     N^{1}-butyl-N^{3}-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
[(1-phenylcyclopropyl)amino]propyl}-N<sup>1</sup>-methyl-5-(1,3-thiazol-2-
vl)isophthalamide;
     N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(1-
phenylcyclopropyl)amino]propyl}-5-(1,3-oxazol-2-yl)-N<sup>3</sup>,N<sup>3</sup>-
dipropylisophthalamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4-
[(ethylamino)sulfonyl]benzamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-
[(methylamino)sulfonyl]benzamide;
      (2E) -3 - (1-butyl-1H-pyrazol-4-yl) -N-{(1S, 2R) -1-(3, 5-)}
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}prop-
2-enamide or (2E)-3-(1-butyl-1H-pyrazol-4-yl)-N-{(1S,2R)-1-}
(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}prop-2-enamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}isoquinoline-7-carboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-
(propylamino) isoquinoline-7-carboxamide or N-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1-
(propylamino) isoquinoline-7-carboxamide;
      N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-2-hydroxy-3-[(3-1)]
isopropylbenzyl)amino]propyl}-5-{[(2-hydroxy-1,1-
dimethylethyl)amino]sulfonyl}-N3,N3-dipropylisophthalamide;
      methyl 3-(2-{3-[({(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}amino)carbonyl]phenyl}-1,3-
oxazol-5-yl)propanoate;
      3-(2-{3-[({(1s,2R)-1-(3,5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}amino)carbonyl]phenyl}-1,3-
oxazol-5-yl)propanoic acid;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-(3-hydroxypropyl)-1H-
indole-6-carboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-ethoxybenzamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-6-(pyrrolidin-1-
ylcarbonyl) isonicotinamide;
```

```
N^{1}-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-{[(6-ethylpyridin-2-
yl)methyl]amino}-2-hydroxypropyl)-5-methyl-N3,N3-
dipropylisophthalamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-3-
[(dipropylamino)sulfonyl]benzamide;
            N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[(6-ethylpyridin-2-
y1) methy1] amino}-2-hydroxypropy1)-5-(1,3-oxazo1-2-y1)-\mathbb{N}^3, \mathbb{N}^3-
dipropylisophthalamide;
             tert-butyl (1R)-1-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-}
[(3-ethylbenzyl)amino]-2-hydroxypropyl}amino)carbonyl]-3-
 (methylsulfinyl)propylcarbamate;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-
 (dipropylamino) isonicotinamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-
 (dipropylamino) isonicotinamide;
              (2R) - 2 - amino - N - \{(1S, 2R) - 1 - (3, 5 - diffluor obenzyl) - 3 - [(3 - 2R) - 1 - (3, 5 - diffluor obenzyl) - 3 - [(3 - 2R) - 1 - (3, 5 - diffluor obenzyl)] - 3 - [(3 - 2R) - 1 - (3, 5 - diffluor obenzyl)] - 3 - [(3 - 2R) - 1 - (3, 5 - diffluor obenzyl)] - 3 - [(3 - 2R) - 1 - (3, 5 - diffluor obenzyl)] - 3 - [(3 - 2R) - 1 - (3, 5 - diffluor obenzyl)] - 3 - [(3 - 2R) - 1 - (3, 5 - diffluor obenzyl)] - 3 - [(3 - 2R) - 1 - (3, 5 - diffluor obenzyl)] - 3 - [(3 - 2R) - 1 - (3, 5 - diffluor obenzyl)] - 3 - [(3 - 2R) - 1 - (3, 5 - diffluor obenzyl)] - 3 - [(3 - 2R) - 1 - (3, 5 - diffluor obenzyl)] - 3 - [(3 - 2R) - 1 - (3, 5 - diffluor obenzyl)] - 3 - [(3 - 2R) - (3 - 2R) - (3 - 2R) - (3 - 2R)]] - 3 - [(3 - 2R) - (3 - 2R) - (3 - 2R) - (3 - 2R)]]
ethylbenzyl)amino]-2-hydroxypropyl}-4-
 (methylsulfinyl)butanamide;
             N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-
 {[ethyl(methyl)amino]sulfonyl}-5-{[(2S)-2-
 (methoxymethyl)pyrrolidin-1-yl]carbonyl}benzamide;
             N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-1-
 [methyl(propyl)amino]isoquinoline-7-carboxamide or N-{(1S,2R)-
1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}-1-[methyl(propyl)amino]isoquinoline-7-
carboxamide;
             N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(1,3-oxazol-2-
yl)benzamide;
             N^{1}-[(1S,2R)-3-{[1-(3-bromophenyl)cyclopropyl]amino}-1-
 (3,5-difluorobenzyl)-2-hydroxypropyl]-5-(1,3-oxazol-2-yl)-
N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
             N^{1}-[(1S,2R)-3-{[1-(3-bromophenyl)cyclopropyl]amino}-1-
 (3,5-difluorobenzyl)-2-hydroxypropyl]-5-(1,3-oxazol-2-yl)-
N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
             N^5 - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - [(3 - 3)] \}
 ethylbenzyl)amino]-2-hydroxypropyl}-N3,N3-dipropyl-1H-pyrazole-
 3,5-dicarboxamide;
             N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - [ (3 - 3) - 3 - (3 - 3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3)
ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>2</sup>,N<sup>2</sup>-dipropylcyclobutane-
 1,2-dicarboxamide;
             N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-3-
 [(dipropylamino)carbonothioyl]benzamide;
              3-[(E)-(cyanoimino)(dipropylamino)methyl]-N-{(1S,2R)-1-
 (3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
```

```
hydroxypropyl}benzamide;
      N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(6-
isopropyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-
yl)amino]propyl}-5-methyl-N³,N³-dipropylisophthalamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mu)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-(1-
propylbutoxy) benzamide;
      N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[(5-ethylpyridin-3-
yl) methyl] amino}-2-hydroxypropyl)-5-(1,3-oxazol-2-yl)-N^3,N^3-
dipropylisophthalamide;
      N^{1}-{(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-[(6-
isopropyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-
yl)amino]propyl}-5-methyl-N³,N³-dipropylisophthalamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-(2-methoxyethyl)-1H-
indole-6-carboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{(3-4)\}
ethylbenzyl)amino]-2-hydroxypropyl}-3,4-dihydro-2H-1,4-
benzoxazine-6-carboxamide:
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2S)-2-
(methoxymethyl)pyrrolidin-1-yl]carbonyl}-5-{[(2R)-2-
(methoxymethyl)pyrrolidin-1-yl]sulfonyl}benzamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4-(1,3-thiazol-2-
yl)benzamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-4,8-diethoxyquinoline-2-
carboxamide;
      2-(4-butyl-3-oxopiperazin-1-yl)-N-{(1S,2R)-1-(3,5-1)}
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}acetamide;
      N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - [(3 - 3) - 3] \}
ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>3</sup>-[2-
(dimethylamino) ethyl] -N<sup>3</sup>, 5-dimethylisophthalamide;
      N^{1}-{ (1S, 2R) -1- (3, 5-difluorobenzyl) -2-hydroxy-3-[(3-
methylbutanoyl)amino]propyl}-5-methyl-N3,N3-
dipropylisophthalamide:
      N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(4-
methylpentanoyl)amino]propyl}-5-methyl-N3,N3-
dipropylisophthalamide;
      isobutyl (2R,3S)-4-(3,5-difluorophenyl)-3-({3-}
[(dipropylamino)carbonyl]-5-methylbenzoyl}amino)-2-
hydroxybutylcarbamate;
      ethyl (2R,3S)-4-(3,5-difluorophenyl)-3-({3-}
[(dipropylamino)carbonyl]-5-methylbenzoyl}amino)-2-
hydroxybutylcarbamate;
      N^{1}-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-(pyrimidin-
2-ylamino)propyl]-5-methyl-N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
      N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [(3 - 3) - 3] \}
```

ethylbenzyl) amino] -2-hydroxypropyl} -5-methyl $-N^3$ -[(1S)-1-methylpropyl] isophthalamide;

- $N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-5-methyl-N^3-[(1R)-1-methylpropyl]isophthalamide;$
- N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(dipropylamino)-6-methylpyrimidine-4-carboxamide;
- 1-[butyl(methyl)amino]-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}isoquinoline-7-carboxamide or 1-[butyl(methyl)amino]-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}isoquinoline-7-carboxamide;
- N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1,3-dihydro-2-benzothiophene-5-carboxamide 2,2-dioxide;
- N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-3-{[(2R)-2-(methoxymethyl)pyrrolidin-1-yl]carbonyl}-5-methylbenzamide;
- N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-3-{[(2R)-2-(methoxymethyl)pyrrolidin-1-yl]carbonyl}-5-methylbenzamide trifluoroacetate;
- N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1-isobutyl-1H-indole-6-carboxamide;
- 1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-(2,5-dimethyl-1H-pyrrol-1-yl)-1H-indole-6-carboxamide;
- 1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-methyl-1H-indole-6-carboxamide;
- N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-oxo-2-propyl-2,3-dihydro-1,2-benzisothiazole-6-carboxamide 1,1-dioxide;
- 1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-(1,3-oxazol-2-yl)-1H-indole-6-carboxamide;
- N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(dipropylamino)-6-methylisonicotinamide;
- N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-[(methylsulfonyl)methyl]-1,3-thiazole-4-carboxamide;
- 4-amino-1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1H-indole-6-carboxamide;
- N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-ethyl-3-oxo-2,3-dihydro-1,2-benzisothiazole-6-carboxamide 1,1-dioxide;
- 3-[(tert-butylamino)sulfonyl]-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-

```
{[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]carbonyl}benzamide;
                       3-\{[(2S)-2-butylpyrrolidin-1-yl]carbonyl\}-N-\{(1S,2R)-1-yl]carbonyl}
 (3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-
 5-methylbenzamide;
                       4-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-3,4-dihydro-2H-1,4-
benzoxazine-6-carboxamide;
                      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-{[(2R)-2-
 (propoxymethyl)pyrrolidin-1-yl]carbonyl}benzamide;
                       2-(1-buty1-2-oxopiperidin-4-y1)-N-{(1S,2R)-1-(3,5-1)}
 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
 hydroxypropyl}acetamide;
                       N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-3-pentylbenzamide;
                       N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-ethylhexyl)benzamide;
                       ethyl 5-{3-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}amino)carbonyl]phenyl}-2-
 furoate;
                       N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-1,1'-biphenyl-3-
 carboxamide;
                       N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
  ethylbenzyl)amino]-2-hydroxypropyl}-2'-(methylthio)-1,1'-
 biphenyl-3-carboxamide;
                       N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
  ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-
  fluorobenzyl)benzamide;
                       N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
  ethylbenzyl)amino]-2-hydroxypropyl}-3-(4-
  fluorobenzyl) benzamide;
                        ethyl 3'-[({(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
  ethylbenzyl)amino]-2-hydroxypropyl}amino)carbonyl]-1,1'-
  biphenyl-2-carboxylate;
                        N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
  ethylbenzyl)amino]-2-hydroxypropyl}-3',5'-difluoro-1,1'-
  biphenyl-3-carboxamide;
                        N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
  ethylbenzyl)amino]-2-hydroxypropyl}-2-phenylacetamide;
                         tert-butyl 4-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
  ethylbenzyl)amino]-2-
  hydroxypropyl amino) carbonyl] benzylcarbamate;
                          (2R) - N - \{(1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - \{(3 - 3, 5 - difluorobenzy1) - (3 - 3, 5 - difluorobenzy1) - (3 - 3, 5 - difluorobenzy1) - (3 - 3
  ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-2-
  phenylethanamide;
                          (2S) -N - \{(1S, 2R) - 1 - (3, 5 - diffluor obenzyl) - 3 - [(3 - 2R) - 1 - (3, 5 - diffluor obenzyl) - 3 - [(3 - 2R) - 1 - (3, 5 - diffluor obenzyl)] - 3 - [(3 - 2R) - 1 - (3, 5 - diffluor obenzyl)] - 3 - [(3 - 2R) - 1 - (3, 5 - diffluor obenzyl)] - 3 - [(3 - 2R) - 1 - (3, 5 - diffluor obenzyl)] - 3 - [(3 - 2R) - 1 - (3, 5 - diffluor obenzyl)] - 3 - [(3 - 2R) - 1 - (3, 5 - diffluor obenzyl)] - 3 - [(3 - 2R) - 1 - (3, 5 - diffluor obenzyl)] - 3 - [(3 - 2R) - 1 - (3, 5 - diffluor obenzyl)] - 3 - [(3 - 2R) - 1 - (3, 5 - diffluor obenzyl)] - 3 - [(3 - 2R) - 1 - (3, 5 - diffluor obenzyl)] - 3 - [(3 - 2R) - 1 - (3, 5 - diffluor obenzyl)] - 3 - [(3 - 2R) - (3 - 2R) - (3 - 2R) - (3 - 2R)]] - [(3 - 2R) - (3 - 2R) - (3 - 2R) - (3 - 2R)]] - [(3 - 2R) - (3 - 2R) - (3 - 2R) - (3 - 2R)]] - [(3 - 2R) - (3 - 2R) - (3 - 2R) - (3 - 2R)]]
  ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-2-
  phenylethanamide;
                         3-(5-\text{chloropentyl})-N-\{(1S,2R)-1-(3,5-\text{difluorobenzyl})-3-(5-\text{difluorobe
```

```
[(3-ethylbenzyl)amino]-2-hydroxypropyl}benzamide;
               N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-(1-phenylethyl)benzamide
trifluoroacetate;
                3-(cyclohexylmethyl)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-}
[(3-ethylbenzyl)amino]-2-hydroxypropyl}benzamide;
                3-\text{cyclopentyl-N-}\{(1S,2R)-1-(3,5-\text{difluorobenzyl})-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}benzamide;
               N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-hex-5-enylbenzamide;
                3-(6-cyanohexyl)-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-a)]
ethylbenzyl)amino]-2-hydroxypropyl}benzamide;
               N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[3-(2-formylthien-3-
yl)benzyl]amino}-2-hydroxypropyl)-5-methyl-N3,N3-
dipropylisophthalamide;
                N^{1}-((1S, 2R)-1-(3,5-difluorobenzyl)-3-{[3-(5-formylthien-3-
yl)benzyl]amino}-2-hydroxypropyl)-5-methyl-N3,N3-
dipropylisophthalamide;
                N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[3-(6-
methoxypyridin-2-yl)benzyl]amino}propyl)-5-methyl-N3,N3-
 dipropylisophthalamide;
                N^{1}-[(1S, 2R)-3-\{[3-(5-cyanopyridin-3-yl)benzyl]amino\}-1-
 (3,5-difluorobenzyl)-2-hydroxypropyl]-5-methyl-N<sup>3</sup>,N<sup>3</sup>-
 dipropylisophthalamide;
                N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[3-(6-fluoropyridin-
 3-y1) benzyl] amino}-2-hydroxypropyl)-5-methyl-N^3, N^3-
 dipropylisophthalamide;
                N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-
 pyrimidin-4-ylbenzyl) amino] propyl\}-5-methyl-\mathbb{N}^3, \mathbb{N}^3-
 dipropylisophthalamide;
                N^{1}-((1S, 2R)-1-(3,5-difluorobenzyl)-3-{[3-(5-
 ethylpyrimidin-2-yl)benzyl]amino}-2-hydroxypropyl)-5-methyl-
 N^3, N^3-dipropylisophthalamide;
                N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-
 pyrimidin-2-ylbenzyl)amino]propyl}-5-methyl-N<sup>3</sup>,N<sup>3</sup>-
 dipropylisophthalamide;
                methyl 2-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}amino)carbonyl]-6-
 methylisonicotinate;
                N^4 - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - [ (3 - 3) - 3 - 3] \}
 ethylbenzyl)amino]-2-hydroxypropyl}-6-methyl-N^2, N^2-
 dipropylpyridine-2,4-dicarboxamide 1-oxide;
                 1-butyl-4-cyano-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-4-cyano-N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-4-cyano-N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-4-cyano-N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-4-cyano-N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-4-cyano-N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-4-cyano-N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-4-cyano-N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-4-cyano-N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-4-cyano-N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-4-cyano-N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-4-cyano-N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-4-cyano-N-(1S,2R)-1-(3-butyl-4-cyano
 ethylbenzyl)amino]-2-hydroxypropyl}-1H-indole-6-carboxamide;
                 1-butyl-4-cyano-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-4-cyano-N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-4-cyano-N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-4-cyano-N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-4-cyano-N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-4-cyano-N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-4-cyano-N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-4-cyano-N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-4-cyano-N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-4-cyano-N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-4-cyano-N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-4-cyano-N-(1S,2R)-1-(3-butyl-4-
 ethylbenzyl)amino]-2-hydroxypropyl}-1H-indole-6-carboxamide;
                 5-(diethylamino)-N^1-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-N3,N3-
```

 $N^{1}-[(1S, 2R)-3-\{[3-(diethylamino)benzyl]amino\}-1-(3, 5-$ 

dipropylisophthalamide;

```
difluorobenzyl) -2-hydroxypropyl] -5-(1,3-oxazol-2-yl) -N^3, N^3-
dipropylisophthalamide;
               N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-(dimethylamino)-N3,N3-
dipropylisophthalamide;
               N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[(2-ethylpyridin-4-
v1) methyl amino -2-hydroxypropyl) -5-(1, 3-oxazol -2-yl) -N^3, N^3-
dipropylisophthalamide;
               N^2-(tert-butoxycarbonyl)-N^1-{(1S, 2R)-1-(3, 5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-L-
norleucinamide;
               N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-[(3H-[1,2,3]triazolo[4,5-
b]pyridin-3-yloxy)methyl]benzamide;
                N-\{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-max)-1-(3,5-di
 iodobenzyl)amino]propyl}-3-{[(2-
hydroxyethyl) (propyl) amino] methyl}-5-methylbenzamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-[(3-1)]
 iodobenzyl)amino]propyl}-3-{[ethyl(propyl)amino]methyl}-5-
methylbenzamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-1-methyl-1,3-dihydro-2,1-
 benzisothiazole-5-carboxamide 2,2-dioxide;
                N^{1}-{ (1s, 2r) -1-(3,5-difluorobenzyl) -3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-L-norleucinamide;
                N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[3-
 (dimethylamino)benzyl]amino}-2-hydroxypropyl)-5-(1,3-oxazol-2-
 y1)-N^3,N^3-dipropylisophthalamide;
                 2-chloro-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-difluorobenzyl)
 ethylbenzyl)amino]-2-hydroxypropyl}-6-methylisonicotinamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-[(3-mu)]
 iodobenzyl)amino]propyl}-3-{[(2-
 hydroxyethyl) (propyl) amino] methyl} benzamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-2-(3-fluoro-4-
 propoxyphenyl)acetamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mathemathem)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-(3-methoxy-4-
 propoxyphenyl) acetamide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-[(3-1)]
 iodobenzyl)amino]propyl}-3-methyl-5-
  {[methyl(propyl)amino]methyl}benzamide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-[(3-1)]
  iodobenzyl)amino]propyl}-3-[(dipropylamino)methyl]-5-
 methylbenzamide;
                  3-\{[butyl(methyl)amino]methyl\}-N-\{(1S,2R)-1-(3,5-1)\}
  difluorobenzyl)-2-hydroxy-3-[(3-iodobenzyl)amino]propyl}-5-
 methylbenzamide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mathemathem)]
  ethylbenzyl)amino]-2-hydroxypropyl}-4-(piperidin-1-
```

```
ylsulfonyl) benzamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-[(6-4)]
isopropyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-
yl)amino]propyl}-3-methylbenzamide;
          N-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-{[1-(3-
ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-4-(3-
methoxypropyl)benzamide;
           5-amino-N^1-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-amino-N^1-(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-amino-N^1-(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-amino-N^1-(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-amino-N^1-(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-amino-N^1-(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-amino-N^1-(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-amino-N^1-(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-amino-N^1-(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-amino-N^1-(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-amino-N^1-(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-amino-N^1-(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-amino-N^1-(1S,2R)-1-(3-amino
ethylbenzyl)amino]-2-hydroxypropyl}-N3,N3-
dipropylisophthalamide;
          N^{1}-[(1S, 2R)-1-(3, 5-difluorobenzyl)-3-({3-
[(dimethylamino)methyl]benzyl}amino)-2-hydroxypropyl]-5-(1,3-
oxazol-2-yl)-N3,N3-dipropylisophthalamide;
           N-(tert-butoxycarbonyl)-3-butyl-N-{(1S,2R)-1-(3,5-
difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-L-
histidinamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-isopentyl-1H-indole-6-
carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-propyl-2,3-dihydro-1,2-
benzisothiazole-6-carboxamide 1,1-dioxide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-ethyl-2,3-dihydro-1,2-
benzisothiazole-6-carboxamide 1,1-dioxide;
           6-bromo-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2,2-dimethylchromane-8-
carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4-
 [(methylsulfonyl)methyl]cyclohexanecarboxamide;
           N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-piperidin-4-yl-N3,N3-
dipropylisophthalamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-(1,3-oxazol-2-
yl)benzamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-
 [(methylsulfonyl)methyl]thiophene-2-carboxamide;
            3-[(cyclohexylamino)methyl]-N-{(1S,2R)-1-(3,5-
difluorobenzyl)-2-hydroxy-3-[(3-iodobenzyl)amino]propyl}-5-
methylbenzamide;
            2-(2-chlorophenoxy)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-}
 [(3-ethylbenzyl)amino]-2-hydroxypropyl}acetamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}pyrazine-2-carboxamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-3-
 (phenylsulfonyl) propanamide;
```

```
N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-[(2S)-2-
(methoxymethyl)pyrrolidin-1-yl]-6-methylisonicotinamide;
          3-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}amino)carbonyl]-5-
methylbenzoic acid;
           6-cyano-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-a)]
ethylbenzyl)amino]-2-hydroxypropyl}-2,2-dimethylchromane-8-
carboxamide;
          N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-(1,3-thiazol-2-
yl)benzamide;
           formic acid compound with N-{(1S, 2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(4-
ethoxyphenyl)acetamide (1:1);
           formic acid compound with N-{(1S, 2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-
methy1-5-{[(2S)-2-propylpyrrolidin-1-yl]carbonyl}benzamide
(1:1);
          N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2R)-2-(2-
methoxyethyl)pyrrolidin-1-yl]carbonyl}-5-methylbenzamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4-
[(methylsulfonyl)methyl]cyclohexanecarboxamide;
           3-butyl-N-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-butyl-N-4)]}
ethylbenzyl)amino]-2-hydroxypropyl}-1-methyl-1H-indole-5-
carboxamide;
           formic acid compound with 2-(1-butyl-2-oxo-1,2-
dihydropyridin-4-y1)-N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-dif
ethylbenzyl)amino]-2-hydroxypropyl}acetamide (1:1);
           3-butyl-N-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzyl)]}
ethylbenzyl)amino]-2-hydroxypropyl}-L-histidinamide;
           5-[(diethylamino)methyl]-N^1-\{(1S, 2R)-1-(3, 5-1)\}
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-
N^3, N^3-dipropylisophthalamide;
           N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-[(dimethylamino)methyl]-
N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
           N-\{(1S, 2R)-3-[(3-ethylbenzyl)amino]-1-[3-expression -1] \}
(hexyloxy)benzyl]-2-hydroxypropyl}-3-(1,3-oxazol-2-
yl)benzamide;
           formic acid compound with N-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(3-
hydroxy-4-methoxyphenyl)acetamide (1:1);
           formic acid compound with N-\{(1S,2R)-1-(3,5-1)\}
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-
(1,3-thiazolidin-3-ylsulfonyl)benzamide (1:1);
           formic acid compound with N-\{(1S,2R)-1-(3,5-1)\}
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-
```

```
(3,4-dihydroisoguinolin-2(1H)-ylsulfonyl)benzamide (1:1);
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4-[(4-phenylpiperazin-1-
yl)sulfonyl]benzamide;
      3-butvl-N-\{(1S,2R)-1-(3,5-difluorobenzvl)-3-[(3-butvl-N-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-1H-indole-5-carboxamide;
     N-\{(1S, 2R) -3 - [(3-ethylbenzyl)amino] -1 - [3-ethylbenzyl)amino] -1 - [3-ethylbenzyl]
(hexyloxy)benzyl]-2-hydroxypropyl)acetamide;
      1-butyl-N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-1)]}
ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-1H-
benzimidazole-6-carboxamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-mathemathem)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-
[(methylsulfonyl)methyl]nicotinamide;
      N^{1}-[(1S, 2R)-3-({3-[(diethylamino)methyl]benzyl}amino)-1-
(3,5-difluorobenzyl)-2-hydroxypropyl]-5-(1,3-oxazol-2-yl)-
N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-[1-methyl-5-(4-
methylbenzoyl)-1H-pyrrol-2-yl]acetamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(dipropylamino)-6-(1,3-
oxazo1-2-yl)isonicotinamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzyl)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-6-(1,3-oxazol-2-
yl) isonicotinamide;
      1-butyl-N-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-{[1-(3-
ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-1H-
benzimidazole-5-carboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-[(6-
isopropyl-2, 2-dioxido-3, 4-dihydro-1H-isothiochromen-4-
yl)amino]propyl}-3-methylbenzamide;
      N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-piperidin-3-yl-N3,N3-
dipropylisophthalamide;
      3-\{[benzyl(methyl)amino]methyl\}-N-\{(1S,2R)-1-(3,5-
difluorobenzyl)-2-hydroxy-3-[(3-iodobenzyl)amino]propyl}-5-
methylbenzamide;
      formic acid compound with N-{(1S, 2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-
{[4-(4-fluorophenyl)piperazin-1-yl]sulfonyl}benzamide (2:1);
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(pyrrolidin-1-
ylsulfonyl) benzamide;
      formic acid compound with N-\{(1S,2R)-1-(3,5-1)\}
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-
(pyrrolidin-1-ylsulfonyl)benzamide (1:1);
      formic acid compound with N-\{(1S,2R)-1-(3,5-1)\}
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-
({4-[3-(trifluoromethyl)phenyl]piperazin-1-
```

```
yl}sulfonyl)benzamide (2:1);
     N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4-
[(dimethylamino)sulfonyl]benzamide;
      formic acid compound with N-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-
[(dimethylamino)sulfonyl]benzamide (1:1);
     N-\{(1S, 2R)-3-[(3-ethylbenzyl)amino]-1-[3-ethylbenzyl)amino]
(hexyloxy)benzyl]-2-hydroxypropyl}-2-[(methylsulfonyl)amino]-
1,3-oxazole-4-carboxamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-6-
[(methylsulfonyl)methyl]nicotinamide;
     N-[(1S, 2R)-3-[(3-bromobenzy1)amino]-1-(3, 5-
difluorobenzyl) -2-hydroxypropyl]-4-methylpentanamide;
      1-butvl-N-\{(1S,2R)-1-(3,5-difluorobenzvl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-1H-pyrrole-2-
carboxamide;
     N^{1}-{ (1S, 2R) -1- (3, 5-difluorobenzyl) -2-hydroxy-3-[(1H-
pyrrol-2-ylmethyl)amino]propyl}-5-methyl-N3,N3-
dipropylisophthalamide;
     N^{1}-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-piperazin-1-yl-N^3, N^3-
dipropylisophthalamide;
      N-[(1S,2R)-3-[(3-bromobenzy1)amino]-1-(3,5-
difluorobenzyl)-2-hydroxypropyl]acetamide;
      N^2 - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 3) - 3 - 3] \}
ethylbenzyl)amino]-2-hydroxypropyl}-6-methyl-N4,N4-
dipropylpyridine-2,4-dicarboxamide;
      N^2-(tert-butoxycarbonyl)-N^1-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-D-
norleucinamide;
      N^{1}-{(1s, 2r)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-D-norleucinamide;
      N-((1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-{((4R)-6-
isopropyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-
yl]amino}propyl)acetamide;
      N-((1s, 2r)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-{[(4s)-6-
isopropyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-
yl]amino}propyl)acetamide;
      formic acid compound with 4-{[(4-
chlorophenyl) (methyl) amino] sulfonyl}-N-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}benzamide (1:1);
      formic acid compound with 4-
{[benzyl(phenyl)amino]sulfonyl}-N-{(1S, 2R)-1-(3, 5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}benzamide (1:1);
      formic acid compound with N-\{(1S,2R)-1-(3,5-1)\}
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-
```

```
(morpholin-4-ylsulfonyl)benzamide (1:1);
               N-[(1S, 2R)-3-[(3-bromobenzyl)amino]-1-(3, 5-
difluorobenzyl)-2-hydroxypropyl]propanamide;
               N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-\{(3-1)-1, (3-1)-1
ethylbenzyl)amino]-2-hydroxypropyl}-2-(3-oxo-4-
propylcyclohexyl)acetamide;
               N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(3-
oxocyclohexyl) acetamide;
               N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-1,1-dipropyl-3,4-dihydro-
1H-isochromene-7-carboxamide;
                formic acid compound with 4-{[(2-
cyanoethyl) (methyl) amino] sulfonyl}-N-{(1S, 2R)-1-(3, 5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}benzamide (1:1);
                formic acid compound with 4-
 \{[\text{cyclohexyl}(\text{methyl}), \text{amino}] \text{ sulfonyl}\}-N-\{(1S, 2R), -1-(3, 5-1), (1S, 2R), -1-(3, 5-1), (1S, 2R), (1S
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}benzamide (1:1);
                formic acid compound with N-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-
 {[methyl(2-pyridin-2-ylethyl)amino]sulfonyl}benzamide (2:1);
                formic acid compound with N-\{(1S, 2R)-1-(3, 5-1)\}
 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-
 {[methyl(phenyl)amino]sulfonyl}benzamide (1:1);
                formic acid compound with 4-
 { [benzyl (methyl) amino] sulfonyl}-N-{ (1S, 2R)-1-(3, 5-1)
 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
 hydroxypropyl}benzamide (1:1);
                formic acid compound with N-\{(1S,2R)-1-(3,5-
 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-
 {[methyl(2-phenylethyl)amino]sulfonyl}benzamide (1:1);
                formic acid compound with 4-
 \{[allyl(methyl)amino]sulfonyl\}-N-\{(1S, 2R)-1-(3, 5-
 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
 hydroxypropyl}benzamide (1:1);
                 formic acid compound with 4-{[[2-
 (diethylamino)ethyl] (methyl)amino]sulfonyl}-N-{(1S,2R)-1-(3,5-
 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
 hydroxypropyl}benzamide (2:1);
                 formic acid compound with N-\{(1S, 2R)-1-(3, 5-1)\}
 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-
 {[methyl(propyl)amino]sulfonyl}benzamide (1:1);
                 formic acid compound with 4-
 { [butyl (methyl) amino] sulfonyl} -N-\{(1S, 2R)-1-(3, 5-1)\}
 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
 hydroxypropyl}benzamide (1:1);
                 formic acid compound with N-\{(1S, 2R)-1-(3, 5-1)\}
 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-
  { [methyl (pentyl) amino] sulfonyl} benzamide (1:1);
```

```
formic acid compound with N-\{(1S,2R)-1-(3,5-1)\}
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-
{[isopentyl(methyl)amino]sulfonyl}benzamide (1:1);
               2-buty1-N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-difluorobenzy1)-
ethylbenzyl)amino]-2-hydroxypropyl}-1,2,3,4-
tetrahydroisoquinoline-7-carboxamide;
               formic acid compound with N-{(1S, 2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-
{[methyl(1-methylpyrrolidin-3-yl)amino]sulfonyl}benzamide
(2:1);
               N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(4-ethylpyridin-
2-yl)cyclopropyl]amino}-2-hydroxypropyl)-5-(1,3-oxazol-2-yl)-
N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
               N-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{[1-(3-
ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-3-(2-
methoxyethyl)benzamide;
                1-butyl-N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-1)]}
ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-2-(2-
methoxyethyl)-1H-benzimidazole-6-carboxamide;
                L-alpha-glutamyl-L-valyl-N^1-\{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-L-
methioninamide:
                3-\{[cyclohexyl(methyl)amino]methyl\}-N-\{(1S,2R)-1-(3,5-1)\}
difluorobenzyl)-2-hydroxy-3-[(3-iodobenzyl)amino]propyl}-5-
methylbenzamide;
                N-\{(1S, 2R)-1-(3-butoxybenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}acetamide;
                formic acid compound with 2-(4-butyl-2,5-dioxopiperazin-
 1-y1)-N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}acetamide (1:1);
                3-bicyclo[2.2.1]hept-2-yl-N-{(1S, 2R)-1-(3, 5-
 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
 hydroxypropyl}benzamide;
                3 - (butylamino) - N - ((1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - ([1 - (3, 5 - difluorobenzyl) - 3 - ([1 - (3, 5 - difluorobenzyl) - (3, 5 - difluorobenzyl) - ([1 - (3, 5 - difluoroben
 (3-ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-4-(2-
 methoxyethyl)benzamide;
                N-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-{[1-(3-
 ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-2-
 (dipropylamino)-6-(1,3-oxazol-2-yl)isonicotinamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-[(1S)-1]
 1,2,3,4-tetrahydronaphthalen-1-ylamino]propyl}-3-
 methylbenzamide;
                formic acid compound with N-\{(1S, 2R)-1-(3, 5-1)\}
 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-
 [(dipropylamino)sulfonyl]benzamide (1:1);
                 formic acid compound with 4-[(diethylamino)sulfonyl]-N-
 {(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
 hydroxypropyl}benzamide (1:1);
                 4-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-difluorobenzyl)]}
```

ethylbenzyl)amino]-2-hydroxypropyl}-1-(methylsulfonyl)-1,2,3,4-

tetrahydroquinoxaline-6-carboxamide;

- 1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}isoquinoline-7-carboxamide;
- 5-{[butyl(methyl)amino]methyl}-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}thiophene-2-carboxamide;
- 3-{[butyl(methyl)amino]methyl}-N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-methylbenzamide;
- 3-{[butyl(methyl)amino]methyl}-N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[3-(trifluoromethyl)benzyl]amino}propyl)-5-methylbenzamide;
- $3-bromo-5-\{[butyl(methyl)amino]methyl\}-N-((1S,2R)-1-(3,5-difluorobenzyl)-3-\{[1-(3-ethynylphenyl)cyclopropyl]amino\}-2-hydroxypropyl)benzamide;$
- 3-{[butyl(methyl)amino]methyl}-N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-methylbenzamide;
- $(2R)-2-(4-butyl-3-oxopiperazin-1-yl)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}propanamide;$
- $3-\{[butyl(methyl)amino]methyl\}-N-\{(1S,2R)-1-\{3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl\}-5-methylbenzamide;$
- N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(dipropylamino)-6-(1,3-thiazol-2-yl)isonicotinamide;
- N-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-iodobenzyl)amino]propyl}-3-{[isopentyl(methyl)amino]methyl}-5-methylbenzamide;
- $N-\{(1S,2R)-1-(3-butoxybenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1\}-2-[(methylsulfony1)amino]-1,3-oxazole-4-carboxamide;$
- 3-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}imidazo[1,2-a]pyridine-6-carboxamide;
- 2-[butyl(methyl)amino]-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-6-(1,3-oxazol-2-yl)isonicotinamide;
- N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-1,3-benzodioxole-5-carboxamide;
- N- $\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(6-ethyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl)amino]-2-hydroxypropyl}acetamide ;$
- N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(6-ethyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl)amino]-2-hydroxypropyl}acetamide;
- N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-[methyl(propyl)amino]-6-

```
(1,3-oxazol-2-yl)isonicotinamide;
      3-\{[butyl(methyl)amino]methyl\}-N-\{(1S,2R)-1-(3,5-1)\}
difluorobenzy1)-2-hydroxy-3-[(1-
phenylcyclopropyl)amino]propyl}-5-methylbenzamide;
      3-\{[butyl(methyl)amino]methyl\}-N-\{(1S,2R)-1-(3,5-1)\}
difluorobenzyl)-2-hydroxy-3-[(3-isopropylbenzyl)amino]propyl}-
5-methylbenzamide;
     N-[(1S, 2R)-3-\{[1-(3-bromophenyl) cyclopropyl] amino}-1-
(3,5-difluorobenzyl)-2-hydroxypropyl]acetamide;
      3-\{[butyl(methyl)amino]methyl\}-N-((1s,2R)-1-(3,5-
difluorobenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2-
hydroxypropyl)-5-(1,3-oxazol-2-yl)benzamide;
      N-((1S, 2R)-1-(3, 5-difluorobenzy1)-2-hydroxy-3-{[2-
(methylsulfonyl)-1-phenylethyl]amino}propyl)acetamide;
      3 - \{ [buty1 (methy1) amino] methy1 \} - 5 - cyano - N - ((1S, 2R) - 1 - (3, 5 - 1) - (3, 5 - 1) \} 
difluorobenzyl)-3-{[1-(3-ethynylphenyl)cyclopropyl]amino}-2-
hydroxypropyl) benzamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}acetamide;
      N-[(1S, 2R)-1-(3, 5-difluorobenzy1)-2-hydroxy-3-({2-}
[(methylsulfonyl)methyl]benzyl}amino)propyl]acetamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2-
furylmethyl) (methyl) amino]methyl}-5-methylbenzamide;
      N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2-
methoxyethyl) (methyl) amino | methyl | -5 - methylbenzamide;
      3-{[[2-(diethylamino)ethyl](methyl)amino]methyl}-N-
{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}-5-methylbenzamide;
      N-[(1S, 2R) -3 - [(3-bromobenzyl)amino] -1 - (3, 5-
difluorobenzy1)-2-hydroxypropy1]-2-methoxyacetamide;
      formic acid compound with N-\{(1S, 2R)-1-(3, 5-1)\}
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-[4-
(ethoxymethyl)piperidin-1-yl]pentanamide (2:1);
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-oxoindane-5-carboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-hydroxyindane-5-
carboxamide;
      formic acid compound with N-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-(4-
propoxypiperidin-1-yl)acetamide (2:1);
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-
{[isobutyl(methyl)amino]methyl}-5-methylbenzamide;
      formic acid compound with 2-(1-buty1-2-oxopiperidin-4-
y1)-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-
2-hydroxypropyl}acetamide (1:1);
      formic acid compound with 2-(4-butylpiperazin-1-yl)-N-
```

```
\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}acetamide (3:1);
           4-butyl-N-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-butyl-N-4)]}
ethylbenzyl)amino]-2-hydroxypropyl}-3,4-dihydro-2H-1,4-
benzothiazine-6-carboxamide;
          N-((1S,2R)-1-(3,5-difluorobenzy1)-2-hydroxy-3-{[(1R,2S)-1]}
2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}propyl)acetamide;
          2-[(2S)-4-buty1-2-methy1-3-oxopiperazin-1-y1]-N-{(1S,2R)-}
1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}acetamide;
           2-[(2R)-4-butyl-2-methyl-3-oxopiperazin-1-yl]-N-{(1S,2R)-}
1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}acetamide;
          N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(2,3-dioxo-4-
propylpiperazin-1-yl)acetamide;
           4-butyl-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-4)-4-butyl-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-4)-4-butyl-N-(3,5-difluorobenzyl)-3-[(3-4)-4-butyl-N-(3,5-difluorobenzyl)-3-[(3-4)-4-butyl-N-(3,5-difluorobenzyl)-3-[(3-4)-4-butyl-N-(3,5-difluorobenzyl)-3-[(3-4)-4-butyl-N-(3,5-difluorobenzyl)-3-[(3-4)-4-butyl-N-(3,5-difluorobenzyl)-3-[(3-4)-4-butyl-N-(3,5-difluorobenzyl)-3-[(3-4)-4-butyl-N-(3,5-difluorobenzyl)-3-[(3-4)-4-butyl-N-(3,5-difluorobenzyl)-3-[(3-4)-4-butyl-N-(3,5-difluorobenzyl)-3-[(3-4)-4-butyl-N-(3,5-difluorobenzyl)-3-[(3-4)-4-butyl-N-(3,5-difluorobenzyl)-3-[(3-4)-4-butyl-N-(3,5-difluorobenzyl)-3-[(3-4)-4-butyl-N-(3,5-difluorobenzyl)-3-[(3-4)-4-butyl-N-(3,5-difluorobenzyl)-3-[(3-4)-4-butyl-N-(3,5-difluorobenzyl)-3-[(3-4)-4-butyl-N-(3,5-difluorobenzyl-N-(3,5-difluoroben
ethylbenzyl)amino]-2-hydroxypropyl}-1,2,3,4-
tetrahydroguinoxaline-6-carboxamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-
{ [methyl (pentyl) amino] methyl} benzamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2R)-2-
 (methoxymethyl)pyrrolidin-1-yl]methyl}-5-methylbenzamide;
           N-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{[1-(3-
ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-2-
 (dipropylamino) isonicotinamide;
           N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(1-\{4-1\})]
 [(dimethylamino)methyl]pyridin-2-yl}cyclopropyl)amino]-2-
hydroxypropyl\}-5-(1,3-oxazol-2-yl)-N^3,N^3-
dipropylisophthalamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-(dipropylamino)-4-methyl-
1,3-thiazole-5-carboxamide;
           N-[(1S, 2R)-1-(3, 5-difluorobenzy1)-3-({2-[(4-1)]}
ethylbenzyl)sulfonyl]ethyl}amino)-2-hydroxypropyl]acetamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
 ethylbenzyl)amino]-2-hydroxypropyl}-1-methyl-3-phenyl-1H-
 thieno[2,3-c]pyrazole-5-carboxamide;
           N-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{[(4R)-6-ethyl-2, 2-
 dioxido-3, 4-dihydro-1H-isothiochromen-4-yl]amino}-2-
hydroxypropyl)-3,5-dimethylbenzamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-[(1S)-1]
 1,2,3,4-tetrahydronaphthalen-1-ylamino]propyl}acetamide;
           3-bromo-5-{[butyl(methyl)amino]methyl}-N-{(1S,2R)-1-(3,5-1)}
 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
 hydroxypropyl}benzamide;
           1-butyl-N-((1S, 2R) -1 - (3, 5-difluorobenzyl) -3 - \{[1 - (3 - 3 - 3)] - (3 - 3)\}
 ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-1H-indole-6-
```

```
carboxamide;
           N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[({4-
[(dimethylamino)methyl]pyridin-2-yl}methyl)amino]-2-
hydroxypropyl\}-5-(1,3-oxazol-2-yl)-N<sup>3</sup>,N<sup>3</sup>-
dipropylisophthalamide;
           3-[(butylamino)methyl]-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-
3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-methylbenzamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2S)-2-
(methoxymethyl)pyrrolidin-1-yl]methyl}-5-methylbenzamide;
            formic acid compound with N-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-2-[4-
(2-methoxyethyl)piperidin-1-yl]acetamide (2:1);
            1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-N-4)]}
ethylbenzyl)amino]-2-hydroxypropyl}-1,2,3,4-
tetrahydroisoquinoline-7-carboxamide;
           N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzyl)-3-
ethylbenzyl)amino]-2-hydroxypropyl}-N1,5-dimethyl-N3,N3-
dipropylisophthalamide;
           N^{1}-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-[3-(dimethylamino)prop-1-
ynyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-
phenoxyphenyl) acetamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-(2,5-
dimethylphenyl)acetamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-[2-
 (trifluoromethoxy) phenyl] acetamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-
 ethoxyphenyl)acetamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-[2-
 (trifluoromethyl)phenyl]acetamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-
 methoxyphenyl)acetamide;
            2-[2-(benzyloxy)phenyl]-N-{(1S, 2R)-1-(3, 5-
 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
 hydroxypropyl acetamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-phenylbutanamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzyl)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-mesitylacetamide;
            N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-max)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-(2,4-
 dimethoxyphenyl)acetamide;
```

```
2-(2-chlorophenyl)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-}
  [(3-ethylbenzyl)amino]-2-hydroxypropyl}acetamide;
                           2-cyclohexyl-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mathemathem)]
 ethylbenzyl)amino]-2-hydroxypropyl}acetamide;
                           2-cyclopent-2-en-1-yl-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-
 3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}acetamide;
                          N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-(1-methyl-5-oxo-2-
 thioxoimidazolidin-4-yl)acetamide;
                           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-
 fluorophenyl) acetamide;
                           2-\text{cyclopropyl-N-}((1S,2R)-1-(3,5-\text{difluorobenzyl})-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}acetamide;
                           2-cyclohex-1-en-1-yl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-}
 [(3-ethylbenzyl)amino]-2-hydroxypropyl}acetamide;
                           2-(1-adamantyl)-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-adamantyl)-N-1-(3,5-difluorobenzyl)-3-[(3-adamantyl)-N-1-(3,5-difluorobenzyl)-3-[(3-adamantyl)-N-1-(3,5-difluorobenzyl)-3-[(3-adamantyl)-N-1-(3,5-difluorobenzyl)-3-[(3-adamantyl)-N-1-(3,5-difluorobenzyl)-3-[(3-adamantyl)-N-1-(3,5-difluorobenzyl)-3-[(3-adamantyl)-N-1-(3,5-difluorobenzyl)-3-[(3-adamantyl)-N-1-(3,5-difluorobenzyl)-3-[(3-adamantyl)-N-1-(3,5-difluorobenzyl)-3-[(3-adamantyl)-N-1-(3,5-difluorobenzyl)-3-[(3-adamantyl)-N-1-(3,5-difluorobenzyl)-3-[(3-adamantyl)-N-1-(3,5-difluorobenzyl)-3-[(3-adamantyl)-N-1-(3-adamantyl)-N-1-(3-adamantyl)-3-[(3-adamantyl)-N-1-(3-adamantyl)-3-[(3-adamantyl)-N-1-(3-adamantyl)-N-1-(3-adamantyl)-3-[(3-adamantyl)-N-1-(3-adamantyl)-N-1-(3-adamantyl)-3-[(3-adamantyl)-N-1-(3-adamantyl)-N
 ethylbenzyl)amino]-2-hydroxypropyl}acetamide;
                            (2S)-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-phenylpropanamide;
                            (2R) - N - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [ (3 - 3) - 1 - (3, 5) - 2] \}
 ethylbenzyl)amino]-2-hydroxypropyl}-2-phenylpropanamide;
                           2-(2,4-dichlorophenyl)-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-1-(3,5-di
 3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}acetamide;
                           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-2-(2,3-
 dimethoxyphenyl) acetamide;
                         N^{1}-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-5-[3-
  (dimethylamino)propyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
                         N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(2, 2-dioxido-3, 4-dioxido-3,
 dihydro-1H-isothiochromen-4-yl)amino]-2-
hydroxypropyl}acetamide;
                         N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(2, 2-dioxido-3, 4-dioxido-3,
 dihydro-1H-isothiochromen-4-yl)amino]-2-
hydroxypropyl acetamide;
                         N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(4-
 ethynylpyridin-2-yl)cyclopropyl]amino}-2-hydroxypropyl)-5-(1,3-
 oxazol-2-yl)-N3,N3-dipropylisophthalamide;
                           4-butyl-N-\{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-instantial)]
  1
 ethylbenzyl)amino]-2-hydroxypropyl}-3,4-dihydro-2H-1,4-
benzothiazine-6-carboxamide 1-oxide;
                         N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-heptyl-4-hydroxy-L-
prolinamide;
                          2-[butyl(methyl)amino]-6-chloro-N-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}isonicotinamide;
                          2-[butyl(methyl)amino]-6-cyano-N-{(1S,2R)-1-(3,5-
```

```
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}isonicotinamide;
               N' - \{ (1S, 2R) - 1 - (3, 5 - diffluorobenzyl) - 3 - [ ({2 - 2R}) - {1 - 2R}) - {1 - 2R} \}
[(dimethylamino)methyl]pyridin-4-yl}methyl)amino]-2-
hydroxypropy1}-5-(1,3-oxazol-2-y1)-N,N-dipropylisophthalamide;
                4-butyl-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzyl
ethylbenzyl)amino]-2-hydroxypropyl}-8-(1,3-oxazol-2-yl)-3,4-
dihydro-2H-1,4-benzoxazine-6-carboxamide or 4-butyl-N-{(1S,2R)-
1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropy1 -8-(1,3-oxazol-2-y1)-3,4-dihydro-2H-1,4-
benzoxazine-6-carboxamide;
               N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-\{(3-4)\}
ethylbenzyl)amino]-2-hydroxypropyl}-3-(4-ethyl-1,3-oxazol-2-
y1)-5-(1,3-oxazol-2-y1)benzamide;
                3-benzyl-4-(4-butylphenyl)-N-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-
oxobutanamide;
                2-(4-buty1-2-oxopiperazin-1-y1)-N-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}acetamide;
               N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{(3-4)\}
ethylbenzyl)amino]-2-hydroxypropyl}-2-[4-
 (ethoxymethyl)piperidin-1-yl]acetamide;
                2-(4-buty1-2,3-dioxopiperazin-1-y1)-N-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}hexanamide;
               N-\{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-max)-1-(3,5-difluorobenzyl)-2-[(3-max)-1-(3,5-difluorobenzyl)-2-[(3-max)-1-(3,5-difluorobenzyl)-2-[(3-max)-1-(3,5-difluorobenzyl)-2-[(3-max)-1-(3,5-difluorobenzyl)-2-[(3-max)-1-(3,5-difluorobenzyl)-2-[(3-max)-1-(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-m
iodobenzyl)amino]propyl}acetamide;
               N^{1}-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-{[1-(4-
ethynylpyridin-2-yl)cyclopropyl]amino}-2-hydroxypropyl)-5-(1,3-
oxazol-2-yl)-N3, N3-dipropylisophthalamide;
                5-[((1s,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)amino]-5-
oxopentanoic acid;
                1-butyl-N-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzyl)]}
ethylbenzyl)amino]-2-hydroxypropyl}-1,2,3,4-
tetrahydroquinoline-7-carboxamide or 1-butyl-N-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-
1,2,3,4-tetrahydroquinoline-7-carboxamide;
                4-[((1s,2R)-1-(3,5-difluorobenzy1)-3-{[1-(3-
ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)amino]-4-
oxobutanoic acid;
               N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-propyl-1,2-benzisoxazole-
5-carboxamide;
                2-[allyl(methyl)amino]-N-{(1S,2R)-1-[3-(allyloxy)-5-]}
fluorobenzyl]-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}isonicotinamide;
                1-ally1-N-{(15,2R)-1-[4-(allyloxy)-3-fluorobenzy1]-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-1H-indole-6-carboxamide;
               N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
```

```
ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-4-phenyl-2-
(1H-pyrrol-1-yl)-1,3-thiazole-5-carboxamide;
               N-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-{[1-(3-
ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-2-
(dipropylamino) -4-(trifluoromethyl) -1,3-thiazole-5-carboxamide;
                (2S)-2-\{[(2R,3S)-3-(acetylamino)-4-(3,5-difluorophenyl)-
2-hydroxybutyl]amino}-N-isobutyl-4-(methylsulfonyl)butanamide;
               hydroxyprop-1-ynyl)benzyl]amino}propyl)acetamide;
               N-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{[1-(3-1)]
ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-2,6-
dimorpholin-4-ylpyrimidine-4-carboxamide;
               N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-{[(2S)-2-ethylpyrrolidin-
1-yl]carbonyl}-5-methylbenzamide;
                (2S)-2-(4-buty1-3-oxopiperazin-1-y1)-N-{(1S,2R)-1-(3,5-
difluorobenzyl) -3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl }propanamide;
               N-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{[(4R)-6-ethyl-2, 2-
dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}-2-
hydroxypropyl)tetrahydrofuran-3-carboxamide;
               N-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{[(4R)-6-ethyl-2, 2-
dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}-2-
hydroxypropyl)propanamide;
               N-((1S,2R)-1-(3,5-difluorobenzy1)-3-\{[(4R)-6-ethy1-2,2-
dioxido-3, 4-dihydro-1H-isothiochromen-4-yl]amino}-2-
hydroxypropyl) -2-(1H-imidazol-4-yl)acetamide;
               N^{1}-((1S, 2R)-1-(3,5-difluorobenzyl)-3-{[(4R)-6-ethyl-2,2-
dioxido-3, 4-dihydro-1H-isothiochromen-4-yl]amino}-2-
hydroxypropyl) -N<sup>2</sup>, 2-dimethylalaninamide;
               N-((1S,2R)-1-(3,5-difluorobenzy1)-3-\{[(4R)-6-ethy1-2,2-
dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}-2-
hydroxypropyl) cyclopentanecarboxamide;
               N-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{[(4R)-6-ethyl-2, 2-
dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}-2-
hydroxypropyl)cyclopropanecarboxamide;
              N-((1S, 2R)-1-(3, 5-difluorobenzy1)-3-\{[(4R)-6-ethy1-2, 2-ethy1-
dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}-2-
hydroxypropyl)-2-phenylacetamide;
               N-((1S, 2R)-1-(3, 5-difluorobenzy1)-3-\{(4R)-6-ethy1-2, 2-6-ethy1-2, 
dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}-2-
hydroxypropyl)tetrahydrofuran-2-carboxamide;
               N-((1S,2R)-1-(3,5-difluorobenzy1)-3-\{[(4R)-6-ethy1-2,2-
dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}-2-
hydroxypropyl)-1,3-thiazolidine-4-carboxamide;
               N-((1S,2R)-1-(3,5-difluorobenzy1)-3-\{[(4R)-6-ethy1-2,2-
```

 $N-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{[(4R)-6-ethyl-2, 2-$ 

dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}-2-

hydroxypropyl) - 3 - hydroxybutanamide;

```
dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}-2-
hydroxypropy1)-3-hydroxypropanamide;
                    N-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{[(4R)-6-ethyl-2, 2-
dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}-2-
hydroxypropyl)-3-hydroxy-2,2-dimethylpropanamide;
                    N-((1S,2R)-1-(3,5-difluorobenzyl)-3-\{[(4R)-6-ethyl-2,2-instance]\}
dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}-2-
hydroxypropyl)-3-methylbutanamide;
                    N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[(4R)-6-ethyl-2,2-
dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}-2-
hydroxypropyl) glycinamide;
                     N^{1}-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[(4R)-6-ethyl-2,2-
dioxido-3,4-dihydro-1H-isothiochromen-4-y1]amino}-2-
hydroxypropyl) -N2-methylglycinamide;
                     N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
 ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-1-methyl-3-
 (trifluoromethyl)-1H-thieno[2,3-c]pyrazole-5-carboxamide;
                      2-[allyl(methyl)amino]-N-{(1S,2R)-1-[4-(allyloxy)-3-
 fluorobenzyl]-3-[(3-ethylbenzyl)amino]-2-
 hydroxypropyl}isonicotinamide;
                      3-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-N-4)]}
 ethylbenzyl)amino]-2-hydroxypropyl}-1,2-benzisoxazole-5-
 carboxamide;
                      5-(3-aminopropyl)-N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-
  [(3-ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>3</sup>,N<sup>3</sup>-
 dipropylisophthalamide;
                      N^{1} - \{(1S, 2R) - 1 - (3, 5 - diffluorobenzyl) - 3 - [(3 - 3, 5 - diffluorobenzyl)] - 3 - [(3 - 3, 5 - diffluorobenzyl
  ethylbenzyl)amino]-2-hydroxypropyl}-5-[3-(methylamino)propyl]-
 N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
                      N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
  ethylbenzyl)amino]-2-hydroxypropyl}-5-[3-(methylamino)prop-1-
  vnvl]-N3, N3-dipropylisophthalamide;
                       5-(3-aminoprop-1-ynyl)-N^1-\{(1S,2R)-1-(3,5-difluorobenzyl)-1-(3,5-
  3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N^3,N^3-
  dipropylisophthalamide 🔗 .
                      N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
  ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-5-pyrrolidin-
  1-ylpyrazine-2-carboxamide;
                       4-butoxy-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butoxy-N-4)]}
  ethylbenzyl)amino]-2-hydroxypropyl}quinoline-2-carboxamide;
                       2-cvano-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzyl)-3-[(3-difluorobenzyl)-3-[(3-difluorobenzyl)]-3-[(3-difluorobenzyl)-3-[(3-difluorobenzyl)]-3-
   ethylbenzyl)amino]-2-hydroxypropyl}-6-
   [methyl(propyl)amino]isonicotinamide;
                        3-acetyl-1-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-acetyl-1-butyl-N-4)]}
   ethylbenzyl)amino]-2-hydroxypropyl}-1H-indole-6-carboxamide;
                       N^{1}-{(1s,2r)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(1H-indol-
   6-ylmethyl)amino]propyl}-5-methyl-N3,N3-dipropylisophthalamide;
```

 $N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1\}-3-isobuty1-1,2-$ 

benzisoxazole-5-carboxamide;  $N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3$ ethylbenzyl)amino]-2-hydroxypropyl}-2-[(2S)-pyrrolidin-2yl]acetamide;  $2-[2-({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3$ ethylbenzyl)amino]-2-hydroxypropyl}amino)-2-oxoethyl]-N-(6methoxypyridin-3-yl)benzamide;  $2-[2-({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3$ ethylbenzyl)amino]-2-hydroxypropyl}amino)-2-oxoethyl]-N-(2,4difluorophenyl)benzamide;  $N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]$ ethylbenzyl)amino]-2-hydroxypropyl}-2-pyridin-3-ylacetamide;  $N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-instance)]$ ethylbenzyl)amino]-2-hydroxypropyl}-2-(1H-imidazol-5yl)acetamide; ethylbenzyl)amino]-2-hydroxypropyl}acetamide;  $N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-instance)]$ ethylbenzyl)amino]-2-hydroxypropyl}-2-(2hydroxyphenyl)acetamide;  $N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-instance)]$ ethylbenzyl)amino]-2-hydroxypropyl}-2-(2methylphenyl)acetamide;  $N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3$ ethylbenzyl)amino]-2-hydroxypropyl}-2-(2-iodophenyl)acetamide; 1-(4-chlorophenyl)-N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5-oxopyrrolidine-3carboxamide;  $4-(2,4-dichlorophenoxy)-N-\{(1S,2R)-1-(3,5$ difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2hydroxypropyl } butanamide;  $4,5-dibromo-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-4,5-difluorobenzyl)-3-[(3-4,5-difluorobenzyl)]$ ethylbenzyl)amino]-2-hydroxypropyl}thiophene-2-carboxamide;  $N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-i)]$ ethylbenzyl)amino]-2-hydroxypropyl}-2-(5-methyl-2-phenyl-1,3oxazol-4-yl)acetamide;  $N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3$ ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-2,6bis (dimethylamino) pyrimidine-4-carboxamide;  $4-butyl-8-cyano-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano-N-1)-3-[(3-butyl-8-cyano$ ethylbenzyl)amino]-2-hydroxypropyl}-3,4-dihydro-2H-1,4benzoxazine-6-carboxamide: 3-(allylsulfonyl)-N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2hydroxypropyl)benzamide;

3-(allylthio)-N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)benzamide;

N-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(7-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)amino]propyl}acetamide;

```
N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-[(7-4)]
methoxy-1,2,3,4-tetrahydronaphthalen-1-
yl)amino]propyl}acetamide;
               formic acid compound with N1-[(3S)-1-azabicyclo[2.2.2]oct-
3-y1]-N^5-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-x)]-1-(3,5-difluorobenzyl)-3-{[1-(3-x)]-1-(3,5-difluorobenzyl)-3-{[1-(3-x)]-1-(3,5-difluorobenzyl)-3-{[1-(3-x)]-1-(3,5-difluorobenzyl)-3-{[1-(3-x)]-1-(3,5-difluorobenzyl)-3-{[1-(3-x)]-1-(3,5-difluorobenzyl)-3-{[1-(3-x)]-1-(3,5-difluorobenzyl)-3-{[1-(3-x)]-1-(3,5-difluorobenzyl)-3-{[1-(3-x)]-1-(3,5-difluorobenzyl)-3-{[1-(3-x)]-1-(3,5-difluorobenzyl)-3-{[1-(3-x)]-1-(3,5-difluorobenzyl)-3-{[1-(3-x)]-1-(3,5-difluorobenzyl)-3-{[1-(3-x)]-1-(3-x)-[
 ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)pentanediamide
 (1:1);
                formic acid compound with N1-[(3R)-1-azabicyclo[2.2.2]oct-
 3-y1]-N<sup>5</sup>-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
 ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)pentanediamide
 (1:1);
                formic acid compound with N1-[(3S)-1-azabicyclo[2.2.2]oct-
 3-y1]-N<sup>4</sup>-((1S, 2R)-1-(3, 5-diffuorobenzyl)-3-{[1-(3-
 ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)succinamide
 (1:1);
                formic acid compound with N1-[(3R)-1-azabicyclo[2.2.2]oct-
 3-y1]-N^4-((1S, 2R)-1-(3, 5-difluorobenzy1)-3-{[1-(3-1)]-1-(3-(3-1)]-3-[1-
 ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)succinamide
 (1:1);
                N-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{[(4R)-6-ethyl-2, 2-
 dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}-2-
 hydroxypropyl)pentanamide;
                N-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{[(4R)-6-ethyl-2, 2-4]\}
 dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}-2-
 hydroxypropyl)-3-phenylpropanamide;
                N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-5-[4-(dimethylamino)but-1-
 ynyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
                 1-butyl-N-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-difluorobenzyl)]}
 ethylbenzyl)amino]-2-hydroxypropyl}-3-(trifluoroacetyl)-1H-
 indole-6-carboxamide;
                N-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{[1-(3-
 ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-3-
 {[isopentyl(methyl)amino]methyl}-5-methylbenzamide;
                 N-((1S, 2R)-1-(3, 5-difluorobenzy1)-3-{[1-(3-
 ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-3-
  {[isopentyl(methyl)amino]methyl}-5-methylbenzamide;
                 N-((1S, 2R)-1-(3, 5-difluorobenzy1)-3-{[1-(3-
 ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-4-
  (dipropylamino) -1-methyl-1H-pyrrole-2-carboxamide;
                 N-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{[(4R)-6-ethyl-2, 2-4]\}
 dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}-2-
 hydroxypropyl)-4-(2-methoxyethyl)benzamide;
                 N^{1}-{(1s.2r)-1-(3.5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-5-[4-(dimethylamino)butyl]-
 N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
                 N-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{[6-ethyl-2-
  (methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-4-yl]amino}-2-
 hydroxypropyl)acetamide;
                 N-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{[6-ethyl-2-
  (methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-4-yl]amino}-2-
```

```
hydroxypropyl)acetamide;
          2,6-dichloro-N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-1)]}
ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)pyrimidine-4-
carboxamide;
          N-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-([(1S)-7-ethyl-
1,2,3,4-tetrahydronaphthalen-1-yl]amino}-2-
hydroxypropyl)acetamide;
          N-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-{[(1R)-7-ethyl-
1,2,3,4-tetrahydronaphthalen-1-yl]amino}-2-
hydroxypropyl)acetamide;
          N-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-{[1-(3-
ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-2-morpholin-
4-yl-4-(trifluoromethyl)-1,3-thiazole-5-carboxamide;
           N-\{(1S, 2R)-1-benzyl-3-\{(6-ethyl-2, 2-dioxido-3, 4-dihydro-kenzyl-3-\{(6-ethyl-2, 2-dioxido-3, 4-dihydro-kenzyl-3-\{(6-ethyl-2, 2-dioxido-3, 4-dihydro-kenzyl-3-\{(6-ethyl-2, 2-dioxido-3, 4-dihydro-kenzyl-3-\{(6-ethyl-2, 2-dioxido-3, 4-dihydro-kenzyl-3-\{(6-ethyl-2, 2-dioxido-3, 4-dihydro-kenzyl-3-\{(6-ethyl-2, 2-dioxido-3, 4-dihydro-kenzyl-3-\{(6-ethyl-2, 2-dioxido-3, 4-dihydro-kenzyl-3-\{(6-ethyl-2, 2-dioxido-3, 4-dihydro-kenzyl-3-\{(6-ethyl-2, 2-dioxido-3, 4-dihydro-kenzyl-3-(6-ethyl-2, 2-dioxido-3, 4-dioxido-3, 4-dioxido-3, 4-dioxido-3, 4-dioxido-3, 4-dioxido-3, 4-dioxido-3, 4-dioxido-3, 4-dioxido-3, 4-dioxido-3, 4-dioxido-3, 4-dioxido-3, 4-dioxido-3, 4-dioxido-3, 4-dioxido-3, 4-dioxido-3, 4-dioxido-3, 4-dioxido-3, 4-dioxido-3, 4-dioxido-4, 4-dioxido-4, 4-dioxido-4, 4-dioxido-4, 4-dioxido-4, 4-dioxido-4, 4-dioxido-4, 4-dioxido-4, 4-dioxido-4, 4-dioxido-4, 4-dioxido-4, 4-dioxido-4, 4-dioxido-4,
1H-isothiochromen-4-yl)amino]-2-hydroxypropyl}acetamide;
           N-[(1s, 2R)-3-\{[1-(3-bromophenyl) cyclopropyl]amino\}-1-
 (3,5-difluorobenzyl)-2-hydroxypropyl]acetamide;
           N^{1}-[(1S,2R)-1-(3,5-difluorobenzyl)-3-({[1-(3-ethylphenyl)-
1H-tetraazol-5-yl]methyl}amino)-2-hydroxypropyl]-5-methyl-
N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
           3-(allylsulfinyl)-N-((1S,2R)-1-(3,5-difluorobenzyl)-3-
 {[1-(3-ethylphenyl)cyclopropyl]amino}-2-
hydroxypropyl) benzamide;
           methyl 3-[3'-(acetylamino)-1,1'-biphenyl-3-yl]-3-
 \{[(2R,3S)-3-(acetylamino)-4-(3,5-difluorophenyl)-2-
 hydroxybutyl]amino}propanoate;
           methyl 3-\{[(2R,3S)-3-(acetylamino)-4-(3,5-
 difluorophenyl)-2-hydroxybutyl]amino}-3-[3-(5-formylthien-2-
yl)phenyl]propanoate;
           methyl 3-\{[(2R,3S)-3-(acetylamino)-4-(3,5-
 difluorophenyl)-2-hydroxybutyl]amino}-3-(2'-acetyl-1,1'-
 biphenyl-3-yl)propanoate;
           methyl 3-\{[(2R,3S)-3-(acetylamino)-4-(3,5-
 difluorophenyl)-2-hydroxybutyl]amino}-3-[3'-(hydroxymethyl)-
 1,1'-biphenyl-3-yl]propanoate;
           N-((1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-{[1-(3'-
 methoxy-1,1'-biphenyl-3-yl)cyclopropyl]amino}propyl)acetamide;
           N-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-({1-[3'-}
 (hydroxymethyl)-1,1'-biphenyl-3-
 yl]cyclopropyl}amino)propyl]acetamide;
           N-[(1S,2R)-3-\{[1-(2'-acetyl-1,1'-biphenyl-3-
 yl)cyclopropyl]amino}-1-(3,5-difluorobenzyl)-2-
 hydroxypropyl]acetamide;
           N-[(1S,2R)-1-(3,5-difluorobenzyl)-3-({1-[3-(5-
 formylthien-2-yl)phenyl]cyclopropyl}amino)-2-
 hydroxypropyl]acetamide;
            N-[(1S,2R)-1-(3,5-difluorobenzyl)-3-(9H-fluoren-9-
 ylamino)-2-hydroxypropyl]acetamide;
            methyl 3-\{[(2R,3S)-3-(acetylamino)-4-(3,5-
```

```
difluorophenyl)-2-hydroxybutyl]amino}-3-[3-
(trifluoromethyl)phenyl)propanoate;
           methyl 3-\{[(2R,3S)-3-(acetylamino)-4-(3,5-
difluorophenyl)-2-hydroxybutyl]amino}-3-(3-
cyanophenyl) propanoate;
          N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzv1) - 3 - [(3 - 3) - 3] \}
ethylbenzyl)amino]-2-hydroxypropyl}-5-[3-
(dimethylamino)propyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylisophthalamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3'-(hydroxymethyl)-5-(1,3-
thiazol-2-yl)-1,1'-biphenyl-3-carboxamide;
           3'-cyano-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-a)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-thiazol-2-yl)-1,1'-
biphenyl-3-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2'-ethoxy-5-(1,3-thiazol-2-
yl)-1,1'-biphenyl-3-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-thiazol-2-yl)-3'-
(trifluoromethoxy)-1,1'-biphenyl-3-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-4'-propoxy-5-(1,3-thiazol-
2-yl)-1,1'-biphenyl-3-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4'-(dimethylamino)-5-(1,3-
thiazol-2-yl)-1,1'-biphenyl-3-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance of the content of the conten
ethylbenzyl)amino]-2-hydroxypropyl}-2'-propoxy-5-(1,3-thiazol-
2-yl)-1,1'-biphenyl-3-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3'-propoxy-5-(1,3-thiazol-
2-yl)-1,1'-biphenyl-3-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-3'-ethoxy-5-(1,3-thiazol-2-
yl)-1,1'-biphenyl-3-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-4'-ethoxy-5-(1,3-thiazol-2-
yl)-1,1'-biphenyl-3-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4'-isopropoxy-5-(1,3-
thiazol-2-yl)-1,1'-biphenyl-3-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4'-(hydroxymethyl)-5-(1,3-
thiazol-2-yl)-1,1'-biphenyl-3-carboxamide;
           4'-butoxy-N-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-thiazol-2-yl)-1,1'-
biphenyl-3-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4'-methoxy-5-(1,3-thiazol-
2-yl)-1,1'-biphenyl-3-carboxamide;
```

```
N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
  ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-thiazol-2-yl)-4'-
  (trifluoromethoxy)-1,1'-biphenyl-3-carboxamide;
                 4'-butyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
  ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-thiazol-2-yl)-1,1'-
  biphenyl-3-carboxamide;
                 3'-butoxy-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-butoxy-N-4)]}
  ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-thiazol-2-yl)-1,1'-
  biphenyl-3-carboxamide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
  ethylbenzyl)amino]-2-hydroxypropyl}-3'-isopropyl-5-(1,3-
  thiazol-2-yl)-1,1'-biphenyl-3-carboxamide;
                  3'-(acetylamino)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
  ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-thiazol-2-yl)-1,1'-
  biphenyl-3-carboxamide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mathemathem)]
  ethylbenzyl)amino]-2-hydroxypropyl}-2'-methyl-5-(1,3-thiazol-2-
  yl)-1,1'-biphenyl-3-carboxamide;
                  2'-acetyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
  ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-thiazol-2-yl)-1,1'-
  biphenyl-3-carboxamide;
                 N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
  ethylbenzyl)amino]-2-hydroxypropyl}-4'-hydroxy-5-(1,3-thiazol-
  2-yl)-1,1'-biphenyl-3-carboxamide;
                  4'-(acetylamino)-N-\{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
  ethylbenzyl)amino]-2-hydroxypropyl}-5-(1,3-thiazol-2-yl)-1,1'-
  biphenyl-3-carboxamide;
                  N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-instance of the content of the conten
  ethylbenzyl)amino]-2-hydroxypropyl}-3-(1H-pyrrol-2-yl)-5-(1,3-
  thiazol-2-yl)benzamide;
                  N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
  ethylbenzyl)amino]-2-hydroxypropyl}-3-[(E)-2-(4-
  fluorophenyl)ethenyl]-5-(1,3-thiazol-2-yl)benzamide;
                  N-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-{[1-(3-
  ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)pyrimidine-4-
  carboxamide;
                  N-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-{[1-(3-
  ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)acetamide;
                  methyl 3-\{[(2R,3S)-3-(acetylamino)-4-(3,5-
  difluorophenyl)-2-hydroxybutyl]amino}-3-(3-
  bromophenyl) propanoate;
                  2-chloro-N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
  ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-6-morpholin-
   4-ylpyrimidine-4-carboxamide;
                  N-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{[1-(3-
  ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-2-
   (dipropylamino)-6-morpholin-4-ylpyrimidine-4-carboxamide;
                  N-((1S, 2R)-1-(3, 5-difluorobenzy1)-3-{[1-(3-
ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)-2,6-
```

bis(dipropylamino)pyrimidine-4-carboxamide;

```
methyl 3-\{[(2R,3S)-3-(acetylamino)-4-(3,5-
  difluorophenyl)-2-hydroxybutyl]amino}-3-(3-
  bromophenyl)propanoate;
                               N-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-{[1-(3-
  ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)acetamide;
                               or pharmaceutically acceptable salts thereof.
                    346. A compound which is:
                              N'-[(1S,2S)-3-(benzylamino)-1-(3,5-difluorobenzyl)-2-
 hydroxypropyl]-5-methyl-N, N-dipropylisophthalamide;
                               N'-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
  ethylbenzyl)amino]-2-hydroxypropyl}-5-ethynyl-N,N-
  dipropylisophthalamide;
                               N-(1-cyclopropylethyl)-N'-{(1S,2R)-1-(3,5-
 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-N-
 phenylsuccinamide
                               N'-[(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-({3-[(1E)-1]})
 prop-1-en-1-yl]benzyl}amino)propyl]-5-methyl-N,N-
 dipropylisophthalamide;
                               N' - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 2 - hydroxy - 3 - [(3 - 1) - 1] - (3, 5 - difluorobenzy1) - 2 - hydroxy - 3 - [(3 - 1) - 1] - (3, 5 - difluorobenzy1) - 2 - hydroxy - 3 - [(3 - 1) - 1] - (3, 5 - difluorobenzy1) - 2 - hydroxy - 3 - [(3 - 1) - 1] - (3, 5 - difluorobenzy1) - 2 - hydroxy - 3 - [(3 - 1) - 1] - (3, 5 - difluorobenzy1) - 2 - hydroxy - 3 - [(3 - 1) - 1] - (3, 5 - difluorobenzy1) - 3 - hydroxy - 3 - [(3 - 1) - 1] - (3, 5 - difluorobenzy1) - 3 - hydroxy - 3 - [(3 - 1) - 1] - (3, 5 - difluorobenzy1) - 3 - hydroxy - 3 - [(3 - 1) - 1] - (3, 5 - difluorobenzy1) - 3 - hydroxy - 3 - [(3 - 1) - 1] - (3, 5 - difluorobenzy1) - 3 - hydroxy - 3 - [(3 - 1) - 1] - (3, 5 - difluorobenzy1) - 3 - hydroxy - 3 - [(3 - 1) - 1] - (3, 5 - difluorobenzy1) - 3 - hydroxy - 3 - [(3 - 1) - 1] - (3, 5 - difluorobenzy1) - 3 - hydroxy - 3 - [(3 - 1) - 1] - (3, 5 - difluorobenzy1) - 3 - hydroxy - 3 - [(3 - 1) - 1] - (3, 5 - difluorobenzy1) - 3 - hydroxy - 3 - [(3 - 1) - 1] - (3, 5 - difluorobenzy1) - 3 - hydroxy - 3 - [(3 - 1) - 1] - (3, 5 - difluorobenzy1) - 3 - hydroxy - 3 - [(3 - 1) - 1] - (3, 5 - difluorobenzy1) - 3 - hydroxy - 3 - [(3 - 1) - 1] - (3, 5 - difluorobenzy1) - 3 - hydroxy - 3 - [(3 - 1) - 1] - (3, 5 - difluorobenzy1) - 3 - hydroxy - 3 - [(3 - 1) - 1] - (3, 5 - difluorobenzy1) - 3 - hydroxy - 3 - [(3 - 1) - 1] - (3, 5 - difluorobenzy1) - 3 - hydroxy - 3 - 
  isopropylbenzyl)amino]propyl}-5-(1,3-oxazol-2-yl)-N,N-
 dipropylisophthalamide;
                               methyl (3-\{[((2R,3S)-4-(3,5-difluorophenyl)-3-\{[3-
  [(dipropylamino)carbonyl]-5-(1,3-oxazol-2-yl)benzoyl]amino}-2-
 hydroxybutyl)amino]methyl}phenyl)methylcarbamate;
                              N'-[(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-({3-}
  [(methylsulfonyl)amino]benzyl}amino)propyl]-5-(1,3-oxazol-2-
 yl)-N, N-dipropylisophthalamide;
                              N' - \{(1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 2 - hydroxy - 3 - [(3 - 1)^2 - 1] - (3, 5 - difluorobenzy1) - (3, 5 - d
 isopropylbenzyl)amino]propyl}-N,N-dipropylpyridine-3,5-
 dicarboxamide;
                              N' - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [(3 - 1)] \}
 ethylbenzyl)amino]-2-hydroxypropyl}-N,N-dipropylpyridine-3,5-
 dicarboxamide 1-oxide;
                              N' - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [(3 - 1)] \}
 ethynylbenzyl)amino]-2-hydroxypropyl}-5-ethynyl-N,N-
 dipropylisophthalamide;
                              N^4 - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 2 - hydroxy - 3 - [ (3 - 1) - 1] \}
 isopropylbenzyl)amino]propyl}-6-methyl-N2,N2-dipropylpyridine-
 2,4-dicarboxamide;
                              N'-[(1S,2R)-3-\{[(2-tert-butylpyrimidin-4-t
 yl)methyl]amino}-1-(3,5-difluorobenzyl)-2-hydroxypropyl]-5-
 methyl-N,N-dipropylisophthalamide;
                              N'-((1s,2R)-1-(3,5-difluorobenzyl)-3-\{[(2-ethylpyrimidin-
 4-yl)methyl]amino}-2-hydroxypropyl)-5-methyl-N,N-
 dipropylisophthalamide:
                              N' - ((1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 - {[(1S) - 1 - (1S) - 1 - (1S) - (1
  [(isobutylamino)carbonyl]-3-
  (methylsulfonyl)propyl]amino)propyl)-5-methyl-N,N-
 dipropylisophthalamide:
                              N'-\{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-max)-1-(3,5-difluorobenzyl)-2-[(3-max)-1-(3,5-difluorobenzyl)-2-[(3-max)-1-(3,5-difluorobenzyl)-2-[(3-max)-1-(3,5-difluorobenzyl)-2-[(3-max)-1-(3,5-difluorobenzyl)-2-[(3-max)-1-(3,5-difluorobenzyl)-2-[(3-max)-1-(3,5-difluorobenzyl)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-2-[(3-max)-1-(3-max)-2-[(3-max)-2-[(3-max)-2-[(3-max)-2-[(3-max)-
hydroxy-1-phenylpropy1)amino}propy1}-5-methyl-N,N-
 dipropylisophthalamide:
                              N'-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-(6,7,8,9-
```

```
tetrahydro-5H-benzo[7]annulen-5-ylamino)propyl]-5-methyl-N,N-
dipropylisophthalamide;
          N' - ((1S, 2S) - 1 - (3, 5 - difluorobenzy1) - 2 - hydroxy - 3 - {((1R) - 6 - 6)}
methoxy-1,2,3,4-tetrahydronaphthalen-1-yl]amino}propyl)-5-
methyl-N,N-dipropylisophthalamide;
          N' - ((1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 2 - hydroxy - 3 - {[(1R) - 6 - 6]}
methoxy-1,2,3,4-tetrahydronaphthalen-1-yl]amino}propyl)-5-
methyl-N,N-dipropylisophthalamide;
          N' - ((1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 2 - hydroxy - 3 - { ((1S) - 2 - 1) - 2 - hydroxy - 3 - ((1S) - 2 - 1) - 2 - 1) - 2 - 1}
oxo-1-methyl-2-(methylamino)ethyl]amino)propyl)-5-methyl-N,N-
dipropylisophthalamide;
          N'-[(1S,2R)-3-{[(1S)-1-benzyl-2-oxo-2-
(methylamino)ethyl]amino}-1-(3,5-difluorobenzyl)-2-
hydroxypropyl]-5-methyl-N,N-dipropylisophthalamide;
          N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - [(3 - 3) - 3] \}
ethylbenzyl)amino]-2-hydroxypropyl}-\mathbb{N}^2-{oxo[3-
(trifluoromethyl)phenyl]methyl}glycinamide;
          2-\{[2-(\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-i)]\}\}\}
ethylbenzyl)amino]-2-hydroxypropyl}amino)-2-oxoethyl]thio}-N-
 (5-methylisoxazol-3-yl)acetamide;
          N' - ((1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 - {[(1S) - 1 - (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 - {[(1S) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 - {[(1S) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 - {[(1S) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 - {[(1S) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 - {[(1S) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 - {[(1S) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 - {[(1S) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 - {[(1S) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 - {[(1S) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 - {[(1S) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 - {[(1S) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 - {[(1S) - (1S) - (1S) - (1S) - (1S) - (1S) - (1S) - (1S) - (1S) - {[(1S) - (1S) - (1S) - (1S) - (1S) - {[(1S) - 
 [oxo(methylamino)methyl]-3-(methylthio)propyl]amino)propyl)-5-
methyl-N,N-dipropylisophthalamide;
          N' - ((1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 2 - hydroxy - 3 - {[(1R) - 1 - (3, 5 - difluorobenzy1)]}
 (hydroxymethyl)-2-oxo-2-(methylamino)ethyl]amino}propyl)-5-
methyl-N,N-dipropylisophthalamide;
          N'-[(1S, 2R)-3-({(1S)-1-[amino(oxo)methyl]-3-}
methylbutyl}amino)-1-(3,5-difluorobenzyl)-2-hydroxypropyl]-5-
methyl-N, N-dipropylisophthalamide;
           N'-[(1S,2R)-3-[(2-amino-2-oxo-1-methylethyl)amino]-1-
 (3,5-difluorobenzyl)-2-hydroxypropyl]-5-methyl-N,N-
 dipropylisophthalamide;
           tert-butyl (1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropylcarbamate;
           tert-butyl (1S,2R)-3-(cyclopropylamino)-1-(3,5-
 difluorobenzyl)-2-hydroxypropylcarbamate;
           tert-butyl (1S,2R)-3-[(cyclopropylmethyl)amino]-1-(3,5-
 difluorobenzyl)-2-hydroxypropylcarbamate;
           tert-butyl ((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
 {[2-oxo-2-(isobutylamino)-1-methylethyl]amino}propyl)carbamate;
           benzyl (1S, 2R)-1-benzyl-3-[(3-ethylbenzyl)amino]-2-
 hydroxypropylcarbamate;
           (2R,3S)-3-amino-4-(3,5-difluoropheny1)-1-{[1-(3-
 ethynylphenyl)cyclopropyl]amino}butan-2-ol;
      tert-butyl [(1S,2R)-3-{[(1S)-2-(benzylamino)-2-oxo-1-
 methylethyl]amino}-1-(3,5-difluorobenzyl)-2-
 hydroxypropyl]carbamate;
           N^2-[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-
 hydroxybutyl]-N1-benzyl-L-alaninamide bis(trifluoroacetate)
 (salt);
           tert-butyl ((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
 {[1-(2-isobuty1-1,3-thiazo1-5-
 v1)cyclopropyl]amino)propyl)carbamate;
            (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-{[1-(2-isobutyl-
 1,3-thiazol-5-yl)cyclopropyl]amino}butan-2-ol
 bis(trifluoroacetate) (salt);
```

```
tert-butyl ((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
{[1-(3-isobutylisoxazol-5-
yl)cyclopropyl]amino}propyl)carbamate;
          (2R, 3S) - 3 - amino - 4 - (3, 5 - diffluorophenyl) - 1 - {[1 - (3 - 3)]}
isobutylisoxazol-5-yl)cyclopropyl]amino}butan-2-ol
bis(trifluoroacetate) (salt);
          tert-butyl ((1S,2R)-1-(3,5-difluorobenzyl)-3-{[(2-
ethylpyrimidin-4-yl)methyl]amino}-2-hydroxypropyl)carbamate;
          (2R, 3S) - 3 - amino - 4 - (3, 5 - difluorophenyl) - 1 - { [(2 - amino - 4 - (3, 5 - difluorophenyl) - 1 - (3, 5 - difluorophenyl) - 1 - (3, 5 - difluorophenyl) - 1 - (3, 5 - difluorophenyl) - 1 - (3, 5 - difluorophenyl) - 1 - (3, 5 - difluorophenyl) - 1 - (3, 5 - difluorophenyl) - 1 - (3, 5 - difluorophenyl) - 1 - (3, 5 - difluorophenyl) - 1 - (3, 5 - difluorophenyl) - 1 - (3, 5 - difluorophenyl) - 1 - (3, 5 - difluorophenyl) - 1 - (3, 5 - difluorophenyl) - 1 - (3, 5 - difluorophenyl) - 1 - (3, 5 - difluorophenyl) - 1 - (3, 5 - difluorophenyl) - 1 - (3, 5 - difluorophenyl) - (3, 5
ethylpyrimidin-4-yl)methyl]amino}butan-2-ol
bis(trifluoroacetate) (salt);
          tert-butyl {(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
[(7-methoxy-1,2,3,4-tetrahydronaphthalen-1-
yl)amino]propyl}carbamate;
          tert-butyl [(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
(6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-
ylamino)propyl]carbamate;
          tert-butyl {(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
[(3-hydroxy-1-phenylpropyl)amino]propyl)carbamate;
          tert-butyl ((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
{[(1S)-1-[oxo(isobutylamino)methyl]-3-
(methylthio)propyl]amino}propyl)carbamate;
          tert-butyl ((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
{[(1S)-1-[(isobutylamino)carbonyl]-3-
(methylsulfonyl)propyl]amino}propyl)carbamate;
          tert-butyl {(1S,2R)-1-(3,5-difluorobenzyl)-3-[(2,2-
dioxido-3,4-dihydro-1,2-benzoxathiin-4-yl)amino]-2-
hydroxypropyl carbamate;
          tert-butyl {(1S,2R)-1-(3,5-difluorobenzyl)-3-[(2,2-
dioxido-3,4-dihydro-1H-2,1-benzothiazin-4-yl)amino]-2-
hydroxypropyl}carbamate;
          tert-butyl ((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
ethylphenyl)cyclopropyl]amino}-2-hydroxypropyl)carbamate;
          tert-butyl ((1S, 2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
ethynylphenyl)cyclopropyl]amino}-2-hydroxypropyl)carbamate;
          tert-butyl ((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
{[1-(3-methylphenyl)cyclopropyl]amino}propyl)carbamate;
          tert-butyl ((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
{[1-(3-iodophenyl)cyclopropyl]amino}propyl)carbamate;
          tert-butyl [(1S,2R)-3-{[3-
 (cyclopropylamino)benzyl]amino}-1-(3,5-difluorobenzyl)-2-
hydroxypropyl]carbamate;
          methyl 3-(\{[(2R,3S)-3-[(tert-butoxycarbonyl)amino]-4-
 (3,5-difluorophenyl)-2-hydroxybutyl]amino}methyl)benzoate;
          methyl [3-(\{(2R,3S)-3-(\text{tert-butoxycarbonyl})amino]-4-
 (3,5-difluorophenyl)-2-
hydroxybutyl]amino}methyl)phenyl]carbamate;
          methyl [3-({[(2R,3S)-3-[(tert-butoxycarbonyl)amino]-4-
 (3,5-difluorophenyl)-2-
hydroxybutyl]amino}methyl)phenyl]methylcarbamate;
           tert-butyl [(1s, 2R)-1-(3, 5-difluorobenzyl)-3-({3-}
[(dimethylamino)sulfonyl]benzyl}amino)-2-
hydroxypropyl]carbamate;
           tert-butyl [(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
 ({3-[(methylsulfonyl)amino]benzyl}amino)propyl]carbamate;
           tert-butyl [(1s, 2R)-3-[(3-cyanobenzyl)amino]-1-(3, 5-
```

```
difluorobenzyl)-2-hydroxypropyl]carbamate;
              3-({[(2R,3S)-3-[(tert-butoxycarbonyl)amino]-4-(3,5-
difluorophenyl)-2-hydroxybutyl]amino}methyl)phenyl
dimethylcarbamate;
              tert-butyl [(2R,3S)-4-(3,5-difluorophenyl)-3-({3-
[(dipropylamino)carbonyl]-5-methylbenzoyl}amino)-2-
hydroxybutyl][3-(ethylthio)benzyl]carbamate;
              tert-butyl {(1S,2R)-1-(3,5-difluorobenzyl)-3-[(1R)-2,3-
dihydro-1H-inden-1-ylamino]-2-hydroxypropyl}carbamate;
              tert-butyl \{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(1S)-2, 3-
dihydro-1H-inden-1-ylamino]-2-hydroxypropyl}carbamate;
              tert-butyl ((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
\{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-
yl]amino}propyl)carbamate;
              tert-butyl ((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
\{[(1R, 2S)-2-hydroxy-2, 3-dihydro-1H-inden-1-
y1]amino)propy1)carbamate;
              tert-butyl ((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
{[(3S)-2-oxoazepan-3-yl]amino}propyl)carbamate;
               tert-butyl ((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
{[(3R)-2-oxoazepan-3-yl]amino}propyl)carbamate;
               tert-butyl [(1S,2R)-1-(3,5-difluorobenzyl)-3-({[(5S)-3-
ethyl-2-oxo-1,3-oxazolidin-5-yl]methyl}amino)-2-
hydroxypropyl]carbamate;
               tert-butyl [(1S,2R)-1-(3,5-difluorobenzyl)-3-({[(5R)-3-
ethyl-2-oxo-1,3-oxazolidin-5-yl]methyl}amino)-2-
hydroxypropyl]carbamate;
               tert-butyl ((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-
ethylphenyl)-1-methylethyl]amino}-2-hydroxypropyl)carbamate;
               tert-butyl ((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
 [(2-naphthylmethyl)amino]propyl}carbamate;
               tert-butyl ((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-
 \{[2-\infty -2-(isobutylamino)-1,1-
dimethylethyl]amino}propyl)carbamate;
               tert-butyl [(1S, 2R)-3-[(benzyloxy)amino]-1-(3, 5-
difluorobenzyl)-2-hydroxypropyl]carbamate;
               tert-butyl 4-[({(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-intert)]}]
ethylbenzyl)amino]-2-hydroxypropyl}amino)carbonyl]piperidine-1-
carboxylate trifluoroacetate;
               N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-4-fluoro-1-naphthamide;
               N-[(1S,2R)-1-benzyl-3-(2-butyryl-1-ethylhydrazino)-2-
hydroxypropyl]-2-(3-methylisoxazol-5-yl)acetamide;
               N' - \{ (1S, 2R) - 1 - (3, 5 - diffluorobenzyl) - 3 - [ (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - 3 - (3 - 3) - (
 ethylbenzyl)amino]-2-hydroxypropyl}-N-hexyl-N,5-
 dimethylisophthalamide;
               N' - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 - [(3 - 1) - 1] - (3, 5 - difluorobenzyl) - 3 - [(3 - 1) - 1] - (3, 5 - difluorobenzyl) - 3 - [(3 - 1) - 1] - (3, 5 - difluorobenzyl) - 3 - [(3 - 1) - 1] - [(3 - 1) - 1] - (3, 5 - difluorobenzyl) - 3 - [(3 - 1) - 1] - [(
methoxybenzoyl)amino]propyl}-5-methyl-N,N-
 dipropylisophthalamide;
               N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-1-methyl-1H-imidazole-2-
 carboxamide;
               N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-3,3-dimethyl-N^2,N^2-
 dipropylcyclopropane-1,2-dicarboxamide;
               tert-butyl 2-[({(15,2R)-1-(3,5-difluorobenzyl)-3-[(3-
```

```
ethylbenzyl)amino]-2-hydroxypropyl}amino)carbonyl]-1-methyl-1H-
imidazol-4-ylcarbamate;
          N^5 - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [(3 - 3, 5 - difluorobenzyl) - [(3 - 3, 5 - difluorobenzyl) - [(3 - 3, 5 - difluorobenzyl) - [(3 - 3, 5 - difluorobenzyl) - [(3 - 3, 5 - difluorobenzyl) - [(3 - 3, 5 - difluorobenzyl)] - [(3 - 3, 5 - difluorobenzyl) - [(3 - 3, 5 - difluorobenzyl) - [(3 - 3, 5 - difluorobenzyl)] - [(3 - 3, 5 - difluorobenzyl) - [(3 - 3, 5 - difluorobenzyl)] - [(3 - 3, 5 - difluorobenzyl)] - [(3 - 3, 5 - difluorobenzyl)] - [(3 - 3, 5 - difluorobenzyl)] - [(3 - 3, 5 - difluorobenzyl)] - [(3 - 3, 5 - difluorobenzyl)] - [(3 - 3, 5 - difluorobenzyl)] - [(3 - 3, 5 - difluorobenzyl)] - [(3 - 3, 5 - difluorobenzyl)] - [(3 - 3, 5 - difluorobenzyl)] - [(3 - 3, 5 - difluorobenzyl)] - [(3 - 3, 5 - difluorobenzyl)] - 
ethylbenzyl)amino]-2-hydroxypropyl}-2,2-dimethyl-N1,N1-
dipropylpentanediamide;
          N-\{(1S,2R)-1-benzyl-2-hydroxy-3-[(2-morpholin-4-
ylethyl)amino]propyl}-2-(4-chlorophenoxy)-2-methylpropanamide
compound with methyl hydroperoxide (1:2);
          N-[(1S, 2R)-3-(benzylamino)-1-(3, 5-difluorobenzyl)-2-
hydroxypropyl]-4-fluoro-1-naphthamide;
          3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-2-hydroxy-3-
(isopentylamino)-1-(4-isopropylbenzyl)propyl)propanamide;
          3-[(dipropylamino)sulfonyl]-N-[(1S, 2R)-2-hydroxy-3-
(isopentylamino)-1-(3-methoxybenzyl)propyl]propanamide;
          N^{1}-[(1S,2R)-1-(3,5-dichlorobenzyl)-2-hydroxy-3-
(isopentylamino)propyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
          N^{1}-[(1S,2R)-3-(benzylamino)-2-hydroxy-1-(4-
methoxybenzyl)propyl]-5-methyl-N3,N3-dipropylisophthalamide;
          N^{1}-[(1S, 2R)-3-(benzylamino)-2-hydroxy-1-(4-
methoxybenzyl)propyl]-N3,N3-dipropylbenzene-1,3,5-
tricarboxamide;
          N^{1}-{(1S, 2R)-2-hydroxy-1-(4-isopropylbenzyl)-3-[(3-
methoxybenzyl)amino]propyl}-N3,N3-dipropylbenzene-1,3,5-
tricarboxamide;
          3-[(dipropylamino)sulfonyl]-N-((1S)-1-{(1R)-1-hydroxy-2-}
[(3-methoxybenzyl)amino]ethyl}but-3-ynyl)propanamide;
          N^{1}-[(1S,2R)-1-(2-furylmethyl)-2-hydroxy-3-
(isopentylamino)propyl]-N<sup>5</sup>, N<sup>5</sup>-dipropylpentanediamide;
          N^{1}-[(1S, 2R)-1-(2-furylmethyl)-2-hydroxy-3-
(isopentylamino)propyl]-5-methyl-N3,N3-dipropylisophthalamide;
          N^{1}-[(1S,2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(1-
naphthylmethyl)propyl]-5-methyl-N³,N³-dipropylisophthalamide;
          N^{1}-((1S)-1-{(1R)-1-hydroxy-2-[(3-
methoxybenzyl) amino ] ethyl] -3-methylbutyl) -N<sup>3</sup>, N<sup>3</sup>-
dipropylbenzene-1,3,5-tricarboxamide;
          N^{1}-[(1S, 2R)-1-(2-furylmethyl)-2-hydroxy-3-
(isopentylamino)propyl]-N<sup>3</sup>, N<sup>3</sup>-dipropylbenzene-1,3,5-
tricarboxamide;
          N^{1}-[(1S,2R)-2-hydroxy-3-[(3-methoxybenzyl)amino]-1-(1-
naphthylmethyl) propyl]-N^3, N^3-dipropylbenzene-1, 3, 5-
tricarboxamide;
          N-\{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-3-{[(2-
methoxyethyl) (propyl) amino] sulfonyl } propanamide;
          N-\{(1S, 2R)-1-benzy1-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-3-(4,5-dimethyl-2-furoyl)-5-
methylbenzamide;
          3-[(dipropylamino)sulfonyl]-N-[(1S,2R)-2-hydroxy-3-
(isopentylamino)-1-(4-methylbenzyl)propyl]propanamide;
          1 3-[(dipropylamino)sulfonyl]-N-{(1S, 2R)-1-(3-fluoro-5-
hydroxybenzyl)-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}propanamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-[(3-1)]
iodobenzyl)amino]propyl}-1,3-benzothiazole-2-carboxamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-[(3-mu)]
iodobenzyl) amino]propyl}-5-(2,5-dimethylphenoxy)-2,2-
```

```
dimethylpentanamide;
          N-[(1S,2R)-3-amino-1-(3,5-difluorobenzyl)-2-
hydroxypropyl]-3-(isopentylsulfonyl)propanamide
trifluoroacetate;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-2-hydroxy-3-[(3-max)-1]
methoxybenzyl)amino]propyl}-2-hydroxy-5-methylbenzamide;
           4-amino-N-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-mino-N-1)]}
ethylbenzyl)amino]-2-hydroxypropyl}butanamide
bis(trifluoroacetate);
          N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-3-[(pyridin-4-
ylmethyl) thio]benzamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2,1,3-benzoxadiazole-5-
carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-methyl-1,2,3-thiadiazole-
5-carboxamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-[(pyridin-2-
ylthio)methyl]-2-furamide;
           N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-phenyl-5-propyl-1H-
pyrazole-4-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-(trifluoromethoxy)-1H-
indole-2-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(5-methyl-1H-tetraazol-1-
yl)benzamide;
           N-\{(1S, 2R) -1 - (3, 5-difluorobenzyl) -3 - [(3-difluorobenzyl)] -3 
ethylbenzyl)amino]-2-hydroxypropyl}-2,8-dimethylquinoline-3-
carboxamide;
           2-(3-\text{chlorophenoxy})-N-\{(1S,2R)-1-(3,5-\text{difluorobenzyl})-3-
 [(3-ethylbenzyl)amino]-2-hydroxypropyl}propanamide;
            2-chloro-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-difluorobenzyl)]}
 ethylbenzyl)amino]-2-hydroxypropyl}-4-(1H-tetraazol-1-
yl)benzamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-4)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-[5-(2-methylphenyl)-2H-
 tetraazol-2-yl]acetamide;
           3-(1,3-benzoxazol-2-ylthio)-N-{(1S,2R)-1-(3,5-)}
 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}propanamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-6-
 methylquinoline-4-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{(3-a)\}
 ethylbenzyl)amino]-2-hydroxypropyl}-3-propylpyrazine-2-
 carboxamide 4-oxide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-1-benzothiophene-3-
 carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mathemathem)]
 ethylbenzyl)amino]-2-hydroxypropyl}-1-methyl-1H-indole-3-
 carboxamide;
```

```
N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-6-methoxy-1,3-
 benzothiazole-2-carboxamide;
                      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-[(6-methoxy-1H-
 benzimidazol-2-yl)thio]acetamide;
                      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-4-phenylthiophene-2-
 carboxamide;
                      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-5-methoxythiophene-2-
 carboxamide;
                      N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-instance)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2,3'-bithiophene-5-
 carboxamide:
                      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-i)]
 ethylbenzyl)amino]-2-hydroxypropyl}-4-morpholin-4-yl-4-
 oxobutanamide:
                      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-1H-indole-3-carboxamide;
                      4-(acetylamino)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-acetylamino)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-acetylamino)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-acetylamino)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-acetylamino)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-acetylamino)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-acetylamino)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-acetylamino)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-acetylamino)-1-(3,5-difluorobenzyl)-3-[(3-acetylamino)-1-(3,5-difluorobenzyl)-3-[(3-acetylamino)-1-(3,5-difluorobenzyl)-3-[(3-acetylamino)-1-(3,5-difluorobenzyl)-3-[(3-acetylamino)-1-(3,5-difluorobenzyl)-3-[(3-acetylamino)-1-(3,5-difluorobenzyl)-3-[(3-acetylamino)-1-
 ethylbenzyl)amino]-2-hydroxypropyl}-2,6-dimethylbenzamide;
                     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-2-furamide;
                     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{(3-4)\}
 ethylbenzyl)amino]-2-hydroxypropyl}-4-hydroxy-3,5-
dimethoxybenzamide;
                      4-acetyl-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}benzamide;
                     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}nicotinamide;
                     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxyquinoline-4-
carboxamide;
                     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-6-hydroxynicotinamide;
                     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mu)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-benzothiophene-2-
carboxamide;
                     7-chloro-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-final fin
ethylbenzyl)amino]-2-hydroxypropyl}-4-hydroxyquinoline-3-
carboxamide;
                    N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-3-methylisoxazole-5-
carboxamide;
                    N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-methylisoxazole-3-
                    N-\{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4-(3,5-dimethyl-1H-pyrazol-
1-y1) benzamide;
                    N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-methoxy-1H-indole-2-
carboxamide;
                    N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2,5-dimethyl-3-furamide;
```

```
N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-6-hydroxy-2-
(methylthio)pyrimidine-4-carboxamide;
     N-\{(1s, 2r)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-1,3-oxazole-4-
carboxamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-1H-pyrazole-5-
carboxamide;
     N-\{(1s, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}thiophene-3-carboxamide;
     6-chloro-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-difluorobenzyl)]}
ethylbenzyl)amino]-2-hydroxypropyl}-1H-indole-2-carboxamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-1H-indole-5-carboxamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mu)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-methyl-1,3-oxazole-5-
carboxamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-methoxybenzamide;
      4-(acetylamino)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}benzamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mu)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-piperidin-1-ylbenzamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-mu)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-methylpyrimidine-5-
carboxamide;
      ethylbenzyl)amino]-2-hydroxypropyl}quinoline-4-carboxamide;
      N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-phenylimidazo[1,2-
a]pyridine-7-carboxamide;
      N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-6-hydroxy-4-methylpyridine-
2-carboxamide;
      N^{1}-{ (1S, 2R) -1- (3, 5-difluorobenzyl) -3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N^4, N^4-diphenylsuccinamide;
      N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-[ethyl(methyl)amino]-4-
hydroxypyrimidine-5-carboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
 ethylbenzyl)amino]-2-hydroxypropyl}-4,8-dihydroxyquinoline-2-
 carboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-1-benzofuran-2-carboxamide;
      N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-1-ethyl-1H-indole-2-
 carboxamide;
      2-(acetylamino)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-4,5-dimethylthiophene-3-
 carboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
 ethylbenzyl)amino]-2-hydroxypropyl}-3-hydroxyquinoxaline-2-
 carboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-max)]
 ethylbenzyl)amino]-2-hydroxypropyl}-1H-indazole-3-carboxamide;
```

```
N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
 ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-2-phenyl-1,3-
 oxazole-4-carboxamide;
                     4-\text{chloro-N-}\{(1S, 2R)-1-(3, 5-\text{difluorobenzyl})-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-6-methylquinoline-2-
 carboxamide;
                    N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>2</sup>, N<sup>2</sup>-dimethylphthalamide:
                    N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}thiophene-2-carboxamide;
                    N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
 ethylbenzyl)amino]-2-hydroxypropyl}-3-furamide;
                    N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-instance of the second of th
 ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-3-furamide;
                    N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-instance)]
 ethylbenzyl)amino]-2-hydroxypropyl}-3-hydroxy-6-
 neopentylpyridine-2-carboxamide;
                    N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-1,3-thiazole-4-carboxamide;
                    N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
 ethylbenzyl)amino]-2-hydroxypropyl}-4-hydroxy-7-methoxy-1-
 benzothiophene-5-carboxamide;
                    N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-i)]
 ethylbenzyl)amino]-2-hydroxypropyl}-4-hydroxy-7-methoxy-1-
 benzofuran-5-carboxamide;
                    N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-phenyl-1,3-oxazole-4-
 carboxamide;
                    N-\{(1s, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance of the content of the conten
ethylbenzyl)amino]-2-hydroxypropyl}-3,4-dihydroxybenzamide;
                    N^{1} - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [(3 - 3)] \}
ethylbenzyl)amino]-2-hydroxypropyl}-N4-phenylsuccinamide;
                    N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N4-pyridin-3-ylsuccinamide;
                    N^{1}-\{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N4-(2,6-
dimethylphenyl) succinamide;
                    N^{1}-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N4-methylsuccinamide;
                    N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-(4-
methoxyphenoxy) propanamide;
                    N-\{(1s, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-instance of the second of th
ethylbenzyl)amino]-2-hydroxypropyl}-4-hydroxy-7-
methoxyquinoline-3-carboxamide;
                    N-\{(1s, 2r)-1-(3, 5-difluorobenzy1)-3-[(3-r)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-
 [methyl (methylsulfonyl) amino] benzamide;
                   N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-(pyrrolidin-3-
ylsulfonyl) benzamide;
                   N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-(4-methyl-1,2,3-
thiadiazol-5-yl)isoxazole-4-carboxamide;
                   N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-2-phenyl-2H-1,2,3-
```

```
triazole-4-carboxamide;
     N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(4-methyl-1,2,3-
thiadiazol-5-y1)-1,3-thiazole-4-carboxamide;
     N-\{(1S, 2R) -1 - (3, 5-difluorobenzyl) -3 - [(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-phenylimidazo[1,2-
a]pyridine-6-carboxamide;
      N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl) amino] -2-hydroxypropyl} -N^5-(1,3-thiazol-2-
yl)pentanediamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-m)]
ethylbenzyl) amino] -2-hydroxypropyl} -2-[(4-methyl-1,2,3-
thiadiazol-5-yl)thio]acetamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-(piperidin-1-ylmethyl)-2-
furamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-2,5-dimethyl-1-phenyl-1H-
pyrrole-3-carboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-\{(3-4)\}
ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-1-phenyl-1H-
pyrazole-3-carboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mu)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-fluoro-4-morpholin-4-
ylbenzamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-3,5-
bis(methylthio)isothiazole-4-carboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-\{(3-4)\}
ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-5-
(trifluoromethyl)isoxazole-4-carboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-5-
(propionylamino)benzamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-phenyl-1H-pyrrole-2-
carboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}pyrazine-2-carboxamide 4-
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-1-pyridin-4-yl-1H-
1,2,3-triazole-4-carboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mu)]
ethylbenzyl)amino]-2-hydroxypropyl}-6-methoxypyrazine-2-
carboxamide 4-oxide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-1-methyl-5-phenyl-1H-
pyrazole-3-carboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mu)]
 ethylbenzyl)amino]-2-hydroxypropyl}-3-hydroxy-3-
propylhexanamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-max)]
 ethylbenzyl)amino]-2-hydroxypropyl}-1H-benzimidazole-5-
 carboxamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
```

```
ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-4-
(propionylamino)benzamide;
               5-chloro-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-difluorobenzyl)]}
ethylbenzyl)amino]-2-hydroxypropyl}-1-benzofuran-2-carboxamide;
               N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-pyridin-3-yl-1,3-
thiazole-4-carboxamide;
               8-cyano-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-hydroxyquinoline-3-
carboxamide:
               N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-1,6-naphthyridine-2-
carboxamide;
               N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-\{(3-1)\}
ethylbenzyl)amino]-2-hydroxypropyl}-2,2-dimethyl-4-oxochromane-
6-carboxamide;
               N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-(morpholin-4-
ylmethyl)benzamide;
               N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mathemathem)]
ethylbenzyl)amino]-2-hydroxypropyl}-4,7-dimethoxy-1-benzofuran-
                3-chloro-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-difluorobenzyl)]}
ethylbenzyl)amino]-2-hydroxypropyl}-5-phenylisothiazole-4-
carboxamide;
                2-(2,1,3-benzothiadiazol-4-yloxy)-N-{(1s,2r)-1-(3,5-
difluorobenzyl) -3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}acetamide;
               N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-methoxy-4-
(methylthio)benzamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-[(4-methyl-1,3-thiazol-2-
yl)thio]acetamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-6-methoxy-1-benzofuran-2-
carboxamide;
                5-chloro-N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-difluorobenzy1)
ethylbenzyl)amino]-2-hydroxypropyl}-2-morpholin-4-ylbenzamide;
                N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-methoxy-1H-pyrrole-3-
carboxamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-1,3-thiazole-4-
carboxamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-methyl-5-(2-thienyl)-3-
furamide:
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{(3-1)-1, (3-1)-1
ethylbenzyl)amino]-2-hydroxypropyl}-4-methoxythiophene-3-
carboxamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-N'-(3,5-dimethylpyrazin-2-
yl) succinamide;
                N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-[(3,4-
```

```
dimethoxyphenyl) thio] acetamide;
          6-chloro-N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-6)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-
(trifluoromethyl)pyridine-2-carboxamide;
         N-(2-acetyl-3-thienyl)-N'-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}succinamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-(4-fluorophenyl)-5-
methyl-1H-1,2,4-triazole-3-carboxamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N'-[2-fluoro-5-
(methylsulfonyl)phenyl]succinamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{(3-1)-1, (3-1)-1
ethylbenzyl)amino]-2-hydroxypropyl}-4-(4-
methoxyphenyl)thiophene-2-carboxamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-[5-(methylsulfinyl)-2,3-
dihydro-1H-indol-1-yl]-4-oxobutanamide;
          2-(acetylamino)-5-chloro-N-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}thiophene-3-carboxamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-propyltetrahydro-2H-
pyran-4-carboxamide;
           4-chloro-N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-7,7-dimethyl-7,8-dihydro-
5H-pyrano[4,3-b]pyridine-2-carboxamide;
           2-(2-chlorophenyl)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-}
 [(3-ethylbenzyl)amino]-2-hydroxypropyl}-1,3-thiazole-4-
carboxamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(3-methylphenyl)-1,3-
thiazole-4-carboxamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-1,2,5-thiadiazole-3-
carboxamide;
          N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-(phenoxymethyl)-1,3-
thiazole-4-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-(4-methylphenyl)-1,3-
 thiazole-4-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-mu)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-pyridin-3-ylbenzamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{(3-4)\}
 ethylbenzyl)amino]-2-hydroxypropyl}-4-methyl-2-phenyl-1,3-
oxazole-5-carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-1-ethyl-3-(2-thienyl)-1H-
pyrazole-5-carboxamide;
           4-(acetylamino)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-1-methyl-1H-pyrrole-2-
 carboxamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
 ethylbenzyl)amino]-2-hydroxypropyl}-2-(2,6-
```

```
dimethylphenoxy) propanamide;
                        N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-max)-1-(3-max)-1-(3-max)-3-[(3-max)-1-(3-max)-1-(3-max)-3-[(3-max)-1-(3-max)-1-(3-max)-3-[(3-max)-1-(3-max)-1-(3-max)-3-[(3-max)-1-(3-max)-1-(3-max)-3-[(3-max)-1-(3-max)-1-(3-max)-3-[(3-max)-1-(3-max)-1-(3-max)-3-[(3-max)-1-(3-max)-1-(3-max)-3-[(3-max)-1-(3-max)-1-(3-max)-3-[(3-max)-1-(3-max)-1-(3-max)-3-[(3-max)-1-(3-max)-1-(3-max)-3-[(3-max)-1-(3-max)-1-(3-max)-3-[(3-max)-1-(3-max)-1-(3-max)-3-[(3-max)-1-(3-max)-1-(3-max)-3-[(3-max)-1-(3-max)-1-(3-max)-3-[(3-max)-1-(3-max)-1-(3-max)-3-[(3-max)-1-(3-max)-1-(3-max)-3-[(3-max)-
      ethylbenzyl)amino]-2-hydroxypropyl}-4-phenyl-1,2,3-thiadiazole-
      5-carboxamide;
                        N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
     ethylbenzyl)amino]-2-hydroxypropyl}-2-(2,5-dimethyl-1H-pyrrol-
     1-yl)thiophene-3-carboxamide;
                         5-(acetylamino)-N-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
    ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxybenzamide;
                        4-(acetylamino)-N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
    ethylbenzyl)amino]-2-hydroxypropyl}butanamide trifluoroacetate;
                       N-\{(1S,2R)-1-benzyl-3-[1-ethyl-2-(4-benzyl-3-[1-ethyl-2-[1-ethy
     methylpentanoyl)hydrazino]-2-hydroxypropyl}-2-
     [(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide;
                       N-\{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
   ethylbenzyl)amino]-2-hydroxypropyl}-3-(1-methyl-1H-imidazol-2-
   yl)benzamide;
                       N'-[(1s,2R)-3-\{[(1R)-3-cyclohexyl-1-phenylpropyl]amino}-
   1-(3,5-difluorobenzy1)-2-hydroxypropyl]-5-methyl-N,N-
   dipropylisophthalamide;
                       N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
   ethylbenzyl)amino]-2-hydroxypropyl}-N3,N3-dipropyl-5-pyridin-3-
   ylisophthalamide;
                       N-\{(1s,2R)-1-(3,5-difluorobenzy1)-3-[(3-
   ethylbenzyl)amino]-2-hydroxypropyl}-4-fluoro-1-naphthamide;
                      N-cyclohexyl-N'-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
   ethylbenzyl)amino]-2-hydroxypropyl}-N,5-dimethylisophthalamide;
                      N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance of the content 
  ethylbenzyl)amino]-2-hydroxypropyl}-1-methyl-1H-imidazole-2-
   carboxamide;
                     N^{1}-{ (1s,2R) -1-benzy1-2-hydroxy-3-[(3-
  methoxybenzyl) amino]propyl}-N³-[oxo(phenyl)methyl]-\beta-
                      N^{1}-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-
  methoxybenzyl)amino]propyl}-N2-[imino(phenyl)methyl]glycinamide;
                     N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
  ethylbenzyl) amino] -2-hydroxypropyl}-\overline{N}^{3}-(2-propylpentanimidoyl) -
  β-alaninamide:
                     6-(4-benzylpiperazin-1-y1)-N-{(1S,2R)-1-(3,5-
 difluorobenzyl)-2-hydroxy-3-[(3-
 iodobenzyl)amino]propyl}nicotinamide;
                    N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
 ethylbenzyl)amino]-2-hydroxypropyl}-3-[(3-
 methoxyphenyl)sulfonyl]propanamide;
                    N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
 ethylbenzyl)amino]-2-hydroxypropyl}-5-methyl-7-
 (trifluoromethyl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;
                   N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-N'-(5-phenyl-1,3,4-
thiadiazo1-2-yl) succinamide;
                   N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-N'-{(1s,2r)-1-yl}
 (3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}succinamide;
                   N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-3-(3-methyl-5-oxo-4,5-
dinydro-14-pyrazol-1-41) benzamide:
```

```
N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}thieno[2,3-b]quinoline-2-
carboxamide;
                   N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-methyl-5-oxo-2-
phenylprolinamide;
                   N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-methyl-4H,6H-pyrrolo[1,2-
a] [4,1]benzoxazepine-4-carboxamide;
                   N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-[(7-hydroxy-5-
methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)thio]acetamide:
                   N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-oxo-2,3-dihydro-1,2-
benzisothiazole-6-carboxamide 1,1-dioxide;
                   N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}thieno[3,2-c]pyridine-2-
carboxamide;
                   N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl) amino] -2-hydroxypropyl} -2-oxo-2, 3-dihydro-1, 3-
benzoxazole-6-carboxamide;
                   N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-
 [oxo(phenoxy)methyl]prolinamide;
                   6-chloro-N-\{(1S, 2R) - 1 - (3, 5 - diffluorobenzyl) - 3 - [(3 - 4) - 2] - (3 - 4) - 
ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-2-oxo-2,3-dihydro-
1,3-benzoxazole-5-carboxamide;
                   N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-[4-(2,5-dioxopyrrolidin-
1-y1) phenoxy] acetamide;
                   N^2 - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzy1) - 3 - [ (3 - 3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - 3 - (3) - (
ethylbenzyl)amino]-2-hydroxypropyl}-N1-phenylpyrrolidine-1,2-
                    2-(1,3-benzothiazol-2-ylmethoxy)-N-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}acetamide;
                   N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-3-methyl-4-oxo-3,4-
dihydrophthalazine-1-carboxamide;
                   N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}indolizine-2-carboxamide;
                   N-\{(1s, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-oxo-4-phenylbutanamide;
                   N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-instance of the content 
ethylbenzyl)amino]-2-hydroxypropyl}-2-(1,3-dimethyl-2,6-dioxo-
1,2,3,6-tetrahydro-7H-purin-7-yl)acetamide;
                   ethylbenzyl)amino]-2-hydroxypropyl}-4-(3-hydroxyphenyl)-4-
oxobutanamide;
                    N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4-(3-methoxyphenyl)-4-
oxobutanamide;
                   N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-\{(3-4)\}
ethylbenzyl)amino]-2-hydroxypropyl}-3',4'-dihydro-1'H-
spiro[1,3-dioxolane-2,2'-naphthalene]-8'-carboxamide;
                   N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
```

```
ethylbenzyl)amino]-2-hydroxypropyl}-3',4'-dihydro-1'H-
 spiro[1,3-dioxolane-2,2'-naphthalene]-7'-carboxamide;
       N^{1}-{ (1s, 2r) -1- (3, 5-difluorobenzyl) -3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-\mathbb{N}^2-
 [mercapto(methylthio)methyl]-D-alaninamide;
       N^2-[(4-chlorophenyl)(oxo)methyl]-N^1-{(1S,2R)-1-(3,5-
 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
 hydroxypropyl}glycinamide;
       N^2-[(4-tert-butylphenyl)(oxo)methyl]-N^1-{(1S,2R)-1-(3,5-
 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
 hydroxypropyl}glycinamide;
      N^{1}-{(1s,2R)-1-(3,5-difluorobenzy1)-3-[(3-
 ethylbenzyl) amino] -2-hydroxypropyl}-N^2-[oxo(pyridin-3-
 yl)methyl]glycinamide;
       2-{[2-({(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}amino)-2-oxoethyl]thio}-N-
 [4-(1,3-oxazol-5-yl)phenyl]acetamide;
      N^2-[(4-chlorophenyl)(oxo)methyl]-N^1-{(1S,2R)-1-(3,5-
 difluorobenzy1)-3-[(3-ethylbenzy1)amino]-2-hydroxypropy1}-D-
 alaninamide;
      N^2-[(3,4-dichlorophenyl)(oxo)methyl]-N^1-{(1S,2R)-1-(3,5-
 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}glycinamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4-(5a,9a-
dihydrodibenzo[b,d]furan-2-y1)-4-oxobutanamide;
      N^{1}-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N^2-{oxo[4-
 (trifluoromethyl)phenyl]methyl}glycinamide;
      N^{1}-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N^2-[(2,6-
difluorophenyl)(oxo)methyl]glycinamide;
      N^{1}-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N2-[oxo(4-
methoxyphenyl)methyl]glycinamide;
      N-\{(1s, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-6)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(2-oxo-1,3-oxazolidin-3-
yl)benzamide;
      N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-5-
(phenylethynyl) nicotinamide;
      N^{1}-{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N³-[oxo(1H-1,2,4-triazol-5-
yl)methyl]-\beta-alaninamide;
      2-{[2-({(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzy1)amino]-2-hydroxypropy1}amino)-2-oxoethy1]thio}-N-
(pyridin-4-ylmethyl) acetamide;
     N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4-
[(methoxymethyl)thio]benzamide;
     N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-(1,5-dimethyl-3-oxo-2-
phenyl-2,3-dihydro-1H-pyrazol-4-yl)-4-oxobutanamide;
     4-(4-benzyl-1,4-diazepan-1-yl)-N-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-4-
: sommanide
                              -1235-
```

```
N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-2,5-dimethyl-1-(pyridin-4-
ylmethyl) -1H-pyrrole-3-carboxamide;
                   N-[(dimethylamino) sulfonyl]glycyl-N^1-\{(1S, 2R)-1-(3, 5-1)\}
difluorobenzyl) -3-[(3-ethylbenzyl)amino]-2-
hydroxypropyl}glycinamide;
                   N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-hydroxy-1-[(1R,2R)-2-
hydroxycyclohexyl]prolinamide:
                    (2S, 3S) - N - \{(1S, 2R) - 1 - (3, 5 - diffluorobenzy1) - 3 - [(3 - 3) - 3 - (3 - 3)] - (3 - 3) - (3 - 3
ethylbenzyl)amino]-2-hydroxypropyl}-1-methyl-5-oxo-2-pyridin-3-
ylpyrrolidine-3-carboxamide;
                   N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-(2,5-dioxopyrrolidin-1-
yl)benzamide;
                   N-(2-cyano-4,5,6,7-tetrahydro-1-benzothien-3-yl)-N'-
\{(1S, 2R) - 1 - (3, 5 - \text{difluorobenzyl}) - 3 - [(3 - \text{ethylbenzyl}) \text{amino}] - 2 - (3, 5 - \text{difluorobenzyl}) - 3 - [(3 - \text{ethylbenzyl}) \text{amino}] - 2 - (3, 5 - \text{difluorobenzyl}) - 3 - [(3 - \text{ethylbenzyl}) \text{amino}] - 2 - (3, 5 - \text{difluorobenzyl}) - 3 - [(3 - \text{ethylbenzyl}) \text{amino}] - 2 - (3, 5 - \text{difluorobenzyl}) - 3 - [(3 - \text{ethylbenzyl}) \text{amino}] - 2 - (3 - \text{ethylbenzyl}) - 3 - [(3 - \text{ethylbenzyl}) \text{amino}] - 2 - (3 - \text{ethylbenzyl}) - 3 - [(3 - \text{ethylbenzyl}) \text{amino}] - 2 - (3 - \text{ethylbenzyl}) - 3 - [(3 - \text{ethylbenzyl}) \text{amino}] - 2 - (3 - \text{ethylbenzyl}) - 3 - [(3 - \text{ethylbenzyl}) \text{amino}] - (3 - \text{ethylbenzyl}) - 3 - [(3 - \text{ethylbenzyl}) \text{amino}] - (3 - \text{ethylbenzyl}) -
hydroxypropyl}succinamide;
                   N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(2,5-dioxoimidazolidin-4-
yl)acetamide;
                   N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)]
ethylbenzyl)amino]-2-hydroxypropyl}-2-(5,7-
dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)acetamide;
                   N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-1-(2-furylmethyl)-5-
oxopyrrolidine-3-carboxamide:
                   N-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-4)]
ethylbenzyl)amino]-2-hydroxypropyl}-4-oxo-4-(5-oxo-1,4-
diazepan-1-yl) butanamide;
                   N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl)-3-(4-methylphenyl)-4,5-
dihydro-1H-pyrazole-5-carboxamide;
                   N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-instance)]
ethylbenzyl)amino]-2-hydroxypropyl}-2,1,3-benzoxadiazole-5-
carboxamide 1-oxide;
                   N-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-3-(2-pyridin-3-ylpiperidin-
1-y1)propanamide;
                   N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-4-oxo-4-(2-propyl-1H-
imidazol-1-yl)butanamide;
                   N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-4a,9a-dihydro-9H-carbazole-
9-carboxamide;
                   N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-6-methyl-4-oxo-1-phenyl-
1,4-dihydropyridazine-3-carboxamide;
                   N'-((1S,2R)-1-(3,5-difluorobenzy1)-2-hydroxy-3-{[1-
methyl-5-(pyrrolidin-1-ylcarbonyl)-1H-pyrrol-3-
yl]amino}propyl)-5-methyl-N, N-dipropylisophthalamide;
                   oxo-2-pyrrolidin-1-ylethoxy)phenyl]amino}propyl)-5-methyl-N,N-
dipropylisophthalamide;
                   N' - \{(1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 - [(3 - \{[3 - [3] + [3 - [3] + [3 - [3] + [3 - [3] + [3 - [3] + [3 - [3] + [3 - [3] + [3 - [3] + 
 (hydroxymethyl)piperidin-1-yl]carbonyl}phenyl)amino]propyl}-5-
```

```
methyl-N, N-dipropylisophthalamide;
                     N^{1}-{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
   ethylbenzyl)amino]-2-hydroxypropyl}-N2-[3-(methylthio)-1-
   oxopropyl]-N2-pentylglycinamide;
                     N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
   ethylbenzyl) amino] -2-hydroxypropyl} -N^2-[3-(methylsulfonyl) -1-
   oxopropyl]-N2-pentylglycinamide:
                     N-\{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-
  methoxybenzyl)amino]propyl}-3-(phenylsulfonyl)propanamide;
                     N'-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-[(7-4)]
   oxabicyclo[2.2.1]hept-2-ylmethyl)amino]propyl}-5-methyl-N,N-
   dipropylisophthalamide;
                     N'-((1S, 2R)-1-(3, 5-difluorobenzyl)-2-hydroxy-3-{[(3R)-2-kydroxy-3-kydroxy-3-{[(3R)-2-kydroxy-3-kydroxy-3-kydroxy-3-[(3R)-2-kydroxy-3-kydroxy-3-[(3R)-2-kydroxy-3-[(3R)-2-kydroxy-3-[(3R)-2-kydroxy-3-kydroxy-3-[(3R)-2-
   oxo-1-propylazepan-3-yl]amino}propyl)-5-methyl-N,N-
  dipropylisophthalamide;
                     N'-[(1S, 2R)-3-[(1-acetylpiperidin-4-yl)amino]-1-(3, 5-
  difluorobenzyl)-2-hydroxypropyl]-5-methyl-N,N-
  dipropylisophthalamide;
                     ethylbenzyl)amino]-2-hydroxypropyl}-N-[2-(dimethylamino)-2-
  oxoethyl]-N,5-dimethylisophthalamide;
                     N' - \{ (1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 3 - [(3 - 1)] \}
  ethylbenzyl)amino]-2-hydroxypropyl}-N-[2-(dimethylamino)ethyl]-
  N-ethyl-5-methylisophthalamide;
                     N-benzyl-N'-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-benzyl-N'-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-benzyl-N'-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-benzyl-N'-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-benzyl-N'-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-benzyl-N'-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-benzyl-N'-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-benzyl-N'-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-benzyl-N'-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-benzyl-N'-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-benzyl-N'-{(1S,2R)-1-(3,5-difluorobenzyl-N'-{(1S,2R)-1-(3,5-difluo
  ethylbenzyl)amino]-2-hydroxypropyl}-N,5-dimethylisophthalamide;
                     N-\{(1S, 2R)-1-(3, 5-difluorobenzy1)-3-[(3-max)-1]
  ethylbenzyl)amino]-2-hydroxypropyl}-3-{[2-(2-
  hydroxyethyl)piperidin-1-yl]carbonyl}-5-methylbenzamide;
                    N'-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-
  ethylbenzyl)amino]-2-hydroxypropyl}-N,5-dimethyl-N-(2-
  phenylethyl) isophthalamide;
                    N'-((1S, 2R)-1-(3, 5-difluorobenzyl)-3-{[3-(3-formyl-2-(3-formyl
  furyl)benzyl]amino}-2-hydroxypropyl)-5-methyl-N,N-
  dipropylisophthalamide:
                    N'-((1S, 2R)-1-(3, 5-difluorobenzy1)-3-{[3-(5-formyl-2-
 thienyl)benzyl]amino}-2-hydroxypropyl)-5-methyl-N,N-
 dipropylisophthalamide;
                    N'-\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-N,5-dimethyl-N-(2-pyridin-
 2-ylethyl)isophthalamide;
                    N'-[(1S,2R)-1-(3,5-difluorobenzy1)-2-hydroxy-3-({[1-
  (methylsulfonyl)piperidin-4-yl]methyl}amino)propyl]-5-methyl-
 N, N-dipropylisophthalamide;
                   N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N3,N3-diethylpiperidine-1,3-
 dicarboxamide:
                   N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N3,N3-dipropylpiperidine-1,3-
 dicarboxamide:
                   N'-((1S, 2R)-1-(3, 5-difluorobenzy1)-3-{[3-(5-formy1-4-
methyl-2-thienyl)benzyl]amino}-2-hydroxypropyl)-5-methyl-N,N-
dipropylisophthalamide;
                   N' - ((1S, 2R) - 1 - (3, 5 - difluorobenzyl) - 2 - hydroxy - 3 - {[3 - (1 - 4)]}
phenylvinyl)benzyl]amino)propyl)-5-methyl-N,N-
dipropylisophthalamide:
```

```
N'-[(1S, 2R)-3-[(3-bicyclo[2.2.1]hept-2-ylbenzyl)amino]-1-
(3,5-difluorobenzyl)-2-hydroxypropyl]-5-methyl-N,N-
dipropylisophthalamide;
         ethyl 3-[3-({[(2R,3S)-4-(3,5-difluorophenyl)-3-({3-
[(dipropylamino)carbonyl]-5-methylbenzoyl}amino)-2-
hydroxybutyl]amino}methyl)phenyl]propanoate;
         ethyl 4-[3-({[(2R,3S)-4-(3,5-difluorophenyl)-3-({3-
[(dipropylamino)carbonyl]-5-methylbenzoyl}amino)-2-
hydroxybutyl]amino}methyl)phenyl]butanoate;
         methyl (2R)-3-[3-({[(2R,3S)-4-(3,5-difluorophenyl)-3-({3-
[(dipropylamino)carbonyl]-5-methylbenzoyl}amino)-2-
hydroxybutyl]amino}methyl)phenyl]-2-methylpropanoate;
         ethyl 3'-(\{[(2R,3S)-4-(3,5-dif_{uorophenyl})-3-(\{3-d
[(dipropylamino)carbonyl]-5-methylbenzoyl}amino)-2-
hydroxybutyl]amino}methyl)biphenyl-2-carboxylate;
         2-\{1-[2-(\{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-i)]\}\}\}
ethylbenzyl)amino]-2-hydroxypropyl}amino)-2-
oxoethyl]cyclopentyl}-N, N-dipropylacetamide;
         N^2-[(benzyloxy)carbonyl]-N^1-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-
[(1-propylbutyl)sulfonyl]-D, L-alaninamide trifluoroacetate;
         N^2-[(benzyloxy)carbonyl]-N^1-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-methylbutyl)amino]-2-hydroxypropyl}-3-
[(1-propylbutyl)sulfonyl]-D, L-alaninamide;
         N^2-[(benzyloxy)carbonyl]-N^1-{(1S, 2R)-1-(3, 5-
difluorobenzyl)-3-(cyclopropylamino)-2-hydroxypropyl}-3-[(1-
propylbutyl)sulfonyl]-D,L-alaninamide trifluoroacetate;
         N^2-[(benzyloxy)carbonyl]-N^1-\{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(cyclopropylmethyl)amino]-2-hydroxypropyl}-
3-[(1-propylbutyl)sulfonyl]-D,L-alaninamide trifluoroacetate;
         N^{1}-{(1s,2r)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N2-{[(3S)-tetrahydrofuran-
3-yloxy]carbonyl}-3-[(1-propylbutyl)sulfonyl]-L-alaninamide
trifluoroacetate;
         N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-N2-{[(3S)-tetrahydrofuran-
3-yloxy]carbonyl}-3-[(1-propylbutyl)sulfonyl]-D-alaninamide
trifluoroacetate;
         N^{1}-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-1)]
ethylbenzyl)amino]-2-hydroxypropyl}-N<sup>2</sup>-{[(3S)-tetrahydrofuran-
3-yloxy]carbonyl}-3-[(1-propylbutyl)sulfonyl]-D,L-alaninamide
trifluoroacetate;
         N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N2-{[(3R)-tetrahydrofuran-
3-yloxy]carbonyl}-3-[(1-propylbutyl)sulfonyl]-D,L-alaninamide
trifluoroacetate;
         N^1-\{(1S, 2R)-1-benzyl-3-[(3-methoxybenzyl)amino]-2-
hydroxypropyl}-N^2-{[(3S)-tetrahydrofuran-3-yloxy]carbonyl}-3-
[(1-propylbutyl)sulfonyl]-D,L-alaninamide;
         N^{1} - \{(1S, 2R) - 1 - (3, 5diflurobenzyl) - 3 - [(3 - ethylbenzyl) amino] -
2-hydroxypropyl}-N<sup>2</sup>-{[(3S)-1,1-dioxidotetrahydrothien-3-
yloxy]carbonyl}-3-[(1-propylbutyl)sulfonyl]-D,L-alaninamide
trifluoroacetate;
         N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl) amino] -2-hydroxypropyl-N^2-{[(3S)-
tetrahydrothiophen-3-yloxy]carbonyl}-3-[(1-
```

```
propylbutyl)sulfonyl]-D,L-alaninamide trifluoroacetate;
       N^{1}-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
  ethylbenzyl)amino]-2-hydroxypropyl}-N²-{[tetrahydropyran-4-
 yloxy]carbonyl}-3-[(1-propylbutyl)sulfonyl]-D,L-alaninamide
  trifluoroacetate;
       N^{1}-{(1S,2R)-1-(3,5-diflourobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-N^2-{[1-
  (methylsulfonyl)piperidin-4-yloxy]carbonyl}-3-[(1-
 propylbutyl)sulfonyl]-D,L-alaninamide trifluoroacetate;
       N^2 - \{[1-acetylpiperidin-4-yloxy]carbonyl\}-N^1 - \{(1s,2r)-1-yloxy\}
 (3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-
 3-[(1-propylbutyl)sulfonyl]-D,L-alaninamide trifluoroacetate;
       N^{1}-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-\bar{N}^2-{[[(3R)-5-oxopyrrolidin-
 3-y1]methy1]carbony1}-3-[(1-propy1buty1)sulfony1]-D,L-
 alaninamide trifluoroacetate;
       N^{1}-{ (1s,2r)-1-benzyl-3-[(3-methoxybenzyl)amino]-2-
 \label{eq:hydroxypropyl} $$ -N^2-[(benzyloxy)carbonyl]-3-[(1-
 propylbutyl)sulfonyl]-D,L-alaninamide;
       N^2 - [(benzyloxy) carbonyl] - N^1 - ((1S, 2R) - 1 - (3, 5 - 1))
 difluorobenzyl)-2-hydroxy-3-{[2-(3-
 methoxyphenyl)ethyl]amino}propyl)-3-[(1-propylbutyl)sulfonyl]-
 D,L-alaninamide trifluoroacetate;
       N^{1}-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
 ethylbenzyl)amino]-2-hydroxypropyl}-N^2-{[(3S)-tetrahydrofuran-
 3-yloxy]carbonyl}-D-leucinamide trifluoracetate;
       N^{1}-{(1s,2R)-1-benzy1-2-hydroxy-3-[(3-
 methoxybenzyl)amino]propyl}-N2-[(benzyloxy)carbonyl]-L-
 leucinamide;
      N^2-[(benzyloxy)carbonyl]-N^1-((1S)-1-{(1R)-2-
 [ethyl(isobutylsulfonyl)amino]-1-hydroxyethyl}-3-methylbutyl)-
 3-[(1-propylbutyl)sulfonyl]-D.L-alaninamide;
      N^2 - [(benzyloxy) carbonyl] - N^1 - {(1S, 2R) - 1 - (3, 5 - 1)}
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-
N^5, N^5-dipropyl-L-glutamamide trifluoroacetate;
      N^2 - [(benzyloxy) carbonyl] - N^1 - {(1S, 2R) - 1 - (3, 5 - 1)}
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-
N<sup>5</sup>, N<sup>5</sup>-dipropyl-D-glutamamide;
      N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N^2-[(1H-pyrazol-4-
yl)carbonyl]-3-[(1-propylbutyl)sulfonyl]-D,L-alaninamide;
      N^2-[(6-chloropyridin-3-yl)carbonyl]-N^1-{(1s,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-
[(1-propylbutyl)sulfonyl]-D,L-alaninamide;
      N^{1}-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N^2-[(pyridin-2-
yl)carbonyl]-3-[(1-propylbutyl)sulfonyl]-D,L-alaninamide;
      N^{1}-{(1s,2R)-1-(3,5-difluorobenzy1)-3-[(3-
ethylbenzyl) amino] -2-hydroxypropyl} -N^2-(2-methylbenzoyl) -3-[(1-
propylbutyl)sulfonyl]-D,L-alaninamide;
      N^{1}-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N^2-(3-methylbenzoyl)-3-[(1-
propylbutyl)sulfonyl]-D,L-alaninamide;
     N^{1}-{(1s,2R)-1-(3,5-difluorobenzy1)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-\bar{N}^2-(4-methylbenzoyl)-3-[(1-
propylbutyl)sulfonyl]-D,L-alaninamide;
```

```
N^2-(3-chlorobenzoyl)-N^1-{(1S,2R)-1-(3,5-difluorobenzyl)-3-
 [(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-
propylbutyl)sulfonyl]-D, L-alaninamide;
         N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N2-(4-methoxybenzoyl)-3-
 [(1-propylbutyl)sulfonyl]-D, L-alaninamide;
         N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl) amino] -2 -hydroxypropyl} -N^2 (4-
triflluoromethylbenzoyl)-3-[(1-propylbutyl)sulfonyl]-D,L-
alaninamide;
         N^2-(cyclohexylcarbonyl)-N^1-{(1S,2R)-1-(3,5-
difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-
 [(1-propylbutyl)sulfonyl]-D, L-alaninamide;
         N^{2} (benzoyl) -N^{1} - { (1S, 2R) -1 - (3, 5-difluorobenzyl) -3 - [ (3-
ethylbenzyl)amino]-2-hydroxypropyl}-3-[(1-
propylbutyl) sulfonyl] -D, L-alaninamide;
         N^{1}-{(1S, 2R)-1-(3,5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-N^2-(phenylacetyl)-3-[(1-
propylbutyl)sulfonyl]-D,L-alaninamide;
         N^{1}-\{(1S,2R)-1-(3,5-difluorobenzy1)-3-[(3-
ethylbenzyl) amino] -2-hydroxypropyl}-N^2-(3-phenylpropanoyl) -3-
 [(1-propylbutyl)sulfonyl]-D,L-alaninamide trifluoroacetate;
        N^{1}-{(1S,2R)-1-benzy1-2-hydroxy-3-[(3-
methoxybenzyl) amino] propyl} -N<sup>2</sup>-(cyclopropylacetyl) -3-[(1-
propylbutyl)sulfonyl]-D,L-alaninamide;
         N^{1}-\{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl) amino]propyl}-N^2-[(methylsulfonyl)acetyl]-3-[(1-
propylbutyl)sulfonyl]-D,L-alaninamide trifluoroacetate;
         N^{1}-{ (1S, 2R) -1-benzy1-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N2-[(methylthio)acetyl]-3-[(1-
propylbutyl)sulfonyl]-D,L-alaninamide;
         N^{1}-\{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N^2-(4-hydroxy-4-oxobutanoyl)-3-[(1-
propylbutyl) sulfonyl]-D, L-alaninamide;
        N^{1}-{ (1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N2-[4-(methylamino)-4-oxobutanoyl]-
3-[(1-propylbutyl)sulfonyl]-D,L-alaninamide;
        N^{1}-{ (1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N^2-(4-methoxy-4-oxobutanoyl)-3-[(1-methoxybenzyl)amino]propyl}-N^2-(4-methoxy-4-oxobutanoyl)-3-[(1-methoxybenzyl)amino]propyl}-N^2-(4-methoxybenzyl)amino]propyl
propylbutyl)sulfonyl]-D,L-alaninamide;
        N-(methylsulfonyl)glycyl-N^1-{(1S,2R)-1-benzyl-2-hydroxy-3-}
[(3-methoxybenzyl)amino]propyl}-3-[(1-propylbutyl)sulfonyl]-
D, L-alaninamide;
        N^2-acetyl-N^1-{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-3-(phenylsulfonyl)-D,L-alaninamide;
         (2S)-2-(4-methoxy-4-oxobutanoyl) amino-N-\{(1S, 2R)-1-
benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-5-oxo-5-
piperidin-1-ylpentanamide;
         (2R)-2-\{[(benzyloxy)carbonyl]amino}-N-\{(1S,2R)-1-benzyl-
2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-5-oxo-5-piperidin-
1-ylpentanamide;
         (2R) -2-(3-ethoxy-3-oxopropanoyl) amino-N-\{(1S, 2R)-1-
benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-5-oxo-5-
piperidin-1-ylpentanamide;
        N^{1}-{(1S,2R)-1-benzy1-3-[(3-methoxybenzy1)amino]-2-
hydroxypropyl\}-N^2-(4-methoxy-4-oxobutanoyl)-N^5, N^5-dipropyl-D-
```

```
glutamamide;
             (2R)-2-(4-methoxy-4-oxobutanoyl) amino-N-{(1S,2R)-1-
  benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-5-oxo-5-
 piperidin-1-ylpentanamide;
             (2R)-2-(5-methoxy-5-oxopentanoy1) amino-N-\{(1S,2R)-1-(1S,2R)\}
  benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-5-oxo-5-
  piperidin-1-ylpentanamide;
            N^2-[(5-chlorothien-2-yl)sulfonyl]-N^1-{(1S, 2R)-1-(3, 5-
  difluorobenzy1)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-
  [(1-propylbutyl)sulfonyl]-D,L-alaninamide;
            N^{1}-{(1s,2R)-1-(3,5-difluorobenzyl)-3-[(3-
  ethylbenzyl) amino] -2-hydroxypropyl} -N^2- (phenylsulfonyl) -3-[(1-
 propylbutyl)sulfonyl]-D,L-alaninamide;
            N^2-[(benzylamino)carbonyl]-N^1-{(1S,2R)-1-(3,5-
 difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-3-
  [(1-propylbutyl)sulfonyl]-D,L-alaninamide;
            4-({(1S,2R)-1-benzy1-2-hydroxy-3-[(3-
 methoxybenzyl)amino]propyl}amino)-3-
  [(isopentylsulfonyl)methyl]-4-oxobutanoic acid;
            methyl 4-({(1S,2R)-1-benzyl-2-hydroxy-3-[(3-
 methoxybenzyl)amino]propyl}amino)-3-
 [(isopentylsulfonyl)methyl]-4-oxobutanoate;
            N^{1}-{ (1S, 2R)-1-benzy1-2-hydroxy-3-[(3-
 methoxybenzyl)amino]propyl}-2-
 [(isopentylsulfonyl)methyl]succinamide;
            N^{1}-{ (1S, 2R) -1-benzy1-2-hydroxy-3-[(3-
 methoxybenzyl) amino] propyl}-2-[(isopentyl sulfonyl) methyl]-N^4-
 methylsuccinamide;
           N^{1}-{(1S, 2R)-1-benzy1-2-hydroxy-3-[(3-
 methoxybenzyl)amino]propy1}-2-[(isopentylsulfonyl)methyl]-
 N4, N4-dimethylsuccinamide;
           N-\{(1S, 2R)-1-(3, 5-difluorobenzyl)-3-[(3-max)]
 ethylbenzyl)amino]-2-hydroxypropyl}-3-(4,4-dimethyl-2,5-
 dioxoimidazolidin-1-yl)-2-{[(1-
propylbutyl)sulfonyl]methyl}propanamide;
           N-{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-3-(ethylsulfonyl)-2-
 {[(isobutylsulfonyl)amino]methyl}propanamide;
           N-\{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-benzyl-2-hydroxy-3-[(3-benzyl-2-hydroxy-3-[(3-benzyl-2-hydroxy-3-[(3-benzyl-2-hydroxy-3-[(3-benzyl-2-hydroxy-3-[(3-benzyl-2-hydroxy-3-[(3-benzyl-2-hydroxy-3-[(3-benzyl-2-hydroxy-3-[(3-benzyl-2-hydroxy-3-[(3-benzyl-2-hydroxy-3-[(3-benzyl-2-hydroxy-3-[(3-benzyl-2-hydroxy-3-[(3-benzyl-2-hydroxy-3-[(3-benzyl-2-hydroxy-3-[(3-benzyl-2-hydroxy-3-[(3-benzyl-3-benzyl-2-hydroxy-3-[(3-benzyl-3-benzyl-3-[(3-benzyl-3-benzyl-3-[(3-benzyl-3-benzyl-3-[(3-benzyl-3-benzyl-3-[(3-benzyl-3-benzyl-3-[(3-benzyl-3-benzyl-3-[(3-benzyl-3-benzyl-3-[(3-benzyl-3-benzyl-3-[(3-benzyl-3-benzyl-3-[(3-benzyl-3-benzyl-3-[(3-benzyl-3-benzyl-3-[(3-benzyl-3-benzyl-3-[(3-benzyl-3-benzyl-3-[(3-benzyl-3-benzyl-3-[(3-benzyl-3-benzyl-3-[(3-b
methoxybenzyl)amino]propyl}-3-(ethylthio)-2-
{[(isobutylsulfonyl)amino]methyl}propanamide;
            (2S) -N-\{ (1S,2R)-1-benzy1-2-hydroxy-3-[ (3-
methoxybenzyl)amino]propyl}-2-[(isopentylsulfonyl)amino]-4-
 (methylsulfonyl)butanamide;
          N^{1}-{ (1S, 2R)-1-benzy1-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N2-(isopentylsulfonyl)-L-
methioninamide;
          S-{3-({(1S,2R)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}amino)-2-
[(isopentylsulfonyl)methyl]-3-oxopropyl} ethanethioate;
          N-\{ (1S, 2R)-1-benzy1-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-2-hydroxy-3-[(1-
propylbutyl)sulfonyl]propanamide;
          N-\{(1s, 2r)-1-(3, 5-difluorobenzyl)-3-[(3-
ethylbenzyl)amino]-2-hydroxypropyl}-2-hydroxy-4-
(phenylsulfonyl)butanamide;
```

```
N-\{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-2-hydroxy-4-
 (isopentylsulfonyl)butanamide;
                    N-\{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-4-(isopentylsulfonyl)-2-
phenoxybutanamide;
                    N-\{(1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-4-(isopentylsulfonyl)-2-(3-
methoxyphenoxy) butanamide;
                     3-[1-[({(1S,2R)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}amino)carbonyl]-3-
(isopentylsulfonyl)propoxy]benzoic acid trifluoroacetate;
                    methyl 3-[1-[({(1S,2R)-1-benzyl-2-hydroxy-3-[(3-benzyl-2-hydroxy-3
methoxybenzyl)amino]propyl}amino)carbonyl]-3-
(isopentylsulfonyl)propoxy]benzoate;
                    N-\{(1S,2R)-1-benzyl-2-hydroxy-3-\{(3-a)\}
methoxybenzyl)amino]propyl}-2-hydroxy-4-
 (phenylsulfonyl) butanamide;
                    N-\{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-2-hydroxy-4-(phenylthio)butanamide;
                    N-\{(1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-2-methoxy-4-
 (phenylsulfonyl) butanamide;
                    N-\{(1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-2-methoxy-4-(phenylthio)butanamide;
                    N-\{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-4-(phenylsulfonyl)-2-
propoxybutanamide;
                    N-\{(1S, 2R)-1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-2-(benzyloxy)-4-
 (phenylsulfonyl) butanamide;
                   N-{(1S, 2R)-1-benzy1-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N<sup>2</sup>-[(benzyloxy)carbonyl]-D,L-
methioninamide;
                     (2S)-2-amino-N-\{(1S,2R)-1-benzyl-2-hydroxy-3-[(3-y)]
methoxybenzyl)amino]propyl}-5-oxo-5-piperidin-1-ylpentanamide;
                     (2S)-2-(2-ethoxy-2-oxoethanyl) amino-N-\{(1S,2R)-1-benzyl-1-ben
2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-5-oxo-5-piperidin-
1-ylpentanamide;
                     (2R) - 2 - amino - N - \{ (1S, 2R) - 1 - benzyl - 2 - hydroxy - 3 - [ (3 - amino - N - 4 - am
methoxybenzyl)amino]propyl}-5-oxo-5-piperidin-1-ylpentanamide;
                     (2R)-2-(2-ethoxy-2-oxoethanyl) amino-N-{(1S,2R)-1-benzyl-
2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-5-oxo-5-piperidin-
1-ylpentanamide;
                     (2R) -2-(4-ethoxy-4-oxobutanyl) amino-N-\{(1S, 2R)-1-benzyl-
2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-5-oxo-5-piperidin-
1-ylpentanamide ditrifluoroacetate;
                   N^{1}-{ (1S, 2R) -1-benzyl-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N2-[(benzyloxy)carbonyl]-L-
                   N^{1}-{ (1S, 2R) -1-benzy1-2-hydroxy-3-[(3-
methoxybenzyl)amino]propyl}-N2-[(tertbutyloxy)carbonyl]-L-
aspartamide;
                    or a pharmacuetically acceptable salt thereof.
```

THIS PAGE BLANK (USPTO)